category mir disease pmid root_name doid icd10cm mesh omim hpo description lncRNA target hsa-mir-204 Acute Kidney Failure 29669307 urinary system disease DOID:3021 N17.9 D058186 HP:0001919 Long non-coding RNA NEAT1 plays an important role in sepsis-induced acute kidney injury by targeting miR-204 and modulating the NF-κB pathway lncRNA target hsa-let-7c Adenocarcinoma, Lung 27566568 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 the oncogenic function of CCAT1 in docetaxel-resistant LAD cells depended on the sponging of let-7c lncRNA target hsa-mir-145 Adenocarcinoma, Lung 28388536 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 Long noncoding RNA ROR regulates chemoresistance in docetaxel-resistant lung adenocarcinoma cells via epithelial mesenchymal transition pathway. lncRNA target hsa-let-7 Adenocarcinoma, Pancreatic Ductal 28947981 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 Lin28B, a Lin28 homologue, represses the biogenesis of let-7 microRNAs (miRNAs), has a role in tumorigenesis, and is considered a potential therapeutic target for various human malignancies lncRNA target hsa-mir-193b Adenocarcinoma, Pancreatic Ductal 26549028 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 MIR31HG is negatively regulated by miR-193b. lncRNA target hsa-mir-17 Atherosclerosis 28676341 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 The Circular RNA Interacts with STAT3, Increasing Its Nuclear Translocation and Wound Repair by Modulating Dnmt3a and miR-17 Function. lncRNA target hsa-mir-221 Atherosclerosis 23697773 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 We further discovered that an Ang II-regulated lncRNA functions as the host transcript for miR-221 and miR-222, 2 microRNAs implicated in cell proliferation. lncRNA target hsa-mir-9 Atherosclerosis 26981838 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 HULC regulated TNF-伪-induced apoptosis through regulation of miR-9 expression. lncRNA target hsa-let-7a-1 Breast Neoplasms 22081076 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 LIN28: A regulator of tumor-suppressing activity of let-7 microRNA in human breast cancer. lncRNA target hsa-let-7a-1 Breast Neoplasms 22808086 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Lin28 Mediates Paclitaxel Resistance by Modulating p21, Rb and Let-7a miRNA in Breast Cancer Cells. lncRNA target hsa-let-7a-2 Breast Neoplasms 22081076 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 LIN28: A regulator of tumor-suppressing activity of let-7 microRNA in human breast cancer. lncRNA target hsa-let-7a-2 Breast Neoplasms 22808086 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Lin28 Mediates Paclitaxel Resistance by Modulating p21, Rb and Let-7a miRNA in Breast Cancer Cells. lncRNA target hsa-let-7a-3 Breast Neoplasms 22081076 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 LIN28: A regulator of tumor-suppressing activity of let-7 microRNA in human breast cancer. lncRNA target hsa-let-7a-3 Breast Neoplasms 22808086 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Lin28 Mediates Paclitaxel Resistance by Modulating p21, Rb and Let-7a miRNA in Breast Cancer Cells. lncRNA target hsa-let-7c Breast Neoplasms 22081076 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 LIN28: A regulator of tumor-suppressing activity of let-7 microRNA in human breast cancer. lncRNA target hsa-let-7d Breast Neoplasms 22081076 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 LIN28: A regulator of tumor-suppressing activity of let-7 microRNA in human breast cancer. lncRNA target hsa-let-7f-1 Breast Neoplasms 22081076 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 LIN28: A regulator of tumor-suppressing activity of let-7 microRNA in human breast cancer. lncRNA target hsa-let-7f-2 Breast Neoplasms 22081076 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 LIN28: A regulator of tumor-suppressing activity of let-7 microRNA in human breast cancer. lncRNA target hsa-mir-19b Breast Neoplasms 28731027 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 PTENP1 acts as a ceRNA to regulate PTEN by sponging miR-19b and explores the biological role of PTENP1 in breast cancer lncRNA target hsa-mir-34a Breast Neoplasms 29037220 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 circGFRA1 and GFRA1 act as ceRNAs in triple negative breast cancer by regulating miR-34a. lncRNA target hsa-mir-9 Breast Neoplasms 28053623 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 LncRNA Taurine-Upregulated Gene 1 Promotes Cell Proliferation by Inhibiting MicroRNA-9 in MCF-7 Cells. lncRNA target hsa-mir-101 Carcinoma, Bladder 27998761 urinary system disease DOID:4007 D09.0 D001749 109800 HP:0002862 LncRNA SPRY4-IT1 sponges miR-101-3p to promote proliferation and metastasis of bladder cancer cells through up-regulating EZH2. lncRNA target hsa-mir-196a Carcinoma, Bladder 27591936 urinary system disease DOID:4007 D09.0 D001749 109800 HP:0002862 Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells. lncRNA target hsa-mir-197 Carcinoma, Bladder 27631965 urinary system disease DOID:4007 D09.0 D001749 109800 HP:0002862 LINC00312 inhibits the migration and invasion of bladder cancer cells by targeting miR-197-3p. lncRNA target hsa-mir-300 Carcinoma, Bladder 28178615 urinary system disease DOID:4007 D09.0 D001749 109800 HP:0002862 Long non-coding RNA TUG1 promotes cell proliferation and metastasis by negatively regulating miR-300 in gallbladder carcinoma. lncRNA target hsa-mir-101 Carcinoma, Breast 28034643 D05 D001943 114480 HP:0003002 The long non-coding RNA NEAT1 interacted with miR-101 modulates breast cancer growth by targeting EZH2. lncRNA target hsa-mir-18a Carcinoma, Breast 27629141 D05 D001943 114480 HP:0003002 Long non-coding RNA UCA1 enhances tamoxifen resistance in breast cancer cells through a miR-18a-HIF1α feedback regulatory loop. lncRNA target hsa-mir-200 Carcinoma, Breast 28187158 D05 D001943 114480 HP:0003002 Role of the long non-coding RNA PVT1 in the dysregulation of the ceRNA-ceRNA network in human breast cancer. lncRNA target hsa-mir-205 Carcinoma, Breast 28063065 D05 D001943 114480 HP:0003002 Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205. lncRNA target hsa-mir-148a Carcinoma, Cervical 27574106 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 Long non-coding RNA HOTAIR modulates HLA-G expression by absorbing miR-148a in human cervical cancer. lncRNA target hsa-mir-196a Carcinoma, Cervical 28671039 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 LncRNA GAS5 suppresses the tumorigenesis of cervical cancer by downregulating miR-196a and miR-205. lncRNA target hsa-mir-205 Carcinoma, Cervical 28671039 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 LncRNA GAS5 suppresses the tumorigenesis of cervical cancer by downregulating miR-196a and miR-205. lncRNA target hsa-mir-100 Carcinoma, Colon 28130225 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 Cellular Model of Colon Cancer Progression Reveals Signatures of mRNAs, miRNA, lncRNAs, and Epigenetic Modifications Associated with Metastasis. lncRNA target hsa-mir-101 Carcinoma, Colon 28720069 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 Long non-coding RNA SPRY4-IT1 promotes proliferation and invasion by acting as a ceRNA of miR-101-3p in colorectal cancer cells. lncRNA target hsa-mir-125b Carcinoma, Colon 28130225 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 Cellular Model of Colon Cancer Progression Reveals Signatures of mRNAs, miRNA, lncRNAs, and Epigenetic Modifications Associated with Metastasis. lncRNA target hsa-mir-138 Carcinoma, Colon 28358427 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 H19 promotes the migration and invasion of colon cancer by sponging miR-138 to upregulate the expression of HMGA1. lncRNA target hsa-mir-193a Carcinoma, Colon 27633443 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 the involvement of competing endogenous RNAs mechanism in Linc00152/miR-193a-3p/ERBB4/AKT signaling axis may provide a novel choice in the investigation of drug resistance lncRNA target hsa-mir-211 Carcinoma, Colon 28214867 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 The Novel Long Noncoding RNA TUSC7 Inhibits Proliferation by Sponging MiR-211 in Colorectal Cancer. lncRNA target hsa-mir-217 Carcinoma, Colon 28472810 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 The Long Non-Coding RNA CRNDE Promotes Colorectal Carcinoma Progression by Competitively Binding miR-217 with TCF7L2 and Enhancing the Wnt/β-Catenin Signaling Pathway. lncRNA target hsa-mir-24 Carcinoma, Colon 28306719 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 Chromosome 19q13 disruption alters expressions of CYP2A7, MIA and MIA-RAB4B lncRNA and contributes to FAP-like phenotype in APC mutation-negative familial colorectal cancer patients. lncRNA target hsa-mir-490 Carcinoma, Colon 28381168 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 Long non-coding RNA colon cancer-associated transcript 1 functions as a competing endogenous RNA to regulate cyclin-dependent kinase 1 expression by sponging miR-490-3p in hepatocellular carcinoma progression. lncRNA target hsa-mir-99a Carcinoma, Colon 28130225 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 Cellular Model of Colon Cancer Progression Reveals Signatures of mRNAs, miRNA, lncRNAs, and Epigenetic Modifications Associated with Metastasis. lncRNA target hsa-mir-103 Carcinoma, Endometrial 26511107 reproductive system disease DOID:2871 D07.0 D016889 608089 HP:0012114 In summary, we demonstrate that GAS5 acts as an tumor suppressor lncRNA in endometrial cancer. Through inhibiting the expression of miR-103, GAS5 significantly enhanced the expression of PTEN to promote cancer cell apoptosis,and, thus, could be an important mediator in the pathogenesis of endometrial cancer. lncRNA target hsa-mir-23b Carcinoma, Endometrial 28653877 reproductive system disease DOID:2871 D07.0 D016889 608089 HP:0012114 Long non-coding RNA tumor suppressor candidate 7 advances chemotherapy sensitivity of endometrial carcinoma through targeted silencing of miR-23b. lncRNA target hsa-mir-200c Carcinoma, Endometrioid Endometrial 27693631 C54.1 D018269 Disrupting MALAT1/miR-200c sponge decreases invasion and migration in endometrioid endometrial carcinoma. lncRNA target hsa-mir-204 Carcinoma, Esophageal 27667646 disease of cellular proliferation DOID:1107 C15.9 D004938 133239 HP:0011459 lncRNA-UCA1 enhances cell proliferation through functioning as a ceRNA of Sox4 in esophageal cancer. lncRNA target hsa-mir-9 Carcinoma, Esophageal 28539329 disease of cellular proliferation DOID:1107 C15.9 D004938 133239 HP:0011459 Aberrant Methylation-Mediated Silencing of lncRNA MEG3 Functions as a ceRNA in Esophageal Cancer. lncRNA target hsa-mir-194 Carcinoma, Gallbladder 26803515 disease of cellular proliferation DOID:4948 C23 D005706 overexpression of H19 in GBC-SD cells downregulated miR-194-5p and markedly increased AKT2 expression, and miR-194-5p mimic reversed these effects. lncRNA target hsa-mir-26a Carcinoma, Gallbladder 27345740 disease of cellular proliferation DOID:4948 C23 D005706 Upregulation of MINCR and enhancer of zeste homolog 2 (EZH2) in GBC coincided with the downregulation of miR-26a-5p in GBC. lncRNA target hsa-mir-1297 Carcinoma, Gastric 27651312 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 HOXA11-AS/miR-1297/EZH2 cross-talk serve as critical effectors in gastric cancer tumorigenesis and progression, suggesting new therapeutic directions in gastric cancer lncRNA target hsa-mir-145 Carcinoma, Gastric 28490034 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 Long Noncoding RNA CRNDE Promotes Proliferation of Gastric Cancer Cells by Targeting miR-145. lncRNA target hsa-mir-186 Carcinoma, Gastric 28122299 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 The long noncoding RNA PVT1 functions as a competing endogenous RNA by sponging miR-186 in gastric cancer. lncRNA target hsa-mir-27b Carcinoma, Gastric 27694794 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 Long Non-Coding RNA (LncRNA) Urothelial Carcinoma Associated 1 (UCA1) Increases Multi-Drug Resistance of Gastric Cancer via Downregulating miR-27b. lncRNA target hsa-mir-32 Carcinoma, Gastric 27871067 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 The lncRNA SNHG5/miR-32 axis regulates gastric cancer cell proliferation and migration by targeting KLF4. lncRNA target hsa-mir-335 Carcinoma, Gastric 28618927 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 Long non-coding RNA MSTO2P promotes the proliferation and colony formation in gastric cancer by indirectly regulating miR-335 expression. lncRNA target hsa-mir-10a Carcinoma, Hepatocellular 27002617 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Long non-coding RNA TUSC7 acts a molecular sponge for miR-10a and suppresses EMT in hepatocellular carcinoma. lncRNA target hsa-mir-129 Carcinoma, Hepatocellular 28526689 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Long non-coding RNA NEAT1 promotes hepatocellular carcinoma cell proliferation through the regulation of miR-129-5p-VCP-IκB. lncRNA target hsa-mir-139 Carcinoma, Hepatocellular 28231734 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Long non-coding RNA XIST promotes cell growth by regulating miR-139-5p/PDK1/AKT axis in hepatocellular carcinoma. lncRNA target hsa-mir-140 Carcinoma, Hepatocellular 27597739 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Long non-coding RNA Unigene56159 promotes epithelial-mesenchymal transition by acting as a ceRNA of miR-140-5p in hepatocellular carcinoma cells. lncRNA target hsa-mir-145 Carcinoma, Hepatocellular 29559320 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Long non-coding RNA ROR promotes radioresistance in hepatocelluar carcinoma cells by acting as a ceRNA for microRNA-145 to regulate RAD18 expression lncRNA target hsa-mir-15a Carcinoma, Hepatocellular 28035067 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Long non-coding RNA AK058003, as a precursor of miR-15a, interacts with HuR to inhibit the expression of γ-synuclein in hepatocellular carcinoma cells. lncRNA target hsa-mir-186 Carcinoma, Hepatocellular 28656879 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Long non-coding RNA PVT1 serves as a competing endogenous RNA for miR-186-5p to promote the tumorigenesis and metastasis of hepatocellular carcinoma. lncRNA target hsa-mir-195 Carcinoma, Hepatocellular 27932778 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Expression of Long Non-Coding RNA (lncRNA) Small Nucleolar RNA Host Gene 1 (SNHG1) Exacerbates Hepatocellular Carcinoma Through Suppressing miR-195. lncRNA target hsa-mir-195 Carcinoma, Hepatocellular 28722813 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Knockdown of long non-coding RNA MALAT1 inhibits growth and motility of human hepatoma cells via modulation of miR-195. lncRNA target hsa-mir-19a Carcinoma, Hepatocellular 28724429 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 its pro-metastatic phenotype can partially be attributed to the HOXD-AS1/miR19a/ARHGAP11A signaling axis lncRNA target hsa-mir-200a Carcinoma, Hepatocellular 28403886 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 The long non-coding RNA TP73-AS1 modulates HCC cell proliferation through miR-200a-dependent HMGB1/RAGE regulation. lncRNA target hsa-mir-203 Carcinoma, Hepatocellular 28271214 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Long non-coding RNA UCA1 regulates the expression of Snail2 by miR-203 to promote hepatocellular carcinoma progression. lncRNA target hsa-mir-204 Carcinoma, Hepatocellular 28720061 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 The long non-coding RNA MALAT1 promotes the migration and invasion of hepatocellular carcinoma by sponging miR-204 and releasing SIRT1. lncRNA target hsa-mir-216b Carcinoma, Hepatocellular 25760077 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway. lncRNA target hsa-mir-372 Carcinoma, Hepatocellular 28415780 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Long noncoding RNA PCAT-14 induces proliferation and invasion by hepatocellular carcinoma cells by inducing methylation of miR-372. lncRNA target hsa-mir-374a Carcinoma, Hepatocellular 27065331 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Long noncoding RNA FTX inhibits hepatocellular carcinoma proliferation and metastasis by binding MCM2 and miR-374a. lncRNA target hsa-mir-494 Carcinoma, Hepatocellular 27689326 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells. lncRNA target hsa-mir-513c Carcinoma, Hepatocellular 29574975 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 LncRNA FLVCR1-AS1 acts as miR-513c sponge to modulate cancer cell proliferation, migration, and invasion in hepatocellular carcinoma. lncRNA target hsa-mir-9 Carcinoma, Hepatocellular 28520103 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Circular RNA circMTO1 acts as the sponge of microRNA-9 to suppress hepatocellular carcinoma progression. lncRNA target hsa-mir-200 Carcinoma, Lung 27852821 disease of cellular proliferation DOID:3905 C34.90 D008175 MEG3 regulated the recruitment of JARID2 and EZH2 and histone H3 methylation on the regulatory regions of CDH1 and microRNA-200 family genes for transcriptional repression lncRNA target hsa-mir-206 Carcinoma, Lung 27906963 disease of cellular proliferation DOID:3905 C34.90 D008175 RMRP acted as an oncogene LncRNA to promote the expression of KRAS, FMNL2 and SOX9 by inhibiting miR-206 expression in lung cancer lncRNA target hsa-mir-21 Carcinoma, Lung 29503447 disease of cellular proliferation DOID:3905 C34.90 D008175 We found that LIN28B overexpression significantly increased the number of CD44+/CD326+ tumor cells, upregulated VEGF-A and miR-21 and promoted tumor angiogenesis and epithelial-to-mesenchymal transition (EMT) accompanied by enhanced AKT phosphorylation and nuclear translocation of c-MYC lncRNA target hsa-mir-101 Carcinoma, Lung, Non-Small-Cell 28147312 C34.90 D002289 HP:0030358 Upregulated lncRNA SNHG1 contributes to progression of non-small cell lung cancer through inhibition of miR-101-3p and activation of Wnt/β-catenin signaling pathway. lncRNA target hsa-mir-124 Carcinoma, Lung, Non-Small-Cell 29034803 C34.90 D002289 HP:0030358 LncRNA HOXA11-AS promotes proliferation and invasion by targeting miR-124 in human non-small cell lung cancer cells. lncRNA target hsa-mir-138 Carcinoma, Lung, Non-Small-Cell 28872894 C34.90 D002289 HP:0030358 Knockdown of Long Noncoding RNA Small Nucleolar RNA Host Gene 12 Inhibits Cell Growth and Induces Apoptosis by Upregulating miR-138 in Nonsmall Cell Lung Cancer. lncRNA target hsa-mir-186 Carcinoma, Lung, Non-Small-Cell 28448993 C34.90 D002289 HP:0030358 The Long Non-Coding RNA XIST Controls Non-Small Cell Lung Cancer Proliferation and Invasion by Modulating miR-186-5p. lncRNA target hsa-mir-449a Carcinoma, Lung, Non-Small-Cell 28248928 C34.90 D002289 HP:0030358 The lncRNA XIST exhibits oncogenic properties via regulation of miR-449a and Bcl-2 in human non-small cell lung cancerThis article has been corrected since Advanced Online Publication, and an erratum is also printed in this issue. lncRNA target hsa-let-7a Carcinoma, Nasopharyngeal 28117929 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 Downregulation of lncRNA ANRIL represses tumorigenicity and enhances cisplatin-induced cytotoxicity via regulating microRNA let-7a in nasopharyngeal carcinoma. lncRNA target hsa-mir-134 Carcinoma, Nasopharyngeal 28728844 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 Long non-coding RNA PCAT7 regulates ELF2 signaling through inhibition of miR-134-5p in nasopharyngeal carcinoma. lncRNA target hsa-mir-181a Carcinoma, Nasopharyngeal 28358263 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 LncRNA CCAT1 modulates the sensitivity of paclitaxel in nasopharynx cancers cells via miR-181a/CPEB2 axis. lncRNA target hsa-mir-204 Carcinoma, Nasopharyngeal 27020592 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 The long non-coding RNA NEAT1 regulates epithelial to mesenchymal transition and radioresistance in through miR-204/ZEB1 axis in nasopharyngeal carcinoma. lncRNA target hsa-mir-214 Carcinoma, Nasopharyngeal 28245169 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 Long Noncoding RNA LINC0086 Functions as a Tumor Suppressor in Nasopharyngeal Carcinoma by Targeting miR-214. lncRNA target hsa-mir-34a Carcinoma, Nasopharyngeal 27461945 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 Long non-coding RNA XIST exerts oncogenic functions in human nasopharyngeal carcinoma by targeting miR-34a-5p lncRNA target hsa-mir-145 Carcinoma, Oral 28443494 gastrointestinal system disease DOID:0050610 Expression profiling of long non-coding RNA identifies linc-RoR as a prognostic biomarker in oral cancer. lncRNA target hsa-mir-106b Carcinoma, Ovarian 28864116 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 lncRNA PCA3 may coordinate EOC tumorigenesis through disrupting miR-106b regulated gene expression lncRNA target hsa-mir-373 Carcinoma, Ovarian 27484896 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 LncRNA HOTAIR controls the expression of Rab22a by sponging miR-373 in ovarian cancer. lncRNA target hsa-mir-124 Carcinoma, Pancreatic 27785603 C25.3 C562463 260350 HP:0002894 Linc-ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR-124/PTBP1/PKM2 axis. lncRNA target hsa-mir-133 Carcinoma, Pancreatic 29772434 C25.3 C562463 260350 HP:0002894 The interaction of long non-coding RNA MIAT and miR-133 play a role in the proliferation and metastasis of pancreatic carcinoma. lncRNA target hsa-mir-214 Carcinoma, Pancreatic 28639886 C25.3 C562463 260350 HP:0002894 A competing endogenous RNA network identifies novel mRNA, miRNA and lncRNA markers for the prognosis of diabetic pancreatic cancer. lncRNA target hsa-mir-429 Carcinoma, Pancreatic 28639886 C25.3 C562463 260350 HP:0002894 A competing endogenous RNA network identifies novel mRNA, miRNA and lncRNA markers for the prognosis of diabetic pancreatic cancer. lncRNA target hsa-mir-506 Carcinoma, Pancreatic 27888106 C25.3 C562463 260350 HP:0002894 Long non-coding RNA NEAT1 facilitates pancreatic cancer progression through negative modulation of miR-506-3p. lncRNA target hsa-mir-199a Carcinoma, Prostate 28400279 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 SNHG1 lncRNA negatively regulates miR-199a-3p to enhance CDK7 expression and promote cell proliferation in prostate cancer. lncRNA target hsa-mir-495 Carcinoma, Renal Cell 28466784 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 LncRNA UCA1 promotes renal cell carcinoma proliferation through epigenetically repressing p21 expression and negatively regulating miR-495. lncRNA target hsa-mir-200a Carcinoma, Renal Cell, Clear-Cell 26461224 disease of cellular proliferation DOID:4467 HP:0006770 LncRNA MALAT1 functions as a competing endogenous RNA to regulate ZEB2 expression by sponging miR-200s in clear cell kidney carcinoma. lncRNA target hsa-mir-200b Carcinoma, Renal Cell, Clear-Cell 26461224 disease of cellular proliferation DOID:4467 HP:0006770 LncRNA MALAT1 functions as a competing endogenous RNA to regulate ZEB2 expression by sponging miR-200s in clear cell kidney carcinoma. lncRNA target hsa-mir-200c Carcinoma, Renal Cell, Clear-Cell 26461224 disease of cellular proliferation DOID:4467 HP:0006770 LncRNA MALAT1 functions as a competing endogenous RNA to regulate ZEB2 expression by sponging miR-200s in clear cell kidney carcinoma. lncRNA target hsa-mir-141 Carcinoma, Renal Cell, Clear-Cell 26461224 disease of cellular proliferation DOID:4467 HP:0006770 LncRNA MALAT1 functions as a competing endogenous RNA to regulate ZEB2 expression by sponging miR-200s in clear cell kidney carcinoma. lncRNA target hsa-mir-429 Carcinoma, Renal Cell, Clear-Cell 26461224 disease of cellular proliferation DOID:4467 HP:0006770 LncRNA MALAT1 functions as a competing endogenous RNA to regulate ZEB2 expression by sponging miR-200s in clear cell kidney carcinoma. lncRNA target hsa-mir-181a Carcinoma, Skin 29514220 disease of cellular proliferation DOID:3451 D04.9 D018280 HP:0008069 Long non-coding RNA CASC2 inhibits tumorigenesis via the miR-181a/PLXNC1 axis in melanoma. lncRNA target hsa-mir-214 Carcinoma, Thyroid 28000845 disease of cellular proliferation DOID:3963 C73 D013964 188550 HP:0002890 Long non-coding RNA NEAT1 promotes malignant progression of thyroid carcinoma by regulating miRNA-214. lncRNA target hsa-mir-124 Carcinoma, Tounge 28260102 Long non-coding RNA MALAT1 interacts with miR-124 and modulates tongue cancer growth by targeting JAG1. lncRNA target hsa-mir-21 Cardiac Fibrosis 28526319 LncRNA GAS5 controls cardiac fibroblast activation and fibrosis by targeting miR-21 via PTEN/MMP-2 signaling pathway. lncRNA target hsa-mir-124 Cardiovascular Diseases [unspecific] 29042195 D002318 Circular RNA WDR77 target FGF-2 to regulate vascular smooth muscle cells proliferation and migration by sponging miR-124. lncRNA target hsa-let-7a Cervical Neoplasms 27487126 disease of cellular proliferation DOID:4362 C53.9 D002583 603956 HP:0030159 LncRNA RSU1P2 contributes to tumorigenesis by acting as a ceRNA against let-7a in cervical cancer cells. lncRNA target hsa-mir-145 Cervical Neoplasms 26311052 disease of cellular proliferation DOID:4362 C53.9 D002583 603956 HP:0030159 Long non-coding RNA MALAT1 modulates radiosensitivity of HR-HPV+ cervical cancer via sponging miR-145. lncRNA target hsa-mir-34a Cervical Neoplasms 29218240 disease of cellular proliferation DOID:4362 C53.9 D002583 603956 HP:0030159 The long noncoding RNA LINC00473, a target of microRNA 34a, promotes tumorigenesis by inhibiting ILF2 degradation in cervical cancer lncRNA target hsa-mir-31 Chordoma 28963737 musculoskeletal system disease DOID:3302 C41.0 D002817 215400 HP:0010762 Long non-coding RNA LOC554202 modulates chordoma cell proliferation and invasion by recruiting EZH2 and regulating miR-31 expression. lncRNA target hsa-mir-204 Choriocarcinoma 28059437 disease of cellular proliferation DOID:3594 C58 D002822 HP:0100768 Long Non-Coding RNA MALAT1 Interacts With miR-204 to Modulate Human Hilar Cholangiocarcinoma Proliferation, Migration, and Invasion by Targeting CXCR4. lncRNA target hsa-let-7 Colitis, Ulcerative 29621481 gastrointestinal system disease DOID:8577 K51 D003093 H19 lncRNA bound to p53 and microRNAs that inhibit cell proliferation, including microRNA 34a and let-7; H19 lncRNA binding blocked their function, leading to increased expression of genes that promote regeneration of the epithelium lncRNA target hsa-mir-145 Colon Neoplasms 27071407 D12.6 D003110 HP:0100273 Knockdown of lincRNA-ROR restored the expression of miR-145, and had a significant influence on colon cancer cell proliferation, migration and invasion. lncRNA target hsa-mir-145 Colon Neoplasms 29690669 D12.6 D003110 HP:0100273 LincRNA-ROR functions as a ceRNA to regulate Oct4, Sox2, and Nanog expression by sponging miR-145 and its effect on biologic characteristics of colonic cancer stem cells lncRNA target hsa-mir-21 Colon Neoplasms 28954383 D12.6 D003110 HP:0100273 Long non-coding RNA CASC7 inhibits the proliferation and migration of colon cancer cells via inhibiting microRNA-21. lncRNA target hsa-mir-143 Colorectal Carcinoma 28619512 disease of cellular proliferation DOID:0080199 C19 D015179 114500 PART-1 functions as a competitive endogenous RNA for promoting tumor progression by sponging miR-143 in colorectal cancer. lncRNA target hsa-mir-181a Colorectal Carcinoma 28086904 disease of cellular proliferation DOID:0080199 C19 D015179 114500 The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/β-catenin signaling. lncRNA target hsa-mir-200a Colorectal Carcinoma 28164117 disease of cellular proliferation DOID:0080199 C19 D015179 114500 The lncRNA H19 Promotes Cell Proliferation by Competitively Binding to miR-200a and Derepressing β-Catenin Expression in Colorectal Cancer. lncRNA target hsa-mir-215 Colorectal Carcinoma 29187907 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Long non-coding RNA UICLM promotes colorectal cancer liver metastasis by acting as a ceRNA for microRNA-215 to regulate ZEB2 expression lncRNA target hsa-mir-218 Colorectal Carcinoma 28069878 disease of cellular proliferation DOID:0080199 C19 D015179 114500 the interaction between lncRNA MALAT1 and miR-218 was observed, which further indicated its prognostic value in patients who received standard FOLFOX treatment lncRNA target hsa-mir-92a Coronary Artery Disease 28760552 cardiovascular system disease DOID:3393 I20-I25 D003324 608320 CDKN2B-AS may indirectly regulate coronary artery disease-associated genes via targeting miR-92a. lncRNA target hsa-mir-23c Diabetic Nephropathy 27964927 E10-11.21 D003928 Long noncoding RNA MALAT1 regulates renal tubular epithelial pyroptosis by modulated miR-23c targeting of ELAVL1 in diabetic nephropathy. lncRNA target hsa-mir-27a Diabetic Nephropathy 29334763 E10-11.21 D003928 Long Noncoding RNA LINC01619 Regulates MicroRNA-27a/Forkhead Box Protein O1 and Endoplasmic Reticulum Stress-Mediated Podocyte Injury in Diabetic Nephropathy lncRNA target hsa-mir-29b Diabetic Retinopathy 28246353 nervous system disease DOID:8947 E10-11.31 D003930 Long non-coding RNA MIAT acts as a biomarker in diabetic retinopathy by absorbing miR-29b and regulating cell apoptosis. lncRNA target hsa-mir-320a Embryonal Testis Carcinoma 26539909 disease of cellular proliferation DOID:5680 C62.00 C104948 273300 The accumulation of NLC1-C in the nucleus repressed miR-320a and miR-383 transcript and promoted testicular embryonal carcinoma cell proliferation by binding to Nucleolin. Here, we define a novel mechanism by which lncRNAs modulate miRNA expression at the transcriptional level by binding to RNA-binding proteins to regulate human spermatogenesis. lncRNA target hsa-let-7b Epilepsy 29795132 nervous system disease DOID:1826 G40 D004827 PS601068 HP:0001250 Long non-coding RNA H19 contributes to apoptosis of hippocampal neurons by inhibiting let-7b in a rat model of temporal lobe epilepsy. lncRNA target hsa-mir-770 Gastric Cardia Adenocarcinoma 28345805 disease of cellular proliferation DOID:6271 Promoter hypermethylation-mediated downregulation of miR-770 and its host gene MEG3, a long non-coding RNA, in the development of gastric cardia adenocarcinoma. lncRNA target hsa-mir-107 Gastric Neoplasms 26636340 disease of cellular proliferation DOID:10534 C16 D013274 137215 Our results suggest that the Lin28/miR-107 pathway could be one of many signaling pathways regulated by Lin28 and associated with gastric cancer chemo-resistance. lncRNA target hsa-mir-152 Gastric Neoplasms 26187665 disease of cellular proliferation DOID:10534 C16 D013274 137215 Long non-coding RNA HOTAIR promotes HLA-G expression via inhibiting miR-152 in gastric cancer cells. lncRNA target hsa-mir-200c Gastric Neoplasms 25986864 disease of cellular proliferation DOID:10534 C16 D013274 137215 LncRNA-ATB plays an important role in EMT to promote invasion and metastasis through the TGF-尾/miR-200s/ZEB axis lncRNA target hsa-mir-206 Gastric Neoplasms 27192121 disease of cellular proliferation DOID:10534 C16 D013274 137215 Acting as a miR-206 sponge, RMRP modulated cell cycle by regulating Cyclin D2 expression. lncRNA target hsa-mir-30a Gastric Neoplasms 29761936 disease of cellular proliferation DOID:10534 C16 D013274 137215 upregulated expression of linc00483 in gastric cancer acts as a sponge to absorb endogenous tumour suppressor miR-30a-3p lncRNA target hsa-mir-34a Gastric Neoplasms 29080815 disease of cellular proliferation DOID:10534 C16 D013274 137215 Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a. lncRNA target hsa-mir-675 Gastric Neoplasms 24388988 disease of cellular proliferation DOID:10534 C16 D013274 137215 The long non-coding RNA H19-derived miR-675 modulates human gastric cancer cell proliferation by targeting tumor suppressor RUNX1. lncRNA target hsa-mir-7 Gastric Neoplasms 28608528 disease of cellular proliferation DOID:10534 C16 D013274 137215 Overexpression of Circular RNA ciRS-7 Abrogates the Tumor Suppressive Effect of miR-7 on Gastric Cancer via PTEN/PI3K/AKT Signaling Pathway. lncRNA target hsa-mir-101 Glioblastoma 29479863 D005909 HP:0100843 Long noncoding RNA MALAT1 knockdown reverses chemoresistance to temozolomide via promoting microRNA-101 in glioblastoma lncRNA target hsa-mir-10a Glioblastoma 27270310 D005909 HP:0100843 Long noncoding RNA RP11-838N2.4 enhances the cytotoxic effects of temozolomide by inhibiting the functions of miR-10a in glioblastoma cell lines. lncRNA target hsa-mir-10a Glioblastoma 29397407 D005909 HP:0100843 Long non-coding RNA TUSC7 inhibits temozolomide resistance by targeting miR-10a in glioblastoma lncRNA target hsa-mir-21 Glioblastoma 28423669 D005909 HP:0100843 The novel long non-coding RNA TALNEC2, regulates tumor cell growth and the stemness and radiation response of glioma stem cells. lncRNA target hsa-mir-26a Glioblastoma 28499919 D005909 HP:0100843 Long non-coding RNA AC023115.3 suppresses chemoresistance of glioblastoma by reducing autophagy. lncRNA target hsa-mir-299 Glioblastoma 27345398 D005909 HP:0100843 TUG1 enhances tumor-induced angiogenesis and VEGF expression through inhibiting miR-299. lncRNA target hsa-mir-107 Glioma 27878295 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Silencing of the long non-coding RNA NEAT1 suppresses glioma stem-like properties through modulation of the miR-107/CDK6 pathway. lncRNA target hsa-mir-124 Glioma 29412778 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 TP73-AS1 was specificallyupregulated in brain glioma cell lines and promoted glioma cell growth through targeting miR-124TP73-AS1 was specifically upregulated in brain glioma cell lines and promoted glioma cell growth through targeting miR-124 lncRNA target hsa-mir-139 Glioma 27434586 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 HCP5 regulated the malignant behavior of glioma cells by binding to microRNA-139, which functions as a tumor suppressor. lncRNA target hsa-mir-140 Glioma 27693036 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 The lncRNA H19 interacts with miR-140 to modulate glioma growth by targeting iASPP. lncRNA target hsa-mir-181a Glioma 28121023 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 LncRNA CASC2 Interacts With miR-181a to Modulate Glioma Growth and Resistance to TMZ Through PTEN Pathway. lncRNA target hsa-mir-182 Glioma 28137422 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 The lncRNA UCA1 interacts with miR-182 to modulate glioma proliferation and migration by targeting iASPP. lncRNA target hsa-mir-26a Glioma 27363339 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Long non-coding RNA TUG1 acts as a miR-26a sponge in human glioma cells lncRNA target hsa-mir-373 Glioma 29310118 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Long Non-Coding RNA HOXA-AS2 Regulates Malignant Glioma Behaviors and Vasculogenic Mimicry Formation via the MiR-373/EGFR Axis lncRNA target hsa-mir-384 Glioma 27058823 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Moreover, CRNDE promoted cell malignant behavior by decreasing miR-384 expression. lncRNA target hsa-mir-410 Glioma 27765628 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Long non-coding RNA CCAT1 promotes glioma cell proliferation via inhibiting microRNA-410. lncRNA target hsa-mir-675 Glioma 24466011 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Long non-coding RNA H19 promotes glioma cell invasion by deriving miR-675. lncRNA target hsa-mir-675 Glioma 27981546 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 LncRNA H19 is overexpressed in glioma tissue, is negatively associated with patient survival, and promotes tumor growth through its derivative miR-675. lncRNA target hsa-mir-9 Glioma 29137410 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 LINC00461 knockdown decreased expression levels of microRNA miR-9 and flanking genes MEF2C and TMEM161B lncRNA target hsa-mir-125b Hepatitis B Virus Infection 28267418 disease by infectious agent DOID:2043 B16/18 D006509 610424 MicroRNA-125b-5p mediates post-transcriptional regulation of hepatitis B virus replication via the LIN28B/let-7 axis. lncRNA target hsa-mir-200a Hepatitis C Virus Infection 28302418 disease by infectious agent DOID:1883 B19.2 D006526 609532 LncRNA-ATB/microRNA-200a/β-catenin regulatory axis involved in the progression of HCV-related hepatic fibrosis. lncRNA target hsa-mir-200b Hepatitis C Virus Infection 28302418 disease by infectious agent DOID:1883 B19.2 D006526 609532 LncRNA-ATB/microRNA-200a/β-catenin regulatory axis involved in the progression of HCV-related hepatic fibrosis. lncRNA target hsa-mir-23a Hypoxic-Ischemic Encephalopathy 29428721 P91.60 D020925 GAS5 regulated hippocampal neuron function by sponging miR-23a lncRNA target hsa-mir-125a Immune Thrombocytopenic Purpura 27522004 immune system disease DOID:8924 D69.3 D016553 188030 Long non-coding RNA MEG3 inhibits microRNA-125a-5p expression and induces immune imbalance of Treg/Th17 in immune thrombocytopenic purpura. lncRNA target hsa-mir-34c Inflammatory Bowel Diseases 28153728 gastrointestinal system disease DOID:0050589 D015212 PS266600 HP:0002037 MiR-34c and PlncRNA1 mediated the function of intestinal epithelial barrier by regulating tight junction proteins in inflammatory bowel disease. lncRNA target hsa-mir-124 Invasive Bladder Transitional Cell Carcinoma 29736319 disease of cellular proliferation DOID:6477 C67.9 HP:0006740 LncRNA MALAT1 promotes tumor growth and metastasis by targeting miR-124/foxq1 in bladder transitional cell carcinoma (BTCC). lncRNA target hsa-mir-125b Leukemia 27740626 C95 D007938 613065 HP:0001909 HOTAIRM1 was revealed to act as a microRNA sponge in a pathway that included miR-20a/106b, miR-125b and their targets ULK1, E2F1 and DRAM2 lncRNA target hsa-mir-16 Leukemia 27854515 C95 D007938 613065 HP:0001909 lncRNA UCA1 Contributes to Imatinib Resistance by Acting as a ceRNA Against miR-16 in Chronic Myeloid Leukemia Cells. lncRNA target hsa-mir-21 Leukemia 28190319 C95 D007938 613065 HP:0001909 LncRNA MEG3 Regulates Imatinib Resistance in Chronic Myeloid Leukemia via Suppressing MicroRNA-21. lncRNA target hsa-let-7 Leukemia, Myeloid, Acute 28693523 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 LIN28B/let-7/IGF2BP1, in leukemogenesis and provide a rationale to target this pathway as effective therapeutic strategy lncRNA target hsa-mir-125a Leukemia, Myeloid, Acute 29663500 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 Knockdown of LncRNA-UCA1 suppresses chemoresistance of pediatric AML by inhibiting glycolysis through the microRNA-125a/hexokinase 2 pathway lncRNA target hsa-mir-193a Leukemia, Myeloid, Acute 25979172 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 Long non-coding RNA HOTAIR modulates c-KIT expression through sponging miR-193a in acute myeloid leukemia. lncRNA target hsa-mir-200a Leukemia, Myeloid, Chronic 28069548 disease of cellular proliferation DOID:8552 C92.1 D015464 HP:0005506 HULC could modulate c-Myc and Bcl-2 by miR-200a as an endogenous sponge lncRNA target hsa-mir-181b Liver Cirrhosis 27610008 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 Identification of a Novel lincRNA-p21-miR-181b-PTEN Signaling Cascade in Liver Fibrosis. lncRNA target hsa-mir-29b Liver Cirrhosis 28129115 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 HOTAIR Epigenetically Modulates PTEN Expression via MicroRNA-29b: A Novel Mechanism in Regulation of Liver Fibrosis. lncRNA target hsa-mir-222 Liver Fibrosis 26446789 K74 D008103 GAS5 could directly bind to miR-222. lncRNA target hsa-mir-200c Lung Fibrosis 29113749 respiratory system disease DOID:3770 J84.10 D011658 178500 Long non-coding RNA-ATB promotes EMT during silica-induced pulmonary fibrosis by competitively binding miR-200c. lncRNA target hsa-mir-150 Lung Injury [unspecific] 28655711 S27.309D D055370 Long noncoding RNA FOXD3-AS1 regulates oxidative stress-induced apoptosis via sponging microRNA-150. lncRNA target hsa-let-7g Lung Neoplasms 19745602 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 increased with response to ionizing radiation when knockdown LIN28B lncRNA target hsa-mir-144 Lung Neoplasms 28762326 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Long Noncoding RNA Urothelial Carcinoma Associated 1 Promotes the Proliferation and Metastasis of Human Lung Tumor Cells by Regulating MicroRNA-144. lncRNA target hsa-mir-218 Lung Neoplasms 27212446 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-218 is negatively regulated by CCAT1 in HBE cells exposed to CSE. lncRNA target hsa-mir-873 Lung Neoplasms 29790668 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 The effects of aberrant expression of LncRNA DGCR5/miR-873-5p/TUSC3 in lung cancer cell progression. lncRNA target hsa-let-7 Malignant Neoplasms [unspecific] 28076679 C80.1 D009369 Molecular Dynamics Simulations for Deciphering the Structural Basis of Recognition of Pre-let-7 miRNAs by LIN28. lncRNA target hsa-mir-19b Medulloblastoma 28415684 disease of cellular proliferation DOID:0050902 C71.6 D008527 155255 HP:0002885 The long noncoding RNA linc-NeD125 controls the expression of medulloblastoma driver genes by microRNA sponge activity. lncRNA target hsa-let-7 Melanoma 26071398 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 we discovered that Lin28B, a well-characterized inhibitor of let-7 miRNA biogenesis, was a direct target of miR-125a-5p in melanoma. lncRNA target hsa-mir-183 Melanoma 27966454 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 Deregulation of miR-183 promotes melanoma development via lncRNA MALAT1 regulation and ITGB1 signal activation. lncRNA target hsa-mir-200b Melanoma 28487474 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 Long noncoding RNA HEIH promotes melanoma cell proliferation, migration and invasion via inhibition of miR-200b/a/429. lncRNA target hsa-mir-429 Melanoma 28487474 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 Long noncoding RNA HEIH promotes melanoma cell proliferation, migration and invasion via inhibition of miR-200b/a/429. lncRNA target hsa-mir-507 Melanoma 27389544 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 We found that miR-507 could directly bind to UCA1 at the miRNA recognition site, and that there was a negative correlation between miR-507 and UCA1. lncRNA target hsa-mir-21 Multiple Myeloma 28801664 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 we identified microRNA-21 as a STAT3 target gene with strong anti-apoptotic potential, suggesting that noncoding RNAs have an impact on the pathogenesis of human multiple myeloma lncRNA target hsa-mir-150 Myocardial Infarction 27649667 cardiovascular system disease DOID:5844 I21 D009203 608557 HP:0001658 LncRNA MIAT enhances cardiac hypertrophy partly through sponging miR-150. lncRNA target hsa-mir-150 Myocardial Infarction 28295592 cardiovascular system disease DOID:5844 I21 D009203 608557 HP:0001658 Knockdown of Long Non-Coding RNA-ZFAS1 Protects Cardiomyocytes Against Acute Myocardial Infarction Via Anti-Apoptosis by Regulating miR-150/CRP. lncRNA target hsa-mir-150 Myocardial Infarction 28843520 cardiovascular system disease DOID:5844 I21 D009203 608557 HP:0001658 The long non-coding RNA MIAT regulates zinc finger E-box binding homeobox 1 expression by sponging miR-150 and promoteing cell invasion in non-small-cell lung cancer. lncRNA target hsa-let-7 Neoplasms [unspecific] 26440890 C80.1 D009369 These findings refine the current model of let-7 regulation by LIN28 proteins and have important implications for understanding the LIN28/let-7 axis in development and disease. lncRNA target hsa-let-7 Neoplasms [unspecific] 27548809 C80.1 D009369 We anticipate that much can be learned from the use of this first reported small molecule antagonist of Lin28, including the potential of the Lin28/let-7 interaction as a new drug target for selected cancers lncRNA target hsa-let-7 Neoplasms [unspecific] 28846452 C80.1 D009369 Concise Review: LIN28/let-7 Signaling, a Critical Double-Negative Feedback Loop During Pluripotency, Reprogramming, and Tumorigenicity. lncRNA target hsa-let-7a Neoplasms [unspecific] 21045151 C80.1 D009369 Our data provide evidence that cancer stem cells may arise through a "reprogramming-like" mechanism. A rebalancing of the LIN28/let-7 regulatory loop could be a novel therapeutic strategy to target ALDH1+ cancer stem cells. lncRNA target hsa-let-7a-1 Neoplasms [unspecific] 19211792 C80.1 D009369 let-7a: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation lncRNA target hsa-let-7a-1 Neoplasms [unspecific] 20005451 C80.1 D009369 Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras lncRNA target hsa-let-7a-2 Neoplasms [unspecific] 19211792 C80.1 D009369 let-7a: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation lncRNA target hsa-let-7a-2 Neoplasms [unspecific] 20005451 C80.1 D009369 Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras lncRNA target hsa-let-7a-3 Neoplasms [unspecific] 19211792 C80.1 D009369 let-7a: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation lncRNA target hsa-let-7a-3 Neoplasms [unspecific] 20005451 C80.1 D009369 Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras lncRNA target hsa-let-7b Neoplasms [unspecific] 19211792 C80.1 D009369 let-7b: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation lncRNA target hsa-let-7b Neoplasms [unspecific] 20005451 C80.1 D009369 Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras lncRNA target hsa-let-7b Neoplasms [unspecific] 21045151 C80.1 D009369 Our data provide evidence that cancer stem cells may arise through a "reprogramming-like" mechanism. A rebalancing of the LIN28/let-7 regulatory loop could be a novel therapeutic strategy to target ALDH1+ cancer stem cells. lncRNA target hsa-let-7c Neoplasms [unspecific] 19211792 C80.1 D009369 let-7c: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation lncRNA target hsa-let-7c Neoplasms [unspecific] 20005451 C80.1 D009369 Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras lncRNA target hsa-let-7c Neoplasms [unspecific] 21045151 C80.1 D009369 Our data provide evidence that cancer stem cells may arise through a "reprogramming-like" mechanism. A rebalancing of the LIN28/let-7 regulatory loop could be a novel therapeutic strategy to target ALDH1+ cancer stem cells. lncRNA target hsa-let-7d Neoplasms [unspecific] 19211792 C80.1 D009369 let-7d: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation lncRNA target hsa-let-7d Neoplasms [unspecific] 20005451 C80.1 D009369 Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras lncRNA target hsa-let-7d Neoplasms [unspecific] 21045151 C80.1 D009369 Our data provide evidence that cancer stem cells may arise through a "reprogramming-like" mechanism. A rebalancing of the LIN28/let-7 regulatory loop could be a novel therapeutic strategy to target ALDH1+ cancer stem cells. lncRNA target hsa-let-7e Neoplasms [unspecific] 19211792 C80.1 D009369 let-7e: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation lncRNA target hsa-let-7e Neoplasms [unspecific] 20005451 C80.1 D009369 Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras lncRNA target hsa-let-7e Neoplasms [unspecific] 21045151 C80.1 D009369 Our data provide evidence that cancer stem cells may arise through a "reprogramming-like" mechanism. A rebalancing of the LIN28/let-7 regulatory loop could be a novel therapeutic strategy to target ALDH1+ cancer stem cells. lncRNA target hsa-let-7f Neoplasms [unspecific] 21045151 C80.1 D009369 Our data provide evidence that cancer stem cells may arise through a "reprogramming-like" mechanism. A rebalancing of the LIN28/let-7 regulatory loop could be a novel therapeutic strategy to target ALDH1+ cancer stem cells. lncRNA target hsa-let-7f-1 Neoplasms [unspecific] 19211792 C80.1 D009369 let-7f: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation lncRNA target hsa-let-7f-1 Neoplasms [unspecific] 20005451 C80.1 D009369 Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras lncRNA target hsa-let-7f-2 Neoplasms [unspecific] 19211792 C80.1 D009369 let-7f: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation lncRNA target hsa-let-7f-2 Neoplasms [unspecific] 20005451 C80.1 D009369 Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras lncRNA target hsa-let-7g Neoplasms [unspecific] 19211792 C80.1 D009369 let-7g: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation lncRNA target hsa-let-7g Neoplasms [unspecific] 20005451 C80.1 D009369 Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras lncRNA target hsa-let-7g Neoplasms [unspecific] 21045151 C80.1 D009369 Our data provide evidence that cancer stem cells may arise through a "reprogramming-like" mechanism. A rebalancing of the LIN28/let-7 regulatory loop could be a novel therapeutic strategy to target ALDH1+ cancer stem cells. lncRNA target hsa-let-7i Neoplasms [unspecific] 19211792 C80.1 D009369 let-7i: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation lncRNA target hsa-let-7i Neoplasms [unspecific] 20005451 C80.1 D009369 Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras lncRNA target hsa-let-7i Neoplasms [unspecific] 21045151 C80.1 D009369 Our data provide evidence that cancer stem cells may arise through a "reprogramming-like" mechanism. A rebalancing of the LIN28/let-7 regulatory loop could be a novel therapeutic strategy to target ALDH1+ cancer stem cells. lncRNA target hsa-mir-107 Neoplasms [unspecific] 26158177 C80.1 D009369 Lin28 could mediate cancer chemotherapy resistance via regulation of miR107 and Let-7 MiRNA. lncRNA target hsa-mir-205 Neoplasms [unspecific] 28825698 C80.1 D009369 Functionally the lncRNA-PNUTS serves as a competitive sponge for miR-205 during epithelial-mesenchymal transition (EMT) lncRNA target hsa-mir-20a Neoplasms [unspecific] 28542387 C80.1 D009369 LncRNA-AF113014 promotes the expression of Egr2 by interaction with miR-20a to inhibit proliferation of hepatocellular carcinoma cells. lncRNA target hsa-mir-143 Neuroblastoma 27263970 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 Binding and release of miR-143-3p by LncND control the expression of Notch receptors. lncRNA target hsa-mir-17 Non-Traumatic Osteonecrosis 28207735 M90.5 D010020 Long non-coding RNA HOTAIR inhibits miR-17-5p to regulate osteogenic differentiation and proliferation in non-traumatic osteonecrosis of femoral head. lncRNA target hsa-mir-21 Osteoarthritis 25196583 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 A long non-coding RNA, GAS5, plays a critical role in the regulation of miR-21 during osteoarthritis. lncRNA target hsa-mir-34a Osteoarthritis 27529373 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 Furthermore, we found that UFC1 regulates survival of OA chondrocytes through physically association with miR-34a. lncRNA target hsa-mir-125b Osteosarcoma 28695772 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Circular RNA GLI2 promotes osteosarcoma cell proliferation, migration, and invasion by targeting miR-125b-5p. lncRNA target hsa-mir-129 Osteosarcoma 28346809 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MALAT1 promotes osteosarcoma development by regulation of HMGB1 via miR-142-3p and miR-129-5p. lncRNA target hsa-mir-142 Osteosarcoma 28346809 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MALAT1 promotes osteosarcoma development by regulation of HMGB1 via miR-142-3p and miR-129-5p. lncRNA target hsa-mir-195 Osteosarcoma 27813492 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Long non-coding RNA PVT1 promotes osteosarcoma development by acting as a molecular sponge to regulate miR-195. lncRNA target hsa-mir-21 Osteosarcoma 29323740 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Long non-coding RNA ASBEL promotes osteosarcoma cell proliferation, migration and invasion by regulating microRNA-21 lncRNA target hsa-mir-210 Osteosarcoma 28415557 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 lncRNA CTA is an essential regulator in DOX-induced OS cell apoptosis, and the lncRNA CTA-miR-210 axis plays an important role in reducing OS chemoresistance lncRNA target hsa-mir-221 Osteosarcoma 28519068 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Long Noncoding RNA GAS5 Suppresses Cell Growth and Epithelial-Mesenchymal Transition in Osteosarcoma by Regulating the miR-221/ARHI Pathway. lncRNA target hsa-mir-29c Osteosarcoma 28789596 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 WITHDRAWN: Circular RNA hsa_circ_0001564 facilitates tumorigenesis of osteosarcoma via sponging miR-29c-3p. lncRNA target hsa-mir-34c Osteosarcoma 29654165 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Knockdown of the oncogene LncRNA NEAT1 restores the availability of miR-34c and improves the sensitivity to cisplatin in osteosarcoma lncRNA target hsa-mir-645 Osteosarcoma 27609068 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Long non-coding RNA LINC00161 sensitises osteosarcoma cells to cisplatin-induced apoptosis by regulating the miR-645-IFIT2 axis. lncRNA target hsa-mir-9 Osteosarcoma 27658774 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Long non-coding RNA TUG1 contributes to tumorigenesis of human osteosarcoma by sponging miR-9-5p and regulating POU2F1 expression. lncRNA target hsa-mir-485 Ovarian Neoplasms 26867765 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 UCA1 could function as an endogenous sponge by directly binding to miR-485-5p. lncRNA target hsa-let-7 Pancreatic Neoplasms 28580169 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 linc-ROR functioned as a competing endogenous RNA (ceRNA) to several tumor suppressor microRNAs, particularly some members of let-7 family lncRNA target hsa-mir-145 Pancreatic Neoplasms 26636540 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 ROR functions as a ceRNA to regulate Nanog expression by sponging miR-145 and predicts poor prognosis in pancreatic cancer. lncRNA target hsa-mir-32 Pancreatic Neoplasms 29225772 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Long non-coding RNA GAS5 suppresses pancreatic cancer metastasis through modulating miR-32-5p/PTEN axis lncRNA target hsa-let-7 Perlman Syndrome 23594738 syndrome DOID:0060476 C536399 267000 A role for the Perlman syndrome exonuclease Dis3l2 in the Lin28-let-7 pathway. lncRNA target hsa-mir-146a Prostate Neoplasms 27794184 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 LncRNA PVT1 regulates prostate cancer cell growth by inducing the methylation of miR-146a. lncRNA target hsa-let-7a Retinal Degeneration 20935637 nervous system disease DOID:8466 H35.40 D012162 605670 HP:0000546 The opposing actions of Lin-28 and let-7 miRNAs on Müller glia differentiation and dedifferentiation are similar to that of embryonic stem cells and suggest novel targets for stimulating Müller glia dedifferentiation and retinal regeneration in mammals. lncRNA target hsa-let-7b Retinal Degeneration 20935637 nervous system disease DOID:8466 H35.40 D012162 605670 HP:0000546 The opposing actions of Lin-28 and let-7 miRNAs on Müller glia differentiation and dedifferentiation are similar to that of embryonic stem cells and suggest novel targets for stimulating Müller glia dedifferentiation and retinal regeneration in mammals. lncRNA target hsa-let-7c Retinal Degeneration 20935637 nervous system disease DOID:8466 H35.40 D012162 605670 HP:0000546 The opposing actions of Lin-28 and let-7 miRNAs on Müller glia differentiation and dedifferentiation are similar to that of embryonic stem cells and suggest novel targets for stimulating Müller glia dedifferentiation and retinal regeneration in mammals. lncRNA target hsa-let-7d Retinal Degeneration 20935637 nervous system disease DOID:8466 H35.40 D012162 605670 HP:0000546 The opposing actions of Lin-28 and let-7 miRNAs on Müller glia differentiation and dedifferentiation are similar to that of embryonic stem cells and suggest novel targets for stimulating Müller glia dedifferentiation and retinal regeneration in mammals. lncRNA target hsa-let-7e Retinal Degeneration 20935637 nervous system disease DOID:8466 H35.40 D012162 605670 HP:0000546 The opposing actions of Lin-28 and let-7 miRNAs on Müller glia differentiation and dedifferentiation are similar to that of embryonic stem cells and suggest novel targets for stimulating Müller glia dedifferentiation and retinal regeneration in mammals. lncRNA target hsa-let-7f Retinal Degeneration 20935637 nervous system disease DOID:8466 H35.40 D012162 605670 HP:0000546 The opposing actions of Lin-28 and let-7 miRNAs on Müller glia differentiation and dedifferentiation are similar to that of embryonic stem cells and suggest novel targets for stimulating Müller glia dedifferentiation and retinal regeneration in mammals. lncRNA target hsa-let-7g Retinal Degeneration 20935637 nervous system disease DOID:8466 H35.40 D012162 605670 HP:0000546 The opposing actions of Lin-28 and let-7 miRNAs on Müller glia differentiation and dedifferentiation are similar to that of embryonic stem cells and suggest novel targets for stimulating Müller glia dedifferentiation and retinal regeneration in mammals. lncRNA target hsa-let-7i Retinal Degeneration 20935637 nervous system disease DOID:8466 H35.40 D012162 605670 HP:0000546 The opposing actions of Lin-28 and let-7 miRNAs on Müller glia differentiation and dedifferentiation are similar to that of embryonic stem cells and suggest novel targets for stimulating Müller glia dedifferentiation and retinal regeneration in mammals. lncRNA target hsa-mir-218 Retinoblastoma 28088735 nervous system disease DOID:768 C69.20 D012175 180200 HP:0009919 Long non-coding RNA CCAT1 promotes human retinoblastoma SO-RB50 and Y79 cells through negative regulation of miR-218-5p. lncRNA target hsa-mir-125b Sepsis 29227823 A41.9 D018805 HP:0100806 MALAT1 aggravates cardiac inflammation and dysfunction in sepsis, which is achieved via interaction with miR-125b and p38 MAPK/NFκB lncRNA target hsa-let-7a Squamous Cell Carcinoma, Esophageal 29393461 disease of cellular proliferation DOID:3748 C562729 Lin28/microRNA-let-7a promotes metastasis under circumstances of hyperactive Wnt signaling in esophageal squamous cell carcinoma lncRNA target hsa-mir-200b Squamous Cell Carcinoma, Esophageal 28640252 disease of cellular proliferation DOID:3748 C562729 Long non-coding RNA ATB promotes malignancy of esophageal squamous cell carcinoma by regulating miR-200b/Kindlin-2 axis. lncRNA target hsa-mir-218 Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal 28631575 disease of cellular proliferation DOID:2876 Long non-coding RNA CCAT1/miR-218/ZFX axis modulates the progression of laryngeal squamous cell cancer. lncRNA target hsa-mir-125b Squamous Cell Carcinoma, Oral 28926115 disease of cellular proliferation DOID:0050866 Long non-coding RNA MALAT1 promotes oral squamous cell carcinoma development via microRNA-125b/STAT3 axis. lncRNA target hsa-mir-184 Squamous Cell Carcinoma, Oral 29125238 disease of cellular proliferation DOID:0050866 LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression. lncRNA target hsa-mir-224 Squamous Cell Carcinoma, Oral 28093311 disease of cellular proliferation DOID:0050866 Long non-coding RNA FTH1P3 facilitates oral squamous cell carcinoma progression by acting as a molecular sponge of miR-224-5p to modulate fizzled 5 expression. lncRNA target hsa-mir-21 Stroke, Ischemic 29238035 I63.9 HP:0002140 our data uncovers a novel mechanism of lncRNA MEG3 as a ceRNA by targeting miR-21/PDCD4 signaling pathway in regulating ischemic neuronal death, which may help develop new strategies for the therapeutic interventions in cerebral ischemic stroke lncRNA target hsa-mir-204 Uterine Corpus Endometrial Carcinoma 28280730 disease of cellular proliferation DOID:0050939 Cancer-Related Triplets of mRNA-lncRNA-miRNA Revealed by Integrative Network in Uterine Corpus Endometrial Carcinoma. lncRNA target hsa-mir-320 Uterine Corpus Endometrial Carcinoma 28280730 disease of cellular proliferation DOID:0050939 Cancer-Related Triplets of mRNA-lncRNA-miRNA Revealed by Integrative Network in Uterine Corpus Endometrial Carcinoma. lncRNA target hsa-mir-195 Wilms Tumor 29159834 C64.2 D009396 PS194070 HP:0002667 LINC00473 as an oncogene is up-regulated to participate into the molecular pathogenesis of Wilms tumour via miR-195/IKKα target gene hsa-mir-21 Acute Cerebral Infarction 28389999 cardiovascular system disease DOID:3526 I63 D002544 Effects of microRNA-21 on Nerve Cell Regeneration and Neural Function Recovery in Diabetes Mellitus Combined with Cerebral Infarction Rats by Targeting PDCD4. target gene hsa-mir-491 Acute Cerebral Infarction 23257658 cardiovascular system disease DOID:3526 I63 D002544 A functional polymorphism at miR-491-5p binding site in the 3'-UTR of MMP-9 gene confers increased risk for atherosclerotic cerebral infarction in a Chinese population target gene hsa-mir-15a Acute Coronary Syndrome 24530761 I24.9 D054058 The present study demonstrated that CARM1 targeted by miR-15a played an important role in chemokine activation in the pathogenesis of ACS. target gene hsa-mir-122 Acute Ischemic Stroke 24911610 cardiovascular system disease DOID:224 I63.9 D002546 HP:0002140 Several miRNA are differentially expressed in blood cells of patients with acute ischemic stroke. These miRNA may regulate leukocyte gene expression in ischemic stroke including pathways involved in immune activation,leukocyte extravasation and thrombosis. target gene hsa-mir-148a Acute Ischemic Stroke 24911610 cardiovascular system disease DOID:224 I63.9 D002546 HP:0002140 Several miRNA are differentially expressed in blood cells of patients with acute ischemic stroke. These miRNA may regulate leukocyte gene expression in ischemic stroke including pathways involved in immune activation,leukocyte extravasation and thrombosis. target gene hsa-mir-19a Acute Ischemic Stroke 24911610 cardiovascular system disease DOID:224 I63.9 D002546 HP:0002140 Several miRNA are differentially expressed in blood cells of patients with acute ischemic stroke. These miRNA may regulate leukocyte gene expression in ischemic stroke including pathways involved in immune activation,leukocyte extravasation and thrombosis. target gene hsa-mir-223 Acute Ischemic Stroke 24708646 cardiovascular system disease DOID:224 I63.9 D002546 HP:0002140 Our results suggest that microRNA-223 is associated with acute ischemic stroke and possibly plays a role in stroke through up-regulating growth factor such as insulin-like growth factor-1 gene. target gene hsa-mir-320d Acute Ischemic Stroke 24911610 cardiovascular system disease DOID:224 I63.9 D002546 HP:0002140 Several miRNA are differentially expressed in blood cells of patients with acute ischemic stroke. These miRNA may regulate leukocyte gene expression in ischemic stroke including pathways involved in immune activation,leukocyte extravasation and thrombosis. target gene hsa-mir-4429 Acute Ischemic Stroke 24911610 cardiovascular system disease DOID:224 I63.9 D002546 HP:0002140 Several miRNA are differentially expressed in blood cells of patients with acute ischemic stroke. These miRNA may regulate leukocyte gene expression in ischemic stroke including pathways involved in immune activation,leukocyte extravasation and thrombosis. target gene hsa-mir-487b Acute Ischemic Stroke 24911610 cardiovascular system disease DOID:224 I63.9 D002546 HP:0002140 Several miRNA are differentially expressed in blood cells of patients with acute ischemic stroke. These miRNA may regulate leukocyte gene expression in ischemic stroke including pathways involved in immune activation,leukocyte extravasation and thrombosis. target gene hsa-mir-107 Acute Kidney Failure 28063928 urinary system disease DOID:3021 N17.9 D058186 HP:0001919 MiR-107 induces TNF-α secretion in endothelial cells causing tubular cell injury in patients with septic acute kidney injury. target gene hsa-mir-181a Acute Lung Injury 27802900 S27 D055371 Downregulation of miR-181a protects mice from LPS-induced acute lung injury by targeting Bcl-2. target gene hsa-mir-181b Acute Lung Injury 26622531 S27 D055371 he overexpression of miR-181b resulted in the induction of an increment in interleukin (IL)-6 levels. target gene hsa-mir-125b Acute Megakaryoblastic Leukemia 25571789 disease of cellular proliferation DOID:8761 C94.2 D007947 606078 MiR-125b and miR-99a encoded on chromosome 21 co-regulate vincristine resistance in childhood acute megakaryoblastic leukemia. target gene hsa-mir-99a Acute Megakaryoblastic Leukemia 25571789 disease of cellular proliferation DOID:8761 C94.2 D007947 606078 MiR-125b and miR-99a encoded on chromosome 21 co-regulate vincristine resistance in childhood acute megakaryoblastic leukemia. target gene hsa-mir-106b Acute Myocardial Infarction 28235791 cardiovascular system disease DOID:9408 I21 D056989 608446 HP:0001658 High-throughput screening identifies microRNAs that target Nox2 and improve function after acute myocardial infarction. target gene hsa-mir-148b Acute Myocardial Infarction 28235791 cardiovascular system disease DOID:9408 I21 D056989 608446 HP:0001658 High-throughput screening identifies microRNAs that target Nox2 and improve function after acute myocardial infarction. target gene hsa-mir-204 Acute Myocardial Infarction 28235791 cardiovascular system disease DOID:9408 I21 D056989 608446 HP:0001658 High-throughput screening identifies microRNAs that target Nox2 and improve function after acute myocardial infarction. target gene hsa-mir-34a Acute Myocardial Infarction 23426265 cardiovascular system disease DOID:9408 I21 D056989 608446 HP:0001658 these results identify age-induced expression of miR-34a and inhibition of its target PNUTS as a key mechanism that regulates cardiac contractile function during ageing and after acute myocardial infarction, by inducing DNA damage responses and telomere attrition. target gene hsa-mir-135a Acute Pancreatitis 24710937 endocrine system disease DOID:2913 K85 D019283 167800 HP:0001735 It was concluded that the expression levels of miR-22 and miR-135a were elevated in AEP. Up-regulating the expression of miR-22 and miR-135a may promote the apoptosis of pancreatic acinar cells by repressing ErbB3 and Ptk2 expression in AEP. target gene hsa-mir-22 Acute Pancreatitis 24710937 endocrine system disease DOID:2913 K85 D019283 167800 HP:0001735 It was concluded that the expression levels of miR-22 and miR-135a were elevated in AEP. Up-regulating the expression of miR-22 and miR-135a may promote the apoptosis of pancreatic acinar cells by repressing ErbB3 and Ptk2 expression in AEP. target gene hsa-mir-199a Acute Respiratory Distress Syndrome 29351405 respiratory system disease DOID:11394 J80 D012128 Acute downregulation of miR-199a attenuates sepsis-induced acute lung injury by targeting SIRT1 target gene hsa-mir-18a Adenocarcinoma, Colon 19372139 disease of cellular proliferation DOID:234 C18 HP:0040276 The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras target gene hsa-mir-18a Adenocarcinoma, Colon 28408657 disease of cellular proliferation DOID:234 C18 HP:0040276 Negative Regulation of Human Pregnane X Receptor by MicroRNA-18a-5p: Evidence for Suppression of MicroRNA-18a-5p Expression by Rifampin and Rilpivirine. target gene hsa-mir-223 Adenocarcinoma, Colon 29660302 disease of cellular proliferation DOID:234 C18 HP:0040276 miR-223-RhoB signaling pathway regulates the proliferation and apoptosis of colon adenocarcinoma target gene hsa-mir-145 Adenocarcinoma, Endometrial 21365617 reproductive system disease DOID:2870 C54.1 D018269 608089 HP:0012114 Up-regulation of microRNA-145 promotes differentiation by repressing OCT4 in human endometrial adenocarcinoma cells. target gene hsa-mir-182 Adenocarcinoma, Endometrial 26847831 reproductive system disease DOID:2870 C54.1 D018269 608089 HP:0012114 miR-182 expression is epigenetically increased leading to decreased CUL5 expression and increased cellular proliferation. target gene hsa-mir-200a Adenocarcinoma, Endometrial 24413994 reproductive system disease DOID:2870 C54.1 D018269 608089 HP:0012114 MiR-200a is involved in proliferation and apoptosis in the human endometrial adenocarcinoma cell line HEC-1B by targeting the tumor suppressor PTEN. target gene hsa-mir-196a Adenocarcinoma, Esophageal 19773200 disease of cellular proliferation DOID:4914 C562730 133239 Recent findings include the following: firstly, miRNA expression profiles can distinguish between BE and EAC; secondly, miR-196a is upregulated in EAC tissues targeting annexin A1, thereby exerting antiapoptotic effects and contributing to EAC cell survival target gene hsa-mir-107 Adenocarcinoma, Gastric 25824045 disease of cellular proliferation DOID:3717 D37.1 D013274 miR-107 and miR-25 simultaneously target LATS2 and regulate proliferation and invasion of gastric adenocarcinoma (GAC) cells. target gene hsa-mir-194 Adenocarcinoma, Gastric 25800782 disease of cellular proliferation DOID:3717 D37.1 D013274 We showed evidence that HNF4纬 (upregulated in intestinal metaplasia) is targeted by miR-30 and that miR-194 targets a known co-regulator of HNF4 activity, NR2F2 (downregulated in intestinal metaplasia). target gene hsa-mir-23a Adenocarcinoma, Gastric 23785404 disease of cellular proliferation DOID:3717 D37.1 D013274 miR-23a targets interferon regulatory factor 1 and modulates cellular proliferation and paclitaxel-induced apoptosis in gastric adenocarcinoma cells. target gene hsa-mir-25 Adenocarcinoma, Gastric 25824045 disease of cellular proliferation DOID:3717 D37.1 D013274 miR-107 and miR-25 simultaneously target LATS2 and regulate proliferation and invasion of gastric adenocarcinoma (GAC) cells. target gene hsa-mir-30a Adenocarcinoma, Gastric 25800782 disease of cellular proliferation DOID:3717 D37.1 D013274 We showed evidence that HNF4纬 (upregulated in intestinal metaplasia) is targeted by miR-30 and that miR-194 targets a known co-regulator of HNF4 activity, NR2F2 (downregulated in intestinal metaplasia). target gene hsa-mir-31 Adenocarcinoma, Gastric 28836853 disease of cellular proliferation DOID:3717 D37.1 D013274 MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells. target gene hsa-mir-645 Adenocarcinoma, Gastric-Esophageal Junction 25174799 disease of cellular proliferation DOID:4944 Our data suggest that miR-645 functions as an oncogene in human AGEJ by, at least partially through, targeting IFIT2. target gene hsa-mir-126 Adenocarcinoma, Lung 26035298 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 These DEGs, and DEG-related histone modifications, TFs and miRNAs may be important in the pathogenesis of lung adenocarcinoma. The present results may indicate directions for the next step in the study of the further elucidation and targeted prevention of lung adenocarcinoma. target gene hsa-mir-133 Adenocarcinoma, Lung 25868726 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 Metastasis-associated lung adenocarcinoma transcript 1 (Malat1) regulates serum response factor through miR-133 as a competing endogenous RNA in myogenesis. target gene hsa-mir-134 Adenocarcinoma, Lung 24258346 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells. target gene hsa-mir-135a Adenocarcinoma, Lung 25230140 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 miR-135a inhibition protects A549 cells from LPS-induced apoptosis by targeting Bcl-2. target gene hsa-mir-136 Adenocarcinoma, Lung 25198664 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 miR-136 directly targeted Smad2 and Smad3, leading to reduced migration and invasiveness of lung adenocarcinoma (ADC) cell lines target gene hsa-mir-145 Adenocarcinoma, Lung 24903381 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 MiR-145 regulates cancer stem-like properties and epithelial-to-mesenchymal transition in lung adenocarcinoma-initiating cells. target gene hsa-mir-145 Adenocarcinoma, Lung 28120164 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 MiRNA-145 suppresses lung adenocarcinoma cell invasion and migration by targeting N-cadherin. target gene hsa-mir-15b Adenocarcinoma, Lung 25721211 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 miR-15b regulates cisplatin resistance and metastasis by targeting PEBP4 in human lung adenocarcinoma cells. target gene hsa-mir-16 Adenocarcinoma, Lung 26061016 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 Quercetin Decreases Claudin-2 Expression Mediated by Up-Regulation of microRNA miR-16 in Lung Adenocarcinoma A549 Cells. target gene hsa-mir-182 Adenocarcinoma, Lung 23877371 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 Downregulation of microRNA-182 inhibits cell growth and invasion by targeting programmed cell death 4 in human lung adenocarcinoma cells. target gene hsa-mir-1827 Adenocarcinoma, Lung 29344280 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 MiR-378 and MiR-1827 Regulate Tumor Invasion, Migration and Angiogenesis in Human Lung Adenocarcinoma by Targeting RBX1 and CRKL, Respectively target gene hsa-mir-183 Adenocarcinoma, Lung 26951513 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 overexpression of miR-183 in CSLCs decreased PTPN4 protein levels while inhibition of miR-183 increased PTPN4 protein levels. target gene hsa-mir-200a Adenocarcinoma, Lung 23938385 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 MiR-200a enhances the migrations of A549 and SK-MES-1 cells by regulating the expression of TSPAN1. target gene hsa-mir-202 Adenocarcinoma, Lung 27887846 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 Long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 regulates the expression of Gli2 by miR-202 to strengthen gastric cancer progression. target gene hsa-mir-203 Adenocarcinoma, Lung 27733346 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 Direct interaction between miR-203 and ZEB2 suppresses epithelial-mesenchymal transition signaling and reduces lung adenocarcinoma chemoresistance. target gene hsa-mir-21 Adenocarcinoma, Lung 29663730 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 MiR-21 improves invasion and migration of drug-resistant lung adenocarcinoma cancer cell and transformation of EMT through targeting HBP1 target gene hsa-mir-222 Adenocarcinoma, Lung 28617551 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 MiR-222 promotes proliferation, migration and invasion of lung adenocarcinoma cells by targeting ETS1. target gene hsa-mir-224 Adenocarcinoma, Lung 24921914 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 Our findings shed novel light on the roles of miR-224/p21(WAF1/CIP1) signalling in the DDP resistance of LA cells, and targeting it will be a potential strategic approach for reversing the DDP resistance in human LAs. target gene hsa-mir-23a Adenocarcinoma, Lung 23437179 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 Among them, we confirmed TGF-β-mediated induction of miR-23a in lung epithelial cell lines,target genes of which were further identified by gene expression profiling. target gene hsa-mir-26a Adenocarcinoma, Lung 28000891 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 Expression of miR‑26a exhibits a negative correlation with HMGA1 and regulates cancer progression by targeting HMGA1 in lung adenocarcinoma cells. target gene hsa-mir-26a Adenocarcinoma, Lung 28214878 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2. target gene hsa-mir-27a Adenocarcinoma, Lung 25128483 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 Our results suggest that up-regulation of miR-27a could suppress RKIP expression and in turn contribute to chemoresistance of lung adenocarcinoma cells to cisplatin. target gene hsa-mir-297 Adenocarcinoma, Lung 27554041 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 miR-297 acts as an oncogene by targeting GPC5 in lung adenocarcinoma. target gene hsa-mir-29a Adenocarcinoma, Lung 25171863 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 MicroRNA-29a suppresses the growth, migration, and invasion of lung adenocarcinoma cells by targeting carcinoembryonic antigen-related cell adhesion molecule 6. target gene hsa-mir-29c Adenocarcinoma, Lung 28241836 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 MicroRNA-29c functions as a tumor suppressor by targeting VEGFA in lung adenocarcinoma. target gene hsa-mir-30c-2 Adenocarcinoma, Lung 26035298 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 These DEGs, and DEG-related histone modifications, TFs and miRNAs may be important in the pathogenesis of lung adenocarcinoma. The present results may indicate directions for the next step in the study of the further elucidation and targeted prevention of lung adenocarcinoma. target gene hsa-mir-31 Adenocarcinoma, Lung 27215092 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 MiR-31 Functions as a Tumor Suppressor in Lung Adenocarcinoma Mainly by Targeting HuR. target gene hsa-mir-326 Adenocarcinoma, Lung 26111641 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 Adam17, a Target of Mir-326, Promotes Emt-Induced Cells Invasion in Lung Adenocarcinoma. target gene hsa-mir-378 Adenocarcinoma, Lung 29344280 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 MiR-378 and MiR-1827 Regulate Tumor Invasion, Migration and Angiogenesis in Human Lung Adenocarcinoma by Targeting RBX1 and CRKL, Respectively target gene hsa-mir-3941 Adenocarcinoma, Lung 28012229 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 miR-3941: A novel microRNA that controls IGBP1 expression and is associated with malignant progression of lung adenocarcinoma. target gene hsa-mir-409 Adenocarcinoma, Lung 25278243 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 MiR-409-3p was an independent prognostic factor and functioned as a tumor suppressor in LAD via regulation of Akt signaling by targeting c-Met. target gene hsa-mir-451 Adenocarcinoma, Lung 25310895 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 MicroRNA-451 induces epithelial-mesenchymal transition in docetaxel-resistant lung adenocarcinoma cells by targeting proto-oncogene c-Myc. target gene hsa-mir-483 Adenocarcinoma, Lung 24710410 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 miR-483-5p promotes invasion and metastasis of lung adenocarcinoma by targeting RhoGDI1 and ALCAM. target gene hsa-mir-487b Adenocarcinoma, Lung 24258346 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells. target gene hsa-mir-590 Adenocarcinoma, Lung 28012926 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 miR-590 accelerates lung adenocarcinoma migration and invasion through directly suppressing functional target OLFM4. target gene hsa-mir-620 Adenocarcinoma, Lung 24682381 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 GPC5, a tumor suppressor, is regulated by miR-620 in lung adenocarcinoma. target gene hsa-mir-655 Adenocarcinoma, Lung 24258346 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells. target gene hsa-mir-9 Adenocarcinoma, Lung 23985560 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 microRNA-9 targets the long non-coding RNA MALAT1 for degradation in the nucleus. target gene hsa-let-7d Adenocarcinoma, Pancreatic Ductal 29137251 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 selinexor induced the expression of two important tumor suppressive miRNAs miR-34c and let-7d leading to the up-regulation of p21WAF1 target gene hsa-mir-107 Adenocarcinoma, Pancreatic Ductal 29111166 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 Deregulated expression of miR-107 inhibits metastasis of PDAC through inhibition PI3K/Akt signaling via caveolin-1 and PTEN. target gene hsa-mir-10b Adenocarcinoma, Pancreatic Ductal 24096486 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-β actions. target gene hsa-mir-135a Adenocarcinoma, Pancreatic Ductal 25013381 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 MicroRNA-135a inhibits cell proliferation by targeting Bmi1 in pancreatic ductal adenocarcinoma. target gene hsa-mir-143 Adenocarcinoma, Pancreatic Ductal 28194669 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 MiR-143 Targeting TAK1 Attenuates Pancreatic Ductal Adenocarcinoma Progression via MAPK and NF-κB Pathway In Vitro. target gene hsa-mir-143 Adenocarcinoma, Pancreatic Ductal 23661430 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 SEL1L mRNA expression levels were found to correlate inversely with the expression of hsa-mir-143, hsa-mir-155, and hsa-mir-223 (P < 0.0001, P < 0.0001, and P = 0.002,srespectively). target gene hsa-mir-153 Adenocarcinoma, Pancreatic Ductal 26062664 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 MicroRNA-153 is a prognostic marker and inhibits cell migration and invasion by targeting SNAI1 in human pancreatic ductal adenocarcinoma. target gene hsa-mir-155 Adenocarcinoma, Pancreatic Ductal 23661430 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 Putative tumor suppressor gene SEL1L was downregulated by aberrantly upregulated hsa-mir-155 in human pancreatic ductal adenocarcinoma. target gene hsa-mir-17 Adenocarcinoma, Pancreatic Ductal 28987387 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 MiR-17-5p enhances pancreatic cancer proliferation by altering cell cycle profiles via disruption of RBL2/E2F4-repressing complexes. target gene hsa-mir-181b Adenocarcinoma, Pancreatic Ductal 23440261 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2. target gene hsa-mir-183 Adenocarcinoma, Pancreatic Ductal 25109303 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 MicroRNA-183 is involved in cell proliferation, survival and poor prognosis in pancreatic ductal adenocarcinoma by regulating Bmi-1. target gene hsa-mir-200b Adenocarcinoma, Pancreatic Ductal 19569050 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 regulate EP300, a metastasis suppressor gene; these miRs are related to reduced EP300 mRNA and protein; target gene hsa-mir-200c Adenocarcinoma, Pancreatic Ductal 19569050 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 regulate EP300, a metastasis suppressor gene; these miRs are related to reduced EP300 mRNA and protein; target gene hsa-mir-21 Adenocarcinoma, Pancreatic Ductal 26077422 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 The role of miR-21 and miR-211 on MMP9 regulation in pancreatic ductal adenocarcinoma: cooperation in invasiveness behaviors target gene hsa-mir-21 Adenocarcinoma, Pancreatic Ductal 25846727 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 Our results demonstrate that p85α expression is a determinant of chemosensitivity in PDAC. Additionally, we provide novel evidence that miR-21 can influence PI3K-AKT signaling via its direct regulation of p85α. These data provide insight into potential mechanisms for the known relationship between increased p85α expression and improved survival in PDAC. target gene hsa-mir-21 Adenocarcinoma, Pancreatic Ductal 23991015 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 miR-21 expression in PDAC TAFs is associated with decreased overall survival and promotes TC invasion. Anti-miR-21 may represent a novel therapeutic strategy for dual targeting of both tumor and stroma in PDAC. target gene hsa-mir-211 Adenocarcinoma, Pancreatic Ductal 26077422 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 The role of miR-21 and miR-211 on MMP9 regulation in pancreatic ductal adenocarcinoma: cooperation in invasiveness behaviors target gene hsa-mir-212 Adenocarcinoma, Pancreatic Ductal 24961235 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 These data suggest that miR-212 could facilitate PDAC progression and metastasis through targeting PTCH1, implicating a novel mechanism for the progression of PDAC. target gene hsa-mir-223 Adenocarcinoma, Pancreatic Ductal 23661430 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 SEL1L mRNA expression levels were found to correlate inversely with the expression of hsa-mir-143, hsa-mir-155, and hsa-mir-223 (P < 0.0001, P < 0.0001, and P = 0.002,srespectively). target gene hsa-mir-34c Adenocarcinoma, Pancreatic Ductal 29137251 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 selinexor induced the expression of two important tumor suppressive miRNAs miR-34c and let-7d leading to the up-regulation of p21WAF1 target gene hsa-mir-429 Adenocarcinoma, Pancreatic Ductal 19569050 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 regulate EP300, a metastasis suppressor gene; these miRs are related to reduced EP300 mRNA and protein; target gene hsa-mir-429 Adenocarcinoma, Pancreatic Ductal 25833382 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 Low level of miR-429 and high level of TBK1 in PDAC promoted PDAC cells growth which might be related to the low survival rate of PDAC patients.MiR-429 play its role in PDAC by targeting TBK1. target gene hsa-mir-545 Adenocarcinoma, Pancreatic Ductal 25315416 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 miR-545 inhibited pancreatic ductal adenocarcinoma growth by targeting RIG-I. target gene hsa-mir-940 Adenocarcinoma, Pancreatic Ductal 25766528 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 Low level of miR-940 and high level of MyD88 in PDAC promoted PDAC cells growth which might be related to the low survival rate of PDAC patients.MiR-940 exerted its effect by targeting MyD88. target gene hsa-mir-103 Adenovirus Infection 26000071 B34.0 D000257 miR-103 Regulates Oxidative Stress by Targeting the BCL2/Adenovirus E1B 19kDa Interacting Protein 3 in HUVECs. target gene hsa-mir-150 Adenovirus Infection 22595456 B34.0 D000257 Our study demonstrates that miR-150 regulates surfactant secretion through P2X7R. target gene hsa-mir-27 Adenovirus Infection 28356525 B34.0 D000257 MicroRNA miR-27 Inhibits Adenovirus Infection by Suppressing the Expression of SNAP25 and TXN2. target gene hsa-mir-27a Adenovirus Infection 28356525 B34.0 D000257 MicroRNA miR-27 Inhibits Adenovirus Infection by Suppressing the Expression of SNAP25 and TXN2. target gene hsa-mir-27b Adenovirus Infection 28356525 B34.0 D000257 MicroRNA miR-27 Inhibits Adenovirus Infection by Suppressing the Expression of SNAP25 and TXN2. target gene hsa-mir-466 Adenovirus Infection 25497012 B34.0 D000257 Coxsackie virus and Adenovirus Receptor (CAR), a cellular receptor, was one of the rno-miR-466d targets involved in viral entry. Subsequent experiments also proved that both the rno-miR-466d and the human hsa-miR-466, which are orthologs of the miR-467 gene family, could effectively down-regulate the levels of rat and human CAR protein expression, respectively. target gene hsa-mir-33a Alcoholic Hepatitis 26945479 endocrine system disease DOID:12351 K70.1 D006519 The relative expression of miR-33a and miR-144 correlated inversely with ABCA1 but not with ABCG1 protein levels. target gene hsa-let-7a Allergic Asthma 26253882 immune system disease DOID:9415 J45.909 C564133 600807 miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases. target gene hsa-let-7g Allergic Asthma 24610935 immune system disease DOID:9415 J45.909 C564133 600807 HDM exposure in WT mice and primary lung epithelial cells resulted in striking decreases in let-7g miRNA that were not observed in mice or primary lung epithelial cells lacking JNK1-/- mice. target gene hsa-mir-106a Allergic Asthma 26253882 immune system disease DOID:9415 J45.909 C564133 600807 miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases. target gene hsa-mir-124 Allergic Asthma 26253882 immune system disease DOID:9415 J45.909 C564133 600807 miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases. target gene hsa-mir-126 Allergic Asthma 26253882 immune system disease DOID:9415 J45.909 C564133 600807 miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases. target gene hsa-mir-135 Allergic Asthma 26253882 immune system disease DOID:9415 J45.909 C564133 600807 miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases. target gene hsa-mir-142 Allergic Asthma 26253882 immune system disease DOID:9415 J45.909 C564133 600807 miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases. target gene hsa-mir-143 Allergic Asthma 23965966 immune system disease DOID:9415 J45.909 C564133 600807 It indicates that miR-143 directly targets IL-13Rα1 and suppresses IL-13Rα1 expression in HMC-1 cells. Therefore, miR-143 may be associated with allergic reaction in human mast cells. target gene hsa-mir-145 Allergic Asthma 26253882 immune system disease DOID:9415 J45.909 C564133 600807 miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases. target gene hsa-mir-146 Allergic Asthma 26253882 immune system disease DOID:9415 J45.909 C564133 600807 miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases. target gene hsa-mir-150 Allergic Asthma 26253882 immune system disease DOID:9415 J45.909 C564133 600807 miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases. target gene hsa-mir-155 Allergic Asthma 26253882 immune system disease DOID:9415 J45.909 C564133 600807 miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases. target gene hsa-mir-193 Allergic Asthma 26253882 immune system disease DOID:9415 J45.909 C564133 600807 miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases. target gene hsa-mir-21 Allergic Asthma 26253882 immune system disease DOID:9415 J45.909 C564133 600807 miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases. target gene hsa-mir-221 Allergic Asthma 26253882 immune system disease DOID:9415 J45.909 C564133 600807 miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases. target gene hsa-mir-223 Allergic Asthma 26253882 immune system disease DOID:9415 J45.909 C564133 600807 miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases. target gene hsa-mir-29 Allergic Asthma 26253882 immune system disease DOID:9415 J45.909 C564133 600807 miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases. target gene hsa-mir-365 Allergic Asthma 26253882 immune system disease DOID:9415 J45.909 C564133 600807 miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases. target gene hsa-mir-375 Allergic Asthma 26253882 immune system disease DOID:9415 J45.909 C564133 600807 miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases. target gene hsa-mir-452 Allergic Asthma 26253882 immune system disease DOID:9415 J45.909 C564133 600807 miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases. target gene hsa-mir-615 Allergic Asthma 26253882 immune system disease DOID:9415 J45.909 C564133 600807 miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases. target gene hsa-mir-143 Allergic Rhinitis 25529447 respiratory system disease DOID:4481 J30.9 D065631 607154 HP:0003193 the IL13Rα1 signaling pathway may be a potential target for the prevention and treatment of AR by miR-143. target gene hsa-mir-181a Allergy 25202021 immune system disease DOID:1205 T78.40 D006967 HP:0012393 miR-218 and miR-181a formed a negative feedback loop with TGaseII and regulated the in vitro and in vivo allergic inflammation. target gene hsa-mir-218 Allergy 25202021 immune system disease DOID:1205 T78.40 D006967 HP:0012393 miR-218 and miR-181a formed a negative feedback loop with TGaseII and regulated the in vitro and in vivo allergic inflammation. target gene hsa-mir-100 Alzheimer Disease 25992776 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR. target gene hsa-mir-101 Alzheimer Disease 20395292 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 Thus, miR-101 is a negative regulator of APP expression and affects the accumulation of Abeta, suggesting a possible role for miR-101 in neuropathological conditions. target gene hsa-mir-101 Alzheimer Disease 24592211 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 Importantly, silencing of endogenous RanBP9 reduced sAPP尾 levels in miR-101 sponge-containing hippocampal cultures, indicating that miR-101 inhibition may increase amyloidogenic processing of APP by RanBP9. target gene hsa-mir-101 Alzheimer Disease 28202389 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 Targeting the HDAC2/HNF-4A/miR-101b/AMPK Pathway Rescues Tauopathy and Dendritic Abnormalities in Alzheimer's Disease. target gene hsa-mir-103 Alzheimer Disease 25992776 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR. target gene hsa-mir-103 Alzheimer Disease 27343180 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 miR-103 and miR-107, regulate CDK5R1 expression and affect the levels of p35 target gene hsa-mir-103a-1 Alzheimer Disease 21179570 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 microRNAs 103 and 107 repress translation of cofilin, and that reduced levels of miR-103 or miR-107 are associated with elevated cofilin protein levels and formation of rod-like structures in a transgenic mouse model of AD target gene hsa-mir-103a-2 Alzheimer Disease 21179570 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 microRNAs 103 and 107 repress translation of cofilin, and that reduced levels of miR-103 or miR-107 are associated with elevated cofilin protein levels and formation of rod-like structures in a transgenic mouse model of AD target gene hsa-mir-106b Alzheimer Disease 20709030 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 miR-106b aberrantly expressed in a double transgenic mouse model for Alzheimer's disease targets TGF-β type II receptor. target gene hsa-mir-106b Alzheimer Disease 27520374 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 miR-106b inhibits Aβ1-42-induced tau phosphorylation at Tyr18 by targeting Fyn. target gene hsa-mir-107 Alzheimer Disease 21179570 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 microRNAs 103 and 107 repress translation of cofilin, and that reduced levels of miR-103 or miR-107 are associated with elevated cofilin protein levels and formation of rod-like structures in a transgenic mouse model of AD target gene hsa-mir-124 Alzheimer Disease 26592243 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 our study indicates that miR-124 plays neuroprotective roles in AD Drosophila by targeting Delta in Notch signaling pathway, which helps further our understanding of miRNAs in the molecular pathology of AD. target gene hsa-mir-124 Alzheimer Disease 26984601 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 The activation of EPAC-Rap1 pathway was involved in the inhibition of miR-124 in hippocampus under hypoxia or A尾 insult. target gene hsa-mir-124-1 Alzheimer Disease 22178568 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 The miR-124 regulates the expression of BACE1/-secretase correlated with cell death in Alzheimer's disease. target gene hsa-mir-124-2 Alzheimer Disease 22178568 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 The miR-124 regulates the expression of BACE1/-secretase correlated with cell death in Alzheimer's disease. target gene hsa-mir-124-3 Alzheimer Disease 22178568 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 The miR-124 regulates the expression of BACE1/-secretase correlated with cell death in Alzheimer's disease. target gene hsa-mir-125b Alzheimer Disease 17629564 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 The main finding was that these ROS-generating neurotoxic metal sulfates also up-regulate a specific set of miRNAs that includes miR-9, miR-125b and miR-128. Notably, these same miRNAs are up-regulated in AD brain. target gene hsa-mir-125b-1 Alzheimer Disease 22302353 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 miR-125b and miR-146a regulate Complement Factor H (CFH) in Alzheimer's Disease (AD) Brain. target gene hsa-mir-125b-2 Alzheimer Disease 22302353 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 miR-125b and miR-146a regulate Complement Factor H (CFH) in Alzheimer's Disease (AD) Brain. target gene hsa-mir-132 Alzheimer Disease 24014289 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 miR-132-3p may contribute to disease progression through aberrant regulation of mRNA targets in the Tau network. The transcription factor (TF) FOXO1a appears to be a key target of miR-132-3p in this pathway. target gene hsa-mir-138 Alzheimer Disease 25680531 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 our data suggest that miR-138 promotes tau phosphorylation by targeting the RARA/GSK-3β pathway. target gene hsa-mir-139 Alzheimer Disease 28218780 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 MicroRNA-139 modulates Alzheimer's-associated pathogenesis in SAMP8 mice by targeting cannabinoid receptor type 2. target gene hsa-mir-146a Alzheimer Disease 18801740 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 An NF-kB-sensitive microRNA-146a-mediated inflammatory circuit in Alzheimer's disease and in stressed human brain cells. target gene hsa-mir-146a Alzheimer Disease 22302353 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 miR-125b and miR-146a regulate Complement Factor H (CFH) in Alzheimer's Disease (AD) Brain. target gene hsa-mir-146a Alzheimer Disease 23990414 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 The pathway hsa-miR-146a→STAT1→MYC, which is the source of all nine significantly active pathways, may play an important role in AD progression, which should be further validated by biological experiments target gene hsa-mir-153-1 Alzheimer Disease 22733824 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 MicroRNA-153 physiologically inhibits expression of amyloid-beta precursor protein in cultured human fetal brain cells and is dysregulated in a subset of Alzheimer disease patients. target gene hsa-mir-153-2 Alzheimer Disease 22733824 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 MicroRNA-153 physiologically inhibits expression of amyloid-beta precursor protein in cultured human fetal brain cells and is dysregulated in a subset of Alzheimer disease patients. target gene hsa-mir-181c Alzheimer Disease 21720722 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 Taken together, our study identifies putative target genes of miRNAs miR-9 and 181c, which may function in brain homeostasis and disease pathogenesis. target gene hsa-mir-18a Alzheimer Disease 28956815 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 hsa-mir-18a, having common key targets in the BARHL1-ESR1 network and AD pathway target gene hsa-mir-195 Alzheimer Disease 22721728 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 MicroRNA-195 downregulates Alzheimer's disease amyloid-beta production by targeting BACE1. target gene hsa-mir-21 Alzheimer Disease 25992776 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR. target gene hsa-mir-219 Alzheimer Disease 25992776 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR. target gene hsa-mir-222 Alzheimer Disease 26398571 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 In conclusion, these results suggest that the abnormal expression of miR-222 may contribute to dysregulation of the cell-cycle in AD, at least in part by affecting the expression of p27Kip1. target gene hsa-mir-296 Alzheimer Disease 25992776 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR. target gene hsa-mir-29a Alzheimer Disease 20202123 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 miR-29a decreased in Alzheimer disease brains targets neuron navigator-3 target gene hsa-mir-29c Alzheimer Disease 26212654 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 miR-29c regulates NAV3 protein expression in a transgenic mouse model of Alzheimer's disease. target gene hsa-mir-339 Alzheimer Disease 24352696 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 MicroRNA-339-5p down-regulates protein expression of β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) in human primary brain cultures and is reduced in brain tissue specimens of Alzheimer disease subjects. target gene hsa-mir-34c Alzheimer Disease 26402112 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 MicroRNA-34c Downregulation Ameliorates Amyloid-β-Induced Synaptic Failure and Memory Deficits by Targeting VAMP2. target gene hsa-mir-3622b Alzheimer Disease 25992776 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR. target gene hsa-mir-375 Alzheimer Disease 25992776 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR. target gene hsa-mir-4467 Alzheimer Disease 25992776 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR. target gene hsa-mir-505 Alzheimer Disease 25992776 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR. target gene hsa-mir-511 Alzheimer Disease 27334923 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 miR-511 is a functional regulator of FKBP5 and can contribute to neuronal differentiation. target gene hsa-mir-512 Alzheimer Disease 26258756 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 Reduced miR-512 and the Elevated Expression of Its Targets cFLIP and MCL1 Localize to Neurons With Hyperphosphorylated Tau Protein in Alzheimer Disease. target gene hsa-mir-613 Alzheimer Disease 27545218 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 MicroRNA-613 regulates the expression of brain-derived neurotrophic factor in Alzheimer's disease. target gene hsa-mir-708 Alzheimer Disease 25992776 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR. target gene hsa-mir-766 Alzheimer Disease 25992776 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR. target gene hsa-mir-9 Alzheimer Disease 21720722 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 Taken together, our study identifies putative target genes of miRNAs miR-9 and 181c, which may function in brain homeostasis and disease pathogenesis. target gene hsa-mir-922 Alzheimer Disease 24950120 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 miR-922 increasing the levels of phosphorylated tau by regulating UCHL1 levels contributed to the pathogenesis of AD. Our study partly explained one of the mechanisms underlying the downregulation of UCHL1 levels in AD patients and could enrich the content of tau pathology in the pathogenesis of AD. target gene hsa-mir-92a Alzheimer Disease 28129110 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 the AD-like tau accumulation induces anxiety through disrupting miR92a-vGAT-GABA signaling, which reveals molecular mechanisms underlying the anxiety behavior in AD patients and potentially leads to the development of new therapeutics for tauopathies target gene hsa-mir-98 Alzheimer Disease 27541017 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 miR-98-5p Acts as a Target for Alzheimer's Disease by Regulating Aβ Production Through Modulating SNX6 Expression. target gene hsa-mir-21 Anaplastic Astrocytoma 27347075 disease of cellular proliferation DOID:3078 D001254 PTEN and miR-21 have been observed to form feedback loops. target gene hsa-mir-25 Anaplastic Astrocytoma 27347075 disease of cellular proliferation DOID:3078 D001254 PTEN which is targeted by miR-21 and miR-106b, regulates miR-25 which in turn targets TP53 target gene hsa-mir-329 Angiosarcoma 23878390 disease of cellular proliferation DOID:0001816 C49.9 D006394 HP:0200058 MicroRNA 329 suppresses angiogenesis by targeting CD146. target gene hsa-mir-10b Ankylosing Spondylitis 28039186 musculoskeletal system disease DOID:7147 M45.9 D013167 miR-10b-5p is a novel Th17 regulator present in Th17 cells from ankylosing spondylitis. target gene hsa-mir-124 Ankylosing Spondylitis 25736362 musculoskeletal system disease DOID:7147 M45.9 D013167 Our results suggested that miR-124 might induce autophagy to participate in AS by targeting ANTXR2, which might be implicated in pathological process of AS. target gene hsa-mir-146a Ankylosing Spondylitis 29145150 musculoskeletal system disease DOID:7147 M45.9 D013167 MicroRNA-146a knockdown suppresses the progression of ankylosing spondylitis by targeting dickkopf 1 target gene hsa-mir-19b Antiphospholipid Syndrome 28028298 immune system disease DOID:2988 D68.61 D016736 107320 MicroRNA expression in antiphospholipid syndrome: a systematic review and microRNA target genes analysis. target gene hsa-mir-20a Antiphospholipid Syndrome 28028298 immune system disease DOID:2988 D68.61 D016736 107320 MicroRNA expression in antiphospholipid syndrome: a systematic review and microRNA target genes analysis. target gene hsa-mir-608 Anxiety 24722204 disease of mental health DOID:14320 F41.1 D001007 607834 HP:0000739 Competing targets of microRNA-608 affect anxiety and hypertension. target gene hsa-mir-4717 Anxiety Disorders 25847876 disease of mental health DOID:2030 F41.9 D001008 607834 HP:0000739 data indicate that MIR4717 regulates human RGS2 and contributes to the genetic risk towards anxiety-related traits. target gene hsa-mir-103a Aortic Aneurysm, Abdominal 28357407 cardiovascular system disease DOID:7693 I71.3-.4 D017544 PS100070 Role of MicroRNA-103a Targeting ADAM10 in Abdominal Aortic Aneurysm. target gene hsa-mir-15a Aortic Aneurysm, Abdominal 25993295 cardiovascular system disease DOID:7693 I71.3-.4 D017544 PS100070 Our data emphasize the potential of miR-15a-3p and miR-30a-5p as biomarkers of AAA but also as triggers of ATLO evolution. Further investigations will be required to evaluate their targets in order to better understand AAA pathophysiology. target gene hsa-mir-15a Aortic Aneurysm, Abdominal 28214350 cardiovascular system disease DOID:7693 I71.3-.4 D017544 PS100070 Upregulation of MicroRNA-15a Contributes to Pathogenesis of Abdominal Aortic Aneurysm (AAA) by Modulating the Expression of Cyclin-Dependent Kinase Inhibitor 2B (CDKN2B). target gene hsa-mir-205 Aortic Aneurysm, Abdominal 26781079 cardiovascular system disease DOID:7693 I71.3-.4 D017544 PS100070 a significant downregulation of LRP1 protein expression was shown in miR-205-overexpressing VSMCs target gene hsa-mir-30a Aortic Aneurysm, Abdominal 25993295 cardiovascular system disease DOID:7693 I71.3-.4 D017544 PS100070 Our data emphasize the potential of miR-15a-3p and miR-30a-5p as biomarkers of AAA but also as triggers of ATLO evolution. Further investigations will be required to evaluate their targets in order to better understand AAA pathophysiology. target gene hsa-mir-489 Aortic Aneurysm, Abdominal 25993295 cardiovascular system disease DOID:7693 I71.3-.4 D017544 PS100070 Our data emphasize the potential of miR-15a-3p and miR-30a-5p as biomarkers of AAA but also as triggers of ATLO evolution. Further investigations will be required to evaluate their targets in order to better understand AAA pathophysiology. target gene hsa-mir-98 Aortic Aneurysm, Abdominal 26045772 cardiovascular system disease DOID:7693 I71.3-.4 D017544 PS100070 our data provide compelling evidence on the association between hypoxia and inflammation triggered by hypoxia and then mediated by MCP-1/miR-98/IL-6/p38 regulatory loop, which leads to hASMCs apoptosis via Stat1 activation to contribute to AAA formation and progression. target gene hsa-mir-30b Aortic Insufficiency 23968872 cardiovascular system disease DOID:57 I35.1 D001022 HP:0001659 We demonstrated a remarkable role of miRNA-30b in calcific aortic valve disease as a regulator of human aortic valvular calcification and apoptosis through direct targeting of Runx2, Smad1, and caspase-3. Targeting of miRNA-30b could serve as a novel therapeutic strategy to limit progressive calcification in aortic stenosis. target gene hsa-mir-141 Aortic Stenosis 22336757 cardiovascular system disease DOID:1712 I35.0 D001024 109730 HP:0001650 miRNA-141 is a novel regulator of BMP-2-mediated calcification in aortic stenosis. target gene hsa-mir-181b Aortic Valve Disease 28236165 cardiovascular system disease DOID:62 PS109730 Mechanosensitive microRNA-181b Regulates Aortic Valve Endothelial Matrix Degradation by Targeting TIMP3. target gene hsa-mir-486 Aortic Valve Disease 28377507 cardiovascular system disease DOID:62 PS109730 miR-486 inhibits Smurf2 expression to augment the miR-204 down-regulation target gene hsa-mir-204 Aplastic Anemia 25187411 hematopoietic system disease DOID:12449 D61.9 D000741 609135 HP:0001915 Arsenic trioxide and microRNA-204 display contrary effects on regulating adipogenic and osteogenic differentiation of mesenchymal stem cells in aplastic anemia. target gene hsa-mir-1 Arrhythmia 17516552 I49.9 D001145 600919 HP:0011675 we also designed the microRNA-masking antisense based on the miR-1 and miR-133 target sites in the 3'UTRs of HCN2 and HCN4 and found that these antisense oligodeoxynucleotides markedly enhanced HCN2/HCN4 expression and function, as reflected by increased protein levels of HCN2/HCN4 and If conductance, by removing the repression of HCN2/HCN4 expression induced by endogenous miR-1/miR-133. target gene hsa-mir-1-1 Arrhythmia 19131648 I49.9 D001145 600919 HP:0011675 miR-1 overexpression enhances Ca(2+) release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B56alpha and causing CaMKII-dependent hyperphosphorylation of RyR2 target gene hsa-mir-1-2 Arrhythmia 19131648 I49.9 D001145 600919 HP:0011675 miR-1 overexpression enhances Ca(2+) release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B56alpha and causing CaMKII-dependent hyperphosphorylation of RyR2 target gene hsa-mir-133 Arrhythmia 17516552 I49.9 D001145 600919 HP:0011675 we also designed the microRNA-masking antisense based on the miR-1 and miR-133 target sites in the 3'UTRs of HCN2 and HCN4 and found that these antisense oligodeoxynucleotides markedly enhanced HCN2/HCN4 expression and function, as reflected by increased protein levels of HCN2/HCN4 and If conductance, by removing the repression of HCN2/HCN4 expression induced by endogenous miR-1/miR-133. target gene hsa-mir-133a-1 Arrhythmia 17965831 I49.9 D001145 600919 HP:0011675 miR-133 was shown to inhibit the expression of ERG (ether-a-go-go-related gene) and cause depression of the potassium channel I(Kr). This inhibition contributed to long QT syndrome and arrhythmia in a diabetic rat model. target gene hsa-mir-133a-2 Arrhythmia 17965831 I49.9 D001145 600919 HP:0011675 miR-133 was shown to inhibit the expression of ERG (ether-a-go-go-related gene) and cause depression of the potassium channel I(Kr). This inhibition contributed to long QT syndrome and arrhythmia in a diabetic rat model. target gene hsa-mir-3144 Arrhythmia 28796037 I49.9 D001145 600919 HP:0011675 miR-3144-5p overexpression plays a role in HCMs by regulating these genes and TF target gene hsa-mir-125b Arteriosclerosis Obliterans 25738314 cardiovascular system disease DOID:5160 D001162 HP:0002634 MicroRNA-125b is involved in atherosclerosis obliterans in vitro by targeting podocalyxin. target gene hsa-mir-125b Arteriosclerosis Obliterans 29689557 cardiovascular system disease DOID:5160 D001162 HP:0002634 Exogenous miR-125b expression modulated SRF expression and inhibited vascular neointimal formation in balloon-injured rat carotid arteries target gene hsa-mir-21 Arteriosclerosis Obliterans 27765464 cardiovascular system disease DOID:5160 D001162 HP:0002634 Cigarette smoking represses expression of cytokine IL-12 and its regulator miR-21-An observational study in patients with coronary artery disease. target gene hsa-mir-22 Arteriosclerosis Obliterans 28848136 cardiovascular system disease DOID:5160 D001162 HP:0002634 Our results indicate that miR-22-3p is a key molecule in regulating HASMC proliferation and migration by targeting HMGB1 and that miR-22-3p and HMGB1 may be therapeutic targets in the treatment of human ASO. target gene hsa-mir-31 Arteriosclerosis Obliterans 29403548 cardiovascular system disease DOID:5160 D001162 HP:0002634 MicroRNA-31 promotes arterial smooth muscle cell proliferation and migration by targeting mitofusin-2 in arteriosclerosis obliterans of the lower extremitie target gene hsa-mir-15a Arthritis 19714650 musculoskeletal system disease DOID:848 M19.90 D001168 induction of apoptosis in the synovium of mice,suppresses apoptosis through inhibition of Bcl-2 target gene hsa-mir-15a Arthritis 28877850 musculoskeletal system disease DOID:848 M19.90 D001168 Gabapentin regulates expression of FGF2 and FGFR1 in dorsal root ganglia via microRNA-15a in the arthritis rat model. target gene hsa-mir-151a Asthenozoospermia 26626315 R86.9 D053627 These results indicate that miR-151a-5p may participate in the regulation of cellular respiration and ATP production through targeting Cytb. target gene hsa-mir-27b Asthenozoospermia 25505194 R86.9 D053627 reduced CRISP2 expression in asthenozoospermia, offering a potential therapeutic target for treating male infertility or for male contraception. target gene hsa-mir-145 Asthma 27902892 respiratory system disease DOID:2841 J45 D001249 600807 HP:0002099 MicroRNA-145 influences the balance of Th1/Th2 via regulating RUNX3 in asthma patients. target gene hsa-mir-146a Asthma 29101850 respiratory system disease DOID:2841 J45 D001249 600807 HP:0002099 MicroRNA-146a promotes IgE class switch in B cells via upregulating 14-3-3σ expression. target gene hsa-mir-148a Asthma 23534973 respiratory system disease DOID:2841 J45 D001249 600807 HP:0002099 These combined results are consistent with +3142 allele-specific targeting of HLA-G by the miR-152 family and support our hypothesis that miRNA regulation of sHLA-G in the airway is influenced by both the asthma status of the subject's mother and the subject's genotype. target gene hsa-mir-148b Asthma 23534973 respiratory system disease DOID:2841 J45 D001249 600807 HP:0002099 These combined results are consistent with +3142 allele-specific targeting of HLA-G by the miR-152 family and support our hypothesis that miRNA regulation of sHLA-G in the airway is influenced by both the asthma status of the subject's mother and the subject's genotype. target gene hsa-mir-152 Asthma 23534973 respiratory system disease DOID:2841 J45 D001249 600807 HP:0002099 These combined results are consistent with +3142 allele-specific targeting of HLA-G by the miR-152 family and support our hypothesis that miRNA regulation of sHLA-G in the airway is influenced by both the asthma status of the subject's mother and the subject's genotype. target gene hsa-mir-155 Asthma 26693910 respiratory system disease DOID:2841 J45 D001249 600807 HP:0002099 MicroRNA Expression Is Altered in an Ovalbumin-Induced Asthma Model and Targeting miR-155 with Antagomirs Reveals Cellular Specificity. target gene hsa-mir-15a Asthma 23954351 respiratory system disease DOID:2841 J45 D001249 600807 HP:0002099 Lower levels of hsa-mir-15a, which decreases VEGFA, in the CD4+ T cells of pediatric patients with asthma. target gene hsa-mir-21 Asthma 29334241 respiratory system disease DOID:2841 J45 D001249 600807 HP:0002099 Disordered expression of genes under the regulation of miRNAs may play an important role in CARAS target gene hsa-mir-3162 Asthma 26959414 respiratory system disease DOID:2841 J45 D001249 600807 HP:0002099 MiR-3162-3p Is a Novel MicroRNA That Exacerbates Asthma by Regulating β-Catenin. target gene hsa-mir-92a Asthma 29334241 respiratory system disease DOID:2841 J45 D001249 600807 HP:0002099 Disordered expression of genes under the regulation of miRNAs may play an important role in CARAS target gene hsa-mir-93 Asthma 29334241 respiratory system disease DOID:2841 J45 D001249 600807 HP:0002099 Disordered expression of genes under the regulation of miRNAs may play an important role in CARAS target gene hsa-mir-106a Astrocytoma 24013584 disease of cellular proliferation DOID:3069 C72.9 D001254 155755 HP:0009592 miR-106a-5p functions as a tumor suppressor during the development of astrocytomas by targeting FASTK. target gene hsa-mir-124 Astrocytoma 27088547 disease of cellular proliferation DOID:3069 C72.9 D001254 155755 HP:0009592 We showed that the repression of PIM1 in astrocytoma cancer cells by miR-124-3p suppressed proliferation, invasion, and aerobic glycolysis and promoted apoptosis. target gene hsa-mir-137 Astrocytoma 26440052 disease of cellular proliferation DOID:3069 C72.9 D001254 155755 HP:0009592 miR-137 acts as a tumor suppressor in astrocytoma by targeting RASGRF1. target gene hsa-mir-22 Astrocytoma 27834627 disease of cellular proliferation DOID:3069 C72.9 D001254 155755 HP:0009592 Promotion of astrocytoma cell invasion by micro RNA-22 targeting of tissue inhibitor of matrix metalloproteinase-2. target gene hsa-let-7c Atherosclerosis 22917031 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Our data suggest that let-7c contributes to endothelial apoptosis through suppression of Bcl-xl target gene hsa-let-7g Atherosclerosis 29254143 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Let-7g suppresses both canonical and non-canonical NF-κB pathways in macrophages leading to anti-atherosclerosis target gene hsa-mir-101 Atherosclerosis 26033364 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 miR-101 promotes intracellular cholesterol retention under inflammatory conditions through suppressing ABCA1 expression and suggests that the miR-101-ABCA1 axis may play an intermediary role in the development of NAFLD and vascular atherosclerosis. target gene hsa-mir-103 Atherosclerosis 26837267 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Endothelial Dicer promotes atherosclerosis and vascular inflammation by miRNA-103-mediated suppression of KLF4. target gene hsa-mir-10a Atherosclerosis 20624982 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 miR-10a:miR-10a contributes to the regulation of proinflammatory endothelial phenotypes in athero-susceptible regions in vivo target gene hsa-mir-1185 Atherosclerosis 28441650 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 MicroRNA-1185 Induces Endothelial Cell Apoptosis by Targeting UVRAG and KRIT1. target gene hsa-mir-1185 Atherosclerosis 28441665 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 MicroRNA-1185 Promotes Arterial Stiffness though Modulating VCAM-1 and E-Selectin Expression. target gene hsa-mir-122 Atherosclerosis 23260873 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Several miRNAs have been described to finely regulate lipid metabolism and the progression and regression of atherosclerosis including, miR-33, miR-122. target gene hsa-mir-126 Atherosclerosis 24140891 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Expression of miR-126 was markedly increased and expression of protein targets VCAM-1 and SDF-1 was altered during the course of CKD target gene hsa-mir-126 Atherosclerosis 27993686 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 MicroRNA-126 suppresses inflammation in endothelial cells under hyperglycemic condition by targeting HMGB1. target gene hsa-mir-126 Atherosclerosis 28425867 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 MiR-126 activates the endothelial production of a chemokine CXCL12 via self-multiplying feedback loop to promote re-endothelialization and support lesion stability target gene hsa-mir-133a Atherosclerosis 28257760 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Induction of MiR133a expression by IL-19 targets LDLRAP1 and reduces oxLDL uptake in VSMC. target gene hsa-mir-135b Atherosclerosis 26184978 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 MiR-135b-5p and MiR-499a-3p Promote Cell Proliferation and Migration in Atherosclerosis by Directly Targeting MEF2C. target gene hsa-mir-145 Atherosclerosis 20415654 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 MicroRNAs also regulate smooth muscle cell phenotypes and control neointima formation and atherosclerosis. In this respect, miR-143 and miR-145 have been shown to play a crucial role. target gene hsa-mir-145 Atherosclerosis 21945499 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 We showed that miR-145 can regulate the fate and phenotype of human ES-pre-SMCs as they become fully differentiated SMCs. target gene hsa-mir-145 Atherosclerosis 24140891 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Both vascular smooth muscle-specific miR-143 and miR-145 expressions were decreased in states of atherosclerosis and/or CKD or both, and the expression level of protein target Myocardin was increased. target gene hsa-mir-145 Atherosclerosis 26992033 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 miR-145 modulates the phenotypic switch of VSMCs from a contractile to a proliferative state via KLF5 and MYOCD in atherosclerosis. target gene hsa-mir-145 Atherosclerosis 27731400 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 miRNA-145 inhibits VSMC proliferation by targeting CD40. target gene hsa-mir-145 Atherosclerosis 29324316 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 MicroRNA-145 alleviates high glucose-induced proliferation and migration of vascular smooth muscle cells through targeting ROCK1 target gene hsa-mir-146a Atherosclerosis 25523239 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 miR-146a and miR-21 were significantly upregulated in atherosclerotic plaque, and cooperated to accelerate VSMC growth and cell cycle progression by targeting Notch2 and Jag1. target gene hsa-mir-146a Atherosclerosis 21236257 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Our study clearly revealed that miRNA-146a regulates the maturation process and pro-inflammatory cytokine secretion in DCs by targeting CD40L in ox-LDL-stimulated DCs. target gene hsa-mir-146a Atherosclerosis 23784108 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 MiRNA-146a regulates the maturation and differentiation of vascular smooth muscle cells by targeting NF-κB expression. target gene hsa-mir-146a Atherosclerosis 24022569 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 miR-146a interacted with the 3' untranslated region of the TRAF6 gene, reducing its expression. target gene hsa-mir-150 Atherosclerosis 28110404 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 MicroRNA-150 targets ELK1 and modulates the apoptosis induced by ox-LDL in endothelial cells. target gene hsa-mir-150 Atherosclerosis 29463607 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 the decreases in phosphorylated p65 expression and inflammatory cytokine secretion induced by miR-150 ablation were reversed by PDLIM1 knockdown target gene hsa-mir-152 Atherosclerosis 24813629 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 MiR-152 reduces human umbilical vein endothelial cell proliferation and migration by targeting ADAM17. target gene hsa-mir-155 Atherosclerosis 23041630 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages target gene hsa-mir-155 Atherosclerosis 26159489 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 microRNA-155 works as a promoter in the atherosclerotic procession. Its mechanism may include enhancing inflammatory response in atherosclerosis by increasing STAT3 and NF-κB signaling via targeting SOCS1. target gene hsa-mir-155 Atherosclerosis 24905663 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Regulation of microRNA-155 in endothelial inflammation by targeting nuclear factor (NF)-κB P65. target gene hsa-mir-16 Atherosclerosis 26936421 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 miR鈥?6 is a direct negative regulator of PDCD4 in atherosclerosis. target gene hsa-mir-17 Atherosclerosis 25785043 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 miR-93 and miR-17 repress ABCA1 expression through directly targeting 3'UTR. target gene hsa-mir-181a Atherosclerosis 22956783 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Thus, abundance of miR-181a reduced c-Fos protein, whereas inhibition of miR-181a increased c-Fos protein in BMDCs. We therefore suggest that miR-181a attenuates ox-LDL-stimulated immune inflammation responses by targeting c-Fos in DCs. target gene hsa-mir-182 Atherosclerosis 28855441 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 MicroRNA-182 Promotes Lipoprotein Lipase Expression and Atherogenesisby Targeting Histone Deacetylase 9 in Apolipoprotein E-Knockout Mice. target gene hsa-mir-19a Atherosclerosis 26483345 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Endothelial Hypoxia-Inducible Factor-1α Promotes Atherosclerosis and Monocyte Recruitment by Upregulating MicroRNA-19a. target gene hsa-mir-19b Atherosclerosis 26117405 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Taken together, these results demonstrate that PGC-1α plays a protective role against the vascular complications of atherosclerosis. Moreover, the posttranscriptional regulation of PGC-1α by miR-19b/221/222 was unveiled,which provides a novel mechanism in which a panel of microRNAs can modulate endothelial cell apoptosis via the regulation mitochondrial function. target gene hsa-mir-206 Atherosclerosis 28342807 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Myocardin inhibited the gap protein connexin 43 via promoted miR-206 to regulate vascular smooth muscle cell phenotypic switch. target gene hsa-mir-21 Atherosclerosis 25523239 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 miR-146a and miR-21 were significantly upregulated in atherosclerotic plaque, and cooperated to accelerate VSMC growth and cell cycle progression by targeting Notch2 and Jag1. target gene hsa-mir-21 Atherosclerosis 28460288 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Thrombin-activated platelet-derived exosomes regulate endothelial cell expression of ICAM-1 via microRNA-223 during the thrombosis-inflammation response. target gene hsa-mir-21 Atherosclerosis 28823833 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 MicroRNA-21 suppresses ox-LDL-induced human aortic endothelial cells injuries in atherosclerosis through enhancement of autophagic flux: Involvement in promotion of lysosomal function. target gene hsa-mir-210 Atherosclerosis 28536634 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 MicroRNA-210 induces endothelial cell apoptosis by directly targeting PDK1 in the setting of atherosclerosis. target gene hsa-mir-216a Atherosclerosis 24481443 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 In conclusion, mir-216a controls ox-LDL induced autophagy in HUVECs by regulating intracellular levels of BECN1 and may have a relevant role in the pathogenesis of cardiovascular disorders and atherosclerosis. target gene hsa-mir-221 Atherosclerosis 26117405 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Taken together, these results demonstrate that PGC-1α plays a protective role against the vascular complications of atherosclerosis. Moreover, the posttranscriptional regulation of PGC-1α by miR-19b/221/222 was unveiled,which provides a novel mechanism in which a panel of microRNAs can modulate endothelial cell apoptosis via the regulation mitochondrial function. target gene hsa-mir-222 Atherosclerosis 26117405 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Taken together, these results demonstrate that PGC-1α plays a protective role against the vascular complications of atherosclerosis. Moreover, the posttranscriptional regulation of PGC-1α by miR-19b/221/222 was unveiled,which provides a novel mechanism in which a panel of microRNAs can modulate endothelial cell apoptosis via the regulation mitochondrial function. target gene hsa-mir-223 Atherosclerosis 28460288 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Thrombin-activated platelet-derived exosomes regulate endothelial cell expression of ICAM-1 via microRNA-223 during the thrombosis-inflammation response. target gene hsa-mir-24 Atherosclerosis 29250154 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 MicroRNA-24 inhibits the proliferation and migration of endothelial cells in patients with atherosclerosis by targeting importin-α3 and regulating inflammatory responses target gene hsa-mir-26a Atherosclerosis 25613580 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 The role of miR-26a in atherosclerosis is mediated by its target EphA2 via a mechanism involving the p38 MAPK/VEGF pathway. target gene hsa-mir-26a Atherosclerosis 25801675 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 MicroRNA-26a prevents endothelial cell apoptosis by directly targeting TRPC6 in the setting of atherosclerosis. target gene hsa-mir-27b Atherosclerosis 26520906 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 The results presented here provide evidence that short-term modulation of miR-27b expression in wild-type mice regulates hepatic LDLR and ABCA1 expression but does not influence plasma and hepatic lipid levels. target gene hsa-mir-27b Atherosclerosis 27755984 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 miRNA-27b modulates endothelial cell angiogenesis by directly targeting Naa15 in atherogenesis. target gene hsa-mir-29a Atherosclerosis 26056009 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 our study demonstrates that miR-29a inhibits QKI, which in turn results in upregulation of scavenger receptor A (SRA) and lipid uptake. target gene hsa-mir-30 Atherosclerosis 26488467 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Upregulation of miR-30 by HFD may impair the protective effects of endothelial cell autophagy against development of atherosclerosis through suppressing protein translation of ATG6. target gene hsa-mir-320a Atherosclerosis 25728840 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 MiR-320a contributes to atherogenesis by augmenting multiple risk factors and down-regulating SRF. target gene hsa-mir-33 Atherosclerosis 23260873 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Several miRNAs have been described to finely regulate lipid metabolism and the progression and regression of atherosclerosis including, miR-33, miR-122. target gene hsa-mir-33a Atherosclerosis 24499083 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Dialysis method alters the expression of microRNA-33a and its target genes ABCA1,ABCG1 in THP-1 macrophages. target gene hsa-mir-34a Atherosclerosis 28485501 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 miR-34a Targets HDAC1-Regulated H3K9 Acetylation on Lipid Accumulation Induced by Homocysteine in Foam Cells. target gene hsa-mir-34a Atherosclerosis 28688900 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 MiR-34a/sirtuin-1/foxo3a is involved in genistein protecting against ox-LDL-induced oxidative damage in HUVECs. target gene hsa-mir-365 Atherosclerosis 28051250 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 MiR-365 participates in coronary atherosclerosis through regulating IL-6. target gene hsa-mir-370 Atherosclerosis 29663491 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 miR-370 can reduce inflammatory reaction and inhibit the ROS production by targeting TLR4 in THP-1 cells target gene hsa-mir-490 Atherosclerosis 23821525 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Ox-LDL could inhibit the expression of miR-490-3p and IGF1, whereas increase IGF2 expression. The inhibition of miR0-490-3p up-regulated its target gene PAPP-A and then increased the proteolysis of IGFBP-4. The increased expression of IGF2 and proteolysis of IGFBP-4 might activate pathways independent or dependent on IGF axis by autocrine and paracrine mechanisms and resulted in the VSMC proliferation. Our results could help us to understand the mechanisms of the pro-atherogenic effects of ox-LDL and the effects of PAPP-A on atherosclerosis development. target gene hsa-mir-495 Atherosclerosis 25466836 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 MiR-495 could affect HUVECs proliferation and apoptosis by directly targeting CCL2. This is the first report to disclose the roles and mechanisms of miR-495 on HUVECs proliferation and apoptosis, which may provide a theoretical basis for clarifying the mechanisms of atherosclerosis. target gene hsa-mir-499a Atherosclerosis 26184978 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 MiR-135b-5p and MiR-499a-3p Promote Cell Proliferation and Migration in Atherosclerosis by Directly Targeting MEF2C. target gene hsa-mir-503 Atherosclerosis 27829550 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 miR-503 inhibits platelet-derived growth factor-induced human aortic vascular smooth muscle cell proliferation and migration through targeting the insulin receptor. target gene hsa-mir-590 Atherosclerosis 25149060 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 MiR-590 attenuates lipid accumulation and pro-inflammatory cytokine secretion by targeting LPL gene in human THP-1 macrophages. Therefore, targeting miR-590 may offer a promising strategy to treat atherosclerotic cardiovascular diseases. target gene hsa-mir-712 Atherosclerosis 26308181 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Multifunctional Nanoparticles Facilitate Molecular Targeting and miRNA Delivery to Inhibit Atherosclerosis in ApoE(-/-) Mice. target gene hsa-mir-9 Atherosclerosis 28334721 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 MicroRNA-9 Inhibits NLRP3 Inflammasome Activation in Human Atherosclerosis Inflammation Cell Models through the JAK1/STAT Signaling Pathway. target gene hsa-mir-99a Atherosclerosis 27403035 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 MiR-99a inhibited the LPS-induced HUVECs inflammation via inhibition of the mTOR/NF-魏B signal. target gene hsa-mir-143 Atopic Dermatitis 27048505 integumentary system disease DOID:3310 L20 D003876 PS603165 HP:0001047 The forced expression of microRNA-143 mimic blocked the IL-13-induced downregulation of filaggrin, loricrin, and involucrin in epidermal keratinocytes. target gene hsa-mir-223 Atopic Dermatitis 29506638 integumentary system disease DOID:3310 L20 D003876 PS603165 HP:0001047 miR-223 participates in AD through upregulating HNMT indirectly to degrade the excessive histamine target gene hsa-mir-199a Atrial Fibrillation 26888839 cardiovascular system disease DOID:0060224 I48.0 D001281 PS608583 HP:0005110 miRNAs regulate the occurrence and development of AF. RFA can change the expression of miRNAs in AF patients, which may be important for reversing the electrical and structural remodeling and maintaining sinus rhythm after RFA.miRNAs, such as miR-30b-5p, miR-377-5p and miR-199a-3p/miR-199b-3p etc., might become the target markers for early diagnosis and intervention of AF in future. target gene hsa-mir-199b Atrial Fibrillation 26888839 cardiovascular system disease DOID:0060224 I48.0 D001281 PS608583 HP:0005110 miRNAs regulate the occurrence and development of AF. RFA can change the expression of miRNAs in AF patients, which may be important for reversing the electrical and structural remodeling and maintaining sinus rhythm after RFA.miRNAs, such as miR-30b-5p, miR-377-5p and miR-199a-3p/miR-199b-3p etc., might become the target markers for early diagnosis and intervention of AF in future. target gene hsa-mir-21 Atrial Fibrillation 28495464 cardiovascular system disease DOID:0060224 I48.0 D001281 PS608583 HP:0005110 MicroRNA-21 via Dysregulation of WW Domain-Containing Protein 1 Regulate Atrial Fibrosis in Atrial Fibrillation. target gene hsa-mir-30b Atrial Fibrillation 26888839 cardiovascular system disease DOID:0060224 I48.0 D001281 PS608583 HP:0005110 miRNAs regulate the occurrence and development of AF. RFA can change the expression of miRNAs in AF patients, which may be important for reversing the electrical and structural remodeling and maintaining sinus rhythm after RFA.miRNAs, such as miR-30b-5p, miR-377-5p and miR-199a-3p/miR-199b-3p etc., might become the target markers for early diagnosis and intervention of AF in future. target gene hsa-mir-377 Atrial Fibrillation 26888839 cardiovascular system disease DOID:0060224 I48.0 D001281 PS608583 HP:0005110 miRNAs regulate the occurrence and development of AF. RFA can change the expression of miRNAs in AF patients, which may be important for reversing the electrical and structural remodeling and maintaining sinus rhythm after RFA.miRNAs, such as miR-30b-5p, miR-377-5p and miR-199a-3p/miR-199b-3p etc., might become the target markers for early diagnosis and intervention of AF in future. target gene hsa-mir-132 Autism Spectrum Disorder 25885346 disease of mental health DOID:0060041 F84.0 D000067877 209850 HP:0000729 We found that through p-CREB/miR-132 signaling cascade is involved in MeCP2-mediated pain transduction. target gene hsa-mir-21 Autism Spectrum Disorder 29334241 disease of mental health DOID:0060041 F84.0 D000067877 209850 HP:0000729 Disordered expression of genes under the regulation of miRNAs may play an important role in CARAS target gene hsa-mir-92a Autism Spectrum Disorder 29334241 disease of mental health DOID:0060041 F84.0 D000067877 209850 HP:0000729 Disordered expression of genes under the regulation of miRNAs may play an important role in CARAS target gene hsa-mir-93 Autism Spectrum Disorder 29334241 disease of mental health DOID:0060041 F84.0 D000067877 209850 HP:0000729 Disordered expression of genes under the regulation of miRNAs may play an important role in CARAS target gene hsa-mir-93 Barrett Esophagus 19422085 gastrointestinal system disease DOID:9206 K22.7 D001471 614266 HP:0100580 MiRs-93 and -106b targeted and inhibited p21, whereas miR-25 targeted and inhibited Bim target gene hsa-mir-106b Barrett Esophagus 19422085 gastrointestinal system disease DOID:9206 K22.7 D001471 614266 HP:0100580 MiRs-93 and -106b targeted and inhibited p21, whereas miR-25 targeted and inhibited Bim target gene hsa-mir-25 Barrett Esophagus 19422085 gastrointestinal system disease DOID:9206 K22.7 D001471 614266 HP:0100580 MiRs-93 and -106b targeted and inhibited p21, whereas miR-25 targeted and inhibited Bim target gene hsa-mir-145 Barrett Esophagus 22504665 gastrointestinal system disease DOID:9206 K22.7 D001471 614266 HP:0100580 microRNA-145 in Barrett's oesophagus: regulating BMP4 signalling via GATA6. target gene hsa-mir-21 Barrett Esophagus 20702469 gastrointestinal system disease DOID:9206 K22.7 D001471 614266 HP:0100580 These data support a significant role for PDCD4 downregulation in the progression of BM to BAc, and confirm miR-21 as a negative regulator of PDCD4 in vivo. Further efforts are needed to validate PDCD4 as a potential prognostic marker in patients with Barrett's oesophagus. target gene hsa-mir-223 Barrett Esophagus 23757351 gastrointestinal system disease DOID:9206 K22.7 D001471 614266 HP:0100580 MicroRNA 223 is Up-regulated in the Multistep Progression of Barrett's Esophagus and Modulates Sensitivity to Chemotherapy by Targeting PARP1. target gene hsa-mir-155 Biliary Atresia 28355202 gastrointestinal system disease DOID:13608 Q44.2 D001656 210500 MicroRNA-155 modulates bile duct inflammation by targeting the suppressor of cytokine signaling 1 in biliary atresia. target gene hsa-mir-200b Biliary Atresia 24412919 gastrointestinal system disease DOID:13608 Q44.2 D001656 210500 Up-regulation of miR-200b in biliary atresia patients accelerates proliferation and migration of hepatic stallate cells by activating PI3K/Akt signaling. target gene hsa-mir-222 Biliary Atresia 25238119 gastrointestinal system disease DOID:13608 Q44.2 D001656 210500 Our results show that miR-222 overexpression is common in BA and contributes to LX-2 cell proliferation by targeting protein phosphatase 2A subunit B and Akt signaling. target gene hsa-mir-421 Biliary Tract Neoplasms 22146319 disease of cellular proliferation DOID:0050625 C24.9 D001661 HP:0100574 MicroRNA-421 functions as an oncogenic miRNA in biliary tract cancer through down-regulating farnesoid X receptor expression. target gene hsa-let-7c Bladder Neoplasms 23013190 C67 D001749 109800 HP:0009725 Expression of 5 miRNAs (miR-34a, let-7c, miR-16, miR-103b, and miR-106b) that target p53, Rb, or Bcl-2 protein pathways was determined for bladder samples and cells via quantitative real-time PCR assay. target gene hsa-mir-1 Bladder Neoplasms 20843712 C67 D001749 109800 HP:0009725 Our data indicate that LASP1 may have an oncogenic function and that it might be regulated by miR-1, miR-133a, and miR-218, which may function as tumor suppressive miRNAs in BC. target gene hsa-mir-1 Bladder Neoplasms 22378464 C67 D001749 109800 HP:0009725 Novel molecular targets regulated by tumor suppressors microRNA-1 and microRNA-133a in bladder cancer. target gene hsa-mir-100 Bladder Neoplasms 23778527 C67 D001749 109800 HP:0009725 Hypoxia, in part via suppression of miR-100, induces FGFR3 expression in bladder cancer, both of which have an important role in maintaining cell viability under conditions of stress. target gene hsa-mir-101 Bladder Neoplasms 23618864 C67 D001749 109800 HP:0009725 MicroRNA-101 suppresses motility of bladder cancer cells by targeting c-Met. target gene hsa-mir-103b Bladder Neoplasms 23013190 C67 D001749 109800 HP:0009725 Expression of 5 miRNAs (miR-34a, let-7c, miR-16, miR-103b, and miR-106b) that target p53, Rb, or Bcl-2 protein pathways was determined for bladder samples and cells via quantitative real-time PCR assay. target gene hsa-mir-106b Bladder Neoplasms 23013190 C67 D001749 109800 HP:0009725 Expression of 5 miRNAs (miR-34a, let-7c, miR-16, miR-103b, and miR-106b) that target p53, Rb, or Bcl-2 protein pathways was determined for bladder samples and cells via quantitative real-time PCR assay. target gene hsa-mir-10b Bladder Neoplasms 24573354 C67 D001749 109800 HP:0009725 MicroRNA-10b promotes migration and invasion through KLF4 and HOXD10 in human bladder cancer. target gene hsa-mir-124 Bladder Neoplasms 24180482 C67 D001749 109800 HP:0009725 miR-124-3p can repress the migration and invasion of bladder cancer cells via regulating ROCK1. Our data indicate that miR-124-3p could be a tumor suppressor and may have a potential to be a diagnostics or predictive biomarker in bladder cancer. target gene hsa-mir-124 Bladder Neoplasms 25348738 C67 D001749 109800 HP:0009725 MiR-124 retards bladder cancer growth by directly targeting CDK4. target gene hsa-mir-125b Bladder Neoplasms 24396870 C67 D001749 109800 HP:0009725 Hsa-miR-125b suppresses bladder cancer development by down-regulating oncogene SIRT7 and oncogenic long non-coding RNA MALAT1. target gene hsa-mir-126 Bladder Neoplasms 24823697 C67 D001749 109800 HP:0009725 MicroRNA-126 inhibits invasion in bladder cancer via regulation of ADAM9. target gene hsa-mir-127 Bladder Neoplasms 24004856 C67 D001749 109800 HP:0009725 These findings provide new insights into the role of miRNAs in the pathway of cancer and give us a hypothesis that miR-127 might play a similar rolein regulation and control of PIK3R1. target gene hsa-mir-133a Bladder Neoplasms 20843712 C67 D001749 109800 HP:0009725 Our data indicate that LASP1 may have an oncogenic function and that it might be regulated by miR-1, miR-133a, and miR-218, which may function as tumor suppressive miRNAs in BC. target gene hsa-mir-133a Bladder Neoplasms 22378464 C67 D001749 109800 HP:0009725 Novel molecular targets regulated by tumor suppressors microRNA-1 and microRNA-133a in bladder cancer. target gene hsa-mir-144 Bladder Neoplasms 23815091 C67 D001749 109800 HP:0009725 miR-144 downregulation increases bladder cancer cell proliferation by targeting EZH2 and regulating Wnt signaling. target gene hsa-mir-144 Bladder Neoplasms 26057453 C67 D001749 109800 HP:0009725 miR-144-5p functions as tumour suppressor in BC cells. CCNE1 and CCNE2 were directly regulated by miR-144-5p and might be good prognostic markers for survival of BC patients. target gene hsa-mir-145 Bladder Neoplasms 24999188 C67 D001749 109800 HP:0009725 MicroRNA-145 directly targets the insulin-like growth factor receptor I in human bladder cancer cells. target gene hsa-mir-145 Bladder Neoplasms 29693148 C67 D001749 109800 HP:0009725 microRNA‑145 modulates migration and invasion of bladder cancer cells by targeting N‑cadherin. target gene hsa-mir-145 Bladder Neoplasms 20843712 C67 D001749 109800 HP:0009725 Our data indicate that LASP1 may have an oncogenic function and that it might be regulated by miR-1, miR-133a, and miR-218, which may function as tumor suppressive miRNAs in BC. target gene hsa-mir-16 Bladder Neoplasms 25196524 C67 D001749 109800 HP:0009725 Artesunate induces apoptosis of bladder cancer cells by miR-16 regulation of COX-2 expression. target gene hsa-mir-16 Bladder Neoplasms 23013190 C67 D001749 109800 HP:0009725 Expression of 5 miRNAs (miR-34a, let-7c, miR-16, miR-103b, and miR-106b) that target p53, Rb, or Bcl-2 protein pathways was determined for bladder samples and cells via quantitative real-time PCR assay. target gene hsa-mir-193a Bladder Neoplasms 25311867 C67 D001749 109800 HP:0009725 In addition to a new mechanistic insight, our results provide a set of the essential genes in this newly identified miR-193a-3p/LOXL4/Oxidative Stress axis as the diagnostic targets for a guided anti-bladder cancer chemotherapy. target gene hsa-mir-193a Bladder Neoplasms 25991669 C67 D001749 109800 HP:0009725 The miR-193a-3p-regulated ING5 gene activates the DNA damage response pathway and inhibits multi-chemoresistance in bladder cancer. target gene hsa-mir-193a Bladder Neoplasms 25444900 C67 D001749 109800 HP:0009725 a set of the essential genes in the miR-193a-3p/HOXC9/DNA damage response/oxidative stress pathway axis as the diagnostic targets for the guided anti-bladder cancer chemotherapy. target gene hsa-mir-19a Bladder Neoplasms 24122582 C67 D001749 109800 HP:0009725 Expression of miR-21, miR-19a and miR-222, known to regulate PTEN expression, was also evaluated target gene hsa-mir-203 Bladder Neoplasms 26599571 C67 D001749 109800 HP:0009725 In conclusion, decreased miR-203 predicts progression and poor prognosis for BC patients treated with cisplatin-based chemotherapy while miR-203 overexpression can enhance cisplatin sensitization by promoting apoptosis via directly targeting Bcl-w and Survivin. target gene hsa-mir-206 Bladder Neoplasms 27904673 C67 D001749 109800 HP:0009725 MicroRNA-206 acts as a tumor suppressor in bladder cancer via targeting YRDC. target gene hsa-mir-20b Bladder Neoplasms 26166554 C67 D001749 109800 HP:0009725 MicroRNA-20b inhibits the proliferation, migration and invasion of bladder cancer EJ cells via the targeting of cell cycle regulation and Sp-1-mediated MMP-2 expression. target gene hsa-mir-21 Bladder Neoplasms 26230405 C67 D001749 109800 HP:0009725 microRNA-21 Regulates Cell Proliferation and Migration and Cross Talk with PTEN and p53 in Bladder Cancer. target gene hsa-mir-214 Bladder Neoplasms 25706919 C67 D001749 109800 HP:0009725 MicroRNA-214 suppresses oncogenesis and exerts impact on prognosis by targeting PDRG1 in bladder cancer. target gene hsa-mir-216 Bladder Neoplasms 27578985 C67 D001749 109800 HP:0009725 MiR-126 regulates proliferation and invasion in the bladder cancer BLS cell line by targeting the PIK3R2-mediated PI3K/Akt signaling pathway. target gene hsa-mir-218 Bladder Neoplasms 25967457 C67 D001749 109800 HP:0009725 MicroRNA-218 inhibits bladder cancer cell proliferation, migration, and invasion by targeting BMI-1. target gene hsa-mir-222 Bladder Neoplasms 24122582 C67 D001749 109800 HP:0009725 Expression of miR-21, miR-19a and miR-222, known to regulate PTEN expression, was also evaluated target gene hsa-mir-23b Bladder Neoplasms 23844063 C67 D001749 109800 HP:0009725 MicroRNA-23b functions as a tumor suppressor by regulating Zeb1 in bladder cancer. target gene hsa-mir-24 Bladder Neoplasms 26252200 C67 D001749 109800 HP:0009725 MicroRNA-24 upregulation inhibits proliferation, metastasis and induces apoptosis in bladder cancer cells by targeting CARMA3. target gene hsa-mir-24-1 Bladder Neoplasms 24999187 C67 D001749 109800 HP:0009725 Tumour-suppressive microRNA-24-1 inhibits cancer cell proliferation through targeting FOXM1 in bladder cancer. target gene hsa-mir-26a Bladder Neoplasms 23796420 C67 D001749 109800 HP:0009725 miR-26a inhibits proliferation and motility in bladder cancer by targeting HMGA1. target gene hsa-mir-27a Bladder Neoplasms 25656571 C67 D001749 109800 HP:0009725 rs11671784 G/A variation in miR-27a decreases chemo-sensitivity of bladder cancer by decreasing miR-27a and increasing the target RUNX-1 expression. target gene hsa-mir-29b-1 Bladder Neoplasms 24265332 C67 D001749 109800 HP:0009725 Both miR-29b-1* and miR-29c regulate cell growth in BUC. The targets of miR-29b-1* and miR-29c may be functionally associated with proliferation, cell cycle and apoptosis. target gene hsa-mir-29c Bladder Neoplasms 24265332 C67 D001749 109800 HP:0009725 Both miR-29b-1* and miR-29c regulate cell growth in BUC. The targets of miR-29b-1* and miR-29c may be functionally associated with proliferation, cell cycle and apoptosis. target gene hsa-mir-320a Bladder Neoplasms 24443232 C67 D001749 109800 HP:0009725 MiR-320a down-regulation mediates bladder carcinoma invasion by targeting ITGB3. target gene hsa-mir-34a Bladder Neoplasms 25878394 C67 D001749 109800 HP:0009725 miR-34a inhibits proliferation and invasion of bladder cancer cells by targeting orphan nuclear receptor HNF4G. target gene hsa-mir-34a Bladder Neoplasms 26198939 C67 D001749 109800 HP:0009725 MicroRNA-34a regulates cell cycle by targeting CD44 in human bladder carcinoma cells. target gene hsa-mir-34a Bladder Neoplasms 23013190 C67 D001749 109800 HP:0009725 Expression of 5 miRNAs (miR-34a, let-7c, miR-16, miR-103b, and miR-106b) that target p53, Rb, or Bcl-2 protein pathways was determined for bladder samples and cells via quantitative real-time PCR assay. target gene hsa-mir-409 Bladder Neoplasms 23820886 C67 D001749 109800 HP:0009725 MicroRNA-409-3p inhibits migration and invasion of bladder cancer cells via targeting c-Met. target gene hsa-mir-490 Bladder Neoplasms 24220339 C67 D001749 109800 HP:0009725 MicroRNA-490-5p inhibits proliferation of bladder cancer by targeting c-Fos. target gene hsa-mir-576 Bladder Neoplasms 25556372 C67 D001749 109800 HP:0009725 miR-576-3p might be a novel suppressor of bladder cancer cell proliferation through targeting cyclin D1. target gene hsa-mir-9 Bladder Neoplasms 26150338 C67 D001749 109800 HP:0009725 miR-9 promotes cell proliferation and inhibits apoptosis by targeting LASS2 in bladder cancer. target gene hsa-mir-96 Bladder Neoplasms 29467898 C67 D001749 109800 HP:0009725 HERG1 was an important target of miR-96 target gene hsa-mir-127 Bone Cancer 28866093 musculoskeletal system disease DOID:184 C79.51 D001859 MiR-127 and miR-376a act as tumor suppressors by in vivo targeting of COA1 and PDIA6 in giant cell tumor of bone. target gene hsa-mir-376a Bone Cancer 28866093 musculoskeletal system disease DOID:184 C79.51 D001859 MiR-127 and miR-376a act as tumor suppressors by in vivo targeting of COA1 and PDIA6 in giant cell tumor of bone. target gene hsa-mir-214 Bone Disease [unspecific] 28109866 musculoskeletal system disease DOID:0080001 M89.9 D001847 miR-214 suppresses osteogenesis by targeting BIRC7, providing a possible therapeutic target for bone degenerative diseases target gene hsa-mir-221 Bone Disease [unspecific] 26062554 musculoskeletal system disease DOID:0080001 M89.9 D001847 Intercellular adhesion molecule-1 was upregulated by microRNA-221 in mesenchymal stem cells because microRNAs are key regulators of various biological functions via gene expression. target gene hsa-mir-93 Bone Disease [unspecific] 28186136 musculoskeletal system disease DOID:0080001 M89.9 D001847 FOXO1-suppressed miR-424 regulates the proliferation and osteogenic differentiation of MSCs by targeting FGF2 under oxidative stress. target gene hsa-mir-128 Borjeson-Forssman-Lehmann Syndrome 25556700 disease of mental health DOID:0050681 C536575 301900 miR-128 regulates neuronal migration, outgrowth and intrinsic excitability via the intellectual disability gene Phf6. target gene hsa-mir-21 Brain Neoplasms 17965831 disease of cellular proliferation DOID:1319 C71 D001932 603688 HP:0030692 The overexpression of miR-21 was recognized in malignant brain tumours, and knockdown of this miRNA in cultured glioblastoma cells resulted in caspase activation and apoptosis. The tumour suppressor tropomyosin 1 (TPM1) was demonstrated to be a target for miR-21, explaining why inhibition of miR-21 results in reduced tumour growth. target gene hsa-mir-296 Brain Neoplasms 18977327 disease of cellular proliferation DOID:1319 C71 D001932 603688 HP:0030692 Growth factor-induced miR-296 contributes significantly to angiogenesis by directly targeting the hepatocyte growth factor-regulated tyrosine kinase substrate (HGS) mRNA, leading to decreased levels of HGS and thereby reducing HGS-mediated degradation of the growth factor receptors VEGFR2 and PDGFRbeta. target gene hsa-mir-7 Brain Neoplasms 29016934 disease of cellular proliferation DOID:1319 C71 D001932 603688 HP:0030692 microRNA-7 upregulates death receptor 5 and primes resistant brain tumors to caspase-mediated apoptosis. target gene hsa-mir-143 Breast Adenocarcinoma 28511343 thoracic disease DOID:3458 Restoration of miR-143 expression could inhibit migration and growth of MDA-MB-468 cells through down-regulating the expression of invasion-related factors. target gene hsa-let-7a Breast Neoplasms 26460550 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our research revealed the mechanisms through which miR-208a functioned in breast cancer and BrCSCs, and identified the miR-208a-SOX2/β-catenin-LIN28-let-7a-DICER1 regulatory feedback loop in regulations of stem cells renewal. target gene hsa-let-7a Breast Neoplasms 27345399 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 let-7a and let-7b mimics attenuated p62-mediated MYC mRNA stabilization target gene hsa-let-7a-1 Breast Neoplasms 22251626 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA let-7a suppresses breast cancer cell migration and invasion through downregulation of C-C chemokine receptor type 7. target gene hsa-let-7a-2 Breast Neoplasms 22251626 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA let-7a suppresses breast cancer cell migration and invasion through downregulation of C-C chemokine receptor type 7. target gene hsa-let-7a-3 Breast Neoplasms 22251626 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA let-7a suppresses breast cancer cell migration and invasion through downregulation of C-C chemokine receptor type 7. target gene hsa-let-7b Breast Neoplasms 27345399 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 let-7a and let-7b mimics attenuated p62-mediated MYC mRNA stabilization target gene hsa-let-7c Breast Neoplasms 28731186 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Let-7c-5p inhibits cell proliferation and induces cell apoptosis by targeting ERCC6 in breast cancer target gene hsa-let-7f-1 Breast Neoplasms 22407818 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1. target gene hsa-mir-1 Breast Neoplasms 28159933 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Tumor suppressor miR-1 inhibits tumor growth and metastasis by simultaneously targeting multiple genes. target gene hsa-mir-100 Breast Neoplasms 26130569 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The role of miR-100 in regulating apoptosis of breast cancer cells. target gene hsa-mir-100 Breast Neoplasms 21634028 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 micro-RNA 100 Regulated beta-tubulin isotypes in MCF7 breast cancer cells. target gene hsa-mir-100 Breast Neoplasms 22926517 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-100 suppresses IGF2 and inhibits breast tumorigenesis by interfering with proliferation and survival signaling. target gene hsa-mir-101 Breast Neoplasms 26927545 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-101 inhibits the proliferation and migration of breast cancer cells via downregulating the expression of DNA methyltransferase 3a. target gene hsa-mir-101-1 Breast Neoplasms 23071542 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiR-101 is involved in human breast carcinogenesis by targeting Stathmin1 target gene hsa-mir-101-2 Breast Neoplasms 23071542 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiR-101 is involved in human breast carcinogenesis by targeting Stathmin1 target gene hsa-mir-106a Breast Neoplasms 21765466 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The experimental results using MDA-MB-231 and MCF-7 human breast cancer cells confirm that miRNAs derived from these clusters, containing miR-17-5p, miR-20a, miR-106a, miR-106b and miR-93, negatively regulate ZBTB4 expression. target gene hsa-mir-106b Breast Neoplasms 24270410 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The miR-106b~25 cluster promotes bypass of doxorubicin-induced senescence and increase in motility and invasion by targeting the E-cadherin transcriptional activator EP300. target gene hsa-mir-106b Breast Neoplasms 22286770 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The miR-106b-25 cluster targets Smad7, activates TGF-beta signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer. target gene hsa-mir-106b Breast Neoplasms 28518139 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiR-106b and miR-93 regulate cell progression by suppression of PTEN via PI3K/Akt pathway in breast cancer. target gene hsa-mir-106b Breast Neoplasms 21765466 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The experimental results using MDA-MB-231 and MCF-7 human breast cancer cells confirm that miRNAs derived from these clusters, containing miR-17-5p, miR-20a, miR-106a, miR-106b and miR-93, negatively regulate ZBTB4 expression. target gene hsa-mir-107 Breast Neoplasms 21841313 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-107 promotes tumor progression by targeting the let-7 microRNA in mice and humans. target gene hsa-mir-10a Breast Neoplasms 19232136 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-10a: miR-10a inhibits transcriptional of Hoxd4 target gene hsa-mir-10b Breast Neoplasms 23839045 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The locus of microRNA-10b: a critical target for breast cancer insurgence and dissemination target gene hsa-mir-10b Breast Neoplasms 26359455 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Combining miR-10b-Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer. target gene hsa-mir-10b Breast Neoplasms 26392359 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our work provides evidence for the involvement of specific miRNAs in triple-negative breast cancer development through regulating BRCA1 expression. target gene hsa-mir-10b Breast Neoplasms 22573479 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Targeting of syndecan-1 by microRNA miR-10b promotes breast cancer cell motility and invasiveness via a Rho-GTPase- and E-cadherin-dependent mechanism. target gene hsa-mir-10b Breast Neoplasms 22847191 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-10b targets E-cadherin and modulates breast cancer metastasis. target gene hsa-mir-122 Breast Neoplasms 25318895 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The association of the expression of miR-122-5p and its target ADAM10 with human breast cancer. target gene hsa-mir-122 Breast Neoplasms 23056576 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiR-122 inhibits cell proliferation and tumorigenesis of breast cancer by targeting IGF1R target gene hsa-mir-1225 Breast Neoplasms 25961594 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 our study demonstrates that HIPK2-kinase and the PLCXD1-phospholipase-C are novel targets of miR-193a-5p/miR-210-3p and miR-575/miR-1225-5p, respectively. target gene hsa-mir-124 Breast Neoplasms 23816858 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-124 plays a critical role in inhibiting the invasive and metastatic potential of breast cancer cells, probably by directly targeting the CD151 genes. Our findings highlight an important role of miR-124 in the regulation of invasion and metastasis by breast cancer cells and suggest a potential application for miR-124 in breast cancer treatment. target gene hsa-mir-124 Breast Neoplasms 24330780 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our study demonstrated that miR-124 might be a tumor suppressor in breast cancer via the regulation of FLOT1. This microRNA could serve as a potential diagnostic marker and therapeutic target for breast cancer. target gene hsa-mir-124 Breast Neoplasms 25085587 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-124 inhibits cellular proliferation and invasion by targeting Ets-1 in breast cancer. target gene hsa-mir-124 Breast Neoplasms 27468577 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Decreased miR-124-3p Expression Prompted Breast Cancer Cell Progression Mainly by Targeting Beclin-1. target gene hsa-mir-124 Breast Neoplasms 27842510 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-124-3p functions as a tumor suppressor in breast cancer by targeting CBL. target gene hsa-mir-124-1 Breast Neoplasms 22085528 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-124 suppresses multiple steps of breast cancer metastasis by targeting a cohort of pro-metastatic genes in vitro. target gene hsa-mir-124-1 Breast Neoplasms 22333974 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-124, miR-147 and miR-193a-3p are three novel tumor suppressors that co-target EGFR-driven cell-cycle network proteins and inhibit cell-cycle progression and proliferation in breast cancer. target gene hsa-mir-124-1 Breast Neoplasms 23250910 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiR-124 targets Slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer target gene hsa-mir-124-2 Breast Neoplasms 22085528 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-124 suppresses multiple steps of breast cancer metastasis by targeting a cohort of pro-metastatic genes in vitro. target gene hsa-mir-124-2 Breast Neoplasms 22333974 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-124, miR-147 and miR-193a-3p are three novel tumor suppressors that co-target EGFR-driven cell-cycle network proteins and inhibit cell-cycle progression and proliferation in breast cancer. target gene hsa-mir-124-2 Breast Neoplasms 23250910 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiR-124 targets Slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer target gene hsa-mir-124-3 Breast Neoplasms 22085528 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-124 suppresses multiple steps of breast cancer metastasis by targeting a cohort of pro-metastatic genes in vitro. target gene hsa-mir-124-3 Breast Neoplasms 22333974 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-124, miR-147 and miR-193a-3p are three novel tumor suppressors that co-target EGFR-driven cell-cycle network proteins and inhibit cell-cycle progression and proliferation in breast cancer. target gene hsa-mir-124-3 Breast Neoplasms 23250910 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiR-124 targets Slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer target gene hsa-mir-1245a Breast Neoplasms 22158906 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Upregulation of miR-1245 by c-myc targets BRCA2 and impairs DNA repair. target gene hsa-mir-1245b Breast Neoplasms 22158906 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Upregulation of miR-1245 by c-myc targets BRCA2 and impairs DNA repair. target gene hsa-mir-125a Breast Neoplasms 25961594 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 our study demonstrates that HIPK2-kinase and the PLCXD1-phospholipase-C are novel targets of miR-193a-5p/miR-210-3p and miR-575/miR-1225-5p, respectively. target gene hsa-mir-125a Breast Neoplasms 25962054 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-125a influences breast cancer stem cells by targeting leukemia inhibitory factor receptor which regulates the Hippo signaling pathway. target gene hsa-mir-125a Breast Neoplasms 19875930 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-125a represses cell growth by targeting HuR in breast cancer target gene hsa-mir-125a Breast Neoplasms 25504437 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 serum miR-125a-5p level in breast cancer may be a useful prognostic biomarker and offer a novel therapeutic avenue by targeting HDAC4 in breast cancer. target gene hsa-mir-125b Breast Neoplasms 26531722 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-125a-5p/miR-125b suppress the expression of TSTA3 target gene hsa-mir-125b Breast Neoplasms 29434858 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-125b regulates the drug-resistance of breast cancer cells to doxorubicin by targeting HAX-1 target gene hsa-mir-125b Breast Neoplasms 19570947 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 In conclusion, this study clearly demonstrates that miR-125b post-transcriptionally regulates the CYP24, which serves as a possible mechanism for the high CYP24 expression in cancer tissues. target gene hsa-mir-125b Breast Neoplasms 19825990 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Thus, the short hairpin-looped ODN-Raf, targeting the same region of c-raf-1 as miR-125b, is a multifunctional molecule reducing the expression of oncoproteins and stimulating cell death. Both features may be useful to interfere with tumor growth. target gene hsa-mir-125b-1 Breast Neoplasms 19738052 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 hsa-mir-125b binding site in BMPR1B is Associated with Breast cancer pathogenesis target gene hsa-mir-125b-1 Breast Neoplasms 20460378 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-125b:MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression target gene hsa-mir-125b-1 Breast Neoplasms 21444677 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-125b is Methylated and Functions as A Tumor Suppressor by Regulating the ETS1 proto-oncogene in Human Invasive Breast Cancer. target gene hsa-mir-125b-1 Breast Neoplasms 22307404 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-125b targets ARID3B in breast cancer cells. target gene hsa-mir-125b-1 Breast Neoplasms 22693547 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-125b induces metastasis by targeting STARD13 in MCF-7 and MDA-MB-231 breast cancer cells. target gene hsa-mir-125b-2 Breast Neoplasms 19738052 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 hsa-mir-125b binding site in BMPR1B is Associated with Breast cancer pathogenesis target gene hsa-mir-125b-2 Breast Neoplasms 20460378 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-125b:MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression target gene hsa-mir-125b-2 Breast Neoplasms 21444677 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-125b is Methylated and Functions as A Tumor Suppressor by Regulating the ETS1 proto-oncogene in Human Invasive Breast Cancer. target gene hsa-mir-125b-2 Breast Neoplasms 22307404 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-125b targets ARID3B in breast cancer cells. target gene hsa-mir-125b-2 Breast Neoplasms 22693547 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-125b induces metastasis by targeting STARD13 in MCF-7 and MDA-MB-231 breast cancer cells. target gene hsa-mir-126 Breast Neoplasms 26261534 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Thus, our study revealed that miR-126 may act as a tumor suppressor via inhibition of cell invasion by downregulating ADAM9 in breast cancer development. target gene hsa-mir-126 Breast Neoplasms 21249429 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Endothelial-specific intron-derived miR-126 is down-regulated in human breast cancer and targets both VEGFA and PIK3R2. target gene hsa-mir-127 Breast Neoplasms 21343399 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Analyses of miRNA expression profiles identified numerous miRNAs implicated in cell proliferation including miR-127, -197, -222, and -223 targeting CXCL12. target gene hsa-mir-128 Breast Neoplasms 27341528 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 AurkA suppressed the expression of miR-128 target gene hsa-mir-128-1 Breast Neoplasms 21953503 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. target gene hsa-mir-128-1 Breast Neoplasms 23526655 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Downregulation of miRNA-128 sensitizes breast cancer cell to chemodrugs by targeting Bax target gene hsa-mir-128-2 Breast Neoplasms 23526655 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Downregulation of miRNA-128 sensitizes breast cancer cell to chemodrugs by targeting Bax target gene hsa-mir-129 Breast Neoplasms 26720492 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The miR-129-5p/HMGB1 axis can regulate irradiation-induced autophagy in breast cancer and might be an important pathway in regulating radiosensitivity of breast cancer cells. target gene hsa-mir-1290 Breast Neoplasms 25528056 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-1290 directly targets the NAT1 3'-UTR and that NAT1 protein expression is correlated with improved OS of breast cancer patients. NAT1 is a possible prognostic biomarker for lymph node-positive breast cancer. Thus, miR-1290 and its target NAT1 are associated with important characteristics of breast cancer. target gene hsa-mir-1290 Breast Neoplasms 23183268 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiR-1290 and its potential targets are associated with characteristics of estrogen receptor alpha-positive breast cancer target gene hsa-mir-130a Breast Neoplasms 25755726 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-130a inhibits cell proliferation, invasion and migration in human breast cancer by targeting the RAB5A. target gene hsa-mir-132 Breast Neoplasms 25450365 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 a critical role of miR-132 in prohibiting cell proliferation, invasion, migration and metastasis in breast cancer through direct suppression of HN1, supporting the potential utility of miR-132 as a novel therapeutic strategy against breast cancer. target gene hsa-mir-133a Breast Neoplasms 23786162 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 microRNA-133a regulates the cell cycle and proliferation of breast cancer cells by targeting epidermal growth factor receptor through the EGFR/Akt signaling pathway. target gene hsa-mir-133b Breast Neoplasms 24935473 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Correlations of common polymorphism of EVI-1 gene targeted by miRNA-206/133b with the pathogenesis of breast cancer. target gene hsa-mir-134 Breast Neoplasms 26318721 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-134 modulates resistance to doxorubicin in breast cancer cells by downregulating the expression of ABCC1 which is known to encode the multidrug resistance-associated protein 1. target gene hsa-mir-135a-1 Breast Neoplasms 22439757 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miRNA-135a promotes breast cancer cell migration and invasion by targeting HOXA10. target gene hsa-mir-135a-2 Breast Neoplasms 22439757 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miRNA-135a promotes breast cancer cell migration and invasion by targeting HOXA10. target gene hsa-mir-135b Breast Neoplasms 23623609 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-135b coordinates progression of ErbB2-driven mammary carcinomas through suppression of MID1 and MTCH2. target gene hsa-mir-137 Breast Neoplasms 22723937 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiR-137 targets estrogen-related receptor alpha and impairs the proliferative and migratory capacity of breast cancer cells. target gene hsa-mir-137 Breast Neoplasms 28407692 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-137 inhibits BMP7 to enhance the epithelial-mesenchymal transition of breast cancer cells. target gene hsa-mir-138 Breast Neoplasms 27155849 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Only 8 APOBEC3B targeting miRNAs were observed to regulate the fusion transcript of which miR-34b-3p and miR-138-5p were found to be frequently downregulated in cancers suggesting miRNA-mediated deregulation of APOBEC3A expression in cancer patients harbouring this particular deletion polymorphism. target gene hsa-mir-139 Breast Neoplasms 26079880 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-139 suppresses proliferation in luminal type breast cancer cells by targeting Topoisomerase II alpha. target gene hsa-mir-139 Breast Neoplasms 26299922 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiR-139-5p not only attenuated the development of breast cancer cells but also mediated drug-resistance by regulating the expression of the downstream target gene Notch1. target gene hsa-mir-141 Breast Neoplasms 25813250 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-141 confers docetaxel chemoresistance of breast cancer cells via regulation of EIF4E expression. target gene hsa-mir-141 Breast Neoplasms 18376396 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. target gene hsa-mir-142 Breast Neoplasms 25406066 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 in some tumors, miR-142 regulates the properties of BCSCs at least in part by activating the WNT signaling pathway and miR-150 expression. target gene hsa-mir-143 Breast Neoplasms 25248370 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Taken together, our findings provide the first clues regarding the role of the miR-143/145 cluster as a tumor suppressor in breast cancer through the inhibition of ERBB3 translation. These results also support the idea that different miRNAs in a cluster can synergistically repress a given target mRNA. target gene hsa-mir-143 Breast Neoplasms 22354042 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. target gene hsa-mir-143 Breast Neoplasms 28559978 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-143-3p targeting LIM domain kinase 1 suppresses the progression of triple-negative breast cancer cells. target gene hsa-mir-145 Breast Neoplasms 25248370 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Taken together, our findings provide the first clues regarding the role of the miR-143/145 cluster as a tumor suppressor in breast cancer through the inhibition of ERBB3 translation. These results also support the idea that different miRNAs in a cluster can synergistically repress a given target mRNA. target gene hsa-mir-145 Breast Neoplasms 25253741 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 lincRNA-RoR and miR-145 regulate invasion in triple negative breast cancer via targeting ARF6. target gene hsa-mir-145 Breast Neoplasms 25450545 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 the expression of an miRNA 145 target protein, c-myc, was determined by Western blotting after intracellular delivery of PSMT/miRNA 145 nanoparticle (NP). target gene hsa-mir-145 Breast Neoplasms 22592534 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF. target gene hsa-mir-145 Breast Neoplasms 23049906 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiR-145 regulates epithelial to mesenchymal transition of breast cancer cells by targeting Oct4 target gene hsa-mir-145 Breast Neoplasms 29565493 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiR-145 affects breast cancer BS524 cell proliferation, infiltration, and migration via positively regulating OCT4 gene expression target gene hsa-mir-145 Breast Neoplasms 19360360 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-145 inhibits breast cancer cell growth through RTKN. target gene hsa-mir-146 Breast Neoplasms 28128741 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-146a and miR-146-5p silencing BRCA1 may trigger formation of triple-negative and basal-like sporadic BC cases target gene hsa-mir-146a Breast Neoplasms 26392359 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our work provides evidence for the involvement of specific miRNAs in triple-negative breast cancer development through regulating BRCA1 expression. target gene hsa-mir-146a Breast Neoplasms 27175941 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 invasion activity in MDA-MB-231 breast cancer cells could be directly influenced by altering miR-146a expression. target gene hsa-mir-147a Breast Neoplasms 22333974 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-124, miR-147 and miR-193a-3p are three novel tumor suppressors that co-target EGFR-driven cell-cycle network proteins and inhibit cell-cycle progression and proliferation in breast cancer. target gene hsa-mir-148a Breast Neoplasms 22935141 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Overexpression of miR-148a or miR-152 significantly inhibits BC cell proliferation, colony formation and tumor angiogenesis via targeting IGF-IR and IRS1 and suppressing their downstream AKT and MAPK/ERK signaling pathways. target gene hsa-mir-148a Breast Neoplasms 28430743 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-148a promotes apoptosis and suppresses growth of breast cancer cells by targeting B-cell lymphoma 2. target gene hsa-mir-148b Breast Neoplasms 23233531 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR148b is a major coordinator of breast cancer progression in a relapse-associated microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS,and CSF1 target gene hsa-mir-149 Breast Neoplasms 24608434 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-149 targets GIT1 to suppress integrin signaling and breast cancer metastasis. target gene hsa-mir-150 Breast Neoplasms 24312495 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-150 promotes human breast cancer growth and malignant behavior by targeting the pro-apoptotic purinergic P2X7 receptor. target gene hsa-mir-152 Breast Neoplasms 22935141 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Overexpression of miR-148a or miR-152 significantly inhibits BC cell proliferation, colony formation and tumor angiogenesis via targeting IGF-IR and IRS1 and suppressing their downstream AKT and MAPK/ERK signaling pathways. target gene hsa-mir-153 Breast Neoplasms 25794773 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiR-153 inhibits epithelial-mesenchymal transition by targeting metadherin in human breast cancer. target gene hsa-mir-153 Breast Neoplasms 26392359 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our work provides evidence for the involvement of specific miRNAs in triple-negative breast cancer development through regulating BRCA1 expression. target gene hsa-mir-155 Breast Neoplasms 24152184 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 TP53INP1 is the direct target of miR-155. MiR-155, which is overexpressed in MCF-7 cells, contributes to proliferation of MCF-7 cells possibly through down-regulating target TP53INP1. target gene hsa-mir-155 Breast Neoplasms 24616504 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation. target gene hsa-mir-155 Breast Neoplasms 24876105 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-155 drives telomere fragility in human breast cancer by targeting TRF1. target gene hsa-mir-155 Breast Neoplasms 20354188 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene target gene hsa-mir-155 Breast Neoplasms 20371610 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-155 regulates cell survival, growth and chemosensitivity by targeting FOXO3a in breast cancer target gene hsa-mir-155 Breast Neoplasms 22354042 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. target gene hsa-mir-155 Breast Neoplasms 23353819 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cance target gene hsa-mir-155 Breast Neoplasms 18794355 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 These data suggest that miR-155 may play an important role in TGF-beta-induced EMT and cell migration and invasion by targeting RhoA and indicate that it is a potential therapeutic target for breast cancer intervention. target gene hsa-mir-155 Breast Neoplasms 22736789 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 This is the first review examining the role of miR-155 in breast cancer progression. The collated data of target genes and biologic pathways of miR-155 identified in this review suggest new avenues of research for this oncogenic miRNA. target gene hsa-mir-155 Breast Neoplasms 27065318 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-155 potently suppresses ErbB2 in breast cancer cells. target gene hsa-mir-15a Breast Neoplasms 23900351 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiR-15a is underexpressed and inhibits the cell cycle by targeting CCNE1 in breast cancer. target gene hsa-mir-15a Breast Neoplasms 25169552 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiR-15a has a critical role in mediating cell cycle arrest and promoting cell apoptosis of BC, probably by directly targeting SNCG. Thus, it may be involved in development and progression of BC. target gene hsa-mir-15a Breast Neoplasms 27713175 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Fatty acid synthase is a primary target of MiR-15a and MiR-16-1 in breast cancer. target gene hsa-mir-15b Breast Neoplasms 25783158 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 EGF induces microRNAs that target suppressors of cell migration: miR-15b targets MTSS1 in breast cancer. target gene hsa-mir-16 Breast Neoplasms 25830480 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-16 modulates HuR regulation of cyclin E1 in breast cancer cells. target gene hsa-mir-16 Breast Neoplasms 26993770 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-16 sensitizes breast cancer cells to Taxol through the suppression of IKBKB expression target gene hsa-mir-16 Breast Neoplasms 27713175 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Fatty acid synthase is a primary target of MiR-15a and MiR-16-1 in breast cancer. target gene hsa-mir-16-1 Breast Neoplasms 19250063 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Two new miR-16 targets: Caprin-1 and HMGA1, proteins implicated in cell proliferation target gene hsa-mir-16-2 Breast Neoplasms 19250063 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Two new miR-16 targets: Caprin-1 and HMGA1, proteins implicated in cell proliferation target gene hsa-mir-17 Breast Neoplasms 18695042 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. target gene hsa-mir-17 Breast Neoplasms 20505989 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 These findings suggest that miR-17-5p plays an important role in breast cancer cell invasion and migration by suppressing HBP1 and subsequent activation of Wnt/β-catenin. target gene hsa-mir-17 Breast Neoplasms 21765466 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The experimental results using MDA-MB-231 and MCF-7 human breast cancer cells confirm that miRNAs derived from these clusters, containing miR-17-5p, miR-20a, miR-106a, miR-106b and miR-93, negatively regulate ZBTB4 expression. target gene hsa-mir-181a Breast Neoplasms 27033456 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-181a, already demonstrated to inhibit ABCG2 translation, was down-regulated by GNT, explaining translational induction. target gene hsa-mir-181b Breast Neoplasms 26572075 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 In summary, the results of the present study suggest that miR-181b functions as an oncogene during breast cancer development, and the miR-181b/Bim pathway may be a novel target used to overcome the chemoresistance in breast cancer. target gene hsa-mir-181b Breast Neoplasms 27102539 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-181b-3p promotes epithelial-mesenchymal transition in breast cancer cells through Snail stabilization by directly targeting YWHAG. target gene hsa-mir-181c Breast Neoplasms 25695913 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-181c promotes proliferation via suppressing PTEN expression in inflammatory breast cancer. target gene hsa-mir-182 Breast Neoplasms 19574223 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Coordinate Regulate FOXO1; highly expressed; a novel mechanism of FOXO1 regulation, and targeting of FOXO1 by microRNAs may contribute to transformation or maintenance of an oncogenic state in breast cancer cells target gene hsa-mir-182 Breast Neoplasms 23333633 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Up-regulation of miR-182 by beta-catenin in breast cancer increases tumorigenicity and invasiveness by targeting the matrix metalloproteinase inhibitor RECK target gene hsa-mir-182 Breast Neoplasms 23430586 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Expression and regulatory function of miRNA-182 in triple-negative breast cancer cells through its targeting of profilin 1 target gene hsa-mir-182 Breast Neoplasms 23474751 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Suppression of MIM by microRNA-182 activates RhoA and promotes breast cancer metastasis target gene hsa-mir-182 Breast Neoplasms 28546132 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Identification of direct target genes of miR-7, miR-9, miR-96, and miR-182 in the human breast cancer cell lines MCF-7 and MDA-MB-231. target gene hsa-mir-183 Breast Neoplasms 27155522 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 among MTUS1 targeting miRNAs, miR-183-5p was identified to be overexpressed in breast cancer and down-regulated in fibroadenoma tissues. target gene hsa-mir-185 Breast Neoplasms 25319390 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-185 suppresses tumor proliferation by directly targeting E2F6 and DNMT1 and indirectly upregulating BRCA1 in triple-negative breast cancer. target gene hsa-mir-185 Breast Neoplasms 25448984 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Vegfa expression was found to be high in human breast cancer tissues. Thus, miR-185-mediated Vegfa targeting may be involved in breast cancer formation. target gene hsa-mir-18a Breast Neoplasms 25069832 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The results of this study reveal a novel role for miR-18a in targeting HIF1A and repressing metastasis of basal-like breast tumors. target gene hsa-mir-190a Breast Neoplasms 24009311 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 A novel estrogen receptor-microRNA 190a-PAR-1-pathway regulates breast cancer progression, a finding initially suggested by genome-wide analysis of loci associated with lymph-node metastasis. target gene hsa-mir-192 Breast Neoplasms 24012720 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 BMP-6 inhibits cell proliferation by targeting microRNA-192 in breast cancer. target gene hsa-mir-193 Breast Neoplasms 25961594 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 our study demonstrates that HIPK2-kinase and the PLCXD1-phospholipase-C are novel targets of miR-193a-5p/miR-210-3p and miR-575/miR-1225-5p, respectively. target gene hsa-mir-193a Breast Neoplasms 22333974 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-124, miR-147 and miR-193a-3p are three novel tumor suppressors that co-target EGFR-driven cell-cycle network proteins and inhibit cell-cycle progression and proliferation in breast cancer. target gene hsa-mir-193b Breast Neoplasms 19701247 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer. target gene hsa-mir-194 Breast Neoplasms 27221739 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 These findings demonstrate that nucleolin expression is down-regulated by miR-194 and miR-206 and upregulated by HuR target gene hsa-mir-194-1 Breast Neoplasms 22829924 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Modulation of MicroRNA-194 and Cell Migration by HER2-Targeting Trastuzumab in Breast Cancer. target gene hsa-mir-194-2 Breast Neoplasms 22829924 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Modulation of MicroRNA-194 and Cell Migration by HER2-Targeting Trastuzumab in Breast Cancer. target gene hsa-mir-195 Breast Neoplasms 22328513 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-195, miR-24-2 and miR-365-2 act as negative regulators of BCL2 through direct binding to their respective binding sites in the 3' UTR of human BCL2 gene.over expression of these miRNAs not only caused an increase in apoptosis but also augmented the ap target gene hsa-mir-195 Breast Neoplasms 23760062 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1. target gene hsa-mir-199b Breast Neoplasms 23296799 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiR-199b-5p targets HER2 in breast cancer cells target gene hsa-mir-19a Breast Neoplasms 22952885 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 These results suggest that the IMPDH1 and NPEPL1 genes are direct targets of miR-19a in breast cancer, while the exogenous expression of these genes is not associated with the growth suppression of MCF-7 cells. target gene hsa-mir-19b Breast Neoplasms 25552929 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 let-7f inhibition induced an increased expression of THBS1 mRNA and TSP-1 protein, but did not affect the proliferation and apoptosis of MCF-7 cells. target gene hsa-mir-19b Breast Neoplasms 27602768 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiR-19b suppresses PTPRG to promote breast tumorigenesis. target gene hsa-mir-200 Breast Neoplasms 25886595 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The ADAM12-L 3'UTR is a direct target of miR-29 and miR-200 family members. Since the miR-29 and miR-200 families play important roles in breast cancer progression, these results may help explain the different prognostic and chemopredictive values of ADAM12-L and ADAM12-S in breast cancer. target gene hsa-mir-200a Breast Neoplasms 24684598 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 microRNA-200a inhibits cell proliferation by targeting mitochondrial transcription factor A in breast cancer. target gene hsa-mir-200a Breast Neoplasms 18376396 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. target gene hsa-mir-200a Breast Neoplasms 20514023 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-200a:Our results suggest that the miR-200 family has a tumor-suppressor function by negatively regulating EGF-driven cell invasion target gene hsa-mir-200a Breast Neoplasms 21224848 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. target gene hsa-mir-200a Breast Neoplasms 21926171 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells. target gene hsa-mir-200a Breast Neoplasms 23209748 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-200c Sensitizes Breast Cancer Cells to Doxorubicin Treatment by Decreasing TrkB and Bmi1 Expression target gene hsa-mir-200a Breast Neoplasms 23340296 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-200a Promotes Anoikis Resistance and Metastasis by Targeting YAP1 in Human Breast Cancer target gene hsa-mir-200a Breast Neoplasms 29329575 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-200a confers chemoresistance by antagonizing TP53INP1 and YAP1 in human breast cancer target gene hsa-mir-200b Breast Neoplasms 24447584 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-200b as a prognostic factor in breast cancer targets multiple members of RAB family. target gene hsa-mir-200b Breast Neoplasms 26011542 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 53BP1 suppresses epithelial-mesenchymal transition by downregulating ZEB1 through microRNA-200b/429 in breast cancer. target gene hsa-mir-200b Breast Neoplasms 18376396 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. target gene hsa-mir-200b Breast Neoplasms 19665978 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 downregulated, modulate Expression of BMI1, suppressed tumor formation of normal stem cell target gene hsa-mir-200b Breast Neoplasms 20514023 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-200b:Our results suggest that the miR-200 family has a tumor-suppressor function by negatively regulating EGF-driven cell invasion target gene hsa-mir-200b Breast Neoplasms 21224848 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. target gene hsa-mir-200b Breast Neoplasms 23209748 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-200c Sensitizes Breast Cancer Cells to Doxorubicin Treatment by Decreasing TrkB and Bmi1 Expression target gene hsa-mir-200b Breast Neoplasms 23975428 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-200b directly inhibits expression of lysyl oxidase (LOX), leading to decreased invasion. target gene hsa-mir-200c Breast Neoplasms 24615544 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer. target gene hsa-mir-200c Breast Neoplasms 24710933 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-200c inhibits metastasis of breast cancer cells by targeting HMGB1. target gene hsa-mir-200c Breast Neoplasms 25044403 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiR-200c inhibits autophagy and enhances radiosensitivity in breast cancer cells by targeting UBQLN1. target gene hsa-mir-200c Breast Neoplasms 26400441 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 PDCD10 is a target gene of miR-200c and also a possible mechanism by which miR-200c plays a role in regulating the stemness of BCSCs and MaSCs. target gene hsa-mir-200c Breast Neoplasms 18376396 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. target gene hsa-mir-200c Breast Neoplasms 20514023 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 mir-200c:Our results suggest that the miR-200 family has a tumor-suppressor function by negatively regulating EGF-driven cell invasion target gene hsa-mir-200c Breast Neoplasms 21224848 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. target gene hsa-mir-200c Breast Neoplasms 22144583 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F. target gene hsa-mir-200c Breast Neoplasms 23209748 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-200c Sensitizes Breast Cancer Cells to Doxorubicin Treatment by Decreasing TrkB and Bmi1 Expression target gene hsa-mir-200c Breast Neoplasms 28933253 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The role of p53-microRNA 200-Moesin axis in invasion and drug resistance of breast cancer cells. target gene hsa-mir-200c Breast Neoplasms 21682933 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Decreased expression of miRNAs of the miR-200 family has been implicated in the growth and metastasis of breast cancer cells. Of this family, miR-200c has garnered particular attention as a consequence of its ability to target ZEB1 and ZEB2, mediators of epithelial- mesenchymal transition. target gene hsa-mir-200c Breast Neoplasms 28829888 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiR-200c inhibits metastasis of breast tumor via the downregulation of Foxf2. target gene hsa-mir-203 Breast Neoplasms 22207897 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Anti-miR-203 Upregulates SOCS3 Expression in Breast Cancer Cells and Enhances Cisplatin Chemosensitivity. target gene hsa-mir-203 Breast Neoplasms 22713668 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. target gene hsa-mir-204 Breast Neoplasms 26191195 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-204 targets JAK2 in breast cancer and induces cell apoptosis through the STAT3/BCl-2/survivin pathway. target gene hsa-mir-204 Breast Neoplasms 28534958 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-204 regulates the biological behavior of breast cancer MCF-7 cells by directly targeting FOXA1. target gene hsa-mir-205 Breast Neoplasms 24098490 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Regulation of HMGB3 by miR-205 reduced both proliferation and invasion of breast cancer cells. Our findings suggest that modulating miR-205 and/or targeting HMGB3 are potential therapies for advanced breast cancer. target gene hsa-mir-205 Breast Neoplasms 24129185 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-205 is a tumor suppressor in human breast cancer by post-transcriptional inhibition of HER3 expression. target gene hsa-mir-205 Breast Neoplasms 26239614 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-205 inhibits the proliferation and invasion of breast cancer by regulating AMOT expression. target gene hsa-mir-205 Breast Neoplasms 18376396 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. target gene hsa-mir-205 Breast Neoplasms 19276373 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-205: a new oncosuppressor regulates HER3 target gene hsa-mir-206 Breast Neoplasms 24373402 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Hsa-miR-206 has negative controls of proliferation, migration and invasion of breast cancer cell by targeting Cx43. target gene hsa-mir-206 Breast Neoplasms 24935473 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Correlations of common polymorphism of EVI-1 gene targeted by miRNA-206/133b with the pathogenesis of breast cancer. target gene hsa-mir-206 Breast Neoplasms 26093295 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Overexpression of miR-206 suppresses glycolysis, proliferation and migration in breast cancer cells via PFKFB3 targeting. target gene hsa-mir-206 Breast Neoplasms 26125274 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our results suggest hsa-miR-206 may repress the tumor proliferation and invasion in breast cancer by targeting Cx43. target gene hsa-mir-206 Breast Neoplasms 17312270 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. target gene hsa-mir-206 Breast Neoplasms 18593897 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer. target gene hsa-mir-206 Breast Neoplasms 25202123 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Antisense-mediated knockdown (anti-miR) revealed that miR-206/21 coordinately promote RAS-ERK signaling and the corresponding cell phenotypes by inhibiting translation of the pathway suppressors RASA1 and SPRED1. target gene hsa-mir-206 Breast Neoplasms 26879016 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 significantly negative correlation between miR-206 and Cx43 expression target gene hsa-mir-206 Breast Neoplasms 27100732 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Tbx3 is directly repressed by miR-206 target gene hsa-mir-208a Breast Neoplasms 26460550 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our research revealed the mechanisms through which miR-208a functioned in breast cancer and BrCSCs, and identified the miR-208a-SOX2/β-catenin-LIN28-let-7a-DICER1 regulatory feedback loop in regulations of stem cells renewal. target gene hsa-mir-20a Breast Neoplasms 26829385 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiR-20a and miR-20b negatively regulate autophagy by targeting RB1CC1/FIP200 in breast cancer cells. target gene hsa-mir-20a Breast Neoplasms 17011485 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 TGF-b-2 receptor is expressed in the epithelium of breast cancer and can be regulated by miR-20a, which is down- regulated in breast cancer. target gene hsa-mir-20a Breast Neoplasms 18695042 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. target gene hsa-mir-20a Breast Neoplasms 21765466 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The experimental results using MDA-MB-231 and MCF-7 human breast cancer cells confirm that miRNAs derived from these clusters, containing miR-17-5p, miR-20a, miR-106a, miR-106b and miR-93, negatively regulate ZBTB4 expression. target gene hsa-mir-20b Breast Neoplasms 26829385 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiR-20a and miR-20b negatively regulate autophagy by targeting RB1CC1/FIP200 in breast cancer cells. target gene hsa-mir-20b Breast Neoplasms 20232316 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-20b modulates VEGF expression by targeting HIF-1alpha and STAT3 in MCF-7 breast cancer cells target gene hsa-mir-21 Breast Neoplasms 26098771 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal breast cancer. target gene hsa-mir-21 Breast Neoplasms 23936642 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our data suggest that miR-21 could promote metastasis in breast cancer via the regulation of TIMP3 translation, and there was consistency between miR-21 of serum and miR-21 in tissue. target gene hsa-mir-21 Breast Neoplasms 24710931 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-21 targets Fas ligand-mediated apoptosis in breast cancer cell line MCF-7. target gene hsa-mir-21 Breast Neoplasms 25647415 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The regulation and function of miR-21-FOXO3a-miR-34b/c signaling in breast cancer. target gene hsa-mir-21 Breast Neoplasms 26363493 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 An immobilization-free electrochemical impedance biosensor based on duplex-specific nuclease assisted target recycling for amplified detection of microRNA. target gene hsa-mir-21 Breast Neoplasms 26549725 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our data suggest that miR-21 expression is increased in breast cancer and plays an important role as a tumor gene by targeting STAT3, which may act as a double-response controller in breast cancer. target gene hsa-mir-21 Breast Neoplasms 26531758 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 In conclusion, our results demonstrated that plasma miR-21 levels may serve as a diagnostic marker in breast cancers, whereas miR-21 promotes breast cancer cell proliferation and invasion by suppressing smad7, which enhances EGF and TGF-β pathways. target gene hsa-mir-21 Breast Neoplasms 20346171 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 our data suggests that miR-21 could promote invasion in breast cancer cells via its regulation of TIMP3 target gene hsa-mir-21 Breast Neoplasms 21761201 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 3,3'-Diindolylmethane inhibits breast cancer cell growth via miR-21-mediated Cdc25A degradation. target gene hsa-mir-21 Breast Neoplasms 21820606 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-21 Modulates Chemosensitivity of Breast Cancer Cells to Doxorubicin by Targeting PTEN. target gene hsa-mir-21 Breast Neoplasms 22435731 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiR-21 regulates EMT phenotype and HIF-1ж┿expression in third-sphereforming breast cancer stem cell-like cells. target gene hsa-mir-21 Breast Neoplasms 22678116 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-21 is targeted by omega-3 polyunsaturated fatty acid to regulate breast tumor CSF-1 expression. target gene hsa-mir-21 Breast Neoplasms 22832383 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Matrine Inhibits Breast Cancer Growth Via miR-21/PTEN/Akt Pathway in MCF-7 Cells. target gene hsa-mir-21 Breast Neoplasms 25202123 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Antisense-mediated knockdown (anti-miR) revealed that miR-206/21 coordinately promote RAS-ERK signaling and the corresponding cell phenotypes by inhibiting translation of the pathway suppressors RASA1 and SPRED1. target gene hsa-mir-21 Breast Neoplasms 28935174 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 TIMP-3 mRNA expression levels positively correlates with levels of miR-21 in in situ BC and negatively in PR positive invasive BC. target gene hsa-mir-210 Breast Neoplasms 25961594 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 our study demonstrates that HIPK2-kinase and the PLCXD1-phospholipase-C are novel targets of miR-193a-5p/miR-210-3p and miR-575/miR-1225-5p, respectively. target gene hsa-mir-214 Breast Neoplasms 25738546 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 microRNA-214 enhances the invasion ability of breast cancer cells by targeting p53. target gene hsa-mir-218 Breast Neoplasms 25900794 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer. target gene hsa-mir-22 Breast Neoplasms 23830207 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. target gene hsa-mir-22 Breast Neoplasms 24906624 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 A regulatory loop involving miR-22, Sp1, and c-Myc modulates CD147 expression in breast cancer invasion and metastasis. target gene hsa-mir-22 Breast Neoplasms 25304371 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-22 as a prognostic factor targets glucose transporter protein type 1 in breast cancer. target gene hsa-mir-22 Breast Neoplasms 19414598 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor alpha mRNA. target gene hsa-mir-221 Breast Neoplasms 23776679 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 mir-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer. target gene hsa-mir-221 Breast Neoplasms 23801152 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Effects of ARHI on breast cancer cell biological behavior regulated by microRNA-221. target gene hsa-mir-221 Breast Neoplasms 23939688 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 From microRNA functions to microRNA therapeutics: novel targets and novel drugs in breast cancer research and treatment (Review). target gene hsa-mir-221 Breast Neoplasms 24736554 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-221/222 control luminal breast cancer tumor progression by regulating different targets. target gene hsa-mir-221 Breast Neoplasms 24924200 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3. target gene hsa-mir-221 Breast Neoplasms 18708351 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-221: MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1 target gene hsa-mir-221 Breast Neoplasms 21868360 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-221/222 Targeting of Trichorhinophalangeal 1 (TRPS1) Promotes Epithelial-to-Mesenchymal Transition in Breast Cancer. target gene hsa-mir-221 Breast Neoplasms 26503209 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 a pro-apoptotic Bcl-2 family protein, was up-regulated by the knockdown of miR-221. target gene hsa-mir-222 Breast Neoplasms 23776679 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 mir-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer. target gene hsa-mir-222 Breast Neoplasms 24736554 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-221/222 control luminal breast cancer tumor progression by regulating different targets. target gene hsa-mir-222 Breast Neoplasms 24924200 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3. target gene hsa-mir-222 Breast Neoplasms 18708351 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-222: MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1 target gene hsa-mir-222 Breast Neoplasms 21868360 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-221/222 Targeting of Trichorhinophalangeal 1 (TRPS1) Promotes Epithelial-to-Mesenchymal Transition in Breast Cancer. target gene hsa-mir-223 Breast Neoplasms 23953883 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Caprin-1 is a novel microRNA-223 target for regulating the proliferation and invasion of human breast cancer cells. target gene hsa-mir-224 Breast Neoplasms 22809510 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-224 targets RKIP to control cell invasion and expression of metastasis genes in human breast cancer cells. target gene hsa-mir-24 Breast Neoplasms 26044523 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miRNA-24-3p promotes cell proliferation and inhibits apoptosis in human breast cancer by targeting p27Kip1. target gene hsa-mir-24 Breast Neoplasms 23359482 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Downregulation of HR genes correlated with increased levels of their predicted microRNAs (miRNAs), miR-183 (predicted target RAD50) and miR-24 (predicted target BRCA1), suggesting that PE may regulate miRNAs involved in DNA repair processes. target gene hsa-mir-24-1 Breast Neoplasms 21986943 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-24 was found to be implicated in the regulation of the EMT program in response to TGF-beta and was shown to be directly involved in the TGF-ж┿induced breast cancer cell invasiveness through Net1A regulation. target gene hsa-mir-24-2 Breast Neoplasms 21463514 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-24-2 controls H2AFX expression regardless of gene copy number alteration and induces apoptosis by targeting anti-apoptotic gene BCL-2: a potential for therapeutic intervention. target gene hsa-mir-24-2 Breast Neoplasms 21986943 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-24 was found to be implicated in the regulation of the EMT program in response to TGF-beta and was shown to be directly involved in the TGF-ж┿induced breast cancer cell invasiveness through Net1A regulation. target gene hsa-mir-24-2 Breast Neoplasms 22328513 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-195, miR-24-2 and miR-365-2 act as negative regulators of BCL2 through direct binding to their respective binding sites in the 3' UTR of human BCL2 gene.over expression of these miRNAs not only caused an increase in apoptosis but also augmented the ap target gene hsa-mir-24-2 Breast Neoplasms 22911661 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Preferential star strand biogenesis of pre-miR-24-2 targets PKC-alpha and suppresses cell survival in MCF-7 breast cancer cells. target gene hsa-mir-25 Breast Neoplasms 25026296 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-25 regulates chemoresistance-associated autophagy in breast cancer cells, a process modulated by the natural autophagy inducer isoliquiritigenin. target gene hsa-mir-25 Breast Neoplasms 22286770 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The miR-106b-25 cluster targets Smad7, activates TGF-beta signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer. target gene hsa-mir-26a Breast Neoplasms 25755724 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The results of the present study indicate that miR-26a may be associated with human breast carcinogenesis, which inhibits tumor cell proliferation by targeting HMGA1. target gene hsa-mir-26a Breast Neoplasms 26392359 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our work provides evidence for the involvement of specific miRNAs in triple-negative breast cancer development through regulating BRCA1 expression. target gene hsa-mir-26a-1 Breast Neoplasms 23750239 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiR-26a Inhibits Proliferation and Migration of Breast Cancer through Repression of MCL-1. target gene hsa-mir-26a-2 Breast Neoplasms 23750239 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiR-26a Inhibits Proliferation and Migration of Breast Cancer through Repression of MCL-1. target gene hsa-mir-26b Breast Neoplasms 21510944 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-26b is underexpressed in human breast cancer and induces cell apoptosis by targeting SLC7A11. target gene hsa-mir-26b Breast Neoplasms 23374284 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiRNA-26b inhibits proliferation by targeting PTGS2 in breast cancer target gene hsa-mir-26b Breast Neoplasms 28944451 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Expression of miRNA-26b-5p and its target TRPS1 is associated with radiation exposure in post-Chernobyl breast cancer. target gene hsa-mir-27a Breast Neoplasms 25223182 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Cinnamaldehyde could inhibit invasive capabilities of human breast cancer cell line MDA-MB-435S. The over-expression of miR-27a played an important role in the invasive capability of MDA-MB-435S. The inhibition of cinnamaldehyde on invasive capabilities of MDA-MB-435S cells was correlated with down-regulating the expression of miR-27a. target gene hsa-mir-27a Breast Neoplasms 18006846 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. target gene hsa-mir-27a Breast Neoplasms 19574223 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Coordinate Regulation of FOXO1 by miR-27a, miR-96, and miR-182 in Breast Cancer Cells. target gene hsa-mir-27a Breast Neoplasms 22407812 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Betulinic acid decreases ER-negative breast cancer cell growth in vitro and in vivo: Role of Sp transcription factors and microRNA-27a:ZBTB10.BA induced cell cycle arrest in the G2/M phase and increased Myt-1 mRNA (a microRNA-27a target gene), which causes inhibition in G2/M by phosphorylation of cdc2. target gene hsa-mir-27a Breast Neoplasms 22553354 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Betulinic Acid Targets YY1 and ErbB2 through Cannabinoid Receptor-dependent Disruption of MicroRNA-27a:ZBTB10 in Breast Cancer. target gene hsa-mir-29 Breast Neoplasms 25886595 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The ADAM12-L 3'UTR is a direct target of miR-29 and miR-200 family members. Since the miR-29 and miR-200 families play important roles in breast cancer progression, these results may help explain the different prognostic and chemopredictive values of ADAM12-L and ADAM12-S in breast cancer. target gene hsa-mir-296 Breast Neoplasms 24527800 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-296/Scribble axis is deregulated in human breast cancer and miR-296 restoration reduces tumour growth in vivo. target gene hsa-mir-298 Breast Neoplasms 22521303 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. target gene hsa-mir-29a Breast Neoplasms 25955714 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-29a inhibits cell migration and invasion by targeting Roundabout 1 in breast cancer cells. target gene hsa-mir-29a Breast Neoplasms 25961594 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 our study demonstrates that HIPK2-kinase and the PLCXD1-phospholipase-C are novel targets of miR-193a-5p/miR-210-3p and miR-575/miR-1225-5p, respectively. target gene hsa-mir-29a Breast Neoplasms 22330642 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Progestin treatment decreases miR-29, thereby relieving repression of one of its direct targets, the gene encoding ATPase, Na(+)/K(+) transporting, beta 1 polypeptide (ATP1B1). ATP1B1 serves to limit migration and invasion in breast cancer cells. Lastly, target gene hsa-mir-29a Breast Neoplasms 22751119 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4. target gene hsa-mir-29a Breast Neoplasms 28222663 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-29a suppresses MCF-7 cell growth by downregulating tumor necrosis factor receptor 1. target gene hsa-mir-29b Breast Neoplasms 25622979 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The distinct modulations of the NF-κB - miR-29b - p53 pathway make S100A7 an oncogene in ER-negative and a cancer-suppressing gene in ER-positive breast cancer cells, with miR-29b being the determining regulatory factor. target gene hsa-mir-29b Breast Neoplasms 28365400 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiRNA-29b suppresses tumor growth through simultaneously inhibiting angiogenesis and tumorigenesis by targeting Akt3. target gene hsa-mir-29b Breast Neoplasms 29256222 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiRNA-29b can inhibit the proliferation, invasion and metastasis of breast cancer cells by inhibiting the expression of RTKN target gene hsa-mir-29b-1 Breast Neoplasms 22330642 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Progestin treatment decreases miR-29, thereby relieving repression of one of its direct targets, the gene encoding ATPase, Na(+)/K(+) transporting, beta 1 polypeptide (ATP1B1). ATP1B1 serves to limit migration and invasion in breast cancer cells. Lastly, target gene hsa-mir-29b-1 Breast Neoplasms 22751119 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4. target gene hsa-mir-29b-1 Breast Neoplasms 22864815 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Three mRNAs (C1QTNF6, SPARC, and COL4A2) that are down-regulated by microRNA-29b and promote invasion ability in the breast cancer cell line MCF-7. target gene hsa-mir-29b-2 Breast Neoplasms 22330642 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Progestin treatment decreases miR-29, thereby relieving repression of one of its direct targets, the gene encoding ATPase, Na(+)/K(+) transporting, beta 1 polypeptide (ATP1B1). ATP1B1 serves to limit migration and invasion in breast cancer cells. Lastly, target gene hsa-mir-29b-2 Breast Neoplasms 22751119 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4. target gene hsa-mir-29b-2 Breast Neoplasms 22864815 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Three mRNAs (C1QTNF6, SPARC, and COL4A2) that are down-regulated by microRNA-29b and promote invasion ability in the breast cancer cell line MCF-7. target gene hsa-mir-29c Breast Neoplasms 24577056 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 We identified miRNAs efficiently downregulating B7-H3 expression.The expression of miR-29c correlated with survival in breast cancer patients,suggesting a tumour suppressive role for this miRNA. target gene hsa-mir-29c Breast Neoplasms 22330642 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Progestin treatment decreases miR-29, thereby relieving repression of one of its direct targets, the gene encoding ATPase, Na(+)/K(+) transporting, beta 1 polypeptide (ATP1B1). ATP1B1 serves to limit migration and invasion in breast cancer cells. Lastly, target gene hsa-mir-29c Breast Neoplasms 22751119 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4. target gene hsa-mir-29c Breast Neoplasms 27994679 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Brown Seaweed Fucoidan Inhibits Cancer Progression by Dual Regulation of mir-29c/ADAM12 and miR-17-5p/PTEN Axes in Human Breast Cancer Cells. target gene hsa-mir-301a Breast Neoplasms 24315818 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Upregulated microRNA-301a in breast cancer promotes tumor metastasis by targeting PTEN and activating Wnt/β-catenin signaling. target gene hsa-mir-302a Breast Neoplasms 26842910 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our results indicate that miR-302 cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein by targeting MEKK1 of ERK pathway. miR-302 gene cluster may be a potential target for reversing P-gp-mediated chemoresistance in breast cancer. target gene hsa-mir-302b Breast Neoplasms 26842910 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our results indicate that miR-302 cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein by targeting MEKK1 of ERK pathway. miR-302 gene cluster may be a potential target for reversing P-gp-mediated chemoresistance in breast cancer. target gene hsa-mir-302c Breast Neoplasms 26842910 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our results indicate that miR-302 cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein by targeting MEKK1 of ERK pathway. miR-302 gene cluster may be a potential target for reversing P-gp-mediated chemoresistance in breast cancer. target gene hsa-mir-302d Breast Neoplasms 26842910 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our results indicate that miR-302 cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein by targeting MEKK1 of ERK pathway. miR-302 gene cluster may be a potential target for reversing P-gp-mediated chemoresistance in breast cancer. target gene hsa-mir-30a Breast Neoplasms 24508260 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-30a suppresses breast cancer cell proliferation and migration by targeting Eya2. target gene hsa-mir-30a Breast Neoplasms 22157765 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy. target gene hsa-mir-30a Breast Neoplasms 22476851 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-30a inhibits cell migration and invasion by downregulating vimentin expression and is a potential prognostic marker in breast cancer. target gene hsa-mir-30a Breast Neoplasms 23445407 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA miR-30 family regulates non-attachment growth of breast cancer cells target gene hsa-mir-30a Breast Neoplasms 23851509 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-30a suppresses breast tumor growth and metastasis by targeting metadherin. breast tumorigenesis target gene hsa-mir-30a Breast Neoplasms 26918943 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 we linked miR-30a to increased expression of claudins target gene hsa-mir-30c Breast Neoplasms 24519092 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Involvement of miR-30c in resistance to doxorubicin by regulating YWHAZ in breast cancer cells. target gene hsa-mir-30c-1 Breast Neoplasms 22701724 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-30c overexpression inhibited proliferation of breast cancer cells.miR-30c binds the 3'UTR of KRAS transcripts and expression of pre-miR-30c down-regulated KRAS mRNA and protein. target gene hsa-mir-30c-1 Breast Neoplasms 23224145 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. target gene hsa-mir-30c-1 Breast Neoplasms 23340433 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11 target gene hsa-mir-30c-2 Breast Neoplasms 22701724 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-30c overexpression inhibited proliferation of breast cancer cells.miR-30c binds the 3'UTR of KRAS transcripts and expression of pre-miR-30c down-regulated KRAS mRNA and protein. target gene hsa-mir-30c-2 Breast Neoplasms 23224145 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. target gene hsa-mir-30c-2 Breast Neoplasms 23340433 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11 target gene hsa-mir-31 Breast Neoplasms 25889182 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 These data provide strong evidence that GNA13 expression in breast cancer cells is regulated by post-transcriptional mechanisms involving miR-31.Additionally our data shows that miR-31 regulates breast cancer cell invasion partially via targeting GNA13 expression in breast cancer cells. Loss of miR-31 expression and increased GNA13 expression could be used as biomarkers of breast cancer progression. target gene hsa-mir-31 Breast Neoplasms 19574223 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Coordinate Regulate FOXO1; highly expressed; a novel mechanism of FOXO1 regulation, and targeting of FOXO1 by microRNAs may contribute to transformation or maintenance of an oncogenic state in breast cancer cells target gene hsa-mir-31 Breast Neoplasms 23364795 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 microRNA-31 sensitizes human breast cells to apoptosis by direct targeting of protein kinase C epsilon target gene hsa-mir-32 Breast Neoplasms 29661250 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 oncogenic miR-32 and miR-92b were identified to suppress IDH1 expression, leading to the inhibition of cell migration and invasion target gene hsa-mir-320a Breast Neoplasms 25736597 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERRγ. target gene hsa-mir-320a Breast Neoplasms 22179046 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression. target gene hsa-mir-320b-1 Breast Neoplasms 22179046 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression. target gene hsa-mir-320b-2 Breast Neoplasms 22179046 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression. target gene hsa-mir-320c-1 Breast Neoplasms 22179046 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression. target gene hsa-mir-320c-2 Breast Neoplasms 22179046 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression. target gene hsa-mir-320d-1 Breast Neoplasms 22179046 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression. target gene hsa-mir-320d-2 Breast Neoplasms 22179046 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression. target gene hsa-mir-320e Breast Neoplasms 22179046 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression. target gene hsa-mir-328 Breast Neoplasms 21219875 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328; -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells. target gene hsa-mir-328 Breast Neoplasms 19270061 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. target gene hsa-mir-335 Breast Neoplasms 25323813 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 microRNA-335 inhibits proliferation, cell-cycle progression, colony formation, and invasion via targeting PAX6 in breast cancer cells. target gene hsa-mir-335 Breast Neoplasms 25492484 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-335 suppresses breast cancer cell migration by negatively regulating the HGF/c-Met pathway. target gene hsa-mir-335 Breast Neoplasms 21618216 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Breast miR-335 regulates the known BRCA1 activators ERж┿ IGF1R, SP1 and the repressor ID4, including a feedback regulation of miR-335 expression by estrogens. Overexpression of miR-335 resulted in an upregulation of BRCA1 mRNA expression.miR-335 affects different targets in the upstream BRCA1-regulatory cascade with impact on key cellular functions such as proliferation and apoptosis. target gene hsa-mir-338 Breast Neoplasms 26252944 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-338-3p functions as tumor suppressor in breast cancer by targeting SOX4. target gene hsa-mir-33b Breast Neoplasms 25919570 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-33b Inhibits Breast Cancer Metastasis by Targeting HMGA2, SALL4 and Twist1. target gene hsa-mir-340 Breast Neoplasms 21225860 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c-Met target gene hsa-mir-340 Breast Neoplasms 21692045 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-340 inhibites breast cancer cell migration and invasion through targeting of oncoprotein c-Met. target gene hsa-mir-342 Breast Neoplasms 24475217 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-342 regulates BRCA1 expression through modulation of ID4 in breast cancer. target gene hsa-mir-342 Breast Neoplasms 24921394 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 TNBC with high expression of miR-342-3p are more sensitive to chemotherapy. miRNA-342-3p may regulate the sensitivity of breast cancer cell line MDA-MB-231 to chemotherapy drugs paclitaxel and cisplatin, but can not affect the chemotherapy sensitivity of doxorubicin. target gene hsa-mir-34a Breast Neoplasms 24050776 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Taken together, these results suggest that miR-34a inhibits breast cancer proliferation by targeting LMTK3 and might be used as an anti-ERα agent in breast cancer therapy. target gene hsa-mir-34a Breast Neoplasms 25623761 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-34a negatively regulates the expression of Notch1 at both mRNA and protein levels. Overexpression of miR-34a may sensitize MCF-7/ADR cells to adriamycin. target gene hsa-mir-34a Breast Neoplasms 25783790 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-34a suppresses the breast cancer stem cell-like characteristics by downregulating Notch1 pathway. target gene hsa-mir-34a Breast Neoplasms 25826085 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Dysregulation of the miR-34a-SIRT1 axis inhibits breast cancer stemness. target gene hsa-mir-34a Breast Neoplasms 21814748 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. target gene hsa-mir-34a Breast Neoplasms 23085450 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1 target gene hsa-mir-34a Breast Neoplasms 23001043 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our results demonstrate that miR-34a/c functions as a metastasis suppressor to regulate breast cancer migration and invasion through targeting Fra-1 oncogene and suggest a therapeutic application of miR-34 in breast cancer. target gene hsa-mir-34a Breast Neoplasms 26902416 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 LDHA was a direct target of miR-34a target gene hsa-mir-34a Breast Neoplasms 29689563 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-34a Inhibition of the TLR Signaling Pathway Via CXCL10 Suppresses Breast Cancer Cell Invasion and Migration target gene hsa-mir-34b Breast Neoplasms 22113133 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 In this study, we identified one such estrogen down-regulated microRNA, miR-34b, as an onco-suppressor that targets cyclin D1 and JAG-1 (jagged 1) in a ER-positive/wild-type p53 breast cancer cell line (MCF-7) as well as in ovarian and endometrial cells, target gene hsa-mir-34b Breast Neoplasms 27155849 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Only 8 APOBEC3B targeting miRNAs were observed to regulate the fusion transcript of which miR-34b-3p and miR-138-5p were found to be frequently downregulated in cancers suggesting miRNA-mediated deregulation of APOBEC3A expression in cancer patients harbouring this particular deletion polymorphism. target gene hsa-mir-34c Breast Neoplasms 23001043 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our results demonstrate that miR-34a/c functions as a metastasis suppressor to regulate breast cancer migration and invasion through targeting Fra-1 oncogene and suggest a therapeutic application of miR-34 in breast cancer. target gene hsa-mir-365b Breast Neoplasms 22328513 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-195, miR-24-2 and miR-365-2 act as negative regulators of BCL2 through direct binding to their respective binding sites in the 3' UTR of human BCL2 gene.over expression of these miRNAs not only caused an increase in apoptosis but also augmented the ap target gene hsa-mir-372 Breast Neoplasms 29456685 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-372 functions as an oncogenic miRNA in breast cancer by targeting LATS2 target gene hsa-mir-373 Breast Neoplasms 22158050 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kB and TGF-beta signaling pathways. target gene hsa-mir-375 Breast Neoplasms 24746361 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 SHOX2 is a direct miR-375 target and a novel epithelial-to-mesenchymal transition inducer in breast cancer cells. target gene hsa-mir-378a Breast Neoplasms 26255816 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-378a-3p modulates tamoxifen sensitivity in breast cancer MCF-7 cells through targeting GOLT1A. target gene hsa-mir-379 Breast Neoplasms 23874748 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-379 regulates cyclin B1 expression and is decreased in breast cancer. target gene hsa-mir-429 Breast Neoplasms 26011542 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 53BP1 suppresses epithelial-mesenchymal transition by downregulating ZEB1 through microRNA-200b/429 in breast cancer. target gene hsa-mir-429 Breast Neoplasms 18376396 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. target gene hsa-mir-448 Breast Neoplasms 29368542 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-448 inhibits cell migration, invasion, and EMT by targeting to the 3'UTR of ZEB1/2 target gene hsa-mir-449a Breast Neoplasms 29518546 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 LINC0092 was co-expressed with SFRP1 and RGMA and regulated by hsa-miR-449a and hsa-miR-452-5p target gene hsa-mir-449a Breast Neoplasms 29653747 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiR-449a suppresses cell migration and invasion by targeting PLAGL2 in breast cancer target gene hsa-mir-450b Breast Neoplasms 25046105 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Targeting HER3 with miR-450b-3p suppresses breast cancer cells proliferation. target gene hsa-mir-451 Breast Neoplasms 26516138 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Increased miR-451 expression may negatively regulate Bcl-2 mRNA and protein expression, followed by affecting the protein expression of caspase 3,and accelerate the apoptosis in breast cancer, indicating that miR-451 might influence the drug resistances of the Paclitaxel-resistant breast cancer cell line. target gene hsa-mir-451a Breast Neoplasms 26896688 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Over-expression of miR-451a can enhance the sensitivity of breast cancer cells to tamoxifen by regulating 14-3-3ζ, estrogen receptor α, and autophagy. target gene hsa-mir-452 Breast Neoplasms 29518546 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 LINC0092 was co-expressed with SFRP1 and RGMA and regulated by hsa-miR-449a and hsa-miR-452-5p target gene hsa-mir-486 Breast Neoplasms 25104088 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-486-5p targeting PIM-1 suppresses cell proliferation in breast cancer cells. target gene hsa-mir-489 Breast Neoplasms 24786471 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiR-489 regulates chemoresistance in breast cancer via epithelial mesenchymal transition pathway. target gene hsa-mir-489 Breast Neoplasms 26828271 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 GSE1 negative regulation by miR-489-5p promotes breast cancer cell proliferation and invasion. target gene hsa-mir-491 Breast Neoplasms 25725194 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-491-5p functions as a tumor suppressor by targeting JMJD2B in ERα-positive breast cancer. target gene hsa-mir-492 Breast Neoplasms 25407488 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-492 represents a potential onco-miR and participates in breast cancer carcinogenesis by suppressing SOX7 expression. target gene hsa-mir-494 Breast Neoplasms 25955111 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-494 suppresses the progression of breast cancer in vitro by targeting CXCR4 through the Wnt/β-catenin signaling pathway. target gene hsa-mir-495 Breast Neoplasms 26020378 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Downregulated miR-495 [Corrected] Inhibits the G1-S Phase Transition by Targeting Bmi-1 in Breast Cancer. target gene hsa-mir-502 Breast Neoplasms 24677135 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Suppressive role of miR-502-5p in breast cancer via downregulation of TRAF2. target gene hsa-mir-513a-1 Breast Neoplasms 22330642 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Progestin treatment decreases miR-29, thereby relieving repression of one of its direct targets, the gene encoding ATPase, Na(+)/K(+) transporting, beta 1 polypeptide (ATP1B1). ATP1B1 serves to limit migration and invasion in breast cancer cells. Lastly, target gene hsa-mir-513a-2 Breast Neoplasms 22330642 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Progestin treatment decreases miR-29, thereby relieving repression of one of its direct targets, the gene encoding ATPase, Na(+)/K(+) transporting, beta 1 polypeptide (ATP1B1). ATP1B1 serves to limit migration and invasion in breast cancer cells. Lastly, target gene hsa-mir-519c Breast Neoplasms 21219875 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328; -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells. target gene hsa-mir-520a Breast Neoplasms 22158050 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kB and TGF-beta signaling pathways. target gene hsa-mir-520b Breast Neoplasms 21343296 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-520b regulates migration of breast cancer cells through targeting hepatitis B X-interacting protein and interleukin-8. target gene hsa-mir-520b Breast Neoplasms 22158050 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kB and TGF-beta signaling pathways. target gene hsa-mir-520c Breast Neoplasms 22158050 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kB and TGF-beta signaling pathways. target gene hsa-mir-520d Breast Neoplasms 22158050 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kB and TGF-beta signaling pathways. target gene hsa-mir-520h Breast Neoplasms 21219875 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328; -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells. target gene hsa-mir-568 Breast Neoplasms 25311085 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 This study unravels a detailed role of NFAT5 in mediating metastatic signaling, and provides broad insights into the involvement of Hotair, in particular, by transcriptionally regulating the expression of microRNA(s), in the metastasis of breast cancers. target gene hsa-mir-575 Breast Neoplasms 25961594 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 our study demonstrates that HIPK2-kinase and the PLCXD1-phospholipase-C are novel targets of miR-193a-5p/miR-210-3p and miR-575/miR-1225-5p, respectively. target gene hsa-mir-625 Breast Neoplasms 26806308 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-625 suppresses cell proliferation and migration by targeting HMGA1 in breast cancer. target gene hsa-mir-630 Breast Neoplasms 24655723 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Taken together, our findings suggest miR-630 as a key regulator of cancer cell progression in HER2 over-expressing breast cancer, through targeting of IGF1R. This study supports miR-630 as a diagnostic and a predictive biomarker for response to HER-targeted drugs and indicates that the therapeutic addition of miR-630 may enhance and improve patients' response to HER-targeting drugs. target gene hsa-mir-632 Breast Neoplasms 22710984 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Micro-RNA-632 downregulates DNAJB6 in breast cancer. target gene hsa-mir-661 Breast Neoplasms 20543867 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-661:miR-661 expression in SNAI1-induced epithelial to mesenchymal transition contributes to breast cancer cell invasion by targeting Nectin-1 and StarD10 messengers target gene hsa-mir-675 Breast Neoplasms 26353930 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b. target gene hsa-mir-7 Breast Neoplasms 24931170 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Targeting WNT1-inducible signaling pathway protein 2 alters human breast cancer cell susceptibility to specific lysis through regulation of KLF-4 and miR-7 expression. target gene hsa-mir-7 Breast Neoplasms 28546132 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Identification of direct target genes of miR-7, miR-9, miR-96, and miR-182 in the human breast cancer cell lines MCF-7 and MDA-MB-231. target gene hsa-mir-7 Breast Neoplasms 29614984 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our data uncovered a crucial role of TINCR-miR-7-KLF4 axis in human breast cancer target gene hsa-mir-7-1 Breast Neoplasms 20099276 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-7:miR-345 and miR-7 target the human multidrug resistance-associated protein 1 target gene hsa-mir-7-1 Breast Neoplasms 22876288 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-7 Inhibits Epithelial-to-Mesenchymal Transition and Metastasis of Breast Cancer Cells via Targeting FAK Expression. target gene hsa-mir-7-1 Breast Neoplasms 23384942 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-7 Suppresses Brain Metastasis of Breast Cancer Stem-Like Cells By Modulating KLF4 target gene hsa-mir-7-1 Breast Neoplasms 23720754 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-7 Suppresses the Invasive Potential of Breast Cancer Cells and Sensitizes Cells to DNA Damages by Targeting Histone Methyltransferase SET8. target gene hsa-mir-7-2 Breast Neoplasms 20099276 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-7:miR-345 and miR-7 target the human multidrug resistance-associated protein 1 target gene hsa-mir-7-2 Breast Neoplasms 22876288 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-7 Inhibits Epithelial-to-Mesenchymal Transition and Metastasis of Breast Cancer Cells via Targeting FAK Expression. target gene hsa-mir-7-2 Breast Neoplasms 23384942 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-7 Suppresses Brain Metastasis of Breast Cancer Stem-Like Cells By Modulating KLF4 target gene hsa-mir-7-2 Breast Neoplasms 23720754 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-7 Suppresses the Invasive Potential of Breast Cancer Cells and Sensitizes Cells to DNA Damages by Targeting Histone Methyltransferase SET8. target gene hsa-mir-720 Breast Neoplasms 24085799 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-720 inhibits tumor invasion and migration in breast cancer by targeting TWIST1. target gene hsa-mir-7-3 Breast Neoplasms 20099276 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-7:miR-345 and miR-7 target the human multidrug resistance-associated protein 1 target gene hsa-mir-7-3 Breast Neoplasms 22876288 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-7 Inhibits Epithelial-to-Mesenchymal Transition and Metastasis of Breast Cancer Cells via Targeting FAK Expression. target gene hsa-mir-7-3 Breast Neoplasms 23384942 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-7 Suppresses Brain Metastasis of Breast Cancer Stem-Like Cells By Modulating KLF4 target gene hsa-mir-7-3 Breast Neoplasms 23720754 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-7 Suppresses the Invasive Potential of Breast Cancer Cells and Sensitizes Cells to DNA Damages by Targeting Histone Methyltransferase SET8. target gene hsa-mir-762 Breast Neoplasms 26597380 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 These results demonstrate that miR-762 tumour effect was achieved by targeting IRF7 in human breast cancer specimens. target gene hsa-mir-874 Breast Neoplasms 25281924 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-874 inhibits cell proliferation and induces apoptosis in human breast cancer by targeting CDK9. target gene hsa-mir-874 Breast Neoplasms 25961594 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 our study demonstrates that HIPK2-kinase and the PLCXD1-phospholipase-C are novel targets of miR-193a-5p/miR-210-3p and miR-575/miR-1225-5p, respectively. target gene hsa-mir-888 Breast Neoplasms 24845571 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiR-888 regulates side population properties and cancer metastasis in breast cancer cells. target gene hsa-mir-9 Breast Neoplasms 28546132 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Identification of direct target genes of miR-7, miR-9, miR-96, and miR-182 in the human breast cancer cell lines MCF-7 and MDA-MB-231. target gene hsa-mir-9 Breast Neoplasms 20173740 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Here we show that miR-9, which is upregulated in breast cancer cells, directly targets CDH1, the E-cadherin-encoding messenger RNA, leading to increased cell motility and invasiveness. target gene hsa-mir-9 Breast Neoplasms 28397066 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-9 promotes the proliferation, migration, and invasion of breast cancer cells via down-regulating FOXO1. target gene hsa-mir-9-1 Breast Neoplasms 22761433 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-9 Inhibition of Cell Proliferation and Identification of Novel miR-9 Targets by Transcriptome Profiling in Breast Cancer Cells. target gene hsa-mir-9-1 Breast Neoplasms 23530058 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-9-3p targets integrin beta 1 to sensitize claudin-low breast cancer cells to MEK inhibition target gene hsa-mir-92 Breast Neoplasms 26437339 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-92 is gradually lost in breast epithelial cells during cancer progression correlating with a shift in ERβ1 immunoreactivity from nuclei to the cytoplasm. Our data support a functional role in fibroblasts where modification of miR-92 expression can influence the invasive capacity of breast cancer epithelial cells. However in silico analysis suggests that ERβ1 may not be the most important miR-92 target in breast cancer. target gene hsa-mir-9-2 Breast Neoplasms 22761433 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-9 Inhibition of Cell Proliferation and Identification of Novel miR-9 Targets by Transcriptome Profiling in Breast Cancer Cells. target gene hsa-mir-9-2 Breast Neoplasms 23530058 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-9-3p targets integrin beta 1 to sensitize claudin-low breast cancer cells to MEK inhibition target gene hsa-mir-92a-1 Breast Neoplasms 20484043 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-92:Estrogen receptor {beta}1 expression is regulated by miR-92 in breast cancer target gene hsa-mir-92a-2 Breast Neoplasms 20484043 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-92:Estrogen receptor {beta}1 expression is regulated by miR-92 in breast cancer target gene hsa-mir-92b Breast Neoplasms 29661250 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 oncogenic miR-32 and miR-92b were identified to suppress IDH1 expression, leading to the inhibition of cell migration and invasion target gene hsa-mir-93 Breast Neoplasms 22685420 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells. target gene hsa-mir-93 Breast Neoplasms 21765466 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The experimental results using MDA-MB-231 and MCF-7 human breast cancer cells confirm that miRNAs derived from these clusters, containing miR-17-5p, miR-20a, miR-106a, miR-106b and miR-93, negatively regulate ZBTB4 expression. target gene hsa-mir-93 Breast Neoplasms 23492819 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-93 regulates NRF2 expression and is associated with breast carcinogenesis. target gene hsa-mir-9-3 Breast Neoplasms 22761433 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-9 Inhibition of Cell Proliferation and Identification of Novel miR-9 Targets by Transcriptome Profiling in Breast Cancer Cells. target gene hsa-mir-9-3 Breast Neoplasms 23530058 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-9-3p targets integrin beta 1 to sensitize claudin-low breast cancer cells to MEK inhibition target gene hsa-mir-940 Breast Neoplasms 25673565 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 A statistically inferred microRNA network identifies breast cancer target miR-940 as an actin cytoskeleton regulator. target gene hsa-mir-96 Breast Neoplasms 24366472 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-96 promotes tumor proliferation and invasion by targeting RECK in breast cancer. target gene hsa-mir-96 Breast Neoplasms 19574223 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Coordinate Regulate FOXO1; highly expressed; a novel mechanism of FOXO1 regulation, and targeting of FOXO1 by microRNAs may contribute to transformation or maintenance of an oncogenic state in breast cancer cells target gene hsa-mir-96 Breast Neoplasms 21203424 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Unregulated miR-96 Induces Cell Proliferation in Human Breast Cancer by Downregulating Transcriptional Factor FOXO3a. target gene hsa-mir-96 Breast Neoplasms 28546132 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Identification of direct target genes of miR-7, miR-9, miR-96, and miR-182 in the human breast cancer cell lines MCF-7 and MDA-MB-231. target gene hsa-mir-99a Breast Neoplasms 25348507 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-99a directly targets the mTOR signalling pathway in breast cancer side population cells. mir-23b,mir-27b,mir-24 target gene hsa-mir-144 Bronchiolitis Obliterans Syndrome 25979625 respiratory system disease DOID:2799 J42 D001989 HP:0011946 miR-144 is a critical regulator of the TGF-β signaling cascade and is over-expressed in lungs with BOS. Therefore, miR-144 is a potential target toward preventing fibrosis leading to BOS after lung transplant. target gene hsa-mir-206 Bronchopulmonary Dysplasia 24040336 P27.1 D001997 The expression of miR-206 and its target gene, fn 1, may contribute to the progression of BPD. target gene hsa-mir-205 Carcinoma, Adrenocortical 26397843 endocrine system disease DOID:3948 D018268 202300 HP:0006744 In conclusion, miR-205 suppresses the growth of ACC SW-13 cells via targeting the anti-apoptotic gene Bcl-2. target gene hsa-mir-21 Carcinoma, Basal Cell 27159391 disease of cellular proliferation DOID:2513 C44.91 D002280 605462 HP:0002671 Moreover, our results identify a miR21/GRHL3/D3 axis that reduces TH in the tumor microenvironment and has potential to be targeted as a therapeutic approach to BCC. target gene hsa-let-7 Carcinoma, Bladder 27620744 urinary system disease DOID:4007 D09.0 D001749 109800 HP:0002862 A let-7 microRNA binding site polymorphism in the KRAS 3'UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population. target gene hsa-mir-1 Carcinoma, Bladder 28268231 urinary system disease DOID:4007 D09.0 D001749 109800 HP:0002862 MiR-1-3p Suppresses the Proliferation, Invasion and Migration of Bladder Cancer Cells by Up-Regulating SFRP1 Expression. target gene hsa-mir-1 Carcinoma, Bladder 28618950 urinary system disease DOID:4007 D09.0 D001749 109800 HP:0002862 MiR-1-3p inhibits the proliferation and invasion of bladder cancer cells by suppressing CCL2 expression. target gene hsa-mir-101 Carcinoma, Bladder 24490857 urinary system disease DOID:4007 D09.0 D001749 109800 HP:0002862 MJ sensitizes bladder cancer cells to GA-induced apoptosis by down-regulating the expression of EZH2 induced by miR-101. Thus, the combination of selective anti-cancer agents MJ and GA could provide a novel strategy for treating human bladder cancer. target gene hsa-mir-130b Carcinoma, Bladder 28042869 urinary system disease DOID:4007 D09.0 D001749 109800 HP:0002862 Genome-Wide Screen of miRNAs and Targeting mRNAs Reveals the Negatively Regulatory Effect of miR-130b-3p on PTEN by PI3K and Integrin β1 Signaling Pathways in Bladder Carcinoma. target gene hsa-mir-135a Carcinoma, Bladder 25888950 urinary system disease DOID:4007 D09.0 D001749 109800 HP:0002862 Our study demonstrates that miR-135a promotes cell proliferation in bladder cancer by targeting PHLPP2 and FOXO1, and is performed as an onco-miR. target gene hsa-mir-138 Carcinoma, Bladder 27978829 urinary system disease DOID:4007 D09.0 D001749 109800 HP:0002862 miR-138-5p contributes to cell proliferation and invasion by targeting Survivin in bladder cancer cells. target gene hsa-mir-139 Carcinoma, Bladder 28720065 urinary system disease DOID:4007 D09.0 D001749 109800 HP:0002862 MicroRNA-139-5p inhibits bladder cancer proliferation and self-renewal by targeting the Bmi1 oncogene. target gene hsa-mir-199 Carcinoma, Bladder 28324890 urinary system disease DOID:4007 D09.0 D001749 109800 HP:0002862 Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer. target gene hsa-mir-199a Carcinoma, Bladder 27814720 urinary system disease DOID:4007 D09.0 D001749 109800 HP:0002862 miR-199a-5p suppresses human bladder cancer cell metastasis by targeting CCR7. target gene hsa-mir-218 Carcinoma, Bladder 28222430 urinary system disease DOID:4007 D09.0 D001749 109800 HP:0002862 MicroRNA-218 Increases the Sensitivity of Bladder Cancer to Cisplatin by Targeting Glut1. target gene hsa-mir-24 Carcinoma, Bladder 28000900 urinary system disease DOID:4007 D09.0 D001749 109800 HP:0002862 miR-24-3p regulates bladder cancer cell proliferation, migration, invasion and autophagy by targeting DEDD. target gene hsa-mir-294 Carcinoma, Bladder 28371605 urinary system disease DOID:4007 D09.0 D001749 109800 HP:0002862 MicroRNA-294 Promotes Cellular Proliferation and Motility through the PI3K/AKT and JAK/STAT Pathways by Upregulation of NRAS in Bladder Cancer. target gene hsa-mir-29c Carcinoma, Bladder 24870742 urinary system disease DOID:4007 D09.0 D001749 109800 HP:0002862 Human bladder cancer cells infected by microRNA- 29c adenovirus can transport microRNA-29c via exosomes. Moreover, exosome-derived microRNA29c induces apoptosis in bladder cancer cells by down-regulating BCL-2 and MCL-1. target gene hsa-mir-451 Carcinoma, Bladder 27571748 urinary system disease DOID:4007 D09.0 D001749 109800 HP:0002862 miR-451 suppresses bladder cancer cell migration and invasion via directly targeting c-Myc. target gene hsa-mir-495 Carcinoma, Bladder 28069380 urinary system disease DOID:4007 D09.0 D001749 109800 HP:0002862 microRNA-495 promotes bladder cancer cell growth and invasion by targeting phosphatase and tensin homolog. target gene hsa-mir-124 Carcinoma, Breast 27748910 D05 D001943 114480 HP:0003002 MicroRNA-124 inhibits cell proliferation and migration by regulating SNAI2 in breast cancer. target gene hsa-mir-124 Carcinoma, Breast 27815936 D05 D001943 114480 HP:0003002 MicroRNA-124 enhances response to radiotherapy in human epidermal growth factor receptor 2-positive breast cancer cells by targeting signal transducer and activator of transcription 3. target gene hsa-mir-125a Carcinoma, Breast 27693788 D05 D001943 114480 HP:0003002 Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signaling. target gene hsa-mir-125a Carcinoma, Breast 28188287 D05 D001943 114480 HP:0003002 A-to-I RNA Editing Up-regulates Human Dihydrofolate Reductase in Breast Cancer. target gene hsa-mir-129 Carcinoma, Breast 27831649 D05 D001943 114480 HP:0003002 MiR-129-5p is downregulated in breast cancer cells partly due to promoter H3K27m3 modification and regulates epithelial-mesenchymal transition and multi-drug resistance. target gene hsa-mir-130b Carcinoma, Breast 28163094 D05 D001943 114480 HP:0003002 miR-130b-3p inhibits cell invasion and migration by targeting the Notch ligand Delta-like 1 in breast carcinoma. target gene hsa-mir-139 Carcinoma, Breast 27916718 D05 D001943 114480 HP:0003002 Loss of the Opa interacting protein 5 inhibits breast cancer proliferation through miR-139-5p/NOTCH1 pathway. target gene hsa-mir-141 Carcinoma, Breast 27596953 D05 D001943 114480 HP:0003002 p16INK4A induces senescence and inhibits EMT through microRNA-141/microRNA-146b-5p-dependent repression of AUF1. target gene hsa-mir-142 Carcinoma, Breast 26657485 D05 D001943 114480 HP:0003002 microRNA miR-142-3p Inhibits Breast Cancer Cell Invasiveness by Synchronous Targeting of WASL, Integrin Alpha V, and Additional Cytoskeletal Elements. HrC-9698 target gene hsa-mir-145 Carcinoma, Breast 28349828 D05 D001943 114480 HP:0003002 Silencing of bach1 gene by small interfering RNA-mediation regulates invasive and expression level of miR-203, miR-145, matrix metalloproteinase-9, and CXCR4 receptor in MDA-MB-468 breast cancer cells. target gene hsa-mir-145 Carcinoma, Breast 28393176 D05 D001943 114480 HP:0003002 miR-145 inhibits proliferation and migration of breast cancer cells by directly or indirectly regulating TGF-β1 expression. target gene hsa-mir-146b Carcinoma, Breast 27596953 D05 D001943 114480 HP:0003002 p16INK4A induces senescence and inhibits EMT through microRNA-141/microRNA-146b-5p-dependent repression of AUF1. target gene hsa-mir-148a Carcinoma, Breast 28063929 D05 D001943 114480 HP:0003002 MiR-148a and miR-152 reduce tamoxifen resistance in ER+ breast cancer via downregulating ALCAM. target gene hsa-mir-151 Carcinoma, Breast 27930738 D05 D001943 114480 HP:0003002 miR-151-3p Targets TWIST1 to Repress Migration of Human Breast Cancer Cells. target gene hsa-mir-152 Carcinoma, Breast 28063929 D05 D001943 114480 HP:0003002 MiR-148a and miR-152 reduce tamoxifen resistance in ER+ breast cancer via downregulating ALCAM. target gene hsa-mir-15a Carcinoma, Breast 27596816 D05 D001943 114480 HP:0003002 miR-15a/miR-16 induces mitochondrial dependent apoptosis in breast cancer cells by suppressing oncogene BMI1. target gene hsa-mir-16 Carcinoma, Breast 27596816 D05 D001943 114480 HP:0003002 miR-15a/miR-16 induces mitochondrial dependent apoptosis in breast cancer cells by suppressing oncogene BMI1. target gene hsa-mir-17 Carcinoma, Breast 27831559 D05 D001943 114480 HP:0003002 Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3. target gene hsa-mir-181 Carcinoma, Breast 28224609 D05 D001943 114480 HP:0003002 miR-181 elevates Akt signaling by co-targeting PHLPP2 and INPP4B phosphatases in luminal breast cancer. target gene hsa-mir-181a Carcinoma, Breast 28288641 D05 D001943 114480 HP:0003002 SOX2 regulates multiple malignant processes of breast cancer development through the SOX2/miR-181a-5p, miR-30e-5p/TUSC3 axis. target gene hsa-mir-185 Carcinoma, Breast 27651238 D05 D001943 114480 HP:0003002 RKIP suppresses the proliferation and metastasis of breast cancer cell lines through up-regulation of miR-185 targeting HMGA2. target gene hsa-mir-199a Carcinoma, Breast 28126676 D05 D001943 114480 HP:0003002 MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM). target gene hsa-mir-200a Carcinoma, Breast 28440475 D05 D001943 114480 HP:0003002 A nine-miRNA signature as a potential diagnostic marker for breast carcinoma: An integrated study of 1,110 cases. target gene hsa-mir-200b Carcinoma, Breast 28972876 D05 D001943 114480 HP:0003002 miR-200b regulates epithelial-mesenchymal transition of chemo-resistant breast cancer cells by targeting FN1. target gene hsa-mir-203 Carcinoma, Breast 28349828 D05 D001943 114480 HP:0003002 Silencing of bach1 gene by small interfering RNA-mediation regulates invasive and expression level of miR-203, miR-145, matrix metalloproteinase-9, and CXCR4 receptor in MDA-MB-468 breast cancer cells. target gene hsa-mir-204 Carcinoma, Breast 28675122 D05 D001943 114480 HP:0003002 MiR-204/ZEB2 axis functions as key mediator for MALAT1-induced epithelial-mesenchymal transition in breast cancer. target gene hsa-mir-206 Carcinoma, Breast 28391353 D05 D001943 114480 HP:0003002 WBP2 modulates G1/S transition in ER+ breast cancer cells and is a direct target of miR-206. target gene hsa-mir-20b Carcinoma, Breast 27831559 D05 D001943 114480 HP:0003002 Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3. target gene hsa-mir-214 Carcinoma, Breast 27693451 D05 D001943 114480 HP:0003002 Crosstalk between the vitamin D receptor (VDR) and miR-214 in regulating SuFu, a hedgehog pathway inhibitor in breast cancer cells. target gene hsa-mir-216b Carcinoma, Breast 27720715 D05 D001943 114480 HP:0003002 miR-216b suppresses breast cancer growth and metastasis by targeting SDCBP. target gene hsa-mir-217 Carcinoma, Breast 27916422 D05 D001943 114480 HP:0003002 PGC-1 alpha interacts with microRNA-217 to functionally regulate breast cancer cell proliferation. target gene hsa-mir-221 Carcinoma, Breast 24286315 D05 D001943 114480 HP:0003002 MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN. target gene hsa-mir-25 Carcinoma, Breast 28188287 D05 D001943 114480 HP:0003002 A-to-I RNA Editing Up-regulates Human Dihydrofolate Reductase in Breast Cancer. target gene hsa-mir-26a Carcinoma, Breast 28637868 D05 D001943 114480 HP:0003002 Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells. target gene hsa-mir-26b Carcinoma, Breast 28637868 D05 D001943 114480 HP:0003002 Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells. target gene hsa-mir-27a Carcinoma, Breast 28099945 D05 D001943 114480 HP:0003002 In vivo and in vitro effects of microRNA-27a on proliferation, migration and invasion of breast cancer cells through targeting of SFRP1 gene via Wnt/β-catenin signaling pathway. target gene hsa-mir-27b Carcinoma, Breast 27809310 D05 D001943 114480 HP:0003002 Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression. target gene hsa-mir-29a Carcinoma, Breast 26802653 D05 D001943 114480 HP:0003002 inhibitors of microRNA-29a promote apoptosis through upregulation of HSP60 level and downregulation of HSP27, HSP40, HSP70, and HSP90 levels target gene hsa-mir-30e Carcinoma, Breast 28288641 D05 D001943 114480 HP:0003002 SOX2 regulates multiple malignant processes of breast cancer development through the SOX2/miR-181a-5p, miR-30e-5p/TUSC3 axis. target gene hsa-mir-330 Carcinoma, Breast 28419078 D05 D001943 114480 HP:0003002 Targeting of CCBE1 by miR-330-3p in human breast cancer promotes metastasis. target gene hsa-mir-346 Carcinoma, Breast 27913185 D05 D001943 114480 HP:0003002 MiR-346 promotes the biological function of breast cancer cells by targeting SRCIN1 and reduces chemosensitivity to docetaxel. target gene hsa-mir-34a Carcinoma, Breast 27813227 D05 D001943 114480 HP:0003002 MiR-34a modulates ErbB2 in breast cancer. target gene hsa-mir-375 Carcinoma, Breast 28075453 D05 D001943 114480 HP:0003002 miR-375 inhibits cancer stem cell phenotype and tamoxifen resistance by degrading HOXB3 in human ER-positive breast cancer. target gene hsa-mir-381 Carcinoma, Breast 28012397 D05 D001943 114480 HP:0003002 miR-381 inhibited breast cancer cells proliferation, epithelial-to-mesenchymal transition and metastasis by targeting CXCR4. target gene hsa-mir-3908 Carcinoma, Breast 28327197 D05 D001943 114480 HP:0003002 Lipid raft-mediated miR-3908 inhibition of migration of breast cancer cell line MCF-7 by regulating the interactions between AdipoR1 and Flotillin-1. target gene hsa-mir-409 Carcinoma, Breast 28459205 D05 D001943 114480 HP:0003002 MicroRNA-409-5p is upregulated in breast cancer and its downregulation inhibits cancer development through downstream target of RSU1. target gene hsa-mir-411 Carcinoma, Breast 27572271 D05 D001943 114480 HP:0003002 miRNA-411 acts as a potential tumor suppressor miRNA via the downregulation of specificity protein 1 in breast cancer. target gene hsa-mir-421 Carcinoma, Breast 27583980 D05 D001943 114480 HP:0003002 MicroRNA-421 inhibits breast cancer metastasis by targeting metastasis associated 1. target gene hsa-mir-4262 Carcinoma, Breast 27629257 D05 D001943 114480 HP:0003002 miR-4262 Promotes Proliferation and Invasion of Human Breast Cancer Cells Through Directly Targeting KLF6 and KLF15. target gene hsa-mir-503 Carcinoma, Breast 26047605 D05 D001943 114480 HP:0003002 MiR-503 inhibited cell proliferation of human breast cancer cells by suppressing CCND1 expression. target gene hsa-mir-519a Carcinoma, Breast 24752803 D05 D001943 114480 HP:0003002 MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer. target gene hsa-mir-520c Carcinoma, Breast 28112380 D05 D001943 114480 HP:0003002 miR520c blocks EMT progression of human breast cancer cells by repressing STAT3. target gene hsa-mir-542 Carcinoma, Breast 24403060 D05 D001943 114480 HP:0003002 MicroRNA-542-3p inhibits tumour angiogenesis by targeting angiopoietin-2. target gene hsa-mir-542 Carcinoma, Breast 28121348 D05 D001943 114480 HP:0003002 miR-542-3p targets sphingosine-1-phosphate receptor 1 and regulates cell proliferation and invasion of breast cancer cells. target gene hsa-mir-590 Carcinoma, Breast 28121351 D05 D001943 114480 HP:0003002 MicroRNA miR-590-5p inhibits breast cancer cell stemness and metastasis by targeting SOX2. target gene hsa-mir-590 Carcinoma, Breast 28443471 D05 D001943 114480 HP:0003002 Suppressing the molecular signaling pathways involved in inflammation and cancer in breast cancer cell lines MDA-MB-231 and MCF-7 by miR-590. target gene hsa-mir-597 Carcinoma, Breast 28393251 D05 D001943 114480 HP:0003002 miR-597 inhibits breast cancer cell proliferation, migration and invasion through FOSL2. target gene hsa-mir-9 Carcinoma, Breast 27520371 D05 D001943 114480 HP:0003002 CYP4Z1 3'UTR was the potential target of miR-9. CYP4Z1 3'UTR could inhibit the migration and EMT of breast cancer cells via acting as a ceRNA for E-cadherin. target gene hsa-mir-939 Carcinoma, Breast 27693459 D05 D001943 114480 HP:0003002 Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers. target gene hsa-mir-99a Carcinoma, Breast 24637915 D05 D001943 114480 HP:0003002 MiR-99a antitumor activity in human breast cancer cells through targeting of mTOR expression. target gene hsa-mir-101 Carcinoma, Breast, Triple Negative 26036638 D064726 MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer. target gene hsa-mir-107 Carcinoma, Breast, Triple Negative 25851994 D064726 MiR-107 down-regulates SIAH1 expression in human breast cancer cells and silencing of miR-107 inhibits tumor growth in a nude mouse model of triple-negative breast cancer. target gene hsa-mir-135b Carcinoma, Breast, Triple Negative 26711213 D064726 The expressions of miRNA-135b were higher in most triple-negative breast cancer cell lines than others. miRNA-135b could promote the proliferation,invasion and migration in triple-negative breast cancer cell lines MDA-MB-231 and MDA-MB-468, and APC was one of the target genes of miRNA- 135b by participating in the process of regulation. target gene hsa-mir-200a Carcinoma, Breast, Triple Negative 29217458 D064726 The identified IMP2/3-miR-200a-PR axis represents a novel double-negative feedback loop and serves as a new potential therapeutic target for the treatment of TNBC target gene hsa-mir-200b Carcinoma, Breast, Triple Negative 24925028 D064726 MicroRNA-200b targets protein kinase Cα and suppresses triple-negative breast cancer metastasis. target gene hsa-mir-200b Carcinoma, Breast, Triple Negative 26062653 D064726 Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer. target gene hsa-mir-206 Carcinoma, Breast, Triple Negative 25074552 D064726 miR-206 inhibits cell migration through direct targeting of the actin-binding protein coronin 1C in triple-negative breast cancer. target gene hsa-mir-206 Carcinoma, Breast, Triple Negative 26053033 D064726 Consistent with increased levels of miR-206 in MaCSCs, the expression of both PDCD4 and CX43 was suppressed in these cells relative to control cells. target gene hsa-mir-211 Carcinoma, Breast, Triple Negative 28571042 D064726 MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1. target gene hsa-mir-217 Carcinoma, Breast, Triple Negative 28437471 D064726 miR-217 inhibits triple-negative breast cancer cell growth, migration, and invasion through targeting KLF5. target gene hsa-mir-223 Carcinoma, Breast, Triple Negative 27618431 D064726 MicroRNA-223 Increases the Sensitivity of Triple-Negative Breast Cancer Stem Cells to TRAIL-Induced Apoptosis by Targeting HAX-1. target gene hsa-mir-30a Carcinoma, Breast, Triple Negative 29666469 D064726 A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressiveness target gene hsa-mir-31 Carcinoma, Breast, Triple Negative 27593563 D064726 MiR-31 inhibits migration and invasion by targeting SATB2 in triple negative breast cancer. target gene hsa-mir-603 Carcinoma, Breast, Triple Negative 28036267 D064726 MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase. target gene hsa-mir-7 Carcinoma, Breast, Triple Negative 26513016 D064726 Our results not only revealed IL-6 as a key regulator of lapatinib-induced metastasis, but also explored the requirement of miR7/Raf-1/MAPK/AP-1 axis in lapatinib-induced IL-6 expression. target gene hsa-mir-720 Carcinoma, Breast, Triple Negative 27039296 D064726 miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells. target gene hsa-mir-761 Carcinoma, Breast, Triple Negative 28054302 D064726 microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression. target gene hsa-mir-9 Carcinoma, Breast, Triple Negative 25963903 D064726 Overexpression of Notch signaling via Notch1 intracellular domain in MDA-MB-231 cell line was suppressed by lentiviruses expressing miR-9. target gene hsa-let-7 Carcinoma, Cervical 26051842 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 Overall, our study suggests that the microRNAs, miR-21 and let-7a function as clinically relevant integral components of STAT3 signaling and are responsible for maintaining activated state of STAT3 in HPV-infected cells during cervical carcinogenesis. target gene hsa-mir-101 Carcinoma, Cervical 24289600 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 MicroRNA-101 inhibits cell proliferation, invasion, and promotes apoptosis by regulating cyclooxygenase-2 in Hela cervical carcinoma cells. target gene hsa-mir-107 Carcinoma, Cervical 25386925 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 miR-107 activates ATR/Chk1 pathway and suppress cervical cancer invasion by targeting MCL1. target gene hsa-mir-124 Carcinoma, Cervical 25218344 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 MiR-124 represses vasculogenic mimicry and cell motility by targeting amotL1 in cervical cancer cells. target gene hsa-mir-124 Carcinoma, Cervical 27571703 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 MicroRNA-124 inhibits proliferation, invasion, migration and epithelial-mesenchymal transition of cervical carcinoma cells by targeting astrocyte-elevated gene-1. target gene hsa-mir-129 Carcinoma, Cervical 24358111 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 Interferon-β induced microRNA-129-5p down-regulates HPV-18 E6 and E7 viral gene expression by targeting SP1 in cervical cancer cells. target gene hsa-mir-130a Carcinoma, Cervical 24787017 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 Prognostic significance of low DICER expression regulated by miR-130a in cervical cancer. target gene hsa-mir-130a Carcinoma, Cervical 24885472 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 NF-κB-modulated miR-130a targets TNF-α in cervical cancer cells. target gene hsa-mir-133a Carcinoma, Cervical 26134491 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 miR-133a inhibits cervical cancer growth by targeting EGFR. target gene hsa-mir-135a Carcinoma, Cervical 24503442 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 miR-135a leads to cervical cancer cell transformation through regulation of β-catenin via a SIAH1-dependent ubiquitin proteosomal pathway. target gene hsa-mir-138 Carcinoma, Cervical 28385388 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 MicroRNA-138 is a potential biomarker and tumor suppressor in human cervical carcinoma by reversely correlated with TCF3 gene. target gene hsa-mir-142 Carcinoma, Cervical 25976503 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 MicroRNA-142-3p inhibits cell proliferation and invasion of cervical cancer cells by targeting FZD7. target gene hsa-mir-143 Carcinoma, Cervical 27998464 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 miR-143 inhibits cell proliferation through targeted regulating the expression of K-ras gene in HeLa cells. target gene hsa-mir-145 Carcinoma, Cervical 27933466 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 microRNA-145 modulates epithelial-mesenchymal transition and suppresses proliferation, migration and invasion by targeting SIP1 in human cervical cancer cells. target gene hsa-mir-150 Carcinoma, Cervical 26715362 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 Taken together, our data demonstrated that elevated miR-150 targets FOXO4 expression and therefore regulates multiple genes expression, resulting in cervical cancer cell growth and survival. target gene hsa-mir-155 Carcinoma, Cervical 25155037 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 Mir-155 promotes cervical cancer cell proliferation through suppression of its target gene LKB1. target gene hsa-mir-181b Carcinoma, Cervical 24269684 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 miR-181b promotes cell proliferation and reduces apoptosis by repressing the expression of adenylyl cyclase 9 (AC9) in cervical cancer cells. target gene hsa-mir-182 Carcinoma, Cervical 26191165 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 miR-182 induces cervical cancer cell apoptosis through inhibiting the expression of DNMT3a. target gene hsa-mir-187 Carcinoma, Cervical 28128400 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 miR-187 induces apoptosis of SiHa cervical carcinoma cells by downregulating Bcl-2. target gene hsa-mir-196b Carcinoma, Cervical 23861821 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 MicroRNA-196b regulates the homeobox B7-vascular endothelial growth factor axis in cervical cancer. target gene hsa-mir-203 Carcinoma, Cervical 25069511 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 the genes BIRC5, HOXA1 and RARB are critical targets that play an important regulatory role in cervical cancer pathogenesis. target gene hsa-mir-203 Carcinoma, Cervical 27466497 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 Although preliminary, the expression levels of 螖Np63 mRNA and miR-203 seem to be promising for cervical cancer screening. target gene hsa-mir-205 Carcinoma, Cervical 28651495 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 MiR-205 serves as a prognostic factor and suppresses proliferation and invasion by targeting insulin-like growth factor receptor 1 in human cervical cancer. target gene hsa-mir-21 Carcinoma, Cervical 25769949 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 miR-21 modulates resistance of HR-HPV positive cervical cancer cells to radiation through targeting LATS1. target gene hsa-mir-21 Carcinoma, Cervical 28495512 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 Modulation of CASC2/miR-21/PTEN pathway sensitizes cervical cancer to cisplatin. target gene hsa-mir-211 Carcinoma, Cervical 27923652 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 MiR-211 inhibits invasion and epithelial-to-mesenchymal transition (EMT) of cervical cancer cells via targeting MUC4. target gene hsa-mir-212 Carcinoma, Cervical 28165569 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 Effect of miR-212 targeting TCF7L2 on the proliferation and metastasis of cervical cancer. target gene hsa-mir-214 Carcinoma, Cervical 28137590 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 miR-214 down-regulates ARL2 and suppresses growth and invasion of cervical cancer cells. target gene hsa-mir-218 Carcinoma, Cervical 25908215 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 MicroRNA-218 increases cellular sensitivity to Rapamycin via targeting Rictor in cervical cancer. target gene hsa-mir-224 Carcinoma, Cervical 27626930 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 Over-Expressed miR-224 Promotes the Progression of Cervical Cancer via Targeting RASSF8. target gene hsa-mir-25 Carcinoma, Cervical 25575057 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 miR-25 could promote cell proliferation by targeting RECK in HeLa cells. target gene hsa-mir-25 Carcinoma, Cervical 27743413 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 miR-25-3p reverses epithelial-mesenchymal transition via targeting Sema4C in cisplatin-resistance cervical cancer cells. target gene hsa-mir-26a Carcinoma, Cervical 24939702 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 MicroRNA-26a inhibits cell proliferation and invasion of cervical cancer cells by targeting protein tyrosine phosphatase type IVA 1 target gene hsa-mir-30b Carcinoma, Cervical 25069511 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 the genes BIRC5, HOXA1 and RARB are critical targets that play an important regulatory role in cervical cancer pathogenesis. target gene hsa-mir-31 Carcinoma, Cervical 24793973 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 MiR-31 is an independent prognostic factor and functions as an oncomir in cervical cancer via targeting ARID1A. target gene hsa-mir-320a Carcinoma, Cervical 26472185 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 CREB1-driven expression of miR-320a promotes mitophagy by down-regulating VDAC1 expression during serum starvation in cervical cancer cells. target gene hsa-mir-329 Carcinoma, Cervical 28393232 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 MicroRNA-329-3p targets MAPK1 to suppress cell proliferation, migration and invasion in cervical cancer. target gene hsa-mir-331 Carcinoma, Cervical 27548144 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 MicroRNA-331-3p Suppresses Cervical Cancer Cell Proliferation and E6/E7 Expression by Targeting NRP2. target gene hsa-mir-337 Carcinoma, Cervical 28641487 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 MicroRNA-337 inhibits cell proliferation and invasion of cervical cancer through directly targeting specificity protein 1. target gene hsa-mir-33a Carcinoma, Cervical 26541838 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 Twist1 is critical for the invasiveness of cervical cancer cells;miR-33a, as a tumor suppressor gene, functions as an upstream regulator of Twist1 and is involved in the invasiveness of cervical cancer cell. target gene hsa-mir-342 Carcinoma, Cervical 25066298 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 miR-342-3p suppresses proliferation, migration and invasion by targeting FOXM1 in human cervical cancer. target gene hsa-mir-346 Carcinoma, Cervical 26518874 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 miR-346 Up-regulates Argonaute 2 (AGO2) Protein Expression to Augment the Activity of Other MicroRNAs (miRNAs) and Contributes to Cervical Cancer Cell Malignancy. target gene hsa-mir-362 Carcinoma, Cervical 27878258 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 MicroRNA-362 is downregulated in cervical cancer and inhibits cell proliferation, migration and invasion by directly targeting SIX1. target gene hsa-mir-373 Carcinoma, Cervical 25747718 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 MicroRNA-373 functions as an oncogene and targets YOD1 gene in cervical cancer. target gene hsa-mir-375 Carcinoma, Cervical 26224081 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 miR-375 Modulates Radiosensitivity of HR-HPV-Positive Cervical Cancer Cells by Targeting UBE3A through the p53 Pathway. target gene hsa-mir-421 Carcinoma, Cervical 27886335 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 microRNA 421 induces apoptosis of c-33a cervical cancer cells via down-regulation of Bcl-xL. target gene hsa-mir-424 Carcinoma, Cervical 28082020 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 miR424-5p functions as an anti-oncogene in cervical cancer cell growth by targeting KDM5B via the Notch signaling pathway. target gene hsa-mir-429 Carcinoma, Cervical 27883176 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 miR-429 is involved in regulation of NF-κBactivity by targeting IKKβ and suppresses oncogenic activity in cervical cancer cells. target gene hsa-mir-432 Carcinoma, Cervical 25280995 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 Heat shock factor 1 regulates hsa-miR-432 expression in human cervical cancer cell line. target gene hsa-mir-433 Carcinoma, Cervical 23915286 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 The results indicate that miR-433 post-transcriptionally regulates the expression of TYMS mRNA and protein, and increases sensitivity to 5-FU in HeLa cells. This is the first report showing that a miRNA regulating TYMS expression has a significant impact on sensitivity to 5-FU treatment. target gene hsa-mir-491 Carcinoma, Cervical 26034994 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 MicroRNA-491-5p suppresses cervical cancer cell growth by targeting hTERT. target gene hsa-mir-494 Carcinoma, Cervical 25738254 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 MicroRNA-494 promotes cervical cancer proliferation through the regulation of PTEN. target gene hsa-mir-497 Carcinoma, Cervical 24909281 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 Over-expressed miR-497 in HeLa cells could suppress cell proliferation by targeting CCNE1. target gene hsa-mir-506 Carcinoma, Cervical 24608427 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 miR-506 acts as a tumor suppressor by directly targeting the hedgehog pathway transcription factor Gli3 in human cervical cancer. target gene hsa-mir-543 Carcinoma, Cervical 28231728 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 MicroRNA-543 acts as a prognostic marker and promotes the cell proliferation in cervical cancer by BRCA1-interacting protein 1. target gene hsa-mir-590 Carcinoma, Cervical 24288179 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 MicroRNA-590 promotes cervical cancer cell growth and invasion by targeting CHL1. target gene hsa-mir-944 Carcinoma, Cervical 25156441 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 Novel functions and targets of miR-944 in human cervical cancer cells. target gene hsa-mir-99a Carcinoma, Cervical 24668416 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 miR-99a and -99b inhibit cervical cancer cell proliferation and invasion by targeting mTOR signaling pathway. target gene hsa-mir-99b Carcinoma, Cervical 24668416 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 miR-99a and -99b inhibit cervical cancer cell proliferation and invasion by targeting mTOR signaling pathway. target gene hsa-mir-133a Carcinoma, Colon 28466778 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 miR-133a acts as a tumor suppressor in colorectal cancer by targeting eIF4A1. target gene hsa-mir-133b Carcinoma, Colon 24870791 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 MiR-133b might act as a tumor suppressor and negatively regulate TBPL1 in CRC. target gene hsa-mir-137 Carcinoma, Colon 28035913 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 MicroRNA-137 chemosensitizes colon cancer cells to the chemotherapeutic drug oxaliplatin (OXA) by targeting YBX1. target gene hsa-mir-139 Carcinoma, Colon 24885920 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 miR-139-5p plays a pivotal role in colon cancer through inhibiting cell proliferation, metastasis, and promoting apoptosis and cell cycle arrest by targeting oncogenic NOTCH1. target gene hsa-mir-143 Carcinoma, Colon 27827523 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 MicroRNA-143 inhibits colorectal cancer cell proliferation by targeting MMP7. target gene hsa-mir-143 Carcinoma, Colon 19062714 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 The increased accumulation of miR-143 inhibits the proliferation of transfected cells, and results in down-regulation of K-ras protein in colorectal carcinoma. target gene hsa-mir-145 Carcinoma, Colon 25928322 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 Our current observations suggest that miR-21, miR-145, and their networks play critical roles in regulating CSCs growth and/or differentiation in the colon cancer and progression of chemo-resistance. target gene hsa-mir-15a Carcinoma, Colon 25623762 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 miR-15a and miR-16 may reverse the drug resistance in human colon cancer cells. A possible mechanism is regulating the expression of bcl-2. target gene hsa-mir-16 Carcinoma, Colon 25623762 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 miR-15a and miR-16 may reverse the drug resistance in human colon cancer cells. A possible mechanism is regulating the expression of bcl-2. target gene hsa-mir-182 Carcinoma, Colon 25695717 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 MicroRNA-183/182/96 cooperatively regulates the proliferation of colon cancer cells. target gene hsa-mir-183 Carcinoma, Colon 25695717 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 MicroRNA-183/182/96 cooperatively regulates the proliferation of colon cancer cells. target gene hsa-mir-18a Carcinoma, Colon 24166503 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 microRNA-18a induces apoptosis in colon cancer cells via the autophagolysosomal degradation of oncogenic heterogeneous nuclear ribonucleoprotein A1. target gene hsa-mir-19a Carcinoma, Colon 28257633 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 miR-19a promotes colorectal cancer proliferation and migration by targeting TIA1. target gene hsa-mir-200a Carcinoma, Colon 27983967 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 MiR-200a acts as an oncogene in colorectal carcinoma by targeting PTEN. target gene hsa-mir-200c Carcinoma, Colon 24682933 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 In conclusion, miR-200c functions as an oncogene in colon cancer cells through regulating tumor cell apoptosis, survival, invasion, and metastasis as well as xenograft tumor growth through inhibition of PTEN expression and p53 phosphorylation. target gene hsa-mir-21 Carcinoma, Colon 24275137 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro. target gene hsa-mir-21 Carcinoma, Colon 25663768 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 RASA1 is a target gene of miR-21, which promotes malignant behaviors of RKO cells through regulation of RASA1 expression. target gene hsa-mir-21 Carcinoma, Colon 25928322 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 Our current observations suggest that miR-21, miR-145, and their networks play critical roles in regulating CSCs growth and/or differentiation in the colon cancer and progression of chemo-resistance. target gene hsa-mir-21 Carcinoma, Colon 26193421 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 The S100P/RAGE signaling pathway regulates expression of microRNA-21 in colon cancer cells. target gene hsa-mir-21 Carcinoma, Colon 26418978 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 MiR-21 can mediate the drug resistance to 5-FU by inhibiting its target PDCD4,which can regulate the expression of ABCC5 and CD44 genes. target gene hsa-mir-21 Carcinoma, Colon 20826792 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. target gene hsa-mir-210 Carcinoma, Colon 25385144 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 Hypoxia-induced autophagy reduces radiosensitivity by the HIF-1α/miR-210/Bcl-2 pathway in colon cancer cells. target gene hsa-mir-214 Carcinoma, Colon 27811858 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 The FOXD3/miR-214/MED19 axis suppresses tumour growth and metastasis in human colorectal cancer. target gene hsa-mir-215 Carcinoma, Colon 27663660 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 MicroRNA-215 suppresses cell proliferation, migration and invasion of colon cancer by repressing Yin-Yang 1. target gene hsa-mir-216a Carcinoma, Colon 28213952 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 Down-regulation of KIAA1199/CEMIP by miR-216a suppresses tumor invasion and metastasis in colorectal cancer. target gene hsa-mir-218 Carcinoma, Colon 25760926 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 miR-218 inhibits the invasion and migration of colon cancer cells by targeting the PI3K/Akt/mTOR signaling pathway. target gene hsa-mir-218 Carcinoma, Colon 27773352 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 DCC Confers Susceptibility to Depression-like Behaviors in Humans and Mice and Is Regulated by miR-218. target gene hsa-mir-219 Carcinoma, Colon 26238082 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 miR-219-5p plays a tumor suppressive role in colon cancer by targeting oncogene Sall4. target gene hsa-mir-26b Carcinoma, Colon 24785257 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 MicroRNA-26b represses colon cancer cell proliferation by inhibiting lymphoid enhancer factor 1 expression. target gene hsa-mir-29a Carcinoma, Colon 27548517 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 MiR-29a Regulates Radiosensitivity in Human Intestinal Cells by Targeting PTEN Gene. target gene hsa-mir-29b Carcinoma, Colon 24130681 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 Since miR-29b plays a role in regulating the migration of cancer cells,we hypothesized that HAG induces miR-29b expression to target matrix metalloproteinase-2 (MMP-2) thereby suppressing the migration of colon cancer cells. target gene hsa-mir-300 Carcinoma, Colon 27779716 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 miR-300 promotes proliferation and EMT-mediated colorectal cancer migration and invasion by targeting p53. target gene hsa-mir-31 Carcinoma, Colon 25362258 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 miR-31 promotes proliferation of colon cancer cells by targeting E2F2. target gene hsa-mir-31 Carcinoma, Colon 20826792 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. target gene hsa-mir-330 Carcinoma, Colon 27633518 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 MicroRNA-330-5p negatively regulates ITGA5 expression in human colorectal cancer. target gene hsa-mir-34a Carcinoma, Colon 26324236 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 These findings demonstrate that miR-34a may act as a negative regulator in colon cancer by targeting PDGFRA. target gene hsa-mir-34a Carcinoma, Colon 28713966 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 Spica Prunellae extract suppresses the growth of human colon carcinoma cells by targeting multiple oncogenes via activating miR-34a. target gene hsa-mir-374b Carcinoma, Colon 28339062 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 p53/microRNA-374b/AKT1 regulates colorectal cancer cell apoptosis in response to DNA damage. target gene hsa-mir-429 Carcinoma, Colon 26058485 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 MicroRNA-429 inhibits the migration and invasion of colon cancer cells by targeting PAK6/cofilin signaling. target gene hsa-mir-4458 Carcinoma, Colon 26607110 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 In conclusion, our findings suggested that miR-4458 inhibited the progression of colon cancer cells by inhibition of glycolysis and lactate production via directly targeting HK2 mRNA. target gene hsa-mir-492 Carcinoma, Colon 25862460 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 MiR-492 is functionally involved in Oxaliplatin resistance in colon cancer cells LS174T via its regulating the expression of CD147. target gene hsa-mir-494 Carcinoma, Colon 25873402 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 MicroRNA-494 sensitizes colon cancer cells to fluorouracil through regulation of DPYD. target gene hsa-mir-494 Carcinoma, Colon 27648301 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 Targeting the metabolic pathway of human colon cancer overcomes resistance to TRAIL-induced apoptosis. target gene hsa-mir-506 Carcinoma, Colon 27993882 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 MicroRNA-506 Inhibits Malignancy of Colorectal Carcinoma Cells by Targeting LAMC1. target gene hsa-mir-522 Carcinoma, Colon 26043974 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 MicroRNA-522 reverses drug resistance of doxorubicin-induced HT29 colon cancer cell by targeting ABCB5. target gene hsa-mir-590 Carcinoma, Colon 27735951 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 MiR-590-5p inhibits colorectal cancer angiogenesis and metastasis by regulating nuclear factor 90/vascular endothelial growth factor A axis. target gene hsa-mir-6734 Carcinoma, Colon 27509128 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 Collectively, our results demonstrated that miR-6734 inhibits the growth of colon cancer cells by up-regulating p21 gene expression and subsequent induction of cell cycle arrest and apoptosis, suggesting its role as an important endogenous regulator of cancer cell proliferation and survival. target gene hsa-mir-675 Carcinoma, Colon 28189050 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 H19 Overexpression Induces Resistance to 1,25(OH)2D3 by Targeting VDR Through miR-675-5p in Colon Cancer Cells. target gene hsa-mir-885 Carcinoma, Colon 24882581 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 MicroRNA-885-3p inhibits the growth of HT-29 colon cancer cell xenografts by disrupting angiogenesis via targeting BMPR1A and blocking BMP/Smad/Id1 signaling. target gene hsa-mir-96 Carcinoma, Colon 25695717 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 MicroRNA-183/182/96 cooperatively regulates the proliferation of colon cancer cells. target gene hsa-mir-98 Carcinoma, Colon 28025745 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 MicroRNA-98 Suppress Warburg Effect by Targeting HK2 in Colon Cancer Cells. target gene hsa-mir-27 Carcinoma, Embryonal 25369332 disease of cellular proliferation DOID:3308 D018236 HP:0002898 miR-27 negatively regulates pluripotency-associated genes in human embryonal carcinoma cells. target gene hsa-mir-302b Carcinoma, Embryonal 18930031 disease of cellular proliferation DOID:3308 D018236 HP:0002898 miR-302b: miR-302b maintains stemness of human embryonal carcinoma cells by post-transcriptional regulation of Cyclin D2 expression target gene hsa-mir-1 Carcinoma, Endometrial 25955017 reproductive system disease DOID:2871 D07.0 D016889 608089 HP:0012114 The tumor-suppressive microRNA-1/133a cluster targets PDE7A and inhibits cancer cell migration and invasion in endometrial cancer. target gene hsa-mir-101 Carcinoma, Endometrial 25153722 reproductive system disease DOID:2871 D07.0 D016889 608089 HP:0012114 MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells. target gene hsa-mir-106b Carcinoma, Endometrial 24002805 reproductive system disease DOID:2871 D07.0 D016889 608089 HP:0012114 MicroRNA-106b modulates epithelial-mesenchymal transition by targeting TWIST1 in invasive endometrial cancer cell lines. target gene hsa-mir-124 Carcinoma, Endometrial 24287565 reproductive system disease DOID:2871 D07.0 D016889 608089 HP:0012114 miR-124 functions as a tumor suppressor in the endometrial carcinoma cell line HEC-1B partly by suppressing STAT3. target gene hsa-mir-133a Carcinoma, Endometrial 25955017 reproductive system disease DOID:2871 D07.0 D016889 608089 HP:0012114 The tumor-suppressive microRNA-1/133a cluster targets PDE7A and inhibits cancer cell migration and invasion in endometrial cancer. target gene hsa-mir-135b Carcinoma, Endometrial 27222184 reproductive system disease DOID:2871 D07.0 D016889 608089 HP:0012114 MiR-135b promotes proliferation of endometrial carcinoma cells by targeting FOXO1. target gene hsa-mir-141 Carcinoma, Endometrial 24742567 reproductive system disease DOID:2871 D07.0 D016889 608089 HP:0012114 EC may have a unique miRNA expression profile. The expression levels of the five miRNAs (miR-141, miR-200a, miR-205, miR-143, miR-145) are significantly deregulated in typeIEC compared to normal control but not in typeIItumors. The findings suggest that the miRNAs related to type Iand typeIIEC might be different. PTEN might be a potential target of miR-141 and miR-200a in endometrial carcinogenesis. target gene hsa-mir-143 Carcinoma, Endometrial 24742567 reproductive system disease DOID:2871 D07.0 D016889 608089 HP:0012114 EC may have a unique miRNA expression profile. The expression levels of the five miRNAs (miR-141, miR-200a, miR-205, miR-143, miR-145) are significantly deregulated in typeIEC compared to normal control but not in typeIItumors. The findings suggest that the miRNAs related to type Iand typeIIEC might be different. PTEN might be a potential target of miR-141 and miR-200a in endometrial carcinogenesis. target gene hsa-mir-145 Carcinoma, Endometrial 24742567 reproductive system disease DOID:2871 D07.0 D016889 608089 HP:0012114 EC may have a unique miRNA expression profile. The expression levels of the five miRNAs (miR-141, miR-200a, miR-205, miR-143, miR-145) are significantly deregulated in typeIEC compared to normal control but not in typeIItumors. The findings suggest that the miRNAs related to type Iand typeIIEC might be different. PTEN might be a potential target of miR-141 and miR-200a in endometrial carcinogenesis. target gene hsa-mir-182 Carcinoma, Endometrial 24021963 reproductive system disease DOID:2871 D07.0 D016889 608089 HP:0012114 miR-182 acts as an oncogenic miRNA in EC, promoting cell proliferation by targeting the tumor suppressor gene TCEAL7 and modulating the activity of its downstream effectors c-Myc, cyclin D1 and NFκB. target gene hsa-mir-199a Carcinoma, Endometrial 23851675 reproductive system disease DOID:2871 D07.0 D016889 608089 HP:0012114 MiR-199a-3p inhibits tumor cell proliferation through negative regulation of mTOR expression. Restoration of intracellular miR-199a-3p levels may serve as a potential option for EEC treatment. target gene hsa-mir-200a Carcinoma, Endometrial 24742567 reproductive system disease DOID:2871 D07.0 D016889 608089 HP:0012114 EC may have a unique miRNA expression profile. The expression levels of the five miRNAs (miR-141, miR-200a, miR-205, miR-143, miR-145) are significantly deregulated in typeIEC compared to normal control but not in typeIItumors. The findings suggest that the miRNAs related to type Iand typeIIEC might be different. PTEN might be a potential target of miR-141 and miR-200a in endometrial carcinogenesis. target gene hsa-mir-200b Carcinoma, Endometrial 28529604 reproductive system disease DOID:2871 D07.0 D016889 608089 HP:0012114 knockdown of DICER1 significantly downregulated miR-200b and let-7i, which may then regulate their targets SUZ12 and EZH2 target gene hsa-mir-200c Carcinoma, Endometrial 29080395 reproductive system disease DOID:2871 D07.0 D016889 608089 HP:0012114 MicroRNA-200c Inhibits Epithelial-Mesenchymal Transition by Targeting the BMI-1 Gene Through the Phospho-AKT Pathway in Endometrial Carcinoma Cells In Vitro. target gene hsa-mir-205 Carcinoma, Endometrial 24929707 reproductive system disease DOID:2871 D07.0 D016889 608089 HP:0012114 For the first time, we demonstrate that the expression of PTEN is directly regulated by miR-205 in endometrial cancer cells and leads the inhibition of cellular apoptosis. This relationship could be targeted for new therapeutic strategies for endometrial cancer. target gene hsa-mir-205 Carcinoma, Endometrial 24742567 reproductive system disease DOID:2871 D07.0 D016889 608089 HP:0012114 EC may have a unique miRNA expression profile. The expression levels of the five miRNAs (miR-141, miR-200a, miR-205, miR-143, miR-145) are significantly deregulated in typeIEC compared to normal control but not in typeIItumors. The findings suggest that the miRNAs related to type Iand typeIIEC might be different. PTEN might be a potential target of miR-141 and miR-200a in endometrial carcinogenesis. target gene hsa-mir-222 Carcinoma, Endometrial 24498137 reproductive system disease DOID:2871 D07.0 D016889 608089 HP:0012114 Elevated MiR-222-3p promotes proliferation and invasion of endometrial carcinoma via targeting ERα. target gene hsa-mir-29b Carcinoma, Endometrial 28222438 reproductive system disease DOID:2871 D07.0 D016889 608089 HP:0012114 MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma. target gene hsa-mir-34a Carcinoma, Endometrial 24497324 reproductive system disease DOID:2871 D07.0 D016889 608089 HP:0012114 Our data suggest that miR-34a can regulate L1CAM expression by targeting L1CAM mRNA for degradation.These findings shed new light on the complex regulation of L1CAM in human tumors. target gene hsa-mir-34c Carcinoma, Endometrial 25846116 reproductive system disease DOID:2871 D07.0 D016889 608089 HP:0012114 our study demonstrated that miR-34c plays a role of tumor suppressor in HEC-1-B cells, and E2F3 protein may be a target of miR-34c. target gene hsa-mir-424 Carcinoma, Endometrial 25708247 reproductive system disease DOID:2871 D07.0 D016889 608089 HP:0012114 MicroRNA-424 may function as a tumor suppressor in endometrial carcinoma cells by targeting E2F7. target gene hsa-mir-424 Carcinoma, Endometrial 29371986 reproductive system disease DOID:2871 D07.0 D016889 608089 HP:0012114 MicroRNA-424/E2F6 feedback loop modulates cell invasion, migration and EMT in endometrial carcinoma target gene hsa-mir-449a Carcinoma, Endometrial 24993091 reproductive system disease DOID:2871 D07.0 D016889 608089 HP:0012114 MiR-449a functions as a tumor suppressor in endometrial cancer by targeting CDC25A. target gene hsa-mir-505 Carcinoma, Endometrial 26832151 reproductive system disease DOID:2871 D07.0 D016889 608089 HP:0012114 Taken together, this study demonstrates that miR-505 acts as tumor suppressor in EC by regulating TGF-α. target gene hsa-mir-543 Carcinoma, Endometrial 24699721 reproductive system disease DOID:2871 D07.0 D016889 608089 HP:0012114 MiR-543 expression is decreased in endometrial cancer and serves as a tumor suppressor by targeting FAK and TWIST1 expression. target gene hsa-mir-200a Carcinoma, Endometrioid Endometrial 25750291 C54.1 D018269 miR-200a, miR-200b and miR-429 are onco-miRs that target the PTEN gene in endometrioid endometrial carcinoma. target gene hsa-mir-200b Carcinoma, Endometrioid Endometrial 25750291 C54.1 D018269 miR-200a, miR-200b and miR-429 are onco-miRs that target the PTEN gene in endometrioid endometrial carcinoma. target gene hsa-mir-21 Carcinoma, Endometrioid Endometrial 23226804 C54.1 D018269 microRNA-21 overexpression contributes to cell proliferation by targeting PTEN in endometrioid endometrial cancer target gene hsa-mir-23a Carcinoma, Endometrioid Endometrial 27601936 C54.1 D018269 MicroRNA-23a regulates epithelial-to-mesenchymal transition in endometrial endometrioid adenocarcinoma by targeting SMAD3. target gene hsa-mir-429 Carcinoma, Endometrioid Endometrial 25750291 C54.1 D018269 miR-200a, miR-200b and miR-429 are onco-miRs that target the PTEN gene in endometrioid endometrial carcinoma. target gene hsa-mir-503 Carcinoma, Endometrioid Endometrial 23731275 C54.1 D018269 MicroRNA-503 suppresses proliferation and cell cycle progression of endometrioid ndometrial cancer via negatively regulating cyclin D1. target gene hsa-mir-1207 Carcinoma, Esophageal 25695396 disease of cellular proliferation DOID:1107 C15.9 D004938 133239 HP:0011459 miRNA-1207-5p is associated with cancer progression by targeting stomatin-like protein 2 in esophageal carcinoma. target gene hsa-mir-122 Carcinoma, Esophageal 24659424 disease of cellular proliferation DOID:1107 C15.9 D004938 133239 HP:0011459 Esophageal cancer-selective expression of TRAIL mediated by MREs of miR-143 and miR-122. target gene hsa-mir-124 Carcinoma, Esophageal 25928665 disease of cellular proliferation DOID:1107 C15.9 D004938 133239 HP:0011459 Collectively, these data suggest that miR-124 functions as a tumor suppressor in esophageal cancer through, at least partially, targeting STAT3 signaling pathway. target gene hsa-mir-126 Carcinoma, Esophageal 28536606 disease of cellular proliferation DOID:1107 C15.9 D004938 133239 HP:0011459 The crucial role of miR-126 on suppressing progression of esophageal cancer by targeting VEGF-A. target gene hsa-mir-133a Carcinoma, Esophageal 24196787 disease of cellular proliferation DOID:1107 C15.9 D004938 133239 HP:0011459 The combined expression of FSCN1 and MMP14 is associated with a poor prognosis, and miR-133a, which regulates their mRNAs, can serve as a strong tumour suppressor of ESCC. target gene hsa-mir-140 Carcinoma, Esophageal 25322669 disease of cellular proliferation DOID:1107 C15.9 D004938 133239 HP:0011459 miR-140 may regulate the cell invasion of EC via controlling Slugexpression. target gene hsa-mir-141 Carcinoma, Esophageal 27644195 disease of cellular proliferation DOID:1107 C15.9 D004938 133239 HP:0011459 Involvement of microRNA-141-3p in 5-fluorouracil and oxaliplatin chemo-resistance in esophageal cancer cells via regulation of PTEN. target gene hsa-mir-143 Carcinoma, Esophageal 24659424 disease of cellular proliferation DOID:1107 C15.9 D004938 133239 HP:0011459 Esophageal cancer-selective expression of TRAIL mediated by MREs of miR-143 and miR-122. target gene hsa-mir-183 Carcinoma, Esophageal 25518924 disease of cellular proliferation DOID:1107 C15.9 D004938 133239 HP:0011459 miR-183 might play an oncogenic role in ESCC by regulating PDCD4 expression. target gene hsa-mir-193a Carcinoma, Esophageal 26743123 disease of cellular proliferation DOID:1107 C15.9 D004938 133239 HP:0011459 miR-193a-3p regulation of chemoradiation resistance in oesophageal cancer cells via the PSEN1 gene. target gene hsa-mir-195 Carcinoma, Esophageal 28487599 disease of cellular proliferation DOID:1107 C15.9 D004938 133239 HP:0011459 miR-195 Regulates Proliferation and Apoptosis through Inhibiting the mTOR/p70s6k Signaling Pathway by Targeting HMGA2 in Esophageal Carcinoma Cells. target gene hsa-mir-203 Carcinoma, Esophageal 25216463 disease of cellular proliferation DOID:1107 C15.9 D004938 133239 HP:0011459 miR-203 is a direct transcriptional target of E2F1 and causes G1 arrest in esophageal cancer cells. target gene hsa-mir-204 Carcinoma, Esophageal 26722467 disease of cellular proliferation DOID:1107 C15.9 D004938 133239 HP:0011459 miR-204 inhibits invasion and epithelial-mesenchymal transition by targeting FOXM1 in esophageal cancer. target gene hsa-mir-21 Carcinoma, Esophageal 24221338 disease of cellular proliferation DOID:1107 C15.9 D004938 133239 HP:0011459 Our findings suggest that miR-21 could be a potential oncomiR,probably by regulation of PTEN, and a novel prognostic factor for ESCC patients. target gene hsa-mir-21 Carcinoma, Esophageal 26345812 disease of cellular proliferation DOID:1107 C15.9 D004938 133239 HP:0011459 Together,these results suggest that miR- 21 might be involved in the development and metastasis of esophageal cancer, through interaction with its PDCD4 and K-ras target genes. target gene hsa-mir-30b Carcinoma, Esophageal 28189678 disease of cellular proliferation DOID:1107 C15.9 D004938 133239 HP:0011459 miR-30b inhibits cancer cell growth, migration, and invasion by targeting homeobox A1 in esophageal cancer. target gene hsa-mir-328 Carcinoma, Esophageal 26773497 disease of cellular proliferation DOID:1107 C15.9 D004938 133239 HP:0011459 MiR-328 suppresses the survival of esophageal cancer cells by targeting PLCE1. target gene hsa-mir-340 Carcinoma, Esophageal 26316084 disease of cellular proliferation DOID:1107 C15.9 D004938 133239 HP:0011459 MiR-340 functions as a tumor suppressor by modulating the expression of PSAT1 and may contribute to the progression and invasiveness of ESCC. target gene hsa-mir-429 Carcinoma, Esophageal 23999873 disease of cellular proliferation DOID:1107 C15.9 D004938 133239 HP:0011459 In primary EC tissues miR-429 is expressed at low levels. Up-regulation of miR-429 inhibits invasion and promotes apoptosis in EC cells by targeting Bcl-2 and SP1. Our findings suggest that Bcl-2 and SP1 may serve as major targets of miR-429. This study paves the way for a better understanding of the mechanism underlying EC pathogenesis and the development of novel, targeted therapies. target gene hsa-mir-499 Carcinoma, Esophageal 26159783 disease of cellular proliferation DOID:1107 C15.9 D004938 133239 HP:0011459 MiR-499 Enhances the Cisplatin Sensitivity of Esophageal Carcinoma Cell Lines by Targeting DNA Polymerase β. target gene hsa-mir-542 Carcinoma, Esophageal 26323919 disease of cellular proliferation DOID:1107 C15.9 D004938 133239 HP:0011459 Taken together, our results indicated that miR-542-3p is a tumor suppressor of esophageal cancer acting at steps that regulate cell growth. target gene hsa-mir-96 Carcinoma, Esophageal 25465153 disease of cellular proliferation DOID:1107 C15.9 D004938 133239 HP:0011459 miR-96 serves as an oncogene role in EC cells through downregulating RECK. target gene hsa-mir-135a Carcinoma, Gallbladder 24903309 disease of cellular proliferation DOID:4948 C23 D005706 MicroRNA-135a acts as a putative tumor suppressor by directly targeting very low density lipoprotein receptor in human gallbladder cancer. target gene hsa-mir-143 Carcinoma, Gallbladder 29416013 disease of cellular proliferation DOID:4948 C23 D005706 miR-143-3p targeting of ITGA6 suppresses tumour growth and angiogenesis by downregulating PLGF expression via the PI3K/AKT pathway in gallbladder carcinoma. target gene hsa-mir-146b Carcinoma, Gallbladder 25760482 disease of cellular proliferation DOID:4948 C23 D005706 MicroRNA-146b-5p inhibits the growth of gallbladder carcinoma by targeting epidermal growth factor receptor. target gene hsa-mir-182 Carcinoma, Gallbladder 24445397 disease of cellular proliferation DOID:4948 C23 D005706 TGF-β upregulates miR-182 expression to promote gallbladder cancer metastasis by targeting CADM1. target gene hsa-mir-26a Carcinoma, Gallbladder 24682444 disease of cellular proliferation DOID:4948 C23 D005706 MicroRNA-26a acts as a tumor suppressor inhibiting gallbladder cancer cell proliferation by directly targeting HMGA2. target gene hsa-mir-30a Carcinoma, Gallbladder 29540696 disease of cellular proliferation DOID:4948 C23 D005706 MicroRNA-30a-5p inhibits gallbladder cancer cell proliferation, migration and metastasis by targeting E2F7. target gene hsa-mir-33a Carcinoma, Gallbladder 27769047 disease of cellular proliferation DOID:4948 C23 D005706 The microRNA miR-33a suppresses IL-6-induced tumor progression by binding Twist in gallbladder cancer. target gene hsa-mir-34 Carcinoma, Gallbladder 24078448 disease of cellular proliferation DOID:4948 C23 D005706 Both low miR-34a expression and long telomere length are markers for poor prognosis of patients with gallbladder adenocarcinoma. Our study also suggests that the miR-34a gene could be a target for targeting therapy of GBC. target gene hsa-mir-663a Carcinoma, Gallbladder 29778567 disease of cellular proliferation DOID:4948 C23 D005706 EMP3, which is regulated by miR-663a, suppresses gallbladder cancer progression via interference with the MAPK/ERK pathway. target gene hsa-mir-103 Carcinoma, Gastric 25407491 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 caveolin-1(Cav-1), a critical component of lipid rafts, was a target of miR-103/107. target gene hsa-mir-107 Carcinoma, Gastric 25407491 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 caveolin-1(Cav-1), a critical component of lipid rafts, was a target of miR-103/107. target gene hsa-mir-10b Carcinoma, Gastric 26191201 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 Augmented miR-10b expression associated with depressed expression of its target gene KLF4 involved in gastric carcinoma. target gene hsa-mir-1228 Carcinoma, Gastric 28465246 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 microRNA-1228⁎ impairs the pro-angiogenic activity of gastric cancer cells by targeting macrophage migration inhibitory factor. target gene hsa-mir-124 Carcinoma, Gastric 24257299 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 miR-124 can suppress the cell proliferation and invasion by targeting SPHK1 in gastric carcinoma. target gene hsa-mir-125a Carcinoma, Gastric 25231560 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 Reduced miR-125a-5p expression is associated with gastric carcinogenesis through the targeting of E2F3. target gene hsa-mir-126 Carcinoma, Gastric 27622325 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 MicroRNA-126 increases chemosensitivity in drug-resistant gastric cancer cells by targeting EZH2. target gene hsa-mir-126 Carcinoma, Gastric 28260063 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 ADAM9 functions as a promoter of gastric cancer growth which is negatively and post-transcriptionally regulated by miR-126. target gene hsa-mir-129 Carcinoma, Gastric 28012924 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 MiR-129 regulates cisplatin-resistance in human gastric cancer cells by targeting P-gp. target gene hsa-mir-129 Carcinoma, Gastric 28653880 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 MiR-129-5p influences the progression of gastric cancer cells through interacting with SPOCK1. target gene hsa-mir-1296 Carcinoma, Gastric 28099468 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 miR 1296-5p Inhibits the Migration and Invasion of Gastric Cancer Cells by Repressing ERBB2 Expression. target gene hsa-mir-133a Carcinoma, Gastric 25815687 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 MicroRNA-133a inhibits proliferation and invasion, and induces apoptosis in gastric carcinoma cells via targeting fascin actin-bundling protein 1. target gene hsa-mir-134 Carcinoma, Gastric 28260021 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 MicroRNA-134 suppresses cell proliferation in gastric cancer cells via targeting of GOLPH3. target gene hsa-mir-136 Carcinoma, Gastric 28656883 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 MiR-136 inhibits gastric cancer-specific peritoneal metastasis by targeting HOXC10. target gene hsa-mir-137 Carcinoma, Gastric 25064845 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 miR-137 effects on gastric carcinogenesis are mediated by targeting Cox-2-activated PI3K/AKT signaling pathway. target gene hsa-mir-137 Carcinoma, Gastric 26102366 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 MicroRNA-137 Contributes to Dampened Tumorigenesis in Human Gastric Cancer by Targeting AKT2. target gene hsa-mir-141 Carcinoma, Gastric 28115163 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 Lnc-ATB contributes to gastric cancer growth through a MiR-141-3p/TGFβ2 feedback loop. target gene hsa-mir-143 Carcinoma, Gastric 28718369 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 MiR-143 inhibits cell proliferation and invasion by targeting DNMT3A in gastric cancer. target gene hsa-mir-144 Carcinoma, Gastric 28111340 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 MicroRNA-144-3p suppresses gastric cancer progression by inhibiting epithelial-to-mesenchymal transition through targeting PBX3. target gene hsa-mir-155 Carcinoma, Gastric 24969405 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 Downregulation of microRNA-155 accelerates cell growth and invasion by targeting c-myc in human gastric carcinoma cells. target gene hsa-mir-16 Carcinoma, Gastric 27683052 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 Direct targeting of HGF by miR-16 regulates proliferation and migration in gastric cancer. target gene hsa-mir-181a Carcinoma, Gastric 28043911 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 miR-181a-5p promotes the progression of gastric cancer via RASSF6-mediated MAPK signalling activation. target gene hsa-mir-185 Carcinoma, Gastric 23846337 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 Our results show that GKN1 has an miR-185-dependent and -independent mechanism for chromatic and DNA epigenetic modification, thereby regulating the cell cycle. Thus, the loss of GKN1 function contributes to malignant transformation and proliferation of gastric epithelial cells in gastric carcinogenesis. target gene hsa-mir-187 Carcinoma, Gastric 27864146 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 MicroRNA-187 regulates gastric cancer progression by targeting the tumor suppressor CRMP1. target gene hsa-mir-187 Carcinoma, Gastric 28098868 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 MicroRNA-187 promotes growth and metastasis of gastric cancer by inhibiting FOXA2. target gene hsa-mir-194 Carcinoma, Gastric 27874950 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 miR-194 inhibits gastric cancer cell proliferation and tumorigenesis by targeting KDM5B. target gene hsa-mir-19b Carcinoma, Gastric 27572553 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 MicroRNA-19b inhibits proliferation of gastric cancer cells by targeting B-cell CLL/lymphoma 3. target gene hsa-mir-200a Carcinoma, Gastric 27144885 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 Depleting endogenous Bart9 of SNU-719 induced a surged expression of miR-200a and miR-141, accompanied by decreased proliferative and invasive ability. target gene hsa-mir-200c Carcinoma, Gastric 29286062 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 miR-200c regulates the proliferation, apoptosis and invasion of gastric carcinoma cells through the downregulation of EDNRA expression target gene hsa-mir-203 Carcinoma, Gastric 27542403 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 MiR-203 inhibits tumor invasion and metastasis in gastric cancer by ATM. target gene hsa-mir-218 Carcinoma, Gastric 27642088 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 miR-218 Inhibits Proliferation, Migration, and EMT of Gastric Cancer Cells by Targeting WASF3. target gene hsa-mir-218 Carcinoma, Gastric 27696291 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 MicroRNA-218 inhibits the proliferation, migration, and invasion and promotes apoptosis of gastric cancer cells by targeting LASP1. target gene hsa-mir-218 Carcinoma, Gastric 28323002 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 miR-218 inhibited tumor angiogenesis by targeting ROBO1 in gastric cancer. target gene hsa-mir-221 Carcinoma, Gastric 28618968 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 miR-221 and miR-222 synergistically regulate hepatocyte growth factor activator inhibitor type 1 to promote cell proliferation and migration in gastric cancer. target gene hsa-mir-222 Carcinoma, Gastric 28618968 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 miR-221 and miR-222 synergistically regulate hepatocyte growth factor activator inhibitor type 1 to promote cell proliferation and migration in gastric cancer. target gene hsa-mir-223 Carcinoma, Gastric 25888377 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 Our findings revealed the roles of miR-223/FBXW7 signaling in the DDP resistance of GC cells and targeting it will be a potential strategic approach for reversing the DDP resistance in human GC. target gene hsa-mir-224 Carcinoma, Gastric 28173803 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 Hypoxia-inducible microRNA-224 promotes the cell growth, migration and invasion by directly targeting RASSF8 in gastric cancer. target gene hsa-mir-27b Carcinoma, Gastric 27844448 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 miR-27b inhibits gastric cancer metastasis by targeting NR2F2. target gene hsa-mir-320a Carcinoma, Gastric 28008607 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 MicroRNA-320a and microRNA-4496 attenuate Helicobacter pylori cytotoxin-associated gene A (CagA)-induced cancer-initiating potential and chemoresistance by targeting β-catenin and ATP-binding cassette, subfamily G, member 2. target gene hsa-mir-34 Carcinoma, Gastric 24970812 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 Yin Yang 1 is a target of microRNA-34 family and contributes to gastric carcinogenesis. target gene hsa-mir-34a Carcinoma, Gastric 28399871 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 IGF2BP3 functions as a potential oncogene and is a crucial target of miR-34a in gastric carcinogenesis. target gene hsa-mir-34c Carcinoma, Gastric 26097561 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 PABPC1 exerts carcinogenesis in gastric carcinoma by targeting miR-34c. target gene hsa-mir-363 Carcinoma, Gastric 23975832 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 These results suggest that miR-363 plays an important role in the increment of gastric carcinogenesis via targeting MBP-1. target gene hsa-mir-4496 Carcinoma, Gastric 28008607 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 MicroRNA-320a and microRNA-4496 attenuate Helicobacter pylori cytotoxin-associated gene A (CagA)-induced cancer-initiating potential and chemoresistance by targeting β-catenin and ATP-binding cassette, subfamily G, member 2. target gene hsa-mir-494 Carcinoma, Gastric 24612089 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 miR-494 is downregulated in human GC and acts as an anti-oncogene by targeting c-myc. miR-494 plays a role in the pathogenesis of gastric cancer in a recessive fashion. target gene hsa-mir-494 Carcinoma, Gastric 27735036 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 miR-494 inhibits invasion and proliferation of gastric cancer by targeting IGF-1R. target gene hsa-mir-495 Carcinoma, Gastric 28159956 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 MicroRNA-495 Inhibits Gastric Cancer Cell Migration and Invasion Possibly via Targeting High Mobility Group AT-Hook 2 (HMGA2). target gene hsa-mir-509 Carcinoma, Gastric 27697095 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 MicroRNA-509-3p Inhibits Cancer Cell Proliferation and Migration via Upregulation of XIAP in Gastric Cancer Cells. target gene hsa-mir-520b Carcinoma, Gastric 27997901 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 MiR-520b/e Regulates Proliferation and Migration by Simultaneously Targeting EGFR in Gastric Cancer. target gene hsa-mir-520e Carcinoma, Gastric 27997901 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 MiR-520b/e Regulates Proliferation and Migration by Simultaneously Targeting EGFR in Gastric Cancer. target gene hsa-mir-532 Carcinoma, Gastric 28356225 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 miR-532 promoted gastric cancer migration and invasion by targeting NKD1. target gene hsa-mir-630 Carcinoma, Gastric 28601080 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 MicroRNA-630 Suppresses Epithelial-to-Mesenchymal Transition by Regulating FoxM1 in Gastric Cancer Cells. target gene hsa-mir-638 Carcinoma, Gastric 26250158 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 MicroRNA-638 inhibits cell proliferation by targeting phospholipase D1 in human gastric carcinoma. target gene hsa-mir-646 Carcinoma, Gastric 28632723 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 MiR-646 inhibited cell proliferation and EMT-induced metastasis by targeting FOXK1 in gastric cancer. target gene hsa-mir-7 Carcinoma, Gastric 26261179 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 MicroRNA-7/NF-κB signaling regulatory feedback circuit regulates gastric carcinogenesis. target gene hsa-mir-9 Carcinoma, Gastric 28127811 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 MicroRNA-9 inhibits the gastric cancer cell proliferation by targeting TNFAIP8. target gene hsa-mir-935 Carcinoma, Gastric, Signet Ring Cell 26742429 D018279 miR-935 suppresses gastric signet ring cell carcinoma tumorigenesis by targeting Notch1 expression. target gene hsa-let-7a Carcinoma, Hepatocellular 27932893 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Let-7a enhances the sensitivity of hepatocellular carcinoma cells to cetuximab by regulating STAT3 expression. target gene hsa-let-7a-1 Carcinoma, Hepatocellular 20347499 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 hsa-let-7a:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma target gene hsa-let-7a-2 Carcinoma, Hepatocellular 20347499 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 hsa-let-7a:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma target gene hsa-let-7a-3 Carcinoma, Hepatocellular 20347499 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 hsa-let-7a:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma target gene hsa-let-7b Carcinoma, Hepatocellular 20347499 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 hsa-let-7b:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma target gene hsa-let-7b Carcinoma, Hepatocellular 28671046 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Let7b modulates the Wnt/β-catenin pathway in liver cancer cells via downregulated Frizzled4. target gene hsa-let-7c Carcinoma, Hepatocellular 20347499 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 hsa-let-7c:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma target gene hsa-let-7c Carcinoma, Hepatocellular 22433309 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 let-7c can inhibit proliferation of HCCLM3 cells and increase the proportion of cells in G1 phase. The mechanism may be that let-7c represses the expressions of cyclin D1 at both protein and mRNA levels. target gene hsa-let-7c Carcinoma, Hepatocellular 25909324 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA let-7c Inhibits Cell Proliferation and Induces Cell Cycle Arrest by Targeting CDC25A in Human Hepatocellular Carcinoma. target gene hsa-let-7d Carcinoma, Hepatocellular 20347499 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 hsa-let-7d:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma target gene hsa-let-7e Carcinoma, Hepatocellular 20347499 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 hsa-let-7e:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma target gene hsa-let-7f-1 Carcinoma, Hepatocellular 20347499 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 hsa-let-7f:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma target gene hsa-let-7f-2 Carcinoma, Hepatocellular 20347499 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 hsa-let-7f:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma target gene hsa-let-7g Carcinoma, Hepatocellular 20309945 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Hsa-let-7g inhibits proliferation of hepatocellular carcinoma Cells by down-regulation of c-Myc and Up-regulation of p16(INK4A). target gene hsa-let-7g Carcinoma, Hepatocellular 20338660 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Let-7g targets collagen type I alpha2 and inhibits cell migration in hepatocellular carcinoma. target gene hsa-let-7g Carcinoma, Hepatocellular 20347499 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 hsa-let-7g:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma target gene hsa-let-7g Carcinoma, Hepatocellular 24724096 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Reexpression of Let-7g microRNA inhibits the proliferation and migration via K-Ras/HMGA2/snail axis in hepatocellular carcinoma. target gene hsa-let-7i Carcinoma, Hepatocellular 20347499 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 hsa-let-7i:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma target gene hsa-let-7i Carcinoma, Hepatocellular 21665888 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 In addition, we showed that HBx up-regulated CD59 by let-7i at post-transcriptional regulation level. target gene hsa-mir-100 Carcinoma, Hepatocellular 25026290 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-100 promotes the autophagy of hepatocellular carcinoma cells by inhibiting the expression of mTOR and IGF-1R. target gene hsa-mir-101 Carcinoma, Hepatocellular 26158762 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-101 targets DUSP1 to regulate the TGF-β secretion in sorafenib inhibits macrophage-induced growth of hepatocarcinoma. target gene hsa-mir-101 Carcinoma, Hepatocellular 24211739 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Tumor suppressor miR-101 represses HCC progression through directly targeting EZH2 oncogene and sensitizes liver cancer cells to chemotherapeutic treatment. Our findings provide significant insights into molecular mechanisms of hepatocarcinogenesis and may have clinical relevance for the development of novel targeted therapies for HCC. target gene hsa-mir-101 Carcinoma, Hepatocellular 25808945 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Our results demonstrate that miR-101 regulates HCC cell phenotype by upregulating the epithelial marker genes and suppressing the mesenchymal ones. target gene hsa-mir-101 Carcinoma, Hepatocellular 25260594 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 A novel AP-1/miR-101 regulatory feedback loop and its implication in the migration and invasion of hepatoma cells. target gene hsa-mir-101 Carcinoma, Hepatocellular 27702662 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Upregulation of SNHG6 regulates ZEB1 expression by competitively binding miR-101-3p and interacting with UPF1 in hepatocellular carcinoma. target gene hsa-mir-101-1 Carcinoma, Hepatocellular 19133651 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-101: MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene target gene hsa-mir-101-2 Carcinoma, Hepatocellular 19133651 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-101: MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene target gene hsa-mir-106b Carcinoma, Hepatocellular 28410209 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-106b inhibitors sensitize TRAIL-induced apoptosis in hepatocellular carcinoma through increase of death receptor 4. target gene hsa-mir-107 Carcinoma, Hepatocellular 27773820 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-107 suppresses proliferation of hepatoma cells through targeting HMGA2 mRNA 3'UTR. target gene hsa-mir-107 Carcinoma, Hepatocellular 28867541 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-107-mediated decrease of HMGCS2 indicates poor outcomes and promotes cell migration in hepatocellular carcinoma target gene hsa-mir-107 Carcinoma, Hepatocellular 26191213 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Our observations suggested that miR-107 could promote HCC cells proliferation via targeting Axin2 and might represent a potential therapeutic target for HCC. target gene hsa-mir-10a Carcinoma, Hepatocellular 22996586 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Our findings highlight the importance of miR-10a in regulating the metastatic properties of HCC by directly targeting EphA4 and may provide new insights into the pathogenesis of HCC target gene hsa-mir-10b Carcinoma, Hepatocellular 22528944 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-10b promotes migration and invasion through CADM1 in human hepatocellular carcinoma cells. target gene hsa-mir-10b Carcinoma, Hepatocellular 27756250 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-10b exerts oncogenic activity in human hepatocellular carcinoma cells by targeting expression of CUB and sushi multiple domains 1 (CSMD1). target gene hsa-mir-10b Carcinoma, Hepatocellular 29375271 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-10b regulates epithelial-mesenchymal transition by modulating KLF4/KLF11/Smads in hepatocellular carcinoma target gene hsa-mir-10b Carcinoma, Hepatocellular 29506532 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 CADM2, as a new target of miR-10b, promotes tumor metastasis through FAK/AKT pathway in hepatocellular carcinoma target gene hsa-mir-1-1 Carcinoma, Hepatocellular 22664953 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-1 and microRNA-499 downregulate the expression of the ets1 proto-oncogene in HepG2 cells. target gene hsa-mir-1-2 Carcinoma, Hepatocellular 22664953 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-1 and microRNA-499 downregulate the expression of the ets1 proto-oncogene in HepG2 cells. target gene hsa-mir-1202 Carcinoma, Hepatocellular 29217161 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-1202 suppresses hepatocellular carcinoma cells migration and invasion by targeting cyclin dependent kinase 14 target gene hsa-mir-122 Carcinoma, Hepatocellular 16777601 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 inhibite CAT-1 target gene hsa-mir-122 Carcinoma, Hepatocellular 17616664 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. target gene hsa-mir-122 Carcinoma, Hepatocellular 18692484 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. target gene hsa-mir-122 Carcinoma, Hepatocellular 19726678 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 The liver specific miR-122 is frequently suppressed in primary hepatocellular carcinomas (HCCs). ADAM-10 (a distintegrin and metalloprotease family-10), SRF (serum response factor), and Igf1R (insulin like growth factor 1 receptor) that promote tumorigenesis were validated as targets of miR- 122 and were repressed by the microRNA. target gene hsa-mir-122 Carcinoma, Hepatocellular 21725618 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-122 inhibits viral replication and cell proliferation in hepatitis B virus-related hepatocellular carcinoma and targets NDRG3. target gene hsa-mir-122 Carcinoma, Hepatocellular 21802841 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. target gene hsa-mir-122 Carcinoma, Hepatocellular 22276989 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/ж┿catenin pathway. target gene hsa-mir-122 Carcinoma, Hepatocellular 24244539 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-122 regulates tumorigenesis in hepatocellular carcinoma by targeting AKT3. target gene hsa-mir-122 Carcinoma, Hepatocellular 24466275 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma. target gene hsa-mir-122 Carcinoma, Hepatocellular 25422324 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 our results reveal a novel Hnf4α/miR-122/GALNT10 regulatory pathway that facilitates EGF miR-122 activation and hepatoma growth in HBV-associated hepatocarcinogenesis. target gene hsa-mir-122 Carcinoma, Hepatocellular 26252254 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-122 affects cell aggressiveness and apoptosis by targeting PKM2 in human hepatocellular carcinoma. target gene hsa-mir-122 Carcinoma, Hepatocellular 24992599 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-122 triggers mesenchymal-epithelial transition and suppresses hepatocellular carcinoma cell motility and invasion by targeting RhoA. target gene hsa-mir-122 Carcinoma, Hepatocellular 27687586 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 WNT1 Gene from WNT Signaling Pathway Is a Direct Target of miR-122 in Hepatocellular Carcinoma. target gene hsa-mir-122 Carcinoma, Hepatocellular 27302319 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-122*, the passenger strand of miR-122, regulates the activity of p53 by targeting Mdm2. target gene hsa-mir-122a Carcinoma, Hepatocellular 26189916 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Targeted Regression of Hepatocellular Carcinoma by Cancer-Specific RNA Replacement through miR-122a Regulation. target gene hsa-mir-1236 Carcinoma, Hepatocellular 25714026 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-1236 down-regulates alpha-fetoprotein, thus causing PTEN accumulation, which inhibits the PI3K/Akt pathway and malignant phenotype in hepatoma cells. target gene hsa-mir-124 Carcinoma, Hepatocellular 24211205 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-124 suppresses growth of human hepatocellular carcinoma by targeting STAT3. target gene hsa-mir-124-1 Carcinoma, Hepatocellular 21672940 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. target gene hsa-mir-124-1 Carcinoma, Hepatocellular 22940133 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-124 suppresses cell proliferation in hepatocellular carcinoma by targeting PIK3CA. target gene hsa-mir-124-2 Carcinoma, Hepatocellular 21672940 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. target gene hsa-mir-124-2 Carcinoma, Hepatocellular 22940133 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-124 suppresses cell proliferation in hepatocellular carcinoma by targeting PIK3CA. target gene hsa-mir-124-3 Carcinoma, Hepatocellular 21672940 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. target gene hsa-mir-1246 Carcinoma, Hepatocellular 25591821 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-1246 is regulated by p53 and suppresses the growth of human HCC by targeting NFIB. Here, we propose a new p53-miR-1246-NFIB pathway in HCC. target gene hsa-mir-125a Carcinoma, Hepatocellular 22768249 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Ectopic expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF. target gene hsa-mir-125a Carcinoma, Hepatocellular 23079745 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 SIRT7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors mir-125a-5p and mir-125b target gene hsa-mir-125a Carcinoma, Hepatocellular 28445974 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Lowered expression of microRNA-125a-5p in human hepatocellular carcinoma and up-regulation of its oncogenic targets sirtuin-7, matrix metalloproteinase-11, and c-Raf. target gene hsa-mir-125b Carcinoma, Hepatocellular 24811246 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Prognostic marker microRNA-125b inhibits tumorigenic properties of carcinoma cells via suppressing tumorigenic molecule eIF5A2. target gene hsa-mir-125b Carcinoma, Hepatocellular 24865963 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Overexpression of microRNA-125b sensitizes human hepatocellular carcinoma cells to 5-fluorouracil through inhibition of glycolysis by targeting hexokinase II. target gene hsa-mir-125b Carcinoma, Hepatocellular 25424744 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 HOTTIP is a novel oncogenic lncRNA, which negatively regulated by miR-125b. Overexpression of HOTTIP contributes to hepatocarcinogenesis by regulating the expression of its neighbouring protein-coding genes. target gene hsa-mir-125b Carcinoma, Hepatocellular 26704017 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-125b has been reported to down-regulate SIRT7 by binding to its 3'UTR target gene hsa-mir-125b-1 Carcinoma, Hepatocellular 22293115 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-125b induces cancer cell apoptosis through suppression of Bcl-2 expression. target gene hsa-mir-125b-1 Carcinoma, Hepatocellular 23079745 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 SIRT7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors mir-125a-5p and mir-125b target gene hsa-mir-125b-2 Carcinoma, Hepatocellular 22293115 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-125b induces cancer cell apoptosis through suppression of Bcl-2 expression. target gene hsa-mir-125b-2 Carcinoma, Hepatocellular 23079745 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 SIRT7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors mir-125a-5p and mir-125b target gene hsa-mir-126 Carcinoma, Hepatocellular 28881749 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Effects of microRNA-126 on cell proliferation, apoptosis and tumor angiogenesis via the down-regulating ERK signaling pathway by targeting EGFL7 in hepatocellular carcinoma target gene hsa-mir-1271 Carcinoma, Hepatocellular 22865282 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-96, miR-129-1-3p, miR-1271, miR-1291 and miR-1303 differentially control GPC3 expression in HCC cells. target gene hsa-mir-1275 Carcinoma, Hepatocellular 26160756 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-1275: A single microRNA that targets the three IGF2-mRNA-binding proteins hindering tumor growth in hepatocellular carcinoma. target gene hsa-mir-128 Carcinoma, Hepatocellular 25962360 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-128-3p suppresses hepatocellular carcinoma proliferation by regulating PIK3R1 and is correlated with the prognosis of HCC patients. target gene hsa-mir-1285 Carcinoma, Hepatocellular 25230788 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-1285-3p acts as a potential tumor suppressor miRNA via downregulating JUN expression in hepatocellular carcinoma. target gene hsa-mir-129 Carcinoma, Hepatocellular 26116538 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-129 suppresses tumor cell growth and invasion by targeting PAK5 in hepatocellular carcinoma. target gene hsa-mir-129 Carcinoma, Hepatocellular 25912876 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-129-5p inhibits hepatocellular carcinoma cell metastasis and invasion via targeting ETS1. target gene hsa-mir-129-1 Carcinoma, Hepatocellular 22865282 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-96, miR-129-1-3p, miR-1271, miR-1291 and miR-1303 differentially control GPC3 expression in HCC cells. target gene hsa-mir-129-2 Carcinoma, Hepatocellular 22865282 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-96, miR-129-1-3p, miR-1271, miR-1291 and miR-1303 differentially control GPC3 expression in HCC cells. target gene hsa-mir-1297 Carcinoma, Hepatocellular 26191190 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-1297 regulates hepatocellular carcinoma cell proliferation and apoptosis by targeting EZH2. target gene hsa-mir-1303 Carcinoma, Hepatocellular 22865282 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-96, miR-129-1-3p, miR-1271, miR-1291 and miR-1303 differentially control GPC3 expression in HCC cells. target gene hsa-mir-130a Carcinoma, Hepatocellular 22846564 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Upregulated miR-130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell. target gene hsa-mir-130b Carcinoma, Hepatocellular 25617495 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Our data collectively highlight a novel pathway interlinking T3/TR, miR-130b, IRF1, the EMT-related genes, p-mTOR, p-STAT3 and the p-AKT cascade, which regulates the motility and invasion of hepatoma cells. target gene hsa-mir-132 Carcinoma, Hepatocellular 26252738 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-132 inhibits cell proliferation, invasion and migration of hepatocellular carcinoma by targeting PIK3R3. target gene hsa-mir-133a Carcinoma, Hepatocellular 26156803 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-133a functions as a tumor suppressor by targeting IGF-1R in hepatocellular carcinoma. target gene hsa-mir-133a Carcinoma, Hepatocellular 26173501 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-145 and MicroRNA-133a Inhibited Proliferation, Migration, and Invasion, While Promoted Apoptosis in Hepatocellular Carcinoma Cells Via Targeting FSCN1. target gene hsa-mir-134 Carcinoma, Hepatocellular 24498348 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Genome-wide screening identified that miR-134 acts as a metastasis suppressor by targeting integrin β1 in hepatocellular carcinoma. target gene hsa-mir-135a Carcinoma, Hepatocellular 27609066 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 HBXIP is able to depress the gluconeogenesis through suppressing PCK1 to promote hepatocarcinogenesis, involving miR-135a/FOXO1 axis and PI3K/Akt/p-FOXO1 pathway target gene hsa-mir-135a Carcinoma, Hepatocellular 28389526 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Regulation of UDP-Glucuronosyltransferases UGT2B4 and UGT2B7 by MicroRNAs in Liver Cancer Cells. target gene hsa-mir-135b Carcinoma, Hepatocellular 24631529 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Gα12gep oncogene inhibits FOXO1 in hepatocellular carcinoma as a consequence of miR-135b and miR-194 dysregulation. target gene hsa-mir-135b Carcinoma, Hepatocellular 26429530 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-135b promotes the invasion and metastasis possibly by targeting the Hippo pathway genes. target gene hsa-mir-137 Carcinoma, Hepatocellular 24970808 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 FoxD3-regulated microRNA-137 suppresses tumour growth and metastasis in human hepatocellular carcinoma by targeting AKT2. target gene hsa-mir-138 Carcinoma, Hepatocellular 28639887 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-138 enhances TRAIL-induced apoptosis through interferon-stimulated gene 15 downregulation in hepatocellular carcinoma cells. target gene hsa-mir-138 Carcinoma, Hepatocellular 28677784 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-138 inhibits cell proliferation in hepatocellular carcinoma by targeting Sirt1. target gene hsa-mir-138 Carcinoma, Hepatocellular 29387246 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-138 targeted SP1 to repress the growth, migration and invasion of HCC cells, and may therefore represent a therapeutic target in human HCC target gene hsa-mir-138-1 Carcinoma, Hepatocellular 22362728 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. target gene hsa-mir-138-2 Carcinoma, Hepatocellular 22362728 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. target gene hsa-mir-139 Carcinoma, Hepatocellular 26022123 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-139-5p inhibits epithelial-mesenchymal transition, migration and invasion of hepatocellular carcinoma cells by targeting ZEB1 and ZEB2. target gene hsa-mir-140 Carcinoma, Hepatocellular 22898998 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiRNA-140 acts as a liver tumor suppressor by controlling NF-kB activity via directly targeting Dnmt1 expression. target gene hsa-mir-140 Carcinoma, Hepatocellular 23401231 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-140-5p suppresses tumor growth and metastasis by targeting TGFBR1 and FGF9 in hepatocellular carcinoma target gene hsa-mir-141 Carcinoma, Hepatocellular 25008569 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-141 targets ZEB2 to suppress HCC progression. target gene hsa-mir-141 Carcinoma, Hepatocellular 25896253 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Our study showed that miR-141 plays a key role in 5-FU resistance by down-regulating Keap1 expression, thereby reactivating the Nrf2-dependent antioxidant pathway, which may serve as a potential target for overcoming 5-FU resistance in hepatocellular carcinoma cells. target gene hsa-mir-141 Carcinoma, Hepatocellular 26790956 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-141 suppression may cause aberrant expression of SPAG9 and promote HCC tumorigenesis via JNK pathway. target gene hsa-mir-142 Carcinoma, Hepatocellular 21482222 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-142-3p, a new regulator of RAC1, suppresses the migration and invasion of hepatocellular carcinoma cells. target gene hsa-mir-143 Carcinoma, Hepatocellular 28765889 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Downregulation of microRNA-143 promotes cell proliferation by regulating PKCε in hepatocellular carcinoma cells. target gene hsa-mir-144 Carcinoma, Hepatocellular 25073510 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-144 might suppress the growth and motility of HCC cells partially by targeting E2F3. target gene hsa-mir-144 Carcinoma, Hepatocellular 28229969 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-144 inhibits hepatocellular carcinoma cell proliferation, invasion and migration by targeting ZFX. target gene hsa-mir-144 Carcinoma, Hepatocellular 27536132 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-144 suppresses cell proliferation, migration, and invasion in hepatocellular carcinoma by targeting SMAD4. target gene hsa-mir-145 Carcinoma, Hepatocellular 23499894 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer target gene hsa-mir-145 Carcinoma, Hepatocellular 25174729 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-145 inhibits cell proliferation by directly targeting ADAM17 in hepatocellular carcinoma. target gene hsa-mir-145 Carcinoma, Hepatocellular 26068913 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-145 regulates chemoresistance in hepatocellular carcinoma via epithelial mesenchymal transition. target gene hsa-mir-145 Carcinoma, Hepatocellular 26173501 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-145 and MicroRNA-133a Inhibited Proliferation, Migration, and Invasion, While Promoted Apoptosis in Hepatocellular Carcinoma Cells Via Targeting FSCN1. target gene hsa-mir-145 Carcinoma, Hepatocellular 28104805 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-145 Modulates N6-Methyladenosine Levels by Targeting the 3'-Untranslated mRNA Region of the N6-Methyladenosine Binding YTH Domain Family 2 Protein. target gene hsa-mir-145 Carcinoma, Hepatocellular 23621665 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-145 suppresses cell invasion in hepatocellular carcinoma cells: miR-145 targets ADAM17. target gene hsa-mir-145 Carcinoma, Hepatocellular 29630879 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Atorvastatin induces MicroRNA-145 expression in HEPG2 cells via regulation of the PI3K/AKT signalling pathway target gene hsa-mir-146a Carcinoma, Hepatocellular 22167321 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 The authors demonstrate that miR-146a, miR-99b and miR-205, induced in HCC1937 BRCA1-expressing cells, bind and regulate TRAF2 gene. In addition, re-expression of miR-146a, miR-99b or miR-205 in HCC1937 BRCA1-null cells was sufficient to modulate NF-ж╩B activity. target gene hsa-mir-146a Carcinoma, Hepatocellular 23671131 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-146a enhances angiogenic activity of endothelial cells in hepatocellular carcinoma by promoting PDGFRA expression. target gene hsa-mir-146a Carcinoma, Hepatocellular 25608619 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 This study identified a novel target of miR-146a and defined miR-146a as a crucial tumor suppressor in human HCC that acts through multiple pathways and mechanisms to suppress HCC invasion or metastasis. target gene hsa-mir-150 Carcinoma, Hepatocellular 22025269 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb. target gene hsa-mir-152 Carcinoma, Hepatocellular 27922690 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-152 inhibits tumor cell growth by directly targeting RTKN in hepatocellular carcinoma. target gene hsa-mir-153 Carcinoma, Hepatocellular 26035427 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-153 inhibits epithelial-to-mesenchymal transition in hepatocellular carcinoma by targeting Snail. target gene hsa-mir-154 Carcinoma, Hepatocellular 26503460 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 In conclusion, these results indicate that miR-154 functions as a tumor suppressor in HCC by suppressing ZEB2,suggesting that miR-154 may serve as a potential target for HCC. target gene hsa-mir-155 Carcinoma, Hepatocellular 21989846 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Aberrant expression of microRNA 155 may accelerate cell proliferation by targeting sex-determining region Y box 6 in hepatocellular carcinoma. target gene hsa-mir-155 Carcinoma, Hepatocellular 29234238 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-155-5p modulates malignant behaviors of hepatocellular carcinoma by directly targeting CTHRC1 and indirectly regulating GSK-3β-involved Wnt/β-catenin signaling target gene hsa-mir-155 Carcinoma, Hepatocellular 29565484 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-155 targeted and inhibited FoxO3a expression to suppress the BIM, depress caspase-3 and caspase-9 activities, therefore inhibiting the HCC cell apoptosis and facilitating proliferation target gene hsa-mir-141 Carcinoma, Hepatocellular 25142234 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-141 suppresses the growth and metastasis of HCC cells by targeting E2F3. target gene hsa-mir-15b Carcinoma, Hepatocellular 28239814 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 microRNA15b induced SMCC7721 apoptosis via down-regulation of XIAP. target gene hsa-mir-16-1 Carcinoma, Hepatocellular 23226427 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Cyclooxygenase-2 Is a Target of MicroRNA-16 in Human Hepatoma Cells target gene hsa-mir-16-2 Carcinoma, Hepatocellular 23226427 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Cyclooxygenase-2 Is a Target of MicroRNA-16 in Human Hepatoma Cells target gene hsa-mir-26b Carcinoma, Hepatocellular 26191168 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-26b inhibits hepatocellular carcinoma cell proliferation, migration, and invasion by targeting EphA2. target gene hsa-mir-17 Carcinoma, Hepatocellular 23418359 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Mature MiR-17-5p and passenger miR-17-3p induce hepatocellular carcinoma by targeting PTEN, GalNT7, and vimentin in different signal pathways target gene hsa-mir-17 Carcinoma, Hepatocellular 25686840 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Pseudogene INTS6P1 regulates its cognate gene INTS6 through competitive binding of miR-17-5p in hepatocellular carcinoma. target gene hsa-mir-181a Carcinoma, Hepatocellular 28930552 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-181a inhibits autophagy by targeting Atg5 in hepatocellular carcinoma target gene hsa-mir-181b Carcinoma, Hepatocellular 20023698 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. target gene hsa-mir-182 Carcinoma, Hepatocellular 24447717 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1. target gene hsa-mir-182 Carcinoma, Hepatocellular 25663355 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 OncomiR miR-96 and miR-182 promote cell proliferation and invasion through targeting ephrinA6 in hepatocellular carcinoma. target gene hsa-mir-184 Carcinoma, Hepatocellular 24558429 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Mir-184 post-transcriptionally regulates SOX7 expression and promotes cell proliferation in human hepatocellular carcinoma. target gene hsa-mir-185 Carcinoma, Hepatocellular 24911372 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-185 inhibits hepatocellular carcinoma growth by targeting the DNMT1/PTEN/Akt pathway. target gene hsa-mir-185 Carcinoma, Hepatocellular 27643556 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 our findings enlarged our knowledge about the roles of PLAC8 in HCC progression and miR-185-5p/PLAC8/β-catenin axis might be a novel pathway for HCC treatment target gene hsa-mir-187 Carcinoma, Hepatocellular 27544906 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-187-3p inhibits the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting S100A4. target gene hsa-mir-18a Carcinoma, Hepatocellular 19203451 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-18: target BTG2 target gene hsa-mir-18a Carcinoma, Hepatocellular 28399983 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 microRNA-18a Promotes Cell Migration and Invasion Through Inhibiting Dicer l Expression in Hepatocellular Carcinoma In Vitro. target gene hsa-mir-18b Carcinoma, Hepatocellular 19203451 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-18: target BTG2 target gene hsa-mir-192 Carcinoma, Hepatocellular 21672525 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-192 inhibits nucleotide excision repair by targeting ERCC3 and ERCC4 in HepG2.2.15 cells. target gene hsa-mir-194 Carcinoma, Hepatocellular 24631529 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Gα12gep oncogene inhibits FOXO1 in hepatocellular carcinoma as a consequence of miR-135b and miR-194 dysregulation. target gene hsa-mir-194 Carcinoma, Hepatocellular 26221053 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 NF-κB signaling relieves negative regulation by miR-194 in hepatocellular carcinoma by suppressing the transcription factor HNF-1α. target gene hsa-mir-194 Carcinoma, Hepatocellular 26722431 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-194 acts as a prognostic marker and inhibits proliferation in hepatocellular carcinoma by targeting MAP4K4. target gene hsa-mir-195 Carcinoma, Hepatocellular 21947305 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miRNA-195 sensitizes human hepatocellular carcinoma cells to 5-FU by targeting BCL-w. target gene hsa-mir-195 Carcinoma, Hepatocellular 22888524 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-195 regulates cell apoptosis of human hepatocellular carcinoma cells by targeting LATS2. target gene hsa-mir-195 Carcinoma, Hepatocellular 23468064 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-195 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting the expression of VEGF, VAV2 and CDC42 target gene hsa-mir-195 Carcinoma, Hepatocellular 23487264 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Genome-wide screening revealed that miR-195 targets the TNF-alpha/NF-kB pathway by downregulating IKK and TAB3 in hepatocellular carcinoma target gene hsa-mir-195 Carcinoma, Hepatocellular 23544130 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 The Tumor-Suppressive miR-497-195 Cluster Targets Multiple Cell-Cycle Regulators in Hepatocellular Carcinoma target gene hsa-mir-195 Carcinoma, Hepatocellular 24740565 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-195 regulates steroid receptor coactivator-3 protein expression in hepatocellular carcinoma cells. target gene hsa-mir-195 Carcinoma, Hepatocellular 25119594 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Hsa-miR-195 targets PCMT1 in hepatocellular carcinoma that increases tumor life span. target gene hsa-mir-195 Carcinoma, Hepatocellular 25174704 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-195 acts as a tumor suppressor by directly targeting Wnt3a in HepG2 hepatocellular carcinoma cells. target gene hsa-mir-195 Carcinoma, Hepatocellular 27574422 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Aptamer-functionalized peptide H3CR5C as a novel nanovehicle for codelivery of fasudil and miRNA-195 targeting hepatocellular carcinoma. target gene hsa-mir-195 Carcinoma, Hepatocellular 28529562 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-195 inhibits cell proliferation via targeting AEG-1 in hepatocellular carcinoma. target gene hsa-mir-198 Carcinoma, Hepatocellular 21658389 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway. target gene hsa-mir-199a Carcinoma, Hepatocellular 25313882 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-199a regulates cell proliferation and survival by targeting FZD7. target gene hsa-mir-199a Carcinoma, Hepatocellular 27599545 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Anti-invasion and anti-migration effects of miR-199a-3p in hepatocellular carcinoma are due in part to targeting CD151. target gene hsa-mir-199a Carcinoma, Hepatocellular 27832779 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-199a-3p inhibits cell proliferation and induces apoptosis by targeting YAP1, suppressing Jagged1-Notch signaling in human hepatocellular carcinoma. target gene hsa-mir-199a Carcinoma, Hepatocellular 28261837 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-199a-5p suppresses tumorigenesis by targeting clathrin heavy chain in hepatocellular carcinoma. target gene hsa-mir-199a-1 Carcinoma, Hepatocellular 20501828 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-199a-3p:MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells target gene hsa-mir-199a-1 Carcinoma, Hepatocellular 21807947 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2. target gene hsa-mir-199a-2 Carcinoma, Hepatocellular 20501828 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-199a-3p:MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells target gene hsa-mir-199a-2 Carcinoma, Hepatocellular 21807947 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2. target gene hsa-mir-199b Carcinoma, Hepatocellular 28588321 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-199b-5p attenuates TGF-β1-induced epithelial-mesenchymal transition in hepatocellular carcinoma. target gene hsa-mir-19a Carcinoma, Hepatocellular 17188425 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miRNA-19a/b activates PI3K by blocking expression of the tumor suppressor PTEN. target gene hsa-mir-19a Carcinoma, Hepatocellular 25985117 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 A systematic investigation based on microRNA-mediated gene regulatory network reveals that dysregulation of microRNA-19a/Cyclin D1 axis confers an oncogenic potential and a worse prognosis in human hepatocellular carcinoma. target gene hsa-mir-19b Carcinoma, Hepatocellular 26453548 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 The overexpression of miR-19b was significantly correlated with better disease-free and overall survival in patients with HCC presenting with vascular invasion or multifocal disease after curative surgery. MiR-19b may influence the expression of NDRG1, EPCAM, HMGB2, HIF1A, and MAPK14. target gene hsa-mir-19b-1 Carcinoma, Hepatocellular 17188425 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miRNA-19a/b activates PI3K by blocking expression of the tumor suppressor PTEN. target gene hsa-mir-19b-2 Carcinoma, Hepatocellular 17188425 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miRNA-19a/b activates PI3K by blocking expression of the tumor suppressor PTEN. target gene hsa-mir-200 Carcinoma, Hepatocellular 24895326 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-200 family members and their targets are significantly deregulated in HCC and liver cirrhosis. The miR-200 family is able to distinguish between cirrhotic and HCC tissue and could serve as an early marker for cirrhosis-associated HCC. target gene hsa-mir-200a Carcinoma, Hepatocellular 17188425 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Integration at FRA1A may silence expression of miRNA-200a, which is known to be decreased in HCC compared to nontumor [59] and [65]. Since most miRNAs suppress their target proteins, and miRNA-200a is known to regulate the expression of RAB30, a member of target gene hsa-mir-200a Carcinoma, Hepatocellular 24009066 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 microRNA-200a is an independent prognostic factor of hepatocellular carcinoma and induces cell cycle arrest by targeting CDK6. target gene hsa-mir-200a Carcinoma, Hepatocellular 28081727 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-200a Suppresses Cell Invasion and Migration by Directly Targeting GAB1 in Hepatocellular Carcinoma. target gene hsa-mir-200a Carcinoma, Hepatocellular 27542259 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Elevated CXCL1 increases hepatocellular carcinoma aggressiveness and is inhibited by miRNA-200a. target gene hsa-mir-200a Carcinoma, Hepatocellular 28367241 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-200a inhibits cell growth and metastasis by targeting Foxa2 in hepatocellular carcinoma. target gene hsa-mir-200a Carcinoma, Hepatocellular 28440466 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-200a targets Gelsolin: A novel mechanism regulating secretion of microvesicles in hepatocellular carcinoma cells. target gene hsa-mir-200b Carcinoma, Hepatocellular 25909223 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-200b/200c/429 subfamily negatively regulates Rho/ROCK signaling pathway to suppress hepatocellular carcinoma metastasis. target gene hsa-mir-200b Carcinoma, Hepatocellular 28695771 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-200b suppresses the invasion and migration of hepatocellular carcinoma by downregulating RhoA and circRNA_000839. target gene hsa-mir-200b Carcinoma, Hepatocellular 28383782 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 The miR-200b-ZEB1 circuit regulates diverse stemness of human hepatocellular carcinoma. target gene hsa-mir-200c Carcinoma, Hepatocellular 25909223 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-200b/200c/428 subfamily negatively regulates Rho/ROCK signaling pathway to suppress hepatocellular carcinoma metastasis. target gene hsa-mir-200c Carcinoma, Hepatocellular 28609841 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-200c-5p suppresses proliferation and metastasis of human hepatocellular carcinoma (HCC) via suppressing MAD2L1. target gene hsa-mir-202 Carcinoma, Hepatocellular 24704686 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-202 suppresses cell proliferation in human hepatocellular carcinoma by downregulating LRP6 post-transcriptionally. target gene hsa-mir-203 Carcinoma, Hepatocellular 22886454 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-203 inhibits proliferation of hepatocellular carcinoma cells by targeting survivin. target gene hsa-mir-203 Carcinoma, Hepatocellular 28781949 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-203a-3p.1 targets IL-24 to modulate hepatocellular carcinoma cell growth and metastasis. target gene hsa-mir-203a Carcinoma, Hepatocellular 27780730 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-203a is involved in HBx-induced inflammation by targeting Rap1a. target gene hsa-mir-204 Carcinoma, Hepatocellular 24833879 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-204-3p acts on its potential target gene, FN1, and inhibits its expression, thus blocking the adhesion function of FN1 in promoting the growth of TECs. target gene hsa-mir-204 Carcinoma, Hepatocellular 27748572 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-204-5p targeting SIRT1 regulates hepatocellular carcinoma progression. target gene hsa-mir-205 Carcinoma, Hepatocellular 22167321 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 The authors demonstrate that miR-146a, miR-99b and miR-205, induced in HCC1937 BRCA1-expressing cells, bind and regulate TRAF2 gene. In addition, re-expression of miR-146a, miR-99b or miR-205 in HCC1937 BRCA1-null cells was sufficient to modulate NF-ж╩B activity. target gene hsa-mir-205 Carcinoma, Hepatocellular 26129839 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-205 regulates ubiquitin specific peptidase 7 protein expression in hepatocellular carcinoma cells. target gene hsa-mir-205 Carcinoma, Hepatocellular 24462768 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-205 modulates abnormal lipid metabolism of hepatoma cells via targeting acyl-CoA synthetase long-chain family member 1 (ACSL1) mRNA. target gene hsa-mir-205 Carcinoma, Hepatocellular 24576478 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Involvement of cholesterol in hepatitis B virus X protein-induced abnormal lipid metabolism of hepatoma cells via up-regulating miR-205-targeted ACSL4. target gene hsa-mir-208 Carcinoma, Hepatocellular 26169693 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-208-3p promotes hepatocellular carcinoma cell proliferation and invasion through regulating ARID2 expression. target gene hsa-mir-20a Carcinoma, Hepatocellular 27748919 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-20a-5p targets RUNX3 to regulate proliferation and migration of human hepatocellular cancer cells. target gene hsa-mir-20a Carcinoma, Hepatocellular 28378640 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Bioinformatics prediction and experimental validation of microRNA-20a targeting Cyclin D1 in hepatocellular carcinoma. target gene hsa-mir-20a Carcinoma, Hepatocellular 28537677 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Targeting of miR-20a against CFLAR to potentiate TRAIL-induced apoptotic sensitivity in HepG2 cells. target gene hsa-mir-21 Carcinoma, Hepatocellular 22322403 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-21 promotes migration and invasion by the miR-21-PDCD4-AP-1 feedback loop in human hepatocellular carcinoma. target gene hsa-mir-21 Carcinoma, Hepatocellular 24633222 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Hepatitis B virus induces cell proliferation via HBx-induced microRNA-21 in hepatocellular carcinoma by targeting programmed cell death protein4 (PDCD4) and phosphatase and tensin homologue (PTEN). target gene hsa-mir-21 Carcinoma, Hepatocellular 25687183 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-21 promotes cell proliferation in human hepatocellular carcinoma partly by targeting HEPN1. target gene hsa-mir-21 Carcinoma, Hepatocellular 26210448 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-21 promoted proliferation and migration in hepatocellular carcinoma through negative regulation of Navigator-3. target gene hsa-mir-21 Carcinoma, Hepatocellular 24098708 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 our results demonstrate that miR-21-3p functions as a tumor suppressor by directly targeting both MAT2A and MAT2B, indicating its therapeutic potential in HCC. target gene hsa-mir-21 Carcinoma, Hepatocellular 27571873 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 HBx-induced miR-21 suppresses cell apoptosis in hepatocellular carcinoma by targeting interleukin-12. target gene hsa-mir-21 Carcinoma, Hepatocellular 23684551 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways. target gene hsa-mir-21 Carcinoma, Hepatocellular 27261510 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Here, we demonstrated that TNF伪 stimulation induced transcriptional downregulation of MSH2, a member of the mismatch repair family, via NF-魏B-dependent miR-21 expression in hepatocytes. target gene hsa-mir-21 Carcinoma, Hepatocellular 29253196 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-122 participates in the regulation of HCC cell apoptosis through modulating the miR-21-targeted programmed cell death 4 (PDCD4) signal pathway target gene hsa-mir-210 Carcinoma, Hepatocellular 22144109 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Hypoxia-inducible MicroRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma. target gene hsa-mir-210 Carcinoma, Hepatocellular 27666683 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-210 promotes cancer angiogenesis by targeting fibroblast growth factor receptor-like 1 in hepatocellular carcinoma. target gene hsa-mir-211 Carcinoma, Hepatocellular 25888635 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-211 suppresses hepatocellular carcinoma by downregulating SATB2. target gene hsa-mir-211 Carcinoma, Hepatocellular 26398845 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-211 promotes invasion of carcinoma cells by directly targeting ESR1. target gene hsa-mir-212 Carcinoma, Hepatocellular 23922798 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 RBP2 is overexpressed in HCC and negatively regulated by hsa-miR-212. The hsa-miR-212-RBP2-CDKI pathway may be important in the pathogenesis of HCC. target gene hsa-mir-212 Carcinoma, Hepatocellular 25965836 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-212 suppresses tumor growth of human hepatocellular carcinoma by targeting FOXA1. target gene hsa-mir-214 Carcinoma, Hepatocellular 23068095 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-214 inhibits cell growth in hepatocellular carcinoma through suppression of beta-catenin target gene hsa-mir-216a Carcinoma, Hepatocellular 22392644 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 The androgen pathway stimulates microRNA-216a transcription to suppress the TSLC1 tumor suppressor gene in early hepatocarcinogenesis. target gene hsa-mir-216a Carcinoma, Hepatocellular 23471579 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer target gene hsa-mir-216b Carcinoma, Hepatocellular 27474751 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Regulation of UGT2B Expression and Activity by miR-216b-5p in Liver Cancer Cell Lines. target gene hsa-mir-216b Carcinoma, Hepatocellular 27524242 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 this study firstly revealed that there is a HIF-2α-MALAT1-miR-216b axis regulating MDR of HCC cells via modulating autophagy. target gene hsa-mir-216b Carcinoma, Hepatocellular 28389526 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Regulation of UDP-Glucuronosyltransferases UGT2B4 and UGT2B7 by MicroRNAs in Liver Cancer Cells. target gene hsa-mir-217 Carcinoma, Hepatocellular 23471579 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer target gene hsa-mir-217 Carcinoma, Hepatocellular 24671492 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-217 inhibits invasion of hepatocellular carcinoma cells through direct suppression of E2F3. target gene hsa-mir-217 Carcinoma, Hepatocellular 28184926 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-217 suppresses proliferation, migration, and invasion promoting apoptosis via targeting MTDH in hepatocellular carcinoma. target gene hsa-mir-218 Carcinoma, Hepatocellular 23996750 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 The low-expression of miR-218 is correlated with malignant clinicopathological characteristics of HCC, and miR-218 may inhibit cell proliferation and promote cell apoptosis by down-regulating Bmi-1 and CDK6 in HCC. target gene hsa-mir-218 Carcinoma, Hepatocellular 25816091 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-218 and microRNA-520a inhibit cell proliferation by downregulating E2F2 in hepatocellular carcinoma. target gene hsa-mir-219 Carcinoma, Hepatocellular 22449976 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-219-5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican-3. target gene hsa-mir-221 Carcinoma, Hepatocellular 22152314 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-221 contributes to the growth of hepatocellular carcinoma cells and miR-221 inhibition can induce cell apoptosis. miR-221 has the potential to become one of the new molecular targets for liver cancer therapy. target gene hsa-mir-221 Carcinoma, Hepatocellular 22396537 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 SND1-induced activation of NF-kappaB resulted in induction of miR-221 and subsequent induction of angiogenic factors Angiogenin and CXCL16. Inhibition of either of these components resulted in significant inhibition of SND1-induced angiogenesis thus highlighting the importance of this molecular cascade in regulating SND1 function. target gene hsa-mir-221 Carcinoma, Hepatocellular 25019494 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-221 accentuates IFN׳s anti-HCV effect by downregulating SOCS1 and SOCS3. target gene hsa-mir-221 Carcinoma, Hepatocellular 26251599 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Targeted delivery of chemically modified anti-miR-221 to hepatocellular carcinoma with negatively charged liposomes. target gene hsa-mir-221 Carcinoma, Hepatocellular 19671867 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. target gene hsa-mir-221 Carcinoma, Hepatocellular 28442344 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-221 regulates CD44 in hepatocellular carcinoma through the PI3K-AKT-mTOR pathway. target gene hsa-mir-221 Carcinoma, Hepatocellular 28539268 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-221 mediates the epithelial-mesenchymal transition of hepatocellular carcinoma by targeting AdipoR1. target gene hsa-mir-222 Carcinoma, Hepatocellular 24417222 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 A highly sensitive target-primed rolling circle amplification (TPRCA) method for fluorescent in situ hybridization detection of microRNA in tumor cells. target gene hsa-mir-222 Carcinoma, Hepatocellular 26420065 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 all the four miRNAs synergistically target PBX3 target gene hsa-mir-223 Carcinoma, Hepatocellular 21492514 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 microRNA-223 and its target gene oncogene c-myc have roles in hepatocellular carcinoma pathogenesis. target gene hsa-mir-224 Carcinoma, Hepatocellular 18319255 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. target gene hsa-mir-224 Carcinoma, Hepatocellular 23922662 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-224 targets SMAD family member 4 to promote cell proliferation and negatively influence patient survival. target gene hsa-mir-224 Carcinoma, Hepatocellular 24219032 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Our findings suggest a previously undescribed regulatory pathway in which the miR-224/HOXD10/p-PAK4/MMP-9 signaling pathway contributes to the regulation of cell migration and invasion and provides a new biotarget for HCC treatment. target gene hsa-mir-23a Carcinoma, Hepatocellular 22318941 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Stat3-mediated activation of miR-23a suppresses gluconeogenesis in hepatocellular carcinoma by downregulating G6PC and PGC-1ж┿ target gene hsa-mir-23a Carcinoma, Hepatocellular 24103454 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Our study sheds light on the role of miR-23a as a potential target in regulating chemosensitivity of HCC cells. target gene hsa-mir-23a Carcinoma, Hepatocellular 24942805 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Our study reveals that miR-23a may be involved in regulating the anti-HCC effect of berberine by mediating the regulation of p53. target gene hsa-mir-23a Carcinoma, Hepatocellular 27279136 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 the miR-23a mimic downregulated IFN纬-induced IRF-1 protein expression, while the miR-23a inhibitor increased IRF-1. target gene hsa-mir-23a Carcinoma, Hepatocellular 29176948 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 The Oncogenic Role of Tribbles 1 in Hepatocellular Carcinoma Is Mediated by a Feedback Loop Involving microRNA-23a and p53 target gene hsa-mir-23b Carcinoma, Hepatocellular 28262617 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 microRNA-23b suppresses epithelial-mesenchymal transition (EMT) and metastasis in hepatocellular carcinoma via targeting Pyk2. target gene hsa-mir-24 Carcinoma, Hepatocellular 25073511 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-24 promotes the proliferation and invasion of HCC cells by targeting SOX7. target gene hsa-mir-24 Carcinoma, Hepatocellular 27650047 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-24-3p enhances cell growth in hepatocellular carcinoma by targeting metallothionein 1M. target gene hsa-mir-24 Carcinoma, Hepatocellular 27780140 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-24 increases hepatocellular carcinoma cell metastasis and invasion by targeting p53: miR-24 targeted p53. target gene hsa-mir-26a Carcinoma, Hepatocellular 24194905 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-26a modulated angiogenesis of HCC through the PIK3C2α/Akt/HIF-1α/VEGFA pathway. The expression of VEGFA was inversely correlated with miR-26a expression in HCC tumors. target gene hsa-mir-26a Carcinoma, Hepatocellular 25494962 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-26a exerts growth inhibition in HCC and that its inhibitory effect is mediated briefly by blocking EZH2 expression. target gene hsa-mir-26a Carcinoma, Hepatocellular 26021873 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-26a expression reduced M-CSF expression and recruitment of macrophages in hepatocellular carcinoma(HCC). target gene hsa-mir-26a-1 Carcinoma, Hepatocellular 23389848 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting IL-6-Stat3 pathway target gene hsa-mir-26a-2 Carcinoma, Hepatocellular 23389848 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting IL-6-Stat3 pathway target gene hsa-mir-26b Carcinoma, Hepatocellular 24565101 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 These data suggest that miR-26b suppresses NF-κB signaling and thereby sensitized HCC cells to the doxorubicin-induced apoptosis by inhibiting the expression of TAK1 and TAB3. Our findings highlight miR-26b as a potent inhibitor of the NF-κB pathway and an attractive target for cancer treatment. target gene hsa-mir-26b Carcinoma, Hepatocellular 24890815 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-26b inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting USP9X. target gene hsa-mir-26b Carcinoma, Hepatocellular 26843134 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-26b Enhances the Radiosensitivity of Hepatocellular Carcinoma Cells by Targeting EphA2. target gene hsa-mir-27a Carcinoma, Hepatocellular 24018051 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-27a could function as a novel regulator to reverse MDR in hepatocellular carcinoma cells by inhibiting the FZD7/β-catenin pathway. target gene hsa-mir-27b Carcinoma, Hepatocellular 27704356 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-27b exerts an oncogenic function by targeting Fbxw7 in human hepatocellular carcinoma. target gene hsa-mir-28 Carcinoma, Hepatocellular 26160280 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Down-regulated miR-28-5p in human hepatocellular carcinoma correlated with tumor proliferation and migration by targeting insulin-like growth factor-1 (IGF-1). target gene hsa-mir-29 Carcinoma, Hepatocellular 27164857 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 SETDB1 is a target of miR-29, which is frequently downregulated in human HCCs. target gene hsa-mir-296 Carcinoma, Hepatocellular 27714806 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-296 inhibits proliferation and induces apoptosis by targeting FGFR1 in human hepatocellular carcinoma. target gene hsa-mir-29a Carcinoma, Hepatocellular 21573166 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Upregulated MicroRNA-29a by Hepatitis B Virus X Protein Enhances Hepatoma Cell Migration by Targeting PTEN in Cell Culture Model. target gene hsa-mir-29a Carcinoma, Hepatocellular 21625215 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. target gene hsa-mir-29a Carcinoma, Hepatocellular 28342862 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-29a suppresses growth and migration of hepatocellular carcinoma by regulating CLDN1. target gene hsa-mir-29b-1 Carcinoma, Hepatocellular 21625215 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. target gene hsa-mir-29b-1 Carcinoma, Hepatocellular 21793034 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-29b suppresses tumor angiogenesis, invasion and metastasis by regulating MMP-2 expression. target gene hsa-mir-29b-2 Carcinoma, Hepatocellular 21625215 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. target gene hsa-mir-29b-2 Carcinoma, Hepatocellular 21793034 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-29b suppresses tumor angiogenesis, invasion and metastasis by regulating MMP-2 expression. target gene hsa-mir-29c Carcinoma, Hepatocellular 21625215 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. target gene hsa-mir-29c Carcinoma, Hepatocellular 21763284 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-29c targets TNFAIP3, inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma. target gene hsa-mir-29c Carcinoma, Hepatocellular 23728341 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma. target gene hsa-mir-29c Carcinoma, Hepatocellular 25888625 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 A suppressive role of ionizing radiation-responsive miR-29c in the development of liver carcinoma via targeting WIP1. target gene hsa-mir-301a Carcinoma, Hepatocellular 22373864 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-301a Is a Candidate Oncogene that Targets the Homeobox Gene Gax in Human Hepatocellular Carcinoma. target gene hsa-mir-302b Carcinoma, Hepatocellular 24337067 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miRNA-302b suppresses human hepatocellular carcinoma by targeting AKT2. target gene hsa-mir-302b Carcinoma, Hepatocellular 26457704 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 This study showed that miR-302b could enhance the sensitivity to 5-FU in HCC cell lines and verified its two putative targeted genes responsible for its 5-FU sensitivity. target gene hsa-mir-302d Carcinoma, Hepatocellular 28352351 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-302d downregulates TGFBR2 expression and promotes hepatocellular carcinoma growth and invasion. target gene hsa-mir-30a Carcinoma, Hepatocellular 22157765 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy. target gene hsa-mir-30a Carcinoma, Hepatocellular 24290372 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 our data suggest that miR-30a-3p is downregulated in HCC and acts as a tumor suppressor in vitro. Regulation of vimentin, E-cadherin and MMP3 by miR-30a-3p suggests a useful therapeutic strategy for tumors with reduced miR-30a-3p expression. target gene hsa-mir-30a Carcinoma, Hepatocellular 29108194 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-30a inhibits proliferation of hepatocellular carcinoma cells via targeted regulation of forkhead-box protein A1. target gene hsa-mir-30c-1 Carcinoma, Hepatocellular 22320217 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-30c-1* promotes natural killer cell cytotoxicity against human hepatoma cells by targeting the transcription factor HMBOX1. target gene hsa-mir-30c-2 Carcinoma, Hepatocellular 22320217 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-30c-1* promotes natural killer cell cytotoxicity against human hepatoma cells by targeting the transcription factor HMBOX1. target gene hsa-mir-30e Carcinoma, Hepatocellular 26966067 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-30e suppresses proliferation of hepatoma cells via targeting prolyl 4-hydroxylase subunit alpha-1 (P4HA1) mRNA. target gene hsa-mir-31 Carcinoma, Hepatocellular 28269758 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA31-NDRG3 regulation axes are essential for hepatocellular carcinoma survival and drug resistance. target gene hsa-mir-31 Carcinoma, Hepatocellular 28623129 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Increased expression of microRNA-31-5p inhibits cell proliferation, migration, and invasion via regulating Sp1 transcription factor in HepG2 hepatocellular carcinoma cell line. target gene hsa-mir-31 Carcinoma, Hepatocellular 29152108 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-31 suppresses the self-renewal capability of α2δ1+ liver tumor-initiating cells by targeting ISL1 target gene hsa-mir-3117 Carcinoma, Hepatocellular 27822662 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-3117 regulates hepatocellular carcinoma cell proliferation by targeting PHLPPL. target gene hsa-mir-3127 Carcinoma, Hepatocellular 25849943 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-3127 promotes cell proliferation and tumorigenicity in hepatocellular carcinoma by disrupting of PI3K/AKT negative regulation. target gene hsa-mir-32 Carcinoma, Hepatocellular 25647261 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-32 induces cell proliferation, migration, and invasion in hepatocellular carcinoma by targeting PTEN. target gene hsa-mir-324 Carcinoma, Hepatocellular 26177288 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-324-5p Suppresses Hepatocellular Carcinoma Cell Invasion by Counteracting ECM Degradation through Post-Transcriptionally Downregulating ETS1 and SP1. target gene hsa-mir-325 Carcinoma, Hepatocellular 26194496 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 These findings implied that miR-325 regulates cell invasion and proliferation via targeting HMGB1 and may be a potential prognostic marker for HCC. target gene hsa-mir-330 Carcinoma, Hepatocellular 28050784 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Roles of microRNA-330 and Its Target Gene ING4 in the Development of Aggressive Phenotype in Hepatocellular Carcinoma Cells. target gene hsa-mir-331 Carcinoma, Hepatocellular 24825302 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-331-3p promotes proliferation and metastasis of hepatocellular carcinoma by targeting PH domain and leucine-rich repeat protein phosphatase. target gene hsa-mir-331 Carcinoma, Hepatocellular 26497554 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Upregulated in Hepatitis B virus-associated hepatocellular carcinoma cells,miR-331-3p promotes proliferation of hepatocellular carcinoma cells by targeting ING5. target gene hsa-mir-338 Carcinoma, Hepatocellular 21671467 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-338-3p suppresses invasion of liver cancer cell by targeting smoothened. target gene hsa-mir-338 Carcinoma, Hepatocellular 25755720 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-338-3p inhibits cell proliferation in hepatocellular carcinoma by target forkhead box P4 (FOXP4). target gene hsa-mir-33b Carcinoma, Hepatocellular 28026002 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-33b suppresses the proliferation and metastasis of hepatocellular carcinoma cells through the inhibition of Sal-like protein 4 expression. target gene hsa-mir-340 Carcinoma, Hepatocellular 25556489 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 lower expression of miR-340 is involved in the development of CDDP resistance in hepatocellular carcinoma cell line, at least partly due to regulating Nrf2-dependent antioxidant pathway. target gene hsa-mir-340 Carcinoma, Hepatocellular 27998770 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-340 inhibits the proliferation and invasion of hepatocellular carcinoma cells by targeting JAK1. target gene hsa-mir-345 Carcinoma, Hepatocellular 28098858 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-345 inhibits tumor metastasis and EMT by targeting IRF1-mediated mTOR/STAT3/AKT pathway in hepatocellular carcinoma. target gene hsa-mir-34a Carcinoma, Hepatocellular 23862748 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment. target gene hsa-mir-34a Carcinoma, Hepatocellular 25686834 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-34a induces cellular senescence via modulation of telomerase activity in human hepatocellular carcinoma by targeting FoxM1/c-Myc pathway. target gene hsa-mir-34a Carcinoma, Hepatocellular 26385595 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-34a is Involved in the Decrease of ATP Contents Induced by Resistin Through Target on ATP5S in HepG2 Cells. target gene hsa-mir-34a Carcinoma, Hepatocellular 28129650 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-34a regulates liver regeneration and the development of liver cancer in rats by targeting Notch signaling pathway. target gene hsa-mir-34a Carcinoma, Hepatocellular 28667294 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 0404 inhibits hepatocellular carcinoma through a p53/miR-34a/SIRT1 positive feedback loop. target gene hsa-mir-34a Carcinoma, Hepatocellular 28667334 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 3'UTR polymorphisms of carbonic anhydrase IX determine the miR-34a targeting efficiency and prognosis of hepatocellular carcinoma. target gene hsa-mir-34a Carcinoma, Hepatocellular 29298665 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Our results may lead researchers to understand the molecular mechanism of miR-34a in the diagnosis, prognosis and therapy of HCC target gene hsa-mir-34a Carcinoma, Hepatocellular 29344126 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 microRNA-34a overexpression inhibits cell migration and invasion via regulating SIRT1 in hepatocellular carcinoma target gene hsa-mir-34b Carcinoma, Hepatocellular 28098861 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Triptolide inhibits viability and induces apoptosis in liver cancer cells through activation of the tumor suppressor gene p53. target gene hsa-mir-34c Carcinoma, Hepatocellular 26722462 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-34c-3p inhibits cell proliferation, migration and invasion of hepatocellular carcinoma by targeting MARCKS. target gene hsa-mir-34c Carcinoma, Hepatocellular 27704267 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-34c-3p promotes cell proliferation and invasion in hepatocellular carcinoma by regulation of NCKAP1 expression. target gene hsa-mir-34c Carcinoma, Hepatocellular 28098861 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Triptolide inhibits viability and induces apoptosis in liver cancer cells through activation of the tumor suppressor gene p53. target gene hsa-mir-361 Carcinoma, Hepatocellular 27641667 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-361-5p inhibits hepatocellular carcinoma cell proliferation and invasion by targeting VEGFA. target gene hsa-mir-362 Carcinoma, Hepatocellular 25649327 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Upregulation of miR-362-3p Modulates Proliferation and Anchorage-Independent Growth by Directly Targeting Tob2 in Hepatocellular Carcinoma. target gene hsa-mir-363 Carcinoma, Hepatocellular 24631531 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-363-mediated downregulation of S1PR1 suppresses the proliferation of hepatocellular carcinoma cells. target gene hsa-mir-3664 Carcinoma, Hepatocellular 28389526 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Regulation of UDP-Glucuronosyltransferases UGT2B4 and UGT2B7 by MicroRNAs in Liver Cancer Cells. target gene hsa-mir-370 Carcinoma, Hepatocellular 28387905 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miRNA-370 acts as a tumor suppressor via the downregulation of PIM1 in hepatocellular carcinoma. target gene hsa-mir-372 Carcinoma, Hepatocellular 24552534 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 The findings demonstrated that miR-372 suppressed the expression of ATAD2, which was highly expressed in HCC and exerted a proto-oncogene effect in hepatic carcinogenesis. In conclusion, ATAD2 may promote HCC progression. target gene hsa-mir-372 Carcinoma, Hepatocellular 25880458 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-372 may play an important role in hepatic carcinogenesis and may serve as a new target or method to detect and treat HCC in the future. target gene hsa-mir-373 Carcinoma, Hepatocellular 21481188 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-373 can regulate cell cycle progression by targeting PPP6C transcripts and promotes the growth activity of hepatocellular carcinoma cells in vitro. This miRNA functions as an oncogene in hepatocellular carcinoma. target gene hsa-mir-375 Carcinoma, Hepatocellular 22056881 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. target gene hsa-mir-375 Carcinoma, Hepatocellular 22504094 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-375 was down-regulated in HCC cells and tissues; it inhibited autophagy under hypoxic conditions by suppressing the conversion of LC3I to LC3II and thereby autophagic flux. target gene hsa-mir-376a Carcinoma, Hepatocellular 25613642 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 HDAC9 plays an important role both as effects and targets of miR-376a. target gene hsa-mir-377 Carcinoma, Hepatocellular 25739101 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-377 suppresses cell proliferation and invasion by inhibiting TIAM1 expression in hepatocellular carcinoma. target gene hsa-mir-377 Carcinoma, Hepatocellular 28081730 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-377 Downregulates Bcl-xL and Increases Apoptosis in Hepatocellular Carcinoma Cells. target gene hsa-mir-377 Carcinoma, Hepatocellular 27222047 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 IRX3 is a direct target of miR-377 target gene hsa-mir-378 Carcinoma, Hepatocellular 24119742 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-378 may suppress growth characteristics of HBV-related HCC by directly targeting the IGF1R 3'-UTR and inhibiting its protein expression. target gene hsa-mir-379 Carcinoma, Hepatocellular 21540293 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Down-regulation of ABCC2 protein expression in HepG2 cells after rifampicin treatment is mediated by microRNA-379. target gene hsa-mir-379 Carcinoma, Hepatocellular 26944318 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-379-5p inhibits tumor invasion and metastasis by targeting FAK/AKT signaling in hepatocellular carcinoma. target gene hsa-mir-384 Carcinoma, Hepatocellular 27542674 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-384 regulated IRS1 expression and suppressed cell proliferation of human hepatocellular carcinoma. target gene hsa-mir-410 Carcinoma, Hepatocellular 28389526 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Regulation of UDP-Glucuronosyltransferases UGT2B4 and UGT2B7 by MicroRNAs in Liver Cancer Cells. target gene hsa-mir-411 Carcinoma, Hepatocellular 25776495 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-411 regulated ITCH expression and promoted cell proliferation in human hepatocellular carcinoma cells. target gene hsa-mir-422a Carcinoma, Hepatocellular 25251503 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Double-negative feedback loop between microRNA-422a and forkhead box (FOX)G1/Q1/E1 regulates hepatocellular carcinoma tumor growth and metastasis. target gene hsa-mir-423 Carcinoma, Hepatocellular 21890460 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-423 Promotes Cell Growth and Regulates G1/S Transition by Targeting p21Cip1/Waf1 in Hepatocellular Carcinoma target gene hsa-mir-423 Carcinoma, Hepatocellular 29312509 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-423 enhances the invasiveness of hepatocellular carcinoma via regulation of BRMS1 target gene hsa-mir-424 Carcinoma, Hepatocellular 25175916 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-424-5p reversed epithelial-mesenchymal transition of anchorage-independent HCC cells by directly targeting ICAT and suppressed HCC progression. target gene hsa-mir-429 Carcinoma, Hepatocellular 25909223 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-200b/200c/427 subfamily negatively regulates Rho/ROCK signaling pathway to suppress hepatocellular carcinoma metastasis. target gene hsa-mir-429 Carcinoma, Hepatocellular 29403024 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 The newly identified miR-429-CRKL axis represents a novel potential therapeutic target for HCC treatment target gene hsa-mir-4417 Carcinoma, Hepatocellular 28394882 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-4417 Targets Tripartite Motif-Containing 35 (TRIM35) and Regulates Pyruvate Kinase Muscle 2 (PKM2) Phosphorylation to Promote Proliferation and Suppress Apoptosis in Hepatocellular Carcinoma Cells. target gene hsa-mir-448 Carcinoma, Hepatocellular 25969175 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-448 may contribute to the progression of HCC via regulating ROCK2 expression. target gene hsa-mir-451a Carcinoma, Hepatocellular 23740840 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-451 Inhibits Cell Proliferation in Human Hepatocellular Carcinoma through Direct Suppression of IKK-beta target gene hsa-mir-452 Carcinoma, Hepatocellular 24381057 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-452 promotes tumorigenesis in hepatocellular carcinoma by targeting cyclin-dependent kinase inhibitor 1B. target gene hsa-mir-455 Carcinoma, Hepatocellular 27748890 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-455 regulates migration and invasion of human hepatocellular carcinoma by targeting Runx2. target gene hsa-mir-485 Carcinoma, Hepatocellular 26054676 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Involvement of miR-485-5p in hepatocellular carcinoma progression targeting EMMPRIN. target gene hsa-mir-491 Carcinoma, Hepatocellular 25196641 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Inhibition of TGF-β/SMAD3/NF-κB signaling by microRNA-491 is involved in arsenic trioxide-induced anti-angiogenesis in hepatocellular carcinoma cells. target gene hsa-mir-491 Carcinoma, Hepatocellular 27053618 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-491 inhibits the proliferation, invasion and migration of hepatocellular carcinoma cell via down-regulating TPX2 expression. target gene hsa-mir-494 Carcinoma, Hepatocellular 26045065 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN. target gene hsa-mir-494 Carcinoma, Hepatocellular 25820676 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-494 is a master epigenetic regulator of multiple invasion-suppressor microRNAs by targeting ten eleven translocation 1 in invasive human hepatocellular carcinoma tumors. target gene hsa-mir-497 Carcinoma, Hepatocellular 23544130 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 The Tumor-Suppressive miR-497-195 Cluster Targets Multiple Cell-Cycle Regulators in Hepatocellular Carcinoma target gene hsa-mir-497 Carcinoma, Hepatocellular 24464213 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Checkpoint kinase 1 is negatively regulated by miR-497 in hepatocellular carcinoma. target gene hsa-mir-499a Carcinoma, Hepatocellular 22311030 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 hsa-mir-499 (rs3746444; adenine to guanine [C-T]) .Significant differences were found in frequency and distribution of the genotypes of miRNA-499 between the HCC and the control group. Compared with miRNA-499 T/T, the odds ratio (OR) of patients with miRNA-499 C/C for developing HCC was 3.630 (95% CI: 1.545-8.532), and OR for developing HBV-related HCC was 3.133 (95% CI: 1.248-7.861). target gene hsa-mir-499a Carcinoma, Hepatocellular 22664953 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-1 and microRNA-499 downregulate the expression of the ets1 proto-oncogene in HepG2 cells. target gene hsa-mir-499b Carcinoma, Hepatocellular 22664953 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-1 and microRNA-499 downregulate the expression of the ets1 proto-oncogene in HepG2 cells. target gene hsa-mir-503 Carcinoma, Hepatocellular 24405610 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 an important role of miR-503 in inhibiting metastasis of HCC through deregulating ARHGEF19. target gene hsa-mir-503 Carcinoma, Hepatocellular 26163260 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-503 suppresses metastasis of hepatocellular carcinoma cell by targeting PRMT1. target gene hsa-mir-503 Carcinoma, Hepatocellular 27840964 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-503 inhibits proliferation making human hepatocellular carcinoma cells susceptible to 5‑fluorouracil by targeting EIF4E. target gene hsa-mir-506 Carcinoma, Hepatocellular 25087998 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-506 suppresses the proliferation of hepatoma cells by targeting YAP mRNA. target gene hsa-mir-511 Carcinoma, Hepatocellular 25608840 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-511 inhibits growth and metastasis of human hepatocellular carcinoma cells by targeting PIK3R3. target gene hsa-mir-512-1 Carcinoma, Hepatocellular 20372864 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-512-3p:Inhibition of c-FLIP expression by miR-512-3p contributes to taxol-induced apoptosis in hepatocellular carcinoma cells target gene hsa-mir-512-2 Carcinoma, Hepatocellular 20372864 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-512-3p:Inhibition of c-FLIP expression by miR-512-3p contributes to taxol-induced apoptosis in hepatocellular carcinoma cells target gene hsa-mir-517a Carcinoma, Hepatocellular 23142219 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Down-regulation of miR-517a and miR-517c promotes proliferation of hepatocellular carcinoma cells via targeting Pyk2 target gene hsa-mir-517c Carcinoma, Hepatocellular 23142219 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Down-regulation of miR-517a and miR-517c promotes proliferation of hepatocellular carcinoma cells via targeting Pyk2 target gene hsa-mir-519d Carcinoma, Hepatocellular 21524841 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-519d targets MKi67 and suppresses cell growth in the hepatocellular carcinoma cell line QGY-7703. target gene hsa-mir-520a Carcinoma, Hepatocellular 25816091 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-218 and microRNA-520a inhibit cell proliferation by downregulating E2F2 in hepatocellular carcinoma. target gene hsa-mir-520b Carcinoma, Hepatocellular 22319632 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-520b inhibits growth of hepatoma cells by targeting MEKK2 and cyclin D1. target gene hsa-mir-520b Carcinoma, Hepatocellular 25824049 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-520b suppresses proliferation of hepatoma cells through targeting ten-eleven translocation 1 (TET1) mRNA. target gene hsa-mir-520e Carcinoma, Hepatocellular 22105365 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-520e suppresses growth of hepatoma cells by targeting the NF-kB-inducing kinase (NIK). target gene hsa-mir-520g Carcinoma, Hepatocellular 25436421 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 high miR-520g expression promotes HCC cell mobility and EMT by targeting SMAD7, and this is correlated with reduced survival in HCC patients. target gene hsa-mir-539 Carcinoma, Hepatocellular 28393215 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-539 inhibits FSCN1 expression and suppresses hepatocellular carcinoma migration and invasion. target gene hsa-mir-542 Carcinoma, Hepatocellular 27815069 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-542-3p inhibits the growth of hepatocellular carcinoma cells by targeting FZD7/Wnt signaling pathway. target gene hsa-mir-550a-1 Carcinoma, Hepatocellular 23145039 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-550a acts as a pro-metastatic gene and directly targets cytoplasmic polyadenylation element-binding protein 4 in hepatocellular carcinoma target gene hsa-mir-550a-2 Carcinoma, Hepatocellular 23145039 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-550a acts as a pro-metastatic gene and directly targets cytoplasmic polyadenylation element-binding protein 4 in hepatocellular carcinoma target gene hsa-mir-550a-3 Carcinoma, Hepatocellular 23145039 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-550a acts as a pro-metastatic gene and directly targets cytoplasmic polyadenylation element-binding protein 4 in hepatocellular carcinoma target gene hsa-mir-570 Carcinoma, Hepatocellular 26084609 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-570 inhibited the cell proliferation and invasion through directly targeting B7-H1 in hepatocellular carcinoma. target gene hsa-mir-582 Carcinoma, Hepatocellular 26002580 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-582-5p inhibits proliferation of hepatocellular carcinoma by targeting CDK1 and AKT3. target gene hsa-mir-590 Carcinoma, Hepatocellular 22684895 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-590-5p regulates proliferation and invasion in human hepatocellular carcinoma cells by targeting TGF-beta RII. target gene hsa-mir-590 Carcinoma, Hepatocellular 23803188 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-590 is an important tumorigenic factor for HCC, and its two arms can both promote tumorigenesis by regulating the expression of their target tumor suppressor gene, PDCD4 and PTEN, to promote HCC cell proliferation and survival and activate the core tumor signal pathway PI3K-AKT. target gene hsa-mir-590 Carcinoma, Hepatocellular 28349829 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-590-3p suppresses hepatocellular carcinoma growth by targeting TEAD1. target gene hsa-mir-592 Carcinoma, Hepatocellular 26722432 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-592 targets DEK oncogene and suppresses cell growth in the hepatocellular carcinoma cell line HepG2. target gene hsa-mir-602 Carcinoma, Hepatocellular 20364114 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-602 regulating tumor suppressive gene RASSF1A is overexpressed in hepatitis B virus-infected liver and hepatocellular carcinoma target gene hsa-mir-616 Carcinoma, Hepatocellular 26499912 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Based on these results, we conclude that miR-616 is a promising prognostic biomarker of HCC and targeting miR-616 may be a potential option to prevent the progression of HCC. target gene hsa-mir-625 Carcinoma, Hepatocellular 24632613 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-625 suppresses tumour migration and invasion by targeting IGF2BP1 in hepatocellular carcinoma. target gene hsa-mir-636 Carcinoma, Hepatocellular 23306701 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 ANT2 suppression by shRNA restores miR-636 expression, thereby downregulating Ras and inhibiting tumorigenesis of hepatocellular carcinoma target gene hsa-mir-638 Carcinoma, Hepatocellular 27878280 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Loss of miR-638 promotes invasion and epithelial-mesenchymal transition by targeting SOX2 in hepatocellular carcinoma. target gene hsa-mir-657 Carcinoma, Hepatocellular 23175432 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-657 promotes tumorigenesis in hepatocellular carcinoma by targeting transducin-like enhancer protein 1 through NF-kB pathways target gene hsa-mir-7 Carcinoma, Hepatocellular 24370822 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-7 arrests cell cycle in G1 phase by directly targeting CCNE1 in human hepatocellular carcinoma cells. target gene hsa-mir-7 Carcinoma, Hepatocellular 26831666 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-7 suppressed the expression of VDAC1 target gene hsa-mir-709 Carcinoma, Hepatocellular 25818666 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 These results suggest that miR-709 may positively regulate invasion and metastasis of HCC through targeting GPC5. target gene hsa-mir-7-1 Carcinoma, Hepatocellular 22234835 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-7 inhibits tumor growth and metastasis by targeting the PI3K/AKT pathway in hepatocellular carcinoma. target gene hsa-mir-718 Carcinoma, Hepatocellular 28070994 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Involvement of microRNA-718, a new regulator of EGR3, in regulation of malignant phenotype of HCC cells. target gene hsa-mir-7-2 Carcinoma, Hepatocellular 22234835 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-7 inhibits tumor growth and metastasis by targeting the PI3K/AKT pathway in hepatocellular carcinoma. target gene hsa-mir-7-3 Carcinoma, Hepatocellular 22234835 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-7 inhibits tumor growth and metastasis by targeting the PI3K/AKT pathway in hepatocellular carcinoma. target gene hsa-mir-877 Carcinoma, Hepatocellular 25973036 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Up-regulation of miR-877 induced by paclitaxel inhibits hepatocellular carcinoma cell proliferation though targeting FOXM1. target gene hsa-mir-9 Carcinoma, Hepatocellular 26125451 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-9-3p was identified as the tumour-suppressor miR targetting TAZ expression in HCC cells. target gene hsa-mir-9 Carcinoma, Hepatocellular 25592151 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 HULC functions as an oncogene in hepatoma cells, acting mechanistically by deregulating lipid metabolism through a signaling pathway involving miR-9, PPARA, and ACSL1 that is reinforced by a feed-forward pathway involving cholesterol and RXRA to drive HULC signaling. target gene hsa-mir-9 Carcinoma, Hepatocellular 29399149 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-9 enhances sensitivity to cetuximab in epithelial phenotypehepatocellular carcinoma cells through regulation of the eukaryotic translation initiation factor 5A-2 target gene hsa-mir-922 Carcinoma, Hepatocellular 28184924 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-922 regulates CYLD expression and promotes the cell proliferation of human hepatocellular carcinoma. target gene hsa-mir-935 Carcinoma, Hepatocellular 27697092 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-935 Promotes Liver Cancer Cell Proliferation and Migration by Targeting SOX7. target gene hsa-mir-940 Carcinoma, Hepatocellular 27807540 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-940 Suppresses Tumor Cell Invasion and Migration via Regulation of CXCR2 in Hepatocellular Carcinoma. target gene hsa-mir-96 Carcinoma, Hepatocellular 22865282 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-96, miR-129-1-3p, miR-1271, miR-1291 and miR-1303 differentially control GPC3 expression in HCC cells. target gene hsa-mir-96 Carcinoma, Hepatocellular 25663355 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 OncomiR miR-96 and miR-182 promote cell proliferation and invasion through targeting ephrinA5 in hepatocellular carcinoma. target gene hsa-mir-98 Carcinoma, Hepatocellular 27890434 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-98 inhibits hepatocellular carcinoma cell proliferation via targeting EZH2 and suppressing Wnt/β-catenin signaling pathway. target gene hsa-mir-98 Carcinoma, Hepatocellular 28244848 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-98-5p Inhibits Cell Proliferation and Induces Cell Apoptosis in Hepatocellular Carcinoma via Targeting IGF2BP1. target gene hsa-mir-99b Carcinoma, Hepatocellular 22167321 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 The authors demonstrate that miR-146a, miR-99b and miR-205, induced in HCC1937 BRCA1-expressing cells, bind and regulate TRAF2 gene. In addition, re-expression of miR-146a, miR-99b or miR-205 in HCC1937 BRCA1-null cells was sufficient to modulate NF-ж╩B activity. target gene hsa-mir-99b Carcinoma, Hepatocellular 26134929 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-99b promotes metastasis of hepatocellular carcinoma through inhibition of claudin 11 expression and may serve as a prognostic marker. target gene hsa-mir-101 Carcinoma, Hepatocellular, HBV-Related 24788845 Downregulation of miR-101-3p by hepatitis B virus promotes proliferation and migration of hepatocellular carcinoma cells by targeting Rab5a. target gene hsa-mir-191 Carcinoma, Hepatocellular, HBV-Related 25814782 These findings highlight the importance of validating reference genes before quantifying target miRNAs.Furthermore, our findings will improve studies that monitor hepatitis progression and will aid in the discovery of noninvasive biomarkers to diagnose early stage HCC. target gene hsa-mir-221 Carcinoma, Hepatocellular, HBV-Related 25814782 These findings highlight the importance of validating reference genes before quantifying target miRNAs.Furthermore, our findings will improve studies that monitor hepatitis progression and will aid in the discovery of noninvasive biomarkers to diagnose early stage HCC. target gene hsa-mir-26a Carcinoma, Hepatocellular, HBV-Related 25814782 These findings highlight the importance of validating reference genes before quantifying target miRNAs.Furthermore, our findings will improve studies that monitor hepatitis progression and will aid in the discovery of noninvasive biomarkers to diagnose early stage HCC. target gene hsa-mir-10b Carcinoma, Laryngeal 25875782 disease of cellular proliferation DOID:2600 C32.3 D007822 21198 HP:0012118 MicroRNA-10b Triggers the Epithelial-Mesenchymal Transition (EMT) of Laryngeal Carcinoma Hep-2 Cells by Directly Targeting the E-cadherin. target gene hsa-mir-133a Carcinoma, Laryngeal 27730543 disease of cellular proliferation DOID:2600 C32.3 D007822 21198 HP:0012118 MicroRNA-133a suppresses the proliferation, migration, and invasion of laryngeal carcinoma cells by targeting CD47. target gene hsa-mir-195 Carcinoma, Laryngeal 28791411 disease of cellular proliferation DOID:2600 C32.3 D007822 21198 HP:0012118 MicroRNA-195 inhibits growth and invasion of laryngeal carcinoma cells by directly targeting DCUN1D1. target gene hsa-mir-205 Carcinoma, Laryngeal 26281062 disease of cellular proliferation DOID:2600 C32.3 D007822 21198 HP:0012118 miRNA-205 might promote the proliferation of Hep-2 cells by regulating the expression of PTEN. target gene hsa-mir-9 Carcinoma, Laryngeal 27694005 disease of cellular proliferation DOID:2600 C32.3 D007822 21198 HP:0012118 Enhanced miR-9 promotes laryngocarcinoma cell survival via down-regulating PTEN. target gene hsa-mir-106b Carcinoma, Lung 27797825 disease of cellular proliferation DOID:3905 C34.90 D008175 MCM7 and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer. target gene hsa-mir-122 Carcinoma, Lung 25472877 disease of cellular proliferation DOID:3905 C34.90 D008175 induce the expression of miR-122-regulating transcriptional factors in lung cancer cells. Collectively, OA induced cell cycle arrest in lung cancer cells through miR-122/Cyclin G1/MEF2D pathway. This finding may contribute to the understanding of the molecular mechanism of OA's anti-tumor activity. target gene hsa-mir-1236 Carcinoma, Lung 28631573 disease of cellular proliferation DOID:3905 C34.90 D008175 Effects of miR-1236-3p and miR-370-5p on activation of p21 in various tumors and its inhibition on the growth of lung cancer cells. target gene hsa-mir-124 Carcinoma, Lung 27735038 disease of cellular proliferation DOID:3905 C34.90 D008175 MicroRNA-124 suppresses Slug-mediated lung cancer metastasis. target gene hsa-mir-125a Carcinoma, Lung 28631574 disease of cellular proliferation DOID:3905 C34.90 D008175 MicroRNA-125a-5p plays a role as a tumor suppressor in lung carcinoma cells by directly targeting STAT3. target gene hsa-mir-133b Carcinoma, Lung 28641694 disease of cellular proliferation DOID:3905 C34.90 D008175 MiR-133b Affect the Proliferation and Drug Sensitivity in A549 Lung Cancer Stem Cells by Targeting PKM2. target gene hsa-mir-187 Carcinoma, Lung 27634346 disease of cellular proliferation DOID:3905 C34.90 D008175 MicroRNA‑187 is an independent prognostic factor in lung cancer and promotes lung cancer cell invasion via targeting of PTRF. target gene hsa-mir-199a Carcinoma, Lung 28363780 disease of cellular proliferation DOID:3905 C34.90 D008175 miR-199a-5p and miR-495 target GRP78 within UPR pathway of lung cancer. target gene hsa-mir-19a Carcinoma, Lung 28364280 disease of cellular proliferation DOID:3905 C34.90 D008175 Oncogenic miR-19a and miR-19b co-regulate tumor suppressor MTUS1 to promote cell proliferation and migration in lung cancer. target gene hsa-mir-19b Carcinoma, Lung 28364280 disease of cellular proliferation DOID:3905 C34.90 D008175 Oncogenic miR-19a and miR-19b co-regulate tumor suppressor MTUS1 to promote cell proliferation and migration in lung cancer. target gene hsa-mir-200c Carcinoma, Lung 27666124 disease of cellular proliferation DOID:3905 C34.90 D008175 miR-200c regulates crizotinib-resistant ALK-positive lung cancer cells by reversing epithelial-mesenchymal transition via targeting ZEB1. target gene hsa-mir-214 Carcinoma, Lung 27494742 disease of cellular proliferation DOID:3905 C34.90 D008175 miR-214 inhibits lung cancer progression by targeting CPD. target gene hsa-mir-218 Carcinoma, Lung 28192397 disease of cellular proliferation DOID:3905 C34.90 D008175 Downregulation of miR-218 contributes to epithelial-mesenchymal transition and tumor metastasis in lung cancer by targeting Slug/ZEB2 signaling. target gene hsa-mir-25 Carcinoma, Lung 27797825 disease of cellular proliferation DOID:3905 C34.90 D008175 MCM7 and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer. target gene hsa-mir-26a Carcinoma, Lung 28237093 disease of cellular proliferation DOID:3905 C34.90 D008175 MiR-26a enhances invasive capacity by suppressing GSK3β in human lung cancer cells. target gene hsa-mir-29c Carcinoma, Lung 28345453 disease of cellular proliferation DOID:3905 C34.90 D008175 Tumor suppressor miR-29c regulates radioresistance in lung cancer cells. target gene hsa-mir-302b Carcinoma, Lung 28231299 disease of cellular proliferation DOID:3905 C34.90 D008175 miR-34a-5p/miR-34c-5p/miR-302b-3p-LEF1-CCND1/WNT2/MYC axis may be a crucial mechanism in inhibition of lung cancer metastasis by curcumin target gene hsa-mir-31 Carcinoma, Lung 25050641 disease of cellular proliferation DOID:3905 C34.90 D008175 miR-31 may be a suppressor that regulates an essential oncogenic pathway, the loss of which may promote lung carcinogenesis. target gene hsa-mir-338 Carcinoma, Lung 25374067 disease of cellular proliferation DOID:3905 C34.90 D008175 microRNA-338-3p functions as a tumor suppressor in human non-small-cell lung carcinoma and targets Ras-related protein 14. target gene hsa-mir-33b Carcinoma, Lung 27559850 disease of cellular proliferation DOID:3905 C34.90 D008175 DNA damage responsive miR-33b-3p promoted lung cancer cells survival and cisplatin resistance by targeting p21WAF1/CIP1. target gene hsa-mir-34a Carcinoma, Lung 27836543 disease of cellular proliferation DOID:3905 C34.90 D008175 miR-34a sensitizes lung cancer cells to cisplatin via p53/miR-34a/MYCN axis. target gene hsa-mir-34a Carcinoma, Lung 28231299 disease of cellular proliferation DOID:3905 C34.90 D008175 miR-34a-5p/miR-34c-5p/miR-302b-3p-LEF1-CCND1/WNT5/MYC axis may be a crucial mechanism in inhibition of lung cancer metastasis by curcumin target gene hsa-mir-34c Carcinoma, Lung 28231299 disease of cellular proliferation DOID:3905 C34.90 D008175 miR-34a-5p/miR-34c-5p/miR-302b-3p-LEF1-CCND1/WNT6/MYC axis may be a crucial mechanism in inhibition of lung cancer metastasis by curcumin target gene hsa-mir-370 Carcinoma, Lung 28631573 disease of cellular proliferation DOID:3905 C34.90 D008175 Effects of miR-1236-3p and miR-370-5p on activation of p21 in various tumors and its inhibition on the growth of lung cancer cells. target gene hsa-mir-383 Carcinoma, Lung 27862077 disease of cellular proliferation DOID:3905 C34.90 D008175 MicroRNA-383 is a tumor suppressor in human lung cancer by targeting endothelial PAS domain-containing protein 1. target gene hsa-mir-451 Carcinoma, Lung 27686452 disease of cellular proliferation DOID:3905 C34.90 D008175 MicroRNA-451 sensitizes lung cancer cells to cisplatin through regulation of Mcl-1. target gene hsa-mir-490 Carcinoma, Lung 27683057 disease of cellular proliferation DOID:3905 C34.90 D008175 MicroRNA-490 regulates lung cancer metastasis by targeting poly r(C)-binding protein 1. target gene hsa-mir-495 Carcinoma, Lung 28363780 disease of cellular proliferation DOID:3905 C34.90 D008175 miR-199a-5p and miR-495 target GRP78 within UPR pathway of lung cancer. target gene hsa-mir-557 Carcinoma, Lung 28639890 disease of cellular proliferation DOID:3905 C34.90 D008175 MiR-557 works as a tumor suppressor in human lung cancers by negatively regulating LEF1 expression. target gene hsa-mir-570 Carcinoma, Lung 26045791 disease of cellular proliferation DOID:3905 C34.90 D008175 MicroRNA-570 promotes lung carcinoma proliferation through targeting tumor suppressor KLF9. target gene hsa-mir-93 Carcinoma, Lung 27797825 disease of cellular proliferation DOID:3905 C34.90 D008175 MCM7 and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer. target gene hsa-let-7 Carcinoma, Lung, Non-Small-Cell 28235063 C34.90 D002289 HP:0030358 Disturbance of the let-7/LIN28 double-negative feedback loop is associated with radio- and chemo-resistance in non-small cell lung cancer. target gene hsa-let-7c Carcinoma, Lung, Non-Small-Cell 26945572 C34.90 D002289 HP:0030358 Also, let-7c directly targeted the 3'-untranslated regions of JMJD1A and EZH2. target gene hsa-mir-1207 Carcinoma, Lung, Non-Small-Cell 26338522 C34.90 D002289 HP:0030358 The three miR-1207-5p, miR-1228* and miR-939 are the most connected miRNA that regulated a large number of genes. target gene hsa-mir-1228 Carcinoma, Lung, Non-Small-Cell 26338522 C34.90 D002289 HP:0030358 The three miR-1207-5p, miR-1228* and miR-939 are the most connected miRNA that regulated a large number of genes. target gene hsa-mir-124 Carcinoma, Lung, Non-Small-Cell 27924500 C34.90 D002289 HP:0030358 miR-124 modulates gefitinib resistance through SNAI2 and STAT3 in non-small cell lung cancer. target gene hsa-mir-124 Carcinoma, Lung, Non-Small-Cell 28488541 C34.90 D002289 HP:0030358 MicroRNA-124 suppresses proliferation and glycolysis in non-small cell lung cancer cells by targeting AKT-GLUT1/HKII. target gene hsa-mir-124 Carcinoma, Lung, Non-Small-Cell 29039564 C34.90 D002289 HP:0030358 Evaluation of microRNA-203 in bone metastasis of patients with non-small cell lung cancer through TGF-β/SMAD2 expression. target gene hsa-mir-1254 Carcinoma, Lung, Non-Small-Cell 28749936 C34.90 D002289 HP:0030358 MiR-1254 suppresses HO-1 expression through seed region-dependent silencing and non-seed interaction with TFAP2A transcript to attenuate NSCLC growth. target gene hsa-mir-125a Carcinoma, Lung, Non-Small-Cell 20723344 C34.90 D002289 HP:0030358 hsa-miR-125a-5p could up-regulate Rock-1 and enhance invasion in lung cancer cells. target gene hsa-mir-125b Carcinoma, Lung, Non-Small-Cell 28378642 C34.90 D002289 HP:0030358 Targeting insulin-like growth factor-binding protein-3 by microRNA-125b promotes tumor invasion and poor outcomes in non-small-cell lung cancer. target gene hsa-mir-125b Carcinoma, Lung, Non-Small-Cell 28713974 C34.90 D002289 HP:0030358 miRNA-125b regulates apoptosis of human non-small cell lung cancer via the PI3K/Akt/GSK3β signaling pathway. target gene hsa-mir-1271 Carcinoma, Lung, Non-Small-Cell 28260088 C34.90 D002289 HP:0030358 Foxk2 inhibits non-small cell lung cancer epithelial-mesenchymal transition and proliferation through the repression of different key target genes. target gene hsa-mir-1285 Carcinoma, Lung, Non-Small-Cell 28631567 C34.90 D002289 HP:0030358 MicroRNA-1285-5p influences the proliferation and metastasis of non-small-cell lung carcinoma cells via downregulating CDH1 and Smad4. target gene hsa-mir-1304 Carcinoma, Lung, Non-Small-Cell 27641735 C34.90 D002289 HP:0030358 MicroRNA-1304 suppresses human non-small cell lung cancer cell growth in vitro by targeting heme oxygenase-1. target gene hsa-mir-132 Carcinoma, Lung, Non-Small-Cell 27735039 C34.90 D002289 HP:0030358 MicroRNA-132 inhibits migration, invasion and epithelial-mesenchymal transition by regulating TGFβ1/Smad2 in human non-small cell lung cancer. target gene hsa-mir-134 Carcinoma, Lung, Non-Small-Cell 28075475 C34.90 D002289 HP:0030358 miR-134 suppresses the migration and invasion of non‑small cell lung cancer by targeting ITGB1. target gene hsa-mir-135b Carcinoma, Lung, Non-Small-Cell 27643554 C34.90 D002289 HP:0030358 miR-135b reverses chemoresistance of non-small cell lung cancer cells by downregulation of FZD1. target gene hsa-mir-137 Carcinoma, Lung, Non-Small-Cell 28239819 C34.90 D002289 HP:0030358 MiR-137 and its target TGFA modulate cell growth and tumorigenesis of non-small cell lung cancer. target gene hsa-mir-137 Carcinoma, Lung, Non-Small-Cell 28610956 C34.90 D002289 HP:0030358 Upregulation of microRNA-137 expression by Slug promotes tumor invasion and metastasis of non-small cell lung cancer cells through suppression of TFAP2C. target gene hsa-mir-138 Carcinoma, Lung, Non-Small-Cell 27665963 C34.90 D002289 HP:0030358 MicroRNA-138 inhibits migration and invasion of non-small cell lung cancer cells by targeting LIMK1. target gene hsa-mir-140 Carcinoma, Lung, Non-Small-Cell 29617683 C34.90 D002289 HP:0030358 MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC target gene hsa-mir-141 Carcinoma, Lung, Non-Small-Cell 27840955 C34.90 D002289 HP:0030358 miR-141 regulation of EIF4E expression affects docetaxel chemoresistance of non-small cell lung cancer. target gene hsa-mir-142 Carcinoma, Lung, Non-Small-Cell 28427045 C34.90 D002289 HP:0030358 MiR-142-3p Overexpression Increases Chemo-Sensitivity of NSCLC by Inhibiting HMGB1-Mediated Autophagy. target gene hsa-mir-145 Carcinoma, Lung, Non-Small-Cell 29541201 C34.90 D002289 HP:0030358 miR-145 suppresses the proliferation, invasion and migration of NSCLC cells by regulating the BAX/BCL-2 ratio and the caspase-3 cascade target gene hsa-mir-146a Carcinoma, Lung, Non-Small-Cell 28202053 C34.90 D002289 HP:0030358 Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J. target gene hsa-mir-146a Carcinoma, Lung, Non-Small-Cell 29344219 C34.90 D002289 HP:0030358 Upregulation of miR-146a increases cisplatin sensitivity of the non-small cell lung cancer A549 cell line by targeting JNK-2 target gene hsa-mir-15 Carcinoma, Lung, Non-Small-Cell 28498424 C34.90 D002289 HP:0030358 MicroRNA-15b promotes proliferation and invasion of non‑small cell lung carcinoma cells by directly targeting TIMP2. target gene hsa-mir-155 Carcinoma, Lung, Non-Small-Cell 27811366 C34.90 D002289 HP:0030358 MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN. target gene hsa-mir-181a Carcinoma, Lung, Non-Small-Cell 20145152 C34.90 D002289 HP:0030358 miR-181a and miR-630 regulate cisplatin-induced cancer cell death. target gene hsa-mir-181a Carcinoma, Lung, Non-Small-Cell 28946554 C34.90 D002289 HP:0030358 MiR-181a inhibits non-small cell lung cancer cell proliferation by targeting CDK1. target gene hsa-mir-185 Carcinoma, Lung, Non-Small-Cell 27906433 C34.90 D002289 HP:0030358 MicroRNA-185-5p modulates chemosensitivity of human non-small cell lung cancer to cisplatin via targeting ABCC1. target gene hsa-mir-186 Carcinoma, Lung, Non-Small-Cell 27714074 C34.90 D002289 HP:0030358 miR-186 regulates chemo-sensitivity to paclitaxel via targeting MAPT in non-small cell lung cancer (NSCLC). target gene hsa-mir-186 Carcinoma, Lung, Non-Small-Cell 28317368 C34.90 D002289 HP:0030358 MiR-186 Inhibited Migration of NSCLC via Targeting cdc42 and Effecting EMT Process. target gene hsa-mir-187 Carcinoma, Lung, Non-Small-Cell 28393200 C34.90 D002289 HP:0030358 MicroRNA-187 modulates epithelial-mesenchymal transition by targeting PTRF in non-small cell lung cancer. target gene hsa-mir-191 Carcinoma, Lung, Non-Small-Cell 28075452 C34.90 D002289 HP:0030358 A novel pathway in NSCLC cells: miR‑191, targeting NFIA, is induced by chronic hypoxia, and promotes cell proliferation and migration. target gene hsa-mir-195 Carcinoma, Lung, Non-Small-Cell 29416000 C34.90 D002289 HP:0030358 miR-195 targets cyclin D3 and survivin to modulate the tumorigenesis of non-small cell lung cancer target gene hsa-mir-196b Carcinoma, Lung, Non-Small-Cell 26586336 C34.90 D002289 HP:0030358 homeobox A9 (HOXA9) as a target gene of miR-196b target gene hsa-mir-19b Carcinoma, Lung, Non-Small-Cell 29455644 C34.90 D002289 HP:0030358 miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer target gene hsa-mir-200 Carcinoma, Lung, Non-Small-Cell 28405157 C34.90 D002289 HP:0030358 Decitabine reverses TGF-β1-induced epithelial-mesenchymal transition in non-small-cell lung cancer by regulating miR-200/ZEB axis. target gene hsa-mir-200c Carcinoma, Lung, Non-Small-Cell 27930974 C34.90 D002289 HP:0030358 miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1. target gene hsa-mir-200c Carcinoma, Lung, Non-Small-Cell 29557087 C34.90 D002289 HP:0030358 Anti-invasive effect of Cyclamen pseudibericum extract on A549 non-small cell lung carcinoma cells via inhibition of ZEB1 mediated by miR-200c target gene hsa-mir-203 Carcinoma, Lung, Non-Small-Cell 28350100 C34.90 D002289 HP:0030358 Overexpression of miR-203 increases the sensitivity of NSCLC A549/H460 cell lines to cisplatin by targeting Dickkopf-1. target gene hsa-mir-203 Carcinoma, Lung, Non-Small-Cell 27237033 C34.90 D002289 HP:0030358 Both miR-145 and miR-203 can directly target the 3'-untranslated region (3'-UTR) of SMAD3 target gene hsa-mir-205 Carcinoma, Lung, Non-Small-Cell 27279345 C34.90 D002289 HP:0030358 overexpression of miR鈥?05 suppressed the expression of Smad4 target gene hsa-mir-20a Carcinoma, Lung, Non-Small-Cell 29375712 C34.90 D002289 HP:0030358 MicroRNA-20a promotes proliferation and invasion by directly targeting early growth response 2 in non-small cell lung carcinoma target gene hsa-mir-214 Carcinoma, Lung, Non-Small-Cell 28076844 C34.90 D002289 HP:0030358 Sulforaphane inhibits cancer stem-like cell properties and cisplatin resistance through miR-214-mediated downregulation of c-MYC in non-small cell lung cancer. target gene hsa-mir-218 Carcinoma, Lung, Non-Small-Cell 28429357 C34.90 D002289 HP:0030358 Inhibition of pulmonary carcinoma proliferation or metastasis of miR-218 via down-regulating CDCP1 expression. target gene hsa-mir-219 Carcinoma, Lung, Non-Small-Cell 28714014 C34.90 D002289 HP:0030358 MicroRNA-219 is downregulated in non-small cell lung cancer and inhibits cell growth and metastasis by targeting HMGA2. target gene hsa-mir-221 Carcinoma, Lung, Non-Small-Cell 28392366 C34.90 D002289 HP:0030358 miRNA-221 acts as an oncogenic role by directly targeting TIMP2 in non-small-cell lung carcinoma. target gene hsa-mir-29a Carcinoma, Lung, Non-Small-Cell 28521487 C34.90 D002289 HP:0030358 MicroRNA-29a functions as a potential tumor suppressor through directly targeting CDC42 in non-small cell lung cancer. target gene hsa-mir-29c Carcinoma, Lung, Non-Small-Cell 29512752 C34.90 D002289 HP:0030358 MicroRNA-29c inhibits proliferation and promotes apoptosis in non-small cell lung cancer cells by targeting VEGFA target gene hsa-mir-30a Carcinoma, Lung, Non-Small-Cell 28259977 C34.90 D002289 HP:0030358 miR-30a radiosensitizes non-small cell lung cancer by targeting ATF1 that is involved in the phosphorylation of ATM. target gene hsa-mir-30a Carcinoma, Lung, Non-Small-Cell 28405690 C34.90 D002289 HP:0030358 MicroRNA-30a-5p suppresses epithelial-mesenchymal transition by targeting profilin-2 in high invasive non-small cell lung cancer cell lines. target gene hsa-mir-30c Carcinoma, Lung, Non-Small-Cell 28443468 C34.90 D002289 HP:0030358 Curcumin increases the sensitivity of Paclitaxel-resistant NSCLC cells to Paclitaxel through microRNA-30c-mediated MTA1 reduction. target gene hsa-mir-330 Carcinoma, Lung, Non-Small-Cell 28629431 C34.90 D002289 HP:0030358 MicroRNA-330-3p promotes cell invasion and metastasis in non-small cell lung cancer through GRIA3 by activating MAPK/ERK signaling pathway. target gene hsa-mir-33a Carcinoma, Lung, Non-Small-Cell 27856248 C34.90 D002289 HP:0030358 MiR-33a suppresses proliferation of NSCLC cells via targeting METTL3 mRNA. target gene hsa-mir-3666 Carcinoma, Lung, Non-Small-Cell 27599551 C34.90 D002289 HP:0030358 MicroRNA-3666-induced suppression of SIRT7 inhibits the growth of non-small cell lung cancer cells. target gene hsa-mir-367 Carcinoma, Lung, Non-Small-Cell 28000899 C34.90 D002289 HP:0030358 miR-367 promotes the proliferation and invasion of non-small cell lung cancer via targeting FBXW7. target gene hsa-mir-373 Carcinoma, Lung, Non-Small-Cell 29025258 C34.90 D002289 HP:0030358 MicroRNA-373 Inhibits Cell Proliferation and Invasion via Targeting BRF2 in Human Non-small Cell Lung Cancer A549 Cell Line. target gene hsa-mir-375 Carcinoma, Lung, Non-Small-Cell 28098887 C34.90 D002289 HP:0030358 miRNA‑375 regulates the cell survival and apoptosis of human non‑small cell carcinoma by targeting HER2. target gene hsa-mir-377 Carcinoma, Lung, Non-Small-Cell 27874949 C34.90 D002289 HP:0030358 miR-377 inhibited tumorous behaviors of non-small cell lung cancer through directly targeting CDK6. target gene hsa-mir-379 Carcinoma, Lung, Non-Small-Cell 28117895 C34.90 D002289 HP:0030358 Suppression of EIF4G2 by miR-379 potentiates the cisplatin chemosensitivity in nonsmall cell lung cancer cells. target gene hsa-mir-382 Carcinoma, Lung, Non-Small-Cell 28006750 C34.90 D002289 HP:0030358 miR-382 inhibits tumor progression by targeting SETD8 in non-small cell lung cancer. target gene hsa-mir-424 Carcinoma, Lung, Non-Small-Cell 28535539 C34.90 D002289 HP:0030358 MiR-424 Promotes Non-Small Cell Lung Cancer Progression and Metastasis through Regulating the Tumor Suppressor Gene TNFAIP1. target gene hsa-mir-449a Carcinoma, Lung, Non-Small-Cell 28800787 C34.90 D002289 HP:0030358 MiR-449a Suppresses LDHA-Mediated Glycolysis to Enhance the Sensitivity of Non-Small Cell Lung Cancer Cells to Ionizing Radiation. target gene hsa-mir-494 Carcinoma, Lung, Non-Small-Cell 23012423 C34.90 D002289 HP:0030358 MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation. target gene hsa-mir-509 Carcinoma, Lung, Non-Small-Cell 27894843 C34.90 D002289 HP:0030358 MiR-509-5p suppresses the proliferation, migration, and invasion of non-small cell lung cancer by targeting YWHAG. target gene hsa-mir-520a Carcinoma, Lung, Non-Small-Cell 27748920 C34.90 D002289 HP:0030358 microRNA-520a-3p inhibits proliferation and cancer stem cell phenotype by targeting HOXD8 in non-small cell lung cancer. target gene hsa-mir-520e Carcinoma, Lung, Non-Small-Cell 28242196 C34.90 D002289 HP:0030358 MicroRNA-520e suppresses non-small-cell lung cancer cell growth by targeting Zbtb7a-mediated Wnt signaling pathway. target gene hsa-mir-585 Carcinoma, Lung, Non-Small-Cell 27743168 C34.90 D002289 HP:0030358 MicroRNA-585 acts as a tumor suppressor in non-small-cell lung cancer by targeting hSMG-1. target gene hsa-mir-590 Carcinoma, Lung, Non-Small-Cell 27770372 C34.90 D002289 HP:0030358 microRNA-590 suppresses the tumorigenesis and invasiveness of non-small cell lung cancer cells by targeting ADAM9. target gene hsa-mir-592 Carcinoma, Lung, Non-Small-Cell 28004116 C34.90 D002289 HP:0030358 miR-592 functions as a tumor suppressor in human non-small cell lung cancer by targeting SOX9. target gene hsa-mir-599 Carcinoma, Lung, Non-Small-Cell 28167280 C34.90 D002289 HP:0030358 The miR-599 promotes non-small cell lung cancer cell invasion via SATB2. target gene hsa-mir-630 Carcinoma, Lung, Non-Small-Cell 20145152 C34.90 D002289 HP:0030358 miR-181a and miR-630 regulate cisplatin-induced cancer cell death. target gene hsa-mir-874 Carcinoma, Lung, Non-Small-Cell 28501870 C34.90 D002289 HP:0030358 Long Non-Coding RNA XLOC_008466 Functions as an Oncogene in Human Non-Small Cell Lung Cancer by Targeting miR-874. target gene hsa-mir-939 Carcinoma, Lung, Non-Small-Cell 26338522 C34.90 D002289 HP:0030358 The three miR-1207-5p, miR-1228* and miR-939 are the most connected miRNA that regulated a large number of genes. target gene hsa-mir-96 Carcinoma, Lung, Non-Small-Cell 26893673 C34.90 D002289 HP:0030358 overexpression of miR-96 in NSCLC cells markedly decreased SAMD9 expression and cisplatin-induced apoptosis, and increased the cisplatin IC50 target gene hsa-mir-98 Carcinoma, Lung, Non-Small-Cell 27938506 C34.90 D002289 HP:0030358 MicroRNA-98 Plays a Suppressive Role in Non-Small Cell Lung Cancer Through Inhibition of SALL4 Protein Expression. target gene hsa-mir-98 Carcinoma, Lung, Non-Small-Cell 28415380 C34.90 D002289 HP:0030358 miR-98 inhibits expression of TWIST to prevent progression of non-small cell lung cancers. target gene hsa-let-7c Carcinoma, Lung, Non-Small-Cell 23981581 C34.90 D002289 HP:0030358 Our results suggest that let-7c,by degrading ITGB3 and MAP4K3, prevents NSCLC metastasis. target gene hsa-mir-101-1 Carcinoma, Lung, Non-Small-Cell 21270667 C34.90 D002289 HP:0030358 MicroRNA-101 Exerts Tumor-Suppressive Functions in Non-small Cell Lung Cancer through Directly Targeting Enhancer of Zeste Homolog 2. target gene hsa-mir-101-2 Carcinoma, Lung, Non-Small-Cell 21270667 C34.90 D002289 HP:0030358 MicroRNA-101 Exerts Tumor-Suppressive Functions in Non-small Cell Lung Cancer through Directly Targeting Enhancer of Zeste Homolog 2. target gene hsa-mir-10a Carcinoma, Lung, Non-Small-Cell 26317552 C34.90 D002289 HP:0030358 We found that PTEN was a direct target of miR-10a in NSCLC. Also miR-10a activated the PTEN/AKT/ERK pathway. We suggest that miR-10a contributes to NSCLC by targeting PTEN. target gene hsa-mir-124 Carcinoma, Lung, Non-Small-Cell 25400731 C34.90 D002289 HP:0030358 miRNA-124 directly targeted and decreased SOX8 in NSCLC cell lines, suggesting smiRNA-124 may regulate NSCLC cell proliferation via decreasing SOX8 (oncogenicity of biomarker in NSCLC). target gene hsa-mir-124 Carcinoma, Lung, Non-Small-Cell 25749519 C34.90 D002289 HP:0030358 NF-κB-mediated miR-124 suppresses metastasis of non-small-cell lung cancer by targeting MYO10. target gene hsa-mir-124 Carcinoma, Lung, Non-Small-Cell 25531908 C34.90 D002289 HP:0030358 miR-124 functions as a tumor suppressor by targeting STAT3, and that miR-124 may potentially serve as a useful biomarker for the prognosis of NSCLC patients. target gene hsa-mir-1246 Carcinoma, Lung, Non-Small-Cell 26209100 C34.90 D002289 HP:0030358 These results suggested that the miR-1246 may promote cell metastasis by targeting CPEB4. Meanwhile, the level of CPEB4 could be used as a potential marker in NSCLC patients. Our findings unraveled novel functions of miR-1246 in lung cancer cells and shed light on NSCLC prognosis. target gene hsa-mir-1258 Carcinoma, Lung, Non-Small-Cell 22488243 C34.90 D002289 HP:0030358 The miR-1258 regulates the expression level of HPSE to influence the morbidity and metastasis of NSCLC. target gene hsa-mir-125a Carcinoma, Lung, Non-Small-Cell 25998575 C34.90 D002289 HP:0030358 miR-125a-3p targets MTA1 to suppress NSCLC cell proliferation, migration, and invasion. target gene hsa-mir-125b Carcinoma, Lung, Non-Small-Cell 25668010 C34.90 D002289 HP:0030358 Kinesin-1 light chain-2 protein overexpression predicts poor survival in elderly NSCLC patients. Kinesin-1 light chain-2 acts as a proto-oncogene and a functional target of miR-125b in NSCLC cells. target gene hsa-mir-126 Carcinoma, Lung, Non-Small-Cell 21439283 C34.90 D002289 HP:0030358 miR-126 inhibits proliferation of small cell lung cancer cells by targeting SLC7A5. target gene hsa-mir-126 Carcinoma, Lung, Non-Small-Cell 22510476 C34.90 D002289 HP:0030358 miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A. target gene hsa-mir-1271 Carcinoma, Lung, Non-Small-Cell 25686496 C34.90 D002289 HP:0030358 miR-1271 promotes non-small-cell lung cancer cell proliferation and invasion via targeting HOXA5. target gene hsa-mir-128 Carcinoma, Lung, Non-Small-Cell 25001183 C34.90 D002289 HP:0030358 microRNA-128 plays a critical role in human non-small cell lung cancer tumourigenesis, angiogenesis and lymphangiogenesis by directly targeting vascular endothelial growth factor-C. target gene hsa-mir-129 Carcinoma, Lung, Non-Small-Cell 25716201 C34.90 D002289 HP:0030358 MiR-129 regulates MMP9 to control metastasis of non-small cell lung cancer. target gene hsa-mir-130a Carcinoma, Lung, Non-Small-Cell 21706050 C34.90 D002289 HP:0030358 miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. target gene hsa-mir-130a Carcinoma, Lung, Non-Small-Cell 24606471 C34.90 D002289 HP:0030358 MiR-130a overcomes gefitinib resistance by targeting met in non-small cell lung cancer cell lines. target gene hsa-mir-132 Carcinoma, Lung, Non-Small-Cell 24158730 C34.90 D002289 HP:0030358 Hsa-miR-132 regulates apoptosis in non-small cell lung cancer independent of acetylcholinesterase. target gene hsa-mir-133b Carcinoma, Lung, Non-Small-Cell 22883469 C34.90 D002289 HP:0030358 MicroRNA-133b Inhibits the Growth of Non-small Cell Lung Cancer by Targeting the Epidermal Growth Factor Receptor. target gene hsa-mir-137 Carcinoma, Lung, Non-Small-Cell 24243432 C34.90 D002289 HP:0030358 miR-137 impairs the proliferative and migratory capacity of human non-small cell lung cancer cells by targeting paxillin. target gene hsa-mir-138 Carcinoma, Lung, Non-Small-Cell 24582749 C34.90 D002289 HP:0030358 miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124. target gene hsa-mir-138 Carcinoma, Lung, Non-Small-Cell 25064732 C34.90 D002289 HP:0030358 Prognostic potential of microRNA-138 and its target mRNA PDK1 in sera for patients with non-small cell lung cancer. target gene hsa-mir-140 Carcinoma, Lung, Non-Small-Cell 24039995 C34.90 D002289 HP:0030358 miR-140 suppresses tumor growth and metastasis of non-small cell lung cancer by targeting insulin-like growth factor 1 receptor. target gene hsa-mir-140 Carcinoma, Lung, Non-Small-Cell 24971538 C34.90 D002289 HP:0030358 Monocyte to macrophage differentiation-associated (MMD) targeted by miR-140-5p regulates tumor growth in non-small cell lung cancer. target gene hsa-mir-141 Carcinoma, Lung, Non-Small-Cell 24945731 C34.90 D002289 HP:0030358 MicroRNA-141 promotes the proliferation of non-small cell lung cancer cells by regulating expression of PHLPP1 and PHLPP2. target gene hsa-mir-142 Carcinoma, Lung, Non-Small-Cell 24558198 C34.90 D002289 HP:0030358 MiR-142-3p represses TGF-β-induced growth inhibition through repression of TGFβR1 in non-small cell lung cancer. target gene hsa-mir-143 Carcinoma, Lung, Non-Small-Cell 25003638 C34.90 D002289 HP:0030358 miR-143 inhibits NSCLC cell growth and metastasis by targeting Limk1. target gene hsa-mir-143 Carcinoma, Lung, Non-Small-Cell 24070896 C34.90 D002289 HP:0030358 Treatment with miR-143 inhibitor mimics cell proliferation and apoptosis imbalance in NSCLC, while inhibition of PKCε can reverse it. Our findings suggest that targeting PKCε overexpression in NSCLC should be beneficial for lung cancer therapy. target gene hsa-mir-145 Carcinoma, Lung, Non-Small-Cell 23876001 C34.90 D002289 HP:0030358 miRNA-145-regulated oncolytic HSV-1 is a promising agent for the treatment of NSCLC. target gene hsa-mir-145 Carcinoma, Lung, Non-Small-Cell 26238532 C34.90 D002289 HP:0030358 MicroRNA-145 inhibits migration and invasion via inhibition of fascin 1 protein expression in non-small-cell lung cancer cells. target gene hsa-mir-146a Carcinoma, Lung, Non-Small-Cell 26238771 C34.90 D002289 HP:0030358 MicroRNA-146a inhibits epithelial mesenchymal transition in non-small cell lung cancer by targeting insulin receptor substrate 2. target gene hsa-mir-148a Carcinoma, Lung, Non-Small-Cell 23670799 C34.90 D002289 HP:0030358 MicroRNA-148a suppresses epithelial-to-mesenchymal transition by targeting ROCK1 in non-small cell lung cancer cells. target gene hsa-mir-148b Carcinoma, Lung, Non-Small-Cell 25927928 C34.90 D002289 HP:0030358 miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNMT1 expression. target gene hsa-mir-149 Carcinoma, Lung, Non-Small-Cell 23762558 C34.90 D002289 HP:0030358 miR-149 Inhibits Non-Small-Cell Lung Cancer Cells EMT by Targeting FOXM1. target gene hsa-mir-150 Carcinoma, Lung, Non-Small-Cell 24532468 C34.90 D002289 HP:0030358 Down-regulation of miR-150 induces cell proliferation inhibition and apoptosis in non-small-cell lung cancer by targeting BAK1 in vitro. target gene hsa-mir-152 Carcinoma, Lung, Non-Small-Cell 24780186 C34.90 D002289 HP:0030358 MicroRNA-152 targets ADAM17 to suppress NSCLC progression. target gene hsa-mir-15a Carcinoma, Lung, Non-Small-Cell 25874488 C34.90 D002289 HP:0030358 MicroRNA-15a induces cell apoptosis and inhibits metastasis by targeting BCL2L2 in non-small cell lung cancer. target gene hsa-mir-16 Carcinoma, Lung, Non-Small-Cell 23954293 C34.90 D002289 HP:0030358 Downregulation of miR-16 promotes growth and motility by targeting HDGF in non-small cell lung cancer cells. target gene hsa-mir-17 Carcinoma, Lung, Non-Small-Cell 24722426 C34.90 D002289 HP:0030358 MiRNA 17 family regulates cisplatin-resistant and metastasis by targeting TGFbetaR2 in NSCLC. target gene hsa-mir-181b Carcinoma, Lung, Non-Small-Cell 26620926 C34.90 D002289 HP:0030358 Consequently, miR-181b functions as a tumor suppressor and has an important role in proliferation, chemosensitivity to DDP and metastasis of NSCLC by targeting TGFβR1/Smad signaling pathway. target gene hsa-mir-182 Carcinoma, Lung, Non-Small-Cell 25012722 C34.90 D002289 HP:0030358 MicroRNA-182 modulates chemosensitivity of human non-small cell lung cancer to cisplatin by targeting PDCD4. target gene hsa-mir-184 Carcinoma, Lung, Non-Small-Cell 25990966 C34.90 D002289 HP:0030358 MiR-184 as a tumor suppressor miR inhibits cell proliferation and invasion capability via targeting CDC25A and c-Myc. Low miR-184 level may predict worse prognosis in NSCLC patients. target gene hsa-mir-184 Carcinoma, Lung, Non-Small-Cell 24976536 C34.90 D002289 HP:0030358 Candidate tumour suppressor CCDC19 regulates miR-184 direct targeting of C-Myc thereby suppressing cell growth in non-small cell lung cancers. target gene hsa-mir-186 Carcinoma, Lung, Non-Small-Cell 24894676 C34.90 D002289 HP:0030358 MiR-186 targets ROCK1 to suppress the growth and metastasis of NSCLC cells. target gene hsa-mir-193a Carcinoma, Lung, Non-Small-Cell 25833338 C34.90 D002289 HP:0030358 miR-193a-3p inhibited the metastasis of lung cancer cells by deregulating the expression of tumor-related proteins. These findings may improve the understanding of the molecular mechanisms underlying the metastatic-inhibitory effect of miR-193a-3p on lung cancer cells. target gene hsa-mir-195 Carcinoma, Lung, Non-Small-Cell 24486218 C34.90 D002289 HP:0030358 MicroRNA-195 inhibits non-small cell lung cancer cell proliferation, migration and invasion by targeting MYB. target gene hsa-mir-195 Carcinoma, Lung, Non-Small-Cell 24874051 C34.90 D002289 HP:0030358 MiR-195 inhibits the growth and metastasis of NSCLC cells by targeting IGF1R. target gene hsa-mir-195 Carcinoma, Lung, Non-Small-Cell 24891187 C34.90 D002289 HP:0030358 MiR-195 targets HDGF to inhibit proliferation and invasion of NSCLC cells. target gene hsa-mir-195 Carcinoma, Lung, Non-Small-Cell 25840419 C34.90 D002289 HP:0030358 MiR-195 suppresses non-small cell lung cancer by targeting CHEK1. target gene hsa-mir-196a-1 Carcinoma, Lung, Non-Small-Cell 22876840 C34.90 D002289 HP:0030358 MicroRNA-196a promotes non-small cell lung cancer cell proliferation and invasion through targeting HOXA5. target gene hsa-mir-196a-2 Carcinoma, Lung, Non-Small-Cell 22876840 C34.90 D002289 HP:0030358 MicroRNA-196a promotes non-small cell lung cancer cell proliferation and invasion through targeting HOXA5. target gene hsa-mir-200b Carcinoma, Lung, Non-Small-Cell 21993663 C34.90 D002289 HP:0030358 miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. target gene hsa-mir-200c Carcinoma, Lung, Non-Small-Cell 21993663 C34.90 D002289 HP:0030358 miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. target gene hsa-mir-200c Carcinoma, Lung, Non-Small-Cell 24205206 C34.90 D002289 HP:0030358 MiR-200c increases the radiosensitivity of non-small-cell lung cancer cell line A549 by targeting VEGF-VEGFR2 pathway. target gene hsa-mir-204 Carcinoma, Lung, Non-Small-Cell 25157435 C34.90 D002289 HP:0030358 miR-204 functions as a tumor suppressor by regulating SIX1 in NSCLC. target gene hsa-mir-205 Carcinoma, Lung, Non-Small-Cell 23856247 C34.90 D002289 HP:0030358 miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer. target gene hsa-mir-205 Carcinoma, Lung, Non-Small-Cell 24084898 C34.90 D002289 HP:0030358 miR-205 promotes the growth, metastasis and chemoresistance of NSCLC cells by targeting PTEN. target gene hsa-mir-21 Carcinoma, Lung, Non-Small-Cell 22956424 C34.90 D002289 HP:0030358 MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN. target gene hsa-mir-21 Carcinoma, Lung, Non-Small-Cell 24331411 C34.90 D002289 HP:0030358 miR-21 is involved in acquired resistance of EGFR-TKI in NSCLC, which is mediated by down-regulating PTEN and PDCD4 and activating PI3K/Akt pathway. target gene hsa-mir-21 Carcinoma, Lung, Non-Small-Cell 25058005 C34.90 D002289 HP:0030358 Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer. target gene hsa-mir-21 Carcinoma, Lung, Non-Small-Cell 25990966 C34.90 D002289 HP:0030358 MiR-184 as a tumor suppressor miR inhibits cell proliferation and invasion capability via targeting CDC25A and c-Myc. Low miR-184 level may predict worse prognosis in NSCLC patients. target gene hsa-mir-212 Carcinoma, Lung, Non-Small-Cell 20388802 C34.90 D002289 HP:0030358 miR-212:miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED target gene hsa-mir-212 Carcinoma, Lung, Non-Small-Cell 22357618 C34.90 D002289 HP:0030358 MiR-212 displays Tumor Promoting properties in NSCLC Cells and targets the Hedgehog Pathway Receptor PTCH1. target gene hsa-mir-212 Carcinoma, Lung, Non-Small-Cell 23974008 C34.90 D002289 HP:0030358 Synaptic acetylcholinesterase targeted by microRNA-212 functions as a tumor suppressor in non-small cell lung cancer. target gene hsa-mir-214 Carcinoma, Lung, Non-Small-Cell 22929890 C34.90 D002289 HP:0030358 miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence. target gene hsa-mir-214 Carcinoma, Lung, Non-Small-Cell 23929716 C34.90 D002289 HP:0030358 miRNA-214 is related to invasiveness of human non-small cell lung cancer and directly regulates alpha protein kinase 2 expression. target gene hsa-mir-218 Carcinoma, Lung, Non-Small-Cell 24247270 C34.90 D002289 HP:0030358 MiRNA-218, a new regulator of HMGB1, suppresses cell migration and invasion in non-small cell lung cancer. target gene hsa-mir-218-1 Carcinoma, Lung, Non-Small-Cell 21159652 C34.90 D002289 HP:0030358 Paxillin Predicts Survival and Relapse in Non-Small Cell Lung Cancer by MicroRNA-218 Targeting. target gene hsa-mir-218-2 Carcinoma, Lung, Non-Small-Cell 21159652 C34.90 D002289 HP:0030358 Paxillin Predicts Survival and Relapse in Non-Small Cell Lung Cancer by MicroRNA-218 Targeting. target gene hsa-mir-221 Carcinoma, Lung, Non-Small-Cell 21706050 C34.90 D002289 HP:0030358 miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. target gene hsa-mir-222 Carcinoma, Lung, Non-Small-Cell 21706050 C34.90 D002289 HP:0030358 miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. target gene hsa-mir-24 Carcinoma, Lung, Non-Small-Cell 25725584 C34.90 D002289 HP:0030358 Upregulation of miR-24 promotes cell proliferation by targeting NAIF1 in non-small cell lung cancer. target gene hsa-mir-25 Carcinoma, Lung, Non-Small-Cell 25576360 C34.90 D002289 HP:0030358 miR-25-BTG2 axis could directly regulated BTG2 expression and affect radiotherapy sensitivity of NSCLC cells. target gene hsa-mir-26b Carcinoma, Lung, Non-Small-Cell 26827826 C34.90 D002289 HP:0030358 MicroRNA-26b suppresses the metastasis of non-small cell lung cancer by targeting MIEN1 via NF-κB/MMP-9/VEGF pathways. target gene hsa-mir-27b Carcinoma, Lung, Non-Small-Cell 24390089 C34.90 D002289 HP:0030358 MiR-27b targets LIMK1 to inhibit growth and invasion of NSCLC cells. target gene hsa-mir-27b Carcinoma, Lung, Non-Small-Cell 25012245 C34.90 D002289 HP:0030358 MicroRNA-27b suppresses growth and invasion of NSCLC cells by targeting Sp1. target gene hsa-mir-29b-1 Carcinoma, Lung, Non-Small-Cell 22290228 C34.90 D002289 HP:0030358 miR-29b is an upstream molecule of PTEN. miR-29b regulates PTEN gene expression through downregulating Dnmts expression and subsequently induces hypomethylation in PTEN promoter. target gene hsa-mir-29b-2 Carcinoma, Lung, Non-Small-Cell 22290228 C34.90 D002289 HP:0030358 miR-29b is an upstream molecule of PTEN. miR-29b regulates PTEN gene expression through downregulating Dnmts expression and subsequently induces hypomethylation in PTEN promoter. target gene hsa-mir-30a Carcinoma, Lung, Non-Small-Cell 23758992 C34.90 D002289 HP:0030358 BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification. target gene hsa-mir-30c Carcinoma, Lung, Non-Small-Cell 23988701 C34.90 D002289 HP:0030358 Down-regulation of miR-30c promotes the invasion of non-small cell lung cancer by targeting MTA1. target gene hsa-mir-30d Carcinoma, Lung, Non-Small-Cell 25843294 C34.90 D002289 HP:0030358 MicroRNA-30d-5p inhibits tumour cell proliferation and motility by directly targeting CCNE2 in non-small cell lung cancer. target gene hsa-mir-31 Carcinoma, Lung, Non-Small-Cell 24099915 C34.90 D002289 HP:0030358 The data demonstrate that miR-31 exerts an anti-apoptotic effect most likely through the inhibition of ABCB9 and thus provide a novel strategy involving the use of miR-31 as a potential target in NSCLC chemotherapy. target gene hsa-mir-325 Carcinoma, Lung, Non-Small-Cell 25776482 C34.90 D002289 HP:0030358 Expression of MicroRNA-325-3p and its potential functions by targeting HMGB1 in non-small cell lung cancer. target gene hsa-mir-330 Carcinoma, Lung, Non-Small-Cell 25935837 C34.90 D002289 HP:0030358 miR-330-3p controls cell proliferation by targeting early growth response 2 in non-small-cell lung cancer. target gene hsa-mir-337 Carcinoma, Lung, Non-Small-Cell 22723956 C34.90 D002289 HP:0030358 miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers. target gene hsa-mir-342 Carcinoma, Lung, Non-Small-Cell 25663460 C34.90 D002289 HP:0030358 miR-342-3p targets RAP2B to suppress proliferation and invasion of non-small cell lung cancer cells. target gene hsa-mir-34a Carcinoma, Lung, Non-Small-Cell 23902763 C34.90 D002289 HP:0030358 Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial-mesenchymal transition (EMT) by miR-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines. target gene hsa-mir-34c Carcinoma, Lung, Non-Small-Cell 22370637 C34.90 D002289 HP:0030358 The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation. miR-34c-5p markedly increased resistance to paclitaxel-induced apoptosis. We demonstrate that Bmf (Bcl-2-modifying factor) is a target of miR-34c-5p, and that its silencing, together with that of c-myc, a known target of miR-34c-5p, contributes to resistance to apoptosis induced by paclitaxel through p53 downregulation. target gene hsa-mir-34c Carcinoma, Lung, Non-Small-Cell 26250586 C34.90 D002289 HP:0030358 miR-34c-3p directly targeted eIF4E and reduced miR-34c-3p expression in NSCLC, promoting cell cycle progression, proliferation, migration and invasion. target gene hsa-mir-370 Carcinoma, Lung, Non-Small-Cell 25976502 C34.90 D002289 HP:0030358 MicroRNA-370 inhibits the progression of non-small cell lung cancer by downregulating oncogene TRAF4. target gene hsa-mir-373 Carcinoma, Lung, Non-Small-Cell 25063738 C34.90 D002289 HP:0030358 miR-373 is silenced by histone modification in lung cancer cells and identified its function as a tumor suppressor and negative regulator of the mesenchymal phenotype through downstream IRAK2 and LAMP1 target genes. target gene hsa-mir-375 Carcinoma, Lung, Non-Small-Cell 25001509 C34.90 D002289 HP:0030358 CLDN1 is a novel target of miR-375, and high miR-375 expression shortens survival in NSCLC. target gene hsa-mir-429 Carcinoma, Lung, Non-Small-Cell 21993663 C34.90 D002289 HP:0030358 miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. target gene hsa-mir-429 Carcinoma, Lung, Non-Small-Cell 24866238 C34.90 D002289 HP:0030358 MicroRNA-429 induces tumorigenesis of human non-small cell lung cancer cells and targets multiple tumor suppressor genes. target gene hsa-mir-451a Carcinoma, Lung, Non-Small-Cell 21358675 C34.90 D002289 HP:0030358 MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). target gene hsa-mir-4782 Carcinoma, Lung, Non-Small-Cell 24556800 C34.90 D002289 HP:0030358 High expression of miR-4782-3p was associated with favorable prognosis in NSCLC patients. MiR-4782-3p inhibited cell proliferation in NSCLC by targeting USP14, ZEB2 and XIAP. target gene hsa-mir-489 Carcinoma, Lung, Non-Small-Cell 25833694 C34.90 D002289 HP:0030358 Down-regulation of miR-489 contributes into NSCLC cell invasion through targeting SUZ12. target gene hsa-mir-495 Carcinoma, Lung, Non-Small-Cell 24293376 C34.90 D002289 HP:0030358 MiR-495 regulates proliferation and migration in NSCLC by targeting MTA3. target gene hsa-mir-497 Carcinoma, Lung, Non-Small-Cell 23673296 C34.90 D002289 HP:0030358 Downregulation of miR-497 promotes tumor growth and angiogenesis by targeting HDGF in non-small cell lung cancer. target gene hsa-mir-503 Carcinoma, Lung, Non-Small-Cell 23856992 C34.90 D002289 HP:0030358 miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2. target gene hsa-mir-503 Carcinoma, Lung, Non-Small-Cell 24486548 C34.90 D002289 HP:0030358 Epigenetic silencing of MicroRNA-503 regulates FANCA expression in non-small cell lung cancer cell. target gene hsa-mir-503 Carcinoma, Lung, Non-Small-Cell 24550137 C34.90 D002289 HP:0030358 MiR-503 targets PI3K p85 and IKK-β and suppresses progression of non-small cell lung cancer. target gene hsa-mir-512 Carcinoma, Lung, Non-Small-Cell 26648284 C34.90 D002289 HP:0030358 In conclusion, our present study revealed miR-512-5p was able to target p21 to induce apoptosis and inhibit glycolysis in A549 and H1299 cell lines. target gene hsa-mir-575 Carcinoma, Lung, Non-Small-Cell 25728273 C34.90 D002289 HP:0030358 MicroRNA-575 targets BLID to promote growth and invasion of non-small cell lung cancer cells. target gene hsa-mir-7 Carcinoma, Lung, Non-Small-Cell 24281003 C34.90 D002289 HP:0030358 All these findings strongly imply that the overexpression of PA28gamma resulted from miR-7 downexpression in NSCLC has an important role in promoting cancer cell progress and consequently results in NSCLC growth. Thus, strategies targeting PA28gamma and/or miR-7 may become promising molecular therapies in NSCLC treatment. target gene hsa-mir-7 Carcinoma, Lung, Non-Small-Cell 26464649 C34.90 D002289 HP:0030358 This study further extends the biological role of miR-7 in NSCLC A549 and H460 cells and identifies BCL-2 as a novel target possibly involved in miR-7-mediated growth suppression and apoptosis induction of NSCLC cells. target gene hsa-mir-7-1 Carcinoma, Lung, Non-Small-Cell 21750649 C34.90 D002289 HP:0030358 MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2. target gene hsa-mir-7-2 Carcinoma, Lung, Non-Small-Cell 21750649 C34.90 D002289 HP:0030358 MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2. target gene hsa-mir-7-3 Carcinoma, Lung, Non-Small-Cell 21750649 C34.90 D002289 HP:0030358 MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2. target gene hsa-mir-761 Carcinoma, Lung, Non-Small-Cell 26278569 C34.90 D002289 HP:0030358 miR-761 promotes progression and metastasis of NSCLC by targeting ING4 and TIMP2. target gene hsa-mir-92b Carcinoma, Lung, Non-Small-Cell 24162673 C34.90 D002289 HP:0030358 Inhibition of miR-92b suppresses nonsmall cell lung cancer cells growth and motility by targeting RECK. target gene hsa-mir-95 Carcinoma, Lung, Non-Small-Cell 24835695 C34.90 D002289 HP:0030358 MiR-95 induces proliferation and chemo- or radioresistance through directly targeting sorting nexin1 (SNX1) in non-small cell lung cancer. target gene hsa-mir-98 Carcinoma, Lung, Non-Small-Cell 21880462 C34.90 D002289 HP:0030358 miR-98 regulates cisplatin-induced A549 cell death by inhibiting TP53 pathway. target gene hsa-mir-98 Carcinoma, Lung, Non-Small-Cell 24712372 C34.90 D002289 HP:0030358 EGCG enhances the efficacy of cisplatin by downregulating hsa-miR-98-5p in NSCLC A549 cells. target gene hsa-mir-125a Carcinoma, Lung, Small-Cell 25833836 C34.90 D055752 182280 HP:0030357 Chemotherapy-Regulated microRNA-125-HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer. target gene hsa-mir-138 Carcinoma, Lung, Small-Cell 25699650 C34.90 D055752 182280 HP:0030357 MicroRNA-138 Regulates DNA Damage Response in Small Cell Lung Cancer Cells by Directly Targeting H2AX. target gene hsa-mir-181a Carcinoma, Lung, Small-Cell 28535543 C34.90 D055752 182280 HP:0030357 MicroRNA-181a-5p Impedes IL-17-Induced Nonsmall Cell Lung Cancer Proliferation and Migration through Targeting VCAM-1. target gene hsa-mir-24 Carcinoma, Lung, Small-Cell 25426560 C34.90 D055752 182280 HP:0030357 miR-24-3p regulates autophagy by targeting ATG4A. Inhibition of autophagy by increasing miR-24-3p could be the basis of a strategy to prevent and treat SCLC with combination chemotherapy, particularly in chemoresistant disease. target gene hsa-mir-335 Carcinoma, Lung, Small-Cell 23966614 C34.90 D055752 182280 HP:0030357 miR-335 inhibits small cell lung cancer bone metastases via IGF-IR and RANKL pathways. target gene hsa-mir-335 Carcinoma, Lung, Small-Cell 27871924 C34.90 D055752 182280 HP:0030357 MiR-335 regulates the chemo-radioresistance of small cell lung cancer cells by targeting PARP-1. target gene hsa-mir-335 Carcinoma, Lung, Small-Cell 27336605 C34.90 D055752 182280 HP:0030357 miR-335 negatively regulated the MDR of WBP5 by targeting its 3'UTR target gene hsa-mir-495 Carcinoma, Lung, Small-Cell 28302484 C34.90 D055752 182280 HP:0030357 TSPAN12 promotes chemoresistance and proliferation of SCLC under the regulation of miR-495. target gene hsa-mir-203 Carcinoma, Merkel Cell 23962809 disease of cellular proliferation DOID:3965 C4A.9 D015266 HP:0030447 Functionally, overexpression of miR-203 was found to inhibit cell growth, induce cell cycle arrest, and regulate survivin expression in MCV- MCC cells, but not in MCV+ MCC cells. bovine target gene hsa-let-7 Carcinoma, Nasopharyngeal 26125802 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 The let-7 and miR-29 families may be related to the development of NPC by regulating the genes involved in cell cycle and ECM-receptor interaction. target gene hsa-mir-1 Carcinoma, Nasopharyngeal 26852690 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 miR-1, regulated by LMP1, suppresses tumour growth and metastasis by targeting K-ras in nasopharyngeal carcinoma. target gene hsa-mir-10b Carcinoma, Nasopharyngeal 25597482 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 hsa-mir-10b gene regulation through LMP1/Twist1 in NPC malignancy. target gene hsa-mir-124 Carcinoma, Nasopharyngeal 25098939 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 Our results demonstrate that miR-124 functions as a tumor-suppressive microRNA in NPC, and that its suppressive effects are mediated chiefly by repressing Foxq1 expression. MiR-124 could serve as an independent biomarker to identify patients with different clinical characteristics.Therefore, our findings provide valuable clues toward the understanding the of mechanisms of NPC pathogenesis and provide an opportunity to develop new effective clinical therapies in the future. target gene hsa-mir-124 Carcinoma, Nasopharyngeal 28579809 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 miR-124 suppresses proliferation and invasion of nasopharyngeal carcinoma cells through the Wnt/β-catenin signaling pathway by targeting Capn4. target gene hsa-mir-125b Carcinoma, Nasopharyngeal 28260044 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 microRNA-125b reverses the multidrug resistance of nasopharyngeal carcinoma cells via targeting of Bcl-2. target gene hsa-mir-125b Carcinoma, Nasopharyngeal 28569771 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 MiR-125b regulates proliferation and apoptosis of nasopharyngeal carcinoma by targeting A20/NF-κB signaling pathway. target gene hsa-mir-125b Carcinoma, Nasopharyngeal 28698199 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 MiR-125b Increases Nasopharyngeal Carcinoma Radioresistance by Targeting A20/NF-κB Signaling Pathway. target gene hsa-mir-138 Carcinoma, Nasopharyngeal 28075468 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 MicroRNA-138-5p controls sensitivity of nasopharyngeal carcinoma to radiation by targeting EIF4EBP1. target gene hsa-mir-143 Carcinoma, Nasopharyngeal 23895853 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 MiR-143 can inhibit the invasion of NPC cells by negative regulation of GLI3 gene, which sheds light on the role of miR-143 and Hh pathway in NPC. target gene hsa-mir-152 Carcinoma, Nasopharyngeal 28000885 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 MicroRNA‑152 inhibits cell proliferation, migration and invasion by directly targeting MAFB in nasopharyngeal carcinoma. target gene hsa-mir-155 Carcinoma, Nasopharyngeal 26698246 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 This study found that aberrant miR-155 expression driven by LMP1 can modulate radio-sensitivity of the NPC cell at least partly through targeting UBQLN1. target gene hsa-mir-15a Carcinoma, Nasopharyngeal 24016566 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 inhibit the proliferation of CNE-2Z cells, promote apoptosis and enhance the sensitivity of the cells to radiotherapy probably by inhibiting bcl-2 expression, activating Caspase-2 and Caspase-3. target gene hsa-mir-15a Carcinoma, Nasopharyngeal 25405832 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 miR-15a/16-1 could inhibit cell proliferation and increase the apoptosis and radiosensitivity of CNE-2 cells, by regulating the bcl-2 gene at post-transcriptional level and by increasing the activation of caspase-2 and caspase-3. target gene hsa-mir-15a Carcinoma, Nasopharyngeal 19144710 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 We found that the tumor suppressor BRCA-1 is a target of miR-15a as well as miR-16, suggesting a miRNA role in NPC pathogenesis. target gene hsa-mir-16 Carcinoma, Nasopharyngeal 25405832 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 miR-15a/16-1 could inhibit cell proliferation and increase the apoptosis and radiosensitivity of CNE-2 cells, by regulating the bcl-2 gene at post-transcriptional level and by increasing the activation of caspase-2 and caspase-3. target gene hsa-mir-16-1 Carcinoma, Nasopharyngeal 24016566 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 inhibit the proliferation of CNE-2Z cells, promote apoptosis and enhance the sensitivity of the cells to radiotherapy probably by inhibiting bcl-2 expression, activating Caspase-2 and Caspase-3. target gene hsa-mir-185 Carcinoma, Nasopharyngeal 25297925 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 miR-185-3p regulates nasopharyngeal carcinoma radioresistance by targeting WNT2B in vitro. target gene hsa-mir-185 Carcinoma, Nasopharyngeal 26390174 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 Combined low miR-185-3p and miR-324-3p might be important markers for prediction of low response to RT/CRT and poor overall survival and recurrence-free survival.MiR-185-3p and miR-324-3p can modulate NPC cell growth and apoptosis, at least partly through targeting SMAD7. target gene hsa-mir-200a Carcinoma, Nasopharyngeal 24190575 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 Furthermore, overexpression of EBNA1 inhibited the expression of microRNA 200a (miR-200a) and miR-200b and, in turn, up-regulated expression of their target genes, zinc finger E-box binding homeobox 1 ( ZEB1) and ZEB2, which are well known mediators of EMT. target gene hsa-mir-200b Carcinoma, Nasopharyngeal 24190575 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 Furthermore, overexpression of EBNA1 inhibited the expression of microRNA 200a (miR-200a) and miR-200b and, in turn, up-regulated expression of their target genes, zinc finger E-box binding homeobox 1 ( ZEB1) and ZEB2, which are well known mediators of EMT. target gene hsa-mir-200c Carcinoma, Nasopharyngeal 28459373 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 MicroRNA-200c plays an oncogenic role in nasopharyngeal carcinoma by targeting PTEN. target gene hsa-mir-203 Carcinoma, Nasopharyngeal 26304234 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 MiRNA-203 Reduces Nasopharyngeal Carcinoma Radioresistance by Targeting IL8/AKT Signaling. target gene hsa-mir-205 Carcinoma, Nasopharyngeal 23564023 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 Our research group established the radioresistant NPC cell line CNE2R derived from the CNE2 cell line, and demonstrated that irradiation-induced miR-205 determined the resistance of NPC through directly targeting PTEN. target gene hsa-mir-21 Carcinoma, Nasopharyngeal 24194922 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 Epstein-Barr Virus_Encoded LMP1 upregulates microRNA-21 to promote the resistance of nasopharyngeal carcinoma cells to cisplatin-induced Apoptosis by suppressing PDCD4 and Fas-L. target gene hsa-mir-21 Carcinoma, Nasopharyngeal 25365510 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 Activation of miR-21 by STAT3 induces proliferation and suppresses apoptosis in nasopharyngeal carcinoma by targeting PTEN gene. target gene hsa-mir-216b Carcinoma, Nasopharyngeal 24332049 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 miR-216b suppresses cell proliferation and invasion by targeting PKCα in nasopharyngeal carcinoma cells target gene hsa-mir-222 Carcinoma, Nasopharyngeal 29115464 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 microRNA-222 promotes tumor growth and confers radioresistance in nasopharyngeal carcinoma by targeting PTEN. target gene hsa-mir-223 Carcinoma, Nasopharyngeal 26055874 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 MiR-223 negatively regulates the growth and migration of NPC cells via reducing MAFB expression, and this finding provides a novel insight into understanding miR-223 regulation mechanism in nasopharyngeal carcinoma tumorigenesis. target gene hsa-mir-23a Carcinoma, Nasopharyngeal 26314966 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 MiR-23a sensitizes nasopharyngeal carcinoma to irradiation by targeting IL-8/Stat3 pathway. target gene hsa-mir-23a Carcinoma, Nasopharyngeal 29520105 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 Metastasis-associated miR-23a from nasopharyngeal carcinoma-derived exosomes mediates angiogenesis by repressing a novel target gene TSGA10 target gene hsa-mir-24 Carcinoma, Nasopharyngeal 27538493 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 Exosomal miR-24-3p impedes T-cell function by targeting FGF11 and serves as a potential prognostic biomarker for nasopharyngeal carcinoma. target gene hsa-mir-27a Carcinoma, Nasopharyngeal 28393229 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 Dysregulated miR-27a-3p promotes nasopharyngeal carcinoma cell proliferation and migration by targeting Mapk10. target gene hsa-mir-29 Carcinoma, Nasopharyngeal 26125802 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 The let-7 and miR-29 families may be related to the development of NPC by regulating the genes involved in cell cycle and ECM-receptor interaction. target gene hsa-mir-29a Carcinoma, Nasopharyngeal 25786138 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 miR-29a/b enhances cell migration and invasion in nasopharyngeal carcinoma progression by regulating SPARC and COL3A1 gene expression. target gene hsa-mir-29b Carcinoma, Nasopharyngeal 25786138 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 miR-29a/b enhances cell migration and invasion in nasopharyngeal carcinoma progression by regulating SPARC and COL3A1 gene expression. target gene hsa-mir-30a Carcinoma, Nasopharyngeal 27656832 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 IGF-I Induces Epithelial-to-Mesenchymal Transition via the IGF-IR-Src-MicroRNA-30a-E-Cadherin Pathway in Nasopharyngeal Carcinoma Cells. target gene hsa-mir-3188 Carcinoma, Nasopharyngeal 27095304 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 miR-3188 regulates nasopharyngeal carcinoma proliferation and chemosensitivity through a FOXO1-modulated positive feedback loop with mTOR-p-PI3K/AKT-c-JUN. target gene hsa-mir-320a Carcinoma, Nasopharyngeal 25171860 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 MicroRNA-320a inhibits cell proliferation, migration and invasion by targeting BMI-1 in nasopharyngeal carcinoma. target gene hsa-mir-324 Carcinoma, Nasopharyngeal 26390174 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 Combined low miR-185-3p and miR-324-3p might be important markers for prediction of low response to RT/CRT and poor overall survival and recurrence-free survival.MiR-185-3p and miR-324-3p can modulate NPC cell growth and apoptosis, at least partly through targeting SMAD7. target gene hsa-mir-338 Carcinoma, Nasopharyngeal 26260688 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 MicroRNA-338 inhibits migration and proliferation by targeting hypoxia-induced factor 1α in nasopharyngeal carcinoma. target gene hsa-mir-374a Carcinoma, Nasopharyngeal 27270423 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 miR-374a direct targeting of CCND1 is modulated by tumor suppressor PDCD4 via suppressing pPI3K/pAKT/c-JUN signaling. target gene hsa-mir-378 Carcinoma, Nasopharyngeal 24481647 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 MicroRNA-378 functions as an onco-miR in nasopharyngeal carcinoma by repressing TOB2 expression. target gene hsa-mir-451 Carcinoma, Nasopharyngeal 25201065 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 MiR-451 increases radiosensitivity of nasopharyngeal carcinoma cells by targeting ras-related protein 14 (RAB14). target gene hsa-mir-4649 Carcinoma, Nasopharyngeal 26081980 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 MicroRNA-4649-3p inhibits cell proliferation by targeting protein tyrosine phosphatase SHP-1 in nasopharyngeal carcinoma cells. target gene hsa-mir-506 Carcinoma, Nasopharyngeal 25856555 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 MiR-506 suppresses tumor proliferation and invasion by targeting FOXQ1 in nasopharyngeal carcinoma. target gene hsa-mir-519 Carcinoma, Nasopharyngeal 28315691 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 miR-519 suppresses nasopharyngeal carcinoma cell proliferation by targeting oncogene URG4/URGCP. target gene hsa-mir-9 Carcinoma, Nasopharyngeal 24170200 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 miR-9 targets CXCR4 and functions as a potential tumor suppressor in nasopharyngeal carcinoma. target gene hsa-mir-9 Carcinoma, Nasopharyngeal 25891118 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 These data demonstrated that miR-9 did not modulate the sensitivity of the CNE2 cells to UV radiation through E-cadherin, but suggested that miR-9 regulated radiosensitivity through its effects on glutathione. These findings suggest that miR-9 may be a potential target for modulating the radiosensitivity of NPC cells. target gene hsa-mir-93 Carcinoma, Nasopharyngeal 25892549 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 MicroRNA-93 promotes cell growth and invasion in nasopharyngeal carcinoma by targeting disabled homolog-2. target gene hsa-mir-940 Carcinoma, Nasopharyngeal 25118937 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 Depletion of intermediate filament protein Nestin, a target of microRNA-940, suppresses tumorigenesis by inducing spontaneous DNA damage accumulation in human nasopharyngeal carcinoma. target gene hsa-mir-125b-1 Carcinoma, Oral 23230394 gastrointestinal system disease DOID:0050610 Subsite-based alterations in miR-21, miR-125b, and miR-203 in squamous cell carcinoma of the oral cavity and correlation to important target proteins target gene hsa-mir-125b-2 Carcinoma, Oral 23230394 gastrointestinal system disease DOID:0050610 Subsite-based alterations in miR-21, miR-125b, and miR-203 in squamous cell carcinoma of the oral cavity and correlation to important target proteins target gene hsa-mir-126 Carcinoma, Oral 22836510 gastrointestinal system disease DOID:0050610 Downregulation of miR-126 induces angiogenesis and lymphangiogenesis by activation of VEGF-A in oral cancer. target gene hsa-mir-146a Carcinoma, Oral 24302991 gastrointestinal system disease DOID:0050610 miR-146a enhances the oncogenicity of oral carcinoma by concomitant targeting of the IRAK1, TRAF6 and NUMB genes. target gene hsa-mir-203 Carcinoma, Oral 23230394 gastrointestinal system disease DOID:0050610 Subsite-based alterations in miR-21, miR-125b, and miR-203 in squamous cell carcinoma of the oral cavity and correlation to important target proteins target gene hsa-mir-205 Carcinoma, Oral 23212344 gastrointestinal system disease DOID:0050610 MicroRNA-205 directly regulates the tumor suppressor, interleukin-24, in human KB oral cancer cells target gene hsa-mir-205 Carcinoma, Oral 24166197 gastrointestinal system disease DOID:0050610 MicroRNA-205 suppresses the oral carcinoma oncogenic activity via down-regulation of Axin-2 in KB human oral cancer cell. target gene hsa-mir-21 Carcinoma, Oral 23230394 gastrointestinal system disease DOID:0050610 Subsite-based alterations in miR-21, miR-125b, and miR-203 in squamous cell carcinoma of the oral cavity and correlation to important target proteins target gene hsa-mir-214 Carcinoma, Oral 28290615 gastrointestinal system disease DOID:0050610 MiR-214 regulates oral cancer KB cell apoptosis through targeting RASSF5. target gene hsa-mir-31 Carcinoma, Oral 22854067 gastrointestinal system disease DOID:0050610 Passenger strand miRNA miR-31* regulates the phenotypes of oral cancer cells by targeting RhoA. target gene hsa-mir-34a Carcinoma, Oral 27612478 gastrointestinal system disease DOID:0050610 miR5423p and miR34a targets the CD44v6-Nanog-PTEN axis, thus playing a vital role in regulating the CSC properties target gene hsa-mir-370 Carcinoma, Oral 23231387 gastrointestinal system disease DOID:0050610 miR-370 modulates insulin receptor substrate-1 expression and inhibits the tumor phenotypes of oral carcinoma target gene hsa-mir-542 Carcinoma, Oral 27612478 gastrointestinal system disease DOID:0050610 miR5423p and miR34a targets the CD44v6-Nanog-PTEN axis, thus playing a vital role in regulating the CSC properties target gene hsa-mir-596 Carcinoma, Oral 23233740 gastrointestinal system disease DOID:0050610 Potential of tumor-suppressive miR-596 targeting LGALS3BP as a therapeutic agent in oral cancer target gene hsa-let-7a Carcinoma, Ovarian 25630839 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 MicroRNA let-7a modifies the effect of self-renewal gene HIWI on patient survival of epithelial ovarian cancer. target gene hsa-let-7e Carcinoma, Ovarian 28376831 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair. target gene hsa-mir-101 Carcinoma, Ovarian 25260883 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 miR-101 regulates expression of EZH2 and contributes to progression of and cisplatin resistance in epithelial ovarian cancer. target gene hsa-mir-101 Carcinoma, Ovarian 24677166 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 MiR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma. target gene hsa-mir-127 Carcinoma, Ovarian 27571744 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 MicroRNA-127-3p acts as a tumor suppressor in epithelial ovarian cancer by regulating the BAG5 gene. target gene hsa-mir-1307 Carcinoma, Ovarian 28086946 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression. target gene hsa-mir-133b Carcinoma, Ovarian 27802259 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 Down-Regulation of MicroRNA-133b Suppresses Apoptosis of Lens Epithelial Cell by Up-Regulating BCL2L2 in Age-Related Cataracts. target gene hsa-mir-134 Carcinoma, Ovarian 28043921 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 MicroRNA-134-3p is a novel potential inhibitor of human ovarian cancer stem cells by targeting RAB27A. target gene hsa-mir-135a Carcinoma, Ovarian 24607788 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 MiR-135a functions as a tumor suppressor in epithelial ovarian cancer and regulates HOXA10 expression. target gene hsa-mir-136 Carcinoma, Ovarian 27887917 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3. target gene hsa-mir-137 Carcinoma, Ovarian 27875524 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 microRNA-137 promotes apoptosis in ovarian cancer cells via the regulation of XIAP. target gene hsa-mir-141 Carcinoma, Ovarian 28095864 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 MicroRNA-141 enhances anoikis resistance in metastatic progression of ovarian cancer through targeting KLF12/Sp1/survivin axis. target gene hsa-mir-145 Carcinoma, Ovarian 25333261 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma. target gene hsa-mir-145 Carcinoma, Ovarian 25444913 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 miR-145 functions as a tumor suppressor in ovarian cancer and directly targets HMGA2 oncoprotein. Low miR-145 and high HMGA2 expressions are potential biomarkers of poor prognosis of ovarian carcinoma and miR-145 is the more powerful predictor of patient outcome. target gene hsa-mir-145 Carcinoma, Ovarian 25937243 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 Quercetin induces the apoptosis of human ovarian carcinoma cells by upregulating the expression of microRNA-145. target gene hsa-mir-150 Carcinoma, Ovarian 25090005 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 MicroRNA-150 predicts a favorable prognosis in patients with epithelial ovarian cancer, and inhibits cell invasion and metastasis by suppressing transcriptional repressor ZEB1. target gene hsa-mir-200 Carcinoma, Ovarian 24512620 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 Several miRNAs differentially expressed between HGSC, CCC and OSE have been identified, suggesting a carcinogenetic role for these miRNAs. miR-200 family members, targeting EMT drivers, were mostly overexpressed in both subgroups, among which miR-200c-3p was associated with survival in HGSC patients.A set of miRNAs differentiates CCC from HGSC, of which miR-509-3-5p and miR-509-5p are the strongest classifiers. Several interactions between miRNAs and mRNAs in HGSC were mapped. target gene hsa-mir-200 Carcinoma, Ovarian 26025631 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells. target gene hsa-mir-206 Carcinoma, Ovarian 29291022 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 NFE2L2/NRF2 silencing-inducible miR-206 targets c-MET/EGFR and suppresses BCRP/ABCG2 in cancer cells target gene hsa-mir-21 Carcinoma, Ovarian 25845681 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 Icariin regulates the proliferation and apoptosis of human ovarian cancer cells through microRNA-21 by targeting PTEN, RECK and Bcl-2. target gene hsa-mir-214 Carcinoma, Ovarian 24033540 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 Nucleoside analog inhibits microRNA-214 through targeting heat-shock factor 1 in human epithelial ovarian cancer. target gene hsa-mir-224 Carcinoma, Ovarian 27663866 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 Upregulated microRNA-224 promotes ovarian cancer cell proliferation by targeting KLLN. target gene hsa-mir-23a Carcinoma, Ovarian 27537390 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 miR-23a promotes IKKα expression but suppresses ST7L expression to contribute to the malignancy of epithelial ovarian cancer cells. target gene hsa-mir-26b Carcinoma, Ovarian 26204489 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 MiR-26b/KPNA2 axis inhibits epithelial ovarian carcinoma proliferation and metastasis through downregulating OCT4. target gene hsa-mir-489 Carcinoma, Ovarian 24686007 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 MiR-489 modulates cisplatin resistance in human ovarian cancer cells by targeting Akt3. target gene hsa-mir-494 Carcinoma, Ovarian 27983981 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 CUL4A functions as an oncogene in ovarian cancer and is directly regulated by miR-494. target gene hsa-mir-506 Carcinoma, Ovarian 25230372 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. target gene hsa-mir-509 Carcinoma, Ovarian 24512620 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 Several miRNAs differentially expressed between HGSC, CCC and OSE have been identified, suggesting a carcinogenetic role for these miRNAs. miR-200 family members, targeting EMT drivers, were mostly overexpressed in both subgroups, among which miR-200c-3p was associated with survival in HGSC patients.A set of miRNAs differentiates CCC from HGSC, of which miR-509-3-5p and miR-509-5p are the strongest classifiers. Several interactions between miRNAs and mRNAs in HGSC were mapped. target gene hsa-mir-509-3 Carcinoma, Ovarian 24512620 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 Several miRNAs differentially expressed between HGSC, CCC and OSE have been identified, suggesting a carcinogenetic role for these miRNAs. miR-200 family members, targeting EMT drivers, were mostly overexpressed in both subgroups, among which miR-200c-3p was associated with survival in HGSC patients.A set of miRNAs differentiates CCC from HGSC, of which miR-509-3-5p and miR-509-5p are the strongest classifiers. Several interactions between miRNAs and mRNAs in HGSC were mapped. target gene hsa-mir-551b Carcinoma, Ovarian 27743201 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 Downregulation of Foxo3 and TRIM31 by miR-551b in side population promotes cell proliferation, invasion, and drug resistance of ovarian cancer. target gene hsa-mir-572 Carcinoma, Ovarian 25893382 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 Upregulation of miR-572 transcriptionally suppresses SOCS1 and p21 and contributes to human ovarian cancer progression. target gene hsa-mir-7 Carcinoma, Ovarian 25862909 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 There is a link between miR-7 expression and TP53 status and tumour grade in serous OC. Molecular mechanisms of these relationships need to be elucidated. Of the two postulated miR-7 target genes we examined, BCL2, but not EGFR, seems to be a possible miR-7 target in OC. target gene hsa-mir-92a Carcinoma, Ovarian 28209618 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 The STAT3-miRNA-92-Wnt Signaling Pathway Regulates Spheroid Formation and Malignant Progression in Ovarian Cancer. target gene hsa-mir-93 Carcinoma, Ovarian 25649143 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 RhoC is a major target of microRNA-93-5P in epithelial ovarian carcinoma tumorigenesis and progression. target gene hsa-mir-939 Carcinoma, Ovarian 25960217 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 MiR-939 promotes the proliferation of human ovarian cancer cells by repressing APC2 expression. target gene hsa-mir-940 Carcinoma, Ovarian 28081739 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 miR-940 Upregulation Suppresses Cell Proliferation and Induces Apoptosis by Targeting PKC-δ in Ovarian Cancer OVCAR3 Cells. target gene hsa-mir-99a Carcinoma, Ovarian 24456664 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 miR-99a promotes proliferation targeting FGFR3 in human epithelial ovarian cancer cells. target gene hsa-let-7b Carcinoma, Ovarian, Serous 24129674 endocrine system disease DOID:0050933 These overwhelmingly observed oncogenic genes were further detected in a sub-network with 32 FFLs centered by miRNA let-7b and TF TCF7L1 to regulate cell differentiation. target gene hsa-mir-106a Carcinoma, Ovarian, Serous 24045973 endocrine system disease DOID:0050933 miR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma. target gene hsa-mir-1236 Carcinoma, Ovarian, Serous 24573236 endocrine system disease DOID:0050933 miR-1236-3p represses the cell migration and invasion abilities by targeting ZEB1 in high-grade serous ovarian carcinoma. target gene hsa-mir-21 Carcinoma, Ovarian, Serous 24888238 endocrine system disease DOID:0050933 PDCD4 and miR-21 are involved in OSC oncogenesis. The transfer of miR-21 by exosomes could promote oncogenic transformation in target cells distant from the primary tumor without direct colonization by cancer cells and could be used as a diagnostic tool. target gene hsa-mir-223 Carcinoma, Ovarian, Serous 29079174 endocrine system disease DOID:0050933 miR-223 potentially targets SWI/SNF complex protein SMARCD1 in atypical proliferative serous tumor and high-grade ovarian serous carcinoma. target gene hsa-mir-133a Carcinoma, Pancreatic 28286270 C25.3 C562463 260350 HP:0002894 USP39, a direct target of microRNA-133a, promotes progression of pancreatic cancer via the AKT pathway. target gene hsa-mir-138 Carcinoma, Pancreatic 28052003 C25.3 C562463 260350 HP:0002894 miR-138-5p suppresses autophagy in pancreatic cancer by targeting SIRT1. target gene hsa-mir-155 Carcinoma, Pancreatic 28152544 C25.3 C562463 260350 HP:0002894 Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK. target gene hsa-mir-181d Carcinoma, Pancreatic 28381166 C25.3 C562463 260350 HP:0002894 Downregulation of microRNA-181d had suppressive effect on pancreatic cancer development through inverse regulation of KNAIN2. target gene hsa-mir-182 Carcinoma, Pancreatic 24736782 C25.3 C562463 260350 HP:0002894 GPC1 regulated by miR-96-5p, rather than miR-182-5p, in inhibition of pancreatic carcinoma cell proliferation. target gene hsa-mir-182 Carcinoma, Pancreatic 27797718 C25.3 C562463 260350 HP:0002894 MicroRNA-182 promotes pancreatic cancer cell proliferation and migration by targeting β-TrCP2. target gene hsa-mir-183 Carcinoma, Pancreatic 28506766 C25.3 C562463 260350 HP:0002894 Effects of microRNA-183 on epithelial-mesenchymal transition, proliferation, migration, invasion and apoptosis in human pancreatic cancer SW1900 cells by targeting MTA1. target gene hsa-mir-195 Carcinoma, Pancreatic 28639885 C25.3 C562463 260350 HP:0002894 MicroRNA-195 inhibits the proliferation and invasion of pancreatic cancer cells by targeting the fatty acid synthase/Wnt signaling pathway. target gene hsa-mir-200a Carcinoma, Pancreatic 28349057 C25.3 C562463 260350 HP:0002894 Interleukin-9 Promotes Pancreatic Cancer Cells Proliferation and Migration via the miR-200a/Beta-Catenin Axis. target gene hsa-mir-200b Carcinoma, Pancreatic 27878247 C25.3 C562463 260350 HP:0002894 Oridonin inhibition and miR‑200b‑3p/ZEB1 axis in human pancreatic cancer. target gene hsa-mir-200 Carcinoma, Pancreatic 28349057 C25.3 C562463 260350 HP:0002894 Interleukin-9 Promotes Pancreatic Cancer Cells Proliferation and Migration via the miR-200a/Beta-Catenin Axis. target gene hsa-mir-216a Carcinoma, Pancreatic 28034748 C25.3 C562463 260350 HP:0002894 MiR-216a decreases MALAT1 expression, induces G2/M arrest and apoptosis in pancreatic cancer cells. target gene hsa-mir-23a Carcinoma, Pancreatic 29141872 C25.3 C562463 260350 HP:0002894 miR-23a acts as an oncogene in pancreatic carcinoma by targeting FOXP2. target gene hsa-mir-301b Carcinoma, Pancreatic 24398967 C25.3 C562463 260350 HP:0002894 MicroRNA-301b promotes cell invasiveness through targeting TP63 in pancreatic carcinoma cells. target gene hsa-mir-33a Carcinoma, Pancreatic 25971209 C25.3 C562463 260350 HP:0002894 MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine. target gene hsa-mir-375 Carcinoma, Pancreatic 24481267 C25.3 C562463 260350 HP:0002894 MicroRNA-375 targets PDK1 in pancreatic carcinoma and suppresses cell growth through the Akt signaling pathway. target gene hsa-mir-377 Carcinoma, Pancreatic 27638830 C25.3 C562463 260350 HP:0002894 MiR-377 inhibits the proliferation of pancreatic cancer by targeting Pim-3. target gene hsa-mir-451 Carcinoma, Pancreatic 28197410 C25.3 C562463 260350 HP:0002894 MiR-451 Promotes Cell Proliferation and Metastasis in Pancreatic Cancer through Targeting CAB39. target gene hsa-mir-7 Carcinoma, Pancreatic 28259961 C25.3 C562463 260350 HP:0002894 MicroRNA-7 functions as a tumor-suppressor gene by regulating ILF2 in pancreatic carcinoma. target gene hsa-mir-874 Carcinoma, Pancreatic 28377226 C25.3 C562463 260350 HP:0002894 Aquaporin 3 facilitates tumor growth in pancreatic cancer by modulating mTOR signaling. target gene hsa-mir-96 Carcinoma, Pancreatic 24736782 C25.3 C562463 260350 HP:0002894 GPC1 regulated by miR-96-5p, rather than miR-182-5p, in inhibition of pancreatic carcinoma cell proliferation. target gene hsa-mir-1207 Carcinoma, Prostate 27693493 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 miR-1207-3p regulates the androgen receptor in prostate cancer via FNDC1/fibronectin. target gene hsa-mir-1271 Carcinoma, Prostate 28153722 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 Inhibition of DIXDC1 by microRNA-1271 suppresses the proliferation and invasion of prostate cancer cells. target gene hsa-mir-1297 Carcinoma, Prostate 27746178 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 MicroRNA-1297 inhibits prostate cancer cell proliferation and invasion by targeting the AEG-1/Wnt signaling pathway. target gene hsa-mir-1307 Carcinoma, Prostate 28122308 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 miR-1307 promotes the proliferation of prostate cancer by targeting FOXO3A. target gene hsa-mir-130a Carcinoma, Prostate 27984115 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1. target gene hsa-mir-138 Carcinoma, Prostate 27562865 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells. target gene hsa-mir-141 Carcinoma, Prostate 26065649 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 The presence of the microRNA-141 target molecules activates the DNA molecular machine powered by the DNA fuel strands, leading to non-enzymatic target cyclic reuse of microRNA-141 and significantly amplified fluorescent signals for sensitive monitoring of microRNA-141 from low numbers of human prostate cancer cells. target gene hsa-mir-141 Carcinoma, Prostate 27956179 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 MiR-141-3p promotes prostate cancer cell proliferation through inhibiting kruppel-like factor-9 expression. target gene hsa-mir-143 Carcinoma, Prostate 28109198 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 miR-143 Induces the Apoptosis of Prostate Cancer LNCap Cells by Suppressing Bcl-2 Expression. target gene hsa-mir-143 Carcinoma, Prostate 28391351 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 Curcumin inhibits prostate cancer by targeting PGK1 in the FOXD3/miR-143 axis. target gene hsa-mir-193a Carcinoma, Prostate 28422308 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 Androgen receptor-regulated miRNA-193a-3p targets AJUBA to promote prostate cancer cell migration. target gene hsa-mir-194 Carcinoma, Prostate 27959429 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 MicroRNA-194 suppresses prostate cancer migration and invasion by downregulating human nuclear distribution protein. target gene hsa-mir-194 Carcinoma, Prostate 28011622 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2. target gene hsa-mir-200b Carcinoma, Prostate 28028835 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 TIMP4 expression is regulated by miR-200b-3p in prostate cancer cells. target gene hsa-mir-204 Carcinoma, Prostate 27686228 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 The UCA1/miR-204/Sirt1 axis modulates docetaxel sensitivity of prostate cancer cells. target gene hsa-mir-204 Carcinoma, Prostate 28050800 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer. target gene hsa-mir-22 Carcinoma, Prostate 28231399 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 MTA1-activated Epi-microRNA-22 regulates E-cadherin and prostate cancer invasiveness. target gene hsa-mir-221 Carcinoma, Prostate 24607843 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 Survival in patients with high-risk prostate cancer is predicted by miR-221,which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3. target gene hsa-mir-26a Carcinoma, Prostate 27562865 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells. target gene hsa-mir-33a Carcinoma, Prostate 27921232 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 Biological function and mechanism of miR-33a in prostate cancer survival and metastasis: via downregulating Engrailed-2. target gene hsa-mir-34 Carcinoma, Prostate 28373004 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7). target gene hsa-mir-3619 Carcinoma, Prostate 27878260 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 miR-3619-5p inhibits prostate cancer cell growth by activating CDKN1A expression. target gene hsa-mir-372 Carcinoma, Prostate 27673408 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 microRNA-372 Suppresses Migration and Invasion by Targeting p65 in Human Prostate Cancer Cells. target gene hsa-mir-375 Carcinoma, Prostate 27832783 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1. target gene hsa-mir-382 Carcinoma, Prostate 27748848 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 MicroRNA-382 inhibits prostate cancer cell proliferation and metastasis through targeting COUP-TFII. target gene hsa-mir-383 Carcinoma, Prostate 27893706 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 MicroRNA-383 located in frequently deleted chromosomal locus 8p22 regulates CD44 in prostate cancer. target gene hsa-mir-449 Carcinoma, Prostate 28373004 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7). target gene hsa-mir-455 Carcinoma, Prostate 28350134 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 MicroRNA-455-3p functions as a tumor suppressor by targeting eIF4E in prostate cancer. target gene hsa-mir-500 Carcinoma, Prostate 28631332 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 Inhibition of microRNA-500 has anti-cancer effect through its conditional downstream target of TFPI in human prostate cancer. target gene hsa-mir-543 Carcinoma, Prostate 28245474 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 MiR-543 Promotes Proliferation and Epithelial-Mesenchymal Transition in Prostate Cancer via Targeting RKIP. target gene hsa-mir-574 Carcinoma, Prostate 27779701 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 Downregulation of microRNA‑574 in cancer stem cells causes recurrence of prostate cancer via targeting REL. target gene hsa-mir-590 Carcinoma, Prostate 28345464 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 MicroRNA-590-3p promotes cell proliferation and invasion by targeting inositol polyphosphate 4-phosphatase type II in human prostate cancer cells. target gene hsa-mir-875 Carcinoma, Prostate 28274892 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 miR-875-5p counteracts epithelial-to-mesenchymal transition and enhances radiation response in prostate cancer through repression of the EGFR-ZEB1 axis. target gene hsa-mir-96 Carcinoma, Prostate 27746161 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 Epidermal growth factor receptor signaling promotes metastatic prostate cancer through microRNA-96-mediated downregulation of the tumor suppressor ETV6. target gene hsa-mir-135a Carcinoma, Rectal 21192341 disease of cellular proliferation DOID:1993 C20 D012004 In this issue, Li and colleagues describe a novel way of targeting miRNA, by using a naturally occurring anti-cancer compound found in mistletoe which they showed to down-regulate miR-135a&b, which target the 3' untranslated region of adenomatous polyposis coli gene, the inactivation of which is a major initiating event in colorectal tumourigenesis. target gene hsa-mir-135a Carcinoma, Rectal 23017832 disease of cellular proliferation DOID:1993 C20 D012004 MiR-135a promotes growth and invasion of colorectal cancer via metastasis suppressor 1 in vitro. target gene hsa-mir-135b Carcinoma, Rectal 21192341 disease of cellular proliferation DOID:1993 C20 D012004 In this issue, Li and colleagues describe a novel way of targeting miRNA, by using a naturally occurring anti-cancer compound found in mistletoe which they showed to down-regulate miR-135a&b, which target the 3' untranslated region of adenomatous polyposis coli gene, the inactivation of which is a major initiating event in colorectal tumourigenesis. target gene hsa-mir-34a Carcinoma, Rectal 26287733 disease of cellular proliferation DOID:1993 C20 D012004 Although miR-34a and miR-34c can regulate Axl expression in vitro,our data indicates that the miR-34 family members are not the primary regulators of Axl expression in RCC. target gene hsa-mir-34a Carcinoma, Rectal 21067862 disease of cellular proliferation DOID:1993 C20 D012004 These findings suggest that miR-34a targeting the Sirt1 and E2F3 genes could negatively regulate, at least in part, the resistance to 5-FU in human colorectal cancer DLD-1 cells. target gene hsa-mir-92a Carcinoma, Rectal 26865277 disease of cellular proliferation DOID:1993 C20 D012004 Integrated genomic profiling identifies microRNA-92a regulation of IQGAP2 in locally advanced rectal cancer. target gene hsa-let-7a Carcinoma, Renal Cell 22155254 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 Our results suggest for the first time that let-7a acts as a tumor suppressor in RCC cell lines by down-regulating c-myc and c-myc target genes. target gene hsa-let-7d Carcinoma, Renal Cell 25686498 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 Rab25 is a target gene of let-7d, and further suggested that Rab25 upregulation in RCC is due to diminished expression of let-7d. target gene hsa-mir-122 Carcinoma, Renal Cell 28231730 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 MiR-122 promotes renal cancer cell proliferation by targeting Sprouty2. target gene hsa-mir-124 Carcinoma, Renal Cell 25861751 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 miR-124 represses FZD5 to attenuate P-glycoprotein-mediated chemo-resistance in renal cell carcinoma. target gene hsa-mir-1285-1 Carcinoma, Renal Cell 22294552 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 Tumor suppressive microRNA-1285 regulates novel molecular targets: Aberrant expression and functional significance in renal cell carcinoma. target gene hsa-mir-1285-2 Carcinoma, Renal Cell 22294552 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 Tumor suppressive microRNA-1285 regulates novel molecular targets: Aberrant expression and functional significance in renal cell carcinoma. target gene hsa-mir-129 Carcinoma, Renal Cell 24802708 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 miR-129-3p, as a diagnostic and prognostic biomarker for renal cell carcinoma, attenuates cell migration and invasion via downregulating multiple metastasis-related genes. target gene hsa-mir-1291 Carcinoma, Renal Cell 23889809 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 Tumor-suppressive microRNA-1291 directly regulates glucose transporter 1 in renal cell carcinoma. target gene hsa-mir-134 Carcinoma, Renal Cell 25811077 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 miR-134 functions as a tumor suppressor in cell proliferation and epithelial-to-mesenchymal Transition by targeting KRAS in renal cell carcinoma cells. target gene hsa-mir-135a-1 Carcinoma, Renal Cell 23176581 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 Tumor-suppressive microRNA-135a inhibits cancer cell proliferation by targeting the c-MYC oncogene in renal cell carcinoma target gene hsa-mir-135a-2 Carcinoma, Renal Cell 23176581 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 Tumor-suppressive microRNA-135a inhibits cancer cell proliferation by targeting the c-MYC oncogene in renal cell carcinoma target gene hsa-mir-138 Carcinoma, Renal Cell 29344205 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 MicroRNA-138 suppresses cell proliferation and invasion of renal cell carcinoma by directly targeting SOX9 target gene hsa-mir-138-1 Carcinoma, Renal Cell 22766839 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 Tumor suppressive microRNA-138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma. target gene hsa-mir-138-2 Carcinoma, Renal Cell 22766839 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 Tumor suppressive microRNA-138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma. target gene hsa-mir-143 Carcinoma, Renal Cell 24033605 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 Thus, our data showed that loss of the tumor-suppressive miR-143/145 cluster enhanced RCC cell proliferation and invasion through targeting HK2. target gene hsa-mir-144 Carcinoma, Renal Cell 27717821 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 miR-144-3p serves as a tumor suppressor for renal cell carcinoma and inhibits its invasion and metastasis by targeting MAP3K8. target gene hsa-mir-145 Carcinoma, Renal Cell 23441135 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 MicroRNA-145 Targets the Metalloprotease ADAM17 and Is Suppressed in Renal Cell Carcinoma Patients target gene hsa-mir-145 Carcinoma, Renal Cell 24033605 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 Thus, our data showed that loss of the tumor-suppressive miR-143/145 cluster enhanced RCC cell proliferation and invasion through targeting HK2. target gene hsa-mir-146 Carcinoma, Renal Cell 26859141 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 We identified novel target genes of dysregulated miRNAs, which are involved in the transition from primary RCC without metastases into tumors generating distant metastasis. target gene hsa-mir-146a Carcinoma, Renal Cell 20709800 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 Loss of inducible nitric oxide synthase expression in the mouse renal cell carcinoma cell line RENCA is mediated by microRNA miR-146a. target gene hsa-mir-148a Carcinoma, Renal Cell 27878305 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 miR-148a suppresses human renal cell carcinoma malignancy by targeting AKT2. target gene hsa-mir-148a Carcinoma, Renal Cell 28098870 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 miR-148a increases the sensitivity to cisplatin by targeting Rab14 in renal cancer cells. target gene hsa-mir-149 Carcinoma, Renal Cell 28902136 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 Dual Strands of Pre-miR-149 Inhibit Cancer Cell Migration and Invasion through Targeting FOXM1 in Renal Cell Carcinoma. target gene hsa-mir-155 Carcinoma, Renal Cell 22307849 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 microRNA-155 silencing inhibits proliferation and migration and induces apoptosis by upregulating BACH1 in renal cancer cells. target gene hsa-mir-15a Carcinoma, Renal Cell 28849086 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 Downregulation of microRNA-15a suppresses the proliferation and invasion of renal cell carcinoma via direct targeting of eIF4E. target gene hsa-mir-181a Carcinoma, Renal Cell 27664584 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 microRNAs target SRSF7 splicing factor to modulate the expression of osteopontin splice variants in renal cancer cells. target gene hsa-mir-183 Carcinoma, Renal Cell 29552228 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 MicroRNA-183 promotes the proliferation and metastasis of renal cell carcinoma through targeting Dickkopf-related protein 3 target gene hsa-mir-193a Carcinoma, Renal Cell 28639901 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 Downregulation of miR-193a-3p inhibits cell growth and migration in renal cell carcinoma by targeting PTEN. target gene hsa-mir-199a-1 Carcinoma, Renal Cell 22093618 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 Re-expression of miR-199a suppresses renal cancer cell proliferation and survival by targeting GSK-3 target gene hsa-mir-19a Carcinoma, Renal Cell 26058752 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 Downregulation of miR-19a exhibits inhibitory effects on metastatic renal cell carcinoma by targeting PIK3CA and inactivating Notch signaling in vitro. target gene hsa-mir-200a Carcinoma, Renal Cell 25813153 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 Tumor suppressive microRNA-200a inhibits renal cell carcinoma development by directly targeting TGFB2. target gene hsa-mir-200a Carcinoma, Renal Cell 26797273 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 MicroRNA-200a-3p suppresses tumor proliferation and induces apoptosis by targeting SPAG9 in renal cell carcinoma. target gene hsa-mir-200a Carcinoma, Renal Cell 28717923 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 MiRNA-200a induce cell apoptosis in renal cell carcinoma by directly targeting SIRT1. target gene hsa-mir-200c Carcinoma, Renal Cell 25150313 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 MiR-200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and imatinib by targeting heme oxygenase-1. target gene hsa-mir-200c Carcinoma, Renal Cell 26248649 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 miR-200c Targets CDK2 and Suppresses Tumorigenesis in Renal Cell Carcinoma. target gene hsa-mir-203a Carcinoma, Renal Cell 25123268 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 miR-203a regulates proliferation, migration, and apoptosis by targeting glycogen synthase kinase-3β in human renal cell carcinoma. target gene hsa-mir-204 Carcinoma, Renal Cell 22516261 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 VHL-Regulated MiR-204 Suppresses Tumor Growth through Inhibition of LC3B-Mediated Autophagy in Renal Clear Cell Carcinoma. target gene hsa-mir-204 Carcinoma, Renal Cell 25517751 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 TRPM3 Ca(2+) and Zn(2+) fluxes inhibit miR-214, which directly targets LC3A and LC3B. The von Hippel-Lindau tumor suppressor (VHL) represses TRPM3 directly through miR-204 and indirectly through another miR-204 target, Caveolin 1 (CAV1). target gene hsa-mir-205 Carcinoma, Renal Cell 25427583 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 miR-205 is a candidate tumor suppressor that targets ZEB2 in RCC. target gene hsa-mir-206 Carcinoma, Renal Cell 27924503 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 miR-206 inhibits renal cell cancer growth by targeting GAK. target gene hsa-mir-21 Carcinoma, Renal Cell 21820586 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 miR-21 Modulates Cell Apoptosis by Targeting Multiple Genes in Renal Cell Carcinoma. target gene hsa-mir-21 Carcinoma, Renal Cell 22685542 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 microRNA-21 governs TORC1 activation in renal cancer cell proliferation and invasion. target gene hsa-mir-21 Carcinoma, Renal Cell 23206776 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 miR-21 Downregulated TCF21 to Inhibit KISS1 in Renal Cancer target gene hsa-mir-21 Carcinoma, Renal Cell 23558936 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 MiR-21 is overexpressed in RCC tissue and modulates the growth, apoptosis and cell cycle progression of RCC cells and regulates the expression of PDCD4 and TPM1 target gene hsa-mir-21 Carcinoma, Renal Cell 27388719 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 in cells treated with AU-1, transient elevation of miR-34 leads to the downregulation of SIRT1, thereby miR-21 is freed from SIRT1-dependent suppression. target gene hsa-mir-21 Carcinoma, Renal Cell 27222255 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 miR鈥?1 was able to decrease the expression of CASC2 in 786鈥慜 and A498 cells. target gene hsa-mir-210 Carcinoma, Renal Cell 23449350 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis target gene hsa-mir-218-1 Carcinoma, Renal Cell 23454155 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 microRNA-218 inhibits cell migration and invasion in renal cell carcinoma through targeting caveolin-2 involved in focal adhesion pathway target gene hsa-mir-218-2 Carcinoma, Renal Cell 23454155 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 microRNA-218 inhibits cell migration and invasion in renal cell carcinoma through targeting caveolin-2 involved in focal adhesion pathway target gene hsa-mir-224 Carcinoma, Renal Cell 21912701 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 MiR-224 Targets the 3'UTR of Type 1 5'-Iodothyronine Deiodinase Possibly Contributing to Tissue Hypothyroidism in Renal Cancer. target gene hsa-mir-23b Carcinoma, Renal Cell 23189187 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 Inhibition of PTEN gene expression by oncogenic miR-23b-3p in renal cancer target gene hsa-mir-26a Carcinoma, Renal Cell 26983694 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 two genes promoting metastasis, LOXL2 and PLOD2, were epigenetically regulated by tumor-suppressive microRNAs, miR-26a and miR-26b target gene hsa-mir-302c Carcinoma, Renal Cell 28412750 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 microRNA-302c-3p inhibits renal cell carcinoma cell proliferation by targeting Grb2-associated binding 2 (Gab2). target gene hsa-mir-30a Carcinoma, Renal Cell 27664584 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 microRNAs target SRSF7 splicing factor to modulate the expression of osteopontin splice variants in renal cancer cells. target gene hsa-mir-30a Carcinoma, Renal Cell 29073630 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 MicroRNA-30a-5p Inhibits the Growth of Renal Cell Carcinoma by Modulating GRP78 Expression. target gene hsa-mir-30b Carcinoma, Renal Cell 28536082 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 MiR-30b-5p functions as a tumor suppressor in cell proliferation, metastasis and epithelial-to-mesenchymal transition by targeting G-protein subunit α-13 in renal cell carcinoma. target gene hsa-mir-34 Carcinoma, Renal Cell 27388719 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 in cells treated with AU-1, transient elevation of miR-34 leads to the downregulation of SIRT1, thereby miR-21 is freed from SIRT1-dependent suppression. Then, elevated miR-21 upregulates p21/Cip1 protein, followed by the suppression of miR-34 expression. target gene hsa-mir-34a Carcinoma, Renal Cell 22159222 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 MicroRNA-34a suppresses malignant transformation by targeting c-Myc transcriptional complexes in human renal cell carcinoma. target gene hsa-mir-372 Carcinoma, Renal Cell 26332146 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 Our data indicated that miR-372 seemed to function as a tumour suppressor in renal cell carcinoma progression by inhibiting the IGF2BP1 expression. target gene hsa-mir-381 Carcinoma, Renal Cell 23778472 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 These data clearly demonstrate that these two miRNAs might synergistically act as novel modulators of tumorigenesis by down-regulating WEE1 expression in renal cell cancer cells. target gene hsa-mir-424 Carcinoma, Renal Cell 23778472 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 These data clearly demonstrate that these two miRNAs might synergistically act as novel modulators of tumorigenesis by down-regulating WEE1 expression in renal cell cancer cells. target gene hsa-mir-429 Carcinoma, Renal Cell 25953723 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 These results revealed a tumor suppressive role for miR-429 in renal cell carcinoma through directly targeting BMI1 and E2F3. target gene hsa-mir-509 Carcinoma, Renal Cell 25815776 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 MicroRNA-509-3p inhibits cancer cell proliferation and migration by targeting the mitogen-activated protein kinase kinase kinase 8 oncogene in renal cell carcinoma. target gene hsa-mir-629 Carcinoma, Renal Cell 25381221 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 miR-629 Targets TRIM33 to Promote TGFβ/Smad Signaling and Metastatic Phenotypes in ccRCC. target gene hsa-mir-646 Carcinoma, Renal Cell 25010867 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 Downregulated miR-646 in ccRCC was associated with tumour metastasis through MAPK pathway by targeting NOB1. miR-646 and NOB1 may play an important role in the development of ccRCC. target gene hsa-mir-96 Carcinoma, Renal Cell 26419932 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 These results suggest that miR-96 suppresses RCC invasion by modulating Ezrin expression. target gene hsa-mir-101 Carcinoma, Renal Cell, Clear-Cell 28138701 disease of cellular proliferation DOID:4467 HP:0006770 Hypoxia-induced hsa-miR-101 promotes glycolysis by targeting TIGAR mRNA in clear cell renal cell carcinoma. target gene hsa-mir-106b Carcinoma, Renal Cell, Clear-Cell 25714014 disease of cellular proliferation DOID:4467 HP:0006770 miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma. target gene hsa-mir-138 Carcinoma, Renal Cell, Clear-Cell 28861152 disease of cellular proliferation DOID:4467 HP:0006770 MicroRNA-138 attenuates epithelial-to-mesenchymal transition by targeting SOX4 in clear cell renal cell carcinoma. target gene hsa-mir-140 Carcinoma, Renal Cell, Clear-Cell 29253611 disease of cellular proliferation DOID:4467 HP:0006770 miRNA-429, miRNA-206, and miRNA-184 and their target gene CCND1, as well as miRNA-140-3p and miRNA-142-5p and their target gene ATP1B1, might play key roles in ccRCC progression and could be useful biomarkers during ccRCC development target gene hsa-mir-142 Carcinoma, Renal Cell, Clear-Cell 29253611 disease of cellular proliferation DOID:4467 HP:0006770 miRNA-429, miRNA-206, and miRNA-184 and their target gene CCND1, as well as miRNA-140-3p and miRNA-142-5p and their target gene ATP1B1, might play key roles in ccRCC progression and could be useful biomarkers during ccRCC development target gene hsa-mir-155 Carcinoma, Renal Cell, Clear-Cell 28565840 disease of cellular proliferation DOID:4467 HP:0006770 Overexpression of miR-155 in clear-cell renal cell carcinoma and its oncogenic effect through targeting FOXO3a. target gene hsa-mir-181a Carcinoma, Renal Cell, Clear-Cell 29066014 disease of cellular proliferation DOID:4467 HP:0006770 Up-regulation of miR-181a in clear cell renal cell carcinoma is associated with lower KLF6 expression, enhanced cell proliferation, accelerated cell cycle transition, and diminished apoptosis. target gene hsa-mir-184 Carcinoma, Renal Cell, Clear-Cell 29253611 disease of cellular proliferation DOID:4467 HP:0006770 miRNA-429, miRNA-206, and miRNA-184 and their target gene CCND1, as well as miRNA-140-3p and miRNA-142-5p and their target gene ATP1B1, might play key roles in ccRCC progression and could be useful biomarkers during ccRCC development target gene hsa-mir-195 Carcinoma, Renal Cell, Clear-Cell 28089832 disease of cellular proliferation DOID:4467 HP:0006770 Androgen receptor (AR) promotes clear cell renal cell carcinoma (ccRCC) migration and invasion via altering the circHIAT1/miR-195-5p/29a-3p/29c-3p/CDC42 signals. target gene hsa-mir-19a Carcinoma, Renal Cell, Clear-Cell 27779660 disease of cellular proliferation DOID:4467 HP:0006770 miR-19a correlates with poor prognosis of clear cell renal cell carcinoma patients via promoting cell proliferation and suppressing PTEN/SMAD4 expression. target gene hsa-mir-200c Carcinoma, Renal Cell, Clear-Cell 26941587 disease of cellular proliferation DOID:4467 HP:0006770 miRNA-200c that could regulate COL5A2 and COL5A3, miRNA-15a that could regulate ATP6V0B and miRNA-155 may play key roles in ccRCC progression. target gene hsa-mir-206 Carcinoma, Renal Cell, Clear-Cell 29253611 disease of cellular proliferation DOID:4467 HP:0006770 miRNA-429, miRNA-206, and miRNA-184 and their target gene CCND1, as well as miRNA-140-3p and miRNA-142-5p and their target gene ATP1B1, might play key roles in ccRCC progression and could be useful biomarkers during ccRCC development target gene hsa-mir-23b Carcinoma, Renal Cell, Clear-Cell 25014580 disease of cellular proliferation DOID:4467 HP:0006770 Expression of the miR-23b/27b cluster was frequently decreased in clear cell renal cell carcinoma tissue. Reduced expression of these miRNAs increased the risk of disease progression and predicted poor survival. Thus,miR-23b and miR-27b function as tumor suppressors, targeting several oncogenic genes in clear cell renal cell carcinoma cells. target gene hsa-mir-27b Carcinoma, Renal Cell, Clear-Cell 25014580 disease of cellular proliferation DOID:4467 HP:0006770 Expression of the miR-23b/27b cluster was frequently decreased in clear cell renal cell carcinoma tissue. Reduced expression of these miRNAs increased the risk of disease progression and predicted poor survival. Thus,miR-23b and miR-27b function as tumor suppressors, targeting several oncogenic genes in clear cell renal cell carcinoma cells. target gene hsa-mir-29a Carcinoma, Renal Cell, Clear-Cell 28089832 disease of cellular proliferation DOID:4467 HP:0006770 Androgen receptor (AR) promotes clear cell renal cell carcinoma (ccRCC) migration and invasion via altering the circHIAT1/miR-195-5p/29a-3p/29c-3p/CDC42 signals. target gene hsa-mir-29c Carcinoma, Renal Cell, Clear-Cell 28089832 disease of cellular proliferation DOID:4467 HP:0006770 Androgen receptor (AR) promotes clear cell renal cell carcinoma (ccRCC) migration and invasion via altering the circHIAT1/miR-195-5p/29a-3p/29c-3p/CDC42 signals. target gene hsa-mir-30a Carcinoma, Renal Cell, Clear-Cell 24189146 disease of cellular proliferation DOID:4467 HP:0006770 Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity. target gene hsa-mir-30a Carcinoma, Renal Cell, Clear-Cell 23826258 disease of cellular proliferation DOID:4467 HP:0006770 Down-Regulated miR-30a in Clear Cell Renal Cell Carcinoma Correlated with Tumor Hematogenous Metastasis by Targeting Angiogenesis-Specific DLL4. target gene hsa-mir-30c-2 Carcinoma, Renal Cell, Clear-Cell 24189146 disease of cellular proliferation DOID:4467 HP:0006770 Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity. target gene hsa-mir-377 Carcinoma, Renal Cell, Clear-Cell 25776481 disease of cellular proliferation DOID:4467 HP:0006770 miR-377 functions as a tumor suppressor in human clear cell renal cell carcinoma by targeting ETS1. target gene hsa-mir-429 Carcinoma, Renal Cell, Clear-Cell 29253611 disease of cellular proliferation DOID:4467 HP:0006770 miRNA-429, miRNA-206, and miRNA-184 and their target gene CCND1, as well as miRNA-140-3p and miRNA-142-5p and their target gene ATP1B1, might play key roles in ccRCC progression and could be useful biomarkers during ccRCC development target gene hsa-mir-155 Carcinoma, Salivary Adenoid Cystic 28668836 disease of cellular proliferation DOID:4866 C08.9 D003528 MicroRNA Profiling and Target Genes Related to Metastasis of Salivary Adenoid Cystic Carcinoma. target gene hsa-mir-17 Carcinoma, Salivary Adenoid Cystic 23825564 disease of cellular proliferation DOID:4866 C08.9 D003528 Our study indicates that the upregulation of miR-17-92 may play a role in the biology of ACC and could be potentially targeted in future therapeutic studies. target gene hsa-mir-205 Carcinoma, Salivary Adenoid Cystic 28668836 disease of cellular proliferation DOID:4866 C08.9 D003528 MicroRNA Profiling and Target Genes Related to Metastasis of Salivary Adenoid Cystic Carcinoma. target gene hsa-mir-20a Carcinoma, Salivary Adenoid Cystic 23825564 disease of cellular proliferation DOID:4866 C08.9 D003528 Our study indicates that the upregulation of miR-17-92 may play a role in the biology of ACC and could be potentially targeted in future therapeutic studies. target gene hsa-mir-21 Carcinoma, Salivary Adenoid Cystic 29328455 disease of cellular proliferation DOID:4866 C08.9 D003528 miR-21 may promote SACC progression via PDCD4, PTEN and Bcl-2 target gene hsa-mir-26a Carcinoma, Skin 28977801 disease of cellular proliferation DOID:3451 D04.9 D018280 HP:0008069 MiR-26a Mediates Ultraviolet B-Induced Apoptosis by Targeting Histone Methyltransferase EZH2 Depending on Myc Expression. target gene hsa-mir-126 Carcinoma, Thyroid 26239517 disease of cellular proliferation DOID:3963 C73 D013964 188550 HP:0002890 miR-126 inhibits papillary thyroid carcinoma growth by targeting LRP6. target gene hsa-mir-129 Carcinoma, Thyroid 24631532 disease of cellular proliferation DOID:3963 C73 D013964 188550 HP:0002890 MiR-129-5p is down-regulated and involved in the growth, apoptosis and migration of medullary thyroid carcinoma cells through targeting RET. target gene hsa-mir-146b Carcinoma, Thyroid 25960292 disease of cellular proliferation DOID:3963 C73 D013964 188550 HP:0002890 Inhibition of miR-146b expression increases radioiodine-sensitivity in poorly differential thyroid carcinoma via positively regulating NIS expression. target gene hsa-mir-148a Carcinoma, Thyroid 27779717 disease of cellular proliferation DOID:3963 C73 D013964 188550 HP:0002890 miR-148a inhibits self-renewal of thyroid cancer stem cells via repressing INO80 expression. target gene hsa-mir-584 Carcinoma, Thyroid 26405762 disease of cellular proliferation DOID:3963 C73 D013964 188550 HP:0002890 These results indicate that miR-584 could inhibit the expression of ROCK1, and ROCK1 knockdown would further affect the migration ability of K1 cells. target gene hsa-mir-639 Carcinoma, Thyroid 27829546 disease of cellular proliferation DOID:3963 C73 D013964 188550 HP:0002890 MiR-639 promoted cell proliferation and cell cycle in human thyroid cancer by suppressing CDKN1A expression. target gene hsa-mir-125b Carcinoma, Thyroid, Anaplastic 28122310 C73 D065646 188550 HP:0011779 MiR-125b inhibits anaplastic thyroid cancer cell migration and invasion by targeting PIK3CD. target gene hsa-mir-200a Carcinoma, Thyroid, Anaplastic 25542369 C73 D065646 188550 HP:0011779 Restoration of miR-200 expression by pre-miR-200a/c transfection reversed the process, including increased E-cadherin and decreased vimentin. target gene hsa-mir-99a Carcinoma, Thyroid, Anaplastic 26163618 C73 D065646 188550 HP:0011779 MiR-99a Inhibits Cell Proliferation and Tumorigenesis through Targeting mTOR in Human Anaplastic Thyroid Cancer. target gene hsa-mir-10a Carcinoma, Thyroid, Follicular 29344146 disease of cellular proliferation DOID:3962 C73 C572845 188470 HP:0006731 Network analysis indicated a co-regulatory association between miR-296-5p, miR-10a, miR-139-5p, miR-452, miR-493, miR-7, miR-137, miR-144, miR-145 and corresponding targeted mRNAs, including TNF receptor superfamily member 11b, benzodiazepine receptor (peripheral) -associated protein 1, and transforming growth factor β receptor 2 target gene hsa-mir-137 Carcinoma, Thyroid, Follicular 29344146 disease of cellular proliferation DOID:3962 C73 C572845 188470 HP:0006731 Network analysis indicated a co-regulatory association between miR-296-5p, miR-10a, miR-139-5p, miR-452, miR-493, miR-7, miR-137, miR-144, miR-145 and corresponding targeted mRNAs, including TNF receptor superfamily member 11b, benzodiazepine receptor (peripheral) -associated protein 1, and transforming growth factor β receptor 2 target gene hsa-mir-139 Carcinoma, Thyroid, Follicular 29344146 disease of cellular proliferation DOID:3962 C73 C572845 188470 HP:0006731 Network analysis indicated a co-regulatory association between miR-296-5p, miR-10a, miR-139-5p, miR-452, miR-493, miR-7, miR-137, miR-144, miR-145 and corresponding targeted mRNAs, including TNF receptor superfamily member 11b, benzodiazepine receptor (peripheral) -associated protein 1, and transforming growth factor β receptor 2 target gene hsa-mir-144 Carcinoma, Thyroid, Follicular 29344146 disease of cellular proliferation DOID:3962 C73 C572845 188470 HP:0006731 Network analysis indicated a co-regulatory association between miR-296-5p, miR-10a, miR-139-5p, miR-452, miR-493, miR-7, miR-137, miR-144, miR-145 and corresponding targeted mRNAs, including TNF receptor superfamily member 11b, benzodiazepine receptor (peripheral) -associated protein 1, and transforming growth factor β receptor 2 target gene hsa-mir-145 Carcinoma, Thyroid, Follicular 29344146 disease of cellular proliferation DOID:3962 C73 C572845 188470 HP:0006731 Network analysis indicated a co-regulatory association between miR-296-5p, miR-10a, miR-139-5p, miR-452, miR-493, miR-7, miR-137, miR-144, miR-145 and corresponding targeted mRNAs, including TNF receptor superfamily member 11b, benzodiazepine receptor (peripheral) -associated protein 1, and transforming growth factor β receptor 2 target gene hsa-mir-146b Carcinoma, Thyroid, Follicular 28427206 disease of cellular proliferation DOID:3962 C73 C572845 188470 HP:0006731 miR-146a and miR-146b promote proliferation, migration and invasion of follicular thyroid carcinoma via inhibition of ST8SIA4. target gene hsa-mir-296 Carcinoma, Thyroid, Follicular 29344146 disease of cellular proliferation DOID:3962 C73 C572845 188470 HP:0006731 Network analysis indicated a co-regulatory association between miR-296-5p, miR-10a, miR-139-5p, miR-452, miR-493, miR-7, miR-137, miR-144, miR-145 and corresponding targeted mRNAs, including TNF receptor superfamily member 11b, benzodiazepine receptor (peripheral) -associated protein 1, and transforming growth factor β receptor 2 target gene hsa-mir-452 Carcinoma, Thyroid, Follicular 29344146 disease of cellular proliferation DOID:3962 C73 C572845 188470 HP:0006731 Network analysis indicated a co-regulatory association between miR-296-5p, miR-10a, miR-139-5p, miR-452, miR-493, miR-7, miR-137, miR-144, miR-145 and corresponding targeted mRNAs, including TNF receptor superfamily member 11b, benzodiazepine receptor (peripheral) -associated protein 1, and transforming growth factor β receptor 2 target gene hsa-mir-493 Carcinoma, Thyroid, Follicular 29344146 disease of cellular proliferation DOID:3962 C73 C572845 188470 HP:0006731 Network analysis indicated a co-regulatory association between miR-296-5p, miR-10a, miR-139-5p, miR-452, miR-493, miR-7, miR-137, miR-144, miR-145 and corresponding targeted mRNAs, including TNF receptor superfamily member 11b, benzodiazepine receptor (peripheral) -associated protein 1, and transforming growth factor β receptor 2 target gene hsa-mir-7 Carcinoma, Thyroid, Follicular 29344146 disease of cellular proliferation DOID:3962 C73 C572845 188470 HP:0006731 Network analysis indicated a co-regulatory association between miR-296-5p, miR-10a, miR-139-5p, miR-452, miR-493, miR-7, miR-137, miR-144, miR-145 and corresponding targeted mRNAs, including TNF receptor superfamily member 11b, benzodiazepine receptor (peripheral) -associated protein 1, and transforming growth factor β receptor 2 target gene hsa-mir-182 Carcinoma, Thyroid, Medullary 28122586 disease of cellular proliferation DOID:3973 C73 C536914 155240 HP:0002865 MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit. target gene hsa-mir-200 Carcinoma, Thyroid, Medullary 24127332 disease of cellular proliferation DOID:3973 C73 C536914 155240 HP:0002865 The members of miR-200 family regulate the expression of E-cadherin by directly targeting ZEB1 and ZEB2 mRNA and through the enhanced expression of tumour growth factor β (TGFβ)-2 and TGFβ-1.The members of miR-200 family associated with metastatic MTC and distinct biological processes providing new potential insights into the mechanisms of MTC metastasis. target gene hsa-let-7a Carcinoma, Thyroid, Papillary 29050238 disease of cellular proliferation DOID:3969 C73 C536915 188550 HP:0002895 Let-7a inhibits migration, invasion and tumor growth by targeting AKT2 in papillary thyroid carcinoma. target gene hsa-mir-150 Carcinoma, Thyroid, Papillary 28656254 disease of cellular proliferation DOID:3969 C73 C536915 188550 HP:0002895 MicroRNA-150 targets Rho-associated protein kinase 1 to inhibit cell proliferation, migration and invasion in papillary thyroid carcinoma. target gene hsa-mir-155 Carcinoma, Thyroid, Papillary 23796566 disease of cellular proliferation DOID:3969 C73 C536915 188550 HP:0002895 Our results indicate that miR-155 functions as an oncogene in PTC. By targeting APC, miR-155 efficiently regulates the Wnt/β-catenin signaling. And miR-155 may be a potential therapeutic or diagnostic/prognostic target for treating PTC. target gene hsa-mir-182 Carcinoma, Thyroid, Papillary 24971532 disease of cellular proliferation DOID:3969 C73 C536915 188550 HP:0002895 miR-182 targets CHL1 and controls tumor growth and invasion in papillary thyroid carcinoma. target gene hsa-mir-183 Carcinoma, Thyroid, Papillary 26063221 disease of cellular proliferation DOID:3969 C73 C536915 188550 HP:0002895 miR-183 regulates biological behavior in papillary thyroid carcinoma by targeting the programmed cell death 4. target gene hsa-mir-199a Carcinoma, Thyroid, Papillary 29427661 disease of cellular proliferation DOID:3969 C73 C536915 188550 HP:0002895 miR-199a-5p inhibits the progression of papillary thyroid carcinoma by targeting SNAI1. target gene hsa-mir-221 Carcinoma, Thyroid, Papillary 18794255 disease of cellular proliferation DOID:3969 C73 C536915 188550 HP:0002895 Microarray analysis showed thousands of genes were directly and indirectly regulated by miR-221 and shifted the gene expression pattern of normal thyroid cells toward PTC. target gene hsa-mir-221 Carcinoma, Thyroid, Papillary 27077469 disease of cellular proliferation DOID:3969 C73 C536915 188550 HP:0002895 miR-221 exacerbated PTC by downregulating the expression of TIMP3. target gene hsa-mir-26a Carcinoma, Thyroid, Papillary 23861775 disease of cellular proliferation DOID:3969 C73 C536915 188550 HP:0002895 Our data indicate that miR-26a functions as a growth suppressive miRNA in PTC, and that its suppressive effects are mediated mainly by repressing CKS2 expression. target gene hsa-mir-31 Carcinoma, Thyroid, Papillary 26731986 disease of cellular proliferation DOID:3969 C73 C536915 188550 HP:0002895 Down regulation of miR-31 contributed to the malignant progression of papillary thyroid carcinoma cells by targeting HuR. target gene hsa-mir-34a Carcinoma, Thyroid, Papillary 24220341 disease of cellular proliferation DOID:3969 C73 C536915 188550 HP:0002895 MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway. target gene hsa-mir-7 Carcinoma, Thyroid, Papillary 27633373 disease of cellular proliferation DOID:3969 C73 C536915 188550 HP:0002895 MicroRNA-7 inhibits proliferation, migration and invasion of thyroid papillary cancer cells via targeting CKS2. target gene hsa-mir-27a Carcinoma, Urothelial 24462738 disease of cellular proliferation DOID:4006 HP:0030409 Role of microRNA-27a in down-regulation of angiogenic factor AGGF1 under hypoxia associated with high-grade bladder urothelial carcinoma. target gene hsa-mir-9 Cardiac Fibrosis 27756824 MicroRNA-9 inhibits high glucose-induced proliferation, differentiation and collagen accumulation of cardiac fibroblasts by down-regulation of TGFBR2. target gene hsa-mir-133a Cardiac Myocyte Injury 23069713 We also discovered that luciferase activity is exclusively decreased by targeting EGFR in hMSCs transfected with miR-133a mimic. These results suggest that EGFR plays a key role in the regulation of cardiogenic differentiation in hMSCs. target gene hsa-mir-214 Cardiac Myocyte Injury 23904244 miR-214 protects cardiac myocytes against H2O2-induced injury via one of its targets, PTEN. target gene hsa-mir-217 Cardiac Myxoma 28642131 D15.1 D009232 255960 HP:0011672 miR-217 suppresses proliferation and promotes apoptosis in cardiac myxoma by targeting Interleukin-6. target gene hsa-mir-218 Cardiac Myxoma 25812649 D15.1 D009232 255960 HP:0011672 miR-218 suppresses cardiac myxoma proliferation by targeting myocyte enhancer factor 2D. target gene hsa-mir-19a Cardiomegaly 24117217 I51.7 D006332 HP:0001640 The results of the present study demonstrate that the miR-19a/b family regulates phenotypes of cardiomyocytes via suppression of multiple direct target genes. target gene hsa-mir-19b Cardiomegaly 24117217 I51.7 D006332 HP:0001640 The results of the present study demonstrate that the miR-19a/b family regulates phenotypes of cardiomyocytes via suppression of multiple direct target genes. target gene hsa-mir-21 Cardiomegaly 25504627 I51.7 D006332 HP:0001640 miR-21-3p in regulating HDAC8 expression and Akt/Gsk3β pathway, and suggest that modulation of miR-21-3p levels may provide a therapeutic approach for cardiac hypertrophy. target gene hsa-mir-214 Cardiomegaly 26572862 I51.7 D006332 HP:0001640 These results provide the first clear link between miRNAs and direct regulation of XBP1 in heart failure and reveal that miR-214 and miR-30* synergistically regulates cardiac VEGF expression and angiogenesis by targeting XBP1 in the progression from adaptive hypertrophy to heart failure. target gene hsa-mir-30 Cardiomegaly 26572862 I51.7 D006332 HP:0001640 These results provide the first clear link between miRNAs and direct regulation of XBP1 in heart failure and reveal that miR-214 and miR-30* synergistically regulates cardiac VEGF expression and angiogenesis by targeting XBP1 in the progression from adaptive hypertrophy to heart failure. target gene hsa-mir-489 Cardiomegaly 24557880 I51.7 D006332 HP:0001640 Our present study reveals a novel cardiac hypertrophy regulating model that is composed of CHRF, miR-489, and Myd88. The modulation of their levels may provide a new approach for tackling cardiac hypertrophy. target gene hsa-mir-96 Cardiomegaly 26782545 I51.7 D006332 HP:0001640 miR-96 inhibits cardiac hypertrophy by targeting growth factor receptor-bound 2. target gene hsa-mir-1 Cardiomegaly 26476318 I51.7 D006332 HP:0001640 Further findings indicated that miR-1, which was depressed by Nkx2.5, might play a fundamental role in mediating cardiac hypertrophy and arrhythmia via its target genes Mef2a and Irx5 after HBCD treatment. target gene hsa-mir-1 Cardiomegaly 20571053 I51.7 D006332 HP:0001640 Taken together, our results demonstrate that the cytoskeleton regulatory protein twinfilin-1 is a novel target of miR-1, and that reduction of miR-1 by hypertrophic stimuli induces the upregulation of twinfilin-1, which in turn evokes hypertrophy through the regulation of cardiac cytoskeleton. target gene hsa-mir-1-1 Cardiomegaly 19188439 I51.7 D006332 HP:0001640 miR-1: MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes target gene hsa-mir-1-1 Cardiomegaly 23156720 I51.7 D006332 HP:0001640 Effects of microRNA-1 on negatively regulating L-type calcium channel beta2 subunit gene expression during cardiac hypertrophy target gene hsa-mir-1-2 Cardiomegaly 19188439 I51.7 D006332 HP:0001640 miR-1: MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes target gene hsa-mir-1-2 Cardiomegaly 23156720 I51.7 D006332 HP:0001640 Effects of microRNA-1 on negatively regulating L-type calcium channel beta2 subunit gene expression during cardiac hypertrophy target gene hsa-mir-133a Cardiomegaly 20177001 I51.7 D006332 HP:0001640 Our data show that reciprocal repression between miR-133 and calcineurin regulates cardiac hypertrophy. target gene hsa-mir-133a-1 Cardiomegaly 23166348 I51.7 D006332 HP:0001640 Mutual antagonism between IP(3)RII and miRNA-133a regulates calcium signals and cardiac hypertrophy target gene hsa-mir-133a-2 Cardiomegaly 23166348 I51.7 D006332 HP:0001640 Mutual antagonism between IP(3)RII and miRNA-133a regulates calcium signals and cardiac hypertrophy target gene hsa-mir-133b Cardiomegaly 20177001 I51.7 D006332 HP:0001640 Our data show that reciprocal repression between miR-133 and calcineurin regulates cardiac hypertrophy. target gene hsa-mir-150 Cardiomegaly 23211718 I51.7 D006332 HP:0001640 miR-150 regulates high glucose-induced cardiomyocyte hypertrophy by targeting the transcriptional co-activator p300 target gene hsa-mir-378a Cardiomegaly 23447532 I51.7 D006332 HP:0001640 A cardiac enriched microRNA, miR-378 blocks cardiac hypertrophy by targeting Ras-signaling target gene hsa-mir-216a Cardiometabolic Disorders 24481443 In conclusion, mir-216a controls ox-LDL induced autophagy in HUVECs by regulating intracellular levels of BECN1 and may have a relevant role in the pathogenesis of cardiovascular disorders and atherosclerosis. target gene hsa-mir-199a-1 Cardiomyopathy 23360823 cardiovascular system disease DOID:0050700 I42 D009202 TWIST1 regulates the activity of ubiquitin proteasome system via the miR-199/214 cluster in human end-stage dilated cardiomyopathy target gene hsa-mir-199a-2 Cardiomyopathy 23360823 cardiovascular system disease DOID:0050700 I42 D009202 TWIST1 regulates the activity of ubiquitin proteasome system via the miR-199/214 cluster in human end-stage dilated cardiomyopathy target gene hsa-mir-199b Cardiomyopathy 23360823 cardiovascular system disease DOID:0050700 I42 D009202 TWIST1 regulates the activity of ubiquitin proteasome system via the miR-199/214 cluster in human end-stage dilated cardiomyopathy target gene hsa-mir-214 Cardiomyopathy 23360823 cardiovascular system disease DOID:0050700 I42 D009202 TWIST1 regulates the activity of ubiquitin proteasome system via the miR-199/214 cluster in human end-stage dilated cardiomyopathy target gene hsa-mir-27a Cardiomyopathy 23143062 cardiovascular system disease DOID:0050700 I42 D009202 MicroRNA-27a regulates cardiomyocytic apoptosis during cardioplegia-induced cardiac arrest by targeting interleukin 10-related pathways target gene hsa-mir-451a Cardiomyopathy 27974462 cardiovascular system disease DOID:0050700 I42 D009202 Down-regulation of microRNA-451a facilitates the activation and proliferation of CD4+ T cells by targeting Myc in patients with dilated cardiomyopathy. target gene hsa-mir-1 Cardiomyopathy, Hypertrophic 25152367 cardiovascular system disease DOID:11984 I42.2 D002312 192600 HP:0001639 Our results show that p65 can upregulate the level of miR-1 and miR-1 can decrease protein expression of myocardin in cardiac myocytes. target gene hsa-mir-106a Cardiomyopathy, Hypertrophic 27565029 cardiovascular system disease DOID:11984 I42.2 D002312 192600 HP:0001639 miR-106a promotes cardiac hypertrophy by targeting mitofusin 2. target gene hsa-mir-21 Cardiomyopathy, Hypertrophic 19336275 cardiovascular system disease DOID:11984 I42.2 D002312 192600 HP:0001639 miR-21: miR-21 can protect this by targeting PDCD4 target gene hsa-mir-30a Cardiomyopathy, Hypertrophic 23326547 cardiovascular system disease DOID:11984 I42.2 D002312 192600 HP:0001639 miR-30a induced alterations in beclin-1 gene expression and autophagy in cardiomyocytes. target gene hsa-mir-34a Cardiomyopathy, Hypertrophic 24728149 cardiovascular system disease DOID:11984 I42.2 D002312 192600 HP:0001639 This study indicates that miR-34a plays a role in regulation of Ang II-induced cardiomyocyte hypertrophy by inhibition of ATG9A expression and autophagic activity. target gene hsa-mir-154 Cardiomyopathy, Ischemic 27542661 I25.5 MiR-154 directly suppresses DKK2 to activate Wnt signaling pathway and enhance activation of cardiac fibroblasts. target gene hsa-mir-21 Cardio-Renal Syndrome 28760335 D059347 MicroRNA-21 regulates peroxisome proliferator-activated receptor alpha, a molecular mechanism of cardiac pathology in Cardiorenal Syndrome Type 4. target gene hsa-mir-106a Cardiovascular Diseases [unspecific] 26266261 D002318 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. target gene hsa-mir-106b Cardiovascular Diseases [unspecific] 26266261 D002318 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. target gene hsa-mir-1248 Cardiovascular Diseases [unspecific] 24088671 D002318 In humans, miR-1248 was found to regulate the expression of mRNAs involved in inflammatory pathways and miR-181a was found to correlate negatively with the pro-inflammatory cytokines IL-6 and TNFα and to correlate positively with the anti-inflammatory cytokines TGFβ and IL-10. target gene hsa-mir-125 Cardiovascular Diseases [unspecific] 26266261 D002318 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. target gene hsa-mir-126 Cardiovascular Diseases [unspecific] 26266261 D002318 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. target gene hsa-mir-133a-1 Cardiovascular Diseases [unspecific] 19720047 D002318 MicroRNA-133 regulates the expression of GLUT4 by targeting KLF15 and is involved in metabolic control in cardiac myocytes target gene hsa-mir-133a-2 Cardiovascular Diseases [unspecific] 19720047 D002318 MicroRNA-133 regulates the expression of GLUT4 by targeting KLF15 and is involved in metabolic control in cardiac myocytes target gene hsa-mir-133b Cardiovascular Diseases [unspecific] 19720047 D002318 MicroRNA-133 regulates the expression of GLUT4 by targeting KLF15 and is involved in metabolic control in cardiac myocytes target gene hsa-mir-143 Cardiovascular Diseases [unspecific] 26221598 D002318 We discuss the potential role of miR-143/-145 as valuable biomarkers for cardiovascular diseases and explore the potential strategy of targeting miR-143 and miR-145. target gene hsa-mir-143 Cardiovascular Diseases [unspecific] 26266261 D002318 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. target gene hsa-mir-145 Cardiovascular Diseases [unspecific] 26221598 D002318 We discuss the potential role of miR-143/-145 as valuable biomarkers for cardiovascular diseases and explore the potential strategy of targeting miR-143 and miR-145. target gene hsa-mir-145 Cardiovascular Diseases [unspecific] 26266261 D002318 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. target gene hsa-mir-145 Cardiovascular Diseases [unspecific] 27412561 D002318 miR-145 is involved in the anti-proliferation and anti-inflammation effects of aspirin on VSMCs by inhibiting the expression of CD40. target gene hsa-mir-151a Cardiovascular Diseases [unspecific] 24088671 D002318 In humans, miR-1248 was found to regulate the expression of mRNAs involved in inflammatory pathways and miR-181a was found to correlate negatively with the pro-inflammatory cytokines IL-6 and TNFα and to correlate positively with the anti-inflammatory cytokines TGFβ and IL-10. target gene hsa-mir-155 Cardiovascular Diseases [unspecific] 29686722 D002318 Analysis of microRNA-155 expression also suggests its intervention in the regulation of eNOS expression. target gene hsa-mir-155 Cardiovascular Diseases [unspecific] 20550618 D002318 MicroRNA-155 prevents necrotic cell death in human cardiomyocyte progenitor cells via targeting RIP1. target gene hsa-mir-17 Cardiovascular Diseases [unspecific] 26266261 D002318 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. target gene hsa-mir-18 Cardiovascular Diseases [unspecific] 26266261 D002318 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. target gene hsa-mir-181b Cardiovascular Diseases [unspecific] 28323879 D002318 miR-181b regulates vascular stiffness age dependently in part by regulating TGF-β signaling. target gene hsa-mir-195 Cardiovascular Diseases [unspecific] 21622680 D002318 MicroRNA-195 promotes palmitate-induced apoptosis in cardiomyocytes by down-regulating Sirt1. target gene hsa-mir-19a Cardiovascular Diseases [unspecific] 26266261 D002318 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. target gene hsa-mir-19b-1 Cardiovascular Diseases [unspecific] 26266261 D002318 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. target gene hsa-mir-200c Cardiovascular Diseases [unspecific] 25791170 D002318 These results demonstrate that induction of a miR-200c-SUMOylated KLF4 feedback loop is a significant aspect of the PDGF-BB proliferative response in VSMCs and that targeting Ubc9 represents a novel approach for the prevention of restenosis. target gene hsa-mir-20a Cardiovascular Diseases [unspecific] 26266261 D002318 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. target gene hsa-mir-21 Cardiovascular Diseases [unspecific] 25898844 D002318 In cardiac fibrosis related to Ang II, miR-21 is transcriptionally activated and targets PTEN/SMAD7 resulting in increased fibroblast survival. OPN KO animals are protected from miR-21 increase and fibrosis development due to impaired AP-1 activation and fibroblast activation. target gene hsa-mir-21 Cardiovascular Diseases [unspecific] 27545313 D002318 Viral Vector-Based Targeting of miR-21 in Cardiac Nonmyocyte Cells Reduces Pathologic Remodeling of the Heart. target gene hsa-mir-21 Cardiovascular Diseases [unspecific] 27663503 D002318 DDAH1 3'-UTR as a target for miR-21, and endogenous miR-21 showed increased inhibitory effect on DDAH1-V3 transcript target gene hsa-mir-221 Cardiovascular Diseases [unspecific] 26266261 D002318 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. target gene hsa-mir-221 Cardiovascular Diseases [unspecific] 26461283 D002318 Among differentially-expressed miRNAs are those involved in the regulation of inflammation or cell adhesion, such as miR-221 and miR-181. target gene hsa-mir-222 Cardiovascular Diseases [unspecific] 26266261 D002318 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. target gene hsa-mir-223 Cardiovascular Diseases [unspecific] 26266261 D002318 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. target gene hsa-mir-2861 Cardiovascular Diseases [unspecific] 26266261 D002318 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. target gene hsa-mir-29b Cardiovascular Diseases [unspecific] 28164126 D002318 The Involvement of miR-29b-3p in Arterial Calcification by Targeting Matrix Metalloproteinase-2. target gene hsa-mir-34a Cardiovascular Diseases [unspecific] 27694688 D002318 it could be considered as a circulating biomarker for anthracycline-induced cardiac damage target gene hsa-mir-378a Cardiovascular Diseases [unspecific] 22119805 D002318 Overexpression of microRNA-378 attenuates ischemia-induced apoptosis by inhibiting caspase-3 expression in cardiac myocytes. target gene hsa-mir-3960 Cardiovascular Diseases [unspecific] 26266261 D002318 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. target gene hsa-mir-9-1 Cardiovascular Diseases [unspecific] 21684288 D002318 MicroRNA-9 is an activation-induced regulator of PDGFR-beta expression in cardiomyocytes. target gene hsa-mir-9-2 Cardiovascular Diseases [unspecific] 21684288 D002318 MicroRNA-9 is an activation-induced regulator of PDGFR-beta expression in cardiomyocytes. target gene hsa-mir-92-1 Cardiovascular Diseases [unspecific] 26266261 D002318 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. target gene hsa-mir-9-3 Cardiovascular Diseases [unspecific] 21684288 D002318 MicroRNA-9 is an activation-induced regulator of PDGFR-beta expression in cardiomyocytes. target gene hsa-mir-99a Cardiovascular Diseases [unspecific] 27403035 D002318 MiR-99a inhibited the LPS-induced HUVECs inflammation via inhibition of the mTOR/NF-魏B signal. target gene hsa-mir-140 Cartilage Disease [unspecific] 29067438 musculoskeletal system disease DOID:1222 M94.9 D002357 miRNA-140 inhibits C3H10T1/2 mesenchymal stem cell proliferation by targeting CXCL12 during transforming growth factor-β3-induced chondrogenic differentiation. target gene hsa-mir-34a Cataract 29299142 nervous system disease DOID:83 H26.9 D002386 PS116200 HP:0000518 MicroRNA-34a promotes mitochondrial dysfunction-induced apoptosis in human lens epithelial cells by targeting Notch2 target gene hsa-mir-34a Cataract 27840975 nervous system disease DOID:83 H26.9 D002386 PS116200 HP:0000518 miR‑34a suppresses proliferation and induces apoptosis of human lens epithelial cells by targeting E2F3. target gene hsa-mir-370 Cerebral Aneurysm 28338184 cardiovascular system disease DOID:0060228 I67.1 D002532 PS105800 HP:0007029 MicroRNA-370-3p inhibits human vascular smooth muscle cell proliferation via targeting KDR/AKT signaling pathway in cerebral aneurysm. target gene hsa-let-7f Cerebral Ischemia 27812761 cardiovascular system disease DOID:2316 I67.82 D002545 HP:0002637 Let-7f Regulates the Hypoxic Response in Cerebral Ischemia by Targeting NDRG3. target gene hsa-mir-134 Cerebral Ischemia 25316150 cardiovascular system disease DOID:2316 I67.82 D002545 HP:0002637 miR-134 regulates ischemia/reperfusion injury-induced neuronal cell death by regulating CREB signaling. target gene hsa-mir-138 Cerebral Ischemia 26998035 cardiovascular system disease DOID:2316 I67.82 D002545 HP:0002637 The expression of Lcn-2 was inhibited by miR-138 mimics and enhanced by miR-138 inhibitors target gene hsa-mir-210 Cerebral Ischemia 29478968 cardiovascular system disease DOID:2316 I67.82 D002545 HP:0002637 miR-210 promoted neovascularization and NPC migration via the SOCS1-STAT3-VEGF-C pathway target gene hsa-mir-376b Cerebral Ischemia 24789343 cardiovascular system disease DOID:2316 I67.82 D002545 HP:0002637 miR-376b-5p regulates angiogenesis in cerebral ischemia. target gene hsa-mir-497 Cerebral Ischemia 20053374 cardiovascular system disease DOID:2316 I67.82 D002545 HP:0002637 Taken together, our data suggest that miR-497 promotes ischemic neuronal death by negatively regulating antiapoptotic proteins, bcl-2 and bcl-w. target gene hsa-mir-124 Cerebrovascular Disease 29530526 cardiovascular system disease DOID:6713 I63.9 D002561 601367 Levels of tight junction protein CLDND1 are regulated by microRNA-124 in the cerebellum of stroke-prone spontaneously hypertensive rats target gene hsa-mir-107 Cervical Neoplasms 29073938 disease of cellular proliferation DOID:4362 C53.9 D002583 603956 HP:0030159 Musashi-2, a novel oncoprotein promoting cervical cancer cell growth and invasion, is negatively regulated by p53-induced miR-143 and miR-107 activation. target gene hsa-mir-130a Cervical Neoplasms 27040383 disease of cellular proliferation DOID:4362 C53.9 D002583 603956 HP:0030159 miR-130a accelerates cervical cancer cell proliferation by targeting the phosphatase and tensin homolog on chromosome 10 (PTEN) target gene hsa-mir-130a Cervical Neoplasms 29099271 disease of cellular proliferation DOID:4362 C53.9 D002583 603956 HP:0030159 SOX9/miR-130a/CTR1 axis modulates DDP-resistance of cervical cancer cell. target gene hsa-mir-138 Cervical Neoplasms 27900047 disease of cellular proliferation DOID:4362 C53.9 D002583 603956 HP:0030159 MicroRNA-138 inhibits proliferation, migration and invasion through targeting hTERT in cervical cancer. target gene hsa-mir-143 Cervical Neoplasms 27177038 disease of cellular proliferation DOID:4362 C53.9 D002583 603956 HP:0030159 upregulation of miR鈥?43 expression reduced Bcl鈥? expression and increased Bax expression in HeLa cells. target gene hsa-mir-143 Cervical Neoplasms 29073938 disease of cellular proliferation DOID:4362 C53.9 D002583 603956 HP:0030159 Musashi-2, a novel oncoprotein promoting cervical cancer cell growth and invasion, is negatively regulated by p53-induced miR-143 and miR-107 activation. target gene hsa-mir-143 Cervical Neoplasms 29271989 disease of cellular proliferation DOID:4362 C53.9 D002583 603956 HP:0030159 MicroRNA-143 regulates the proliferation and apoptosis of cervical cancer cells by targeting HIF-1α target gene hsa-mir-150 Cervical Neoplasms 29091902 disease of cellular proliferation DOID:4362 C53.9 D002583 603956 HP:0030159 MicroRNA-150 promotes cell proliferation, migration, and invasion of cervical cancer through targeting PDCD4. target gene hsa-mir-16 Cervical Neoplasms 26629104 disease of cellular proliferation DOID:4362 C53.9 D002583 603956 HP:0030159 CCNE1 gene is targeted by miR-16-1 in CC cells. target gene hsa-mir-200b Cervical Neoplasms 26935796 disease of cellular proliferation DOID:4362 C53.9 D002583 603956 HP:0030159 miR鈥?00b was shown to inhibit the function of RhoE and suppress the EMT of cervical cancer target gene hsa-mir-204 Cervical Neoplasms 28800788 disease of cellular proliferation DOID:4362 C53.9 D002583 603956 HP:0030159 MiR-204 Regulates Cell Proliferation and Invasion by Targeting EphB2 in Human Cervical Cancer target gene hsa-mir-205 Cervical Neoplasms 27929537 disease of cellular proliferation DOID:4362 C53.9 D002583 603956 HP:0030159 Upregulation of MiR-205 under hypoxia promotes epithelial-mesenchymal transition by targeting ASPP2. target gene hsa-mir-21 Cervical Neoplasms 27220494 disease of cellular proliferation DOID:4362 C53.9 D002583 603956 HP:0030159 MiR-21 overexpression decreases PTEN, increases p-Akt, and subsequently increases HIF-1伪 expression target gene hsa-mir-21 Cervical Neoplasms 29177591 disease of cellular proliferation DOID:4362 C53.9 D002583 603956 HP:0030159 MicroRNA-21 promotes proliferation, migration, and invasion of cervical cancer through targeting TIMP3 target gene hsa-mir-210 Cervical Neoplasms 28401751 disease of cellular proliferation DOID:4362 C53.9 D002583 603956 HP:0030159 Down-Regulation of MicroRNA-210 Confers Sensitivity towards 1'S-1'-Acetoxychavicol Acetate (ACA) in Cervical Cancer Cells by Targeting SMAD4. target gene hsa-mir-214 Cervical Neoplasms 19859982 disease of cellular proliferation DOID:4362 C53.9 D002583 603956 HP:0030159 these results suggest that miR-214 negatively regulates HeLa cell proliferation by targeting the noncoding regions of MEK3 and JNK1 mRNAs. target gene hsa-mir-218 Cervical Neoplasms 17998940 disease of cellular proliferation DOID:4362 C53.9 D002583 603956 HP:0030159 We also show that LAMB3 expression is increased in the presence of the HPV-16 E6 oncogene and this effect is mediated through miR-218. These findings may contribute to a better understanding of the molecular mechanisms involved in cervical carcinogenesis. target gene hsa-mir-218-1 Cervical Neoplasms 23483249 disease of cellular proliferation DOID:4362 C53.9 D002583 603956 HP:0030159 Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion by targeting focal adhesion pathways in cervical squamous cell carcinoma target gene hsa-mir-218-2 Cervical Neoplasms 23483249 disease of cellular proliferation DOID:4362 C53.9 D002583 603956 HP:0030159 Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion by targeting focal adhesion pathways in cervical squamous cell carcinoma target gene hsa-mir-31 Cervical Neoplasms 29159179 disease of cellular proliferation DOID:4362 C53.9 D002583 603956 HP:0030159 miR-31 Functions as an Oncomir Which Promotes Epithelial-Mesenchymal Transition via Regulating BAP1 in Cervical Cancer target gene hsa-mir-34a Cervical Neoplasms 25675046 disease of cellular proliferation DOID:4362 C53.9 D002583 603956 HP:0030159 MiR-34a Inhibits Viability and Invasion of Human Papillomavirus-Positive Cervical Cancer Cells by Targeting E2F3 and Regulating Survivin. target gene hsa-mir-483 Cervical Neoplasms 27693430 disease of cellular proliferation DOID:4362 C53.9 D002583 603956 HP:0030159 miR-483 is a self-regulating microRNA and can activate its own expression via USF1 in HeLa cells. target gene hsa-mir-219 Child Development Disorders, Pervasive 20374639 F84.9 D002659 Putative gene targets (ID3 and PLK2) of two RT-PCR-confirmed brain-specific miRNAs (hsa-miR-29b and hsa-miR-219-5p),were validated by miRNA overexpression or knockdown assays target gene hsa-mir-29b Child Development Disorders, Pervasive 20374639 F84.9 D002659 Putative gene targets (ID3 and PLK2) of two RT-PCR-confirmed brain-specific miRNAs (hsa-miR-29b and hsa-miR-219-5p),were validated by miRNA overexpression or knockdown assays target gene hsa-mir-106b Cholangiocarcinoma 28881782 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 miR-106b regulates the 5-fluorouracil resistance by targeting Zbtb7a in cholangiocarcinoma target gene hsa-mir-144 Cholangiocarcinoma 25479763 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 miR-144 was reduced in CCA tissues and suggested that miR-144 may be an essential suppresser of CCA cell proliferation and invasion through targeting LIS1. target gene hsa-mir-148a Cholangiocarcinoma 20146264 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 These data indicate that IL-6 can regulate the activity of DNMT-1 and expression of methylation-dependent tumor suppressor genes by modulation of miR-148a and miR-152, and provide a link between this inflammation-associated cytokine and oncogenesis in cholangiocarcinoma. target gene hsa-mir-152 Cholangiocarcinoma 20146264 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 These data indicate that IL-6 can regulate the activity of DNMT-1 and expression of methylation-dependent tumor suppressor genes by modulation of miR-148a and miR-152, and provide a link between this inflammation-associated cytokine and oncogenesis in cholangiocarcinoma. target gene hsa-mir-16 Cholangiocarcinoma 28915618 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 Suppression of miR-16 promotes tumor growth and metastasis through reversely regulating YAP1 in human cholangiocarcinoma. target gene hsa-mir-17 Cholangiocarcinoma 25239565 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 miR-17-92 cluster promotes cholangiocarcinoma growth: evidence for PTEN as downstream target and IL-6/Stat3 as upstream activator. target gene hsa-mir-18 Cholangiocarcinoma 25239565 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 miR-17-92 cluster promotes cholangiocarcinoma growth: evidence for PTEN as downstream target and IL-6/Stat3 as upstream activator. target gene hsa-mir-19a Cholangiocarcinoma 25239565 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 miR-17-92 cluster promotes cholangiocarcinoma growth: evidence for PTEN as downstream target and IL-6/Stat3 as upstream activator. target gene hsa-mir-19b-1 Cholangiocarcinoma 25239565 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 miR-17-92 cluster promotes cholangiocarcinoma growth: evidence for PTEN as downstream target and IL-6/Stat3 as upstream activator. target gene hsa-mir-205 Cholangiocarcinoma 24147037 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 miRNA expression profiling was used to identify key miRNAs that regulate Gem sensitivity in CCA cells, and software that predicts miRNA targets was used to identify promising target genes for anti-tumor therapies. target gene hsa-mir-20a Cholangiocarcinoma 25239565 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 miR-17-92 cluster promotes cholangiocarcinoma growth: evidence for PTEN as downstream target and IL-6/Stat3 as upstream activator. target gene hsa-mir-21 Cholangiocarcinoma 22770403 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 PTEN and PDCD4 are bona fide targets of microRNA-21 in human cholangiocarcinoma. target gene hsa-mir-21 Cholangiocarcinoma 24699315 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 miR-21 targets 15-PGDH and promotes cholangiocarcinoma growth. target gene hsa-mir-21 Cholangiocarcinoma 25803229 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN. target gene hsa-mir-21 Cholangiocarcinoma 26191158 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 MicroRNA-21 regulates biological behavior by inducing EMT in human cholangiocarcinoma. target gene hsa-mir-21 Cholangiocarcinoma 23254774 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 These data indicated that TPM1 is downregulated in HuCCT1 cells and that the Ras signaling pathway as well as DNA methylation, histone deacetylation and miR-21 upregulation play important roles in the suppression of TPM1 expression in HuCCT1 cells. Thus, compounds that inhibit genetic and epigenetic mechanisms may be promising agents in treating cholangiocarcinoma. target gene hsa-mir-21 Cholangiocarcinoma 23480766 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 The expression level of miR-21 had an inverse correlation with the mRNA level of its target RECK, a metastasis suppressor, in human CCA target gene hsa-mir-21 Cholangiocarcinoma 23621247 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 MicroRNA-21 regulates the invasion and metastasis in cholangiocarcinoma and may be a potential biomarker for cancer prognosis. target gene hsa-mir-214 Cholangiocarcinoma 22540680 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 Downregulated miR-214 contributes to intrahepatic cholangiocarcinoma metastasis by targeting Twist. target gene hsa-mir-221 Cholangiocarcinoma 24147037 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 miRNA expression profiling was used to identify key miRNAs that regulate Gem sensitivity in CCA cells, and software that predicts miRNA targets was used to identify promising target genes for anti-tumor therapies. target gene hsa-mir-25 Cholangiocarcinoma 21953056 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 miR-25 targets TRAIL death Receptor-4 and promotes apoptosis resistance in cholangiocarcinoma. target gene hsa-mir-26a Cholangiocarcinoma 25691459 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 Omega-3 Polyunsaturated Fatty Acids Upregulate 15-PGDH Expression in Cholangiocarcinoma Cells by Inhibiting miR-26a/b Expression. target gene hsa-mir-26a-1 Cholangiocarcinoma 22484120 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 MicroRNA-26a Promotes Cholangiocarcinoma Growth by Activating beta-catenin. target gene hsa-mir-26a-2 Cholangiocarcinoma 22484120 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 MicroRNA-26a Promotes Cholangiocarcinoma Growth by Activating beta-catenin. target gene hsa-mir-26b Cholangiocarcinoma 25691459 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 Omega-3 Polyunsaturated Fatty Acids Upregulate 15-PGDH Expression in Cholangiocarcinoma Cells by Inhibiting miR-26a/b Expression. target gene hsa-mir-29b Cholangiocarcinoma 24147037 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 miRNA expression profiling was used to identify key miRNAs that regulate Gem sensitivity in CCA cells, and software that predicts miRNA targets was used to identify promising target genes for anti-tumor therapies. target gene hsa-mir-34a Cholangiocarcinoma 26077733 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 microRNA-34a inhibits epithelial mesenchymal transition in human cholangiocarcinoma by targeting Smad4 through transforming growth factor-beta/Smad pathway. target gene hsa-mir-373 Cholangiocarcinoma 21086164 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 miR-373 is one negative regulator of MBD2. In hilar cholangiocarcinoma, down-expression of miR-373 leads to increase of MBD2, which in turn suppresses the methylation-mediated gene such as RASSF1A. target gene hsa-mir-605 Cholangiocarcinoma 25131931 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 MiR-605 represses PSMD10/Gankyrin and inhibits intrahepatic cholangiocarcinoma cell progression. target gene hsa-mir-92-1 Cholangiocarcinoma 25239565 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 miR-17-92 cluster promotes cholangiocarcinoma growth: evidence for PTEN as downstream target and IL-6/Stat3 as upstream activator. target gene hsa-mir-100 Chondrosarcoma 24568519 disease of cellular proliferation DOID:3371 M91-M94 D002813 215300 HP:0006765 MicroRNA-100 resensitizes resistant chondrosarcoma cells to cisplatin through direct targeting of mTOR. target gene hsa-mir-126 Chondrosarcoma 24975661 disease of cellular proliferation DOID:3371 M91-M94 D002813 215300 HP:0006765 Naringin suppress chondrosarcoma migration through inhibition vascular adhesion molecule-1 expression by modulating miR-126. target gene hsa-mir-23b Chondrosarcoma 28085008 disease of cellular proliferation DOID:3371 M91-M94 D002813 215300 HP:0006765 Inhibition of Src by microRNA-23b increases the cisplatin sensitivity of chondrosarcoma cells. target gene hsa-mir-30a Chondrosarcoma 25572678 disease of cellular proliferation DOID:3371 M91-M94 D002813 215300 HP:0006765 SOX4 was oncogenic in chondrosarcoma and negatively regulated by miR-30a in vitro. Importantly, SOX4 overexpression may serve as a prognostic marker for patients with low-histological-grade chondrosarcoma target gene hsa-mir-494 Chondrosarcoma 26317788 disease of cellular proliferation DOID:3371 M91-M94 D002813 215300 HP:0006765 MicroRNA-494 inhibits cell proliferation and invasion of chondrosarcoma cells in vivo and in vitro by directly targeting SOX9. target gene hsa-mir-1 Chordoma 24760686 musculoskeletal system disease DOID:3302 C41.0 D002817 215400 HP:0010762 MicroRNA-1 (miR-1) inhibits chordoma cell migration and invasion by targeting slug. target gene hsa-mir-34a Chordoma 24621885 musculoskeletal system disease DOID:3302 C41.0 D002817 215400 HP:0010762 MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET. target gene hsa-mir-608 Chordoma 24621885 musculoskeletal system disease DOID:3302 C41.0 D002817 215400 HP:0010762 MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET. target gene hsa-mir-145 Choriocarcinoma 23251245 disease of cellular proliferation DOID:3594 C58 D002822 HP:0100768 Cell proliferation and invasion ability of human choriocarcinoma cells lessened due to inhibition of Sox2 expression by microRNA-145 target gene hsa-mir-183 Choriocarcinoma 26951513 disease of cellular proliferation DOID:3594 C58 D002822 HP:0100768 overexpression of miR-183 in CSLCs decreased PTPN4 protein levels while inhibition of miR-183 increased PTPN4 protein levels. target gene hsa-mir-192 Choriocarcinoma 27079614 disease of cellular proliferation DOID:3594 C58 D002822 HP:0100768 microRNA-192 suppresses the expression of FXR and FXR target genes in vitro and in vivo. target gene hsa-mir-21 Choriocarcinoma 27475963 disease of cellular proliferation DOID:3594 C58 D002822 HP:0100768 We find various mechanisms of PTEN protein loss in the different tumour cell populations, including allelic PTEN deletions, gross chromosomal 10 aberrations and altered miR-21 expression. target gene hsa-mir-218 Choriocarcinoma 24973709 disease of cellular proliferation DOID:3594 C58 D002822 HP:0100768 MicroRNA-218 inhibits the proliferation of human choriocarcinoma JEG-3 cell line by targeting Fbxw8. target gene hsa-mir-221 Choriocarcinoma 26501139 disease of cellular proliferation DOID:3594 C58 D002822 HP:0100768 In conclusion, our results suggested that miR-221 promotes EMT through targeting PTEN and forms a positive feedback loop with β-catenin/c-Jun signaling pathway in EHCC. target gene hsa-mir-29 Choroidal Neovascularization 24886609 H44.2A9 D020256 HP:0011506 The results suggest that in CNV, NFκB activation inhibits miR-29s,which may contribute to angiogenesis by up-regulating the MMP-2 protein level in RPE cells. These observations may help in developing a strategy for resolving CNV by targeting miR-29s levels. target gene hsa-mir-96 Chromosome 22Q11.2 Deletion Syndrome, Distal 25556186 genetic disease DOID:0060413 611867 Tbx1 regulates the proliferation of dental progenitor cells and craniofacial development through miR-96-5p and PITX2. Together, these data suggest a new molecular mechanism controlling pathogenesis of dental anomalies in human 22q11.2DS miR-7a target gene hsa-mir-146a Chronic Heart Failure 20495188 cardiovascular system disease DOID:6000 I50 D006333 HP:0001635 These findings suggested that the up-regulation of miR-146a after Dox treatment is involved in acute Dox-induced cardiotoxicity by targeting ErbB4. target gene hsa-mir-423 Chronic Heart Failure 25776937 cardiovascular system disease DOID:6000 I50 D006333 HP:0001635 the results of the present study indicated that miR-423-5p was involved in CHF via the direct targeting of OGT and the induction of apoptosis in cardiomyocytes. target gene hsa-mir-720 Chronic Hepatitis B 26199080 B18.0-.1 D019694 610424 therapies targeting miR-720 may help restore impaired immunity in chronic HBV infection (CHB) patients. target gene hsa-mir-122 Chronic Hepatitis C 27677491 B18.2 D019698 609532 microRNA-122 target sites in the hepatitis C virus RNA NS5B coding region and 3' untranslated region: function in replication and influence of RNA secondary structure. target gene hsa-mir-122 Chronic Hepatitis C 29182758 B18.2 D019698 609532 miR-122 regulates ALDOB and PKM2 expression at the mRNA level target gene hsa-mir-122 Chronic Hepatitis C 29593672 B18.2 D019698 609532 the liver-specific microRNA-122 (miR-122) binds to two target sites at the 5' end of the viral RNA genome as well as to at least three additional target sites in the coding region and the 3' UTR target gene hsa-mir-122 Chronic Hepatitis C 29669014 B18.2 D019698 609532 miR-122 positively regulates HCV replication by a direct interaction with the 5' untranslated region (UTR) of the viral RNA target gene hsa-mir-155 Chronic Hepatitis C 25772938 B18.2 D019698 609532 MicroRNA-155 regulates interferon-γ production in natural killer cells via Tim-3 signalling in chronic hepatitis C virus infection. target gene hsa-mir-448 Chronic Hepatitis C 24158346 B18.2 D019698 609532 Besides miR-122, let-7b, miR-196, miR-199a* and miR-448 have also been reported to interact directly with the HCV RNA. target gene hsa-mir-130a Chronic Inflammation 26436920 Therefore,miR-142-5p and miR-130a-3p regulate macrophage profibrogenic gene expression in chronic inflammation. target gene hsa-mir-142 Chronic Inflammation 26436920 Therefore,miR-142-5p and miR-130a-3p regulate macrophage profibrogenic gene expression in chronic inflammation. target gene hsa-mir-16 Chronic Inflammatory Pain 27770129 MicroRNA-16 Alleviates Inflammatory Pain by Targeting Ras-Related Protein 23 (RAB23) and Inhibiting p38 MAPK Activation. target gene hsa-mir-1-1 Chronic Obstructive Pulmonary Disease 21998125 respiratory system disease DOID:3083 J44.9 D029424 606963 HP:0006510 A reduction in expression of miR-1 (2.5-fold, p=0.01) and the myocardin-related transcription factors (MRTFs) A and B was observed in patients compared with controls (MRTF-A mRNA: twofold, p=0.028; MRTF-B mRNA: fourfold, p=0.011). miR-1 expression was associated with smoking history, lung function, fat-free mass index, 6 min walk distance and percentage of type 1 fibres. miR-133 and miR-206 were negatively correlated with daily physical activity. Insulin-like growth factor 1 mRNA was increased in the patients and miR-1 was negatively correlated with phosphorylation of the kinase Akt. Furthermore, the protein levels of histone deacetylase 4, another miR-1 target, were increased in the patients. target gene hsa-mir-1-2 Chronic Obstructive Pulmonary Disease 21998125 respiratory system disease DOID:3083 J44.9 D029424 606963 HP:0006510 A reduction in expression of miR-1 (2.5-fold, p=0.01) and the myocardin-related transcription factors (MRTFs) A and B was observed in patients compared with controls (MRTF-A mRNA: twofold, p=0.028; MRTF-B mRNA: fourfold, p=0.011). miR-1 expression was associated with smoking history, lung function, fat-free mass index, 6 min walk distance and percentage of type 1 fibres. miR-133 and miR-206 were negatively correlated with daily physical activity. Insulin-like growth factor 1 mRNA was increased in the patients and miR-1 was negatively correlated with phosphorylation of the kinase Akt. Furthermore, the protein levels of histone deacetylase 4, another miR-1 target, were increased in the patients. target gene hsa-mir-133a-1 Chronic Obstructive Pulmonary Disease 21998125 respiratory system disease DOID:3083 J44.9 D029424 606963 HP:0006510 A reduction in expression of miR-1 (2.5-fold, p=0.01) and the myocardin-related transcription factors (MRTFs) A and B was observed in patients compared with controls (MRTF-A mRNA: twofold, p=0.028; MRTF-B mRNA: fourfold, p=0.011). miR-1 expression was associated with smoking history, lung function, fat-free mass index, 6 min walk distance and percentage of type 1 fibres. miR-133 and miR-206 were negatively correlated with daily physical activity. Insulin-like growth factor 1 mRNA was increased in the patients and miR-1 was negatively correlated with phosphorylation of the kinase Akt. Furthermore, the protein levels of histone deacetylase 4, another miR-1 target, were increased in the patients. target gene hsa-mir-133a-2 Chronic Obstructive Pulmonary Disease 21998125 respiratory system disease DOID:3083 J44.9 D029424 606963 HP:0006510 A reduction in expression of miR-1 (2.5-fold, p=0.01) and the myocardin-related transcription factors (MRTFs) A and B was observed in patients compared with controls (MRTF-A mRNA: twofold, p=0.028; MRTF-B mRNA: fourfold, p=0.011). miR-1 expression was associated with smoking history, lung function, fat-free mass index, 6 min walk distance and percentage of type 1 fibres. miR-133 and miR-206 were negatively correlated with daily physical activity. Insulin-like growth factor 1 mRNA was increased in the patients and miR-1 was negatively correlated with phosphorylation of the kinase Akt. Furthermore, the protein levels of histone deacetylase 4, another miR-1 target, were increased in the patients. target gene hsa-mir-133b Chronic Obstructive Pulmonary Disease 21998125 respiratory system disease DOID:3083 J44.9 D029424 606963 HP:0006510 A reduction in expression of miR-1 (2.5-fold, p=0.01) and the myocardin-related transcription factors (MRTFs) A and B was observed in patients compared with controls (MRTF-A mRNA: twofold, p=0.028; MRTF-B mRNA: fourfold, p=0.011). miR-1 expression was associated with smoking history, lung function, fat-free mass index, 6 min walk distance and percentage of type 1 fibres. miR-133 and miR-206 were negatively correlated with daily physical activity. Insulin-like growth factor 1 mRNA was increased in the patients and miR-1 was negatively correlated with phosphorylation of the kinase Akt. Furthermore, the protein levels of histone deacetylase 4, another miR-1 target, were increased in the patients. target gene hsa-mir-199a Chronic Obstructive Pulmonary Disease 24634990 respiratory system disease DOID:3083 J44.9 D029424 606963 HP:0006510 Blunted expression of miR-199a-5p in regulatory T cells of patients with chronic obstructive pulmonary disease compared to unaffected smokers. target gene hsa-mir-203 Chronic Obstructive Pulmonary Disease 26617776 respiratory system disease DOID:3083 J44.9 D029424 606963 HP:0006510 miR-203 represses NF-κB signaling via targeting TAK1 and PI3KCA and miR-203 overexpression may contribute to the COPD initiation. target gene hsa-mir-206 Chronic Obstructive Pulmonary Disease 21998125 respiratory system disease DOID:3083 J44.9 D029424 606963 HP:0006510 A reduction in expression of miR-1 (2.5-fold, p=0.01) and the myocardin-related transcription factors (MRTFs) A and B was observed in patients compared with controls (MRTF-A mRNA: twofold, p=0.028; MRTF-B mRNA: fourfold, p=0.011). miR-1 expression was associated with smoking history, lung function, fat-free mass index, 6 min walk distance and percentage of type 1 fibres. miR-133 and miR-206 were negatively correlated with daily physical activity. Insulin-like growth factor 1 mRNA was increased in the patients and miR-1 was negatively correlated with phosphorylation of the kinase Akt. Furthermore, the protein levels of histone deacetylase 4, another miR-1 target, were increased in the patients. target gene hsa-mir-34a Chronic Obstructive Pulmonary Disease 29373969 respiratory system disease DOID:3083 J44.9 D029424 606963 HP:0006510 miR-34a is involved in CSE-induced apoptosis of human pulmonary microvascular endothelial cells by targeting Notch-1 receptor protein target gene hsa-mir-185 Cleidocranial Dysplasia 29242628 musculoskeletal system disease DOID:13994 Q74.0 D002973 119600 Mutant Runx2 regulates amelogenesis and osteogenesis through a miR-185-5p-Dlx2 axis. target gene hsa-let-7d Cocaine Abuse 19703567 disease of mental health DOID:809 F14.1 D019970 downregulated;These miRNAs target many genes involved in cocaine addiction. Precursor and mature miRNA quantification by qRT-PCR showed that miR-124 and let-7d are significantly downregulated target gene hsa-mir-124-1 Cocaine Abuse 19703567 disease of mental health DOID:809 F14.1 D019970 downregulated;These miRNAs target many genes involved in cocaine addiction. Precursor and mature miRNA quantification by qRT-PCR showed that miR-124 and let-7d are significantly downregulated target gene hsa-mir-124-2 Cocaine Abuse 19703567 disease of mental health DOID:809 F14.1 D019970 downregulated;These miRNAs target many genes involved in cocaine addiction. Precursor and mature miRNA quantification by qRT-PCR showed that miR-124 and let-7d are significantly downregulated target gene hsa-mir-124-3 Cocaine Abuse 19703567 disease of mental health DOID:809 F14.1 D019970 downregulated;These miRNAs target many genes involved in cocaine addiction. Precursor and mature miRNA quantification by qRT-PCR showed that miR-124 and let-7d are significantly downregulated target gene hsa-mir-181a-2 Cocaine Abuse 19703567 disease of mental health DOID:809 F14.1 D019970 miR-124, let-7d and miR-181a may be involved in a complex feedback loop with cocaine-responsive plasticity genes target gene hsa-mir-19a Colitis 23795660 gastrointestinal system disease DOID:0060180 K52.9 D003092 191390 HP:0002583 Taken together, this study determines the levels of miR-19a and TNF-α in both DSS-induced experimental murine colitis and human UC and further demonstrates that miR-19a might directly regulate TNF-α. The findings may provide a new insight in the clinical treatment of UC. target gene hsa-mir-31 Colitis 27901018 gastrointestinal system disease DOID:0060180 K52.9 D003092 191390 HP:0002583 The signaling axis of microRNA-31/interleukin-25 regulates Th1/Th17-mediated inflammation response in colitis. target gene hsa-mir-124 Colitis, Ulcerative 23856509 gastrointestinal system disease DOID:8577 K51 D003093 miR-124 appears to regulate the expression of STAT3. Reduced levels of miR-124 in colon tissues of children with active UC appear to increase expression and activity of STAT3, which could promote inflammation and the pathogenesis of UC in children. target gene hsa-mir-126 Colitis, Ulcerative 23285182 gastrointestinal system disease DOID:8577 K51 D003093 Up-Regulation of microRNA-126 May Contribute to Pathogenesis of Ulcerative Colitis via Regulating NF-kappaB Inhibitor Iж╩Bж┿ target gene hsa-mir-155 Colitis, Ulcerative 24583476 gastrointestinal system disease DOID:8577 K51 D003093 miR-155 appears to play a role in the intestinal inflammation of patients with active UC by downregulating the expression of FOXO3a. This process may activate the nuclear factor kappa B signaling pathway. target gene hsa-mir-155 Colitis, Ulcerative 25998827 gastrointestinal system disease DOID:8577 K51 D003093 MiR-155 modulates the inflammatory phenotype of intestinal myofibroblasts by targeting SOCS1 in ulcerative colitis. target gene hsa-mir-155 Colitis, Ulcerative 28461115 gastrointestinal system disease DOID:8577 K51 D003093 MiR-155 contributes to Th17 cells differentiation in dextran sulfate sodium (DSS)-induced colitis mice via Jarid2. target gene hsa-mir-195 Colitis, Ulcerative 26303523 gastrointestinal system disease DOID:8577 K51 D003093 miR-195 plays a role in steroid resistance of ulcerative colitis by targeting Smad7. target gene hsa-mir-29a Colitis, Ulcerative 25674218 gastrointestinal system disease DOID:8577 K51 D003093 miR-29a is involved in the pathogenesis of UC by regulating intestinal epithelial apoptosis via Mcl-1. target gene hsa-mir-4284 Colitis, Ulcerative 25738378 gastrointestinal system disease DOID:8577 K51 D003093 Our data reveal a novel microRNA pediatric UC signature and provide evidence that miR-4284 directly regulates CXCL5 and correlates with the disease activity. target gene hsa-mir-182 Colon Adenoma 25269767 disease of cellular proliferation DOID:0050912 Sequential expression of miR-182 and miR-503 cooperatively targets FBXW7,contributing to the malignant transformation of colon adenoma to adenocarcinoma. target gene hsa-mir-503 Colon Adenoma 25269767 disease of cellular proliferation DOID:0050912 Sequential expression of miR-182 and miR-503 cooperatively targets FBXW7,contributing to the malignant transformation of colon adenoma to adenocarcinoma. target gene hsa-mir-106a Colon Neoplasms 18521848 D12.6 D003110 HP:0100273 Deregulated expression of miR-106a predicts survival in human colon cancer patients. target gene hsa-mir-126 Colon Neoplasms 23744532 D12.6 D003110 HP:0100273 Expression of miR-126 suppresses migration and invasion of colon cancer cells by targeting CXCR4. target gene hsa-mir-133a Colon Neoplasms 24464560 D12.6 D003110 HP:0100273 Overexpression of miR-223, one of the main miRNA showing strong upregulation during AOM/DSS tumor growth, inhibited Akt phosphorylation and IGF-1R expression in these cells. target gene hsa-mir-143 Colon Neoplasms 22691140 D12.6 D003110 HP:0100273 microRNA-143 down-regulates Hexokinase 2 in colon cancer cells. target gene hsa-mir-145 Colon Neoplasms 17827156 D12.6 D003110 HP:0100273 Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. target gene hsa-mir-145 Colon Neoplasms 21917858 D12.6 D003110 HP:0100273 The expression of miR-145 is downregulated in colon and ovarian cancer tissues and cell lines. MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. target gene hsa-mir-145 Colon Neoplasms 22766504 D12.6 D003110 HP:0100273 MiR-145 regulates PAK4 via the MAPK pathway and exhibits an antitumor effect in human colon cells. target gene hsa-mir-145 Colon Neoplasms 20098684 D12.6 D003110 HP:0100273 MicroRNA-145 targets YES and STAT1 in colon cancer cells. target gene hsa-mir-145 Colon Neoplasms 20737575 D12.6 D003110 HP:0100273 Taken together, these results suggest that miR-145 functions as a tumor suppressor by down-regulating oncogenic FLI1 in colon cancer. target gene hsa-mir-155 Colon Neoplasms 29104623 D12.6 D003110 HP:0100273 MicroRNA-155 regulates the proliferation, cell cycle, apoptosis and migration of colon cancer cells and targets CBL. target gene hsa-mir-17 Colon Neoplasms 18521848 D12.6 D003110 HP:0100273 Deregulated expression of miR-106a predicts survival in human colon cancer patients. target gene hsa-mir-17 Colon Neoplasms 27278684 D12.6 D003110 HP:0100273 miR鈥?7 overexpression led to the degradation of CYP7B1 mRNA expression in DLD1 cells. target gene hsa-mir-204 Colon Neoplasms 29460671 D12.6 D003110 HP:0100273 Targeted delivery of miRNA-204-5p by PEGylated polymer nanoparticles for colon cancer therapy target gene hsa-mir-21 Colon Neoplasms 22072622 D12.6 D003110 HP:0100273 MicroRNA-21 induces stemness by downregulating transforming growth factor beta receptor 2 (TGFbetaR2) in colon cancer cells. target gene hsa-mir-21 Colon Neoplasms 22322462 D12.6 D003110 HP:0100273 microRNA-21-mediated regulation of Sprouty2 protein expression enhances the cytotoxic effect of 5-fluorouracil and metformin in colon cancer cells. target gene hsa-mir-21 Colon Neoplasms 29564000 D12.6 D003110 HP:0100273 Berberine regulates the microRNA-21-ITGΒ4-PDCD4 axis and inhibits colon cancer viability target gene hsa-mir-218-1 Colon Neoplasms 23255074 D12.6 D003110 HP:0100273 MicroRNA-218 inhibits cell cycle progression and promotes apoptosis in colon cancer by downregulating oncogene BMI-1 target gene hsa-mir-218-2 Colon Neoplasms 23255074 D12.6 D003110 HP:0100273 MicroRNA-218 inhibits cell cycle progression and promotes apoptosis in colon cancer by downregulating oncogene BMI-1 target gene hsa-mir-221 Colon Neoplasms 22126772 D12.6 D003110 HP:0100273 MicroRNA-221 promotes colon carcinoma cell proliferation in vitro by inhibiting CDKN1C/p57 expression. target gene hsa-mir-24 Colon Neoplasms 27888625 D12.6 D003110 HP:0100273 TRIM11, a direct target of miR-24-3p, promotes cell proliferation and inhibits apoptosis in colon cancer. target gene hsa-mir-30a Colon Neoplasms 22287560 D12.6 D003110 HP:0100273 MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL. target gene hsa-mir-31 Colon Neoplasms 23258531 D12.6 D003110 HP:0100273 miR-31 acts as an oncogene in colon cancer and identified RhoBTB1 as a new target of miR-31 further study demonstrated that miR-31 contributed to the development of colon cancer at least partly by targeting RhoBTB1 target gene hsa-mir-330 Colon Neoplasms 22132977 D12.6 D003110 HP:0100273 Expression of miR-330 in various colon and lung cancer cell lines, as measured by QRT-PCR, varied five-fold between samples and correlated with in-vitro gemcitabine resistance (R = 0.82, p = 0.04). Exposure to gemcitabine also appeared to influence miR-330 levels in these cell lines. Furthermore, in our cell line panel, miR-330 expression negatively correlated with dCK mRNA expression (R = 0.74), suggesting a role of miR-330 in post-transcriptional regulation of dCK. target gene hsa-mir-339 Colon Neoplasms 25193859 D12.6 D003110 HP:0100273 MicroRNA-339-5p inhibits colorectal tumorigenesis through regulation of the MDM2/p53 signaling. target gene hsa-mir-34a Colon Neoplasms 22198213 D12.6 D003110 HP:0100273 MicroRNA-34a inhibits migration and invasion of colon cancer cells via targeting to Fra-1. target gene hsa-mir-34a Colon Neoplasms 22479251 D12.6 D003110 HP:0100273 miR-34a induces colon cancer apoptosis through SIRT1, and miR-34a also promotes senescence in endothelial cells via SIRT1. target gene hsa-mir-34a Colon Neoplasms 26849305 D12.6 D003110 HP:0100273 miR-34a directly suppresses Numb in early-stage colon cancer stem cells (CCSCs) target gene hsa-mir-378 Colon Neoplasms 28725241 D12.6 D003110 HP:0100273 miR-378 suppresses the proliferation, migration and invasion of colon cancer cells by inhibiting SDAD1. target gene hsa-mir-506 Colon Neoplasms 22036718 D12.6 D003110 HP:0100273 MicroRNA 506 regulates expression of PPAR alpha in hydroxycamptothecin-resistant human colon cancer cells. target gene hsa-mir-1 Colorectal Carcinoma 28471448 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-1 suppresses tumor cell proliferation in colorectal cancer by inhibition of Smad3-mediated tumor glycolysis. target gene hsa-mir-100 Colorectal Carcinoma 24626817 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-100 regulates SW620 colorectal cancer cell proliferation and invasion by targeting RAP1B. target gene hsa-mir-101 Colorectal Carcinoma 25057058 disease of cellular proliferation DOID:0080199 C19 D015179 114500 We have successfully constructed a SW620 cell line stably overexpressing mir-101. mir-101 can suppress RAC1 gene expression by targeting the specific sequence of RAC1 3'UTR. target gene hsa-mir-101 Colorectal Carcinoma 28000868 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Methyl jasmonate induces the apoptosis of human colorectal cancer cells via downregulation of EZH2 expression by microRNA‑101. target gene hsa-mir-103 Colorectal Carcinoma 24393525 disease of cellular proliferation DOID:0080199 C19 D015179 114500 PER3, a novel target of miR-103, plays a suppressive role in colorectal cancer in vitro. target gene hsa-mir-103 Colorectal Carcinoma 24828205 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-103 promotes colorectal cancer by targeting tumor suppressor DICER and PTEN. target gene hsa-mir-124 Colorectal Carcinoma 23940556 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-124 suppresses growth of human colorectal cancer by inhibiting STAT3. target gene hsa-mir-124 Colorectal Carcinoma 25081869 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Low expression levels of microRNA-124-5p correlated with poor prognosis in colorectal cancer via targeting of SMC4. target gene hsa-mir-124 Colorectal Carcinoma 26248089 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR124 inhibits DNA synthesis and proliferation by reducing levels of pentose phosphate pathway enzymes in CRC cells. Expression of miR124 and its targets correlate with survival times and might be used in prognosis. target gene hsa-mir-124 Colorectal Carcinoma 26497367 disease of cellular proliferation DOID:0080199 C19 D015179 114500 In conclusion, our data showed that miR-124 and miR-506 inhibit progression and increase sensitivity to chemotherapy by targeting DNMT3B and DNMT1 in CRC. These findings may provide novel avenues for the development of targeted therapies. target gene hsa-mir-126 Colorectal Carcinoma 24189753 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-126 functions as a tumor suppressor in CRC cells by regulating CXCR4 expression via the AKT and ERK1/2 signaling pathways and might be a novel target for therapeutic strategies in CRC. target gene hsa-mir-126 Colorectal Carcinoma 24312276 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-126 may play roles in regulation of the biological behavior of CRC cells, at least in part, by targeting IRS-1 via AKT and ERK1/2 signaling pathways. target gene hsa-mir-126 Colorectal Carcinoma 23922111 disease of cellular proliferation DOID:0080199 C19 D015179 114500 The results validate the previous findings on the prognostic value of miRNA-126 in mCRC and may suggest a relationship between treatment efficacy and EGFL7 expression. As miRNA 126 may target VEGF-A as well as EGFL7, the results may provide predictive information in relation to next-generation anti-angiogenetics. target gene hsa-mir-129 Colorectal Carcinoma 20404570 disease of cellular proliferation DOID:0080199 C19 D015179 114500 our data indicate that miR-129 plays an important role in regulating cell proliferation by downregulation of Cdk6. target gene hsa-mir-130a Colorectal Carcinoma 28849155 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-130a is upregulated in colorectal cancer and promotes cell growth and motility by directly targeting forkhead box F2. target gene hsa-mir-130b Colorectal Carcinoma 24468585 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer. target gene hsa-mir-130b Colorectal Carcinoma 26873488 disease of cellular proliferation DOID:0080199 C19 D015179 114500 colorectal cancer target gene hsa-mir-133b Colorectal Carcinoma 24330809 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Our study demonstrated that downregulated miR-133b contributed to increased cell invasion and migration in CRC by negatively regulating CXCR4.These findings may be significant for the development of therapy target for CRC. target gene hsa-mir-135b Colorectal Carcinoma 24343340 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-135b regulates metastasis suppressor 1 expression and promotes migration and invasion in colorectal cancer. target gene hsa-mir-135b Colorectal Carcinoma 26061281 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-135b Promotes Cancer Progression by Targeting Transforming Growth Factor Beta Receptor II (TGFBR2) in Colorectal Cancer. target gene hsa-mir-137 Colorectal Carcinoma 25940441 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Tumor suppressive microRNA-137 negatively regulates Musashi-1 and colorectal cancer progression. target gene hsa-mir-138 Colorectal Carcinoma 24171926 disease of cellular proliferation DOID:0080199 C19 D015179 114500 These data highlight a pivotal role for miR-138 in the regulation of CRC metastasis by targeting TWIST2, and suggest a potential application of miR-138 in prognosis prediction and CRC treatment. target gene hsa-mir-138 Colorectal Carcinoma 28707774 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Hsa_circ_0020397 regulates colorectal cancer cell viability, apoptosis and invasion by promoting the expression of the miR-138 targets TERT and PD-L1. target gene hsa-mir-139 Colorectal Carcinoma 25149074 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-139-5p inhibits migration and invasion of colorectal cancer by downregulating AMFR and NOTCH1. target gene hsa-mir-140 Colorectal Carcinoma 26402430 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Our results suggested a tumor suppressive role of miR-140-5p in CRC tumorigenesis and progression by targeting VEGFA. target gene hsa-mir-140 Colorectal Carcinoma 29499953 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-140 might be a key suppressor of CRC progression and metastasis through inhibiting EMT process by targeting Smad3 target gene hsa-mir-145 Colorectal Carcinoma 24642628 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-145 has a critical role in the inhibition of invasive and metastatic capacities of CRC, probably through directly targeting Fascin-1. This miRNA may be involved in the development and progression of CRC. target gene hsa-mir-145 Colorectal Carcinoma 25913620 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Tumor suppressor miR-145 reverses drug resistance by directly targeting DNA damage-related gene RAD18 in colorectal cancer. target gene hsa-mir-145 Colorectal Carcinoma 27572146 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-145 suppresses colorectal cancer cell migration and invasion by targeting an ETS-related gene. target gene hsa-mir-145 Colorectal Carcinoma 28534337 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-145 inhibits drug resistance to Oxaliplatin in colorectal cancer cells through regulating G protein coupled receptor 98. target gene hsa-mir-145 Colorectal Carcinoma 28802228 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MTDH and MAP3K1 are direct targets of apoptosis-regulating miRNAs in colorectal carcinoma target gene hsa-mir-146 Colorectal Carcinoma 29722931 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-146b-5p was shown to increase EMT by targeting Smad4, and the miR-146b-5p-Smad4 cascade regulated EMT in CRC target gene hsa-mir-146b Colorectal Carcinoma 28560062 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-146b-5p regulates cell growth, invasion, and metabolism by targeting PDHB in colorectal cancer. target gene hsa-mir-146b Colorectal Carcinoma 29722931 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-146b-5p was shown to increase EMT by targeting Smad4, and the miR-146b-5p-Smad4 cascade regulated EMT in CRC target gene hsa-mir-149 Colorectal Carcinoma 25613903 disease of cellular proliferation DOID:0080199 C19 D015179 114500 mR-149 was an independent prognostic factor and could inhibit migration and invasion of CRC cells, at least partially by targeting FOXM1. target gene hsa-mir-150 Colorectal Carcinoma 25230975 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-150 functions as a tumour suppressor in human colorectal cancer by targeting c-Myb. target gene hsa-mir-154 Colorectal Carcinoma 24242044 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-154 suppresses colorectal cancer cell growth and motility by targeting TLR2. target gene hsa-mir-155 Colorectal Carcinoma 29556299 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-155 acts as a tumor suppressor in colorectal cancer by targeting CTHRC1 in vitro target gene hsa-mir-155 Colorectal Carcinoma 24793496 disease of cellular proliferation DOID:0080199 C19 D015179 114500 We validate, for the first time, that E2F2 is a direct target of miR-155 using western blot and a luciferase reporter assay and that miR-155 regulates the proliferation and cell cycle of colorectal carcinoma cells by targeting E2F2 using siRNA technology. target gene hsa-mir-155 Colorectal Carcinoma 26340059 disease of cellular proliferation DOID:0080199 C19 D015179 114500 We further showed that miR-155 acted to repress the Warburg effect through the mechanism of inactivating the IL-6/STAT3 pathway. target gene hsa-mir-16 Colorectal Carcinoma 27857191 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Deregulation of the miR-16-KRAS axis promotes colorectal cancer. target gene hsa-mir-17 Colorectal Carcinoma 24912422 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-17-5p is a predictive factor for chemotherapy response and a prognostic factor for overall survival in CRC, which is due to its regulation of PTEN expression. target gene hsa-mir-181b Colorectal Carcinoma 27647131 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-181b functions as an oncomiR in colorectal cancer by targeting PDCD4. target gene hsa-mir-182 Colorectal Carcinoma 25738520 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-182 promotes cell growth and invasion by targeting forkhead box F2 transcription factor in colorectal cancer. target gene hsa-mir-182 Colorectal Carcinoma 28767179 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Upregulation of microRNA-135b and microRNA-182 promotes chemoresistance of colorectal cancer by targeting ST6GALNAC2 via PI3K/AKT pathway. target gene hsa-mir-185 Colorectal Carcinoma 25531324 disease of cellular proliferation DOID:0080199 C19 D015179 114500 expression of STIM1 is regulated by a posttranscriptional regulatory mechanism mediated by a new EMT-related miRNA. This novel miR-185-STIM1 axis promotes CRC metastasis and may be a candidate biomarker for prognosis and a target for new therapies. target gene hsa-mir-187 Colorectal Carcinoma 26820227 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-187, a downstream effector of TGFβ pathway, suppresses Smad-mediated epithelial-mesenchymal transition in colorectal cancer. target gene hsa-mir-18a Colorectal Carcinoma 26398009 disease of cellular proliferation DOID:0080199 C19 D015179 114500 These findings demonstrate that miR-18a exhibits a protective role in CRC via inhibiting proliferation, invasion and migration of CRC cells by directly targeting the TBPL1 gene. target gene hsa-mir-191 Colorectal Carcinoma 25784653 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-191 promotes tumorigenesis of human colorectal cancer through targeting C/EBPβ. target gene hsa-mir-193b Colorectal Carcinoma 22674437 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-199a-3p, microRNA-193b, and microRNA-320c are correlated to aging and regulate human cartilage metabolism. target gene hsa-mir-194 Colorectal Carcinoma 25285168 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-194 deregulation contributes to colorectal carcinogenesis via targeting AKT2 pathway. target gene hsa-mir-195 Colorectal Carcinoma 24787958 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-195 inhibits colorectal cancer cell proliferation, colony-formation and invasion through targeting CARMA3. target gene hsa-mir-195 Colorectal Carcinoma 28345460 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Coactivator-associated arginine methyltransferase 1 promotes cell growth and is targeted by microRNA-195-5p in human colorectal cancer. target gene hsa-mir-197 Colorectal Carcinoma 26055341 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-197 mediates the response of colorectal cancer cells to 5-FU by regulating TYMS expression. target gene hsa-mir-198 Colorectal Carcinoma 25174450 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-198 represses tumor growth and metastasis in colorectal cancer by targeting fucosyl transferase 8. target gene hsa-mir-199a Colorectal Carcinoma 24972723 disease of cellular proliferation DOID:0080199 C19 D015179 114500 NLK, a novel target of miR-199a-3p, functions as a tumor suppressor in colorectal cancer. target gene hsa-mir-199a Colorectal Carcinoma 25772759 disease of cellular proliferation DOID:0080199 C19 D015179 114500 FZD6 expression is negatively regulated by miR-199a-5p in human colorectal cancer. target gene hsa-mir-199a-1 Colorectal Carcinoma 22674437 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-199a-3p, microRNA-193b, and microRNA-320c are correlated to aging and regulate human cartilage metabolism. target gene hsa-mir-199a-2 Colorectal Carcinoma 22674437 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-199a-3p, microRNA-193b, and microRNA-320c are correlated to aging and regulate human cartilage metabolism. target gene hsa-mir-200b Colorectal Carcinoma 24151081 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-200b stimulates tumour growth in TGFBR2-null colorectal cancers by negatively regulating p27/kip1. target gene hsa-mir-200b Colorectal Carcinoma 25826661 disease of cellular proliferation DOID:0080199 C19 D015179 114500 microRNA-200b and microRNA-200c promote colorectal cancer cell proliferation via targeting the reversion-inducing cysteine-rich protein with Kazal motifs. target gene hsa-mir-200c Colorectal Carcinoma 25826661 disease of cellular proliferation DOID:0080199 C19 D015179 114500 microRNA-200b and microRNA-200c promote colorectal cancer cell proliferation via targeting the reversion-inducing cysteine-rich protein with Kazal motifs. target gene hsa-mir-200c Colorectal Carcinoma 27315529 disease of cellular proliferation DOID:0080199 C19 D015179 114500 ZEB1 expression was seen in connection with decreased miR-200c expression target gene hsa-mir-200c Colorectal Carcinoma 28543447 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Fas signaling induces stemness properties in colorectal cancer by regulation of Bmi1. target gene hsa-mir-203 Colorectal Carcinoma 24145123 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase. target gene hsa-mir-204 Colorectal Carcinoma 29402343 disease of cellular proliferation DOID:0080199 C19 D015179 114500 microRNA-204 inhibits the growth and motility of colorectal cancer cells by downregulation of CXCL8 target gene hsa-mir-205 Colorectal Carcinoma 28990808 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-205 Mediates Proteinase-Activated Receptor 2 (PAR2) -Promoted Cancer Cell Migration. target gene hsa-mir-20a Colorectal Carcinoma 28004114 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-20a-directed regulation of BID is associated with the TRAIL sensitivity in colorectal cancer. target gene hsa-mir-20b Colorectal Carcinoma 24468585 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer. target gene hsa-mir-21 Colorectal Carcinoma 24468585 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer. target gene hsa-mir-21 Colorectal Carcinoma 26419959 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Our data support a possible role of tumor epigenetic deregulation by noncoding RNA in suppressing the antitumor T-cell-mediated adaptive immune response and suggest MIR21 as a potential target for immunotherapy and prevention in colorectal cancer. target gene hsa-mir-21 Colorectal Carcinoma 26811607 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-21 increases the levels of IL-10 and prostaglandin E2, which suppress antitumor T-cell-mediated adaptive immunity target gene hsa-mir-21 Colorectal Carcinoma 27350731 disease of cellular proliferation DOID:0080199 C19 D015179 114500 PTEN is one of the direct target genes of miR-21. target gene hsa-mir-21 Colorectal Carcinoma 28347230 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Inhibition of microRNA-21 via locked nucleic acid-anti-miR suppressed metastatic features of colorectal cancer cells through modulation of programmed cell death 4. target gene hsa-mir-21 Colorectal Carcinoma 28957811 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-21 (Mir-21) Promotes Cell Growth and Invasion by Repressing Tumor Suppressor PTEN in Colorectal Cancer. target gene hsa-mir-215 Colorectal Carcinoma 25775580 disease of cellular proliferation DOID:0080199 C19 D015179 114500 The CDX1-microRNA-215 axis regulates colorectal cancer stem cell differentiation. target gene hsa-mir-215 Colorectal Carcinoma 26287603 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Identification of miR-215 mediated targets/pathways via translational immunoprecipitation expression analysis (TrIP-chip). target gene hsa-mir-218 Colorectal Carcinoma 27779719 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Downregulation of YEATS4 by miR-218 sensitizes colorectal cancer cells to L-OHP-induced cell apoptosis by inhibiting cytoprotective autophagy. target gene hsa-mir-22 Colorectal Carcinoma 28347238 disease of cellular proliferation DOID:0080199 C19 D015179 114500 The predicted target gene validation, function, and prognosis studies of miRNA-22 in colorectal cancer tissue. target gene hsa-mir-221 Colorectal Carcinoma 24269686 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-221 promotes colorectal cancer cell invasion and metastasis by targeting RECK. target gene hsa-mir-221 Colorectal Carcinoma 24931456 disease of cellular proliferation DOID:0080199 C19 D015179 114500 In human CRC cells, miR-221 and miR-222 act in a positive feedback loop to increase expression levels of RelA and STAT3. Antagonism of miR-221 and miR-222 reduces growth of colon tumors in mice with colitis. target gene hsa-mir-221 Colorectal Carcinoma 29434757 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-221 inhibits autophagy and targets TP53INP1 in colorectal cancer cells target gene hsa-mir-221 Colorectal Carcinoma 23688995 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Anti-miR-221 can enhance the radiosensitivity of colorectal carcinoma cells by up-regulating the expression of PTEN target gene hsa-mir-222 Colorectal Carcinoma 24931456 disease of cellular proliferation DOID:0080199 C19 D015179 114500 In human CRC cells, miR-221 and miR-222 act in a positive feedback loop to increase expression levels of RelA and STAT3. Antagonism of miR-221 and miR-222 reduces growth of colon tumors in mice with colitis. target gene hsa-mir-222 Colorectal Carcinoma 23173124 disease of cellular proliferation DOID:0080199 C19 D015179 114500 On the other hand, miR-222 targeting ADAM-17, a disintegrin and metalloproteinase, and miR-328 interacting with ABCG2, an ABC transporter, may overcome drug resistance of cancer cells. target gene hsa-mir-222 Colorectal Carcinoma 28855850 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-222 influences migration and invasion through MIA3 in colorectal cancer target gene hsa-mir-223 Colorectal Carcinoma 27916606 disease of cellular proliferation DOID:0080199 C19 D015179 114500 FBX8 is a metastasis suppressor downstream of miR-223 and targeting mTOR for degradation in colorectal carcinoma. target gene hsa-mir-224 Colorectal Carcinoma 24817781 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-224 suppresses colorectal cancer cell migration by targeting Cdc42. target gene hsa-mir-23a Colorectal Carcinoma 24992592 disease of cellular proliferation DOID:0080199 C19 D015179 114500 The involvement of miR-23a/APAF1 regulation axis in colorectal cancer. target gene hsa-mir-23a Colorectal Carcinoma 25929864 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Elevated microRNA-23a Expression Enhances the Chemoresistance of Colorectal Cancer Cells with Microsatellite Instability to 5-Fluorouracil by Directly Targeting ABCF1. target gene hsa-mir-23b Colorectal Carcinoma 28487386 disease of cellular proliferation DOID:0080199 C19 D015179 114500 our results define a critical function for miR-23b, which, by targeting LGR5, contributes to overpopulation of ALDH+ CSCs and colorectal cancer target gene hsa-mir-25 Colorectal Carcinoma 25174582 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Angiopoietin-like protein 2 negatively regulated by microRNA-25 contributes to the malignant progression of colorectal cancer. target gene hsa-mir-26a Colorectal Carcinoma 24935220 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-26a regulates glucose metabolism of colorectal cancer cells by direct targeting the PDHX, which inhibits the conversion of pyruvate to acetyl coenzyme A in the citric acid cycle. target gene hsa-mir-26a Colorectal Carcinoma 28443472 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-26a downregulates retinoblastoma in colorectal cancer. target gene hsa-mir-26a Colorectal Carcinoma 28640257 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Tumor-suppressive miR-26a and miR-26b inhibit cell aggressiveness by regulating FUT4 in colorectal cancer. target gene hsa-mir-26b Colorectal Carcinoma 23922874 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Nicotinamide phosphoribosyl transferase (Nampt) is a target of microRNA-26b in colorectal cancer cells. target gene hsa-mir-26b Colorectal Carcinoma 28640257 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Tumor-suppressive miR-26a and miR-26b inhibit cell aggressiveness by regulating FUT4 in colorectal cancer. target gene hsa-mir-27a Colorectal Carcinoma 25166914 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Tumor suppressor microRNA-27a in colorectal carcinogenesis and progression by targeting SGPP1 and Smad2. target gene hsa-mir-27a Colorectal Carcinoma 26913609 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-27a modulates a group of proteins involved in MHC class I cell surface exposure target gene hsa-mir-29a Colorectal Carcinoma 24281002 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Increased expression of miR-29a promoted CRC metastasis by regulating MMP2/E-cad through direct targeting KLF4, which highlights the potential of the miR-29a inhibitor as a novel agent against CRC metastasis. target gene hsa-mir-29a Colorectal Carcinoma 23173124 disease of cellular proliferation DOID:0080199 C19 D015179 114500 microRNA levels may serve as a predictive CRC marker, which was confirmed by the serum level of miR-29a targeting KLF4, a marker of cell stemness, and the plasma level of miR-221 down-regulating c-Kit, Stat5A and ETS1, which are signal transducers and transcription factor, respectively target gene hsa-mir-29b Colorectal Carcinoma 24913975 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-29b downregulates canonical Wnt signaling by suppressing coactivators of β-catenin in human colorectal cancer cells. target gene hsa-mir-29b Colorectal Carcinoma 25472644 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-29b may be a useful, novel,prognostic marker and may play important roles in regulating apoptosis and cell cycle in CRC. target gene hsa-mir-29b Colorectal Carcinoma 25592039 disease of cellular proliferation DOID:0080199 C19 D015179 114500 the potential signaling pathway,IFN-γ/IRF1/miR-29b/IGF1, and its implication for CRC tumorigenesis. A positive feedback loop between IRF1 and miR-29b may contribute to the sensitivity of CRC cells to IFN-γ. Targeting miR-29b may provide a strategy for blocking CRC growth and metastasis. target gene hsa-mir-29b Colorectal Carcinoma 25032858 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-29b suppresses tumor growth and metastasis in colorectal cancer via downregulating Tiam1 expression and inhibiting epithelial-mesenchymal transition. target gene hsa-mir-301a Colorectal Carcinoma 25551793 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-301a correlated with the metastatic and invasive ability in human colorectal cancers and miR-301a exerted its role as oncogene by targeting TGFBR2. target gene hsa-mir-302a Colorectal Carcinoma 26191138 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Up-regulation of microRNA-302a inhibited the proliferation and invasion of colorectal cancer cells by regulation of the MAPK and PI3K/Akt signaling pathways. target gene hsa-mir-30a Colorectal Carcinoma 27576787 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-30a-5p Suppresses Tumor Metastasis of Human Colorectal Cancer by Targeting ITGB3. target gene hsa-mir-30b Colorectal Carcinoma 24293274 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2. target gene hsa-mir-30b Colorectal Carcinoma 24593661 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-30b regulates migration and invasion of human colorectal cancer via SIX1. target gene hsa-mir-30c Colorectal Carcinoma 25799050 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Role of microRNA-30c targeting ADAM19 in colorectal cancer. target gene hsa-mir-31 Colorectal Carcinoma 24386467 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Elevated microRNA-31 expression regulates colorectal cancer progression by repressing its target gene SATB2. target gene hsa-mir-31 Colorectal Carcinoma 24521875 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-31 contributes to colorectal cancer development by targeting factor inhibiting HIF-1α (FIH-1). target gene hsa-mir-31 Colorectal Carcinoma 29463215 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-31 down-regulated c-MET in DLD-1 colon cancer cells target gene hsa-mir-320a Colorectal Carcinoma 24265291 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-320a suppresses colorectal cancer progression by targeting Rac1. target gene hsa-mir-320c-1 Colorectal Carcinoma 22674437 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-199a-3p, microRNA-193b, and microRNA-320c are correlated to aging and regulate human cartilage metabolism. target gene hsa-mir-320c-2 Colorectal Carcinoma 22674437 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-199a-3p, microRNA-193b, and microRNA-320c are correlated to aging and regulate human cartilage metabolism. target gene hsa-mir-331 Colorectal Carcinoma 26718987 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Overall, we identified that miR-331-3p is underexpressed in CRC and contributes to cell growth regulation by targeting HER2 through activating the PI3K/Akt and ERK1/2 signaling pathways. target gene hsa-mir-34a Colorectal Carcinoma 24370784 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-34a is frequently downregulated in CRC and modulates the phosphorylation of FAK by negatively regulating VEGF. target gene hsa-mir-34a Colorectal Carcinoma 26103003 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-34a targets FMNL2 and E2F5 and suppresses the progression of colorectal cancer. target gene hsa-mir-34a Colorectal Carcinoma 28348487 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-34a mediates oxaliplatin resistance of colorectal cancer cells by inhibiting macroautophagy via transforming growth factor-β/Smad4 pathway. target gene hsa-mir-34c Colorectal Carcinoma 25213795 disease of cellular proliferation DOID:0080199 C19 D015179 114500 KITLG is a novel target of miR-34c that is associated with the inhibition of growth and invasion in colorectal cancer cells. target gene hsa-mir-375 Colorectal Carcinoma 24440701 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-375 inhibits colorectal cancer growth by targeting PIK3CA. target gene hsa-mir-375 Colorectal Carcinoma 28374902 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Impact of microRNA-375 and its target gene SMAD-7 polymorphism on susceptibility of colorectal cancer. target gene hsa-mir-375 Colorectal Carcinoma 28802228 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MTDH and MAP3K1 are direct targets of apoptosis-regulating miRNAs in colorectal carcinoma target gene hsa-mir-409 Colorectal Carcinoma 25991585 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-409-3p suppresses colorectal cancer invasion and metastasis partly by targeting GAB1 expression. target gene hsa-mir-451 Colorectal Carcinoma 27612504 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Expression pattern of miR-451 and its target MIF (macrophage migration inhibitory factor) in colorectal cancer. target gene hsa-mir-454 Colorectal Carcinoma 25824771 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-454 prompts cell proliferation of human colorectal cancer cells by repressing CYLD expression. target gene hsa-mir-455 Colorectal Carcinoma 25355599 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-455 inhibits proliferation and invasion of colorectal cancer by targeting RAF proto-oncogene serine/threonine-protein kinase. target gene hsa-mir-487b Colorectal Carcinoma 28000854 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Identification of microRNA-487b as a negative regulator of liver metastasis by regulation of KRAS in colorectal cancer. target gene hsa-mir-497 Colorectal Carcinoma 26840372 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Thus our results provide evidence that miR-497 might function as a metastasis suppressor in CRC. Targeting miR-497 may provide a strategy for blocking its metastasis. target gene hsa-mir-506 Colorectal Carcinoma 26497367 disease of cellular proliferation DOID:0080199 C19 D015179 114500 In conclusion, our data showed that miR-124 and miR-506 inhibit progression and increase sensitivity to chemotherapy by targeting DNMT3B and DNMT1 in CRC. These findings may provide novel avenues for the development of targeted therapies. target gene hsa-mir-518a Colorectal Carcinoma 24559209 disease of cellular proliferation DOID:0080199 C19 D015179 114500 We have shown that miR-518a-5p functionally interacts with CCR6 and that transfection of CRC cells with miR-518a-5p leads to significant CCR6 down-regulation. Consequently, CCR6 expression is regulated by miR-518a-5p in CRC cells indicating that regulation of CCR6 expression by miR-518a-5p might be a regulatory mechanism involved in CRC pathogenesis. target gene hsa-mir-519c Colorectal Carcinoma 26386386 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer. target gene hsa-mir-522 Colorectal Carcinoma 29386092 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-522-3p promotes tumorigenesis in human colorectal cancer via targeting bloom syndrome protein. target gene hsa-mir-587 Colorectal Carcinoma 26247730 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-587 antagonizes 5-FU-induced apoptosis and confers drug resistance by regulating PPP2R1B expression in colorectal cancer. target gene hsa-mir-590 Colorectal Carcinoma 28433598 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-590-5p, a density-sensitive microRNA, inhibits tumorigenesis by targeting YAP1 in colorectal cancer. target gene hsa-mir-612 Colorectal Carcinoma 26158514 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-612 negatively regulates colorectal cancer growth and metastasis by targeting AKT2. target gene hsa-mir-622 Colorectal Carcinoma 25961730 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Radiation-induced microRNA-622 causes radioresistance in colorectal cancer cells by down-regulating Rb. target gene hsa-mir-630 Colorectal Carcinoma 26263387 disease of cellular proliferation DOID:0080199 C19 D015179 114500 CREB-miR-630-BCL2L2 and TP53RK comprise a novel signaling cascade regulating radiosensitivity in CRC cell lines by inducing cell apoptosis and death. target gene hsa-mir-646 Colorectal Carcinoma 29391877 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Low-level miR-646 in colorectal cancer inhibits cell proliferation and migration by targeting NOB1 expression target gene hsa-mir-892a Colorectal Carcinoma 26054685 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-892a regulated PPP2R2A expression and promoted cell proliferation of human colorectal cancer cells. target gene hsa-mir-96 Colorectal Carcinoma 25369914 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-96 promotes the proliferation of colorectal cancer cells and targets tumor protein p53 inducible nuclear protein 1, forkhead box protein O1 (FOXO1) and FOXO3a. target gene hsa-mir-96 Colorectal Carcinoma 25502560 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-96 may modulate 5-FU sensitivity in CRC cells by promoting apoptosis; however, differential expression of target genes in TSs warrants further studies on the 5-FU resistance mechanism under 3D conditions target gene hsa-mir-99b Colorectal Carcinoma 26259252 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miRNA-99b-5p suppresses liver metastasis of colorectal cancer by down-regulating mTOR. target gene hsa-let-7a-1 Colorectal Carcinoma 22018986 disease of cellular proliferation DOID:0080199 C19 D015179 114500 NIRF is frequently upregulated in colorectal cancer and its oncogenicity can be suppressed by let-7a microRNA. target gene hsa-let-7a-2 Colorectal Carcinoma 22018986 disease of cellular proliferation DOID:0080199 C19 D015179 114500 NIRF is frequently upregulated in colorectal cancer and its oncogenicity can be suppressed by let-7a microRNA. target gene hsa-let-7a-3 Colorectal Carcinoma 22018986 disease of cellular proliferation DOID:0080199 C19 D015179 114500 NIRF is frequently upregulated in colorectal cancer and its oncogenicity can be suppressed by let-7a microRNA. target gene hsa-let-7c Colorectal Carcinoma 21984339 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Let-7c functions as a metastasis suppressor by targeting MMP11 and PBX3 in colorectal cancer. target gene hsa-mir-1 Colorectal Carcinoma 24244701 disease of cellular proliferation DOID:0080199 C19 D015179 114500 The miR-1-NOTCH3-Asef pathway is important for colorectal tumor cell migration. target gene hsa-mir-103a-1 Colorectal Carcinoma 22593189 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-103/107 Promote Metastasis of Colorectal Cancer by Targeting the Metastasis Suppressors DAPK and KLF4. target gene hsa-mir-103a-2 Colorectal Carcinoma 22593189 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-103/107 Promote Metastasis of Colorectal Cancer by Targeting the Metastasis Suppressors DAPK and KLF4. target gene hsa-mir-103b-1 Colorectal Carcinoma 22593189 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-103/107 Promote Metastasis of Colorectal Cancer by Targeting the Metastasis Suppressors DAPK and KLF4. target gene hsa-mir-103b-2 Colorectal Carcinoma 22593189 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-103/107 Promote Metastasis of Colorectal Cancer by Targeting the Metastasis Suppressors DAPK and KLF4. target gene hsa-mir-106a Colorectal Carcinoma 22912877 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-106a inhibits the expression of transforming growth factor-beta receptor 2 (TGFBR2), leading to increased CRC cell migration and invasion. Importantly, miR-106a expression levels in primary CRCs are correlated with clinical cancer progression. target gene hsa-mir-107 Colorectal Carcinoma 22593189 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-103/107 Promote Metastasis of Colorectal Cancer by Targeting the Metastasis Suppressors DAPK and KLF4. target gene hsa-mir-124 Colorectal Carcinoma 24705396 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-124 Radiosensitizes human colorectal cancer cells by targeting PRRX1. target gene hsa-mir-124-1 Colorectal Carcinoma 22895557 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-124, miR-137 and miR-340 regulate colorectal cancer growth via inhibition of the Warburg effect. target gene hsa-mir-124-2 Colorectal Carcinoma 22895557 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-124, miR-137 and miR-340 regulate colorectal cancer growth via inhibition of the Warburg effect. target gene hsa-mir-126 Colorectal Carcinoma 25245095 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Selective targeting of KRAS-mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-mutant cells. target gene hsa-mir-128 Colorectal Carcinoma 26352220 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Taken together, these data suggested that miR-128 serves as a tumor suppressor and blocks CRC growth and metastasis by targeting IRS1. target gene hsa-mir-130a Colorectal Carcinoma 23393589 disease of cellular proliferation DOID:0080199 C19 D015179 114500 The Oncogenic Role of microRNA-130a/301a/454 in Human Colorectal Cancer via Targeting Smad4 Expression target gene hsa-mir-133a-1 Colorectal Carcinoma 23723074 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-133a activates the p53/p21 pathway and functions as a tumor suppressor in colorectal cancer by repressing RFFL. target gene hsa-mir-133a-2 Colorectal Carcinoma 23723074 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-133a activates the p53/p21 pathway and functions as a tumor suppressor in colorectal cancer by repressing RFFL. target gene hsa-mir-135a-1 Colorectal Carcinoma 18632633 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-135a: miR-135 family: Regulation of the adenomatous polyposis coli gene target gene hsa-mir-135a-2 Colorectal Carcinoma 18632633 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-135a: miR-135 family: Regulation of the adenomatous polyposis coli gene target gene hsa-mir-135b Colorectal Carcinoma 18632633 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-135b: miR-135 family: Regulation of the adenomatous polyposis coli gene target gene hsa-mir-135b Colorectal Carcinoma 23143558 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Estradiol regulates miR-135b and mismatch repair gene expressions via estrogen receptor-beta in colorectal cells target gene hsa-mir-137 Colorectal Carcinoma 22895557 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-124, miR-137 and miR-340 regulate colorectal cancer growth via inhibition of the Warburg effect. target gene hsa-mir-139 Colorectal Carcinoma 22580051 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type I insulin-like growth factor receptor. target gene hsa-mir-139 Colorectal Carcinoma 22642900 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Regulation of RAP1B by miR-139 suppresses human colorectal carcinoma cell proliferation. target gene hsa-mir-143 Colorectal Carcinoma 19137007 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-143 directly recognize the 3'-untranslated region of KRAS transcripts target gene hsa-mir-143 Colorectal Carcinoma 19638978 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. target gene hsa-mir-143 Colorectal Carcinoma 22533346 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-143 targets MACC1 to inhibit cell invasion and migration in colorectal cancer. target gene hsa-mir-143 Colorectal Carcinoma 22549179 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer. target gene hsa-mir-145 Colorectal Carcinoma 23499891 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Tumor-suppressive microRNA-145 targets catenin to regulate Wnt/beta-catenin signaling in human colon cancer cells target gene hsa-mir-145 Colorectal Carcinoma 25973017 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-145 suppresses cell migration and invasion by targeting paxillin in human colorectal cancer cells. target gene hsa-mir-148a Colorectal Carcinoma 21455217 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-148a promotes apoptosis by targeting Bcl-2 in colorectal cancer. target gene hsa-mir-148b Colorectal Carcinoma 22020560 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-148b suppresses cell growth by targeting cholecystokinin-2 receptor in colorectal cancer. target gene hsa-mir-155 Colorectal Carcinoma 26303353 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Thus, it is hypothesized that miR-155 may be a promising target for antagonizing COX-2 expression in colorectal and other cancers. target gene hsa-mir-16-1 Colorectal Carcinoma 23380758 disease of cellular proliferation DOID:0080199 C19 D015179 114500 microRNA-16 represses colorectal cancer cell growth in vitro by regulating the p53/survivin signaling pathway target gene hsa-mir-16-2 Colorectal Carcinoma 23380758 disease of cellular proliferation DOID:0080199 C19 D015179 114500 microRNA-16 represses colorectal cancer cell growth in vitro by regulating the p53/survivin signaling pathway target gene hsa-mir-17 Colorectal Carcinoma 22132820 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Up-regulated miR-17 promotes cell proliferation, tumor growth and cell cycle progression by targeting RND3 tumor suppressor gene in colorectal carcinoma. target gene hsa-mir-17 Colorectal Carcinoma 23250421 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Elevated oncofoetal miR-17-5p expression regulates colorectal cancer progression by repressing its target gene P130 target gene hsa-mir-185 Colorectal Carcinoma 21186079 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-185 targets RhoA and Cdc42 expression and inhibits the proliferation potential of human colorectal cells.miR-185 is a negative regulator of RhoA and Cdc42 and their cellular activities, and could inhibit proliferation and invasion of colorectal cancer target gene hsa-mir-186 Colorectal Carcinoma 23137536 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-186, miR-216b, miR-337-3p, and miR-760 cooperatively induce cellular senescence by targeting alpha subunit of protein kinase CKII in human colorectal cancer cells target gene hsa-mir-191 Colorectal Carcinoma 24195505 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-191 correlates with poor prognosis of colorectal carcinoma and plays multiple roles by targeting tissue inhibitor of metalloprotease 3. target gene hsa-mir-1915 Colorectal Carcinoma 22121083 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells. target gene hsa-mir-194-1 Colorectal Carcinoma 22028325 disease of cellular proliferation DOID:0080199 C19 D015179 114500 p53-responsive miR-194 inhibits thrombospondin-1 and promotes angiogenesis in colon cancers. target gene hsa-mir-194-2 Colorectal Carcinoma 22028325 disease of cellular proliferation DOID:0080199 C19 D015179 114500 p53-responsive miR-194 inhibits thrombospondin-1 and promotes angiogenesis in colon cancers. target gene hsa-mir-195 Colorectal Carcinoma 23526568 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-195 chemosensitizes colon cancer cells to the chemotherapeutic drug doxorubicin by targeting the first binding site of BCL2L2 mRNA target gene hsa-mir-196a-1 Colorectal Carcinoma 23138850 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-186, miR-216b, miR-337-3p, and miR-760 cooperatively induce cellular senescence by targeting alpha subunit of protein kinase CKII in human colorectal cancer cells target gene hsa-mir-196a-2 Colorectal Carcinoma 23138850 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-186, miR-216b, miR-337-3p, and miR-760 cooperatively induce cellular senescence by targeting alpha subunit of protein kinase CKII in human colorectal cancer cells target gene hsa-mir-200a Colorectal Carcinoma 25818799 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-200a plays a role in regulating the invasiveness and metastasis of CRC, and overexpression of miR-200a causes a significant reduction of cell proliferation and migration and promotes apoptosis and cell-cell adhesion in LoVo cells. target gene hsa-mir-200c Colorectal Carcinoma 24658157 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Our findings indicate that miR-200c regulates Sox2 expression through a feedback loop and is associated with CRC stemness, growth, and metastasis. target gene hsa-mir-200c Colorectal Carcinoma 22407310 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-200c inhibits invasion and migration in human colon cancer cells SW480/620 by targeting ZEB1.miR-200c inhibits metastatic ability by targeting ZEB1 in colon cancer cells SW480/620 and suggested that modulation of miR-200c could serve as therapeutic to target gene hsa-mir-202 Colorectal Carcinoma 24327274 disease of cellular proliferation DOID:0080199 C19 D015179 114500 microRNA-202-3p inhibits cell proliferation by targeting ADP-ribosylation factor-like 5A in human colorectal carcinoma. target gene hsa-mir-20a Colorectal Carcinoma 21242194 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines. target gene hsa-mir-21 Colorectal Carcinoma 21546206 disease of cellular proliferation DOID:0080199 C19 D015179 114500 This study demonstrates the inverse relationship between miR-21 and PDCD4, thus suggesting that miR-21 post-transcriptionally modulates PDCD4 via mRNA degradation. Pharmacological manipulation of the miR-21/PDCD4 axis could represent a novel therapeutic strategy in the treatment of colorectal cancer. target gene hsa-mir-21 Colorectal Carcinoma 21872591 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-21 targets the tumor suppressor RhoB and regulates proliferation, invasion and apoptosis in colorectal cancer cells. target gene hsa-mir-21 Colorectal Carcinoma 22099878 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-21 functionally interacts with the 3'UTR of chemokine CCL20 and down-regulates CCL20 expression in miR-21 transfected colorectal cancer cells. target gene hsa-mir-21 Colorectal Carcinoma 22267128 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Significant inverse correlations were demonstrated between PDCD4 and miR-21. target gene hsa-mir-21 Colorectal Carcinoma 23174819 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-21 regulates biological behavior through the PTEN/PI-3 K/Akt signaling pathway in human colorectal cancer cells target gene hsa-mir-21 Colorectal Carcinoma 23817679 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-21 and its target gene CCL20 are both highly overexpressed in the microenvironment of colorectal tumors: significance of their regulation. target gene hsa-mir-211 Colorectal Carcinoma 22235338 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-211 expression promotes colorectal cancer cell growth in vitro and in vivo by targeting tumor suppressor CHD5. target gene hsa-mir-216b Colorectal Carcinoma 23137536 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-186, miR-216b, miR-337-3p, and miR-760 cooperatively induce cellular senescence by targeting alpha subunit of protein kinase CKII in human colorectal cancer cells target gene hsa-mir-22 Colorectal Carcinoma 21594648 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells. target gene hsa-mir-221 Colorectal Carcinoma 24409057 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Anti-miR-221 can enhance the radiosensitivity of CRC cells by upregulating PTEN. target gene hsa-mir-221 Colorectal Carcinoma 21278784 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-221 inhibits CDKN1C/p57 expression in human colorectal carcinoma. target gene hsa-mir-221 Colorectal Carcinoma 21538272 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-221 controls CDKN1C/P57 expression in human colorectal carcinoma target gene hsa-mir-222 Colorectal Carcinoma 22677042 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-222 modulates multidrug resistance in human colorectal carcinoma by down-regulating ADAM-17. target gene hsa-mir-23a Colorectal Carcinoma 22455847 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-23a expression promotes colon carcinoma cell growth, invasion and metastasis through inhibition of MTSS gene. target gene hsa-mir-25 Colorectal Carcinoma 23435373 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-25 functions as a potential tumor suppressor in colon cancer by targeting Smad7 target gene hsa-mir-27a Colorectal Carcinoma 23471840 disease of cellular proliferation DOID:0080199 C19 D015179 114500 The drug resistance suppression induced by curcuminoids in colon cancer SW-480 cells is mediated by reactive oxygen species-induced disruption of the microRNA-27a-ZBTB10-Sp axis target gene hsa-mir-297 Colorectal Carcinoma 22676135 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2. target gene hsa-mir-29c Colorectal Carcinoma 25193986 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Our findings highlight the important role of miR-29c in regulating CRC EMT via GSK-3β/β-catenin signaling by targeting GNA13 and PTP4A and provide new insights into the metastatic basis of CRC. target gene hsa-mir-301a Colorectal Carcinoma 23393589 disease of cellular proliferation DOID:0080199 C19 D015179 114500 The Oncogenic Role of microRNA-130a/301a/454 in Human Colorectal Cancer via Targeting Smad4 Expression target gene hsa-mir-30a Colorectal Carcinoma 23486085 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-30a Suppresses Cell Migration and Invasion Through Downregulation of PIK3CD in Colorectal Carcinoma target gene hsa-mir-31 Colorectal Carcinoma 23322774 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-31 activates the Ras pathway and functions as an oncogenic microRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1(RASA1). target gene hsa-mir-320a Colorectal Carcinoma 22134529 disease of cellular proliferation DOID:0080199 C19 D015179 114500 microRNA-320a inhibits tumor invasion by targeting neuropilin 1 and is associated with liver metastasis in colorectal cancer. target gene hsa-mir-320a Colorectal Carcinoma 22459450 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-320a suppresses human colon cancer cell proliferation by directly targeting beta-catenin. target gene hsa-mir-328 Colorectal Carcinoma 22453125 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA expression profiling identifies miR-328 regulates cancer stem cell-like SP cells in colorectal cancer. target gene hsa-mir-330 Colorectal Carcinoma 23337504 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-330 regulates the proliferation of colorectal cancer cells by targeting Cdc42 target gene hsa-mir-337 Colorectal Carcinoma 23137536 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-186, miR-216b, miR-337-3p, and miR-760 cooperatively induce cellular senescence by targeting alpha subunit of protein kinase CKII in human colorectal cancer cells target gene hsa-mir-339 Colorectal Carcinoma 23696794 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-339-5p Regulates the Growth, Colony Formation and Metastasis of Colorectal Cancer Cells by Targeting PRL-1. target gene hsa-mir-340 Colorectal Carcinoma 22895557 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-124, miR-137 and miR-340 regulate colorectal cancer growth via inhibition of the Warburg effect. target gene hsa-mir-342 Colorectal Carcinoma 21565830 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-342 Inhibits Colorectal Cancer Cell Proliferation and Invasion by Directly Targeting DNA Methyltransferase 1. target gene hsa-mir-34b Colorectal Carcinoma 21329882 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MK5 regulates translation of Myc, since it is required for expression of miR-34b and miR-34c that bind to the 3'UTR of MYC. MK5 activates miR-34b/c expression via phosphorylation of FoxO3a, thereby promoting nuclear localization of FoxO3a and enabling it target gene hsa-mir-34c Colorectal Carcinoma 21329882 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MK5 regulates translation of Myc, since it is required for expression of miR-34b and miR-34c that bind to the 3'UTR of MYC. MK5 activates miR-34b/c expression via phosphorylation of FoxO3a, thereby promoting nuclear localization of FoxO3a and enabling it target gene hsa-mir-361 Colorectal Carcinoma 25965817 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-361-5p inhibits colorectal and gastric cancer growth and metastasis by targeting staphylococcal nuclease domain containing-1. target gene hsa-mir-362 Colorectal Carcinoma 23280316 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiRNA-362-3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancer target gene hsa-mir-363 Colorectal Carcinoma 24452072 disease of cellular proliferation DOID:0080199 C19 D015179 114500 The miR-363-GATA6-Lgr5 pathway is critical for colorectal tumourigenesis. target gene hsa-mir-429 Colorectal Carcinoma 24402783 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-429 inhibits cells growth and invasion and regulates EMT-related marker genes by targeting Onecut2 in colorectal carcinoma. target gene hsa-mir-429 Colorectal Carcinoma 23111103 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MiR-429 is an independent prognostic factor in colorectal cancer and exerts its anti-apoptotic function by targeting SOX2 target gene hsa-mir-454 Colorectal Carcinoma 23393589 disease of cellular proliferation DOID:0080199 C19 D015179 114500 The Oncogenic Role of microRNA-130a/301a/454 in Human Colorectal Cancer via Targeting Smad4 Expression target gene hsa-mir-491 Colorectal Carcinoma 20039318 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-491:Functional screening identifies a microRNA, miR-491 that induces apoptosis by targeting Bcl-X(L) in colorectal cancer cells target gene hsa-mir-497 Colorectal Carcinoma 22710713 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer. target gene hsa-mir-499a Colorectal Carcinoma 21934092 disease of cellular proliferation DOID:0080199 C19 D015179 114500 microRNA-499-5p promotes cellular invasion and tumor metastasis in colorectal cancer by targeting FOXO4 and PDCD4. target gene hsa-mir-574 Colorectal Carcinoma 22490519 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-574-5p negatively regulates Qki6/7 to impact ж┿catenin/Wnt signalling and the development of colorectal cancer. target gene hsa-mir-638 Colorectal Carcinoma 24885288 disease of cellular proliferation DOID:0080199 C19 D015179 114500 These results demonstrate that the loss of miR-638 promotes invasion and a mesenchymal-like transition by directly targeting SOX2 in vitro. These findings define miR-638 as a new,invasion-associated tumor suppressor of CRC. target gene hsa-mir-638 Colorectal Carcinoma 25301729 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-638 inhibits cell proliferation, invasion and regulates cell cycle by targeting tetraspanin 1 in human colorectal carcinoma. target gene hsa-mir-7-1 Colorectal Carcinoma 23208495 disease of cellular proliferation DOID:0080199 C19 D015179 114500 microRNA-7 is a novel inhibitor of YY1 contributing to colorectal tumorigenesis target gene hsa-mir-7-2 Colorectal Carcinoma 23208495 disease of cellular proliferation DOID:0080199 C19 D015179 114500 microRNA-7 is a novel inhibitor of YY1 contributing to colorectal tumorigenesis target gene hsa-mir-7-3 Colorectal Carcinoma 23208495 disease of cellular proliferation DOID:0080199 C19 D015179 114500 microRNA-7 is a novel inhibitor of YY1 contributing to colorectal tumorigenesis target gene hsa-mir-760 Colorectal Carcinoma 23137536 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-186, miR-216b, miR-337-3p, and miR-760 cooperatively induce cellular senescence by targeting alpha subunit of protein kinase CKII in human colorectal cancer cells target gene hsa-mir-93 Colorectal Carcinoma 22581829 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-93 inhibits tumor growth and early relapse of human colorectal cancer by affecting genes involved in the cell cycle. target gene hsa-mir-95 Colorectal Carcinoma 21427358 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-95 Promotes Cell Proliferation and Targets Sorting Nexin 1 in Human Colorectal Carcinoma. target gene hsa-mir-34a Complex Regional Pain Syndrome 26940669 nervous system disease DOID:3223 G90.50 D020918 We show that hsa-miR-34a is a negative regulator of CRHR1; overexpression of hsa-miR-34a in Jurkat cells resulted in reduction of CRH-mediated POMC expression. target gene hsa-mir-10a Congenital Heart Diseases 24714979 cardiovascular system disease DOID:1682 Q24 D006330 617912 HP:0030680 In conclusion, the study results indicate that miR-10a and miR-10b inhibit TBX5 expression at the level of translation. Higher levels of miR-10a and miR-10b expression are associated with a higher risk of congenital heart defects. target gene hsa-mir-10b Congenital Heart Diseases 24714979 cardiovascular system disease DOID:1682 Q24 D006330 617912 HP:0030680 In conclusion, the study results indicate that miR-10a and miR-10b inhibit TBX5 expression at the level of translation. Higher levels of miR-10a and miR-10b expression are associated with a higher risk of congenital heart defects. target gene hsa-mir-181a Congenital Heart Diseases 20884876 cardiovascular system disease DOID:1682 Q24 D006330 617912 HP:0030680 We showed that Dicer loss of function was, at least in part, mediated by miRNA-21 (miR-21) and miRNA-181a (miR-181a), which in turn repressed the protein level of Sprouty 2, an inhibitor of Erk1/2 signaling. target gene hsa-mir-21 Congenital Heart Diseases 20884876 cardiovascular system disease DOID:1682 Q24 D006330 617912 HP:0030680 We showed that Dicer loss of function was, at least in part, mediated by miRNA-21 (miR-21) and miRNA-181a (miR-181a), which in turn repressed the protein level of Sprouty 2, an inhibitor of Erk1/2 signaling. target gene hsa-mir-34a Congenital Heart Diseases 29175286 cardiovascular system disease DOID:1682 Q24 D006330 617912 HP:0030680 miR-34a increases the risk of CHD through its downregulation of NOTCH-1 by modulating the Notch signaling pathway target gene hsa-mir-124 Congenital Hypothyroidism 29805523 endocrine system disease DOID:0050328 E00.1 D003409 PS275200 HP:0000851 microRNA-124-3p inhibits the progression of congenital hypothyroidism via targeting programmed cell death protein 6. target gene hsa-mir-185 Congenital Microtia 26282502 Q17.2 D065817 251800 The expression of has-miR-203, has-miR-200c and has-miR-451 were significantly different in microtia. Target gene of SOCS3, TFs of STAT1 and STAT2, and lncRNA of MALAT1 may play important roles in the development of the external ear. target gene hsa-mir-200c Congenital Microtia 26282502 Q17.2 D065817 251800 The expression of has-miR-203, has-miR-200c and has-miR-451 were significantly different in microtia. Target gene of SOCS3, TFs of STAT1 and STAT2, and lncRNA of MALAT1 may play important roles in the development of the external ear. target gene hsa-mir-203 Congenital Microtia 26282502 Q17.2 D065817 251800 The expression of has-miR-203, has-miR-200c and has-miR-451 were significantly different in microtia. Target gene of SOCS3, TFs of STAT1 and STAT2, and lncRNA of MALAT1 may play important roles in the development of the external ear. target gene hsa-mir-451 Congenital Microtia 26282502 Q17.2 D065817 251800 The expression of has-miR-203, has-miR-200c and has-miR-451 were significantly different in microtia. Target gene of SOCS3, TFs of STAT1 and STAT2, and lncRNA of MALAT1 may play important roles in the development of the external ear. target gene hsa-mir-206 Congenital Myasthenic Syndrome 25765662 musculoskeletal system disease DOID:3635 G70.2 D020294 PS610542 Our data demonstrate that the c.*22C>A mutation in the GFPT1 gene leads to illegitimate binding of microRNA resulting in reduced protein expression. We confirm that c.*22C>A is a causative mutation and suggest that formation of microRNA target sites might be a relevant pathomechanism in Mendelian disorders. Variants in the 3'-UTRs should be considered in genetic diagnostic procedures. target gene hsa-mir-146a Cor Pulmonale 29667303 cardiovascular system disease DOID:8515 I27.81 D011660 HP:0001648 miR-146a can negatively feedback regulate PM1 -induced inflammation via NF-κB signaling pathway in BEAS-2B cells target gene hsa-let-7i Coronary Artery Disease 21899916 cardiovascular system disease DOID:3393 I20-I25 D003324 608320 This study suggests that atorvastatin down-regulates TLR4 signal via let-7i expression in CAD patients, possibly contributing to the beneficial effects of atorvastatin on let-7i-mediated TLR4 signal in this disorder. target gene hsa-mir-1 Coronary Artery Disease 22883088 cardiovascular system disease DOID:3393 I20-I25 D003324 608320 Association study on the microRNA-1 target gene polymorphism and the risk of premature coronary artery disease target gene hsa-mir-154 Coronary Artery Disease 24913032 cardiovascular system disease DOID:3393 I20-I25 D003324 608320 miR-545-TFEC and miR-585-SPOCK1 were highly positively correlated (ρ = 0.808091264; ρ = 0.874680776) in CAD samples.Therefore, differentially expressed miRNAs might participate in the pathogenesis of CAD by regulating their target genes. target gene hsa-mir-15b Coronary Artery Disease 28254819 cardiovascular system disease DOID:3393 I20-I25 D003324 608320 MiR-15b-5p Regulates Collateral Artery Formation by Targeting AKT3 (Protein Kinase B-3). target gene hsa-mir-17 Coronary Artery Disease 24913032 cardiovascular system disease DOID:3393 I20-I25 D003324 608320 miR-545-TFEC and miR-585-SPOCK1 were highly positively correlated (ρ = 0.808091264; ρ = 0.874680776) in CAD samples.Therefore, differentially expressed miRNAs might participate in the pathogenesis of CAD by regulating their target genes. target gene hsa-mir-199a Coronary Artery Disease 24913032 cardiovascular system disease DOID:3393 I20-I25 D003324 608320 miR-545-TFEC and miR-585-SPOCK1 were highly positively correlated (ρ = 0.808091264; ρ = 0.874680776) in CAD samples.Therefore, differentially expressed miRNAs might participate in the pathogenesis of CAD by regulating their target genes. target gene hsa-mir-206 Coronary Artery Disease 26175229 cardiovascular system disease DOID:3393 I20-I25 D003324 608320 Role of the microRNA, miR-206, and its target PIK3C2α in endothelial progenitor cell function – potential link with coronary artery disease. target gene hsa-mir-21 Coronary Artery Disease 26383248 cardiovascular system disease DOID:3393 I20-I25 D003324 608320 Because the smad7 expression pattern was similar to that of TGF-β,our study suggests that miR-21 can negatively regulate the frequency of circulating Treg cells through a TGF-β1/smad-independent signaling pathway in PBMCs. target gene hsa-mir-22 Coronary Artery Disease 27537567 cardiovascular system disease DOID:3393 I20-I25 D003324 608320 miR-22 contributes to the pathogenesis of patients with coronary artery disease by targeting MCP-1: An observational study. target gene hsa-mir-221 Coronary Artery Disease 23333386 cardiovascular system disease DOID:3393 I20-I25 D003324 608320 Overall, these findings demonstrate that miR-221 affects the MEK/ERK pathway by targeting PAK1 to inhibit the proliferation of EPCs. target gene hsa-mir-221 Coronary Artery Disease 25236949 cardiovascular system disease DOID:3393 I20-I25 D003324 608320 Overexpression of miR-221 and miR-222 resulted in the reduction of genes involved in hypoxia response, metabolism, TGF-beta signalling, and cell motion. target gene hsa-mir-222 Coronary Artery Disease 25236949 cardiovascular system disease DOID:3393 I20-I25 D003324 608320 Overexpression of miR-221 and miR-222 resulted in the reduction of genes involved in hypoxia response, metabolism, TGF-beta signalling, and cell motion. target gene hsa-mir-223 Coronary Artery Disease 26221610 cardiovascular system disease DOID:3393 I20-I25 D003324 608320 our recent data demonstrated that the level of both intraplatelet and circulating miR-223 is an independent predictor for HTPR, thus providing a link between miR-223 and MACE. These lines of evidence indicate that miR-223 may serve as a potential regulatory target for HTPR, as well as a diagnostic tool for identification of HTPR in clinical settings. target gene hsa-mir-339 Coronary Artery Disease 24913032 cardiovascular system disease DOID:3393 I20-I25 D003324 608320 miR-545-TFEC and miR-585-SPOCK1 were highly positively correlated (ρ = 0.808091264; ρ = 0.874680776) in CAD samples.Therefore, differentially expressed miRNAs might participate in the pathogenesis of CAD by regulating their target genes. target gene hsa-mir-340 Coronary Artery Disease 24913032 cardiovascular system disease DOID:3393 I20-I25 D003324 608320 miR-545-TFEC and miR-585-SPOCK1 were highly positively correlated (ρ = 0.808091264; ρ = 0.874680776) in CAD samples.Therefore, differentially expressed miRNAs might participate in the pathogenesis of CAD by regulating their target genes. target gene hsa-mir-34a Coronary Artery Disease 22364258 cardiovascular system disease DOID:3393 I20-I25 D003324 608320 MicroRNA-34a regulates the longevity-associated protein, SIRT1, in coronary artery disease. target gene hsa-mir-451 Coronary Artery Disease 24913032 cardiovascular system disease DOID:3393 I20-I25 D003324 608320 miR-545-TFEC and miR-585-SPOCK1 were highly positively correlated (ρ = 0.808091264; ρ = 0.874680776) in CAD samples.Therefore, differentially expressed miRNAs might participate in the pathogenesis of CAD by regulating their target genes. target gene hsa-mir-454 Coronary Artery Disease 24913032 cardiovascular system disease DOID:3393 I20-I25 D003324 608320 miR-545-TFEC and miR-585-SPOCK1 were highly positively correlated (ρ = 0.808091264; ρ = 0.874680776) in CAD samples.Therefore, differentially expressed miRNAs might participate in the pathogenesis of CAD by regulating their target genes. target gene hsa-mir-526b Coronary Artery Disease 24247647 cardiovascular system disease DOID:3393 I20-I25 D003324 608320 The miRNA-526b is significantly upregulated in patients with CAD and the target gene of miRNA-526b participates in the VEGF signaling pathway. Whether or not the miRNA-526b can be used as a biomarker remains to be elucidated in a larger prospective study. target gene hsa-mir-545 Coronary Artery Disease 24913032 cardiovascular system disease DOID:3393 I20-I25 D003324 608320 miR-545-TFEC and miR-585-SPOCK1 were highly positively correlated (ρ = 0.808091264; ρ = 0.874680776) in CAD samples.Therefore, differentially expressed miRNAs might participate in the pathogenesis of CAD by regulating their target genes. target gene hsa-mir-585 Coronary Artery Disease 24913032 cardiovascular system disease DOID:3393 I20-I25 D003324 608320 miR-545-TFEC and miR-585-SPOCK1 were highly positively correlated (ρ = 0.808091264; ρ = 0.874680776) in CAD samples.Therefore, differentially expressed miRNAs might participate in the pathogenesis of CAD by regulating their target genes. target gene hsa-mir-624 Coronary Artery Disease 24913032 cardiovascular system disease DOID:3393 I20-I25 D003324 608320 miR-545-TFEC and miR-585-SPOCK1 were highly positively correlated (ρ = 0.808091264; ρ = 0.874680776) in CAD samples.Therefore, differentially expressed miRNAs might participate in the pathogenesis of CAD by regulating their target genes. target gene hsa-mir-939 Coronary Artery Disease 28115160 cardiovascular system disease DOID:3393 I20-I25 D003324 608320 MicroRNA-939 governs vascular integrity and angiogenesis through targeting γ-catenin in endothelial cells. target gene hsa-mir-125a Coronary Atherosclerosis 24877885 I25.1 D003324 HP:0004929 We focused on the human coronary arteries with atherosclerotic plaques. The expression of ET-1, as well as its upstream miRNAs, was determined. Unlikeany of previous study regarding miRNAs expression, we could exclude the discrepancy of artery-bed-specific miRNA expression. Besides, our data indicated,to some degree, that ET-1 might play a more vital role than Ang II in coronary atherosclerosis. target gene hsa-mir-155 Coronary Atherosclerosis 24877885 I25.1 D003324 HP:0004929 We focused on the human coronary arteries with atherosclerotic plaques. The expression of ET-1, as well as its upstream miRNAs, was determined. Unlikeany of previous study regarding miRNAs expression, we could exclude the discrepancy of artery-bed-specific miRNA expression. Besides, our data indicated,to some degree, that ET-1 might play a more vital role than Ang II in coronary atherosclerosis. target gene hsa-mir-199a Coronary Atherosclerosis 24877885 I25.1 D003324 HP:0004929 We focused on the human coronary arteries with atherosclerotic plaques. The expression of ET-1, as well as its upstream miRNAs, was determined. Unlikeany of previous study regarding miRNAs expression, we could exclude the discrepancy of artery-bed-specific miRNA expression. Besides, our data indicated,to some degree, that ET-1 might play a more vital role than Ang II in coronary atherosclerosis. target gene hsa-mir-199b Coronary Atherosclerosis 24877885 I25.1 D003324 HP:0004929 We focused on the human coronary arteries with atherosclerotic plaques. The expression of ET-1, as well as its upstream miRNAs, was determined. Unlikeany of previous study regarding miRNAs expression, we could exclude the discrepancy of artery-bed-specific miRNA expression. Besides, our data indicated,to some degree, that ET-1 might play a more vital role than Ang II in coronary atherosclerosis. target gene hsa-mir-21 Coronary Atherosclerosis 24594117 I25.1 D003324 HP:0004929 miR-21 might be a biomarker for plaque instability by suppressing target gene RECK to promote the expression and secretion of MMP-9 in macrophages. target gene hsa-mir-146a Coronavirus Infections 29702211 B34.2 D018352 miR-146a-5p promotes replication of infectious bronchitis virus by targeting IRAK2 and TNFRSF18. target gene hsa-mir-122 Crohn Disease 23872065 gastrointestinal system disease DOID:8778 K50 D003424 266600 HP:0100280 miR-122 targets NOD2 to decrease intestinal epithelial cell injury in Crohn's disease. target gene hsa-mir-143 Crohn Disease 29562274 gastrointestinal system disease DOID:8778 K50 D003424 266600 HP:0100280 MicroRNA-143 Targets ATG2B to Inhibit Autophagy and Increase Inflammatory Responses in Crohn's Disease target gene hsa-mir-192 Crohn Disease 24297055 gastrointestinal system disease DOID:8778 K50 D003424 266600 HP:0100280 Overexpression of miR-192, miR-495, miR-512, and miR-671 suppressed NOD2 expression, muramyl dipeptide-mediated NF-魏B activation, and messenger RNA expressions of interleukin-8 and CXCL3 in HCT116 cells. target gene hsa-mir-27b Cryptosporidium infection 22615562 disease by infectious agent DOID:1733 A07.2 D003457 miR-27b targets KSRP to coordinate TLR4-mediated epithelial defense against Cryptosporidium parvum infection. target gene hsa-mir-125b Cutaneous Melanoma 24762088 disease of cellular proliferation DOID:8923 C43 C562393 PS155600 HP:0012056 Our results confirm the theory that miR-125b functions as a tumour supressor in cutaneous malignant melanoma by regulating cellular senescence,which is one of the central mechanisms protecting against the development and progression of malignant melanoma. target gene hsa-mir-4262 Cutaneous Melanoma 27779691 disease of cellular proliferation DOID:8923 C43 C562393 PS155600 HP:0012056 miR-4262 promotes the proliferation of human cutaneous malignant melanoma cells through KLF6-mediated EGFR inactivation and p21 upregulation. target gene hsa-mir-132 Dementia 22895706 disease of mental health DOID:1307 F03 D003704 127750 HP:0000726 TMEM106B, the Risk Gene for Frontotemporal Dementia, Is Regulated by the microRNA-132/212 Cluster and Affects Progranulin Pathways. target gene hsa-mir-21 Dementia 21170291 disease of mental health DOID:1307 F03 D003704 127750 HP:0000726 MicroRNA-21 dysregulates the expression of MEF2C in neurons in monkey and human SIV/HIV neurological disease. target gene hsa-mir-212 Dementia 22895706 disease of mental health DOID:1307 F03 D003704 127750 HP:0000726 TMEM106B, the Risk Gene for Frontotemporal Dementia, Is Regulated by the microRNA-132/212 Cluster and Affects Progranulin Pathways. target gene hsa-mir-301a Demyelinating Diseases 22517757 nervous system disease DOID:3213 G37.9 D003711 118200 Both in vivo and in vitro, myelin antigen stimulation resulted in significant up-regulation of miR-301a, miR-21, and miR-155. miR-301a has a role in regulating the function of myelin-reactive T-helper type 17 cells, supporting a role for miR-301a as candidate for therapeutic targets for controlling of autoimmune demyelination. target gene hsa-let-7e Dengue Shock Syndrome 29768655 disease by infectious agent DOID:0050125 Let-7e inhibits TNF-α expression by targeting the methyl transferase EZH2 in DENV2-infected THP-1 cells. target gene hsa-mir-133a Dengue Virus Infection 26818704 disease by infectious agent DOID:12205 A90 D003715 614371 miRNA-133a regulates DENV replication possibly through the modulation of a host factor such as PTB. Further investigations are needed to verify whether miRNA-133a has an anti-DENV effect in vivo. target gene hsa-mir-147 Dengue Virus Infection 21810247 disease by infectious agent DOID:12205 A90 D003715 614371 a microRNA which may negatively regulate pro-inflammatory cytokines in dengue infected peripheral blood cells, mIR-147 (NMES1). target gene hsa-mir-146a Dermatomyositis 27889748 integumentary system disease DOID:10223 M33 D003882 MiR-146a Regulates Inflammatory Infiltration by Macrophages in Polymyositis/Dermatomyositis by Targeting TRAF6 and Affecting IL-17/ICAM-1 Pathway. target gene hsa-mir-205 Dermatomyositis 24525843 integumentary system disease DOID:10223 M33 D003882 miR-205 down-regulation promotes proliferation of dermatofibrosarcoma protuberans tumor cells by regulating LRP-1 and ERK phosphorylation. target gene hsa-mir-1 Diabetes Mellitus 24394957 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 miRNA-1 regulates endothelin-1 in diabetes. target gene hsa-mir-126 Diabetes Mellitus 22525256 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 Downregulation of microRNA-126 in endothelial progenitor cells from diabetes patients, impairs their functional properties, via target gene Spred-1. target gene hsa-mir-126 Diabetes Mellitus 27127202 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 low miR-126 levels to be associated with markedly increased TF protein and TF-mediated thrombogenicity. target gene hsa-mir-126 Diabetes Mellitus 28598282 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 MicroRNA-126 Regulates Inflammatory Cytokine Secretion in Human Gingival Fibroblasts Under High Glucose via Targeting Tumor Necrosis Factor Receptor Associated Factor 6. target gene hsa-mir-130a Diabetes Mellitus 23874686 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 Downregulation of microRNA-130a contributes to endothelial progenitor cell dysfunction in diabetic patients via its target Runx3. target gene hsa-mir-133a Diabetes Mellitus 27411382 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 Our results revealed that miR-133a mimic treatment improved the contractility of the diabetic rat's heart concomitant with upregulation of TH, cardiac NE, 尾-AR, and downregulation of TAT and plasma levels of NE. target gene hsa-mir-146a Diabetes Mellitus 28301595 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 miR-146a regulates glucose induced upregulation of inflammatory cytokines extracellular matrix proteins in the retina and kidney in diabetes. target gene hsa-mir-146b Diabetes Mellitus 25815338 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 MicroRNA-146b-3p regulates retinal inflammation by suppressing adenosine deaminase-2 in diabetes. target gene hsa-mir-17 Diabetes Mellitus 26858253 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 In fact, miR-17 knockdown was able to mimic the IFN纬 effects on TXNIP, whereas miR-17 overexpression blunted the cytokine effect. target gene hsa-mir-185 Diabetes Mellitus 25658748 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 MicroRNA-185 targets SOCS3 to inhibit beta-cell dysfunction in diabetes. target gene hsa-mir-19a Diabetes Mellitus 27666763 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 MicroRNA-19a-3p enhances the proliferation and insulin secretion, while it inhibits the apoptosis of pancreatic β cells via the inhibition of SOCS3. target gene hsa-mir-200a Diabetes Mellitus 27121251 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 Transfection with an miR-200a inhibitor increased Rheb protein levels and enhanced the feedback action on insulin receptor substrate-dependent insulin signaling, whereas transfection with an miR-200a mimic produced the opposite effects. target gene hsa-mir-200b Diabetes Mellitus 25884496 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 Polycomb repressive complex 2 regulates MiR-200b in retinal endothelial cells:potential relevance in diabetic retinopathy. target gene hsa-mir-204 Diabetes Mellitus 27384111 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 Taken together, we have identified PERK as a novel target of miR-204 and show that miR-204 inhibits PERK signaling and increases ER stress-induced cell death, revealing for the first time a link between this miRNA and UPR. target gene hsa-mir-21 Diabetes Mellitus 28230206 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 MiRNA-21 mediates the antiangiogenic activity of metformin through targeting PTEN and SMAD7 expression and PI3K/AKT pathway. target gene hsa-mir-27a Diabetes Mellitus 29462799 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 miR-27a may contribute to detrusor fibrosis in STZ-induced diabetic rats by targeting PRKAA2 via the TGF-β1/Smad3 signaling pathway target gene hsa-mir-27a Diabetes Mellitus 29100869 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 Oxidative stress-induced miR-27a targets the redox gene nuclear factor erythroid 2-related factor 2 in diabetic embryopathy. target gene hsa-mir-29a Diabetes Mellitus 25062042 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 insulin and mTORC1 regulate cardiac miR-29-MCL-1 axis and its dysregulation caused by reduced insulin and mTORC1 inhibition increases the vulnerability of a diabetic heart to structural damage. target gene hsa-mir-29a Diabetes Mellitus 26199111 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 Using gain- and loss-of-function studies, five of these genes were confirmed as endogenous targets of miR-29a target gene hsa-mir-29b Diabetes Mellitus 25062042 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 insulin and mTORC1 regulate cardiac miR-29-MCL-1 axis and its dysregulation caused by reduced insulin and mTORC1 inhibition increases the vulnerability of a diabetic heart to structural damage. target gene hsa-mir-29c Diabetes Mellitus 21310958 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 MicroRNA-29c is a signature MicroRNA under high glucose conditions which targets sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy. target gene hsa-mir-29c Diabetes Mellitus 25062042 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 insulin and mTORC1 regulate cardiac miR-29-MCL-1 axis and its dysregulation caused by reduced insulin and mTORC1 inhibition increases the vulnerability of a diabetic heart to structural damage. target gene hsa-mir-29c Diabetes Mellitus 28539664 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 MiRNA-29c regulates the expression of inflammatory cytokines in diabetic nephropathy by targeting tristetraprolin. target gene hsa-mir-34a Diabetes Mellitus 27297797 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 Subsequent overexpression of miR-34a inhibited Fndc5 expression, whereas blockade of miR-34a increased Fndc5 expression in myoblasts. target gene hsa-mir-375 Diabetes Mellitus 24120394 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 Because of the special role of miR-375, it may be a potential target to treat diabetes. Antagonising miR-375 may enhance the effects of exendin-4 in patients, and controlling the expression of miR-375 could assist mature hESCs-derived β-cells. target gene hsa-mir-463 Diabetes Mellitus 27664094 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 MicroRNA-463-3p/ABCG4: A new axis in glucose-stimulated insulin secretion. target gene hsa-mir-494 Diabetes Mellitus 29333131 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 miR-494 protects pancreatic β-cell function by targeting PTEN in gestational diabetes mellitus target gene hsa-mir-92a Diabetes Mellitus 29660330 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 MiRNA-92a protects pancreatic B-cell function by targeting KLF2 in diabetes mellitus target gene hsa-mir-101 Diabetes Mellitus, Gestational 25614281 disease of metabolism DOID:11714 O24.4 D016640 606176 HP:0009800 GDM impairs HUVEC function via miR-101 upregulation. EZH2 is both a transcriptional inhibitor and a target gene of miR-101 in HUVECs, and it contributes to some of the miR-101-induced defects of GDM-HUVECs. target gene hsa-mir-518d Diabetes Mellitus, Gestational 24639097 disease of metabolism DOID:11714 O24.4 D016640 606176 HP:0009800 MicroRNA-518d regulates PPARα protein expression in the placentas of females with gestational diabetes mellitus. target gene hsa-mir-149 Diabetes Mellitus, Type 1 27737950 disease of metabolism DOID:9744 E10 D003922 222100 HP:0100651 MicroRNAs miR-23a-3p, miR-23b-3p, and miR-149-5p Regulate the Expression of Proapoptotic BH3-Only Proteins DP5 and PUMA in Human Pancreatic β-Cells. target gene hsa-mir-21 Diabetes Mellitus, Type 1 28280903 disease of metabolism DOID:9744 E10 D003922 222100 HP:0100651 MicroRNA 21 targets BCL2 mRNA to increase apoptosis in rat and human beta cells. target gene hsa-mir-23a Diabetes Mellitus, Type 1 27737950 disease of metabolism DOID:9744 E10 D003922 222100 HP:0100651 MicroRNAs miR-23a-3p, miR-23b-3p, and miR-149-5p Regulate the Expression of Proapoptotic BH3-Only Proteins DP5 and PUMA in Human Pancreatic β-Cells. target gene hsa-mir-23b Diabetes Mellitus, Type 1 27737950 disease of metabolism DOID:9744 E10 D003922 222100 HP:0100651 MicroRNAs miR-23a-3p, miR-23b-3p, and miR-149-5p Regulate the Expression of Proapoptotic BH3-Only Proteins DP5 and PUMA in Human Pancreatic β-Cells. target gene hsa-let-7d Diabetes Mellitus, Type 2 24105413 disease of metabolism DOID:9352 E11 D003924 125853 HP:0005978 Expression of microRNA let-7a and let-7d, which are direct translational repressors of the IL-13 gene, was increased in skeletal muscle from T2DM patients. target gene hsa-mir-124a Diabetes Mellitus, Type 2 25408296 disease of metabolism DOID:9352 E11 D003924 125853 HP:0005978 We uncovered a major hyperexpression of miR-124a in T2D islets, whose silencing resulted in increased expression of target genes of major importance for beta cell function and whose overexpression impaired glucose-stimulated insulin secretion, leading to the hypothesis that an altered miR-124a expression may contribute to beta cell dysfunction in type 2 diabetes. target gene hsa-mir-1271 Diabetes Mellitus, Type 2 27613089 disease of metabolism DOID:9352 E11 D003924 125853 HP:0005978 MiR-1271 upregulated by saturated fatty acid palmitate provokes impaired insulin signaling by repressing INSR and IRS-1 expression in HepG2 cells. target gene hsa-mir-144 Diabetes Mellitus, Type 2 21829658 disease of metabolism DOID:9352 E11 D003924 125853 HP:0005978 MicroRNA 144 Impairs Insulin Signaling by Inhibiting the Expression of Insulin Receptor Substrate 1 in Type 2 Diabetes Mellitus. target gene hsa-mir-155 Diabetes Mellitus, Type 2 26125263 disease of metabolism DOID:9352 E11 D003924 125853 HP:0005978 In type 2 diabetes mellitus (T2DM) retinopathy, miR-155 may play an important role in the pathogenesis of T2DM retinopathy by regulating the Treg cells with TGF-β. target gene hsa-mir-17 Diabetes Mellitus, Type 2 29477089 disease of metabolism DOID:9352 E11 D003924 125853 HP:0005978 miR-17 improved inflammation-induced insulin resistance by suppressing ASK1 expression in macrophages target gene hsa-mir-187 Diabetes Mellitus, Type 2 24149837 disease of metabolism DOID:9352 E11 D003924 125853 HP:0005978 Our findings suggest a role for miR-187 in the blunting of insulin secretion, potentially involving regulation of HIPK3, which occurs during the pathogenesis of type 2 diabetes. target gene hsa-mir-199a Diabetes Mellitus, Type 2 25084986 disease of metabolism DOID:9352 E11 D003924 125853 HP:0005978 MiR-199a is overexpressed in plasma of type 2 diabetes patients which contributes to type 2 diabetes by targeting GLUT4. target gene hsa-mir-200 Diabetes Mellitus, Type 2 25985365 disease of metabolism DOID:9352 E11 D003924 125853 HP:0005978 The microRNA-200 family regulates pancreatic beta cell survival in type 2 diabetes. target gene hsa-mir-200b Diabetes Mellitus, Type 2 25814674 disease of metabolism DOID:9352 E11 D003924 125853 HP:0005978 This study reports that (1) inflammation underlying nonhealing wounds in patients with type 2 diabetes mellitus influences plasma miRNA concentrations and (2) miR-191 modulates cellular migration and angiogenesis via paracrine regulation of zonula occludens-1 to delay the tissue repair process. target gene hsa-mir-223 Diabetes Mellitus, Type 2 20080987 disease of metabolism DOID:9352 E11 D003924 125853 HP:0005978 These data demonstrate a role for miR-223 in Glut4 regulation and glucose metabolism in the heart, reveal the pleiotropic effects of miRNAs across tissues, and show that miRNAs can upregulate target genes in terminally differentiated cardiomyocytes. target gene hsa-mir-23b Diabetes Mellitus, Type 2 27467285 disease of metabolism DOID:9352 E11 D003924 125853 HP:0005978 Survival of autoreactive T lymphocytes by microRNA-mediated regulation of apoptosis through TRAIL and Fas in type 1 diabetes. target gene hsa-mir-24 Diabetes Mellitus, Type 2 23761103 disease of metabolism DOID:9352 E11 D003924 125853 HP:0005978 MicroRNA-24/MODY gene regulatory pathway mediates pancreatic β-cell dysfunction. target gene hsa-mir-375 Diabetes Mellitus, Type 2 25408296 disease of metabolism DOID:9352 E11 D003924 125853 HP:0005978 We uncovered a major hyperexpression of miR-124a in T2D islets, whose silencing resulted in increased expression of target genes of major importance for beta cell function and whose overexpression impaired glucose-stimulated insulin secretion, leading to the hypothesis that an altered miR-124a expression may contribute to beta cell dysfunction in type 2 diabetes. target gene hsa-mir-590 Diabetes Mellitus, Type 2 27467285 disease of metabolism DOID:9352 E11 D003924 125853 HP:0005978 Transcriptome analysis revealed reduced expression of TRAIL, TRAIL-R2, FAS and FASLG (members of the extrinsic apoptosis pathway) in patient-derived compared with healthy donor-derived T cells. This was mirrored by increased expression of microRNAs predicted to regulate these particular genes, namely miR-98, miR-23b and miR-590-5p. target gene hsa-mir-696 Diabetes Mellitus, Type 2 27432632 disease of metabolism DOID:9352 E11 D003924 125853 HP:0005978 Taken together, our findings demonstrate that miR-696 plays an important role in the development of hepatic gluconeogenesis and insulin resistance through the inhibition of PGC-1伪 translation in the liver. target gene hsa-mir-96 Diabetes Mellitus, Type 2 28036389 disease of metabolism DOID:9352 E11 D003924 125853 HP:0005978 Induction of miR-96 by Dietary Saturated Fatty Acids Exacerbates Hepatic Insulin Resistance through the Suppression of INSR and IRS-1. target gene hsa-mir-98 Diabetes Mellitus, Type 2 27467285 disease of metabolism DOID:9352 E11 D003924 125853 HP:0005978 Transcriptome analysis revealed reduced expression of TRAIL, TRAIL-R2, FAS and FASLG (members of the extrinsic apoptosis pathway) in patient-derived compared with healthy donor-derived T cells. This was mirrored by increased expression of microRNAs predicted to regulate these particular genes, namely miR-98, miR-23b and miR-590-5p. target gene hsa-mir-1 Diabetic Cardiomyopathies 29024600 D058065 Liver X receptor α is targeted by microRNA-1 to inhibit cardiomyocyte apoptosis through a ROS-mediated mitochondrial pathway. target gene hsa-mir-9 Diabetic Cardiomyopathies 26898797 D058065 Inhibition of miR-9 upregulates ELAVL1 expression and activates caspase-1. target gene hsa-mir-30a Diabetic Cataract 28442786 nervous system disease DOID:13328 MicroRNA-30a Regulation of Epithelial-Mesenchymal Transition in Diabetic Cataracts Through Targeting SNAI1. target gene hsa-mir-30a Diabetic Cataract 29100392 nervous system disease DOID:13328 MiR-30a inhibits BECN1-mediated autophagy in diabetic cataract. target gene hsa-mir-1207 Diabetic Nephropathy 24204837 E10-11.21 D003928 Role of microRNA 1207-5P and its host gene, the long non-coding RNA Pvt1, as mediators of extracellular matrix accumulation in the kidney: implications for diabetic nephropathy. target gene hsa-mir-1227 Diabetic Nephropathy 26930277 E10-11.21 D003928 In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-β-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies. target gene hsa-mir-1234 Diabetic Nephropathy 26930277 E10-11.21 D003928 In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-β-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies. target gene hsa-mir-125b Diabetic Nephropathy 27775793 E10-11.21 D003928 microRNA-125b contributes to high glucose-induced reactive oxygen species generation and apoptosis in HK-2 renal tubular epithelial cells by targeting angiotensin-converting enzyme 2. target gene hsa-mir-1915 Diabetic Nephropathy 26930277 E10-11.21 D003928 In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-β-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies. target gene hsa-mir-21 Diabetic Nephropathy 24887517 E10-11.21 D003928 miR-21 overexpression enhances TGF-β1-induced epithelial-to-mesenchymal transition by target smad7 and aggravates renal damage in diabetic nephropathy. target gene hsa-mir-2861 Diabetic Nephropathy 26930277 E10-11.21 D003928 In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-β-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies. target gene hsa-mir-30d Diabetic Nephropathy 26930277 E10-11.21 D003928 In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-β-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies. target gene hsa-mir-30e Diabetic Nephropathy 26930277 E10-11.21 D003928 In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-β-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies. target gene hsa-mir-320c Diabetic Nephropathy 26930277 E10-11.21 D003928 In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-β-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies. target gene hsa-mir-371b Diabetic Nephropathy 26930277 E10-11.21 D003928 In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-β-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies. target gene hsa-mir-4270 Diabetic Nephropathy 26930277 E10-11.21 D003928 In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-β-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies. target gene hsa-mir-451a Diabetic Nephropathy 21827757 E10-11.21 D003928 MicroRNA-451 regulates p38 MAPK signaling by targeting of Ywhaz and suppresses the mesangial hypertrophy in early Diabetic Nephropathies. target gene hsa-mir-4739 Diabetic Nephropathy 26930277 E10-11.21 D003928 In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-β-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies. target gene hsa-mir-4778 Diabetic Nephropathy 26930277 E10-11.21 D003928 In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-β-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies. target gene hsa-mir-572 Diabetic Nephropathy 26930277 E10-11.21 D003928 In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-β-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies. target gene hsa-mir-6068 Diabetic Nephropathy 26930277 E10-11.21 D003928 In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-β-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies. target gene hsa-mir-6126 Diabetic Nephropathy 26930277 E10-11.21 D003928 In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-β-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies. target gene hsa-mir-6133 Diabetic Nephropathy 26930277 E10-11.21 D003928 In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-β-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies. target gene hsa-mir-638 Diabetic Nephropathy 26930277 E10-11.21 D003928 In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-β-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies. target gene hsa-mir-155 Diabetic Peripheral Neuropathy 29545091 E11.40 MiR-155 targets PTCH1 to mediate endothelial progenitor cell dysfunction caused by high glucose. target gene hsa-mir-96 Diabetic Peripheral Neuropathy 29689688 E11.40 Swimming Exercise Induced Reversed Expression of miR-96 and Its Target Gene NaV1.3 in Diabetic Peripheral Neuropathy in Rats target gene hsa-mir-126 Diabetic Retinopathy 28943945 nervous system disease DOID:8947 E10-11.31 D003930 MicroRNA-126 inhibits cell viability and invasion in a diabetic retinopathy model via targeting IRS-1. target gene hsa-mir-146a Diabetic Retinopathy 28433754 nervous system disease DOID:8947 E10-11.31 D003930 miR-146a suppresses STAT3/VEGF pathways and reduces apoptosis through IL-6 signaling in primary human retinal microvascular endothelial cells in high glucose conditions. target gene hsa-mir-152 Diabetic Retinopathy 25802486 nervous system disease DOID:8947 E10-11.31 D003930 We have demonstrated that miR-152 interacting with PRR regulates downstream VEGF, VRGFR-2, and TGFβ1 expressions in hRECs in HG conditions. These studies suggest miR-152 and PRR may play a role in the pathogenesis of diabetic retinopathy (DR). target gene hsa-mir-195 Diabetic Retinopathy 24570140 nervous system disease DOID:8947 E10-11.31 D003930 These studies identified a novel mechanism whereby miR-195 regulates SIRT1-mediated tissue damage in diabetic retinopathy. target gene hsa-mir-20b Diabetic Retinopathy 27421659 nervous system disease DOID:8947 E10-11.31 D003930 Transfection of miR-20b mimic in high glucose (HG)-treated human retinal endothelial cells (HRECs) increased miR-20b expression and decreased the expression level of VEGF mRNA, while transfection of miR-20b inhibitor in control HRECs reduced the miR-20b expression with a corresponding increase of VEGF mRNA. target gene hsa-mir-27b Diabetic Retinopathy 26696637 nervous system disease DOID:8947 E10-11.31 D003930 The authors assessed 155 baseline or DR progressors and 145 control samples (selected from 3,326 study participants) for a panel of 29 candidate miRNAs that were based on previous studies related to diabetes and myocardial infarction. They identified miR-27b and miR-320a as being significantly and independently associated with high DR risk. Complementing this analysis, they also elucidated the potential mechanism using cultured human endothelial cells and identified antiangiogenic thrombospondin-1 as a common target of these two miRNAs. target gene hsa-mir-29a Diabetic Retinopathy 28189547 nervous system disease DOID:8947 E10-11.31 D003930 Role of microRNA-29a in the development of diabetic retinopathy by targeting AGT gene in a rat model. target gene hsa-mir-29a Diabetic Retinopathy 29409329 nervous system disease DOID:8947 E10-11.31 D003930 Downregulation of MicroRNA 29a/b exacerbated diabetic retinopathy by impairing the function of Müller cells via Forkhead box protein O4. target gene hsa-mir-29b Diabetic Retinopathy 29409329 nervous system disease DOID:8947 E10-11.31 D003930 Downregulation of MicroRNA 29a/b exacerbated diabetic retinopathy by impairing the function of Müller cells via Forkhead box protein O4. target gene hsa-mir-320a Diabetic Retinopathy 26696637 nervous system disease DOID:8947 E10-11.31 D003930 The authors assessed 155 baseline or DR progressors and 145 control samples (selected from 3,326 study participants) for a panel of 29 candidate miRNAs that were based on previous studies related to diabetes and myocardial infarction. They identified miR-27b and miR-320a as being significantly and independently associated with high DR risk. Complementing this analysis, they also elucidated the potential mechanism using cultured human endothelial cells and identified antiangiogenic thrombospondin-1 as a common target of these two miRNAs. target gene hsa-mir-216b Diabetic Vasculopathy 29477872 cardiovascular system disease DOID:11713 D003925 MicroRNA-216b actively modulates diabetic angiopathy through inverse regulation on FZD5. target gene hsa-mir-194 Disease of Metabolism 25412310 disease of metabolism DOID:0014667 E88.9 D008659 miR-194 and COUP-TFII may be good target molecules for controlling bone and metabolic diseases. target gene hsa-mir-155 Down Syndrome 25869329 genetic disease DOID:14250 Q90 D004314 190685 These results suggest that regulation of TFAM by hsa-miR-155-5p impacts mitochondrial biogenesis in the diploid setting but not in the DS setting. target gene hsa-mir-383 Embryonal Testis Carcinoma 24462707 disease of cellular proliferation DOID:5680 C62.00 C104948 273300 microRNA-383 impairs phosphorylation of H2AX by targeting PNUTS and inducing cell cycle arrest in testicular embryonal carcinoma cells. target gene hsa-mir-513b Embryonal Testis Carcinoma 28512062 disease of cellular proliferation DOID:5680 C62.00 C104948 273300 Hsa-miR-513b-5p suppresses cell proliferation and promotes P53 expression by targeting IRF2 in testicular embryonal carcinoma cells. target gene hsa-mir-206 Encephalitis 28765968 disease by infectious agent DOID:9588 G04.90 D004660 HP:0002383 Downregulation of CCL2 induced by the upregulation of microRNA-206 is associated with the severity of HEV71 encephalitis target gene hsa-mir-17 Encephalomyelitis 23858035 nervous system disease DOID:640 B01.11 D004679 microRNA-17-92 regulates IL-10 production by regulatory T cells and control of experimental autoimmune encephalomyelitis. target gene hsa-mir-20b Encephalomyelitis 24842756 nervous system disease DOID:640 B01.11 D004679 miR-20b suppresses Th17 differentiation and the pathogenesis of experimental autoimmune encephalomyelitis by targeting RORγt and STAT3. target gene hsa-let-7a-1 Endometrial Neoplasms 22014978 reproductive system disease DOID:1380 C54.1 D016889 608089 The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells. target gene hsa-let-7a-2 Endometrial Neoplasms 22014978 reproductive system disease DOID:1380 C54.1 D016889 608089 The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells. target gene hsa-let-7a-3 Endometrial Neoplasms 22014978 reproductive system disease DOID:1380 C54.1 D016889 608089 The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells. target gene hsa-let-7b Endometrial Neoplasms 22014978 reproductive system disease DOID:1380 C54.1 D016889 608089 The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells. target gene hsa-let-7c Endometrial Neoplasms 22014978 reproductive system disease DOID:1380 C54.1 D016889 608089 The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells. target gene hsa-let-7d Endometrial Neoplasms 22014978 reproductive system disease DOID:1380 C54.1 D016889 608089 The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells. target gene hsa-let-7e Endometrial Neoplasms 22014978 reproductive system disease DOID:1380 C54.1 D016889 608089 The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells. target gene hsa-let-7f-1 Endometrial Neoplasms 22014978 reproductive system disease DOID:1380 C54.1 D016889 608089 The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells. target gene hsa-let-7f-2 Endometrial Neoplasms 22014978 reproductive system disease DOID:1380 C54.1 D016889 608089 The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells. target gene hsa-let-7g Endometrial Neoplasms 22014978 reproductive system disease DOID:1380 C54.1 D016889 608089 The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells. target gene hsa-let-7i Endometrial Neoplasms 22014978 reproductive system disease DOID:1380 C54.1 D016889 608089 The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells. target gene hsa-mir-100 Endometrial Neoplasms 21472251 reproductive system disease DOID:1380 C54.1 D016889 608089 hsa-mir-100 and hsa-miR-99a were predicted to target ESR1, and hsa-miR-378 and hsa-miR-768-3p to target PGR. Hsa-miR-100 was significantly down-regulated in the estrogen-dependent endometrial cancer samples as compared to the estrogen-independent samples and thus has the potential to target ESR1. target gene hsa-mir-103a-1 Endometrial Neoplasms 22783422 reproductive system disease DOID:1380 C54.1 D016889 608089 microRNA-103 regulates the growth and invasion of endometrial cancer cells through the downregulation of tissue inhibitor of metalloproteinase 3. target gene hsa-mir-103a-2 Endometrial Neoplasms 22783422 reproductive system disease DOID:1380 C54.1 D016889 608089 microRNA-103 regulates the growth and invasion of endometrial cancer cells through the downregulation of tissue inhibitor of metalloproteinase 3. target gene hsa-mir-103b-1 Endometrial Neoplasms 22783422 reproductive system disease DOID:1380 C54.1 D016889 608089 microRNA-103 regulates the growth and invasion of endometrial cancer cells through the downregulation of tissue inhibitor of metalloproteinase 3. target gene hsa-mir-103b-2 Endometrial Neoplasms 22783422 reproductive system disease DOID:1380 C54.1 D016889 608089 microRNA-103 regulates the growth and invasion of endometrial cancer cells through the downregulation of tissue inhibitor of metalloproteinase 3. target gene hsa-mir-125b-1 Endometrial Neoplasms 21970405 reproductive system disease DOID:1380 C54.1 D016889 608089 MiR-125b promotes proliferation and migration of type II endometrial carcinoma cells through targeting TP53INP1 tumor suppressor in vitro and in vivo. target gene hsa-mir-125b-1 Endometrial Neoplasms 22460089 reproductive system disease DOID:1380 C54.1 D016889 608089 MicroRNA-125b down-regulation mediates endometrial cancer invasion by targeting ERBB2. target gene hsa-mir-125b-2 Endometrial Neoplasms 21970405 reproductive system disease DOID:1380 C54.1 D016889 608089 MiR-125b promotes proliferation and migration of type II endometrial carcinoma cells through targeting TP53INP1 tumor suppressor in vitro and in vivo. target gene hsa-mir-125b-2 Endometrial Neoplasms 22460089 reproductive system disease DOID:1380 C54.1 D016889 608089 MicroRNA-125b down-regulation mediates endometrial cancer invasion by targeting ERBB2. target gene hsa-mir-130b Endometrial Neoplasms 23392577 reproductive system disease DOID:1380 C54.1 D016889 608089 miR-130b is an EMT-related microRNA that targets DICER1 for aggression in endometrial cancer target gene hsa-mir-193a Endometrial Neoplasms 22907428 reproductive system disease DOID:1380 C54.1 D016889 608089 YY1 overexpression was found to be a consequence of miR-193a-5p downregulation through direct miR-193a-5p-YY1 interplay. target gene hsa-mir-194-1 Endometrial Neoplasms 21851624 reproductive system disease DOID:1380 C54.1 D016889 608089 MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. target gene hsa-mir-194-2 Endometrial Neoplasms 21851624 reproductive system disease DOID:1380 C54.1 D016889 608089 MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. target gene hsa-mir-200a Endometrial Neoplasms 29442045 reproductive system disease DOID:1380 C54.1 D016889 608089 MiR-200a promotes epithelial-mesenchymal transition of endometrial cancer cells by negatively regulating FOXA2 expression target gene hsa-mir-200b Endometrial Neoplasms 23205572 reproductive system disease DOID:1380 C54.1 D016889 608089 MicroRNA-200b Is Overexpressed in Endometrial Adenocarcinomas and Enhances MMP2 Activity by Downregulating TIMP2 in Human Endometrial Cancer Cell Line HEC-1A Cells target gene hsa-mir-200c Endometrial Neoplasms 22015043 reproductive system disease DOID:1380 C54.1 D016889 608089 We found that miR-200c expression was increased in endometrial carcinoma compared with normal endometrial tissues. Anti-miR or pre-miR-200c could regulate cell survival, proliferation, and apoptosis and affect cytotoxicity in endometrial cancer cells. Through mRNA microarray analysis, we found that miR-200c inhibits the expression of BRD7, which was recently reported as a potential tumor suppressor gene. MiR-200c regulated the translocation of ж┿catenin from the cytoplasm to the nucleus via inhibition of BRD7, resulting in increased expression of its transcriptional target genes, cyclinD1 and c-myc. target gene hsa-mir-204 Endometrial Neoplasms 21400511 reproductive system disease DOID:1380 C54.1 D016889 608089 Dysregulation of microRNA-204 mediates migration and invasion of endometrial cancer by regulating FOXC1. target gene hsa-mir-205 Endometrial Neoplasms 28427207 reproductive system disease DOID:1380 C54.1 D016889 608089 miR-205 inhibits cell growth by targeting AKT-mTOR signaling in progesterone-resistant endometrial cancer Ishikawa cells. target gene hsa-mir-31 Endometrial Neoplasms 20980827 reproductive system disease DOID:1380 C54.1 D016889 608089 These findings provide new insights into tumor-stroma interaction and document that miR-31 and its target gene SATB2, are involved in regulation of tumor cell motility. target gene hsa-mir-34c Endometrial Neoplasms 23412924 reproductive system disease DOID:1380 C54.1 D016889 608089 Furthermore, miR-34c mimics significantly enhanced apoptosis in Ishikawa cells by inhibiting IL-6R expression. Therefore, a combination of miR-34c mimics and DDP could be an effective therapeutic strategy for controlling Ishikawa cell proliferation. target gene hsa-mir-378a Endometrial Neoplasms 21472251 reproductive system disease DOID:1380 C54.1 D016889 608089 hsa-mir-100 and hsa-miR-99a were predicted to target ESR1, and hsa-miR-378 and hsa-miR-768-3p to target PGR. Hsa-miR-100 was significantly down-regulated in the estrogen-dependent endometrial cancer samples as compared to the estrogen-independent samples and thus has the potential to target ESR1. target gene hsa-mir-99a Endometrial Neoplasms 21472251 reproductive system disease DOID:1380 C54.1 D016889 608089 hsa-mir-100 and hsa-miR-99a were predicted to target ESR1, and hsa-miR-378 and hsa-miR-768-3p to target PGR. Hsa-miR-100 was significantly down-regulated in the estrogen-dependent endometrial cancer samples as compared to the estrogen-independent samples and thus has the potential to target ESR1. target gene hsa-mir-10b Endometriosis 23206733 reproductive system disease DOID:289 N80.0 D004715 131200 HP:0030127 Targeting of syndecan-1 by micro-ribonucleic acid miR-10b modulates invasiveness of endometriotic cells via dysregulation of the proteolytic milieu and interleukin-6 secretion target gene hsa-mir-126 Endometriosis 22012249 reproductive system disease DOID:289 N80.0 D004715 131200 HP:0030127 The expression level of miR-126 was significantly downregulated in ECs versus EUs (p = 5.45E(-5)) in the experimental group and in EUs versus ENs (p = 0.019).miR-126 may play an initial role in the development and progression of EMs. Crk may be regulated by miR-126, and synergism between abnormal expressions may play an important role in the pathogenesis of EMs. target gene hsa-mir-135a-1 Endometriosis 21956427 reproductive system disease DOID:289 N80.0 D004715 131200 HP:0030127 miR-135a Regulates HOXA10 Expression in Endometriosis. target gene hsa-mir-135a-2 Endometriosis 21956427 reproductive system disease DOID:289 N80.0 D004715 131200 HP:0030127 miR-135a Regulates HOXA10 Expression in Endometriosis. target gene hsa-mir-135b Endometriosis 21956427 reproductive system disease DOID:289 N80.0 D004715 131200 HP:0030127 miR-135b Regulates HOXA10 Expression in Endometriosis. target gene hsa-mir-145 Endometriosis 23312222 reproductive system disease DOID:289 N80.0 D004715 131200 HP:0030127 MicroRNA miR-145 inhibits proliferation, invasiveness, and stem cell phenotype of an in vitro endometriosis model by targeting multiple cytoskeletal elements and pluripotency factors target gene hsa-mir-15a Endometriosis 27608888 reproductive system disease DOID:289 N80.0 D004715 131200 HP:0030127 miRNA-15a-5p regulates VEGFA in endometrial mesenchymal stem cells and contributes to the pathogenesis of endometriosis. target gene hsa-mir-17 Endometriosis 29042983 reproductive system disease DOID:289 N80.0 D004715 131200 HP:0030127 MicroRNA-17 downregulates expression of the PTEN gene to promote the occurrence and development of adenomyosis. target gene hsa-mir-183 Endometriosis 26357653 reproductive system disease DOID:289 N80.0 D004715 131200 HP:0030127 These findings, together with the fact that ITGB1 is a critical factor for cell adhesion and invasiveness, suggest that miR-183 may be involved in the development of endometriosis by regulating ITGB1 in endometrial stromal cells. target gene hsa-mir-191 Endometriosis 25819812 reproductive system disease DOID:289 N80.0 D004715 131200 HP:0030127 miR-191 can directly regulate TIMP3 expression, thereby affecting cell proliferation rate and invasion ability. The miR-191-TIMP3 axis might be critical in the malignant transformation of endometriosis to EAOC. target gene hsa-mir-191 Endometriosis 26191186 reproductive system disease DOID:289 N80.0 D004715 131200 HP:0030127 MiR-191 inhibits TNF-α induced apoptosis of ovarian endometriosis and endometrioid carcinoma cells by targeting DAPK1. target gene hsa-mir-195 Endometriosis 24294368 reproductive system disease DOID:289 N80.0 D004715 131200 HP:0030127 MiR-195 inhibits proliferation and growth and induces apoptosis of endometrial stromal cells by targeting FKN. target gene hsa-mir-196b Endometriosis 23293219 reproductive system disease DOID:289 N80.0 D004715 131200 HP:0030127 miR-196b targets c-myc and Bcl-2 expression, inhibits proliferation and induces apoptosis in endometriotic stromal cells target gene hsa-mir-199a Endometriosis 24155090 reproductive system disease DOID:289 N80.0 D004715 131200 HP:0030127 miRNA-199a-5p regulates VEGFA in endometrial mesenchymal stem cells and contributes to the pathogenesis of endometriosis. target gene hsa-mir-199a Endometriosis 26191163 reproductive system disease DOID:289 N80.0 D004715 131200 HP:0030127 MiR-199a inhibits the angiogenic potential of endometrial stromal cells under hypoxia by targeting HIF-1α/VEGF pathway. target gene hsa-mir-199a-1 Endometriosis 21989168 reproductive system disease DOID:289 N80.0 D004715 131200 HP:0030127 MiR-199a attenuates endometrial stromal cell invasiveness through suppression of the IKK{beta}/NF-kB pathway and reduced interleukin-8 expression. target gene hsa-mir-199a-2 Endometriosis 21989168 reproductive system disease DOID:289 N80.0 D004715 131200 HP:0030127 MiR-199a attenuates endometrial stromal cell invasiveness through suppression of the IKK{beta}/NF-kB pathway and reduced interleukin-8 expression. target gene hsa-mir-200c Endometriosis 29116025 reproductive system disease DOID:289 N80.0 D004715 131200 HP:0030127 miR-200c suppresses endometriosis by targeting MALAT1 in vitro and in vivo. target gene hsa-mir-20a Endometriosis 24972566 reproductive system disease DOID:289 N80.0 D004715 131200 HP:0030127 miR-20a contributes to endometriosis by regulating NTN4 expression. target gene hsa-mir-23a Endometriosis 23450049 reproductive system disease DOID:289 N80.0 D004715 131200 HP:0030127 MicroRNA23a and MicroRNA23b Deregulation Derepresses SF-1 and Upregulates Estrogen Signaling in Ovarian Endometriosis target gene hsa-mir-23b Endometriosis 23450049 reproductive system disease DOID:289 N80.0 D004715 131200 HP:0030127 MicroRNA23a and MicroRNA23b Deregulation Derepresses SF-1 and Upregulates Estrogen Signaling in Ovarian Endometriosis target gene hsa-mir-122 Endomyocardial Fibrosis 24168656 cardiovascular system disease DOID:12932 I42.3 D004719 HP:0006685 microRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-β1 up-regulation. target gene hsa-mir-21 Endomyocardial Fibrosis 26968995 cardiovascular system disease DOID:12932 I42.3 D004719 HP:0006685 miR-21 specific degradation of Smad7 may decrease the inhibitory feedback regulation of TGF-尾1/Smad signaling target gene hsa-mir-98 Endomyocardial Fibrosis 28251559 cardiovascular system disease DOID:12932 I42.3 D004719 HP:0006685 MicroRNA-98 inhibits TGF-β1-induced differentiation and collagen production of cardiac fibroblasts by targeting TGFBR1. target gene hsa-mir-197 Enterovirus Infection 26581983 B97.10 D004769 Host MicroRNA miR-197 Plays a Negative Regulatory Role in the Enterovirus 71 Infectious Cycle by Targeting the RAN Protein. target gene hsa-mir-27a Enterovirus Infection 25212431 B97.10 D004769 miR-27a suppresses EV71 replication by directly targeting EGFR. target gene hsa-mir-30a Enterovirus Infection 26515789 B97.10 D004769 We provided further evidence that by modulating cellular miR-30a level through either overexpression or inhibition, one can inhibit or promote EV71 replication, respectively, through regulating autophagic activity. target gene hsa-mir-29 Ependymoma 25958202 disease of cellular proliferation DOID:5074 C71.0 D004806 HP:0002888 microRNA network analysis identifies miR-29 cluster as key regulator of LAMA2 in ependymoma. target gene hsa-mir-139 Epilepsy 27731509 nervous system disease DOID:1826 G40 D004827 PS601068 HP:0001250 MicroRNA-139-5p negatively regulates NR2A-containing NMDA receptor in the rat pilocarpine model and patients with temporal lobe epilepsy. target gene hsa-mir-206 Epithelioid Sarcoma 24327545 disease of cellular proliferation DOID:6193 D012509 SMARCB1 expression in epithelioid sarcoma is regulated by miR-206, miR-381, and miR-671-5p on Both mRNA and protein levels. target gene hsa-mir-381 Epithelioid Sarcoma 24327545 disease of cellular proliferation DOID:6193 D012509 SMARCB1 expression in epithelioid sarcoma is regulated by miR-206, miR-381, and miR-671-5p on Both mRNA and protein levels. target gene hsa-mir-671 Epithelioid Sarcoma 24327545 disease of cellular proliferation DOID:6193 D012509 SMARCB1 expression in epithelioid sarcoma is regulated by miR-206, miR-381, and miR-671-5p on Both mRNA and protein levels. target gene hsa-mir-221 Epstein-Barr Virus Infection 26153983 B27.90 D020031 300853 Epstein-Barr Virus Proteins EBNA3A and EBNA3C Together Induce Expression of the Oncogenic MicroRNA Cluster miR-221/miR-222 and Ablate Expression of Its Target p57KIP2. ebv-miR-BART20-5p target gene hsa-mir-222 Epstein-Barr Virus Infection 26153983 B27.90 D020031 300853 Epstein-Barr Virus Proteins EBNA3A and EBNA3C Together Induce Expression of the Oncogenic MicroRNA Cluster miR-221/miR-222 and Ablate Expression of Its Target p57KIP2. ebv-miR-BART20-5p target gene hsa-let-7a Esophageal Neoplasms 21600139 C15.9 D004938 133239 HP:0100751 Eighteen miRNAs had their target genes, 10 of them had the potential to individually target up to 200 mRNAs. Hsa-let-7a, hsa-miR-185, hsa-miR-141, hsa-miR-92b, hsa-miR-22 and hsa-miR-301a were known as important genes associated with radioresistance. target gene hsa-mir-100 Esophageal Neoplasms 23292834 C15.9 D004938 133239 HP:0100751 MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma target gene hsa-mir-133a-1 Esophageal Neoplasms 22641236 C15.9 D004938 133239 HP:0100751 CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma. target gene hsa-mir-133a-2 Esophageal Neoplasms 22641236 C15.9 D004938 133239 HP:0100751 CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma. target gene hsa-mir-141 Esophageal Neoplasms 21289630 C15.9 D004938 133239 HP:0100751 MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma. target gene hsa-mir-141 Esophageal Neoplasms 21600139 C15.9 D004938 133239 HP:0100751 Eighteen miRNAs had their target genes, 10 of them had the potential to individually target up to 200 mRNAs. Hsa-let-7a, hsa-miR-185, hsa-miR-141, hsa-miR-92b, hsa-miR-22 and hsa-miR-301a were known as important genes associated with radioresistance. target gene hsa-mir-143 Esophageal Neoplasms 22457808 C15.9 D004938 133239 HP:0100751 The Cluster of miR-143 and miR-145 Affects the Risk for Esophageal Squamous Cell Carcinoma through Co-Regulating Fascin Homolog 1. target gene hsa-mir-145 Esophageal Neoplasms 22457808 C15.9 D004938 133239 HP:0100751 The Cluster of miR-143 and miR-145 Affects the Risk for Esophageal Squamous Cell Carcinoma through Co-Regulating Fascin Homolog 1. target gene hsa-mir-150 Esophageal Neoplasms 23301507 C15.9 D004938 133239 HP:0100751 MiR-150 regulates the EMT-inducer ZEB1 in esophageal squamous cell carcinoma.Wound healing assays of premiR-150-treated esophageal squamous cell carcinoma TE-8 cells target gene hsa-mir-185 Esophageal Neoplasms 21600139 C15.9 D004938 133239 HP:0100751 Eighteen miRNAs had their target genes, 10 of them had the potential to individually target up to 200 mRNAs. Hsa-let-7a, hsa-miR-185, hsa-miR-141, hsa-miR-92b, hsa-miR-22 and hsa-miR-301a were known as important genes associated with radioresistance. target gene hsa-mir-192-2 Esophageal Neoplasms 23677061 C15.9 D004938 133239 HP:0100751 miR-129-2 suppresses proliferation and migration of esophageal carcinoma cells through downregulation of SOX4 expression. target gene hsa-mir-19a Esophageal Neoplasms 21271217 C15.9 D004938 133239 HP:0100751 TNF-alpha is a novel target of miR-19a. target gene hsa-mir-203 Esophageal Neoplasms 21299870 C15.9 D004938 133239 HP:0100751 MicroRNA-203 inhibits cell proliferation by repressing DeltaNp63 expression in human esophageal squamous cell carcinoma. target gene hsa-mir-203 Esophageal Neoplasms 22940702 C15.9 D004938 133239 HP:0100751 miR-203 inhibits the migration and invasion of esophageal squamous cell carcinoma by regulating LASP1. target gene hsa-mir-205 Esophageal Neoplasms 21426561 C15.9 D004938 133239 HP:0100751 MiRNA-205 modulates cellular invasion and migration via regulating zinc finger E-box binding homeobox 2 expression in esophageal squamous cell carcinoma cells. target gene hsa-mir-21 Esophageal Neoplasms 23504349 C15.9 D004938 133239 HP:0100751 miR-21 Down-Regulation Suppresses Cell Growth, Invasion and Induces Cell Apoptosis by Targeting FASL, TIMP3, and RECK Genes in Esophageal Carcinoma target gene hsa-mir-214 Esophageal Neoplasms 22867052 C15.9 D004938 133239 HP:0100751 microRNA-98 and microRNA-214 post-transcriptionally regulate enhancer of zeste homolog 2 and inhibit migration and invasion in human esophageal squamous cell carcinoma. target gene hsa-mir-22 Esophageal Neoplasms 21600139 C15.9 D004938 133239 HP:0100751 Eighteen miRNAs had their target genes, 10 of them had the potential to individually target up to 200 mRNAs. Hsa-let-7a, hsa-miR-185, hsa-miR-141, hsa-miR-92b, hsa-miR-22 and hsa-miR-301a were known as important genes associated with radioresistance. target gene hsa-mir-26a-1 Esophageal Neoplasms 23108995 C15.9 D004938 133239 HP:0100751 MiR-26a regulates cell cycle and anoikis of human esophageal adenocarcinoma cells through Rb1-E2F1 signaling pathway target gene hsa-mir-26a-2 Esophageal Neoplasms 23108995 C15.9 D004938 133239 HP:0100751 MiR-26a regulates cell cycle and anoikis of human esophageal adenocarcinoma cells through Rb1-E2F1 signaling pathway target gene hsa-mir-29c Esophageal Neoplasms 21551130 C15.9 D004938 133239 HP:0100751 miR-29c induces cell cycle arrest in Esophageal Squamous Cell Carcinoma by modulating Cyclin E expression. target gene hsa-mir-301a Esophageal Neoplasms 21600139 C15.9 D004938 133239 HP:0100751 Eighteen miRNAs had their target genes, 10 of them had the potential to individually target up to 200 mRNAs. Hsa-let-7a, hsa-miR-185, hsa-miR-141, hsa-miR-92b, hsa-miR-22 and hsa-miR-301a were known as important genes associated with radioresistance. target gene hsa-mir-373 Esophageal Neoplasms 19501585 C15.9 D004938 133239 HP:0100751 we demonstrated that the direct inhibition of LATS2 protein was mediated by miR-373 and manipulated the expression of miR-373 to affect esophageal cancer cells growth. target gene hsa-mir-375 Esophageal Neoplasms 28599478 C15.9 D004938 133239 HP:0100751 MicroRNA-375 suppresses esophageal cancer cell growth and invasion by repressing metadherin expression. target gene hsa-mir-593 Esophageal Neoplasms 21170987 C15.9 D004938 133239 HP:0100751 Polo-like kinase 1 regulates cell proliferation and is targeted by miR-593* in esophageal cancer. target gene hsa-mir-92b Esophageal Neoplasms 21600139 C15.9 D004938 133239 HP:0100751 Eighteen miRNAs had their target genes, 10 of them had the potential to individually target up to 200 mRNAs. Hsa-let-7a, hsa-miR-185, hsa-miR-141, hsa-miR-92b, hsa-miR-22 and hsa-miR-301a were known as important genes associated with radioresistance. target gene hsa-mir-98 Esophageal Neoplasms 22867052 C15.9 D004938 133239 HP:0100751 microRNA-98 and microRNA-214 post-transcriptionally regulate enhancer of zeste homolog 2 and inhibit migration and invasion in human esophageal squamous cell carcinoma. target gene hsa-mir-99a Esophageal Neoplasms 23292834 C15.9 D004938 133239 HP:0100751 MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma target gene hsa-mir-203 Essential Thrombocythemia 26990535 disease of cellular proliferation DOID:2224 D47.3 D013920 PS187950 miR-203 and miR-221 regulate SOCS1 and SOCS3 in essential thrombocythemia. target gene hsa-mir-221 Essential Thrombocythemia 26990535 disease of cellular proliferation DOID:2224 D47.3 D013920 PS187950 miR-203 and miR-221 regulate SOCS1 and SOCS3 in essential thrombocythemia. target gene hsa-let-7a-1 Ewing Sarcoma 21853155 musculoskeletal system disease DOID:3369 D012512 612219 HP:0012254 Let-7a Is a Direct EWS-FLI-1 Target Implicated in Ewing's Sarcoma Development. target gene hsa-let-7a-2 Ewing Sarcoma 21853155 musculoskeletal system disease DOID:3369 D012512 612219 HP:0012254 Let-7a Is a Direct EWS-FLI-1 Target Implicated in Ewing's Sarcoma Development. target gene hsa-let-7a-3 Ewing Sarcoma 21853155 musculoskeletal system disease DOID:3369 D012512 612219 HP:0012254 Let-7a Is a Direct EWS-FLI-1 Target Implicated in Ewing's Sarcoma Development. target gene hsa-mir-708 Ewing Sarcoma 22723308 musculoskeletal system disease DOID:3369 D012512 612219 HP:0012254 EWS/FLI1 Regulates EYA3 in Ewing Sarcoma via Modulation of miRNA-708, Resulting in Increased Cell Survival and Chemoresistance. target gene hsa-mir-10b Fatty Liver, Non-Alcoholic 19780876 disease of metabolism DOID:0080208 K75.81 D065626 613282 Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD target gene hsa-mir-144 Fatty Liver, Non-Alcoholic 25534427 disease of metabolism DOID:0080208 K75.81 D065626 613282 Decreased miR-144 could enhance TNF-α and IFN-γ production by targeting TLR2 in vitro, and might contribute to TLR2 up-regulation and the progression of NASH in HFD-MetS E3 rats. This might offer a novel and potential target for NASH therapy. target gene hsa-mir-150 Fatty Liver, Non-Alcoholic 29107687 disease of metabolism DOID:0080208 K75.81 D065626 613282 MiR-150 deficiency ameliorated hepatosteatosis and insulin resistance in nonalcoholic fatty liver disease via targeting CASP8 and FADD-like apoptosis regulator. target gene hsa-mir-182 Fatty Liver, Non-Alcoholic 26001595 disease of metabolism DOID:0080208 K75.81 D065626 613282 E3 ubiquitin protein ligase (FBXW7) as potential targets of miR-182 target gene hsa-mir-27a Fatty Liver, Non-Alcoholic 29101357 disease of metabolism DOID:0080208 K75.81 D065626 613282 MicroRNA-27a regulates hepatic lipid metabolism and alleviates NAFLD via repressing FAS and SCD1. target gene hsa-mir-29a Fatty Liver, Non-Alcoholic 28454323 disease of metabolism DOID:0080208 K75.81 D065626 613282 MicroRNA-29a/b/c targets iNOS and is involved in protective remote ischemic preconditioning in an ischemia-reperfusion rat model of non-alcoholic fatty liver disease. target gene hsa-mir-29b Fatty Liver, Non-Alcoholic 28454323 disease of metabolism DOID:0080208 K75.81 D065626 613282 MicroRNA-29a/b/c targets iNOS and is involved in protective remote ischemic preconditioning in an ischemia-reperfusion rat model of non-alcoholic fatty liver disease. target gene hsa-mir-29c Fatty Liver, Non-Alcoholic 28454323 disease of metabolism DOID:0080208 K75.81 D065626 613282 MicroRNA-29a/b/c targets iNOS and is involved in protective remote ischemic preconditioning in an ischemia-reperfusion rat model of non-alcoholic fatty liver disease. target gene hsa-mir-30c Fatty Liver, Non-Alcoholic 28088781 disease of metabolism DOID:0080208 K75.81 D065626 613282 MiR-30c-5p ameliorates hepatic steatosis in leptin receptor-deficient (db/db) mice via down-regulating FASN. target gene hsa-mir-34a Fatty Liver, Non-Alcoholic 28899784 disease of metabolism DOID:0080208 K75.81 D065626 613282 MiR-181b regulates steatosis in nonalcoholic fatty liver disease via targeting SIRT1. target gene hsa-mir-375 Fatty Liver, Non-Alcoholic 29569260 disease of metabolism DOID:0080208 K75.81 D065626 613282 Down-regulation of microRNA-375 regulates adipokines and inhibits inflammatory cytokines by targeting AdipoR2 in non-alcoholic fatty liver disease target gene hsa-mir-577 Fatty Liver, Non-Alcoholic 27179781 disease of metabolism DOID:0080208 K75.81 D065626 613282 NS5ATP6 regulated the expression of miR-577, which directly targeted and regulated FGF21. target gene hsa-mir-9 Fatty Liver, Non-Alcoholic 27756894 disease of metabolism DOID:0080208 K75.81 D065626 613282 Altered microRNA-9 Expression Level is Directly Correlated with Pathogenesis of Nonalcoholic Fatty Liver Disease by Targeting Onecut2 and SIRT1. target gene hsa-mir-142 Fever 26825461 R50.9 D005334 RBM3 regulates temperature sensitive miR-142-5p and miR-143 (thermomiRs), which target immune genes and control fever. target gene hsa-mir-143 Fever 26825461 R50.9 D005334 RBM3 regulates temperature sensitive miR-142-5p and miR-143 (thermomiRs), which target immune genes and control fever. target gene hsa-mir-150 Fever 24907421 R50.9 D005334 We demonstrate for the first time that augmented miR-150 expression with depressed SOCS1 expression in CD14(+) cells are associated with the pathogenesis of DHF. target gene hsa-mir-373 Fibrosarcoma 21898400 disease of cellular proliferation DOID:3355 D005354 HP:0100244 miR-520c and miR-373 increased the expression of MMP9 by directly targeting the 3'UTRs of mRNAs of mTOR and SIRT1 and suppressing their translation; resulting in activation of the Ras/Raf/MEK/Erk signaling pathway and NF-ж╩B; and finally increasing the mRN target gene hsa-mir-429 Fibrosarcoma 28432002 disease of cellular proliferation DOID:3355 D005354 HP:0100244 miR-429 inhibits metastasis by targeting KIAA0101 in Soft Tissue Sarcoma. target gene hsa-mir-520c Fibrosarcoma 21898400 disease of cellular proliferation DOID:3355 D005354 HP:0100244 miR-520c and miR-373 increased the expression of MMP9 by directly targeting the 3'UTRs of mRNAs of mTOR and SIRT1 and suppressing their translation; resulting in activation of the Ras/Raf/MEK/Erk signaling pathway and NF-ж╩B; and finally increasing the mRN target gene hsa-mir-29a Focal Segmental Glomerulosclerosis 27460630 urinary system disease DOID:1312 N04.1 D005923 PS603278 HP:0000097 We also demonstrated that miR-29a acts as a positive regulator of Wnt/尾-catenin signaling in cultured mesangial cells and functions to protect cell apoptosis and fibrosis. target gene hsa-let-7g Follicular Atresia 25817543 D005496 let-7g regulates the apoptosis of GCs in the pig ovary by targeting TGFBR1 and down-regulating the TGF-尾 signaling pathway. target gene hsa-mir-134 Fragile X Syndrome 17982590 genetic disease DOID:14261 Q99.2 D005600 300624 spine morphology in patients with Fragile-X mental retardation syndrome (FXS) is not dissimilar from the spine structure observed on miR-134 overexpression or in neurons deficient for the miR-134 target Limk1 target gene hsa-mir-155 Fungal Keratitis 24403554 H15.8 D007634 miR-155 suppresses bacterial clearance in Pseudomonas aeruginosa-induced keratitis by targeting Rheb. target gene hsa-mir-141 Gastric Cardia Adenocarcinoma 29765447 disease of cellular proliferation DOID:6271 MicroRNA-141 inhibits proliferation of gastric cardia adenocarcinoma by targeting MACC1. target gene hsa-let-7a Gastric Neoplasms 18413822 disease of cellular proliferation DOID:10534 C16 D013274 137215 Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. target gene hsa-let-7f-1 Gastric Neoplasms 21533124 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA Let-7f Inhibits Tumor Invasion and Metastasis by Targeting MYH9 in Human Gastric Cancer. target gene hsa-let-7f-2 Gastric Neoplasms 21533124 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA Let-7f Inhibits Tumor Invasion and Metastasis by Targeting MYH9 in Human Gastric Cancer. target gene hsa-let-7g Gastric Neoplasms 25972194 disease of cellular proliferation DOID:10534 C16 D013274 137215 Hsa-let-7g miRNA regulates the anti-tumor effects of gastric cancer cells under oxidative stress through the expression of DDR genes. target gene hsa-mir-1 Gastric Neoplasms 25874496 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-1 (miR-1) inhibits gastric cancer cell proliferation and migration by targeting MET. target gene hsa-mir-100 Gastric Neoplasms 26404754 disease of cellular proliferation DOID:10534 C16 D013274 137215 This study demonstrated that miR-100 could be induced by C/EBPα and may act as a tumor suppressor gene by inhibiting ZBTB7A. target gene hsa-mir-101 Gastric Neoplasms 26573417 disease of cellular proliferation DOID:10534 C16 D013274 137215 In conclusion, the results of the present study suggested that miR-101 inhibited the proliferation and promoted DDP-induced apoptosis of DDP-resistant gastric cancer cells, at least in part via targeting VEGF-C. target gene hsa-mir-101 Gastric Neoplasms 26460960 disease of cellular proliferation DOID:10534 C16 D013274 137215 We conclude that miR-27b,miR-101 and miR-128 inhibit angiogenesis by down-regulating VEGF-C expression in gastric cancers. target gene hsa-mir-101 Gastric Neoplasms 25561270 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-101 functions as a growth-suppressive miRNA in H. pylori related GC, and that its suppressive effects are mediated mainly by repressing SOCS2 expression. target gene hsa-mir-101-1 Gastric Neoplasms 20712078 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-101-3p: MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion target gene hsa-mir-101-2 Gastric Neoplasms 20712078 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-101-3p: MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion target gene hsa-mir-103a Gastric Neoplasms 25530421 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-103a functioned as a tumour suppressor by targeting c-Myb. These findings indicate that miR-103a might play a significant role in pathogenesis of GC target gene hsa-mir-106a Gastric Neoplasms 23932924 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-106a induces multidrug resistance in gastric cancer by targeting RUNX3. target gene hsa-mir-106a Gastric Neoplasms 24108762 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-106a confers cisplatin resistance by regulating PTEN/Akt pathway in gastric cancer cells target gene hsa-mir-106a Gastric Neoplasms 24440352 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-106a targets TIMP2 to regulate invasion and metastasis of gastric cancer. target gene hsa-mir-106b Gastric Neoplasms 23803041 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-106b may promote cell cycling of gastric cancer cells through regulation of p21 and E2F5 target gene expression. target gene hsa-mir-106b Gastric Neoplasms 19153141 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-106b: inhibite p21,p27, and p57 target gene hsa-mir-106b Gastric Neoplasms 28489839 disease of cellular proliferation DOID:10534 C16 D013274 137215 Deregulation of microRNAs in gastric cancer: up regulation by miR-21 and miR-106. target gene hsa-mir-107 Gastric Neoplasms 24374340 disease of cellular proliferation DOID:10534 C16 D013274 137215 Upregulation of microRNA-107 induces proliferation in human gastric cancer cells by targeting the transcription factor FOXO1. target gene hsa-mir-10b Gastric Neoplasms 22293682 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-10b promotes cell invasion through RhoC-AKT signaling pathway by targeting HOXD10 in gastric cancer. target gene hsa-mir-1182 Gastric Neoplasms 25662441 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-1182 attenuates gastric cancer proliferation and metastasis by targeting the open reading frame of hTERT. target gene hsa-mir-1207 Gastric Neoplasms 24481448 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-1207-5p and miR-1266 suppress gastric cancer growth and invasion by targeting telomerase reverse transcriptase. target gene hsa-mir-122 Gastric Neoplasms 28337380 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-122 inhibits proliferation and invasion in gastric cancer by targeting CREB1. target gene hsa-mir-124 Gastric Neoplasms 24658854 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-124 inhibits proliferation and induces apoptosis by directly repressing EZH2 in gastric cancer. target gene hsa-mir-124 Gastric Neoplasms 25169484 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-124 inhibits growth and invasion of gastric cancer by targeting ROCK1. target gene hsa-mir-124 Gastric Neoplasms 28829503 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-124 inhibits cell invasion and epithelial-mesenchymal transition by directly repressing Snail2 in gastric cancer target gene hsa-mir-124 Gastric Neoplasms 28941308 disease of cellular proliferation DOID:10534 C16 D013274 137215 In vivo and in vitro effects of microRNA-124 on human gastric cancer by targeting JAG1 through the Notch signaling pathway. target gene hsa-mir-124 Gastric Neoplasms 29234151 disease of cellular proliferation DOID:10534 C16 D013274 137215 SRGAP1, a crucial target of miR-340 and miR-124, functions as a potential oncogene in gastric tumorigenesis target gene hsa-mir-124-1 Gastric Neoplasms 22450659 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-124 Inhibits Cell Proliferation in Gastric Cancer through Downregulation of SPHK1. target gene hsa-mir-124-2 Gastric Neoplasms 22450659 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-124 Inhibits Cell Proliferation in Gastric Cancer through Downregulation of SPHK1. target gene hsa-mir-124-3 Gastric Neoplasms 22450659 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-124 Inhibits Cell Proliferation in Gastric Cancer through Downregulation of SPHK1. target gene hsa-mir-125a Gastric Neoplasms 26398444 disease of cellular proliferation DOID:10534 C16 D013274 137215 Collectively, our results indicated that miR-125a regulated the paracrine of VEGF-A in gastric cancer and thereby controlled the angiogenesis of the tumor. target gene hsa-mir-125a Gastric Neoplasms 21220473 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-125a-5p is an independent prognostic factor in gastric cancer,and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. target gene hsa-mir-125b Gastric Neoplasms 24846940 disease of cellular proliferation DOID:10534 C16 D013274 137215 Expression profiling and functional analysis of hsa-miR-125b and its target genes in drug-resistant cell line of human gastric cancer. target gene hsa-mir-125b Gastric Neoplasms 26504803 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-125b Suppresses Proliferation and Invasion by Targeting MCL1 in Gastric Cancer. target gene hsa-mir-126 Gastric Neoplasms 24055140 disease of cellular proliferation DOID:10534 C16 D013274 137215 CRKL promotes cell proliferation in gastric cancer and is negatively regulated by miR-126. target gene hsa-mir-126 Gastric Neoplasms 24969300 disease of cellular proliferation DOID:10534 C16 D013274 137215 Mir-126 inhibits growth of SGC-7901 cells by synergistically targeting the oncogenes PI3KR2 and Crk, and the tumor suppressor PLK2. target gene hsa-mir-126 Gastric Neoplasms 26054677 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-126 inhibits cell proliferation in gastric cancer by targeting LAT-1. target gene hsa-mir-1266 Gastric Neoplasms 24481448 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-1207-5p and miR-1266 suppress gastric cancer growth and invasion by targeting telomerase reverse transcriptase. target gene hsa-mir-1271 Gastric Neoplasms 24875127 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2. target gene hsa-mir-1271 Gastric Neoplasms 26159618 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-1271 Inhibits Cell Proliferation, Invasion and EMT in Gastric Cancer by Targeting FOXQ1. target gene hsa-mir-1274a Gastric Neoplasms 25753202 disease of cellular proliferation DOID:10534 C16 D013274 137215 The role of microRNA-1274a in the tumorigenesis of gastric cancer: accelerating cancer cell proliferation and migration via directly targeting FOXO4. target gene hsa-mir-128 Gastric Neoplasms 26460960 disease of cellular proliferation DOID:10534 C16 D013274 137215 We conclude that miR-27b,miR-101 and miR-128 inhibit angiogenesis by down-regulating VEGF-C expression in gastric cancers. target gene hsa-mir-129-1 Gastric Neoplasms 25008064 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-129-1-3p inhibits cell migration by targeting BDKRB2 in gastric cancer. target gene hsa-mir-1303 Gastric Neoplasms 24647998 disease of cellular proliferation DOID:10534 C16 D013274 137215 Downregulation of miR-1303 can inhibit proliferation, migration and invasion of GC cells by targeting CLDN18. target gene hsa-mir-130a Gastric Neoplasms 26134263 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-130a acts as a potential diagnostic biomarker and promotes gastric cancer migration, invasion and proliferation by targeting RUNX3. target gene hsa-mir-130a Gastric Neoplasms 28831264 disease of cellular proliferation DOID:10534 C16 D013274 137215 microRNA-130a is an oncomir suppressing the expression of CRMP4 in gastric cancer target gene hsa-mir-130b Gastric Neoplasms 20176475 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-130b:MicroRNA-130b regulates the tumour suppressor RUNX3 in gastric cancer target gene hsa-mir-133 Gastric Neoplasms 25152372 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-133 is a key negative regulator of CDC42-PAK pathway in gastric cancer. target gene hsa-mir-133a Gastric Neoplasms 24613927 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer. target gene hsa-mir-133b Gastric Neoplasms 24613927 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer. target gene hsa-mir-133b Gastric Neoplasms 23296701 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-133b acts as a tumor suppressor and negatively regulates FGFR1 in gastric cancer target gene hsa-mir-135a-1 Gastric Neoplasms 22310976 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-135a targets JAK2 and inhibits gastric cancer cell proliferation. target gene hsa-mir-135a-2 Gastric Neoplasms 22310976 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-135a targets JAK2 and inhibits gastric cancer cell proliferation. target gene hsa-mir-137 Gastric Neoplasms 21221794 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-137 Is Frequently Down-Regulated in Gastric Cancer and Is a Negative Regulator of Cdc42. target gene hsa-mir-141 Gastric Neoplasms 24276755 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-141 suppresses proliferation and motility of gastric cancer cells by targeting HDGF. target gene hsa-mir-141 Gastric Neoplasms 24628843 disease of cellular proliferation DOID:10534 C16 D013274 137215 Altogether, these findings demonstrated that the H. pylori infection could modulate cisplatin sensitivity through miR-141-mediated regulation of KEAP1. target gene hsa-mir-141 Gastric Neoplasms 24732377 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-141 may play a pivotal role in controlling gastric cancer invasion through regulating STAT4 and maybe a potential target to treat gastric cancer. target gene hsa-mir-141 Gastric Neoplasms 25975736 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-141 inhibits migration of gastric cancer by targeting zinc finger E-box-binding homeobox 2. target gene hsa-mir-141 Gastric Neoplasms 26160158 disease of cellular proliferation DOID:10534 C16 D013274 137215 These results were the first to demonstrate that H19 and miR-141 could compete with each other and affect their target genes in gastric cancer,which provide important clues for understanding the key roles of lncRNA-miRNA functional network in cancer. target gene hsa-mir-143 Gastric Neoplasms 24283360 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-143 regulates collagen type III expression in stromal fibroblasts of scirrhous type gastric cancer. target gene hsa-mir-143 Gastric Neoplasms 24616567 disease of cellular proliferation DOID:10534 C16 D013274 137215 Both miR-143-5p and miR-143-3p function as anti-oncomirs in gastric cancer. However, miR-143-5p alone directly targets COX-2, and it exhibits a stronger tumor suppressive effect than miR-143-3p. target gene hsa-mir-143 Gastric Neoplasms 25492481 disease of cellular proliferation DOID:10534 C16 D013274 137215 hsa-mir-143 could modulate cisplatin resistance of human gastric cancer cell line at least in part by targeting IGF1R and BCL2. target gene hsa-mir-143 Gastric Neoplasms 29321084 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-143 inhibits cell proliferation of gastric cancer cells through targeting GATA6 target gene hsa-mir-144 Gastric Neoplasms 25927670 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-144 inhibits the metastasis of gastric cancer by targeting MET expression. target gene hsa-mir-144 Gastric Neoplasms 29456712 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-144 functions as a tumor suppressor in gastric cancer by targeting cyclooxygenase-2 target gene hsa-mir-145 Gastric Neoplasms 24613927 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer. target gene hsa-mir-145 Gastric Neoplasms 25051317 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-145 may contribute to the progression of scirrhous type GC by regulating activation of peri-tumoral fibroblasts target gene hsa-mir-145 Gastric Neoplasms 25470111 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-145 inhibits invasion of gastric cancer cells not only by down-regulating cytoplasmic CTNND1 expression but also by inducing the translocation of CTNND1 and E-cadherin from the cytoplasm to the cell membrane through down-regulating N-cadherin. target gene hsa-mir-145 Gastric Neoplasms 25762621 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-145 mediates the antiproliferative and gene regulatory effects of vitamin D3 by directly targeting E2F3 in gastric cancer cells. target gene hsa-mir-145 Gastric Neoplasms 23233482 disease of cellular proliferation DOID:10534 C16 D013274 137215 microRNA-145 targets v-ets erythroblastosis virus E26 oncogene homolog 1 to suppress the invasion, metastasis and angiogenesis of gastric cancer cells target gene hsa-mir-146a Gastric Neoplasms 23982143 disease of cellular proliferation DOID:10534 C16 D013274 137215 Regulation of UHRF1 by miR-146a/b modulates gastric cancer invasion and metastasis target gene hsa-mir-146a Gastric Neoplasms 22020746 disease of cellular proliferation DOID:10534 C16 D013274 137215 Increased miR-146a in gastric cancer directly targets SMAD4 and is involved in modulating cell proliferation and apoptosis. target gene hsa-mir-146a Gastric Neoplasms 22711166 disease of cellular proliferation DOID:10534 C16 D013274 137215 microRNA-146a targets the L1 cell adhesion molecule and suppresses the metastatic potential of gastric cancer. target gene hsa-mir-146a Gastric Neoplasms 23435376 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-146a acts as a metastasis suppressor in gastric cancer by targeting WASF2 target gene hsa-mir-146a Gastric Neoplasms 28560435 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-146a promotes gastric cancer cell apoptosis by targeting transforming growth factor β-activated kinase 1. target gene hsa-mir-146b Gastric Neoplasms 23982143 disease of cellular proliferation DOID:10534 C16 D013274 137215 Regulation of UHRF1 by miR-146a/b modulates gastric cancer invasion and metastasis target gene hsa-mir-148a Gastric Neoplasms 25341915 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-148a expression is down-regulated in gastric cancer tissues and inhibits gastric cancer cell proliferation. CDC25B may be the target gene ofmiR-148a that plays a role in tumor suppressor. target gene hsa-mir-148a Gastric Neoplasms 23549984 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-148a can regulate runt-related transcription factor 3 gene expression via modulation of DNA methyltransferase 1 in gastric cancer target gene hsa-mir-148a Gastric Neoplasms 21552422 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-148a Promoted Cell Proliferation by Targeting p27 in Gastric Cancer Cells. target gene hsa-mir-148a Gastric Neoplasms 21994419 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-148a Suppresses Tumor Cell Invasion and Metastasis by Downregulating ROCK1 in Gastric Cancer. target gene hsa-mir-149 Gastric Neoplasms 23144691 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-149 inhibits proliferation and cell cycle progression through the targeting of ZBTB2 in human gastric cancer target gene hsa-mir-150 Gastric Neoplasms 20067763 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-150 promotes gastric cancer proliferation by negatively regulating the pro-apoptotic gene EGR2 target gene hsa-mir-152 Gastric Neoplasms 25119599 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-152 suppresses gastric cancer cell proliferation and motility by targeting CD151. target gene hsa-mir-155 Gastric Neoplasms 27113301 disease of cellular proliferation DOID:10534 C16 D013274 137215 Target research on tumor biology characteristics of mir-155-5p regulation on gastric cancer cell. target gene hsa-mir-15b Gastric Neoplasms 18449891 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. target gene hsa-mir-16 Gastric Neoplasms 28667493 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-16-1 Targeted Silences Far Upstream Element Binding Protein 1 to Advance the Chemosensitivity to Adriamycin in Gastric Cancer. target gene hsa-mir-16-1 Gastric Neoplasms 18449891 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. target gene hsa-mir-16-2 Gastric Neoplasms 18449891 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. target gene hsa-mir-17 Gastric Neoplasms 24801601 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-17-5p promotes proliferation by targeting SOCS6 in gastric cancer cells. target gene hsa-mir-17 Gastric Neoplasms 25115392 disease of cellular proliferation DOID:10534 C16 D013274 137215 F-box protein FBXO31 is down-regulated in gastric cancer and negatively regulated by miR-17 and miR-20a. target gene hsa-mir-17 Gastric Neoplasms 25760688 disease of cellular proliferation DOID:10534 C16 D013274 137215 Inhibition of microRNA-17/20a suppresses cell proliferation in gastric cancer by modulating UBE2C expression. target gene hsa-mir-181a Gastric Neoplasms 28447759 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-181a modulates proliferation, migration and autophagy in AGS gastric cancer cells and downregulates MTMR3. target gene hsa-mir-181a-2 Gastric Neoplasms 22581522 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-181a promotes gastric cancer by negatively regulating tumor suppressor KLF6. target gene hsa-mir-181b Gastric Neoplasms 29113265 disease of cellular proliferation DOID:10534 C16 D013274 137215 The present study confirmed that CDX2 was suppressed by activation of the IL-6/STAT3 signaling pathway via miR-181b in vitro target gene hsa-mir-181b-1 Gastric Neoplasms 20162574 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines target gene hsa-mir-181b-1 Gastric Neoplasms 22539488 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-181b targets cAMP responsive element binding protein 1 in gastric adenocarcinomas. target gene hsa-mir-181b-2 Gastric Neoplasms 20162574 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines target gene hsa-mir-181b-2 Gastric Neoplasms 22539488 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-181b targets cAMP responsive element binding protein 1 in gastric adenocarcinomas. target gene hsa-mir-182 Gastric Neoplasms 25682742 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-182 inhibits proliferation through targeting oncogenic ANUBL1 in gastric cancer. target gene hsa-mir-182 Gastric Neoplasms 22325466 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-182 targets cAMP-responsive element-binding protein 1 and suppresses cell growth in human gastric adenocarcinoma. target gene hsa-mir-183 Gastric Neoplasms 25337200 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-183 inhibits invasion of gastric cancer by targeting Ezrin. target gene hsa-mir-185 Gastric Neoplasms 24763054 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-185 regulates chemotherapeutic sensitivity in gastric cancer by targeting apoptosis repressor with caspase recruitment domain. target gene hsa-mir-185 Gastric Neoplasms 26191199 disease of cellular proliferation DOID:10534 C16 D013274 137215 TRIM29 functions as an oncogene in gastric cancer and is regulated by miR-185. target gene hsa-mir-18a Gastric Neoplasms 26173586 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-18a modulates P53 expression by targeting IRF2 in gastric cancer patients. target gene hsa-mir-18a Gastric Neoplasms 23322197 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-18a modulates STAT3 activity through negative regulation of PIAS3 during gastric adenocarcinogenesis target gene hsa-mir-19 Gastric Neoplasms 26762410 disease of cellular proliferation DOID:10534 C16 D013274 137215 MEF2D is a direct target of miR-19, which was found to be decreased in gastric cancer clinical specimens. target gene hsa-mir-191 Gastric Neoplasms 21947487 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-191 targets N-deacetylase/N-sulfotransferase 1 and promotes cell growth in human gastric carcinoma cell line MGC803. target gene hsa-mir-194 Gastric Neoplasms 24748184 disease of cellular proliferation DOID:10534 C16 D013274 137215 Our study clearly demonstrates that miR-194 inhibits the acquisition of the EMT phenotype in gastric cancer cells by downregulating FoxM1, thereby inhibiting cell migration and invasion during cancer progression. target gene hsa-mir-196a Gastric Neoplasms 24933454 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-196a/-196b promote cell metastasis via negative regulation of radixin in human gastric cancer. target gene hsa-mir-196a Gastric Neoplasms 25773825 disease of cellular proliferation DOID:10534 C16 D013274 137215 Overexpression of mir-196a-5p is associated with lymph node metastasis and clinical stage, and enriched KEGG pathway analyses showed that targeted genes regulated by mir-196a-5p may contribute to tumorgenesis,suggesting roles as an oncogenic miRNA biomarker in gastric cancer. target gene hsa-mir-196a-1 Gastric Neoplasms 22343731 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-196a Is Up-regulated in Gastric cancer and Promotes Cell proliferation by Down-regulating p27kip1. target gene hsa-mir-196a-2 Gastric Neoplasms 22343731 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-196a Is Up-regulated in Gastric cancer and Promotes Cell proliferation by Down-regulating p27kip1. target gene hsa-mir-196b Gastric Neoplasms 24933454 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-196a/-196b promote cell metastasis via negative regulation of radixin in human gastric cancer. target gene hsa-mir-199a Gastric Neoplasms 24655788 disease of cellular proliferation DOID:10534 C16 D013274 137215 Our present study suggests that miR-199a-5p acts as an oncogene in gastric cancer and functions by targeting klotho. target gene hsa-mir-199a Gastric Neoplasms 25448600 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-199a-3p may function as a novel tumor promoter in GC and its oncogenic activity may involve the direct targeting and inhibition of ZHX1. target gene hsa-mir-19a Gastric Neoplasms 24675462 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-19a/b modulate the metastasis of gastric cancer cells by targeting the tumour suppressor MXD1. target gene hsa-mir-19b Gastric Neoplasms 24675462 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-19a/b modulate the metastasis of gastric cancer cells by targeting the tumour suppressor MXD1. target gene hsa-mir-19b Gastric Neoplasms 23868977 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-19b/20a/92a regulates the self-renewal and proliferation of gastric cancer stem cells. target gene hsa-mir-200a Gastric Neoplasms 23381389 disease of cellular proliferation DOID:10534 C16 D013274 137215 Downregulated microRNA-200a promotes EMT and tumor growth through the wnt/beta-catenin pathway by targeting the E-cadherin repressors ZEB1/ZEB2 in gastric adenocarcinoma target gene hsa-mir-200b Gastric Neoplasms 21993663 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. target gene hsa-mir-200b Gastric Neoplasms 22311119 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-200b Regulates Cell Proliferation, Invasion, and Migration by Directly Targeting ZEB2 in Gastric Carcinoma. target gene hsa-mir-200c Gastric Neoplasms 23821457 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-200c regulates the sensitivity of chemotherapy of gastric cancer SGC7901/DDP cells by directly targeting RhoE. target gene hsa-mir-200c Gastric Neoplasms 24885194 disease of cellular proliferation DOID:10534 C16 D013274 137215 Together, these findings demonstrate that the ubiquitin ligase Cbl-b represses IGF-I-induced EMT, likely through targeting IGF-IR for degradation and further inhibiting the Akt/ERK-miR-200c-ZEB2 axis in gastric cancer cells. target gene hsa-mir-200c Gastric Neoplasms 21993663 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. target gene hsa-mir-200c Gastric Neoplasms 29138864 disease of cellular proliferation DOID:10534 C16 D013274 137215 Expression level of microRNA-200c is associated with cell morphology in vitro and histological differentiation through regulation of ZEB1/2 and E-cadherin in gastric carcinoma. target gene hsa-mir-203 Gastric Neoplasms 25373785 disease of cellular proliferation DOID:10534 C16 D013274 137215 Down-regulation of miR-203 induced by Helicobacter pylori infection promotes the proliferation and invasion of gastric cancer by targeting CASK. target gene hsa-mir-203 Gastric Neoplasms 26980572 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-203 suppresses gastric cancer growth by targeting PIBF1/Akt signaling. target gene hsa-mir-204 Gastric Neoplasms 23768087 disease of cellular proliferation DOID:10534 C16 D013274 137215 Our results suggest that down-regulation of mir-204 promotes gastric cancer cell invasion by activating the SIRT1-LKB1 pathway. These data demonstrate that mir-204 plays an important role in regulating metastasis of gastric cancer, which is involved in post-transcriptional repression of SIRT1. target gene hsa-mir-204 Gastric Neoplasms 24984017 disease of cellular proliferation DOID:10534 C16 D013274 137215 Taken together, our findings demonstrated that miR-204 may act as a tumor suppressor in H. pylori induced gastric cancer by targeting SOX4. target gene hsa-mir-204 Gastric Neoplasms 25429829 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-204-5p acts as a tumor suppressor in GC through inhibiting USP47 and RAB22A. target gene hsa-mir-204 Gastric Neoplasms 21416062 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-204, which was predicted to target ezrin, was downregulated in gastric cancer cells and gastric carcinomas. MiR-204 inhibited ezrin expression, Ras activation, cell growth and cell migration target gene hsa-mir-204 Gastric Neoplasms 23152059 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer target gene hsa-mir-205 Gastric Neoplasms 27082508 disease of cellular proliferation DOID:10534 C16 D013274 137215 transfection with miR鈥?05, the epithelial marker CDH1 (E鈥慶adherin) was upregulated, and the mesenchymal markers CDH2 (N鈥慶adherin) and vimentin were suppressed. target gene hsa-mir-205 Gastric Neoplasms 28987942 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-205 regulation of ICT1 has an oncogenic potential via promoting the migration and invasion of gastric cancer cells. target gene hsa-mir-206 Gastric Neoplasms 23348698 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-206 inhibits gastric cancer proliferation in part by repressing CyclinD2 target gene hsa-mir-20a Gastric Neoplasms 23924943 disease of cellular proliferation DOID:10534 C16 D013274 137215 Involvement of miR-20a in promoting gastric cancer progression by targeting early growth response 2 (EGR2). target gene hsa-mir-20a Gastric Neoplasms 25115392 disease of cellular proliferation DOID:10534 C16 D013274 137215 F-box protein FBXO31 is down-regulated in gastric cancer and negatively regulated by miR-17 and miR-20a. target gene hsa-mir-20a Gastric Neoplasms 25760688 disease of cellular proliferation DOID:10534 C16 D013274 137215 Inhibition of microRNA-17/20a suppresses cell proliferation in gastric cancer by modulating UBE2C expression. target gene hsa-mir-20a Gastric Neoplasms 23868977 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-19b/20a/92a regulates the self-renewal and proliferation of gastric cancer stem cells. target gene hsa-mir-21 Gastric Neoplasms 24659669 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-21 is overexpressed in gastric cancer and its aberrant expression may have important role in gastric cancer growth and dissemination by modulating the expression of the tumor suppressors PTEN and PDCD4, as well as by modulating the pathways involved in mediating cell growth, migration, invasion and apoptosis. Targeting miR-21 may help develop novel therapeutics for gastric cancer, once its pathophysiology is completely investigated. target gene hsa-mir-21 Gastric Neoplasms 24154840 disease of cellular proliferation DOID:10534 C16 D013274 137215 To our knowledge, this study was the first reveal the miR-21/PTEN pathway regulated the sensitivity of HER2-positive GC cell lines to trastuzumab through modulation apoptosis. These findings suggest that this pathway may be crucial to the mechanism of resistance to trastuzumab in GC, which may lead to the development of individualized treatment in clinical practice. target gene hsa-mir-21 Gastric Neoplasms 24821435 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-21 regulates N-methyl-N-nitro-N'-nitrosoguanidine-induced gastric tumorigenesis by targeting FASLG and BTG2. target gene hsa-mir-21 Gastric Neoplasms 22267008 disease of cellular proliferation DOID:10534 C16 D013274 137215 microRNA-21 promotes tumor proliferation and invasion in gastric cancer by targeting PTEN. target gene hsa-mir-21 Gastric Neoplasms 22464652 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-21 inhibits Serpini1, a gene with novel tumour suppressive effects in gastric cancer. target gene hsa-mir-21 Gastric Neoplasms 22792096 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-21 Is a Promising Novel Biomarker for Lymph Node Metastasis in Patients with Gastric Cancer. target gene hsa-mir-21 Gastric Neoplasms 23466500 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN target gene hsa-mir-21 Gastric Neoplasms 27611950 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-21 promotes TGF-β1-induced epithelial-mesenchymal transition in gastric cancer through up-regulating PTEN expression. target gene hsa-mir-21 Gastric Neoplasms 29101039 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-21 modulates prostaglandin signaling and promotes gastric tumorigenesis by targeting 15-PGDH. target gene hsa-mir-21 Gastric Neoplasms 29687845 disease of cellular proliferation DOID:10534 C16 D013274 137215 miRNA-21 may promote the growth of gastric cancer cells by adjusting and controlling PTEN/Akt signal passage mediated PEG2 target gene hsa-mir-212 Gastric Neoplasms 23794145 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-212 inhibits proliferation of gastric cancer by directly repressing retinoblastoma binding protein 2. target gene hsa-mir-214 Gastric Neoplasms 21688200 disease of cellular proliferation DOID:10534 C16 D013274 137215 Down-Regulated miRNA-214 Induces a Cell Cycle G1 Arrest in Gastric Cancer Cells by Up-Regulating the PTEN Protein. target gene hsa-mir-217 Gastric Neoplasms 25869101 disease of cellular proliferation DOID:10534 C16 D013274 137215 microRNA-217 inhibits tumor progression and metastasis by downregulating EZH2 and predicts favorable prognosis in gastric cancer. target gene hsa-mir-217 Gastric Neoplasms 26098560 disease of cellular proliferation DOID:10534 C16 D013274 137215 The MicroRNA-217 Functions as a Potential Tumor Suppressor in Gastric Cancer by Targeting GPC5. target gene hsa-mir-218 Gastric Neoplasms 25170221 disease of cellular proliferation DOID:10534 C16 D013274 137215 Our results indicated that targeting miR-218 may provide a strategy for blocking the development of gastric cancer and reverse the multi-drug resistance of gastric cell lines. target gene hsa-mir-218 Gastric Neoplasms 26261515 disease of cellular proliferation DOID:10534 C16 D013274 137215 These findings suggest that miR-218 inhibits MDR of gastric cancer cells by down-regulating SMO expression. target gene hsa-mir-218-1 Gastric Neoplasms 20300657 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. target gene hsa-mir-218-2 Gastric Neoplasms 20300657 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. target gene hsa-mir-22 Gastric Neoplasms 24495805 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-22 suppresses the proliferation and invasion of gastric cancer cells by inhibiting CD151. target gene hsa-mir-22 Gastric Neoplasms 25323629 disease of cellular proliferation DOID:10534 C16 D013274 137215 microRNA-22 acts as a metastasis suppressor by targeting metadherin in gastric cancer. target gene hsa-mir-22 Gastric Neoplasms 23529765 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-22 is down-regulated in gastric cancer, and its overexpression inhibits cell migration and invasion via targeting transcription factor Sp1 target gene hsa-mir-221 Gastric Neoplasms 19153141 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-221: inhibite p21,p27, and p57 target gene hsa-mir-222 Gastric Neoplasms 19153141 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-222: inhibite p21,p27, and p57 target gene hsa-mir-222 Gastric Neoplasms 22321642 disease of cellular proliferation DOID:10534 C16 D013274 137215 Increased miR-222 in H. pylori-associated gastric cancer correlated with tumor progression by promoting cancer cell proliferation and targeting RECK. target gene hsa-mir-223 Gastric Neoplasms 25159729 disease of cellular proliferation DOID:10534 C16 D013274 137215 The sensitivity of gastric cancer to trastuzumab is regulated by the miR-223/FBXW7 pathway. target gene hsa-mir-223 Gastric Neoplasms 21628394 disease of cellular proliferation DOID:10534 C16 D013274 137215 miRNA-223 Promotes Gastric Cancer Invasion and Metastasis by Targeting Tumor Suppressor EPB41L3. target gene hsa-mir-223 Gastric Neoplasms 22270966 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-223 functions as an oncogene in human gastric cancer by targeting FBXW7/hCdc4. target gene hsa-mir-223 Gastric Neoplasms 22470493 disease of cellular proliferation DOID:10534 C16 D013274 137215 Stathmin1 Plays Oncogenic Role and Is a Target of MicroRNA-223 in Gastric Cancer. target gene hsa-mir-23a Gastric Neoplasms 24997345 disease of cellular proliferation DOID:10534 C16 D013274 137215 Downregulation of PPP2R5E expression by miR-23a suppresses apoptosis to facilitate the growth of gastric cancer cells. target gene hsa-mir-23a Gastric Neoplasms 23553990 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-23a in Amplified 19p13.13 Loci Targets Metallothionein 2A and Promotes Growth in Gastric Cancer Cells target gene hsa-mir-23b Gastric Neoplasms 25996293 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2. target gene hsa-mir-23b Gastric Neoplasms 28981115 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-23a/b promote tumor growth and suppress apoptosis by targeting PDCD4 in gastric cancer. target gene hsa-mir-25 Gastric Neoplasms 25043310 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-25 promotes gastric cancer migration, invasion and proliferation by directly targeting transducer of ERBB2, 1 and correlates with poor survival. target gene hsa-mir-25 Gastric Neoplasms 25944166 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-25 promotes gastric cancer proliferation, invasion, and migration by directly targeting F-box and WD-40 Domain Protein 7, FBXW7. target gene hsa-mir-25 Gastric Neoplasms 24078004 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-25 promotes gastric cancer cells growth and motility by targeting RECK. target gene hsa-mir-25 Gastric Neoplasms 19153141 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-25: inhibite p21,p27, and p57 target gene hsa-mir-26a Gastric Neoplasms 26458859 disease of cellular proliferation DOID:10534 C16 D013274 137215 Our results suggest that miR-26a can improve the sensitivity of GC cells to cisplatin-based chemotherapies through targeting NRAS and E2F2, and provide the first evidence of the potential utility of miR-26a as a sensitizer in chemotherapy for GC. target gene hsa-mir-27a Gastric Neoplasms 28327189 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-27a contributes to the malignant behavior of gastric cancer cells by directly targeting PH domain and leucine-rich repeat protein phosphatase 2. target gene hsa-mir-27b Gastric Neoplasms 26460960 disease of cellular proliferation DOID:10534 C16 D013274 137215 We conclude that miR-27b,miR-101 and miR-128 inhibit angiogenesis by down-regulating VEGF-C expression in gastric cancers. target gene hsa-mir-27b Gastric Neoplasms 29393383 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-27b may act as a potential biomarker for differentiating patients with GC from healthy controls, and serve as a tumor suppressor in GC by targeting VEGFC target gene hsa-mir-296 Gastric Neoplasms 23353818 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-296-5p increases proliferation in gastric cancer through repression of Caudal-related homeobox 1 target gene hsa-mir-29a Gastric Neoplasms 25997819 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-29a inhibits cell migration and invasion via targeting Roundabout homolog 1 in gastric cancer cells. target gene hsa-mir-29a Gastric Neoplasms 24209632 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-29a suppresses growth and invasion of gastric cancer cells in vitro by targeting VEGF-A. target gene hsa-mir-29a Gastric Neoplasms 21998710 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-29a Inhibits Cell Proliferation and Induces Cell Cycle Arrest through the Downregulation of p42.3 in Human Gastric Cancer. target gene hsa-mir-29b Gastric Neoplasms 26564501 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-29b can enhance the sensitivity of S gastric cancer cell by directly targeting PI3K/Akt pathway. target gene hsa-mir-29c Gastric Neoplasms 24054006 disease of cellular proliferation DOID:10534 C16 D013274 137215 There are special miRNA expression profile in gastric cancer. The expression of miR-29c is closely related to biological behavior of human gastric cancer. miR-29c is involved in targeted regulation of Mcl-1, and may be one of mechanisms of the carcinogenesis of gastric cancer. target gene hsa-mir-29c Gastric Neoplasms 23442884 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-29c is downregulated in gastric carcinomas and regulates cell proliferation by targeting RCC2 target gene hsa-mir-29c Gastric Neoplasms 28173777 disease of cellular proliferation DOID:10534 C16 D013274 137215 microRNA-29c inhibits cell proliferation by targeting NASP in human gastric cancer. target gene hsa-mir-301a Gastric Neoplasms 23338485 disease of cellular proliferation DOID:10534 C16 D013274 137215 Overexpressed miR-301a promotes cell proliferation and invasion by targeting RUNX3 in gastric cancer target gene hsa-mir-30a Gastric Neoplasms 24447545 disease of cellular proliferation DOID:10534 C16 D013274 137215 RUNX3 regulates vimentin expression via miR-30a during epithelial-mesenchymal transition in gastric cancer cells. target gene hsa-mir-320 Gastric Neoplasms 28713899 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-320a serves as a negative regulator in the progression of gastric cancer by targeting RAB14. target gene hsa-mir-326 Gastric Neoplasms 26359764 disease of cellular proliferation DOID:10534 C16 D013274 137215 Our study demonstrated that miR-326 overexpression was a poor prognostic marker for gastric cancer patients, and miR-326 served as a tumor suppressor in gastric cancer via directly regulating FSCN1. target gene hsa-mir-329 Gastric Neoplasms 25654811 disease of cellular proliferation DOID:10534 C16 D013274 137215 By downregulating TIAM1 expression, microRNA-329 suppresses gastric cancer invasion and growth. target gene hsa-mir-331 Gastric Neoplasms 20510161 disease of cellular proliferation DOID:10534 C16 D013274 137215 miRNA-331-3p:miRNA-331-3p directly targets E2F1 and induces growth arrest in human gastric cancer target gene hsa-mir-335 Gastric Neoplasms 21822301 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1. target gene hsa-mir-338 Gastric Neoplasms 23826132 disease of cellular proliferation DOID:10534 C16 D013274 137215 Epigenetic silencing of miR-338-3p contributes to tumorigenicity in gastric cancer by targeting SSX2IP. target gene hsa-mir-338 Gastric Neoplasms 24375644 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-338-3p suppresses gastric cancer progression through a PTEN-AKT axis by targeting P-REX2a. target gene hsa-mir-338 Gastric Neoplasms 24736504 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-338 inhibits growth, invasion and metastasis of gastric cancer by targeting NRP1 expression. target gene hsa-mir-338 Gastric Neoplasms 25945841 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-338-3p inhibits epithelial-mesenchymal transition in gastric cancer cells by targeting ZEB2 and MACC1/Met/Akt signaling. target gene hsa-mir-340 Gastric Neoplasms 29234151 disease of cellular proliferation DOID:10534 C16 D013274 137215 SRGAP1, a crucial target of miR-340 and miR-124, functions as a potential oncogene in gastric tumorigenesis target gene hsa-mir-34a Gastric Neoplasms 24837198 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-34A inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression. target gene hsa-mir-34a Gastric Neoplasms 26035691 disease of cellular proliferation DOID:10534 C16 D013274 137215 Depletion of histone deacetylase 1 inhibits metastatic abilities of gastric cancer cells by regulating the miR-34a/CD44 pathway. target gene hsa-mir-34a Gastric Neoplasms 23264087 disease of cellular proliferation DOID:10534 C16 D013274 137215 Expression and regulatory function of miRNA-34a in targeting survivin in gastric cancer cells target gene hsa-mir-34a Gastric Neoplasms 27497057 disease of cellular proliferation DOID:10534 C16 D013274 137215 Our NVs-mediated miR-34a delivery system specifically increased endogenous target miR levels, thereby attenuating proliferation and migration of gastric cancer cells by repressing the expression of CD44 with decreased levels of Bcl-2, Oct 3/4 and Nanog genes. target gene hsa-mir-34a Gastric Neoplasms 29581731 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-34a regulates proliferation and apoptosis of gastric cancer cells by targeting silent information regulator 1 target gene hsa-mir-34c Gastric Neoplasms 23423488 disease of cellular proliferation DOID:10534 C16 D013274 137215 Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel target gene hsa-mir-362 Gastric Neoplasms 24495516 disease of cellular proliferation DOID:10534 C16 D013274 137215 The results suggest that miR-362 plays an important role in repressing the tumor suppressor CYLD and present a novel mechanism of miRNA-mediated NF-κB activation in gastric cancer. target gene hsa-mir-362 Gastric Neoplasms 25652145 disease of cellular proliferation DOID:10534 C16 D013274 137215 Anti-miR-362-3p Inhibits Migration and Invasion of Human Gastric Cancer Cells by Its Target CD82. target gene hsa-mir-363 Gastric Neoplasms 26709677 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-363-3p showed low levels in GC tissues and cells. Enforced expression of miR-363-3p inhibited cell growth and migration of GC cells and vice versa. NOTCH1 is the targeted gene of miR-363-3p. CONCLUSIONS MiR-363-3p plays a tumor suppressor role in GC. target gene hsa-mir-370 Gastric Neoplasms 23576572 disease of cellular proliferation DOID:10534 C16 D013274 137215 Fork head box M1 is overexpressed in Helicobacter pylori-induced gastric carcinogenesis and is negatively regulated by hsa-miR-370 target gene hsa-mir-370 Gastric Neoplasms 23721824 disease of cellular proliferation DOID:10534 C16 D013274 137215 Upregulation of miR-370 contributes to the progression of gastric carcinoma via suppression of FOXO1. target gene hsa-mir-372 Gastric Neoplasms 23242208 disease of cellular proliferation DOID:10534 C16 D013274 137215 microRNA-372 maintains oncogene characteristics by targeting TNFAIP1 and affects NFkB signaling in human gastric carcinoma cells target gene hsa-mir-372 Gastric Neoplasms 19937137 disease of cellular proliferation DOID:10534 C16 D013274 137215 Taken together, these findings demonstrate an oncogenic role for miR-372 in controlling cell growth, cell cycle, and apoptosis through down-regulation of a tumor suppressor gene, LATS2. target gene hsa-mir-372 Gastric Neoplasms 24179536 disease of cellular proliferation DOID:10534 C16 D013274 137215 These findings demonstrate an oncogenic role for miR-373, similar to that of miR-372, in controlling cell growth through the downregulation of TNFAIP1. target gene hsa-mir-373 Gastric Neoplasms 24179536 disease of cellular proliferation DOID:10534 C16 D013274 137215 These findings demonstrate an oncogenic role for miR-373, similar to that of miR-372, in controlling cell growth through the downregulation of TNFAIP1. target gene hsa-mir-375 Gastric Neoplasms 25055044 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-375 may be negatively regulated by Snail and involved in gastric cancer cell migration and invasion potentially by targeting JAK2. target gene hsa-mir-375 Gastric Neoplasms 20548334 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-375:MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2 target gene hsa-mir-377 Gastric Neoplasms 25998046 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-377 predicts poor clinical outcome of gastric cancer and induces tumorigenesis by targeting multiple tumor-suppressor genes. target gene hsa-mir-378 Gastric Neoplasms 24139413 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-378 inhibits progression of human gastric cancer MGC-803 cells by targeting MAPK1 in vitro. target gene hsa-mir-409 Gastric Neoplasms 22179828 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-409 suppresses tumour cell invasion and metastasis by directly targeting radixin in gastric cancers. target gene hsa-mir-409 Gastric Neoplasms 22388101 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-409-3p regulates cell proliferation and apoptosis by targeting PHF10 in gastric cancer. target gene hsa-mir-410 Gastric Neoplasms 25136862 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-410 suppresses migration and invasion by targeting MDM2 in gastric cancer. target gene hsa-mir-421 Gastric Neoplasms 25041019 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-421 regulates apoptosis of BGC-823 gastric cancer cells by targeting caspase-3. target gene hsa-mir-425 Gastric Neoplasms 24571667 disease of cellular proliferation DOID:10534 C16 D013274 137215 NF-kappaB-dependent microRNA-425 upregulation promotes gastric cancer cell growth by targeting PTEN upon IL-1β induction. target gene hsa-mir-429 Gastric Neoplasms 21993663 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. target gene hsa-mir-449a Gastric Neoplasms 24248414 disease of cellular proliferation DOID:10534 C16 D013274 137215 This is the first report to provide evidence that miR-449a could modulate cell cycle and apoptosis through regulating cyclin D1 and BCL2 expression in SGC7901 cells. target gene hsa-mir-491 Gastric Neoplasms 29569792 disease of cellular proliferation DOID:10534 C16 D013274 137215 Downregulation of miR-491-5p promotes gastric cancer metastasis by regulating SNAIL and FGFR4. target gene hsa-mir-495 Gastric Neoplasms 22469786 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-495 and miR-551a inhibit the migration and invasion of human gastric cancer cells by directly interacting with PRL-3. target gene hsa-mir-503 Gastric Neoplasms 24931256 disease of cellular proliferation DOID:10534 C16 D013274 137215 Our findings suggest that hsa-miR-503 modulates cisplatin resistance of human gastric cancer cells at least in part by targeting IGF1R and BCL2. target gene hsa-mir-506 Gastric Neoplasms 25846731 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-506 inhibits gastric cancer proliferation and invasion by directly targeting Yap1. target gene hsa-mir-506 Gastric Neoplasms 26362716 disease of cellular proliferation DOID:10534 C16 D013274 137215 In conclusion, miR-506 was identified as an ETS1 targeting suppressor of metastatic invasion and angiogenesis in gastric cancer. target gene hsa-mir-508 Gastric Neoplasms 23893241 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. target gene hsa-mir-513b Gastric Neoplasms 25095979 disease of cellular proliferation DOID:10534 C16 D013274 137215 Upregulation of miR-513b inhibits cell proliferation, migration, and promotes apoptosis by targeting high mobility group-box 3 protein in gastric cancer. target gene hsa-mir-519 Gastric Neoplasms 26819420 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-may inhibit the gastric cancer cell activity through suppression of HuR expression. target gene hsa-mir-544a Gastric Neoplasms 22934698 disease of cellular proliferation DOID:10534 C16 D013274 137215 Oncogenic miR-544 is an Important Molecular Target in Gastric Cancer. target gene hsa-mir-544b Gastric Neoplasms 22934698 disease of cellular proliferation DOID:10534 C16 D013274 137215 Oncogenic miR-544 is an Important Molecular Target in Gastric Cancer. target gene hsa-mir-551a Gastric Neoplasms 22469786 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-495 and miR-551a inhibit the migration and invasion of human gastric cancer cells by directly interacting with PRL-3. target gene hsa-mir-570 Gastric Neoplasms 23430453 disease of cellular proliferation DOID:10534 C16 D013274 137215 A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma target gene hsa-mir-622 Gastric Neoplasms 21528065 disease of cellular proliferation DOID:10534 C16 D013274 137215 Down-regulation of miR-622 in gastric cancer promotes cellular invasion and tumor metastasis by targeting ING1 gene. target gene hsa-mir-625 Gastric Neoplasms 22677169 disease of cellular proliferation DOID:10534 C16 D013274 137215 Down-regulated miR-625 suppresses invasion and metastasis of gastric cancer by targeting ILK. target gene hsa-mir-7 Gastric Neoplasms 29467883 disease of cellular proliferation DOID:10534 C16 D013274 137215 YCS inhibits proliferation and induces apoptosis of GC cells mediated by miR-7 targeting EGFR, which may be one of the mechanisms whereby YZSJD exerts its effects on GC target gene hsa-mir-7-1 Gastric Neoplasms 22614005 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor. target gene hsa-mir-7-2 Gastric Neoplasms 22614005 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor. target gene hsa-mir-7-3 Gastric Neoplasms 22614005 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor. target gene hsa-mir-9-1 Gastric Neoplasms 20102618 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-9 targets NF-kappaB1 and regulates gastric cancer cell growth target gene hsa-mir-9-1 Gastric Neoplasms 21225631 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-9 down-regulates CDX2 expression in gastric cancer cells. target gene hsa-mir-9-1 Gastric Neoplasms 23383271 disease of cellular proliferation DOID:10534 C16 D013274 137215 microRNA-9 Suppresses the Proliferation, Invasion and Metastasis of Gastric Cancer Cells through Targeting Cyclin D1 and Ets1 target gene hsa-mir-92 Gastric Neoplasms 25095974 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-92 promotes gastric cancer cell proliferation and invasion through targeting FXR. target gene hsa-mir-9-2 Gastric Neoplasms 20102618 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-9 targets NF-kappaB1 and regulates gastric cancer cell growth target gene hsa-mir-9-2 Gastric Neoplasms 21225631 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-9 down-regulates CDX2 expression in gastric cancer cells. target gene hsa-mir-9-2 Gastric Neoplasms 23383271 disease of cellular proliferation DOID:10534 C16 D013274 137215 microRNA-9 Suppresses the Proliferation, Invasion and Metastasis of Gastric Cancer Cells through Targeting Cyclin D1 and Ets1 target gene hsa-mir-92a Gastric Neoplasms 23868977 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-19b/20a/92a regulates the self-renewal and proliferation of gastric cancer stem cells. target gene hsa-mir-93 Gastric Neoplasms 19153141 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-93: inhibite p21,p27, and p57 target gene hsa-mir-9-3 Gastric Neoplasms 20102618 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-9 targets NF-kappaB1 and regulates gastric cancer cell growth target gene hsa-mir-9-3 Gastric Neoplasms 21225631 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-9 down-regulates CDX2 expression in gastric cancer cells. target gene hsa-mir-9-3 Gastric Neoplasms 23383271 disease of cellular proliferation DOID:10534 C16 D013274 137215 microRNA-9 Suppresses the Proliferation, Invasion and Metastasis of Gastric Cancer Cells through Targeting Cyclin D1 and Ets1 target gene hsa-mir-940 Gastric Neoplasms 26317898 disease of cellular proliferation DOID:10534 C16 D013274 137215 MicroRNA-940 promotes tumor cell invasion and metastasis by downregulating ZNF24 in gastric cancer. target gene hsa-let-7a-1 Gastrointestinal Neoplasms 21349817 D37.9 D005770 let-7a is significant in suppressing gastric cancer growth in vivo and in vitro and provided the first evidence that RAB40C is negatively regulated by let-7a at the post-transcriptional level via binding to the 3'-untranslated region of RAB40C mRNA in gas target gene hsa-let-7a-2 Gastrointestinal Neoplasms 21349817 D37.9 D005770 let-7a is significant in suppressing gastric cancer growth in vivo and in vitro and provided the first evidence that RAB40C is negatively regulated by let-7a at the post-transcriptional level via binding to the 3'-untranslated region of RAB40C mRNA in gas target gene hsa-let-7a-3 Gastrointestinal Neoplasms 21349817 D37.9 D005770 let-7a is significant in suppressing gastric cancer growth in vivo and in vitro and provided the first evidence that RAB40C is negatively regulated by let-7a at the post-transcriptional level via binding to the 3'-untranslated region of RAB40C mRNA in gas target gene hsa-mir-106b Gastrointestinal Neoplasms 18328430 D37.9 D005770 Together, these results suggest that the miR-106b-25 cluster is involved in E2F1 posttranscriptional regulation and may play a key role in the development of TGFbeta resistance in gastric cancer. target gene hsa-mir-107 Gastrointestinal Neoplasms 21264532 D37.9 D005770 miR-107 targets cyclin-dependent kinase 6 expression, induces cell cycle G1 arrest and inhibits invasion in gastric cancer cells. target gene hsa-mir-107 Gastrointestinal Neoplasms 21029372 D37.9 D005770 MicroRNA-107, an oncogene microRNA that regulates tumour invasion and metastasis by targeting DICER1 in gastric cancer. target gene hsa-mir-126 Gastrointestinal Neoplasms 21304604 D37.9 D005770 miR-126 is a novel miRNA that targets SOX2, and PLAC1 may be a novel downstream target gene of SOX2 in gastric cancer cells. These findings suggest that aberrant over-expression of miR-126 and consequent SOX2 down-regulation may contribute to gastric carc target gene hsa-mir-155 Gastrointestinal Neoplasms 22719182 D37.9 D005770 As a possible new mechanism underlying MSI, overexpression of miR-155 has been shown to downregulate expression of MLH1, MSH2, and MSH6. Thus, a subset of MSI-positive (MSI+) cancers without known MMR defects may result from miR-155 overexpression. target gene hsa-mir-155 Gastrointestinal Neoplasms 16875667 D37.9 D005770 Therefore, we concluded that artificial miRNA can depress the expression of PRL-3, and that PRL-3 might be a potential therapeutic target for gastric cancer peritoneal metastasis. target gene hsa-mir-19a Gastrointestinal Neoplasms 23603256 D37.9 D005770 MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. target gene hsa-mir-19a Gastrointestinal Neoplasms 23621248 D37.9 D005770 miR-19a promotes cell growth and tumorigenesis through targeting SOCS1 in gastric cancer. target gene hsa-mir-19b Gastrointestinal Neoplasms 23603256 D37.9 D005770 MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. target gene hsa-mir-24 Gastrointestinal Neoplasms 20062076 D37.9 D005770 These findings establish a novel regulation of miR-24-related AE1 expression in gastric carcinogenesis and erythropoiesis. target gene hsa-mir-24 Gastrointestinal Neoplasms 23688438 D37.9 D005770 Dual-luciferase reporter assays showed that miR-24 inhibited the expression of B7-H2 through binding with the B7-H2 3'-UTR, and this inhibitory role of miR-24 was impacted by rs4819388. target gene hsa-mir-375 Gastrointestinal Neoplasms 21557705 D37.9 D005770 The genes targeted by miR-375, including JAK2 and 3'-phosphoinositide dependent protein kinase-1(PDK1), are also candidates for gastric cancer therapy target gene hsa-mir-43c Gastrointestinal Neoplasms 21156161 D37.9 D005770 Furthermore, a luciferase reporter assay demonstrates that miR-43c directly targets adherens junctions' transmembrane protein (VEZT) and suppresses VEZT protein expression. target gene hsa-mir-494 Gastrointestinal Neoplasms 22042971 D37.9 D005770 MicroRNA-494 Downregulates KIT and Inhibits Gastrointestinal Stromal Tumor Cell Proliferation. target gene hsa-mir-497 Gastrointestinal Neoplasms 21258880 D37.9 D005770 miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. target gene hsa-mir-137 Gastrointestinal Stromal Tumor 25027394 disease of cellular proliferation DOID:9253 C49.A D046152 606764 MiR-137 regulates epithelial-mesenchymal transition in gastrointestinal stromal tumor. target gene hsa-mir-17 Gastrointestinal Stromal Tumor 23969726 disease of cellular proliferation DOID:9253 C49.A D046152 606764 MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours. target gene hsa-mir-18 Gastrointestinal Stromal Tumor 23969726 disease of cellular proliferation DOID:9253 C49.A D046152 606764 MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours. target gene hsa-mir-19a Gastrointestinal Stromal Tumor 23969726 disease of cellular proliferation DOID:9253 C49.A D046152 606764 MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours. target gene hsa-mir-19b-1 Gastrointestinal Stromal Tumor 23969726 disease of cellular proliferation DOID:9253 C49.A D046152 606764 MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours. target gene hsa-mir-20a Gastrointestinal Stromal Tumor 23969726 disease of cellular proliferation DOID:9253 C49.A D046152 606764 MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours. target gene hsa-mir-218 Gastrointestinal Stromal Tumor 24375253 disease of cellular proliferation DOID:9253 C49.A D046152 606764 MicroRNA-218 inhibits gastrointestinal stromal tumor cell and invasion by targeting KIT. target gene hsa-mir-221 Gastrointestinal Stromal Tumor 23969726 disease of cellular proliferation DOID:9253 C49.A D046152 606764 MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours. target gene hsa-mir-222 Gastrointestinal Stromal Tumor 23969726 disease of cellular proliferation DOID:9253 C49.A D046152 606764 MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours. target gene hsa-mir-335 Gastrointestinal Stromal Tumor 26214687 disease of cellular proliferation DOID:9253 C49.A D046152 606764 Our results suggest that miR-34a and miR-335 are candidate tumor suppressive miRNAs in GISTs, and that they are frequent targets of epigenetic silencing in GISTs. target gene hsa-mir-34a Gastrointestinal Stromal Tumor 26214687 disease of cellular proliferation DOID:9253 C49.A D046152 606764 Our results suggest that miR-34a and miR-335 are candidate tumor suppressive miRNAs in GISTs, and that they are frequent targets of epigenetic silencing in GISTs. target gene hsa-mir-92-1 Gastrointestinal Stromal Tumor 23969726 disease of cellular proliferation DOID:9253 C49.A D046152 606764 MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours. target gene hsa-mir-106b Giant Cell Tumor of Bone 26053181 disease of cellular proliferation DOID:4305 D018212 HP:0011847 MicroRNA-106b inhibits osteoclastogenesis and osteolysis by targeting RANKL in giant cell tumor of bone. target gene hsa-mir-126 Giant Cell Tumor of Bone 24973691 disease of cellular proliferation DOID:4305 D018212 HP:0011847 MiR-126-5p regulates osteolysis formation and stromal cell proliferation in giant cell tumor through inhibition of PTHrP. target gene hsa-let-7g Glioblastoma 27634309 D005909 HP:0100843 Let-7g-5p inhibits epithelial-mesenchymal transition consistent with reduction of glioma stem cell phenotypes by targeting VSIG4 in glioblastoma. target gene hsa-mir-100 Glioblastoma 24244722 D005909 HP:0100843 microRNA-100 targets SMRT/NCOR2, reduces proliferation, and improves survival in glioblastoma animal models. target gene hsa-mir-101 Glioblastoma 21297974 D005909 HP:0100843 Down-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2. target gene hsa-mir-101 Glioblastoma 27792996 D005909 HP:0100843 MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma. target gene hsa-mir-101 Glioblastoma 27911279 D005909 HP:0100843 MicroRNA-101 inhibits proliferation, migration and invasion of human glioblastoma by targeting SOX9. target gene hsa-mir-106a Glioblastoma 21656380 D005909 HP:0100843 MiR-106a inhibits glioma cell growth by targeting E2F1 independent of p53 status. target gene hsa-mir-106a Glioblastoma 27815074 D005909 HP:0100843 MicroRNA-106a-5p facilitates human glioblastoma cell proliferation and invasion by targeting adenomatosis polyposis coli protein. target gene hsa-mir-10a Glioblastoma 22558405 D005909 HP:0100843 a tumor suppressor, CSMD1, as a downstream target of miR-10a and miR-10b, two of the up-regulated miRNAs. target gene hsa-mir-10b Glioblastoma 21419107 D005909 HP:0100843 MicroRNA-10b induces glioma cell invasion by modulating MMP-14 and uPAR expression via HOXD10. target gene hsa-mir-10b Glioblastoma 22558405 D005909 HP:0100843 a tumor suppressor, CSMD1, as a downstream target of miR-10a and miR-10b, two of the up-regulated miRNAs. target gene hsa-mir-10b Glioblastoma 28393237 D005909 HP:0100843 MicroRNA-10b mediates TGF-β1-regulated glioblastoma proliferation, migration and epithelial-mesenchymal transition. target gene hsa-mir-124 Glioblastoma 23624869 D005909 HP:0100843 Downregulation of miR-124 promotes the growth and invasiveness of glioblastoma cells involving upregulation of PPP1R13L. target gene hsa-mir-124 Glioblastoma 23636127 D005909 HP:0100843 miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. target gene hsa-mir-124 Glioblastoma 28040710 D005909 HP:0100843 REST represses miR-124 and miR-203 to regulate distinct oncogenic properties of glioblastoma stem cells. target gene hsa-mir-124 Glioblastoma 28242198 D005909 HP:0100843 miR-124 suppresses glioblastoma growth and potentiates chemosensitivity by inhibiting AURKA. target gene hsa-mir-124a Glioblastoma 24068568 D005909 HP:0100843 The result indicates that miR-124a expression may also be modulated through the upstream targeting of REST. Preclinical studies involving inhibitors of REST and treatment with demethylating agents with the intent to increase miR-124a levels could be interesting. target gene hsa-mir-125b Glioblastoma 23857508 D005909 HP:0100843 miR-125b could play a role in the development of temozolomide resistance in GSCs. Inhibition of miR-125b expression may enhance sensitivity of GSCs to temozolomide by targeting PIAS3 on cell invasion. target gene hsa-mir-125b Glioblastoma 24356103 D005909 HP:0100843 miR-125b promotes cell proliferation by directly targeting Lin28 in glioblastoma stem cells with low expression levels of miR-125b. target gene hsa-mir-125b Glioblastoma 24643683 D005909 HP:0100843 miR-125b inhibitor enhance the chemosensitivity of glioblastoma stem cells to temozolomide by targeting Bak1. target gene hsa-mir-125b Glioblastoma 24901050 D005909 HP:0100843 miR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas. target gene hsa-mir-125b-1 Glioblastoma 22415301 D005909 HP:0100843 Myc-associated zinc finger protein (MAZ) is regulated by miR-125b and mediates VEGF-induced angiogenesis in glioblastoma. target gene hsa-mir-125b-2 Glioblastoma 22415301 D005909 HP:0100843 Myc-associated zinc finger protein (MAZ) is regulated by miR-125b and mediates VEGF-induced angiogenesis in glioblastoma. target gene hsa-mir-127 Glioblastoma 24517116 D005909 HP:0100843 Next generation sequencing analysis of miRNAs: MiR-127-3p inhibits glioblastoma proliferation and activates TGF-β signaling by targeting SKI. target gene hsa-mir-127 Glioblastoma 24604520 D005909 HP:0100843 MicroRNA-127-3p promotes glioblastoma cell migration and invasion by targeting the tumor-suppressor gene SEPT7. target gene hsa-mir-128 Glioblastoma 19010882 D005909 HP:0100843 This showed that miR-128 specifically blocked glioma self-renewal consistent with Bmi-1 down-regulation. target gene hsa-mir-128 Glioblastoma 27507538 D005909 HP:0100843 We demonstrated that miR-31 and miR-128 can bind to the 3'UTR of PVRL4 and decrease PVRL4 levels while anti-miR-31/128 increase PVRL4 levels suggesting that PVRL4 is miRNA targeted. target gene hsa-mir-129 Glioblastoma 26180082 D005909 HP:0100843 Neurotensin signaling stimulates glioblastoma cell proliferation by upregulating c-Myc and inhibiting miR-29b-1 and miR-129-3p. target gene hsa-mir-129 Glioblastoma 28068630 D005909 HP:0100843 Potential mechanisms of microRNA-129-5p in inhibiting cell processes including viability, proliferation, migration and invasiveness of glioblastoma cells U87 through targeting FNDC3B. target gene hsa-mir-133b Glioblastoma 26857280 D005909 HP:0100843 several miRNAs (miR-133b, miR-30b-3p, miR-145-5p, and miR-146a-5p) targeting EGFR target gene hsa-mir-134 Glioblastoma 23467648 D005909 HP:0100843 MiR-134 regulates the proliferation and invasion of glioblastoma cells by reducing Nanog expression target gene hsa-mir-135b Glioblastoma 25936394 D005909 HP:0100843 MicroRNA-135b exerts oncogenic activity in glioblastoma via the inhibition of glycerol kinase 5 expression. target gene hsa-mir-135b Glioblastoma 25265336 D005909 HP:0100843 miR-135b contributes to the radioresistance by targeting GSK3β in human glioblastoma multiforme cells. target gene hsa-mir-137 Glioblastoma 23714687 D005909 HP:0100843 MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. target gene hsa-mir-137 Glioblastoma 25939439 D005909 HP:0100843 MiR-137 inhibits proliferation and angiogenesis of human glioblastoma cells by targeting EZH2. target gene hsa-mir-137 Glioblastoma 28386374 D005909 HP:0100843 MicroRNA-137 inhibits growth of glioblastoma through EGFR suppression. target gene hsa-mir-139 Glioblastoma 26449464 D005909 HP:0100843 We concluded that ectopic expression of miR-139-5p in GBM cell lines significantly suppressed cell proliferation and inducing apoptosis. Bioinformatics coupled with luciferase and western blot assays also revealed that miR-139-5p suppresses glioma cell proliferation by targeting ELTD1 and regulating cell cycle. target gene hsa-mir-143 Glioblastoma 27081712 D005909 HP:0100843 miR鈥?43 inhibited the proliferation, migration and invasion of the glioblastoma cells. target gene hsa-mir-144 Glioblastoma 26250785 D005909 HP:0100843 miR-144-3p exerts anti-tumor effects in glioblastoma by targeting c-Met. target gene hsa-mir-145 Glioblastoma 22098779 D005909 HP:0100843 The expression of miR145 (a tumor-suppressive miRNA) is inversely correlated with the levels of Oct4 and Sox2 in GBM-CD133(+) cells and malignant glioma specimens.miR145 negatively regulates GBM tumorigenesis by targeting Oct4 and Sox2 in GBM-CD133(+). Using polyurethane-short branch polyethylenimine (PU-PEI) as a therapeutic-delivery vehicle, PU-PEI-mediated miR145 delivery to GBM-CD133(+) significantly inhibited their tumorigenic and CSC-like abilities and facilitated their differentiation into CD133(-)-non-CSCs. Furthermore, PU-PEI-miR145-treated GBM-CD133(+) effectively suppressed the expression of drug-resistance and anti-apoptotic genes and increased the sensitivity of the cells to radiation and temozolomide. Finally, the in vivo delivery of PU-PEI-miR145 alone significantly suppressed tumorigenesis with stemness, and synergistically improved the survival rate when used in combination with radiotherapy and temozolomide in orthotopic GBM-CD133(+)-transplanted immunocompromised mice. Therefore, PU-PEI-miR145 is a novel therapeutic approach for malignant brain tumors. target gene hsa-mir-145 Glioblastoma 22869051 D005909 HP:0100843 NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. target gene hsa-mir-145 Glioblastoma 26681767 D005909 HP:0100843 ISO attenuated SOX2 expression by specific induction of miR-145 target gene hsa-mir-145 Glioblastoma 26857280 D005909 HP:0100843 several miRNAs (miR-133b, miR-30b-3p, miR-145-5p, and miR-146a-5p) targeting EGFR target gene hsa-mir-146a Glioblastoma 26857280 D005909 HP:0100843 several miRNAs (miR-133b, miR-30b-3p, miR-145-5p, and miR-146a-5p) targeting EGFR target gene hsa-mir-148a Glioblastoma 24425048 D005909 HP:0100843 microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to regulate EGFR and apoptosis in glioblastoma. target gene hsa-mir-148a Glioblastoma 25903473 D005909 HP:0100843 miR-31 and miR-148a regulate glioma growth by maintaining tumor stem cells and their niche, and providing the tumor a way to activate angiogenesis even in a normoxic environment.This is the first study that demonstrates intratumoral uptake and growth-inhibiting effects of uncomplexed antagomirs in orthotopic glioma. target gene hsa-mir-148a Glioblastoma 25971746 D005909 HP:0100843 These findings uncover a plausible mechanism for NF-κB-sustained TGF-β/Smad activation via miR-148a in glioblastoma, and may suggest a new target for clinical intervention in human cancer. target gene hsa-mir-152 Glioblastoma 25218589 D005909 HP:0100843 MiR-152 functions as a tumor suppressor in glioblastoma stem cells by targeting Krüppel-like factor 4. target gene hsa-mir-153 Glioblastoma 28218035 D005909 HP:0100843 MicroRNA-153 regulates glutamine metabolism in glioblastoma through targeting glutaminase. target gene hsa-mir-155 Glioblastoma 19559015 D005909 HP:0100843 overexpressed; contributes to tumor resistance to VM-26 chemotherapy; targets LRRFIP1; target gene hsa-mir-155 Glioblastoma 22470130 D005909 HP:0100843 miR-155 is up-regulated in primary and secondary glioblastoma and promotes tumour growth by inhibiting GABA receptors. target gene hsa-mir-15b Glioblastoma 27896672 D005909 HP:0100843 miR-15b Inhibits the Progression of Glioblastoma Cells Through Targeting Insulin-like Growth Factor Receptor 1. target gene hsa-mir-16 Glioblastoma 28497156 D005909 HP:0100843 Tumor suppressors microRNA-302d and microRNA-16 inhibit human glioblastoma multiforme by targeting NF-κB and FGF2. target gene hsa-mir-17 Glioblastoma 19676043 D005909 HP:0100843 inhibite Bcl-2 and Mcl-1, induce apoptosis target gene hsa-mir-17 Glioblastoma 23391506 D005909 HP:0100843 Stress Response of Glioblastoma Cells Mediated by miR-17-5p Targeting PTEN and the Passenger Strand miR-17-3p Targeting MDM2 target gene hsa-mir-17 Glioblastoma 23792642 D005909 HP:0100843 microRNA-17 regulates the expression of ATG7 and modulates the autophagy process,improving the sensitivity to temozolomide and low-dose ionizing radiation treatments in human glioblastoma cells. target gene hsa-mir-181a Glioblastoma 20204284 D005909 HP:0100843 MicroRNA-181a sensitizes human malignant glioma U87MG cells to radiation by targeting Bcl-2. target gene hsa-mir-181a Glioblastoma 28389242 D005909 HP:0100843 Upregulation of miR-181a suppresses the formation of glioblastoma stem cells by targeting the Notch2 oncogene and correlates with good prognosis in patients with glioblastoma multiforme. target gene hsa-mir-181b Glioblastoma 28459461 D005909 HP:0100843 MiR-181b modulates EGFR-dependent VCAM-1 expression and monocyte adhesion in glioblastoma. target gene hsa-mir-181b Glioblastoma 28501897 D005909 HP:0100843 MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor. target gene hsa-mir-181d Glioblastoma 22570426 D005909 HP:0100843 miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. target gene hsa-mir-181d Glioblastoma 28286260 D005909 HP:0100843 miR-181d/MALT1 regulatory axis attenuates mesenchymal phenotype through NF-κB pathways in glioblastoma. target gene hsa-mir-181d Glioblastoma 28389653 D005909 HP:0100843 Identification of IGF-1-enhanced cytokine expressions targeted by miR-181d in glioblastomas via an integrative miRNA/mRNA regulatory network analysis. target gene hsa-mir-18a Glioblastoma 19676043 D005909 HP:0100843 inhibite Bcl-2 and Mcl-1, induce apoptosis target gene hsa-mir-18a Glioblastoma 23249750 D005909 HP:0100843 Targeting of TGFbeta signature and its essential component CTGF by miR-18 correlates with improved survival in glioblastoma target gene hsa-mir-18a Glioblastoma 24657544 D005909 HP:0100843 MiR-18a regulates the proliferation, migration and invasion of human glioblastoma cell by targeting neogenin. target gene hsa-mir-18a Glioblastoma 28123848 D005909 HP:0100843 The malignancy of miR-18a in human glioblastoma via directly targeting CBX7. target gene hsa-mir-193b Glioblastoma 26857280 D005909 HP:0100843 microRNAs (miRNAs) (miR-193b-3p, miR-518b, miR-520f-3p, and miR-506-5p) targeting PDGFRB were downregulated target gene hsa-mir-195 Glioblastoma 22217655 D005909 HP:0100843 MicroRNA-195 plays a tumor-suppressor role in human glioblastoma cells by targeting signaling pathways involved in cellular proliferation and invasion. target gene hsa-mir-19a Glioblastoma 19676043 D005909 HP:0100843 inhibite Bcl-2 and Mcl-1, induce apoptosis target gene hsa-mir-203 Glioblastoma 24270883 D005909 HP:0100843 the present study demonstrated the clinical significance of miR-203 in gliomas and suggested that miR-203 was able to inhibit the proliferation and invasion of glioma cells,partially at least via suppressing the protein expression of PLD2. Thus, miR-203 may be a novel candidate for the development of therapeutic strategies for gliomas. target gene hsa-mir-203 Glioblastoma 27820599 D005909 HP:0100843 Tissue mechanics promote IDH1-dependent HIF1α-tenascin C feedback to regulate glioblastoma aggression. target gene hsa-mir-203 Glioblastoma 28040710 D005909 HP:0100843 REST represses miR-124 and miR-203 to regulate distinct oncogenic properties of glioblastoma stem cells. target gene hsa-mir-205 Glioblastoma 22159356 D005909 HP:0100843 MicroRNA-205 functions as a tumor suppressor in human glioblastoma cells by targeting VEGF-A. target gene hsa-mir-20a Glioblastoma 25960225 D005909 HP:0100843 miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression. target gene hsa-mir-21 Glioblastoma 19013014 D005909 HP:0100843 miR-21: MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G target gene hsa-mir-21 Glioblastoma 21636706 D005909 HP:0100843 Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo. target gene hsa-mir-21 Glioblastoma 22353043 D005909 HP:0100843 Ursolic Acid Inhibits Proliferation and Induces Apoptosis in Human Glioblastoma Cell Lines U251 by Suppressing TGF-beta1/miR-21 /PDCD4 Pathway. target gene hsa-mir-21 Glioblastoma 22709411 D005909 HP:0100843 MiR-21 Modulates hTERT Through a STAT3-Dependent Manner on Glioblastoma Cell Growth. target gene hsa-mir-21 Glioblastoma 23904372 D005909 HP:0100843 MiR-21 mediates the radiation resistance of glioblastoma cells by regulating PDCD4 and hMSH2. target gene hsa-mir-21 Glioblastoma 25394756 D005909 HP:0100843 FASLG was a specific and direct target gene of miR-21. The advanced effects of anti-miR-21 on GSCs apoptosis and proliferation were mediated by expression of silenced FASLG. In summary, aberrantly expressed miR-21 regulates GSCs apoptosis and proliferation partly through directly down-regulating FASLG protein expression in GSCs and this might offer a new potential therapeutic stratagem for glioblastoma. target gene hsa-mir-21 Glioblastoma 26142886 D005909 HP:0100843 Targeting strategies on miRNA-21 and PDCD4 for glioblastoma. target gene hsa-mir-21 Glioblastoma 26558781 D005909 HP:0100843 Further, analysis of the miR-21-Sox2 relationship in mouse neural stem cells and in the mouse brain at different developmental stages indicates that miR-21 and Sox2 are predominantly expressed in mutually exclusive patterns, suggesting a role in normal neural development. target gene hsa-mir-21 Glioblastoma 19559015 D005909 HP:0100843 MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. target gene hsa-mir-21 Glioblastoma 25059666 D005909 HP:0100843 MicroRNA-21 promotes glioblastoma tumorigenesis by down-regulating insulin-like growth factor-binding protein-3 (IGFBP3). target gene hsa-mir-21 Glioblastoma 24012640 D005909 HP:0100843 Blockage of a miR-21/EGFR regulatory feedback loop augments anti-EGFR therapy in glioblastomas. target gene hsa-mir-21 Glioblastoma 28410224 D005909 HP:0100843 Glioma stem cells-derived exosomes promote the angiogenic ability of endothelial cells through miR-21/VEGF signal. target gene hsa-mir-21 Glioblastoma 29228449 D005909 HP:0100843 miR-21 enhances the resistance of human glioma cells to BCNU by decreasing the expression of Spry2 protein target gene hsa-mir-210 Glioblastoma 29226333 D005909 HP:0100843 p53 and miR-210 regulated NeuroD2, a neuronal basic helix-loop-helix transcription factor, is downregulated in glioblastoma patients and functions as a tumor suppressor under hypoxic microenvironment target gene hsa-mir-212 Glioblastoma 25720694 D005909 HP:0100843 MiR-212-3p inhibits glioblastoma cell proliferation by targeting SGK3. target gene hsa-mir-218 Glioblastoma 26012781 D005909 HP:0100843 MiR-218 Inhibited Growth and Metabolism of Human Glioblastoma Cells by Directly Targeting E2F2. target gene hsa-mir-218 Glioblastoma 25042866 D005909 HP:0100843 The emerging role of tumor-suppressive microRNA-218 in targeting glioblastoma stemness. target gene hsa-mir-218-1 Glioblastoma 22766851 D005909 HP:0100843 MiR-218 reverses high invasiveness of glioblastoma cells by targeting the oncogenic transcription factor LEF1. target gene hsa-mir-218-2 Glioblastoma 22766851 D005909 HP:0100843 MiR-218 reverses high invasiveness of glioblastoma cells by targeting the oncogenic transcription factor LEF1. target gene hsa-mir-219 Glioblastoma 26081620 D005909 HP:0100843 MicroRNA-219-5p exerts tumor suppressor function by targeting ROBO1 in glioblastoma. target gene hsa-mir-221 Glioblastoma 21743492 D005909 HP:0100843 miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTP mu. target gene hsa-mir-221 Glioblastoma 22294051 D005909 HP:0100843 miR-221/222 is the regulator of Cx43 expression in human glioblastoma cells. target gene hsa-mir-221 Glioblastoma 24780067 D005909 HP:0100843 MicroRNA-221 targeting PI3-K/Akt signaling axis induces cell proliferation and BCNU resistance in human glioblastoma. target gene hsa-mir-221 Glioblastoma 19953484 D005909 HP:0100843 Up-regulation of p27(kip1) by miR-221/222 antisense oligonucleotides enhances the radiosensitivity of U251 glioblastoma] target gene hsa-mir-221 Glioblastoma 20813046 D005909 HP:0100843 To our knowledge, these data indicate for the first time that miR-221/222 directly regulate apoptosis by targeting PUMA in glioblastoma and that miR-221/222 could be potential therapeutic targets for glioblastoma intervention. target gene hsa-mir-221 Glioblastoma 21109963 D005909 HP:0100843 These results were confirmed by the protein expression of p27kip1, the validated target of miR-221/222, the effect on cell cycle arrest in G1 phase, and the impact on cell apoptosis. target gene hsa-mir-222 Glioblastoma 21743492 D005909 HP:0100843 miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTP mu. target gene hsa-mir-222 Glioblastoma 19953484 D005909 HP:0100843 Up-regulation of p27(kip1) by miR-221/222 antisense oligonucleotides enhances the radiosensitivity of U251 glioblastoma] target gene hsa-mir-222 Glioblastoma 20813046 D005909 HP:0100843 To our knowledge, these data indicate for the first time that miR-221/222 directly regulate apoptosis by targeting PUMA in glioblastoma and that miR-221/222 could be potential therapeutic targets for glioblastoma intervention. target gene hsa-mir-222 Glioblastoma 21109963 D005909 HP:0100843 These results were confirmed by the protein expression of p27kip1, the validated target of miR-221/222, the effect on cell cycle arrest in G1 phase, and the impact on cell apoptosis. target gene hsa-mir-223 Glioblastoma 23970099 D005909 HP:0100843 microRNA-223 promotes the growth and invasion of glioblastoma cells by targeting tumor suppressor PAX6. target gene hsa-mir-23b Glioblastoma 22745829 D005909 HP:0100843 miRNA expression profiling in migrating glioblastoma cells: regulation of cell migration and invasion by miR-23b via targeting of Pyk2. target gene hsa-mir-24 Glioblastoma 28352781 D005909 HP:0100843 SOX7 inhibits tumor progression of glioblastoma and is regulated by miRNA-24. target gene hsa-mir-25 Glioblastoma 22431589 D005909 HP:0100843 In this study, two miRNAs, miR-25 and -32, are identified as p53-repressed miRNAs by p53-dependent negative regulation of their transcriptional regulators, E2F1 and MYC. However, miR-25 and -32 result in p53 accumulation by directly targeting Mdm2 and TSC1, which are negative regulators of p53. target gene hsa-mir-25 Glioblastoma 26209061 D005909 HP:0100843 miR-25 promotes glioblastoma cell proliferation and invasion by directly targeting NEFL. target gene hsa-mir-297 Glioblastoma 24158111 D005909 HP:0100843 This work shows miR-297 as a novel and physiologic regulator of cancer cell survival, largely through targeting of DGK-α, and also indicates that hypoxia ameliorates miR-297 toxicity to cancer cells. target gene hsa-mir-29b Glioblastoma 26155940 D005909 HP:0100843 miR-29b attenuates tumorigenicity and stemness maintenance in human glioblastoma multiforme by directly targeting BCL2L2. target gene hsa-mir-29b-1 Glioblastoma 26180082 D005909 HP:0100843 Neurotensin signaling stimulates glioblastoma cell proliferation by upregulating c-Myc and inhibiting miR-29b-1 and miR-129-3p. target gene hsa-mir-29b-2 Glioblastoma 26240386 D005909 HP:0100843 our findings reveal a novel function of YB-1 in regulating non-coding RNA expression, which has important implications in tumorigenesis. target gene hsa-mir-302a Glioblastoma 21720384 D005909 HP:0100843 The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network. target gene hsa-mir-302b Glioblastoma 21720384 D005909 HP:0100843 The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network. target gene hsa-mir-302c Glioblastoma 21720384 D005909 HP:0100843 The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network. target gene hsa-mir-302d Glioblastoma 21720384 D005909 HP:0100843 The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network. target gene hsa-mir-302d Glioblastoma 28497156 D005909 HP:0100843 Tumor suppressors microRNA-302d and microRNA-16 inhibit human glioblastoma multiforme by targeting NF-κB and FGF2. target gene hsa-mir-30b Glioblastoma 26857280 D005909 HP:0100843 miRNAs (miR-133b, miR-30b-3p, miR-145-5p, and miR-146a-5p) targeting EGFR target gene hsa-mir-31 Glioblastoma 25903473 D005909 HP:0100843 miR-31 and miR-148a regulate glioma growth by maintaining tumor stem cells and their niche, and providing the tumor a way to activate angiogenesis even in a normoxic environment.This is the first study that demonstrates intratumoral uptake and growth-inhibiting effects of uncomplexed antagomirs in orthotopic glioma. target gene hsa-mir-32 Glioblastoma 22431589 D005909 HP:0100843 In this study, two miRNAs, miR-25 and -32, are identified as p53-repressed miRNAs by p53-dependent negative regulation of their transcriptional regulators, E2F1 and MYC. However, miR-25 and -32 result in p53 accumulation by directly targeting Mdm2 and TSC1, which are negative regulators of p53. target gene hsa-mir-330 Glioblastoma 24736727 D005909 HP:0100843 MiR-330-mediated regulation of SH3GL2 expression enhances malignant behaviors of glioblastoma stem cells by activating ERK and PI3K/AKT signaling pathways. target gene hsa-mir-331 Glioblastoma 24142150 D005909 HP:0100843 miR-331-3p regulates expression of neuropilin-2 in glioblastoma. target gene hsa-mir-34a Glioblastoma 21743299 D005909 HP:0100843 MicroRNA-34a targets notch1 and inhibits cell proliferation in glioblastoma multiforme. target gene hsa-mir-34a Glioblastoma 22580610 D005909 HP:0100843 miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme. target gene hsa-mir-34a Glioblastoma 22750848 D005909 HP:0100843 microRNA Regulatory Network Inference Identifies miR-34a as a Novel Regulator of TGF-beta Signaling in Glioblastoma. target gene hsa-mir-34a Glioblastoma 19773441 D005909 HP:0100843 MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes target gene hsa-mir-367 Glioblastoma 21720384 D005909 HP:0100843 The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network. target gene hsa-mir-429 Glioblastoma 28749077 D005909 HP:0100843 MiR-429 suppresses glioblastoma multiforme by targeting SOX2. target gene hsa-mir-431 Glioblastoma 24584142 D005909 HP:0100843 Downregulation of microRNA-431 by human interferon-β inhibits viability of medulloblastoma and glioblastoma cells via upregulation of SOCS6. target gene hsa-mir-503 Glioblastoma 24378652 D005909 HP:0100843 MicroRNA-503 acts as a tumor suppressor in glioblastoma for multiple antitumor effects by targeting IGF-1R. target gene hsa-mir-506 Glioblastoma 26857280 D005909 HP:0100843 microRNAs (miRNAs) (miR-193b-3p, miR-518b, miR-520f-3p, and miR-506-5p) targeting PDGFRB were downregulated target gene hsa-mir-518b Glioblastoma 26857280 D005909 HP:0100843 microRNAs (miRNAs) (miR-193b-3p, miR-518b, miR-520f-3p, and miR-506-5p) targeting PDGFRB were downregulated target gene hsa-mir-520f Glioblastoma 26857280 D005909 HP:0100843 microRNAs (miRNAs) (miR-193b-3p, miR-518b, miR-520f-3p, and miR-506-5p) targeting PDGFRB were downregulated target gene hsa-mir-522 Glioblastoma 25776496 D005909 HP:0100843 MiR-522 contributes to cell proliferation of human glioblastoma cells by suppressing PHLPP1 expression. target gene hsa-mir-590 Glioblastoma 26556542 D005909 HP:0100843 miR-590-3p suppresses cancer cell migration, invasion and epithelial-mesenchymal transition in glioblastoma multiforme by targeting ZEB1 and ZEB2. target gene hsa-mir-663 Glioblastoma 26717894 D005909 HP:0100843 MicroRNA-663 inhibits the proliferation, migration and invasion of glioblastoma cells via targeting TGF-β1. target gene hsa-mir-7-1 Glioblastoma 22040413 D005909 HP:0100843 MicroRNA-7 regulates glioblastoma cell invasion via targeting focal adhesion kinase expression. target gene hsa-mir-7-2 Glioblastoma 22040413 D005909 HP:0100843 MicroRNA-7 regulates glioblastoma cell invasion via targeting focal adhesion kinase expression. target gene hsa-mir-7-3 Glioblastoma 22040413 D005909 HP:0100843 MicroRNA-7 regulates glioblastoma cell invasion via targeting focal adhesion kinase expression. target gene hsa-mir-873 Glioblastoma 25670861 D005909 HP:0100843 MicroRNA-873 (miRNA-873) inhibits glioblastoma tumorigenesis and metastasis by suppressing the expression of IGF2BP1. target gene hsa-mir-9 Glioblastoma 24436148 D005909 HP:0100843 Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity. target gene hsa-mir-9-1 Glioblastoma 21385897 D005909 HP:0100843 miR-9 suppresses mesenchymal differentiation in glioblastoma by downregulating expression of JAK kinases and inhibiting activation of STAT3. target gene hsa-mir-9-1 Glioblastoma 21531766 D005909 HP:0100843 ID4 Imparts Chemoresistance and Cancer Stemness to Glioma Cells by Derepressing miR-9*-Mediated Suppression of SOX2. target gene hsa-mir-9-1 Glioblastoma 21857646 D005909 HP:0100843 CAMTA1 is a novel tumour suppressor regulated by miR-9/9(*) in glioblastoma stem cells. target gene hsa-mir-9-2 Glioblastoma 21385897 D005909 HP:0100843 miR-9 suppresses mesenchymal differentiation in glioblastoma by downregulating expression of JAK kinases and inhibiting activation of STAT3. target gene hsa-mir-9-2 Glioblastoma 21531766 D005909 HP:0100843 ID4 Imparts Chemoresistance and Cancer Stemness to Glioma Cells by Derepressing miR-9*-Mediated Suppression of SOX2. target gene hsa-mir-9-2 Glioblastoma 21857646 D005909 HP:0100843 CAMTA1 is a novel tumour suppressor regulated by miR-9/9(*) in glioblastoma stem cells. target gene hsa-mir-92a-1 Glioblastoma 22895567 D005909 HP:0100843 miR-92a is a critical regulator of the apoptosis pathway in glioblastoma with inverse expression of BCL2L11. target gene hsa-mir-92a-2 Glioblastoma 22895567 D005909 HP:0100843 miR-92a is a critical regulator of the apoptosis pathway in glioblastoma with inverse expression of BCL2L11. target gene hsa-mir-92b Glioblastoma 23892108 D005909 HP:0100843 The miR-92b functions as a potential oncogene by targeting on Smad3 in glioblastomas. target gene hsa-mir-93 Glioblastoma 20956944 D005909 HP:0100843 MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-β8. target gene hsa-mir-9-3 Glioblastoma 21385897 D005909 HP:0100843 miR-9 suppresses mesenchymal differentiation in glioblastoma by downregulating expression of JAK kinases and inhibiting activation of STAT3. target gene hsa-mir-9-3 Glioblastoma 21531766 D005909 HP:0100843 ID4 Imparts Chemoresistance and Cancer Stemness to Glioma Cells by Derepressing miR-9*-Mediated Suppression of SOX2. target gene hsa-mir-9-3 Glioblastoma 21857646 D005909 HP:0100843 CAMTA1 is a novel tumour suppressor regulated by miR-9/9(*) in glioblastoma stem cells. target gene hsa-mir-218 Glioblastoma Mesenchymal Subtype 24368849 disease of cellular proliferation DOID:0050805 miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma. target gene hsa-let-7 Glioma 26028311 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MDM4 regulation by the let-7 miRNA family in the DNA damage response of glioma cells. target gene hsa-mir-101 Glioma 23788032 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 CPEB1, a histone-modified hypomethylated gene, is regulated by miR-101 and involved in cell senescence in glioma. target gene hsa-mir-105 Glioma 27736002 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-105 targets SOX9 and inhibits human glioma cell progression. target gene hsa-mir-105 Glioma 28618952 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-105 inhibits human glioma cell malignancy by directly targeting SUZ12. target gene hsa-mir-106a Glioma 24124917 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Decreased miR-106a inhibits glioma cell glucose uptake and proliferation by targeting SLC2A3 in GBM. target gene hsa-mir-106a Glioma 24704830 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Oncogenic miR-20a and miR-106a enhance the invasiveness of human glioma stem cells by directly targeting TIMP-2. target gene hsa-mir-106b Glioma 23377830 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-106b facilitates glioma cell growth by promoting cell cycle progression through the negative regulation of RBL2 target gene hsa-mir-106b Glioma 24166509 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-106b-5p boosts glioma tumorigensis by targeting multiple tumor suppressor genes. target gene hsa-mir-107 Glioma 23299462 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-107 inhibits glioma cell migration and invasion by modulating Notch2 expression target gene hsa-mir-107 Glioma 26084601 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Upregulation of miR-107 Inhibits Glioma Angiogenesis and VEGF Expression. target gene hsa-mir-10a Glioma 25683004 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-10a controls glioma migration and invasion through regulating epithelial-mesenchymal transition via EphA8. target gene hsa-mir-1202 Glioma 28443461 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-1202 functions as a tumor suppressor in glioma cells by targeting Rab1A. target gene hsa-mir-1224 Glioma 25648114 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-1224-5p acts as a tumor suppressor by targeting CREB1 in malignant gliomas. target gene hsa-mir-124 Glioma 23792158 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Circadian gene Clock contributes to cell proliferation and migration of glioma and is directly regulated by tumor-suppressive miR-124. target gene hsa-mir-124 Glioma 28791348 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-124 inhibits the proliferation of C6 glioma cells by targeting Smad4. target gene hsa-mir-124 Glioma 25348135 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-124 could simultaneously regulate up-regulated (ELAVL1 and EZH2) and down-regulated (BACE1) DEGs. target gene hsa-mir-124 Glioma 28272711 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Down-regulation of miR-124 target protein SCP-1 inhibits neuroglioma cell migration. target gene hsa-mir-124 Glioma 28393219 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Inhibition of the Hedgehog signaling pathway suppresses cell proliferation by regulating the Gli2/miR-124/AURKA axis in human glioma cells. target gene hsa-mir-124-1 Glioma 23761023 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-124 radiosensitizes human glioma cells by targeting CDK4. target gene hsa-mir-124-2 Glioma 23761023 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-124 radiosensitizes human glioma cells by targeting CDK4. target gene hsa-mir-125b Glioma 24046143 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 We conclude that miR-125b regulates glioma growth partly through Connexin43 protein. target gene hsa-mir-128 Glioma 18810376 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a. target gene hsa-mir-128 Glioma 23835497 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-128 promotes cell-cell adhesion in U87 glioma cells via regulation of EphB2. target gene hsa-mir-128 Glioma 25781272 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Proteomic screening and identification of microRNA-128 targets in glioma cells. target gene hsa-mir-128-1 Glioma 22442669 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-128 expression levels were decreased in glioma. MiR-128 Inhibits Tumor Growth and Angiogenesis by Targeting p70S6K1. target gene hsa-mir-128-1 Glioma 23733246 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-128 coordinately targets Polycomb Repressor Complexes in glioma stem cells. target gene hsa-mir-128-2 Glioma 22442669 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-128 expression levels were decreased in glioma. MiR-128 Inhibits Tumor Growth and Angiogenesis by Targeting p70S6K1. target gene hsa-mir-128-2 Glioma 23733246 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-128 coordinately targets Polycomb Repressor Complexes in glioma stem cells. target gene hsa-mir-130b Glioma 26653558 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 In conclusion, miR-130b is an independent prognostic biomarker for indicating survival of glioma patients and promotes glioma cell migration and invasion by targeting PPARγ. target gene hsa-mir-133b Glioma 25355491 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-133b contributes to arsenic-induced apoptosis in U251 glioma cells by targeting the hERG channel. target gene hsa-mir-136 Glioma 25139024 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-136 targets E2F1 to reverse cisplatin chemosensitivity in glioma cells. target gene hsa-mir-139 Glioma 23551751 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-139 Inhibits Mcl-1 Expression and Potentiates TMZ-Induced Apoptosis in Glioma target gene hsa-mir-141 Glioma 27608897 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-200c and miR-141 inhibit ZEB1 synergistically and suppress glioma cell growth and migration. target gene hsa-mir-141 Glioma 28595907 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-141-3p functions as a tumor suppressor modulating activating transcription factor 5 in glioma. target gene hsa-mir-143 Glioma 23250070 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Rapamycin inhibits human glioma cell proliferation through down-regulating mammalian target of rapamycin pathway and up-regulating microRNA-143 target gene hsa-mir-143 Glioma 24980823 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma. target gene hsa-mir-145 Glioma 23076445 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-145 reduces ADAM17 expression and inhibits in vitro migration and invasion of glioma cells target gene hsa-mir-145 Glioma 23390502 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-145 Is Downregulated in Glial Tumors and Regulates Glioma Cell Migration by Targeting Connective Tissue Growth Factor target gene hsa-mir-145 Glioma 24777293 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-145 inhibits migration and invasion of glioma stem cells by targeting ABCG2. target gene hsa-mir-146b Glioma 19265686 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 microRNA-146b inhibits glioma cell migration and invasion by targeting MMPs. target gene hsa-mir-146b Glioma 23796692 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-146b-5p inhibits glioma migration and invasion by targeting MMP16. target gene hsa-mir-149 Glioma 23298478 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-149 inhibits proliferation and invasion of glioma cells via blockade of AKT1 signaling target gene hsa-mir-152 Glioma 23142217 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-15b and miR-152 reduce glioma cell invasion and angiogenesis via NRP-2 and MMP-3 target gene hsa-mir-153 Glioma 26124081 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-153/Nrf-2/GPx1 pathway regulates radiosensitivity and stemness of glioma stem cells via reactive oxygen species. target gene hsa-mir-155 Glioma 23970205 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 microRNA-155 regulates cell proliferation and invasion by targeting FOXO3a in glioma. target gene hsa-mir-155 Glioma 24376632 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-155 promotes glioma cell proliferation via the regulation of MXI1. target gene hsa-mir-155 Glioma 25535908 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Knockdown of miR-155 enhanced the anticancer effect of TMZ on glioma by targeting the MAPK13 and MAPK14-mediated oxidative stress and apoptosis, but did not affect the secretion of MMP2 and MMP9. target gene hsa-mir-15b Glioma 19135980 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-15b regulates cell cycle progression by targeting cyclins in glioma cells. target gene hsa-mir-15b Glioma 23142217 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-15b and miR-152 reduce glioma cell invasion and angiogenesis via NRP-2 and MMP-3 target gene hsa-mir-15b Glioma 25901555 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Mangiferin regulates proliferation and apoptosis in glioma cells by induction of microRNA-15b and inhibition of MMP-9 expression. target gene hsa-mir-15b Glioma 29323737 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-15b/HOTAIR/p53 form a regulatory loop that affects the growth of glioma cells target gene hsa-mir-16 Glioma 27748823 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-16 inhibits the proliferation, migration and invasion of glioma cells by targeting Sal-like protein 4. target gene hsa-mir-16-1 Glioma 23175429 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Zyxin may be one of putative target genes of miR-16-1 target gene hsa-mir-16-2 Glioma 23175429 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Zyxin may be one of putative target genes of miR-16-1 target gene hsa-mir-17 Glioma 28081732 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Inhibition of Beclin-1-Mediated Autophagy by MicroRNA-17-5p Enhanced the Radiosensitivity of Glioma Cells. target gene hsa-mir-181b Glioma 27938503 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-181b Inhibits Cellular Proliferation and Invasion of Glioma Cells via Targeting Sal-Like Protein 4. target gene hsa-mir-181b-1 Glioma 23431408 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiRNA-181b suppresses IGF-1R and functions as a tumor suppressor gene in gliomas target gene hsa-mir-181b-2 Glioma 23431408 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiRNA-181b suppresses IGF-1R and functions as a tumor suppressor gene in gliomas target gene hsa-mir-181d Glioma 22207524 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-181d acts as a tumor suppressor in glioma by targeting K-ras and Bcl-2. target gene hsa-mir-182 Glioma 24404152 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Disturbing miR-182 and -381 inhibits BRD7 transcription and glioma growth by directly targeting LRRC4. target gene hsa-mir-182 Glioma 27246830 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-182-5p negatively regulated PCDH8 expression by directly targeting its 3'-untranslated region. target gene hsa-mir-19 Glioma 29340016 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-19 regulates the proliferation and invasion of glioma by RUNX3 via β-catenin/Tcf-4 signaling target gene hsa-mir-193b Glioma 24496888 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Thus, our study indicates that miR-193b promotes cell proliferation by targeting Smad3 in human glioma, which may serve as a potentially useful target for development of miRNA-based therapies in the future. target gene hsa-mir-194 Glioma 28098896 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-194 represses glioma cell epithelial‑to‑mesenchymal transition by targeting Bmi1. target gene hsa-mir-195 Glioma 23383003 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-195 Inhibits the Proliferation of Human Glioma Cells by Directly Targeting Cyclin D1 and Cyclin E1 target gene hsa-mir-199a Glioma 25854175 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-199a-3p suppresses glioma cell proliferation by regulating the AKT/mTOR signaling pathway. target gene hsa-mir-200 Glioma 28362995 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Targeting effect of microRNA on CD133 and its impact analysis on proliferation and invasion of glioma cells. target gene hsa-mir-200a Glioma 24162743 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-200a impairs glioma cell growth, migration, and invasion by targeting SIM2-s. target gene hsa-mir-200b Glioma 23543137 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-200b targets CREB1 and suppresses cell growth in human malignant glioma target gene hsa-mir-200b Glioma 24477653 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-200b as a prognostic factor targets multiple members of RAB family in glioma. target gene hsa-mir-200b Glioma 25877314 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-200b may suppress cell invasion by targeting PROM1 in glioma. target gene hsa-mir-200b Glioma 26648487 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-200b inhibits the growth and metastasis of glioma cells via targeting ZEB2. target gene hsa-mir-200b Glioma 27545608 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-200b-3p suppresses epithelial-mesenchymal transition and inhibits tumor growth of glioma through down-regulation of ERK5. target gene hsa-mir-200b Glioma 28362995 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Targeting effect of microRNA on CD133 and its impact analysis on proliferation and invasion of glioma cells. target gene hsa-mir-200c Glioma 27608897 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-200c and miR-141 inhibit ZEB1 synergistically and suppress glioma cell growth and migration. target gene hsa-mir-203 Glioma 26678661 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 These data demonstrate that miR-203 potentially controls DNA damage repair via the PI3K/AKT and JAK/STAT3 pathways and may collectively contribute to the modulation of radiation sensitivity in MG cells by inhibiting DNA damage repair, prosurvival signaling, and epithelium-mesenchyme transition. Taken together, these findings demonstrate that miR-203 could be a target for overcoming the radiation resistance of GBM. target gene hsa-mir-204 Glioma 25055875 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-204, a direct negative regulator of ezrin gene expression, inhibits glioma cell migration and invasion. target gene hsa-mir-20a Glioma 24704830 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Oncogenic miR-20a and miR-106a enhance the invasiveness of human glioma stem cells by directly targeting TIMP-2. target gene hsa-mir-21 Glioma 18591254 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. target gene hsa-mir-21 Glioma 21278789 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas. target gene hsa-mir-21 Glioma 22630347 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-21 expression is regulated by ж┿catenin/STAT3 pathway and promotes glioma cell invasion by direct targeting RECK. target gene hsa-mir-21 Glioma 24161395 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Sirt2 suppresses glioma cell growth through targeting NF-κB-miR-21 axis. target gene hsa-mir-21 Glioma 26701969 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 These findings suggest that miR-21 is linked to glioma angiogenesis,that miR-21 is unlikely to regulate PTEN, and that miR-21-positive tumor cells do not possess stem cell characteristics. target gene hsa-mir-21 Glioma 29228450 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-21 enhanced glioma cells resistance to carmustine via decreasing Spry2 expression target gene hsa-mir-21 Glioma 29316313 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-21 promotes glioma cell proliferation and inhibits senescence and apoptosis by targeting SPRY1 via the PTEN/PI3K/AKT signaling pathway target gene hsa-mir-214 Glioma 23187003 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 microRNA-214-mediated UBC9 expression in glioma target gene hsa-mir-214 Glioma 26722446 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 In summary, our data indicate that miR-214 may function as tumor suppressor in glioma by targeting PCBP2. target gene hsa-mir-215 Glioma 18810376 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a. target gene hsa-mir-215 Glioma 26766590 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B. target gene hsa-mir-215 Glioma 27837373 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-215 enhances invasion and migration by targeting retinoblastoma tumor suppressor gene 1 in high-grade glioma. target gene hsa-mir-218 Glioma 23950210 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-218 inhibits glioma invasion, migration, proliferation, and cancer stem-like cell self-renewal by targeting the polycomb group gene Bmi1. target gene hsa-mir-218-1 Glioma 23243056 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-218 sensitizes glioma cells to apoptosis and inhibits tumorigenicity by regulating ECOP-mediated suppression of NF-kB activity target gene hsa-mir-218-2 Glioma 23243056 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-218 sensitizes glioma cells to apoptosis and inhibits tumorigenicity by regulating ECOP-mediated suppression of NF-kB activity target gene hsa-mir-221 Glioma 19424584 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo. target gene hsa-mir-221 Glioma 22075712 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status. target gene hsa-mir-221 Glioma 24147153 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-221/222 target the DNA methyltransferase MGMT in glioma cells. target gene hsa-mir-221 Glioma 24595467 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Uptake by human glioma cell lines and biological effects of a peptide-nucleic acids targeting miR-221. target gene hsa-mir-221 Glioma 25731730 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-221/222 promote human glioma cell invasion and angiogenesis by targeting TIMP2. target gene hsa-mir-222 Glioma 19424584 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo. target gene hsa-mir-222 Glioma 22075712 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status. target gene hsa-mir-222 Glioma 24147153 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-221/222 target the DNA methyltransferase MGMT in glioma cells. target gene hsa-mir-222 Glioma 25731730 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-221/222 promote human glioma cell invasion and angiogenesis by targeting TIMP2. target gene hsa-mir-223 Glioma 23946414 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 The miR-223/nuclear factor I-A axis regulates glial precursor proliferation and tumorigenesis in the CNS. target gene hsa-mir-23a Glioma 23865473 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Anti-miRNA-23a oligonucleotide suppresses glioma cells growth by targeting apoptotic protease activating factor-1. target gene hsa-mir-23a Glioma 24305689 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Targeting microRNA-23a to inhibit glioma cell invasion via HOXD10. target gene hsa-mir-23b Glioma 24002170 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 TFAM is directly regulated by miR-23b in glioma. target gene hsa-mir-24-1 Glioma 23142218 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-24 regulates the proliferation and invasion of glioma by ST7L via beta-catenin/Tcf-4 signaling target gene hsa-mir-24-1 Glioma 23254855 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-24-3p and miR-27a-3p promote cell proliferation in glioma cells via cooperative regulation of MXI1 target gene hsa-mir-24-2 Glioma 23142218 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-24 regulates the proliferation and invasion of glioma by ST7L via beta-catenin/Tcf-4 signaling target gene hsa-mir-24-2 Glioma 23254855 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-24-3p and miR-27a-3p promote cell proliferation in glioma cells via cooperative regulation of MXI1 target gene hsa-mir-25 Glioma 25960208 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-25 promotes glioma cell proliferation by targeting CDKN1C. target gene hsa-mir-26a Glioma 23870455 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 These results reveal that miR-26a regulates PHB and promotes glioma progression both in vitro and in vivo and that miR-26a and its target PHB are associated with glioma development, which can be helpful in developing microRNA-based treatment for glioma in the future. target gene hsa-mir-26b Glioma 21264258 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 This study demonstrated that miR-26b may act as a tumor suppressor in glioma and it directly regulates EphA2 expression. EphA2 is a direct target of miR-26b, and the down-regulation of EphA2 mediated by miR-26b is dependent on the binding of miR-26b to a target gene hsa-mir-27a Glioma 22614734 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Lentiviral expression of anti-microRNAs targeting miR-27a inhibits proliferation and invasiveness of U87 glioma cells. target gene hsa-mir-27a Glioma 23254855 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-24-3p and miR-27a-3p promote cell proliferation in glioma cells via cooperative regulation of MXI1 target gene hsa-mir-27a Glioma 26164457 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-27a regulates Wnt/beta-catenin signaling through targeting SFRP1 in glioma. target gene hsa-mir-27a Glioma 25777779 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Emerging role of microRNA-27a in human malignant glioma cell survival via targeting of prohibitin. target gene hsa-mir-29a Glioma 24595468 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Heat shock protein 47 regulated by miR-29a to enhance glioma tumor growth and invasion. target gene hsa-mir-29a Glioma 27543358 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Long non-coding RNA H19 regulates glioma angiogenesis and the biological behavior of glioma-associated endothelial cells by inhibiting microRNA-29a. target gene hsa-mir-30 Glioma 25840690 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-30 overexpression promotes glioma stem cells by regulating Jak/STAT3 signaling pathway. target gene hsa-mir-302a Glioma 28000880 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-302a targets GAB2 to suppress cell proliferation, migration and invasion of glioma. target gene hsa-mir-302b Glioma 28323865 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 The microRNA-302b-inhibited insulin-like growth factor-binding protein 2 signaling pathway induces glioma cell apoptosis by targeting nuclear factor IA. target gene hsa-mir-302c Glioma 26176806 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-302c-3p suppresses invasion and proliferation of glioma cells via down-regulating metadherin (MTDH) expression. target gene hsa-mir-30a Glioma 23348703 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 PRDM1 is directly targeted by miR-30a-5p and modulates the Wnt/beta-catenin pathway in a Dkk1-dependent manner during glioma growth target gene hsa-mir-30a Glioma 23383034 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-30a-5p Antisense Oligonucleotide Suppresses Glioma Cell Growth by Targeting SEPT7 target gene hsa-mir-30e Glioma 25691332 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Ionizing radiation-inducible miR-30e promotes glioma cell invasion through EGFR stabilization by directly targeting CBL-B. target gene hsa-mir-31 Glioma 22089331 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Human miR-31 targets radixin and inhibits migration and invasion of glioma cells. target gene hsa-mir-31 Glioma 26801671 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 the suppressive effect of miR-31 on glioma cell migration and invasion is p21-dependent target gene hsa-mir-320 Glioma 25901521 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-320 inhibits cell proliferation in glioma by targeting E2F1. target gene hsa-mir-320 Glioma 28934982 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-320 inhibits the growth of glioma cells through downregulating PBX3. target gene hsa-mir-320a Glioma 25117070 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-320a suppresses in GBM patients and modulates glioma cell functions by targeting IGF-1R. target gene hsa-mir-320a Glioma 28160566 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-320a functions as a suppressor for gliomas by targeting SND1 and β-catenin, and predicts the prognosis of patients. target gene hsa-mir-324 Glioma 24706306 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 The miR-324-5p can inhibit proliferation of the glioma cells via the targeted regulation of the glioma-associated oncogene 1. target gene hsa-mir-326 Glioma 20667897 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells target gene hsa-mir-326 Glioma 23869222 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-326 functions as a tumor suppressor in glioma by targeting the Nin one binding protein (NOB1). target gene hsa-mir-329 Glioma 23866847 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-329 may inhibit cell proliferation in human glioma cells through regulating E2F1-mediated suppression of Akt pathway. target gene hsa-mir-335 Glioma 24737483 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 PAX6, a novel target of miR-335, inhibits cell proliferation and invasion in glioma cells. target gene hsa-mir-34a Glioma 22479456 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-34a Repression in Proneural Malignant Gliomas Upregulates Expression of Its Target PDGFRA and Promotes Tumorigenesis. target gene hsa-mir-34a Glioma 22684560 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-34a inhibits human brain glioma cell growth by down-regulation of Notch1. target gene hsa-mir-34a Glioma 24393844 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-34a serves as a tumor suppressor in human glioma mainly by decreasing NOX2 expression. target gene hsa-mir-34a Glioma 20470934 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Our results demonstrate that miR-34a acts as a tumor suppressor in p53-mutant glioma cells U251, partially through regulating SIRT1. target gene hsa-mir-34a Glioma 28859546 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-34a induces transdifferentiation of glioma stem cells into vascular endothelial cells by targeting Notch pathway. target gene hsa-mir-361 Glioma 28184914 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-361-5p inhibits epithelial-to-mesenchymal transition of glioma cells through targeting Twist1. target gene hsa-mir-365 Glioma 28260020 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-365 inhibits proliferation, migration and invasion of glioma by targeting PIK3R3. target gene hsa-mir-372 Glioma 25160587 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-372 regulates glioma cell proliferation and invasion by directly targeting PHLPP2. target gene hsa-mir-381 Glioma 24404152 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Disturbing miR-182 and -381 inhibits BRD7 transcription and glioma growth by directly targeting LRRC4. target gene hsa-mir-383 Glioma 23564324 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Downregulation of miR-383 promotes glioma cell invasion by targeting insulin-like growth factor 1 receptor target gene hsa-mir-383 Glioma 25450356 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-383 plays the role of tumor suppressor by targeting CCND1 in glioma cells, and may be useful for developing a new therapeutic strategy for gliomas. target gene hsa-mir-383 Glioma 25936342 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-383 expression regulates proliferation, migration, invasion, and apoptosis in human glioma cells. target gene hsa-mir-410 Glioma 22750473 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-410 regulates MET to influence the proliferation and invasion of glioma. target gene hsa-mir-422a Glioma 28277190 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-422a Inhibits Glioma Proliferation and Invasion by Targeting IGF1 and IGF1R. target gene hsa-mir-449a Glioma 26502848 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 The expression of microRNA-449a is low in patients with glioma,which may inhibit the proliferation of glioma and promote its cell apoptosis via affecting the expression of PKCα. target gene hsa-mir-451a Glioma 22179124 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA miR-451 downregulates the PI3K/AKT pathway through CAB39 in human glioma. target gene hsa-mir-483 Glioma 22465663 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-483-5p suppresses the proliferation of glioma cells via directly targeting ERK1. target gene hsa-mir-491 Glioma 27905892 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-491 regulates glioma cells proliferation by targeting TRIM28 in vitro. target gene hsa-mir-494 Glioma 24316134 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Ionizing radiation-inducible miR-494 promotes glioma cell invasion through EGFR stabilization by targeting p190B rhoGAP. target gene hsa-mir-495 Glioma 25759932 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-495 mediates metabolic shift in glioma cells via targeting Glut1. target gene hsa-mir-504 Glioma 26854715 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 A tumor-suppressive microRNA, miR-504, inhibits cell proliferation and promotes apoptosis by targeting FOXP1 in human glioma. target gene hsa-mir-520c Glioma 28184932 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-520c inhibits glioma cell migration and invasion by the suppression of transforming growth factor-β receptor type 2. target gene hsa-mir-524 Glioma 28778566 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 EGFR/c-myc axis regulates TGFβ/Hippo/Notch pathway via epigenetic silencing miR-524 in gliomas. target gene hsa-mir-542 Glioma 22871495 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 The Putative Tumor Suppressor miR-524-5p Directly Targets Jagged-1 and Hes-1 in Glioma. target gene hsa-mir-584 Glioma 25674221 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-584 functions as a tumor suppressor and targets PTTG1IP in glioma. target gene hsa-mir-592 Glioma 28718372 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-592 functions as a tumor suppressor in glioma by targeting IGFBP2. target gene hsa-mir-622 Glioma 25258251 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-622 suppresses proliferation, invasion and migration by directly targeting activating transcription factor 2 in glioma cells. target gene hsa-mir-656 Glioma 24480809 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-656 inhibits glioma tumorigenesis through repression of BMPR1A. target gene hsa-mir-661 Glioma 26585488 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 These results indicate that miR-661 can inhibit glioma cell proliferation,migration and invasion by targeting hTERT. target gene hsa-mir-873 Glioma 28583401 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-873 suppresses H9C2 cardiomyocyte proliferation by targeting GLI1. target gene hsa-mir-9 Glioma 28430789 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-9-3p augments apoptosis induced by H2O2 through down regulation of Herpud1 in glioma. target gene hsa-mir-92a Glioma 27801803 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-92a-3p Exerts Various Effects in Glioma and Glioma Stem-Like Cells Specifically Targeting CDH1/β-Catenin and Notch-1/Akt Signaling Pathways. target gene hsa-mir-92b Glioma 23416699 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-92b controls glioma proliferation and invasion through regulating Wnt/beta-catenin signaling via Nemo-like kinase target gene hsa-mir-92b Glioma 24325785 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 The present data indicates that miR-92b directly regulate cell proliferation and apoptosis by targeting DKK3 and act as prognostic factors for glioma patients. target gene hsa-mir-93 Glioma 26449498 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 In conclusion, our results suggest an increasing role of miR-93 in regulating the level of expression of several genes involved in the angiogenesis of gliomas. target gene hsa-mir-93 Glioma 25277195 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 LNA inhibitor-mediated miRNA silencing up-regulated cell surface NKG2DL expression, which translated into increased susceptibility to NK cell-mediated lysis. target gene hsa-mir-95 Glioma 26165303 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Downregulation of miR-95-3p inhibits proliferation, and invasion promoting apoptosis of glioma cells by targeting CELF2. target gene hsa-mir-96 Glioma 24931370 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-96/HBP1/Wnt/β-catenin regulatory circuitry promotes glioma growth. target gene hsa-mir-148a Glomerulonephritis 28637300 urinary system disease DOID:2921 N05 D005921 305800 HP:0000099 The type of diet intake also influenced cytokine production, fecal microbiota (increased Lachnospiraceae in mice fed on 2018), altered microRNAs (miRNAs; higher levels of lupus-associated miR-148a and miR-183 in mice fed on 7013 and/or 2018) and altered DNA methylation. target gene hsa-mir-183 Glomerulonephritis 28637300 urinary system disease DOID:2921 N05 D005921 305800 HP:0000099 The type of diet intake also influenced cytokine production, fecal microbiota (increased Lachnospiraceae in mice fed on 2018), altered microRNAs (miRNAs; higher levels of lupus-associated miR-148a and miR-183 in mice fed on 7013 and/or 2018) and altered DNA methylation. target gene hsa-mir-140 Gout 27906093 musculoskeletal system disease DOID:13189 M10 D006073 HP:0001997 microRNA -140-5p inhibits colorectal cancer invasion and metastasis by targeting ADAMTS5 and IGFBP5. target gene hsa-mir-21 Granular Corneal Dystrophy 26915797 nervous system disease DOID:12318 H18.53 D003317 121900 HP:0007802 TGF-β regulates TGFBIp expression in corneal fibroblasts via miR-21, miR-181a,and Smad signaling. target gene hsa-mir-320a Granulosa Cell Tumor 24828505 disease of cellular proliferation DOID:2999 D006106 Transactivation of micrornA-320 by microRNA-383 regulates granulosa cell functions by targeting E2F1 and SF-1 proteins. target gene hsa-mir-383 Granulosa Cell Tumor 24828505 disease of cellular proliferation DOID:2999 D006106 Transactivation of micrornA-320 by microRNA-383 regulates granulosa cell functions by targeting E2F1 and SF-1 proteins. target gene hsa-mir-146a Graves Disease 28278511 immune system disease DOID:12361 E05.00 D006111 275000 HP:0100647 Mechanism of MicroRNA-146a/Notch2 Signaling Regulating IL-6 in Graves Ophthalmopathy. target gene hsa-mir-183 Graves Disease 25871842 immune system disease DOID:12361 E05.00 D006111 275000 HP:0100647 Our study highlights the possibility that miRNA-target gene network may be involved in the pathogenesis of GD and could provide new insights into understanding the pathophysiological mechanisms of GD. target gene hsa-mir-197 Graves Disease 25871842 immune system disease DOID:12361 E05.00 D006111 275000 HP:0100647 Our study highlights the possibility that miRNA-target gene network may be involved in the pathogenesis of GD and could provide new insights into understanding the pathophysiological mechanisms of GD. target gene hsa-mir-22 Graves Disease 25871842 immune system disease DOID:12361 E05.00 D006111 275000 HP:0100647 Our study highlights the possibility that miRNA-target gene network may be involved in the pathogenesis of GD and could provide new insights into understanding the pathophysiological mechanisms of GD. target gene hsa-mir-346 Graves Disease 25666935 immune system disease DOID:12361 E05.00 D006111 275000 HP:0100647 MiR-346 regulates CD4(+)CXCR5(+) T cells by targeting Bcl-6, a positive regulator of Tfh cells, and might play an important role in the pathogenesis of Graves' disease. target gene hsa-mir-660 Graves Disease 25871842 immune system disease DOID:12361 E05.00 D006111 275000 HP:0100647 Our study highlights the possibility that miRNA-target gene network may be involved in the pathogenesis of GD and could provide new insights into understanding the pathophysiological mechanisms of GD. target gene hsa-mir-21 Hand, Foot And Mouth Disease 28506791 disease by infectious agent DOID:10881 B08.4 D006232 Enterovirus 71-induced has-miR-21 contributes to evasion of host immune system by targeting MyD88 and IRAK1. target gene hsa-let-7a Head And Neck Neoplasms 23340306 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies. target gene hsa-let-7b Head And Neck Neoplasms 23340306 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies. target gene hsa-let-7c Head And Neck Neoplasms 23340306 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies. target gene hsa-let-7d Head And Neck Neoplasms 23340306 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies. target gene hsa-let-7e Head And Neck Neoplasms 23340306 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies. target gene hsa-let-7f Head And Neck Neoplasms 23340306 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies. target gene hsa-let-7g Head And Neck Neoplasms 23340306 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies. target gene hsa-let-7i Head And Neck Neoplasms 23340306 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies. target gene hsa-mir-10b Head And Neck Neoplasms 23340306 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies. target gene hsa-mir-1-1 Head And Neck Neoplasms 21378409 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. target gene hsa-mir-1-2 Head And Neck Neoplasms 21378409 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. target gene hsa-mir-125b-1 Head And Neck Neoplasms 23416980 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway target gene hsa-mir-125b-2 Head And Neck Neoplasms 23416980 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway target gene hsa-mir-133a Head And Neck Neoplasms 22378351 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 The genome-wide gene expression analysis and bioinformatics study showed that actin-related protein 2/3 complex subunit 5 (ARPC5) is a candidate target of miR-133a. target gene hsa-mir-133a-1 Head And Neck Neoplasms 22266319 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 Tumor suppressive microRNA-133a regulates novel targets: Moesin contributes to cancer cell proliferation and invasion in head and neck squamous cell carcinoma. target gene hsa-mir-134 Head And Neck Neoplasms 23824713 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 miR-134 induces oncogenicity and metastasis in head and neck carcinoma through targeting WWOX gene. target gene hsa-mir-143 Head And Neck Neoplasms 22469988 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 miR-143 regulates hexokinase 2 expression in cancer cells. target gene hsa-mir-145 Head And Neck Neoplasms 23548270 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 miR145 targets the SOX9/ADAM17 axis to inhibit tumor initiating cells and IL-6-mediated paracrine effects in head and neck cancer target gene hsa-mir-15a Head And Neck Neoplasms 19117988 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 miR-15a: feed-forward loop: PKCalpha down-regulates miR-15a, which directly inhibits protein synthesis of cyclin E target gene hsa-mir-196a Head And Neck Neoplasms 25523631 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 miR-196a as a potential important biomarker of prognosis and response of HNSCC to radiotherapy. Furthermore, our data suggest that miR-196a and/or its target gene ANXA1 could represent important therapeutic targets in HNSCC. target gene hsa-mir-200c Head And Neck Neoplasms 21899661 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 The expression of ZEB1, a target mRNA for miR-200c, was up-regulated 3 and 6 hours after HGF stimulation. target gene hsa-mir-21 Head And Neck Neoplasms 23340306 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies. target gene hsa-mir-211 Head And Neck Neoplasms 23726841 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 miR-211 promotes the progression of head and neck carcinomas by targeting TGFbeta R2. target gene hsa-mir-27b Head And Neck Neoplasms 21899661 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 The expression of ST14/matriptase an enzyme for extracellular matrix (ECM) degradation and HGF activation and a target mRNA for miR-27b, was drastically up-regulated in protein level after HGF stimulation. target gene hsa-mir-31 Head And Neck Neoplasms 23340306 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies. target gene hsa-mir-363 Head And Neck Neoplasms 23246488 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 Dysregulated miR-363 affects head and neck cancer invasion and metastasis by targeting podoplanin target gene hsa-mir-375 Head And Neck Neoplasms 22031094 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 MiR-375 expression was significantly reduced (p=0.01), and conversely, MTDH was significantly increased (p=0.0001) in NPC samples. Quantitative RT-PCR, western blots and luciferase assays corroborated MTDH as a target of miR-375. Re-expression of miR-375 and siRNA knock-down of MTDH both decreased cell viability and clonogenic survival, cell migration/invasion, as well as in vivo tumour formation. NPC patients whose tumours expressed high levels of MTDH experienced significantly lower survival, and in particular, higher distant relapse rates (5-year distant relapse rates: 26% vs. 5%; p=0.005). target gene hsa-mir-504 Head And Neck Neoplasms 23340306 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies. target gene hsa-mir-27a Heart Diseases [unspecific] 29694513 I51.9 D006333 miR-27a protects human mitral valve interstitial cell from TNF-α-induced inflammatory injury via up-regulation of NELL-1. target gene hsa-let-7a Heart Failure 28060734 I50 D006331 HP:0001635 Let-7a regulates expression of β1-adrenoceptors and forms a negative feedback circuit with the β1-adrenoceptor signaling pathway in chronic ischemic heart failure. target gene hsa-mir-1 Heart Failure 22045061 I50 D006331 HP:0001635 MicroRNA-1 represses Cx43 expression in viral myocarditis. target gene hsa-mir-1 Heart Failure 23024758 I50 D006331 HP:0001635 Time-course analysis revealed that decreased expression of miR-1 and miR-133a commences at a pre-disease stage, and precedes upregulation of target genes causal of cardiac hypertrophy and extracellular matrix remodelling, suggesting a role for miR-1 and miR-133a in early disease development. target gene hsa-mir-1 Heart Failure 23141496 I50 D006331 HP:0001635 Biochemical assays and an inducible cardiac-specific transgenic mouse model overexpressing miR-1 were used to demonstrate that heart-type fatty acid-binding protein-3 (FABP3) is a target of miR-1. target gene hsa-mir-1 Heart Failure 23436819 I50 D006331 HP:0001635 The decrease of miR-1 and increase of AnxA5 appear as important modulators of NCX1 expression and activity during heart failure. target gene hsa-mir-1 Heart Failure 27213338 I50 D006331 HP:0001635 miR-1 repressed the expression of gap junction protein 伪1 (GJA1) in VMC target gene hsa-mir-105 Heart Failure 27185878 I50 D006331 HP:0001635 miR-155 and miR-105, were found to modulate ANP production in human cardiomyocytes target gene hsa-mir-125b Heart Failure 27592695 I50 D006331 HP:0001635 MiR-125b regulates SFRP5 expression to promote growth and activation of cardiac fibroblasts. target gene hsa-mir-133a Heart Failure 23024758 I50 D006331 HP:0001635 Time-course analysis revealed that decreased expression of miR-1 and miR-133a commences at a pre-disease stage, and precedes upregulation of target genes causal of cardiac hypertrophy and extracellular matrix remodelling, suggesting a role for miR-1 and miR-133a in early disease development. target gene hsa-mir-133a Heart Failure 26440278 I50 D006331 HP:0001635 miR-133a acts as a repressor of SRF and CTGF expression target gene hsa-mir-155 Heart Failure 23956210 I50 D006331 HP:0001635 Our findings reveal that microRNA-155 expression in macrophages promotes cardiac inflammation, hypertrophy, and failure in response to pressure overload. These data support the causative significance of inflammatory signaling in hypertrophic heart disease and demonstrate the feasibility of therapeutic microRNA targeting of inflammation in heart failure. target gene hsa-mir-155 Heart Failure 27185878 I50 D006331 HP:0001635 miR-155 and miR-105, were found to modulate ANP production in human cardiomyocytes target gene hsa-mir-182 Heart Failure 27763637 I50 D006331 HP:0001635 miR-182 negatively regulated Nogo-C expression and was downregulated during MI target gene hsa-mir-18a Heart Failure 21501375 I50 D006331 HP:0001635 MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. target gene hsa-mir-18b Heart Failure 21501375 I50 D006331 HP:0001635 MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. target gene hsa-mir-195 Heart Failure 29330215 I50 D006331 HP:0001635 increased levels of miR-195 in failing myocardium regulate a novel pathway that involves direct SIRT3 suppression and enzymatic inhibition via increased acetylation of PDH and ATP synthase that are essential for cardiac energy metabolism target gene hsa-mir-199a Heart Failure 24011070 I50 D006331 HP:0001635 our data suggest a mechanism whereby miR-199a∼214 actively represses cardiac PPARδ expression, facilitating a metabolic shift from predominant reliance on fatty acid utilization in the healthy myocardium toward increased reliance on glucose metabolism at the onset of heart failure. target gene hsa-mir-19a Heart Failure 21501375 I50 D006331 HP:0001635 MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. target gene hsa-mir-19b Heart Failure 27213338 I50 D006331 HP:0001635 a miR-19b inhibitor increased, while its mimics suppressed the expression of GJA1 in HL-1 cells. target gene hsa-mir-19b-1 Heart Failure 21501375 I50 D006331 HP:0001635 MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. target gene hsa-mir-19b-2 Heart Failure 21501375 I50 D006331 HP:0001635 MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. target gene hsa-mir-21 Heart Failure 19336275 I50 D006331 HP:0001635 miR-21: miR-21 can protect this by targeting PDCD4 target gene hsa-mir-214 Heart Failure 26572862 I50 D006331 HP:0001635 These results provide the first clear link between miRNAs and direct regulation of XBP1 in heart failure and reveal that miR-214 and miR-30* synergistically regulates cardiac VEGF expression and angiogenesis by targeting XBP1 in the progression from adaptive hypertrophy to heart failure. target gene hsa-mir-214 Heart Failure 25656649 I50 D006331 HP:0001635 MicroRNA-214 Is Upregulated in Heart Failure Patients and Suppresses XBP1-Mediated Endothelial Cells Angiogenesis. target gene hsa-mir-22 Heart Failure 27997889 I50 D006331 HP:0001635 MiR-22 may Suppress Fibrogenesis by Targeting TGFβR I in Cardiac Fibroblasts. target gene hsa-mir-22 Heart Failure 28112401 I50 D006331 HP:0001635 MicroRNA-22 regulates inflammation and angiogenesis via targeting VE-cadherin. target gene hsa-mir-24 Heart Failure 22891046 I50 D006331 HP:0001635 MiR-24-mediated suppression of JP2 expression provides a novel molecular mechanism for E-C coupling regulation in heart cells and suggests a new target against heart failure. target gene hsa-mir-24 Heart Failure 29457789 I50 D006331 HP:0001635 miR-24 potently suppresses SCN5A expression and that rs1805126 modulates this regulation target gene hsa-mir-26a Heart Failure 22664106 I50 D006331 HP:0001635 Up-regulation of miR-26a promotes apoptosis of hypoxic rat neonatal cardiomyocytes by repressing GSK-3β protein expression. target gene hsa-mir-26a Heart Failure 25608527 I50 D006331 HP:0001635 MicroRNA-26a, which targets KCNJ2, was downregulated in CHF fibroblasts. target gene hsa-mir-30 Heart Failure 26572862 I50 D006331 HP:0001635 These results provide the first clear link between miRNAs and direct regulation of XBP1 in heart failure and reveal that miR-214 and miR-30* synergistically regulates cardiac VEGF expression and angiogenesis by targeting XBP1 in the progression from adaptive hypertrophy to heart failure. target gene hsa-mir-30c Heart Failure 27633839 I50 D006331 HP:0001635 MiRNA-30e mediated cardioprotection of ACE2 in rats with Doxorubicin-induced heart failure through inhibiting cardiomyocytes autophagy. target gene hsa-mir-30e Heart Failure 27633839 I50 D006331 HP:0001635 MiRNA-30e mediated cardioprotection of ACE2 in rats with Doxorubicin-induced heart failure through inhibiting cardiomyocytes autophagy. target gene hsa-mir-325 Heart Failure 24531537 I50 D006331 HP:0001635 Our present study reveals a novel autophagic regulating model that is composed of E2F1,miR-325 and ARC. Modulation of their levels may provide a new approach for tackling cardiac failure. target gene hsa-mir-340 Heart Failure 26084457 I50 D006331 HP:0001635 microRNA-340-5p Functions Downstream of Cardiotrophin-1 to Regulate Cardiac Eccentric Hypertrophy and Heart Failure via Target Gene Dystrophin. target gene hsa-mir-365 Heart Failure 28130111 I50 D006331 HP:0001635 MicroRNA-365 accelerates cardiac hypertrophy by inhibiting autophagy via the modulation of Skp2 expression. target gene hsa-mir-425 Heart Failure 23867623 I50 D006331 HP:0001635 Atrial natriuretic peptide is negatively regulated by microRNA-425. target gene hsa-mir-425 Heart Failure 27185878 I50 D006331 HP:0001635 microRNA 425 (miR-425) was found to regulate ANP production target gene hsa-mir-497 Heart Failure 27992564 I50 D006331 HP:0001635 MicroRNA-497 Inhibits Cardiac Hypertrophy by Targeting Sirt4. target gene hsa-mir-539 Heart Failure 25183011 I50 D006331 HP:0001635 MicroRNA-539 is up-regulated in failing heart, and suppresses O-GlcNAcase expression. target gene hsa-mir-17 Hemangiosarcoma 22383169 D48.1 D006394 The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification. target gene hsa-mir-18a Hemangiosarcoma 22383169 D48.1 D006394 The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification. target gene hsa-mir-19a Hemangiosarcoma 22383169 D48.1 D006394 The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification. target gene hsa-mir-19b-1 Hemangiosarcoma 22383169 D48.1 D006394 The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification. target gene hsa-mir-20a Hemangiosarcoma 22383169 D48.1 D006394 The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification. target gene hsa-mir-92a-1 Hemangiosarcoma 22383169 D48.1 D006394 The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification. target gene hsa-mir-1226 Hematologic Neoplasms 20514397 disease of cellular proliferation DOID:2531 C96.9 D019337 HP:0004377 These findings indicate that expression of the MUC1 oncoprotein is downregulated by miR-1226 and that miR-1226 thereby functions as a tumor suppressor by promoting the induction of cell death. target gene hsa-mir-210 Hemoglobin Diseases 25849663 D58.2 D006450 141900 microRNA-210 and raptor are involved in mithramycin-mediated erythroid differentiation of K562 cells and participate to the fine-tuning and control of γ-globin gene expression in erythroid precursor cells. target gene hsa-mir-124 Hepatic Ischemia-Reperfusion Injury 24875359 Many miRNAs are involved in hepatic IRI in rats, and miR-124 is significantly decreased in this model. MiR-124 significantly decreases the H2O2-induced apoptosis of human hepatic L02 cells by targeting the Rab38 gene and activating the AKT pathway. target gene hsa-mir-122 Hepatitis B Virus Infection 24667324 disease by infectious agent DOID:2043 B16/18 D006509 610424 In conclusion, HBx is a critical protein derived from HBV,which regulates miR-122 via down-regulating Gld2. target gene hsa-mir-122 Hepatitis B Virus Infection 25766860 disease by infectious agent DOID:2043 B16/18 D006509 610424 Down-regulation of suppressor of cytokine signaling 3 by miR-122 enhances interferon-mediated suppression of hepatitis B virus. target gene hsa-mir-1231 Hepatitis B Virus Infection 24835118 disease by infectious agent DOID:2043 B16/18 D006509 610424 Human microRNA hsa-miR-1231 suppresses hepatitis B virus replication by targeting core mRNA. target gene hsa-mir-125a Hepatitis B Virus Infection 23783428 disease by infectious agent DOID:2043 B16/18 D006509 610424 Biogenesis, evolution and functional targets of microRNA-125a. target gene hsa-mir-125b Hepatitis B Virus Infection 25173609 disease by infectious agent DOID:2043 B16/18 D006509 610424 miR-125b inhibits hepatitis B virus expression in vitro through targeting of the SCNN1A gene. target gene hsa-mir-130a Hepatitis B Virus Infection 25595716 disease by infectious agent DOID:2043 B16/18 D006509 610424 miR-130a could contribute to metabolic homeostasis by dual targeting PGC1α and PPARγ simultaneously. target gene hsa-mir-141 Hepatitis B Virus Infection 22479552 disease by infectious agent DOID:2043 B16/18 D006509 610424 MicroRNA-141 Represses HBV Replication by Targeting PPARA target gene hsa-mir-141 Hepatitis B Virus Infection 28135713 disease by infectious agent DOID:2043 B16/18 D006509 610424 MicroRNA-141 Targets Sirt1 and Inhibits Autophagy to Reduce HBV Replication. target gene hsa-mir-146a Hepatitis B Virus Infection 23698745 disease by infectious agent DOID:2043 B16/18 D006509 610424 MicroRNA-146a Feedback Suppresses T Cell Immune Function by Targeting Stat1 in Patients with Chronic Hepatitis B. target gene hsa-mir-146a Hepatitis B Virus Infection 25805734 disease by infectious agent DOID:2043 B16/18 D006509 610424 Upregulation of microRNA-146a by hepatitis B virus X protein contributes to hepatitis development by downregulating complement factor H. target gene hsa-mir-155 Hepatitis B Virus Infection 25720442 disease by infectious agent DOID:2043 B16/18 D006509 610424 our study established a correlation between miR-155 and TLR7 during HBV infection and also demonstrated in vitro that increased miR-155 level could help to reduce HBV viral load by targeting C/EBP-β. target gene hsa-mir-15a Hepatitis B Virus Infection 24089558 disease by infectious agent DOID:2043 B16/18 D006509 610424 we identified a novel HBV mRNA-miR-15a/16-Bcl-2 regulatory pathway that is involved in inhibiting etoposide-induced apoptosis of hepatoma cells, which may contribute to facilitating chronic HBV infection and hepatoma development. target gene hsa-mir-16 Hepatitis B Virus Infection 24089558 disease by infectious agent DOID:2043 B16/18 D006509 610424 we identified a novel HBV mRNA-miR-15a/16-Bcl-2 regulatory pathway that is involved in inhibiting etoposide-induced apoptosis of hepatoma cells, which may contribute to facilitating chronic HBV infection and hepatoma development. target gene hsa-mir-26b Hepatitis B Virus Infection 25342750 disease by infectious agent DOID:2043 B16/18 D006509 610424 MicroRNA-26b inhibits hepatitis B virus transcription and replication by targeting the host factor CHORDC1 protein. target gene hsa-mir-338 Hepatitis B Virus Infection 22942717 disease by infectious agent DOID:2043 B16/18 D006509 610424 miR-338-3p Is Down-Regulated by Hepatitis B Virus X and Inhibits Cell Proliferation by Targeting the 3'-UTR Region of CyclinD1. target gene hsa-mir-370 Hepatitis B Virus Infection 27664977 disease by infectious agent DOID:2043 B16/18 D006509 610424 miR-370 suppresses HBV gene expression and replication by targeting nuclear factor IA. target gene hsa-mir-372 Hepatitis B Virus Infection 21608007 disease by infectious agent DOID:2043 B16/18 D006509 610424 MicroRNAs-372/373 promote the expression of hepatitis B Virus through the targeting of nuclear factor I/B. target gene hsa-mir-373 Hepatitis B Virus Infection 21608007 disease by infectious agent DOID:2043 B16/18 D006509 610424 MicroRNAs-372/373 promote the expression of hepatitis B Virus through the targeting of nuclear factor I/B. target gene hsa-mir-4717 Hepatitis B Virus Infection 25895129 disease by infectious agent DOID:2043 B16/18 D006509 610424 microRNA-4717 differentially interacts with its polymorphic target in the PD1 3' untranslated region: A mechanism for regulating PD-1 expression and function in HBV-associated liver diseases. target gene hsa-mir-501 Hepatitis B Virus Infection 23266610 disease by infectious agent DOID:2043 B16/18 D006509 610424 MicroRNA-501 promotes HBV replication by targeting HBXIP target gene hsa-mir-602 Hepatitis B Virus Infection 20364114 disease by infectious agent DOID:2043 B16/18 D006509 610424 MicroRNA-602 regulating tumor suppressive gene RASSF1A is overexpressed in hepatitis B virus-infected liver and hepatocellular carcinoma target gene hsa-mir-107 Hepatitis C Virus Infection 24429361 disease by infectious agent DOID:1883 B19.2 D006526 609532 Hepatitis C virus-induced changes in microRNA 107 (miRNA-107) and miRNA-449a modulate CCL2 by targeting the interleukin-6 receptor complex in hepatitis. miR-122,miR-126,miR-136,hsa-mir-181a target gene hsa-mir-122 Hepatitis C Virus Infection 25302477 disease by infectious agent DOID:1883 B19.2 D006526 609532 This study uncovers a novel antiviral effect of miR-122 on human liver cells and shows that over-expression of miR-122 can decrease HCV entry into hepatocytes through down-regulation of OCLN. target gene hsa-mir-122 Hepatitis C Virus Infection 17462786 disease by infectious agent DOID:1883 B19.2 D006526 609532 Although miRNA regulation of cellular target genes through 3'UTR binding seems to be only negative, the hepatitis C virus (HCV) has creatively made use of the liver-specific and abundantly expressed miR-122 to promote viral replication. target gene hsa-mir-122 Hepatitis C Virus Infection 22957141 disease by infectious agent DOID:1883 B19.2 D006526 609532 Silencing of microRNA-122 enhances interferon-alpha signaling in the liver through regulating SOCS3 promoter methylation. target gene hsa-mir-122 Hepatitis C Virus Infection 24068553 disease by infectious agent DOID:1883 B19.2 D006526 609532 MiR-122 is a liver-specific miRNA with an important role in the life cycle of hepatitis C virus (HCV). It is the target of miravirsen (SPC3649), an antimiR drug candidate currently in clinical testing for treatment of HCV infections. target gene hsa-mir-1273g Hepatitis C Virus Infection 27423040 disease by infectious agent DOID:1883 B19.2 D006526 609532 Overexpression of miR-1273g-3p could inhibit translation of PTEN, increase the expression of 伪-SMA, Col1A1, and reduce apoptosis in HSCs. target gene hsa-mir-15b Hepatitis C Virus Infection 24705650 disease by infectious agent DOID:1883 B19.2 D006526 609532 Modulation of HBV replication by microRNA-15b through targeting hepatocyte nuclear factor 1α. target gene hsa-mir-182 Hepatitis C Virus Infection 26518141 disease by infectious agent DOID:1883 B19.2 D006526 609532 miR-182 was never investigated before, neither in HCV infection nor in NK cells, and we found it to have dysregulated expression in both liver tissues and NK cells of HCV-infected patients compared to control. In addition to that, miR-182 was found to have a contradicting effect in both effector cell and its HCV-infected target cell regarding HCV replication. target gene hsa-mir-185 Hepatitis C Virus Infection 25914460 disease by infectious agent DOID:1883 B19.2 D006526 609532 HCV core protein disturbs the cholesterol homeostasis in HepG2 cells via the SREBP2 pathway; miR-185-5p is involved in the regulation of SREBP2 by the core protein. target gene hsa-mir-194 Hepatitis C Virus Infection 25218426 disease by infectious agent DOID:1883 B19.2 D006526 609532 This study showed that mir-194 hinders HCV entry through targeting CD81 receptors. target gene hsa-mir-199a Hepatitis C Virus Infection 26027911 disease by infectious agent DOID:1883 B19.2 D006526 609532 Inhibition of microRNA-199a-5p reduces the replication of HCV via regulating the pro-survival pathway. target gene hsa-mir-215 Hepatitis C Virus Infection 29749134 disease by infectious agent DOID:1883 B19.2 D006526 609532 miR-215 Enhances HCV Replication by Targeting TRIM22 and Inactivating NF-κB Signaling. target gene hsa-mir-224 Hepatitis C Virus Infection 17188425 disease by infectious agent DOID:1883 B19.2 D006526 609532 miRNA-224 regulates PDGFR expression, and decreases as disease progresses from chronic hepatitis to cirrhosis [59], suggesting that miRNA normally suppresses PDGFR in the liver until HBV integration and genetic instability upsets this balance. miRNA-224 a target gene hsa-mir-27a Hepatitis C Virus Infection 23449803 disease by infectious agent DOID:1883 B19.2 D006526 609532 MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells target gene hsa-mir-373 Hepatitis C Virus Infection 25589644 disease by infectious agent DOID:1883 B19.2 D006526 609532 the role of miR-373 in HCV infection and suggest a new potential target against HCV infection. target gene hsa-mir-449a Hepatitis C Virus Infection 24429361 disease by infectious agent DOID:1883 B19.2 D006526 609532 Hepatitis C virus-induced changes in microRNA 107 (miRNA-107) and miRNA-449a modulate CCL2 by targeting the interleukin-6 receptor complex in hepatitis. miR-122,miR-126,miR-136,hsa-mir-181a target gene hsa-mir-491 Hepatitis C Virus Infection 21802413 disease by infectious agent DOID:1883 B19.2 D006526 609532 miR-491 was involved in regulation of HCV replication via the PI3 kinase/Akt pathway. target gene hsa-mir-942 Hepatitis C Virus Infection 24727952 disease by infectious agent DOID:1883 B19.2 D006526 609532 MiR-942 mediates hepatitis C virus-induced apoptosis via regulation of ISG12a. target gene hsa-mir-143 Hepatoblastoma 19472311 disease of cellular proliferation DOID:687 C22.2 D018197 HP:0002884 Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression. target gene hsa-mir-328 Hepatoblastoma 24318997 disease of cellular proliferation DOID:687 C22.2 D018197 HP:0002884 Macrophage-derived reactive oxygen species suppress miR-328 targeting CD44 in cancer cells and promote redox adaptation. target gene hsa-mir-424 Hepatoblastoma 25524739 disease of cellular proliferation DOID:687 C22.2 D018197 HP:0002884 miR-424 regulates the myofibroblast differentiation during EMT by potentiating the TGF-β signaling pathway, likely through Smurf2 target gene hsa-mir-492 Hepatoblastoma 29314711 disease of cellular proliferation DOID:687 C22.2 D018197 HP:0002884 MiR-492 regulates metastatic properties of hepatoblastoma via CD44 target gene hsa-mir-569 Hepatoblastoma 25490449 disease of cellular proliferation DOID:687 C22.2 D018197 HP:0002884 targeting miR569 could potentially benefit patients with the 3q26.2 amplicon and subsequent miR569 elevatio target gene hsa-mir-96 hepatocellular carcinoma 28892647 miR-96 targets SOX6 and promotes proliferation, migration, and invasion of hepatocellular carcinoma target gene hsa-let-7a Hirschsprung Disease 26991540 gastrointestinal system disease DOID:10487 Q43.1 D006627 600156 HP:0002251 Our study demonstrates that the miR-24-1*/let-7a*-ARP2/3 complex-RAC isoforms pathway may represent a novel pathogenic mechanism for HSCR. target gene hsa-mir-141 Hirschsprung Disease 24334875 gastrointestinal system disease DOID:10487 Q43.1 D006627 600156 HP:0002251 The present study demonstrates for the first time the role of miR-141 and its target genes in the occurrence of HSCR, and provides us a new direction for the study of the pathogenesis of Hirschsprung's disease. target gene hsa-mir-192 Hirschsprung Disease 25857602 gastrointestinal system disease DOID:10487 Q43.1 D006627 600156 HP:0002251 Nidogen-1 is a common target of microRNAs MiR-192/215 in the pathogenesis of Hirschsprung's disease. target gene hsa-mir-200 Hirschsprung Disease 25116353 gastrointestinal system disease DOID:10487 Q43.1 D006627 600156 HP:0002251 The miR-200 family may play a crucial role in the pathogenesis of HSCR by co-regulating PTEN. target gene hsa-mir-215 Hirschsprung Disease 25857602 gastrointestinal system disease DOID:10487 Q43.1 D006627 600156 HP:0002251 Nidogen-1 is a common target of microRNAs MiR-192/215 in the pathogenesis of Hirschsprung's disease. target gene hsa-mir-215 Hirschsprung Disease 28006787 gastrointestinal system disease DOID:10487 Q43.1 D006627 600156 HP:0002251 Role of MiR-215 in Hirschsprung's Disease Pathogenesis by Targeting SIGLEC-8. target gene hsa-mir-24 Hirschsprung Disease 26991540 gastrointestinal system disease DOID:10487 Q43.1 D006627 600156 HP:0002251 Our study demonstrates that the miR-24-1*/let-7a*-ARP2/3 complex-RAC isoforms pathway may represent a novel pathogenic mechanism for HSCR. target gene hsa-mir-122 Human Immunodeficiency Virus Infection 24503097 B20 D015658 609423 Genome-wide mRNA and miRNA analysis of peripheral blood mononuclear cells (PBMC) reveals different miRNAs regulating HIV/HCV co-infection. target gene hsa-mir-1236 Human Immunodeficiency Virus Infection 24932481 B20 D015658 609423 miRNA-1236 inhibits HIV-1 infection of monocytes by repressing translation of cellular factor VprBP. target gene hsa-mir-125b Human Immunodeficiency Virus Infection 17906637 B20 D015658 609423 We have found that the 3' ends of HIV-1 messenger RNAs are targeted by a cluster of cellular miRNAs including miR-28, miR-125b, miR-150, miR-223 and miR-382, which are enriched in resting CD4+ T cells as compared to activated CD4+ T cells. target gene hsa-mir-146a Human Immunodeficiency Virus Infection 20181935 B20 D015658 609423 mir-146a:CCL8/MCP-2 is a target for mir-146a in HIV-1-infected human microglial cells target gene hsa-mir-150 Human Immunodeficiency Virus Infection 17906637 B20 D015658 609423 We have found that the 3' ends of HIV-1 messenger RNAs are targeted by a cluster of cellular miRNAs including miR-28, miR-125b, miR-150, miR-223 and miR-382, which are enriched in resting CD4+ T cells as compared to activated CD4+ T cells. target gene hsa-mir-155 Human Immunodeficiency Virus Infection 22080513 B20 D015658 609423 microRNA-223 levels were significantly enriched in HIV-1-infected CD4(+)CD8(-) PBMCs, microRNA-29a/b, microRNA-155 and microRNA-21 levels were significantly reduced. Based on the potential for microRNA binding sites in a conserved sequence of the Nef-3'-LTR, several host microRNAs potentially could affect HIV-1 gene expression. Among those microRNAs, the microRNA-29 family has seed complementarity in the HIV-1 3'-UTR, but the potential suppressive effect of microRNA-29 on HIV-1 is severely blocked by the secondary structure of the target region. target gene hsa-mir-155 Human Immunodeficiency Virus Infection 28096489 B20 D015658 609423 miR-155 and miR-92a, were reported previously to at least weakly bind HIV-1 transcripts target gene hsa-mir-17 Human Immunodeficiency Virus Infection 25146963 B20 D015658 609423 HIV-1 Tat C modulates NOX2 and NOX4 expressions through miR-17 in a human microglial cell line. target gene hsa-mir-182 Human Immunodeficiency Virus Infection 23153509 B20 D015658 609423 Down-regulation of NAMPT expression by miR-182 is involved in Tat-induced HIV-1 long terminal repeat (LTR) transactivation target gene hsa-mir-21 Human Immunodeficiency Virus Infection 19560422 B20 D015658 609423 highly abundant; specifically targets the HIV-1 3'UTR region; Inhibiting miR-29a enhanced HIV-1 viral production and infectivity; specific miR-29a-HIV-1 mRNA interactions enhance viral mRNA association with RISC and P body proteins target gene hsa-mir-21 Human Immunodeficiency Virus Infection 22080513 B20 D015658 609423 microRNA-223 levels were significantly enriched in HIV-1-infected CD4(+)CD8(-) PBMCs, microRNA-29a/b, microRNA-155 and microRNA-21 levels were significantly reduced. Based on the potential for microRNA binding sites in a conserved sequence of the Nef-3'-LTR, several host microRNAs potentially could affect HIV-1 gene expression. Among those microRNAs, the microRNA-29 family has seed complementarity in the HIV-1 3'-UTR, but the potential suppressive effect of microRNA-29 on HIV-1 is severely blocked by the secondary structure of the target region. target gene hsa-mir-223 Human Immunodeficiency Virus Infection 22080513 B20 D015658 609423 microRNA-223 levels were significantly enriched in HIV-1-infected CD4(+)CD8(-) PBMCs, microRNA-29a/b, microRNA-155 and microRNA-21 levels were significantly reduced. Based on the potential for microRNA binding sites in a conserved sequence of the Nef-3'-LTR, several host microRNAs potentially could affect HIV-1 gene expression. Among those microRNAs, the microRNA-29 family has seed complementarity in the HIV-1 3'-UTR, but the potential suppressive effect of microRNA-29 on HIV-1 is severely blocked by the secondary structure of the target region. target gene hsa-mir-223 Human Immunodeficiency Virus Infection 17906637 B20 D015658 609423 We have found that the 3' ends of HIV-1 messenger RNAs are targeted by a cluster of cellular miRNAs including miR-28, miR-125b, miR-150, miR-223 and miR-382, which are enriched in resting CD4+ T cells as compared to activated CD4+ T cells. target gene hsa-mir-28 Human Immunodeficiency Virus Infection 17906637 B20 D015658 609423 We have found that the 3' ends of HIV-1 messenger RNAs are targeted by a cluster of cellular miRNAs including miR-28, miR-125b, miR-150, miR-223 and miR-382, which are enriched in resting CD4+ T cells as compared to activated CD4+ T cells. target gene hsa-mir-29a Human Immunodeficiency Virus Infection 22080513 B20 D015658 609423 microRNA-223 levels were significantly enriched in HIV-1-infected CD4(+)CD8(-) PBMCs, microRNA-29a/b, microRNA-155 and microRNA-21 levels were significantly reduced. Based on the potential for microRNA binding sites in a conserved sequence of the Nef-3'-LTR, several host microRNAs potentially could affect HIV-1 gene expression. Among those microRNAs, the microRNA-29 family has seed complementarity in the HIV-1 3'-UTR, but the potential suppressive effect of microRNA-29 on HIV-1 is severely blocked by the secondary structure of the target region. target gene hsa-mir-382 Human Immunodeficiency Virus Infection 17906637 B20 D015658 609423 We have found that the 3' ends of HIV-1 messenger RNAs are targeted by a cluster of cellular miRNAs including miR-28, miR-125b, miR-150, miR-223 and miR-382, which are enriched in resting CD4+ T cells as compared to activated CD4+ T cells. target gene hsa-mir-34a Human Immunodeficiency Virus Infection 26188041 B20 D015658 609423 The miRNA miR-34a enhances HIV-1 replication by targeting PNUTS/PPP1R10, which negatively regulates HIV-1 transcriptional complex formation. target gene hsa-mir-92a Human Immunodeficiency Virus Infection 28096489 B20 D015658 609423 miR-155 and miR-92a, were reported previously to at least weakly bind HIV-1 transcripts target gene hsa-mir-145 Human Papilloma Virus Infection 27386862 B97.7 D027383 KLF4 levels are increased in HPV-positive cells through a post-transcriptional mechanism involving E7-mediated suppression of cellular miR-145 target gene hsa-mir-15a Human Papilloma Virus Infection 27573302 B97.7 D027383 miR-15a induces cell apoptosis by targeting BCL2L2 and BCL2 in HPV-positive hypopharyngeal squamous cell carcinoma. target gene hsa-mir-3144 Human Papilloma Virus Infection 25913515 B97.7 D027383 Two less common human microRNAs miR-875 and miR-3144 target a conserved site of E6 oncogene in most high-risk human papillomavirus subtypes. target gene hsa-mir-875 Human Papilloma Virus Infection 25913515 B97.7 D027383 Two less common human microRNAs miR-875 and miR-3144 target a conserved site of E6 oncogene in most high-risk human papillomavirus subtypes. target gene hsa-mir-125b-1 Huntington Disease 21887328 nervous system disease DOID:12858 G10 D006816 143100 The authors conclude that (i) miR-125b and miR-150 target p53, which in turn regulates RelA/NFkB and miR-146a expressions; (ii) reduced miR-125b and miR-150 expressions, increased p53 level and decreased RelA/NFkB and miR-146a expressions originate from mutant HTT (iii) p53 directly or indirectly regulates the expression of miR-146a. target gene hsa-mir-125b-1 Huntington Disease 22048026 nervous system disease DOID:12858 G10 D006816 143100 Micro RNA -214,-150,-146a and-125b target Huntingtin gene. target gene hsa-mir-125b-2 Huntington Disease 21887328 nervous system disease DOID:12858 G10 D006816 143100 The authors conclude that (i) miR-125b and miR-150 target p53, which in turn regulates RelA/NFkB and miR-146a expressions; (ii) reduced miR-125b and miR-150 expressions, increased p53 level and decreased RelA/NFkB and miR-146a expressions originate from mutant HTT (iii) p53 directly or indirectly regulates the expression of miR-146a. target gene hsa-mir-125b-2 Huntington Disease 22048026 nervous system disease DOID:12858 G10 D006816 143100 Micro RNA -214,-150,-146a and-125b target Huntingtin gene. target gene hsa-mir-146a Huntington Disease 21887328 nervous system disease DOID:12858 G10 D006816 143100 The authors conclude that (i) miR-125b and miR-150 target p53, which in turn regulates RelA/NFkB and miR-146a expressions; (ii) reduced miR-125b and miR-150 expressions, increased p53 level and decreased RelA/NFkB and miR-146a expressions originate from mutant HTT (iii) p53 directly or indirectly regulates the expression of miR-146a. target gene hsa-mir-146a Huntington Disease 22048026 nervous system disease DOID:12858 G10 D006816 143100 Micro RNA -214,-150,-146a and-125b target Huntingtin gene. target gene hsa-mir-150 Huntington Disease 21887328 nervous system disease DOID:12858 G10 D006816 143100 The authors conclude that (i) miR-125b and miR-150 target p53, which in turn regulates RelA/NFkB and miR-146a expressions; (ii) reduced miR-125b and miR-150 expressions, increased p53 level and decreased RelA/NFkB and miR-146a expressions originate from mutant HTT (iii) p53 directly or indirectly regulates the expression of miR-146a. target gene hsa-mir-150 Huntington Disease 22048026 nervous system disease DOID:12858 G10 D006816 143100 Micro RNA -214,-150,-146a and-125b target Huntingtin gene. target gene hsa-mir-214 Huntington Disease 22048026 nervous system disease DOID:12858 G10 D006816 143100 Micro RNA -214,-150,-146a and-125b target Huntingtin gene. target gene hsa-mir-214 Huntington Disease 26307536 nervous system disease DOID:12858 G10 D006816 143100 In summary, we have shown that increased expression of miR-214 observed in HD cell model could target MFN2, altered mitochondrial morphology and deregulated cell cycle. Inhibition of miR-214 could be a possible target of intervention in HD pathogenesis. target gene hsa-mir-22 Huntington Disease 23349832 nervous system disease DOID:12858 G10 D006816 143100 MicroRNA-22 (miR-22) Overexpression Is Neuroprotective via General Anti-Apoptotic Effects and May also Target Specific Huntington's Disease-Related Mechanisms target gene hsa-mir-34a Huntington Disease 29289683 nervous system disease DOID:12858 G10 D006816 143100 Perturbations in the p53/miR-34a/SIRT1 pathway in the R6/2 Huntington's disease model target gene hsa-mir-491 Hypercholesterolaemia 27575876 E78.3 D006937 143890 Atorvastatin attenuation of ABCB1 expression is mediated by microRNA miR-491-3p in Caco-2 cells. target gene hsa-let-7b Hypertension 27286171 cardiovascular system disease DOID:10763 I10 D006973 145500 HP:0000822 micro-RNA Let-7b in post-transcriptional regulation target gene hsa-mir-105 Hypertension 27185878 cardiovascular system disease DOID:10763 I10 D006973 145500 HP:0000822 miR-155 and miR-105, were found to modulate ANP production in human cardiomyocytes target gene hsa-mir-1283 Hypertension 26149214 cardiovascular system disease DOID:10763 I10 D006973 145500 HP:0000822 inhibition of miR-1283 in HA-VSMCs enhanced the expression of Activating transcription factor 1 mRNA as well as the ROS levels. target gene hsa-mir-133a-1 Hypertension 21769867 cardiovascular system disease DOID:10763 I10 D006973 145500 HP:0000822 MiR-133a regulates collagen 1A1, which has potential role in myocardial fibrosis in angiotensin II dependent hypertension. target gene hsa-mir-133a-2 Hypertension 21769867 cardiovascular system disease DOID:10763 I10 D006973 145500 HP:0000822 MiR-133a regulates collagen 1A1, which has potential role in myocardial fibrosis in angiotensin II dependent hypertension. target gene hsa-mir-155 Hypertension 17668390 cardiovascular system disease DOID:10763 I10 D006973 145500 HP:0000822 Since hsa-miR-155 is on chromosome 21, we hypothesize that the observed lower blood pressure in trisomy 21 is partially caused by the overexpression of hsa-miR-155 leading to allele-specific underexpression of AGTR1. target gene hsa-mir-155 Hypertension 27185878 cardiovascular system disease DOID:10763 I10 D006973 145500 HP:0000822 miR-155 and miR-105, were found to modulate ANP production in human cardiomyocytes target gene hsa-mir-16 Hypertension 28531963 cardiovascular system disease DOID:10763 I10 D006973 145500 HP:0000822 MiR-19b and miR-16 cooperatively signaling target the regulator ADRA1A in Hypertensive heart disease. target gene hsa-mir-19b Hypertension 28531963 cardiovascular system disease DOID:10763 I10 D006973 145500 HP:0000822 MiR-19b and miR-16 cooperatively signaling target the regulator ADRA1A in Hypertensive heart disease. target gene hsa-mir-204 Hypertension 28839162 cardiovascular system disease DOID:10763 I10 D006973 145500 HP:0000822 MicroRNA-204 promotes vascular endoplasmic reticulum stress and endothelial dysfunction by targeting Sirtuin1. target gene hsa-mir-328 Hypertension 22392900 cardiovascular system disease DOID:10763 I10 D006973 145500 HP:0000822 The MicroRNA-328 Regulates Hypoxic Pulmonary Hypertension by Targeting at Insulin Growth Factor 1 Receptor and L-Type Calcium Channel-alpha1C. target gene hsa-mir-424 Hypertension 23263626 cardiovascular system disease DOID:10763 I10 D006973 145500 HP:0000822 An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension target gene hsa-mir-425 Hypertension 27185878 cardiovascular system disease DOID:10763 I10 D006973 145500 HP:0000822 microRNA 425 (miR-425) was found to regulate ANP production target gene hsa-mir-503 Hypertension 23263626 cardiovascular system disease DOID:10763 I10 D006973 145500 HP:0000822 An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension target gene hsa-mir-608 Hypertension 24722204 cardiovascular system disease DOID:10763 I10 D006973 145500 HP:0000822 Competing targets of microRNA-608 affect anxiety and hypertension. target gene hsa-mir-10a Hypertrophic Scar 25554417 L91.0 D017439 miR-181c-uPA and miR-10a-PAI-1 regulatory pathways have an integral role in HS pathogenesis. target gene hsa-mir-145 Hypertrophic Scar 25704091 L91.0 D017439 Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist inhibits collagen synthesis in human hypertrophic scar fibroblasts by targeting Smad3 via miR-145. target gene hsa-mir-181c Hypertrophic Scar 25554417 L91.0 D017439 miR-181c-uPA and miR-10a-PAI-1 regulatory pathways have an integral role in HS pathogenesis. target gene hsa-mir-21 Hypertrophic Scar 24817011 L91.0 D017439 MicroRNA-21 regulates hTERT via PTEN in hypertrophic scar fibroblasts. target gene hsa-mir-222 Hypertrophic Scar 29658663 L91.0 D017439 microRNA-222 regulates proliferation and apoptosis of fibroblasts in hypertrophic scar via matrix metalloproteinase 1 target gene hsa-mir-1 Hypertrophy 29073097 D006984 Content of mitochondrial calcium uniporter (MCU) in cardiomyocytes is regulated by microRNA-1 in physiologic and pathologic hypertrophy. target gene hsa-mir-1-1 Hypertrophy 18458081 D006984 Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart. target gene hsa-mir-1-2 Hypertrophy 18458081 D006984 Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart. target gene hsa-mir-133a-1 Hypertrophy 18458081 D006984 Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart. target gene hsa-mir-133a-2 Hypertrophy 18458081 D006984 Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart. target gene hsa-mir-133b Hypertrophy 18458081 D006984 Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart. target gene hsa-mir-221 Hypertrophy 22275134 D006984 MiR-221 promotes cardiac hypertrophy in vitro through the modulation of p27 expression. target gene hsa-let-7b Hypohidrotic Ectodermal Dysplasia 29344666 musculoskeletal system disease DOID:14793 D053358 PS305100 HP:0007607 Let-7b regulates alpaca hair growth by downregulating ectodysplasin A. target gene hsa-let-7a Hypoxic-Ischemic Encephalopathy 29562785 P91.60 D020925 The expression levels of the microRNAs (miRs) let-7a and let-7e, known regulators of Casp3, were inversely correlated to Casp3 target gene hsa-let-7e Hypoxic-Ischemic Encephalopathy 29562785 P91.60 D020925 The expression levels of the microRNAs (miRs) let-7a and let-7e, known regulators of Casp3, were inversely correlated to Casp3 target gene hsa-mir-155 Idiopathic Pulmonary Fibrosis 27746237 respiratory system disease DOID:0050156 J84.112 D054990 178500 The role of microRNA-155/liver X receptor pathway in experimental and idiopathic pulmonary fibrosis. target gene hsa-mir-29c Idiopathic Pulmonary Fibrosis 27765762 respiratory system disease DOID:0050156 J84.112 D054990 178500 MicroRNA-29c regulates apoptosis sensitivity via modulation of the cell-surface death receptor, Fas, in lung fibroblasts. target gene hsa-mir-30a Idiopathic Pulmonary Fibrosis 28294974 respiratory system disease DOID:0050156 J84.112 D054990 178500 miR-30a as Potential Therapeutics by Targeting TET1 through Regulation of Drp-1 Promoter Hydroxymethylation in Idiopathic Pulmonary Fibrosis. target gene hsa-mir-92a Idiopathic Pulmonary Fibrosis 24953558 respiratory system disease DOID:0050156 J84.112 D054990 178500 miR-92a regulates TGF-β1-induced WISP1 expression in pulmonary fibrosis. target gene hsa-mir-100 IgA Nephropathy 27542871 urinary system disease DOID:2986 N02.8 D005922 161950 HP:0000794 MiR-100-3p and miR-877-3p regulate overproduction of IL-8 and IL-1β in mesangial cells activated by secretory IgA from IgA nephropathy patients. target gene hsa-mir-29a IgA Nephropathy 25664031 urinary system disease DOID:2986 N02.8 D005922 161950 HP:0000794 we found that miR-29b-3p down-regulation caused CDK6 overexpression can promote NF-魏B signal by phosphorylating p65 which may enhance inflammation during IgAN pathogenesis. target gene hsa-mir-877 IgA Nephropathy 27542871 urinary system disease DOID:2986 N02.8 D005922 161950 HP:0000794 MiR-100-3p and miR-877-3p regulate overproduction of IL-8 and IL-1β in mesangial cells activated by secretory IgA from IgA nephropathy patients. target gene hsa-mir-19a Ileus 28537131 gastrointestinal system disease DOID:8440 K56.7 D045823 HP:0002595 Acupuncture Ameliorates Postoperative Ileus via IL-6-miR-19a-KIT Axis to Protect Interstitial Cells of Cajal. target gene hsa-let-7i Immune System Disease [unspecific] 17660297 immune system disease DOID:2914 D89.9 D007154 These results indicate that let-7i regulates TLR4 expression in cholangiocytes and contributes to epithelial immune responses against C. parvum infection. target gene hsa-mir-101 Immune System Disease [unspecific] 21068409 immune system disease DOID:2914 D89.9 D007154 Together, these results indicate that miR-101 regulates the innate immune responses of macrophages to LPS through targeting MKP-1. target gene hsa-mir-126 Immune System Disease [unspecific] 20083669 immune system disease DOID:2914 D89.9 D007154 These data show that miR-126 is differentially regulated in CF versus non-CF airway epithelial cells and that TOM1 is a miR-126 target that may have an important role in regulating innate immune responses in the CF lung. target gene hsa-mir-155 Immune System Disease [unspecific] 19144316 immune system disease DOID:2914 D89.9 D007154 Our studies suggest that Foxp3-dependent regulation of miR155 maintains competitive fitness of Treg cell subsets by targeting SOCS1, and they provide experimental support for a proposed role for miRNAs in ensuring the robustness of cellular phenotypes. target gene hsa-mir-17 Immune System Disease [unspecific] 23812097 immune system disease DOID:2914 D89.9 D007154 MicroRNAs of the miR-17~92 family are critical regulators of T(FH) differentiation. target gene hsa-mir-181a Immune System Disease [unspecific] 18701320 immune system disease DOID:2914 D89.9 D007154 In addition to facilitating cell fate decisions of immune cells (e.g. miR-181a and miR-223), miRs also regulate central elements of the adaptive immune response such as antigen presentation (e.g. miR-155) and T cell receptor signaling (mir-181a). target gene hsa-mir-199 Immune System Disease [unspecific] 24062059 immune system disease DOID:2914 D89.9 D007154 We demonstrated for the first time that CD14 knockdown significantly changed the expression of 199a-3p, miR-199a-5p, and miR-21-5p in RAW264.7 cells, and significantly enriched GO terms in the predicted target genes of these miRNAs were apoptosis process, immune response, inflammatory response, innate immune response, anti-apoptosis, cytokine production, and cytokine-mediated signaling pathway. target gene hsa-mir-21 Immune System Disease [unspecific] 23998932 immune system disease DOID:2914 D89.9 D007154 miRNA-21 inhibition enhances RANTES and IP-10 release in MCF-7 via PIAS3 and STAT3 signalling and causes increased lymphocyte migration. target gene hsa-mir-21 Immune System Disease [unspecific] 28129531 immune system disease DOID:2914 D89.9 D007154 MicroRNA-21 contributes to suppress cytokines production by targeting TLR28 in teleost fish. target gene hsa-mir-146a Infection [unspecific] 27156837 D007239 The in vitro study suggested that transfected mmu-miR-146a-5p inhibitor upregulated TNF-α and its target gene Traf6 in microglia following stimulation with A. cantonensis larval antigen. target gene hsa-mir-16 Infection [unspecific] 26184511 D007239 miR- 16 targeted the 3鈥?untranslated region of IL-6 and suppressed its translation in mesangial cells induced by SIgA. target gene hsa-mir-513 Infection [unspecific] 19916867 D007239 These data suggest a role of miR-513 in regulating B7-H1 expression by cholangiocytes in response to C. parvum infection. target gene hsa-mir-122 Infertility 23327642 reproductive system disease DOID:5223 N46.9/N97.9 D007246 MicroRNA-122 influences the development of sperm abnormalities from human induced pluripotent stem cells by regulating TNP2 expression. target gene hsa-let-7a-1 Inflammation 21616524 D007249 Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation. target gene hsa-let-7a-2 Inflammation 21616524 D007249 Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation. target gene hsa-let-7a-3 Inflammation 21616524 D007249 Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation. target gene hsa-let-7b Inflammation 21616524 D007249 Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation. target gene hsa-let-7c Inflammation 21616524 D007249 Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation. target gene hsa-let-7d Inflammation 21616524 D007249 Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation. target gene hsa-let-7e Inflammation 21616524 D007249 Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation. target gene hsa-let-7f-1 Inflammation 21616524 D007249 Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation. target gene hsa-let-7f-2 Inflammation 21616524 D007249 Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation. target gene hsa-let-7g Inflammation 21616524 D007249 Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation. target gene hsa-let-7i Inflammation 21616524 D007249 Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation. target gene hsa-mir-105 Inflammation 19509287 D007249 We identified miRNA (miR)-105 as a modulator of TLR-2 protein translation in human gingival keratinocytes. target gene hsa-mir-1236 Inflammation 22223733 D007249 Mirtron MicroRNA-1236 Inhibits VEGFR-3 Signaling During Inflammatory Lymphangiogenesis. target gene hsa-mir-125a Inflammation 27836539 D007249 these findings identify a PPARγ-miR-125a-NOD1 signaling axis in endothelial cells that is critical in the regulation of inflammation-mediated angiogenesis target gene hsa-mir-125b Inflammation 25728278 D007249 MiR-193b may inhibit early chondrogenesis by targeting TGFB2 and TGFBR3, and may regulate inflammation by repressing TNF-alpha expression in inflamed chondrocytes. target gene hsa-mir-125b Inflammation 25620312 D007249 miR-125b is a negative regulator of CCL4 and its reduction is partially responsible for the age-related increase of CCL4. target gene hsa-mir-127 Inflammation 22287715 D007249 MicroRNA-127 Inhibits Lung Inflammation by Targeting IgG Fcgamma Receptor I. target gene hsa-mir-132 Inflammation 25728278 D007249 MiR-193b may inhibit early chondrogenesis by targeting TGFB2 and TGFBR3, and may regulate inflammation by repressing TNF-alpha expression in inflamed chondrocytes. target gene hsa-mir-132 Inflammation 29377244 D007249 MicroRNA-132 attenuates LPS-induced inflammatory injury by targeting TRAF6 in neuronal cell line HT-22 target gene hsa-mir-135a Inflammation 20634564 D007249 Specifically, miR-181a and b, miR-9, miR-204, miR-199b, and miR-135a suppressed SIRT1 protein expression. target gene hsa-mir-142 Inflammation 28275790 D007249 MiR-142-3p inhibits lipopolysaccharide-induced inflammatory response in human periodontal ligament cells through targeting IRAK1. target gene hsa-mir-143 Inflammation 25728278 D007249 MiR-193b may inhibit early chondrogenesis by targeting TGFB2 and TGFBR3, and may regulate inflammation by repressing TNF-alpha expression in inflamed chondrocytes. target gene hsa-mir-146 Inflammation 24112639 D007249 apolipoprotein-mediated lipid transport emerged as an infection-inducible pathway under miR-146 knockdown conditions, suggesting a possible function of miR-146 in regulating lipid metabolism during inflammation. target gene hsa-mir-146a Inflammation 29288795 D007249 miR-146a inhibits inflammatory cytokine production in B cells through directly targeting IRAK1 target gene hsa-mir-146a Inflammation 29074132 D007249 MicroRNA-146a promotes red spotted grouper nervous necrosis virus (RGNNV) replication by targeting TRAF6 in orange spotted grouper, Epinephelus coioides. target gene hsa-mir-146b Inflammation 20956612 D007249 e.g., miR-146b targeted NF-κB signaling, and miR-219 targeted 5-lipoxygenase and reduced leukotriene production. target gene hsa-mir-146b Inflammation 23733368 D007249 We demonstrate that miR-146 negatively regulates inflammation. Over-expression of miR-146a blunts endothelial activation, while knock-down of miR-146a/b in vitro or deletion of miR-146a in mice has the opposite effect. target gene hsa-mir-148a Inflammation 25728278 D007249 MiR-193b may inhibit early chondrogenesis by targeting TGFB2 and TGFBR3, and may regulate inflammation by repressing TNF-alpha expression in inflamed chondrocytes. target gene hsa-mir-148a Inflammation 25630970 D007249 cyclic stretch of human AVICs activates inflammatory genes in a tissue-autonomous manner via a microRNA that regulates a central inflammatory pathway. target gene hsa-mir-150 Inflammation 26549736 D007249 miR-150 can effectively prevent CD28/B7 co-stimulatory signaling transduction, decrease production of inflammatory cytokines, such as IL-2 and TNF, and elicit the induction of immune tolerance. target gene hsa-mir-155 Inflammation 21310411 D007249 HUVECs highly expressed miR-155 may co-target AT1R and Ets-1 while miR-221/222 targets Ets-1, which indirectly regulate the expression of several inflammatory molecules of ECs, and therefore attenuate the adhesion of Jurkat T cells to activated HUVECs and target gene hsa-mir-155 Inflammation 25892184 D007249 miR-155-dependent regulation of mammalian sterile 20-like kinase 2 (MST2) coordinates inflammation, oxidative stress and proliferation in vascular smooth muscle cells. target gene hsa-mir-17 Inflammation 19949084 D007249 In this study, we report that TNF-mediated induction of endothelial adhesion molecules can be regulated by miRNAs that are induced by TNF. Specifically, E-selectin and ICAM-1 are targets of TNF-induced miRNAs miR-31 and miR-17-3p, respectively. target gene hsa-mir-181a Inflammation 20634564 D007249 Specifically, miR-181a and b, miR-9, miR-204, miR-199b, and miR-135a suppressed SIRT1 protein expression. target gene hsa-mir-181a Inflammation 23516523 D007249 we provide the first evidence for anti-inflammatory effects of miR-181a mediated at least in part by down-regulating IL1a. target gene hsa-mir-181b Inflammation 20634564 D007249 Specifically, miR-181a and b, miR-9, miR-204, miR-199b, and miR-135a suppressed SIRT1 protein expression. target gene hsa-mir-181b Inflammation 22622040 D007249 MicroRNA-181b regulates NF-κB-mediated vascular inflammation. target gene hsa-mir-182 Inflammation 23825948 D007249 miR-182 and miR-10a are key regulators of Treg specialisation and stability during Schistosome and Leishmania-associated inflammation. target gene hsa-mir-192 Inflammation 18835392 D007249 Macrophage inflammatory peptide (MIP)-2 alpha, a chemokine expressed by epithelial cells, was identified as a target of miR-192. target gene hsa-mir-193b Inflammation 25728278 D007249 MiR-193b may inhibit early chondrogenesis by targeting TGFB2 and TGFBR3, and may regulate inflammation by repressing TNF-alpha expression in inflamed chondrocytes. target gene hsa-mir-194 Inflammation 25984739 D007249 We conclude that miR-194 negatively regulates the TLR4 signal pathway which is activated by PA through directly negative TRAF6 expression. target gene hsa-mir-199b Inflammation 20634564 D007249 Specifically, miR-181a and b, miR-9, miR-204, miR-199b, and miR-135a suppressed SIRT1 protein expression. target gene hsa-mir-203 Inflammation 22679274 D007249 The top-ranked predicted target of the highly down-regulated miRNA-203 in asthmatic cells was the aquaporin gene AQP4. target gene hsa-mir-203 Inflammation 22846677 D007249 miR-203 may regulate expression of the novel nociceptive mediator PLAA after incision. Furthermore, the regulation of miR-203 and PLAA levels is reliant upon intact substance P signaling. target gene hsa-mir-203 Inflammation 29242191 D007249 The inducible microRNA-203 in fish represses the inflammatory responses to Gram-negative bacteria by targeting IL-1 receptor-associated kinase 4 target gene hsa-mir-204 Inflammation 20634564 D007249 Specifically, miR-181a and b, miR-9, miR-204, miR-199b, and miR-135a suppressed SIRT1 protein expression. target gene hsa-mir-21 Inflammation 21636785 D007249 MicroRNA-21 targets peroxisome proliferators-activated receptor-alpha in an autoregulatory loop to modulate flow-induced endothelial inflammation. target gene hsa-mir-219 Inflammation 20956612 D007249 e.g., miR-146b targeted NF-κB signaling, and miR-219 targeted 5-lipoxygenase and reduced leukotriene production. target gene hsa-mir-221 Inflammation 21310411 D007249 HUVECs highly expressed miR-155 may co-target AT1R and Ets-1 while miR-221/222 targets Ets-1, which indirectly regulate the expression of several inflammatory molecules of ECs, and therefore attenuate the adhesion of Jurkat T cells to activated HUVECs and target gene hsa-mir-221 Inflammation 25865302 D007249 these results indicated that miR-221 targets AdipoR1 to regulate endothelial inflammatory response. target gene hsa-mir-221 Inflammation 25810396 D007249 Moreover, downregulation of KIT expression by miRNA-221 overexpression or the proteasome inhibitor bortezomib also reduced 3BP2 and MITF expression. target gene hsa-mir-222 Inflammation 21310411 D007249 HUVECs highly expressed miR-155 may co-target AT1R and Ets-1 while miR-221/222 targets Ets-1, which indirectly regulate the expression of several inflammatory molecules of ECs, and therefore attenuate the adhesion of Jurkat T cells to activated HUVECs and target gene hsa-mir-223 Inflammation 25728278 D007249 MiR-193b may inhibit early chondrogenesis by targeting TGFB2 and TGFBR3, and may regulate inflammation by repressing TNF-alpha expression in inflamed chondrocytes. target gene hsa-mir-223 Inflammation 18791161 D007249 miR-223, which is markedly enhanced by estrogen,regulates LPS-induced IFNgamma, but not iNOS or nitric oxide in splenic lymphocytes. Inhibition of miR-223 activity decreased LPS-induced IFNgamma in splenic lymphocytes from estrogen-treated mice. target gene hsa-mir-23b Inflammation 22660635 D007249 The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-a. target gene hsa-mir-25 Inflammation 19541842 D007249 Our study demonstrates that inhibition of miR-25 in cytokine-stimulated ASM cells up-regulates KLF4 expression via a post-transcriptional mechanism. target gene hsa-mir-26a Inflammation 29315680 D007249 the effect of bta-miR-26a in mastitis, mediated at least in part by enhancing FGA expression, involves host defense, inflammation and tissue damage target gene hsa-mir-29a Inflammation 21276447 D007249 microRNA-29a could regulate pro-inflammatory cytokine secretion and scavenger receptor expression by targeting lipoprotein lipase in oxLDL-stimulated dendritic cells. target gene hsa-mir-29b Inflammation 29665646 D007249 miR-29b could regulate LPS-induced endothelial cells inflammatory injury through regulation of NF-κB and JNK signaling pathways target gene hsa-mir-31 Inflammation 19949084 D007249 In this study, we report that TNF-mediated induction of endothelial adhesion molecules can be regulated by miRNAs that are induced by TNF. Specifically, E-selectin and ICAM-1 are targets of TNF-induced miRNAs miR-31 and miR-17-3p, respectively. target gene hsa-mir-328 Inflammation 27573788 D007249 UPF1 regulates myeloid cell functions and S100A9 expression by the hnRNP E2/miRNA-328 balance. target gene hsa-mir-708 Inflammation 25175907 D007249 In human ASM cells, TNF-α-induced CD38 expression is regulated by miR-708 directly binding to 3'UTR and indirectly by regulating JNK MAPK and PI3K/AKT signaling and has the potential to control airway inflammation, ASM contractility and proliferation. target gene hsa-mir-9 Inflammation 20634564 D007249 Specifically, miR-181a and b, miR-9, miR-204, miR-199b, and miR-135a suppressed SIRT1 protein expression. target gene hsa-mir-9 Inflammation 23525285 D007249 MicroRNA-9 regulates the expression of peroxisome proliferator-activated receptor δ in human monocytes during the inflammatory response. target gene hsa-mir-142 Inflammation 25601927 D007249 miR-24,miR-30b, and miR-142-3p regulate phagocytosis and associated cytokine production in myeloid inflammatory cells through modulation of various genes involved in the pathway. target gene hsa-mir-146b Inflammation 25824148 D007249 Ang-1 disrupts TLR4 signalling, resulting in inhibition of LPS-induced inflammatory responses in endothelial cells. This inhibition occurs through selective targeting of IRAK1 and TRAF6 proteins by miR-146b-5p. target gene hsa-mir-149 Inflammation 24375488 D007249 MicroRNA-149 negatively regulates TLR-triggered inflammatory response in macrophages by targeting MyD88. target gene hsa-mir-155 Inflammation 25231976 D007249 MicroRNA-155 potentiates the inflammatory response in hypothermia by suppressing IL-10 production. target gene hsa-mir-24 Inflammation 25601927 D007249 miR-24,miR-30b, and miR-142-3p regulate phagocytosis and associated cytokine production in myeloid inflammatory cells through modulation of various genes involved in the pathway. target gene hsa-mir-30b Inflammation 25601927 D007249 miR-24,miR-30b, and miR-142-3p regulate phagocytosis and associated cytokine production in myeloid inflammatory cells through modulation of various genes involved in the pathway. target gene hsa-mir-744 Inflammation 26259828 D007249 our data indicate that by targeting PTP1B, miR-744 plays a feed-forward role in regulating type I IFN signaling pathway. These findings give us new insights into the functions of renal miRNAs in regulating important signaling pathways. target gene hsa-mir-124 Inflammatory Bowel Diseases 27977009 gastrointestinal system disease DOID:0050589 D015212 PS266600 HP:0002037 Downregulated expression of microRNA-124 in pediatric intestinal failure patients modulates macrophages activation by inhibiting STAT3 and AChE. target gene hsa-mir-125b Inflammatory Bowel Diseases 28082316 gastrointestinal system disease DOID:0050589 D015212 PS266600 HP:0002037 miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea. target gene hsa-mir-150 Inflammatory Bowel Diseases 21590770 gastrointestinal system disease DOID:0050589 D015212 PS266600 HP:0002037 Together, the present study presents the first evidence that miR-150 and its targeting of c-Myb may serve as a new mechanism underlying the colonic epithelial disruption in DSS-induced murine experimental colitis and in active human IBD. target gene hsa-mir-16 Inflammatory Bowel Diseases 28082316 gastrointestinal system disease DOID:0050589 D015212 PS266600 HP:0002037 miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea. target gene hsa-mir-191a Inflammatory Bowel Diseases 28111380 gastrointestinal system disease DOID:0050589 D015212 PS266600 HP:0002037 Baicalin Protects against TNF-α-Induced Injury by Down-Regulating miR-191a That Targets the Tight Junction Protein ZO-1 in IEC-6 Cells. target gene hsa-mir-193a Inflammatory Bowel Diseases 25931122 gastrointestinal system disease DOID:0050589 D015212 PS266600 HP:0002037 These findings suggest that miR-193a-3p regulation of PepT1 mediates the uptake of bacterial products and is a potent mechanism during the colonic inflammation process. Overall, we believe miR-193a-3p may be a potent regulator of colonic PepT1 for maintaining intestinal homeostasis. target gene hsa-mir-200b Inflammatory Bowel Diseases 27979826 gastrointestinal system disease DOID:0050589 D015212 PS266600 HP:0002037 miR-200b inhibits TNF-α-induced IL-8 secretion and tight junction disruption of intestinal epithelial cells in vitro. target gene hsa-mir-223 Inflammatory Bowel Diseases 28487310 gastrointestinal system disease DOID:0050589 D015212 PS266600 HP:0002037 Myeloid-derived miR-223 regulates intestinal inflammation via repression of the NLRP3 inflammasome. target gene hsa-mir-224 Inflammatory Bowel Diseases 23399735 gastrointestinal system disease DOID:0050589 D015212 PS266600 HP:0002037 MicroRNA-224 Negatively Regulates p21 Expression During Late Neoplastic Progression in Inflammatory Bowel Disease target gene hsa-mir-320 Inflammatory Bowel Diseases 26752466 gastrointestinal system disease DOID:0050589 D015212 PS266600 HP:0002037 Exogenous miR-320 transfection in HT29 cells leads to a significant decrease of NOD2 expression target gene hsa-mir-144 Influenza 28380049 respiratory system disease DOID:8469 J09-J11 D007251 614680 miR-144 attenuates the host response to influenza virus by targeting the TRAF6-IRF7 signaling axis. target gene hsa-mir-146a Influenza 28131813 respiratory system disease DOID:8469 J09-J11 D007251 614680 MicroRNA-146a induction during influenza H3N2 virus infection targets and regulates TRAF6 levels in human nasal epithelial cells (hNECs). target gene hsa-mir-24 Influenza 25234642 respiratory system disease DOID:8469 J09-J11 D007251 614680 Human microRNA-24 modulates highly pathogenic avian-origin H5N1 influenza A virus infection in A549 cells by targeting secretory pathway furin. target gene hsa-mir-302c Influenza 26602079 respiratory system disease DOID:8469 J09-J11 D007251 614680 Mir-302c mediates influenza A virus-induced IFNβ expression by targeting NF-κB inducing kinase. target gene hsa-mir-34a Influenza 27610823 respiratory system disease DOID:8469 J09-J11 D007251 614680 MicroRNA 34a contributes to virus-mediated apoptosis through binding to its target gene Bax in influenza A virus infection. target gene hsa-mir-449b Influenza 24086750 respiratory system disease DOID:8469 J09-J11 D007251 614680 These findings demonstrate miRNA induction by influenza A virus infection and elucidate an example of miRNA control of antiviral gene expression in human cells, defining a role for miR-449b in regulation of HDAC1 and antiviral cytokine signaling. target gene hsa-mir-224 Inner Ear Inflammation 24470395 microRNA-224 regulates Pentraxin 3, a component of the humoral arm of innate immunity, in inner ear inflammation. target gene hsa-mir-137 Intellectual Disability 22003227 disease of mental health DOID:1059 F79 D008607 617991 The patients displayed a significantly decreased expression of both precursor and mature miR-137 levels, as well as significantly increased expression of the validated downstream targets microphthalmia-associated transcription factor (MITF) and Enhancer of Zeste, Drosophila, Homologue 2 (EZH2), and the newly identified target Kruppel-like factor 4 (KLF4). The study also demonstrated significant enrichment of miR-137 at the synapses of cortical and hippocampal neurons, suggesting a role of miR-137 in regulating local synaptic protein synthesis machinery. target gene hsa-mir-320a Interstitial Cystitis 29531336 urinary system disease DOID:13949 N30.10-.11 D018856 three transcription factors, E2F-1, E2F-2 and TUB, are regulated by miR-320 family miRNAs target gene hsa-mir-320b Interstitial Cystitis 29531336 urinary system disease DOID:13949 N30.10-.11 D018856 three transcription factors, E2F-1, E2F-2 and TUB, are regulated by miR-321 family miRNAs target gene hsa-mir-320c Interstitial Cystitis 29531336 urinary system disease DOID:13949 N30.10-.11 D018856 three transcription factors, E2F-1, E2F-2 and TUB, are regulated by miR-322 family miRNAs target gene hsa-mir-320d Interstitial Cystitis 29531336 urinary system disease DOID:13949 N30.10-.11 D018856 three transcription factors, E2F-1, E2F-2 and TUB, are regulated by miR-323 family miRNAs target gene hsa-mir-10b Intervertebral Disc Degeneration 24376640 musculoskeletal system disease DOID:90 M51 D055959 603932 HP:0008419 MicroRNA-10b promotes nucleus pulposus cell proliferation through RhoC-Akt pathway by targeting HOXD10 in intervetebral disc degeneration. target gene hsa-mir-155 Intervertebral Disc Degeneration 21706480 musculoskeletal system disease DOID:90 M51 D055959 603932 HP:0008419 Deregulated miR-155 promotes Fas-mediated apoptosis in human intervertebral disc degeneration by targeting FADD and caspase-3. target gene hsa-mir-15a Intervertebral Disc Degeneration 28081468 musculoskeletal system disease DOID:90 M51 D055959 603932 HP:0008419 Role of miR-15a in intervertebral disc degeneration through targeting MAP3K9. target gene hsa-mir-494 Intervertebral Disc Degeneration 28427186 musculoskeletal system disease DOID:90 M51 D055959 603932 HP:0008419 MicroRNA-494 promotes ECM degradation and apoptosis of degenerative human NP cells by directly targeting SOX9 target gene hsa-mir-7 Intervertebral Disc Degeneration 27583982 musculoskeletal system disease DOID:90 M51 D055959 603932 HP:0008419 MicroRNA-7 regulates IL-1β-induced extracellular matrix degeneration by targeting GDF5 in human nucleus pulposus cells. target gene hsa-mir-93 Intervertebral Disc Degeneration 25818544 musculoskeletal system disease DOID:90 M51 D055959 603932 HP:0008419 Taken together, we demonstrated that miR-93 contributed to abnormal NP cell type II collagen expression by targeting MMP3, involved in intervertebral disc degeneration. target gene hsa-mir-92a Intracranial Aneurysm 26718427 cardiovascular system disease DOID:10941 I67.1 D002532 105800 In conclusion, our research demonstrated that miR-92a and KLF2 were negative correlation in intracranial aneurysm model, and miR-92a could directly target KLF2 in endothelial cells through complementary sequence of 3'UTR region. target gene hsa-mir-145 Intrahepatic Cholangiocarcinoma 26255969 disease of cellular proliferation DOID:4928 C22.1 D018281 615619 MiR-145 functions as a tumor suppressor targeting NUAK1 in human intrahepatic cholangiocarcinoma. target gene hsa-mir-204 Intrahepatic Cholangiocarcinoma 24280681 disease of cellular proliferation DOID:4928 C22.1 D018281 615619 These findings suggest that miR-204 plays negative roles in the invasive and/or metastatic potential of ICC, and that its suppressive effects are mediated by repressing Slug expression. target gene hsa-mir-376c Intrahepatic Cholangiocarcinoma 23922722 disease of cellular proliferation DOID:4928 C22.1 D018281 615619 MiR-376c down-regulation accelerates EGF-dependent migration by targeting GRB2 in the HuCCT1 human intrahepatic cholangiocarcinoma cell line. target gene hsa-mir-605 Intrahepatic Cholangiocarcinoma 25131931 disease of cellular proliferation DOID:4928 C22.1 D018281 615619 MiR-605 represses PSMD10/Gankyrin and inhibits intrahepatic cholangiocarcinoma cell progression. target gene hsa-mir-218 Iron Metabolism Disease 26703568 disease of metabolism DOID:2351 E83.1 D019189 Taken together, our results show that miR-218 inhibits erythroid differentiation and alters iron metabolism by targeting ALAS2 in K562 cells. target gene hsa-mir-181a-2 Ischemia 21983159 cardiovascular system disease DOID:326 D007511 601367 miR-181 regulates GRP78 and influences outcome from cerebral ischemia in vitro and in vivo. target gene hsa-mir-23a Ischemia 21709246 cardiovascular system disease DOID:326 D007511 601367 miR-23a regulation of X-linked inhibitor of apoptosis (XIAP) contributes to sex differences in the response to cerebral ischemia. target gene hsa-mir-494 Ischemia 20837890 cardiovascular system disease DOID:326 D007511 601367 miR-494:MicroRNA-494 targeting both proapoptotic and antiapoptotic proteins protects against ischemia/reperfusion-induced cardiac injury target gene hsa-let-7b Ischemia-Reperfusion Injury 26296645 D015427 we report that let-7b targets caspase-3 to regulate apoptosis and autophagy in MSCs exposed to ROS. target gene hsa-let-7e Ischemia-Reperfusion Injury 21827835 D015427 MicroRNA let-7e regulates the expression of caspase-3 during apoptosis of PC12 cells following anoxia/reoxygenation injury. target gene hsa-mir-133a Ischemia-Reperfusion Injury 28198596 D015427 Propofol protects against hepatic ischemia/reperfusion injury via miR-133a-5p regulating the expression of MAPK6. target gene hsa-mir-133a Ischemia-Reperfusion Injury 23102905 D015427 Therefore, targeting of microRNA-133a represents a potentially novel means for regulating the cascade of profibrotic events after ischemia-reperfusion. target gene hsa-mir-146a Ischemia-Reperfusion Injury 23143987 D015427 MicroRNA-146a-mediated downregulation of IRAK1 protects mouse and human small intestine against ischemia/reperfusion injury. target gene hsa-mir-148a Ischemia-Reperfusion Injury 27609576 D015427 The miR-148a alleviates hepatic ischemia/reperfusion injury in mice via targeting CaMKIIα. target gene hsa-mir-155 Ischemia-Reperfusion Injury 28006785 D015427 MiR-155 is Involved in Renal Ischemia-Reperfusion Injury via Direct Targeting of FoxO3a and Regulating Renal Tubular Cell Pyroptosis. target gene hsa-mir-15a Ischemia-Reperfusion Injury 28440490 D015427 MicroRNA-15a inhibition protects against hypoxia/reoxygenation-induced apoptosis of cardiomyocytes by targeting mothers against decapentaplegic homolog 7. target gene hsa-mir-21 Ischemia-Reperfusion Injury 28737660 D015427 Renal Protection Mediated by Hypoxia Inducible Factor-1α Depends on Proangiogenesis Function of miR-21 by Targeting Thrombospondin 1. target gene hsa-mir-21 Ischemia-Reperfusion Injury 29674977 D015427 the programmed cell death 4 (PDCD4) expression was identified as a target gene of miR-21 target gene hsa-mir-210 Ischemia-Reperfusion Injury 29461605 D015427 miR-210, as an upstream factor, plays a protective role in cardiomyocytes through directly inhibiting the protein expression of its target gene E2F3 target gene hsa-mir-214 Ischemia-Reperfusion Injury 27894079 D015427 MicroRNA-214 protects against hypoxia/reoxygenation induced cell damage and myocardial ischemia/reperfusion injury via suppression of PTEN and Bim1 expression. target gene hsa-mir-29a Ischemia-Reperfusion Injury 29238305 D015427 MiR-29a Suppresses Spermatogenic Cell Apoptosis in Testicular Ischemia-Reperfusion Injury by Targeting TRPV4 Channels target gene hsa-mir-320a Ischemia-Reperfusion Injury 26850728 D015427 intrathecal infusion of miR-320a mimic attenuated IR-induced lower limb motor function deficits target gene hsa-mir-494 Ischemia-Reperfusion Injury 20837890 D015427 miR-494:MicroRNA-494 targeting both proapoptotic and antiapoptotic proteins protects against ischemia/reperfusion-induced cardiac injury target gene hsa-mir-494 Ischemia-Reperfusion Injury 28842516 D015427 miR-494 up-regulates the PI3K/Akt pathway via targetting PTEN and attenuates hepatic ischemia/reperfusion injury in a rat model. target gene hsa-mir-874 Ischemia-Reperfusion Injury 24462679 D015427 MiR-874 promotes intestinal barrier dysfunction through targeting AQP3 following intestinal ischemic injury. target gene hsa-mir-132 Ischemic Diseases [unspecific] 25945589 D007511 601367 The miR-132/212 cluster promotes arteriogenesis by modulating Ras-MAPK signalling via direct targeting of its inhibitors Rasa1 and Spred1. target gene hsa-mir-210 Ischemic Diseases [unspecific] 28661226 D007511 601367 MicroRNA-210 alleviates oxidative stress-associated cardiomyocyte apoptosis by regulating BNIP3. target gene hsa-mir-212 Ischemic Diseases [unspecific] 25945589 D007511 601367 The miR-132/212 cluster promotes arteriogenesis by modulating Ras-MAPK signalling via direct targeting of its inhibitors Rasa1 and Spred1. target gene hsa-mir-26a Ischemic Diseases [unspecific] 24047927 D007511 601367 These findings establish miR-26a as a regulator of bone morphogenic protein/SMAD1-mediated EC angiogenic responses, and that manipulating miR-26a expression could provide a new target for rapid angiogenic therapy in ischemic disease states. target gene hsa-mir-28 Ischemic Diseases [unspecific] 25807426 D007511 601367 These findings suggest that miR-28 promotes myocardial ischemia through the inhibition of ALDH2 expression in mus. miRNAs is as a probable index in identification of myocardial ischemia after acute myocardial infarction. target gene hsa-mir-592 Ischemic Diseases [unspecific] 24573298 D007511 601367 Mir-592 regulates the induction and cell death-promoting activity of p75NTR in neuronal ischemic injury. target gene hsa-mir-139 Ischemic Heart Disease 26175501 I25.9/I24.9 D017202 Gene enrichment studies of hsa-miR-139-5p,hsa-miR-483-3p targets demonstrated an association with cardiovascular disease, cell death,and metabolism. target gene hsa-mir-141 Ischemic Heart Disease 26371161 I25.9/I24.9 D017202 MicroRNA-141 regulates the expression level of ICAM-1 on endothelium to decrease myocardial ischemia-reperfusion injury. target gene hsa-mir-377 Ischemic Heart Disease 25251394 I25.9/I24.9 D017202 MicroRNA-377 regulates mesenchymal stem cell-induced angiogenesis in ischemic hearts by targeting VEGF. target gene hsa-mir-483 Ischemic Heart Disease 26175501 I25.9/I24.9 D017202 Gene enrichment studies of hsa-miR-139-5p,hsa-miR-483-3p targets demonstrated an association with cardiovascular disease, cell death,and metabolism. target gene hsa-mir-155 Japanese Encephalitis Virus Infection 24885259 A83.0 D018349 Induction of miR-155 in human microglial cells may negatively modulate JEV-induced innate immune gene expression and may have a beneficial role in limiting JEV replication in human microglial cells. target gene hsa-mir-15b Japanese Encephalitis Virus Infection 26202983 A83.0 D018349 MicroRNA-15b Modulates Japanese Encephalitis Virus-Mediated Inflammation via Targeting RNF125. target gene hsa-mir-19b Japanese Encephalitis Virus Infection 26937036 A83.0 D018349 MicroRNA-19b-3p Modulates Japanese Encephalitis Virus-Mediated Inflammation via Targeting RNF11. target gene hsa-mir-33a Japanese Encephalitis Virus Infection 26819305 A83.0 D018349 MicroRNA-33a-5p Modulates Japanese Encephalitis Virus Replication by Targeting Eukaryotic Translation Elongation Factor 1A1. target gene hsa-mir-146a Juvenile Rheumatoid Arthritis 24719227 musculoskeletal system disease DOID:676 M08.4 D001171 604302 Association of microRNA-146a and its target gene IRAK1 polymorphism with enthesitis related arthritis category of juvenile idiopathic arthritis. target gene hsa-mir-146a Juvenile Rheumatoid Arthritis 27541693 musculoskeletal system disease DOID:676 M08.4 D001171 604302 MiR-146a modulates macrophage polarization in systemic juvenile idiopathic arthritis by targeting INHBA. target gene hsa-mir-100 Kaposi Sarcoma 24027049 disease of cellular proliferation DOID:8632 C46 D012514 The predicted target genes for differentially expressed miRNAs included genes which are involved in a variety of cellular processes such as angiogenesis (i.e. THBS1) and apoptosis (i.e. CASP3, MCL1), suggesting a role for these miRNAs in Kaposi's sarcoma pathogenesis. target gene hsa-mir-1258 Kaposi Sarcoma 24554664 disease of cellular proliferation DOID:8632 C46 D012514 These results illustrate that, in addition to viral miRNAs,cellular miRNAs also play an important role in regulating the life cycle of KSHV.Overall, this is the first study to report the involvement of Nef in KSHV latency, implying its likely important role in the pathogenesis of AIDS-related malignancies. target gene hsa-mir-1293 Kaposi Sarcoma 21984125 disease of cellular proliferation DOID:8632 C46 D012514 We show a direct repression of vIL-6 by hsa-miR-1293 and hIL-6 by hsa-miR-608. The repression of vIL-6 by miR-1293 was reversed by disruption of the vIL-6 miR-1293 seed match through the introduction of point mutations. In addition, expression of vIL-6 or target gene hsa-mir-199b Kaposi Sarcoma 24027049 disease of cellular proliferation DOID:8632 C46 D012514 The predicted target genes for differentially expressed miRNAs included genes which are involved in a variety of cellular processes such as angiogenesis (i.e. THBS1) and apoptosis (i.e. CASP3, MCL1), suggesting a role for these miRNAs in Kaposi's sarcoma pathogenesis. target gene hsa-mir-200 Kaposi Sarcoma 24027049 disease of cellular proliferation DOID:8632 C46 D012514 The predicted target genes for differentially expressed miRNAs included genes which are involved in a variety of cellular processes such as angiogenesis (i.e. THBS1) and apoptosis (i.e. CASP3, MCL1), suggesting a role for these miRNAs in Kaposi's sarcoma pathogenesis. target gene hsa-mir-320d-1 Kaposi Sarcoma 23418466 disease of cellular proliferation DOID:8632 C46 D012514 Cellular MicroRNAs 498 and 320d Regulate Herpes Simplex Virus 1 Induction of Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication by Targeting RTA target gene hsa-mir-320d-2 Kaposi Sarcoma 23418466 disease of cellular proliferation DOID:8632 C46 D012514 Cellular MicroRNAs 498 and 320d Regulate Herpes Simplex Virus 1 Induction of Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication by Targeting RTA target gene hsa-mir-335 Kaposi Sarcoma 24027049 disease of cellular proliferation DOID:8632 C46 D012514 The predicted target genes for differentially expressed miRNAs included genes which are involved in a variety of cellular processes such as angiogenesis (i.e. THBS1) and apoptosis (i.e. CASP3, MCL1), suggesting a role for these miRNAs in Kaposi's sarcoma pathogenesis. target gene hsa-mir-498 Kaposi Sarcoma 23418466 disease of cellular proliferation DOID:8632 C46 D012514 Cellular MicroRNAs 498 and 320d Regulate Herpes Simplex Virus 1 Induction of Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication by Targeting RTA target gene hsa-mir-608 Kaposi Sarcoma 21984125 disease of cellular proliferation DOID:8632 C46 D012514 We show a direct repression of vIL-6 by hsa-miR-1293 and hIL-6 by hsa-miR-608. The repression of vIL-6 by miR-1293 was reversed by disruption of the vIL-6 miR-1293 seed match through the introduction of point mutations. In addition, expression of vIL-6 or target gene hsa-mir-99a Kaposi Sarcoma 24027049 disease of cellular proliferation DOID:8632 C46 D012514 The predicted target genes for differentially expressed miRNAs included genes which are involved in a variety of cellular processes such as angiogenesis (i.e. THBS1) and apoptosis (i.e. CASP3, MCL1), suggesting a role for these miRNAs in Kaposi's sarcoma pathogenesis. target gene hsa-mir-483 Kawasaki Syndrome 27923814 immune system disease DOID:13378 M30.3 D009080 611775 miR-483 Targeting of CTGF Suppresses Endothelial-to-Mesenchymal Transition: Therapeutic Implications in Kawasaki Disease. target gene hsa-mir-181a Keloid 27915346 L91.0 D007627 148100 HP:0010562 MiR-181a Targets PHLPP2 to Augment AKT Signaling and Regulate Proliferation and Apoptosis in Human Keloid Fibroblasts. target gene hsa-mir-185 Keloid 28259900 L91.0 D007627 148100 HP:0010562 MicroRNA‑185 regulates transforming growth factor‑β1 and collagen‑1 in hypertrophic scar fibroblasts. target gene hsa-mir-136 Keratitis 25654102 nervous system disease DOID:4677 H16 D007634 148190 HP:0000491 miR-136 modulates TGF-β1-induced proliferation arrest by targeting PPP2R2A in keratinocytes. target gene hsa-mir-155 Kidney Diseases [unspecific] 25672593 N18.9 D007674 this study not only demonstrated that hypoxia-induced miR-155 was a pro-fibrotic cytokine which was positively regulated by HIF-1α, but also revealed that miR-155 promoted the fibrosis of proximal tubule cells by regulating both TGF-β1 and the process of epithelial-mesenchymal transition (EMT) under hypoxia. target gene hsa-mir-21 Kidney Diseases [unspecific] 28808068 N18.9 D007674 Overexpression of renal Smad7 protects against hypertensive nephropathy by inactivating angiotensin II-induced TGF-β/Smad3 and NF-κB pathways and by targeting the Smad3-dependent microRNA-21 axis target gene hsa-mir-324 Kidney Diseases [unspecific] 22822076 N18.9 D007674 MicroRNA-324-3p Promotes Renal Fibrosis and Is a Target of ACE Inhibition. target gene hsa-mir-20a Kidney Injury 26165754 S37.0 D058186 MiR-20a-5p mediates hypoxia-induced autophagy by targeting ATG16L1 in ischemic kidney injury. target gene hsa-mir-210 Kidney Injury 29387863 S37.0 D058186 miR-210 protects renal cell against hypoxia-induced apoptosis by targeting HIF-1 alpha target gene hsa-mir-106a Kidney Neoplasms 26018509 disease of cellular proliferation DOID:263 C64 D007680 miR-106a* inhibits the proliferation of renal carcinoma cells by targeting IRS-2. target gene hsa-mir-138 Kidney Neoplasms 24406044 disease of cellular proliferation DOID:263 C64 D007680 MiR-138 induces renal carcinoma cell senescence by targeting EZH2 and is downregulated in human clear cell renal cell carcinoma. target gene hsa-mir-141 Kidney Neoplasms 22431721 disease of cellular proliferation DOID:263 C64 D007680 miR-192, miR-194, miR-215, miR-200c and miR-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms. target gene hsa-mir-155 Kidney Neoplasms 29228417 disease of cellular proliferation DOID:263 C64 D007680 Inhibition of miR-155 increased GSK-3β expression, attenuated Wnt/β-catenin signaling pathway, weakened proliferation and invasion, and facilitated apoptosis in renal carcinoma cells target gene hsa-mir-183 Kidney Neoplasms 25152390 disease of cellular proliferation DOID:263 C64 D007680 microRNA-183 plays as oncogenes by increasing cell proliferation, migration and invasion via targeting protein phosphatase 2A in renal cancer cells. target gene hsa-mir-192 Kidney Neoplasms 22431721 disease of cellular proliferation DOID:263 C64 D007680 miR-192, miR-194, miR-215, miR-200c and miR-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms. target gene hsa-mir-200c Kidney Neoplasms 22431721 disease of cellular proliferation DOID:263 C64 D007680 miR-192, miR-194, miR-215, miR-200c and miR-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms. target gene hsa-mir-203 Kidney Neoplasms 25890121 disease of cellular proliferation DOID:263 C64 D007680 Our study suggested that miR-203 could be a potential prognostic marker and functions as a tumor suppressor in human renal cancer by post-transcriptionally targeting FGF2. target gene hsa-mir-21 Kidney Neoplasms 25016284 disease of cellular proliferation DOID:263 C64 D007680 microRNA-21-induced dissociation of PDCD4 from rictor contributes t Akt-IKKβ-mTORC1 axis to regulate renal cancer cell invasion. target gene hsa-mir-215 Kidney Neoplasms 22431721 disease of cellular proliferation DOID:263 C64 D007680 miR-192, miR-194, miR-215, miR-200c and miR-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms. target gene hsa-mir-23b Kidney Neoplasms 20562915 disease of cellular proliferation DOID:263 C64 D007680 miR-23b:miR-23b targets proline oxidase, a novel tumor suppressor protein in renal cancer target gene hsa-mir-27a Kidney Neoplasms 25197360 disease of cellular proliferation DOID:263 C64 D007680 Primary microcephaly gene MCPH1 shows a novel molecular biomarker of human renal carcinoma and is regulated by miR-27a. target gene hsa-mir-381 Kidney Neoplasms 26541837 disease of cellular proliferation DOID:263 C64 D007680 MiRNA-381 can inhibit cell invasion in renal cancer by block the function of CBP, β-catenin and LEF-1. target gene hsa-mir-454 Kidney Neoplasms 25115181 disease of cellular proliferation DOID:263 C64 D007680 Our results indicate that BTG1 is a direct target of miR-454-3p. Down-regulation of BTG1 by miR-454-3p renders tumor cells sensitive to radiation. These results may shed light on the potential application in tumor radiotherapy. target gene hsa-mir-590 Kidney Neoplasms 24063284 disease of cellular proliferation DOID:263 C64 D007680 Enhancement of proliferation and invasion by MicroRNA-590-5p via targeting PBRM1 in clear cell renal carcinoma cells. target gene hsa-mir-106a Kidney Osteogenic Sarcoma 29072688 disease of cellular proliferation DOID:5983 MiR-106a-5p inhibits the cell migration and invasion of renal cell carcinoma through targeting PAK5. target gene hsa-mir-9 Knee Osteoarthritis 27603333 M17 D020370 165720 HP:0005086 MicroRNA-9 regulates the development of knee osteoarthritis through the NF-kappaB1 pathway in chondrocytes. target gene hsa-mir-106b Laryngeal Neoplasms 21819631 C32.3 D007822 MiR-106b promotes cell proliferation via targeting RB in laryngeal carcinoma. target gene hsa-mir-1-1 Laryngeal Neoplasms 21924268 C32.3 D007822 miRNA-1 targets fibronectin1 and suppresses the migration and invasion of the HEp2 laryngeal squamous carcinoma cell line. target gene hsa-mir-1-2 Laryngeal Neoplasms 21924268 C32.3 D007822 miRNA-1 targets fibronectin1 and suppresses the migration and invasion of the HEp2 laryngeal squamous carcinoma cell line. target gene hsa-mir-155 Laryngeal Neoplasms 23437123 C32.3 D007822 Overexpression of miR -155 Promotes Proliferation and Invasion of Human Laryngeal Squamous Cell Carcinoma via Targeting SOCS1 and STAT3 target gene hsa-mir-16-1 Laryngeal Neoplasms 21360639 C32.3 D007822 MicroRNA-16 targets zyxin and promotes cell motility in human laryngeal carcinoma cell line HEp-2. target gene hsa-mir-16-2 Laryngeal Neoplasms 21360639 C32.3 D007822 MicroRNA-16 targets zyxin and promotes cell motility in human laryngeal carcinoma cell line HEp-2. target gene hsa-mir-203 Laryngeal Neoplasms 22306317 C32.3 D007822 MicroRNA-203 leads to G1 phase cell cycle arrest in laryngeal carcinoma cells by directly targeting survivin. target gene hsa-mir-206 Laryngeal Neoplasms 22110210 C32.3 D007822 Down-regulation of MiR-206 Promotes Proliferation and Invasion of Laryngeal Cancer by Regulating VEGF Expression. target gene hsa-mir-21 Laryngeal Neoplasms 23104547 C32.3 D007822 Downregulation of miR-21 regulates MMP-2 expression and suppress migration of Laryngeal squamous cell carcinoma target gene hsa-mir-210 Laryngeal Neoplasms 25639884 C32.3 D007822 our findings reveal a new mechanism of adaptation to hypoxia that miR-210 inhibits the proliferation via inducing cell cycle arrest and apoptosis by the targeting of FGFRL1. target gene hsa-mir-24-1 Laryngeal Neoplasms 22139384 C32.3 D007822 miR-24 functions as a tumor suppressor in Hep2 laryngeal carcinoma cells partly through down-regulation of the S100A8 protein. target gene hsa-mir-24-2 Laryngeal Neoplasms 22139384 C32.3 D007822 miR-24 functions as a tumor suppressor in Hep2 laryngeal carcinoma cells partly through down-regulation of the S100A8 protein. target gene hsa-mir-34a Laryngeal Neoplasms 22246523 C32.3 D007822 MicroRNA-34a affects the occurrence of laryngeal squamous cell carcinoma by targeting the antiapoptotic gene survivin. target gene hsa-mir-34c Laryngeal Neoplasms 29435079 C32.3 D007822 miR-34c may be involved in the pathogenesis of laryngeal cancer, and BCL2 may be negatively regulated by miR-34c in M4e cell target gene hsa-mir-206 Legg-Calve-Perthes Disease 29387248 musculoskeletal system disease DOID:14415 M91.2 D007873 150600 Downregulated SOX9 mediated by miR-206 promoted cell apoptosis in Legg-Calvé-Perthes disease. target gene hsa-let-7c Leiomyoma 17243163 disease of cellular proliferation DOID:127 D25 D007889 150699 HMGA2 was identified as one of target genes of the let-7 family of miRNAs and has been found to be suppressed by let-7 in vitro. target gene hsa-let-7c Leiomyoma 18403645 disease of cellular proliferation DOID:127 D25 D007889 150699 Our findings suggest that the Let-7-mediated repression of HMGA2 mechanism can be an important molecular event in leiomyoma growth. target gene hsa-mir-106b Leiomyoma 22556343 disease of cellular proliferation DOID:127 D25 D007889 150699 miR-93/106b and Their Host Gene, MCM7, Are Differentially Expressed in Leiomyomas and Functionally Target F3 and IL-8. target gene hsa-mir-200a Leiomyoma 22685266 disease of cellular proliferation DOID:127 D25 D007889 150699 miR-200c is aberrantly expressed in leiomyomas in an ethnic-dependent manner and targets ZEBs, VEGFA, TIMP2, and FBLN5. target gene hsa-mir-200c Leiomyoma 22685266 disease of cellular proliferation DOID:127 D25 D007889 150699 miR-200c is aberrantly expressed in leiomyomas in an ethnic-dependent manner and targets ZEBs, VEGFA, TIMP2, and FBLN5. target gene hsa-mir-200c Leiomyoma 24755559 disease of cellular proliferation DOID:127 D25 D007889 150699 miR-200c regulates IL8 expression by targeting IKBKB: a potential mediator of inflammation in leiomyoma pathogenesis. target gene hsa-mir-93 Leiomyoma 22556343 disease of cellular proliferation DOID:127 D25 D007889 150699 miR-93/106b and Their Host Gene, MCM7, Are Differentially Expressed in Leiomyomas and Functionally Target F3 and IL-8. target gene hsa-mir-126 Leishmaniasis 26941729 disease by infectious agent DOID:9065 B55 D007896 602068 Development of Th2 type specific immune response can be suppressed by binding of miR-135 and miR-126 miRNAs over the 3'-UTR region of GATA-3 transcription factor of Th2 specific CD4(+) T helper cells. target gene hsa-mir-21 Leprosy 22286305 disease by infectious agent DOID:1024 A30.9 D007918 609888 MicroRNA-21 targets the vitamin D-dependent antimicrobial pathway in leprosy target gene hsa-mir-107 Leukemia 20884628 C95 D007938 613065 HP:0001909 Recent findings indicate that GRN is regulated strongly by the microRNA miR-107, which functionally overlaps with miR-15, miR-16, and miR-195 due to a common 5' sequence critical for target specificity. target gene hsa-mir-122 Leukemia 23791922 C95 D007938 613065 HP:0001909 Hydroquinone-induced miR-122 down-regulation elicits ADAM17 up regulation,leading to increased soluble TNF-α production in human leukemia cells with expressed Bcr/Abl. target gene hsa-mir-125a Leukemia 25961914 C95 D007938 613065 HP:0001909 microRNA-125a (miR-125a) was identified as a miRNA that suppressed WT1 expression via binding to the WT1-3'UTR. target gene hsa-mir-125a Leukemia 26713860 C95 D007938 613065 HP:0001909 miR-125a suppressed Zbtb7a expression through its direct binding to the Zbtb7a-3'UTR. target gene hsa-mir-125b Leukemia 28389358 C95 D007938 613065 HP:0001909 MicroRNA-125b inhibits AML cells differentiation by directly targeting Fes. target gene hsa-mir-125b-1 Leukemia 22366319 C95 D007938 613065 HP:0001909 Oncomir miR-125b regulates hematopoiesis by targeting the gene Lin28A. target gene hsa-mir-125b-2 Leukemia 22366319 C95 D007938 613065 HP:0001909 Oncomir miR-125b regulates hematopoiesis by targeting the gene Lin28A. target gene hsa-mir-138 Leukemia 28153721 C95 D007938 613065 HP:0001909 MiR-138 indirectly regulates the MDR1 promoter by NF-κB/p65 silencing. target gene hsa-mir-139 Leukemia 27605510 C95 D007938 613065 HP:0001909 MicroRNA-139-5p regulates proliferation of hematopoietic progenitors and is repressed during BCR-ABL-mediated leukemogenesis. target gene hsa-mir-143 Leukemia 21518477 C95 D007938 613065 HP:0001909 the expression of miR-143 was negatively correlated with the expression of DNMT3A mRNA, a known target gene of miR-143. target gene hsa-mir-144 Leukemia 26078353 C95 D007938 613065 HP:0001909 The long noncoding RNA TUG1 regulates blood-tumor barrier permeability by targeting miR-144. target gene hsa-mir-15 Leukemia 20884628 C95 D007938 613065 HP:0001909 Recent findings indicate that GRN is regulated strongly by the microRNA miR-107, which functionally overlaps with miR-15, miR-16, and miR-195 due to a common 5' sequence critical for target specificity. target gene hsa-mir-150 Leukemia 23604034 C95 D007938 613065 HP:0001909 In conclusion, we demonstrate that miR-150 is a potent leukemic tumor suppressor that regulates multiple oncogenes. target gene hsa-mir-15a Leukemia 18818396 C95 D007938 613065 HP:0001909 Using a luciferase reporter assay, we found that miR-15a directly binds the 3'-UTR of c-myb mRNA. By transfecting K562 myeloid leukemia cells with a miR-15a mimic, functionality of binding was shown. target gene hsa-mir-15a Leukemia 20068100 C95 D007938 613065 HP:0001909 Compared with M non-IGHV3-23 CLL, the gene expression profile of M IGHV3-23 CLL was deprived in genes, including the growth/tumor suppressor genes PDCD4, TIA1, and RASSF5, whose downregulation is under control of miR-15a and miR-16-1. target gene hsa-mir-15a Leukemia 22856663 C95 D007938 613065 HP:0001909 we review the main achievements made on targeting of prosurvival Bcl-2 proteins through the use of different approaches, i.e. anti-sense methodology, small molecules that mimic the action of BH3 domain and microRNAs (mainly miRNA-15a and miRNA-16-1). target gene hsa-mir-15a Leukemia 23551855 C95 D007938 613065 HP:0001909 miR-15a/16-1 is known to regulate Bcl2 in chronic lymphocytic leukemia target gene hsa-mir-16 Leukemia 20884628 C95 D007938 613065 HP:0001909 Recent findings indicate that GRN is regulated strongly by the microRNA miR-107, which functionally overlaps with miR-15, miR-16, and miR-195 due to a common 5' sequence critical for target specificity. target gene hsa-mir-16-1 Leukemia 20068100 C95 D007938 613065 HP:0001909 Compared with M non-IGHV3-23 CLL, the gene expression profile of M IGHV3-23 CLL was deprived in genes, including the growth/tumor suppressor genes PDCD4, TIA1, and RASSF5, whose downregulation is under control of miR-15a and miR-16-1. target gene hsa-mir-16-1 Leukemia 23551855 C95 D007938 613065 HP:0001909 miR-15a/16-1 is known to regulate Bcl2 in chronic lymphocytic leukemia target gene hsa-mir-17 Leukemia 20406979 C95 D007938 613065 HP:0001909 The miR-17-92 microRNA Polycistron Regulates MLL Leukemia Stem Cell Potential by Modulating p21 Expression target gene hsa-mir-17 Leukemia 25732734 C95 D007938 613065 HP:0001909 WEE1 is a validated target of the microRNA miR-17-92 cluster in leukemia. target gene hsa-mir-17 Leukemia 23056458 C95 D007938 613065 HP:0001909 we demonstrated that physiological re-expression of exogenous miR-17 and miR-20a are able to partially rescue the proliferation loss induced by Fli-1 knock-down and identified HBP1 as a target of these miRNA in erythroleukemic cells. target gene hsa-mir-18 Leukemia 25732734 C95 D007938 613065 HP:0001909 WEE1 is a validated target of the microRNA miR-17-92 cluster in leukemia. target gene hsa-mir-181a-2 Leukemia 22285729 C95 D007938 613065 HP:0001909 miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2. target gene hsa-mir-183 Leukemia 27307158 C95 D007938 613065 HP:0001909 FOXP3-induced miR-183 expression reduced 尾-TrCP mRNA stability and suppressed 尾-TrCP-mediated Sp1 degradation target gene hsa-mir-18a Leukemia 20406979 C95 D007938 613065 HP:0001909 The miR-17-92 microRNA Polycistron Regulates MLL Leukemia Stem Cell Potential by Modulating p21 Expression target gene hsa-mir-18a Leukemia 26314433 C95 D007938 613065 HP:0001909 The miR-18a can regulated the sensitivity of leukemia HL-60 cells to VP-16 and VCR by targeting ATM. target gene hsa-mir-195 Leukemia 20884628 C95 D007938 613065 HP:0001909 Recent findings indicate that GRN is regulated strongly by the microRNA miR-107, which functionally overlaps with miR-15, miR-16, and miR-195 due to a common 5' sequence critical for target specificity. target gene hsa-mir-196b Leukemia 22353710 C95 D007938 613065 HP:0001909 miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. target gene hsa-mir-196b Leukemia 28000876 C95 D007938 613065 HP:0001909 miR-196b/miR-1290 participate in the antitumor effect of resveratrol via regulation of IGFBP3 expression in acute lymphoblastic leukemia. target gene hsa-mir-19a Leukemia 25732734 C95 D007938 613065 HP:0001909 WEE1 is a validated target of the microRNA miR-17-92 cluster in leukemia. target gene hsa-mir-19a Leukemia 20406979 C95 D007938 613065 HP:0001909 The miR-17-92 microRNA Polycistron Regulates MLL Leukemia Stem Cell Potential by Modulating p21 Expression target gene hsa-mir-19b-1 Leukemia 25732734 C95 D007938 613065 HP:0001909 WEE1 is a validated target of the microRNA miR-17-92 cluster in leukemia. target gene hsa-mir-19b-1 Leukemia 20406979 C95 D007938 613065 HP:0001909 The miR-17-92 microRNA Polycistron Regulates MLL Leukemia Stem Cell Potential by Modulating p21 Expression target gene hsa-mir-19b-2 Leukemia 20406979 C95 D007938 613065 HP:0001909 The miR-17-92 microRNA Polycistron Regulates MLL Leukemia Stem Cell Potential by Modulating p21 Expression target gene hsa-mir-20a Leukemia 25732734 C95 D007938 613065 HP:0001909 WEE1 is a validated target of the microRNA miR-17-92 cluster in leukemia. target gene hsa-mir-20a Leukemia 20406979 C95 D007938 613065 HP:0001909 The miR-17-92 microRNA Polycistron Regulates MLL Leukemia Stem Cell Potential by Modulating p21 Expression target gene hsa-mir-20a Leukemia 18596985 C95 D007938 613065 HP:0001909 Here we report, for the first time, that LRF is post-transcriptionally regulated by miR-20a. Using a gene reporter assay, direct interaction of miR-20a with the LRF 3'UTR is demonstrated. target gene hsa-mir-20a Leukemia 23056458 C95 D007938 613065 HP:0001909 we demonstrated that physiological re-expression of exogenous miR-17 and miR-20a are able to partially rescue the proliferation loss induced by Fli-1 knock-down and identified HBP1 as a target of these miRNA in erythroleukemic cells. target gene hsa-mir-21 Leukemia 21187093 C95 D007938 613065 HP:0001909 Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line. target gene hsa-mir-21 Leukemia 23834154 C95 D007938 613065 HP:0001909 Targeting miR-21 induces autophagy and chemosensitivity of leukemia cells. target gene hsa-mir-21 Leukemia 27644439 C95 D007938 613065 HP:0001909 Bmi-1 regulates stem cell-like properties of gastric cancer cells via modulating miRNAs. target gene hsa-mir-21 Leukemia 28947822 C95 D007938 613065 HP:0001909 Microenvironment regulates the expression of miR-21 and tumor suppressor genes PTEN, PIAS3 and PDCD4 through ZAP-70 in chronic lymphocytic leukemia. target gene hsa-mir-223 Leukemia 19017354 C95 D007938 613065 HP:0001909 Thus,our results suggest that miR-223 reversibly regulates erythroid and megakaryocytic differentiation of K562 cells via down-modulation of LMO2. target gene hsa-mir-2278 Leukemia 25953263 C95 D007938 613065 HP:0001909 Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted hsa-miR-2278 as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A. target gene hsa-mir-27b Leukemia 24974217 C95 D007938 613065 HP:0001909 Ionizing radiation-inducible miR-27b suppresses leukemia proliferation via targeting cyclin A2. target gene hsa-mir-31 Leukemia 22264793 C95 D007938 613065 HP:0001909 Polycomb-mediated loss of miR-31 activates NIK-dependent NF-kB pathway in adult T cell leukemia and other cancers. target gene hsa-mir-3151 Leukemia 24736457 C95 D007938 613065 HP:0001909 Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway. target gene hsa-mir-34a Leukemia 25788289 C95 D007938 613065 HP:0001909 MiR-34a regulates blood-tumor barrier function by targeting protein kinase Cε. target gene hsa-mir-34a Leukemia 21367750 C95 D007938 613065 HP:0001909 miR-34a induces the down-regulation of both E2F1 and B-Myb oncogenes in leukemic cells. target gene hsa-mir-34c Leukemia 25201524 C95 D007938 613065 HP:0001909 miR-34c regulates the permeability of blood-tumor barrier via MAZ-mediated expression changes of ZO-1, occludin, and claudin-5. target gene hsa-mir-424 Leukemia 23801117 C95 D007938 613065 HP:0001909 MiR-424 regulates monocytic differentiation of human leukemia U937 cells by directly targeting CDX2. target gene hsa-mir-485 Leukemia 21252292 C95 D007938 613065 HP:0001909 Novel regulation of NF-YB by miR-485-3p affects expression of DNA topoisomerase II{alpha} and drug responsiveness in human lymphoblastic leukemia CEM cells. target gene hsa-mir-486 Leukemia 28043832 C95 D007938 613065 HP:0001909 Exosomal miR-486 regulates hypoxia-induced erythroid differentiation of erythroleukemia cells through targeting Sirt1. target gene hsa-mir-92-1 Leukemia 25732734 C95 D007938 613065 HP:0001909 WEE1 is a validated target of the microRNA miR-17-92 cluster in leukemia. target gene hsa-mir-125b-1 Leukemia, B-Cell 22139839 C91.31 D015448 151430 MiR-125b and miR-155 contribute to BCL2 repression and proliferation in response to CD40 ligand (CD154) in human leukemic B-cells. target gene hsa-mir-125b-2 Leukemia, B-Cell 22139839 C91.31 D015448 151430 MiR-125b and miR-155 contribute to BCL2 repression and proliferation in response to CD40 ligand (CD154) in human leukemic B-cells. target gene hsa-mir-155 Leukemia, B-Cell 22139839 C91.31 D015448 151430 MiR-125b and miR-155 contribute to BCL2 repression and proliferation in response to CD40 ligand (CD154) in human leukemic B-cells. target gene hsa-mir-193b Leukemia, Lymphoblastic 25231743 disease of cellular proliferation DOID:1037 C91.0 D007945 613065 MicroRNA-193b-3p acts as a tumor suppressor by targeting the MYB oncogene in T-cell acute lymphoblastic leukemia. target gene hsa-mir-100 Leukemia, Lymphoblastic, Acute 24030073 disease of cellular proliferation DOID:9952 C91.0 D054198 247640 HP:0006721 MiR-100 and miR-99a have critical roles in altering cellular processes by targeting both the FKBP51 and IGF1R/mTOR signalling pathways in vitro and might represent a potential novel strategy for ALL treatment. target gene hsa-mir-101 Leukemia, Lymphoblastic, Acute 22677230 disease of cellular proliferation DOID:9952 C91.0 D054198 247640 HP:0006721 We also found that p23 was regulated by hsa-miR-101 which was down-regulated in childhood ALL cases. target gene hsa-mir-124 Leukemia, Lymphoblastic, Acute 28578002 disease of cellular proliferation DOID:9952 C91.0 D054198 247640 HP:0006721 MiR-124 contributes to glucocorticoid resistance in acute lymphoblastic leukemia by promoting proliferation, inhibiting apoptosis and targeting the glucocorticoid receptor. target gene hsa-mir-1290 Leukemia, Lymphoblastic, Acute 28000876 disease of cellular proliferation DOID:9952 C91.0 D054198 247640 HP:0006721 miR-196b/miR-1290 participate in the antitumor effect of resveratrol via regulation of IGFBP3 expression in acute lymphoblastic leukemia. target gene hsa-mir-142 Leukemia, Lymphoblastic, Acute 24057258 disease of cellular proliferation DOID:9952 C91.0 D054198 247640 HP:0006721 MicroRNA-142-3p inhibits cell proliferation in human acute lymphoblastic leukemia by targeting the MLL-AF4 oncogene. target gene hsa-mir-181a Leukemia, Lymphoblastic, Acute 26580398 disease of cellular proliferation DOID:9952 C91.0 D054198 247640 HP:0006721 ectopic expression of miR-181a also resulted in decreased CD10 hyperexpression in ETV6/RUNX1+ primary patient samples. target gene hsa-mir-181a Leukemia, Lymphoblastic, Acute 28732737 disease of cellular proliferation DOID:9952 C91.0 D054198 247640 HP:0006721 MicroRNA-181a and its target Smad 7 as potential biomarkers for tracking child acute lymphoblastic leukemia target gene hsa-mir-196b Leukemia, Lymphoblastic, Acute 20924650 disease of cellular proliferation DOID:9952 C91.0 D054198 247640 HP:0006721 Results of the present study revealed that miR-196b becomes non-functional in T-cell ALL as a consequence of mutations in 3'-UTR of c-myc gene in T-cell ALL cellular models. target gene hsa-mir-2909 Leukemia, Lymphoblastic, Acute 25037230 disease of cellular proliferation DOID:9952 C91.0 D054198 247640 HP:0006721 This study identified a novel miR-2909-KLF4 molecular axis able to differentiate between the pathogeneses of pediatric B- and T-cell ALLs, and which may represent a new diagnostic/prognostic marker. target gene hsa-mir-339 Leukemia, Lymphoblastic, Acute 29735550 disease of cellular proliferation DOID:9952 C91.0 D054198 247640 HP:0006721 miR-339 Promotes Development of Stem Cell Leukemia/Lymphoma Syndrome via Downregulation of the BCL2L11 and BAX Proapoptotic Genes. target gene hsa-mir-520h Leukemia, Lymphoblastic, Acute 29768346 disease of cellular proliferation DOID:9952 C91.0 D054198 247640 HP:0006721 Additionally, POLD1 and MCM2 were found to be regulated by miR-520H via E2F1 target gene hsa-mir-664 Leukemia, Lymphoblastic, Acute 25735976 disease of cellular proliferation DOID:9952 C91.0 D054198 247640 HP:0006721 miR-664 negatively regulates PLP2 and promotes cell proliferation and invasion in T-cell acute lymphoblastic leukaemia. target gene hsa-mir-708 Leukemia, Lymphoblastic, Acute 23970374 disease of cellular proliferation DOID:9952 C91.0 D054198 247640 HP:0006721 The expression level of miR-708 reflects differences among the clinical types of common-ALL, and CNTFR, NNAT, and GNG12 were identified as targets of miR-708. target gene hsa-mir-99a Leukemia, Lymphoblastic, Acute 24030073 disease of cellular proliferation DOID:9952 C91.0 D054198 247640 HP:0006721 MiR-100 and miR-99a have critical roles in altering cellular processes by targeting both the FKBP51 and IGF1R/mTOR signalling pathways in vitro and might represent a potential novel strategy for ALL treatment. target gene hsa-mir-15a Leukemia, Lymphoblastic, Acute, B-Cell 28101583 disease of cellular proliferation DOID:0060592 C91.0 613065 HP:0004812 we proposed a cellular model to discuss MYC/miR-15a-5p/FLT3 feed-forward loop (FFL) with Jak-STAT signaling pathway in B-ALL target gene hsa-mir-101 Leukemia, Lymphoblastic, Acute, T-Cell 27666896 disease of cellular proliferation DOID:5602 C91.0 613065 HP:0006727 MicroRNA-101 regulates T-cell acute lymphoblastic leukemia progression and chemotherapeutic sensitivity by targeting Notch1. target gene hsa-mir-128 Leukemia, Lymphoblastic, Acute, T-Cell 24895337 disease of cellular proliferation DOID:5602 C91.0 613065 HP:0006727 MicroRNA-128-3p is a novel oncomiR targeting PHF6 in T-cell acute lymphoblastic leukemia. target gene hsa-mir-223 Leukemia, Lymphoblastic, Acute, T-Cell 23857984 disease of cellular proliferation DOID:5602 C91.0 613065 HP:0006727 The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia. target gene hsa-mir-106b Leukemia, Lymphocytic, Chronic, B-Cell 19096009 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 miR-106b: Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase, Itch for degradation target gene hsa-mir-130a Leukemia, Lymphocytic, Chronic, B-Cell 22350415 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 MicroRNA-130a targets ATG2B and DICER1 to inhibit autophagy and trigger killing of chronic lymphocytic leukemia cells. target gene hsa-mir-150 Leukemia, Lymphocytic, Chronic, B-Cell 24787006 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. target gene hsa-mir-15a Leukemia, Lymphocytic, Chronic, B-Cell 21205967 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. target gene hsa-mir-15a Leukemia, Lymphocytic, Chronic, B-Cell 22133358 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 miR-15a and miR-16-1 inhibit the proliferation of leukemic cells by down-regulating WT1 protein level. target gene hsa-mir-15b Leukemia, Lymphocytic, Chronic, B-Cell 21205967 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. target gene hsa-mir-16-1 Leukemia, Lymphocytic, Chronic, B-Cell 21205967 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. target gene hsa-mir-16-2 Leukemia, Lymphocytic, Chronic, B-Cell 21205967 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. target gene hsa-mir-17 Leukemia, Lymphocytic, Chronic, B-Cell 22343732 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 The miR-17-92 family regulates the response to toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. target gene hsa-mir-181a-2 Leukemia, Lymphocytic, Chronic, B-Cell 22610076 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. target gene hsa-mir-181b-1 Leukemia, Lymphocytic, Chronic, B-Cell 22610076 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. target gene hsa-mir-181b-2 Leukemia, Lymphocytic, Chronic, B-Cell 22610076 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. target gene hsa-mir-18a Leukemia, Lymphocytic, Chronic, B-Cell 22343732 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 The miR-17-92 family regulates the response to toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. target gene hsa-mir-195 Leukemia, Lymphocytic, Chronic, B-Cell 21205967 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. target gene hsa-mir-19a Leukemia, Lymphocytic, Chronic, B-Cell 22343732 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 The miR-17-92 family regulates the response to toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. target gene hsa-mir-19b-1 Leukemia, Lymphocytic, Chronic, B-Cell 22343732 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 The miR-17-92 family regulates the response to toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. target gene hsa-mir-20a Leukemia, Lymphocytic, Chronic, B-Cell 22343732 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 The miR-17-92 family regulates the response to toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. target gene hsa-mir-21 Leukemia, Lymphocytic, Chronic, B-Cell 25909590 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 IL-4 Up-Regulates MiR-21 and the MiRNAs Hosted in the CLCN5 Gene in Chronic Lymphocytic Leukemia. target gene hsa-mir-34a Leukemia, Lymphocytic, Chronic, B-Cell 24217154 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients. target gene hsa-mir-34a Leukemia, Lymphocytic, Chronic, B-Cell 21565980 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. target gene hsa-mir-34b Leukemia, Lymphocytic, Chronic, B-Cell 21205967 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. target gene hsa-mir-34c Leukemia, Lymphocytic, Chronic, B-Cell 21205967 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. target gene hsa-mir-3676 Leukemia, Lymphocytic, Chronic, B-Cell 25646413 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia. target gene hsa-mir-92a-1 Leukemia, Lymphocytic, Chronic, B-Cell 19336759 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 miR-92-1: overexpressed, can target the VHL transcript target gene hsa-mir-92a-1 Leukemia, Lymphocytic, Chronic, B-Cell 22343732 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 The miR-17-92 family regulates the response to toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. target gene hsa-mir-138 Leukemia, Lymphocytic, Chronic, B-Cell 25670628 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 2 new target genes, namely acyl protein thioesterase (APT) 1 and 2, which are under control of both miRs and thereby significantly overexpressed in CLL cells. target gene hsa-mir-155 Leukemia, Lymphocytic, Chronic, B-Cell 22797699 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 In the present study, we show that an 8-mer locked nucleic acid anti-miR-155 oligonucleotide targeting the seed region of miR-155 inhibits WM and chronic lymphocytic leukemia cell proliferation in vitro. target gene hsa-mir-155 Leukemia, Lymphocytic, Chronic, B-Cell 23597135 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 Here we review studies that provide evidence suggesting that certain miRNAs (e.g. miR-155, miR-17-92, miR-181, miR-29) can regulate the activated phenotype of CLL cells and/or fitness of the surface-immunoglobulin (sIg) B cell receptor (BCR) complex expressed by CLL cells, thereby accounting for the differential leukemia-cell expression of these miRNAs in different CLL prognostic subgroups. target gene hsa-mir-155 Leukemia, Lymphocytic, Chronic, B-Cell 29658610 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 Overexpression of IL-9 induced by STAT3 phosphorylation is mediated by miR-155 and miR-21 in chronic lymphocytic leukemia target gene hsa-mir-15a Leukemia, Lymphocytic, Chronic, B-Cell 19498445 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 miR-15a and miR-16-1 function by targeting multiple oncogenes, including BCL2, MCL1, CCND1, and WNT3A. Down-regulation of these miRNAs has been reported in chronic lymphocytic lymphoma (CLL), pituitary adenomas, and prostate carcinoma. target gene hsa-mir-16-1 Leukemia, Lymphocytic, Chronic, B-Cell 19498445 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 miR-15a and miR-16-1 function by targeting multiple oncogenes, including BCL2, MCL1, CCND1, and WNT3A. Down-regulation of these miRNAs has been reported in chronic lymphocytic lymphoma (CLL), pituitary adenomas, and prostate carcinoma. target gene hsa-mir-17 Leukemia, Lymphocytic, Chronic, B-Cell 23597135 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 Here we review studies that provide evidence suggesting that certain miRNAs (e.g. miR-155, miR-17-92, miR-181, miR-29) can regulate the activated phenotype of CLL cells and/or fitness of the surface-immunoglobulin (sIg) B cell receptor (BCR) complex expressed by CLL cells, thereby accounting for the differential leukemia-cell expression of these miRNAs in different CLL prognostic subgroups. target gene hsa-mir-18 Leukemia, Lymphocytic, Chronic, B-Cell 23597135 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 Here we review studies that provide evidence suggesting that certain miRNAs (e.g. miR-155, miR-17-92, miR-181, miR-29) can regulate the activated phenotype of CLL cells and/or fitness of the surface-immunoglobulin (sIg) B cell receptor (BCR) complex expressed by CLL cells, thereby accounting for the differential leukemia-cell expression of these miRNAs in different CLL prognostic subgroups. target gene hsa-mir-181 Leukemia, Lymphocytic, Chronic, B-Cell 20357824 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 We recently reported that levels of TCL1 expression in B-CLL are regulated by miR-29 and miR-181 that target 3' UTR of TCL1. target gene hsa-mir-181 Leukemia, Lymphocytic, Chronic, B-Cell 23597135 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 Here we review studies that provide evidence suggesting that certain miRNAs (e.g. miR-155, miR-17-92, miR-181, miR-29) can regulate the activated phenotype of CLL cells and/or fitness of the surface-immunoglobulin (sIg) B cell receptor (BCR) complex expressed by CLL cells, thereby accounting for the differential leukemia-cell expression of these miRNAs in different CLL prognostic subgroups. target gene hsa-mir-19a Leukemia, Lymphocytic, Chronic, B-Cell 23597135 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 Here we review studies that provide evidence suggesting that certain miRNAs (e.g. miR-155, miR-17-92, miR-181, miR-29) can regulate the activated phenotype of CLL cells and/or fitness of the surface-immunoglobulin (sIg) B cell receptor (BCR) complex expressed by CLL cells, thereby accounting for the differential leukemia-cell expression of these miRNAs in different CLL prognostic subgroups. target gene hsa-mir-19b-1 Leukemia, Lymphocytic, Chronic, B-Cell 23597135 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 Here we review studies that provide evidence suggesting that certain miRNAs (e.g. miR-155, miR-17-92, miR-181, miR-29) can regulate the activated phenotype of CLL cells and/or fitness of the surface-immunoglobulin (sIg) B cell receptor (BCR) complex expressed by CLL cells, thereby accounting for the differential leukemia-cell expression of these miRNAs in different CLL prognostic subgroups. target gene hsa-mir-20a Leukemia, Lymphocytic, Chronic, B-Cell 23597135 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 Here we review studies that provide evidence suggesting that certain miRNAs (e.g. miR-155, miR-17-92, miR-181, miR-29) can regulate the activated phenotype of CLL cells and/or fitness of the surface-immunoglobulin (sIg) B cell receptor (BCR) complex expressed by CLL cells, thereby accounting for the differential leukemia-cell expression of these miRNAs in different CLL prognostic subgroups. target gene hsa-mir-21 Leukemia, Lymphocytic, Chronic, B-Cell 29658610 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 Overexpression of IL-9 induced by STAT3 phosphorylation is mediated by miR-155 and miR-21 in chronic lymphocytic leukemia target gene hsa-mir-29 Leukemia, Lymphocytic, Chronic, B-Cell 20357824 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 We recently reported that levels of TCL1 expression in B-CLL are regulated by miR-29 and miR-181 that target 3' UTR of TCL1. target gene hsa-mir-29 Leukemia, Lymphocytic, Chronic, B-Cell 23597135 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 Here we review studies that provide evidence suggesting that certain miRNAs (e.g. miR-155, miR-17-92, miR-181, miR-29) can regulate the activated phenotype of CLL cells and/or fitness of the surface-immunoglobulin (sIg) B cell receptor (BCR) complex expressed by CLL cells, thereby accounting for the differential leukemia-cell expression of these miRNAs in different CLL prognostic subgroups. target gene hsa-mir-34b Leukemia, Lymphocytic, Chronic, B-Cell 19536169 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 miR-34b/miR-34c: a regulator of TCL1 expression in 11q- chronic lymphocytic leukaemia target gene hsa-mir-34c Leukemia, Lymphocytic, Chronic, B-Cell 19536169 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 miR-34b/miR-34c: a regulator of TCL1 expression in 11q- chronic lymphocytic leukaemia target gene hsa-mir-92-1 Leukemia, Lymphocytic, Chronic, B-Cell 23597135 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 Here we review studies that provide evidence suggesting that certain miRNAs (e.g. miR-155, miR-17-92, miR-181, miR-29) can regulate the activated phenotype of CLL cells and/or fitness of the surface-immunoglobulin (sIg) B cell receptor (BCR) complex expressed by CLL cells, thereby accounting for the differential leukemia-cell expression of these miRNAs in different CLL prognostic subgroups. target gene hsa-mir-126 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 25015105 C92.1 D015464 Our results show that the miR-126 shuttled by exosomes is biologically active in the target cells, and support the hypothesis that exosomal miRNAs have an important role in tumor-endothelial crosstalk occurring in the bone marrow microenvironment, potentially affecting disease progression. target gene hsa-mir-181a Leukemia, Myelogenous, Chronic, BCR-ABL Positive 28103766 C92.1 D015464 inhibition of miR-181a using a microRNA sponge inhibitor resulted in decreased transcription of SOX2 and SALL4 target gene hsa-mir-17 Leukemia, Myeloid 23059786 disease of cellular proliferation DOID:8692 C92 D007951 HP:0012324 HIF-1a downregulates miR-17/20a directly targeting p21 and STAT3: a role in myeloid leukemic cell differentiation target gene hsa-mir-20a Leukemia, Myeloid 23059786 disease of cellular proliferation DOID:8692 C92 D007951 HP:0012324 HIF-1a downregulates miR-17/20a directly targeting p21 and STAT3: a role in myeloid leukemic cell differentiation target gene hsa-mir-100 Leukemia, Myeloid, Acute 21643017 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 MiR-100 regulates cell differentiation and survival by targeting RBSP3, a phosphatase-like tumor suppressor in acute myeloid leukemia. target gene hsa-mir-125a Leukemia, Myeloid, Acute 24484870 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 miR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia. target gene hsa-mir-127 Leukemia, Myeloid, Acute 29402726 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 mRNA and miRNA integrative analyses showed aberrant expression of several hub oncogenes appear to be regulated by some miRNAs like miR-127-5p, miR-494, miR-21 and miR-616 in high TET1 expressers target gene hsa-mir-128 Leukemia, Myeloid, Acute 23022987 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 A Renilla-luciferase assay and flow cytometry after transfection with pre-microRNAs confirmed that RET is regulated by miR-218, miR-128, miR-27b, miR-15a and miR-195. target gene hsa-mir-146a Leukemia, Myeloid, Acute 22829170 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 miR-146a and AMD3100, acting through different mechanism, downmodulate CXCR4 protein levels, impair leukemic cell proliferation and then may be used in combination with anti-leukemia drugs, for development of new therapeutic strategies. target gene hsa-mir-149 Leukemia, Myeloid, Acute 28013316 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 Inhibition of MicroRNA-149-5p Induces Apoptosis of Acute Myeloid Leukemia Cell Line THP-1 by Targeting Fas Ligand (FASLG). target gene hsa-mir-150 Leukemia, Myeloid, Acute 27601730 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 AML suppresses hematopoiesis by releasing exosomes that contain microRNAs targeting c-MYB. target gene hsa-mir-155 Leukemia, Myeloid, Acute 25092144 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia. target gene hsa-mir-155 Leukemia, Myeloid, Acute 25175984 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 SHIP1 is targeted by miR-155 in acute myeloid leukemia. target gene hsa-mir-155 Leukemia, Myeloid, Acute 25971362 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia. target gene hsa-mir-155 Leukemia, Myeloid, Acute 27786352 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 Targeting miR-155 suppresses proliferation and induces apoptosis of HL-60 cells by targeting Slug/PUMA signal. target gene hsa-mir-155 Leukemia, Myeloid, Acute 27601730 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 AML suppresses hematopoiesis by releasing exosomes that contain microRNAs targeting c-MYB. target gene hsa-mir-155 Leukemia, Myeloid, Acute 27530922 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 our evidence show that IRF3 overexpression in AML promotes cell growth and survival, and miR-155 is involved, indicating that IRF3 may be a potential new biomarker and therapeutic target for AML. target gene hsa-mir-15a Leukemia, Myeloid, Acute 22133358 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 miR-15a and miR-16-1 inhibit the proliferation of leukemic cells by down-regulating WT1 protein level. target gene hsa-mir-15a Leukemia, Myeloid, Acute 23022987 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 A Renilla-luciferase assay and flow cytometry after transfection with pre-microRNAs confirmed that RET is regulated by miR-218, miR-128, miR-27b, miR-15a and miR-195. target gene hsa-mir-16 Leukemia, Myeloid, Acute 22970245 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 our data demonstrated that over-expression of miR-16 mimics suppressed Pim-1 expression in FD-FLT3/ITD cells suggesting that increased miR-16 expression contributes to depletion of Pim-1 after FLT3 inhibition and that miR-16 repression may be associated with up-regulated Pim-1 in FLT3/ITD expressing cells. target gene hsa-mir-17 Leukemia, Myeloid, Acute 20406979 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 miR-17:The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression target gene hsa-mir-17 Leukemia, Myeloid, Acute 23872792 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 Hoxb8 appears to promote miR-17∼92 expression through c-Myc, a known transcriptional regulator of the miR-17∼92 cluster. target gene hsa-mir-181a-2 Leukemia, Myeloid, Acute 23100311 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 Lenalidomide-mediated enhanced translation of C/EBPalpha-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia target gene hsa-mir-181b Leukemia, Myeloid, Acute 24756163 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1. target gene hsa-mir-18a Leukemia, Myeloid, Acute 20406979 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 miR-18a:The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression target gene hsa-mir-193b Leukemia, Myeloid, Acute 21724256 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 MicroRNA-193b regulates c-Kit proto-oncogene and represses cell proliferation in acute myeloid leukemia. target gene hsa-mir-195 Leukemia, Myeloid, Acute 23022987 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 A Renilla-luciferase assay and flow cytometry after transfection with pre-microRNAs confirmed that RET is regulated by miR-218, miR-128, miR-27b, miR-15a and miR-195. target gene hsa-mir-199b Leukemia, Myeloid, Acute 22374871 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 miR-199b-5p directly targets PODXL and DDR1 and decreased levels of miR-199b-5p correlate with elevated expressions of PODXL and DDR1 in acute myeloid leukemia. target gene hsa-mir-19a Leukemia, Myeloid, Acute 20406979 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 miR-19a:The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression target gene hsa-mir-19b-1 Leukemia, Myeloid, Acute 20406979 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 miR-19b:The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression target gene hsa-mir-19b-2 Leukemia, Myeloid, Acute 20406979 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 miR-19b:The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression target gene hsa-mir-20a Leukemia, Myeloid, Acute 20406979 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 miR-20a:The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression target gene hsa-mir-21 Leukemia, Myeloid, Acute 29100302 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 A tyrosine kinase-STAT5-miR21-PDCD4 regulatory axis in chronic and acute myeloid leukemia cells. target gene hsa-mir-21 Leukemia, Myeloid, Acute 29402726 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 mRNA and miRNA integrative analyses showed aberrant expression of several hub oncogenes appear to be regulated by some miRNAs like miR-127-5p, miR-494, miR-21 and miR-616 in high TET1 expressers target gene hsa-mir-218 Leukemia, Myeloid, Acute 23022987 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 A Renilla-luciferase assay and flow cytometry after transfection with pre-microRNAs confirmed that RET is regulated by miR-218, miR-128, miR-27b, miR-15a and miR-195. target gene hsa-mir-23a Leukemia, Myeloid, Acute 27197200 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 overexpression of miR-23a decreased RKIP mRNA and protein expression target gene hsa-mir-26a-1 Leukemia, Myeloid, Acute 23096114 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 The microRNA-26a target E2F7 sustains cell proliferation and inhibits monocytic differentiation of acute myeloid leukemia cells target gene hsa-mir-26a-2 Leukemia, Myeloid, Acute 23096114 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 The microRNA-26a target E2F7 sustains cell proliferation and inhibits monocytic differentiation of acute myeloid leukemia cells target gene hsa-mir-27a Leukemia, Myeloid, Acute 23236401 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 MiR-27a Functions as a Tumor Suppressor in Acute Leukemia by Regulating 14-3-3 target gene hsa-mir-27a Leukemia, Myeloid, Acute 27013583 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 Overexpression of miR-424&27a, by targeting the 3'UTR of PLAG1, enhanced TRAIL sensitivity in AML cells. target gene hsa-mir-27b Leukemia, Myeloid, Acute 23022987 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 A Renilla-luciferase assay and flow cytometry after transfection with pre-microRNAs confirmed that RET is regulated by miR-218, miR-128, miR-27b, miR-15a and miR-195. target gene hsa-mir-29a Leukemia, Myeloid, Acute 20212066 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 Our data indicate that miR-29a regulates early hematopoiesis and suggest that miR-29a initiates AML by converting myeloid progenitors into self-renewing LSC. target gene hsa-mir-29b-1 Leukemia, Myeloid, Acute 23493348 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 Targeted Delivery of microRNA-29b by Transferrin Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia target gene hsa-mir-29b-2 Leukemia, Myeloid, Acute 23493348 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 Targeted Delivery of microRNA-29b by Transferrin Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia target gene hsa-mir-3151 Leukemia, Myeloid, Acute 22529287 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. target gene hsa-mir-330 Leukemia, Myeloid, Acute 27341144 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 miR-330-5p is able to strongly silence TIM-3 expression (98.15% silencing) in HL-60 cell line (p = 0.0001). target gene hsa-mir-34a Leukemia, Myeloid, Acute 28478444 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 MiR-34a Promotes Apoptosis and Inhibits Autophagy by Targeting HMGB1 in Acute Myeloid Leukemia Cells. target gene hsa-mir-34b Leukemia, Myeloid, Acute 19258499 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 miR-34b: miR-34b targets cyclic AMP-responsive element binding protein target gene hsa-mir-370 Leukemia, Myeloid, Acute 22900969 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 The tumor suppressive role of miRNA-370 by targeting FoxM1 in acute myeloid leukemia. target gene hsa-mir-451 Leukemia, Myeloid, Acute 27764807 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 c-Myc suppresses miR-451⊣YWTAZ/AKT axis via recruiting HDAC3 in acute myeloid leukemia. target gene hsa-mir-494 Leukemia, Myeloid, Acute 29402726 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 mRNA and miRNA integrative analyses showed aberrant expression of several hub oncogenes appear to be regulated by some miRNAs like miR-127-5p, miR-494, miR-21 and miR-616 in high TET1 expressers target gene hsa-mir-519 Leukemia, Myeloid, Acute 26499919 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 The results of the present study indicate that miR-519 may contribute to HL60 cell apoptosis by regulating the expression of HuR. target gene hsa-mir-616 Leukemia, Myeloid, Acute 29402726 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 mRNA and miRNA integrative analyses showed aberrant expression of several hub oncogenes appear to be regulated by some miRNAs like miR-127-5p, miR-494, miR-21 and miR-616 in high TET1 expressers target gene hsa-mir-92a Leukemia, Myeloid, Acute 28059050 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 miR-92a Inhibits Proliferation and Induces Apoptosis by Regulating Methylenetetrahydrofolate Dehydrogenase 2 (MTHFD2) Expression in Acute Myeloid Leukemia. target gene hsa-mir-92a-1 Leukemia, Myeloid, Acute 20406979 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 miR-92a:The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression target gene hsa-mir-92a-2 Leukemia, Myeloid, Acute 20406979 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 miR-92a:The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression target gene hsa-mir-183 Leukemia, Myeloid, Acute, Pediatric 27738758 C92.0 MicroRNA-183 promotes cell proliferation via regulating programmed cell death 6 in pediatric acute myeloid leukemia. target gene hsa-mir-502 Leukemia, Myeloid, Acute, Pediatric 25048968 C92.0 Association of functional polymorphism at the miR-502-binding site in the 3' untranslated region of the SETD8 gene with risk of childhood acute lymphoblastic leukemia, a preliminary report. target gene hsa-mir-138 Leukemia, Myeloid, Chronic 26967056 disease of cellular proliferation DOID:8552 C92.1 D015464 HP:0005506 miR-138 in BCR-ABL tyrosine kinase target gene hsa-mir-17 Leukemia, Myeloid, Chronic 26967056 disease of cellular proliferation DOID:8552 C92.1 D015464 HP:0005506 and miR-17, miR-19a, miR-17-92 cluster with MAPK/ERK proteins. target gene hsa-mir-181a Leukemia, Myeloid, Chronic 26967056 disease of cellular proliferation DOID:8552 C92.1 D015464 HP:0005506 miR-155, miR-181a with SOS proteins; target gene hsa-mir-196b Leukemia, Myeloid, Chronic 23894305 disease of cellular proliferation DOID:8552 C92.1 D015464 HP:0005506 Low expression of miR-196b enhances the expression of BCR-ABL1 and HOXA9 oncogenes in chronic myeloid leukemogenesis. target gene hsa-mir-19a Leukemia, Myeloid, Chronic 26967056 disease of cellular proliferation DOID:8552 C92.1 D015464 HP:0005506 miR-155, miR-19a, with KRAS proteins; miR-19a with RAF1 protein; target gene hsa-mir-19b Leukemia, Myeloid, Chronic 28461114 disease of cellular proliferation DOID:8552 C92.1 D015464 HP:0005506 miR-17-92 promotes leukemogenesis in chronic myeloid leukemia via targeting A20 and activation of NF-κB signaling. target gene hsa-mir-212 Leukemia, Myeloid, Chronic 22241070 disease of cellular proliferation DOID:8552 C92.1 D015464 HP:0005506 ABCG2 protein was 7.2-fold elevated after long-term treatment with imatinib and decreased gradually at higher concentrations. miRNAs miR-212 and miR-328 were identified to correlate inversely with ABCG2 expression under these conditions. target gene hsa-mir-22 Leukemia, Myeloid, Chronic 27889568 disease of cellular proliferation DOID:8552 C92.1 D015464 HP:0005506 FosB regulates expression of miR-22 during PMA induced differentiation of K562 cells to megakaryocytes. target gene hsa-mir-23a Leukemia, Myeloid, Chronic 25213664 disease of cellular proliferation DOID:8552 C92.1 D015464 HP:0005506 The malignancy suppression role of miR-23a by targeting the BCR/ABL oncogene in chromic myeloid leukemia. target gene hsa-mir-320a Leukemia, Myeloid, Chronic 26228085 disease of cellular proliferation DOID:8552 C92.1 D015464 HP:0005506 MicroRNA-320a acts as a tumor suppressor by targeting BCR/ABL oncogene in chronic myeloid leukemia. target gene hsa-mir-328 Leukemia, Myeloid, Chronic 22241070 disease of cellular proliferation DOID:8552 C92.1 D015464 HP:0005506 ABCG2 protein was 7.2-fold elevated after long-term treatment with imatinib and decreased gradually at higher concentrations. miRNAs miR-212 and miR-328 were identified to correlate inversely with ABCG2 expression under these conditions. target gene hsa-mir-34a Leukemia, Myeloid, Chronic 28157629 disease of cellular proliferation DOID:8552 C92.1 D015464 HP:0005506 The epigenetically-regulated miR-34a targeting c-SRC suppresses RAF/MEK/ERK signaling pathway in K-562 cells. target gene hsa-mir-4701 Leukemia, Myeloid, Chronic 27088512 disease of cellular proliferation DOID:8552 C92.1 D015464 HP:0005506 miR-4701-5p directly targeted ST3GAL1 to reduce CML cells resistance to multiple chemotherapeutics in vitro and to convert tumor cells from adriamycin resistant to susceptible in vivo of mice. target gene hsa-mir-486 Leukemia, Myeloid, Chronic 25515961 disease of cellular proliferation DOID:8552 C92.1 D015464 HP:0005506 miR-486-5p in regulating normal hematopoiesis and of BCR-ABL-induced miR-486-5p overexpression in modulating CML progenitor growth, survival, and drug sensitivity. target gene hsa-mir-9 Leukemia, Myeloid, Chronic 28260112 disease of cellular proliferation DOID:8552 C92.1 D015464 HP:0005506 miR-9 regulates the multidrug resistance of chronic myelogenous leukemia by targeting ABCB1. target gene hsa-mir-29a Leukemia, Myeloid, Chronic-Phase 23113544 C92.1 D015466 Regulation of Human RNase-L by the miR-29 Family Reveals a Novel Oncogenic Role in Chronic Myelogenous Leukemia target gene hsa-mir-29b-1 Leukemia, Myeloid, Chronic-Phase 23113544 C92.1 D015466 Regulation of Human RNase-L by the miR-29 Family Reveals a Novel Oncogenic Role in Chronic Myelogenous Leukemia target gene hsa-mir-29b-2 Leukemia, Myeloid, Chronic-Phase 23113544 C92.1 D015466 Regulation of Human RNase-L by the miR-29 Family Reveals a Novel Oncogenic Role in Chronic Myelogenous Leukemia target gene hsa-mir-30a Leukemia, Myeloid, Chronic-Phase 22395361 C92.1 D015466 Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells. target gene hsa-mir-126 Leukemia, Promyelocytic, Acute 26274316 disease of cellular proliferation DOID:0060318 C92.4 D015473 612376 HP:0004836 These results demonstrate that ATO inhibits the growth of HUVECs and induces apoptosis by downregulating VEGFA. One mechanism by which this occurs is Ets-2 upregulation, which results in an increase in miR-126 levels and downregulation of VEGFA expression. target gene hsa-mir-182 Leukemia, Promyelocytic, Acute 28298075 disease of cellular proliferation DOID:0060318 C92.4 D015473 612376 HP:0004836 Inducing cell proliferative prevention in human acute promyelocytic leukemia by miR-182 inhibition through modulation of CASP9 expression. target gene hsa-mir-18b Leukemia, Promyelocytic, Acute 26041820 disease of cellular proliferation DOID:0060318 C92.4 D015473 612376 HP:0004836 PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia. target gene hsa-mir-92a Leukemia, Promyelocytic, Acute 24481878 disease of cellular proliferation DOID:0060318 C92.4 D015473 612376 HP:0004836 Inhibition of microRNA miR-92a induces apoptosis and inhibits cell proliferation in human acute promyelocytic leukemia through modulation of p63 expression. target gene hsa-mir-181 Leukemia, T-Cell 27889686 disease of cellular proliferation DOID:715 C91.5 D015458 MicroRNA-181 contributes to downregulation of SAMHD1 expression in CD4+ T-cells derived from Sèzary syndrome patients. target gene hsa-mir-142 Leukemia-Lymphoma, Adult T-Cell 21979877 C91.51 D015459 HP:0005517 miR-142-3p plans an oncogenic role in human T-cell acute lymphoblastic leukemia (T-ALL) by targeting glucocorticoid receptor-ж┿and cAMP/PKA pathways. target gene hsa-mir-150 Leukemia-Lymphoma, Adult T-Cell 26025667 C91.51 D015459 HP:0005517 STAT1: A Novel Target of miR-150 and miR-223 Is Involved in the Proliferation of HTLV-I-Transformed and ATL Cells. target gene hsa-mir-19a Leukemia-Lymphoma, Adult T-Cell 22362744 C91.51 D015459 HP:0005517 miR-19 inhibits CYLD in T-cell acute lymphoblastic leukemia. target gene hsa-mir-19b-1 Leukemia-Lymphoma, Adult T-Cell 22362744 C91.51 D015459 HP:0005517 miR-19 inhibits CYLD in T-cell acute lymphoblastic leukemia. target gene hsa-mir-19b-2 Leukemia-Lymphoma, Adult T-Cell 22362744 C91.51 D015459 HP:0005517 miR-19 inhibits CYLD in T-cell acute lymphoblastic leukemia. target gene hsa-mir-223 Leukemia-Lymphoma, Adult T-Cell 26025667 C91.51 D015459 HP:0005517 STAT1: A Novel Target of miR-150 and miR-223 Is Involved in the Proliferation of HTLV-I-Transformed and ATL Cells. target gene hsa-mir-125b-1 Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic 22469780 disease of cellular proliferation DOID:5599 C83.5 D054218 B-cell regulator of immunoglobulin heavy chain transcription (Bright)/ARID3a is a direct target of the oncomir microRNA-125b in progenitor B-cells. target gene hsa-mir-125b-2 Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic 22469780 disease of cellular proliferation DOID:5599 C83.5 D054218 B-cell regulator of immunoglobulin heavy chain transcription (Bright)/ARID3a is a direct target of the oncomir microRNA-125b in progenitor B-cells. target gene hsa-mir-155 Lichen Planus 29813046 integumentary system disease DOID:9201 L43 D008010 151620 MicroRNA Microarray-Based Identification of Involvement of miR-155 and miR-19a in Development of Oral Lichen Planus (OLP) by Modulating Th1/Th2 Balance via Targeting eNOS and Toll-Like Receptor 2 (TLR2). target gene hsa-mir-19a Lichen Planus 29813046 integumentary system disease DOID:9201 L43 D008010 151620 MicroRNA Microarray-Based Identification of Involvement of miR-155 and miR-19a in Development of Oral Lichen Planus (OLP) by Modulating Th1/Th2 Balance via Targeting eNOS and Toll-Like Receptor 2 (TLR2). target gene hsa-mir-155 Liposarcoma 22350414 disease of cellular proliferation DOID:3382 C49.9 D008080 613488 HP:0012034 MiR-155 is a liposarcoma oncogene that targets casein kinase-1ж┿and enhances ж┿catenin signaling. target gene hsa-mir-122 Liver Cirrhosis 24033414 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 Samples at recurrence of HCV and after antiviral therapy revealed distinct HCV-related miR expression profiles, with significant dysregulation of those miRNAs potentially targeting mRNAs of HCV receptors. In particular, miR-194 and miR-21 might be involved in the regulation of HCV receptor proteins'expression during HCV infection and antiviral therapy. target gene hsa-mir-125b Liver Cirrhosis 24033414 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 Samples at recurrence of HCV and after antiviral therapy revealed distinct HCV-related miR expression profiles, with significant dysregulation of those miRNAs potentially targeting mRNAs of HCV receptors. In particular, miR-194 and miR-21 might be involved in the regulation of HCV receptor proteins'expression during HCV infection and antiviral therapy. target gene hsa-mir-126 Liver Cirrhosis 25974152 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 Further, miR-126 promoted TNF-a-induced TGF-β1 and collagen I mRNA expression in LX-2 cells. miR-126 may play an important role in hepatic fibrosis by downregulating the expression of IκBα partly through the NF-κB signaling pathway. target gene hsa-mir-1273g Liver Cirrhosis 27423040 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 Overexpression of miR-1273g-3p could inhibit translation of PTEN, increase the expression of 伪-SMA, Col1A1, and reduce apoptosis in HSCs. target gene hsa-mir-133a-1 Liver Cirrhosis 23183523 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 miR-133a mediates TGF-beta-dependent de-repression of collagen-synthesis in hepatic stellate cells during liver fibrosis target gene hsa-mir-133a-2 Liver Cirrhosis 23183523 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 miR-133a mediates TGF-beta-dependent de-repression of collagen-synthesis in hepatic stellate cells during liver fibrosis target gene hsa-mir-155 Liver Cirrhosis 24058572 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 The strong association between certain miRNAs, notably miR-155, and lower hepatic CYP3A activity suggest that altered miRNA expression may regulate hepatic CYP3A activity. target gene hsa-mir-181a-2 Liver Cirrhosis 24033414 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 Samples at recurrence of HCV and after antiviral therapy revealed distinct HCV-related miR expression profiles, with significant dysregulation of those miRNAs potentially targeting mRNAs of HCV receptors. In particular, miR-194 and miR-21 might be involved in the regulation of HCV receptor proteins'expression during HCV infection and antiviral therapy. target gene hsa-mir-181b-1 Liver Cirrhosis 22446332 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 miR-181b Promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients. target gene hsa-mir-181b-2 Liver Cirrhosis 22446332 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 miR-181b Promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients. target gene hsa-mir-194 Liver Cirrhosis 24033414 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 Samples at recurrence of HCV and after antiviral therapy revealed distinct HCV-related miR expression profiles, with significant dysregulation of those miRNAs potentially targeting mRNAs of HCV receptors. In particular, miR-194 and miR-21 might be involved in the regulation of HCV receptor proteins'expression during HCV infection and antiviral therapy. target gene hsa-mir-195 Liver Cirrhosis 24033414 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 Samples at recurrence of HCV and after antiviral therapy revealed distinct HCV-related miR expression profiles, with significant dysregulation of those miRNAs potentially targeting mRNAs of HCV receptors. In particular, miR-194 and miR-21 might be involved in the regulation of HCV receptor proteins'expression during HCV infection and antiviral therapy. target gene hsa-mir-199a Liver Cirrhosis 27662798 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 Fibrogenic Signaling Is Suppressed in Hepatic Stellate Cells through Targeting of Connective Tissue Growth Factor (CCN2) by Cellular or Exosomal MicroRNA-199a-5p. target gene hsa-mir-200a Liver Cirrhosis 25049078 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 By using miRNA mimic, we observed miRNA-200a silencing in activated hepatic stellate cell and demonstrated that upon re-expression, miRNA-200a targets the Keap1, and leading to Keap1 mRNA degradation. target gene hsa-mir-21 Liver Cirrhosis 25303175 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 MiR-21 modulates ERK1 signaling and EMT in liver fibrosis by regulating SPRY2 and HNF4α expression. MiR-21 may serve as a potentially biomarker as well as intervention target for hepatic cirrhosis. target gene hsa-mir-21 Liver Cirrhosis 24196965 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 The autoregulatory feedback loop of microRNA-21/programmed cell death protein 4/activation protein-1 (MiR 21/PDCD4/AP-1) as a driving force for hepatic fibrosis development. target gene hsa-mir-21 Liver Cirrhosis 24033414 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 Samples at recurrence of HCV and after antiviral therapy revealed distinct HCV-related miR expression profiles, with significant dysregulation of those miRNAs potentially targeting mRNAs of HCV receptors. In particular, miR-194 and miR-21 might be involved in the regulation of HCV receptor proteins'expression during HCV infection and antiviral therapy. target gene hsa-mir-21 Liver Cirrhosis 23417858 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 Overexpression of microRNA-21 regulating PDCD4 during tumorigenesis of liver fluke-associated cholangiocarcinoma contributes to tumor growth and metastasis target gene hsa-mir-21 Liver Cirrhosis 29250171 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 The miRNA-target regulatory network may provide additional insight into the current data regarding the role of miRNAs in liver cirrhosis target gene hsa-mir-217 Liver Cirrhosis 24033414 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 Samples at recurrence of HCV and after antiviral therapy revealed distinct HCV-related miR expression profiles, with significant dysregulation of those miRNAs potentially targeting mRNAs of HCV receptors. In particular, miR-194 and miR-21 might be involved in the regulation of HCV receptor proteins'expression during HCV infection and antiviral therapy. target gene hsa-mir-221 Liver Cirrhosis 24033414 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 Samples at recurrence of HCV and after antiviral therapy revealed distinct HCV-related miR expression profiles, with significant dysregulation of those miRNAs potentially targeting mRNAs of HCV receptors. In particular, miR-194 and miR-21 might be involved in the regulation of HCV receptor proteins'expression during HCV infection and antiviral therapy. target gene hsa-mir-224 Liver Cirrhosis 24033414 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 Samples at recurrence of HCV and after antiviral therapy revealed distinct HCV-related miR expression profiles, with significant dysregulation of those miRNAs potentially targeting mRNAs of HCV receptors. In particular, miR-194 and miR-21 might be involved in the regulation of HCV receptor proteins'expression during HCV infection and antiviral therapy. target gene hsa-mir-23a Liver Cirrhosis 24033414 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 Samples at recurrence of HCV and after antiviral therapy revealed distinct HCV-related miR expression profiles, with significant dysregulation of those miRNAs potentially targeting mRNAs of HCV receptors. In particular, miR-194 and miR-21 might be involved in the regulation of HCV receptor proteins'expression during HCV infection and antiviral therapy. target gene hsa-mir-34a Liver Cirrhosis 24033414 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 Samples at recurrence of HCV and after antiviral therapy revealed distinct HCV-related miR expression profiles, with significant dysregulation of those miRNAs potentially targeting mRNAs of HCV receptors. In particular, miR-194 and miR-21 might be involved in the regulation of HCV receptor proteins'expression during HCV infection and antiviral therapy. target gene hsa-mir-378a Liver Cirrhosis 27832641 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 Activation of Hepatic Stellate Cells is Inhibited by microRNA-378a-3p via Wnt10a. target gene hsa-mir-506 Liver Cirrhosis 22383162 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 Upregulation of mir-506 leads to decreased AE2 expression in biliary epithelium of patients with primary biliary cirrhosis target gene hsa-mir-9 Liver Cirrhosis 28098912 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 MicroRNA-9 limits hepatic fibrosis by suppressing the activation and proliferation of hepatic stellate cells by directly targeting MRP1/ABCC1. target gene hsa-mir-96 Liver Cirrhosis 24033414 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 Samples at recurrence of HCV and after antiviral therapy revealed distinct HCV-related miR expression profiles, with significant dysregulation of those miRNAs potentially targeting mRNAs of HCV receptors. In particular, miR-194 and miR-21 might be involved in the regulation of HCV receptor proteins'expression during HCV infection and antiviral therapy. target gene hsa-mir-99a Liver Cirrhosis 24033414 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 Samples at recurrence of HCV and after antiviral therapy revealed distinct HCV-related miR expression profiles, with significant dysregulation of those miRNAs potentially targeting mRNAs of HCV receptors. In particular, miR-194 and miR-21 might be involved in the regulation of HCV receptor proteins'expression during HCV infection and antiviral therapy. target gene hsa-mir-122 Liver Diseases [unspecific] 25537773 K76.9 D008107 Development of novel technologies for targeted delivery of miR-122 to tumor cells and for direct monitoring of miR-122 in biological fluids is urgently needed for translating the basic research to the bedside. This review focuses on miR-122, the most abundant hepatic miRNA, in the context of liver health and diseases. target gene hsa-mir-125b Liver Diseases [unspecific] 25968989 K76.9 D008107 Our data suggest a mechanism for the marked changes in hepatic gene expression between the fetal and pediatric developmental periods, and support a role for these age-dependent miRNAs in regulating drug disposition. target gene hsa-mir-185 Liver Diseases [unspecific] 25548489 K76.9 D008107 miR-185 plays an important role in regulating fatty-acid metabolism and cholesterol homeostasis in hepatocytes, as well as in improving insulin sensitivity, both in vitro and in vivo. target gene hsa-mir-34a Liver Diseases [unspecific] 25968989 K76.9 D008107 Our data suggest a mechanism for the marked changes in hepatic gene expression between the fetal and pediatric developmental periods, and support a role for these age-dependent miRNAs in regulating drug disposition. target gene hsa-mir-34a Liver Diseases [unspecific] 26100857 K76.9 D008107 miR-34a-HNF4α pathway is activated under common conditions of metabolic stress and may have a role in the pathogenesis of Non-alcoholic fatty liver disease(NAFLD) and in regulating plasma lipoprotein metabolism. target gene hsa-mir-34a Liver Diseases [unspecific] 29018509 K76.9 D008107 These findings indicate a circRNA_0046367/miR-34a/PPARα regulatory system underlying hepatic steatosis target gene hsa-mir-15b Liver Failure 22374434 K72 D017093 613070 HP:0001399 miR-15b and miR-16 regulate TNF mediated hepatocyte apoptosis via BCL2 in acute liver failure. target gene hsa-mir-16-1 Liver Failure 22374434 K72 D017093 613070 HP:0001399 miR-15b and miR-16 regulate TNF mediated hepatocyte apoptosis via BCL2 in acute liver failure. target gene hsa-mir-16-2 Liver Failure 22374434 K72 D017093 613070 HP:0001399 miR-15b and miR-16 regulate TNF mediated hepatocyte apoptosis via BCL2 in acute liver failure. target gene hsa-mir-101 Liver Fibrosis 24817606 K74 D008103 MicroRNA-101 suppresses liver fibrosis by targeting the TGFβ signalling pathway. target gene hsa-mir-130a Liver Fibrosis 26255201 K74 D008103 These findings suggest that miR-130a and miR-130b are involved in downregulation of PPAR纬 in liver fibrosis. target gene hsa-mir-134 Liver Fibrosis 27321552 K74 D008103 Dieckol suppresses liver fibrosis via caspase activation and miR134 mediated JNK activation and NF-kB inhibition. target gene hsa-mir-144 Liver Fibrosis 26097586 K74 D008103 miR-144 regulates transforming growth factor-β1 iduced hepatic stellate cell activation in human fibrotic liver. target gene hsa-mir-193 Liver Fibrosis 26120970 K74 D008103 These results suggest that miR-30 and miR-193 are members of a network of miRNAs modifying the TGF-β-dependent regulation of extracellular matrix-related genes in HSCs in the manifestation and resolution of liver fibrosis. target gene hsa-mir-27b Liver Fibrosis 26255201 K74 D008103 In carbon tetrachloride injection (CCl4) and common bile duct ligation (CBDL) liver fibrosis models, miRNAs miR-130a, miR-130b, miR-301a, miR-27b and miR-340 levels were found to be increased and PPAR纬 expression decreased. target gene hsa-mir-29b Liver Fibrosis 25356754 K74 D008103 microRNA-29b prevents liver fibrosis by attenuating hepatic stellate cell activation and inducing apoptosis through targeting PI3K/AKT pathway. target gene hsa-mir-30 Liver Fibrosis 26120970 K74 D008103 These results suggest that miR-30 and miR-193 are members of a network of miRNAs modifying the TGF-β-dependent regulation of extracellular matrix-related genes in HSCs in the manifestation and resolution of liver fibrosis. target gene hsa-mir-30a Liver Fibrosis 29587268 K74 D008103 miR-30a inhibits EMT process, at least in part, via reduction of Snai1, leading to the suppression of HSC activation in liver fibrosis target gene hsa-let-7 Liver Injury 28536261 S36.11 D056486 The let-7/Lin28 axis regulates activation of hepatic stellate cells in alcoholic liver injury. target gene hsa-mir-125b Liver Injury 24176857 S36.11 D056486 miR-125b is transcriptionally activated by Nrf2 and serves as an inhibitor of AhRR, which contributes to protecting kidney from acute injury. target gene hsa-mir-221 Liver Injury 28232457 S36.11 D056486 Dicer-dependent production of microRNA221 in hepatocytes inhibits p27 and is required for liver regeneration in mice. target gene hsa-mir-27a Liver Injury 29156532 S36.11 D056486 paclitaxel significantly attenuated septic induced liver injury through reducing inflammatory response via miR-27a/TAB3/NF-κB signaling pathway target gene hsa-mir-101 Liver Neoplasms 24189458 disease of cellular proliferation DOID:916 C22.0 D008113 HP:0002896 we suggest that miR-101 functions as a tumor suppressor by regulating abnormal NLK activity in liver. target gene hsa-mir-122 Liver Neoplasms 26987776 disease of cellular proliferation DOID:916 C22.0 D008113 HP:0002896 Differential TGFβ pathway targeting by miR-122 in humans and mice affects liver cancer metastasis. target gene hsa-mir-124a Liver Neoplasms 29286137 disease of cellular proliferation DOID:916 C22.0 D008113 HP:0002896 MicroRNA-124a inhibits cell proliferation and migration in liver cancer by regulating interleukin-11 target gene hsa-mir-125b Liver Neoplasms 25953743 disease of cellular proliferation DOID:916 C22.0 D008113 HP:0002896 MicroRNA-125b attenuates epithelial-mesenchymal transitions and targets stem-like liver cancer cells through small mothers against decapentaplegic 2 and 4. target gene hsa-mir-126 Liver Neoplasms 25710939 disease of cellular proliferation DOID:916 C22.0 D008113 HP:0002896 this study demonstrates that human CYP2A6 is post-transcriptionally regulated by miR-126* and that CYP2A7 affects CYP2A6 expression by competing for miR-126* binding. target gene hsa-mir-132 Liver Neoplasms 26096363 disease of cellular proliferation DOID:916 C22.0 D008113 HP:0002896 Hsa-miR-132 inhibits proliferation of hepatic carcinoma cells by targeting YAP. target gene hsa-mir-148b Liver Neoplasms 25997710 disease of cellular proliferation DOID:916 C22.0 D008113 HP:0002896 miRNA-148b suppresses hepatic cancer stem cell by targeting neuropilin-1. target gene hsa-mir-155 Liver Neoplasms 25601564 disease of cellular proliferation DOID:916 C22.0 D008113 HP:0002896 miR-155 may play an important role in promoting the generation of stem cell-like cells and their self-renewal by targeting the gene TP53INP1. target gene hsa-mir-182 Liver Neoplasms 23874989 disease of cellular proliferation DOID:916 C22.0 D008113 HP:0002896 Inferring potential microRNA-microRNA associations based on targeting propensity and connectivity in the context of protein interaction network. target gene hsa-mir-199a Liver Neoplasms 26054020 disease of cellular proliferation DOID:916 C22.0 D008113 HP:0002896 MiR-199a-5p is negatively associated with malignancies and regulates glycolysis and lactate production by targeting hexokinase 2 in liver cancer. target gene hsa-mir-200a Liver Neoplasms 25412960 disease of cellular proliferation DOID:916 C22.0 D008113 HP:0002896 miR-200a played an important role in linking the characteristics of cancer stem cells with EMT phenotype in HCC, and targeting miR-200a might be an effective strategy to weaken the invasive behavior of LCSCs. target gene hsa-mir-218 Liver Neoplasms 25416134 disease of cellular proliferation DOID:916 C22.0 D008113 HP:0002896 THA might be a potential anti-cancer drug candidate, at least in part, through the activation of miR-218 and suppression of Bmi-1 expression. target gene hsa-mir-31 Liver Neoplasms 25797269 disease of cellular proliferation DOID:916 C22.0 D008113 HP:0002896 MicroRNA-31 functions as a tumor suppressor by regulating cell cycle and epithelial-mesenchymal transition regulatory proteins in liver cancer. target gene hsa-mir-378 Liver Neoplasms 25562172 disease of cellular proliferation DOID:916 C22.0 D008113 HP:0002896 miR-378 enhanced cell migration and metastasis by down-regulating Fus expression. target gene hsa-mir-449a Liver Neoplasms 28088579 disease of cellular proliferation DOID:916 C22.0 D008113 HP:0002896 The microRNA-449 family inhibits TGF-β-mediated liver cancer cell migration by targeting SOX4. target gene hsa-mir-449b Liver Neoplasms 28088579 disease of cellular proliferation DOID:916 C22.0 D008113 HP:0002896 The microRNA-449 family inhibits TGF-β-mediated liver cancer cell migration by targeting SOX4. target gene hsa-mir-451 Liver Neoplasms 24968707 disease of cellular proliferation DOID:916 C22.0 D008113 HP:0002896 MicroRNA-451 regulates activating transcription factor 2 expression and inhibits liver cancer cell migration. target gene hsa-mir-506 Liver Neoplasms 26549227 disease of cellular proliferation DOID:916 C22.0 D008113 HP:0002896 Thus, we conclude that miR-506 depresses the angiogenesis of liver cancer through targeting 3'UTR of SPHK1 mRNA. Our finding provides new insights into the mechanism of tumor angiogenesis. target gene hsa-mir-525 Liver Neoplasms 24599008 disease of cellular proliferation DOID:916 C22.0 D008113 HP:0002896 MiR-525-3p enhances the migration and invasion of liver cancer cells by downregulating ZNF395. target gene hsa-mir-122 Liver Neoplasms 23373973 disease of cellular proliferation DOID:916 C22.0 D008113 HP:0002896 Effect of miR-122 and its target gene cationic amino acid transporter 1 on colorectal liver metastasis target gene hsa-mir-133b Liver Neoplasms 26945106 disease of cellular proliferation DOID:916 C22.0 D008113 HP:0002896 miR-133b regulation of CTGF is a novel mechanism critical for the proliferation and migration of HCC cells and OC response. target gene hsa-mir-24-1 Liver Neoplasms 28499244 disease of cellular proliferation DOID:916 C22.0 D008113 HP:0002896 MicroRNA-24-1 suppresses mouse hepatoma cell invasion and metastasis via directly targeting O-GlcNAc transferase. target gene hsa-mir-375 Liver Neoplasms 20226166 disease of cellular proliferation DOID:916 C22.0 D008113 HP:0002896 MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties target gene hsa-mir-9500 Liver Neoplasms 24658401 disease of cellular proliferation DOID:916 C22.0 D008113 HP:0002896 The novel miR-9500 regulates the proliferation and migration of human lung cancer cells by targeting Akt1. target gene hsa-mir-106b Liver Transplant Rejection 26707312 T86.41 These results suggest that miR-18b, miR-340, and miR-106b, which regulate the expression of specific immunophenotypes, can be used as potential biomarkers to identify long-term stable liver transplant recipients from recipients with acute rejection. target gene hsa-mir-18b Liver Transplant Rejection 26707312 T86.41 These results suggest that miR-18b, miR-340, and miR-106b, which regulate the expression of specific immunophenotypes, can be used as potential biomarkers to identify long-term stable liver transplant recipients from recipients with acute rejection. target gene hsa-mir-340 Liver Transplant Rejection 26707312 T86.41 These results suggest that miR-18b, miR-340, and miR-106b, which regulate the expression of specific immunophenotypes, can be used as potential biomarkers to identify long-term stable liver transplant recipients from recipients with acute rejection. target gene hsa-mir-133a-1 Long QT Syndrome 17965831 cardiovascular system disease DOID:2843 I45.81 D008133 192500 HP:0001657 miR-133 was shown to inhibit the expression of ERG (ether-a-go-go-related gene) and cause depression of the potassium channel I(Kr). This inhibition contributed to long QT syndrome and arrhythmia in a diabetic rat model. target gene hsa-mir-133a-2 Long QT Syndrome 17965831 cardiovascular system disease DOID:2843 I45.81 D008133 192500 HP:0001657 miR-133 was shown to inhibit the expression of ERG (ether-a-go-go-related gene) and cause depression of the potassium channel I(Kr). This inhibition contributed to long QT syndrome and arrhythmia in a diabetic rat model. target gene hsa-mir-130b Lung Fibrosis 26953888 respiratory system disease DOID:3770 J84.10 D011658 178500 miR-130b-3p Modulates Epithelial-Mesenchymal Crosstalk in Lung Fibrosis by Targeting IGF-1. target gene hsa-mir-18a Lung Fibrosis 28131417 respiratory system disease DOID:3770 J84.10 D011658 178500 miR-18a-5p Inhibits Sub-pleural Pulmonary Fibrosis by Targeting TGF-β Receptor II. target gene hsa-mir-21 Lung Fibrosis 27916096 respiratory system disease DOID:3770 J84.10 D011658 178500 miR-21 promotes pulmonary fibrosis in rats via down-regulating the expression of ADAMTS-1. target gene hsa-mir-21 Lung Fibrosis 29084974 respiratory system disease DOID:3770 J84.10 D011658 178500 Mir-21 Mediates the Inhibitory Effect of Ang (1-7) on AngII-induced NLRP3 Inflammasome Activation by Targeting Spry1 in lung fibroblasts. target gene hsa-mir-326 Lung Fibrosis 24279830 respiratory system disease DOID:3770 J84.10 D011658 178500 MicroRNA-326 regulates profibrotic functions of transforming growth factor-β in pulmonary fibrosis. target gene hsa-let-7a Lung Neoplasms 22970031 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 The upregulation of let-7a/7g repressed the expression of their targets,C-MYC and the regulatory protein of LIN-28, at the mRNA and protein levels. target gene hsa-let-7a-1 Lung Neoplasms 15172979 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 decreased abundance; negatively regulate the RAS gene. target gene hsa-let-7a-2 Lung Neoplasms 15172979 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 decreased abundance; negatively regulate the RAS gene. target gene hsa-let-7a-3 Lung Neoplasms 15172979 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 decreased abundance; negatively regulate the RAS gene. target gene hsa-let-7b Lung Neoplasms 15172979 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 decreased abundance; negatively regulate the RAS gene. target gene hsa-let-7c Lung Neoplasms 15172979 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 decreased abundance; negatively regulate the RAS gene. target gene hsa-let-7c Lung Neoplasms 23850892 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Our results demonstrate that, through regulating the expression of TRIB2 and its downstream factors, let-7c can effectively inhibit A549 cell proliferation in vitro and in vivo. target gene hsa-let-7d Lung Neoplasms 15172979 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 decreased abundance; negatively regulate the RAS gene. target gene hsa-let-7e Lung Neoplasms 15172979 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 decreased abundance; negatively regulate the RAS gene. target gene hsa-let-7f-1 Lung Neoplasms 15172979 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 decreased abundance; negatively regulate the RAS gene. target gene hsa-let-7f-2 Lung Neoplasms 15172979 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 decreased abundance; negatively regulate the RAS gene. target gene hsa-let-7g Lung Neoplasms 15172979 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 decreased abundance; negatively regulate the RAS gene. target gene hsa-let-7g Lung Neoplasms 21464588 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-9 and let-7g enhance the sensitivity to ionizing radiation by suppression of NFKB1. target gene hsa-let-7g Lung Neoplasms 22970031 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 The upregulation of let-7a/7g repressed the expression of their targets,C-MYC and the regulatory protein of LIN-28, at the mRNA and protein levels. target gene hsa-let-7i Lung Neoplasms 15172979 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 decreased abundance; negatively regulate the RAS gene. target gene hsa-mir-100 Lung Neoplasms 24559685 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Downregulation of HOXA1 gene affects small cell lung cancer cell survival and chemoresistance under the regulation of miR-100. target gene hsa-mir-100 Lung Neoplasms 22120675 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MiR-100 Resensitizes Docetaxel-Resistant Human Lung Adenocarcinoma Cells (SPC-A1) to Docetaxel by Targeting Plk1. target gene hsa-mir-100 Lung Neoplasms 23151088 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1 target gene hsa-mir-101 Lung Neoplasms 26349988 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-101 represses lung cancer by inhibiting interaction of fibroblasts and cancer cells by down-regulating CXCL12. target gene hsa-mir-101 Lung Neoplasms 22977606 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Overexpression of miR-101 induced a marked reduction in EZH2 mRNA levels in several lung cancer cell lines target gene hsa-mir-103a-1 Lung Neoplasms 22157681 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ɛ (PKC-ɛ) and sarcoma viral oncogene homolog (SRC). target gene hsa-mir-103a-2 Lung Neoplasms 22157681 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ɛ (PKC-ɛ) and sarcoma viral oncogene homolog (SRC). target gene hsa-mir-103b-1 Lung Neoplasms 22157681 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ɛ (PKC-ɛ) and sarcoma viral oncogene homolog (SRC). target gene hsa-mir-103b-2 Lung Neoplasms 22157681 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ɛ (PKC-ɛ) and sarcoma viral oncogene homolog (SRC). target gene hsa-mir-106a Lung Neoplasms 25339370 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-106a confers cisplatin resistance in non-small cell lung cancer A549 cells by targeting adenosine triphosphatase-binding cassette A1. target gene hsa-mir-106a Lung Neoplasms 26097565 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-106a promotes growth and metastasis of non-small cell lung cancer by targeting PTEN. target gene hsa-mir-106a Lung Neoplasms 27372519 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 An inverse correlation of miR-106a and ULK1 expression was seen in lung adenocarcinoma. target gene hsa-mir-10a Lung Neoplasms 25586740 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-10a may be a potential target for improving the effectiveness of lung cancer chemotherapy via regulation of the TGF-β/Smad2/STAT3/STAT5 pathway. target gene hsa-mir-10b Lung Neoplasms 25063061 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-10b may promote proliferation and invasion of 95-C cells by down regulating the expression of KLF4 protein. target gene hsa-mir-10b Lung Neoplasms 25214146 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Our results indicated that miR-10b expression was an independent prognostic factor in NSCLC patients. Furthermore, miR-10b might be necessary for driving the expression of E-cad in NSCLC. target gene hsa-mir-1-1 Lung Neoplasms 23142026 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-1 targets Slug and endows lung cancer A549 cells with epithelial and anti-tumorigenic properties target gene hsa-mir-1-2 Lung Neoplasms 23142026 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-1 targets Slug and endows lung cancer A549 cells with epithelial and anti-tumorigenic properties target gene hsa-mir-1238 Lung Neoplasms 26189214 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-1238 inhibits cell proliferation by targeting LHX2 in non-small cell lung cancer. target gene hsa-mir-124 Lung Neoplasms 25550787 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miRNA-124 functions as a tumor suppressor in NSCLC. We also demonstrate miRNA-124 directly targeted and decreased SOX8 in NSCLC cell lines, suggesting smiRNA-124 may regulate NSCLC cell proliferation via decreasing SOX8 (oncogenicity of biomarker in NSCLC) target gene hsa-mir-124 Lung Neoplasms 25869366 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Novel potential regulatory miRNAs for RHOA (miR-9-1/-3, -34b/c, -129-2, -125b-1, -375, -1258) and NKIRAS1 (miR-34b/c, -129-2, -125b-1, -193a, -124a-1/-2/-3, -212, -132) genes in lung cancer were identified. target gene hsa-mir-1258 Lung Neoplasms 25869366 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Novel potential regulatory miRNAs for RHOA (miR-9-1/-3, -34b/c, -129-2, -125b-1, -375, -1258) and NKIRAS1 (miR-34b/c, -129-2, -125b-1, -193a, -124a-1/-2/-3, -212, -132) genes in lung cancer were identified. target gene hsa-mir-125a Lung Neoplasms 21777146 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA HSA-miR-125a-5p induces apoptosis by activating p53 in lung cancer cells. target gene hsa-mir-127 Lung Neoplasms 22349807 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Bberrant expression of miRNAs such as miR-29ab, miR-183, miR-17-5p and miR-127-3P may play an important role in regulating the bio-behavior of TICs (tumor initiating cells). target gene hsa-mir-129 Lung Neoplasms 25869366 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Novel potential regulatory miRNAs for RHOA (miR-9-1/-3, -34b/c, -129-2, -125b-1, -375, -1258) and NKIRAS1 (miR-34b/c, -129-2, -125b-1, -193a, -124a-1/-2/-3, -212, -132) genes in lung cancer were identified. target gene hsa-mir-129-1 Lung Neoplasms 25373388 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MCRS1 overexpression, which is specifically inhibited by miR-129*, promotes the epithelial-mesenchymal transition and metastasis in non-small cell lung cancer. target gene hsa-mir-1297 Lung Neoplasms 23071539 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-511 and miR-1297 inhibit human lung adenocarcinoma cell proliferation by targeting oncogene TRIB2 target gene hsa-mir-1298 Lung Neoplasms 27698189 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-1298 Inhibits Mutant KRAS-Driven Tumor Growth by Repressing FAK and LAMB3. target gene hsa-mir-132 Lung Neoplasms 24626466 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MiR-132 suppresses the migration and invasion of lung cancer cells via targeting the EMT regulator ZEB2. target gene hsa-mir-132 Lung Neoplasms 25869366 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Novel potential regulatory miRNAs for RHOA (miR-9-1/-3, -34b/c, -129-2, -125b-1, -375, -1258) and NKIRAS1 (miR-34b/c, -129-2, -125b-1, -193a, -124a-1/-2/-3, -212, -132) genes in lung cancer were identified. target gene hsa-mir-134 Lung Neoplasms 26166818 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-134 regulates lung cancer cell H69 growth and apoptosis by targeting WWOX gene and suppressing the ERK1/2 signaling pathway. target gene hsa-mir-135a Lung Neoplasms 26235874 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MiR-135a inhibits migration and invasion and regulates EMT-related marker genes by targeting KLF8 in lung cancer cells. target gene hsa-mir-135a-1 Lung Neoplasms 23715500 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 A microRNA-135a/b binding polymorphism in CD133 confers decreased risk and favorable prognosis of lung cancer in Chinese by reducing CD133 expression. target gene hsa-mir-135a-2 Lung Neoplasms 23715500 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 A microRNA-135a/b binding polymorphism in CD133 confers decreased risk and favorable prognosis of lung cancer in Chinese by reducing CD133 expression. target gene hsa-mir-135b Lung Neoplasms 23715500 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 A microRNA-135a/b binding polymorphism in CD133 confers decreased risk and favorable prognosis of lung cancer in Chinese by reducing CD133 expression. target gene hsa-mir-137 Lung Neoplasms 23178712 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-137 inhibits the proliferation of lung cancer cells by targeting Cdc42 and Cdk6 target gene hsa-mir-138-1 Lung Neoplasms 23343715 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MiR-138 Inhibits Tumor Growth Through Repression of EZH2 in Non-Small Cell Lung Cancer target gene hsa-mir-138-2 Lung Neoplasms 23343715 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MiR-138 Inhibits Tumor Growth Through Repression of EZH2 in Non-Small Cell Lung Cancer target gene hsa-mir-139 Lung Neoplasms 26097570 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Our results indicated that miR-139-5p acts as a tumor suppressor in non-small cell lung cancer (NSCLC) partially via down-regulating IGF1R expression. target gene hsa-mir-139 Lung Neoplasms 26497851 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Taken together, our results demonstrated that miR-139-5p plays a pivotal role in lung cancer through inhibiting cell proliferation, metastasis, and promoting apoptosis by targeting oncogenic c-Met. target gene hsa-mir-140 Lung Neoplasms 26722475 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-140-3p inhibits proliferation, migration and invasion of lung cancer cells by targeting ATP6AP2. target gene hsa-mir-142 Lung Neoplasms 24338464 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MIR-142-5p and miR-9 may be involved in squamous lung cancer by regulating cell cycle related genes. target gene hsa-mir-143 Lung Neoplasms 25322940 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-143 inhibits cell proliferation by targeting autophagy-related 2B in non-small cell lung cancer H1299 cells. target gene hsa-mir-144 Lung Neoplasms 25660220 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 inhibits proliferation and induces apoptosis and autophagy in lung cancer cells by targeting TIGAR. target gene hsa-mir-144 Lung Neoplasms 26191328 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Expression of miR-144 is reduced in malignant SPN tissues and peripheral blood, being of clinical value in the diagnosis of malignant SPN.miR-144 promotes the apoptosis of lung cancer cells, and inhibits the proliferation, invasion and migration of lung cancer by regulating ZEB1 gene. target gene hsa-mir-145 Lung Neoplasms 25483817 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-145 inhibited lung cancer cell metastasis and EMT via targeting the Oct4 mediated Wnt/β-catenin signaling pathway. target gene hsa-mir-145 Lung Neoplasms 26440147 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 In aggregate, our results attribute to miR-145-5p and its direct targets pivotal roles in malignancy progression and in metastasis. target gene hsa-mir-145 Lung Neoplasms 21289483 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. target gene hsa-mir-145 Lung Neoplasms 21479367 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 microRNA-145 suppresses lung adenocarcinoma-initiating cell proliferation by targeting OCT4. target gene hsa-mir-145 Lung Neoplasms 21496429 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-145 Inhibits Lung Adenocarcinoma Stem Cells Proliferation by Targeting OCT4 Gene. target gene hsa-mir-145 Lung Neoplasms 21092188 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. target gene hsa-mir-145 Lung Neoplasms 23879998 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 EGFR-ERK signaling pathway down-regulates miRNA-145 in lung cancer cells target gene hsa-mir-146a Lung Neoplasms 25047043 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Regulation of COX-2 expression by miR-146a in lung cancer cells. target gene hsa-mir-150 Lung Neoplasms 24456795 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-150 promotes the proliferation and migration of lung cancer cells by targeting SRC kinase signalling inhibitor 1. target gene hsa-mir-150 Lung Neoplasms 23747308 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-150 promotes the proliferation of lung cancer cells by targeting P53. target gene hsa-mir-150 Lung Neoplasms 28891208 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Serum MicroRNA-150 Predicts Prognosis for Early-Stage Non-Small Cell Lung Cancer and Promotes Tumor Cell Proliferation by Targeting Tumor Suppressor Gene SRCIN1. target gene hsa-mir-150 Lung Neoplasms 28108217 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 CDK3 is a major target of miR-150 in cell proliferation and anti-cancer effect. target gene hsa-mir-153 Lung Neoplasms 25066607 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Suppression of AKT expression by miR-153 produced anti-tumor activity in lung cancer. target gene hsa-mir-155 Lung Neoplasms 22027557 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Hypoxic conditions induce miR-155 expression in lung cancer cells and trigger a corresponding decrease in a validated target, FOXO3A. Furthermore, we find that increased levels of miR-155 radioprotects lung cancer cells, while inhibition of miR-155 radiosensitizes these cells. Moreover, we reveal a therapeutically important link between miR-155 expression, hypoxia, and irradiation by demonstrating that anti-miR-155 molecules also sensitize hypoxic lung cancer cells to irradiation. Our study helps explain how miR-155 becomes elevated in lung cancers, which contain extensive hypoxic microenvironments, and demonstrates that inhibition of miR-155 may have important therapeutic potential as a means to radiosensitize hypoxic lung cancer cells. target gene hsa-mir-155 Lung Neoplasms 28688901 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-155 regulates arsenite-induced malignant transformation by targeting Nrf2-mediated oxidative damage in human bronchial epithelial cells. target gene hsa-mir-16 Lung Neoplasms 25435430 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 though miR-17 and miR-16 had no common target, both miR-16 and miR-17 jointly played roles in the development of paclitaxel resistance in lung cancer. miR-17 overexpression reduced cytoprotective autophagy by targeting Beclin-1, whereas overexpression of miR-16 potentiated paclitaxel induced apoptotic cell death by inhibiting anti-apoptotic protein Bcl-2. target gene hsa-mir-17 Lung Neoplasms 24755562 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin1 expression. target gene hsa-mir-17 Lung Neoplasms 25435430 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 though miR-17 and miR-16 had no common target, both miR-16 and miR-17 jointly played roles in the development of paclitaxel resistance in lung cancer. miR-17 overexpression reduced cytoprotective autophagy by targeting Beclin-1, whereas overexpression of miR-16 potentiated paclitaxel induced apoptotic cell death by inhibiting anti-apoptotic protein Bcl-2. target gene hsa-mir-17 Lung Neoplasms 22349807 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Bberrant expression of miRNAs such as miR-29ab, miR-183, miR-17-5p and miR-127-3P may play an important role in regulating the bio-behavior of TICs (tumor initiating cells). target gene hsa-mir-181b-1 Lung Neoplasms 20162574 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines target gene hsa-mir-181b-2 Lung Neoplasms 20162574 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines target gene hsa-mir-181c Lung Neoplasms 28806967 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-181c inhibits cigarette smoke-induced chronic obstructive pulmonary disease by regulating CCN1 expression. target gene hsa-mir-182 Lung Neoplasms 24519909 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Sp1-mediated microRNA-182 expression regulates lung cancer progression. target gene hsa-mir-182 Lung Neoplasms 26338969 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 These results suggest that modulation of miR-182 and miR-185 and their target genes may contribute to lung carcinogenesis attributable to PM2.5 exposure. target gene hsa-mir-182 Lung Neoplasms 20420807 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 mir-182:Hsa-mir-182 suppresses lung tumorigenesis through down regulation of RGS17 expression in vitro target gene hsa-mir-182 Lung Neoplasms 25798833 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 The miR-200 family and the miR-183~96~182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers. target gene hsa-mir-182 Lung Neoplasms 27641336 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 The microRNA-182-PDK4 axis regulates lung tumorigenesis by modulating pyruvate dehydrogenase and lipogenesis. target gene hsa-mir-183 Lung Neoplasms 22349807 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Bberrant expression of miRNAs such as miR-29ab, miR-183, miR-17-5p and miR-127-3P may play an important role in regulating the bio-behavior of TICs (tumor initiating cells). target gene hsa-mir-183 Lung Neoplasms 25798833 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 The miR-200 family and the miR-183~96~182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers. target gene hsa-mir-185 Lung Neoplasms 26338969 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 These results suggest that modulation of miR-182 and miR-185 and their target genes may contribute to lung carcinogenesis attributable to PM2.5 exposure. target gene hsa-mir-192 Lung Neoplasms 24854555 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Our data suggested that miR-192 induced Cisplatin-resistance and inhibited cell apoptosis in lung cancer via negative targeting Bim expression. target gene hsa-mir-193a Lung Neoplasms 24469061 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-193a-3p and -5p suppress the metastasis of human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway. target gene hsa-mir-193a Lung Neoplasms 26655272 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Overall, we concluded that UCA1 functions as an oncogene in NSCLC, acting mechanistically by upregulating ERBB4 in part through 'spongeing' miR-193a-3p. target gene hsa-mir-193a Lung Neoplasms 25869366 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Novel potential regulatory miRNAs for RHOA (miR-9-1/-3, -34b/c, -129-2, -125b-1, -375, -1258) and NKIRAS1 (miR-34b/c, -129-2, -125b-1, -193a, -124a-1/-2/-3, -212, -132) genes in lung cancer were identified. target gene hsa-mir-195 Lung Neoplasms 28752530 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 HMGA2 regulation by microRNA-195 (miR-195) was validated by real time-PCR, Western blotting, and luciferase reporter assays target gene hsa-mir-197 Lung Neoplasms 24488097 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Antitumor effect of miR-197 targeting in p53 wild-type lung cancer. target gene hsa-mir-197 Lung Neoplasms 19671678 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 regulate tumor suppressor gene FUS1 target gene hsa-mir-1973 Lung Neoplasms 25962089 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 This may open the door for using epigenetic profile/miRNA expression of some cancer cells as resistance markers/targets to improve response of resistant cells to doxorubicin and for the use of combination doxorubicin/epigenetic modifiers to reduce doxorubicin toxicity. target gene hsa-mir-198 Lung Neoplasms 24357456 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-198 inhibits proliferation and induces apoptosis of lung cancer cells via targeting FGFR1. target gene hsa-mir-19a Lung Neoplasms 26367773 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Uncovering Direct Targets of MiR-19a Involved in Lung Cancer Progression. target gene hsa-mir-200 Lung Neoplasms 25798833 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 The miR-200 family and the miR-183~96~182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers. target gene hsa-mir-200a Lung Neoplasms 26184032 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration, Invasion, and Gefitinib Resistance in Non-Small Cell Lung Cancer. target gene hsa-mir-200b Lung Neoplasms 24769353 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Zinc finger E-box-binding homeobox 2 (ZEB2) regulated by miR-200b contributes to multi-drug resistance of small cell lung cancer. target gene hsa-mir-200b Lung Neoplasms 22139708 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3. target gene hsa-mir-200c Lung Neoplasms 28727734 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-200c inhibits epithelial-mesenchymal transition, invasion, and migration of lung cancer by targeting HMGB1. target gene hsa-mir-203 Lung Neoplasms 24040137 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-203 inhibits cell proliferation and migration of lung cancer cells by targeting PKCα. target gene hsa-mir-203 Lung Neoplasms 25140799 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-203 suppresses the proliferation and migration and promotes the apoptosis of lung cancer cells by targeting SRC. target gene hsa-mir-203 Lung Neoplasms 22157681 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ɛ (PKC-ɛ) and sarcoma viral oncogene homolog (SRC). target gene hsa-mir-203 Lung Neoplasms 23073851 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-203 negatively regulates survivin protein expression and inhibits the proliferation and invasion of lung cancer cells target gene hsa-mir-203a Lung Neoplasms 26177443 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 ERGIC3, which is regulated by miR-203a, is a potential biomarker for non-small cell lung cancer. target gene hsa-mir-205 Lung Neoplasms 27929537 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Upregulation of MiR-205 under hypoxia promotes epithelial-mesenchymal transition by targeting ASPP2. target gene hsa-mir-205 Lung Neoplasms 28199217 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-205 targets SMAD4 in non-small cell lung cancer and promotes lung cancer cell growth in vitro and in vivo. target gene hsa-mir-21 Lung Neoplasms 20223231 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC) target gene hsa-mir-21 Lung Neoplasms 22806311 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-21 induces cell cycle at S phase and modulates cell proliferation by down-regulating hMSH2 in lung cancer. target gene hsa-mir-210 Lung Neoplasms 19654003 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 low expression, targets pro-survival molecules MCL-1 and BCL2L2 target gene hsa-mir-212 Lung Neoplasms 25869366 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Novel potential regulatory miRNAs for RHOA (miR-9-1/-3, -34b/c, -129-2, -125b-1, -375, -1258) and NKIRAS1 (miR-34b/c, -129-2, -125b-1, -193a, -124a-1/-2/-3, -212, -132) genes in lung cancer were identified. target gene hsa-mir-217 Lung Neoplasms 26415832 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 The results indicate that miR-217 regulation of EZH2/H3K27me3 via MALAT1 is involved in CSE-induced EMT and malignant transformation of HBE cells. The posttranscriptional silencing of MALAT1 by miR-217 provides a link, through EZH2,between ncRNAs and the EMT and establishes a mechanism for CSE-induced lung carcinogenesis. target gene hsa-mir-22 Lung Neoplasms 22484852 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-22 suppresses lung cancer cell progression through post-transcriptional regulation of ErbB3. target gene hsa-mir-221 Lung Neoplasms 22157681 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ɛ (PKC-ɛ) and sarcoma viral oncogene homolog (SRC). target gene hsa-mir-222 Lung Neoplasms 22157681 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ɛ (PKC-ɛ) and sarcoma viral oncogene homolog (SRC). target gene hsa-mir-223 Lung Neoplasms 25881295 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Our study demonstrates for the first time that platelet-secreted miR-223 via P-MVs can promote lung cancer cell invasion via targeting tumor suppressor EPB41L3. target gene hsa-mir-23a Lung Neoplasms 22752005 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MiR-23a regulates TGF-beta-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells. target gene hsa-mir-25 Lung Neoplasms 25550809 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-25 is overexpressed in SCLC and acting as oncogenic regulator by regulating cyclin E2. target gene hsa-mir-25 Lung Neoplasms 25998847 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-25 targets the modulator of apoptosis 1 gene in lung cancer. target gene hsa-mir-25 Lung Neoplasms 26416661 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Elevated microRNA-25 inhibits cell apoptosis in lung cancer by targeting RGS3. target gene hsa-mir-26a Lung Neoplasms 25100863 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-26a/b regulate DNA replication licensing, tumorigenesis, and prognosis by targeting CDC6 in lung cancer. target gene hsa-mir-26a-1 Lung Neoplasms 22469510 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells. target gene hsa-mir-26a-1 Lung Neoplasms 22885155 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MiR-26a enhances metastasis potential of lung cancer cells via AKT pathway by targeting PTEN. target gene hsa-mir-26a-2 Lung Neoplasms 22469510 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells. target gene hsa-mir-26a-2 Lung Neoplasms 22885155 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MiR-26a enhances metastasis potential of lung cancer cells via AKT pathway by targeting PTEN. target gene hsa-mir-26b Lung Neoplasms 25100863 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-26a/b regulate DNA replication licensing, tumorigenesis, and prognosis by targeting CDC6 in lung cancer. target gene hsa-mir-26b Lung Neoplasms 26068649 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Down-regulation of microRNA-26b modulates non-small cell lung cancer cells chemoresistance and migration through the association of PTEN. target gene hsa-mir-26b Lung Neoplasms 21901137 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Expression of miR-26b was down regulated, and its target activating transcription factor 2 (ATF2) mRNA was up regulated in ж┿irradiated H1299 cells. target gene hsa-mir-27a Lung Neoplasms 23117485 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-27a regulates the self renewal of the H446 small cell lung cancer cell line in vitro target gene hsa-mir-29a Lung Neoplasms 22349807 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Bberrant expression of miRNAs such as miR-29ab, miR-183, miR-17-5p and miR-127-3P may play an important role in regulating the bio-behavior of TICs (tumor initiating cells). target gene hsa-mir-29b Lung Neoplasms 25962089 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 This may open the door for using epigenetic profile/miRNA expression of some cancer cells as resistance markers/targets to improve response of resistant cells to doxorubicin and for the use of combination doxorubicin/epigenetic modifiers to reduce doxorubicin toxicity. target gene hsa-mir-29b-1 Lung Neoplasms 22349807 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Bberrant expression of miRNAs such as miR-29ab, miR-183, miR-17-5p and miR-127-3P may play an important role in regulating the bio-behavior of TICs (tumor initiating cells). target gene hsa-mir-29b-2 Lung Neoplasms 22349807 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Bberrant expression of miRNAs such as miR-29ab, miR-183, miR-17-5p and miR-127-3P may play an important role in regulating the bio-behavior of TICs (tumor initiating cells). target gene hsa-mir-29c Lung Neoplasms 23936390 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miRNA-29c suppresses lung cancer cell adhesion to extracellular matrix and metastasis by targeting integrin β1 and matrix metalloproteinase2 (MMP2). target gene hsa-mir-30a Lung Neoplasms 26025408 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MiR-30a suppresses non-small cell lung cancer progression through AKT signaling pathway by targeting IGF1R. target gene hsa-mir-30a Lung Neoplasms 28678320 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MiR-30 suppresses lung cancer cell 95D epithelial mesenchymal transition and invasion through targeted regulating Snail. target gene hsa-mir-30b Lung Neoplasms 22157681 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ɛ (PKC-ɛ) and sarcoma viral oncogene homolog (SRC). target gene hsa-mir-30c-1 Lung Neoplasms 22157681 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ɛ (PKC-ɛ) and sarcoma viral oncogene homolog (SRC). target gene hsa-mir-30c-2 Lung Neoplasms 22157681 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ɛ (PKC-ɛ) and sarcoma viral oncogene homolog (SRC). target gene hsa-mir-31 Lung Neoplasms 26657862 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Our study distinguishes miR-31 as a driver of lung tumorigenesis that promotes mutant KRAS-mediated oncogenesis and reveals that miR-31 directly targets and reduces expression of negative regulators of RAS/MAPK signaling. target gene hsa-mir-330 Lung Neoplasms 22132977 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Expression of miR-330 in various colon and lung cancer cell lines, as measured by QRT-PCR, varied five-fold between samples and correlated with in-vitro gemcitabine resistance (R = 0.82, p = 0.04). Exposure to gemcitabine also appeared to influence miR-330 levels in these cell lines. Furthermore, in our cell line panel, miR-330 expression negatively correlated with dCK mRNA expression (R = 0.74), suggesting a role of miR-330 in post-transcriptional regulation of dCK. target gene hsa-mir-335 Lung Neoplasms 23232114 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Genetic variation in a miR-335 binding site in BIRC5 alters susceptibility to lung cancer in Chinese Han populations target gene hsa-mir-340 Lung Neoplasms 25151966 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-340 inhibits tumor cell proliferation and induces apoptosis by targeting multiple negative regulators of p27 in non-small cell lung cancer. target gene hsa-mir-342 Lung Neoplasms 26483346 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-342-3p regulates MYC transcriptional activity via direct repression of E2F1 in human lung cancer. target gene hsa-mir-34a Lung Neoplasms 24983493 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET. target gene hsa-mir-34a Lung Neoplasms 25038915 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Downregulation of PEBP4, a target of miR-34a, sensitizes drug-resistant lung cancer cells. target gene hsa-mir-34a Lung Neoplasms 26667302 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Therefore, we propose that AXL is autoregulated by miR-34a in a feedback loop; this may provide a novel opportunity for developing AXL-targeted anticancer therapies. target gene hsa-mir-34a Lung Neoplasms 23349340 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Ectopic expression of miR-34a enhances radiosensitivity of non-small cell lung cancer cells, partly by suppressing the LyGDI signaling pathway target gene hsa-mir-34b Lung Neoplasms 25869366 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Novel potential regulatory miRNAs for RHOA (miR-9-1/-3, -34b/c, -129-2, -125b-1, -375, -1258) and NKIRAS1 (miR-34b/c, -129-2, -125b-1, -193a, -124a-1/-2/-3, -212, -132) genes in lung cancer were identified. target gene hsa-mir-34c Lung Neoplasms 24479666 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Differences in miRNA expression are associated with emphysema severity in COPD patients. MiR-34c modulates expression of its putative target gene, SERPINE1, in vitro in respiratory cell lines and ex vivo in emphysematous lung tissue. target gene hsa-mir-34c Lung Neoplasms 25869366 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Novel potential regulatory miRNAs for RHOA (miR-9-1/-3, -34b/c, -129-2, -125b-1, -375, -1258) and NKIRAS1 (miR-34b/c, -129-2, -125b-1, -193a, -124a-1/-2/-3, -212, -132) genes in lung cancer were identified. target gene hsa-mir-365a Lung Neoplasms 22185756 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MiR-365 regulates lung cancer and developmental gene thyroid transcription factor 1. target gene hsa-mir-365b Lung Neoplasms 22185756 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MiR-365 regulates lung cancer and developmental gene thyroid transcription factor 1. target gene hsa-mir-372 Lung Neoplasms 22451061 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 In addition, there is evidence that miR-372 posttranscriptionally downregulates large tumor suppressor, homolog 2 (Lats2), resulting in tumorigenesis and proliferation. target gene hsa-mir-375 Lung Neoplasms 26642205 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Thus, our study demonstrates the differential expression profiles of miR-375 in 3 subtypes of lung carcinomas and finds thatmiR-375 directly targets ITPKB and promoted cell growth in SCLC cell line. target gene hsa-mir-375 Lung Neoplasms 21856745 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-375 is activated by ASH1 and inhibits YAP1 in a lineage dependent manner in lung cancer. target gene hsa-mir-375 Lung Neoplasms 23206448 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-375 is a novel prognostic indicator in NSCLC and might be a potential target for diagnosis and gene therapy target gene hsa-mir-375 Lung Neoplasms 25869366 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Novel potential regulatory miRNAs for RHOA (miR-9-1/-3, -34b/c, -129-2, -125b-1, -375, -1258) and NKIRAS1 (miR-34b/c, -129-2, -125b-1, -193a, -124a-1/-2/-3, -212, -132) genes in lung cancer were identified. target gene hsa-mir-381 Lung Neoplasms 22592211 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-381 represses ID1 and is deregulated in lung adenocarcinoma. target gene hsa-mir-410 Lung Neoplasms 26149213 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-410 promotes cell proliferation by targeting BRD7 in non-small cell lung cancer. target gene hsa-mir-4286 Lung Neoplasms 25962089 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 This may open the door for using epigenetic profile/miRNA expression of some cancer cells as resistance markers/targets to improve response of resistant cells to doxorubicin and for the use of combination doxorubicin/epigenetic modifiers to reduce doxorubicin toxicity. target gene hsa-mir-449a Lung Neoplasms 24211326 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Tumor-suppressive microRNA-449a induces growth arrest and senescence by targeting E2F3 in human lung cancer cells. target gene hsa-mir-449a Lung Neoplasms 25818739 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Our data indicate that miR-449a may function as a suppressor of lung cancer, and affects the expression of NEAT1 in lung cancer cells. target gene hsa-mir-486 Lung Neoplasms 23474761 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer target gene hsa-mir-490 Lung Neoplasms 24440705 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-490-3p inhibits proliferation of A549 lung cancer cells by targeting CCND1. target gene hsa-mir-493 Lung Neoplasms 25105419 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-493 suppresses tumor growth, invasion and metastasis of lung cancer by regulating E2F1. target gene hsa-mir-494 Lung Neoplasms 25962089 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 This may open the door for using epigenetic profile/miRNA expression of some cancer cells as resistance markers/targets to improve response of resistant cells to doxorubicin and for the use of combination doxorubicin/epigenetic modifiers to reduce doxorubicin toxicity. target gene hsa-mir-497 Lung Neoplasms 21258880 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. target gene hsa-mir-506 Lung Neoplasms 24469051 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Selective killing of lung cancer cells by miRNA-506 molecule through inhibiting NF-κB p65 to evoke reactive oxygen species generation and p53 activation. target gene hsa-mir-5100 Lung Neoplasms 25754817 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-5100 promotes tumor growth in lung cancer by targeting Rab6. target gene hsa-mir-511 Lung Neoplasms 23071539 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-511 and miR-1297 inhibit human lung adenocarcinoma cell proliferation by targeting oncogene TRIB2 target gene hsa-mir-513a-1 Lung Neoplasms 22749944 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-513a-3p sensitizes human lung adenocarcinoma cells to chemotherapy by targeting GSTP1. target gene hsa-mir-513a-2 Lung Neoplasms 22749944 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-513a-3p sensitizes human lung adenocarcinoma cells to chemotherapy by targeting GSTP1. target gene hsa-mir-517a Lung Neoplasms 24846831 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 This study demonstrated that miR-517a-3p promoted lung cancer cell proliferation and invasion by targeting of FOXJ3 expression. target gene hsa-mir-520h Lung Neoplasms 22410781 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol. target gene hsa-mir-542 Lung Neoplasms 22426479 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-542-5p targets EGFR and inhibited the growth of human lung cancer cells. target gene hsa-mir-545 Lung Neoplasms 24505359 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-545 suppresses cell proliferation by targeting cyclin D1 and CDK4 in lung cancer cells. target gene hsa-mir-574 Lung Neoplasms 23133627 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-574-5p was pivotal for TLR9 signaling enhanced tumor progression via down-regulating checkpoint suppressor 1 in human lung cancer target gene hsa-mir-610 Lung Neoplasms 25241780 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-610 suppresses lung cancer cell proliferation and invasion by targeting GJA3 expression. target gene hsa-mir-614 Lung Neoplasms 25342037 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MiR-614 inhibited cell invasion and proliferationa targeting PSA in lung cancer cells, PGCL3. target gene hsa-mir-630 Lung Neoplasms 25255219 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MiR-630 inhibits proliferation by targeting CDC7 kinase, but maintains the apoptotic balance by targetingmultiple modulators in human lung cancer A549 cells. target gene hsa-mir-638 Lung Neoplasms 24842609 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Downregulation of miR-638 promotes invasion and proliferation by regulating SOX2 and induces EMT in NSCLC. target gene hsa-mir-7 Lung Neoplasms 25880778 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 KCNJ2/Kir2.1 modulates cell growth and drug resistance by regulating MRP1/ABCC1 expression and is simultaneously regulated by the Ras/MAPK pathway and miR-7. KCNJ2/Kir2.1 may be a prognostic predictor and a potentially novel target for interfering with chemoresistance in SCLC. target gene hsa-mir-7 Lung Neoplasms 26135959 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-7 inhibits the malignant phenotypes of non-small cell lung cancer in vitro by targeting Pax6. target gene hsa-mir-7 Lung Neoplasms 24004462 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Moreover, overexpression of HuR could reduce the expression of miR-7 in lung cancer cells. target gene hsa-mir-7-1 Lung Neoplasms 23135998 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-7-regulated TLR9 signaling-enhanced growth and metastatic potential of human lung cancer cells by altering the phosphoinositide-3-kinase, regulatory subunit 3/Akt pathway target gene hsa-mir-7-2 Lung Neoplasms 23135998 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-7-regulated TLR9 signaling-enhanced growth and metastatic potential of human lung cancer cells by altering the phosphoinositide-3-kinase, regulatory subunit 3/Akt pathway target gene hsa-mir-7-3 Lung Neoplasms 23135998 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-7-regulated TLR9 signaling-enhanced growth and metastatic potential of human lung cancer cells by altering the phosphoinositide-3-kinase, regulatory subunit 3/Akt pathway target gene hsa-mir-9 Lung Neoplasms 25869366 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Novel potential regulatory miRNAs for RHOA (miR-9-1/-3, -34b/c, -129-2, -125b-1, -375, -1258) and NKIRAS1 (miR-34b/c, -129-2, -125b-1, -193a, -124a-1/-2/-3, -212, -132) genes in lung cancer were identified. target gene hsa-mir-9-1 Lung Neoplasms 21464588 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-9 and let-7g enhance the sensitivity to ionizing radiation by suppression of NFKB1. target gene hsa-mir-9-2 Lung Neoplasms 21464588 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-9 and let-7g enhance the sensitivity to ionizing radiation by suppression of NFKB1. target gene hsa-mir-93 Lung Neoplasms 24037530 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-93-directed downregulation of DAB2 defines a novel oncogenic pathway in lung cancer. target gene hsa-mir-93 Lung Neoplasms 19671678 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 regulate tumor suppressor gene FUS1 target gene hsa-mir-9-3 Lung Neoplasms 21464588 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-9 and let-7g enhance the sensitivity to ionizing radiation by suppression of NFKB1. target gene hsa-mir-96 Lung Neoplasms 25798833 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 The miR-200 family and the miR-183~96~182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers. target gene hsa-mir-96 Lung Neoplasms 24338464 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MIR-142-5p and miR-9 may be involved in squamous lung cancer by regulating cell cycle related genes. target gene hsa-mir-96 Lung Neoplasms 24469470 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MiR-96 downregulates RECK to promote growth and motility of non-small cell lung cancer cells. target gene hsa-mir-96 Lung Neoplasms 25286764 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Expression of microRNA-96 and its potential functions by targeting FOXO3 innon-small cell lung cancer. target gene hsa-mir-98 Lung Neoplasms 19671678 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 regulate tumor suppressor gene FUS1 target gene hsa-mir-99a Lung Neoplasms 25187230 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-99a suppresses the metastasis of human non-small cell lung cancer cells by targeting AKT1 signaling pathway. LC-related miRNAs target gene hsa-mir-10a Lupus Nephritis 29109423 urinary system disease DOID:0080162 M32.14 D008181 Transcriptomic profiling in human mesangial cells using patient-derived lupus autoantibodies identified miR-10a as a potential regulator of IL8. target gene hsa-mir-130b Lupus Nephritis 26316103 urinary system disease DOID:0080162 M32.14 D008181 MiR-130b-3p negatively regulated ERBB2IP expression by directly targeting the 3'-UTR of ERBB2IP The circulating miR-130b-3p might serve as a biomarker and play an important role in renal damage in early stage LN patients. target gene hsa-mir-146a Lupus Nephritis 28338190 urinary system disease DOID:0080162 M32.14 D008181 The role of miR-146a in modulating TRAF6-induced inflammation during lupus nephritis. target gene hsa-mir-148a Lupus Nephritis 26791485 urinary system disease DOID:0080162 M32.14 D008181 miR-148a-3p overexpression contributes to glomerular cell proliferation by targeting PTEN in lupus nephritis. target gene hsa-mir-371 Lupus Nephritis 27878241 urinary system disease DOID:0080162 M32.14 D008181 Hsa‑miR‑371‑5p inhibits human mesangial cell proliferation and promotes apoptosis in lupus nephritis by directly targeting hypoxia‑inducible factor 1α. target gene hsa-mir-155 Lymphocytic Choriomeningitis 29768211 disease by infectious agent DOID:12155 A87.2 D008216 Long-Term Persistence of Exhausted CD8 T Cells in Chronic Infection Is Regulated by MicroRNA-155. target gene hsa-mir-122 Lymphoma 22235305 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 miR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma. target gene hsa-mir-1275 Lymphoma 26705180 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 MiR-664b-5p, miR-1275, miR-4739, miR-4736 and miR-504-5p may become an important indicator in the differentiation ALK-negative anaplastic large cell lymphoma from CD30-positive peripheral T cell lymphoma (not otherwise specified).MiR-4739, miR-4736 and miR-1275 may play important role in pathogenesis of negative-anaplastic large cell lymphoma by target genes: TNFRSF8 and TMOD1. target gene hsa-mir-143 Lymphoma 28736328 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 Down regulation of miR-143 promotes radiation - Induced thymic lymphoma by targeting B7H1. target gene hsa-mir-146a Lymphoma 21610143 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 MicroRNA-146a downregulates NF{kappa}B activity via targeting TRAF6, and functions as a tumor suppressor having strong prognostic implications in NK/T cell lymphoma. target gene hsa-mir-150 Lymphoma 23521217 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 Re-expression of miR-150 induces EBV-positive Burkitt lymphoma differentiation by modulating c-Myb in vitro target gene hsa-mir-155 Lymphoma 25480585 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 reduction in miRNA-155 expression can inhibit the proliferation of SNK-6 lymphoma cells and promote their apoptosis, which may be associated with regulation of FOXO3a gene. target gene hsa-mir-155 Lymphoma 26261072 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 Oncogenic microRNA-155 and its target PU.1: an integrative gene expression study in six of the most prevalent lymphomas. target gene hsa-mir-155 Lymphoma 23852382 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 In experimental models, some lymphomas are considered to be addicted to the sustained expression of targetable oncomiRs, such as miR-155 and miR-21. target gene hsa-mir-17 Lymphoma 19666108 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 The expression of these genes was also reduced in response to miR-17 and miR-20a transfection, and more specifically they were also shown to contain functional miRNA recognition elements for members of the miR-17 family by reporter gene assay. target gene hsa-mir-17 Lymphoma 24169826 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop. target gene hsa-mir-200a Lymphoma 22183793 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 MicroRNA-200 is commonly repressed in conjunctival MALT lymphoma, and targets cyclin E2. target gene hsa-mir-200b Lymphoma 22183793 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 MicroRNA-200 is commonly repressed in conjunctival MALT lymphoma, and targets cyclin E2. target gene hsa-mir-200c Lymphoma 22183793 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 MicroRNA-200 is commonly repressed in conjunctival MALT lymphoma, and targets cyclin E2. target gene hsa-mir-20a Lymphoma 19666108 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 The expression of these genes was also reduced in response to miR-17 and miR-20a transfection, and more specifically they were also shown to contain functional miRNA recognition elements for members of the miR-17 family by reporter gene assay. target gene hsa-mir-26a Lymphoma 20441582 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 MicroRNA-26a-mediated regulation of interleukin-2 expression in transformed avian lymphocyte lines. target gene hsa-mir-365 Lymphoma 26191184 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 MicroRNA-365 inhibits growth, invasion and metastasis of malignant melanoma by targeting NRP1 expression. target gene hsa-mir-383 Lymphoma 29387204 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 western blot analysis identified zinc finger E-box binding homeobox 2 (ZEB2) as a direct target gene of miR-383 target gene hsa-mir-4736 Lymphoma 26705180 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 MiR-664b-5p, miR-1275, miR-4739, miR-4736 and miR-504-5p may become an important indicator in the differentiation ALK-negative anaplastic large cell lymphoma from CD30-positive peripheral T cell lymphoma (not otherwise specified).MiR-4739, miR-4736 and miR-1275 may play important role in pathogenesis of negative-anaplastic large cell lymphoma by target genes: TNFRSF8 and TMOD1. target gene hsa-mir-4739 Lymphoma 26705180 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 MiR-664b-5p, miR-1275, miR-4739, miR-4736 and miR-504-5p may become an important indicator in the differentiation ALK-negative anaplastic large cell lymphoma from CD30-positive peripheral T cell lymphoma (not otherwise specified).MiR-4739, miR-4736 and miR-1275 may play important role in pathogenesis of negative-anaplastic large cell lymphoma by target genes: TNFRSF8 and TMOD1. target gene hsa-mir-504 Lymphoma 26705180 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 MiR-664b-5p, miR-1275, miR-4739, miR-4736 and miR-504-5p may become an important indicator in the differentiation ALK-negative anaplastic large cell lymphoma from CD30-positive peripheral T cell lymphoma (not otherwise specified).MiR-4739, miR-4736 and miR-1275 may play important role in pathogenesis of negative-anaplastic large cell lymphoma by target genes: TNFRSF8 and TMOD1. target gene hsa-mir-664 Lymphoma 26287415 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 Taken together, our results suggest that miR-664 may play an important role in suppressing proliferation of CMM cells and present a novel mechanism of miR-mediated direct suppression of PLP2 expression in cancer cells. target gene hsa-mir-664b Lymphoma 26705180 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 MiR-664b-5p, miR-1275, miR-4739, miR-4736 and miR-504-5p may become an important indicator in the differentiation ALK-negative anaplastic large cell lymphoma from CD30-positive peripheral T cell lymphoma (not otherwise specified).MiR-4739, miR-4736 and miR-1275 may play important role in pathogenesis of negative-anaplastic large cell lymphoma by target genes: TNFRSF8 and TMOD1. target gene hsa-mir-92a Lymphoma 24375836 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 MiR-92a mediates AZD6244 induced apoptosis and G1-phase arrest of lymphoma cells by targeting Bim. target gene hsa-mir-155 Lymphoma, B-Cell 26497687 disease of cellular proliferation DOID:707 D016393 109565 HP:0012191 miR-155 targeting of DET1, NIAM, TRIM32, HOMEZ, PSIP1 and JARID2. target gene hsa-mir-17 Lymphoma, B-Cell 25634356 disease of cellular proliferation DOID:707 D016393 109565 HP:0012191 this molecular and bioinformatic study of 44 patient skin biopsy samples showed that the oncogenic miR-17-92 cluster and its paralogs were involved in cutaneous B-cell lymphoma progression, and that the downregulation of the target gene PTEN was associated with shorter DFS. target gene hsa-mir-204 Lymphoma, B-Cell 25651400 disease of cellular proliferation DOID:707 D016393 109565 HP:0012191 MicroRNA-204 targets signal transducer and activator of transcription 5 expression and inhibits proliferation of B-cell lymphoma cells. target gene hsa-mir-21 Lymphoma, B-Cell 25909227 disease of cellular proliferation DOID:707 D016393 109565 HP:0012191 MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma. target gene hsa-mir-224 Lymphoma, B-Cell 25146331 disease of cellular proliferation DOID:707 D016393 109565 HP:0012191 Deregulated expression of miR-224 and its target gene: CD59 predicts outcome of diffuse large B-cell lymphoma patients treated with R-CHOP. target gene hsa-mir-92 Lymphoma, B-Cell 25634356 disease of cellular proliferation DOID:707 D016393 109565 HP:0012191 this molecular and bioinformatic study of 44 patient skin biopsy samples showed that the oncogenic miR-17-92 cluster and its paralogs were involved in cutaneous B-cell lymphoma progression, and that the downregulation of the target gene PTEN was associated with shorter DFS. target gene hsa-mir-127 Lymphoma, Burkitt 19530237 disease of cellular proliferation DOID:8584 C83.7 D002051 113970 HP:0030080 B cell differentiation in EBV-positive Burkitt Lymphoma is impaired at post-transcriptional level by miRNA altered expression. target gene hsa-mir-17 Lymphoma, Burkitt 29458013 disease of cellular proliferation DOID:8584 C83.7 D002051 113970 HP:0030080 In contrast to normal B cells, miRNA target genes in BL were enriched for targets of the oncogenic miR-17 to 92 cluster, and were involved mainly in cell cycle and cell death target gene hsa-mir-18 Lymphoma, Burkitt 29458013 disease of cellular proliferation DOID:8584 C83.7 D002051 113970 HP:0030080 In contrast to normal B cells, miRNA target genes in BL were enriched for targets of the oncogenic miR-17 to 93 cluster, and were involved mainly in cell cycle and cell death target gene hsa-mir-19a Lymphoma, Burkitt 29458013 disease of cellular proliferation DOID:8584 C83.7 D002051 113970 HP:0030080 In contrast to normal B cells, miRNA target genes in BL were enriched for targets of the oncogenic miR-17 to 94 cluster, and were involved mainly in cell cycle and cell death target gene hsa-mir-19b-1 Lymphoma, Burkitt 29458013 disease of cellular proliferation DOID:8584 C83.7 D002051 113970 HP:0030080 In contrast to normal B cells, miRNA target genes in BL were enriched for targets of the oncogenic miR-17 to 96 cluster, and were involved mainly in cell cycle and cell death target gene hsa-mir-20a Lymphoma, Burkitt 29458013 disease of cellular proliferation DOID:8584 C83.7 D002051 113970 HP:0030080 In contrast to normal B cells, miRNA target genes in BL were enriched for targets of the oncogenic miR-17 to 95 cluster, and were involved mainly in cell cycle and cell death target gene hsa-mir-92-1 Lymphoma, Burkitt 29458013 disease of cellular proliferation DOID:8584 C83.7 D002051 113970 HP:0030080 In contrast to normal B cells, miRNA target genes in BL were enriched for targets of the oncogenic miR-17 to 97 cluster, and were involved mainly in cell cycle and cell death target gene hsa-mir-15a Lymphoma, Extranodal NK-T-Cell 23963825 C86.0 D054391 miR-15a could be a potential target for antitumor therapy and a prognostic predictor for NNKTL. target gene hsa-mir-106a Lymphoma, Hodgkin 21953646 disease of cellular proliferation DOID:8567 C81 D006689 236000 HP:0012189 MiR-17/106b seed family regulates p21 in Hodgkin's lymphoma. target gene hsa-mir-106b Lymphoma, Hodgkin 21953646 disease of cellular proliferation DOID:8567 C81 D006689 236000 HP:0012189 MiR-17/106b seed family regulates p21 in Hodgkin's lymphoma. target gene hsa-mir-17 Lymphoma, Hodgkin 21953646 disease of cellular proliferation DOID:8567 C81 D006689 236000 HP:0012189 MiR-17/106b seed family regulates p21 in Hodgkin's lymphoma. target gene hsa-mir-205 Lymphoma, Hodgkin 19666866 disease of cellular proliferation DOID:8567 C81 D006689 236000 HP:0012189 Regulates JAK2, prognostic impact target gene hsa-mir-28 Lymphoma, Hodgkin 28188132 disease of cellular proliferation DOID:8567 C81 D006689 236000 HP:0012189 miR-28 regulates the germinal center reaction and blocks tumor growth in preclinical models of non-Hodgkin lymphoma. target gene hsa-mir-9-1 Lymphoma, Hodgkin 22310293 disease of cellular proliferation DOID:8567 C81 D006689 236000 HP:0012189 Inhibition of miR-9 de-represses HuR and DICER1 and impairs Hodgkin lymphoma tumour outgrowth in vivo. target gene hsa-mir-9-2 Lymphoma, Hodgkin 22310293 disease of cellular proliferation DOID:8567 C81 D006689 236000 HP:0012189 Inhibition of miR-9 de-represses HuR and DICER1 and impairs Hodgkin lymphoma tumour outgrowth in vivo. target gene hsa-mir-9-3 Lymphoma, Hodgkin 22310293 disease of cellular proliferation DOID:8567 C81 D006689 236000 HP:0012189 Inhibition of miR-9 de-represses HuR and DICER1 and impairs Hodgkin lymphoma tumour outgrowth in vivo. target gene hsa-mir-92a Lymphoma, Large B-Cell 27806315 C83.3 D016403 109565 Primary mediastinal large B-cell lymphoma: transcriptional regulation by miR-92a through FOXP1 targeting. target gene hsa-mir-10a Lymphoma, Large B-Cell, Diffuse 27815824 disease of cellular proliferation DOID:0050745 C83.3 D016403 109565 miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma. target gene hsa-mir-17 Lymphoma, Large B-Cell, Diffuse 26305986 disease of cellular proliferation DOID:0050745 C83.3 D016403 109565 In the present review, we focus on the role of the miR-17-92 cluster in lymphoproliferative disorders, including diagnostic/prognostic implications, and on the potential applications of anti-miRNAs based therapies targeting miRNAs belonging to the cluster. target gene hsa-mir-18 Lymphoma, Large B-Cell, Diffuse 26305986 disease of cellular proliferation DOID:0050745 C83.3 D016403 109565 In the present review, we focus on the role of the miR-17-92 cluster in lymphoproliferative disorders, including diagnostic/prognostic implications, and on the potential applications of anti-miRNAs based therapies targeting miRNAs belonging to the cluster. target gene hsa-mir-19a Lymphoma, Large B-Cell, Diffuse 26305986 disease of cellular proliferation DOID:0050745 C83.3 D016403 109565 In the present review, we focus on the role of the miR-17-92 cluster in lymphoproliferative disorders, including diagnostic/prognostic implications, and on the potential applications of anti-miRNAs based therapies targeting miRNAs belonging to the cluster. target gene hsa-mir-19b-1 Lymphoma, Large B-Cell, Diffuse 26305986 disease of cellular proliferation DOID:0050745 C83.3 D016403 109565 In the present review, we focus on the role of the miR-17-92 cluster in lymphoproliferative disorders, including diagnostic/prognostic implications, and on the potential applications of anti-miRNAs based therapies targeting miRNAs belonging to the cluster. target gene hsa-mir-20a Lymphoma, Large B-Cell, Diffuse 26305986 disease of cellular proliferation DOID:0050745 C83.3 D016403 109565 In the present review, we focus on the role of the miR-17-92 cluster in lymphoproliferative disorders, including diagnostic/prognostic implications, and on the potential applications of anti-miRNAs based therapies targeting miRNAs belonging to the cluster. target gene hsa-mir-21 Lymphoma, Large B-Cell, Diffuse 24763002 disease of cellular proliferation DOID:0050745 C83.3 D016403 109565 The expression of miR-21 is high in DLBCL and its overexpression may be related with poor prognosis of DLCBL. These findings suggest that PTEN is possibly one of the targets of miR-21 in DLBCL. target gene hsa-mir-21 Lymphoma, Large B-Cell, Diffuse 23275230 disease of cellular proliferation DOID:0050745 C83.3 D016403 109565 MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen target gene hsa-mir-21 Lymphoma, Large B-Cell, Diffuse 29067124 disease of cellular proliferation DOID:0050745 C83.3 D016403 109565 MicroRNA-21 regulates the viability and apoptosis of diffuse large B-cell lymphoma cells by upregulating B cell lymphoma-2. target gene hsa-mir-26a Lymphoma, Large B-Cell, Diffuse 28640256 disease of cellular proliferation DOID:0050745 C83.3 D016403 109565 MicroRNA-26a/cyclin-dependent kinase 5 axis controls proliferation, apoptosis and in vivo tumor growth of diffuse large B-cell lymphoma cell lines. target gene hsa-mir-520c Lymphoma, Large B-Cell, Diffuse 24497838 disease of cellular proliferation DOID:0050745 C83.3 D016403 109565 Down-regulation of eIF4GII by miR-520c-3p represses diffuse large B cell lymphoma development. target gene hsa-mir-92-1 Lymphoma, Large B-Cell, Diffuse 26305986 disease of cellular proliferation DOID:0050745 C83.3 D016403 109565 In the present review, we focus on the role of the miR-17-92 cluster in lymphoproliferative disorders, including diagnostic/prognostic implications, and on the potential applications of anti-miRNAs based therapies targeting miRNAs belonging to the cluster. target gene hsa-mir-16-1 Lymphoma, Mantle-Cell 18483394 C83.10 D020522 Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. target gene hsa-mir-17 Lymphoma, Mantle-Cell 22116552 C83.10 D020522 The miRNA-17-92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. target gene hsa-mir-18a Lymphoma, Mantle-Cell 22116552 C83.10 D020522 The miRNA-17-92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. target gene hsa-mir-19a Lymphoma, Mantle-Cell 22116552 C83.10 D020522 The miRNA-17-92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. target gene hsa-mir-19b-1 Lymphoma, Mantle-Cell 22116552 C83.10 D020522 The miRNA-17-92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. target gene hsa-mir-20a Lymphoma, Mantle-Cell 22116552 C83.10 D020522 The miRNA-17-92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. target gene hsa-mir-92a-1 Lymphoma, Mantle-Cell 22116552 C83.10 D020522 The miRNA-17-92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. target gene hsa-mir-1291 Lymphoma, T-Cell 24246916 disease of cellular proliferation DOID:0050749 C84.4 D016399 186960 HP:0012190 Eight miRNAs are aberrantly expressed in PTCL-NOS, which may be involved in molecular regulation during the development of PTCL-NOS. The underlying mechanism is also related to a number of target genes and signaling pathways target gene hsa-mir-223 Lymphoma, T-Cell 24438193 disease of cellular proliferation DOID:0050749 C84.4 D016399 186960 HP:0012190 Our findings reveal that the downregulation of the tumour suppressor PRDM1 in EN-NK/T-NT samples is mediated by miR-223 and that PRDM1-positive staining might have prognostic value for evaluating the clinical outcome of EN-NK/T-NT patients. target gene hsa-mir-223 Lymphoma, T-Cell 24304814 disease of cellular proliferation DOID:0050749 C84.4 D016399 186960 HP:0012190 miR-223 regulates cell growth and targets proto-oncogenes in mycosis fungoides/cutaneous T-cell lymphoma. target gene hsa-mir-25 Lymphoma, T-Cell 24246916 disease of cellular proliferation DOID:0050749 C84.4 D016399 186960 HP:0012190 Eight miRNAs are aberrantly expressed in PTCL-NOS, which may be involved in molecular regulation during the development of PTCL-NOS. The underlying mechanism is also related to a number of target genes and signaling pathways target gene hsa-mir-26a Lymphoma, T-Cell 26314438 disease of cellular proliferation DOID:0050749 C84.4 D016399 186960 HP:0012190 that abnormal expression of miR-26a may participate in genesis and development of ENKTCL through regulating the expression of its target gene CDK6. target gene hsa-mir-27a Lymphoma, T-Cell 24246916 disease of cellular proliferation DOID:0050749 C84.4 D016399 186960 HP:0012190 Eight miRNAs are aberrantly expressed in PTCL-NOS, which may be involved in molecular regulation during the development of PTCL-NOS. The underlying mechanism is also related to a number of target genes and signaling pathways target gene hsa-mir-373 Lymphoma, T-Cell 27874957 disease of cellular proliferation DOID:0050749 C84.4 D016399 186960 HP:0012190 Restoration of microRNA-373 suppresses growth of human T-cell lymphoma cells by repressing CCND1. target gene hsa-mir-511 Lymphoma, T-Cell 24246916 disease of cellular proliferation DOID:0050749 C84.4 D016399 186960 HP:0012190 Eight miRNAs are aberrantly expressed in PTCL-NOS, which may be involved in molecular regulation during the development of PTCL-NOS. The underlying mechanism is also related to a number of target genes and signaling pathways target gene hsa-mir-572 Lymphoma, T-Cell 24246916 disease of cellular proliferation DOID:0050749 C84.4 D016399 186960 HP:0012190 Eight miRNAs are aberrantly expressed in PTCL-NOS, which may be involved in molecular regulation during the development of PTCL-NOS. The underlying mechanism is also related to a number of target genes and signaling pathways target gene hsa-mir-886 Lymphoma, T-Cell 24246916 disease of cellular proliferation DOID:0050749 C84.4 D016399 186960 HP:0012190 Eight miRNAs are aberrantly expressed in PTCL-NOS, which may be involved in molecular regulation during the development of PTCL-NOS. The underlying mechanism is also related to a number of target genes and signaling pathways target gene hsa-mir-150 Lymphoma, T-Cell, Cutaneous 24385540 disease of cellular proliferation DOID:0060061 C84.A0 D016410 608856 HP:0012192 MicroRNA-150 inhibits tumor invasion and metastasis by targeting the chemokine receptor CCR6, in advanced cutaneous T-cell lymphoma. target gene hsa-mir-155 Lymphoma, T-Cell, Cutaneous 24106870 disease of cellular proliferation DOID:0060061 C84.A0 D016410 608856 HP:0012192 Recent data show that miR-155 is expressed in situ by both malignant and non-malignant T cells, induced via the STAT5 signal pathway and IL-2Rbeta/gamma cytokines, and thus suggest the importance of miR-155 in malignant proliferation, clinical diagnosis, and prognosis in CTCL. target gene hsa-mir-155 Lynch Syndrome 25701956 genetic disease DOID:3883 D003123 120435 overexpression of miR-155 or miR-21 has been shown to downregulate the expression of the MMR genes. target gene hsa-mir-4480 Macular Degeneration 26765636 nervous system disease DOID:4448 H35.30 D008268 PS603075 HP:0000608 Functional single nucleotide polymorphism in IL-17A 3' untranslated region is targeted by miR-4480 in vitro and may be associated with age-related macular degeneration. target gene hsa-mir-30c Malignant Neoplasms [unspecific] 27085140 C80.1 D009369 miR-30c-1-3p altered basal and induced expression of cytochrome P450 3A4 (CYP3A4), a prototypical target gene of PXR. target gene hsa-mir-3151 Malignant Neoplasms [unspecific] 26582795 C80.1 D009369 In conclusion, we identify miR-3151 as a previously unidentified player in MM and PTC pathogenesis, which is driven by BRAF-dependent and BRAF-independent mechanisms. Characterization of TP53 as a downstream effector of miR-3151 provides evidence for a causal link between BRAF mutations and TP53 inactivation. target gene hsa-mir-210 Malignant Peripheral Nerve Sheath Tumor 24512729 disease of cellular proliferation DOID:5940 D009442 HP:0100697 MicroRNA-210 promotes proliferation and invasion of peripheral nerve sheath tumor cells targeting EFNA3. target gene hsa-mir-30d Malignant Peripheral Nerve Sheath Tumor 24132643 disease of cellular proliferation DOID:5940 D009442 HP:0100697 EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell survival and tumourigenesis. target gene hsa-mir-320a MALT Lymphoma 29788729 disease of cellular proliferation DOID:0050909 C88.4 137245 the TF MYC was a co-target of miR-320a, miR-622, and miR-429 target gene hsa-mir-429 MALT Lymphoma 29788729 disease of cellular proliferation DOID:0050909 C88.4 137245 the TF MYC was a co-target of miR-320a, miR-622, and miR-429 target gene hsa-mir-622 MALT Lymphoma 29788729 disease of cellular proliferation DOID:0050909 C88.4 137245 the TF MYC was a co-target of miR-320a, miR-622, and miR-429 target gene hsa-mir-155 Marek Disease 28757026 D008380 Marek's disease virus type 1 encoded analog of miR-155 promotes proliferation of chicken embryo fibroblast and DF-1 cells by targeting hnRNPAB. target gene hsa-mir-221 Marek Disease 19264608 D008380 miR-221: miR-221/222 target p27Kip1 in Marek's disease virus-transformed tumour cell line MSB-1 target gene hsa-mir-222 Marek Disease 19264608 D008380 miR-222: miR-221/222 target p27Kip1 in Marek's disease virus-transformed tumour cell line MSB-1 target gene hsa-let-7f-1 Medulloblastoma 25014664 disease of cellular proliferation DOID:0050902 C71.6 D008527 155255 HP:0002885 miR-let-7f-1 regulates SPARC mediated cisplatin resistance in medulloblastoma cells. target gene hsa-mir-124 Medulloblastoma 19427019 disease of cellular proliferation DOID:0050902 C71.6 D008527 155255 HP:0002885 miR-124 is frequently down-regulated in medulloblastoma and is a negative regulator of SLC16A1. target gene hsa-mir-124-1 Medulloblastoma 18607543 disease of cellular proliferation DOID:0050902 C71.6 D008527 155255 HP:0002885 miR-124: regulates cyclin dependent kinase 6 target gene hsa-mir-124-1 Medulloblastoma 22249617 disease of cellular proliferation DOID:0050902 C71.6 D008527 155255 HP:0002885 hsa-mir-124a targeted 3'UTR of HMGA1 and negatively modulated the expression in MB cells. target gene hsa-mir-124-2 Medulloblastoma 18607543 disease of cellular proliferation DOID:0050902 C71.6 D008527 155255 HP:0002885 miR-124: regulates cyclin dependent kinase 6 target gene hsa-mir-124-3 Medulloblastoma 18607543 disease of cellular proliferation DOID:0050902 C71.6 D008527 155255 HP:0002885 miR-124: regulates cyclin dependent kinase 6 target gene hsa-mir-125b Medulloblastoma 18756266 disease of cellular proliferation DOID:0050902 C71.6 D008527 155255 HP:0002885 Specifically, we identify miR-125b and miR-326 as suppressors of the pathway activator Smoothened together with miR-324-5p, which also targets the downstream transcription factor Gli1. target gene hsa-mir-182 Medulloblastoma 22402744 disease of cellular proliferation DOID:0050902 C71.6 D008527 155255 HP:0002885 Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma. target gene hsa-mir-183 Medulloblastoma 22402744 disease of cellular proliferation DOID:0050902 C71.6 D008527 155255 HP:0002885 Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma. target gene hsa-mir-218-1 Medulloblastoma 23212916 disease of cellular proliferation DOID:0050902 C71.6 D008527 155255 HP:0002885 MicroRNA 218 acts as a tumor suppressor by targeting multiple cancer phenotype associated genes in medulloblastoma target gene hsa-mir-218-2 Medulloblastoma 23212916 disease of cellular proliferation DOID:0050902 C71.6 D008527 155255 HP:0002885 MicroRNA 218 acts as a tumor suppressor by targeting multiple cancer phenotype associated genes in medulloblastoma target gene hsa-mir-219 Medulloblastoma 24756834 disease of cellular proliferation DOID:0050902 C71.6 D008527 155255 HP:0002885 miR-219 inhibits the proliferation, migration and invasion of medulloblastoma cells by targeting CD164. target gene hsa-mir-22 Medulloblastoma 24576181 disease of cellular proliferation DOID:0050902 C71.6 D008527 155255 HP:0002885 MiR-22 is frequently downregulated in medulloblastomas and inhibits cell proliferation via the novel target PAPST1. target gene hsa-mir-324 Medulloblastoma 18756266 disease of cellular proliferation DOID:0050902 C71.6 D008527 155255 HP:0002885 Specifically, we identify miR-125b and miR-326 as suppressors of the pathway activator Smoothened together with miR-324-5p, which also targets the downstream transcription factor Gli1. target gene hsa-mir-326 Medulloblastoma 18756266 disease of cellular proliferation DOID:0050902 C71.6 D008527 155255 HP:0002885 Specifically, we identify miR-125b and miR-326 as suppressors of the pathway activator Smoothened together with miR-324-5p, which also targets the downstream transcription factor Gli1. target gene hsa-mir-34a Medulloblastoma 21931765 disease of cellular proliferation DOID:0050902 C71.6 D008527 155255 HP:0002885 MiR-34a Targeting of Notch Ligand Delta-Like 1 Impairs CD15/CD133 Tumor-Propagating Cells and Supports Neural Differentiation in Medulloblastoma. target gene hsa-mir-383 Medulloblastoma 23227829 disease of cellular proliferation DOID:0050902 C71.6 D008527 155255 HP:0002885 MiR-383 is Downregulated in Medulloblastoma and Targets Peroxiredoxin 3 (PRDX3) target gene hsa-mir-431 Medulloblastoma 24584142 disease of cellular proliferation DOID:0050902 C71.6 D008527 155255 HP:0002885 Downregulation of microRNA-431 by human interferon-β inhibits viability of medulloblastoma and glioblastoma cells via upregulation of SOCS6. target gene hsa-mir-495 Medulloblastoma 26160158 disease of cellular proliferation DOID:0050902 C71.6 D008527 155255 HP:0002885 Our results suggest that miR-495 may be a prognostic predictor in medulloblastoma and that Gfi1 is a potential functional target of miR-495. target gene hsa-mir-96 Medulloblastoma 22402744 disease of cellular proliferation DOID:0050902 C71.6 D008527 155255 HP:0002885 Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma. target gene hsa-let-7a Melanoma 28698805 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 MicroRNA-26a inhibits the growth and invasiveness of malignant melanoma and directly targets on MITF gene. target gene hsa-let-7a-1 Melanoma 18679415 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 let-7a: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma target gene hsa-let-7a-2 Melanoma 18679415 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 let-7a: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma target gene hsa-let-7a-3 Melanoma 18679415 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 let-7a: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma target gene hsa-let-7b Melanoma 18379589 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. target gene hsa-let-7b Melanoma 18679415 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 let-7b: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma target gene hsa-let-7c Melanoma 18679415 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 let-7c: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma target gene hsa-let-7d Melanoma 18679415 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 let-7d: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma target gene hsa-let-7e Melanoma 18679415 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 let-7e: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma target gene hsa-let-7f-1 Melanoma 18679415 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 let-7f: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma target gene hsa-let-7f-2 Melanoma 18679415 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 let-7f: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma target gene hsa-let-7g Melanoma 18679415 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 let-7g: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma target gene hsa-let-7i Melanoma 18679415 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 let-7i: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma target gene hsa-mir-101 Melanoma 23962556 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 MiR-101 inhibits melanoma cell invasion and proliferation by targeting MITF and EZH2. target gene hsa-mir-124 Melanoma 27657824 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 Upregulation of miR-124 by physcion 8-O-β-glucopyranoside inhibits proliferation and invasion of malignant melanoma cells via repressing RLIP76. target gene hsa-mir-124 Melanoma 29042947 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-124 inhibits proliferation, migration and invasion of malignant melanoma cells via targeting versican. target gene hsa-mir-125a Melanoma 26071398 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 we discovered that Lin28B, a well-characterized inhibitor of let-7 miRNA biogenesis, was a direct target of miR-125a-5p in melanoma. target gene hsa-mir-125b Melanoma 28108732 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 FAK regulates E-cadherin expression via p-SrcY416/p-ERK1/2/p-Stat3Y705 and PPARγ/miR-125b/Stat3 signaling pathway in B16F10 melanoma cells. target gene hsa-mir-125b-1 Melanoma 22797068 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 MicroRNA miR-125b controls melanoma progression by direct regulation of c-Jun protein expression. target gene hsa-mir-125b-2 Melanoma 22797068 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 MicroRNA miR-125b controls melanoma progression by direct regulation of c-Jun protein expression. target gene hsa-mir-126 Melanoma 23437250 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-126&126* Restored Expressions Play a Tumor Suppressor Role by Directly Regulating ADAM9 and MMP7 in Melanoma target gene hsa-mir-137 Melanoma 20644734 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-137:Our data show that miR-148 and miR-137 present an additional level of regulating Mitf expression in melanocytes and melanoma cells. target gene hsa-mir-137 Melanoma 21278922 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 MicroRNA-137 Targets Carboxyl-terminal Binding Protein 1 in Melanoma Cell Lines. target gene hsa-mir-137 Melanoma 23151846 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-137 Inhibits the Invasion of Melanoma Cells through Downregulation of Multiple Oncogenic Target Genes target gene hsa-mir-137 Melanoma 21051724 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 The results showed that miR-137 can act as a tumor suppressor in uveal melanoma cell proliferation through downregulation of the targets MITF and CDK6. miR-137 may be epigenetically silenced during uveal melanoma tumorigenesis. target gene hsa-mir-137 Melanoma 28757416 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 The tumour suppressor, miR-137, inhibits malignant melanoma migration by targetting the TBX3 transcription factor. target gene hsa-mir-137 Melanoma 29097210 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-137 inhibits glutamine catabolism and growth of malignant melanoma by targeting glutaminase. target gene hsa-mir-137 Melanoma 29307109 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-137 inhibits melanoma cell proliferation through downregulation of GLO1 target gene hsa-mir-137 Melanoma 29348676 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-137 regulates ferroptosis by targeting glutamine transporter SLC1A5 in melanoma target gene hsa-mir-143 Melanoma 19639204 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-27a and its target gene ZBTB10 significantly different based on the dose of genistein target gene hsa-mir-143 Melanoma 24722758 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 MicroRNA-143 targets Syndecan-1 to repress cell growth in melanoma. target gene hsa-mir-143 Melanoma 29230879 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 These results support a functional role for miR-143-5p in regulating alpaca melanocyte migration, proliferation and melanogenesis through direct targeting of TAK1 target gene hsa-mir-146a Melanoma 24550252 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-146a promotes the initiation and progression of melanoma by activating Notch signaling. target gene hsa-mir-148a Melanoma 20644734 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-148:Our data show that miR-148 and miR-137 present an additional level of regulating Mitf expression in melanocytes and melanoma cells. target gene hsa-mir-148b Melanoma 28656878 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 Proteasome beta-4 subunit contributes to the development of melanoma and is regulated by miR-148b. target gene hsa-mir-150 Melanoma 29434838 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 MicroRNA-150 inhibitors enhance cell apoptosis of melanoma by targeting PDCD4 target gene hsa-mir-155 Melanoma 21466664 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 MicroRNA-155 Targets the SKI Gene in Human Melanoma Cell Lines target gene hsa-mir-155 Melanoma 25853464 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 microRNA-155, induced by interleukin-1ß, represses the expression of microphthalmia-associated transcription factor (MITF-M) in melanoma cells. target gene hsa-mir-155 Melanoma 29333944 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 MiR-155 Promotes Uveal Melanoma Cell Proliferation and Invasion by Regulating NDFIP1 Expression target gene hsa-mir-16 Melanoma 28991221 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 TYRP1-dependent miR-16 sequestration can also be overcome in vivo by using small oligonucleotides that mask miR-16-binding sites on TYRP1 mRNA target gene hsa-mir-17 Melanoma 26158900 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-17 regulates melanoma cell motility by inhibiting the translation of ETV1. target gene hsa-mir-17 Melanoma 23728176 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 We found that cancer cells silence ADAR1 by overexpressing miR-17 and miR-432, which both directly target the ADAR1 transcript. target gene hsa-mir-182 Melanoma 19188590 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-182: Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor target gene hsa-mir-182 Melanoma 22848417 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-182, a p53 dependent miRNA, suppressed the expression of MITF, BCL2, cyclin D2 and functioned as a potent tumor suppressor in uveal melanoma cells. target gene hsa-mir-186 Melanoma 27698793 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-186 suppressed CYLD expression and promoted cell proliferation in human melanoma. target gene hsa-mir-193b Melanoma 20304954 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 MicroRNA-193b Represses Cell Proliferationand Regulates Cyclin D1 in Melanoma target gene hsa-mir-193b Melanoma 21893020 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-193b is expressed at a significantly lower level in malignant melanoma than in benign nevi. In a survey of melanoma samples, the level of Mcl-1 is inversely correlated with the level of miR-193b. Overexpression of miR-193b in melanoma cells represses Mcl-1 expression. Furthermore, the effect of miR-193b on the expression of Mcl-1 seems to be mediated by direct interaction between miR-193b and seed and seedless pairing sequences in the 3' untranslated region of Mcl-1 mRNA. target gene hsa-mir-194 Melanoma 28358423 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 Circulating microRNA-194 regulates human melanoma cells via PI3K/AKT/FoxO3a and p53/p21 signaling pathway. target gene hsa-mir-196a Melanoma 21077158 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 As it was stated before that miR-196a might negatively regulate expression of the transcription factor HOX-C8, we analyzed HOX-C8 levels in NHEMs and melanoma cells and found a strong up-regulation of HOX-C8 expression in malignant melanoma cell lines and tissue samples compared with melanocytes. target gene hsa-mir-199a Melanoma 25400815 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-199a-5p regulates melanoma metastasis-related genes, and may provide a basis for the development of novel, molecularly targeted drugs. target gene hsa-mir-19b Melanoma 25643913 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-19b regulates hTERT mRNA expression through targeting PITX1 mRNA in melanoma cells. target gene hsa-mir-200a Melanoma 28526299 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic Melanoma. target gene hsa-mir-200b Melanoma 28535666 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 A miR-200b inhibitor induced the direct regulation of SOX-2 by DDX53 target gene hsa-mir-200c Melanoma 22982443 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1. target gene hsa-mir-203 Melanoma 22354972 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 Anti-oncogenic MicroRNA-203 Induces Senescence by Targeting E2F3 in Human Melanoma Cells. target gene hsa-mir-203 Melanoma 23884313 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 MicroRNA-203 regulates melanosome transport and tyrosinase expression in melanoma cells by targeting kinesin superfamily protein 5b. target gene hsa-mir-203 Melanoma 25475727 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-203 regulated melanoma invasive and proliferative abilities in part by targeting BMI1, providing new insights into potential mechanisms of melanoma metastasis. target gene hsa-mir-204 Melanoma 29075789 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 BANCR contributes to the growth and invasion of melanoma by functioning as a competing endogenous RNA to upregulate Notch2 expression by sponging miR‑204. target gene hsa-mir-205 Melanoma 21454583 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1. target gene hsa-mir-205 Melanoma 22871739 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry. target gene hsa-mir-205 Melanoma 23638671 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 Our data suggest that miR-203 is a new prognostic factor in canine oral MMs and that miR-205 functions as a tumour suppressor by targeting erbb3 in both canine and human MM cells. target gene hsa-mir-20b Melanoma 24405508 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-20b regulates expression of proteinase-activated receptor-1 (PAR-1) thrombin receptor in melanoma cells. target gene hsa-mir-21 Melanoma 22130252 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 Increased levels of microRNA-21 expression were shown from dysplastic nevi to primary cutaneous melanomas to melanoma metastases. Moreover, high miR-21 expression was found to be correlated with Breslow thickness and advanced clinical stage. Patients with high microRNA-21 expression showed shorter 5-year disease-free or overall survival than those with low microRNA-21 expression. Furthermore, multivariate regression analysis showed that the status of microRNA-21 expression was an independent prognostic factor for overall survival of patients. Antisense-mediated microRNA-21 inhibition could significantly suppress growth, increase apoptosis and enhance chemo- or radiosensitivity of human cutaneous melanoma cells by inducing the increased Bax/Bcl-2 ratio. Thus, the status of microRNA-21 might be an independent prognostic factor for patients with cutaneous melanoma, and microRNA-21 has the potential of being a novel molecular target for the treatment of human cutaneous melanoma. target gene hsa-mir-21 Melanoma 25587717 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 increased expression of miR-21 enhanced the invasive potential of melanoma cell lines through TIMP3 inhibition. Therefore, inhibition of miR-21 in melanoma may reduce melanoma invasiveness. target gene hsa-mir-211 Melanoma 24039954 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 New target genes of MITF-induced microRNA-211 contribute to melanoma cell invasion. target gene hsa-mir-211 Melanoma 21072171 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 our findings that miR-211 is a direct posttranscriptional regulator of KCNMA1 expression as well as the dependence of this miRNA's expression on MITF activity, establishes miR-211 as an important regulatory agent in human melanoma. target gene hsa-mir-211 Melanoma 26599548 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 Overexpression of mature miR-211 in Bcl-2 overexpressing cells rescued Bcl-2 ability to increase cell migration. target gene hsa-mir-214 Melanoma 21468029 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-214 is highly expressed in human melanomas and contributes to melanoma tumour progression through suppression of TFAP2C target gene hsa-mir-214 Melanoma 23667173 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-214 coordinates melanoma progression by upregulating ALCAM through TFAP2 and miR-148b downmodulation. target gene hsa-mir-216a Melanoma 28225180 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 microRNA-216b inhibits cell proliferation and migration in human melanoma by targeting FOXM1 in vitro and in vivo. target gene hsa-mir-218 Melanoma 24839010 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 Expression patterns of microRNA-218 and its potential functions by targeting CIP2A and BMI1 genes in melanoma. target gene hsa-mir-221 Melanoma 19126397 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-221: mir-221 can directly interact with c-kit 3'UTR and inhibit cKit protein translation target gene hsa-mir-223 Melanoma 22356618 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 MiRTrail identified several deregulated miRNAs that target deregulated mRNAs including miRNAs hsa-miR-23b and hsa-miR-223, which target the highest numbers of deregulated mRNAs and regulate the pathway "basal cell carcinoma". target gene hsa-mir-23b Melanoma 22356618 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 MiRTrail identified several deregulated miRNAs that target deregulated mRNAs including miRNAs hsa-miR-23b and hsa-miR-223, which target the highest numbers of deregulated mRNAs and regulate the pathway "basal cell carcinoma". target gene hsa-mir-25 Melanoma 27801786 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 Upregulated MicroRNA-25 Mediates the Migration of Melanoma Cells by Targeting DKK3 through the WNT/β-Catenin Pathway. target gene hsa-mir-26a Melanoma 28698805 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 MicroRNA-26a inhibits the growth and invasiveness of malignant melanoma and directly targets on MITF gene. target gene hsa-mir-29a Melanoma 23245396 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 Interferon-gamma-induced activation of Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells target gene hsa-mir-29b-1 Melanoma 23245396 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 Interferon-gamma-induced activation of Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells target gene hsa-mir-29b-2 Melanoma 23245396 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 Interferon-gamma-induced activation of Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells target gene hsa-mir-328 Melanoma 25743834 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 MicroRNA-328 inhibits proliferation of human melanoma cells by targeting TGFβ2. target gene hsa-mir-33b Melanoma 25725129 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 MicroRNA-33b, upregulated by EF24, a curcumin analog, suppresses the epithelial-to-mesenchymal transition (EMT) and migratory potential of melanoma cells by targeting HMGA2. target gene hsa-mir-33b Melanoma 25868853 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 Cordycepin (3'-deoxyadenosine) suppressed HMGA2, Twist1 and ZEB1-dependent melanoma invasion and metastasis by targeting miR-33b. target gene hsa-mir-340 Melanoma 25414259 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 the RNA-binding protein, coding region determinant-binding protein, was shown to be highly expressed in melanoma, directly binds to the 3'-UTR of MITF mRNA, and prevents the binding of miR-340 to its target sites, resulting in the stabilization of MITF transcripts, elevated expression, and transcriptional activity of MITF. This regulatory interplay between RNA-binding protein and miRNA highlights an important mechanism for the regulation of MITF in melanocytes and malignant melanomas. target gene hsa-mir-342 Melanoma 29495972 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 MicroRNA-342 prohibits proliferation and invasion of melanoma cells by directly targeting Zinc-finger E-box binding homeobox 1 target gene hsa-mir-34a Melanoma 19029026 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-34a: MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met target gene hsa-mir-34b Melanoma 22419847 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 MicroRNA-34b/c suppresses uveal melanoma cell proliferation and migration through multiple targets. target gene hsa-mir-34c Melanoma 22419847 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 MicroRNA-34b/c suppresses uveal melanoma cell proliferation and migration through multiple targets. target gene hsa-mir-367 Melanoma 28829890 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-367 promotes uveal melanoma cell proliferation and migration by regulating PTEN. target gene hsa-mir-375 Melanoma 28723760 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 CXCL8 interacted with STAT1, CCL27, and IGF1R targeted by hsa-miR-375 target gene hsa-mir-432 Melanoma 23728176 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 We found that cancer cells silence ADAR1 by overexpressing miR-17 and miR-432, which both directly target the ADAR1 transcript. target gene hsa-mir-488 Melanoma 28328082 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 MicroRNA-488-3p sensitizes malignant melanoma cells to cisplatin by targeting PRKDC. target gene hsa-mir-493 Melanoma 28475006 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 Downregulation of miR-493 promoted melanoma proliferation by suppressing IRS4 expression. target gene hsa-mir-514a Melanoma 25980496 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma. target gene hsa-mir-524 Melanoma 25275294 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2. target gene hsa-mir-532 Melanoma 19336521 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-532-5p: miR-532-5p is a regulatory factor of RUNX3, which is down-regulated during melanoma progression target gene hsa-mir-675 Melanoma 24940649 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 Cadherin 11, a miR-675 target, induces N-cadherin expression and epithelial-mesenchymal transition in melasma. target gene hsa-mir-7-1 Melanoma 23206698 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-7-5p may represent a novel tumor suppressor miRNA in melanoma, acting at least in part via its inhibition of IRS-2 expression and oncogenic Akt signaling target gene hsa-mir-7-2 Melanoma 23206698 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-7-5p may represent a novel tumor suppressor miRNA in melanoma, acting at least in part via its inhibition of IRS-2 expression and oncogenic Akt signaling target gene hsa-mir-7-3 Melanoma 23206698 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-7-5p may represent a novel tumor suppressor miRNA in melanoma, acting at least in part via its inhibition of IRS-2 expression and oncogenic Akt signaling target gene hsa-mir-767 Melanoma 29054757 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 MiR-767 promoted cell proliferation in human melanoma by suppressing CYLD expression. target gene hsa-mir-9 Melanoma 26104682 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 These results identify a novel YY1~miR-9~RYBP axis involved in melanoma tumorigenesis and reinforce the idea that regulatory circuitries involving miRNAs and TFs are prevalent mechanisms. target gene hsa-mir-9 Melanoma 27895497 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 MicroRNA-9 suppresses the growth, migration, and invasion of malignant melanoma cells via targeting NRP1. target gene hsa-mir-9 Melanoma 28810544 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 MicroRNA-9 inhibits the proliferation and migration of malignant melanoma cells via targeting sirituin 1. target gene hsa-mir-98 Melanoma 25277211 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-98 suppresses melanoma metastasis through a negative feedback loop with its target gene IL-6. target gene hsa-mir-675 Melasma 24335901 D008548 Reduced MiR-675 in exosome in H19 RNA-related melanogenesis via MITF as a direct target. target gene hsa-mir-224 Meningioma 25783051 disease of cellular proliferation DOID:3565 D32.9 D008579 607174 HP:0002858 MicroRNA-224 targets ERG2 and contributes to malignant progressions of meningioma. target gene hsa-mir-335 Meningioma 22886530 disease of cellular proliferation DOID:3565 D32.9 D008579 607174 HP:0002858 miR-335 promotes cell proliferation by directly targeting Rb1 in meningiomas. target gene hsa-mir-125b Meningitis, Pneumococcal 29611100 G00.1 D008586 hsa-miR-25-3p and hsa-miR-125b-5p target the transcription factor TEF-1, for which there are binding sites in Il-1β, Ccl 2 , and Ccl 3 genes target gene hsa-mir-25 Meningitis, Pneumococcal 29611100 G00.1 D008586 hsa-miR-25-3p and hsa-miR-125b-5p target the transcription factor TEF-1, for which there are binding sites in Il-1β, Ccl 2 , and Ccl 3 genes target gene hsa-mir-146a Mesial Temporal Lobe Epilepsy 29590637 G40.209 D004833 608096 modulation of the miR-146a-CFH-IL-1β loop circuit could be a novel therapeutic target for TLE target gene hsa-let-7a-1 Mesothelioma 21869823 disease of cellular proliferation DOID:1790 C45.9 C562839 156240 HP:0100001 EphrinA1 inhibits malignant mesothelioma tumor growth via let-7 microRNA-mediated repression of the RAS oncogene.EphrinA1 activation induced several fold increases in let-7a1, let-7a3, let-7f1 and let-7f2 miRNA expression in MMCs. target gene hsa-let-7a-3 Mesothelioma 21869823 disease of cellular proliferation DOID:1790 C45.9 C562839 156240 HP:0100001 EphrinA1 inhibits malignant mesothelioma tumor growth via let-7 microRNA-mediated repression of the RAS oncogene.EphrinA1 activation induced several fold increases in let-7a1, let-7a3, let-7f1 and let-7f2 miRNA expression in MMCs. target gene hsa-let-7f-1 Mesothelioma 21869823 disease of cellular proliferation DOID:1790 C45.9 C562839 156240 HP:0100001 EphrinA1 inhibits malignant mesothelioma tumor growth via let-7 microRNA-mediated repression of the RAS oncogene.EphrinA1 activation induced several fold increases in let-7a1, let-7a3, let-7f1 and let-7f2 miRNA expression in MMCs. target gene hsa-let-7f-2 Mesothelioma 21869823 disease of cellular proliferation DOID:1790 C45.9 C562839 156240 HP:0100001 EphrinA1 inhibits malignant mesothelioma tumor growth via let-7 microRNA-mediated repression of the RAS oncogene.EphrinA1 activation induced several fold increases in let-7a1, let-7a3, let-7f1 and let-7f2 miRNA expression in MMCs. target gene hsa-mir-126 Mesothelioma 24444362 disease of cellular proliferation DOID:1790 C45.9 C562839 156240 HP:0100001 MicroRNA-126 suppresses mesothelioma malignancy by targeting IRS1 and interfering with the mitochondrial function. target gene hsa-mir-379 Mesothelioma 25231602 disease of cellular proliferation DOID:1790 C45.9 C562839 156240 HP:0100001 MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma. target gene hsa-mir-411 Mesothelioma 25231602 disease of cellular proliferation DOID:1790 C45.9 C562839 156240 HP:0100001 MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma. target gene hsa-mir-503 Microvascular Disease 26268439 Collectively, our data demonstrate that miR-503 regulates pericyte-endothelial crosstalk in microvascular diabetic complications. target gene hsa-mir-106b Mitochondrial Metabolism Disease 25529328 disease of metabolism DOID:700 E88.40 D028361 miR-106b negatively regulated skeletal muscle mitochondrial function and insulin sensitivity under PA-induced insulin resistance by targeting Mfn2, which may be associated with reduced ROS and upregulation of the ERR-α/PGC-1α/Mfn2 axis. target gene hsa-mir-29a Mitochondrial Metabolism Disease 29322081 disease of metabolism DOID:700 E88.40 D028361 Data of expression status of miR-29a and its putative target mitochondrial apoptosis regulatory gene DRP1 upon miR-15a and miR-214 inhibition target gene hsa-let-7c Moyamoya Disease 26070522 cardiovascular system disease DOID:13099 I67.5 D009072 PS252350 HP:0011834 Increased expression of let-7c in MMD patients may contribute to MMD pathogenesis by targeting RNF213. Thus, let-7c may be a potential biomarker for the diagnosis of MMD. target gene hsa-mir-137 Multiple Myeloma 25724519 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma. target gene hsa-mir-137 Multiple Myeloma 27531781 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 The miR137-MITF is an important index in judging the prognosis of multiple myeloma. target gene hsa-mir-148a Multiple Myeloma 27842905 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 MiR-148a participates in the growth of RPMI8226 multiple myeloma cells by regulating CDKN1B. target gene hsa-mir-15a Multiple Myeloma 22133358 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 miR-15a and miR-16-1 inhibit the proliferation of leukemic cells by down-regulating WT1 protein level. target gene hsa-mir-15a Multiple Myeloma 23104180 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF target gene hsa-mir-15a Multiple Myeloma 26117022 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 High expression of miR-15a can induce cell cycle arrest and apoptosis of MM cells, then inhibit their growth. The mechanisms may be related with the negative regulation of BMI-1 and BCL-2 genes in post-transcription level caused by miR-15a. target gene hsa-mir-15a Multiple Myeloma 19401561 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. target gene hsa-mir-16 Multiple Myeloma 19401561 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. target gene hsa-mir-16 Multiple Myeloma 20962322 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 We validated designated genes showing binding sites within the conserved 3'-UTR and also within the mRNA coding region as direct miR-16 targets, thus indicating that the miRNAs may have many more targets than anticipated by conventional prediction methods. target gene hsa-mir-16-1 Multiple Myeloma 23104180 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF target gene hsa-mir-16-2 Multiple Myeloma 23104180 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF target gene hsa-mir-197 Multiple Myeloma 25724519 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma. target gene hsa-mir-199a Multiple Myeloma 24839982 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity. target gene hsa-mir-19a Multiple Myeloma 29201171 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 the results of the present study indicate that targets genes of miR-19a are potential candidate biomarkers for MM target gene hsa-mir-202 Multiple Myeloma 24506956 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 MiR-202 can inhibit the proliferation and induce apoptosis in MM cells via regulating BAFF. JNK/SAPK signaling pathway is involved in the regulation of BAFF by miR-202. target gene hsa-mir-21 Multiple Myeloma 23446999 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth target gene hsa-mir-21 Multiple Myeloma 25825239 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 Downregulation of Sprouty homolog 2 by microRNA-21 inhibits proliferation,metastasis and invasion, however promotes the apoptosis of multiple myeloma cells. target gene hsa-mir-21 Multiple Myeloma 26687742 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 STAT3 and hsa-miR-125b, PIAS3 and hsa-miR-21 respectively formed self adaptation feedback regulations. target gene hsa-mir-221 Multiple Myeloma 26249174 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma. target gene hsa-mir-222 Multiple Myeloma 26249174 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma. target gene hsa-mir-29b-1 Multiple Myeloma 21951844 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 Overexpression of microRNA-29b induces apoptosis of multiple myeloma cells through down regulating Mcl-1. target gene hsa-mir-451 Multiple Myeloma 25915427 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma. target gene hsa-mir-631 Multiple Myeloma 28000886 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10. target gene hsa-mir-122 Multiple Sclerosis 19617918 nervous system disease DOID:2377 G35 D009103 PS126200 The genes targeted by hsa-miR-96 are involved inimmunological pathways as Interleukin signaling and in other pathways as wnt signaling target gene hsa-mir-132 Multiple Sclerosis 25136908 nervous system disease DOID:2377 G35 D009103 PS126200 Over-expression of miR-132 in normal B cells significantly enhanced their production of lymphotoxin and tumor necrosis factor 伪. The over-expression of miR-132 also suppressed the miR-132 target, sirtuin-1. target gene hsa-mir-155 Multiple Sclerosis 23818336 nervous system disease DOID:2377 G35 D009103 PS126200 Our results demonstrate that miR-155 regulates proinflammatory responses in both blood-derived and central nervous system (CNS)-resident myeloid cells, in addition to impacting subsequent adaptive immune responses.Differential miRNA expression may therefore provide insight into mechanisms responsible for distinct phenotypic and functional properties of myeloid cells,thus impacting their ability to influence CNS injury and repair. target gene hsa-mir-15b Multiple Sclerosis 28228555 nervous system disease DOID:2377 G35 D009103 PS126200 MicroRNA-15b Suppresses Th17 Differentiation and Is Associated with Pathogenesis of Multiple Sclerosis by Targeting O-GlcNAc Transferase. target gene hsa-mir-17 Multiple Sclerosis 20148420 nervous system disease DOID:2377 G35 D009103 PS126200 Functional experiments with a synthetic inhibitor of miR-17 supported the link between miRNA expression and the altered target gene expression. target gene hsa-mir-197 Multiple Sclerosis 23895517 nervous system disease DOID:2377 G35 D009103 PS126200 MicroRNA regulate immune pathways in T-cells in multiple sclerosis (MS). target gene hsa-mir-29a Multiple Sclerosis 22772450 nervous system disease DOID:2377 G35 D009103 PS126200 miR-29ab Deficiency Identifies a Negative Feedback Loop Controlling Th1 Bias That Is Dysregulated in Multiple Sclerosis. target gene hsa-mir-29b-1 Multiple Sclerosis 22772450 nervous system disease DOID:2377 G35 D009103 PS126200 miR-29ab Deficiency Identifies a Negative Feedback Loop Controlling Th1 Bias That Is Dysregulated in Multiple Sclerosis. target gene hsa-mir-29b-2 Multiple Sclerosis 22772450 nervous system disease DOID:2377 G35 D009103 PS126200 miR-29ab Deficiency Identifies a Negative Feedback Loop Controlling Th1 Bias That Is Dysregulated in Multiple Sclerosis. target gene hsa-mir-326 Multiple Sclerosis 29181619 nervous system disease DOID:2377 G35 D009103 PS126200 MicroRNA-326 contributes to autoimmune thyroiditis by targeting the Ets-1 protein target gene hsa-mir-448 Multiple Sclerosis 28342869 nervous system disease DOID:2377 G35 D009103 PS126200 MicroRNA-448 promotes multiple sclerosis development through induction of Th17 response through targeting protein tyrosine phosphatase non-receptor type 2 (PTPN2). target gene hsa-mir-494 Multiple Sclerosis 23895517 nervous system disease DOID:2377 G35 D009103 PS126200 MicroRNA regulate immune pathways in T-cells in multiple sclerosis (MS). target gene hsa-mir-18a Muscle Atrophy 28782600 M62.5 D009133 HP:0100295 miR-18a induces myotubes atrophy by down-regulating IgfI. target gene hsa-mir-206 Muscle Diseases [unspecific] 24107628 M63.80 D009135 miR-206 directly targets cyclin D1 and contributes to the regulation of CCND1 gene expression in both myogenic and non-muscle, transformed cells. target gene hsa-mir-23a Muscular Dystrophy 21926429 G71.0 D009136 310200 HP:0003560 miR-23a suppresses the translation of both MAFbx/atrogin-1 and MuRF1 in a 3UTR-dependent manner. Ectopic expression of miR-23a is sufficient to protect muscles from atrophy in vitro and in vivo. target gene hsa-mir-143 Muscular Dystrophy, Duchenne 27223470 musculoskeletal system disease DOID:11723 G71.0 D020388 310200 miRNA-143 as a direct regulator of 尾-dystrobrevin expression target gene hsa-mir-31 Muscular Dystrophy, Duchenne 21212803 musculoskeletal system disease DOID:11723 G71.0 D020388 310200 miR-31 represses dystrophin expression by targeting its 3' untranslated region. target gene hsa-mir-25 Muscular Dystrophy, Facioscapulohumeral 20519410 musculoskeletal system disease DOID:11727 G71.0 D020391 158900 miR-25:We report for the first time that FXR1P is regulated through miRNA binding, with one site being the miR-25/32/92/363/367 seed sequence target gene hsa-mir-32 Muscular Dystrophy, Facioscapulohumeral 20519410 musculoskeletal system disease DOID:11727 G71.0 D020391 158900 miR-32:We report for the first time that FXR1P is regulated through miRNA binding, with one site being the miR-25/32/92/363/367 seed sequence target gene hsa-mir-363 Muscular Dystrophy, Facioscapulohumeral 20519410 musculoskeletal system disease DOID:11727 G71.0 D020391 158900 miR-363:We report for the first time that FXR1P is regulated through miRNA binding, with one site being the miR-25/32/92/363/367 seed sequence target gene hsa-mir-367 Muscular Dystrophy, Facioscapulohumeral 20519410 musculoskeletal system disease DOID:11727 G71.0 D020391 158900 miR-367:We report for the first time that FXR1P is regulated through miRNA binding, with one site being the miR-25/32/92/363/367 seed sequence target gene hsa-mir-92a-1 Muscular Dystrophy, Facioscapulohumeral 20519410 musculoskeletal system disease DOID:11727 G71.0 D020391 158900 miR-92:We report for the first time that FXR1P is regulated through miRNA binding, with one site being the miR-25/32/92/363/367 seed sequence target gene hsa-mir-92a-2 Muscular Dystrophy, Facioscapulohumeral 20519410 musculoskeletal system disease DOID:11727 G71.0 D020391 158900 miR-92:We report for the first time that FXR1P is regulated through miRNA binding, with one site being the miR-25/32/92/363/367 seed sequence target gene hsa-mir-15a Myasthenia Gravis 26845678 musculoskeletal system disease DOID:437 G70.0 D009157 254200 MiR-15a contributes abnormal immune response in myasthenia gravis by targeting CXCL10. target gene hsa-mir-15b Myasthenia Gravis 26087886 musculoskeletal system disease DOID:437 G70.0 D009157 254200 This study is the first to report the miR-15b-IL-15 axis can directly regulate IL15 expression, which helps to further explain the abnormal IL-15 expression in MG patients and the pathogenesis of MG. target gene hsa-mir-320a Myasthenia Gravis 23196978 musculoskeletal system disease DOID:437 G70.0 D009157 254200 MiR-320a is Downregulated in Patients with Myasthenia Gravis and Modulates Inflammatory Cytokines Production by Targeting Mitogen-activated Protein Kinase 1 target gene hsa-let-7 Mycobacterium tuberculosis Infection 25683052 A18 D014376 607948 MicroRNA let-7 modulates the immune response to Mycobacterium tuberculosis infection via control of A20, an inhibitor of the NF-κB pathway. target gene hsa-mir-26a Mycobacterium tuberculosis Infection 28558034 A18 D014376 607948 MicroRNA 26a (miR-26a)/KLF4 and CREB-C/EBPβ regulate innate immune signaling, the polarization of macrophages and the trafficking of Mycobacterium tuberculosis to lysosomes during infection. target gene hsa-mir-27b Mycobacterium tuberculosis Infection 29661829 A18 D014376 607948 we revealed a novel role of the miR-27b/Bag2 axis in the regulation of inflammatory response and apoptosis and provide a potential molecular host defense mechanism against mycobacteria target gene hsa-mir-32 Mycobacterium tuberculosis Infection 28215633 A18 D014376 607948 TLR-4/miRNA-32-5p/FSTL1 signaling regulates mycobacterial survival and inflammatory responses in Mycobacterium tuberculosis-infected macrophages. target gene hsa-mir-17 Myelodysplastic Syndromes 23246221 disease of cellular proliferation DOID:0050908 D46.9 D009190 614286 HP:0002863 Expression analysis of mir-17-5p, mir-20a and let-7a microRNAs and their target proteins in CD34+ bone marrow cells of patients with myelodysplastic syndromes target gene hsa-mir-20a Myelodysplastic Syndromes 23246221 disease of cellular proliferation DOID:0050908 D46.9 D009190 614286 HP:0002863 Expression analysis of mir-17-5p, mir-20a and let-7a microRNAs and their target proteins in CD34+ bone marrow cells of patients with myelodysplastic syndromes target gene hsa-mir-22 Myelodysplastic Syndromes 23827711 disease of cellular proliferation DOID:0050908 D46.9 D009190 614286 HP:0002863 The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. target gene hsa-mir-23a Myelodysplastic Syndromes 24584347 disease of cellular proliferation DOID:0050908 D46.9 D009190 614286 HP:0002863 MicroRNA-23a mediates post-transcriptional regulation of CXCL12 in bone marrow stromal cells. target gene hsa-mir-125b Myeloma 25987254 C90.0 D009101 254500 Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo. target gene hsa-mir-125b Myeloma 27903272 C90.0 D009101 254500 BETi-mediated inhibition of cMYC correlates with the upregulation of miR-125b-5p and the downregulation of the cMYC/miR-125b-5p target gene IRF4, a transcriptional repressor of MICA target gene hsa-mir-135b Myeloma 25320245 C90.0 D009101 254500 Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. target gene hsa-mir-15a Myeloma 27596960 C90.0 D009101 254500 MiR-15a/16 regulates the growth of myeloma cells, angiogenesis and antitumor immunity by inhibiting Bcl-2, VEGF-A and IL-17 expression in multiple myeloma. target gene hsa-mir-15a Myeloma 29399181 C90.0 D009101 254500 Downregulation of miRNA-15a and miRNA-16 promote tumor proliferation in multiple myeloma by increasing CABIN1 expression target gene hsa-mir-16 Myeloma 27596960 C90.0 D009101 254500 MiR-15a/16 regulates the growth of myeloma cells, angiogenesis and antitumor immunity by inhibiting Bcl-2, VEGF-A and IL-17 expression in multiple myeloma. target gene hsa-mir-16 Myeloma 29399181 C90.0 D009101 254500 Downregulation of miRNA-15a and miRNA-16 promote tumor proliferation in multiple myeloma by increasing CABIN2 expression target gene hsa-mir-203 Myeloma 27748826 C90.0 D009101 254500 miR-203 inhibits cell growth and regulates G1/S transition by targeting Bmi-1 in myeloma cells. target gene hsa-mir-125a Myeloproliferative Neoplasms 23012470 disease of cellular proliferation DOID:2226 D47.1 616871 we demonstrate that miR-125a targets multiple protein phosphatases. Our data demonstrate that miR-125a-induced MPN is addicted to its sustained overexpression, and highlight the complex nature of oncogenic miRNA dependence in an early neoplastic state. target gene hsa-mir-1 Myocardial Infarction 25995211 cardiovascular system disease DOID:5844 I21 D009203 608557 HP:0001658 These experiments revealed the role of inducible cAMP early repressor as a repressor of miR-1 and Ito target gene hsa-mir-107 Myocardial Infarction 22482882 cardiovascular system disease DOID:5844 I21 D009203 608557 HP:0001658 IPC enhances stem cell survival via the combined participation of hypoxia responsive miRs miR-107 and miR-210 via their respective putative target genes Pdcd10 and Casp8ap2. target gene hsa-mir-149 Myocardial Infarction 23873935 cardiovascular system disease DOID:5844 I21 D009203 608557 HP:0001658 A pre-microRNA-149 (miR-149) genetic variation affects miR-149 maturation and its ability to regulate the Puma protein in apoptosis. target gene hsa-mir-150 Myocardial Infarction 22039399 cardiovascular system disease DOID:5844 I21 D009203 608557 HP:0001658 microRNA-150 regulates mobilization and migration of bone marrow-derived mononuclear cells by targeting Cxcr4. target gene hsa-mir-150 Myocardial Infarction 28597963 cardiovascular system disease DOID:5844 I21 D009203 608557 HP:0001658 miR-181a and miR-150 regulate dendritic cell immune inflammatory responses and cardiomyocyte apoptosis via targeting JAK1-STAT1/c-Fos pathway. target gene hsa-mir-16 Myocardial Infarction 28423616 cardiovascular system disease DOID:5844 I21 D009203 608557 HP:0001658 Suppression of microRNA-16 protects against acute myocardial infarction by reversing beta2-adrenergic receptor down-regulation in rats. target gene hsa-mir-17 Myocardial Infarction 26265044 cardiovascular system disease DOID:5844 I21 D009203 608557 HP:0001658 The delivery of exogenous miR-17 suppressed Apaf-1 expression and consequently attenuated formation of the apoptosome complex containing caspase-9, as demonstrated by co-immunoprecipitation and immunocytochemistry. target gene hsa-mir-181a Myocardial Infarction 28597963 cardiovascular system disease DOID:5844 I21 D009203 608557 HP:0001658 miR-181a and miR-150 regulate dendritic cell immune inflammatory responses and cardiomyocyte apoptosis via targeting JAK1-STAT1/c-Fos pathway. target gene hsa-mir-186 Myocardial Infarction 27205869 cardiovascular system disease DOID:5844 I21 D009203 608557 HP:0001658 MicroRNA-186 promotes macrophage lipid accumulation and pro-inflammatory cytokine secretion by targeting cystathionine 纬-lyase in THP-1 macrophages. target gene hsa-mir-206 Myocardial Infarction 21731608 cardiovascular system disease DOID:5844 I21 D009203 608557 HP:0001658 HMGB1 injected into chronically failing hearts enhanced LV function and attenuated LV remodelling; these effects were associated with cardiac regeneration, increased collagenolytic activity, miR-206 overexpression and miR-206 -mediated inhibition of TIMP-3. target gene hsa-mir-208a Myocardial Infarction 26861724 cardiovascular system disease DOID:5844 I21 D009203 608557 HP:0001658 miR-208a can promote Ang II-induced cardiomyocyte apoptosis via negatively regulating NLK expression target gene hsa-mir-21 Myocardial Infarction 19336275 cardiovascular system disease DOID:5844 I21 D009203 608557 HP:0001658 miR-21: miR-21 can protect this by targeting PDCD4 target gene hsa-mir-21 Myocardial Infarction 28817807 cardiovascular system disease DOID:5844 I21 D009203 608557 HP:0001658 Mir-21 Promotes Cardiac Fibrosis After Myocardial Infarction Via Targeting Smad7. target gene hsa-mir-21 Myocardial Infarction 29674977 cardiovascular system disease DOID:5844 I21 D009203 608557 HP:0001658 the programmed cell death 4 (PDCD4) expression was identified as a target gene of miR-21 target gene hsa-mir-210 Myocardial Infarction 22482882 cardiovascular system disease DOID:5844 I21 D009203 608557 HP:0001658 IPC enhances stem cell survival via the combined participation of hypoxia responsive miRs miR-107 and miR-210 via their respective putative target genes Pdcd10 and Casp8ap2. target gene hsa-let-7 Myocardial Ischemic-Reperfusion Injury 26844226 D015428 After Myocardial Ischemia-Reperfusion, miR-29a, and Let7 Could Affect Apoptosis through Regulating IGF-1. target gene hsa-mir-21 Myocardial Ischemic-Reperfusion Injury 19336275 D015428 miR-21: miR-21 can protect this by targeting PDCD4 target gene hsa-mir-384 Myocardial Ischemic-Reperfusion Injury 23315007 D015428 MicroRNA-384-5p regulates ischemia-induced cardioprotection by targeting phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta (PI3Kp110ж─) target gene hsa-mir-328 Myopia 22447870 nervous system disease DOID:11830 H52.1 D009216 PS160700 MicroRNA-328 may influence myopia development by mediating the PAX6 gene. target gene hsa-mir-148a Myositis Ossificans 22408438 musculoskeletal system disease DOID:668 D009221 ACVR1, a Therapeutic Target of Fibrodysplasia Ossificans Progressiva, Is Negatively Regulated by miR-148a. target gene hsa-mir-103a-1 Myotonic Muscular Dystrophy 17697356 G71.11 D009223 160900 These results support a role for miRNAs in DM1 pathogenesis, and, in particular, highlight mir-107 and mir-103 as attractive candidates for binding to DMPK. target gene hsa-mir-103a-2 Myotonic Muscular Dystrophy 17697356 G71.11 D009223 160900 These results support a role for miRNAs in DM1 pathogenesis, and, in particular, highlight mir-107 and mir-103 as attractive candidates for binding to DMPK. target gene hsa-mir-107 Myotonic Muscular Dystrophy 17697356 G71.11 D009223 160900 These results support a role for miRNAs in DM1 pathogenesis, and, in particular, highlight mir-107 and mir-103 as attractive candidates for binding to DMPK. target gene hsa-mir-135b Myxoid Liposarcoma 27157622 disease of cellular proliferation DOID:5363 C49.9 D018208 613488 HP:0012268 Decreased THBS2 expression by miR-135b increases the total amount of matrix metalloproteinase 2 (MMP2) and influences cellular density and an extracellular matrix structure, thereby resulting in morphological change in tumor. target gene hsa-mir-100 Nasopharyngeal Neoplasms 19739117 C11.9 D009303 607107 HP:0100630 miR-100 can directly target Plk1 target gene hsa-mir-101-1 Nasopharyngeal Neoplasms 21368858 C11.9 D009303 607107 HP:0100630 Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. target gene hsa-mir-101-2 Nasopharyngeal Neoplasms 21368858 C11.9 D009303 607107 HP:0100630 Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. target gene hsa-mir-1-1 Nasopharyngeal Neoplasms 22059741 C11.9 D009303 607107 HP:0100630 MicroRNA-1 induces apoptosis by targeting prothymosin alpha in nasopharyngeal carcinoma cells. target gene hsa-mir-1-2 Nasopharyngeal Neoplasms 22059741 C11.9 D009303 607107 HP:0100630 MicroRNA-1 induces apoptosis by targeting prothymosin alpha in nasopharyngeal carcinoma cells. target gene hsa-mir-138-1 Nasopharyngeal Neoplasms 22739938 C11.9 D009303 607107 HP:0100630 MiR-138 suppressed nasopharyngeal carcinoma growth and tumorigenesis by targeting the CCND1 oncogene. target gene hsa-mir-138-2 Nasopharyngeal Neoplasms 22739938 C11.9 D009303 607107 HP:0100630 MiR-138 suppressed nasopharyngeal carcinoma growth and tumorigenesis by targeting the CCND1 oncogene. target gene hsa-mir-144 Nasopharyngeal Neoplasms 23125220 C11.9 D009303 607107 HP:0100630 MicroRNA-144 promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTEN target gene hsa-mir-205 Nasopharyngeal Neoplasms 22306986 C11.9 D009303 607107 HP:0100630 MiR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN. target gene hsa-mir-205 Nasopharyngeal Neoplasms 22374676 C11.9 D009303 607107 HP:0100630 MiR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN. target gene hsa-mir-214 Nasopharyngeal Neoplasms 23479198 C11.9 D009303 607107 HP:0100630 miR-214 promotes tumorigenesis by targeting lactotransferrin in nasopharyngeal carcinoma target gene hsa-mir-216b Nasopharyngeal Neoplasms 21878506 C11.9 D009303 607107 HP:0100630 miR-216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma. target gene hsa-mir-218-1 Nasopharyngeal Neoplasms 21385904 C11.9 D009303 607107 HP:0100630 miR-218 Suppresses Nasopharyngeal Cancer Progression through Downregulation of Survivin and the SLIT2-ROBO1 Pathway. target gene hsa-mir-218-2 Nasopharyngeal Neoplasms 21385904 C11.9 D009303 607107 HP:0100630 miR-218 Suppresses Nasopharyngeal Cancer Progression through Downregulation of Survivin and the SLIT2-ROBO1 Pathway. target gene hsa-mir-26a-1 Nasopharyngeal Neoplasms 21199804 C11.9 D009303 607107 HP:0100630 MiR-26a Inhibits Cell Growth and Tumorigenesis of Nasopharyngeal Carcinoma through Repression of EZH2 target gene hsa-mir-26a-1 Nasopharyngeal Neoplasms 21368858 C11.9 D009303 607107 HP:0100630 Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. target gene hsa-mir-26a-2 Nasopharyngeal Neoplasms 21199804 C11.9 D009303 607107 HP:0100630 MiR-26a Inhibits Cell Growth and Tumorigenesis of Nasopharyngeal Carcinoma through Repression of EZH2 target gene hsa-mir-26a-2 Nasopharyngeal Neoplasms 21368858 C11.9 D009303 607107 HP:0100630 Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. target gene hsa-mir-663a Nasopharyngeal Neoplasms 22249270 C11.9 D009303 607107 HP:0100630 MiR-663, a microRNA targeting p21(WAF1/CIP1), promotes the proliferation and tumorigenesis of nasopharyngeal carcinoma. target gene hsa-mir-9-1 Nasopharyngeal Neoplasms 23291181 C11.9 D009303 607107 HP:0100630 miR-9 modulates the expression of interferon-regulated genes and MHC class I molecules in human nasopharyngeal carcinoma cells target gene hsa-mir-9-2 Nasopharyngeal Neoplasms 23291181 C11.9 D009303 607107 HP:0100630 miR-9 modulates the expression of interferon-regulated genes and MHC class I molecules in human nasopharyngeal carcinoma cells target gene hsa-mir-98 Nasopharyngeal Neoplasms 21368858 C11.9 D009303 607107 HP:0100630 Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. target gene hsa-let-7a Neoplasms [unspecific] 28057739 C80.1 D009369 the let-7-HMGA2 axis plays a prominent role in the pathogenesis of the disease that leads to unique clinical phenotypes target gene hsa-let-7a-1 Neoplasms [unspecific] 20033209 C80.1 D009369 let-7a:The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice target gene hsa-let-7a-1 Neoplasms [unspecific] 17322030 C80.1 D009369 Disrupting the pairing between let-7 and Hmga2 target gene hsa-let-7a-1 Neoplasms [unspecific] 17989227 C80.1 D009369 let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes target gene hsa-let-7a-1 Neoplasms [unspecific] 18758960 C80.1 D009369 Let-7a: Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3 target gene hsa-let-7a-2 Neoplasms [unspecific] 20033209 C80.1 D009369 let-7a:The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice target gene hsa-let-7a-2 Neoplasms [unspecific] 17322030 C80.1 D009369 Disrupting the pairing between let-7 and Hmga2 target gene hsa-let-7a-2 Neoplasms [unspecific] 17989227 C80.1 D009369 let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes target gene hsa-let-7a-2 Neoplasms [unspecific] 18758960 C80.1 D009369 Let-7a: Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3 target gene hsa-let-7a-3 Neoplasms [unspecific] 20033209 C80.1 D009369 let-7a:The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice target gene hsa-let-7a-3 Neoplasms [unspecific] 17322030 C80.1 D009369 Disrupting the pairing between let-7 and Hmga2 target gene hsa-let-7a-3 Neoplasms [unspecific] 17989227 C80.1 D009369 let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes target gene hsa-let-7a-3 Neoplasms [unspecific] 18758960 C80.1 D009369 Let-7a: Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3 target gene hsa-let-7b Neoplasms [unspecific] 17322030 C80.1 D009369 Disrupting the pairing between let-7 and Hmga2 target gene hsa-let-7b Neoplasms [unspecific] 17989227 C80.1 D009369 let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes target gene hsa-let-7c Neoplasms [unspecific] 17322030 C80.1 D009369 Disrupting the pairing between let-7 and Hmga2 target gene hsa-let-7c Neoplasms [unspecific] 17989227 C80.1 D009369 let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes target gene hsa-let-7c Neoplasms [unspecific] 18006822 C80.1 D009369 In addition to known genes, siRNAs targeting CDK4, PTGS1, ALG2, CLCN3, IRAK4, and MAP3K8 altered TRAIL-induced caspase-3 activation responses. Introduction of the miRNAs let-7c, mir-10a, mir-144, mir-150, mir-155, and mir-193 also affected the activation of the caspase cascade. target gene hsa-let-7d Neoplasms [unspecific] 17322030 C80.1 D009369 Disrupting the pairing between let-7 and Hmga2 target gene hsa-let-7d Neoplasms [unspecific] 17989227 C80.1 D009369 let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes target gene hsa-let-7e Neoplasms [unspecific] 17322030 C80.1 D009369 Disrupting the pairing between let-7 and Hmga2 target gene hsa-let-7e Neoplasms [unspecific] 17989227 C80.1 D009369 let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes target gene hsa-let-7f-1 Neoplasms [unspecific] 17322030 C80.1 D009369 Disrupting the pairing between let-7 and Hmga2 target gene hsa-let-7f-1 Neoplasms [unspecific] 17989227 C80.1 D009369 let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes target gene hsa-let-7f-2 Neoplasms [unspecific] 17322030 C80.1 D009369 Disrupting the pairing between let-7 and Hmga2 target gene hsa-let-7f-2 Neoplasms [unspecific] 17989227 C80.1 D009369 let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes target gene hsa-let-7g Neoplasms [unspecific] 17322030 C80.1 D009369 Disrupting the pairing between let-7 and Hmga2 target gene hsa-let-7g Neoplasms [unspecific] 17989227 C80.1 D009369 let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes target gene hsa-let-7i Neoplasms [unspecific] 17322030 C80.1 D009369 Disrupting the pairing between let-7 and Hmga2 target gene hsa-let-7i Neoplasms [unspecific] 17989227 C80.1 D009369 let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes target gene hsa-let-7i Neoplasms [unspecific] 27770612 C80.1 D009369 Let-7i-Induced Atg4B Suppression Is Essential for Autophagy of Placental Trophoblast in Preeclampsia. target gene hsa-mir-1 Neoplasms [unspecific] 27819721 C80.1 D009369 miR-1 association with cell proliferation inhibition and apoptosis in vestibular schwannoma by targeting VEGFA. target gene hsa-mir-101 Neoplasms [unspecific] 18096665 C80.1 D009369 The most up-regulated miR-196b and its precursors are highly expressed in the skin and showed similar tissue-specific expression patterns after treatment, indicating a common pattern of regulation by E(2). MiR-196b was shown to fine-tune the expression of its target gene Hoxb8a after treatment in whole-body homogenates. target gene hsa-mir-101-1 Neoplasms [unspecific] 20586854 C80.1 D009369 miR-101:Targeting DNA-PKcs and ATM with miR-101 sensitizes tumors to radiation target gene hsa-mir-101-1 Neoplasms [unspecific] 23178713 C80.1 D009369 MicroRNA-101 suppresses SOX9-dependent tumorigenicity and promotes favorable prognosis of human hepatocellular carcinoma target gene hsa-mir-101-2 Neoplasms [unspecific] 20586854 C80.1 D009369 miR-101:Targeting DNA-PKcs and ATM with miR-101 sensitizes tumors to radiation target gene hsa-mir-101-2 Neoplasms [unspecific] 23178713 C80.1 D009369 MicroRNA-101 suppresses SOX9-dependent tumorigenicity and promotes favorable prognosis of human hepatocellular carcinoma target gene hsa-mir-106a Neoplasms [unspecific] 20049626 C80.1 D009369 miR-106:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53 target gene hsa-mir-107 Neoplasms [unspecific] 20308559 C80.1 D009369 Taken together these data suggest that miR-107 can mediate p53 regulation of hypoxic signaling and tumor angiogenesis. target gene hsa-mir-10a Neoplasms [unspecific] 18006822 C80.1 D009369 In addition to known genes, siRNAs targeting CDK4, PTGS1, ALG2, CLCN3, IRAK4, and MAP3K8 altered TRAIL-induced caspase-3 activation responses. Introduction of the miRNAs let-7c, mir-10a, mir-144, mir-150, mir-155, and mir-193 also affected the activation of the caspase cascade. target gene hsa-mir-10b Neoplasms [unspecific] 22915757 C80.1 D009369 MiR-10b downregulates the stress-induced cell surface molecule MICB, a critical ligand for cancer cell recognition by natural killer cells. target gene hsa-mir-10b Neoplasms [unspecific] 25074381 C80.1 D009369 3'LIFE is a rapid and sensitive method to detect miRNA targets in high-throughput target gene hsa-mir-122 Neoplasms [unspecific] 19584290 C80.1 D009369 down-regulated; modulates expression of immunoinhibitory molecule B7-H3;directly target B7-H3 3' untranslated region, and knock-in and knockdown of miR-29a led to down-regulation and up-regulation of B7-H3 protein expression; potential immune based therapy target gene hsa-mir-1248 Neoplasms [unspecific] 24088671 C80.1 D009369 In humans, miR-1248 was found to regulate the expression of mRNAs involved in inflammatory pathways and miR-181a was found to correlate negatively with the pro-inflammatory cytokines IL-6 and TNFα and to correlate positively with the anti-inflammatory cytokines TGFβ and IL-10. target gene hsa-mir-125a Neoplasms [unspecific] 20049626 C80.1 D009369 miR-125:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53 target gene hsa-mir-125a Neoplasms [unspecific] 25725290 C80.1 D009369 our study has demonstrated that Egr1 is able to regulate miRNA activity of miR-125a-3p in human cells through binding TRBP, which highlights an unexpected function of Egr1 in miRNA pathway. target gene hsa-mir-125a Neoplasms [unspecific] 26713860 C80.1 D009369 miR-125a suppressed Zbtb7a expression through its direct binding to the Zbtb7a-3'UTR. target gene hsa-mir-125b Neoplasms [unspecific] 26966351 C80.1 D009369 miR-125b acts as a tumor suppressor in chondrosarcoma cells by the sensitization to doxorubicin through direct targeting the ErbB2-regulated glucose metabolism. target gene hsa-mir-125b Neoplasms [unspecific] 20935678 C80.1 D009369 Thus, beyond miR-125b and miR-504, the human TP53 gene is negatively regulated by two more miRNAs: miR-25 and miR-30d. target gene hsa-mir-126 Neoplasms [unspecific] 24603804 C80.1 D009369 MicroRNA-126 modulates the tumor microenvironment by targeting calmodulin-regulated spectrin-associated protein 1 (Camsap1). target gene hsa-mir-126 Neoplasms [unspecific] 24274104 C80.1 D009369 Prometastatic GPCR CD97 is a direct target of tumor suppressor microRNA-126. target gene hsa-mir-126 Neoplasms [unspecific] 27611944 C80.1 D009369 MicroRNA-126 inhibits tumor proliferation and angiogenesis of hepatocellular carcinoma by down-regulating EGFL7 expression. target gene hsa-mir-127 Neoplasms [unspecific] 26655997 C80.1 D009369 Restoration of miR-127-3p and miR-376a-3p counteracts the neoplastic phenotype of giant cell tumor of bone derived stromal cells by targeting COA1, GLE1 and PDIA6. target gene hsa-mir-127 Neoplasms [unspecific] 17012848 C80.1 D009369 For example, mir-127, which is generally expressed in normal cells but absent in cancer cells, was markedly induced after treatment. Intriguingly, a predicted target of mir-127, BCL6, was translationally downregulated after treatment. target gene hsa-mir-128 Neoplasms [unspecific] 23958464 C80.1 D009369 miR-128 and its target genes in tumorigenesis and metastasis. target gene hsa-mir-128 Neoplasms [unspecific] 29568354 C80.1 D009369 miR-128 inhibits telomerase activity by targeting TERT mRNA target gene hsa-mir-129 Neoplasms [unspecific] 28536635 C80.1 D009369 the regulation of NG2 expression underlies inflammation and hypoxia and is mediated by methyltransferases, transcription factors, including Sp1, paired box (Pax) 3 and Egr-1, and the microRNA miR129-2 target gene hsa-mir-1291 Neoplasms [unspecific] 25934574 C80.1 D009369 Chimeric MicroRNA-1291 Biosynthesized Efficiently in Escherichia coli Is Effective to Reduce Target Gene Expression in Human Carcinoma Cells and Improve Chemosensitivity. target gene hsa-mir-130a Neoplasms [unspecific] 17957028 C80.1 D009369 From these data, we conclude that miR-130a is a regulator of the angiogenic phenotype of vascular ECs largely through its ability to modulate the expression of GAX and HOXA5. target gene hsa-mir-130a Neoplasms [unspecific] 28393235 C80.1 D009369 Epigenetic silencing of miR-130a ameliorates hemangioma by targeting tissue factor pathway inhibitor 2 through FAK/PI3K/Rac1/mdm2 signaling. target gene hsa-mir-130a Neoplasms [unspecific] 28935812 C80.1 D009369 miR-130a Deregulates PTEN and Stimulates Tumor Growth. target gene hsa-mir-135a-1 Neoplasms [unspecific] 23438844 C80.1 D009369 MiR-138 and MiR-135 Directly Target Focal Adhesion Kinase, Inhibit Cell Invasion, and Increase Sensitivity to Chemotherapy in Cancer Cells target gene hsa-mir-135a-2 Neoplasms [unspecific] 23438844 C80.1 D009369 MiR-138 and MiR-135 Directly Target Focal Adhesion Kinase, Inhibit Cell Invasion, and Increase Sensitivity to Chemotherapy in Cancer Cells target gene hsa-mir-137 Neoplasms [unspecific] 23178914 C80.1 D009369 miR-137 restoration sensitizes multidrug-resistant MCF-7/ADM cells to anticancer agents by targeting YB-1 target gene hsa-mir-138-1 Neoplasms [unspecific] 20232393 C80.1 D009369 we demonstrate that miR-138 suppresses TSCC cell migration and invasion by regulating two key genes in the Rho GTPase signaling pathway target gene hsa-mir-138-1 Neoplasms [unspecific] 23438844 C80.1 D009369 MiR-138 and MiR-135 Directly Target Focal Adhesion Kinase, Inhibit Cell Invasion, and Increase Sensitivity to Chemotherapy in Cancer Cells target gene hsa-mir-138-2 Neoplasms [unspecific] 20232393 C80.1 D009369 we demonstrate that miR-138 suppresses TSCC cell migration and invasion by regulating two key genes in the Rho GTPase signaling pathway target gene hsa-mir-138-2 Neoplasms [unspecific] 23438844 C80.1 D009369 MiR-138 and MiR-135 Directly Target Focal Adhesion Kinase, Inhibit Cell Invasion, and Increase Sensitivity to Chemotherapy in Cancer Cells target gene hsa-mir-139 Neoplasms [unspecific] 25833697 C80.1 D009369 miR-139-5p suppresses cancer cell migration and invasion through targeting ZEB1 and ZEB2 in GBM. target gene hsa-mir-141 Neoplasms [unspecific] 24616104 C80.1 D009369 Long non-coding RNA HOTAIR is targeted and regulated by miR-141 in human cancer cells. target gene hsa-mir-141 Neoplasms [unspecific] 25505268 C80.1 D009369 PLK1 inhibition down-regulates BMI1 by upregulating the miRNA-200c/141 cluster, which encodes miR-200c and miR-141, both of which are known to post-transcriptionally downregulate BMI1 expression. target gene hsa-mir-141 Neoplasms [unspecific] 19182522 C80.1 D009369 miR-141: miR-200 family:inhibit the initiating step of metastasis, epithelial-mesenchymal transition (EMT), by maintaining the epithelial phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB2 target gene hsa-mir-142 Neoplasms [unspecific] 26805039 C80.1 D009369 Our observations suggest that miR-142-3p functioned as a tumor suppressor by targeting CDC25C. target gene hsa-mir-143 Neoplasms [unspecific] 23804075 C80.1 D009369 De-targeting by miR-143 decreases unwanted transgene expression in non-tumorigenic cells. target gene hsa-mir-144 Neoplasms [unspecific] 25151965 C80.1 D009369 Transcriptional control of PAX4-regulated miR-144/451 modulates metastasis by suppressing ADAMs expression. target gene hsa-mir-144 Neoplasms [unspecific] 26169798 C80.1 D009369 Our approach provides important insights into miRNAs and their role in regulatory networks. The methodology can be applied to systematically investigate the differences in target genes and pathways of arbitrary miRNA sets. target gene hsa-mir-144 Neoplasms [unspecific] 25907866 C80.1 D009369 MicroRNA-144 suppresses tumorigenesis and tumor progression of astrocytoma by targeting EZH2. target gene hsa-mir-144 Neoplasms [unspecific] 18006822 C80.1 D009369 In addition to known genes, siRNAs targeting CDK4, PTGS1, ALG2, CLCN3, IRAK4, and MAP3K8 altered TRAIL-induced caspase-3 activation responses. Introduction of the miRNAs let-7c, mir-10a, mir-144, mir-150, mir-155, and mir-193 also affected the activation of the caspase cascade. target gene hsa-mir-145 Neoplasms [unspecific] 24845504 C80.1 D009369 Differential expression of speckled POZ protein, SPOP: putative regulation by miR-145. target gene hsa-mir-145 Neoplasms [unspecific] 25124875 C80.1 D009369 MicroRNA-145: a potent tumour suppressor that regulates multiple cellular pathways. target gene hsa-mir-145 Neoplasms [unspecific] 25445287 C80.1 D009369 miR-145 has the ability to regulate DDC mRNA expression and potentially this occurs by recognizing its mRNA as a target. target gene hsa-mir-145 Neoplasms [unspecific] 25069957 C80.1 D009369 Our network propagation based method takes advantage of the network effect of the miRNA perturbation on its target genes. It is a useful approach to infer the perturbed miRNAs and their key target genes associated with the studied biological processes using gene expression data. target gene hsa-mir-145 Neoplasms [unspecific] 23714355 C80.1 D009369 Insulin receptor substrate-1 (IRS1) was identified as a target gene of miR-145, by which miR-145 was able to suppress cell proliferation. target gene hsa-mir-146a Neoplasms [unspecific] 28401709 C80.1 D009369 The role of microRNA-93 regulating angiopoietin2 in the formation of malignant pleural effusion. target gene hsa-mir-146b Neoplasms [unspecific] 24473196 C80.1 D009369 STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-κB to IL-6 signaling axis and STAT3-driven cancer phenotypes. target gene hsa-mir-148a Neoplasms [unspecific] 24084367 C80.1 D009369 MicroRNA-148a (miR-148a) which suppresses tumor growth by directly decreasing DNMT1 expression has been demonstrated as an important role for cancer therapy. The mechanisms for miR-148a in cancer will become potential future researches. target gene hsa-mir-149 Neoplasms [unspecific] 20623644 C80.1 D009369 miR-149:miR-149* induces apoptosis by inhibiting Akt1 and E2F1 in human cancer cells target gene hsa-mir-15 Neoplasms [unspecific] 24704828 C80.1 D009369 c-Myc-mediated repression of miR-15-16 in hypoxia is induced by increased HIF-2α and promotes tumor angiogenesis and metastasis by upregulating FGF2. target gene hsa-mir-15 Neoplasms [unspecific] 20385127 C80.1 D009369 Our data thus imply that miR-15a regulates cell size and proliferation by fine-tuning Dlk1 among others, and further emphasize miR-15a and DLK1 levels to play important roles in growth signaling networks. target gene hsa-mir-150 Neoplasms [unspecific] 20049626 C80.1 D009369 miR-150:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53 target gene hsa-mir-150 Neoplasms [unspecific] 24203759 C80.1 D009369 Microvesicle-delivery miR-150 promotes tumorigenesis by up-regulating VEGF, and the neutralization of miR-150 attenuate tumor development. target gene hsa-mir-150 Neoplasms [unspecific] 18006822 C80.1 D009369 In addition to known genes, siRNAs targeting CDK4, PTGS1, ALG2, CLCN3, IRAK4, and MAP3K8 altered TRAIL-induced caspase-3 activation responses. Introduction of the miRNAs let-7c, mir-10a, mir-144, mir-150, mir-155, and mir-193 also affected the activation of the caspase cascade. target gene hsa-mir-151a Neoplasms [unspecific] 24088671 C80.1 D009369 In humans, miR-1248 was found to regulate the expression of mRNAs involved in inflammatory pathways and miR-181a was found to correlate negatively with the pro-inflammatory cytokines IL-6 and TNFα and to correlate positively with the anti-inflammatory cytokines TGFβ and IL-10. target gene hsa-mir-151a Neoplasms [unspecific] 20445018 C80.1 D009369 miR-151:down-modulating MPL and other targets of miR-28, and of related miR-708 and miR-151, could contribute to MPN pathogenicity target gene hsa-mir-152 Neoplasms [unspecific] 25311946 C80.1 D009369 Mir-152 inhibits cell proliferation and colony formation of CD133(+) liver cancer stem cells by targeting KIT. target gene hsa-mir-152 Neoplasms [unspecific] 25194984 C80.1 D009369 MicroRNA-152 modulates the canonical Wnt pathway activation by targeting DNA methyltransferase 1 in arthritic rat model. target gene hsa-mir-155 Neoplasms [unspecific] 25633840 C80.1 D009369 miR-155 regulates TP53INP1 expression, to induce the epithelial-mesenchymal transition and acquisition of a stem cell phenotype. target gene hsa-mir-155 Neoplasms [unspecific] 24177167 C80.1 D009369 TAp63 regulates oncogenic miR-155 to mediate migration and tumour growth. target gene hsa-mir-155 Neoplasms [unspecific] 18006822 C80.1 D009369 In addition to known genes, siRNAs targeting CDK4, PTGS1, ALG2, CLCN3, IRAK4, and MAP3K8 altered TRAIL-induced caspase-3 activation responses. Introduction of the miRNAs let-7c, mir-10a, mir-144, mir-150, mir-155, and mir-193 also affected the activation of the caspase cascade. target gene hsa-mir-155 Neoplasms [unspecific] 28338203 C80.1 D009369 MiR-155 regulates oral squamous cell carcinoma Tca8113 cell proliferation, cycle, and apoptosis via regulating p27Kip1. target gene hsa-mir-155 Neoplasms [unspecific] 29066622 C80.1 D009369 MicroRNA-155 induction via TNF-α and IFN-γ suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells. target gene hsa-mir-15a Neoplasms [unspecific] 26686086 C80.1 D009369 In vivo inhibition of a PPAR纬-regulated miR-15a/angiopoietin-1 pathway blocked increased angiogenesis and MSC expansion. target gene hsa-mir-15b Neoplasms [unspecific] 20154725 C80.1 D009369 miR-15b:RECK is a target of at least three groups of miRNAs (miR-15b/16, miR-21 and miR-372/373) target gene hsa-mir-16 Neoplasms [unspecific] 23941513 C80.1 D009369 In summary, the present study identifies several novel miR-16 targets and illustrates a novel function of miR-16 targeting MAP7 in modulating proliferation in cancer cells. target gene hsa-mir-16-1 Neoplasms [unspecific] 20049626 C80.1 D009369 miR-16:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53 target gene hsa-mir-16-1 Neoplasms [unspecific] 20154725 C80.1 D009369 miR-16:RECK is a target of at least three groups of miRNAs (miR-15b/16, miR-21 and miR-372/373) target gene hsa-mir-16-2 Neoplasms [unspecific] 20049626 C80.1 D009369 miR-16:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53 target gene hsa-mir-16-2 Neoplasms [unspecific] 20154725 C80.1 D009369 miR-16:RECK is a target of at least three groups of miRNAs (miR-15b/16, miR-21 and miR-372/373) target gene hsa-mir-17 Neoplasms [unspecific] 24194900 C80.1 D009369 MicroRNA-17, 20a regulates the proangiogenic function of tumor-associated macrophages via targeting hypoxia-inducible factor 2α. target gene hsa-mir-17 Neoplasms [unspecific] 20049626 C80.1 D009369 miR-17:miR-16, miR-17, miR-34a-c, and miR-125 served as tumor suppressor miRNAs, while miR-20, miR-106, and miR-150 acted as oncogenic miRNAs target gene hsa-mir-17 Neoplasms [unspecific] 25069957 C80.1 D009369 Our network propagation based method takes advantage of the network effect of the miRNA perturbation on its target genes. It is a useful approach to infer the perturbed miRNAs and their key target genes associated with the studied biological processes using gene expression data. target gene hsa-mir-17 Neoplasms [unspecific] 20851997 C80.1 D009369 miR-17-92 inhibits apoptosis by suppressing Pten via the miR-19 components, our results indicate that this miRNA cluster promotes tumorigenesis by antagonizing both tumor-suppressing mechanisms, apoptosis, and senescence, through the activities of different miRNA components encoded in this cluster target gene hsa-mir-17 Neoplasms [unspecific] 29574928 C80.1 D009369 The role of miR-17/92 family in development and progression of various cancers has been established. The members of this miRNA family have been shown to be over expressed and target various genes within proliferation, metastasis and angiogenesis pathways. target gene hsa-mir-18 Neoplasms [unspecific] 20851997 C80.1 D009369 miR-17-92 inhibits apoptosis by suppressing Pten via the miR-19 components, our results indicate that this miRNA cluster promotes tumorigenesis by antagonizing both tumor-suppressing mechanisms, apoptosis, and senescence, through the activities of different miRNA components encoded in this cluster target gene hsa-mir-18 Neoplasms [unspecific] 29574928 C80.1 D009369 The role of miR-17/92 family in development and progression of various cancers has been established. The members of this miRNA family have been shown to be over expressed and target various genes within proliferation, metastasis and angiogenesis pathways. target gene hsa-mir-181a-1 Neoplasms [unspecific] 23085757 C80.1 D009369 miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer target gene hsa-mir-181a-2 Neoplasms [unspecific] 23085757 C80.1 D009369 miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer target gene hsa-mir-181b Neoplasms [unspecific] 17965831 C80.1 D009369 Many miRNAs are located at chromosomal break points or fragile sites associated with cancer. Indeed miR-29a and miR-29b are associated with the fragile site FRA7H. In addition, miR-29b along with miR-181b may target the oncogene TCL1 in CLL patients [163] target gene hsa-mir-181c Neoplasms [unspecific] 26607087 C80.1 D009369 Transfection with miR-181 mimics can suppress glycolysis in CAFs by inhibiting HK2 expression. target gene hsa-mir-185 Neoplasms [unspecific] 20603620 C80.1 D009369 miRNA-185:MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers target gene hsa-mir-186 Neoplasms [unspecific] 24935378 C80.1 D009369 miR-186 regulates glycolysis through Glut1 during the formation of cancer-associated fibroblasts. target gene hsa-mir-18a Neoplasms [unspecific] 25923049 C80.1 D009369 this probe can be used for cell-specific intracellular miRNA sensing with a confocal microscope. Using miRNA-18a as a target model, the dynamic changes of its expression level inside living cells can be monitored with the proposed method. This method possesses promising applications in the study of miRNA related bioprocesses and biomedicine. target gene hsa-mir-19 Neoplasms [unspecific] 25308476 C80.1 D009369 miR-19, a component of the oncogenic miR-17-92 cluster, targets the DNA-end resection factor CtIP. target gene hsa-mir-190 Neoplasms [unspecific] 24962367 C80.1 D009369 The synergistic regulation of VEGF-mediated angiogenesis through miR-190 and target genes. target gene hsa-mir-191 Neoplasms [unspecific] 25992613 C80.1 D009369 MiR-191 Regulates Primary Human Fibroblast Proliferation and Directly Targets Multiple Oncogenes. target gene hsa-mir-192 Neoplasms [unspecific] 27041221 C80.1 D009369 A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. target gene hsa-mir-193 Neoplasms [unspecific] 18006822 C80.1 D009369 In addition to known genes, siRNAs targeting CDK4, PTGS1, ALG2, CLCN3, IRAK4, and MAP3K8 altered TRAIL-induced caspase-3 activation responses. Introduction of the miRNAs let-7c, mir-10a, mir-144, mir-150, mir-155, and mir-193 also affected the activation of the caspase cascade. target gene hsa-mir-193a Neoplasms [unspecific] 28449010 C80.1 D009369 Excess of a Rassf1-targeting microRNA, miR-193a-3p, perturbs cell division fidelity. target gene hsa-mir-193b Neoplasms [unspecific] 23335975 C80.1 D009369 MicroRNA-193b enhances tumor progression via down regulation of neurofibromin 1 target gene hsa-mir-195 Neoplasms [unspecific] 25047265 C80.1 D009369 Our findings taken together suggest that ZNF367 regulates cancer progression. target gene hsa-mir-196 Neoplasms [unspecific] 26141604 C80.1 D009369 The miR-196 miRNA gene family located within the Hox gene clusters hsa been shown to function during embryogenesis and to be aberrantly expressed in various malignancies target gene hsa-mir-196a Neoplasms [unspecific] 24463357 C80.1 D009369 MiR-196a exerts its oncogenic effect in GBM by inhibiting IκBα both in vitro and in vivo. target gene hsa-mir-196b Neoplasms [unspecific] 18663355 C80.1 D009369 miR-196: MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers target gene hsa-mir-196b Neoplasms [unspecific] 25889892 C80.1 D009369 we identified IGF2BP1 as a direct and functional target of miR-196b and showed that miR-196b overexpression reverses the chemoresistance induced by hypoxia. These results emphasize that the chemoresistance induced by hypoxia is a complex mechanism. target gene hsa-mir-198 Neoplasms [unspecific] 26225959 C80.1 D009369 we have identified that miR-198 inhibited HaCaT cell proliferation by directly targeting CCND2. target gene hsa-mir-199a Neoplasms [unspecific] 24413338 C80.1 D009369 The findings establish critical roles of miR-199a-5p and its downstream targets HIF-1/COX-2 in arsenic-induced tumor growth and angiogenesis. target gene hsa-mir-199a-1 Neoplasms [unspecific] 21189327 C80.1 D009369 microRNAs miR-199a-5p and -3p target the Brm subunit of SWI/SNF to generate a double-negative feedback loop in a variety of human cancers. target gene hsa-mir-199a-1 Neoplasms [unspecific] 23085757 C80.1 D009369 miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer target gene hsa-mir-199a-2 Neoplasms [unspecific] 21189327 C80.1 D009369 microRNAs miR-199a-5p and -3p target the Brm subunit of SWI/SNF to generate a double-negative feedback loop in a variety of human cancers. target gene hsa-mir-199a-2 Neoplasms [unspecific] 23085757 C80.1 D009369 miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer target gene hsa-mir-19a Neoplasms [unspecific] 20851997 C80.1 D009369 miR-17-92 inhibits apoptosis by suppressing Pten via the miR-19 components, our results indicate that this miRNA cluster promotes tumorigenesis by antagonizing both tumor-suppressing mechanisms, apoptosis, and senescence, through the activities of different miRNA components encoded in this cluster target gene hsa-mir-19a Neoplasms [unspecific] 29574928 C80.1 D009369 The role of miR-17/92 family in development and progression of various cancers has been established. The members of this miRNA family have been shown to be over expressed and target various genes within proliferation, metastasis and angiogenesis pathways. target gene hsa-mir-19b Neoplasms [unspecific] 24742936 C80.1 D009369 miR-19b promotes tumor growth and metastasis via targeting TP53. target gene hsa-mir-19b-1 Neoplasms [unspecific] 20851997 C80.1 D009369 miR-17-92 inhibits apoptosis by suppressing Pten via the miR-19 components, our results indicate that this miRNA cluster promotes tumorigenesis by antagonizing both tumor-suppressing mechanisms, apoptosis, and senescence, through the activities of different miRNA components encoded in this cluster target gene hsa-mir-19b-1 Neoplasms [unspecific] 29574928 C80.1 D009369 The role of miR-17/92 family in development and progression of various cancers has been established. The members of this miRNA family have been shown to be over expressed and target various genes within proliferation, metastasis and angiogenesis pathways. target gene hsa-mir-200 Neoplasms [unspecific] 25348003 C80.1 D009369 Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. target gene hsa-mir-200a Neoplasms [unspecific] 19182522 C80.1 D009369 miR-200a: miR-200 family:inhibit the initiating step of metastasis, epithelial-mesenchymal transition (EMT), by maintaining the epithelial phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB2 target gene hsa-mir-200a Neoplasms [unspecific] 28817830 C80.1 D009369 MicroRNA-200a Inhibits Transforming Growth Factor β1-Induced Proximal Tubular Epithelial-Mesenchymal Transition by Targeting β-Catenin. target gene hsa-mir-200b Neoplasms [unspecific] 24174534 C80.1 D009369 miR-200b and cancer/testis antigen CAGE form a feedback loop to regulate the invasion and tumorigenic and angiogenic responses of a cancer cell line to microtubule-targeting drugs. target gene hsa-mir-200b Neoplasms [unspecific] 19182522 C80.1 D009369 miR-200b: miR-200 family:inhibit the initiating step of metastasis, epithelial-mesenchymal transition (EMT), by maintaining the epithelial phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB2 target gene hsa-mir-200c Neoplasms [unspecific] 25505268 C80.1 D009369 PLK1 inhibition down-regulates BMI1 by upregulating the miRNA-200c/141 cluster, which encodes miR-200c and miR-141, both of which are known to post-transcriptionally downregulate BMI2 expression. target gene hsa-mir-200c Neoplasms [unspecific] 26203557 C80.1 D009369 miR-200c dampens cancer cell migration via regulation of protein kinase A subunits. target gene hsa-mir-200c Neoplasms [unspecific] 19182522 C80.1 D009369 miR-200c: miR-200 family:inhibit the initiating step of metastasis, epithelial-mesenchymal transition (EMT), by maintaining the epithelial phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB2 target gene hsa-mir-200c Neoplasms [unspecific] 19665999 C80.1 D009369 inhibits through down-regulating LRP1 target gene hsa-mir-200c Neoplasms [unspecific] 24368337 C80.1 D009369 The proto-oncogene KRAS is targeted by miR-200c. target gene hsa-mir-200c Neoplasms [unspecific] 28029649 C80.1 D009369 MiR-200c is a cMyc-activated miRNA that promotes nasopharyngeal carcinoma by downregulating PTEN. target gene hsa-mir-200b Neoplasms [unspecific] 26079153 C80.1 D009369 Our results demonstrate that the p53 target miR-200b/200c/429 miRNAs are negative regulators of the CRKL oncogene. target gene hsa-mir-200c Neoplasms [unspecific] 26079153 C80.1 D009369 Our results demonstrate that the p53 target miR-200b/200c/429 miRNAs are negative regulators of the CRKL oncogene. target gene hsa-mir-429 Neoplasms [unspecific] 26079153 C80.1 D009369 Our results demonstrate that the p53 target miR-200b/200c/429 miRNAs are negative regulators of the CRKL oncogene. target gene hsa-mir-203 Neoplasms [unspecific] 23968727 C80.1 D009369 Hyper-methylated miR-203 dysregulates ABL1 and contributes to the nickel-induced tumorigenesis. target gene hsa-mir-204 Neoplasms [unspecific] 25342468 C80.1 D009369 Transformer 2β and miR-204 regulate apoptosis through competitive binding to 3' UTR of BCL2 mRNA. target gene hsa-mir-205 Neoplasms [unspecific] 25973003 C80.1 D009369 These results indicate that miR-205 might inhibitor the proliferation of A549 cells by regulating the expression of PTEN. target gene hsa-mir-205 Neoplasms [unspecific] 24911147 C80.1 D009369 MicroRNA-205 signaling regulates mammary stem cell fate and tumorigenesis. target gene hsa-mir-205 Neoplasms [unspecific] 23487795 C80.1 D009369 Arf tumor suppressor and miR-205 regulate cell adhesion and formation of extraembryonic endoderm from pluripotent stem cells target gene hsa-mir-205 Neoplasms [unspecific] 26586569 C80.1 D009369 miR-205 is upregulated upon NF-魏B activation and suppresses COMMD1 expression in stemness-enriched cancer cells. target gene hsa-mir-205 Neoplasms [unspecific] 26831618 C80.1 D009369 This alteration inverts relative expression levels of ZEB1 and its antagonizing microRNAs, miR-205 and miR-200c target gene hsa-mir-206 Neoplasms [unspecific] 19723635 C80.1 D009369 inhibits Notch3 target gene hsa-mir-206 Neoplasms [unspecific] 26325180 C80.1 D009369 Taken together, our results demonstrated that miR-206 suppressed c-Met and Bcl2 expression in NSCLS and could function as a potent tumor suppressor in c-Met/Bcl2-over expressing tumors. Inhibition of miR-206 function could contribute to aberrant cell proliferation, migration, invasion and apoptosis,leading to NSCLS development. target gene hsa-mir-20a Neoplasms [unspecific] 24194900 C80.1 D009369 MicroRNA-17, 20a regulates the proangiogenic function of tumor-associated macrophages via targeting hypoxia-inducible factor 2α. target gene hsa-mir-20a Neoplasms [unspecific] 20049626 C80.1 D009369 miR-20:miR-16, miR-17, miR-34a-c, and miR-125 served as tumor suppressor miRNAs, while miR-20, miR-106, and miR-150 acted as oncogenic miRNAs target gene hsa-mir-20a Neoplasms [unspecific] 20851997 C80.1 D009369 miR-17-92 inhibits apoptosis by suppressing Pten via the miR-19 components, our results indicate that this miRNA cluster promotes tumorigenesis by antagonizing both tumor-suppressing mechanisms, apoptosis, and senescence, through the activities of different miRNA components encoded in this cluster target gene hsa-mir-20a Neoplasms [unspecific] 29574928 C80.1 D009369 The role of miR-17/92 family in development and progression of various cancers has been established. The members of this miRNA family have been shown to be over expressed and target various genes within proliferation, metastasis and angiogenesis pathways. target gene hsa-mir-21 Neoplasms [unspecific] 25242444 C80.1 D009369 By regulating the expression of its target gene PTEN, which subsequently affects the PI3K/AKT signalling pathway, miR-21 exerts its regulatory role on the radiation sensitivity of K562 cells. These results may help to provide the basis for microRNA-based targeted therapies to overcome radiation resistance in tumour cells. target gene hsa-mir-21 Neoplasms [unspecific] 26082192 C80.1 D009369 we describe the ever-expanding role of miR-21 and its target genes in different cancers, and provide insight into how this oncogenic miRNA regulates cancer cell proliferation, migration, and apoptosis by suppressing the expression of tumor suppressors. target gene hsa-mir-21 Neoplasms [unspecific] 26194786 C80.1 D009369 the miRNA-21 target is cyclically reused, and many MB-DNA fuel strands are attached to the sensor surface, leading to a significantly amplified current response for sensitive detection of miRNA-21 down to 1.4 fM. The developed sensor also shows high sequence discrimination capability and can be used to monitor miRNA-21 expression levels in cancer cells. Moreover, this sensor avoids the involvement of any enzymes for target recycling amplification and features with highly minimized background noise for miRNA detection, which makes this method hold great potential for convenient monitoring of different miRNA biomarkers for early diagnosis of various cancers. target gene hsa-mir-21 Neoplasms [unspecific] 20154725 C80.1 D009369 miR-21:RECK is a target of at least three groups of miRNAs (miR-15b/16, miR-21 and miR-372/373) target gene hsa-mir-21 Neoplasms [unspecific] 21328460 C80.1 D009369 miR-21 downregulates the tumor suppressor P12(CDK2AP1) and Stimulates Cell Proliferation and Invasion. target gene hsa-mir-21 Neoplasms [unspecific] 23940701 C80.1 D009369 The curcumin analog EF24 targets NF-κB and miRNA-21, and has potent anticancer activity in vitro and in vivo. aca-mir-146a target gene hsa-mir-21 Neoplasms [unspecific] 23890123 C80.1 D009369 MicroRNA-21 plays a significant role in cancer growth by regulating stemness in cancer cells. target gene hsa-mir-21 Neoplasms [unspecific] 23872064 C80.1 D009369 miR-21 coordinates tumor growth and modulates KRIT1 levels. target gene hsa-mir-21 Neoplasms [unspecific] 25589783 C80.1 D009369 the oncogenic miRNA miR-21 decreases the expression of FBXO11, which normally acts as a tumor suppressor, and thereby promotesz tumorigenesis. target gene hsa-mir-21 Neoplasms [unspecific] 25997617 C80.1 D009369 Our results suggest that miR-21 may regulate intestinal epithelial tight junction permeability through PTEN/PI3K/Akt signalling pathway. This promotes the feasibility of targeting miR-21 in the clinical to preserve the intestinal barrier. target gene hsa-mir-21 Neoplasms [unspecific] 18372920 C80.1 D009369 The demonstration that miR-21 promotes cell transformation supports the concept that mir-21 functions as an oncogene by a mechanism that involves translational repression of the tumor suppressor Pdcd4. target gene hsa-mir-21 Neoplasms [unspecific] 28571917 C80.1 D009369 Targeting miR-21 with Sophocarpine Inhibits Tumor Progression and Reverses Epithelial-Mesenchymal Transition in Head and Neck Cancer. target gene hsa-mir-211 Neoplasms [unspecific] 23934065 C80.1 D009369 Transcription factor/microRNA axis blocks melanoma invasion program by miR-211 targeting NUAK1. target gene hsa-mir-216 Neoplasms [unspecific] 24384842 C80.1 D009369 miR-126 functions as a tumor suppressor in osteosarcoma by targeting Sox2. target gene hsa-mir-22 Neoplasms [unspecific] 25627978 C80.1 D009369 a central role of miR-22 in the physiologic regulation of MDC1-dependent DDR and suggest a molecular mechanism for how aberrant Akt1 activation and senescence lead to increased genomic instability, fostering an environment that promotes tumorigenesis. target gene hsa-mir-22 Neoplasms [unspecific] 20562918 C80.1 D009369 miR-22:miR-22 acts as a tumor suppressor through direct repression of MYCBP expression and subsequent reduction of oncogenic c-Myc activities. target gene hsa-mir-221 Neoplasms [unspecific] 24969479 C80.1 D009369 Expression patterns of miR-221 and its target Caspase-3 in different cancer cell lines. target gene hsa-mir-24-1 Neoplasms [unspecific] 23418360 C80.1 D009369 MicroRNA miR-24 Enhances Tumor Invasion and Metastasis by Targeting PTPN9 and PTPRF to Promote EGF Signaling target gene hsa-mir-24-2 Neoplasms [unspecific] 23418360 C80.1 D009369 MicroRNA miR-24 Enhances Tumor Invasion and Metastasis by Targeting PTPN9 and PTPRF to Promote EGF Signaling target gene hsa-mir-25 Neoplasms [unspecific] 20935678 C80.1 D009369 Thus, beyond miR-125b and miR-504, the human TP53 gene is negatively regulated by two more miRNAs: miR-25 and miR-30d. target gene hsa-mir-25 Neoplasms [unspecific] 28920955 C80.1 D009369 miR-25/93 mediates hypoxia-induced immunosuppression by repressing cGAS. target gene hsa-mir-26 Neoplasms [unspecific] 25069957 C80.1 D009369 Our network propagation based method takes advantage of the network effect of the miRNA perturbation on its target genes. It is a useful approach to infer the perturbed miRNAs and their key target genes associated with the studied biological processes using gene expression data. target gene hsa-mir-26a Neoplasms [unspecific] 24056962 C80.1 D009369 miR-26a enhances miRNA biogenesis by targeting Lin28B and Zcchc11 to suppress tumor growth and metastasis. target gene hsa-mir-26a Neoplasms [unspecific] 27613140 C80.1 D009369 MiR-26a inhibits proliferation and migration of HaCaT keratinocytes through regulating PTEN expression. target gene hsa-mir-26a Neoplasms [unspecific] 28126920 C80.1 D009369 Sustained expression of miR-26a promotes chromosomal instability and tumorigenesis through regulation of CHFR. target gene hsa-mir-27a Neoplasms [unspecific] 26687066 C80.1 D009369 Importantly, we find that Six1 expression leads to marked resistance to therapies targeting the p53-MDM2 interaction. Thus, we identify a competitive mechanism of p53 regulation, which may have consequences for drugs aimed at reinstating p53 function in tumours. target gene hsa-mir-27a Neoplasms [unspecific] 18619946 C80.1 D009369 miR-27a: miR-27a and miR-451 regulate expression of MDR1/P-glycoprotein target gene hsa-mir-28 Neoplasms [unspecific] 20445018 C80.1 D009369 miR-28:down-modulating MPL and other targets of miR-28, and of related miR-708 and miR-151, could contribute to MPN pathogenicity target gene hsa-mir-28 Neoplasms [unspecific] 24491803 C80.1 D009369 miR-28-5p promotes chromosomal instability in VHL-associated cancers by inhibiting Mad2 translation. target gene hsa-mir-29 Neoplasms [unspecific] 26470025 C80.1 D009369 MiR-29 restrained K562 cell growth and proliferation. MiR-29 induced K562 cell apoptosis through down-regulating FoxM1. target gene hsa-mir-299 Neoplasms [unspecific] 28426762 C80.1 D009369 Human microRNA-299-3p decreases invasive behavior of cancer cells by downregulation of Oct4 expression and causes apoptosis. target gene hsa-mir-29a Neoplasms [unspecific] 17965831 C80.1 D009369 Many miRNAs are located at chromosomal break points or fragile sites associated with cancer. Indeed miR-29a and miR-29b are associated with the fragile site FRA7H. In addition, miR-29b along with miR-181b may target the oncogene TCL1 in CLL patients [163], while miR-29b reduced Mcl-1 protein and rendered cholangiocarcinoma cells more susceptible to apoptosis. target gene hsa-mir-29a Neoplasms [unspecific] 19079265 C80.1 D009369 miR-29a: miR-29 directly suppress p85 alpha and CDC42, both of which negatively regulate p53 target gene hsa-mir-29b Neoplasms [unspecific] 25422179 C80.1 D009369 Our review highlights the diverse relationships between miR-29b and its target genes in malignant tumors. target gene hsa-mir-29b-1 Neoplasms [unspecific] 17965831 C80.1 D009369 Many miRNAs are located at chromosomal break points or fragile sites associated with cancer. Indeed miR-29a and miR-29b are associated with the fragile site FRA7H. In addition, miR-29b along with miR-181b may target the oncogene TCL1 in CLL patients [163], while miR-29b reduced Mcl-1 protein and rendered cholangiocarcinoma cells more susceptible to apoptosis. target gene hsa-mir-29b-2 Neoplasms [unspecific] 17965831 C80.1 D009369 Many miRNAs are located at chromosomal break points or fragile sites associated with cancer. Indeed miR-29a and miR-29b are associated with the fragile site FRA7H. In addition, miR-29b along with miR-181b may target the oncogene TCL1 in CLL patients [163] target gene hsa-mir-29a Neoplasms [unspecific] 26096783 C80.1 D009369 Tumour-suppressive microRNA-29s directly regulate LOXL2 expression and inhibit cancer cell migration and invasion in renal cell carcinoma. target gene hsa-mir-29b Neoplasms [unspecific] 26096783 C80.1 D009369 Tumour-suppressive microRNA-29s directly regulate LOXL2 expression and inhibit cancer cell migration and invasion in renal cell carcinoma. target gene hsa-mir-29c Neoplasms [unspecific] 26096783 C80.1 D009369 Tumour-suppressive microRNA-29s directly regulate LOXL2 expression and inhibit cancer cell migration and invasion in renal cell carcinoma. target gene hsa-mir-30 Neoplasms [unspecific] 24599134 C80.1 D009369 miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway. target gene hsa-mir-302 Neoplasms [unspecific] 27756792 C80.1 D009369 A MicroRNA302-367-Erk1/2-Klf2-S1pr1 Pathway Prevents Tumor Growth via Restricting Angiogenesis and Improving Vascular Stability. target gene hsa-mir-30a Neoplasms [unspecific] 26473838 C80.1 D009369 In summary, we uncovered the protective function of miR30a targeting NFATc3 in the regulation of podocyte injury response to EMT. target gene hsa-mir-30b Neoplasms [unspecific] 24898602 C80.1 D009369 Of the upregulated miRNAs, miR-30b expression demonstrated the greatest increase. The administration of miR-30b ASO for two weeks significantly reduced 伪-SMA excretion and upregulated E-cadherin and BMP-7 expression. target gene hsa-mir-30d Neoplasms [unspecific] 23085757 C80.1 D009369 miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer target gene hsa-mir-30d Neoplasms [unspecific] 20935678 C80.1 D009369 Thus, beyond miR-125b and miR-504, the human TP53 gene is negatively regulated by two more miRNAs: miR-25 and miR-30d. target gene hsa-mir-30e Neoplasms [unspecific] 19223510 C80.1 D009369 miR-30e: directly targets Ubc9 target gene hsa-mir-31 Neoplasms [unspecific] 23539435 C80.1 D009369 MicroRNA-31-5p modulates cell cycle by targeting human mutL homolog 1 in human cancer cells target gene hsa-mir-31 Neoplasms [unspecific] 23999990 C80.1 D009369 The diverse role of miR-31 in regulating cancer associated phenotypes. target gene hsa-mir-31 Neoplasms [unspecific] 26663584 C80.1 D009369 We identified VAV3, a regulator of actin remodeling and MRTF-A activity, as a miR-31 target. target gene hsa-mir-32 Neoplasms [unspecific] 26394836 C80.1 D009369 SETD1A modulates cell cycle progression through a miRNA network that regulates p53 target genes target gene hsa-mir-326 Neoplasms [unspecific] 25138213 C80.1 D009369 miR-326-histone deacetylase-3 feedback loop regulates the invasion and tumorigenic and angiogenic response to anti-cancer drugs. target gene hsa-mir-326 Neoplasms [unspecific] 25760058 C80.1 D009369 MicroRNA-326 functions as a tumor suppressor in colorectal cancer by targeting the nin one binding protein. target gene hsa-mir-326 Neoplasms [unspecific] 27960279 C80.1 D009369 Resveratrol Induces Cancer Cell Apoptosis through MiR-326/PKM2-Mediated ER Stress and Mitochondrial Fission. target gene hsa-mir-331 Neoplasms [unspecific] 19584269 C80.1 D009369 miR-331-3p; a c/EBPalpha target,; Inhibits metastatic tumor antigen 1 target gene hsa-mir-335 Neoplasms [unspecific] 24223803 C80.1 D009369 Metastasis suppressor microRNA-335 targets the formin family of actin nucleators. target gene hsa-mir-335 Neoplasms [unspecific] 25997740 C80.1 D009369 miR-335 Targets SIAH2 and Confers Sensitivity to Anti-Cancer Drugs by Increasing the Expression of HDAC3. target gene hsa-mir-335 Neoplasms [unspecific] 26204513 C80.1 D009369 Our data suggest that differences in response to miR-335 by tumor cells may lie in part in the mechanism of regulation of MT1-MMP production. target gene hsa-mir-34 Neoplasms [unspecific] 19221490 C80.1 D009369 Based on this observation, we propose a positive feedback loop, in which p53 induces expression of miR-34a which suppresses SIRT1, increasing p53 activity. target gene hsa-mir-34a Neoplasms [unspecific] 20351093 C80.1 D009369 miR-34a:MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells target gene hsa-mir-34a Neoplasms [unspecific] 20049626 C80.1 D009369 miR-34a:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53 target gene hsa-mir-34a Neoplasms [unspecific] 23361983 C80.1 D009369 Modeling miRNA Regulation in Cancer Signaling Systems: miR-34a Regulation of the p53/Sirt1 Signaling Module target gene hsa-mir-34a Neoplasms [unspecific] 23533633 C80.1 D009369 CD24 Induces Expression of the Oncomir miR-21 via Src, and CD24 and Src Are Both Post-Transcriptionally Downregulated by the Tumor Suppressor miR-34a target gene hsa-mir-34a Neoplasms [unspecific] 24185900 C80.1 D009369 SNAIL and miR-34a feed-forward regulation of ZNF281/ZBP99 promotes epithelial-mesenchymal transition. target gene hsa-mir-34a Neoplasms [unspecific] 23860128 C80.1 D009369 A miR-34a-SIRT6 axis in the squamous cell differentiation network. target gene hsa-mir-34a Neoplasms [unspecific] 24970682 C80.1 D009369 Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1α/Nrf2 pathway,leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents. target gene hsa-mir-34a Neoplasms [unspecific] 18755897 C80.1 D009369 Finally, miR-34a itself is a transcriptional target of p53, suggesting a positive feedback loop between p53 and miR-34a. Thus, miR-34a functions as a tumor suppressor, in part, through a SIRT1-p53 pathway. target gene hsa-mir-34a Neoplasms [unspecific] 29285066 C80.1 D009369 miR-34a may serve an important role in hyperthermia-regulated apoptosis and proliferation in HCT116 cells by influencing the transcriptional activity of p53 target gene hsa-mir-34b Neoplasms [unspecific] 20049626 C80.1 D009369 miR-34c:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53 target gene hsa-mir-34c Neoplasms [unspecific] 20049626 C80.1 D009369 miR-34c:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53 target gene hsa-mir-34c Neoplasms [unspecific] 28125315 C80.1 D009369 miRNA-34c inhibits myoblasts proliferation by targeting YY1. target gene hsa-mir-372 Neoplasms [unspecific] 17989227 C80.1 D009369 the related miR-372/373 miRNAs promote tumorigenesis in combination with oncogenic RAS, at least in part by directly inhibiting the tumor suppressor LATS2. target gene hsa-mir-372 Neoplasms [unspecific] 20154725 C80.1 D009369 miR-372:RECK is a target of at least three groups of miRNAs (miR-15b/16, miR-21 and miR-372/373) target gene hsa-mir-373 Neoplasms [unspecific] 17989227 C80.1 D009369 the related miR-372/373 miRNAs promote tumorigenesis in combination with oncogenic RAS, at least in part by directly inhibiting the tumor suppressor LATS2. target gene hsa-mir-373 Neoplasms [unspecific] 20154725 C80.1 D009369 miR-373:RECK is a target of at least three groups of miRNAs (miR-15b/16, miR-21 and miR-372/373) target gene hsa-mir-376a Neoplasms [unspecific] 26655997 C80.1 D009369 Restoration of miR-127-3p and miR-376a-3p counteracts the neoplastic phenotype of giant cell tumor of bone derived stromal cells by targeting COA1, GLE1 and PDIA6. target gene hsa-mir-378 Neoplasms [unspecific] 18077375 C80.1 D009369 Our results suggest that miR-378 transfection enhanced cell survival, tumor growth, and angiogenesis through repression of the expression of two tumor suppressors, Sufu and Fus-1. target gene hsa-mir-378g Neoplasms [unspecific] 26473472 C80.1 D009369 MiR-378g enhanced radiosensitivity partially by targeting SHP-1 in NPC cells. Cell invasion was also partially inhibited by miR-378g, but the effect was not mediated by SHP-1. target gene hsa-mir-382 Neoplasms [unspecific] 24914051 C80.1 D009369 miR-382 induced by hypoxia promotes angiogenesis and acts as an angiogenic oncogene by repressing PTEN. target gene hsa-mir-383 Neoplasms [unspecific] 25415264 C80.1 D009369 miR-383 can specifically regulates the expression of Gadd45g by directly targeting to the 3-UTR region of Gadd45g mRNA, a regulatory process conserved in human tumor cells and mouse embryonic stem cells. These two compotents can be potentially used as antineoplastic agents in cancer chemotherapy. target gene hsa-mir-384 Neoplasms [unspecific] 24827165 C80.1 D009369 MicroRNA-384 regulates both amyloid precursor protein and β-secretase expression and is a potential biomarker for Alzheimer's disease. target gene hsa-mir-429 Neoplasms [unspecific] 19182522 C80.1 D009369 miR-429: miR-200 family:inhibit the initiating step of metastasis, epithelial-mesenchymal transition (EMT), by maintaining the epithelial phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB2 target gene hsa-mir-449a Neoplasms [unspecific] 19833767 C80.1 D009369 Our study reveals a tumor suppressor function of miR-449a/b through regulating Rb/E2F1 activity, and suggests that escape from this regulation through an aberrant epigenetic event contributes to E2F1 deregulation and unrestricted proliferation in human cancer. target gene hsa-mir-449b Neoplasms [unspecific] 19833767 C80.1 D009369 Our study reveals a tumor suppressor function of miR-449a/b through regulating Rb/E2F1 activity, and suggests that escape from this regulation through an aberrant epigenetic event contributes to E2F1 deregulation and unrestricted proliferation in human cancer. target gene hsa-mir-451 Neoplasms [unspecific] 25151965 C80.1 D009369 Transcriptional control of PAX4-regulated miR-144/451 modulates metastasis by suppressing ADAMs expression. target gene hsa-mir-451 Neoplasms [unspecific] 24445140 C80.1 D009369 MicroRNA-451 suppresses tumor cell growth by down-regulating IL6R gene expression. target gene hsa-mir-451a Neoplasms [unspecific] 18619946 C80.1 D009369 miR-451: miR-27a and miR-451 regulate expression of MDR1/P-glycoprotein target gene hsa-mir-4732 Neoplasms [unspecific] 23886136 C80.1 D009369 From our findings we propose designing further studies focused on overexpression of miRNA-4732-5p and introducing different mutations in the overlapping region of wrap53 and p53 genes in order to study their effects on p53 and its δN isoform (δ40p53) expression. The results may provide new pieces in the p53 targeting puzzle for cancer therapy. target gene hsa-mir-494 Neoplasms [unspecific] 26686085 C80.1 D009369 the regulatory effect of p100 on PTEN expression is mediated by its downregulation of miR-494 as a result of the inactivation of extracellular signal-regulated kinase 2 target gene hsa-mir-503 Neoplasms [unspecific] 25653011 C80.1 D009369 miR-503 represses human cell proliferation and directly targets the oncogene DDHD2 by non-canonical target pairing. target gene hsa-mir-504 Neoplasms [unspecific] 20935678 C80.1 D009369 Thus, beyond miR-125b and miR-504, the human TP53 gene is negatively regulated by two more miRNAs: miR-25 and miR-30d. target gene hsa-mir-509 Neoplasms [unspecific] 24802056 C80.1 D009369 Inhibition of cell proliferation and migration by miR-509-3p that targets CDK2, Rac1, and PIK3C2A. target gene hsa-mir-509 Neoplasms [unspecific] 25144722 C80.1 D009369 Mir-509-5p joins the Mdm2/p53 feedback loop and regulates cancer cell growth. target gene hsa-mir-520f Neoplasms [unspecific] 28209612 C80.1 D009369 miRNA-520f Reverses Epithelial-to-Mesenchymal Transition by Targeting ADAM9 and TGFBR2. target gene hsa-mir-526a Neoplasms [unspecific] 26002288 C80.1 D009369 miR-526a regulates apoptotic cell growth in human carcinoma cells. target gene hsa-mir-542 Neoplasms [unspecific] 21860426 C80.1 D009369 downregulation of miR-542-3p is significantly correlated with the upregulation of c-Src and ILK. Our results suggest that the novel c-Src-miR-542-3p-ILK-FAK circuit plays a crucial role in controlling tumor progression. target gene hsa-mir-590 Neoplasms [unspecific] 26394836 C80.1 D009369 SETD1A modulates cell cycle progression through a miRNA network that regulates p53 target genes target gene hsa-mir-620 Neoplasms [unspecific] 26068950 C80.1 D009369 miR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD). target gene hsa-mir-638 Neoplasms [unspecific] 25088422 C80.1 D009369 Characterization of dual PTEN and p53-targeting microRNAs identifies microRNA-638/Dnm2 as a two-hit oncogenic locus. target gene hsa-mir-7 Neoplasms [unspecific] 25181544 C80.1 D009369 MiR-7 promotes epithelial cell transformation by targeting the tumor suppressor KLF4. target gene hsa-mir-708 Neoplasms [unspecific] 20445018 C80.1 D009369 miR-708:down-modulating MPL and other targets of miR-28, and of related miR-708 and miR-151, could contribute to MPN pathogenicity target gene hsa-mir-9 Neoplasms [unspecific] 26091714 C80.1 D009369 our findings have identified a critical role of miR-9 in regulating the differentiation and function of Myeloid-derived suppressor cells (MDSCs). target gene hsa-mir-92-1 Neoplasms [unspecific] 20851997 C80.1 D009369 miR-17-92 inhibits apoptosis by suppressing Pten via the miR-19 components, our results indicate that this miRNA cluster promotes tumorigenesis by antagonizing both tumor-suppressing mechanisms, apoptosis, and senescence, through the activities of different miRNA components encoded in this cluster target gene hsa-mir-92-1 Neoplasms [unspecific] 29574928 C80.1 D009369 The role of miR-17/92 family in development and progression of various cancers has been established. The members of this miRNA family have been shown to be over expressed and target various genes within proliferation, metastasis and angiogenesis pathways. target gene hsa-mir-92a Neoplasms [unspecific] 26062558 C80.1 D009369 An In Vivo Method to Identify microRNA Targets Not Predicted by Computation Algorithms: p21 Targeting by miR-92a in Cancer. target gene hsa-mir-92a Neoplasms [unspecific] 23820254 C80.1 D009369 The STAT3-induced miR-92a promotes cancer invasion by suppressing RECK and targeting of the STAT3/miR-92a axis may be helpful for cancer treatment. target gene hsa-mir-92a Neoplasms [unspecific] 24394541 C80.1 D009369 miR-92a family and their target genes in tumorigenesis and metastasis. target gene hsa-mir-93 Neoplasms [unspecific] 28401709 C80.1 D009369 The role of microRNA-93 regulating angiopoietin2 in the formation of malignant pleural effusion. target gene hsa-mir-98 Neoplasms [unspecific] 23211491 C80.1 D009369 MicroRNA miR-98 inhibits tumor angiogenesis and invasion by targeting activin receptor-like kinase-4 and matrix metalloproteinase-11 target gene hsa-mir-99 Neoplasms [unspecific] 26608597 C80.1 D009369 We have developed an efficient SVM-based model for miRNA target prediction using recent CLIP-seq data, demonstrating superior performance, evaluated using ROC curves, specifically about 20 % better than the state-of-the-art, for different species (human or mouse), or different target types (canonical or non-canonical). To the best of our knowledge we provide the first distributed framework for microRNA target prediction based on Apache Hadoop and Spark. target gene hsa-mir-155 Nephrolithiasis 25197634 urinary system disease DOID:585 N20.0 D053040 167030 Serum and urinary levels of miR-155 were significantly elevated in patients with nephrolithiasis, and the upregulation of miR-155 was correlated with decline of eGFR and elevation of CRP. Our results suggested that miR-155 might play important roles in the pathophysiology of nephrolithiasis via regulating inflammatory cytokines expression. Further study on the molecular pathogenic mechanism and larger scale of clinical trial are required. target gene hsa-mir-503 Nephrotic Syndrome 26882816 urinary system disease DOID:1184 N04 D009404 PS256300 HP:0000100 In this study, we determined that serum miR-503 was significantly decreased in NS children. MiR-503 contributes to the aberrant proliferation of RMCs by targeting cyclin E, which may represent potential diagnostic and prognostic biomarkers for idiopathic pediatric NS. target gene hsa-let-7b Nervous System Diseases [unspecific] 28436683 C72.9 D009422 Dexmedetomidine Protects PC12 Cells from Lidocaine-Induced Cytotoxicity Through Downregulation of COL3A1 Mediated by miR-let-7b. target gene hsa-mir-204 Nervous System Diseases [unspecific] 22718995 C72.9 D009422 MicroRNA-204 critically regulates carcinogenesis in malignant peripheral nerve sheath tumors. target gene hsa-mir-210 Nervous System Diseases [unspecific] 24577088 C72.9 D009422 The gain-of-function and loss-of-dysfunction assays revealed that miR-210 mediated the ISCU1/2 suppression, energy metabolism alterations, and ISC-containing metabolic enzyme inactivation after nickel exposure. target gene hsa-mir-29b-1 Nervous System Diseases [unspecific] 22932723 C72.9 D009422 Exosome-mediated shuttling of microRNA-29b regulates HIV Tat and morphine-mediated Neuronal dysfunction. target gene hsa-mir-29b-2 Nervous System Diseases [unspecific] 22932723 C72.9 D009422 Exosome-mediated shuttling of microRNA-29b regulates HIV Tat and morphine-mediated Neuronal dysfunction. target gene hsa-mir-29a Neurilemmoma 29023945 disease of cellular proliferation DOID:3192 D36.10 D009442 MicroRNA-29a inhibits proliferation and motility of schwannoma cells by targeting CDK6. target gene hsa-mir-29c Neurilemmoma 29023945 disease of cellular proliferation DOID:3192 D36.10 D009442 MicroRNA-29a inhibits proliferation and motility of schwannoma cells by targeting CDK6. target gene hsa-mir-10a Neuroblastoma 21212796 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 MicroRNAs 10a and 10b are potent inducers of neuroblastoma cell differentiation through targeting of nuclear receptor corepressor 2. target gene hsa-mir-10a Neuroblastoma 21118818 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 MicroRNAs-10a and -10b contribute to retinoic acid-induced differentiation of neuroblastoma cells and target the alternative splicing regulatory factor SFRS1 target gene hsa-mir-10b Neuroblastoma 21212796 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 MicroRNAs 10a and 10b are potent inducers of neuroblastoma cell differentiation through targeting of nuclear receptor corepressor 2. target gene hsa-mir-128-1 Neuroblastoma 21143953 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 Overexpression of miR-128 specifically inhibits the truncated isoform of NTRK3 and upregulates BCL2 in SH-SY5Y neuroblastoma cells. target gene hsa-mir-128-2 Neuroblastoma 21143953 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 Overexpression of miR-128 specifically inhibits the truncated isoform of NTRK3 and upregulates BCL2 in SH-SY5Y neuroblastoma cells. target gene hsa-mir-137 Neuroblastoma 23400681 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 miR-137 directly targets KDM1A mRNA in neuroblastoma cells, and activates cell properties consistent with tumor suppression target gene hsa-mir-137 Neuroblastoma 23934188 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 miR-137 regulates the constitutive androstane receptor and modulates doxorubicin sensitivity in parental and doxorubicin-resistant neuroblastoma cells. target gene hsa-mir-145 Neuroblastoma 23222716 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 MicroRNA-145 inhibits the growth, invasion, metastasis and angiogenesis of neuroblastoma cells through targeting hypoxia-inducible factor 2 alpha target gene hsa-mir-145 Neuroblastoma 29619741 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 Expression of miR-145 and Its Target Proteins Are Regulated by miR-29b in Differentiated Neurons target gene hsa-mir-153 Neuroblastoma 26633009 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 A Proteomics Approach to Investigate miR-153-3p and miR-205-5p Targets in Neuroblastoma Cells. target gene hsa-mir-15a Neuroblastoma 23176145 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 MicroRNA-15a promotes neuroblastoma migration by targeting reversion-inducing cysteine-rich protein with Kazal motifs (RECK) and regulating matrix metalloproteinase-9 expression target gene hsa-mir-17 Neuroblastoma 18493594 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM target gene hsa-mir-17 Neuroblastoma 21145484 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 The miR-17-92 MicroRNA Cluster Regulates Multiple Components of the TGF-beta Pathway in Neuroblastoma. target gene hsa-mir-17 Neuroblastoma 21796614 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma target gene hsa-mir-17 Neuroblastoma 17894887 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 miRNAs from the miR-17-92 cluster modulate tumor formation and function as oncogenes by influencing the translation of E2F1 mRNA. target gene hsa-mir-17 Neuroblastoma 28560387 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 Reciprocal antagonistic regulation of N-myc mRNA by miR‑17 and the neuronal-specific RNA-binding protein HuD. target gene hsa-mir-18 Neuroblastoma 17894887 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 miRNAs from the miR-17-92 cluster modulate tumor formation and function as oncogenes by influencing the translation of E2F1 mRNA. target gene hsa-mir-181c Neuroblastoma 24345480 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 MiR-181c modulates the proliferation, migration, and invasion of neuroblastoma cells by targeting Smad7. target gene hsa-mir-183 Neuroblastoma 27239679 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 Our results reveal the MCM complex to be a critical and directly regulated node within the miR-183 signaling network in MYCN-amplified neuroblastoma cells. target gene hsa-mir-18a Neuroblastoma 20080637 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 miR-18a and miR-19a target and repress the expression of estrogen receptor-alpha (ESR1) target gene hsa-mir-18a Neuroblastoma 21145484 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 The miR-17-92 MicroRNA Cluster Regulates Multiple Components of the TGF-beta Pathway in Neuroblastoma. target gene hsa-mir-18a Neuroblastoma 21796614 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma target gene hsa-mir-192 Neuroblastoma 24223844 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 MiR-192 directly binds and regulates Dicer1 expression in neuroblastoma. target gene hsa-mir-19a Neuroblastoma 20080637 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 miR-18a and miR-19a target and repress the expression of estrogen receptor-alpha (ESR1) target gene hsa-mir-19a Neuroblastoma 21145484 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 The miR-17-92 MicroRNA Cluster Regulates Multiple Components of the TGF-beta Pathway in Neuroblastoma. target gene hsa-mir-19a Neuroblastoma 21796614 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma target gene hsa-mir-19a Neuroblastoma 17894887 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 miRNAs from the miR-17-92 cluster modulate tumor formation and function as oncogenes by influencing the translation of E2F1 mRNA. target gene hsa-mir-19b-1 Neuroblastoma 21145484 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 The miR-17-92 MicroRNA Cluster Regulates Multiple Components of the TGF-beta Pathway in Neuroblastoma. target gene hsa-mir-19b-1 Neuroblastoma 21796614 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma target gene hsa-mir-19b-1 Neuroblastoma 17894887 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 miRNAs from the miR-17-92 cluster modulate tumor formation and function as oncogenes by influencing the translation of E2F1 mRNA. target gene hsa-mir-203 Neuroblastoma 26136151 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 MicroRNA-203 inhibits the malignant progression of neuroblastoma by targeting Sam68. target gene hsa-mir-205 Neuroblastoma 26633009 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 A Proteomics Approach to Investigate miR-153-3p and miR-205-5p Targets in Neuroblastoma Cells. target gene hsa-mir-20a Neuroblastoma 21145484 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 The miR-17-92 MicroRNA Cluster Regulates Multiple Components of the TGF-beta Pathway in Neuroblastoma. target gene hsa-mir-20a Neuroblastoma 21796614 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma target gene hsa-mir-20a Neuroblastoma 17894887 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 miRNAs from the miR-17-92 cluster modulate tumor formation and function as oncogenes by influencing the translation of E2F1 mRNA. target gene hsa-mir-20a Neuroblastoma 28560387 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 Reciprocal antagonistic regulation of N-myc mRNA by miR‑17 and the neuronal-specific RNA-binding protein HuD. target gene hsa-mir-21 Neuroblastoma 23084187 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 Micro-RNA-21 regulates the sensitivity to cisplatin in human neuroblastoma cells target gene hsa-mir-210 Neuroblastoma 23108914 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 MicroRNA-210 targets antiapoptotic Bcl-2 expression and mediates hypoxia-induced apoptosis of neuroblastoma cells target gene hsa-mir-221 Neuroblastoma 28003306 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma. target gene hsa-mir-27b Neuroblastoma 22120719 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 MiR-27b targets PPARgamma to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells. target gene hsa-mir-29b Neuroblastoma 29619741 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 Expression of miR-145 and Its Target Proteins Are Regulated by miR-29b in Differentiated Neurons target gene hsa-mir-29b Neuroblastoma 29399057 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 MicroRNA-29b alleviates oxygen and glucose deprivation/reperfusion-induced injury via inhibition of the p53-dependent apoptosis pathway in N2a neuroblastoma cells target gene hsa-mir-329 Neuroblastoma 24316513 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 miR-329 suppresses the growth and motility of neuroblastoma by targeting KDM1A. target gene hsa-mir-335 Neuroblastoma 22382496 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 MiRNA-335 Suppresses Neuroblastoma Cell Invasiveness By Direct Targeting of Multiple Genes from the non-Canonical TGF-ж┿Signalling Pathway. target gene hsa-mir-338 Neuroblastoma 24140344 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 miR-338-3p suppresses neuroblastoma proliferation, invasion and migration through targeting PREX2a. target gene hsa-mir-34a Neuroblastoma 17965831 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 miR-34a induces apoptosis in neuroblastoma cells, possibly by targeting the transcription factor E2F3. This p53-induced up-regulation of miR-34a results in an enhanced reduction in cell proliferation, strongly suggesting that miR-34a reinforces the tumour suppressor function of p53. target gene hsa-mir-34a Neuroblastoma 18504438 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 The MYCN oncogene is a direct target of miR-34a. target gene hsa-mir-34a Neuroblastoma 18505919 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. target gene hsa-mir-34a Neuroblastoma 22703967 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN-survivin pathway. target gene hsa-mir-34a Neuroblastoma 17894887 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 miR-34a acts as a suppressor of neuroblastoma tumorigenesis by targeting the mRNA encoding E2F3 and reducing E2F3 protein levels. target gene hsa-mir-34a Neuroblastoma 21182263 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 YY1 is a negative regulator of p53, and it plays an essential role in cancer biology. Therefore, YY1 is another important direct target of miR-34a which closely regulates TP53 activities. target gene hsa-mir-34a Neuroblastoma 22160687 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 Notably, the axis TAp73/miR-34a/synaptotagmin-1 is conserved in brains from Alzheimer's patients. target gene hsa-mir-34b Neuroblastoma 28525978 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 miRNA-34b is able to significantly downregulate DLL1 mRNA expression levels target gene hsa-mir-362 Neuroblastoma 26073258 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 miR-362-5p inhibits proliferation and migration of neuroblastoma cells by targeting phosphatidylinositol 3-kinase-C2β. target gene hsa-mir-375 Neuroblastoma 25864587 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 Targeting MYCN IRES in MYCN-amplified neuroblastoma with miR-375 inhibits tumor growth and sensitizes tumor cells to radiation. target gene hsa-mir-421 Neuroblastoma 25012242 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 miR-421 may promote neuroblastoma cell growth and motility partially by targeting menin. target gene hsa-mir-432 Neuroblastoma 24657437 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 MicroRNA-432 contributes to dopamine cocktail and retinoic acid induced differentiation of human neuroblastoma cells by targeting NESTIN and RCOR1 genes. target gene hsa-mir-4487 Neuroblastoma 26183158 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 we identified that miR-4487 and miR-595 could target ULK1 and experimentally verified they could negatively or positively regulate ULK1-mediated autophagy target gene hsa-mir-497 Neuroblastoma 23531080 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1 target gene hsa-mir-595 Neuroblastoma 26183158 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 Identification of ULK1 as a novel biomarker involved in miR-4487 and miR-595 regulation in neuroblastoma SH-SY5Y cell autophagy. target gene hsa-mir-885 Neuroblastoma 21233845 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 MicroRNA miR-885-5p targets CDK2 and MCM5, activates p53 and inhibits proliferation and survival. target gene hsa-mir-9-1 Neuroblastoma 22564723 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 microRNA-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells. target gene hsa-mir-9-2 Neuroblastoma 22564723 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 microRNA-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells. target gene hsa-mir-92-1 Neuroblastoma 17894887 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 miRNAs from the miR-17-92 cluster modulate tumor formation and function as oncogenes by influencing the translation of E2F1 mRNA. target gene hsa-mir-92a-1 Neuroblastoma 21145484 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 The miR-17-92 MicroRNA Cluster Regulates Multiple Components of the TGF-beta Pathway in Neuroblastoma. target gene hsa-mir-92a-1 Neuroblastoma 21796614 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma target gene hsa-mir-9-3 Neuroblastoma 22564723 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 microRNA-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells. target gene hsa-mir-144 Neurodegenerative Diseases [unspecific] 27370936 D019636 HP:0002180 the expression of 14-3-3纬 was upregulated following transfection with miR-7 and miR-144 mimics. target gene hsa-mir-203 Neurodegenerative Diseases [unspecific] 27370936 D019636 HP:0002180 miR-203 resulted in a down-regulation of 14-3-3胃 transcript target gene hsa-mir-7 Neurodegenerative Diseases [unspecific] 27370936 D019636 HP:0002180 the expression of 14-3-3纬 was upregulated following transfection with miR-7 and miR-144 mimics. target gene hsa-mir-7-1 Neurofibromatosis type 2 21454924 genetic disease DOID:8712 Q85.02 C537392 101000 We found that miR-7 functions as a tumor suppressor by targeting proteins in three major oncogenic pathways - EGFR, Pak1, and Ack1. target gene hsa-mir-7-2 Neurofibromatosis type 2 21454924 genetic disease DOID:8712 Q85.02 C537392 101000 We found that miR-7 functions as a tumor suppressor by targeting proteins in three major oncogenic pathways - EGFR, Pak1, and Ack1. target gene hsa-mir-7-3 Neurofibromatosis type 2 21454924 genetic disease DOID:8712 Q85.02 C537392 101000 We found that miR-7 functions as a tumor suppressor by targeting proteins in three major oncogenic pathways - EGFR, Pak1, and Ack1. target gene hsa-mir-124 Neuronal Apoptosis-Related Diseases 24166354 MicroRNA-124 (miR-124) regulates Ku70 expression and is correlated with neuronal death induced by ischemia/reperfusion. target gene hsa-mir-23a Neuronal Apoptosis-Related Diseases 24651435 MicroRNA-23a/b and microRNA-27a/b suppress Apaf-1 protein and alleviate hypoxia-induced neuronal apoptosis. target gene hsa-mir-23b Neuronal Apoptosis-Related Diseases 24651435 MicroRNA-23a/b and microRNA-27a/b suppress Apaf-1 protein and alleviate hypoxia-induced neuronal apoptosis. target gene hsa-mir-27a Neuronal Apoptosis-Related Diseases 24651435 MicroRNA-23a/b and microRNA-27a/b suppress Apaf-1 protein and alleviate hypoxia-induced neuronal apoptosis. target gene hsa-mir-27b Neuronal Apoptosis-Related Diseases 24651435 MicroRNA-23a/b and microRNA-27a/b suppress Apaf-1 protein and alleviate hypoxia-induced neuronal apoptosis. target gene hsa-mir-150 Neuropathic Pain 28685867 D009437 MiR-150 alleviates neuropathic pain via inhibiting toll-like receptor 5. target gene hsa-mir-150 Neuropathic Pain 29323698 D009437 It was revealed that XIST/miR-150/ZEB1 axis can be provided as a therapeutic target in neuropathic pain target gene hsa-mir-93 Neuropathic Pain 28284149 D009437 MicroRNA-93 alleviates neuropathic pain through targeting signal transducer and activator of transcription 3. target gene hsa-mir-17 Non-Syndromic Orofacial Clefts 24068957 PS119530 our data indicate that miR-17-92 modulates expression of critical T-box transcriptional regulators during midface development and is itself a target of Bmp-signaling and the craniofacial pioneer factor AP-2α. Our data are the first genetic evidence that an individual miR or miR cluster is functionally important in mammalian CL/P. target gene hsa-mir-18 Non-Syndromic Orofacial Clefts 24068957 PS119530 our data indicate that miR-17-92 modulates expression of critical T-box transcriptional regulators during midface development and is itself a target of Bmp-signaling and the craniofacial pioneer factor AP-2α. Our data are the first genetic evidence that an individual miR or miR cluster is functionally important in mammalian CL/P. target gene hsa-mir-19a Non-Syndromic Orofacial Clefts 24068957 PS119530 our data indicate that miR-17-92 modulates expression of critical T-box transcriptional regulators during midface development and is itself a target of Bmp-signaling and the craniofacial pioneer factor AP-2α. Our data are the first genetic evidence that an individual miR or miR cluster is functionally important in mammalian CL/P. target gene hsa-mir-19b-1 Non-Syndromic Orofacial Clefts 24068957 PS119530 our data indicate that miR-17-92 modulates expression of critical T-box transcriptional regulators during midface development and is itself a target of Bmp-signaling and the craniofacial pioneer factor AP-2α. Our data are the first genetic evidence that an individual miR or miR cluster is functionally important in mammalian CL/P. target gene hsa-mir-20a Non-Syndromic Orofacial Clefts 24068957 PS119530 our data indicate that miR-17-92 modulates expression of critical T-box transcriptional regulators during midface development and is itself a target of Bmp-signaling and the craniofacial pioneer factor AP-2α. Our data are the first genetic evidence that an individual miR or miR cluster is functionally important in mammalian CL/P. target gene hsa-mir-92-1 Non-Syndromic Orofacial Clefts 24068957 PS119530 our data indicate that miR-17-92 modulates expression of critical T-box transcriptional regulators during midface development and is itself a target of Bmp-signaling and the craniofacial pioneer factor AP-2α. Our data are the first genetic evidence that an individual miR or miR cluster is functionally important in mammalian CL/P. target gene hsa-mir-17 Non-Traumatic Osteonecrosis 25060766 M90.5 D010020 MiR-17-5p modulates osteoblastic differentiation and cell proliferation by targeting SMAD7 in non-traumatic osteonecrosis. target gene hsa-mir-126 Obesity 25887648 disease of metabolism DOID:9970 E66 D009765 601665 HP:0001513 We identified 23 active miRNA-TF-gene regulatory pathways that were significantly related to obesity-related inflammation. target gene hsa-mir-126 Obesity 28367267 disease of metabolism DOID:9970 E66 D009765 601665 HP:0001513 Obesity Downregulates MicroRNA-126 Inducing Capillary Rarefaction in Skeletal Muscle: Effects of Aerobic Exercise Training. target gene hsa-mir-130 Obesity 28242765 disease of metabolism DOID:9970 E66 D009765 601665 HP:0001513 APCDD1 positively regulates adipogenic differentiation and that its down-regulation by miR-130 during DIO may contribute to impaired adipogenic differentiation and obesity-related metabolic disease target gene hsa-mir-143 Obesity 16195701 disease of metabolism DOID:9970 E66 D009765 601665 HP:0001513 Modified oligonucleotide complementary to miR-143 effectively suppressed adipocyte differentiation by modulation of its putative target ERK5, a protein previously known to be implicated in MAP kinase signaling pathways. target gene hsa-mir-145 Obesity 25887648 disease of metabolism DOID:9970 E66 D009765 601665 HP:0001513 We identified 23 active miRNA-TF-gene regulatory pathways that were significantly related to obesity-related inflammation. target gene hsa-mir-146b Obesity 24428800 disease of metabolism DOID:9970 E66 D009765 601665 HP:0001513 IL-6 and TNF-α induced obesity-related inflammatory response through transcriptional regulation of miR-146b. target gene hsa-mir-193b Obesity 25887648 disease of metabolism DOID:9970 E66 D009765 601665 HP:0001513 We identified 23 active miRNA-TF-gene regulatory pathways that were significantly related to obesity-related inflammation. target gene hsa-mir-21 Obesity 25887648 disease of metabolism DOID:9970 E66 D009765 601665 HP:0001513 We identified 23 active miRNA-TF-gene regulatory pathways that were significantly related to obesity-related inflammation. target gene hsa-mir-26b Obesity 26016996 disease of metabolism DOID:9970 E66 D009765 601665 HP:0001513 Obesity-associated microRNA-26b regulates the proliferation of human preadipocytes via arrest of the G1/S transition. target gene hsa-mir-27a Obesity 20060380 disease of metabolism DOID:9970 E66 D009765 601665 HP:0001513 Together, these results suggest that miR-27a would suppress adipocyte differentiation through targeting PPARgamma and thereby down-regulation of miR-27a might be associated with adipose tissue dysregulation in obesity. target gene hsa-mir-29b Obesity 25887648 disease of metabolism DOID:9970 E66 D009765 601665 HP:0001513 We identified 23 active miRNA-TF-gene regulatory pathways that were significantly related to obesity-related inflammation. target gene hsa-mir-342 Obesity 25895816 disease of metabolism DOID:9970 E66 D009765 601665 HP:0001513 miR-342-3p is a powerful enhancer of the adipogenesis of human adipose-derived MSCs that acts by inhibiting CtBP2 and releasing the key adipogenic regulator C/EBPα from CtBP2 binding, subsequently activating the expression of adipogenic transcription factors and markers. target gene hsa-mir-145 Obstructive Sleep Apnea 28465478 disease of mental health DOID:0050848 G47.33 D020181 107650 HP:0002870 Chronic obstructive sleep apnea promotes aortic remodeling in canines through miR-145/Smad3 signaling pathway. target gene hsa-mir-15a Odontogenic Tumors 22684875 D009808 HP:0100612 miR-15a/16-1 influences BCL2 expression in keratocystic odontogenic tumors. target gene hsa-mir-16-1 Odontogenic Tumors 22684875 D009808 HP:0100612 miR-15a/16-1 influences BCL2 expression in keratocystic odontogenic tumors. target gene hsa-mir-16-2 Odontogenic Tumors 22684875 D009808 HP:0100612 miR-15a/16-1 influences BCL2 expression in keratocystic odontogenic tumors. target gene hsa-mir-137 Oligodendroglioma 23252729 disease of cellular proliferation DOID:3181 D009837 MIR-137 Suppresses Growth and Invasion, is Downregulated in Oligodendroglial Tumors and Targets CSE1L target gene hsa-mir-139 Oral Neoplasms 26191149 C06.9 D009062 HP:0100649 MiRNA-139 regulates oral cancer Tca8113 cells apoptosis through Akt signaling pathway. target gene hsa-mir-21 Oral Neoplasms 23999978 C06.9 D009062 HP:0100649 MicroRNA-21 promotes oral cancer invasion via the Wnt/β-catenin pathway by targeting DKK2. target gene hsa-mir-320 Oral Neoplasms 24114198 C06.9 D009062 HP:0100649 miR-320 regulates the function of vascular endothelial cells by targeting NRP1 and has the potential to be developed as an anti-angiogenic or anti-cancer drug. target gene hsa-mir-499 Oral Neoplasms 26867589 C06.9 D009062 HP:0100649 This study describes the regulation of PDCD4 specifically in tonsil SCC by miR-499 and miR-21 and has documented the loss of PDCD4 in tonsil SCCs.These findings highlight the complex interplay between miRNAs and tumour suppressor gene regulation and suggest that PDCD4 loss may be an important step in tonsillar carcinogenesis. target gene hsa-mir-518c Oral Neoplasms 25536052 C06.9 D009062 HP:0100649 miR-518c-5p regulates the growth and metastasis of oral cancer as a downstream target of the SDF-1/CXCR4 system. target gene hsa-mir-203 Oral Submucous Fibrosis 25872484 gastrointestinal system disease DOID:5773 K13.5 D009914 Thus, we provide evidence to illustrate that miR-203 plays a role in the pathogenesis of OSF, which may be a target for OSF management. target gene hsa-mir-21 Oral Submucous Fibrosis 26943153 gastrointestinal system disease DOID:5773 K13.5 D009914 PDGF-BB Enhances the Proliferation of Cells in Human Orbital Fibroblasts by Suppressing PDCD4 Expression Via Up-Regulation of microRNA-21. target gene hsa-mir-125b Osteoarthritis 28260078 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 Upregulation of microRNA-125b-5p is involved in the pathogenesis of osteoarthritis by downregulating SYVN1. target gene hsa-mir-125b Osteoarthritis 29550827 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 miR-125b could play an important role in inflammatory injury of chondrogenic cells and miR-125b affected inflammatory injury of ATDC5 cells via regulating expression of MIP-1α and regulating NF-κB and JNK signaling pathways target gene hsa-mir-127 Osteoarthritis 24022470 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 MicroRNA-127-5p is an important regulator of MMP-13 in human chondrocytes and may contribute to the development of OA. target gene hsa-mir-130a Osteoarthritis 27999816 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 miR-204, which targets RUNX2, and miR-130a, which inhibits PPARγ, were lower and higher, respectively, in F versus OA serum samples target gene hsa-mir-140 Osteoarthritis 21872590 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 MiR-140 is co-expressed with Wwp2-C transcript and activated by Sox9 to target Sp1 in maintaining the chondrocyte proliferation. target gene hsa-mir-140 Osteoarthritis 24257415 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 This is the first study to provide evidence of a regulatory mechanism of miR-140 independent of WWP2, and new and differential roles for NFAT3 and SMAD3 in the OA process in the regulation of miR-140 transcription.Such knowledge could advance therapeutic strategies targeting OA. target gene hsa-mir-145 Osteoarthritis 27922673 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 Effects of miR-145 on the inhibition of chondrocyte proliferation and fibrosis by targeting TNFRSF11B in human osteoarthritis. target gene hsa-mir-146a Osteoarthritis 24107356 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 Our study demonstrated that HDAC inhibitor treatment in OA-FLS significantly increased miR-146a expression and mediated markedly negative regulation to inhibit IL-1β-induced signaling and cytokine secretion. Our results indicate the potential rationale of anti-inflammatory effects for HDAC inhibitors. target gene hsa-mir-146a Osteoarthritis 25311550 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 Transfection of miR-146a decreases IL-1 induced mRNA levels of inflammatory genes and catabolic proteases in NP cells target gene hsa-mir-146a Osteoarthritis 26492575 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 Simply, hypoxia induced HIF-1伪, and HIF-1伪 increased miR-146a, but miR-146a suppressed Bcl-2, an autophagy inhibitor. target gene hsa-mir-146a Osteoarthritis 27845876 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 Hypoxia-induced microRNA-146a represses Bcl-2 through Traf6/IRAK1 but not Smad4 to promote chondrocyte autophagy. target gene hsa-mir-146a Osteoarthritis 28314786 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 Effects of microRNA-146a on the proliferation and apoptosis of human osteoarthritis chondrocytes by targeting TRAF6 through the NF-κB signalling pathway. target gene hsa-mir-146a Osteoarthritis 28383548 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 miR-146a facilitates osteoarthritis by regulating cartilage homeostasis via targeting Camk2d and Ppp3r2. target gene hsa-mir-146a Osteoarthritis 28634214 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 Effects of microRNA-146a on the proliferation and apoptosis of human osteochondrocytes by targeting TRAF6 through the NF- κB signalling pathway. target gene hsa-mir-146a Osteoarthritis 29183039 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 MiR-146a Aggravates LPS-Induced Inflammatory Injury by Targeting CXCR4 in the Articular Chondrocytes target gene hsa-mir-15a Osteoarthritis 27916780 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 MiR-15a-5p regulates viability and matrix degradation of human osteoarthritis chondrocytes via targeting VEGFA. target gene hsa-mir-16 Osteoarthritis 26350536 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 Our results indicate that miR-16-5p is an important regulator of SMAD3 expression in human chondrocytes and may contribute to the development of OA. target gene hsa-mir-181 Osteoarthritis 28177757 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 MicroRNA-181 inhibits proliferation and promotes apoptosis of chondrocytes in osteoarthritis by targeting PTEN. target gene hsa-mir-181a Osteoarthritis 28280258 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 miR-181a Modulates Chondrocyte Apoptosis by Targeting Glycerol-3-Phosphate Dehydrogenase 1-Like Protein (GPD1L) in Osteoarthritis. target gene hsa-mir-199a Osteoarthritis 27515563 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 Transfection of OA chondrocytes with anti-miR-199a-3p significantly enhanced COX-2 expression and PGE2 production (P < 0.001). target gene hsa-mir-19a Osteoarthritis 29306212 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 MicroRNA-19a promotes cell viability and migration of chondrocytes via up-regulating SOX9 through NF-κB pathway target gene hsa-mir-204 Osteoarthritis 27999816 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 miR-204, which targets RUNX2, and miR-130a, which inhibits PPARγ, were lower and higher, respectively, in F versus OA serum samples target gene hsa-mir-21 Osteoarthritis 24577233 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 MicroRNA-21 controls the development of osteoarthritis by targeting GDF-5 in chondrocytes. target gene hsa-mir-24 Osteoarthritis 24572376 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 We disclosed herein a new role of the senescence marker p16INK4a and its regulation by miR-24 during OA and terminal chondrogenesis. target gene hsa-mir-24 Osteoarthritis 29143973 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 Effects of microRNA-24 targeting C-myc on apoptosis, proliferation and cytokine expressions in chondrocytes of rats with osteoarthritis via MAPK signaling pathway. target gene hsa-mir-26a Osteoarthritis 26854724 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 MicroRNA-26a-5p regulates the expression of inducible nitric oxide synthase via activation of NF-κB pathway in human osteoarthritis chondrocytes. target gene hsa-mir-26a Osteoarthritis 29208566 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 miR-26a/-26b/FUT4/NF-κB axis may serve as a predictive biomarker and a potential therapeutic target in OA treatment target gene hsa-mir-30b Osteoarthritis 26653555 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 In conclusion, miR-30b was involved in the process of OA, and it probably functioned through its target gene ERG. target gene hsa-mir-33a Osteoarthritis 25880168 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 Our findings suggest, for the first time to our knowledge, that miR-33a regulates cholesterol synthesis through the TGF-β1/Akt/SREBP-2 pathway,as well as cholesterol efflux-related genes ABCA1 and ApoA1, in OA chondrocytes, pointing to its identification as a novel target for ameliorating the OA phenotype. target gene hsa-mir-370 Osteoarthritis 26103880 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 miR-370 and miR-373 regulate the pathogenesis of osteoarthritis by modulating one-carbon metabolism via SHMT-2 and MECP-2, respectively. target gene hsa-mir-373 Osteoarthritis 26103880 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 miR-370 and miR-373 regulate the pathogenesis of osteoarthritis by modulating one-carbon metabolism via SHMT-2 and MECP-2, respectively. target gene hsa-mir-373 Osteoarthritis 28343378 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 Adipose-Derived Stem Cells Suppress Inflammation Induced by IL-1β through Down-Regulation of P2X7R Mediated by miR-373 in Chondrocytes of Osteoarthritis. target gene hsa-mir-9 Osteoarthritis 24928913 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 However, luciferase reporter assays and transient miR overexpression in the ATDC5 chondrogenic cell line only support that miR-9 was a negative post-transcriptional regulator of PC-1, Pit-1 and TNAP mRNAs. target gene hsa-mir-92a Osteoarthritis 29241192 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 MiR-92a-3p is an important regulator of ADAMTS-4/5 in human chondrocytes and may contribute to the development of OA target gene hsa-mir-98 Osteoarthritis 27590063 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 MiR-98 promotes chondrocyte apoptosis by decreasing Bcl-2 expression in a rat model of osteoarthritis. target gene hsa-mir-24 Osteomyelitis 25976273 musculoskeletal system disease DOID:1019 M86 D010019 612852 The Role of MicroRNA, miR-24, and Its Target CHI3L1 in Osteomyelitis Caused by Staphylococcus aureus. target gene hsa-mir-320a Osteopetrosis 24084574 musculoskeletal system disease DOID:13533 Q78.2 D010022 259700 Collectively, the present study established a new system approach for the investigation of microRNAs, and the microRNA-target pairs, particular has-miR-320a and Arf1, may have important roles in osteopetrosis. target gene hsa-mir-548d Osteopetrosis 24929254 musculoskeletal system disease DOID:13533 Q78.2 D010022 259700 miR-548d-5p is downregulated during dexamethasone-induced adipogenic differentiation of hBMSCs. By directly targeting and downregulating PPARγ,miR-548d-5p suppresses the dexamethasone-induced adipogenic differentiation of hBMSCs and enhances their osteogenic potential. Our findings suggest that miR-548d-5p has potential in the treatment of corticosteroid-induced osteonecrosis of the femoral head. target gene hsa-mir-133 Osteoporosis 26013661 musculoskeletal system disease DOID:11476 M80 D010024 166710 HP:0000939 Estrogen deficiency is associated with miR-133 overexpression.MiR-133 can induce postmenopausal osteoporosis by weakening osteogenic differentiation of hMSCs, at least partly through repressing SLC39A1 expression. target gene hsa-mir-205 Osteoporosis 26170952 musculoskeletal system disease DOID:11476 M80 D010024 166710 HP:0000939 The miR-205 antisense largely abolished the inhibitory effect of STAT3 activation on the levels of CHOP protein. target gene hsa-mir-23b Osteoporosis 29234953 musculoskeletal system disease DOID:11476 M80 D010024 166710 HP:0000939 Involvement of microRNA-23b in TNF-α-reduced BMSC osteogenic differentiation via targeting runx2 target gene hsa-mir-705 Osteoporosis 26700816 musculoskeletal system disease DOID:11476 M80 D010024 166710 HP:0000939 Mechanistically, TNF-α activated NF-κB pathway to promote microRNA-705 expression, which function as a repressor of FoxO1 through post-transcriptional regulation. target gene hsa-mir-1 Osteosarcoma 24969180 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-1 functions as a potential tumor suppressor in osteosarcoma by targeting Med1 and Med31. target gene hsa-mir-1 Osteosarcoma 27777493 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-1 Inhibits Cell Growth, Migration, and Invasion by Targeting VEGFA in Osteosarcoma Cells. target gene hsa-mir-100 Osteosarcoma 24317814 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-100 inhibits osteosarcoma cell proliferation by targeting Cyr61. target gene hsa-mir-101 Osteosarcoma 25190211 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-101 inhibits the metastasis of osteosarcoma cells by downregulation of EZH2 expression. target gene hsa-mir-107 Osteosarcoma 28682874 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 In vitro effect of microRNA-107 targeting Dkk-1 by regulation of Wnt/β-catenin signaling pathway in osteosarcoma target gene hsa-mir-10b Osteosarcoma 27764757 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-10b promotes invasion by targeting KLF4 in osteosarcoma cells. target gene hsa-mir-124 Osteosarcoma 26259653 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-124 suppresses the migration and invasion of osteosarcoma cells via targeting ROR2-mediated non-canonical Wnt signaling. target gene hsa-mir-124 Osteosarcoma 26339404 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Our findings may help to understand the molecular mechanisms of OS and identify targets of effective targeted therapies for OS. target gene hsa-mir-124 Osteosarcoma 27644254 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 The tumor suppressor miR-124 inhibits cell proliferation and invasion by targeting B7-H3 in osteosarcoma. target gene hsa-mir-124 Osteosarcoma 27743351 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-124 upregulation inhibits proliferation and invasion of osteosarcoma cells by targeting sphingosine kinase 1. target gene hsa-mir-124 Osteosarcoma 29552134 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-124 acts as a tumor-suppressive miRNA by inhibiting the expression of Snail2 in osteosarcoma target gene hsa-mir-1247 Osteosarcoma 25973030 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MiRNA profile of osteosarcoma with CD117 and stro-1 expression: miR-1247 functions as an onco-miRNA by targeting MAP3K9. target gene hsa-mir-125a Osteosarcoma 28950256 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-125a Regulates Cell Proliferation Via Directly Targeting E2F2 in Osteosarcoma target gene hsa-mir-126 Osteosarcoma 23877372 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-126 inhibits osteosarcoma cells proliferation by targeting Sirt1. target gene hsa-mir-126 Osteosarcoma 25213697 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-126 inhibits cell growth, invasion, and migration of osteosarcoma cells by downregulating ADAM-9. target gene hsa-mir-128 Osteosarcoma 24132591 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-128 promotes proliferation in osteosarcoma cells by downregulating PTEN target gene hsa-mir-132 Osteosarcoma 24449507 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-132 targeting cyclin E1 suppresses cell proliferation in osteosarcoma cells. target gene hsa-mir-133a Osteosarcoma 27794430 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Down-regulation of RBP-J mediated by microRNA-133a suppresses dendritic cells and functions as a potential tumor suppressor in osteosarcoma. target gene hsa-mir-133a-1 Osteosarcoma 23756231 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 microRNA-133a, downregulated in osteosarcoma, suppresses proliferation and promotes apoptosis by targeting Bcl-xL and Mcl-1. target gene hsa-mir-133a-2 Osteosarcoma 23756231 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 microRNA-133a, downregulated in osteosarcoma, suppresses proliferation and promotes apoptosis by targeting Bcl-xL and Mcl-1. target gene hsa-mir-135b Osteosarcoma 25025684 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-135b may function as a tumor suppressor to regulate osteosarcoma cell proliferation and invasion through a mechanism that targets the c-Myc oncogene. These findings indicate that miR-135b may play a role in the pathogenesis of osteosarcoma. target gene hsa-mir-135b Osteosarcoma 25190111 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-135b promotes proliferation, invasion and migration of osteosarcoma cells by degrading myocardin. target gene hsa-mir-135b Osteosarcoma 25416447 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-135b functions as an onco-miRNA in OS to promote OS cells proliferation and invasion, and its oncogenic effects are mediated chiefly through targeting FOXO1. target gene hsa-mir-137 Osteosarcoma 26302771 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 We revealed novel functional role of miR-137 in osteosarcoma regulation, likely through FXYD6 binding. target gene hsa-mir-138 Osteosarcoma 27019355 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MiR-138 Acts as a Tumor Suppressor by Targeting EZH2 and Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells. target gene hsa-mir-138 Osteosarcoma 29042962 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-138 directly targets TNFAIP8 and acts as a tumor suppressor in osteosarcoma. target gene hsa-mir-140 Osteosarcoma 28341864 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-140-5p regulates osteosarcoma chemoresistance by targeting HMGN5 and autophagy. target gene hsa-mir-142 Osteosarcoma 24803022 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MiR-142-3p functions as a potential tumor suppressor in human osteosarcoma by targeting HMGA1. target gene hsa-mir-143 Osteosarcoma 28734729 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MiR-143 regulates the proliferation and migration of osteosarcoma cells through targeting MAPK7. target gene hsa-mir-144 Osteosarcoma 26081423 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-144 acts as a tumor suppressor by targeting Rho-associated coiled-coil containing protein kinase 1 in osteosarcoma cells. target gene hsa-mir-144 Osteosarcoma 25912304 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-144 suppresses osteosarcoma growth and metastasis by targeting ROCK1 and ROCK2. target gene hsa-mir-144 Osteosarcoma 29387244 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-144 suppresses proliferation and induces apoptosis of osteosarcoma cells via direct regulation of mTOR expression. target gene hsa-mir-145 Osteosarcoma 22472569 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-145 targets vascular endothelial growth factor and inhibits invasion and metastasis of osteosarcoma cells. target gene hsa-mir-145 Osteosarcoma 24789502 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 microRNA-145 inhibits osteosarcoma cell proliferation and invasion by targeting ROCK1. target gene hsa-mir-145 Osteosarcoma 24801908 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MiR-145 inhibits osteosarcoma cells proliferation and invasion by targeting ROCK1. target gene hsa-mir-145 Osteosarcoma 28051259 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-145 inhibits tumour growth and metastasis in osteosarcoma by targeting cyclin-dependent kinase, CDK6. target gene hsa-mir-150 Osteosarcoma 27900020 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-150 upregulation reduces osteosarcoma cell invasion and metastasis by downregulating Ezrin. target gene hsa-mir-150 Osteosarcoma 28070040 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-150 inhibits osteosarcoma cell proliferation by targeting RUNX2 gene. target gene hsa-mir-150 Osteosarcoma 28454380 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-150 is downregulated in osteosarcoma and suppresses cell proliferation, migration and invasion by targeting ROCK1. target gene hsa-mir-150 Osteosarcoma 28547952 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Mir-150 Up-Regulates Glut1 and Increases Glycolysis in Osteosarcoma Cells target gene hsa-mir-153 Osteosarcoma 25793604 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-153 inhibits osteosarcoma cells proliferation and invasion by targeting TGF-β2. target gene hsa-mir-155 Osteosarcoma 28214207 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-155 targets MAP3K10 and regulates osteosarcoma cell growth. target gene hsa-mir-15a Osteosarcoma 22922827 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma. target gene hsa-mir-15a Osteosarcoma 26261520 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MiRNA-15a inhibits proliferation, migration and invasion by targeting TNFAIP1 in human osteosarcoma cells. target gene hsa-mir-16-1 Osteosarcoma 22922827 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma. target gene hsa-mir-16-1 Osteosarcoma 23507142 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-16 inhibits cell proliferation by targeting IGF1R and the Raf1-MEK1/2-ERK1/2 pathway in osteosarcoma target gene hsa-mir-16-2 Osteosarcoma 23507142 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-16 inhibits cell proliferation by targeting IGF1R and the Raf1-MEK1/2-ERK1/2 pathway in osteosarcoma target gene hsa-mir-17 Osteosarcoma 24462867 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-17 inhibitor suppressed osteosarcoma tumor growth and metastasis via increasing PTEN expression. target gene hsa-mir-181a Osteosarcoma 27600004 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-181a promotes the proliferation and metastasis of osteosarcoma cells by targeting RASSF1A. target gene hsa-mir-181a Osteosarcoma 28381158 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Triptolide inhibits the growth of osteosarcoma by regulating microRNA-181a via targeting PTEN gene in vivo and vitro. target gene hsa-mir-181b Osteosarcoma 27063156 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 microRNA-181b promotes migration and invasion of osteosarcoma cells by targeting N-myc downstream regulated gene 2. target gene hsa-mir-182 Osteosarcoma 29254169 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-182 downregulates Wnt/β-catenin signaling, inhibits proliferation, and promotes apoptosis in human osteosarcoma cells by targeting HOXA9 target gene hsa-mir-183 Osteosarcoma 22525461 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Down-regulation of miR-183 promotes migration and invasion of osteosarcoma by targeting Ezrin. target gene hsa-mir-183 Osteosarcoma 22922800 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-183 inhibits the metastasis of osteosarcoma via downregulation of the expression of Ezrin in F5M2 cells. target gene hsa-mir-183 Osteosarcoma 24352761 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Clinical significance of microRNA-183/Ezrin axis in judging the prognosis of patients with osteosarcoma. target gene hsa-mir-19 Osteosarcoma 29702193 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-19a-mediated downregulation of RhoB inhibits the dephosphorylation of AKT1 and induces osteosarcoma cell metastasis. target gene hsa-mir-1908 Osteosarcoma 26328886 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Collectively, the results showed that, miR-1908 promotes proliferation and invasion of osteosarcoma cells by repressing PTEN expression. target gene hsa-mir-191 Osteosarcoma 25773391 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-191 promotes osteosarcoma cells proliferation by targeting checkpoint kinase 2. target gene hsa-mir-192 Osteosarcoma 27683056 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Upregulation of miR-192 inhibits cell growth and invasion and induces cell apoptosis by targeting TCF7 in human osteosarcoma. target gene hsa-mir-193a Osteosarcoma 26913720 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MiR-193a-3p and miR-193a-5p suppress the metastasis of human osteosarcoma cells by down-regulating Rab27B and SRR, respectively. target gene hsa-mir-194 Osteosarcoma 25096247 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 microRNA-194 suppresses osteosarcoma cell proliferation and metastasis in vitro and in vivo by targeting CDH2 and IGF1R. target gene hsa-mir-195 Osteosarcoma 23162665 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 microRNA-195 suppresses osteosarcoma cell invasion and migration in vitro by targeting FASN target gene hsa-mir-195 Osteosarcoma 25823925 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA profiling identifies MiR-195 suppresses osteosarcoma cell metastasis by targeting CCND1. target gene hsa-mir-195 Osteosarcoma 28032380 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-195-5p suppresses osteosarcoma cell proliferation and invasion by suppressing naked cuticle homolog 1. target gene hsa-mir-198 Osteosarcoma 26970302 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-198 inhibited tumorous behaviors of human osteosarcoma through directly targeting ROCK1. target gene hsa-mir-199a Osteosarcoma 26079799 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma. target gene hsa-mir-19a Osteosarcoma 28475001 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MiR-19a regulates the cell growth and apoptosis of osteosarcoma stem cells by targeting PTEN. target gene hsa-mir-19b Osteosarcoma 24824927 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-19b targets Mfn1 to inhibit Mfn1-induced apoptosis in osteosarcoma cells. target gene hsa-mir-19b Osteosarcoma 26339404 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Our findings may help to understand the molecular mechanisms of OS and identify targets of effective targeted therapies for OS. target gene hsa-mir-200b Osteosarcoma 27307751 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-200b inhibits the proliferation, migration, and invasion of osteosarcoma cells, probably via the inhibition of ZEB1 expression. target gene hsa-mir-202 Osteosarcoma 25156120 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-202 suppresses proliferation and induces apoptosis of osteosarcoma cells by downregulating Gli2. target gene hsa-mir-202 Osteosarcoma 26276504 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 This study provides new insights into miRNA-202 in osteosarcoma as a potential molecular target for chemotherapy. target gene hsa-mir-203 Osteosarcoma 26382657 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Take together, our results demonstrated that miR-203 act as a tumor suppressor miRNA through regulating RAB22A expression and suggested its involvement in osteosarcoma progression and carcinogenesis. target gene hsa-mir-204 Osteosarcoma 25998694 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-204 inhibits proliferation, migration, invasion and epithelial-mesenchymal transition in osteosarcoma cells via targeting Sirtuin 1. target gene hsa-mir-205 Osteosarcoma 26708425 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 In conclusion, our study suggested that miR-205 may function as a tumor suppressor via targeting TGF-α in OS, and the abnormal expression of miR-205 might be a key factor in OS progression. target gene hsa-mir-206 Osteosarcoma 23886177 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 These findings indicate that miR-206 may have a key role in osteosarcoma pathogenesis and development. It could serve as a useful biomarker for prediction of osteosarcoma progression, and provide a potential target for gene therapy. target gene hsa-mir-206 Osteosarcoma 29462818 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Effects of MicroRNA-206 on Osteosarcoma Cell Proliferation, Apoptosis, Migration and Invasion by Targeting ANXA2 Through the AKT Signaling Pathway target gene hsa-mir-208b Osteosarcoma 28618961 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-208b inhibits human osteosarcoma progression by targeting ROR2. target gene hsa-mir-20a Osteosarcoma 22186140 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-20a increases the metastatic potential of osteosarcoma cells by regulating Fas expression. target gene hsa-mir-20a Osteosarcoma 26339404 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Our findings may help to understand the molecular mechanisms of OS and identify targets of effective targeted therapies for OS. target gene hsa-mir-21 Osteosarcoma 25381586 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-21 regulates the sensitivity to cisplatin in a human osteosarcoma cell line. target gene hsa-mir-21 Osteosarcoma 20480266 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-21 is involved in osteosarcoma cell invasion and migration. target gene hsa-mir-21 Osteosarcoma 28260111 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-21-5p may be associated with metastasis via target genes target gene hsa-mir-214 Osteosarcoma 24802407 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-214 promotes the proliferation and invasion of osteosarcoma cells through direct suppression of LZTS1. target gene hsa-mir-214 Osteosarcoma 25310480 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-214 regulates osteosarcoma survival and growth by directly targeting phosphatase and tensin homolog. target gene hsa-mir-214 Osteosarcoma 28081735 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-214-5p Targets ROCK1 and Suppresses Proliferation and Invasion of Human Osteosarcoma Cells. target gene hsa-mir-217 Osteosarcoma 25289936 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-217 regulates WASF3 expression and suppresses tumor growth and metastasis in osteosarcoma. target gene hsa-mir-217 Osteosarcoma 26054690 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-217 targeting Wnt5a in osteosarcoma functions as a potential tumor suppressor. target gene hsa-mir-218 Osteosarcoma 23886165 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miRNA-218 inhibits osteosarcoma cell migration and invasion by down-regulating of TIAM1, MMP2 and MMP9. target gene hsa-mir-22 Osteosarcoma 24609901 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-22 targets the 3' UTR of HMGB1 and inhibits the HMGB1-associated autophagy in osteosarcoma cells during chemotherapy. target gene hsa-mir-22 Osteosarcoma 24752578 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-22 inhibits osteosarcoma cell proliferation and migration by targeting HMGB1 and inhibiting HMGB1-mediated autophagy. target gene hsa-mir-223 Osteosarcoma 23208072 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Heat Shock Protein 90B1 Plays an Oncogenic Role and is a Target of microRNA-223 in Human Osteosarcoma target gene hsa-mir-24 Osteosarcoma 28189676 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-24 represses metastasis of human osteosarcoma cells by targeting Ack1 via AKT/MMPs pathway. target gene hsa-mir-24-1 Osteosarcoma 23578572 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-24 Inhibits Osteosarcoma Cell Proliferation Both In Vitro and In Vivo by Targeting LPAAT target gene hsa-mir-24-2 Osteosarcoma 23578572 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-24 Inhibits Osteosarcoma Cell Proliferation Both In Vitro and In Vivo by Targeting LPAAT target gene hsa-mir-25 Osteosarcoma 28705117 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-25 suppresses proliferation, migration, and invasion of osteosarcoma by targeting SOX4. target gene hsa-mir-26b Osteosarcoma 25761878 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-26b inhibits metastasis of osteosarcoma via targeting CTGF and Smad1. target gene hsa-mir-26b Osteosarcoma 26681033 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR- 26b may inhibit osteosarcoma cell proliferation, migration, and invasion by regulating PFKFB3 protein expression.miR-26b may have a tumor suppressor role in tumor occurrence and development. target gene hsa-mir-27a Osteosarcoma 24556602 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 This is the first study showing that miR-27a can function as an oncogene by targeting MAP2K4 in the osteosarcoma MG63 cell line. Inhibition of miR-27a increases MAP2K4 expression, which in turn inhibits cell proliferation and migration through the JNK/p38 signaling pathway in MG63 cells. These findings may help us understand the molecular mechanism of miR-27a in the tumorigenesis of osteosarcoma and may provide new diagnostic and therapeutic options for the treatment of this neoplasia. target gene hsa-mir-29 Osteosarcoma 27649654 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Targeting miR-29 induces apoptosis of osteosarcoma MG-63 cells via regulation of TGF-β1/PUMA signal. target gene hsa-mir-29a Osteosarcoma 23113351 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 data obtained highlight the role of miRNA-29a in the regulation of osteoblastic cell apoptosis by silencing Bcl-2 and Mcl-1 and inducing E2F1 and E2F3 expression target gene hsa-mir-300 Osteosarcoma 26010572 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Up-Regulation of MiR-300 Promotes Proliferation and Invasion of Osteosarcoma by Targeting BRD7. target gene hsa-mir-301a Osteosarcoma 25727016 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-301a modulates doxorubicin resistance in osteosarcoma cells by targeting AMP-activated protein kinase alpha 1. target gene hsa-mir-301a Osteosarcoma 27323075 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Upregulated microRNA-301a in osteosarcoma promotes tumor progression by targeting CDC14A. target gene hsa-mir-302a Osteosarcoma 29563995 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-302a inhibits osteosarcoma cell migration and invasion by directly targeting IGF-1R. target gene hsa-mir-30a Osteosarcoma 25264196 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MiR-30a inhibits osteolysis by targeting RunX2 in giant cell tumor of bone. target gene hsa-mir-32 Osteosarcoma 24989927 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-32 inhibits osteosarcoma cell proliferation and invasion by targeting Sox9. target gene hsa-mir-320 Osteosarcoma 24390663 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-320 inhibits osteosarcoma cells proliferation by directly targeting fatty acid synthase. target gene hsa-mir-320 Osteosarcoma 27721258 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Inhibitory roles of miR-320 in osteosarcoma via regulating E2F1. target gene hsa-mir-326 Osteosarcoma 27723574 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MiR-326 is a diagnostic biomarker and regulates cell survival and apoptosis by targeting Bcl-2 in osteosarcoma. target gene hsa-mir-335 Osteosarcoma 23975506 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-335 suppresses migration and invasion by targeting ROCK1 in osteosarcoma cells target gene hsa-mir-33a Osteosarcoma 24468065 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST. target gene hsa-mir-33b Osteosarcoma 25546234 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-33b inhibits osteosarcoma cells migration and invasion by targeting the c-Myc gene, acting as tumor suppressor. The findings of this study contribute to current understanding of the functions of miR-33b in osteosarcoma. target gene hsa-mir-33b Osteosarcoma 27662380 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-33b Inhibits the Proliferation and Migration of Osteosarcoma Cells via Targeting Hypoxia-Inducible Factor-1α. target gene hsa-mir-340 Osteosarcoma 23872151 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-340 suppresses osteosarcoma tumor growth and metastasis by directly targeting ROCK1. target gene hsa-mir-340 Osteosarcoma 28443990 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-340-5p modulates cisplatin resistance by targeting LPAATβ in osteosarcoma. target gene hsa-mir-340 Osteosarcoma 29769415 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Upregulation of microRNA-340 promotes osteosarcoma cell apoptosis while suppressing proliferation, migration and invasion by inactivating the CTNNB1-mediated Notch signaling pathway. target gene hsa-mir-34a Osteosarcoma 23314380 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-34a inhibits the metastasis of osteosarcoma cells by repressing the expression of CD44. target gene hsa-mir-34a Osteosarcoma 23569431 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-34a Inhibits Human Osteosarcoma Proliferation by Downregulating Ether go-go 1 Expression target gene hsa-mir-34a Osteosarcoma 29312491 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-34a promotes cell cycle arrest and apoptosis and suppresses cell adhesion by targeting DUSP1 in osteosarcoma. target gene hsa-mir-34a Osteosarcoma 28275089 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 The miR-34a/STMN1/βIII-tubulin axis maintains the microtubule cytoskeleton in osteosarcoma, and combining miR-34a with microtubule inhibitors can be investigated as a novel therapeutic strategy target gene hsa-mir-34c Osteosarcoma 28075441 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR‑34c‑3p acts as a tumor suppressor gene in osteosarcoma by targeting MARCKS. target gene hsa-mir-365 Osteosarcoma 26728377 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-365 could inhibit the proliferation and promote the apoptosis in SOSP-9607 osteosarcoma cells probably by mediating the expression of KRAS. target gene hsa-mir-375 Osteosarcoma 26036761 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-375 functions as a tumor suppressor in osteosarcoma by targeting PIK3CA. target gene hsa-mir-377 Osteosarcoma 25577249 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-377 can suppress proliferation in MG-63 cells in part by targeting CDK6. target gene hsa-mir-379 Osteosarcoma 27781416 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-379 suppresses osteosarcoma progression by targeting PDK1. target gene hsa-mir-381 Osteosarcoma 28406476 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 WISP-1 enhances VEGF-A expression and angiogenesis through the FAK/JNK/HIF-1α signaling pathways, as well as via down-regulation of miR-381 expression target gene hsa-mir-382 Osteosarcoma 25292190 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-382 inhibits osteosarcoma metastasis and relapse by targeting Y box-binding protein 1. target gene hsa-mir-3928 Osteosarcoma 24854843 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Down-expression of miR-3928 in osteosarcoma promoted tumor growth by targeting ERBB3, IL-6R and CDK6. MiR-3928 may be a potential therapy target worth further investigation. target gene hsa-mir-409 Osteosarcoma 26992637 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-409-3p inhibits osteosarcoma cell migration and invasion by targeting catenin-δ1. target gene hsa-mir-410 Osteosarcoma 28138700 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-410 regulates autophagy-related gene ATG16L1 expression and enhances chemosensitivity via autophagy inhibition in osteosarcoma. target gene hsa-mir-449a Osteosarcoma 29117539 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Hsa_circ_0009910 promotes carcinogenesis by promoting the expression of miR-449a target IL6R in osteosarcoma. target gene hsa-mir-451 Osteosarcoma 24218283 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-451 played a tumor-suppressing role through modulating the expression of PGE2 and CCND1, suggesting a novel target for the diagnosis and treatment of osteosarcoma. target gene hsa-mir-451 Osteosarcoma 27908732 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-451 inhibits cell growth, migration and angiogenesis in human osteosarcoma via down-regulating IL 6R. target gene hsa-mir-451 Osteosarcoma 28086136 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MiR-451 suppresses proliferation, migration and promotes apoptosis of the human osteosarcoma by targeting macrophage migration inhibitory factor. target gene hsa-mir-491 Osteosarcoma 27704627 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Up-regulation of microRNA-491-5p suppresses cell proliferation and promotes apoptosis by targeting FOXP4 in human osteosarcoma. target gene hsa-mir-542 Osteosarcoma 26498360 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Taken together, our results indicated that miR-542-5p plays a critical role in the proliferation of osteosarcoma and targets HUWE1. target gene hsa-mir-543 Osteosarcoma 28108312 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 CTGF promotes osteosarcoma angiogenesis by regulating miR-543/angiopoietin 2 signaling. target gene hsa-mir-646 Osteosarcoma 25403884 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-646 might be a tumor suppressor in osteosarcoma via the regulation of FGF2, which provided a potential prognostic biomarker and therapeutic target. target gene hsa-mir-661 Osteosarcoma 28391262 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-661 Enhances TRAIL or STS Induced Osteosarcoma Cell Apoptosis by Modulating the Expression of Cytochrome c1. target gene hsa-mir-664a Osteosarcoma 28669734 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Inhibition of miR-664a interferes with the migration of osteosarcoma cells via modulation of MEG3. target gene hsa-mir-675 Osteosarcoma 29626470 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Exosomal miR-675 from metastatic osteosarcoma promotes cell migration and invasion by targeting CALN1. target gene hsa-let-7a Osteosarcoma 25647078 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Tumor-suppressive microRNA-let-7a inhibits cell proliferation via targeting of E2F2 in osteosarcoma cells. target gene hsa-mir-802 Osteosarcoma 24460254 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MicroRNA-802 promotes osteosarcoma cell proliferation by targeting p27. target gene hsa-mir-9 Osteosarcoma 26107195 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-9 Modulates Osteosarcoma Cell Growth by Targeting the GCIP Tumor Suppressor. target gene hsa-mir-92a Osteosarcoma 28260104 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-92a promotes tumor growth of osteosarcoma by targeting PTEN/AKT signaling pathway. target gene hsa-mir-93 Osteosarcoma 21959981 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Levels of miR-93 were significantly higher in metastases from osteosarcoma than in paired primary tumours. When 143B and MG-63 were transfected with miR-93, clones appeared to respond differently to microRNA overexpression. Ectopic expression of miR-93 more significantly increased cell proliferation and invasivity in 143B than in MG-63 clones. Furthermore, increased mRNA and protein levels of E2F1, one of the potential miR-93 targets, were seen in osteosarcoma cellular clones and its involvement in 143B cell proliferation was confirmed by E2F1 silencing. target gene hsa-mir-93 Osteosarcoma 28056303 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 MiR-93 targets NKD2 to promote proliferation and inhibit apoptosis of osteosarcoma cells target gene hsa-mir-96 Osteosarcoma 29656060 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 microRNA-96 acts as a tumor suppressor gene in human osteosarcoma via target regulation of EZRIN target gene hsa-let-7 Ovarian Neoplasms 21109987 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Involvement of let-7/miR-98 microRNAs in the regulation of progesterone receptor membrane component 1 expression in ovarian cancer cells. target gene hsa-let-7a Ovarian Neoplasms 23136250 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 The hsa-let-7 family member hsa-let-7a is a modulator of KLK6 protein expression that is independent of the KLK6 copy number status. target gene hsa-let-7d Ovarian Neoplasms 23268403 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Construction of let-7d expression vector and its inhibitory effect on HMGA2 and ras expression in human ovarian cancer cells in vitro target gene hsa-let-7f-1 Ovarian Neoplasms 20354523 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 When we co-transfected cells with pMIR-KLK10 and either let-7f, miR-224, or mR-516a, we saw decreased luciferase signal, suggesting that these miRNAs can target KLK10. target gene hsa-let-7f-2 Ovarian Neoplasms 20354523 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 When we co-transfected cells with pMIR-KLK10 and either let-7f, miR-224, or mR-516a, we saw decreased luciferase signal, suggesting that these miRNAs can target KLK10. target gene hsa-mir-1 Ovarian Neoplasms 26117268 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 The mRNA level of HOTAIR and MAPK1 in ovarian SKOV3 decreased when transected with miR-1, miR-214-3p, or miR-330-5p compared to negative control (p<0.05). target gene hsa-mir-106a Ovarian Neoplasms 23807165 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MiR-106a and miR-591 have important roles in conferring PTX resistance to ovarian cancer cells. Modulation of these microRNAs resensitizes PTX-resistant cancer cells by targeting BCL10, caspase-7,and ZEB1. target gene hsa-mir-106a Ovarian Neoplasms 23904379 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells. target gene hsa-mir-124 Ovarian Neoplasms 29344168 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MiR-124 inhibits invasion and induces apoptosis of ovarian cancer cells by targeting programmed cell death 6 target gene hsa-mir-125b-1 Ovarian Neoplasms 21823019 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1. target gene hsa-mir-125b-2 Ovarian Neoplasms 21823019 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1. target gene hsa-mir-1271 Ovarian Neoplasms 26477861 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Low levels of miR-1271 in ovarian cancer tissues promoted cancer cell growth. MiR-1271 may be a new predictor of prognosis in ovarian cancer.MiR-1271 exerted its role by targeting CCNG1. target gene hsa-mir-128-1 Ovarian Neoplasms 22909061 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Both miR-128 and miR-152 down-regulate CSF-1 mRNA and protein expression in ovarian cancer cells leading to decreased cell motility and adhesion in vitro, two major aspects of the metastatic potential of cancer cells. target gene hsa-mir-128-2 Ovarian Neoplasms 22909061 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Both miR-128 and miR-152 down-regulate CSF-1 mRNA and protein expression in ovarian cancer cells leading to decreased cell motility and adhesion in vitro, two major aspects of the metastatic potential of cancer cells. target gene hsa-mir-130a Ovarian Neoplasms 24490491 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MiR-130a expression may be associated with cisplatin resistance of ovarian cancer cells. MiR-130a inhibitor can reverse the cisplatin resistance by upregulating the expression of PTEN proteins and down-regulating P-gp in A2780 cell lines. MiR-130 may become a new potential target of genetic therapy for cisplatin-resistant ovarian cancers. target gene hsa-mir-130a Ovarian Neoplasms 26573160 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 NRP1 is targeted by miR-130a and miR-130b, and is associated with multidrug resistance in epithelial ovarian cancer based on integrated gene network analysis. target gene hsa-mir-130a Ovarian Neoplasms 24145606 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly. target gene hsa-mir-130b Ovarian Neoplasms 26573160 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 NRP1 is targeted by miR-130a and miR-130b, and is associated with multidrug resistance in epithelial ovarian cancer based on integrated gene network analysis. target gene hsa-mir-133a Ovarian Neoplasms 24127040 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 miR-133a suppresses ovarian cancer cell proliferation by directly targeting insulin-like growth factor 1 receptor. target gene hsa-mir-133a-1 Ovarian Neoplasms 22452920 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Other pairs of potentially biological relevance include: hsa-miR-145/E2F3, hsa-miR-139-5p/TOP2A, and hsa-miR-133a/GCLC. target gene hsa-mir-133a-2 Ovarian Neoplasms 22452920 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Other pairs of potentially biological relevance include: hsa-miR-145/E2F3, hsa-miR-139-5p/TOP2A, and hsa-miR-133a/GCLC. target gene hsa-mir-133b Ovarian Neoplasms 26396496 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MicroRNA-133b may reduce ovarian cancer drug resistance by silencing the expression of the drug-resistance-related proteins, GST-π and MDR1. In future, the combination of miR-133b with chemotherapy agents may prevent the development of drug resistance in ovarian cancers. target gene hsa-mir-133b Ovarian Neoplasms 26617770 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Altogether, our results indicated that miR-133b overexpression was shown to inhibit proliferation and invasion of OC cells through suppression of the MAPK and PI3K/Akt signaling pathways by targeting EGFR. target gene hsa-mir-135a Ovarian Neoplasms 24016480 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 miR-135a may play an important role in cell proliferation and apoptosis of ovarian cancer cells by regulating HOXA10 and its downstream pathways. target gene hsa-mir-136 Ovarian Neoplasms 25482209 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 miR-136 may function as an anti-oncogene and deficiency of miR-136 expression in ovarian cancer can induce chemoresistance at least in part by downregulating apoptosis and promoting the repair of cisplatin-induced DNA damage. Thus, miR-136 may provide a biomarker for predicting the chemosensitivity to cisplatin in patients with epithelial ovarian cancer. target gene hsa-mir-137 Ovarian Neoplasms 24144591 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 miR-137 suppresses cell growth in ovarian cancer by targeting AEG-1. target gene hsa-mir-138 Ovarian Neoplasms 25190487 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Upregulation of Limk1 caused by microRNA-138 loss aggravates the metastasis of ovarian cancer by activation of Limk1/cofilin signaling. target gene hsa-mir-138-1 Ovarian Neoplasms 23389731 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1a target gene hsa-mir-138-2 Ovarian Neoplasms 23389731 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1a target gene hsa-mir-141 Ovarian Neoplasms 23045278 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells target gene hsa-mir-145 Ovarian Neoplasms 23919393 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MicroRNA-145 function as a cell growth repressor by directly targeting c-Myc in human ovarian cancer. target gene hsa-mir-145 Ovarian Neoplasms 24510775 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6. target gene hsa-mir-145 Ovarian Neoplasms 24157791 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MiR-145 is downregulated in human ovarian cancer and modulates cell growth and invasion by targeting p70S6K1 and MUC1. target gene hsa-mir-145 Ovarian Neoplasms 21917858 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 The expression of miR-145 is downregulated in colon and ovarian cancer tissues and cell lines. MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. target gene hsa-mir-145 Ovarian Neoplasms 22452920 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Other pairs of potentially biological relevance include: hsa-miR-145/E2F3, hsa-miR-139-5p/TOP2A, and hsa-miR-133a/GCLC. target gene hsa-mir-148a Ovarian Neoplasms 26004124 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MicroRNA-148a inhibits the proliferation and promotes the paclitaxel-induced apoptosis of ovarian cancer cells by targeting PDIA3. target gene hsa-mir-148a Ovarian Neoplasms 26004261 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MicroRNA-148a inhibits migration and invasion of ovarian cancer cells via targeting sphingosine-1-phosphate receptor 1. target gene hsa-mir-149 Ovarian Neoplasms 26223974 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Our findings suggest that miRNA-149 mediates the susceptibility of paclitaxel by regulating MyD88 expression in ovarian cancer cells. target gene hsa-mir-151 Ovarian Neoplasms 24188450 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 the up-regulated miR-151 and miR-672 can also target expression of TNFSF10 and FNDC1, which have been shown to positively regulate cell apoptosis. target gene hsa-mir-152 Ovarian Neoplasms 23318422 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine target gene hsa-mir-152 Ovarian Neoplasms 29434752 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MicroRNA-152 inhibits ovarian cancer cell proliferation and migration and may infer improved outcomes in ovarian cancer through targeting FOXP1. target gene hsa-mir-153 Ovarian Neoplasms 25954928 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MicroRNA-153 functions as a tumor suppressor by targeting SET7 and ZEB2 in ovarian cancer cells. target gene hsa-mir-155 Ovarian Neoplasms 26779627 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 miR-155 mediates cisplatin-induced apoptosis by targeting XIAP in ovarian cancer target gene hsa-mir-16 Ovarian Neoplasms 23990444 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Two regulatory networks for miRNA target genes and TF target genes were established and then both were combined, in which E2F transcription factor 1, cyclin-dependent kinase inhibitor 1A, cyclin E1, and miR-16 were the hub genes. These genes may be potential biomarkers for ovarian cancer. target gene hsa-mir-16-1 Ovarian Neoplasms 23302126 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MicroRNA-16 regulates the proliferation, invasion and apoptosis of ovarian epithelial carcinoma cells in vitro target gene hsa-mir-16-2 Ovarian Neoplasms 23302126 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MicroRNA-16 regulates the proliferation, invasion and apoptosis of ovarian epithelial carcinoma cells in vitro target gene hsa-mir-17 Ovarian Neoplasms 25561420 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 miR-17-5p might play a role in human ovarian cancer by up-regulating YES1 expression. target gene hsa-mir-17 Ovarian Neoplasms 23396109 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Downregulation of miR-17~92 Expression Increase Paclitaxel Sensitivity in Human Ovarian Carcinoma SKOV3-TR30 Cells via BIM Instead of PTEN target gene hsa-mir-181b Ovarian Neoplasms 24735543 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MicroRNA-181b promotes ovarian cancer cell growth and invasion by targeting LATS2. target gene hsa-mir-182 Ovarian Neoplasms 23296900 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MicroRNA-182 promotes cell growth, invasion and chemoresistance by targeting programmed cell death 4 (PDCD4) in human ovarian carcinomas target gene hsa-mir-182 Ovarian Neoplasms 26472020 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 In normal FTSE cells, miR-182 overexpression triggers cellular senescence by p53-mediated upregulation of p21. target gene hsa-mir-183 Ovarian Neoplasms 22469921 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Tiam1, negatively regulated by miR-22, miR-183 and miR-31, is involved in migration, invasion and viability of ovarian cancer cells. target gene hsa-mir-185 Ovarian Neoplasms 23318422 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine target gene hsa-mir-186 Ovarian Neoplasms 25867064 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin. target gene hsa-mir-186 Ovarian Neoplasms 26626440 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Our results are the first to demonstrate that miR-186 may sensitize ovarian cancer cell to paclitaxel and cisplatin by targeting ABCB1 and modulating the expression of GST-π. target gene hsa-mir-187 Ovarian Neoplasms 21725366 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 microRNA-187 Regulates of ovarian cancer progression through targeting Disabled homolog-2. target gene hsa-mir-18a Ovarian Neoplasms 28588697 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MicroRNA-18a inhibits ovarian cancer growth via directly targeting TRIAP1 and IPMK. target gene hsa-mir-191 Ovarian Neoplasms 21084273 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 We conclude that acquisition of an illegitimate miR-191 target site causes downregulation of MDM4 expression,thereby significantly delaying ovarian carcinoma progression and tumor-related death. target gene hsa-mir-193a Ovarian Neoplasms 23588298 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 We demonstrated that miR-193a decreased the amount of MCL1 protein by binding 3'UTR of its mRNA. target gene hsa-mir-197 Ovarian Neoplasms 25833695 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MiR-197 induces Taxol resistance in human ovarian cancer cells by regulating NLK. target gene hsa-mir-199a Ovarian Neoplasms 26711828 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 miR-199a regulates the sensitivity of ovarian cancer cells to cisplatin through modulating expression of mTOR, and involves in the cisplatin resistance process of ovarian cancer cells. target gene hsa-mir-199a Ovarian Neoplasms 24706848 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis. target gene hsa-mir-199a Ovarian Neoplasms 18408758 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Furthermore, we describe for the first time the identification of the microRNA hsa-miR-199a as a regulator of IKKbeta expression. Our study describes the property of ovarian cancer cells to enhance the inflammatory microenvironment as a result of the expression of an active IKKbeta pathway. target gene hsa-mir-199a-1 Ovarian Neoplasms 22498306 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MicroRNA-199a targets CD44 to suppress the tumorigenicity and multi-drug resistance of ovarian cancer-initiating cells. target gene hsa-mir-199a-2 Ovarian Neoplasms 22498306 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MicroRNA-199a targets CD44 to suppress the tumorigenicity and multi-drug resistance of ovarian cancer-initiating cells. target gene hsa-mir-200a Ovarian Neoplasms 24503464 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Our research demonstrates that VM, miR-200a and EphA2 play key roles in the progression and prognosis of ovarian cancer, and for the first time suggests that miR-200a inhibits VM by directly regulating EphA2. Therefore, we might have identified a genetic mechanism underlying the involvement of miR-200a in ovarian cancer VM. target gene hsa-mir-200a Ovarian Neoplasms 21529905 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MicroRNA-200a inhibits CD133/1+ ovarian cancer stem cells migration and invasion by targeting E-cadherin repressor ZEB2. target gene hsa-mir-200c Ovarian Neoplasms 25052237 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 miR-200c modulates ovarian cancer cell metastasis potential by targeting zinc finger E-box-binding homeobox 2 (ZEB2) expression. target gene hsa-mir-200c Ovarian Neoplasms 25860109 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 This network included four separate types of interactions among miRNAs and genes. Simply analyzing each interaction component in isolation, such as the eQTL associations, the miRNA-target interactions or the protein-protein interactions, would create a much more limited network than the integrated one. target gene hsa-mir-20a Ovarian Neoplasms 24813230 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Ovarian tumor-associated microRNA-20a decreases natural killer cell cytotoxicity by downregulating MICA/B expression. target gene hsa-mir-20a Ovarian Neoplasms 20458444 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 miR-20a:miR-20a promotes proliferation and invasion by targeting APP in human ovarian cancer cells target gene hsa-mir-20a Ovarian Neoplasms 23869765 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 transfection of miR-20a or miR-200c led to corresponding reduction in endogenous PTEN protein target gene hsa-mir-21 Ovarian Neoplasms 23824073 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Berberine sensitizes ovarian cancer cells to cisplatin through miR-21/PDCD4 axis. target gene hsa-mir-21 Ovarian Neoplasms 25579119 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 miR-21-3p can induce cisplatin resistance in ovarian tumours, potentially by targeting the NAV3 gene. target gene hsa-mir-21 Ovarian Neoplasms 22176994 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 miR-21 might play an important role in the proliferation and apoptosis of ovarian epithelial carcinoma cells through negatively control the expression of PDCD4. target gene hsa-mir-210 Ovarian Neoplasms 24549370 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Inactivation of von Hippel-Lindau increases ovarian cancer cell aggressiveness through the HIF1α/miR-210/VMP1 signaling pathway. target gene hsa-mir-212 Ovarian Neoplasms 25201063 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MiR-212 exerts suppressive effect on SKOV3 ovarian cancer cells through targeting HBEGF. target gene hsa-mir-214 Ovarian Neoplasms 22927443 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MiR-214 regulates ovarian cancer cell stemness by targeting p53/nanog. target gene hsa-mir-22 Ovarian Neoplasms 25860109 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 This network included four separate types of interactions among miRNAs and genes. Simply analyzing each interaction component in isolation, such as the eQTL associations, the miRNA-target interactions or the protein-protein interactions, would create a much more limited network than the integrated one. target gene hsa-mir-22 Ovarian Neoplasms 22469921 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Tiam1, negatively regulated by miR-22, miR-183 and miR-31, is involved in migration, invasion and viability of ovarian cancer cells. target gene hsa-mir-222 Ovarian Neoplasms 27811362 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MicroRNA-222-3p/GNAI2/AKT axis inhibits epithelial ovarian cancer cell growth and associates with good overall survival. target gene hsa-mir-224 Ovarian Neoplasms 25017423 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 miR-224-5p may function as an oncogene and induce platinum resistance in OPSC at least in part by downregulating PRKCD, thereby providing a biomarker for predicting chemosensitivity to cisplatin in patients with ovarian cancer. target gene hsa-mir-224 Ovarian Neoplasms 20354523 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 When we co-transfected cells with pMIR-KLK10 and either let-7f, miR-224, or mR-516a, we saw decreased luciferase signal, suggesting that these miRNAs can target KLK10. target gene hsa-mir-23a Ovarian Neoplasms 25613625 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 nhibition of miR-23a expression increases the sensitivity of A2780 cells to cisplatin possibly by inhibiting the negative regulation by miR-23a target genes that causes inhibition of P-gp protein expression. target gene hsa-mir-23b Ovarian Neoplasms 24613919 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MicroRNA-23b is an independent prognostic marker and suppresses ovarian cancer progression by targeting runt-related transcription factor-2. target gene hsa-mir-23b Ovarian Neoplasms 26872615 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Our findings show that miR-23b may inhibit ovarian cancer tumorigenesis and progression by downregulating CCNG1 and the expression of the relevant genes. MiR-23b is a potentially novel application for regulating ovarian carcinoma progression. target gene hsa-mir-25 Ovarian Neoplasms 25179841 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MiR-25 promotes ovarian cancer proliferation and motility by targeting LATS2. target gene hsa-mir-25 Ovarian Neoplasms 22076535 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MiR-25 regulates apoptosis by targeting Bim in human ovarian cancer. target gene hsa-mir-27a Ovarian Neoplasms 20624637 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MiR-27a:MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells target gene hsa-mir-27a Ovarian Neoplasms 23438830 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Oncogenic MicroRNA-27a is a Target for Genistein in Ovarian Cancer Cells target gene hsa-mir-27a Ovarian Neoplasms 20646448 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 The expression of miR-27a is upregulated in A2780/Taxol cells, which may regulate MDR1 and P-gp expression by targeting HIPK2. target gene hsa-mir-296 Ovarian Neoplasms 27186401 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 deregulated miR-296/S100A4 promotes tumor progression target gene hsa-mir-29b Ovarian Neoplasms 29050034 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Mir-29b Regulates Oxidative Stress by Targeting SIRT1 in Ovarian Cancer Cells. target gene hsa-mir-302b Ovarian Neoplasms 25562167 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MiR-302b functions as a tumor suppressor in EOC by targeting RUNX1 and modulating the activity of the STAT3 signaling pathway. target gene hsa-mir-30a Ovarian Neoplasms 22157765 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy. target gene hsa-mir-30a Ovarian Neoplasms 25621074 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 miR-30a overexpression upregulates BCL2A1, IER3 and cyclin D2 expression by inhibiting FOXL2. target gene hsa-mir-30c-1 Ovarian Neoplasms 22024689 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MicroRNA-30c-2* expressed in ovarian cancer cells suppresses growth factor induced cellular proliferation and downregulates the oncogene BCL9. target gene hsa-mir-30c-2 Ovarian Neoplasms 22024689 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MicroRNA-30c-2* expressed in ovarian cancer cells suppresses growth factor induced cellular proliferation and downregulates the oncogene BCL9. target gene hsa-mir-31 Ovarian Neoplasms 22469921 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Tiam1, negatively regulated by miR-22, miR-183 and miR-31, is involved in migration, invasion and viability of ovarian cancer cells. target gene hsa-mir-330 Ovarian Neoplasms 29485916 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p. target gene hsa-mir-335 Ovarian Neoplasms 23708561 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 miR-335 represents an invasion suppressor gene in ovarian cancer by targeting Bcl-w. target gene hsa-mir-34a Ovarian Neoplasms 25895459 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MiR-34a suppresses ovarian cancer proliferation and motility by targeting AXL. target gene hsa-mir-370 Ovarian Neoplasms 25063739 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 miR-370 acts as a tumor suppressor in endometrioid ovarian cancer via ENG regulation. target gene hsa-mir-376c Ovarian Neoplasms 21224400 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance. target gene hsa-mir-382 Ovarian Neoplasms 26575700 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 these findings revealed that miR-382 inhibits migration and invision by targeting ROR1 through regulating EMT in ovarian cancer, and might serve as a tumor suppressor in ovarian cancer. target gene hsa-mir-433 Ovarian Neoplasms 22069160 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MAD2 protein expression levels were downregulated in pre-miR-433 transfected A2780 cells. Secondly, Pre-miR-433 suppressed the activity of a reporter construct containing the 3'-UTR of MAD2. Thirdly, blocking miR-433 binding to the MAD2 3'UTR protected MAD2 from miR-433 induced protein downregulation. Importantly, reduced MAD2 protein expression in pre-miR-433 transfected A2780 cells rendered these cells less sensitive to paclitaxel. In conclusion, loss of MAD2 protein expression results in increased resistance to paclitaxel in EOC cells. target gene hsa-mir-448 Ovarian Neoplasms 26103953 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Our data indicate that miR-448 functions as a tumor suppressor in ovarian cancer, which exerts its activity by suppressing the expression of CXCL12. target gene hsa-mir-486 Ovarian Neoplasms 26871282 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 OLFM4 is downregulated by miR-486-5p, which contributes to ovarian cancer tumorigenesis. target gene hsa-mir-488 Ovarian Neoplasms 29113360 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 microRNA-488 inhibits chemoresistance of ovarian cancer cells by targeting Six1 and mitochondrial function. target gene hsa-mir-497 Ovarian Neoplasms 24858688 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MicroRNA-497 inhibition of ovarian cancer cell migration and invasion through targeting of SMAD specific E3 ubiquitin protein ligase 1. target gene hsa-mir-497 Ovarian Neoplasms 25176450 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MicroRNA-497 suppresses angiogenesis by targeting vascular endothelial growth factor A through the PI3K/AKT and MAPK/ERK pathways in ovarian cancer. target gene hsa-mir-497 Ovarian Neoplasms 26238185 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1. target gene hsa-mir-498 Ovarian Neoplasms 26054675 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MiR-498 regulated FOXO3 expression and inhibited the proliferation of human ovarian cancer cells. target gene hsa-mir-506 Ovarian Neoplasms 24604117 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer. target gene hsa-mir-516a-1 Ovarian Neoplasms 20354523 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 When we co-transfected cells with pMIR-KLK10 and either let-7f, miR-224, or mR-516a, we saw decreased luciferase signal, suggesting that these miRNAs can target KLK10. target gene hsa-mir-516a-2 Ovarian Neoplasms 20354523 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 When we co-transfected cells with pMIR-KLK10 and either let-7f, miR-224, or mR-516a, we saw decreased luciferase signal, suggesting that these miRNAs can target KLK10. target gene hsa-mir-532 Ovarian Neoplasms 29558748 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Ginsenoside 20(S)-Rg3 Inhibits the Warburg Effect Via Modulating DNMT3A/ MiR-532-3p/HK2 Pathway in Ovarian Cancer Cells. target gene hsa-mir-591 Ovarian Neoplasms 23807165 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MiR-106a and miR-591 have important roles in conferring PTX resistance to ovarian cancer cells. Modulation of these microRNAs resensitizes PTX-resistant cancer cells by targeting BCL10, caspase-7,and ZEB1. target gene hsa-mir-629 Ovarian Neoplasms 28972400 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Knockdown of miR-629 Inhibits Ovarian Cancer Malignant Behaviors by Targeting Testis-Specific Y-Like Protein 5. target gene hsa-mir-873 Ovarian Neoplasms 26850595 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 overexpression of miR-873 increased the sensitivity of ovarian cancer cells to cisplatin and paclitaxel by targeting MDR1 expression. target gene hsa-mir-9 Ovarian Neoplasms 19702828 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Ovarian cancer tissues display significantly low expression of miR-9 and a high level of NF-kappaB1 compared with normal tissues, indicating that regulation of NF-kappaB1 by miR-9 is an important mechanism for miR-9 to inhibit ovarian cancer proliferation. target gene hsa-mir-9 Ovarian Neoplasms 23722670 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 miR-9 functions as a tumor suppressor in ovarian serous carcinoma by targeting TLN1. target gene hsa-mir-92a-1 Ovarian Neoplasms 23396109 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Downregulation of miR-17~92 Expression Increase Paclitaxel Sensitivity in Human Ovarian Carcinoma SKOV3-TR30 Cells via BIM Instead of PTEN target gene hsa-mir-92a-2 Ovarian Neoplasms 23396109 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Downregulation of miR-17~92 Expression Increase Paclitaxel Sensitivity in Human Ovarian Carcinoma SKOV3-TR30 Cells via BIM Instead of PTEN target gene hsa-mir-93 Ovarian Neoplasms 22465665 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. target gene hsa-mir-93 Ovarian Neoplasms 24626475 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 miRNA expression analysis determined that miR-93, miR-144 and miR-382 had significantly lower levels of expression in primary serous OvCa tumors than normal tissues; treatment of an OvCa cell line with miRNA mimics and inhibitors specifically modulated KIF14 mRNA levels, pointing to potential novel mechanisms of KIF14 overexpression in primary tumors. target gene hsa-mir-98 Ovarian Neoplasms 24771265 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 EZH2-specific microRNA-98 inhibits human ovarian cancer stem cell proliferation via regulating the pRb-E2F pathway. target gene hsa-mir-98 Ovarian Neoplasms 21109987 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Involvement of let-7/miR-98 microRNAs in the regulation of progesterone receptor membrane component 1 expression in ovarian cancer cells. target gene hsa-mir-490 Ovary Mixed Epithelial Carcinoma 25819031 endocrine system disease DOID:6898 MicroRNA-490-3P targets CDK1 and inhibits ovarian epithelial carcinoma tumorigenesis and progression. target gene hsa-mir-183 Pain 28214854 R52 D010146 MicroRNA-183 Suppresses Neuropathic Pain and Expression of AMPA Receptors by Targeting mTOR/VEGF Signaling Pathway. target gene hsa-mir-23b Pain 22149086 R52 D010146 MiR23b Ameliorates Neuropathic Pain in Spinal Cord by Silencing NOX4. target gene hsa-mir-96 Pain 24234845 R52 D010146 miR-96 participate in the regulation of neuropathic pain through inhibiting the expression of Nav1.3 in the DRG of CCI rats. target gene hsa-mir-372 Pancreatic Adenocarcinoma 28677209 disease of cellular proliferation DOID:4074 C25.3 Downregulation of ULK1 by microRNA-372 inhibits the survival of human pancreatic adenocarcinoma cells. target gene hsa-let-7b Pancreatic Diseases 23684747 K86.9 D010182 Let-7b, miR-495, and their targets constitute a gene network that is required to establish and maintain pancreatic acinar cell differentiation. target gene hsa-mir-495 Pancreatic Diseases 23684747 K86.9 D010182 Let-7b, miR-495, and their targets constitute a gene network that is required to establish and maintain pancreatic acinar cell differentiation. target gene hsa-let-7 Pancreatic Neoplasms 24491408 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 MicroRNA let-7 downregulates STAT3 phosphorylation in pancreatic cancer cells by increasing SOCS3 expression. target gene hsa-let-7d Pancreatic Neoplasms 22384141 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 The miRNA is downregulated and regulate known PDAC oncogenes target gene hsa-let-7i Pancreatic Neoplasms 22261338 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 The miRNAs, let-7i and miR-143 was found to target Ras, and forced re-expression of let-7i and miR-143 inhibited Ras activity, cell proliferation and colony formation in vitro. target gene hsa-mir-10 Pancreatic Neoplasms 21738581 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Predicted target mRNAs FGFR1 (miR-10) and MLH1 (miR-155) were found downregulated. target gene hsa-mir-100 Pancreatic Neoplasms 25344675 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 MicroRNA-100 regulates pancreatic cancer cells growth and sensitivity to chemotherapy through targeting FGFR3. target gene hsa-mir-100 Pancreatic Neoplasms 23373509 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 MicroRNA-100 regulates IGF1-receptor expression in metastatic pancreatic cancer cells target gene hsa-mir-106b Pancreatic Neoplasms 25807437 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Our findings may provide new insights into the knowledge of molecular mechanisms of pancreatic cancer and development of novel targeting therapies. target gene hsa-mir-10a Pancreatic Neoplasms 22407312 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Based on the microarray data, the authors found frequent and marked overexpression of miR-10a, miR-92, and miR-17-5p in pancreatic cancer cell lines. MicroRNA-10a is Overexpressed in Human Pancreatic Cancer and Involved in Its Invasiveness Partially via Suppression of the HOXA1 Gene. target gene hsa-mir-1178 Pancreatic Neoplasms 25635996 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 miR-1178 acts as an oncomiR in pancreatic cancer cells by inhibiting CHIP expression. target gene hsa-mir-1247 Pancreatic Neoplasms 24588767 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 miR-1247 is correlated with prognosis of pancreatic cancer and inhibits cell proliferation by targeting neuropilins. target gene hsa-mir-124a Pancreatic Neoplasms 17462994 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 MicroRNA-124a regulates Foxa2 expression and intracellular signaling in pancreatic beta-cell lines. target gene hsa-mir-125a Pancreatic Neoplasms 25807437 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Our findings may provide new insights into the knowledge of molecular mechanisms of pancreatic cancer and development of novel targeting therapies. target gene hsa-mir-126 Pancreatic Neoplasms 22064652 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9. target gene hsa-mir-126 Pancreatic Neoplasms 22384141 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 The miRNA is downregulated and regulate known PDAC oncogenes target gene hsa-mir-1271 Pancreatic Neoplasms 26940738 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 miR-1271 inhibits migration, invasion and epithelial-mesenchymal transition by targeting ZEB1 and TWIST1 in pancreatic cancer cells. target gene hsa-mir-130b Pancreatic Neoplasms 24040078 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 MiR-130b is a prognostic marker and inhibits cell proliferation and invasion in pancreatic cancer through targeting STAT3. target gene hsa-mir-132 Pancreatic Neoplasms 21329664 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor, rb1. target gene hsa-mir-139 Pancreatic Neoplasms 25955258 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 miR-139 and miR-200c regulate pancreatic cancer endothelial cell migration and angiogenesis. target gene hsa-mir-141 Pancreatic Neoplasms 24013097 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 miR-141 targets MAP4K4, acts as a tumor suppressor in pancreatic cancer cells, and may serve as a novel therapeutic agent for miRNA-based pancreatic cancer therapy. target gene hsa-mir-143 Pancreatic Neoplasms 23973710 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 miR-143 decreases COX-2 mRNA stability and expression in pancreatic cancer cells. target gene hsa-mir-143 Pancreatic Neoplasms 22261338 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 The miRNAs, let-7i and miR-143 was found to target Ras, and forced re-expression of let-7i and miR-143 inhibited Ras activity, cell proliferation and colony formation in vitro. target gene hsa-mir-143 Pancreatic Neoplasms 21622730 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Two miRNA candidates known to be downregulated in the majority of pancreatic cancers were selected for nanovector delivery: miR-34a, which is a component of the p53 transcriptional network and regulates cancer stem cell survival, and the miR-143/145 cluster, which together repress the expression of KRAS2 and its downstream effector Ras-responsive element binding protein-1 (RREB1). target gene hsa-mir-145 Pancreatic Neoplasms 25277192 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer. target gene hsa-mir-145 Pancreatic Neoplasms 25354783 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Identification of miR-145 targets through an integrated omics analysis. target gene hsa-mir-145 Pancreatic Neoplasms 25646678 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 MicroRNA-145 suppresses cell proliferation, invasion and migration in pancreatic cancer cells by targeting NEDD9 target gene hsa-mir-145 Pancreatic Neoplasms 21622730 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Two miRNA candidates known to be downregulated in the majority of pancreatic cancers were selected for nanovector delivery: miR-34a, which is a component of the p53 transcriptional network and regulates cancer stem cell survival, and the miR-143/145 cluster, which together repress the expression of KRAS2 and its downstream effector Ras-responsive element binding protein-1 (RREB1). target gene hsa-mir-146b Pancreatic Neoplasms 21823013 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 miR-146b-5p has inhibitory effects of on cell migration and invasion of pancreatic cancer by targeting MMP16. target gene hsa-mir-148a Pancreatic Neoplasms 23975374 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 MiR-148a regulates the growth and apoptosis in pancreatic cancer by targeting CCKBR and Bcl-2. target gene hsa-mir-148a Pancreatic Neoplasms 21709669 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 MicroRNA-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting CDC25B. target gene hsa-mir-148b Pancreatic Neoplasms 24448385 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 MicroRNA-148b and microRNA-152 reactivate tumor suppressor genes through suppression of DNA methyltransferase-1 gene in pancreatic cancer cell lines. target gene hsa-mir-150 Pancreatic Neoplasms 25522282 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 miR-150 is an important suppressor of pancreatic ductal carcinoma and acts as a regulator of c-Myb and MUC4 in aggressive progress. target gene hsa-mir-150 Pancreatic Neoplasms 21983127 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells. target gene hsa-mir-150 Pancreatic Neoplasms 23675407 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Upregulation of miR-150* and miR-630 Induces Apoptosis in Pancreatic Cancer Cells by Targeting IGF-1R. target gene hsa-mir-152 Pancreatic Neoplasms 24448385 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 MicroRNA-148b and microRNA-152 reactivate tumor suppressor genes through suppression of DNA methyltransferase-1 gene in pancreatic cancer cell lines. target gene hsa-mir-153 Pancreatic Neoplasms 25807437 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Our findings may provide new insights into the knowledge of molecular mechanisms of pancreatic cancer and development of novel targeting therapies. target gene hsa-mir-155 Pancreatic Neoplasms 17911264 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. target gene hsa-mir-155 Pancreatic Neoplasms 23715647 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 MLH1 as a Direct Target of MiR-155 and a Potential Predictor of Favorable Prognosis in Pancreatic Cancer. target gene hsa-mir-155 Pancreatic Neoplasms 21738581 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Predicted target mRNAs FGFR1 (miR-10) and MLH1 (miR-155) were found downregulated. target gene hsa-mir-16-1 Pancreatic Neoplasms 22384141 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 The miRNA is downregulated and regulate known PDAC oncogenes target gene hsa-mir-16-2 Pancreatic Neoplasms 22384141 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 The miRNA is downregulated and regulate known PDAC oncogenes target gene hsa-mir-17 Pancreatic Neoplasms 22407312 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Based on the microarray data, the authors found frequent and marked overexpression of miR-10a, miR-92, and miR-17-5p in pancreatic cancer cell lines. MicroRNA-10a is Overexpressed in Human Pancreatic Cancer and Involved in Its Invasiveness Partially via Suppression of the HOXA1 Gene. target gene hsa-mir-17 Pancreatic Neoplasms 23194063 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 The mechanism of curcumin-/RL197-induced repression of Sp transcription factors was ROS-dependent and due to induction of the Sp repressors ZBTB10 and ZBTB4 and downregulation of microRNAs (miR)-27a, miR-20a and miR-17-5p that regulate these repressors. target gene hsa-mir-181b Pancreatic Neoplasms 24075517 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 The present study demonstrated that miR-181b was associated with the resistance of pancreatic cancer cells to gemcitabine, and verified that miR-181b enhances the activity of NF-κB by inhibiting CYLD, leading to the resistance to gemcitabine. Our results suggest that miR-181b is a potential target for decreasing gemcitabine resistance. target gene hsa-mir-181c Pancreatic Neoplasms 25807437 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Our findings may provide new insights into the knowledge of molecular mechanisms of pancreatic cancer and development of novel targeting therapies. target gene hsa-mir-183 Pancreatic Neoplasms 25776494 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 miR-183 induces cell proliferation, migration, and invasion by regulating PDCD4 expression in the SW1990 pancreatic cancer cell line. target gene hsa-mir-19 Pancreatic Neoplasms 26531836 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 A positive feedback loop of p53/miR-19/TP53INP1 modulates pancreatic cancer cell proliferation and apoptosis. target gene hsa-mir-191 Pancreatic Neoplasms 25168367 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 MicroRNA-191 promotes pancreatic cancer progression by targeting USP10. target gene hsa-mir-193b Pancreatic Neoplasms 25215905 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 miR-193b directly targets STMN1 and uPA genes and suppresses tumor growth and metastasis in pancreatic cancer. target gene hsa-mir-193b Pancreatic Neoplasms 25905463 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Deregulation of the MiR-193b-KRAS Axis Contributes to Impaired Cell Growth in Pancreatic Cancer. target gene hsa-mir-196a Pancreatic Neoplasms 24504166 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 MiR-196a promotes pancreatic cancer progression by targeting nuclear factor kappa-B-inhibitor alpha. target gene hsa-mir-197 Pancreatic Neoplasms 23139153 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 MiR-197 induces epithelial-mesenchymal transition in pancreatic cancer cells by targeting p120 catenin target gene hsa-mir-200a Pancreatic Neoplasms 20551052 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 miR-200a:The elevated serum levels of miR-200a and miR-200b in most patients with pancreatic cancer could have diagnostic utility target gene hsa-mir-200a Pancreatic Neoplasms 21224848 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. target gene hsa-mir-200a Pancreatic Neoplasms 22637745 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer. target gene hsa-mir-200a Pancreatic Neoplasms 28281184 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 TGF-β1-miR-200a-PTEN induces epithelial-mesenchymal transition and fibrosis of pancreatic stellate cells. target gene hsa-mir-200b Pancreatic Neoplasms 20551052 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 miR-200b:The elevated serum levels of miR-200a and miR-200b in most patients with pancreatic cancer could have diagnostic utility target gene hsa-mir-200b Pancreatic Neoplasms 21224848 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. target gene hsa-mir-200b Pancreatic Neoplasms 22637745 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer. target gene hsa-mir-200c Pancreatic Neoplasms 24204560 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 MicroRNA-200c modulates the expression of MUC4 and MUC16 by directly targeting their coding sequences in human pancreatic cancer. target gene hsa-mir-200c Pancreatic Neoplasms 25955258 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 miR-139 and miR-200c regulate pancreatic cancer endothelial cell migration and angiogenesis. target gene hsa-mir-200c Pancreatic Neoplasms 21224848 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. target gene hsa-mir-200c Pancreatic Neoplasms 22637745 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer. target gene hsa-mir-200c Pancreatic Neoplasms 26400206 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 More importantly, garcinol treatment led to the upregulation of several tumor suppressor microRNAs, and miR-200c increased by garcinol treatment was found to target and downregulate Notch1. target gene hsa-mir-200c Pancreatic Neoplasms 26609108 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Paradoxically, targeting eIF4E, the best-characterized effector of MNKs, increases ZEB1 mRNA expression through repression of ZEB1-targeting miRNAs, miR-200c and miR-141. target gene hsa-mir-202 Pancreatic Neoplasms 25611699 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 down regulation of miR-202 increased the expression of its target Mxd1, followed by Mxd1 recruitment to the Sin3A repressor complex and through its dimerization with Max, and increased repression of Myc-Max target proteins. target gene hsa-mir-203 Pancreatic Neoplasms 25290620 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Pancreatic cancer derived exosomes regulate the expression of TLR4 in dendritic cells via miR-203. target gene hsa-mir-203 Pancreatic Neoplasms 23732815 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 miR-203 regulates the proliferation, apoptosis and cell cycle progression of pancreatic cancer cells by targeting Survivin. target gene hsa-mir-206 Pancreatic Neoplasms 27233476 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Mechanistically, the Nampt expression was independent of Kras and p16 status, but it was directly regulated by miR-206 target gene hsa-mir-20a Pancreatic Neoplasms 23194063 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 The mechanism of curcumin-/RL197-induced repression of Sp transcription factors was ROS-dependent and due to induction of the Sp repressors ZBTB10 and ZBTB4 and downregulation of microRNAs (miR)-27a, miR-20a and miR-17-5p that regulate these repressors. target gene hsa-mir-21 Pancreatic Neoplasms 21376256 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Bcl-2 Upregulation Induced by miR-21 Via a Direct Interaction Is Associated with Apoptosis and Chemoresistance in MIA PaCa-2 Pancreatic Cancer Cells. target gene hsa-mir-21 Pancreatic Neoplasms 23177026 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL target gene hsa-mir-21 Pancreatic Neoplasms 23359184 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Resveratrol induces apoptosis of pancreatic cancers cells by inhibiting miR-21 regulation of BCL-2 expression target gene hsa-mir-21 Pancreatic Neoplasms 29464088 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 the expression of two miRComb miR-21 predicted targets, PDCD4 and BTG2, was significantly upregulated in these cells in comparison to control PANC-1 target gene hsa-mir-210 Pancreatic Neoplasms 23831622 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 miR-210 regulates the interaction between pancreatic cancer cells and stellate cells. target gene hsa-mir-211 Pancreatic Neoplasms 24940696 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells. target gene hsa-mir-212 Pancreatic Neoplasms 26337469 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p. target gene hsa-mir-212 Pancreatic Neoplasms 21329664 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor. target gene hsa-mir-216a Pancreatic Neoplasms 25220761 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 MicroRNA-216a inhibits pancreatic cancer by directly targeting Janus kinase 2. target gene hsa-mir-216a Pancreatic Neoplasms 26149212 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 miR-216a may inhibit pancreatic tumor growth by targeting JAK2. target gene hsa-mir-217 Pancreatic Neoplasms 25172416 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Chronic pancreatitis and pancreatic cancer demonstrate active epithelial-mesenchymal transition profile, regulated by miR-217-SIRT1 pathway. target gene hsa-mir-217 Pancreatic Neoplasms 20675343 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. target gene hsa-mir-218 Pancreatic Neoplasms 25010661 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 MicroRNA-218 inhibits cell invasion and migration of pancreatic cancer via regulating ROBO1. target gene hsa-mir-218-1 Pancreatic Neoplasms 23733161 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 The microRNA-218 and ROBO-1 signaling axis correlates with the lymphatic metastasis of pancreatic cancer. target gene hsa-mir-218-2 Pancreatic Neoplasms 23733161 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 The microRNA-218 and ROBO-1 signaling axis correlates with the lymphatic metastasis of pancreatic cancer. target gene hsa-mir-221 Pancreatic Neoplasms 23967190 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 MicroRNA-221 mediates the effects of PDGF-BB on migration, proliferation, and the epithelial-mesenchymal transition in pancreatic cancer cells. target gene hsa-mir-221 Pancreatic Neoplasms 25639539 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 the inhibition of miR-21 and miR-221 appear particularly suitable to target stem-like subpopulations and address their specific biological function to promote tumor progression in pancreatic cancer target gene hsa-mir-221 Pancreatic Neoplasms 25883224 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 miR-221/222 induces pancreatic cancer progression through the regulation of matrix metalloproteinases. target gene hsa-mir-221 Pancreatic Neoplasms 27726102 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 MiRNA-221-3p desensitizes pancreatic cancer cells to 5-fluorouracil by targeting RB1. target gene hsa-mir-222 Pancreatic Neoplasms 25883224 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 miR-221/222 induces pancreatic cancer progression through the regulation of matrix metalloproteinases. target gene hsa-mir-223 Pancreatic Neoplasms 28423622 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 HnRNPK/miR-223/FBXW7 feedback cascade promotes pancreatic cancer cell growth and invasion. target gene hsa-mir-224 Pancreatic Neoplasms 28036293 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 A retrospective study of NENs and miR-224 promotes apoptosis of BON-1 cells by targeting PCSK9 inhibition. target gene hsa-mir-23b Pancreatic Neoplasms 23916944 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 In pancreatic cancer cells, reduced levels of the miRNA miR-23b increase levels of ATG12 and autophagy to promote radioresistance. miR-23b might be used to increase the sensitivity of pancreatic cancer cells to radiation therapy. target gene hsa-mir-27a Pancreatic Neoplasms 24060073 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 PSMA1 is the direct target gene of miR-27a in pancreatic cancer. target gene hsa-mir-27a Pancreatic Neoplasms 23194063 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 The mechanism of curcumin-/RL197-induced repression of Sp transcription factors was ROS-dependent and due to induction of the Sp repressors ZBTB10 and ZBTB4 and downregulation of microRNAs (miR)-27a, miR-20a and miR-17-5p that regulate these repressors. target gene hsa-mir-29a Pancreatic Neoplasms 26036346 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells. target gene hsa-mir-29c Pancreatic Neoplasms 25605017 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Wnt hyperactivation in pancreatic cancer and may suggest a new target for clinical intervention in pancreatic cancer. target gene hsa-mir-30 Pancreatic Neoplasms 26965588 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 high expression of the miR-30 family modulated by CD133 promotes migratory and invasive abilities in CD133(+) pancreatic cancer cells. target gene hsa-mir-301a Pancreatic Neoplasms 26019136 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 MiR-301a-3p functions as a novel oncogene in PDAC and the oncogenic activity may involve its inhibition of the target gene SMAD4. target gene hsa-mir-330 Pancreatic Neoplasms 26036346 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells. target gene hsa-mir-335 Pancreatic Neoplasms 24859837 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 MiR-335 functions as a tumor suppressor in pancreatic cancer by targeting OCT4. target gene hsa-mir-34b Pancreatic Neoplasms 23305226 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 MicroRNA-34b inhibits pancreatic cancer metastasis through repressing Smad3 target gene hsa-mir-365 Pancreatic Neoplasms 24216611 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 MiR-365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro-apoptotic regulator BAX. target gene hsa-mir-410 Pancreatic Neoplasms 25646808 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 MicroRNA-410 functions as a tumor suppressor by targeting angiotensin II type 1 receptor in pancreatic cancer. target gene hsa-mir-494 Pancreatic Neoplasms 25965392 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Ectopic expression of miR-494 inhibited the proliferation, invasion and chemoresistance of pancreatic cancer by regulating SIRT1 and c-Myc. target gene hsa-mir-497 Pancreatic Neoplasms 24667580 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Insulin-like growth factor 1 receptor (IGF-1R) as a target of MiR-497 and plasma IGF-1R levels associated with TNM stage of pancreatic cancer. target gene hsa-mir-630 Pancreatic Neoplasms 23675407 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Upregulation of miR-150* and miR-630 Induces Apoptosis in Pancreatic Cancer Cells by Targeting IGF-1R. target gene hsa-mir-652 Pancreatic Neoplasms 26498682 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 MiR-652 inhibits acidic microenvironment-induced epithelial-mesenchymal transition of pancreatic cancer cells by targeting ZEB1. target gene hsa-mir-92a-1 Pancreatic Neoplasms 22407312 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Based on the microarray data, the authors found frequent and marked overexpression of miR-10a, miR-92, and miR-17-5p in pancreatic cancer cell lines. MicroRNA-10a is Overexpressed in Human Pancreatic Cancer and Involved in Its Invasiveness Partially via Suppression of the HOXA1 Gene. target gene hsa-mir-96 Pancreatic Neoplasms 20610624 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 miRNA-96:miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer target gene hsa-mir-96 Pancreatic Neoplasms 25242509 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 miR-96 suppresses the expression of NUAK1 by targeting its 3' UTR. target gene hsa-mir-99a Pancreatic Neoplasms 24461517 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Antagonism of microRNA-99a promotes cell invasion and down-regulates E-cadherin expression in pancreatic cancer cells by regulating mammalian target of rapamycin. target gene hsa-let-7d Parkinson Disease 29082467 nervous system disease DOID:14330 G20 D010300 PS168600 Let-7d microRNA Attenuates 6-OHDA-Induced Injury by Targeting Caspase-3 in MN9D Cells. target gene hsa-mir-126 Parkinson Disease 24559646 nervous system disease DOID:14330 G20 D010300 PS168600 miR-126 contributes to Parkinson's disease by dysregulating the insulin-like growth factor/phosphoinositide 3-kinase signaling. target gene hsa-mir-133b Parkinson Disease 20468068 nervous system disease DOID:14330 G20 D010300 PS168600 MiR-133b has been implicated in Parkinson's disease (PD) by a mechanism that involves the regulation of the transcription factor PITX3. target gene hsa-mir-16-1 Parkinson Disease 25054189 nervous system disease DOID:14330 G20 D010300 PS168600 miR-16-1 promotes the aberrant α-synuclein accumulation in parkinson disease via targeting heat shock protein 70. target gene hsa-mir-205 Parkinson Disease 23125283 nervous system disease DOID:14330 G20 D010300 PS168600 MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein target gene hsa-mir-22 Parkinson Disease 27631550 nervous system disease DOID:14330 G20 D010300 PS168600 Neuroprotective Role of MicroRNA-22 in a 6-Hydroxydopamine-Induced Cell Model of Parkinson's Disease via Regulation of Its Target Gene TRPM7. target gene hsa-mir-221 Parkinson Disease 24055409 nervous system disease DOID:14330 G20 D010300 PS168600 Trasferrin receptor 2 gene regulation by microRNA 221 in SH-SY5Y cells treated with MPP as Parkinson's disease cellular model. target gene hsa-mir-30e Parkinson Disease 29274035 nervous system disease DOID:14330 G20 D010300 PS168600 MicroRNA-30e regulates neuroinflammation in MPTP model of Parkinson's disease by targeting Nlrp3. target gene hsa-mir-34b Parkinson Disease 24892887 nervous system disease DOID:14330 G20 D010300 PS168600 Increased striatal adenosine A2A receptor levels is an early event in Parkinson's disease-related pathology and it is potentially regulated by miR-34b. target gene hsa-mir-4271 Parkinson Disease 27217159 nervous system disease DOID:14330 G20 D010300 PS168600 hsa-miR-4271 was downregulated, which could influence EFNA3 translation target gene hsa-mir-433 Parkinson Disease 18252210 nervous system disease DOID:14330 G20 D010300 PS168600 Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. target gene hsa-mir-7 Parkinson Disease 25814668 nervous system disease DOID:14330 G20 D010300 PS168600 microRNA-7, by down-regulating RelA,augments Glut3 expression, promotes glycolysis, and subsequently prevents MPP(+)-induced cell death. This protective effect of microRNA-7 could be exploited to correct the defects in oxidative phosphorylation in Parkinson disease. target gene hsa-mir-7 Parkinson Disease 27158385 nervous system disease DOID:14330 G20 D010300 PS168600 The altered molecular expressions downstream of Bax and Sirt2 are also involved in miR-7 regulation of the MPP(+)-triggered neuronal apoptosis. target gene hsa-mir-15a Patau Syndrome 21205891 genetic disease DOID:11665 Q91.7 D000073839 MicroRNA-15a and -16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13. target gene hsa-mir-16-1 Patau Syndrome 21205891 genetic disease DOID:11665 Q91.7 D000073839 MicroRNA-15a and -16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13. target gene hsa-mir-16-2 Patau Syndrome 21205891 genetic disease DOID:11665 Q91.7 D000073839 MicroRNA-15a and -16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13. target gene hsa-mir-124 Pediatric Ependymoma 28437838 disease of cellular proliferation DOID:5509 Prognostic relevance of miR-124-3p and its target TP53INP1 in pediatric ependymoma. target gene hsa-mir-30c Pediatric Osteosarcoma 29364496 disease of cellular proliferation DOID:3361 Biological function of microRNA-30c/SOX9 in pediatric osteosarcoma cell growth and metastasis. target gene hsa-mir-182 Peripheral Nerve Injury 22917588 D059348 Our data indicate that nerve injury inhibits SC proliferation and migration through rapid regulation of miR-182 by targeting FGF9 and NTM, providing novel insights into the roles of miRNAs in nerve injury and repair. target gene hsa-mir-210 Pheochromocytoma 29018330 C74.10 D010673 171300 HP:0002666 MicroRNA-210 Protects PC-12 Cells Against Hypoxia-Induced Injury by Targeting BNIP3. target gene hsa-mir-16 Pineal Gland Cancer 29359963 disease of cellular proliferation DOID:5032 C75.3 D010871 Melatonin Inhibits the Proliferation of Gastric Cancer Cells Through Regulating the miR-16-5p-Smad3 Pathway. target gene hsa-mir-145 Pituitary Adenoma 28352194 disease of cellular proliferation DOID:3829 D35.2 D010911 102200 HP:0002893 MicroRNA-145 inhibits the activation of the mTOR signaling pathway to suppress the proliferation and invasion of invasive pituitary adenoma cells by targeting AKT3 in vivo and in vitro. target gene hsa-mir-200c Pituitary Adenoma 24512727 disease of cellular proliferation DOID:3829 D35.2 D010911 102200 HP:0002893 MicroRNA-200c inhibits apoptosis in pituitary adenoma cells by targeting the PTEN/Akt signaling pathway. target gene hsa-mir-107 Pituitary Neoplasms 22811466 disease of cellular proliferation DOID:1785 C75.1 D010911 HP:0040277 MicroRNA miR-107 is overexpressed in pituitary adenomas and in vitro inhibits the expression of aryl hydrocarbon receptor-interacting protein (AIP). target gene hsa-mir-132 Pituitary Neoplasms 25305447 disease of cellular proliferation DOID:1785 C75.1 D010911 HP:0040277 MiR-132, miR-15a and miR-16 synergistically inhibit pituitary tumor cell proliferation, invasion and migration by targeting Sox5. target gene hsa-mir-15a Pituitary Neoplasms 25305447 disease of cellular proliferation DOID:1785 C75.1 D010911 HP:0040277 MiR-132, miR-15a and miR-16 synergistically inhibit pituitary tumor cell proliferation, invasion and migration by targeting Sox5. target gene hsa-mir-15a Pituitary Neoplasms 26309203 disease of cellular proliferation DOID:1785 C75.1 D010911 HP:0040277 GAA-induced decrease in cell proliferation is associated with decreased expression of Bcl-2 and increased miR-15a. target gene hsa-mir-16 Pituitary Neoplasms 25305447 disease of cellular proliferation DOID:1785 C75.1 D010911 HP:0040277 MiR-132, miR-15a and miR-16 synergistically inhibit pituitary tumor cell proliferation, invasion and migration by targeting Sox5. target gene hsa-mir-16 Pituitary Neoplasms 29399695 disease of cellular proliferation DOID:1785 C75.1 D010911 HP:0040277 MicroRNA‑16/VEGFR2/p38/NF‑κB signaling pathway regulates cell growth of human pituitary neoplasms. target gene hsa-mir-21 Pituitary Neoplasms 28742208 disease of cellular proliferation DOID:1785 C75.1 D010911 HP:0040277 Effects of microRNA-21 targeting PITX2 on proliferation and apoptosis of pituitary tumor cells. target gene hsa-mir-410 Pituitary Neoplasms 26125663 disease of cellular proliferation DOID:1785 C75.1 D010911 HP:0040277 Downregulation of miR-410 targeting the cyclin B1 gene plays a role in pituitary gonadotroph tumors. target gene hsa-mir-203 Pneumonia 24996183 respiratory system disease DOID:552 J18.9 D011014 HP:0002090 MicroRNA-203 accelerates apoptosis in LPS-stimulated alveolar epithelial cells by targeting PIK3CA. target gene hsa-mir-15a Polycystic Kidney Disease 18949056 Q61.19 D007690 PS173900 HP:0000113 miR-15a: MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis target gene hsa-mir-365a Polycystic Kidney Disease 22411058 Q61.19 D007690 PS173900 HP:0000113 PKHD1 post-transcriptionally modulated by miR-365-1 inhibits cell-cell adhesion. target gene hsa-mir-145 Polycystic Ovarian Syndrome 27799458 syndrome DOID:11612 E28.2 D011085 184700 MicroRNA-145 Negatively Regulates Cell Proliferation Through Targeting IRS1 in Isolated Ovarian Granulosa Cells From Patients With Polycystic Ovary Syndrome. target gene hsa-mir-21 Polycystic Ovarian Syndrome 26427146 syndrome DOID:11612 E28.2 D011085 184700 In comparison with normal subjects, serum miR-21 is obviously increased in PCOS patients. Through targeting LATS1, miR-21 could prompt PCOS progression and could act as a novel non-invasive biomarker for diagnosis of PCOS. target gene hsa-mir-27a Polycystic Ovarian Syndrome 29089199 syndrome DOID:11612 E28.2 D011085 184700 MicroRNA-27a-3p affects estradiol and androgen imbalance by targeting Creb1 in the granulosa cells in mouse polycytic ovary syndrome model. target gene hsa-mir-320a Polycystic Ovarian Syndrome 27965096 syndrome DOID:11612 E28.2 D011085 184700 Deregulation of RUNX2 by miR-320a deficiency impairs steroidogenesis in cumulus granulosa cells from polycystic ovary syndrome (PCOS) patients. target gene hsa-mir-93 Polycystic Ovarian Syndrome 23493574 syndrome DOID:11612 E28.2 D011085 184700 miRNA-93 inhibits GLUT4 and is overexpressed in adipose tissue of Polycystic Ovary Syndrome patients and women with insulin resistance target gene hsa-mir-181a-1 Porcine Reproductive and Respiratory Syndrome Virus Infection 23740977 MicroRNA-181 suppresses PRRSV infection by targeting its receptor CD163. target gene hsa-mir-181a-2 Porcine Reproductive and Respiratory Syndrome Virus Infection 23740977 MicroRNA-181 suppresses PRRSV infection by targeting its receptor CD163. target gene hsa-mir-181b-1 Porcine Reproductive and Respiratory Syndrome Virus Infection 23740977 MicroRNA-181 suppresses PRRSV infection by targeting its receptor CD163. target gene hsa-mir-181b-2 Porcine Reproductive and Respiratory Syndrome Virus Infection 23740977 MicroRNA-181 suppresses PRRSV infection by targeting its receptor CD163. target gene hsa-mir-181c Porcine Reproductive and Respiratory Syndrome Virus Infection 23740977 MicroRNA-181 suppresses PRRSV infection by targeting its receptor CD163. target gene hsa-mir-212 Post-Traumatic Stress Disorder 26632874 disease of mental health DOID:2055 F43.1 D013313 DICER1 is an enzyme that generates mature microRNAs (miRNAs), which regulate gene expression post-transcriptionally in brain and other tissues and is involved in synaptic maturation and plasticity. Here, through genome-wide differential gene expression survey of post-traumatic stress disorder (PTSD) with comorbid depression (PTSD&Dep), we find that blood DICER1 expression is significantly reduced in cases versus controls, and replicate this in two independent cohorts. target gene hsa-mir-3130 Post-Traumatic Stress Disorder 26632874 disease of mental health DOID:2055 F43.1 D013313 DICER1 is an enzyme that generates mature microRNAs (miRNAs), which regulate gene expression post-transcriptionally in brain and other tissues and is involved in synaptic maturation and plasticity. Here, through genome-wide differential gene expression survey of post-traumatic stress disorder (PTSD) with comorbid depression (PTSD&Dep), we find that blood DICER1 expression is significantly reduced in cases versus controls, and replicate this in two independent cohorts. target gene hsa-mir-106b Preeclampsia 28545271 cardiovascular system disease DOID:10591 O14 D011225 PS189800 HP:0100602 Effect of microRNA-106b on the invasion and proliferation of trophoblasts through targeting MMP-2. target gene hsa-mir-125b Preeclampsia 27935985 cardiovascular system disease DOID:10591 O14 D011225 PS189800 HP:0100602 miR-125b Enhances IL-8 Production in Early-Onset Severe Preeclampsia by Targeting Sphingosine-1-Phosphate Lyase 1. target gene hsa-mir-125b-1 Preeclampsia 25251470 cardiovascular system disease DOID:10591 O14 D011225 PS189800 HP:0100602 miR-125b-1-3p inhibits trophoblast cell invasion by targeting sphingosine-1-phosphate receptor 1 in preeclampsia. target gene hsa-mir-1324 Preeclampsia 25143393 cardiovascular system disease DOID:10591 O14 D011225 PS189800 HP:0100602 Susceptibility allele-specific loss of miR-1324-mediated silencing of the INO80B chromatin-assembly complex gene in pre-eclampsia. target gene hsa-mir-144 Preeclampsia 28772212 cardiovascular system disease DOID:10591 O14 D011225 PS189800 HP:0100602 miR-144 may regulate the proliferation, migration and invasion of trophoblastic cells through targeting PTEN in preeclampsia. target gene hsa-mir-155 Preeclampsia 24806148 cardiovascular system disease DOID:10591 O14 D011225 PS189800 HP:0100602 MicroRNA-155 inhibits migration of trophoblast cells and contributes to the pathogenesis of severe preeclampsia by regulating endothelial nitric oxide synthase. target gene hsa-mir-155 Preeclampsia 20452491 cardiovascular system disease DOID:10591 O14 D011225 PS189800 HP:0100602 miR-155:MicroRNA-155 contributes to preeclampsia by down-regulating CYR61 target gene hsa-mir-155 Preeclampsia 21234519 cardiovascular system disease DOID:10591 O14 D011225 PS189800 HP:0100602 microRNA-155 regulates angiotensin II type 1 receptor expression in umbilical vein endothelial cells from severely pre-eclamptic pregnant women. target gene hsa-mir-155 Preeclampsia 27375191 cardiovascular system disease DOID:10591 O14 D011225 PS189800 HP:0100602 These miRNAs have previously been linked to PE and are predicted to regulate members of the TGF-尾 pathway. target gene hsa-mir-16 Preeclampsia 25135655 cardiovascular system disease DOID:10591 O14 D011225 PS189800 HP:0100602 the physiological roles of miR-16 and miR-136 in the down-regulation of VEGFA and PPP2R2A, respectively, were confirmed through reporter assays. target gene hsa-mir-17 Preeclampsia 22438230 cardiovascular system disease DOID:10591 O14 D011225 PS189800 HP:0100602 Preeclampsia Up-Regulates Angiogenesis-Associated MicroRNA (i.e., miR-17, -20a, and -20b) That Target Ephrin-B2 and EPHB4 in Human Placenta. target gene hsa-mir-181a Preeclampsia 29339719 cardiovascular system disease DOID:10591 O14 D011225 PS189800 HP:0100602 miR-181a-5p suppresses invasion and migration of HTR-8/SVneo cells by directly targeting IGF2BP2. target gene hsa-mir-195 Preeclampsia 22723898 cardiovascular system disease DOID:10591 O14 D011225 PS189800 HP:0100602 Downregulated miR-195 detected in preeclamptic placenta affects trophoblast cell invasion via modulating ActRIIA expression. target gene hsa-mir-195 Preeclampsia 27176145 cardiovascular system disease DOID:10591 O14 D011225 PS189800 HP:0100602 miR-195 could directly target and suppress the expression of ActRIIB target gene hsa-mir-20a Preeclampsia 22438230 cardiovascular system disease DOID:10591 O14 D011225 PS189800 HP:0100602 Preeclampsia Up-Regulates Angiogenesis-Associated MicroRNA (i.e., miR-17, -20a, and -20b) That Target Ephrin-B2 and EPHB4 in Human Placenta. target gene hsa-mir-20b Preeclampsia 22438230 cardiovascular system disease DOID:10591 O14 D011225 PS189800 HP:0100602 Preeclampsia Up-Regulates Angiogenesis-Associated MicroRNA (i.e., miR-17, -20a, and -20b) That Target Ephrin-B2 and EPHB4 in Human Placenta. target gene hsa-mir-210 Preeclampsia 24980667 cardiovascular system disease DOID:10591 O14 D011225 PS189800 HP:0100602 MicroRNA-210 contributes to preeclampsia by downregulating potassium channel modulatory factor 1. target gene hsa-mir-210 Preeclampsia 21801864 cardiovascular system disease DOID:10591 O14 D011225 PS189800 HP:0100602 miR-210 Targets Iron-Sulfur Cluster Scaffold Homologue target gene hsa-mir-210 Preeclampsia 22203747 cardiovascular system disease DOID:10591 O14 D011225 PS189800 HP:0100602 Hydroxysteroid (17-beta) Dehydrogenase 1 Is Dysregulated by Mir-210 and Mir-518c That Are Aberrantly Expressed in Preeclamptic Placentas. target gene hsa-mir-26a Preeclampsia 27375191 cardiovascular system disease DOID:10591 O14 D011225 PS189800 HP:0100602 These miRNAs have previously been linked to PE and are predicted to regulate members of the TGF-尾 pathway. target gene hsa-mir-30a Preeclampsia 26555189 cardiovascular system disease DOID:10591 O14 D011225 PS189800 HP:0100602 MiR-30a attenuates immunosuppressive functions of IL-1β-elicited mesenchymal stem cells via targeting TAB3 target gene hsa-mir-346 Preeclampsia 27619846 cardiovascular system disease DOID:10591 O14 D011225 PS189800 HP:0100602 miR-346 and miR-582-3p-regulated EG-VEGF expression and trophoblast invasion via matrix metalloproteinases 2 and 9. target gene hsa-mir-34a Preeclampsia 29022890 cardiovascular system disease DOID:10591 O14 D011225 PS189800 HP:0100602 Elevated microRNA-34a contributes to trophoblast cell apoptosis in preeclampsia by targeting BCL-2. target gene hsa-mir-495 Preeclampsia 28628915 cardiovascular system disease DOID:10591 O14 D011225 PS189800 HP:0100602 MiR-495 Promotes Senescence of Mesenchymal Stem Cells by Targeting Bmi-1. target gene hsa-mir-518c Preeclampsia 22203747 cardiovascular system disease DOID:10591 O14 D011225 PS189800 HP:0100602 Hydroxysteroid (17-beta) Dehydrogenase 1 Is Dysregulated by Mir-210 and Mir-518c That Are Aberrantly Expressed in Preeclamptic Placentas. target gene hsa-mir-582 Preeclampsia 27619846 cardiovascular system disease DOID:10591 O14 D011225 PS189800 HP:0100602 miR-346 and miR-582-3p-regulated EG-VEGF expression and trophoblast invasion via matrix metalloproteinases 2 and 9. target gene hsa-mir-18a Pregnancy Complications [unspecific] 25955393 D011248 The results of the present study suggested that miR-18a expression suppression led to a decrease in JEG-3 cell invasion and an increase in JEG-3 cell apoptosis, by inducing ESRα expression. The present study provides evidence for the involvement of miR-18a in the pathogenesis of pre-eclamptic pregnancies. target gene hsa-mir-144 Premature Ovarian Failure 24188450 endocrine system disease DOID:5426 E28.3 D016649 PS311360 miR-29a and miR-144 were down-regulated in POF tissues, which may target expression of PLA2G4A that is involved in prostaglandin biosynthesis target gene hsa-mir-29a Premature Ovarian Failure 24188450 endocrine system disease DOID:5426 E28.3 D016649 PS311360 miR-29a and miR-144 were down-regulated in POF tissues, which may target expression of PLA2G4A that is involved in prostaglandin biosynthesis target gene hsa-let-7b Prostate Neoplasms 26540468 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Finally, we hypothesized that miR-218, miR-145, miR-197, miR-149, miR-122, and let-7b may contribute to the development of CRPC through the influence of Ras, Rho proteins,and the SCF complex. Further investigation is needed to verify the functions of the identified novel pathways in CRPC development. target gene hsa-let-7c Prostate Neoplasms 22128178 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. target gene hsa-mir-101 Prostate Neoplasms 22505648 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 The repressing activity of EZH2 on RKIP expression was dependent on histone deacetylase promoter recruitment and was negatively regulated upstream by miR-101. target gene hsa-mir-101 Prostate Neoplasms 23739676 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 In conclusion, EZH2 is essential for PCSC growth, partly through a negative regulation by miR-101 and positively regulating cyclin E2. target gene hsa-mir-106a Prostate Neoplasms 28889725 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Oncogene miR-106a promotes proliferation and metastasis of prostate cancer cells by directly targeting PTEN in vivo and in vitro. target gene hsa-mir-106b Prostate Neoplasms 26124181 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-93/miR-106b/miR-375-CIC-CRABP1: a novel regulatory axis in prostate cancer progression. target gene hsa-mir-1-1 Prostate Neoplasms 22068816 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. target gene hsa-mir-1-1 Prostate Neoplasms 22370643 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Mir-1 and miR-200 were reduced with progression of prostate adenocarcinoma, and we identify Slug as one of the phylogenetically conserved targets of these miRs. The authors demonstrate that SLUG is a direct repressor of miR-1 and miR-200 transcription. Th target gene hsa-mir-1-2 Prostate Neoplasms 22068816 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. target gene hsa-mir-1-2 Prostate Neoplasms 22370643 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Mir-1 and miR-200 were reduced with progression of prostate adenocarcinoma, and we identify Slug as one of the phylogenetically conserved targets of these miRs. The authors demonstrate that SLUG is a direct repressor of miR-1 and miR-200 transcription. Th target gene hsa-mir-122 Prostate Neoplasms 26540468 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Finally, we hypothesized that miR-218, miR-145, miR-197, miR-149, miR-122, and let-7b may contribute to the development of CRPC through the influence of Ras, Rho proteins,and the SCF complex. Further investigation is needed to verify the functions of the identified novel pathways in CRPC development. target gene hsa-mir-122 Prostate Neoplasms 22914437 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR122 regulation of Ad6 significantly improves its safety profile after systemic administration, which allows increasing therapeutic doses leading to improved anticancer efficacy of systemic treatment for castration-resistant prostate cancer. target gene hsa-mir-124 Prostate Neoplasms 24969691 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 MicroRNA-124 regulates TGF-α-induced epithelial-mesenchymal transition in human prostate cancer cells. target gene hsa-mir-124 Prostate Neoplasms 26540468 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Finally, we hypothesized that miR-218, miR-145, miR-197, miR-149, miR-122, and let-7b may contribute to the development of CRPC through the influence of Ras, Rho proteins,and the SCF complex. Further investigation is needed to verify the functions of the identified novel pathways in CRPC development. target gene hsa-mir-124 Prostate Neoplasms 25969668 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 overexpression of miR-124 by transient transfection of mimics led to a significant decrease in talin 1 levels. target gene hsa-mir-124-1 Prostate Neoplasms 23069658 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells target gene hsa-mir-124-2 Prostate Neoplasms 23069658 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells target gene hsa-mir-124-3 Prostate Neoplasms 23069658 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells target gene hsa-mir-1247 Prostate Neoplasms 25731699 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 MiR-1247-5p is overexpressed in castration resistant prostate cancer and targets MYCBP2. target gene hsa-mir-125b Prostate Neoplasms 26540468 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Finally, we hypothesized that miR-218, miR-145, miR-197, miR-149, miR-122, and let-7b may contribute to the development of CRPC through the influence of Ras, Rho proteins,and the SCF complex. Further investigation is needed to verify the functions of the identified novel pathways in CRPC development. target gene hsa-mir-125b-1 Prostate Neoplasms 21308711 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-125b suppresses MUC1 translation in LNCaP cells and that an anti-sense miR-125b upregulates expression of MUC1 protein. In addition, stable expression of miR-125b in DU145 cells resulted in decreases in MUC1 levels. target gene hsa-mir-125b-2 Prostate Neoplasms 21308711 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-125b suppresses MUC1 translation in LNCaP cells and that an anti-sense miR-125b upregulates expression of MUC1 protein. In addition, stable expression of miR-125b in DU145 cells resulted in decreases in MUC1 levels. target gene hsa-mir-128 Prostate Neoplasms 24859886 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Loss of SNAIL inhibits cellular growth and metabolism through the miR-128-mediated RPS6KB1/HIF-1α/PKM2 signaling pathway in prostate cancer cells. target gene hsa-mir-128 Prostate Neoplasms 24903149 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miRNA-128 suppresses prostate cancer by inhibiting BMI-1 to inhibit tumor-initiating cells. target gene hsa-mir-1301 Prostate Neoplasms 28483517 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 MicroRNA-1301 suppresses tumor cell migration and invasion by targeting the p53/UBE4B pathway in multiple human cancer cells. target gene hsa-mir-133a-1 Prostate Neoplasms 22068816 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. target gene hsa-mir-133a-1 Prostate Neoplasms 22407299 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor. target gene hsa-mir-133a-2 Prostate Neoplasms 22068816 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. target gene hsa-mir-133a-2 Prostate Neoplasms 22407299 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor. target gene hsa-mir-133b Prostate Neoplasms 22407299 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor. target gene hsa-mir-133b Prostate Neoplasms 23451058 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-133b is directly up-regulated by AR, and represses CDC2L5, PTPRK, RB1CC1, and CPNE3, respectively. Moreover, we found miR-133b is essential to PCa cell survival. target gene hsa-mir-135a Prostate Neoplasms 25065599 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Androgen-regulated microRNA-135a decreases prostate cancer cell migration and invasion through downregulating ROCK1 and ROCK2. target gene hsa-mir-135b Prostate Neoplasms 25907805 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 MicroRNA-135b regulates ERα, AR and HIF1AN and affects breast and prostate cancer cell growth. target gene hsa-mir-135b Prostate Neoplasms 21343391 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 3'UTR-binding assays validated 13 miRNAs that are able to regulate this long AR 3'UTR (miR-135b, miR-185, miR-297, miR-299-3p, miR-34a, miR-34c, miR-371-3p, miR-421, miR-449a, miR-449b, miR-634, miR-654-5p, and miR-9). target gene hsa-mir-135b Prostate Neoplasms 22473899 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 The results show that MUC1-C activates a posttranscriptional mechanism involving miR-135b-mediated downregulation of AR mRNA levels. target gene hsa-mir-138 Prostate Neoplasms 26474967 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-138 specifically targeted K2 and inhibited its expression, thereby regulating a miR-138/K2/尾1-integrin signaling axis in mCRPC that is critical for the modulation of sensitivity to chemotherapeutics. target gene hsa-mir-141 Prostate Neoplasms 26062412 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-141-3p regulates the expression of androgen receptor by targeting its 3'UTR in prostate cancer LNCaP cells target gene hsa-mir-141 Prostate Neoplasms 22314666 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-141 modulates androgen receptor transcriptional activity in human prostate cancer cells through targeting the small heterodimer partner protein. target gene hsa-mir-143 Prostate Neoplasms 24284362 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer. target gene hsa-mir-143 Prostate Neoplasms 20353999 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Our data indicate that miR-143 and miR-145 are involved in the regulation of MYO6 expression and possibly in the development of prostate cancer target gene hsa-mir-143 Prostate Neoplasms 21197560 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS target gene hsa-mir-143 Prostate Neoplasms 23383988 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Up-regulated microRNA-143 in cancer stem cells differentiation promotes prostate cancer cells metastasis by modulating FNDC3B expression target gene hsa-mir-143 Prostate Neoplasms 23732700 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 MicroRNA-143 inhibits cell migration and invasion by targeting matrix metalloproteinase 13 in prostate cancer. target gene hsa-mir-145 Prostate Neoplasms 24284362 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer. target gene hsa-mir-145 Prostate Neoplasms 24846918 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Effects of miR-145 on the migration and invasion of prostate cancer PC3 cells by targeting DAB2 target gene hsa-mir-145 Prostate Neoplasms 25645686 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Tumor-suppressive microRNA-145 induces growth arrest by targeting SENP1 in human prostate cancer cells. target gene hsa-mir-145 Prostate Neoplasms 26540468 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Finally, we hypothesized that miR-218, miR-145, miR-197, miR-149, miR-122, and let-7b may contribute to the development of CRPC through the influence of Ras, Rho proteins,and the SCF complex. Further investigation is needed to verify the functions of the identified novel pathways in CRPC development. target gene hsa-mir-145 Prostate Neoplasms 25296715 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Double-negative feedback loop between ZEB2 and miR-145 regulates epithelial-mesenchymal transition and stem cell properties in prostate cancer cells. target gene hsa-mir-145 Prostate Neoplasms 23480797 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 The proto-oncogene ERG is a target of microRNA miR-145 in prostate cancer target gene hsa-mir-145 Prostate Neoplasms 19544444 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 regulates PDGF-D, which mediate epithelial-mesenchymal transition, adhesion, and invasion, which was associated with the downregulation of ZEB1, ZEB2,and Snail2 expression; target gene hsa-mir-145 Prostate Neoplasms 20332243 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 MicroRNA145 targets BNIP3 and suppresses prostate cancer progression. target gene hsa-mir-145 Prostate Neoplasms 20353999 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Our data indicate that miR-143 and miR-145 are involved in the regulation of MYO6 expression and possibly in the development of prostate cancer target gene hsa-mir-145 Prostate Neoplasms 21258769 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. target gene hsa-mir-145 Prostate Neoplasms 23355420 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 HEF1 promotes epithelial mesenchymal transition and bone invasion in prostate cancer under the regulation of microRNA-145 target gene hsa-mir-146a Prostate Neoplasms 22161865 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer. target gene hsa-mir-146a Prostate Neoplasms 18174313 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Given that ROCK1 is one of the key kinases for the activation of hyaluronan (HA)-mediated HRPC transformation in vivo and in PC3 cells, mir-146a may function as a tumor-suppressor gene in modulating HA/ROCK1-mediated tumorigenecity in androgen-dependent prostate cancer. target gene hsa-mir-148a Prostate Neoplasms 20406806 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-148a:MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression target gene hsa-mir-148a Prostate Neoplasms 20820187 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-148a is an androgen-responsive microRNA that promotes LNCaP prostate cell growth by repressing its target CAND1 expression. target gene hsa-mir-149 Prostate Neoplasms 26540468 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Finally, we hypothesized that miR-218, miR-145, miR-197, miR-149, miR-122, and let-7b may contribute to the development of CRPC through the influence of Ras, Rho proteins,and the SCF complex. Further investigation is needed to verify the functions of the identified novel pathways in CRPC development. target gene hsa-mir-150 Prostate Neoplasms 26636522 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Increased miR-150 expression might participate in the development and progression of human prostate CSC by suppressing p27. This supported our previous study which found miR-150 was positively correlated with prostate tumor recurrence or metastasis. target gene hsa-mir-150 Prostate Neoplasms 29441850 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 MiR-150 promotes the cell invasion of prostate cancer cells by directly regulating the expression of p53 target gene hsa-mir-152 Prostate Neoplasms 23460133 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-152 controls migration and invasive potential by targeting TGFα in prostate cancer cell lines target gene hsa-mir-153-1 Prostate Neoplasms 23060044 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer target gene hsa-mir-153-2 Prostate Neoplasms 23060044 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer target gene hsa-mir-154 Prostate Neoplasms 23428540 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-154 inhibits prostate cancer cell proliferation by targeting CCND2 target gene hsa-mir-155 Prostate Neoplasms 25339368 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 microRNA-155 promotes the proliferation of prostate cancer cells by targeting annexin 7. target gene hsa-mir-155 Prostate Neoplasms 28599307 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Morin promotes prostate cancer cells chemosensitivity to paclitaxel through miR-155/GATA3 axis. target gene hsa-mir-15a Prostate Neoplasms 25761682 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Downregulation of miR-221, -30d, and -15a contributes to pathogenesis of prostate cancer by targeting Bmi-1. target gene hsa-mir-15a Prostate Neoplasms 18931683 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. target gene hsa-mir-15b Prostate Neoplasms 29363862 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-15b-5p facilitates the tumorigenicity by targeting RECK and predicts tumour recurrence in prostate cancer target gene hsa-mir-16-1 Prostate Neoplasms 18931683 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. target gene hsa-mir-16-2 Prostate Neoplasms 18931683 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-16: The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities target gene hsa-mir-17 Prostate Neoplasms 23095762 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-17-5p targets the p300/CBP-associated factor and modulates androgen receptor transcriptional activity in cultured prostate cancer cells target gene hsa-mir-182 Prostate Neoplasms 23874837 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Overexpressed microRNA-182 promotes proliferation and invasion in prostate cancer PC-3 cells by down-regulating N-myc downstream regulated gene 1 (NDRG1). target gene hsa-mir-182 Prostate Neoplasms 23329838 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 MicroRNA-182 and microRNA-200a control G-protein subunit alpha-13 (GNA13) expression and cell invasion synergistically in prostate cancer cells. target gene hsa-mir-182 Prostate Neoplasms 23383207 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 MicroRNA-182-5p Promotes Cell Invasion and Proliferation by Down Regulating FOXF2, RECK and MTSS1 Genes in Human Prostate Cancer target gene hsa-mir-183 Prostate Neoplasms 23538390 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 microRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer target gene hsa-mir-185 Prostate Neoplasms 23417242 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 MicroRNA-185 suppresses proliferation, invasion, migration, and tumorigenicity of human prostate cancer cells through targeting androgen receptor target gene hsa-mir-187 Prostate Neoplasms 25969992 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 MiR-187 Targets the Androgen-Regulated Gene ALDH1A3 in Prostate Cancer. target gene hsa-mir-188 Prostate Neoplasms 25714029 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expression. target gene hsa-mir-193b Prostate Neoplasms 26129688 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Epigenetically altered miR-193b targets cyclin D1 in prostate cancer. target gene hsa-mir-193b Prostate Neoplasms 22797075 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer. target gene hsa-mir-195 Prostate Neoplasms 29665645 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 MicroRNA-195 regulates docetaxel resistance by targeting clusterin in prostate cancer target gene hsa-mir-197 Prostate Neoplasms 26540468 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Finally, we hypothesized that miR-218, miR-145, miR-197, miR-149, miR-122, and let-7b may contribute to the development of CRPC through the influence of Ras, Rho proteins,and the SCF complex. Further investigation is needed to verify the functions of the identified novel pathways in CRPC development. target gene hsa-mir-198 Prostate Neoplasms 23069480 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Livin expression may be regulated by miR-198 in human prostate cancer cell lines target gene hsa-mir-19a Prostate Neoplasms 25936765 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 MicroRNA-19a regulates proliferation and apoptosis of castration-resistant prostate cancer cells by targeting BTG1. target gene hsa-mir-19a Prostate Neoplasms 23451058 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-19a is directly up-regulated by AR, and represses SUZ12, RAB13, SC4MOL, PSAP and ABCA1, respectively. target gene hsa-mir-200a Prostate Neoplasms 21224847 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Targeting Notch signalling by the conserved miR-8/200 microRNA family in development and cancer cells. target gene hsa-mir-200a Prostate Neoplasms 22370643 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Mir-1 and miR-200 were reduced with progression of prostate adenocarcinoma, and we identify Slug as one of the phylogenetically conserved targets of these miRs. The authors demonstrate that SLUG is a direct repressor of miR-1 and miR-200 transcription. Th target gene hsa-mir-200a Prostate Neoplasms 23329838 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 MicroRNA-182 and microRNA-200a control G-protein subunit alpha-13 (GNA13) expression and cell invasion synergistically in prostate cancer cells. target gene hsa-mir-200b Prostate Neoplasms 24317363 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-200b suppresses cell proliferation, migration and enhances chemosensitivity in prostate cancer by regulating Bmi-1. target gene hsa-mir-200b Prostate Neoplasms 21224847 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Targeting Notch signalling by the conserved miR-8/200 microRNA family in development and cancer cells. target gene hsa-mir-200b Prostate Neoplasms 22370643 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Mir-1 and miR-200 were reduced with progression of prostate adenocarcinoma, and we identify Slug as one of the phylogenetically conserved targets of these miRs. The authors demonstrate that SLUG is a direct repressor of miR-1 and miR-200 transcription. Th target gene hsa-mir-200c Prostate Neoplasms 25017995 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Autoregulatory feedback loop of EZH2/miR-200c/E2F3 as a driving force for prostate cancer development. target gene hsa-mir-200c Prostate Neoplasms 21224847 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Targeting Notch signalling by the conserved miR-8/200 microRNA family in development and cancer cells. target gene hsa-mir-200c Prostate Neoplasms 22370643 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Mir-1 and miR-200 were reduced with progression of prostate adenocarcinoma, and we identify Slug as one of the phylogenetically conserved targets of these miRs. The authors demonstrate that SLUG is a direct repressor of miR-1 and miR-200 transcription. Th target gene hsa-mir-203a Prostate Neoplasms 25636908 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 a crucial role for miR-203 in inhibiting metastasis of PCa through the suppression of Rap1A expression. target gene hsa-mir-204 Prostate Neoplasms 25797256 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 A dual yet opposite growth-regulating function of miR-204 and its target XRN1 in prostate adenocarcinoma cells and neuroendocrine-like prostate cancer cells. target gene hsa-mir-204 Prostate Neoplasms 21446014 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 PDEF expression is regulated via a functional microRNA-204 (miR-204) binding site within the 3'UTR. Furthermore, we demonstrate the biologic significance of miR-204 expression and that miR-204 is over-expressed in human prostate cancer specimens. target gene hsa-mir-204 Prostate Neoplasms 28861151 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 microRNA-204 modulates chemosensitivity and apoptosis of prostate cancer cells by targeting zinc-finger E-box-binding homeobox 1 (ZEB1). target gene hsa-mir-205 Prostate Neoplasms 26211479 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Editorial Comment to MicroRNA-205 inhibits cancer cell migration and invasion via modulation of centromere protein F regulating pathways in prostate cancer. target gene hsa-mir-205 Prostate Neoplasms 22555458 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-205 regulates basement membrane deposition in human prostate. target gene hsa-mir-205 Prostate Neoplasms 22949650 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. target gene hsa-mir-205 Prostate Neoplasms 23571738 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients target gene hsa-mir-20a Prostate Neoplasms 24464651 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-20a promotes prostate cancer invasion and migration through targeting ABL2. target gene hsa-mir-20a Prostate Neoplasms 22785209 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 CX43 expression is suppressed by miR-20a in the progression of human prostate cancer. target gene hsa-mir-20b Prostate Neoplasms 29163708 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-20b promotes cellular proliferation and migration by directly regulating phosphatase and tensin homolog in prostate cancer target gene hsa-mir-21 Prostate Neoplasms 24037531 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer. target gene hsa-mir-21 Prostate Neoplasms 24106176 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 The exosome-encased SNAs are secreted into the extracellular environment from which they can be isolated and selectively re-introduced into the cell type from which they were derived. In the context of anti-miR21 experiments, the exosome-encased SNAs knockdown miR-21 target by approximately 50%. Similar knockdown of miR-21 by free SNAs requires a ≈3000-fold higher concentration. target gene hsa-mir-21 Prostate Neoplasms 25890570 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer. target gene hsa-mir-21 Prostate Neoplasms 26252635 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 IL-6 Inhibits the Targeted Modulation of PDCD4 by miR-21 in Prostate Cancer. target gene hsa-mir-21 Prostate Neoplasms 19302977 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-21: MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells target gene hsa-mir-21 Prostate Neoplasms 21317927 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4 target gene hsa-mir-21 Prostate Neoplasms 21826097 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Spry1 is a target for miR-21-mediated gene silencing. target gene hsa-mir-21 Prostate Neoplasms 22642976 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer. target gene hsa-mir-218 Prostate Neoplasms 24815849 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Tumor-suppressive microRNA-218 inhibits cancer cell migration and invasion via targeting of LASP1 in prostate cancer. target gene hsa-mir-218 Prostate Neoplasms 26540468 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Finally, we hypothesized that miR-218, miR-145, miR-197, miR-149, miR-122, and let-7b may contribute to the development of CRPC through the influence of Ras, Rho proteins,and the SCF complex. Further investigation is needed to verify the functions of the identified novel pathways in CRPC development. target gene hsa-mir-218 Prostate Neoplasms 27278788 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 ectopic expression of these miRNAs suppressed PCa cell aggressiveness target gene hsa-mir-221 Prostate Neoplasms 24892674 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Down-regulation of mir-221 and mir-222 restrain prostate cancer cell proliferation and migration that is partly mediated by activation of SIRT1. target gene hsa-mir-221 Prostate Neoplasms 25761682 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Downregulation of miR-221, -30d, and -15a contributes to pathogenesis of prostate cancer by targeting Bmi-1. target gene hsa-mir-221 Prostate Neoplasms 26325107 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Loss of the tumour-suppressive miR-221/222 cluster enhanced migration and invasion in PCa cells. Our data describing targets regulated by the tumour-suppressive miR-221/222 cluster provide insights into the mechanisms of PCa and CRPC progression. target gene hsa-mir-221 Prostate Neoplasms 23770851 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 mir-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A. target gene hsa-mir-221 Prostate Neoplasms 17569667 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. target gene hsa-mir-221 Prostate Neoplasms 21487968 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 MiR-221 expression affects invasion potential of human prostate carcinoma cell lines by targeting DVL2. target gene hsa-mir-221 Prostate Neoplasms 21071579 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 This study demonstrates for the first time that prostate cancer cells have decreased level of ARHI which could be caused by direct targeting of 3'UTR of ARHI by miR221/222. target gene hsa-mir-222 Prostate Neoplasms 26325107 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Loss of the tumour-suppressive miR-221/222 cluster enhanced migration and invasion in PCa cells. Our data describing targets regulated by the tumour-suppressive miR-221/222 cluster provide insights into the mechanisms of PCa and CRPC progression. target gene hsa-mir-222 Prostate Neoplasms 24892674 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Down-regulation of mir-221 and mir-222 restrain prostate cancer cell proliferation and migration that is partly mediated by activation of SIRT1. target gene hsa-mir-222 Prostate Neoplasms 17569667 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. target gene hsa-mir-222 Prostate Neoplasms 22854542 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Tumor suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based on microRNA expression signature in prostate cancer. target gene hsa-mir-223 Prostate Neoplasms 26509963 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Tumor-suppressive microRNA-223 inhibits cancer cell migration and invasion by targeting ITGA3/ITGB1 signaling in prostate cancer. target gene hsa-mir-224 Prostate Neoplasms 24382668 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1. target gene hsa-mir-224 Prostate Neoplasms 24768995 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Tumour-suppressive microRNA-224 inhibits cancer cell migration and invasion via targeting oncogenic TPD52 in prostate cancer. target gene hsa-mir-224 Prostate Neoplasms 25394900 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-224 and its target gene CAMKK2 may synergistically contribute to the malignant progression of PCa. Combined detection of miR-224 and CAMKK2 expressions represents an efficient predictor of patient prognosis and may be a novel marker which can provide additional prognostic information in PCa. target gene hsa-mir-224 Prostate Neoplasms 25532941 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 the dysregulated miR-224/APLN axis may be associated with tumorigenesis and aggressive progression of PCa. More importantly, miR-224 down-regulation and APLN up-regulation may synergistically predict biochemical recurrence-free survival in patients with PCa. target gene hsa-mir-23a Prostate Neoplasms 25714010 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Downregulation of microRNA-23a suppresses prostate cancer metastasis by targeting the PAK6-LIMK1 signaling pathway. target gene hsa-mir-23b Prostate Neoplasms 22710126 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 MicroRNA-23b downregulates peroxiredoxin III in human prostate cancer. target gene hsa-mir-26a Prostate Neoplasms 24972966 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 MiR-26a inhibits prostate cancer progression by repression of Wnt5a. target gene hsa-mir-26a Prostate Neoplasms 26063484 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 MicroRNA-26a/b directly regulate La-related protein 1 and inhibit cancer cell invasion in prostate cancer. target gene hsa-mir-26a Prostate Neoplasms 24098737 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 We here report that a combination of four microRNAs (miR-19b, miR-23b, miR-26a and miR-92a) promotes prostate cell proliferation by regulating PTEN and its downstream signals in vitro. target gene hsa-mir-26a Prostate Neoplasms 27278788 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 the lysyl oxidase-like 2 (LOXL2) gene was directly controlled by these tumor-suppressive miRNAs target gene hsa-mir-26a Prostate Neoplasms 27900011 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Downregulated microRNA-26a modulates prostate cancer cell proliferation and apoptosis by targeting COX-2. target gene hsa-mir-26b Prostate Neoplasms 26063484 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 MicroRNA-26a/b directly regulate La-related protein 1 and inhibit cancer cell invasion in prostate cancer. target gene hsa-mir-26b Prostate Neoplasms 26920049 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 MiR-26b inhibits autophagy by targeting ULK2 in prostate cancer cells. target gene hsa-mir-26b Prostate Neoplasms 27278788 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 the lysyl oxidase-like 2 (LOXL2) gene was directly controlled by these tumor-suppressive miRNAs target gene hsa-mir-27a Prostate Neoplasms 19584056 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 decreased in prostate cancer; Regulates ERBB-2 Expression; blocked downstream phosphatidylinositol 3-kinase/AKT signaling, reducing activity of an androgen-stimulated prostate-specific antigen promoter and blocking prostate-specific antigen expression target gene hsa-mir-27a Prostate Neoplasms 22505583 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Androgen regulated processing of the oncomir MiR-27a, which targets Prohibitin in prostate cancer. target gene hsa-mir-27a Prostate Neoplasms 27594411 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Androgen-induced miR-27A acted as a tumor suppressor by targeting MAP2K4 and mediated prostate cancer progression. target gene hsa-mir-27a Prostate Neoplasms 23451058 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-27a is directly up-regulated by AR, and represses ABCA1 and PDS5B. target gene hsa-mir-29 Prostate Neoplasms 24820027 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Tumor-suppressive microRNA-29s inhibit cancer cell migration and invasion via targeting LAMC1 in prostate cancer. target gene hsa-mir-296 Prostate Neoplasms 24915000 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 MicroRNA-296-5p (miR-296-5p) functions as a tumor suppressor in prostate cancer by directly targeting Pin1. target gene hsa-mir-296 Prostate Neoplasms 21138859 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Regulation of HMGA1 expression by microRNA296 affects prostate cancer growth and invasion target gene hsa-mir-29a Prostate Neoplasms 24100420 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 the tumor suppressor microRNA, miR-29a, is one of the regulators of TRAF4 expression in metastatic prostate cancer. target gene hsa-mir-29a Prostate Neoplasms 27278788 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 the lysyl oxidase-like 2 (LOXL2) gene was directly controlled by these tumor-suppressive miRNAs target gene hsa-mir-29b Prostate Neoplasms 27278788 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 the lysyl oxidase-like 2 (LOXL2) gene was directly controlled by these tumor-suppressive miRNAs target gene hsa-mir-29c Prostate Neoplasms 27278788 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 the lysyl oxidase-like 2 (LOXL2) gene was directly controlled by these tumor-suppressive miRNAs target gene hsa-mir-301a Prostate Neoplasms 29331421 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Hyperglycaemia-induced miR-301a promotes cell proliferation by repressing p21 and Smad4 in prostate cancer. target gene hsa-mir-30d Prostate Neoplasms 25761682 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Downregulation of miR-221, -30d, and -15a contributes to pathogenesis of prostate cancer by targeting Bmi-1. target gene hsa-mir-31 Prostate Neoplasms 23984644 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Overexpression of hsa-mir-31 can be a significant marker to distinguish cancer tissues from benign tissues. The targets such as ITGA5 and RDX regulated by hsa-mir-31 are candidate genes of prostate cancer, which provide new treatment strategies for its gene therapy. target gene hsa-mir-31 Prostate Neoplasms 22854542 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Tumor suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based on microRNA expression signature in prostate cancer. target gene hsa-mir-32 Prostate Neoplasms 22266859 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. target gene hsa-mir-320a Prostate Neoplasms 23188675 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway target gene hsa-mir-330 Prostate Neoplasms 23670210 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 microRNA-330 inhibits cell motility by downregulating Sp1 in prostate cancer cells. target gene hsa-mir-331 Prostate Neoplasms 19584056 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-311-3p regulate ERBB-2 expression and androgen receptor signaling in prostate cancer target gene hsa-mir-331 Prostate Neoplasms 22908221 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Regulation of expression of deoxyhypusine hydroxylase (DOHH), the enzyme that catalyzes the activation of eIF5A, by miR-331-3p and miR-642-5p in prostate cancer cells. target gene hsa-mir-34a Prostate Neoplasms 26499184 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Collectively, miR-34a enhances chemosensitivity by directly downregulating ATG4B-induced autophagy through AMPK/mTOR pathway in PCa. target gene hsa-mir-34a Prostate Neoplasms 21240262 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. target gene hsa-mir-34b Prostate Neoplasms 26107383 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Deregulation of MiR-34b/Sox2 Predicts Prostate Cancer Progression. target gene hsa-mir-34c Prostate Neoplasms 26808578 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Functional analysis revealed that miR-34c and miR-297 overexpression down-regulated AR expression and inhibited the expression of downstream AR targets target gene hsa-mir-3607 Prostate Neoplasms 24817628 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Regulation of SRC kinases by microRNA-3607 located in a frequently deleted locus in prostate cancer. target gene hsa-mir-361 Prostate Neoplasms 24491557 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 MiR-361-5p acts as a tumor suppressor in prostate cancer by targeting signal transducer and activator of transcription-6(STAT6). target gene hsa-mir-375 Prostate Neoplasms 26124181 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-93/miR-106b/miR-375-CIC-CRABP1: a novel regulatory axis in prostate cancer progression. target gene hsa-mir-375 Prostate Neoplasms 21593139 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miRNA-375 Downregulated Sec23A protein in prostate carcinoma. target gene hsa-mir-375 Prostate Neoplasms 27270433 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 The transcription factor YAP1 was found to be a direct target of miR-375 in prostate cancer. target gene hsa-mir-429 Prostate Neoplasms 25351256 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Downregulation of microRNA-429 inhibits cell proliferation by targeting p27Kip1 in human prostate cancer cells. target gene hsa-mir-449a Prostate Neoplasms 19252524 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. target gene hsa-mir-483 Prostate Neoplasms 26020509 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Based on our findings, we suggest that blood-based miRNA expression profiling can be used in the diagnosis and maybe even prognosis of the disease.In the future, miRNA profiling could possibly be used in targeted screening,together with Prostate Specific Antigene (PSA) testing, to identify men with an elevated PrCa risk. target gene hsa-mir-488 Prostate Neoplasms 21710544 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR 488* inhibits androgen receptor expression in prostate carcinoma cells. target gene hsa-mir-493 Prostate Neoplasms 29423080 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Downregulation of N6-methyladenosine binding YTHDF2 protein mediated by miR-493-3p suppresses prostate cancer by elevating N6-methyladenosine levels. target gene hsa-mir-495 Prostate Neoplasms 27031291 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 MicroRNA-495 Regulates Migration and Invasion in Prostate Cancer Cells Via Targeting Akt and mTOR Signaling. target gene hsa-mir-503 Prostate Neoplasms 26231797 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-503 suppresses tumor cell proliferation and metastasis by directly targeting RNF31 in prostate cancer. target gene hsa-mir-616 Prostate Neoplasms 21224345 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 microRNA-616 Induces Androgen-Independent Growth of Prostate Cancer Cells by Suppressing Expression of Tissue Factor Pathway Inhibitor TFPI-2. target gene hsa-mir-631 Prostate Neoplasms 26620225 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 In all, our study demonstrates that miR-631 decreases PCa cell migration and invasion by dampening ZAP70 expression. target gene hsa-mir-642a Prostate Neoplasms 22908221 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Regulation of expression of deoxyhypusine hydroxylase (DOHH), the enzyme that catalyzes the activation of eIF5A, by miR-331-3p and miR-642-5p in prostate cancer cells. target gene hsa-mir-642b Prostate Neoplasms 22908221 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Regulation of expression of deoxyhypusine hydroxylase (DOHH), the enzyme that catalyzes the activation of eIF5A, by miR-331-3p and miR-642-5p in prostate cancer cells. target gene hsa-mir-652 Prostate Neoplasms 29721191 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 MicroRNA-652 induces NED in LNCaP and EMT in PC3 prostate cancer cells. target gene hsa-mir-675 Prostate Neoplasms 24988946 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 lncRNA H19/miR-675 axis represses prostate cancer metastasis by targeting TGFBI. target gene hsa-mir-7 Prostate Neoplasms 26172296 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 MicroRNA-7 inhibits the stemness of prostate cancer stem-like cells and tumorigenesis by repressing KLF4/PI3K/Akt/p21 pathway. target gene hsa-mir-93 Prostate Neoplasms 26124181 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-93/miR-106b/miR-375-CIC-CRABP1: a novel regulatory axis in prostate cancer progression. target gene hsa-mir-940 Prostate Neoplasms 25406943 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 implicate miR-940, a regulator of MIEN1, as a promising novel diagnostic and prognostic tool for prostate cancer. target gene hsa-mir-95 Prostate Neoplasms 24145350 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miRNA-95 mediates radioresistance in tumors by targeting the sphingolipid phosphatase SGPP1. target gene hsa-mir-96 Prostate Neoplasms 23951320 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Upregulation of miR-96 enhances cellular proliferation of prostate cancer cells through FOXO1. target gene hsa-mir-96 Prostate Neoplasms 24260486 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 The antiapoptotic function of miR-96 in prostate cancer by inhibition of FOXO1. target gene hsa-mir-98 Prostate Neoplasms 23188821 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Identification of microRNA-98 as a Therapeutic Target Inhibiting Prostate Cancer Growth and a Biomarker Induced by Vitamin D target gene hsa-let-7a Psoriasis 28494466 integumentary system disease DOID:8893 L40.9 D011565 PS177900 HP:0003765 Let-7a Inhibits T-Cell Proliferation and IFN-γ Secretion by Down-Regulating STAT3 Expression in Patients with Psoriasis. target gene hsa-mir-125b-1 Psoriasis 21412257 integumentary system disease DOID:8893 L40.9 D011565 PS177900 HP:0003765 MiR-125b, a MicroRNA Downregulated in Psoriasis, Modulates Keratinocyte Proliferation by Targeting FGFR2. target gene hsa-mir-125b-2 Psoriasis 21412257 integumentary system disease DOID:8893 L40.9 D011565 PS177900 HP:0003765 MiR-125b, a MicroRNA Downregulated in Psoriasis, Modulates Keratinocyte Proliferation by Targeting FGFR2. target gene hsa-mir-130a Psoriasis 28085489 integumentary system disease DOID:8893 L40.9 D011565 PS177900 HP:0003765 microRNA-130a Promotes Human Keratinocyte Viability and Migration and Inhibits Apoptosis Through Direct Regulation of STK40-Mediated NF-κB Pathway and Indirect Regulation of SOX9-Meditated JNK/MAPK Pathway: A Potential Role in Psoriasis. target gene hsa-mir-138 Psoriasis 26045321 integumentary system disease DOID:8893 L40.9 D011565 PS177900 HP:0003765 MicroRNA-138 regulates the balance of Th1/Th2 via targeting RUNX3 in psoriasis. target gene hsa-mir-138 Psoriasis 27936398 integumentary system disease DOID:8893 L40.9 D011565 PS177900 HP:0003765 MicroRNA138 regulates keratin 17 protein expression to affect HaCaT cell proliferation and apoptosis by targeting hTERT in psoriasis vulgaris. target gene hsa-mir-146a Psoriasis 23018031 integumentary system disease DOID:8893 L40.9 D011565 PS177900 HP:0003765 Inability of miR-146a inhibiting target gene IRAK1 may contribute to the persistent inflammation in lesions of psoriasis. target gene hsa-mir-146b Psoriasis 29279330 integumentary system disease DOID:8893 L40.9 D011565 PS177900 HP:0003765 MicroRNA-146 and cell trauma down-regulate expression of the psoriasis-associated atypical chemokine receptor ACKR2 target gene hsa-mir-150 Psoriasis 28399173 integumentary system disease DOID:8893 L40.9 D011565 PS177900 HP:0003765 MiR-150 regulates human keratinocyte proliferation in hypoxic conditions through targeting HIF-1α and VEGFA: Implications for psoriasis treatment. target gene hsa-mir-181b Psoriasis 27641447 integumentary system disease DOID:8893 L40.9 D011565 PS177900 HP:0003765 MicroRNA-181b negatively regulates the proliferation of human epidermal keratinocytes in psoriasis through targeting TLR4. target gene hsa-mir-194 Psoriasis 28040329 integumentary system disease DOID:8893 L40.9 D011565 PS177900 HP:0003765 MicroRNA-194 regulates keratinocyte proliferation and differentiation by targeting Grainyhead-like 2 in psoriasis. target gene hsa-mir-203 Psoriasis 22917968 integumentary system disease DOID:8893 L40.9 D011565 PS177900 HP:0003765 Our findings suggest that miR-203 serves to fine-tune cytokine signaling and may dampen skin immune responses by repressing key pro-inflammatory cytokines. target gene hsa-mir-210 Psoriasis 24316592 integumentary system disease DOID:8893 L40.9 D011565 PS177900 HP:0003765 Up-regulation of microRNA-210 induces immune dysfunction via targeting FOXP3 in CD4(+) T cells of psoriasis vulgaris. target gene hsa-mir-26b Psoriasis 27015452 integumentary system disease DOID:8893 L40.9 D011565 PS177900 HP:0003765 Psoriasis Skin Inflammation-Induced microRNA-26b Targets NCEH1 in Underlying Subcutaneous Adipose Tissue. target gene hsa-mir-31 Psoriasis 23233723 integumentary system disease DOID:8893 L40.9 D011565 PS177900 HP:0003765 MicroRNA-31 Is Overexpressed in Psoriasis and Modulates Inflammatory Cytokine and Chemokine Production in Keratinocytes via Targeting Serine/Threonine Kinase 40 target gene hsa-mir-99a Psoriasis 21687694 integumentary system disease DOID:8893 L40.9 D011565 PS177900 HP:0003765 differentially expressed. miR-99a is one of the regulators of the IGF-1R signaling pathway in keratinocytes. Activation of IGF1 signaling results in elevation of miR-99a which represses the expression of IGF-1R. target gene hsa-mir-146a Psoriatic Arthritis 20500689 syndrome DOID:9008 L40.5 D015535 607507 miR-146a:The role of microRNA-146a (miR-146a) and its target IL-1R-associated kinase (IRAK1) in psoriatic arthritis susceptibility target gene hsa-mir-15a Psoriatic Arthritis 19714650 syndrome DOID:9008 L40.5 D015535 607507 suppresses apoptosis through inhibition of Bcl-2 target gene hsa-mir-641 Psychotic Disorders 24391914 F24 D011618 Association of impulsivity and polymorphic microRNA-641 target sites in the SNAP-25 gene. target gene hsa-mir-200a Pterygium 26995143 nervous system disease DOID:0002116 H11.0 D011625 178200 Up-regulated miR-200a levels were positively correlated with and p53 protein expression target gene hsa-let-7g Pulmonary Hypertension 27889560 cardiovascular system disease DOID:6432 I27.20 D006976 PS178600 HP:0002092 MicroRNA let-7g inhibited hypoxia-induced proliferation of PASMCs via G0/G1 cell cycle arrest by targeting c-myc. target gene hsa-mir-124 Pulmonary Hypertension 28972001 cardiovascular system disease DOID:6432 I27.20 D006976 PS178600 HP:0002092 Metabolic and Proliferative State of Vascular Adventitial Fibroblasts in Pulmonary Hypertension Is Regulated Through a MicroRNA-124/PTBP1 (Polypyrimidine Tract Binding Protein 1)/Pyruvate Kinase Muscle Axis. target gene hsa-mir-130a Pulmonary Hypertension 28514291 cardiovascular system disease DOID:6432 I27.20 D006976 PS178600 HP:0002092 Role of microRNA-130a in the pathogeneses of obstructive sleep apnea hypopnea syndrome-associated pulmonary hypertension by targeting the GAX gene. target gene hsa-mir-138 Pulmonary Hypertension 27648837 cardiovascular system disease DOID:6432 I27.20 D006976 PS178600 HP:0002092 MicroRNA-138 and MicroRNA-25 Down-regulate Mitochondrial Calcium Uniporter, Causing the Pulmonary Arterial Hypertension Cancer Phenotype. target gene hsa-mir-17 Pulmonary Hypertension 27640178 cardiovascular system disease DOID:6432 I27.20 D006976 PS178600 HP:0002092 Upregulated miR-17 Regulates Hypoxia-Mediated Human Pulmonary Artery Smooth Muscle Cell Proliferation and Apoptosis by Targeting Mitofusin 2. target gene hsa-mir-204 Pulmonary Hypertension 26224795 cardiovascular system disease DOID:6432 I27.20 D006976 PS178600 HP:0002092 BRD4 expression in PAH is microRNA-204 dependent target gene hsa-mir-204 Pulmonary Hypertension 27149112 cardiovascular system disease DOID:6432 I27.20 D006976 PS178600 HP:0002092 miR-204 diminution promotes RUNX2 up-regulation target gene hsa-mir-21 Pulmonary Hypertension 26208095 cardiovascular system disease DOID:6432 I27.20 D006976 PS178600 HP:0002092 these results demonstrate that PPARγ ligands regulate proliferative responses to hypoxia by preventing hypoxic increases in miR-21 and reductions in PTEN. These findings further clarify molecular mechanisms that support targeting PPARγ to attenuate pathogenic derangements in PH. target gene hsa-mir-25 Pulmonary Hypertension 27648837 cardiovascular system disease DOID:6432 I27.20 D006976 PS178600 HP:0002092 MicroRNA-138 and MicroRNA-25 Down-regulate Mitochondrial Calcium Uniporter, Causing the Pulmonary Arterial Hypertension Cancer Phenotype. target gene hsa-mir-29b Pulmonary Hypertension 29662889 cardiovascular system disease DOID:6432 I27.20 D006976 PS178600 HP:0002092 Effect of miR-29b on the Proliferation and Apoptosis of Pulmonary Artery Smooth Muscle Cells by Targeting Mcl-1 and CCND2 target gene hsa-mir-637 Pulmonary Hypertension 27794186 cardiovascular system disease DOID:6432 I27.20 D006976 PS178600 HP:0002092 Downregulation of microRNA-637 Increases Risk of Hypoxia-Induced Pulmonary Hypertension by Modulating Expression of Cyclin Dependent Kinase 6 (CDK6) in Pulmonary Smooth Muscle Cells. target gene hsa-mir-21 Rectal Neoplasms 28927090 disease of cellular proliferation DOID:1984 D012004 Downregulation of PDCD4 by miR-21 suppresses tumor transformation and proliferation in a nude mouse renal cancer model. target gene hsa-mir-21 Rectal Neoplasms 29085468 disease of cellular proliferation DOID:1984 D012004 miR-21 inhibition of LATS1 promotes proliferation and metastasis of renal cancer cells and tumor stem cell phenotype. target gene hsa-mir-21 Rectal Neoplasms 29131259 disease of cellular proliferation DOID:1984 D012004 MicroRNA-21 functions as an oncogene and promotes cell proliferation and invasion via TIMP3 in renal cancer. target gene hsa-mir-452 Rectal Neoplasms 24440748 disease of cellular proliferation DOID:1984 D012004 Firstly, we found that miR-452 directly regulates the expression of thyroid hormone receptor TR尾1 in renal cancer cells. In turn, the expression of miR-224/452/GABRE cluster and other microRNAs targeting TR尾1 was influenced by T3 treatment and/or TR silencing. target gene hsa-mir-16 Recurrent Spontaneous Abortion 27748453 O03 D000022 MicroRNA-16 inhibits feto-maternal angiogenesis and causes recurrent spontaneous abortion by targeting vascular endothelial growth factor. target gene hsa-mir-1908 Renal Fibrosis 26648305 urinary system disease DOID:0050855 N26.9 HP:0030760 miR-1908 could inhibit renal fibrosis through targeting TGF-β1. target gene hsa-mir-30e Renal Fibrosis 23515048 urinary system disease DOID:0050855 N26.9 HP:0030760 A microRNA-30e/mitochondrial uncoupling protein 2 axis mediates TGF-β1-induced tubular epithelial cell extracellular matrix production and kidney fibrosis. target gene hsa-mir-125a Retinal Degeneration 27527066 nervous system disease DOID:8466 H35.40 D012162 605670 HP:0000546 Possibly more than 30 miRNAs interact with Rac1 in retina, targeting both UTRs and coding regions. target gene hsa-mir-142 Retinal Degeneration 27527066 nervous system disease DOID:8466 H35.40 D012162 605670 HP:0000546 Possibly more than 30 miRNAs interact with Rac1 in retina, targeting both UTRs and coding regions. target gene hsa-mir-146 Retinal Degeneration 24985472 nervous system disease DOID:8466 H35.40 D012162 605670 HP:0000546 We uncovered a novel negative feedback regulatory mechanism on thrombin-induced GPCR-mediated NF-κB activation by miR-146. In combination with the negative feedback regulation of miR-146 on the IL-1R/toll-like receptor (TLR)-mediated NF-κB activation in RECs that we reported previously, our results underscore a pivotal, negative regulatory role of miR-146 on multiple NF-κB activation pathways and related inflammatory processes in DR. target gene hsa-mir-200b Retinal Degeneration 26617758 nervous system disease DOID:8466 H35.40 D012162 605670 HP:0000546 MiR-200b can regulate RECs growth and proliferation by changing VEGF and TGFβ1 expression to delay DR. target gene hsa-mir-410 Retinal Degeneration 25351180 nervous system disease DOID:8466 H35.40 D012162 605670 HP:0000546 miR-410 Inhibition Induces RPE Differentiation of Amniotic Epithelial Stem Cells via Overexpression of OTX2 and RPE65. target gene hsa-mir-96 Retinal Degeneration 27527066 nervous system disease DOID:8466 H35.40 D012162 605670 HP:0000546 Validation of miRNA-target mRNA interactions for miR-1, miR-96/182 and miR-96 targeting Ctbp2, Rac1 and Slc6a9, respectively, was demonstrated in vitro. target gene hsa-let-7b Retinoblastoma 26730174 nervous system disease DOID:768 C69.20 D012175 180200 HP:0009919 Several critical miRNAs were identified in RB progression.Hsa-miR-373 might regulate RB invasion and metastasis, hsa-miR-181a might involve in the CDKN1B-mediated cell cycle pathway, and hsa-miR-125b and hsa-let-7b might serve as tumor suppressors by coregulating CDK6, CDC25A, and LIN28A. The miRNAs hsa-miR-25, hsa-miR-18a, and hsa-miR-20a might exert their function by coregulating BCL2L1. target gene hsa-let-7b Retinoblastoma 18026111 nervous system disease DOID:768 C69.20 D012175 180200 HP:0009919 We experimentally verified our predictions by investigating the result of let-7b downregulation in retinoblastoma using quantitative reverse transcriptase (RT)-PCR and microarray profiling: some of our verified let-7b targets include CDC25A and BCL7A. target gene hsa-mir-101 Retinoblastoma 24807198 nervous system disease DOID:768 C69.20 D012175 180200 HP:0009919 MiR-101, downregulated in retinoblastoma, functions as a tumor suppressor in human retinoblastoma cells by targeting EZH2. target gene hsa-mir-106b Retinoblastoma 29085029 nervous system disease DOID:768 C69.20 D012175 180200 HP:0009919 HBeAg-induced miR-106b promotes cell growth by targeting the retinoblastoma gene. target gene hsa-mir-125b Retinoblastoma 26730174 nervous system disease DOID:768 C69.20 D012175 180200 HP:0009919 Several critical miRNAs were identified in RB progression.Hsa-miR-373 might regulate RB invasion and metastasis, hsa-miR-181a might involve in the CDKN1B-mediated cell cycle pathway, and hsa-miR-125b and hsa-let-7b might serve as tumor suppressors by coregulating CDK6, CDC25A, and LIN28A. The miRNAs hsa-miR-25, hsa-miR-18a, and hsa-miR-20a might exert their function by coregulating BCL2L1. target gene hsa-mir-145 Retinoblastoma 28706438 nervous system disease DOID:768 C69.20 D012175 180200 HP:0009919 Genistein suppresses retinoblastoma cell viability and growth and induces apoptosis by upregulating miR-145 and inhibiting its target ABCE1. target gene hsa-mir-181b Retinoblastoma 25872572 nervous system disease DOID:768 C69.20 D012175 180200 HP:0009919 Hypoxia-induced miR-181b enhances angiogenesis of retinoblastoma cells by targeting PDCD10 and GATA6. target gene hsa-mir-183 Retinoblastoma 24289859 nervous system disease DOID:768 C69.20 D012175 180200 HP:0009919 MicroRNA-183 suppresses retinoblastoma cell growth, invasion and migration by targeting LRP6. target gene hsa-mir-18a Retinoblastoma 26730174 nervous system disease DOID:768 C69.20 D012175 180200 HP:0009919 Several critical miRNAs were identified in RB progression.Hsa-miR-373 might regulate RB invasion and metastasis, hsa-miR-181a might involve in the CDKN1B-mediated cell cycle pathway, and hsa-miR-125b and hsa-let-7b might serve as tumor suppressors by coregulating CDK6, CDC25A, and LIN28A. The miRNAs hsa-miR-25, hsa-miR-18a, and hsa-miR-20a might exert their function by coregulating BCL2L1. target gene hsa-mir-20a Retinoblastoma 26730174 nervous system disease DOID:768 C69.20 D012175 180200 HP:0009919 Several critical miRNAs were identified in RB progression.Hsa-miR-373 might regulate RB invasion and metastasis, hsa-miR-181a might involve in the CDKN1B-mediated cell cycle pathway, and hsa-miR-125b and hsa-let-7b might serve as tumor suppressors by coregulating CDK6, CDC25A, and LIN28A. The miRNAs hsa-miR-25, hsa-miR-18a, and hsa-miR-20a might exert their function by coregulating BCL2L1. target gene hsa-mir-24-1 Retinoblastoma 22336108 nervous system disease DOID:768 C69.20 D012175 180200 HP:0009919 Regulation of p14ARF expression by miR-24: a potential mechanism compromising the p53 response during retinoblastoma development. target gene hsa-mir-24-2 Retinoblastoma 22336108 nervous system disease DOID:768 C69.20 D012175 180200 HP:0009919 Regulation of p14ARF expression by miR-24: a potential mechanism compromising the p53 response during retinoblastoma development. target gene hsa-mir-25 Retinoblastoma 26730174 nervous system disease DOID:768 C69.20 D012175 180200 HP:0009919 Several critical miRNAs were identified in RB progression.Hsa-miR-373 might regulate RB invasion and metastasis, hsa-miR-181a might involve in the CDKN1B-mediated cell cycle pathway, and hsa-miR-125b and hsa-let-7b might serve as tumor suppressors by coregulating CDK6, CDC25A, and LIN28A. The miRNAs hsa-miR-25, hsa-miR-18a, and hsa-miR-20a might exert their function by coregulating BCL2L1. target gene hsa-mir-26a Retinoblastoma 27421000 nervous system disease DOID:768 C69.20 D012175 180200 HP:0009919 Beclin 1 is the target of miR-26a in human RB cell lines Y79 and WERi-RB-1, and miR-26a inhibits the expression of Beclin 1 by reducing its mRNA and protein levels. target gene hsa-mir-29a Retinoblastoma 29251322 nervous system disease DOID:768 C69.20 D012175 180200 HP:0009919 miR-29a inhibits human retinoblastoma progression by targeting STAT3 target gene hsa-mir-373 Retinoblastoma 26730174 nervous system disease DOID:768 C69.20 D012175 180200 HP:0009919 Several critical miRNAs were identified in RB progression.Hsa-miR-373 might regulate RB invasion and metastasis, hsa-miR-181a might involve in the CDKN1B-mediated cell cycle pathway, and hsa-miR-125b and hsa-let-7b might serve as tumor suppressors by coregulating CDK6, CDC25A, and LIN28A. The miRNAs hsa-miR-25, hsa-miR-18a, and hsa-miR-20a might exert their function by coregulating BCL2L1. target gene hsa-mir-613 Retinoblastoma 28351331 nervous system disease DOID:768 C69.20 D012175 180200 HP:0009919 MiR-613 suppresses retinoblastoma cell proliferation, invasion, and tumor formation by targeting E2F5. target gene hsa-mir-193a Rhabdoid Cancer 24287458 disease of cellular proliferation DOID:3672 D018335 Differential microRNA expression profiles between malignant rhabdoid tumor and epithelioid sarcoma: miR193a-5p is suggested to downregulate SMARCB1 mRNA expression. target gene hsa-mir-1 Rhabdomyosarcoma 28981396 disease of cellular proliferation DOID:3247 M62.82 D012208 268220 HP:0002859 miR-133b also knock downed PAX3-FOXO1 target gene hsa-mir-106a Rhabdomyosarcoma 22330340 disease of cellular proliferation DOID:3247 M62.82 D012208 268220 HP:0002859 Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma. target gene hsa-mir-1-1 Rhabdomyosarcoma 19710019 disease of cellular proliferation DOID:3247 M62.82 D012208 268220 HP:0002859 inhibits rhabdomyosarcoma through downregulating c-Met target gene hsa-mir-1-1 Rhabdomyosarcoma 22330340 disease of cellular proliferation DOID:3247 M62.82 D012208 268220 HP:0002859 Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma. target gene hsa-mir-1-2 Rhabdomyosarcoma 19710019 disease of cellular proliferation DOID:3247 M62.82 D012208 268220 HP:0002859 inhibits rhabdomyosarcoma through downregulating c-Met target gene hsa-mir-1-2 Rhabdomyosarcoma 22330340 disease of cellular proliferation DOID:3247 M62.82 D012208 268220 HP:0002859 Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma. target gene hsa-mir-206 Rhabdomyosarcoma 19710019 disease of cellular proliferation DOID:3247 M62.82 D012208 268220 HP:0002859 inhibits rhabdomyosarcoma through downregulating c-Met target gene hsa-mir-29a Rhabdomyosarcoma 22330340 disease of cellular proliferation DOID:3247 M62.82 D012208 268220 HP:0002859 Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma. target gene hsa-mir-29b-1 Rhabdomyosarcoma 22330340 disease of cellular proliferation DOID:3247 M62.82 D012208 268220 HP:0002859 Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma. target gene hsa-mir-29b-2 Rhabdomyosarcoma 22330340 disease of cellular proliferation DOID:3247 M62.82 D012208 268220 HP:0002859 Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma. target gene hsa-mir-29c Rhabdomyosarcoma 22330340 disease of cellular proliferation DOID:3247 M62.82 D012208 268220 HP:0002859 Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma. target gene hsa-mir-411 Rhabdomyosarcoma 26291313 disease of cellular proliferation DOID:3247 M62.82 D012208 268220 HP:0002859 These results establish an autoregulatory loop between TGF-β1/miR-411-5p/SPRY4 and MAPK in RMS, which governs the switch between proliferation and differentiation. target gene hsa-mir-205 Rheumatic Heart Diseases 29548280 cardiovascular system disease DOID:0050827 I09.9 D012214 Hsa miR-205-3p and hsa-miR-3909 were predicted to target the 3'UTR of IL-1β and IL1R1 respectively target gene hsa-mir-3909 Rheumatic Heart Diseases 29548280 cardiovascular system disease DOID:0050827 I09.9 D012214 Hsa miR-205-3p and hsa-miR-3909 were predicted to target the 3'UTR of IL-1β and IL1R1 respectively target gene hsa-mir-101 Rheumatic Heart Diseases 26022377 cardiovascular system disease DOID:0050827 I09.9 D012214 The present study confirmed that miR-101 targets TLR2 3'UTR and represses TLR2 expression. This work also found an association between down-regulated miR-101 and rheumatic heart disease. target gene hsa-mir-126 Rheumatoid Arthritis 27729613 musculoskeletal system disease DOID:7148 M06.9 D001172 180300 HP:0001370 MicroRNA-126 affects rheumatoid arthritis synovial fibroblast proliferation and apoptosis by targeting PIK3R2 and regulating PI3K-AKT signal pathway. target gene hsa-mir-146a Rheumatoid Arthritis 24562503 musculoskeletal system disease DOID:7148 M06.9 D001172 180300 HP:0001370 Our results suggest that in RA miR-146a facilitates a pro-inflammatory phenotype of Tregs via increased STAT1 activation, and contributes thereby to RA pathogenesis. target gene hsa-mir-155 Rheumatoid Arthritis 24351865 musculoskeletal system disease DOID:7148 M06.9 D001172 180300 HP:0001370 Rheumatoid arthritis-associated microRNA-155 targets SOCS1 and upregulates TNF-α and IL-1β in PBMCs. target gene hsa-mir-155 Rheumatoid Arthritis 24562503 musculoskeletal system disease DOID:7148 M06.9 D001172 180300 HP:0001370 Our results suggest that in RA miR-146a facilitates a pro-inflammatory phenotype of Tregs via increased STAT1 activation, and contributes thereby to RA pathogenesis. target gene hsa-mir-19a Rheumatoid Arthritis 22105995 musculoskeletal system disease DOID:7148 M06.9 D001172 180300 HP:0001370 TLR2 Expression Is Regulated by MicroRNA miR-19 in Rheumatoid Fibroblast-like Synoviocytes.Downregulation of miR-19b and miR-19a, which belongs to the same cluster, was confirmed by real-time quantitative PCR. Transfection of RA FLS with miR-19a/b mimics decreased TLR2 protein expression. In parallel, we found that both IL-6 and matrix metalloproteinase 3 secretion was significantly downregulated in activated FLS transfected with either mimic. Moreover, using a luciferase assay, we showed that miR-19a/b directly target Tlr2 mRNA. target gene hsa-mir-19b-1 Rheumatoid Arthritis 22105995 musculoskeletal system disease DOID:7148 M06.9 D001172 180300 HP:0001370 TLR2 Expression Is Regulated by MicroRNA miR-19 in Rheumatoid Fibroblast-like Synoviocytes.Downregulation of miR-19b and miR-19a, which belongs to the same cluster, was confirmed by real-time quantitative PCR. Transfection of RA FLS with miR-19a/b mimics decreased TLR2 protein expression. In parallel, we found that both IL-6 and matrix metalloproteinase 3 secretion was significantly downregulated in activated FLS transfected with either mimic. Moreover, using a luciferase assay, we showed that miR-19a/b directly target Tlr2 mRNA. target gene hsa-mir-19b-2 Rheumatoid Arthritis 22105995 musculoskeletal system disease DOID:7148 M06.9 D001172 180300 HP:0001370 TLR2 Expression Is Regulated by MicroRNA miR-19 in Rheumatoid Fibroblast-like Synoviocytes.Downregulation of miR-19b and miR-19a, which belongs to the same cluster, was confirmed by real-time quantitative PCR. Transfection of RA FLS with miR-19a/b mimics decreased TLR2 protein expression. In parallel, we found that both IL-6 and matrix metalloproteinase 3 secretion was significantly downregulated in activated FLS transfected with either mimic. Moreover, using a luciferase assay, we showed that miR-19a/b directly target Tlr2 mRNA. target gene hsa-mir-22 Rheumatoid Arthritis 24449575 musculoskeletal system disease DOID:7148 M06.9 D001172 180300 HP:0001370 A novel p53/microRNA-22/Cyr61 axis in synovial cells regulates inflammation in rheumatoid arthritis. target gene hsa-mir-223 Rheumatoid Arthritis 28056105 musculoskeletal system disease DOID:7148 M06.9 D001172 180300 HP:0001370 miR-223-3p may contribute to the pathogenesis of RA by downregulating the expression of IL-17RD and upregulating that of IL-6 in synovial cells target gene hsa-mir-23a Rheumatoid Arthritis 27936459 musculoskeletal system disease DOID:7148 M06.9 D001172 180300 HP:0001370 MiR-23a inhibited IL-17-mediated proinflammatory mediators expression via targeting IKKα in articular chondrocytes. target gene hsa-mir-26b Rheumatoid Arthritis 26088648 musculoskeletal system disease DOID:7148 M06.9 D001172 180300 HP:0001370 MiR-26b regulates β-catenin and CyclinD1 levels by inhibiting GSK-3β expression, which in-turn alters the Wnt/GSK-3β/β-catenin pathway to lower RAFLS proliferation and elevate cell apoptosis and the secretion of TNF-α,IL-1β and IL-6 cytokines. Therefore, our results show that miR-26B plays a central role in inhibiting the inflammation associated with rheumatoid arthritis. target gene hsa-mir-29a Rheumatoid Arthritis 28987940 musculoskeletal system disease DOID:7148 M06.9 D001172 180300 HP:0001370 MicroRNA-29a inhibits proliferation and induces apoptosis in rheumatoid arthritis fibroblast-like synoviocytes by repressing STAT3. target gene hsa-mir-363 Rheumatoid Arthritis 28376277 musculoskeletal system disease DOID:7148 M06.9 D001172 180300 HP:0001370 Dendritic Cells from Rheumatoid Arthritis Patient Peripheral Blood Induce Th17 Cell Differentiation via miR-363/Integrin αv/TGF-β Axis. target gene hsa-mir-650 Rheumatoid Arthritis 28129626 musculoskeletal system disease DOID:7148 M06.9 D001172 180300 HP:0001370 MiR-650 inhibits proliferation, migration and invasion of rheumatoid arthritis synovial fibroblasts by targeting AKT2. target gene hsa-mir-133 Roberts Syndrome 26434741 genetic disease DOID:5325 C535687 268300 miR-133-dependent cx43 overexpression rescues esco2-dependent growth defects target gene hsa-mir-17 Sarcoma [unspecific] 23128393 disease of cellular proliferation DOID:1115 C49 D012509 HP:0100242 Interestingly, the levels of onco-miR-17 locus coded miRNAs (miR-17-5p and miR-20a) were decreased upon TAF15 depletion and shown to affect the post-transcriptional regulation of TAF15-dependent genes,such as CDKN1A/p21. target gene hsa-mir-182 Sarcoma [unspecific] 25180607 disease of cellular proliferation DOID:1115 C49 D012509 HP:0100242 MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes. target gene hsa-mir-20a Sarcoma [unspecific] 23128393 disease of cellular proliferation DOID:1115 C49 D012509 HP:0100242 Interestingly, the levels of onco-miR-17 locus coded miRNAs (miR-17-5p and miR-20a) were decreased upon TAF15 depletion and shown to affect the post-transcriptional regulation of TAF15-dependent genes,such as CDKN1A/p21. target gene hsa-mir-137 Schizophrenia 22182936 disease of mental health DOID:5419 F20 D012559 181500 HP:0100753 Schizophrenia-associated genes CSMD1, C10orf26, CACNA1C and TCF4 are miR-137 targets. target gene hsa-mir-137 Schizophrenia 22883350 disease of mental health DOID:5419 F20 D012559 181500 HP:0100753 Candidate schizophrenia gene ZNF804A is a target for hsa-miR-137. target gene hsa-mir-137 Schizophrenia 24275578 disease of mental health DOID:5419 F20 D012559 181500 HP:0100753 MIR137 gene and target gene CACNA1C of miR-137 contribute to schizophrenia susceptibility in Han Chinese. target gene hsa-mir-137 Schizophrenia 26163462 disease of mental health DOID:5419 F20 D012559 181500 HP:0100753 Experimental validation of candidate schizophrenia gene CALN1 as a target for microRNA-137. target gene hsa-mir-137 Schizophrenia 26925706 disease of mental health DOID:5419 F20 D012559 181500 HP:0100753 MicroRNA-137 (miR-137) is a brain-enriched RNA with a critical role in regulating brain development and in mediating synaptic plasticity. target gene hsa-mir-17 Schizophrenia 22228753 disease of mental health DOID:5419 F20 D012559 181500 HP:0100753 Expression of NPAS3 in the Human Cortex is regulated by miR-17 During Development and has Implications for Schizophrenia. target gene hsa-mir-212 Schizophrenia 25392085 disease of mental health DOID:5419 F20 D012559 181500 HP:0100753 NMDA receptor, the molecular cascades controlled by these miRNAs and commonly predicted target genes of the two miRNAs. target gene hsa-mir-193b Scleroderma, Systemic 25384965 musculoskeletal system disease DOID:418 M34 D012595 181750 Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression. target gene hsa-mir-202 Scleroderma, Systemic 28068631 musculoskeletal system disease DOID:418 M34 D012595 181750 MicroRNA-202-3p regulates scleroderma fibrosis by targeting matrix metalloproteinase 1. target gene hsa-mir-29a Scleroderma, Systemic 26335042 musculoskeletal system disease DOID:418 M34 D012595 181750 miRNA-29a in systemic sclerosis: A valid target. target gene hsa-mir-30a Scleroderma, Systemic 25360821 musculoskeletal system disease DOID:418 M34 D012595 181750 MiR-30a-3p negatively regulates BAFF synthesis in systemic sclerosis and rheumatoid arthritis fibroblasts. target gene hsa-mir-183 Sensorineural Hearing Loss 23472202 nervous system disease DOID:10003 H90.5 D006313 304400 The miR-183/Taok1 target pair is implicated in cochlear responses to acoustic trauma. target gene hsa-mir-122 Sepsis 26889043 A41.9 D018805 HP:0100806 These findings demonstrate that host cellular RNA and specific miRNAs are released into the circulation during polymicrobial sepsis and may function as extracellular mediators capable of promoting cfB production and AP activation through specific TLR7 and MyD88 signaling. target gene hsa-mir-125b Sepsis 26482503 A41.9 D018805 HP:0100806 miR-125b modulates PCT expression by manipulating the amount and transcriptional activity of Stat3. target gene hsa-mir-145 Sepsis 26889043 A41.9 D018805 HP:0100806 These findings demonstrate that host cellular RNA and specific miRNAs are released into the circulation during polymicrobial sepsis and may function as extracellular mediators capable of promoting cfB production and AP activation through specific TLR7 and MyD88 signaling. target gene hsa-mir-146a Sepsis 26889043 A41.9 D018805 HP:0100806 These findings demonstrate that host cellular RNA and specific miRNAs are released into the circulation during polymicrobial sepsis and may function as extracellular mediators capable of promoting cfB production and AP activation through specific TLR7 and MyD88 signaling. target gene hsa-mir-146a Sepsis 21562054 A41.9 D018805 HP:0100806 MicroRNA-146a regulates both transcription silencing and translation disruption of TNF-α during TLR4-induced gene reprogramming. target gene hsa-mir-146a Sepsis 23825193 A41.9 D018805 HP:0100806 We conclude that a TLR4-, miR-146a-, p38 MAPK-, and MKP-1-dependent autoregulatory pathway regulates the translation of proinflammatory genes during the acute inflammatory response by spatially and temporally modifying the phosphorylation state of RBM4 translational repressor protein. target gene hsa-mir-146a Sepsis 28288804 A41.9 D018805 HP:0100806 MiR-146a potentially promotes IVIg-mediated inhibition of TLR4 signaling in LPS-activated human monocytes. target gene hsa-mir-146a Sepsis 28662100 A41.9 D018805 HP:0100806 miR-146a, miR-146b, and miR-155 increase expression of IL-6 and IL-8 and support HSP10 in an In vitro sepsis model. target gene hsa-mir-146b Sepsis 28662100 A41.9 D018805 HP:0100806 miR-146a, miR-146b, and miR-155 increase expression of IL-6 and IL-8 and support HSP10 in an In vitro sepsis model. target gene hsa-mir-155 Sepsis 28662100 A41.9 D018805 HP:0100806 miR-146a, miR-146b, and miR-155 increase expression of IL-6 and IL-8 and support HSP10 in an In vitro sepsis model. target gene hsa-mir-210 Sepsis 26889043 A41.9 D018805 HP:0100806 These findings demonstrate that host cellular RNA and specific miRNAs are released into the circulation during polymicrobial sepsis and may function as extracellular mediators capable of promoting cfB production and AP activation through specific TLR7 and MyD88 signaling. target gene hsa-mir-30a Sepsis 24858600 A41.9 D018805 HP:0100806 STAT1 regulates MD-2 expression in monocytes of sepsis via miR-30a. target gene hsa-mir-31 Sepsis 26978146 A41.9 D018805 HP:0100806 Down-regulation of MicroRNA-31 in CD4+ T Cells Contributes to Immunosuppression in Human Sepsis by Promoting TH2 Skewing. target gene hsa-mir-34a Sepsis 26889043 A41.9 D018805 HP:0100806 These findings demonstrate that host cellular RNA and specific miRNAs are released into the circulation during polymicrobial sepsis and may function as extracellular mediators capable of promoting cfB production and AP activation through specific TLR7 and MyD88 signaling. target gene hsa-mir-718 Sepsis 28209713 A41.9 D018805 HP:0100806 miR-718 represses proinflammatory cytokine production through targeting phosphatase and tensin homolog (PTEN). target gene hsa-mir-155 Sezary Disease 29582620 disease of cellular proliferation DOID:8541 C84.1 D012751 HERV-K and HERV-W expression is regulated by mir-155 in Sézary syndrome target gene hsa-mir-486 Sezary Disease 24062018 disease of cellular proliferation DOID:8541 C84.1 D012751 we demonstrate that PTEN level can be also reduced by a group of miRs previously found upregulated and of prognostic relevance in SS; particularly, miR-21, miR-106b, and miR-486 were able to control PTEN abundance either in vitro or in vivo target gene hsa-mir-34a Sickle Cell Anemia 26940952 genetic disease DOID:10923 D57.1 D000755 603903 miR-34a promoted cell differentiation supported by increased expression of KLF1, glycophorin A, and the erythropoietin receptor. target gene hsa-mir-302c Skin Neoplasms 22486352 disease of cellular proliferation DOID:4159 C44.90 D012878 HP:0008069 Co-treatment with decitabine and doxorubicin results first in increased OCT4 and mir-145, then a decrease in both, suggesting that OCT4 and mir-145 regulate each other. target gene hsa-mir-34a Somatotropinoma 25658813 F45.9 D049912 miR-34a is a negative regulator of AIP-protein expression and could be responsible for the low AIP expression observed in somatotropinomas with an invasive phenotype and resistance to SSA. target gene hsa-mir-574 Spinal Chordoma 29051990 musculoskeletal system disease DOID:4153 D002817 Clinicopathologic implications of CD8+/Foxp3+ ratio and miR-574-3p/PD-L1 axis in spinal chordoma patients. target gene hsa-mir-140 Spinal Cord Injuries 28501777 S34.139A D013119 MiR-140/BDNF axis regulates normal human astrocyte proliferation and LPS-induced IL-6 and TNF-α secretion. target gene hsa-mir-16 Spinal Cord Injuries 25936407 S34.139A D013119 A number of microRNAs (e.g. miR210, miR-487b and miR-16) were observed to target cholesterol metabolism-associated DGEs. target gene hsa-mir-34b Spinal Cord Injuries 27780189 S34.139A D013119 Changes in the Expression of miR-34a and its Target Genes Following Spinal Cord Injury In Rats. target gene hsa-mir-34c Spinal Cord Injuries 27780189 S34.139A D013119 Changes in the Expression of miR-34a and its Target Genes Following Spinal Cord Injury In Rats. target gene hsa-mir-494 Spinal Cord Injuries 28368292 S34.139A D013119 Long Coding RNA XIST Contributes to Neuronal Apoptosis through the Downregulation of AKT Phosphorylation and Is Negatively Regulated by miR-494 in Rat Spinal Cord Injury. target gene hsa-mir-185 Squamous Cell Carcinoma 24070899 disease of cellular proliferation DOID:1749 D002294 Phospho-ΔNp63α regulates AQP3, ALOX12B, CASP14 and CLDN1 expression through transcription and microRNA modulation. target gene hsa-mir-1246 Squamous Cell Carcinoma, Cerevial 24806621 endocrine system disease DOID:5531 MiR-1246 promotes SiHa cervical cancer cell proliferation, invasion, and migration through suppression of its target gene thrombospondin 2. target gene hsa-mir-138 Squamous Cell Carcinoma, Cerevial 26267680 endocrine system disease DOID:5531 miR-138 and miR-720 are the down-regulated target miRNAs in HPV16-positive squamous carcinoma of the cervix in the Uygur of southern Xinjiang. The common target gene for miR-138 and miR-720 is EZH2, which might be related to cervical squamous carcinoma invasion and metastasis. target gene hsa-mir-29a Squamous Cell Carcinoma, Cerevial 24141696 endocrine system disease DOID:5531 Tumor-suppressive microRNA-29a inhibits cancer cell migration and invasion via targeting HSP47 in cervical squamous cell carcinoma. target gene hsa-mir-720 Squamous Cell Carcinoma, Cerevial 26267680 endocrine system disease DOID:5531 miR-138 and miR-720 are the down-regulated target miRNAs in HPV16-positive squamous carcinoma of the cervix in the Uygur of southern Xinjiang. The common target gene for miR-138 and miR-720 is EZH2, which might be related to cervical squamous carcinoma invasion and metastasis. target gene hsa-let-7 Squamous Cell Carcinoma, Esophageal 24612219 disease of cellular proliferation DOID:3748 C562729 Expression of let-7 can suppress cell proliferation by acting directly on regulation of HMGA2 in OSCC. High expression of Snail and its correlation with HMGA2 expression and tumour invasion suggest that HMGA2 may be involved in EMT in the OSCC of Kazakh patients. target gene hsa-mir-106b Squamous Cell Carcinoma, Esophageal 27619676 disease of cellular proliferation DOID:3748 C562729 MiR-106b promotes migration and invasion through enhancing EMT via downregulation of Smad 7 in Kazakh's esophageal squamous cell carcinoma. target gene hsa-mir-107 Squamous Cell Carcinoma, Esophageal 28393193 disease of cellular proliferation DOID:3748 C562729 miR-107 functions as a tumor suppressor in human esophageal squamous cell carcinoma and targets Cdc42. target gene hsa-mir-126 Squamous Cell Carcinoma, Esophageal 26191164 disease of cellular proliferation DOID:3748 C562729 MicroRNA-126 is down-regulated in human esophageal squamous cell carcinoma and inhibits the proliferation and migration in EC109 cell via PI3K/AKT signaling pathway. target gene hsa-mir-127 Squamous Cell Carcinoma, Esophageal 27645894 disease of cellular proliferation DOID:3748 C562729 MicroRNA-127 is a tumor suppressor in human esophageal squamous cell carcinoma through the regulation of oncogene FMNL3. target gene hsa-mir-1290 Squamous Cell Carcinoma, Esophageal 26653554 disease of cellular proliferation DOID:3748 C562729 Taken together, our findings suggested that miR-1290 functions as a tumor oncogene in the progression of ESCC by targeting NFIX. target gene hsa-mir-133a-1 Squamous Cell Carcinoma, Esophageal 21351259 disease of cellular proliferation DOID:3748 C562729 miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. target gene hsa-mir-133a-2 Squamous Cell Carcinoma, Esophageal 21351259 disease of cellular proliferation DOID:3748 C562729 miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. target gene hsa-mir-133b Squamous Cell Carcinoma, Esophageal 21351259 disease of cellular proliferation DOID:3748 C562729 miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. target gene hsa-mir-138 Squamous Cell Carcinoma, Esophageal 23319823 disease of cellular proliferation DOID:3748 C562729 Downregulation of miR-138 sustains NF-κB activation and promotes lipid raft formation in esophageal squamous cell carcinoma. target gene hsa-mir-143 Squamous Cell Carcinoma, Esophageal 26806810 disease of cellular proliferation DOID:3748 C562729 MiR-143 inhibits tumor cell proliferation and invasion by targeting STAT3 in esophageal squamous cell carcinoma. target gene hsa-mir-143 Squamous Cell Carcinoma, Esophageal 29137232 disease of cellular proliferation DOID:3748 C562729 Integration of metabolomics, transcriptomics, and microRNA expression profiling reveals a miR-143-HK2-glucose network underlying zinc-deficiency-associated esophageal neoplasia. target gene hsa-mir-145 Squamous Cell Carcinoma, Esophageal 21351259 disease of cellular proliferation DOID:3748 C562729 miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. target gene hsa-mir-145 Squamous Cell Carcinoma, Esophageal 24356567 disease of cellular proliferation DOID:3748 C562729 miR-145 inhibits proliferation and invasion of esophageal squamous cell carcinoma in part by targeting c-Myc. target gene hsa-mir-145 Squamous Cell Carcinoma, Esophageal 27771733 disease of cellular proliferation DOID:3748 C562729 MicroRNA-145 Inhibits Cell Migration and Invasion and Regulates Epithelial-Mesenchymal Transition (EMT) by Targeting Connective Tissue Growth Factor (CTGF) in Esophageal Squamous Cell Carcinoma. target gene hsa-mir-145 Squamous Cell Carcinoma, Esophageal 29430188 disease of cellular proliferation DOID:3748 C562729 The ROR/miR-145/FSCN1 pathway was shown to take part in the metastasis of ESCC. ROR is likely an oncogene biomarker for ESCC early diagnosis and prognosis target gene hsa-mir-146a Squamous Cell Carcinoma, Esophageal 27832663 disease of cellular proliferation DOID:3748 C562729 miR-146a-5p mediates epithelial-mesenchymal transition of oesophageal squamous cell carcinoma via targeting Notch2. target gene hsa-mir-148a Squamous Cell Carcinoma, Esophageal 29067119 disease of cellular proliferation DOID:3748 C562729 MiR-148a modulates HLA-G expression and influences tumor apoptosis in esophageal squamous cell carcinoma. target gene hsa-mir-155 Squamous Cell Carcinoma, Esophageal 24551280 disease of cellular proliferation DOID:3748 C562729 microRNA-155 acts as an oncogene by targeting the tumor protein 53-induced nuclear protein 1 in esophageal squamous cell carcinoma. target gene hsa-mir-155 Squamous Cell Carcinoma, Esophageal 25823933 disease of cellular proliferation DOID:3748 C562729 a novel pattern of differential miRNA-target expression was constructed, which with further investigation, may provide novel targets for diagnosing and understanding the mechanism of ESCC. target gene hsa-mir-16 Squamous Cell Carcinoma, Esophageal 24852767 disease of cellular proliferation DOID:3748 C562729 Aberrant increased level of miR-16 was detected in the ESCC tissues compared with the corresponding adjacent tumor tissues. MiR-16 could inhibit cell apoptosis while promote cell proliferation by down-regulating RECK and SOX6 in TE-1 and Eca-109 cell lines through binding the 3'UTR of both RECK and SOX6 mRNA. CONCLUSIONS: Aberrant expression level of miR-16 could suppress cell apoptosis while promote growth by regulating RECK and SOX6 which play important roles in the pathogenesis of ESCC. target gene hsa-mir-181d Squamous Cell Carcinoma, Esophageal 27572270 disease of cellular proliferation DOID:3748 C562729 MicroRNA-181d is a tumor suppressor in human esophageal squamous cell carcinoma inversely regulating Derlin-1. target gene hsa-mir-183 Squamous Cell Carcinoma, Esophageal 25211657 disease of cellular proliferation DOID:3748 C562729 MiR-183 promotes ESCC cell proliferation and invasion by directly targeting PDCD4, which suggests that it is involved in the pathogenesis of ESCC. target gene hsa-mir-195 Squamous Cell Carcinoma, Esophageal 25400770 disease of cellular proliferation DOID:3748 C562729 The main findings of this study indicate the involvement of miR-195-Cdc42 axis in the progression of ESCC and suggest that the combined aberrant expression of miR-195 and Cdc42 mRNA can serve as a promising unfavorable prognostic biomarker in ESCC. target gene hsa-mir-195 Squamous Cell Carcinoma, Esophageal 24025765 disease of cellular proliferation DOID:3748 C562729 miR-195 may act as a tumor suppressor in ESCC by targeting Cdc42. target gene hsa-mir-200a Squamous Cell Carcinoma, Esophageal 26341629 disease of cellular proliferation DOID:3748 C562729 These results reaffirm the potential role of MSA as a chemopreventive agent via the regulation of KLF4/miR-200a/Keap1/Nrf2 axis in ESCC cells. target gene hsa-mir-200b Squamous Cell Carcinoma, Esophageal 24064224 disease of cellular proliferation DOID:3748 C562729 miR-200b suppresses invasiveness and modulates the cytoskeletal and adhesive machinery in esophageal squamous cell carcinoma cells via targeting Kindlin-2. target gene hsa-mir-202 Squamous Cell Carcinoma, Esophageal 25823933 disease of cellular proliferation DOID:3748 C562729 a novel pattern of differential miRNA-target expression was constructed, which with further investigation, may provide novel targets for diagnosing and understanding the mechanism of ESCC. target gene hsa-mir-202 Squamous Cell Carcinoma, Esophageal 28277193 disease of cellular proliferation DOID:3748 C562729 miR-202 Promotes Cell Apoptosis in Esophageal Squamous Cell Carcinoma by Targeting HSF2. target gene hsa-mir-203 Squamous Cell Carcinoma, Esophageal 21299870 disease of cellular proliferation DOID:3748 C562729 MicroRNA-203 inhibits cell proliferation by repressing DeltaNp63 expression in human esophageal squamous cell carcinoma. target gene hsa-mir-205 Squamous Cell Carcinoma, Esophageal 21426561 disease of cellular proliferation DOID:3748 C562729 MiRNA-205 modulates cellular invasion and migration via regulating zinc finger E-box binding homeobox 2 expression in esophageal squamous cell carcinoma cells. target gene hsa-mir-208a Squamous Cell Carcinoma, Esophageal 25023649 disease of cellular proliferation DOID:3748 C562729 These results suggest that miR-208 represents a potential onco-miR and participates in ESCC carcinogenesis by suppressing SOX6 expression. target gene hsa-mir-214 Squamous Cell Carcinoma, Esophageal 26234674 disease of cellular proliferation DOID:3748 C562729 Overexpression of miR-214-3p in esophageal squamous cancer cells enhances sensitivity to cisplatin by targeting survivin directly and indirectly through CUG-BP1. target gene hsa-mir-214 Squamous Cell Carcinoma, Esophageal 27619677 disease of cellular proliferation DOID:3748 C562729 miR-214 inhibits invasion and migration via downregulating GALNT7 in esophageal squamous cell cancer. target gene hsa-mir-214 Squamous Cell Carcinoma, Esophageal 28954387 disease of cellular proliferation DOID:3748 C562729 MiR-214 inhibits the proliferation and invasion of esophageal squamous cell carcinoma cells by targeting CDC25B. target gene hsa-mir-218 Squamous Cell Carcinoma, Esophageal 25999024 disease of cellular proliferation DOID:3748 C562729 MicroRNA-218 inhibits the proliferation and metastasis of esophageal squamous cell carcinoma cells by targeting BMI1. target gene hsa-mir-224 Squamous Cell Carcinoma, Esophageal 26245343 disease of cellular proliferation DOID:3748 C562729 The current study demonstrated that miR-224 acts as an oncogenic miRNA in esophageal squamous cell carcinoma (ESCC), possibly by targeting PHLPP1 and PHLPP2. target gene hsa-mir-25 Squamous Cell Carcinoma, Esophageal 29250158 disease of cellular proliferation DOID:3748 C562729 PTEN, TP53, MDM2, E2F1, PRMT5, MCM2, RB1, CDKN1A, SHAD7 and EZH2 may be targeted by the miR-106b-25 cluster, and act together to regulate the development of ESCC target gene hsa-mir-27a Squamous Cell Carcinoma, Esophageal 24154848 disease of cellular proliferation DOID:3748 C562729 microRNA-27a functions as a tumor suppressor in esophageal squamous cell carcinoma by targeting KRAS. target gene hsa-mir-29c Squamous Cell Carcinoma, Esophageal 21551130 disease of cellular proliferation DOID:3748 C562729 miR-29c induces cell cycle arrest in Esophageal Squamous Cell Carcinoma by modulating Cyclin E expression. target gene hsa-mir-302b Squamous Cell Carcinoma, Esophageal 24438167 disease of cellular proliferation DOID:3748 C562729 miR-302b is a potential molecular marker of ESCC and functions as a tumor suppressor by post-transcriptionally regulating ErbB4 target gene hsa-mir-30d Squamous Cell Carcinoma, Esophageal 28184915 disease of cellular proliferation DOID:3748 C562729 MicroRNA-30d inhibits the migration and invasion of human esophageal squamous cell carcinoma cells via the post‑transcriptional regulation of enhancer of zeste homolog 2. target gene hsa-mir-34a Squamous Cell Carcinoma, Esophageal 25954903 disease of cellular proliferation DOID:3748 C562729 miR-34a inhibits the migration and invasion of esophageal squamous cell carcinoma by targeting Yin Yang-1. target gene hsa-mir-34a Squamous Cell Carcinoma, Esophageal 28534990 disease of cellular proliferation DOID:3748 C562729 Tumor suppressor microRNA-34a inhibits cell migration and invasion by targeting MMP-2/MMP-9/FNDC3B in esophageal squamous cell carcinoma. target gene hsa-mir-34a Squamous Cell Carcinoma, Esophageal 29094237 disease of cellular proliferation DOID:3748 C562729 MicroRNA-34a suppresses invasion and metastatic in esophageal squamous cell carcinoma by regulating CD44. target gene hsa-mir-34a Squamous Cell Carcinoma, Esophageal 29190930 disease of cellular proliferation DOID:3748 C562729 MicroRNA-34a functions as a tumor suppressor by directly targeting oncogenic PLCE1 in Kazakh esophageal squamous cell carcinoma target gene hsa-mir-367 Squamous Cell Carcinoma, Esophageal 26777997 disease of cellular proliferation DOID:3748 C562729 MiR-367 is a potential biomarker for ESCC and may act as an oncogene in regulating ESCC development. target gene hsa-mir-375 Squamous Cell Carcinoma, Esophageal 21813472 disease of cellular proliferation DOID:3748 C562729 MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. target gene hsa-mir-375 Squamous Cell Carcinoma, Esophageal 28069583 disease of cellular proliferation DOID:3748 C562729 MiR-375 suppresses invasion and metastasis by direct targeting of SHOX2 in esophageal squamous cell carcinoma. target gene hsa-mir-375 Squamous Cell Carcinoma, Esophageal 27779648 disease of cellular proliferation DOID:3748 C562729 Regulation of MMP13 by antitumor microRNA-375 markedly inhibits cancer cell migration and invasion in esophageal squamous cell carcinoma. target gene hsa-mir-518 Squamous Cell Carcinoma, Esophageal 28119087 disease of cellular proliferation DOID:3748 C562729 miR-518 inhibited the proliferation and invasion of esophageal squamous cell carcinoma (ESCC) cells possibly by targeting RAP1B target gene hsa-mir-520a Squamous Cell Carcinoma, Esophageal 24589589 disease of cellular proliferation DOID:3748 C562729 miR-520a regulates the expression of ErbB4 and suppresses the proliferation and invasion of ESCC cells in vitro, suggesting its role as a tumor suppressor. target gene hsa-mir-577 Squamous Cell Carcinoma, Esophageal 24294352 disease of cellular proliferation DOID:3748 C562729 Effects and interactions of MiR-577 and TSGA10 in regulating esophageal squamous cell carcinoma. target gene hsa-mir-7 Squamous Cell Carcinoma, Esophageal 27956498 disease of cellular proliferation DOID:3748 C562729 In cytoplasm, CCAT1 regulates HOXB13 as a molecular decoy for miR-7, a microRNA that targets both CCAT1 and HOXB13, thus facilitating cell growth and migration target gene hsa-mir-92b Squamous Cell Carcinoma, Esophageal 27659550 disease of cellular proliferation DOID:3748 C562729 RAB23, regulated by miR-92b, promotes the progression of esophageal squamous cell carcinoma. target gene hsa-let-7i Squamous Cell Carcinoma, Head and Neck 23454123 disease of cellular proliferation DOID:5520 C76.0 C535575 In clinical HNSCC samples, let-7i expression was inversely correlated with BMP4 expression. Our results revealed that let-7i attenuates mesenchymal-mode migration of HNSCC cells through repression of a novel target, BMP4. target gene hsa-mir-101-1 Squamous Cell Carcinoma, Head and Neck 21532618 disease of cellular proliferation DOID:5520 C76.0 C535575 The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma. target gene hsa-mir-101-2 Squamous Cell Carcinoma, Head and Neck 21532618 disease of cellular proliferation DOID:5520 C76.0 C535575 The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma. target gene hsa-mir-106a Squamous Cell Carcinoma, Head and Neck 26694379 disease of cellular proliferation DOID:5520 C76.0 C535575 MicroRNA-Target Network Inference and Local Network Enrichment Analysis Identify Two microRNA Clusters with Distinct Functions in Head and Neck Squamous Cell Carcinoma. target gene hsa-mir-1-1 Squamous Cell Carcinoma, Head and Neck 21378409 disease of cellular proliferation DOID:5520 C76.0 C535575 miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. target gene hsa-mir-1-2 Squamous Cell Carcinoma, Head and Neck 21378409 disease of cellular proliferation DOID:5520 C76.0 C535575 miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. target gene hsa-mir-124 Squamous Cell Carcinoma, Head and Neck 28212569 disease of cellular proliferation DOID:5520 C76.0 C535575 MiR-124 acts as a tumor suppressor by inhibiting the expression of sphingosine kinase 1 and its downstream signaling in head and neck squamous cell carcinoma. target gene hsa-mir-125b Squamous Cell Carcinoma, Head and Neck 26694379 disease of cellular proliferation DOID:5520 C76.0 C535575 MicroRNA-Target Network Inference and Local Network Enrichment Analysis Identify Two microRNA Clusters with Distinct Functions in Head and Neck Squamous Cell Carcinoma. target gene hsa-mir-138 Squamous Cell Carcinoma, Head and Neck 24565984 disease of cellular proliferation DOID:5520 C76.0 C535575 These findings strongly suggest that the inhibition of RhoC can be achieved by over expressing miR-138, which further attenuates the downstream signaling cascade leading to cancer progression and survival. Moreover, this study for the first time shows that down regulation of FAK, Src and Erk(1/2) by miR-138 overexpression is due to inhibition of RhoC in HNSCC. target gene hsa-mir-155 Squamous Cell Carcinoma, Head and Neck 26694378 disease of cellular proliferation DOID:5520 C76.0 C535575 MicroRNA-Target Network Inference and Local Network Enrichment Analysis Identify Two microRNA Clusters with Distinct Functions in Head and Neck Squamous Cell Carcinoma. target gene hsa-mir-15b Squamous Cell Carcinoma, Head and Neck 26694379 disease of cellular proliferation DOID:5520 C76.0 C535575 MicroRNA-Target Network Inference and Local Network Enrichment Analysis Identify Two microRNA Clusters with Distinct Functions in Head and Neck Squamous Cell Carcinoma. target gene hsa-mir-182 Squamous Cell Carcinoma, Head and Neck 29356167 disease of cellular proliferation DOID:5520 C76.0 C535575 there is frequent and concordant upregulation of miR-31, miR-96, and miR-182 during HNSCC and these miRNAs co-target Numb target gene hsa-mir-193b Squamous Cell Carcinoma, Head and Neck 26694379 disease of cellular proliferation DOID:5520 C76.0 C535575 MicroRNA-Target Network Inference and Local Network Enrichment Analysis Identify Two microRNA Clusters with Distinct Functions in Head and Neck Squamous Cell Carcinoma. target gene hsa-mir-200c Squamous Cell Carcinoma, Head and Neck 21899661 disease of cellular proliferation DOID:5520 C76.0 C535575 The expression of ZEB1, a target mRNA for miR-200c, was up-regulated 3 and 6 hours after HGF stimulation. target gene hsa-mir-203 Squamous Cell Carcinoma, Head and Neck 18483491 disease of cellular proliferation DOID:5520 C76.0 C535575 we have shown that miR-203 can regulate DeltaNp63 levels upon genotoxic damage in head and neck squamous cell carcinoma cells, thus controlling cell survival. target gene hsa-mir-206 Squamous Cell Carcinoma, Head and Neck 28987947 disease of cellular proliferation DOID:5520 C76.0 C535575 MiR-206 inhibits Head and neck squamous cell carcinoma cell progression by targeting HDAC6 via PTEN/AKT/mTOR pathway. target gene hsa-mir-20b Squamous Cell Carcinoma, Head and Neck 26694379 disease of cellular proliferation DOID:5520 C76.0 C535575 MicroRNA-Target Network Inference and Local Network Enrichment Analysis Identify Two microRNA Clusters with Distinct Functions in Head and Neck Squamous Cell Carcinoma. target gene hsa-mir-21 Squamous Cell Carcinoma, Head and Neck 28138036 disease of cellular proliferation DOID:5520 C76.0 C535575 Suppression of the Growth and Invasion of Human Head and Neck Squamous Cell Carcinomas via Regulating STAT3 Signaling and the miR-21/β-catenin Axis with HJC0152. target gene hsa-mir-218-1 Squamous Cell Carcinoma, Head and Neck 23159910 disease of cellular proliferation DOID:5520 C76.0 C535575 Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion through targeting laminin-332 in head and neck squamous cell carcinoma target gene hsa-mir-218-2 Squamous Cell Carcinoma, Head and Neck 23159910 disease of cellular proliferation DOID:5520 C76.0 C535575 Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion through targeting laminin-332 in head and neck squamous cell carcinoma target gene hsa-mir-27b Squamous Cell Carcinoma, Head and Neck 21899661 disease of cellular proliferation DOID:5520 C76.0 C535575 The expression of ST14/matriptase an enzyme for extracellular matrix (ECM) degradation and HGF activation and a target mRNA for miR-27b, was drastically up-regulated in protein level after HGF stimulation. target gene hsa-mir-29a Squamous Cell Carcinoma, Head and Neck 24091622 disease of cellular proliferation DOID:5520 C76.0 C535575 Downregulation of miR-29s was a frequent event in HNSCC. The miR-29s acted as tumour suppressors and directly targeted laminin-integrin signalling. Recognition of tumour-suppressive miRNA-mediated cancer pathways provides new insights into the potential mechanisms of HNSCC oncogenesis and metastasis and suggests novel therapeutic strategies for the disease. target gene hsa-mir-29b Squamous Cell Carcinoma, Head and Neck 24091622 disease of cellular proliferation DOID:5520 C76.0 C535575 Downregulation of miR-29s was a frequent event in HNSCC. The miR-29s acted as tumour suppressors and directly targeted laminin-integrin signalling. Recognition of tumour-suppressive miRNA-mediated cancer pathways provides new insights into the potential mechanisms of HNSCC oncogenesis and metastasis and suggests novel therapeutic strategies for the disease. target gene hsa-mir-29c Squamous Cell Carcinoma, Head and Neck 24091622 disease of cellular proliferation DOID:5520 C76.0 C535575 Downregulation of miR-29s was a frequent event in HNSCC. The miR-29s acted as tumour suppressors and directly targeted laminin-integrin signalling. Recognition of tumour-suppressive miRNA-mediated cancer pathways provides new insights into the potential mechanisms of HNSCC oncogenesis and metastasis and suggests novel therapeutic strategies for the disease. target gene hsa-mir-31 Squamous Cell Carcinoma, Head and Neck 29356167 disease of cellular proliferation DOID:5520 C76.0 C535575 there is frequent and concordant upregulation of miR-31, miR-96, and miR-182 during HNSCC and these miRNAs co-target Numb target gene hsa-mir-34a Squamous Cell Carcinoma, Head and Neck 26323460 disease of cellular proliferation DOID:5520 C76.0 C535575 MicroRNA-34a regulates epithelial-mesenchymal transition and cancer stem cell phenotype of head and neck squamous cell carcinoma in vitro. target gene hsa-mir-375 Squamous Cell Carcinoma, Head and Neck 21753766 disease of cellular proliferation DOID:5520 C76.0 C535575 Tumor suppressive microRNA-375 regulates oncogene AEG-1/MTDH in head and neck squamous cell carcinoma (HNSCC). target gene hsa-mir-375 Squamous Cell Carcinoma, Head and Neck 28499703 disease of cellular proliferation DOID:5520 C76.0 C535575 miR-375 Regulates Invasion-Related Proteins Vimentin and L-Plastin. target gene hsa-mir-512 Squamous Cell Carcinoma, Head and Neck 26258591 disease of cellular proliferation DOID:5520 C76.0 C535575 miR-512-5p suppresses tumor growth by targeting hTERT in telomerase positive head and neck squamous cell carcinoma in vitro and in vivo. target gene hsa-mir-548b Squamous Cell Carcinoma, Head and Neck 26694379 disease of cellular proliferation DOID:5520 C76.0 C535575 MicroRNA-Target Network Inference and Local Network Enrichment Analysis Identify Two microRNA Clusters with Distinct Functions in Head and Neck Squamous Cell Carcinoma. target gene hsa-mir-582 Squamous Cell Carcinoma, Head and Neck 26694379 disease of cellular proliferation DOID:5520 C76.0 C535575 MicroRNA-Target Network Inference and Local Network Enrichment Analysis Identify Two microRNA Clusters with Distinct Functions in Head and Neck Squamous Cell Carcinoma. target gene hsa-mir-874 Squamous Cell Carcinoma, Head and Neck 23558898 disease of cellular proliferation DOID:5520 C76.0 C535575 Tumour-suppressive microRNA-874 contributes to cell proliferation through targeting of histone deacetylase 1 in head and neck squamous cell carcinoma target gene hsa-mir-885 Squamous Cell Carcinoma, Head and Neck 22071691 disease of cellular proliferation DOID:5520 C76.0 C535575 miR-885-3p modulated the cisplatin-induced TP53-dependent mitochondrial apoptosis by up regulation of MDM4 levels and down regulation of BCL2 levels in mitochondria. Altogether, our results support the notion that miR-885-3p might contribute in regulation of cell viability, apoptosis and/or autophagy in squamous cell carcinoma cells upon cisplatin exposure. target gene hsa-mir-9-1 Squamous Cell Carcinoma, Head and Neck 26694379 disease of cellular proliferation DOID:5520 C76.0 C535575 MicroRNA-Target Network Inference and Local Network Enrichment Analysis Identify Two microRNA Clusters with Distinct Functions in Head and Neck Squamous Cell Carcinoma. target gene hsa-mir-9-2 Squamous Cell Carcinoma, Head and Neck 26694379 disease of cellular proliferation DOID:5520 C76.0 C535575 MicroRNA-Target Network Inference and Local Network Enrichment Analysis Identify Two microRNA Clusters with Distinct Functions in Head and Neck Squamous Cell Carcinoma. target gene hsa-mir-96 Squamous Cell Carcinoma, Head and Neck 29356167 disease of cellular proliferation DOID:5520 C76.0 C535575 there is frequent and concordant upregulation of miR-31, miR-96, and miR-182 during HNSCC and these miRNAs co-target Numb target gene hsa-mir-1-1 Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal 21924268 disease of cellular proliferation DOID:2876 miRNA-1 targets fibronectin1 and suppresses the migration and invasion of the HEp2 laryngeal squamous carcinoma cell line. target gene hsa-mir-1-2 Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal 21924268 disease of cellular proliferation DOID:2876 miRNA-1 targets fibronectin1 and suppresses the migration and invasion of the HEp2 laryngeal squamous carcinoma cell line. target gene hsa-mir-132 Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal 27751825 disease of cellular proliferation DOID:2876 MiR-132 plays an oncogenic role in laryngeal squamous cell carcinoma by targeting FOXO1 and activating the PI3K/AKT pathway. target gene hsa-mir-138 Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal 28962111 disease of cellular proliferation DOID:2876 MicroRNA-138 suppresses cell proliferation in laryngeal squamous cell carcinoma via inhibiting EZH2 and PI3K/AKT signaling. target gene hsa-mir-139 Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal 24318902 disease of cellular proliferation DOID:2876 MiR-139 targets CXCR4 and inhibits the proliferation and metastasis of laryngeal squamous carcinoma cells. target gene hsa-mir-140 Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal 27033573 disease of cellular proliferation DOID:2876 miR-140-5p affects the migration and invasion of hypopharyngeal carcinoma cells by downregulating ADAM10 expression. target gene hsa-mir-19a Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal 26502748 disease of cellular proliferation DOID:2876 Our preliminary outcomes suggest the utility of miR-19a in the challenging differential diagnosis of laryngeal VSCC. Although miR-19a has been found to regulate SOCS-1 expression, this evidence was not confirmed by this investigation. target gene hsa-mir-19a Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal 24427326 disease of cellular proliferation DOID:2876 MiR-19a is correlated with prognosis and apoptosis of laryngeal squamous cell carcinoma by regulating TIMP-2 expression. target gene hsa-mir-214 Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal 25623865 disease of cellular proliferation DOID:2876 miR-214 is expressed at a low level in advanced hypopharyngeal carcinoma tissues, and can obviously inhibit the invasion and migration abilities of FaDu cells, possibly because of its inhibiting effect on Twist expression. Additionally, miR-214 plays no significant role in the proliferation of FaDu cells. target gene hsa-mir-373 Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal 29307338 disease of cellular proliferation DOID:2876 Expression of miR-373 and its predicted target genes E-cadherin and CD44 in patients with laryngeal squamous cell carcinoma target gene hsa-mir-375 Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal 25184138 disease of cellular proliferation DOID:2876 miR-375 suppresses IGF1R expression and contributes to inhibition of cell progression in laryngeal squamous cell carcinoma. target gene hsa-mir-4497 Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal 29843929 disease of cellular proliferation DOID:2876 MicroRNA-4497 functions as a tumor suppressor in laryngeal squamous cell carcinoma via negatively modulation the GBX2. target gene hsa-mir-489 Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal 20700123 disease of cellular proliferation DOID:2876 miR-489:miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma target gene hsa-mir-504 Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal 24647829 disease of cellular proliferation DOID:2876 microRNA-504 inhibits cancer cell proliferation via targeting CDK6 in hypopharyngeal squamous cell carcinoma. target gene hsa-mir-93 Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal 25309979 disease of cellular proliferation DOID:2876 MicroRNA-93 regulates cyclin G2 expression and plays an oncogenic role in laryngeal squamous cell carcinoma. target gene hsa-mir-205 Squamous Cell Carcinoma, Lung 24438615 disease of cellular proliferation DOID:3907 C34.91 We confirmed the high diagnostic accuracy of miR-205 in discriminating SQ from AC and SCLC in Chinese patients. Moreover, we identified 11 significant target genes of miR-205 which could be used for further functional studies as the basis for the development of SQ targeted therapies. target gene hsa-mir-21 Squamous Cell Carcinoma, Lung 25084400 disease of cellular proliferation DOID:3907 C34.91 MicroRNA-21 (miR-21) regulates cellular proliferation, invasion, migration, and apoptosis by targeting PTEN, RECK and Bcl-2 in lung squamous carcinoma, Gejiu City, China. target gene hsa-mir-218 Squamous Cell Carcinoma, Lung 27633630 disease of cellular proliferation DOID:3907 C34.91 Regulation of TPD52 by antitumor microRNA-218 suppresses cancer cell migration and invasion in lung squamous cell carcinoma. target gene hsa-mir-24 Squamous Cell Carcinoma, Lung 27666488 disease of cellular proliferation DOID:3907 C34.91 MicroRNAs modulate the expression of the SOX18 transcript in lung squamous cell carcinoma. target gene hsa-mir-29 Squamous Cell Carcinoma, Lung 26676674 disease of cellular proliferation DOID:3907 C34.91 Elucidation of the novel lung SCC molecular pathways and targets regulated by tumor-suppressive miR-29s will provide new insights into the potential mechanisms of oncogenesis and metastasis of the disease. target gene hsa-mir-588 Squamous Cell Carcinoma, Lung 27571908 disease of cellular proliferation DOID:3907 C34.91 MicroRNA-588 suppresses tumor cell migration and invasion by targeting GRN in lung squamous cell carcinoma. target gene hsa-let-7a Squamous Cell Carcinoma, Lung 27666488 disease of cellular proliferation DOID:3907 C34.91 MicroRNAs modulate the expression of the SOX18 transcript in lung squamous cell carcinoma. target gene hsa-mir-101 Squamous Cell Carcinoma, Oral 25762643 disease of cellular proliferation DOID:0050866 Snail and Slug collaborate on EMT and tumor metastasis through miR-101-mediated EZH2 axis in oral tongue squamous cell carcinoma. target gene hsa-mir-101 Squamous Cell Carcinoma, Oral 27904690 disease of cellular proliferation DOID:0050866 miRNA-101 acts as a tumor suppressor in oral squamous cell carcinoma by targeting CX chemokine receptor 7. target gene hsa-mir-125a Squamous Cell Carcinoma, Oral 25266720 disease of cellular proliferation DOID:0050866 MicroRNA-125a reduces proliferation and invasion of oral squamous cell carcinoma cells by targeting estrogen-related receptor α: implications for cancertherapeutics. target gene hsa-mir-138 Squamous Cell Carcinoma, Oral 26239136 disease of cellular proliferation DOID:0050866 miR-138 suppresses the proliferation of oral squamous cell carcinoma cells by targeting Yes-associated protein 1. target gene hsa-mir-140 Squamous Cell Carcinoma, Oral 22470160 disease of cellular proliferation DOID:0050866 miR-140-3p, miR-29c, and miR-29a were differentially expressed in metastasis versus nonmetastatic samples and had a strong positive correlation with their DNA copy numbers and a negative correlation with the expression of their target genes. target gene hsa-mir-143 Squamous Cell Carcinoma, Oral 26625772 disease of cellular proliferation DOID:0050866 Low levels of miR-380-5p and miR-504 that directly target the 3'UTR of TP53 suggest that p53 may not be repressed by these two miRNAs in OSCC. On the other hand, low levels of miR-34a or miR-143 may relieve MDM4 and SIRT1 or MDM2 respectively, which will sequester p53 indicating an indirect mode of p53 suppression in oral tumors. target gene hsa-mir-143 Squamous Cell Carcinoma, Oral 28174335 disease of cellular proliferation DOID:0050866 MicroRNA-143 suppresses oral squamous cell carcinoma cell growth, invasion and glucose metabolism through targeting hexokinase 2. target gene hsa-mir-181a-1 Squamous Cell Carcinoma, Oral 21167132 disease of cellular proliferation DOID:0050866 miR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras target gene hsa-mir-181a-2 Squamous Cell Carcinoma, Oral 21167132 disease of cellular proliferation DOID:0050866 miR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras target gene hsa-mir-19a Squamous Cell Carcinoma, Oral 27581787 disease of cellular proliferation DOID:0050866 Micronome revealed miR-19a/b as key regulator of SOCS3 during cancer related inflammation of oral squamous cell carcinoma. target gene hsa-mir-19b Squamous Cell Carcinoma, Oral 27581787 disease of cellular proliferation DOID:0050866 Micronome revealed miR-19a/b as key regulator of SOCS3 during cancer related inflammation of oral squamous cell carcinoma. target gene hsa-mir-205 Squamous Cell Carcinoma, Oral 29150940 disease of cellular proliferation DOID:0050866 Tumor-suppressive roles of ΔNp63β-miR-205 axis in epithelial-mesenchymal transition of oral squamous cell carcinoma via targeting ZEB1 and ZEB2 target gene hsa-mir-21 Squamous Cell Carcinoma, Oral 20831814 disease of cellular proliferation DOID:0050866 Programmed cell death 4 loss increases tumor cell invasion and is regulated by miR-21 in oral squamous cell carcinoma. target gene hsa-mir-216a Squamous Cell Carcinoma, Oral 25955794 disease of cellular proliferation DOID:0050866 MicroRNA-216a inhibits the growth and metastasis of oral squamous cell carcinoma by targeting eukaryotic translation initiation factor 4B. target gene hsa-mir-218 Squamous Cell Carcinoma, Oral 24894864 disease of cellular proliferation DOID:0050866 Paxillin promotes tumor progression and predicts survival and relapse in oral cavity squamous cell carcinoma by microRNA-218 targeting. target gene hsa-mir-218-1 Squamous Cell Carcinoma, Oral 21795477 disease of cellular proliferation DOID:0050866 The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. target gene hsa-mir-218-2 Squamous Cell Carcinoma, Oral 21795477 disease of cellular proliferation DOID:0050866 The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. target gene hsa-mir-221 Squamous Cell Carcinoma, Oral 28101204 disease of cellular proliferation DOID:0050866 Downregulation of miR-221/222 by a microRNA sponge promotes apoptosis in oral squamous cell carcinoma cells through upregulation of PTEN. target gene hsa-mir-222 Squamous Cell Carcinoma, Oral 24452416 disease of cellular proliferation DOID:0050866 miR-222 regulates the cell biological behavior of oral squamous cell carcinoma by targeting PUMA. target gene hsa-mir-222 Squamous Cell Carcinoma, Oral 28101204 disease of cellular proliferation DOID:0050866 Downregulation of miR-221/222 by a microRNA sponge promotes apoptosis in oral squamous cell carcinoma cells through upregulation of PTEN. target gene hsa-mir-23b Squamous Cell Carcinoma, Oral 27573718 disease of cellular proliferation DOID:0050866 The tumor-suppressive microRNA-23b/27b cluster regulates the MET oncogene in oral squamous cell carcinoma. target gene hsa-mir-27b Squamous Cell Carcinoma, Oral 28735227 disease of cellular proliferation DOID:0050866 MicroRNA-27b inhibits cell proliferation in oral squamous cell carcinoma by targeting FZD7 and Wnt signaling pathway. target gene hsa-mir-27b Squamous Cell Carcinoma, Oral 27573718 disease of cellular proliferation DOID:0050866 The tumor-suppressive microRNA-23b/27b cluster regulates the MET oncogene in oral squamous cell carcinoma. target gene hsa-mir-29a Squamous Cell Carcinoma, Oral 22470160 disease of cellular proliferation DOID:0050866 miR-140-3p, miR-29c, and miR-29a were differentially expressed in metastasis versus nonmetastatic samples and had a strong positive correlation with their DNA copy numbers and a negative correlation with the expression of their target genes. target gene hsa-mir-29c Squamous Cell Carcinoma, Oral 22470160 disease of cellular proliferation DOID:0050866 miR-140-3p, miR-29c, and miR-29a were differentially expressed in metastasis versus nonmetastatic samples and had a strong positive correlation with their DNA copy numbers and a negative correlation with the expression of their target genes. target gene hsa-mir-338 Squamous Cell Carcinoma, Oral 25204970 disease of cellular proliferation DOID:0050866 MiR-338 suppresses the growth and metastasis of OSCC cells by targeting NRP1. target gene hsa-mir-340 Squamous Cell Carcinoma, Oral 26541225 disease of cellular proliferation DOID:0050866 The findings suggest that miR-340 might act as a molecular switch that contributes to the regulation of glycolysis in OSCC by regulating Glut1 expression. target gene hsa-mir-34a Squamous Cell Carcinoma, Oral 26625772 disease of cellular proliferation DOID:0050866 Low levels of miR-380-5p and miR-504 that directly target the 3'UTR of TP53 suggest that p53 may not be repressed by these two miRNAs in OSCC. On the other hand, low levels of miR-34a or miR-143 may relieve MDM4 and SIRT1 or MDM2 respectively, which will sequester p53 indicating an indirect mode of p53 suppression in oral tumors. target gene hsa-mir-375 Squamous Cell Carcinoma, Oral 28627030 disease of cellular proliferation DOID:0050866 MiR-375/SLC7A11 axis regulates oral squamous cell carcinoma proliferation and invasion. target gene hsa-mir-375 Squamous Cell Carcinoma, Oral 28810236 disease of cellular proliferation DOID:0050866 MicroRNA-375 Inhibits Growth and Enhances Radiosensitivity in Oral Squamous Cell Carcinoma by Targeting Insulin Like Growth Factor 1 Receptor. target gene hsa-mir-375 Squamous Cell Carcinoma, Oral 28000902 disease of cellular proliferation DOID:0050866 MicroRNA‑375 inhibits oral squamous cell carcinoma cell migration and invasion by targeting platelet‑derived growth factor‑A. target gene hsa-mir-377 Squamous Cell Carcinoma, Oral 28267394 disease of cellular proliferation DOID:0050866 Downregulation of miR-377 Promotes Oral Squamous Cell Carcinoma Growth and Migration by Targeting HDAC9. target gene hsa-mir-504 Squamous Cell Carcinoma, Oral 21927029 disease of cellular proliferation DOID:0050866 Connective tissue growth factor modulates oral squamous cell carcinoma invasion by activating a miR-504/FOXP1 signalling. target gene hsa-mir-9 Squamous Cell Carcinoma, Oral 24141785 disease of cellular proliferation DOID:0050866 MicroRNA-9 inhibits the proliferation of oral squamous cell carcinoma cells by suppressing expression of CXCR4 via the Wnt/β-catenin signaling pathway. target gene hsa-mir-99a Squamous Cell Carcinoma, Oral 24410957 disease of cellular proliferation DOID:0050866 Overall, results indicate that miR-99a functions as a tumor metastasis suppressor in OSCC cells and mutually regulates IGF1R expression in a reciprocal regulation. target gene hsa-mir-99b Squamous Cell Carcinoma, Oral 26315788 disease of cellular proliferation DOID:0050866 miRNA-99b-3p functions as a potential tumor suppressor by targeting glycogen synthase kinase-3β in oral squamous cell carcinoma Tca-8113 cells. target gene hsa-mir-124-1 Squamous Cell Carcinoma, Skin or Unspecific 22828925 disease of cellular proliferation DOID:3151 C44.92 HP:0006739 Down-regulation of miR-124/-214 in cutaneous squamous cell carcinoma mediates abnormal cell proliferation via the induction of ERK. target gene hsa-mir-124-2 Squamous Cell Carcinoma, Skin or Unspecific 22828925 disease of cellular proliferation DOID:3151 C44.92 HP:0006739 Down-regulation of miR-124/-214 in cutaneous squamous cell carcinoma mediates abnormal cell proliferation via the induction of ERK. target gene hsa-mir-125b-1 Squamous Cell Carcinoma, Skin or Unspecific 22782903 disease of cellular proliferation DOID:3151 C44.92 HP:0006739 MicroRNA-125b Down-regulates Matrix Metallopeptidase 13 and Inhibits Cutaneous Squamous Cell Carcinoma Cell Proliferation, Migration, and Invasion. target gene hsa-mir-125b-2 Squamous Cell Carcinoma, Skin or Unspecific 22782903 disease of cellular proliferation DOID:3151 C44.92 HP:0006739 MicroRNA-125b Down-regulates Matrix Metallopeptidase 13 and Inhibits Cutaneous Squamous Cell Carcinoma Cell Proliferation, Migration, and Invasion. target gene hsa-mir-154 Squamous Cell Carcinoma, Skin or Unspecific 29727714 disease of cellular proliferation DOID:3151 C44.92 HP:0006739 Inhibitory effect of microRNA-154 targeting WHSC1 on cell proliferation of human skin squamous cell carcinoma through mediating the P53 signaling pathway. target gene hsa-mir-15b Squamous Cell Carcinoma, Skin or Unspecific 28165568 disease of cellular proliferation DOID:3151 C44.92 HP:0006739 MicroRNA15b regulates apoptosis of cutaneous squamous cell carcinoma SCL-1 cell line: a mechanism study. target gene hsa-mir-181a Squamous Cell Carcinoma, Skin or Unspecific 28931048 disease of cellular proliferation DOID:3151 C44.92 HP:0006739 miR-181a decelerates proliferation in cutaneous squamous cell carcinoma by targeting the proto-oncogene KRAS. target gene hsa-mir-199a Squamous Cell Carcinoma, Skin or Unspecific 26026896 disease of cellular proliferation DOID:3151 C44.92 HP:0006739 These results suggested that miR-199a-5p plays a role in pathogenesis of cSCC via inhibition of invasiveness through regulation of BCAM, FZD6 and DDR1 expression. target gene hsa-mir-214 Squamous Cell Carcinoma, Skin or Unspecific 22828925 disease of cellular proliferation DOID:3151 C44.92 HP:0006739 Down-regulation of miR-124/-214 in cutaneous squamous cell carcinoma mediates abnormal cell proliferation via the induction of ERK. target gene hsa-mir-31 Squamous Cell Carcinoma, Skin or Unspecific 28454216 disease of cellular proliferation DOID:3151 C44.92 HP:0006739 MicroRNA-31 functions as an oncogenic microRNA in cutaneous squamous cell carcinoma cells by targeting RhoTBT1. target gene hsa-mir-34a Squamous Cell Carcinoma, Skin or Unspecific 29285100 disease of cellular proliferation DOID:3151 C44.92 HP:0006739 MicroRNA-34a directly targets high-mobility group box 1 and inhibits the cancer cell proliferation, migration and invasion in cutaneous squamous cell carcinoma target gene hsa-mir-361 Squamous Cell Carcinoma, Skin or Unspecific 23166713 disease of cellular proliferation DOID:3151 C44.92 HP:0006739 The expression levels of microRNA-361-5p and its target VEGFA are inversely correlated in human cutaneous squamous cell carcinoma target gene hsa-mir-365 Squamous Cell Carcinoma, Skin or Unspecific 26072217 disease of cellular proliferation DOID:3151 C44.92 HP:0006739 microRNA-365-targeted nuclear factor I/B transcriptionally represses cyclin-dependent kinase 6 and 4 to inhibit the progression of cutaneous squamous cell carcinoma. target gene hsa-mir-365 Squamous Cell Carcinoma, Skin or Unspecific 24949940 disease of cellular proliferation DOID:3151 C44.92 HP:0006739 miR-365 promotes cutaneous squamous cell carcinoma (CSCC) through targeting nuclear factor I/B (NFIB). target gene hsa-let-7a Squamous Cell Carcinoma, Tongue 29523225 disease of cellular proliferation DOID:0050865 C02.9 These findings revealed that H19/let-7a/HMGA2/EMT axis plays a critical role in the regulation of TSCC migration and invasion, which may provide a new therapeutic target for TSCC cancers target gene hsa-mir-138 Squamous Cell Carcinoma, Tongue 21079996 disease of cellular proliferation DOID:0050865 C02.9 Identification and experimental validation of G protein alpha inhibiting activity polypeptide 2 (GNAI2) as a microRNA-138 target in tongue squamous cell carcinoma. target gene hsa-mir-15b Squamous Cell Carcinoma, Tongue 28350138 disease of cellular proliferation DOID:0050865 C02.9 miR-15b inhibits cancer-initiating cell phenotypes and chemoresistance of cisplatin by targeting TRIM14 in oral tongue squamous cell cancer. target gene hsa-mir-182 Squamous Cell Carcinoma, Tongue 27698823 disease of cellular proliferation DOID:0050865 C02.9 miRNA-335 and miRNA-182 affect the occurrence of tongue squamous cell carcinoma by targeting survivin. target gene hsa-mir-183 Squamous Cell Carcinoma, Tongue 25760063 disease of cellular proliferation DOID:0050865 C02.9 a novel differential miRNA-mRNA expression network was constructed, and further investigation may provide novel targets for the diagnosis of TSCC. target gene hsa-mir-195 Squamous Cell Carcinoma, Tongue 26885901 disease of cellular proliferation DOID:0050865 C02.9 Relationships between microRNA expressions and prognosis in patients with tongue squamous cell carcinoma and the mechanisms microRNA regulating tongue squamous cell carcinoma biological behavior. target gene hsa-mir-21 Squamous Cell Carcinoma, Tongue 26191167 disease of cellular proliferation DOID:0050865 C02.9 Targeting miR-21 with AS-miR-21 suppresses aggressive growth of human tongue squamous cell carcinoma in vivo. target gene hsa-mir-21 Squamous Cell Carcinoma, Tongue 24609942 disease of cellular proliferation DOID:0050865 C02.9 MiR-21 modulates chemosensitivity of tongue squamous cell carcinoma cells to cisplatin by targeting PDCD4. target gene hsa-mir-222 Squamous Cell Carcinoma, Tongue 19487542 disease of cellular proliferation DOID:0050865 C02.9 MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1(MMP1) and manganese superoxide dismutase 2 (SOD2) in tongue squamous cellcarcinoma cell lines. target gene hsa-mir-24-1 Squamous Cell Carcinoma, Tongue 20816961 disease of cellular proliferation DOID:0050865 C02.9 miR-24:MicroRNA-24 targeting RNA-binding protein DND1 in tongue squamous cell carcinoma target gene hsa-mir-24-2 Squamous Cell Carcinoma, Tongue 20816961 disease of cellular proliferation DOID:0050865 C02.9 miR-24:MicroRNA-24 targeting RNA-binding protein DND1 in tongue squamous cell carcinoma target gene hsa-mir-26a Squamous Cell Carcinoma, Tongue 26885901 disease of cellular proliferation DOID:0050865 C02.9 Relationships between microRNA expressions and prognosis in patients with tongue squamous cell carcinoma and the mechanisms microRNA regulating tongue squamous cell carcinoma biological behavior. target gene hsa-mir-29b Squamous Cell Carcinoma, Tongue 26885901 disease of cellular proliferation DOID:0050865 C02.9 Relationships between microRNA expressions and prognosis in patients with tongue squamous cell carcinoma and the mechanisms microRNA regulating tongue squamous cell carcinoma biological behavior. target gene hsa-mir-33a Squamous Cell Carcinoma, Tongue 29804249 disease of cellular proliferation DOID:0050865 C02.9 Long non-coding RNA CASC15 promotes tongue squamous carcinoma progression through targeting miR-33a-5p. target gene hsa-mir-34a Squamous Cell Carcinoma, Tongue 26885901 disease of cellular proliferation DOID:0050865 C02.9 Relationships between microRNA expressions and prognosis in patients with tongue squamous cell carcinoma and the mechanisms microRNA regulating tongue squamous cell carcinoma biological behavior. target gene hsa-mir-373 Squamous Cell Carcinoma, Tongue 28337453 disease of cellular proliferation DOID:0050865 C02.9 miR-373-3p Targets DKK1 to Promote EMT-Induced Metastasis via the Wnt/β-Catenin Pathway in Tongue Squamous Cell Carcinoma. target gene hsa-mir-375 Squamous Cell Carcinoma, Tongue 26885901 disease of cellular proliferation DOID:0050865 C02.9 Relationships between microRNA expressions and prognosis in patients with tongue squamous cell carcinoma and the mechanisms microRNA regulating tongue squamous cell carcinoma biological behavior. target gene hsa-mir-483 Squamous Cell Carcinoma, Tongue 25843291 disease of cellular proliferation DOID:0050865 C02.9 miR-483-5p determines mitochondrial fission and cisplatin sensitivity in tongue squamous cell carcinoma by targeting FIS1. target gene hsa-mir-494 Squamous Cell Carcinoma, Tongue 25760063 disease of cellular proliferation DOID:0050865 C02.9 a novel differential miRNA-mRNA expression network was constructed, and further investigation may provide novel targets for the diagnosis of TSCC. target gene hsa-mir-96 Squamous Cell Carcinoma, Tongue 25760063 disease of cellular proliferation DOID:0050865 C02.9 a novel differential miRNA-mRNA expression network was constructed, and further investigation may provide novel targets for the diagnosis of TSCC. target gene hsa-mir-96 Squamous Cell Carcinoma, Tongue 26629033 disease of cellular proliferation DOID:0050865 C02.9 MiR-96 is confirmed to be a direct target of MTSS1 gene and could regulate MTSS1 mediated Tca8113 cells proliferation and metastasis. target gene hsa-mir-103 Stroke 24954474 I64 D020521 601367 HP:0001297 MicroRNA-103-1 selectively downregulates brain NCX1 and its inhibition by anti-miRNA ameliorates stroke damage and neurological deficits. target gene hsa-mir-122 Stroke 29715465 I64 D020521 601367 HP:0001297 Up-regulation of miR-122 protects against neuronal cell death in ischemic stroke through the heat shock protein 70-dependent NF-κB pathway by targeting FOXO3. target gene hsa-mir-145 Stroke 29057271 I64 D020521 601367 HP:0001297 Overexpression of MicroRNA-145 Ameliorates Astrocyte Injury by Targeting Aquaporin 4 in Cerebral Ischemic Stroke target gene hsa-mir-146a Stroke 28202285 I64 D020521 601367 HP:0001297 Decreased miR-146a expression in acute ischemic stroke directly targets the Fbxl10 mRNA and is involved in modulating apoptosis. target gene hsa-mir-155 Stroke 25811992 I64 D020521 601367 HP:0001297 miR-155 mediates inflammatory responses in ischemic cerebral tissue by modulating TLR4/MyD88 and SOCS1 expression target gene hsa-mir-181a Stroke 28522364 I64 D020521 601367 HP:0001297 Inhibition of miR-181a protects female mice from transient focal cerebral ischemia by targeting astrocyte estrogen receptor-α. target gene hsa-mir-126 Systemic Lupus Erythematosus 26531267 musculoskeletal system disease DOID:9074 M32.9 D008180 152700 HP:0002725 miRNA-126 expression is reduced in SLE patients. miRNA-126 may be involved in the initiation and development of SLE by inhibiting the production of IFN. target gene hsa-mir-150 Systemic Lupus Erythematosus 27940256 musculoskeletal system disease DOID:9074 M32.9 D008180 152700 HP:0002725 Enhanced expression of TREM-1 in splenic cDCs in lupus prone mice and it was modulated by miRNA-150. target gene hsa-mir-155 Systemic Lupus Erythematosus 25775145 musculoskeletal system disease DOID:9074 M32.9 D008180 152700 HP:0002725 The results of the present study demonstrated for the first time that there is a differential expression and inverse correlation between the levels the miR-155, miR-17, and miR-181b and target molecules, AID and IFN-α mRNAs, in PBMCs of untreated SLE patients. These alterations may contribute to the pathogenesis of SLE. target gene hsa-mir-17 Systemic Lupus Erythematosus 26175399 musculoskeletal system disease DOID:9074 M32.9 D008180 152700 HP:0002725 Targeting E2F1 and c-Myc expression by microRNA-17-5p represses interferon-stimulated gene MxA in peripheral blood mononuclear cells of pediatric systemic lupus erythematosus patients. target gene hsa-mir-17 Systemic Lupus Erythematosus 25775145 musculoskeletal system disease DOID:9074 M32.9 D008180 152700 HP:0002725 The results of the present study demonstrated for the first time that there is a differential expression and inverse correlation between the levels the miR-155, miR-17, and miR-181b and target molecules, AID and IFN-α mRNAs, in PBMCs of untreated SLE patients. These alterations may contribute to the pathogenesis of SLE. target gene hsa-mir-181b Systemic Lupus Erythematosus 25775145 musculoskeletal system disease DOID:9074 M32.9 D008180 152700 HP:0002725 The results of the present study demonstrated for the first time that there is a differential expression and inverse correlation between the levels the miR-155, miR-17, and miR-181b and target molecules, AID and IFN-α mRNAs, in PBMCs of untreated SLE patients. These alterations may contribute to the pathogenesis of SLE. target gene hsa-mir-21 Systemic Lupus Erythematosus 21602271 musculoskeletal system disease DOID:9074 M32.9 D008180 152700 HP:0002725 miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression.Upregulated miR-21 affects PDCD4 expression and regulates aberrant T cell responses in human SLE. target gene hsa-mir-30a Systemic Lupus Erythematosus 23450709 musculoskeletal system disease DOID:9074 M32.9 D008180 152700 HP:0002725 MicroRNA-30a promotes B cell hyperactivity in patient with SLE by direct interaction with LYN target gene hsa-mir-3148 Systemic Lupus Erythematosus 23468661 musculoskeletal system disease DOID:9074 M32.9 D008180 152700 HP:0002725 MicroRNA-3148 Modulates Allelic Expression of Toll-Like Receptor 7 Variant Associated with Systemic Lupus Erythematosus target gene hsa-mir-381 Systemic Mastocytosis 21273305 hematopoietic system disease DOID:349 D47.2 D034721 154800 We found that miR-539 and miR-381 are downregulated by KIT signaling and they repressed MITF expression through conserved miRNA binding sites in the MITF 3' UTR. target gene hsa-mir-539 Systemic Mastocytosis 21273305 hematopoietic system disease DOID:349 D47.2 D034721 154800 We found that miR-539 and miR-381 are downregulated by KIT signaling and they repressed MITF expression through conserved miRNA binding sites in the MITF 3' UTR. target gene hsa-mir-199a Testicular Germ Cell Tumor 25231260 disease of cellular proliferation DOID:5557 C563236 273300 A miR-199a/miR-214 self-regulatory network via PSMD10, TP53 and DNMT1 in testicular germ cell tumor. target gene hsa-mir-214 Testicular Germ Cell Tumor 25231260 disease of cellular proliferation DOID:5557 C563236 273300 A miR-199a/miR-214 self-regulatory network via PSMD10, TP53 and DNMT1 in testicular germ cell tumor. target gene hsa-mir-223 Testicular Germ Cell Tumor 28000896 disease of cellular proliferation DOID:5557 C563236 273300 miR‑223‑3p regulates cell growth and apoptosis via FBXW7 suggesting an oncogenic role in human testicular germ cell tumors. target gene hsa-mir-372 Testicular Neoplasms 16564011 disease of cellular proliferation DOID:2998 D013736 273300 HP:0010788 A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. target gene hsa-mir-373 Testicular Neoplasms 16564011 disease of cellular proliferation DOID:2998 D013736 273300 HP:0010788 A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. target gene hsa-mir-155 Thrombocytopenia 25413124 hematopoietic system disease DOID:1588 D69.6 D013921 313900 HP:0001873 miR-155 might be involved in the pathogenesis of ITP by regulating cytokine profiles, which may be mediated by miR-155 targeting SOCS1. target gene hsa-mir-99a Thrombocytopenia 26055579 hematopoietic system disease DOID:1588 D69.6 D013921 313900 HP:0001873 We believe that miR-99a regulates CTDSPL, which induces the G1/Stransition by increasing Cyclin expression and play a significant role in proliferation of CB-MKs. target gene hsa-mir-1-1 Thyroid Neoplasms 21752897 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 MiR-1 suppress Thyroid Cancer by Targeting CCND2, CXCR4, and SDF-1{alpha} target gene hsa-mir-1-2 Thyroid Neoplasms 21752897 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 MiR-1 suppress Thyroid Cancer by Targeting CCND2, CXCR4, and SDF-1{alpha} target gene hsa-mir-142 Thyroid Neoplasms 25238203 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 These data demonstrate that miR-142-3p downregulation has a role in thyroid tumorigenesis, by regulating ASH1L and MLL1. target gene hsa-mir-144 Thyroid Neoplasms 24968735 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 Down-regulation of miR-144 promotes thyroid cancer cell invasion by targeting ZEB1 and ZEB2. target gene hsa-mir-144 Thyroid Neoplasms 27099512 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 Transcription factor zinc finger E-box-binding homeobox 1 (ZEB1), as one of the key inducers of epithelial-mesenchymal transition, has been reported to be regulated by microRNA-144 and Bcl-2-associated athanogene 3 target gene hsa-mir-145 Thyroid Neoplasms 24781864 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3. target gene hsa-mir-146a Thyroid Neoplasms 17012848 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 Mir-221, mir-22 and mir-146 are significantly upregulated in this disease, whereas the expression of their predicted target gene KIT is lost, concurrently with the miRNA upregulation. target gene hsa-mir-146a Thyroid Neoplasms 21159845 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 Papillary Thyroid Carcinoma (PTC). Direct interaction with THRB was shown for miR-21 and miR-146a. target gene hsa-mir-146a Thyroid Neoplasms 23457043 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 MicroRNA-146a targets PRKCE to modulate papillary thyroid tumor development target gene hsa-mir-146b Thyroid Neoplasms 17012848 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 Mir-221, mir-22 and mir-146 are significantly upregulated in this disease, whereas the expression of their predicted target gene KIT is lost, concurrently with the miRNA upregulation. target gene hsa-mir-146b Thyroid Neoplasms 21874046 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 MicroRNA miR-146b-5p regulates signal transduction of TGF-beta by repressing SMAD4 in thyroid cancer. target gene hsa-mir-150 Thyroid Neoplasms 29023429 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 MiR-150 Inhibits Cell Growth In Vitro and In Vivo by Restraining the RAB11A/WNT/β-Catenin Pathway in Thyroid Cancer. target gene hsa-mir-181a Thyroid Neoplasms 29271997 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 MiR-181a promotes growth of thyroid cancer cells by targeting tumor suppressor RB1 target gene hsa-mir-191 Thyroid Neoplasms 21956418 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 miR-191 Down-Regulation Plays a Role in Thyroid Follicular Tumors through CDK6 Targeting. target gene hsa-mir-19a Thyroid Neoplasms 23998804 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 High iodine abrogates BRAF(V600E)-induced activation of miR-19, a newly identified Smad4 regulator, through Notch pathway inhibition and restores responsiveness to TGFβ signaling. target gene hsa-mir-200a Thyroid Neoplasms 22797360 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 The miR-200 family regulates the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells. target gene hsa-mir-200b Thyroid Neoplasms 22797360 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 The miR-200 family regulates the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells. target gene hsa-mir-200c Thyroid Neoplasms 22797360 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 The miR-200 family regulates the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells. target gene hsa-mir-21 Thyroid Neoplasms 21159845 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 Papillary Thyroid Carcinoma (PTC). Direct interaction with THRB was shown for miR-21 and miR-146a. target gene hsa-mir-218-2 Thyroid Neoplasms 23720784 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 Down-regulation of miR-218-2 and its host gene SLIT3 cooperate to promote invasion and progression of thyroid cancer. target gene hsa-mir-22 Thyroid Neoplasms 17012848 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 Mir-221, mir-22 and mir-146 are significantly upregulated in this disease, whereas the expression of their predicted target gene KIT is lost, concurrently with the miRNA upregulation. target gene hsa-mir-221 Thyroid Neoplasms 17012848 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 Mir-221, mir-22 and mir-146 are significantly upregulated in this disease, whereas the expression of their predicted target gene KIT is lost, concurrently with the miRNA upregulation. target gene hsa-mir-25 Thyroid Neoplasms 22399519 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 Down-Regulation of the miR-25 and miR-30d Contributes to the Development of Anaplastic Thyroid Carcinoma Targeting the Polycomb Protein EZH2. target gene hsa-mir-29b Thyroid Neoplasms 27125250 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 Functional assays confirmed PATZ1 as a target of miR-29b target gene hsa-mir-302b Thyroid Neoplasms 17355635 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 Genetically PTC is defined by several alterations which cause abnormal activation of the mitogen-activated protein kinase (MAPK) pathway, the most prevalent being point mutations in the intracellular signalling kinase BRAF. Of particular interest in this study is the downregulation of miR-323 and miR-302b in BRAF mutated cell line. miRBASE target database predicted that the BRAF transcript has binding sites for miR-323 and miR-302b to potentially bind and down- regulate BRAF expression. target gene hsa-mir-30d Thyroid Neoplasms 22399519 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 Down-Regulation of the miR-25 and miR-30d Contributes to the Development of Anaplastic Thyroid Carcinoma Targeting the Polycomb Protein EZH2. target gene hsa-mir-323a Thyroid Neoplasms 17355635 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 Genetically PTC is defined by several alterations which cause abnormal activation of the mitogen-activated protein kinase (MAPK) pathway, the most prevalent being point mutations in the intracellular signalling kinase BRAF. Of particular interest in this study is the downregulation of miR-323 and miR-302b in BRAF mutated cell line. miRBASE target database predicted that the BRAF transcript has binding sites for miR-323 and miR-302b to potentially bind and down- regulate BRAF expression. target gene hsa-mir-539 Thyroid Neoplasms 26206083 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 MiR-539 inhibits thyroid cancer cell migration and invasion by directly targeting CARMA1. target gene hsa-mir-146a Thyroid-Associated Ophthalmopathy 28485799 D049970 Decreased microRNA-146a in CD4+T cells promote ocular inflammation in thyroid-associated ophthalmopathy by targeting NUMB. target gene hsa-mir-15b Tongue Neoplasms 21725369 gastrointestinal system disease DOID:8649 C01 D014062 HP:0100648 MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. target gene hsa-mir-200b Tongue Neoplasms 21725369 gastrointestinal system disease DOID:8649 C01 D014062 HP:0100648 MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. target gene hsa-mir-491 Tongue Neoplasms 25749387 gastrointestinal system disease DOID:8649 C01 D014062 HP:0100648 The miR-491-3p/mTORC2/FOXO1 regulatory loop modulates chemo-sensitivity in human tongue cancer. target gene hsa-mir-639 Tongue Neoplasms 25130698 gastrointestinal system disease DOID:8649 C01 D014062 HP:0100648 miR-639 regulates transforming growth factor beta-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting FOXC1. target gene hsa-mir-155 Tuberculosis 26324048 disease by infectious agent DOID:399 A15-A19 D014376 From these results, it was concluded that mycobacteria can improve the level of miR-155, while BCG can induce apoptosis in THP-1 cells. The results suggested FOXO3 is a downstream target gene of miR-155, which combines 3'-UTRs to inhibit the expression of FOXO3. target gene hsa-mir-20a Tuberculosis 27803889 disease by infectious agent DOID:399 A15-A19 D014376 microRNA-20a Inhibits Autophagic Process by Targeting ATG7 and ATG16L1 and Favors Mycobacterial Survival in Macrophage Cells. target gene hsa-mir-223 Tuberculosis 24084739 disease by infectious agent DOID:399 A15-A19 D014376 Our study not only reveals an essential role for a single miRNA in TB, it also identifies new targets for, and assigns biological functions to, miR-223. By regulating leukocyte chemotaxis via chemoattractants, miR-223 is critical for the control of TB and potentially other chronic inflammatory diseases. target gene hsa-mir-223 Tuberculosis 26296289 disease by infectious agent DOID:399 A15-A19 D014376 It is concluded that miR-223 can regulate macrophage function by inhibition of cytokine production and NF-κB activation. target gene hsa-mir-223 Tuberculosis 26505221 disease by infectious agent DOID:399 A15-A19 D014376 Our data provide new clues for the essential role of miR-223 in the regulation of anti-Mtb-directed immune responses, which relies on the regulation of FOXO3 expression. target gene hsa-mir-29 Tuberculosis 24304957 disease by infectious agent DOID:399 A15-A19 D014376 The expression of miR-29 family was increased and target gene IFN-γ in CD4(+) T cells was decreased by latent and active pulmonary TB, which might play important role in alteration of signal pathway. target gene hsa-mir-381 Tuberculosis 27296666 disease by infectious agent DOID:399 A15-A19 D014376 inhibition of miR-381-3p could reverse suppression of CD1c expression and promote T cell responses against BCG infection. target gene hsa-mir-582 Tuberculosis 24205217 disease by infectious agent DOID:399 A15-A19 D014376 miR-582-5p is upregulated in patients with active tuberculosis and inhibits apoptosis of monocytes by targeting FOXO1. target gene hsa-mir-124 Tuberculosis, Pulmonary 24705038 disease by infectious agent DOID:2957 A15 D014397 Mycobacterium bovis BCG triggered MyD88 induces miR-124 feedback negatively regulates immune response in alveolar epithelial cells. target gene hsa-mir-29a Tuberculosis, Pulmonary 23856141 disease by infectious agent DOID:2957 A15 D014397 Level of miR-29a was increased significantly in serum of patients with active pulmonary tuberculosis. Target genes of miR-29a were mainly involved in biological processes including cell adhesion, regulation of transcription and so on. target gene hsa-mir-618 Tuberculosis, Pulmonary 23948412 disease by infectious agent DOID:2957 A15 D014397 Level of miR-618 in both sputa and sera was significantly lower in the tuberculosis group than that in the control group and predicted target genes of miR-618 were mainly involved in biological processes such as regulation of transcription and RNA metabolism. target gene hsa-mir-155 Unstable Angina 25760478 cardiovascular system disease DOID:8805 I20.0 D000789 Upregulation of miR-155 in CD4(+) T Cells Promoted Th1 Bias in Patients With Unstable Angina. target gene hsa-mir-100 Urinary Bladder Cancer 23270926 urinary system disease DOID:11054 C67 D001749 109800 MicroRNA-100 inhibits human bladder urothelial carcinogenesis by directly targeting mTOR target gene hsa-mir-100 Urinary Bladder Cancer 21636267 urinary system disease DOID:11054 C67 D001749 109800 Reduced expression and had carcinogenic effect through targeting PLK1 protein. target gene hsa-mir-101-1 Urinary Bladder Cancer 19258506 urinary system disease DOID:11054 C67 D001749 109800 miR-101: putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2 target gene hsa-mir-101-2 Urinary Bladder Cancer 19258506 urinary system disease DOID:11054 C67 D001749 109800 miR-101: putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2 target gene hsa-mir-10a Urinary Bladder Cancer 22634495 urinary system disease DOID:11054 C67 D001749 109800 MicroRNA-10a targets CHL1 and promotes cell growth, migration and invasion in human cervical cancer cells. target gene hsa-mir-1-1 Urinary Bladder Cancer 21304530 urinary system disease DOID:11054 C67 D001749 109800 The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. target gene hsa-mir-1-1 Urinary Bladder Cancer 22178073 urinary system disease DOID:11054 C67 D001749 109800 Tumor suppressive microRNA-1 mediated novel apoptosis pathways through direct inhibition of splicing factor serine/arginine-rich 9 (SRSF9/SRp30c) in bladder cancer. target gene hsa-mir-1-2 Urinary Bladder Cancer 21304530 urinary system disease DOID:11054 C67 D001749 109800 The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. target gene hsa-mir-1-2 Urinary Bladder Cancer 22178073 urinary system disease DOID:11054 C67 D001749 109800 Tumor suppressive microRNA-1 mediated novel apoptosis pathways through direct inhibition of splicing factor serine/arginine-rich 9 (SRSF9/SRp30c) in bladder cancer. target gene hsa-mir-125b-1 Urinary Bladder Cancer 23425975 urinary system disease DOID:11054 C67 D001749 109800 microRNA-125b inhibits cell migration and invasion by targeting matrix metallopeptidase 13 in bladder cancer target gene hsa-mir-125b-1 Urinary Bladder Cancer 23160634 urinary system disease DOID:11054 C67 D001749 109800 MiR-125b Inhibits Tumor Growth and Promotes Apoptosis of Cervical Cancer Cells by Targeting Phosphoinositide 3-Kinase Catalytic Subunit Delta target gene hsa-mir-125b-2 Urinary Bladder Cancer 23425975 urinary system disease DOID:11054 C67 D001749 109800 microRNA-125b inhibits cell migration and invasion by targeting matrix metallopeptidase 13 in bladder cancer target gene hsa-mir-125b-2 Urinary Bladder Cancer 23160634 urinary system disease DOID:11054 C67 D001749 109800 MiR-125b Inhibits Tumor Growth and Promotes Apoptosis of Cervical Cancer Cells by Targeting Phosphoinositide 3-Kinase Catalytic Subunit Delta target gene hsa-mir-1280 Urinary Bladder Cancer 23056431 urinary system disease DOID:11054 C67 D001749 109800 MicroRNA-1280 inhibits invasion and metastasis by targeting ROCK1 in bladder cancer target gene hsa-mir-133a-1 Urinary Bladder Cancer 21304530 urinary system disease DOID:11054 C67 D001749 109800 The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. target gene hsa-mir-133a-1 Urinary Bladder Cancer 21396852 urinary system disease DOID:11054 C67 D001749 109800 MiR-133a induces apoptosis through direct regulation of GSTP1 in bladder cancer cell lines. target gene hsa-mir-133a-1 Urinary Bladder Cancer 23206218 urinary system disease DOID:11054 C67 D001749 109800 MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer target gene hsa-mir-133a-2 Urinary Bladder Cancer 21304530 urinary system disease DOID:11054 C67 D001749 109800 The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. target gene hsa-mir-133a-2 Urinary Bladder Cancer 23206218 urinary system disease DOID:11054 C67 D001749 109800 MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer target gene hsa-mir-133b Urinary Bladder Cancer 23206218 urinary system disease DOID:11054 C67 D001749 109800 MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer target gene hsa-mir-143 Urinary Bladder Cancer 21790228 urinary system disease DOID:11054 C67 D001749 109800 Expression of miR-143 Reduces Growth and Migration of Human Bladder Carcinoma Cells by Targeting Cyclooxygenase-2. target gene hsa-mir-143 Urinary Bladder Cancer 22108519 urinary system disease DOID:11054 C67 D001749 109800 The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer. target gene hsa-mir-143 Urinary Bladder Cancer 23104321 urinary system disease DOID:11054 C67 D001749 109800 Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways target gene hsa-mir-143 Urinary Bladder Cancer 22160209 urinary system disease DOID:11054 C67 D001749 109800 miR-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2. target gene hsa-mir-145 Urinary Bladder Cancer 22108519 urinary system disease DOID:11054 C67 D001749 109800 The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer. target gene hsa-mir-145 Urinary Bladder Cancer 23104321 urinary system disease DOID:11054 C67 D001749 109800 Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways target gene hsa-mir-145 Urinary Bladder Cancer 23392170 urinary system disease DOID:11054 C67 D001749 109800 socs7, a target gene of microRNA-145, regulates interferon-alpha induction through STAT3 nuclear translocation in bladder cancer cells target gene hsa-mir-17 Urinary Bladder Cancer 22730212 urinary system disease DOID:11054 C67 D001749 109800 MiR-17-5p targets TP53INP1 and regulates cell proliferation and apoptosis of cervical cancer cells. target gene hsa-mir-181a-1 Urinary Bladder Cancer 22847611 urinary system disease DOID:11054 C67 D001749 109800 MiR-181a confers resistance of cervical cancer to radiation therapy through targeting the pro-apoptotic PRKCD gene. target gene hsa-mir-181a-2 Urinary Bladder Cancer 22847611 urinary system disease DOID:11054 C67 D001749 109800 MiR-181a confers resistance of cervical cancer to radiation therapy through targeting the pro-apoptotic PRKCD gene. target gene hsa-mir-182 Urinary Bladder Cancer 23226455 urinary system disease DOID:11054 C67 D001749 109800 Oncogenic miRNA-182-5p Targets Smad4 and RECK in Human Bladder Cancer target gene hsa-mir-182 Urinary Bladder Cancer 23284967 urinary system disease DOID:11054 C67 D001749 109800 Synthetic miRNA-Mowers Targeting miR-183-96-182 Cluster or miR-210 Inhibit Growth and Migration and Induce Apoptosis in Bladder Cancer Cells target gene hsa-mir-183 Urinary Bladder Cancer 23284967 urinary system disease DOID:11054 C67 D001749 109800 Synthetic miRNA-Mowers Targeting miR-183-96-182 Cluster or miR-210 Inhibit Growth and Migration and Induce Apoptosis in Bladder Cancer Cells target gene hsa-mir-18a Urinary Bladder Cancer 21935572 urinary system disease DOID:11054 C67 D001749 109800 microRNA-18a, a member of the oncogenic miR-17-92 cluster, targets Dicer and suppresses cell proliferation in bladder cancer T24 cells. target gene hsa-mir-195 Urinary Bladder Cancer 22265971 urinary system disease DOID:11054 C67 D001749 109800 MicroRNA-195-5p suppresses glucose uptake and proliferation of human bladder cancer T24 cells by regulating GLUT3 expression. target gene hsa-mir-195 Urinary Bladder Cancer 22289176 urinary system disease DOID:11054 C67 D001749 109800 Cyclin-dependent kinase 4 is a novel target in micoRNA-195-mediated cell cycle arrest in bladder cancer cells. target gene hsa-mir-199a-1 Urinary Bladder Cancer 21807947 urinary system disease DOID:11054 C67 D001749 109800 MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2. target gene hsa-mir-199a-2 Urinary Bladder Cancer 21807947 urinary system disease DOID:11054 C67 D001749 109800 MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2. target gene hsa-mir-19a Urinary Bladder Cancer 22561557 urinary system disease DOID:11054 C67 D001749 109800 MicroRNA-19a and -19b regulate cervical carcinoma cell proliferation and invasion by targeting CUL5. target gene hsa-mir-19b-1 Urinary Bladder Cancer 22561557 urinary system disease DOID:11054 C67 D001749 109800 MicroRNA-19a and -19b regulate cervical carcinoma cell proliferation and invasion by targeting CUL5. target gene hsa-mir-19b-2 Urinary Bladder Cancer 22561557 urinary system disease DOID:11054 C67 D001749 109800 MicroRNA-19a and -19b regulate cervical carcinoma cell proliferation and invasion by targeting CUL5. target gene hsa-mir-200c Urinary Bladder Cancer 23159064 urinary system disease DOID:11054 C67 D001749 109800 Epithelial-mesenchymal transition, a novel target of sulforaphane via COX-2/MMP2,9/Snail, ZEB1 and miR-200c/ZEB1 pathways in human bladder cancer cells target gene hsa-mir-203 Urinary Bladder Cancer 21205209 urinary system disease DOID:11054 C67 D001749 109800 microRNA-203 suppresses bladder cancer development by repressing bcl-w expression. target gene hsa-mir-20a Urinary Bladder Cancer 22449978 urinary system disease DOID:11054 C67 D001749 109800 miR-20a promotes migration and invasion by regulating TNKS2 in human cervical cancer cells. target gene hsa-mir-21 Urinary Bladder Cancer 22001440 urinary system disease DOID:11054 C67 D001749 109800 MiR-21 is involved in cervical squamous cell tumorigenesis and regulates CCL20. target gene hsa-mir-210 Urinary Bladder Cancer 23284967 urinary system disease DOID:11054 C67 D001749 109800 Synthetic miRNA-Mowers Targeting miR-183-96-182 Cluster or miR-210 Inhibit Growth and Migration and Induce Apoptosis in Bladder Cancer Cells target gene hsa-mir-214 Urinary Bladder Cancer 21216304 urinary system disease DOID:11054 C67 D001749 109800 Plexin-B1 is a target of miR-214 in cervical cancer and promotes the growth and invasion of HeLa Cells. target gene hsa-mir-214 Urinary Bladder Cancer 22399294 urinary system disease DOID:11054 C67 D001749 109800 MicroRNA-214 Suppresses The Growth and Invasiveness of Cervical Cancer Cells by Targeting UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7. target gene hsa-mir-302a Urinary Bladder Cancer 23185040 urinary system disease DOID:11054 C67 D001749 109800 The microRNA-302-367 cluster suppresses the proliferation of cervical carcinoma cells through the novel target AKT1 target gene hsa-mir-34a Urinary Bladder Cancer 22684561 urinary system disease DOID:11054 C67 D001749 109800 microRNA-34a inhibit cell migration and invasion of invasive urothelial bladder carcinoma by targeting Notch1. target gene hsa-mir-367 Urinary Bladder Cancer 23185040 urinary system disease DOID:11054 C67 D001749 109800 The microRNA-302-367 cluster suppresses the proliferation of cervical carcinoma cells through the novel target AKT1 target gene hsa-mir-372 Urinary Bladder Cancer 21646351 urinary system disease DOID:11054 C67 D001749 109800 MicroRNA-372 Is Down-regulated and Targets Cyclin-dependent Kinase 2 (CDK2) and Cyclin A1 in Human Cervical Cancer, Which May Contribute to Tumorigenesis. target gene hsa-mir-375 Urinary Bladder Cancer 21945323 urinary system disease DOID:11054 C67 D001749 109800 miR-375, Down-Regulated in Squamous Cervical Cancer, Inhibits Cell Migration and Invasion via Targeting Transcription Factor SP1. target gene hsa-mir-449a Urinary Bladder Cancer 22266187 urinary system disease DOID:11054 C67 D001749 109800 MicroRNA-449a acts as a tumor suppressor in human bladder cancer through the regulation of pocket proteins. target gene hsa-mir-493 Urinary Bladder Cancer 22057916 urinary system disease DOID:11054 C67 D001749 109800 Tumor suppressor microRNA-493 decreases cell motility and migration ability in human bladder cancer cells by down-regulating RhoC and FZD4. target gene hsa-mir-494 Urinary Bladder Cancer 21859890 urinary system disease DOID:11054 C67 D001749 109800 miR-494 Competitively regulates Nucleolin expression with HuR. target gene hsa-mir-497 Urinary Bladder Cancer 23453369 urinary system disease DOID:11054 C67 D001749 109800 MicroRNA-497 is a potential prognostic marker in human cervical cancer and functions as a tumor suppressor by targeting the insulin-like growth factor 1 receptor target gene hsa-mir-7-1 Urinary Bladder Cancer 23742934 urinary system disease DOID:11054 C67 D001749 109800 MicroRNA-7 downregulates XIAP expression to suppress cell growth and promote apoptosis in cervical cancer cells. target gene hsa-mir-7-2 Urinary Bladder Cancer 23742934 urinary system disease DOID:11054 C67 D001749 109800 MicroRNA-7 downregulates XIAP expression to suppress cell growth and promote apoptosis in cervical cancer cells. target gene hsa-mir-7-3 Urinary Bladder Cancer 23742934 urinary system disease DOID:11054 C67 D001749 109800 MicroRNA-7 downregulates XIAP expression to suppress cell growth and promote apoptosis in cervical cancer cells. target gene hsa-mir-96 Urinary Bladder Cancer 23284967 urinary system disease DOID:11054 C67 D001749 109800 Synthetic miRNA-Mowers Targeting miR-183-96-182 Cluster or miR-210 Inhibit Growth and Migration and Induce Apoptosis in Bladder Cancer Cells target gene hsa-mir-96 Urinary Bladder Cancer 23741253 urinary system disease DOID:11054 C67 D001749 109800 miR-96 regulates FOXO1-mediated cell apoptosis in bladder cancer. target gene hsa-mir-197 Uterine Leiomyoma 25990270 D25.9 D007889 150699 HP:0000131 Upregulation of miR-197 inhibits cell proliferation by directly targeting IGFBP5 in human uterine leiomyoma cells. target gene hsa-mir-29c Uterine Leiomyoma 26453978 D25.9 D007889 150699 HP:0000131 MiR-29c expression is suppressed in leiomyoma, resulting in an increase in expression of its targets COL3A1 and DNMT3A. The suppression of miR-29c in LSMC is primarily mediated by SP1, NF-κB signaling, and epigenetic modification. Collectively, these results indicate a significant role for miR-29c in leiomyoma pathogenesis. target gene hsa-mir-15a Varicocele 24481955 cardiovascular system disease DOID:12337 I86.1 D014646 Expressions of miR-15a and its target gene HSPA1B in the spermatozoa of patients with varicocele. target gene hsa-mir-142 Vascular Disease [unspecific] 25832008 cardiovascular system disease DOID:178 I72.9 D000783 this study demonstrates that miR-142-3p is a key regulator of the TGFβ-mediated contractile phenotype of VSMCs that acts through inhibiting cell migration through targeting DOCK6. target gene hsa-mir-145 Vascular Disease [unspecific] 19690387 cardiovascular system disease DOID:178 I72.9 D000783 MicroRNA-modulated targeting of vascular smooth muscle cells target gene hsa-mir-145 Vascular Disease [unspecific] 24848371 cardiovascular system disease DOID:178 I72.9 D000783 Mechanical stretch suppresses microRNA-145 expression by activating extracellular signal-regulated kinase 1/2 and upregulating angiotensin-converting enzyme to alter vascular smooth muscle cell phenotype. target gene hsa-mir-146a Vascular Disease [unspecific] 27908889 cardiovascular system disease DOID:178 I72.9 D000783 MicroRNA-146a Induces Lineage-Negative Bone Marrow Cell Apoptosis and Senescence by Targeting Polo-Like Kinase 2 Expression. target gene hsa-mir-155 Vascular Disease [unspecific] 26012521 cardiovascular system disease DOID:178 I72.9 D000783 knockdown of miR155 could modulate ROS production, NO generation, apoptosis and function of HBMECs via regulating diverse gene expression, such as caspase-3, ICAM-1 and EGFR/ERK/p38 MAPK and PI3K/Akt pathways. target gene hsa-mir-17 Vascular Disease [unspecific] 19690387 cardiovascular system disease DOID:178 I72.9 D000783 miR-17-92 and miR-17-5p/miR-20a; MicroRNA-modulated targeting of vascular smooth muscle cells target gene hsa-mir-18a Vascular Disease [unspecific] 19690387 cardiovascular system disease DOID:178 I72.9 D000783 miR-17-92 and miR-17-5p/miR-20a; MicroRNA-modulated targeting of vascular smooth muscle cells target gene hsa-mir-19a Vascular Disease [unspecific] 19690387 cardiovascular system disease DOID:178 I72.9 D000783 miR-17-92 and miR-17-5p/miR-20a; MicroRNA-modulated targeting of vascular smooth muscle cells target gene hsa-mir-20a Vascular Disease [unspecific] 19690387 cardiovascular system disease DOID:178 I72.9 D000783 miR-17-92 and miR-17-5p/miR-20a; MicroRNA-modulated targeting of vascular smooth muscle cells target gene hsa-mir-22 Vascular Disease [unspecific] 27325558 cardiovascular system disease DOID:178 I72.9 D000783 miR-22-3p, had its binding site on the 3' UTR of VASH1 mRNA target gene hsa-mir-221 Vascular Disease [unspecific] 19088079 cardiovascular system disease DOID:178 I72.9 D000783 Our study demonstrates that PDGF signaling, by modulating the expression of miR-221, regulates two critical determinants of the vSMC phenotype; they are SMC gene expression and cell proliferation. target gene hsa-mir-221 Vascular Disease [unspecific] 18550634 cardiovascular system disease DOID:178 I72.9 D000783 In contrast, miR-221 and miR-222 inhibit endothelial cell migration, proliferation, and angiogenesis in vitro by targeting the stem cell factor receptor c-kit and indirectly regulating endothelial nitric oxide synthase expression. target gene hsa-mir-222 Vascular Disease [unspecific] 18550634 cardiovascular system disease DOID:178 I72.9 D000783 In contrast, miR-221 and miR-222 inhibit endothelial cell migration, proliferation, and angiogenesis in vitro by targeting the stem cell factor receptor c-kit and indirectly regulating endothelial nitric oxide synthase expression. target gene hsa-mir-663 Vascular Disease [unspecific] 24014830 cardiovascular system disease DOID:178 I72.9 D000783 targeting miR-663 or its specific downstream targets in human VSMCs may represent an attractive approach for the treatment of proliferative vascular diseases. target gene hsa-mir-106b Vascular Disease [unspecific] 26013412 cardiovascular system disease DOID:178 I72.9 D000783 The knowledge of molecular targets that change during the senescence can ultimately contribute to a better understanding and prevention of age-related vascular diseases. target gene hsa-mir-16 Vascular Disease [unspecific] 26013412 cardiovascular system disease DOID:178 I72.9 D000783 The knowledge of molecular targets that change during the senescence can ultimately contribute to a better understanding and prevention of age-related vascular diseases. target gene hsa-mir-221 Vascular Disease [unspecific] 18068232 cardiovascular system disease DOID:178 I72.9 D000783 miR-221 and miR-222 block endothelial cell migration, proliferation and angiogenesis in vitro by targeting the stem cell factor receptor c-Kit and indirectly regulating expression of endothelial nitric oxide synthase. target gene hsa-mir-222 Vascular Disease [unspecific] 18068232 cardiovascular system disease DOID:178 I72.9 D000783 miR-221 and miR-222 block endothelial cell migration, proliferation and angiogenesis in vitro by targeting the stem cell factor receptor c-Kit and indirectly regulating expression of endothelial nitric oxide synthase. target gene hsa-mir-23a Vascular Disease [unspecific] 22038739 cardiovascular system disease DOID:178 I72.9 D000783 Our results suggest that miR-23a may be involved in TNF-α-induced endothelial cell apoptosis through regulation of the caspase-7 and serine/threonine kinase 4-caspase-3 pathways. target gene hsa-mir-28 Vascular Disease [unspecific] 26013412 cardiovascular system disease DOID:178 I72.9 D000783 The knowledge of molecular targets that change during the senescence can ultimately contribute to a better understanding and prevention of age-related vascular diseases. target gene hsa-mir-376a Vascular Disease [unspecific] 26013412 cardiovascular system disease DOID:178 I72.9 D000783 The knowledge of molecular targets that change during the senescence can ultimately contribute to a better understanding and prevention of age-related vascular diseases. target gene hsa-mir-886 Vascular Disease [unspecific] 26013412 cardiovascular system disease DOID:178 I72.9 D000783 The knowledge of molecular targets that change during the senescence can ultimately contribute to a better understanding and prevention of age-related vascular diseases. target gene hsa-let-7a Vascular Hypertrophy 28123343 Let-7a Is an Antihypertrophic Regulator in the Heart via Targeting Calmodulin. target gene hsa-mir-1 Vascular Hypertrophy 23922949 In conclusion, miR-1 regulates Cx43 expression and activity in hypertrophic cardiomyocytes in vitro and in vivo. target gene hsa-mir-1 Vascular Hypertrophy 25995211 These experiments revealed the role of inducible cAMP early repressor as a repressor of miR-1 and Ito target gene hsa-mir-133a Vascular Hypertrophy 24113045 MiR-133a can negatively regulate the expression of L-type calcium α1C subunit, resulting in the decrease of intracellular Ca(2+) content and the attenuation of ISO-induced cardiomyocyte hypertrophy. target gene hsa-mir-133a Vascular Hypertrophy 26553694 Of 37 direct targets of miR-133a defined in unstressed hearts target gene hsa-mir-133a Vascular Hypertrophy 28795305 microRNA-133a attenuates cardiomyocyte hypertrophy by targeting PKCδ and Gq. target gene hsa-mir-200c Vascular Hypertrophy 23020145 Increased miR-21 and miR-200c contents were associated with reduced expression of their targets, Sprouty-1 and ZEB2, respectively. target gene hsa-mir-206 Vascular Hypertrophy 24023888 we show that inhibition of the established pro-myogenic regulator miR-206 can promote hypertrophy and increased protein synthesis in post-mitotic cells of the myogenic lineage. target gene hsa-mir-206 Vascular Hypertrophy 28114137 MiR-206 affected the process of cardiomyocytes hypertrophy by regulating histone deacetylase 4 (HDAC4) target gene hsa-mir-21 Vascular Hypertrophy 23020145 Increased miR-21 and miR-200c contents were associated with reduced expression of their targets, Sprouty-1 and ZEB2, respectively. target gene hsa-mir-1283 Vascular Injuries 27537404 D057772 miRNA-1283 Regulates the PERK/ATF4 Pathway in Vascular Injury by Targeting ATF4. target gene hsa-mir-145 Vascular Injuries 20841497 D057772 In addition, specific miRNAs such as miR-145, miR-21, and miR-221 have been found to regulate neointimal hyperplasia following vascular injury, which provides interesting possibilities for future herapeutical targets against vascular disease. target gene hsa-mir-124 Viral Infectious Disease 26865716 disease by infectious agent DOID:934 A94 D001102 Our data show that microRNA targeting can be used to further increase the safety of an attenuated mengovirus, providing a basis for its development as an oncolytic platform. target gene hsa-mir-125 Viral Infectious Disease 26865716 disease by infectious agent DOID:934 A94 D001102 Our data show that microRNA targeting can be used to further increase the safety of an attenuated mengovirus, providing a basis for its development as an oncolytic platform. target gene hsa-mir-133 Viral Infectious Disease 26865716 disease by infectious agent DOID:934 A94 D001102 Our data show that microRNA targeting can be used to further increase the safety of an attenuated mengovirus, providing a basis for its development as an oncolytic platform. target gene hsa-mir-138 Viral Infectious Disease 24721573 disease by infectious agent DOID:934 A94 D001102 A neuron-specific host microRNA targets herpes simplex virus-1 ICP0 expression and promotes latency. target gene hsa-mir-142 Viral Infectious Disease 26865716 disease by infectious agent DOID:934 A94 D001102 Our data show that microRNA targeting can be used to further increase the safety of an attenuated mengovirus, providing a basis for its development as an oncolytic platform. target gene hsa-mir-155 Viral Infectious Disease 23572582 disease by infectious agent DOID:934 A94 D001102 NK cells constitutively expressing Noxa and SOCS1 exhibit profound defects in expansion during the response to MCMV infection, suggesting that their regulation by miR-155 promotes antiviral immunity. target gene hsa-mir-199a-1 Viral Infectious Disease 23760629 disease by infectious agent DOID:934 A94 D001102 MiR-199a-5p promotes migration and tube formation of human cytomegalovirus-infected endothelial cells through downregulation of SIRT1 and eNOS. target gene hsa-mir-199a-2 Viral Infectious Disease 23760629 disease by infectious agent DOID:934 A94 D001102 MiR-199a-5p promotes migration and tube formation of human cytomegalovirus-infected endothelial cells through downregulation of SIRT1 and eNOS. target gene hsa-mir-208 Viral Infectious Disease 26865716 disease by infectious agent DOID:934 A94 D001102 Our data show that microRNA targeting can be used to further increase the safety of an attenuated mengovirus, providing a basis for its development as an oncolytic platform. target gene hsa-mir-26a Viral Infectious Disease 25012295 disease by infectious agent DOID:934 A94 D001102 EBV microRNA BART 18-5p targets MAP3K2 to facilitate persistence in vivo by inhibiting viral replication in B cells. target gene hsa-mir-29b Viral Infectious Disease 25234643 disease by infectious agent DOID:934 A94 D001102 Lentivirus-mediated Bos taurus bta-miR-29b overexpression interferes with bovine viral diarrhoea virus replication and viral infection-related autophagy by directly targeting ATG14 and ATG9A in Madin-Darby bovine kidney cells. target gene hsa-mir-32 Viral Infectious Disease 17462786 disease by infectious agent DOID:934 A94 D001102 This has been reported for the retrovirus primate foamy virus-1 (PFV-1), which can be targeted by the host miR-32 [150], which was suggested to restrict its infection. target gene hsa-mir-155 Viral Myocarditis 29136142 B33.2 D009205 The forkhead transcription factor Foxo3 negatively regulates natural killer cell function and viral clearance in myocarditis. target gene hsa-mir-20b Viral Myocarditis 28247213 B33.2 D009205 MicroRNA-20b suppresses the expression of ZFP-148 in viral myocarditis. target gene hsa-mir-223 Viral Myocarditis 29524390 B33.2 D009205 the data suggest that miR-223 protects against CVB3-induced inflammation and myocardial damage, which may partly attribute to the regulation of macrophage polarization via targeting Pknox1 target gene hsa-mir-3147 Vulvar Squamous Cell Carcinoma 29512734 disease of cellular proliferation DOID:2101 miR‑3147 serves as an oncomiR in vulvar squamous cell cancer via Smad4 suppression. target gene hsa-mir-155 Wound Healing 28247149 D014945 HP:0001058 miR-155 promotes cutaneous wound healing through enhanced keratinocytes migration by MMP-2. target gene hsa-mir-21 Wound Healing 27735045 D014945 HP:0001058 microRNA-21 mediates the TGF-β1-induced migration of keratinocytes via targeting PTEN. target gene hsa-mir-205 Wounds and Injuries [unspecific] 23950153 D014947 miR-205 stimulates wound healing by inhibiting its target gene KCNJ10. target gene hsa-mir-21 Wounds and Injuries [unspecific] 23159215 D014947 miR-21 regulates skin wound healing by targeting multiple aspects of the healing process target gene hsa-mir-34 Wounds and Injuries [unspecific] 25978377 D014947 our results provide compelling evidence supporting the existence of 106 novel miRNAs and the dynamic expression of miRNAs that extensively targets the TGF-β pathway at different gestational ages in fetal KCs.MiRNAs showing altered expression at different gestational ages in fetal KCs may contribute to scarless wound healing in early- to mid-gestational fetal Keratinocytes (KCs), and thus may be new targets for potential scar prevention and reduction therapies. therapeutic target hsa-mir-155 Acute Coronary Syndrome 25319951 I24.9 D054058 Our study suggests that high loading dose rosuvastatin pretreatment may reduce the incidence of cardiovascular events and levels of inflammatory markers in patients with ACS receiving PCI, which may be explained at least in part, by mechanism involving suppression of miR-155/SHIP-1 signaling pathway. therapeutic target hsa-mir-23a Acute Erythroid Leukemia 27086927 C94.0 D004915 indicating the therapeutic significance of miR-23a, -27a and -24 for AEL treatment. therapeutic target hsa-mir-24 Acute Erythroid Leukemia 27086927 C94.0 D004915 indicating the therapeutic significance of miR-23a, -27a and -24 for AEL treatment. therapeutic target hsa-mir-27a Acute Erythroid Leukemia 27086927 C94.0 D004915 indicating the therapeutic significance of miR-23a, -27a and -24 for AEL treatment. therapeutic target hsa-mir-124 Acute Ischemic Stroke 26459744 cardiovascular system disease DOID:224 I63.9 D002546 HP:0002140 The confirmed miRNA-targeted genes identified serve as potential therapeutic targets for acute ischemic stroke. therapeutic target hsa-mir-125 Acute Ischemic Stroke 26459744 cardiovascular system disease DOID:224 I63.9 D002546 HP:0002140 The confirmed miRNA-targeted genes identified serve as potential therapeutic targets for acute ischemic stroke. therapeutic target hsa-mir-218 Acute Ischemic Stroke 26459744 cardiovascular system disease DOID:224 I63.9 D002546 HP:0002140 The confirmed miRNA-targeted genes identified serve as potential therapeutic targets for acute ischemic stroke. therapeutic target hsa-mir-22 Acute Ischemic Stroke 26459744 cardiovascular system disease DOID:224 I63.9 D002546 HP:0002140 The confirmed miRNA-targeted genes identified serve as potential therapeutic targets for acute ischemic stroke. therapeutic target hsa-mir-23 Acute Ischemic Stroke 26459744 cardiovascular system disease DOID:224 I63.9 D002546 HP:0002140 The confirmed miRNA-targeted genes identified serve as potential therapeutic targets for acute ischemic stroke. therapeutic target hsa-mir-30 Acute Ischemic Stroke 26459744 cardiovascular system disease DOID:224 I63.9 D002546 HP:0002140 The confirmed miRNA-targeted genes identified serve as potential therapeutic targets for acute ischemic stroke. therapeutic target hsa-mir-33 Acute Ischemic Stroke 26459744 cardiovascular system disease DOID:224 I63.9 D002546 HP:0002140 The confirmed miRNA-targeted genes identified serve as potential therapeutic targets for acute ischemic stroke. therapeutic target hsa-mir-330 Acute Ischemic Stroke 26459744 cardiovascular system disease DOID:224 I63.9 D002546 HP:0002140 The confirmed miRNA-targeted genes identified serve as potential therapeutic targets for acute ischemic stroke. therapeutic target hsa-mir-9 Acute Ischemic Stroke 26459744 cardiovascular system disease DOID:224 I63.9 D002546 HP:0002140 The confirmed miRNA-targeted genes identified serve as potential therapeutic targets for acute ischemic stroke. therapeutic target hsa-mir-4262 Acute Lung Injury 26356266 S27 D055371 ACE2-induced suppression of miR-4262 partially contribute to the inhibition of the PEC apoptosis after ALI through Bcl-2. MiR-4262 may be a novel promising treatment target for ALI and ARDS. therapeutic target hsa-mir-210 Acute Myocardial Infarction 27392480 cardiovascular system disease DOID:9408 I21 D056989 608446 HP:0001658 HAR could reduce the infarction area, alleviate the interstitial fibrosis and improve the cardiac function of AMI rats. Those effects could be related to promoting myocardium angiogenesis of HAR by up-regulating miR-210 and VEGF. therapeutic target hsa-mir-203 Adenocarcinoma, Colon 23285092 disease of cellular proliferation DOID:234 C18 HP:0040276 in situ hybridization showed that miR-203 expression is attenuated in colon tumour tissues compared to normal colon tissues, suggesting that miR-203 could be a potential new prognostic marker and therapeutic target to explore in colon cancer. therapeutic target hsa-mir-1201 Adenocarcinoma, Esophageal 25631748 disease of cellular proliferation DOID:4914 C562730 133239 The exosomal onco-miRs identified seem to play a major role and may be applied for noninvasive diagnosis and therapy monitoring of adenocarcinoma of the esophagus. therapeutic target hsa-mir-149 Adenocarcinoma, Esophageal 25631748 disease of cellular proliferation DOID:4914 C562730 133239 The exosomal onco-miRs identified seem to play a major role and may be applied for noninvasive diagnosis and therapy monitoring of adenocarcinoma of the esophagus. therapeutic target hsa-mir-203 Adenocarcinoma, Esophageal 25631748 disease of cellular proliferation DOID:4914 C562730 133239 The exosomal onco-miRs identified seem to play a major role and may be applied for noninvasive diagnosis and therapy monitoring of adenocarcinoma of the esophagus. therapeutic target hsa-mir-22 Adenocarcinoma, Esophageal 25631748 disease of cellular proliferation DOID:4914 C562730 133239 The exosomal onco-miRs identified seem to play a major role and may be applied for noninvasive diagnosis and therapy monitoring of adenocarcinoma of the esophagus. therapeutic target hsa-mir-224 Adenocarcinoma, Esophageal 25631748 disease of cellular proliferation DOID:4914 C562730 133239 The exosomal onco-miRs identified seem to play a major role and may be applied for noninvasive diagnosis and therapy monitoring of adenocarcinoma of the esophagus. therapeutic target hsa-mir-23b Adenocarcinoma, Esophageal 25631748 disease of cellular proliferation DOID:4914 C562730 133239 The exosomal onco-miRs identified seem to play a major role and may be applied for noninvasive diagnosis and therapy monitoring of adenocarcinoma of the esophagus. therapeutic target hsa-mir-27b Adenocarcinoma, Esophageal 25631748 disease of cellular proliferation DOID:4914 C562730 133239 The exosomal onco-miRs identified seem to play a major role and may be applied for noninvasive diagnosis and therapy monitoring of adenocarcinoma of the esophagus. therapeutic target hsa-mir-452 Adenocarcinoma, Esophageal 25631748 disease of cellular proliferation DOID:4914 C562730 133239 The exosomal onco-miRs identified seem to play a major role and may be applied for noninvasive diagnosis and therapy monitoring of adenocarcinoma of the esophagus. therapeutic target hsa-mir-671 Adenocarcinoma, Esophageal 25631748 disease of cellular proliferation DOID:4914 C562730 133239 The exosomal onco-miRs identified seem to play a major role and may be applied for noninvasive diagnosis and therapy monitoring of adenocarcinoma of the esophagus. therapeutic target hsa-mir-944 Adenocarcinoma, Esophageal 25631748 disease of cellular proliferation DOID:4914 C562730 133239 The exosomal onco-miRs identified seem to play a major role and may be applied for noninvasive diagnosis and therapy monitoring of adenocarcinoma of the esophagus. therapeutic target hsa-mir-100 Adenocarcinoma, Gastric 26460735 disease of cellular proliferation DOID:3717 D37.1 D013274 these results develop a comprehensive expression and functional profile of differentially expressed miRNAs related to gastric oncogenesis. This profile may serve as a potential tool for biomarker and therapeutic target identification in GC patients. therapeutic target hsa-mir-106a Adenocarcinoma, Gastric 26460735 disease of cellular proliferation DOID:3717 D37.1 D013274 these results develop a comprehensive expression and functional profile of differentially expressed miRNAs related to gastric oncogenesis. This profile may serve as a potential tool for biomarker and therapeutic target identification in GC patients. therapeutic target hsa-mir-125b Adenocarcinoma, Gastric 26460735 disease of cellular proliferation DOID:3717 D37.1 D013274 these results develop a comprehensive expression and functional profile of differentially expressed miRNAs related to gastric oncogenesis. This profile may serve as a potential tool for biomarker and therapeutic target identification in GC patients. therapeutic target hsa-mir-127 Adenocarcinoma, Gastric 26460735 disease of cellular proliferation DOID:3717 D37.1 D013274 these results develop a comprehensive expression and functional profile of differentially expressed miRNAs related to gastric oncogenesis. This profile may serve as a potential tool for biomarker and therapeutic target identification in GC patients. therapeutic target hsa-mir-145 Adenocarcinoma, Gastric 26460735 disease of cellular proliferation DOID:3717 D37.1 D013274 these results develop a comprehensive expression and functional profile of differentially expressed miRNAs related to gastric oncogenesis. This profile may serve as a potential tool for biomarker and therapeutic target identification in GC patients. therapeutic target hsa-mir-15a Adenocarcinoma, Gastric 25743273 disease of cellular proliferation DOID:3717 D37.1 D013274 In conclusion, targeting YAP1 by tumor suppressor miRNA miR-15a and miR-16-1 plays inhibitory effect and this might have a therapeutic potential in GAC. therapeutic target hsa-mir-16-1 Adenocarcinoma, Gastric 25743273 disease of cellular proliferation DOID:3717 D37.1 D013274 In conclusion, targeting YAP1 by tumor suppressor miRNA miR-15a and miR-16-1 plays inhibitory effect and this might have a therapeutic potential in GAC. therapeutic target hsa-mir-17 Adenocarcinoma, Gastric 26460735 disease of cellular proliferation DOID:3717 D37.1 D013274 these results develop a comprehensive expression and functional profile of differentially expressed miRNAs related to gastric oncogenesis. This profile may serve as a potential tool for biomarker and therapeutic target identification in GC patients. therapeutic target hsa-mir-193a Adenocarcinoma, Gastric 26460735 disease of cellular proliferation DOID:3717 D37.1 D013274 these results develop a comprehensive expression and functional profile of differentially expressed miRNAs related to gastric oncogenesis. This profile may serve as a potential tool for biomarker and therapeutic target identification in GC patients. therapeutic target hsa-mir-20a Adenocarcinoma, Gastric 26460735 disease of cellular proliferation DOID:3717 D37.1 D013274 these results develop a comprehensive expression and functional profile of differentially expressed miRNAs related to gastric oncogenesis. This profile may serve as a potential tool for biomarker and therapeutic target identification in GC patients. therapeutic target hsa-mir-20b Adenocarcinoma, Gastric 26460735 disease of cellular proliferation DOID:3717 D37.1 D013274 these results develop a comprehensive expression and functional profile of differentially expressed miRNAs related to gastric oncogenesis. This profile may serve as a potential tool for biomarker and therapeutic target identification in GC patients. therapeutic target hsa-mir-381 Adenocarcinoma, Gastric 26460735 disease of cellular proliferation DOID:3717 D37.1 D013274 these results develop a comprehensive expression and functional profile of differentially expressed miRNAs related to gastric oncogenesis. This profile may serve as a potential tool for biomarker and therapeutic target identification in GC patients. therapeutic target hsa-mir-455 Adenocarcinoma, Gastric 26460735 disease of cellular proliferation DOID:3717 D37.1 D013274 these results develop a comprehensive expression and functional profile of differentially expressed miRNAs related to gastric oncogenesis. This profile may serve as a potential tool for biomarker and therapeutic target identification in GC patients. therapeutic target hsa-mir-483 Adenocarcinoma, Gastric 26460735 disease of cellular proliferation DOID:3717 D37.1 D013274 these results develop a comprehensive expression and functional profile of differentially expressed miRNAs related to gastric oncogenesis. This profile may serve as a potential tool for biomarker and therapeutic target identification in GC patients. therapeutic target hsa-mir-601 Adenocarcinoma, Gastric 26460735 disease of cellular proliferation DOID:3717 D37.1 D013274 these results develop a comprehensive expression and functional profile of differentially expressed miRNAs related to gastric oncogenesis. This profile may serve as a potential tool for biomarker and therapeutic target identification in GC patients. therapeutic target hsa-mir-671 Adenocarcinoma, Gastric 26460735 disease of cellular proliferation DOID:3717 D37.1 D013274 these results develop a comprehensive expression and functional profile of differentially expressed miRNAs related to gastric oncogenesis. This profile may serve as a potential tool for biomarker and therapeutic target identification in GC patients. therapeutic target hsa-mir-92a Adenocarcinoma, Gastric 26460735 disease of cellular proliferation DOID:3717 D37.1 D013274 these results develop a comprehensive expression and functional profile of differentially expressed miRNAs related to gastric oncogenesis. This profile may serve as a potential tool for biomarker and therapeutic target identification in GC patients. therapeutic target hsa-mir-96 Adenocarcinoma, Gastric 26460735 disease of cellular proliferation DOID:3717 D37.1 D013274 these results develop a comprehensive expression and functional profile of differentially expressed miRNAs related to gastric oncogenesis. This profile may serve as a potential tool for biomarker and therapeutic target identification in GC patients. therapeutic target hsa-let-7g Adenocarcinoma, Lung 24441398 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 Multifunctional aptamer-miRNA conjugates for targeted cancer therapy. therapeutic target hsa-mir-106a Adenocarcinoma, Lung 24743967 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 These results contribute to unravelling miRNA-controlled networks involved in the pathogenesis of adenocarcinoma and COPD, and provide new tools of potential use as biomarkers for diagnosis and/or therapeutic purposes. therapeutic target hsa-mir-106b Adenocarcinoma, Lung 24743967 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 These results contribute to unravelling miRNA-controlled networks involved in the pathogenesis of adenocarcinoma and COPD, and provide new tools of potential use as biomarkers for diagnosis and/or therapeutic purposes. therapeutic target hsa-mir-132 Adenocarcinoma, Lung 24743967 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 These results contribute to unravelling miRNA-controlled networks involved in the pathogenesis of adenocarcinoma and COPD, and provide new tools of potential use as biomarkers for diagnosis and/or therapeutic purposes. therapeutic target hsa-mir-145 Adenocarcinoma, Lung 26687391 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 MicroRNA 25, microRNA 145, and microRNA 210 as biomarkers for predicting the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who are negative for epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations. therapeutic target hsa-mir-17 Adenocarcinoma, Lung 24743967 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 These results contribute to unravelling miRNA-controlled networks involved in the pathogenesis of adenocarcinoma and COPD, and provide new tools of potential use as biomarkers for diagnosis and/or therapeutic purposes. therapeutic target hsa-mir-192 Adenocarcinoma, Lung 24743967 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 These results contribute to unravelling miRNA-controlled networks involved in the pathogenesis of adenocarcinoma and COPD, and provide new tools of potential use as biomarkers for diagnosis and/or therapeutic purposes. therapeutic target hsa-mir-200 Adenocarcinoma, Lung 26395571 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 BMP4 functions as a pro-tumorigenic factor in a murine lung cancer model, and its transcription is regulated by miR-200 and GATA4/6. Thus, we propose that BMP4 and its antagonists may be suitable therapeutic targets for the treatment of lung cancer. therapeutic target hsa-mir-204 Adenocarcinoma, Lung 29281186 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 Clinically, the miR-204/JAK2/STAT3 signaling pathway is a putative therapeutic target in lung adenocarcinoma therapeutic target hsa-mir-210 Adenocarcinoma, Lung 26687391 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 MicroRNA 25, microRNA 145, and microRNA 210 as biomarkers for predicting the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who are negative for epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations. therapeutic target hsa-mir-25 Adenocarcinoma, Lung 26687391 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 MicroRNA 25, microRNA 145, and microRNA 210 as biomarkers for predicting the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who are negative for epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations. therapeutic target hsa-mir-33b Adenocarcinoma, Lung 26459797 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 In conclusion, the present study provided novel insight into the molecular mechanism of lung adenocarcinoma progression. MicroRNA-33b should be further investigated as a potential therapeutic target in human lung adenocarcinoma. therapeutic target hsa-mir-100 Adenocarcinoma, Pancreatic Ductal 26606261 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 Consistent miR expression profiles, in part regulated by mutant TP53 gene, were identified in gemcitabine-resistant PDAC with significant MRP-1 and Bcl-2 overexpression. These results provide a basis for further elucidation of chemoresistance mechanisms and therapeutic approaches to overcome chemoresistance in PDAC. therapeutic target hsa-mir-106a Adenocarcinoma, Pancreatic Ductal 26259238 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets therapeutic target hsa-mir-10a Adenocarcinoma, Pancreatic Ductal 26259238 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets therapeutic target hsa-mir-10b Adenocarcinoma, Pancreatic Ductal 21816909 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 microRNA-10b (miR-10b) expression in pancreatic ductal adenocarcinoma (PDAC), as identified by in situ hybridization, is highly correlated with cancer diagnosis, therapy response, and prognosis. therapeutic target hsa-mir-124 Adenocarcinoma, Pancreatic Ductal 26259238 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets therapeutic target hsa-mir-125b Adenocarcinoma, Pancreatic Ductal 26606261 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 Consistent miR expression profiles, in part regulated by mutant TP53 gene, were identified in gemcitabine-resistant PDAC with significant MRP-1 and Bcl-2 overexpression. These results provide a basis for further elucidation of chemoresistance mechanisms and therapeutic approaches to overcome chemoresistance in PDAC. therapeutic target hsa-mir-138 Adenocarcinoma, Pancreatic Ductal 26606261 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 Consistent miR expression profiles, in part regulated by mutant TP53 gene, were identified in gemcitabine-resistant PDAC with significant MRP-1 and Bcl-2 overexpression. These results provide a basis for further elucidation of chemoresistance mechanisms and therapeutic approaches to overcome chemoresistance in PDAC. therapeutic target hsa-mir-143 Adenocarcinoma, Pancreatic Ductal 26554910 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 miRNA expression profiles should be investigated to evaluate the potential function as biomarkers for early diagnosis, disease progression, response to therapy, and prognosis because of their characteristics of high stability, tissue specificity and ease of availability. therapeutic target hsa-mir-145 Adenocarcinoma, Pancreatic Ductal 26554910 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 miRNA expression profiles should be investigated to evaluate the potential function as biomarkers for early diagnosis, disease progression, response to therapy, and prognosis because of their characteristics of high stability, tissue specificity and ease of availability. therapeutic target hsa-mir-148a Adenocarcinoma, Pancreatic Ductal 26259238 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets therapeutic target hsa-mir-155 Adenocarcinoma, Pancreatic Ductal 26259238 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets therapeutic target hsa-mir-194 Adenocarcinoma, Pancreatic Ductal 26259238 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets therapeutic target hsa-mir-200b Adenocarcinoma, Pancreatic Ductal 26345967 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 Our study screened out some target miRNAs and mRNAs for pancreatic ductal adenocarcinoma, which may be helpful in its diagnosis and treatment. therapeutic target hsa-mir-200b Adenocarcinoma, Pancreatic Ductal 26259238 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets therapeutic target hsa-mir-200c Adenocarcinoma, Pancreatic Ductal 26259238 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic target therapeutic target hsa-mir-21 Adenocarcinoma, Pancreatic Ductal 25591761 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 miR-21/FoxO1 axis as a novel therapeutic target for inhibiting the growth of PDAC. therapeutic target hsa-mir-21 Adenocarcinoma, Pancreatic Ductal 25623117 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 miR-21/FoxO1 axis appears to be a novel therapeutic target for inhibiting the growth of PDAC. therapeutic target hsa-mir-21 Adenocarcinoma, Pancreatic Ductal 26606261 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 Consistent miR expression profiles, in part regulated by mutant TP53 gene, were identified in gemcitabine-resistant PDAC with significant MRP-1 and Bcl-2 overexpression. These results provide a basis for further elucidation of chemoresistance mechanisms and therapeutic approaches to overcome chemoresistance in PDAC. therapeutic target hsa-mir-21 Adenocarcinoma, Pancreatic Ductal 26259238 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic target therapeutic target hsa-mir-210 Adenocarcinoma, Pancreatic Ductal 26606261 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 Consistent miR expression profiles, in part regulated by mutant TP53 gene, were identified in gemcitabine-resistant PDAC with significant MRP-1 and Bcl-2 overexpression. These results provide a basis for further elucidation of chemoresistance mechanisms and therapeutic approaches to overcome chemoresistance in PDAC. therapeutic target hsa-mir-221 Adenocarcinoma, Pancreatic Ductal 26259238 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic target therapeutic target hsa-mir-222 Adenocarcinoma, Pancreatic Ductal 26259238 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic target therapeutic target hsa-mir-224 Adenocarcinoma, Pancreatic Ductal 26259238 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic target therapeutic target hsa-mir-23a Adenocarcinoma, Pancreatic Ductal 25701323 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 It is suggested that miR-23a, acting as an oncogenic regulator by directly targeting APAF 1 in pancreatic cancer, is a useful potential biomarker in diagnosis and treatment of pancreatic cancer. therapeutic target hsa-mir-27a Adenocarcinoma, Pancreatic Ductal 26259238 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic target therapeutic target hsa-mir-31 Adenocarcinoma, Pancreatic Ductal 26606261 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 Consistent miR expression profiles, in part regulated by mutant TP53 gene, were identified in gemcitabine-resistant PDAC with significant MRP-1 and Bcl-2 overexpression. These results provide a basis for further elucidation of chemoresistance mechanisms and therapeutic approaches to overcome chemoresistance in PDAC. therapeutic target hsa-mir-330 Adenocarcinoma, Pancreatic Ductal 26606261 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 Consistent miR expression profiles, in part regulated by mutant TP53 gene, were identified in gemcitabine-resistant PDAC with significant MRP-1 and Bcl-2 overexpression. These results provide a basis for further elucidation of chemoresistance mechanisms and therapeutic approaches to overcome chemoresistance in PDAC. therapeutic target hsa-mir-34 Adenocarcinoma, Pancreatic Ductal 26259238 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic target therapeutic target hsa-mir-367 Adenocarcinoma, Pancreatic Ductal 25867271 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 The present study identified and characterised a signalling pathway,the miR-367/Smad7-TGF-β pathway, which is involved in the invasion and metastasis of pancreatic cancer cells. Our results suggest that miR-367 may be a promising therapeutic target for the treatment of human pancreatic cancer. therapeutic target hsa-mir-367 Adenocarcinoma, Pancreatic Ductal 26259238 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic target therapeutic target hsa-mir-378 Adenocarcinoma, Pancreatic Ductal 26606261 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 Consistent miR expression profiles, in part regulated by mutant TP53 gene, were identified in gemcitabine-resistant PDAC with significant MRP-1 and Bcl-2 overexpression. These results provide a basis for further elucidation of chemoresistance mechanisms and therapeutic approaches to overcome chemoresistance in PDAC. therapeutic target hsa-mir-429 Adenocarcinoma, Pancreatic Ductal 26259238 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic target therapeutic target hsa-mir-486 Adenocarcinoma, Pancreatic Ductal 26259238 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic target therapeutic target hsa-mir-494 Adenocarcinoma, Pancreatic Ductal 24859161 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 Loss of SMAD4 in PDAC cells leads to reduced levels of miR-494,increased levels of FOXM1, and nuclear localization of β-catenin. miR-494 might be developed as a prognostic marker for patients with PDAC or a therapeutic target. therapeutic target hsa-mir-615 Adenocarcinoma, Pancreatic Ductal 25856297 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 These results show that miR-615-5p inhibits pancreatic cancer cell proliferation, migration, and invasion by targeting AKT2. The data implicate miR-615-5p in the prognosis and treatment of PDAC. therapeutic target hsa-mir-615 Adenocarcinoma, Pancreatic Ductal 26259238 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic target therapeutic target hsa-mir-96 Adenocarcinoma, Pancreatic Ductal 26554910 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 miRNA expression profiles should be investigated to evaluate the potential function as biomarkers for early diagnosis, disease progression, response to therapy, and prognosis because of their characteristics of high stability, tissue specificity and ease of availability. therapeutic target hsa-mir-99a Adenocarcinoma, Pancreatic Ductal 26606261 disease of cellular proliferation DOID:3498 C25.3 D021441 260350 Consistent miR expression profiles, in part regulated by mutant TP53 gene, were identified in gemcitabine-resistant PDAC with significant MRP-1 and Bcl-2 overexpression. These results provide a basis for further elucidation of chemoresistance mechanisms and therapeutic approaches to overcome chemoresistance in PDAC. therapeutic target hsa-mir-328 Adenovirus Infection 21098446 B34.0 D000257 The study therefore uncovered a novel molecular mechanism for AF and indicated miR-328 as a potential therapeutic target for AF. therapeutic target hsa-mir-93 Age-Related Macular Degeneration 27349759 nervous system disease DOID:10871 H35.30 D008268 PS603075 these results highlight the therapeutic potential of miR-93 therapeutic target hsa-mir-122 Alcoholic Hepatitis 26264599 endocrine system disease DOID:12351 K70.1 D006519 Elevated level of EVs/exosomes and exosome-associated miRNA signature could serve as potential diagnostic markers for AH. In addition to the biomarker diagnostic capabilities, these findings may facilitate development of novel strategies for diagnostics, monitoring, and therapeutics of AH. therapeutic target hsa-mir-1246 Alcoholic Hepatitis 26264599 endocrine system disease DOID:12351 K70.1 D006519 Elevated level of EVs/exosomes and exosome-associated miRNA signature could serve as potential diagnostic markers for AH. In addition to the biomarker diagnostic capabilities, these findings may facilitate development of novel strategies for diagnostics, monitoring, and therapeutics of AH. therapeutic target hsa-mir-130a Alcoholic Hepatitis 26264599 endocrine system disease DOID:12351 K70.1 D006519 Elevated level of EVs/exosomes and exosome-associated miRNA signature could serve as potential diagnostic markers for AH. In addition to the biomarker diagnostic capabilities, these findings may facilitate development of novel strategies for diagnostics, monitoring, and therapeutics of AH. therapeutic target hsa-mir-192 Alcoholic Hepatitis 26264599 endocrine system disease DOID:12351 K70.1 D006519 Elevated level of EVs/exosomes and exosome-associated miRNA signature could serve as potential diagnostic markers for AH. In addition to the biomarker diagnostic capabilities, these findings may facilitate development of novel strategies for diagnostics, monitoring, and therapeutics of AH. therapeutic target hsa-mir-212 Alcoholic Hepatitis 26207424 endocrine system disease DOID:12351 K70.1 D006519 These studies thus support a novel miR-212 mechanism for alcohol-induced gut leakiness and a potential target that could be exploited for therapeutic intervention to prevent leaky gut and liver injury in alcoholics. therapeutic target hsa-mir-30a Alcoholic Hepatitis 26264599 endocrine system disease DOID:12351 K70.1 D006519 Elevated level of EVs/exosomes and exosome-associated miRNA signature could serve as potential diagnostic markers for AH. In addition to the biomarker diagnostic capabilities, these findings may facilitate development of novel strategies for diagnostics, monitoring, and therapeutics of AH. therapeutic target hsa-mir-30b Alcoholic Hepatitis 26264599 endocrine system disease DOID:12351 K70.1 D006519 Elevated level of EVs/exosomes and exosome-associated miRNA signature could serve as potential diagnostic markers for AH. In addition to the biomarker diagnostic capabilities, these findings may facilitate development of novel strategies for diagnostics, monitoring, and therapeutics of AH. therapeutic target hsa-mir-744 Alcoholic Hepatitis 26264599 endocrine system disease DOID:12351 K70.1 D006519 Elevated level of EVs/exosomes and exosome-associated miRNA signature could serve as potential diagnostic markers for AH. In addition to the biomarker diagnostic capabilities, these findings may facilitate development of novel strategies for diagnostics, monitoring, and therapeutics of AH. therapeutic target hsa-mir-155 Allergic Asthma 27783037 immune system disease DOID:9415 J45.909 C564133 600807 miR-155: A Novel Target in Allergic Asthma. therapeutic target hsa-mir-146a Allergic Rhinitis 26700406 respiratory system disease DOID:4481 J30.9 D065631 607154 HP:0003193 miR-146a can enforce OVA-specific immunotherapy via inducing antigen-specific regulatory T cells. miR-146a may have therapeutic potential to be used in the immunotherapy of allergic diseases. therapeutic target hsa-mir-146a Allergy 26663191 immune system disease DOID:1205 T78.40 D006967 HP:0012393 Further characterization of microRNA functions is important, as similar to other conditions, the modulation of microRNA expression could potentially be used for therapeutic purposes in allergic diseases in the future. In addition, miRNAs could be implemented as biomarkers for endotyping complex allergic conditions. therapeutic target hsa-mir-155 Allergy 26663191 immune system disease DOID:1205 T78.40 D006967 HP:0012393 Further characterization of microRNA functions is important, as similar to other conditions, the modulation of microRNA expression could potentially be used for therapeutic purposes in allergic diseases in the future. In addition, miRNAs could be implemented as biomarkers for endotyping complex allergic conditions. therapeutic target hsa-mir-21 Allergy 26663191 immune system disease DOID:1205 T78.40 D006967 HP:0012393 Further characterization of microRNA functions is important, as similar to other conditions, the modulation of microRNA expression could potentially be used for therapeutic purposes in allergic diseases in the future. In addition, miRNAs could be implemented as biomarkers for endotyping complex allergic conditions. therapeutic target hsa-mir-575 Alopecia 25955790 integumentary system disease DOID:987 L65.9 D000505 300042 HP:0001596 these results indicated that ROS-mediated cellular damage was inhibited by troxerutin and suggested that the use of troxerutin may be an effective approach in the treatment of alopecia. therapeutic target hsa-mir-602 Alopecia 25955790 integumentary system disease DOID:987 L65.9 D000505 300042 HP:0001596 these results indicated that ROS-mediated cellular damage was inhibited by troxerutin and suggested that the use of troxerutin may be an effective approach in the treatment of alopecia. therapeutic target hsa-let-7d Alzheimer Disease 29543360 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study therapeutic target hsa-let-7g Alzheimer Disease 29543360 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study therapeutic target hsa-mir-101 Alzheimer Disease 29543360 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study therapeutic target hsa-mir-125b Alzheimer Disease 29543360 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study therapeutic target hsa-mir-132 Alzheimer Disease 26362250 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 These findings support a role for miR-132/212 in the regulation of tau pathology in mice and humans and provide new alternatives for therapeutic development. therapeutic target hsa-mir-137 Alzheimer Disease 21994399 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 We identified that the loss of miR-137, -181c, -9, and 29a/b-1 increases SPT and in turn Abeta levels, and provides a mechanism for the elevated risk of AD associated with age, high-saturated-fat diet, and gender. Finally, these results suggest SPT and the respective miRNAs may be potential therapeutic targets for sporadic AD. therapeutic target hsa-mir-146a Alzheimer Disease 20937840 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 The combinatorial use of NF-κB inhibitors with miRNA-146a or antisense miRNA-146a may have potential as a bi-pronged therapeutic strategy directed against IRAK-2-driven pathogenic signaling. therapeutic target hsa-mir-155 Alzheimer Disease 29543360 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study therapeutic target hsa-mir-15b Alzheimer Disease 29543360 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study therapeutic target hsa-mir-181c Alzheimer Disease 21994399 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 We identified that the loss of miR-137, -181c, -9, and 29a/b-1 increases SPT and in turn Abeta levels, and provides a mechanism for the elevated risk of AD associated with age, high-saturated-fat diet, and gender. Finally, these results suggest SPT and the respective miRNAs may be potential therapeutic targets for sporadic AD. therapeutic target hsa-mir-191 Alzheimer Disease 29543360 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study therapeutic target hsa-mir-206 Alzheimer Disease 28123152 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 miR-206-3p is involved in the anti-dementia effects of donepezil, and could be a novel pharmacological target for treating AD therapeutic target hsa-mir-212 Alzheimer Disease 26362250 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 These findings support a role for miR-132/212 in the regulation of tau pathology in mice and humans and provide new alternatives for therapeutic development. therapeutic target hsa-mir-26b Alzheimer Disease 29543360 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study therapeutic target hsa-mir-29a Alzheimer Disease 21994399 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 We identified that the loss of miR-137, -181c, -9, and 29a/b-1 increases SPT and in turn Abeta levels, and provides a mechanism for the elevated risk of AD associated with age, high-saturated-fat diet, and gender. Finally, these results suggest SPT and the respective miRNAs may be potential therapeutic targets for sporadic AD. therapeutic target hsa-mir-29b Alzheimer Disease 29543360 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study therapeutic target hsa-mir-29b-1 Alzheimer Disease 21994399 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 We identified that the loss of miR-137, -181c, -9, and 29a/b-1 increases SPT and in turn Abeta levels, and provides a mechanism for the elevated risk of AD associated with age, high-saturated-fat diet, and gender. Finally, these results suggest SPT and the respective miRNAs may be potential therapeutic targets for sporadic AD. therapeutic target hsa-mir-29c Alzheimer Disease 25815896 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 the present study suggested that miR-29c may be a promising potential therapeutic target in the treatment of AD. therapeutic target hsa-mir-29c Alzheimer Disease 25955795 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 The results demonstrated that the upregulation of miR-29c promoted learning and memory behaviors in SAMP8 mice, at least partially, by increasing the activity of protein kinase A/cAMP response element-binding protein, involved in neuroprotection. This evidence suggested that miR-29c may be a promising potential therapeutic target against AD. therapeutic target hsa-mir-33 Alzheimer Disease 26538644 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 we demonstrate that inhibition of microRNA-33 increases lipidation of brain ApoE and reduces Aβ levels by inducing ABCA1. We provide a unique approach for AD therapeutics to increase ApoE lipidation and reduce Aβ levels via pharmacological inhibition of microRNA in vivo. therapeutic target hsa-mir-342 Alzheimer Disease 29543360 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study therapeutic target hsa-mir-34a Alzheimer Disease 29543360 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study therapeutic target hsa-mir-9 Alzheimer Disease 29543360 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study therapeutic target hsa-mir-9-1 Alzheimer Disease 21994399 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 We identified that the loss of miR-137, -181c, -9, and 29a/b-1 increases SPT and in turn Abeta levels, and provides a mechanism for the elevated risk of AD associated with age, high-saturated-fat diet, and gender. Finally, these results suggest SPT and the respective miRNAs may be potential therapeutic targets for sporadic AD. therapeutic target hsa-mir-9-2 Alzheimer Disease 21994399 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 We identified that the loss of miR-137, -181c, -9, and 29a/b-1 increases SPT and in turn Abeta levels, and provides a mechanism for the elevated risk of AD associated with age, high-saturated-fat diet, and gender. Finally, these results suggest SPT and the respective miRNAs may be potential therapeutic targets for sporadic AD. therapeutic target hsa-mir-9-3 Alzheimer Disease 21994399 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 We identified that the loss of miR-137, -181c, -9, and 29a/b-1 increases SPT and in turn Abeta levels, and provides a mechanism for the elevated risk of AD associated with age, high-saturated-fat diet, and gender. Finally, these results suggest SPT and the respective miRNAs may be potential therapeutic targets for sporadic AD. therapeutic target hsa-mir-937 Alzheimer Disease 26316079 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 Overexpression of as-miR-937 in MSCs may substantially improve the therapeutic effects of MSCs on AD, possibly through augmenting Brn-4 levels in MSCs. therapeutic target hsa-mir-141 Amyotrophic Lateral Sclerosis 25004804 nervous system disease DOID:332 G12.21 D000690 PS105400 HP:0007354 Our results reveal a possible correlation between deregulation of this regulatory circuit and ALS pathogenesis, and open interesting perspectives in the treatment of these mutations through ad hoc-modified microRNAs. therapeutic target hsa-mir-200a Amyotrophic Lateral Sclerosis 25004804 nervous system disease DOID:332 G12.21 D000690 PS105400 HP:0007354 Our results reveal a possible correlation between deregulation of this regulatory circuit and ALS pathogenesis, and open interesting perspectives in the treatment of these mutations through ad hoc-modified microRNAs. therapeutic target hsa-mir-205 Aortic Aneurysm, Abdominal 24812324 cardiovascular system disease DOID:7693 I71.3-.4 D017544 PS100070 miRNAs may be a novel therapeutic strategy to prevent AAA. therapeutic target hsa-mir-1 Arrhythmia 26671473 I49.9 D001145 600919 HP:0011675 We aim at emphasizing the relationship between miR-1 and ion channels and proteins involved in the process of arrhythmia. In addition, we will pay attention to its future therapeutic prospects. therapeutic target hsa-mir-1298 Arteriosclerosis Obliterans 26025955 cardiovascular system disease DOID:5160 D001162 HP:0002634 Our data demonstrate a specific role of the upstream DNA methylation/miR-1298/Cx43 pathway in regulating VSMC function and suggest that modulation of miR-1298 levels may offer a novel therapeutic approach for ASO. therapeutic target hsa-mir-133a Arteriosclerosis Obliterans 25445891 cardiovascular system disease DOID:5160 D001162 HP:0002634 miR-133a regulates the functions of HASMCs by targeting RhoA and may be involved in the pathogenesis of ASO. These findings may lead to the development of potential therapeutic targets for ASO of the lower extremities. therapeutic target hsa-mir-24 Arteriosclerosis Obliterans 26159387 cardiovascular system disease DOID:5160 D001162 HP:0002634 The results suggest that miR-24-3p regulates the proliferation and migration of hsaMCs by targeting PDGFRB and c-Myc. The PDGF/miR-24-3p/PDGFRB and PDGF/miR-24-3p/c-Myc pathways may play critical roles in the pathogenesis of ASO.These findings highlight the potential for new therapeutic targets for ASO. therapeutic target hsa-mir-18a Arteriovenous Malformation 24837588 disease of cellular proliferation DOID:11294 I77.0 D001165 108010 Ago-2 facilitates miR-18a entry into brain endothelial cells in vitro and in vivo. This study highlights the clinical potential of Ago-2 as a miRNA delivery platform for the treatment of brain vascular diseases. therapeutic target hsa-mir-18a Arteriovenous Malformation 24203843 disease of cellular proliferation DOID:11294 I77.0 D001165 108010 We report VEGF-D overexpression in AVM and the capacity of miR-18a to induce AVM-BECs to function more normally. This highlights the clinical potential of microRNA as a treatment for AVM and other vascular diseases. therapeutic target hsa-mir-155 Arthritis 29354135 musculoskeletal system disease DOID:848 M19.90 D001168 we review the evidence for the pathogenic role of miR-155 in driving aberrant activation of the immune system in rheumatoid arthritis, and its potential as a disease biomarker and therapeutic target therapeutic target hsa-mir-1 Asthma 24043765 respiratory system disease DOID:2841 J45 D001249 600807 HP:0002099 These experiments define a novel VEGF-miR-1-Mpl-P-selectin effector pathway in lung Th2 inflammation and herald the utility of miR-1 and Mpl as potential therapeutic targets for asthma. therapeutic target hsa-mir-1 Asthma 25961389 respiratory system disease DOID:2841 J45 D001249 600807 HP:0002099 Targeting of miRNA-1 and miRNA-145 has been used to inhibit lung inflammation in mouse models of asthma. therapeutic target hsa-mir-122 Asthma 27485847 respiratory system disease DOID:2841 J45 D001249 600807 HP:0002099 First clinical trials using the blockade of liver specific miR-122 showed very promising results in the treatment of chronic hepatitis C virus infection. Results of preclinical and animal studies are also promising providing future rationale for the development of new therapeutics for various internal diseases including heart failure, bronchial asthma or inflammatory bowel diseases. therapeutic target hsa-mir-1260a Asthma 26118177 respiratory system disease DOID:2841 J45 D001249 600807 HP:0002099 These results indicate that circulating miR-3162-3p and miR-1260a should be further evaluated as potential non-invasive biomarkers in diagnosis and treatment for childhood asthma. therapeutic target hsa-mir-155 Asthma 23967196 respiratory system disease DOID:2841 J45 D001249 600807 HP:0002099 Mechanical stretch modulates the homeostasis of the hBEC secretome involving miR-155 and that hMSCs can be used as a potential therapeutic approach to reverse bronchial epithelial inflammation in asthma. therapeutic target hsa-mir-21 Asthma 26874829 respiratory system disease DOID:2841 J45 D001249 600807 HP:0002099 This study suggested that serum miRNA-21 is stable and detectable in serum of asthmatic children, which could promise potential biomarker in diagnosis as well as in response to therapy of asthma. therapeutic target hsa-mir-3162 Asthma 26118177 respiratory system disease DOID:2841 J45 D001249 600807 HP:0002099 These results indicate that circulating miR-3162-3p and miR-1260a should be further evaluated as potential non-invasive biomarkers in diagnosis and treatment for childhood asthma. therapeutic target hsa-mir-708 Asthma 26998837 respiratory system disease DOID:2841 J45 D001249 600807 HP:0002099 These results demonstrate that miR-708 and miR-140-3p exert distinct effects on inflammation-associated gene expression and biological function of ASM cells. Targeting these miRNA networks may provide a novel therapeutic mechanism to down-regulate airway inflammation and ASM proliferation in asthma. therapeutic target hsa-mir-9 Asthma 25772595 respiratory system disease DOID:2841 J45 D001249 600807 HP:0002099 MiR-9 regulates GR signaling and steroid-resistant AHR. Targeting miR-9 function might be a novel approach for the treatment of steroid-resistant asthma. therapeutic target hsa-mir-146a Astrocytoma 25873300 disease of cellular proliferation DOID:3069 C72.9 D001254 155755 HP:0009592 The current findings demonstrated that β2-AR signaling has growth inhibitory effects via modulation of the cAMP/PKA pathway in A-1321N1 cells through increasing the expression level of Cx43 and miR-146a as well as decreasing miR-155 and miR-27a levels. Thus, stimulation of the β2-AR and PKA signaling pathway may be a useful approach for astrocytoma therapy. therapeutic target hsa-mir-155 Astrocytoma 25873300 disease of cellular proliferation DOID:3069 C72.9 D001254 155755 HP:0009592 The current findings demonstrated that β2-AR signaling has growth inhibitory effects via modulation of the cAMP/PKA pathway in A-1321N1 cells through increasing the expression level of Cx43 and miR-146a as well as decreasing miR-155 and miR-27a levels. Thus, stimulation of the β2-AR and PKA signaling pathway may be a useful approach for astrocytoma therapy. therapeutic target hsa-mir-27a Astrocytoma 25873300 disease of cellular proliferation DOID:3069 C72.9 D001254 155755 HP:0009592 The current findings demonstrated that β2-AR signaling has growth inhibitory effects via modulation of the cAMP/PKA pathway in A-1321N1 cells through increasing the expression level of Cx43 and miR-146a as well as decreasing miR-155 and miR-27a levels. Thus, stimulation of the β2-AR and PKA signaling pathway may be a useful approach for astrocytoma therapy. therapeutic target hsa-mir-542 Astrocytoma 26286747 disease of cellular proliferation DOID:3069 C72.9 D001254 155755 HP:0009592 These findings suggest that miR-542-3p acts as a negative regulator in astrocytoma progression and that miR-542-3p down-regulation contributes to aberrant activation of AKT signaling, leaving open the possibility that miR-542-3p may be a potential therapeutic target for high grade astrocytoma. therapeutic target hsa-mir-100 Atherosclerosis 29208678 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Our findings of miR-100 as a potential protective anti-athero-miR suggest that the therapeutic replacement of this microRNA could be a potential strategy for the treatment of chronic inflammatory diseases, such as atherosclerosis, in the future therapeutic target hsa-mir-107 Atherosclerosis 25522185 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Since chronodisruption has been linked to metabolic disorders such as type 2 diabetes, atherosclerosis, obesity, and CVD, our findings suggests that miR-107 could represent a new approach for pharmacological treatment of these diseases. therapeutic target hsa-mir-10a Atherosclerosis 29459264 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 EC miR-10a induction by RARα/RXRα-specific agonists is a potential hemodynamics-based strategy for atherosclerosis treatment therapeutic target hsa-mir-10b Atherosclerosis 25612666 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 The modulation of miR-10b in VSMCs provides a potential target for the therapy of atherosclerosis. therapeutic target hsa-mir-126 Atherosclerosis 25450610 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 we will discuss novel aspects of miR-mediated regulatory mechanisms, namely the regulation by competing RNA targets, miRNA tandems, or complementary miR strand pairs, as well as their potential diagnostic and therapeutic value in atherosclerosis. This article is part of a Special Issue entitled 'Non-coding RNAs'. therapeutic target hsa-mir-127 Atherosclerosis 25411193 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Significant changes in genomic methylation were identified in atherosclerotic lesions. The most prominent gene cluster activated via hypomethylation was detected at imprinted chromosomal locus 14q32 with several clustered miRNAs that were up-regulated. These results suggest that epigenetic changes are involved in atherogenesis and may offer new potential therapeutic targets for vascular diseases. therapeutic target hsa-mir-132 Atherosclerosis 24924687 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 SIRT1 mRNAs are direct targets of miR-132. miR-132 controls lipogenesis and cholesterogenesis in HUVECs by inhibiting SIRT1 and SREBP-1c expression and their downstream regulated genes, including FASN and HMGCR.Inhibition of SIRT1 by miR-132 was associated with lipid metabolism-dependent pro-inflammatory processes in HUVECs. The newly identified miRNA, miR-132 represents a novel targeting mechanism for AS therapy. therapeutic target hsa-mir-134 Atherosclerosis 26546816 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Collectively, our findings indicate that miR-134 may regulate lipid accumulation and proinfiammatory cytokine secretion in macrophages by targeting the ANGPTL4 gene. Our results have also suggested a promising and potential therapeutic target for atherosclerosis. therapeutic target hsa-mir-136 Atherosclerosis 25411193 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Significant changes in genomic methylation were identified in atherosclerotic lesions. The most prominent gene cluster activated via hypomethylation was detected at imprinted chromosomal locus 14q32 with several clustered miRNAs that were up-regulated. These results suggest that epigenetic changes are involved in atherogenesis and may offer new potential therapeutic targets for vascular diseases. therapeutic target hsa-mir-144 Atherosclerosis 24733347 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Our findings clearly indicate that miR-144-3p is essential for the regulation of cholesterol homeostasis and inflammatory reactions, supporting its utility as a potential therapeutic target of atherosclerosis and a promising diagnostic biomarker of AMI. therapeutic target hsa-mir-145 Atherosclerosis 22965997 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 VSMC-specific overexpression of microRNA-145 is a novel in vivo therapeutic target to limit atherosclerotic plaque morphology and cellular composition, shifting the balance toward plaque stability vs plaque rupture. therapeutic target hsa-mir-146a Atherosclerosis 21511256 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Finding important factors that regulate endothelial cell senescence, like miR-146a, will help provide novel therapeutic strategies for vascular disorders. therapeutic target hsa-mir-146a Atherosclerosis 26956647 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 delivery of microRNA (miR)-146a and miR-181b with an E-selectin-targeting multistage vector (ESTA-MSV) to inflamed endothelium covering atherosclerotic plaques inhibits atherosclerosis therapeutic target hsa-mir-155 Atherosclerosis 24675724 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Our findings reveal a new regulatory pathway of YY1/HDACs/miR-155/HBP1 in macrophage-derived foam cell formation during early atherogenesis and suggest that miR-155 is a potential therapeutic target for atherosclerosis. therapeutic target hsa-mir-155 Atherosclerosis 25450610 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 we will discuss novel aspects of miR-mediated regulatory mechanisms, namely the regulation by competing RNA targets, miRNA tandems, or complementary miR strand pairs, as well as their potential diagnostic and therapeutic value in atherosclerosis. This article is part of a Special Issue entitled 'Non-coding RNAs'. therapeutic target hsa-mir-181b Atherosclerosis 26956647 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 delivery of microRNA (miR)-146a and miR-181b with an E-selectin-targeting multistage vector (ESTA-MSV) to inflamed endothelium covering atherosclerotic plaques inhibits atherosclerosis therapeutic target hsa-mir-21 Atherosclerosis 25755729 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 These findings may help the development of strategies to enhance the vitality of EPCs for therapeutic applications. therapeutic target hsa-mir-21 Atherosclerosis 29228671 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 our results demonstrated that metformin improved IRSM by inhibiting miR-21 expression, and that miR-21 may be one of the therapeutic targets for IR therapeutic target hsa-mir-221 Atherosclerosis 25893733 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 These findings suggest that manipulation of the miR-221/222-Ets-1-p21 pathway may offer a novel strategy for treatment of endothelial apoptosis and atherosclerosis. therapeutic target hsa-mir-221 Atherosclerosis 22138289 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 The opposite cellular effects of miR-221/222 on VSMCs and ECs may have important therapeutic applications in many vascular diseases such as atherosclerosis and restenosis after angioplasty. therapeutic target hsa-mir-222 Atherosclerosis 25893733 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 These findings suggest that manipulation of the miR-221/222-Ets-1-p21 pathway may offer a novel strategy for treatment of endothelial apoptosis and atherosclerosis. therapeutic target hsa-mir-222 Atherosclerosis 22138289 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 The opposite cellular effects of miR-221/222 on VSMCs and ECs may have important therapeutic applications in many vascular diseases such as atherosclerosis and restenosis after angioplasty. therapeutic target hsa-mir-24 Atherosclerosis 24990232 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Taken together, our data demonstrates that downregulation of microRNA-24 promotes an invasive macrophage subset and plays a novel regulatory role in MMP-14 proteolytic activity and, therefore, plaque stability,highlighting its therapeutic potential. therapeutic target hsa-mir-29b Atherosclerosis 25131924 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 The effect of miR-29b on endothelial permeability and apoptosis is mediated through the down-regulation of MT1. Thus, miR-29b may be a new therapeutic target for atherosclerosis. therapeutic target hsa-mir-302a Atherosclerosis 25524771 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 miR-302a as a novel modulator of cholesterol efflux and a potential therapeutic target for suppressing atherosclerosis. therapeutic target hsa-mir-33a Atherosclerosis 26645139 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 This review summarizes the current understanding of the functions of miR-33a/b and the progress in miRNA therapeutics for treatment of various diseases, including atherosclerosis. therapeutic target hsa-mir-33b Atherosclerosis 26645139 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 This review summarizes the current understanding of the functions of miR-33a/b and the progress in miRNA therapeutics for treatment of various diseases, including atherosclerosis. therapeutic target hsa-mir-378 Atherosclerosis 24675662 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 This study identified activator protein-1/miR-378/ATP-binding cassette transporter G1 as a novel cascade for CoQ10 in facilitating macrophage cholesterol efflux in vitro and in vivo. Our data thus imply that both CoQ10 and miR-378 are promising candidates for atherosclerosis prevention and treatment. therapeutic target hsa-mir-382 Atherosclerosis 25265644 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Our findings indicated that the RP5-833A20.1/miR-382-5p/NFIA pathway was essential to the regulation of cholesterol homeostasis and inflammatory reactions and suggested that NFIA may represent a therapeutic target to ameliorate cardiovascular disease. therapeutic target hsa-mir-410 Atherosclerosis 25411193 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Significant changes in genomic methylation were identified in atherosclerotic lesions. The most prominent gene cluster activated via hypomethylation was detected at imprinted chromosomal locus 14q32 with several clustered miRNAs that were up-regulated. These results suggest that epigenetic changes are involved in atherogenesis and may offer new potential therapeutic targets for vascular diseases. therapeutic target hsa-mir-431 Atherosclerosis 25411193 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Significant changes in genomic methylation were identified in atherosclerotic lesions. The most prominent gene cluster activated via hypomethylation was detected at imprinted chromosomal locus 14q32 with several clustered miRNAs that were up-regulated. These results suggest that epigenetic changes are involved in atherogenesis and may offer new potential therapeutic targets for vascular diseases. therapeutic target hsa-mir-432 Atherosclerosis 25411193 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Significant changes in genomic methylation were identified in atherosclerotic lesions. The most prominent gene cluster activated via hypomethylation was detected at imprinted chromosomal locus 14q32 with several clustered miRNAs that were up-regulated. These results suggest that epigenetic changes are involved in atherogenesis and may offer new potential therapeutic targets for vascular diseases. therapeutic target hsa-mir-433 Atherosclerosis 25411193 cardiovascular system disease DOID:1936 I70 D050197 108725 HP:0002621 Significant changes in genomic methylation were identified in atherosclerotic lesions. The most prominent gene cluster activated via hypomethylation was detected at imprinted chromosomal locus 14q32 with several clustered miRNAs that were up-regulated. These results suggest that epigenetic changes are involved in atherogenesis and may offer new potential therapeutic targets for vascular diseases. therapeutic target hsa-mir-106b Atrial Fibrillation 25389315 cardiovascular system disease DOID:0060224 I48.0 D001281 PS608583 HP:0005110 miR-106b-25 cluster-mediated post-transcriptional regulation of RyR2 is a potential molecular mechanism involved in paroxysmal AF pathogenesis. As such, the miR-106b-25 cluster could be a novel gene-therapy target in AF associated with enhanced RyR2 expression. therapeutic target hsa-mir-25 Atrial Fibrillation 25389315 cardiovascular system disease DOID:0060224 I48.0 D001281 PS608583 HP:0005110 miR-106b-25 cluster-mediated post-transcriptional regulation of RyR2 is a potential molecular mechanism involved in paroxysmal AF pathogenesis. As such, the miR-106b-25 cluster could be a novel gene-therapy target in AF associated with enhanced RyR3 expression therapeutic target hsa-mir-93 Atrial Fibrillation 25389315 cardiovascular system disease DOID:0060224 I48.0 D001281 PS608583 HP:0005110 miR-106b-25 cluster-mediated post-transcriptional regulation of RyR2 is a potential molecular mechanism involved in paroxysmal AF pathogenesis. As such, the miR-106b-25 cluster could be a novel gene-therapy target in AF associated with enhanced RyR4 expression therapeutic target hsa-mir-150 Autoimmune Diseases [unspecific] 26287504 D001327 607836 HP:0002960 Though much remains to be explored about the roles of miR-150 in pathogenic infection and autoimmune diseases, targeting miR-150 may serve as a promising therapy strategy. therapeutic target hsa-mir-30a Autoimmune Diseases [unspecific] 26376209 D001327 607836 HP:0002960 Thus, we concluded that the downregulation of miR-30a in autoimmune diseases may exacerbate IL-17-mediated inflammation, which may serve as a potential target for the therapy of these diseases. therapeutic target hsa-mir-146a Autoimmune Lymphoproliferative Syndrome 23645835 immune system disease DOID:6688 D89.82 D056735 PS308240 These results indicate that miR-146a may be involved in the pathogenesis of ALPS by targeting Fas and may therefore serve as a novel therapeutic target. therapeutic target hsa-mir-21 Biliary Atresia 25487473 gastrointestinal system disease DOID:13608 Q44.2 D001656 210500 The miRNA-21/PTEN/AKT axis promotes the fibrosis process in BA, which might be a potential therapeutic target to improve the prognosis of patients with BA. therapeutic target hsa-mir-132 Bipolar Disorder 25708817 disease of mental health DOID:3312 F31 D001714 HP:0007302 our observation of altered miRNA expression in the blood prior to the onset of illness provides hope that one day blood-based tests may aid in the risk-stratification and treatment of BD. therapeutic target hsa-mir-134 Bipolar Disorder 20546789 disease of mental health DOID:3312 F31 D001714 HP:0007302 Plasma miRNA-134 in BD may be considered as a potential peripheral marker that can respond to acute manic episodes and associate with effective mood stabilizers treatment. therapeutic target hsa-mir-15b Bipolar Disorder 25708817 disease of mental health DOID:3312 F31 D001714 HP:0007302 our observation of altered miRNA expression in the blood prior to the onset of illness provides hope that one day blood-based tests may aid in the risk-stratification and treatment of BD. therapeutic target hsa-mir-206 Bipolar Disorder 24767015 disease of mental health DOID:3312 F31 D001714 HP:0007302 Our findings provide initial evidence of the gene-to-gene interaction of MIR206 and BDNF in regards to the risk for BD-I as well as treatment response to mood stabilizers. therapeutic target hsa-mir-652 Bipolar Disorder 25708817 disease of mental health DOID:3312 F31 D001714 HP:0007302 our observation of altered miRNA expression in the blood prior to the onset of illness provides hope that one day blood-based tests may aid in the risk-stratification and treatment of BD. therapeutic target hsa-mir-133 Bladder Fibrosis 25451078 A novel antifibrotic functional role for miR-133 is presented which may represent a potential target for diagnostic and therapeutic strategies in bladder fibrosis. therapeutic target hsa-mir-106b Bladder Neoplasms 25955758 C67 D001749 109800 HP:0009725 DE-miRNAs in bladder cancer tissue samples and DE-targeted genes, such as miR-106b and CDKN2A, which were identified in the present study, may provide the basis for targeted therapy for breast cancer and enhance understanding of its pathogenesis. therapeutic target hsa-mir-1182 Bladder Neoplasms 26772886 C67 D001749 109800 HP:0009725 In conclusion, these results demonstrate that miR-1182 acts as a tumor suppressor and may be a potential biomarker for bladder cancer diagnosis and treatment. therapeutic target hsa-mir-125b Bladder Neoplasms 25955758 C67 D001749 109800 HP:0009725 DE-miRNAs in bladder cancer tissue samples and DE-targeted genes, such as miR-106b and CDKN2A, which were identified in the present study, may provide the basis for targeted therapy for breast cancer and enhance understanding of its pathogenesis. therapeutic target hsa-mir-145 Bladder Neoplasms 24954107 C67 D001749 109800 HP:0009725 Our results indicate that miR-145 inhibits bladder cancer cell invasion, at least partly through targeting PAK1. Restoration or replacement of miR-145 could be an efficient approach to inhibit PAK1 and bladder cancer development in the tumor therapy. therapeutic target hsa-mir-145 Bladder Neoplasms 26318860 C67 D001749 109800 HP:0009725 In summary, our data indicated that blocking TUG1 function may be an effective anti-cancer therapy. therapeutic target hsa-mir-145 Bladder Neoplasms 26544536 C67 D001749 109800 HP:0009725 Taken together, our results identified that lncRNA-UCA1 enhances bladder cancer cell migration and invasion in part through the hsa-miR-145/ZEB1/2/FSCN1 pathway. Therefore, lncRNA-UCA1 might act as a promising therapeutic target for the invasion and metastasis of bladder cancer. therapeutic target hsa-mir-150 Bladder Neoplasms 25287716 C67 D001749 109800 HP:0009725 This study provides novel evidence that miR-150 functions as a tumor promoter in reducing chemosensitivity and promoting invasiveness of MIBC cells via targeting PDCD4. Thus, modulation of the miR-150-PDCD4 axis shows promise as a therapeutic strategy for MIBC. therapeutic target hsa-mir-186 Bladder Neoplasms 26290438 C67 D001749 109800 HP:0009725 Our data first time identified miR-186 as the upstream regulator of NSBP1 and also suggest miR-186-suppressed NSBP1 as a novel therapeutic approach for bladder cancer. therapeutic target hsa-mir-193a Bladder Neoplasms 25542424 C67 D001749 109800 HP:0009725 the key players in this microRNA-193a-3p/PSEN1 axis are likely the diagnostic and/or therapeutic targets for an effective chemotherapy of bladder cancer. therapeutic target hsa-mir-19a Bladder Neoplasms 20857258 C67 D001749 109800 HP:0009725 The synergy effect between miRNA-19a and arsenic trioxide that advocates targeting the mir-19a may represent a potential approach to enhance the efficacy and safety of ATO to treat bladder cancer by a decrease in dose. therapeutic target hsa-mir-205 Bladder Neoplasms 26469956 C67 D001749 109800 HP:0009725 This study elucidates an important role that miR-205 had in the regulation of proliferation,migration and invasion of bladder cancer cells, suggesting a potential therapeutic target for combating bladder cancer. therapeutic target hsa-mir-26a Bladder Neoplasms 25455159 C67 D001749 109800 HP:0009725 Tumors with miR-26a downregulation in combination with high expression of HMGA1 showed a worse prognosis than the other tumors. Combined detection of their expression might be particularly helpful for surveillance of disease progression and treatment stratification. therapeutic target hsa-mir-27a Bladder Neoplasms 24516043 C67 D001749 109800 HP:0009725 Our findings indicate that miRNA-27a negatively regulates SLC7A11 in cisplatin-resistant bladder cancer, and shows promise as a marker for patients likely to benefit from cisplatin-based chemotherapy. SLC7A11 inhibition with sulfasalazine may be a promising therapeutic approach to the treatment of cisplatin-resistant disease. therapeutic target hsa-mir-29 Bladder Neoplasms 26471361 C67 D001749 109800 HP:0009725 Taken together, our findings established a role for ATDC as a robust pathogenic driver of bladder cancer identified downstream effector pathways, and implicated ATDC as a candidatedevelopment,biomarker and therapeutic target. therapeutic target hsa-mir-320c Bladder Neoplasms 25178497 C67 D001749 109800 HP:0009725 miR-320c could inhibit the proliferation, migration and invasion of bladder cancer cells via regulating CDK6. Our study revealed that miR-320c could be a therapeutic biomarker of bladder cancer in the future. therapeutic target hsa-mir-34a Bladder Neoplasms 25556547 C67 D001749 109800 HP:0009725 the need for further clinical studies of miR-34a as a guide for recurrence screening and as a possible candidate therapeutic target in the bladder. therapeutic target hsa-mir-34a Bladder Neoplasms 25551284 C67 D001749 109800 HP:0009725 a major metastasis and angiogenesis suppressive role for mir-34a, a microRNA functions as a tumor suppressor in bladder cancer by directly targeting CD44, which would be helpful as a therapeutic approach to block bladder cancer metastasis. therapeutic target hsa-mir-542 Bladder Neoplasms 26723509 C67 D001749 109800 HP:0009725 MiR-542-3p and its target gene survivin may play crucial roles in the aggressive progression of human bladder cancer. More interestingly, miR-542-3p may function as a tumor suppressor and inhibit the proliferation of bladder cancer cells, implying that miR-542-3p-survivin signal axis might be a novel therapeutic target of this disease. therapeutic target hsa-mir-378 Bone Disease [unspecific] 29686962 musculoskeletal system disease DOID:0080001 M89.9 D001847 miR378 was an ideal target to osteogenesis-angiogenesis coupling for bone regeneration, which provides a potential tool for the gene therapy of bone regeneration. therapeutic target hsa-let-7a Brain Neoplasms 24947843 disease of cellular proliferation DOID:1319 C71 D001932 603688 HP:0030692 Combined magnetic nanoparticle-based microRNA and hyperthermia therapy to enhance apoptosis in brain cancer cells. therapeutic target hsa-mir-221 Brain Neoplasms 20012062 disease of cellular proliferation DOID:1319 C71 D001932 603688 HP:0030692 As anti-miR therapy was recently proposed as an alternative treatment for cancer, these findings suggest that anti-miR-221/222 therapy might have therapeutic potential in ATRT. therapeutic target hsa-mir-222 Brain Neoplasms 20012062 disease of cellular proliferation DOID:1319 C71 D001932 603688 HP:0030692 As anti-miR therapy was recently proposed as an alternative treatment for cancer, these findings suggest that anti-miR-221/222 therapy might have therapeutic potential in ATRT. therapeutic target hsa-mir-326 Brain Neoplasms 19955368 disease of cellular proliferation DOID:1319 C71 D001932 603688 HP:0030692 The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors therapeutic target hsa-mir-34a Brain Neoplasms 25250818 disease of cellular proliferation DOID:1319 C71 D001932 603688 HP:0030692 Mir-34a mimics are potential therapeutic agents for p53-mutated and chemo-resistant brain tumour cells. therapeutic target hsa-let-7 Breast Neoplasms 26717565 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Taken together, these findings provide evidence that a miRNA expression signature can be developed to aid existing methods to determine the risk of recurrence for women with estrogen receptor positive breast cancers treated with endocrine therapy. therapeutic target hsa-let-7 Breast Neoplasms 29336465 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 the findings identified a biochemical and functional link between Let-7 and endocrine therapy in breast CSCs therapeutic target hsa-let-7e Breast Neoplasms 25451164 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 we identified 10 dysregulated miRNAs in both breast cancer cells and chemoresistant tissues, which might be biomarkers for the prognosis of breast cancer chemoresistance. Our study contributes to a comprehensive understanding of prognostic biomarkers during clinical treatment, and we hypothesize that the miRNA signatures of drug-resistant carcinoma tissues could be useful for developing new strategies for targeted therapies in patients with chemoresistant breast cancer. therapeutic target hsa-mir-100 Breast Neoplasms 25537513 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 aggressive breast cancers responsive to standard treatments. therapeutic target hsa-mir-103 Breast Neoplasms 25547678 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 This signature may serve as a minimally invasive predictor of tumor relapse and overall survival for patients with TNBC. This prediction model may ultimately lead to better treatment options for patients with TNBC. therapeutic target hsa-mir-106a Breast Neoplasms 25883093 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our results confirm that TNBC has a unique metabolic profile that may be exploited for therapeutic intervention. therapeutic target hsa-mir-107 Breast Neoplasms 25547678 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 This signature may serve as a minimally invasive predictor of tumor relapse and overall survival for patients with TNBC. This prediction model may ultimately lead to better treatment options for patients with TNBC. therapeutic target hsa-mir-10b Breast Neoplasms 25428807 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 a set of specific microRNAs may play an important role in modulating tumor microenvironment through exosomes.Thus, a better understanding of this process may aid in the development of novel therapeutic agents. therapeutic target hsa-mir-10b Breast Neoplasms 25596707 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miRNA-10b and MCM5 mRNA as prognostic markers and potential therapeutic targets in breast cancer to be applied to other patient data sets. therapeutic target hsa-mir-10b Breast Neoplasms 26206152 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 We propose miR-10b-HDAC4 nexus as one of the molecular mechanism of tamoxifen resistance which can potentially be expolited as a novel targeted therapeutic approach for the clinical management of tamoxifen-resistant breast cancers. therapeutic target hsa-mir-10b Breast Neoplasms 21067538 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 In particular, recent studies provide the first functional evidence that overexpression of a specific miRNA, miR-10b, can contribute to the development of metastasis, which can be exploited herapeutically in treating breast cancer metastasis in mice. therapeutic target hsa-mir-1207 Breast Neoplasms 25047087 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The study suggests that breast cancer in very young women appears as a distinct molecular signature. To our knowledge, this is the first time that a validated microRNA profile, distinctive to breast cancer in very young women, has been presented. The miRNA signature may be relevant to open an important field of research in order to elucidate the underlying mechanism in this particular disease, which in a more clinical setting, could potentially help to identify therapeutic targets in this particular set of patients. therapeutic target hsa-mir-1207 Breast Neoplasms 25954907 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The miRNA profile changes demonstrated in this study provide a data set regarding their effects on the pathways that regulate telomerase activity in MCF-7 breast cancer cells treated with G. lucidum. These data should aid the development of novel cancer treatment strategies. therapeutic target hsa-mir-1228 Breast Neoplasms 25047087 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The study suggests that breast cancer in very young women appears as a distinct molecular signature. To our knowledge, this is the first time that a validated microRNA profile, distinctive to breast cancer in very young women, has been presented. The miRNA signature may be relevant to open an important field of research in order to elucidate the underlying mechanism in this particular disease, which in a more clinical setting, could potentially help to identify therapeutic targets in this particular set of patients. therapeutic target hsa-mir-1228 Breast Neoplasms 26261546 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Taken together, this study provides evidences that miR-1228 serves as an oncogene to promote breast cancer proliferation, invasion and migration, which may become a critical therapeutic target for breast cancer treatment. therapeutic target hsa-mir-124 Breast Neoplasms 27266580 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-124-M-Oba may have potential applications in breast cancer therapy. therapeutic target hsa-mir-125b Breast Neoplasms 25633049 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-125b is a new biomarker of poor prognosis and a candidate therapeutic target in AI-resistant breast cancers. therapeutic target hsa-mir-125b Breast Neoplasms 25883093 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our results confirm that TNBC has a unique metabolic profile that may be exploited for therapeutic intervention. therapeutic target hsa-mir-125b Breast Neoplasms 25894378 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The role of miR-125b-mitochondria-caspase-3 pathway in doxorubicin resistance and therapy in human breast cancer. therapeutic target hsa-mir-125b Breast Neoplasms 26335100 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our data suggest a mechanism by which CT-Cx43 may regulate cell proliferation. Targeting of CT-Cx43 and/or miR-125b may be instrumental for therapeutic intervention in human breast cancer. therapeutic target hsa-mir-125b-1 Breast Neoplasms 25451164 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 we identified 10 dysregulated miRNAs in both breast cancer cells and chemoresistant tissues, which might be biomarkers for the prognosis of breast cancer chemoresistance. Our study contributes to a comprehensive understanding of prognostic biomarkers during clinical treatment, and we hypothesize that the miRNA signatures of drug-resistant carcinoma tissues could be useful for developing new strategies for targeted therapies in patients with chemoresistant breast cancer. therapeutic target hsa-mir-126 Breast Neoplasms 25844955 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The use of the TRA-miR-126 chimera or the combination of the delivery strategy with other endothelial or tumor specific aptamers may provide an interesting therapeutic option to treat vascular disease or cancers. therapeutic target hsa-mir-127 Breast Neoplasms 25477702 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 status of miR-127 was an independent prognostic factor for patients. Functional analyses showed that upregulation of miR-127 significantly inhibited growth, enhanced apoptosis, and reduced migration and invasion in BC cells by targeting the protooncogene BCL-6. Therefore, miR-127 may be a potential biomarker for predicting the survival of BC patients and might be a molecular target for treatment of human BCs. therapeutic target hsa-mir-1274a Breast Neoplasms 26581147 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Biomarkers of DNA repair and cell cycle control can identify patients at high risk of treatment failure in those receiving radiation therapy for early breast cancer in independent cohorts. These should be further investigated prospectively, especially TOP2A and SKP2, for which targeted therapies are available. therapeutic target hsa-mir-1275 Breast Neoplasms 25047087 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The study suggests that breast cancer in very young women appears as a distinct molecular signature. To our knowledge, this is the first time that a validated microRNA profile, distinctive to breast cancer in very young women, has been presented. The miRNA signature may be relevant to open an important field of research in order to elucidate the underlying mechanism in this particular disease, which in a more clinical setting, could potentially help to identify therapeutic targets in this particular set of patients. therapeutic target hsa-mir-1285 Breast Neoplasms 25954907 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The miRNA profile changes demonstrated in this study provide a data set regarding their effects on the pathways that regulate telomerase activity in MCF-7 breast cancer cells treated with G. lucidum. These data should aid the development of novel cancer treatment strategies. therapeutic target hsa-mir-129 Breast Neoplasms 26487539 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our findings suggest that miR-129-3p down-regulation potentially sensitizes breast cancer cells to docetaxel treatment. therapeutic target hsa-mir-135 Breast Neoplasms 25634212 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 aberrant expression of Runx2 in aggressive tumor cells is related to the loss of specific Runx2-targeting miRNAs and that a clinically relevant replacement strategy by delivery of synthetic miRNAs is a candidate for a therapeutic approach to prevent metastatic bone disease by this route. therapeutic target hsa-mir-135b Breast Neoplasms 25883093 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our results confirm that TNBC has a unique metabolic profile that may be exploited for therapeutic intervention. therapeutic target hsa-mir-137 Breast Neoplasms 26337822 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Moreover, we also found that carboxyl-terminal binding protein 1 (CtBP1) was a putative target gene of miR-137 in MCF-7 cells, and might be involved in the suppressive effects, which might provide novel diagnostic and therapeutic options for human breast cancer in the future. therapeutic target hsa-mir-139 Breast Neoplasms 25047087 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The study suggests that breast cancer in very young women appears as a distinct molecular signature. To our knowledge, this is the first time that a validated microRNA profile, distinctive to breast cancer in very young women, has been presented. The miRNA signature may be relevant to open an important field of research in order to elucidate the underlying mechanism in this particular disease, which in a more clinical setting, could potentially help to identify therapeutic targets in this particular set of patients. therapeutic target hsa-mir-139 Breast Neoplasms 26581147 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Biomarkers of DNA repair and cell cycle control can identify patients at high risk of treatment failure in those receiving radiation therapy for early breast cancer in independent cohorts. These should be further investigated prospectively, especially TOP2A and SKP2, for which targeted therapies are available. therapeutic target hsa-mir-141 Breast Neoplasms 25451164 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 we identified 10 dysregulated miRNAs in both breast cancer cells and chemoresistant tissues, which might be biomarkers for the prognosis of breast cancer chemoresistance. Our study contributes to a comprehensive understanding of prognostic biomarkers during clinical treatment, and we hypothesize that the miRNA signatures of drug-resistant carcinoma tissues could be useful for developing new strategies for targeted therapies in patients with chemoresistant breast cancer. therapeutic target hsa-mir-141 Breast Neoplasms 26095675 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-21, miR-155, miR-9, miR-34a, miR-143/145, and miR-31 were found to be altered in both CMTs and human breast cancer. These altered miRNAs might serve as potential targets for advancing the development of future therapeuticreagents. These findings further strengthen the validity and use of canine breast cancers as appropriate models for the study of human breast cancers. therapeutic target hsa-mir-143 Breast Neoplasms 26095675 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-21, miR-155, miR-9, miR-34a, miR-143/145, and miR-31 were found to be altered in both CMTs and human breast cancer. These altered miRNAs might serve as potential targets for advancing the development of future therapeuticreagents. These findings further strengthen the validity and use of canine breast cancers as appropriate models for the study of human breast cancers. therapeutic target hsa-mir-145 Breast Neoplasms 24517586 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Integrated analysis of microRNA, mRNA and ChIP-seq data in a model cell line supports the hypothesis that microRNA expression under hypoxia is regulated at transcriptional and post-transcriptional level, with the presence of HIF binding sites at microRNA genomic loci associated with up-regulation. The identification of hypoxia and HIF regulated microRNAs relevant for breast cancer is important for our understanding of disease development and design of therapeutic interventions. therapeutic target hsa-mir-145 Breast Neoplasms 25451164 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 we identified 10 dysregulated miRNAs in both breast cancer cells and chemoresistant tissues, which might be biomarkers for the prognosis of breast cancer chemoresistance. Our study contributes to a comprehensive understanding of prognostic biomarkers during clinical treatment, and we hypothesize that the miRNA signatures of drug-resistant carcinoma tissues could be useful for developing new strategies for targeted therapies in patients with chemoresistant breast cancer. therapeutic target hsa-mir-145 Breast Neoplasms 21723890 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Ad-miR-145 suppressed cell growth and motility in both the in vitro and in vivo systems. Furthermore, a treatment combining Ad-miR-145 with 5-FU significantly showed anti-tumor effects, compared to treating alone. therapeutic target hsa-mir-145 Breast Neoplasms 26095675 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-21, miR-155, miR-9, miR-34a, miR-143/145, and miR-31 were found to be altered in both CMTs and human breast cancer. These altered miRNAs might serve as potential targets for advancing the development of future therapeuticreagents. These findings further strengthen the validity and use of canine breast cancers as appropriate models for the study of human breast cancers. therapeutic target hsa-mir-146a Breast Neoplasms 25417703 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 a novel BRCA1miR-146aEGFR paradigm by which BRCA1 carries out an aspect of tumor suppressor function that is potentially amenable to therapeutic intervention. therapeutic target hsa-mir-146b Breast Neoplasms 26338965 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 These results show that miR-146b-5p has non-cell-autonomous tumor suppressor function through inhibition of IL-6, suggesting that targeting this microRNA in breast stromal fibroblasts could be of great therapeutic value. therapeutic target hsa-mir-155 Breast Neoplasms 21946536 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Mechanistically, we found that BRCA1 epigenetically represses miR-155 expression via its association with HDAC2, which deacetylates histones H2A and H3 on the miR-155 promoter. We show that overexpression of miR-155 accelerates but the knockdown of miR-155 attenuates the growth of tumor cell lines in vivo. Our findings demonstrate a new mode of tumor suppression by BRCA1 and suggest that miR-155 is a potential therapeutic target for BRCA1-deficient tumors. therapeutic target hsa-mir-155 Breast Neoplasms 26095675 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-21, miR-155, miR-9, miR-34a, miR-143/145, and miR-31 were found to be altered in both CMTs and human breast cancer. These altered miRNAs might serve as potential targets for advancing the development of future therapeuticreagents. These findings further strengthen the validity and use of canine breast cancers as appropriate models for the study of human breast cancers. therapeutic target hsa-mir-155 Breast Neoplasms 22652783 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 This review summarizes the signaling pathways that are regulated by miR-155 in breast cancer and discusses therapeutic possibilities related to miR-155. therapeutic target hsa-mir-15a Breast Neoplasms 26397135 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Together, our results suggest that overexpression of E2F7 represses miR-15a/16 and then increases Cyclin E1 and Bcl-2 that result in tamoxifen resistance. E2F7 may be a valuable prognostic marker and a therapeutic target of tamoxifen resistance in breast cancer. therapeutic target hsa-mir-15a Breast Neoplasms 29394261 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 modulatingspecific miRNAs may serve as a therapeutic approach for the treatment of breast cancer therapeutic target hsa-mir-16 Breast Neoplasms 26397135 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Together, our results suggest that overexpression of E2F7 represses miR-15a/16 and then increases Cyclin E1 and Bcl-2 that result in tamoxifen resistance. E2F7 may be a valuable prognostic marker and a therapeutic target of tamoxifen resistance in breast cancer. therapeutic target hsa-mir-182 Breast Neoplasms 26563369 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 downregulation of miR-182 might find therapeutical value for overcoming trastuzumab resistance. therapeutic target hsa-mir-182 Breast Neoplasms 21195000 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Together these results suggest that miR-182-mediated downregulation of BRCA1 impedes DNA repair and may impact breast cancer therapy. therapeutic target hsa-mir-18a Breast Neoplasms 25883093 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our results confirm that TNBC has a unique metabolic profile that may be exploited for therapeutic intervention. therapeutic target hsa-mir-18b Breast Neoplasms 25547678 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 This signature may serve as a minimally invasive predictor of tumor relapse and overall survival for patients with TNBC. This prediction model may ultimately lead to better treatment options for patients with TNBC. therapeutic target hsa-mir-190b Breast Neoplasms 25883093 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our results confirm that TNBC has a unique metabolic profile that may be exploited for therapeutic intervention. therapeutic target hsa-mir-193b Breast Neoplasms 26526790 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Together, our findings provide evidence that the modulation of miR-193b may represent a novel therapeutic target for the treatment of breast cancer. therapeutic target hsa-mir-195 Breast Neoplasms 24402230 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-195-5p is a potential diagnostic and therapeutic target for breast cancer. therapeutic target hsa-mir-195 Breast Neoplasms 21350001 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 both miR-195 and miR-497 play important inhibitory roles in breast cancer malignancy and may be the potential therapeutic and diagnostic targets. therapeutic target hsa-mir-196b Breast Neoplasms 25451164 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 we identified 10 dysregulated miRNAs in both breast cancer cells and chemoresistant tissues, which might be biomarkers for the prognosis of breast cancer chemoresistance. Our study contributes to a comprehensive understanding of prognostic biomarkers during clinical treatment, and we hypothesize that the miRNA signatures of drug-resistant carcinoma tissues could be useful for developing new strategies for targeted therapies in patients with chemoresistant breast cancer. therapeutic target hsa-mir-200a Breast Neoplasms 25451164 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 we identified 10 dysregulated miRNAs in both breast cancer cells and chemoresistant tissues, which might be biomarkers for the prognosis of breast cancer chemoresistance. Our study contributes to a comprehensive understanding of prognostic biomarkers during clinical treatment, and we hypothesize that the miRNA signatures of drug-resistant carcinoma tissues could be useful for developing new strategies for targeted therapies in patients with chemoresistant breast cancer. therapeutic target hsa-mir-200a Breast Neoplasms 21389093 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 these results suggest a role of miR-200s(miR-200a, miR-200b, and miR-200c) in PGI/AMF-induced EMT and thus approaches for upregulation of miR-200s could be a novel therapeutic strategy for the treatment of highly invasive breast cancer. therapeutic target hsa-mir-200b Breast Neoplasms 25639535 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-200b has potential to serve as prognostic biomarker and tumour suppressor for BC patients. As a direct and functional target of miR-200b, Sp1 and miR-200b both could be an exciting target for BC treatment strategy. therapeutic target hsa-mir-200b Breast Neoplasms 21389093 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 these results suggest a role of miR-200s(miR-200a, miR-200b, and miR-200c) in PGI/AMF-induced EMT and thus approaches for upregulation of miR-201s could be a novel therapeutic strategy for the treatment of highly invasive breast cancer. therapeutic target hsa-mir-200c Breast Neoplasms 25445393 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miRNA may provide novel therapeutic molecular targets for TNBC treatment and new directions for the development of anticancer drugs. therapeutic target hsa-mir-200c Breast Neoplasms 26392416 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our findings provide clues regarding the role of miR-200c as a tumor suppressor in breast cancer through the inhibition of KRAS translation both in vitro and in vivo. miR-200c could be a potential therapeutic target in breast cancer. therapeutic target hsa-mir-200c Breast Neoplasms 25451164 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 we identified 10 dysregulated miRNAs in both breast cancer cells and chemoresistant tissues, which might be biomarkers for the prognosis of breast cancer chemoresistance. Our study contributes to a comprehensive understanding of prognostic biomarkers during clinical treatment, and we hypothesize that the miRNA signatures of drug-resistant carcinoma tissues could be useful for developing new strategies for targeted therapies in patients with chemoresistant breast cancer. therapeutic target hsa-mir-200c Breast Neoplasms 21389093 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 these results suggest a role of miR-200s(miR-200a, miR-200b, and miR-200c) in PGI/AMF-induced EMT and thus approaches for upregulation of miR-202s could be a novel therapeutic strategy for the treatment of highly invasive breast cancer. therapeutic target hsa-mir-203 Breast Neoplasms 25634212 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 aberrant expression of Runx2 in aggressive tumor cells is related to the loss of specific Runx2-targeting miRNAs and that a clinically relevant replacement strategy by delivery of synthetic miRNAs is a candidate for a therapeutic approach to prevent metastatic bone disease by this route. therapeutic target hsa-mir-203 Breast Neoplasms 26278219 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our data thus highlight miR203 as a novel therapeutic target for breast cancer. therapeutic target hsa-mir-204 Breast Neoplasms 26656364 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our study reveals that Sam68 is regulated by miR-204 and may play an important role in the self-renewal of BCSCs via activating the Wnt/beta-catenin pathway. Sam68 may represent a novel therapeutic target for breast cancer. therapeutic target hsa-mir-205 Breast Neoplasms 25633049 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-125b is a new biomarker of poor prognosis and a candidate therapeutic target in AI-resistant breast cancers. therapeutic target hsa-mir-205 Breast Neoplasms 25883093 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our results confirm that TNBC has a unique metabolic profile that may be exploited for therapeutic intervention. therapeutic target hsa-mir-205 Breast Neoplasms 26181203 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance. therapeutic target hsa-mir-205 Breast Neoplasms 27064979 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Variations in serum miRNA levels during NAC treatment may be therapeutically significant for predicting response and survival outcomes. therapeutic target hsa-mir-206 Breast Neoplasms 25202071 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Decreased miR-206 expression in BRCA1 wild-type triple-negative breast cancer cells after concomitant treatment with gemcitabine and a Poly(ADP-ribose) polymerase-1 inhibitor. therapeutic target hsa-mir-20a Breast Neoplasms 29179464 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Therapy directed at uPAR-induced miR-17/20a is a potential option for breast cancer and TNBC therapeutic target hsa-mir-21 Breast Neoplasms 25958353 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 two miRNAs, miR-21 and miR-34, are discussed as the most promising targets for RNA-based therapy in non-invasive and invasive breast cancer, respectively.Finally, relevant and commercialized therapeutic strategies are highlighted. therapeutic target hsa-mir-21 Breast Neoplasms 26169933 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miRNA oligonucleotide and sponge for miRNA-21 inhibition mediated by PEI-PLL in breast cancer therapy. therapeutic target hsa-mir-21 Breast Neoplasms 26387181 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The regulation effects of DNA methylation by transient transfection of miR-21 in MCF-7 and MDA-MB-231 cells are almost opposite, whilst the expression of miR-21 in two cell lines were all upregulated by decreased DNA methylation level and our results may provide some experimental evidences for the future development of rational therapy for different breast cancer. therapeutic target hsa-mir-21 Breast Neoplasms 26452030 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Collectively, these data provide a rationale for using miR-21 expression as a biomarker to select trastuzumab-chemotherapy-resistant HER2-positive breast cancer patients who may benefit from treatments containing PI3K inhibitors or immunomodulatory drugs. therapeutic target hsa-mir-21 Breast Neoplasms 26676464 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Taken together, we provide novel evidence that miR-21 knockdown suppresses cell growth, migration and invasion partly by inhibiting PI3K/AKT activation via direct targeting PIK3R1 and reversing EMT in breast cancer. p85α downregulation defined a specific subgroup of breast cancer with shorter 5-year DFS and OS, which may require more aggressive treatment. therapeutic target hsa-mir-21 Breast Neoplasms 27064979 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Variations in serum miRNA levels during NAC treatment may be therapeutically significant for predicting response and survival outcomes. therapeutic target hsa-mir-21 Breast Neoplasms 26095675 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-21, miR-155, miR-9, miR-34a, miR-143/145, and miR-31 were found to be altered in both CMTs and human breast cancer. These altered miRNAs might serve as potential targets for advancing the development of future therapeuticreagents. These findings further strengthen the validity and use of canine breast cancers as appropriate models for the study of human breast cancers. therapeutic target hsa-mir-21 Breast Neoplasms 29567152 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 chemically modified miRNA-21 inhibitor based on gold nanoparticles would be as a promising diagnostic and therapeutic platform for breast cancer clinically therapeutic target hsa-mir-210 Breast Neoplasms 24517586 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Integrated analysis of microRNA, mRNA and ChIP-seq data in a model cell line supports the hypothesis that microRNA expression under hypoxia is regulated at transcriptional and post-transcriptional level, with the presence of HIF binding sites at microRNA genomic loci associated with up-regulation. The identification of hypoxia and HIF regulated microRNAs relevant for breast cancer is important for our understanding of disease development and design of therapeutic interventions. therapeutic target hsa-mir-214 Breast Neoplasms 25883093 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our results confirm that TNBC has a unique metabolic profile that may be exploited for therapeutic intervention. therapeutic target hsa-mir-214 Breast Neoplasms 26666173 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiR-214 increased the sensitivity of breast cancer cells to TAM and FUL through inhibition of autophagy by targeting UCP2. MiR-214 shows potential as a novel therapeutic strategy for overcoming endocrine resistance in ER(+) breast cancers. therapeutic target hsa-mir-214 Breast Neoplasms 27422604 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 In conclusion, miR-214 functions as a tumor suppressor by regulating the RFWD2-p53 cascade, thus delivery of miR-214 analogs could be a potential adjunct therapy in breast cancer harboring wild type p53. therapeutic target hsa-mir-218 Breast Neoplasms 25394901 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-218 has a significant function in the development of cisplatin resistance in breast cancer. Restoring miR-218 expression may constitute a novel therapeutic approach by which to increase cisplatin sensitivity in breast cancer. therapeutic target hsa-mir-221 Breast Neoplasms 24129242 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 This study demonstrates a significant role for highly expressed miR-221/-222 in advanced breast cancers allowing for the identification of significantly different prognostic groups, particularly for HER2-positive and lymph-node-positive breast cancers. Considering that miR-221/-222 are strongly involved in cell invasion, these miRNAs may be promising markers for breast cancer prognosis and therapy. therapeutic target hsa-mir-221 Breast Neoplasms 25797271 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 These results demonstrate a direct and positive regulation of the secreted uPAR isoform 2 by miR-221, increasing its protein expression, a prerequisite for malignancy, while the other uPAR isoforms (1, 3 and 4) are indirectly regulated through miR-10b and miR-221/-222. By targeting uPAR isoforms and/or miRNA-221/-222, the diagnosis and therapy of breast cancer, in particular in TNBC, could be significantly improved. therapeutic target hsa-mir-221 Breast Neoplasms 26253160 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-221 is a potential biomarker for predicting the survival of BC patients and may be a molecular therapeutic target for BC. therapeutic target hsa-mir-222 Breast Neoplasms 24129242 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 This study demonstrates a significant role for highly expressed miR-221/-222 in advanced breast cancers allowing for the identification of significantly different prognostic groups, particularly for HER2-positive and lymph-node-positive breast cancers. Considering that miR-221/-222 are strongly involved in cell invasion, these miRNAs may be promising markers for breast cancer prognosis and therapy. therapeutic target hsa-mir-222 Breast Neoplasms 24517586 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Integrated analysis of microRNA, mRNA and ChIP-seq data in a model cell line supports the hypothesis that microRNA expression under hypoxia is regulated at transcriptional and post-transcriptional level, with the presence of HIF binding sites at microRNA genomic loci associated with up-regulation. The identification of hypoxia and HIF regulated microRNAs relevant for breast cancer is important for our understanding of disease development and design of therapeutic interventions. therapeutic target hsa-mir-222 Breast Neoplasms 27282281 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 downregulation of miR-222 in MCF-7/Adr increased sensitivity to Adr and Adr-induced apoptosis therapeutic target hsa-mir-224 Breast Neoplasms 26701615 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our results indicate that FUT4 and miR-224-3p are crucial regulators of cancer response to chemotherapy, and may serve as therapeutic targets to reverse chemotherapy resistance in breast cancer. therapeutic target hsa-mir-23a Breast Neoplasms 24517586 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Integrated analysis of microRNA, mRNA and ChIP-seq data in a model cell line supports the hypothesis that microRNA expression under hypoxia is regulated at transcriptional and post-transcriptional level, with the presence of HIF binding sites at microRNA genomic loci associated with up-regulation. The identification of hypoxia and HIF regulated microRNAs relevant for breast cancer is important for our understanding of disease development and design of therapeutic interventions. therapeutic target hsa-mir-24 Breast Neoplasms 24517586 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Integrated analysis of microRNA, mRNA and ChIP-seq data in a model cell line supports the hypothesis that microRNA expression under hypoxia is regulated at transcriptional and post-transcriptional level, with the presence of HIF binding sites at microRNA genomic loci associated with up-regulation. The identification of hypoxia and HIF regulated microRNAs relevant for breast cancer is important for our understanding of disease development and design of therapeutic interventions. therapeutic target hsa-mir-24-2 Breast Neoplasms 24517586 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Integrated analysis of microRNA, mRNA and ChIP-seq data in a model cell line supports the hypothesis that microRNA expression under hypoxia is regulated at transcriptional and post-transcriptional level, with the presence of HIF binding sites at microRNA genomic loci associated with up-regulation. The identification of hypoxia and HIF regulated microRNAs relevant for breast cancer is important for our understanding of disease development and design of therapeutic interventions. therapeutic target hsa-mir-26b Breast Neoplasms 25536365 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 ANXA1-regulated miR26b* and miR562 may play a role in wound healing and tumor-induced endothelial cell tube formation by targeting NF-κB expression and point towards a potential therapeutic target for breast cancer. therapeutic target hsa-mir-27a Breast Neoplasms 24517586 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Integrated analysis of microRNA, mRNA and ChIP-seq data in a model cell line supports the hypothesis that microRNA expression under hypoxia is regulated at transcriptional and post-transcriptional level, with the presence of HIF binding sites at microRNA genomic loci associated with up-regulation. The identification of hypoxia and HIF regulated microRNAs relevant for breast cancer is important for our understanding of disease development and design of therapeutic interventions. therapeutic target hsa-mir-27a Breast Neoplasms 25954907 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The miRNA profile changes demonstrated in this study provide a data set regarding their effects on the pathways that regulate telomerase activity in MCF-7 breast cancer cells treated with G. lucidum. These data should aid the development of novel cancer treatment strategies. therapeutic target hsa-mir-27a Breast Neoplasms 26592661 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our findings provide a novel anti-tumor mechanism of ATO involved in miR-27a for the treatment of breast cancer. therapeutic target hsa-mir-301a Breast Neoplasms 25883093 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our results confirm that TNBC has a unique metabolic profile that may be exploited for therapeutic intervention. therapeutic target hsa-mir-302a Breast Neoplasms 25030358 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-302a mimics are potential therapeutic agents for breast cancer metastasis. therapeutic target hsa-mir-302b Breast Neoplasms 26744520 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Collectively, our findings reveal new insights underlying increased breast cancer mortality in obese individuals and provide a novel preclinical rationale to test the efficacy of Src inhibitors for breast cancer treatment. therapeutic target hsa-mir-30b Breast Neoplasms 24517586 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Integrated analysis of microRNA, mRNA and ChIP-seq data in a model cell line supports the hypothesis that microRNA expression under hypoxia is regulated at transcriptional and post-transcriptional level, with the presence of HIF binding sites at microRNA genomic loci associated with up-regulation. The identification of hypoxia and HIF regulated microRNAs relevant for breast cancer is important for our understanding of disease development and design of therapeutic interventions. therapeutic target hsa-mir-30d Breast Neoplasms 24517586 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Integrated analysis of microRNA, mRNA and ChIP-seq data in a model cell line supports the hypothesis that microRNA expression under hypoxia is regulated at transcriptional and post-transcriptional level, with the presence of HIF binding sites at microRNA genomic loci associated with up-regulation. The identification of hypoxia and HIF regulated microRNAs relevant for breast cancer is important for our understanding of disease development and design of therapeutic interventions. therapeutic target hsa-mir-31 Breast Neoplasms 25451164 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 we identified 10 dysregulated miRNAs in both breast cancer cells and chemoresistant tissues, which might be biomarkers for the prognosis of breast cancer chemoresistance. Our study contributes to a comprehensive understanding of prognostic biomarkers during clinical treatment, and we hypothesize that the miRNA signatures of drug-resistant carcinoma tissues could be useful for developing new strategies for targeted therapies in patients with chemoresistant breast cancer. therapeutic target hsa-mir-31 Breast Neoplasms 26095675 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-21, miR-155, miR-9, miR-34a, miR-143/145, and miR-31 were found to be altered in both CMTs and human breast cancer. These altered miRNAs might serve as potential targets for advancing the development of future therapeuticreagents. These findings further strengthen the validity and use of canine breast cancers as appropriate models for the study of human breast cancers. therapeutic target hsa-mir-3196 Breast Neoplasms 25047087 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The study suggests that breast cancer in very young women appears as a distinct molecular signature. To our knowledge, this is the first time that a validated microRNA profile, distinctive to breast cancer in very young women, has been presented. The miRNA signature may be relevant to open an important field of research in order to elucidate the underlying mechanism in this particular disease, which in a more clinical setting, could potentially help to identify therapeutic targets in this particular set of patients. therapeutic target hsa-mir-3200 Breast Neoplasms 27064979 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Variations in serum miRNA levels during NAC treatment may be therapeutically significant for predicting response and survival outcomes. therapeutic target hsa-mir-331 Breast Neoplasms 25883093 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our results confirm that TNBC has a unique metabolic profile that may be exploited for therapeutic intervention. therapeutic target hsa-mir-34 Breast Neoplasms 25958353 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 two miRNAs, miR-21 and miR-34, are discussed as the most promising targets for RNA-based therapy in non-invasive and invasive breast cancer, respectively.Finally, relevant and commercialized therapeutic strategies are highlighted. therapeutic target hsa-mir-34 Breast Neoplasms 19421141 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 These observations confirm that mir-34 is required for a normal cellular response to DNA damage in vivo resulting in altered cellular survival post-irradiation, and point to a potential therapeutic use for anti-miR-34 as a radiosensitizing agent in p53-mutant breast cancer. therapeutic target hsa-mir-340 Breast Neoplasms 26573744 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 In brief, miR-340 plays an important role in breast cancer progression. Thus, miR-340 may be further explored as a novel biomarker for breast cancer metastasis and prognosis,and potentially a therapeutic target. therapeutic target hsa-mir-342 Breast Neoplasms 25883093 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our results confirm that TNBC has a unique metabolic profile that may be exploited for therapeutic intervention. therapeutic target hsa-mir-345 Breast Neoplasms 25883093 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our results confirm that TNBC has a unique metabolic profile that may be exploited for therapeutic intervention. therapeutic target hsa-mir-34a Breast Neoplasms 25173798 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7 in breast cancer. therapeutic target hsa-mir-34a Breast Neoplasms 25396727 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 DADS could be a promising anticancer agent for breast cancer. miR-34a may also demonstrate a potential gene therapy agent that could enhance the antitumor effects of DADS. therapeutic target hsa-mir-34a Breast Neoplasms 26095675 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-21, miR-155, miR-9, miR-34a, miR-143/145, and miR-31 were found to be altered in both CMTs and human breast cancer. These altered miRNAs might serve as potential targets for advancing the development of future therapeuticreagents. These findings further strengthen the validity and use of canine breast cancers as appropriate models for the study of human breast cancers. therapeutic target hsa-mir-363 Breast Neoplasms 25416050 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-363 was a negative regulator of Mcl-1 expression, and the combination of miR-363 and cisplatin may be a novel approach in the treatment for breast cancer. therapeutic target hsa-mir-3648 Breast Neoplasms 26717565 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Taken together, these findings provide evidence that a miRNA expression signature can be developed to aid existing methods to determine the risk of recurrence for women with estrogen receptor positive breast cancers treated with endocrine therapy. therapeutic target hsa-mir-3687 Breast Neoplasms 25954907 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The miRNA profile changes demonstrated in this study provide a data set regarding their effects on the pathways that regulate telomerase activity in MCF-7 breast cancer cells treated with G. lucidum. These data should aid the development of novel cancer treatment strategies. therapeutic target hsa-mir-370 Breast Neoplasms 25451164 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 we identified 10 dysregulated miRNAs in both breast cancer cells and chemoresistant tissues, which might be biomarkers for the prognosis of breast cancer chemoresistance. Our study contributes to a comprehensive understanding of prognostic biomarkers during clinical treatment, and we hypothesize that the miRNA signatures of drug-resistant carcinoma tissues could be useful for developing new strategies for targeted therapies in patients with chemoresistant breast cancer. therapeutic target hsa-mir-375 Breast Neoplasms 25883093 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our results confirm that TNBC has a unique metabolic profile that may be exploited for therapeutic intervention. therapeutic target hsa-mir-377 Breast Neoplasms 26717565 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Taken together, these findings provide evidence that a miRNA expression signature can be developed to aid existing methods to determine the risk of recurrence for women with estrogen receptor positive breast cancers treated with endocrine therapy. therapeutic target hsa-mir-378a Breast Neoplasms 25268374 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Downregulation of Aurora B by excess miR-378a-5p can explain the observed microtubule drug resistance and increased chromosomal imbalance in the microRNA overexpressing cells. The results suggest that breast tumours may deploy high miR-378a-5p levels to gain growth advantage and antagonise taxane therapy. therapeutic target hsa-mir-381 Breast Neoplasms 26450928 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Therefore we are the first to identify that miR-381 suppresses C/EBPα-dependent Cx43 expression in breast cancer cells. The miR-381-C/EBPα-Cx43 axis might be a useful diagnostic and therapeutic target of metastatic breast cancer. therapeutic target hsa-mir-409 Breast Neoplasms 26631969 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our data collectively indicate that miR-409-3p functions as a tumor suppressor in BC through downregulating Akt1, supporting the targeting of the novel miR-409-3p/Akt1 axis as a potentially effective therapeutic approach for BC. therapeutic target hsa-mir-424 Breast Neoplasms 25633049 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-125b is a new biomarker of poor prognosis and a candidate therapeutic target in AI-resistant breast cancers. therapeutic target hsa-mir-429 Breast Neoplasms 25451164 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 we identified 10 dysregulated miRNAs in both breast cancer cells and chemoresistant tissues, which might be biomarkers for the prognosis of breast cancer chemoresistance. Our study contributes to a comprehensive understanding of prognostic biomarkers during clinical treatment, and we hypothesize that the miRNA signatures of drug-resistant carcinoma tissues could be useful for developing new strategies for targeted therapies in patients with chemoresistant breast cancer. therapeutic target hsa-mir-448 Breast Neoplasms 20798686 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Disruption of the NF-κB-miR-448 feedback loop during clinical treatment may improve the chemotherapy response of human breast cancers in which EMT is a critical component. therapeutic target hsa-mir-451 Breast Neoplasms 27064979 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Variations in serum miRNA levels during NAC treatment may be therapeutically significant for predicting response and survival outcomes. therapeutic target hsa-mir-4521 Breast Neoplasms 24517586 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Integrated analysis of microRNA, mRNA and ChIP-seq data in a model cell line supports the hypothesis that microRNA expression under hypoxia is regulated at transcriptional and post-transcriptional level, with the presence of HIF binding sites at microRNA genomic loci associated with up-regulation. The identification of hypoxia and HIF regulated microRNAs relevant for breast cancer is important for our understanding of disease development and design of therapeutic interventions. therapeutic target hsa-mir-493 Breast Neoplasms 27375041 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The miR-493-5p/FUT4 pathway has therapeutic potential in breast cancer. therapeutic target hsa-mir-495 Breast Neoplasms 25070379 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-495 could facilitate breast cancer progression through the repression of JAM-A, making this miRNA a potential therapeutic target. therapeutic target hsa-mir-497 Breast Neoplasms 21350001 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 both miR-195 and miR-497 play important inhibitory roles in breast cancer malignancy and may be the potential therapeutic and diagnostic targets. therapeutic target hsa-mir-499 Breast Neoplasms 25883093 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our results confirm that TNBC has a unique metabolic profile that may be exploited for therapeutic intervention. therapeutic target hsa-mir-503 Breast Neoplasms 25860935 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 our data are the first to reveal the involvement of the endothelium in the modulation of tumor development via the secretion of circulating miR-503 in response to chemotherapy treatment. therapeutic target hsa-mir-506 Breast Neoplasms 26398880 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 In conclusion, the present study is the first to provide evidence that miR-506 acts as a tumor suppressor, at least partially,by directly downregulating IQGAP1 in breast cancer cells. The miR-506/IQGAP1/ERK pathway may be a novel therapeutic target in breast cancer. therapeutic target hsa-mir-510 Breast Neoplasms 23971998 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Taken together, these data support a pivotal role for miR-510 in breast cancer progression and suggest it as a potential therapeutic target in breast cancer patients. therapeutic target hsa-mir-548d Breast Neoplasms 26663100 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our study showed that miR-548d-3p/TP53BP2 pathway is critically involved in the proliferation and apoptosis of breast cancer cells and may be new therapeutic target of breast cancer cells. therapeutic target hsa-mir-548t Breast Neoplasms 26717565 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Taken together, these findings provide evidence that a miRNA expression signature can be developed to aid existing methods to determine the risk of recurrence for women with estrogen receptor positive breast cancers treated with endocrine therapy. therapeutic target hsa-mir-562 Breast Neoplasms 25536365 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 ANXA1-regulated miR26b* and miR562 may play a role in wound healing and tumor-induced endothelial cell tube formation by targeting NF-κB expression and point towards a potential therapeutic target for breast cancer. therapeutic target hsa-mir-576 Breast Neoplasms 25451164 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 we identified 10 dysregulated miRNAs in both breast cancer cells and chemoresistant tissues, which might be biomarkers for the prognosis of breast cancer chemoresistance. Our study contributes to a comprehensive understanding of prognostic biomarkers during clinical treatment, and we hypothesize that the miRNA signatures of drug-resistant carcinoma tissues could be useful for developing new strategies for targeted therapies in patients with chemoresistant breast cancer. therapeutic target hsa-mir-629 Breast Neoplasms 28629464 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer. therapeutic target hsa-mir-633b Breast Neoplasms 26717565 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Taken together, these findings provide evidence that a miRNA expression signature can be developed to aid existing methods to determine the risk of recurrence for women with estrogen receptor positive breast cancers treated with endocrine therapy. therapeutic target hsa-mir-638 Breast Neoplasms 25228385 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our findings suggest that miR-638 plays an important role in TNBC progression via BRCA1 deregulation. Therefore, miR-638 might serve as a potential prognostic biomarker and therapeutic target for breast cancer. therapeutic target hsa-mir-652 Breast Neoplasms 25547678 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 This signature may serve as a minimally invasive predictor of tumor relapse and overall survival for patients with TNBC. This prediction model may ultimately lead to better treatment options for patients with TNBC. therapeutic target hsa-mir-760 Breast Neoplasms 25451164 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 we identified 10 dysregulated miRNAs in both breast cancer cells and chemoresistant tissues, which might be biomarkers for the prognosis of breast cancer chemoresistance. Our study contributes to a comprehensive understanding of prognostic biomarkers during clinical treatment, and we hypothesize that the miRNA signatures of drug-resistant carcinoma tissues could be useful for developing new strategies for targeted therapies in patients with chemoresistant breast cancer. therapeutic target hsa-mir-765 Breast Neoplasms 25451164 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 we identified 10 dysregulated miRNAs in both breast cancer cells and chemoresistant tissues, which might be biomarkers for the prognosis of breast cancer chemoresistance. Our study contributes to a comprehensive understanding of prognostic biomarkers during clinical treatment, and we hypothesize that the miRNA signatures of drug-resistant carcinoma tissues could be useful for developing new strategies for targeted therapies in patients with chemoresistant breast cancer. therapeutic target hsa-mir-873 Breast Neoplasms 25531331 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-873 is a novel tumor suppressor in ER-positive breast cancer and a potential therapeutic approach for treatment of tamoxifen-resistant breast cancer. therapeutic target hsa-mir-886 Breast Neoplasms 24641359 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Our data show that downregulation of miR-886-5p expression in MCF-7 cells could significantly inhibit cell growth and migration. This might imply that inhibiting miR-886-5p could be a therapeutic strategy in breast cancer. therapeutic target hsa-mir-9 Breast Neoplasms 26095675 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-21, miR-155, miR-9, miR-34a, miR-143/145, and miR-31 were found to be altered in both CMTs and human breast cancer. These altered miRNAs might serve as potential targets for advancing the development of future therapeuticreagents. These findings further strengthen the validity and use of canine breast cancers as appropriate models for the study of human breast cancers. therapeutic target hsa-mir-92b Breast Neoplasms 25047087 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The study suggests that breast cancer in very young women appears as a distinct molecular signature. To our knowledge, this is the first time that a validated microRNA profile, distinctive to breast cancer in very young women, has been presented. The miRNA signature may be relevant to open an important field of research in order to elucidate the underlying mechanism in this particular disease, which in a more clinical setting, could potentially help to identify therapeutic targets in this particular set of patients. therapeutic target hsa-mir-99a Breast Neoplasms 26417931 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Collectively, our data indicate that miR-99a plays a tumor-suppressor role in the development of breast cancer, and could serve as a potential therapeutic target for breast cancer treatment. therapeutic target hsa-mir-23b Burns 26153982 M61.30 D002056 Our findings suggest that downregulation of miR-23b contributes to the recovery of denatured dermis, which may be valuable for treatment of skin burns. therapeutic target hsa-mir-143 Carcinoma, Bladder 26484567 urinary system disease DOID:4007 D09.0 D001749 109800 HP:0002862 Our data suggest a promising therapeutic option to develop drugs targeting EZH2/miR-143 axis, such as honokiol, for bladder cancer treatment. therapeutic target hsa-mir-145 Carcinoma, Bladder 26036261 urinary system disease DOID:4007 D09.0 D001749 109800 HP:0002862 Intravesical administration of exogenous microRNA-145 as a therapy for mouse orthotopic human bladder cancer xenograft. therapeutic target hsa-mir-221 Carcinoma, Bladder 25928257 urinary system disease DOID:4007 D09.0 D001749 109800 HP:0002862 Our study demonstrated that miR-221 facilitated TGFβ1-induced EMT in human bladder cancer cells by targeting STMN1 and represented a promising therapeutic target in the process of metastasis. therapeutic target hsa-mir-106a Carcinoma, Breast 25499219 D05 D001943 114480 HP:0003002 EZH2 is reciprocally regulated by a novel signaling network consisting of Sp proteins, oncogenic miRs and ZBTB4, and modulation of this gene network is a novel therapeutic approach for treatment of breast cancer and possibly other cancers. therapeutic target hsa-mir-106b Carcinoma, Breast 25499219 D05 D001943 114480 HP:0003002 EZH2 is reciprocally regulated by a novel signaling network consisting of Sp proteins, oncogenic miRs and ZBTB4, and modulation of this gene network is a novel therapeutic approach for treatment of breast cancer and possibly other cancers. therapeutic target hsa-mir-145 Carcinoma, Breast 25923846 D05 D001943 114480 HP:0003002 Inclusion of miR-145 target sequences into the 3'-UTR of the Renilla luciferase gene is a feasible strategy for restricting transgene expression in a breast cancer cell line while sparing a breast normal cell line. therapeutic target hsa-mir-146b Carcinoma, Breast 24667374 D05 D001943 114480 HP:0003002 Overall, this study contributes to our understanding of how inflammation is involved in oncogenic transformation. Further studies could evaluate the therapeutic potential of targeting this circuit in estrogen receptor-negative breast cancers. therapeutic target hsa-mir-17 Carcinoma, Breast 25499219 D05 D001943 114480 HP:0003002 EZH2 is reciprocally regulated by a novel signaling network consisting of Sp proteins, oncogenic miRs and ZBTB4, and modulation of this gene network is a novel therapeutic approach for treatment of breast cancer and possibly other cancers. therapeutic target hsa-mir-21 Carcinoma, Breast 28067096 D05 D001943 114480 HP:0003002 Differential response of normal and transformed mammary epithelial cells to combined treatment of anti-miR-21 and radiation. therapeutic target hsa-mir-7 Carcinoma, Breast 25070049 D05 D001943 114480 HP:0003002 the overexpression of miR-7 might serve as a good strategy for treating highly invasive breast cancer. therapeutic target hsa-mir-103a Carcinoma, Breast, Triple Negative 24945253 D064726 This model based on miRNA and node status covariates may be used to stratify TNBC patients into different prognostic subgroups for potentially individualized therapy. therapeutic target hsa-mir-107 Carcinoma, Breast, Triple Negative 24945253 D064726 This model based on miRNA and node status covariates may be used to stratify TNBC patients into different prognostic subgroups for potentially individualized therapy. therapeutic target hsa-mir-143 Carcinoma, Breast, Triple Negative 28621239 D064726 A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer. therapeutic target hsa-mir-17 Carcinoma, Breast, Triple Negative 26629823 D064726 Our results imply that therapeutic antisense sequences against miRNAs should be designed to target the miRNA strand with the greatest number of putative binding sites in the target mRNAs, while minimizing affinity for the minor strand. therapeutic target hsa-mir-18a Carcinoma, Breast, Triple Negative 27338043 D064726 MiR-18a overexpression significantly increased PTX IC50 and reduced PTX induced cell apoptosis therapeutic target hsa-mir-21 Carcinoma, Breast, Triple Negative 26387848 D064726 The results demonstrate the clinical potentials of RNA nanotechnology based platform to deliver miRNA based therapeutics for cancer treatment. therapeutic target hsa-mir-27a Carcinoma, Breast, Triple Negative 25943633 D064726 The miR-27a-CDC27 axis might play an important role in modulating response to radiotherapy in TNBC cells. Testing miR-27a expression might be a useful way to identify a subgroup of patients who will benefit from an IR-based therapeutic approach. therapeutic target hsa-mir-27b Carcinoma, Breast, Triple Negative 24945253 D064726 This model based on miRNA and node status covariates may be used to stratify TNBC patients into different prognostic subgroups for potentially individualized therapy. therapeutic target hsa-mir-30a Carcinoma, Breast, Triple Negative 28621239 D064726 A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer. therapeutic target hsa-mir-34a Carcinoma, Breast, Triple Negative 24565525 D064726 Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. therapeutic target hsa-mir-34a Carcinoma, Breast, Triple Negative 25044638 D064726 HP-IPECs have a great potential as a biodegradable vector for microRNA-based therapy against triple-negative breast cancer. therapeutic target hsa-mir-34a Carcinoma, Breast, Triple Negative 26676753 D064726 Together, our results demonstrate that miR-34a exerts potent antitumorigenic effects in vitro and in vivo and suggests that miR-34a replacement therapy, which is currently being tested in human clinical trials, represents a promising therapeutic strategy for TNBC. therapeutic target hsa-mir-770 Carcinoma, Breast, Triple Negative 28621239 D064726 A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer. therapeutic target hsa-mir-9 Carcinoma, Breast, Triple Negative 28621239 D064726 A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer. therapeutic target hsa-mir-96 Carcinoma, Breast, Triple Negative 27170187 D064726 3 directly engages pri-miR-96 in breast cancer cells. therapeutic target hsa-mir-101 Carcinoma, Cervical 24987920 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 We concluded that by targeting the proto-oncogene Fos, miR-101 is involved in G1-to-S phase transition in cervical cancer cells in vitro and might provide a new approach for the pharmacological interference node in cervical cancer treatment. therapeutic target hsa-mir-101 Carcinoma, Cervical 26617722 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 MiR-101 likely acts as a tumor suppressor in cervical cancer.Overexpression of miR-101 decreased expression of its target gene Cox-2 and inhibited proliferation and invasion, and promoted apoptosis to suppress tumorigenicity. MiR-101 is a promising new target for the development of therapeutic strategies for the clinical treatment of cervical cancer. therapeutic target hsa-mir-125a Carcinoma, Cervical 26389681 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 These data highlight the importance of miR-125a in the cell proliferation and progression of cervical cancer, and indicate that miR-125a may be a useful therapeutic target for cervical cancer. therapeutic target hsa-mir-125a Carcinoma, Cervical 26766902 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 The molecular pathway of miR-125a-5p/ABL2 plays an important role in human cervical carcinoma. Targeting miR-125a-5p/ABL2 pathway may provide a new treatment strategy for patients with cervical carcinoma. therapeutic target hsa-mir-126 Carcinoma, Cervical 24013227 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 the temporal, spatial and progressive nature of tumor-stroma interactions during carcinogenesis, while in turn suggesting therapeutic strategies. therapeutic target hsa-mir-126 Carcinoma, Cervical 24516357 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 MicroRNA in cervical cancer: OncomiRs and tumor suppressor miRs in diagnosis and treatment. therapeutic target hsa-mir-143 Carcinoma, Cervical 24516357 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 MicroRNA in cervical cancer: OncomiRs and tumor suppressor miRs in diagnosis and treatment. therapeutic target hsa-mir-183 Carcinoma, Cervical 26873866 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 In conclusion, our study revealed that miR-183 might be a tumor suppressor via inhibiting the invasion and metastasis of cervical cancer cells through targeting MMP-9, indicating that miR-183 may be a novel potential therapeutic target for cervical cancer. therapeutic target hsa-mir-196a Carcinoma, Cervical 24120501 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 The findings provide new insights about the functional role of miR-196a in cervical carcinogenesis and suggested a potential use of miR-196a for clinical diagnosis and as a therapeutic target. therapeutic target hsa-mir-196a Carcinoma, Cervical 24423924 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 miR-196a has an important role in promoting human cervical cancer cell proliferation and may represent a novel therapeutic target of microRNA-mediated suppression of cell proliferation in cervical cancer. therapeutic target hsa-mir-203 Carcinoma, Cervical 23867971 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 Our collective findings indicate that miR-203 functions as a tumor suppressor by targeting VEGFA, resulting in the inhibition of tumor growth and angiogenesis. Thus, miR-203 may be a potential therapeutic target and prognostic marker in cervical cancer. therapeutic target hsa-mir-206 Carcinoma, Cervical 26775359 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 miR-206 may act not only as a novel diagnostic and prognostic marker, but also as a potential target for molecular therapy of cervical cancer. therapeutic target hsa-mir-21 Carcinoma, Cervical 24516357 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 MicroRNA in cervical cancer: OncomiRs and tumor suppressor miRs in diagnosis and treatment. therapeutic target hsa-mir-214 Carcinoma, Cervical 25556274 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 miRNA-214 and MTFA may become important candidates for developing promising therapeutic strategies for the treatment of cervical cancer. therapeutic target hsa-mir-218 Carcinoma, Cervical 25473903 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 the miR-218~survivin axis inhibits cervical cancer progression by regulating clonogenicity, migration, and invasion, and suggest that the inhibition of survivin could be a potential therapeutic strategy to improve outcome in this disease. therapeutic target hsa-mir-222 Carcinoma, Cervical 24895988 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 MiR-222 plays an important role in the tumorigenesis of CC, possibly by specifically down-regulating p27Kip1 and PTEN. Our findings suggest that miR-222 may serve as a new therapeutic target in CC. therapeutic target hsa-mir-224 Carcinoma, Cervical 26390698 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 The results suggests that miR-224 might serve as a predictor for paclitaxel response or a therapeutic target in cervical cancer therapy. therapeutic target hsa-mir-375 Carcinoma, Cervical 23778521 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 Collectively, our results suggest that miR-375 might be a therapeutic target in paclitaxel-resistant cervical cancer. therapeutic target hsa-mir-520h Carcinoma, Cervical 25047463 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 Our results indicate a functional link between ATO-mediated PP2A/C regulation, CXCR4 expression, and tumor-suppressing ability. This information will be critical in realizing the potential for synergy between ATO and other anti-cancer agents, thus providing enhanced benefit in cancer therapy. therapeutic target hsa-mir-92a Carcinoma, Cervical 25623537 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 miR-92a acts as an onco-miRNA and may contribute to the progression and invasion of cervical cancer, suggesting miR-92a as a potential novel diagnostic and therapeutic target of cervical cancer. therapeutic target hsa-mir-1 Carcinoma, Colon 26459459 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 Our findings demonstrated that miR-145 and miR-1 play a negative regulatory role in the proliferation of colon cancer by targeting NAIP; thus, miR-145 and miR-1 may prove to be novel therapeutic targets in the treatment of colon cancer. therapeutic target hsa-mir-100 Carcinoma, Colon 25483280 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 the results of the current study elucidate a novel regulatory pathway involving miR-100 and Lgr5 in colon cancer cells, which may present a potential therapeutic target. therapeutic target hsa-mir-126 Carcinoma, Colon 23981989 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 MiR-126 was able to inhibit the development of colon cancer and its level was closely related with the prognosis of patients with colon cancer. The potential target genes for miR-126 might include IRS1, SLC7A5 and TOM1. Therefore, miR-126 might be a therapeutic target for colon cancer diagnosis and treatment. therapeutic target hsa-mir-133b Carcinoma, Colon 24594999 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 TAp63 and microRNA-133b were able to suppress the metastasis of colon cancer. Both TAp63 and microRNA-133b may be potential biomarkers for diagnosis in colon cancer metastasis and may provide unique therapeutic targets for this common malignancy. therapeutic target hsa-mir-141 Carcinoma, Colon 28112364 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 MicroRNA-141 inhibits tumor growth and minimizes therapy resistance in colorectal cancer. therapeutic target hsa-mir-145 Carcinoma, Colon 26459459 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 Our findings demonstrated that miR-145 and miR-1 play a negative regulatory role in the proliferation of colon cancer by targeting NAIP; thus, miR-145 and miR-1 may prove to be novel therapeutic targets in the treatment of colon cancer. therapeutic target hsa-mir-145 Carcinoma, Colon 27482839 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 The results in this work show that miR-145 has been effectively delivered to colon carcinomas through a PLGA/PEI/HA vehicle, indicating a promising miRNA replacement therapy strategy. therapeutic target hsa-mir-146a Carcinoma, Colon 24670457 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 miR-146a may serve as a potential therapeutic target for colonic cancer for its role in inhibiting colonic cancer cell proliferation. therapeutic target hsa-mir-17 Carcinoma, Colon 26463716 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 Our findings identify a novel cellular mechanism whereby butyrate inhibits miR-92a transcription by reducing c-Myc, thus augmenting p57 levels.These actions diminish colon cancer cell proliferation and stimulate apoptosis.This newly described regulation of oncogenic miRNA biogenesis expands our understanding of colon cancer cell biology and identifies novel therapeutic targets. therapeutic target hsa-mir-18 Carcinoma, Colon 26463716 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 Our findings identify a novel cellular mechanism whereby butyrate inhibits miR-92a transcription by reducing c-Myc, thus augmenting p57 levels.These actions diminish colon cancer cell proliferation and stimulate apoptosis.This newly described regulation of oncogenic miRNA biogenesis expands our understanding of colon cancer cell biology and identifies novel therapeutic targets. therapeutic target hsa-mir-19a Carcinoma, Colon 26463716 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 Our findings identify a novel cellular mechanism whereby butyrate inhibits miR-92a transcription by reducing c-Myc, thus augmenting p57 levels.These actions diminish colon cancer cell proliferation and stimulate apoptosis.This newly described regulation of oncogenic miRNA biogenesis expands our understanding of colon cancer cell biology and identifies novel therapeutic targets. therapeutic target hsa-mir-19b-1 Carcinoma, Colon 26463716 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 Our findings identify a novel cellular mechanism whereby butyrate inhibits miR-92a transcription by reducing c-Myc, thus augmenting p57 levels.These actions diminish colon cancer cell proliferation and stimulate apoptosis.This newly described regulation of oncogenic miRNA biogenesis expands our understanding of colon cancer cell biology and identifies novel therapeutic targets. therapeutic target hsa-mir-20a Carcinoma, Colon 26463716 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 Our findings identify a novel cellular mechanism whereby butyrate inhibits miR-92a transcription by reducing c-Myc, thus augmenting p57 levels.These actions diminish colon cancer cell proliferation and stimulate apoptosis.This newly described regulation of oncogenic miRNA biogenesis expands our understanding of colon cancer cell biology and identifies novel therapeutic targets. therapeutic target hsa-mir-21 Carcinoma, Colon 25051407 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 This population-based study supports miRNA-21 as an additional prognostic biomarker in patients with stage II colon cancer. Furthermore, the introduction of a risk index may guide the use of postoperative adjuvant treatment in a more appropriate way compared with current practice. bta-hsa-mir-142-5p,hsa-mir-223 therapeutic target hsa-mir-31 Carcinoma, Colon 28147317 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 EZH2 expression is a prognostic biomarker in patients with colorectal cancer treated with anti-EGFR therapeutics. therapeutic target hsa-mir-320 Carcinoma, Colon 25446103 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 miR-320-FOXM1 axis may overcome chemo-resistance of colon cancer cells and provide a new therapeutic target for the treatment of colon cancer. therapeutic target hsa-mir-92-1 Carcinoma, Colon 26463716 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 Our findings identify a novel cellular mechanism whereby butyrate inhibits miR-92a transcription by reducing c-Myc, thus augmenting p57 levels.These actions diminish colon cancer cell proliferation and stimulate apoptosis.This newly described regulation of oncogenic miRNA biogenesis expands our understanding of colon cancer cell biology and identifies novel therapeutic targets. therapeutic target hsa-mir-92a Carcinoma, Colon 26463716 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 Our findings identify a novel cellular mechanism whereby butyrate inhibits miR-92a transcription by reducing c-Myc, thus augmenting p57 levels.These actions diminish colon cancer cell proliferation and stimulate apoptosis.This newly described regulation of oncogenic miRNA biogenesis expands our understanding of colon cancer cell biology and identifies novel therapeutic targets. therapeutic target hsa-mir-34a Carcinoma, Embryonal 25551588 disease of cellular proliferation DOID:3308 D018236 HP:0002898 Deeper understanding of the aberrant miRNA expression in pediatric embryonal brain tumors might aid in the development of tumor-specific miRNA signatures, which could potentially afford promising biomarkers related to diagnosis, prognosis and patient targeted therapy. therapeutic target hsa-mir-601 Carcinoma, Embryonal 25551588 disease of cellular proliferation DOID:3308 D018236 HP:0002898 Deeper understanding of the aberrant miRNA expression in pediatric embryonal brain tumors might aid in the development of tumor-specific miRNA signatures, which could potentially afford promising biomarkers related to diagnosis, prognosis and patient targeted therapy. therapeutic target hsa-mir-200 Carcinoma, Endometrial 25738863 reproductive system disease DOID:2871 D07.0 D016889 608089 HP:0012114 These results suggest that acquirement of EXM-resistance in Ish/EXM cells induces up regulation of ZEB1 via suppression of the miR-200 family following suppression of E-cadherin. Since suppression of ZEB1 in Ish/EXM cells by treatment with its siRNA did not restore the miR-200 family expression,miR-200 family was placed upstream of ZEB1 to regulate the expression. therapeutic target hsa-mir-204 Carcinoma, Endometrial 24321270 reproductive system disease DOID:2871 D07.0 D016889 608089 HP:0012114 This study uncovers a new regulatory loop involving TrkB/miR-204-5p that is critical to the tumorigenesis of EC and proposes that reestablishment of miR-204-5p expression could be explored as a potential new therapeutic target for this disease. therapeutic target hsa-mir-218 Carcinoma, Endometrial 26261543 reproductive system disease DOID:2871 D07.0 D016889 608089 HP:0012114 These results reveal novel potential role of miR-218 against chemotherapy resistance during the treatment of endometrial carcinoma. therapeutic target hsa-mir-30c Carcinoma, Endometrial 24595016 reproductive system disease DOID:2871 D07.0 D016889 608089 HP:0012114 Taken together, our results suggest that miR-30c is an important deregulated miRNA in EC and might serve as a potential biomarker and novel therapeutic target for EC. therapeutic target hsa-mir-424 Carcinoma, Endometrial 26638889 reproductive system disease DOID:2871 D07.0 D016889 608089 HP:0012114 Taken together, our study suggests that increased miR-424 suppresses E2-induced cell growth, and providing a potential therapeutic target for estrogen-associated endometrial carcinoma. therapeutic target hsa-mir-106a Carcinoma, Esophageal 26314198 disease of cellular proliferation DOID:1107 C15.9 D004938 133239 HP:0011459 Our data indicate that miR-106a* might play an anti-oncogenic role in EC by regulating CACUL1 expression, which suggest miR-106a* as a new potential diagnostic and therapeutic target for EC. therapeutic target hsa-mir-21 Carcinoma, Esophageal 24324076 disease of cellular proliferation DOID:1107 C15.9 D004938 133239 HP:0011459 The effect of miR-21 on PTEN/AKT signaling pathway is abrogated by the novel arene Ru(II) drug Rawq01. Our data may be useful for the future development of a chemosensitizing strategies through manipulating microRNA expression for tumor treatment. therapeutic target hsa-mir-217 Carcinoma, Esophageal 25703328 disease of cellular proliferation DOID:1107 C15.9 D004938 133239 HP:0011459 these data demonstrate that epigenetic repression of miR-217 contributes to the pathogenesis of EAC via upregulation of KLK7 and suggest that restoration of miR-217 expression may be a novel treatment strategy for these malignancies. therapeutic target hsa-mir-34a Carcinoma, Esophageal 24528540 disease of cellular proliferation DOID:1107 C15.9 D004938 133239 HP:0011459 Our findings suggest that miR-34a is involved in the etiology of ESCC and that hypermethylated miR-34a is a potential biomarker for ESCC diagnosis and prognosis. Moreover, targeting miR-34a methylation by demethylating agents may offer a novel strategy for anticancer therapy of ESCC. therapeutic target hsa-mir-451 Carcinoma, Esophageal 26019450 disease of cellular proliferation DOID:1107 C15.9 D004938 133239 HP:0011459 These findings suggest that miR-451 might be a novel prognostic biomarker and a potential target for the treatment of esophageal squamous cell carcinoma in the future. therapeutic target hsa-mir-20a Carcinoma, Gallbladder 23665284 disease of cellular proliferation DOID:4948 C23 D005706 TGF-β1-mediated activation of the miR-20a/Smad7/β-catenin axis plays a pivotal role in the pathogenesis and worse prognosis of GBCs and may serve as a potential therapeutic target in the future. therapeutic target hsa-mir-27a Carcinoma, Gallbladder 26288960 disease of cellular proliferation DOID:4948 C23 D005706 In conclusion, the miRNA variants cumulatively influence GBC susceptibility and treatment outcomes. therapeutic target hsa-mir-570 Carcinoma, Gallbladder 26288960 disease of cellular proliferation DOID:4948 C23 D005706 In conclusion, the miRNA variants cumulatively influence GBC susceptibility and treatment outcomes. therapeutic target hsa-mir-29c Carcinoma, Gastric 24870620 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 MiR-29c acts as a tumour suppressor in GC by directly targeting ITGB1. Loss of miR-29c expression is an early event in the initiation of gastric carcinogenesis and may serve as a diagnostic and therapeutic biomarker for patients with GC. therapeutic target hsa-mir-31 Carcinoma, Gastric 26494556 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 Therefore, miR-31 could be a useful biomarker for monitoring GC development and progression, and also could potential by targeting SGPP2, Smad4 and STAT3 for GC therapy.have a therapeutic therapeutic target hsa-mir-32 Carcinoma, Gastric 26471298 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 We conclude that miR-32 promotes GC cell proliferation,migration and invasion by targeting KLF4, suggesting that the miR-32-KLF4 pathway may be useful in clinical diagnosis and therapeutics. therapeutic target hsa-mir-339 Carcinoma, Gastric 26391641 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 These findings uncover a novel role for miR-339 in gastric carcinogenesis, and restoration of miR-339 could be considered as a potential therapeutic strategy for GC treatment. therapeutic target hsa-mir-508 Carcinoma, Gastric 26801246 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 All these findings supports that canonical NF-κB signaling pathway is activated in GC at least by the inactivation of miR-508-3p and this might have therapeutic potential in GC treatment. therapeutic target hsa-mir-647 Carcinoma, Gastric 28098914 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 miR-647 exerts powerful antitumorigenic effects in vitro and in vivo, and may represent a promising therapeutic agent against GC therapeutic target hsa-let-7a Carcinoma, Hepatocellular 26468984 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 These findings suggest that the detection of elevated plasma DCLK1 may provide a cost-effective, less invasive tool for confirmation of clinical signs of cirrhosis, and a potential companion diagnostic marker for patients with cirrhosis and HCC. Our results support evaluating DCLK1 as a biomarker for detection and as a therapeutic target for eradicating HCC. therapeutic target hsa-let-7a Carcinoma, Hepatocellular 25429777 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Chol-let-7a inhibited the viability and mobility of HCC cells. therapeutic target hsa-mir-101 Carcinoma, Hepatocellular 24002871 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 c-Myc collaborates with EZH2-containing PRC2 complex in silencing tumor-suppressive miRNAs during hepatocarcinogenesis and provides promising therapeutic candidates for human HCC. therapeutic target hsa-mir-101 Carcinoma, Hepatocellular 25693145 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Systemic delivery of microRNA-101 potently inhibits hepatocellular carcinoma in vivo by repressing multiple targets. therapeutic target hsa-mir-103 Carcinoma, Hepatocellular 26646106 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 These findings indicate that miR-103 potentially acts as an oncogene in HCC by inhibiting AKAP12 expression and raise the possibility that miR-103 increases telomerase activity by increasing PKCα activity. Thus, miR-103 may represent a new potential diagnostic and therapeutic target for HCC treatment. therapeutic target hsa-mir-106a Carcinoma, Hepatocellular 25510666 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 upregulated expression of miR-106a by its promoter hypomethylation might contribute to the progression of HCC, which might be considered as a potentially effective biomarker and therapeutic approach in the future therapeutic target hsa-mir-106b Carcinoma, Hepatocellular 25811030 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 These results highlight the potential implications of pretreatment miRNAs expression profiling in prediction of the patients' response to TACE treatment in liver cancer. therapeutic target hsa-mir-106b Carcinoma, Hepatocellular 25393367 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 The HDACi SAHA epigenetically upregulates MICA expression through regulating the expression of miR-17-92 cluster and MCM7 in hepatoma, thus enhancing the sensitivity of HCC to natural killer cell-mediated lysis. This novel mechanism of action provides promise for HDACi in therapy of HCC. therapeutic target hsa-mir-10b Carcinoma, Hepatocellular 25236186 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Our results suggested that miR-10b was overexpressed in HCC and promoted HCC cell migration and invasion through the HOXD10/ RhoC/ uPAR/ MMPs pathway which may provide a novel bio-target for HCC therapy. therapeutic target hsa-mir-122 Carcinoma, Hepatocellular 26506419 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Our findings suggest that enhanced glycolysis is associated with CD133 (+) stem-like characteristics and that metabolic reprogramming through miR-122 or PDK4 may represent a novel therapeutic approach for the treatment of hepatocellular cancer. therapeutic target hsa-mir-122 Carcinoma, Hepatocellular 26302777 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-122 is a novel target gene of FXR, and the upregulation of miR-122 by FXR represses the growth of HCC cells, suggesting that FXR may serve as a key transcriptional regulator for manipulating miR-122 expression, and the FXR/miR-122 pathway may therefore be a novel target for the treatment of HCC. therapeutic target hsa-mir-122 Carcinoma, Hepatocellular 26151503 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 These results suggested that differential miRNA profiling in malignant hepatocytes may account for the variable pathophysiological manifestations associated with the HCV NS4 protein. These differentially expressed miRNAs may offer potential as candidates for the development of miRNA-based therapeutics. therapeutic target hsa-mir-122 Carcinoma, Hepatocellular 27059462 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA profiling of distinct tumor foci, coupled with methods that address within-subject tumor heterogeneity, has the potential to significantly improve prediction of HCC recurrence post-transplantation. The development of a clinically applicable HCC biomarker would inform treatment options for patients and contribute to liver transplant selection criteria for practitioners. therapeutic target hsa-mir-126 Carcinoma, Hepatocellular 23378255 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 down-regulation of miR-126 plays an important role in HCC metastasis, and suggest a potential application of miR-126 in prognosis prediction and HCC treatment therapeutic target hsa-mir-126 Carcinoma, Hepatocellular 25240815 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Our results demonstrates that deregulation of miR-126-3p contributes to metastasis and angiogenesis in HCC. The restoration of miR-126-3p expression may be a promising strategy for HCC therapy. therapeutic target hsa-mir-126 Carcinoma, Hepatocellular 25585946 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-126 as a tumor suppressor in HCC through, at least partially by targeting Sox2. This may provide novel diagnostic and therapeutic options for human HCC in future. therapeutic target hsa-mir-126 Carcinoma, Hepatocellular 27059462 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA profiling of distinct tumor foci, coupled with methods that address within-subject tumor heterogeneity, has the potential to significantly improve prediction of HCC recurrence post-transplantation. The development of a clinically applicable HCC biomarker would inform treatment options for patients and contribute to liver transplant selection criteria for practitioners. therapeutic target hsa-mir-127 Carcinoma, Hepatocellular 26708147 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 In summary, we found that miR-127-5p suppressed NF-κB activity by directly targeting BLVRB in HCC cells, and this finding improves our understanding of the molecular mechanism of inflammation-induced HCC growth and proliferation and the successful inhibition of NF-κB activity by cancer treatment. therapeutic target hsa-mir-1297 Carcinoma, Hepatocellular 26398017 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Collectively,miR-1297 was revealed to regulate the proliferation, apoptosis and migration of hepatocellular carcinoma cells via acting on HMGA2. The finding provides a new target for the treatment of hepatocellular carcinoma. therapeutic target hsa-mir-130a Carcinoma, Hepatocellular 26817584 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Our findings provide a molecular insight on understanding drug resistance in HCC cells. Therefore, activation of miR-130a-3p or inactivation of Smad4 could be a novel approach for the treatment of HCC. therapeutic target hsa-mir-130a Carcinoma, Hepatocellular 26151503 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 These results suggested that differential miRNA profiling in malignant hepatocytes may account for the variable pathophysiological manifestations associated with the HCV NS3 protein. These differentially expressed miRNAs may offer potential as candidates for the development of miRNA-based therapeutics. therapeutic target hsa-mir-133a Carcinoma, Hepatocellular 25607810 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MMP-9 may be used for the development of novel molecular markers and therapeutic approaches to inhibit hepatocellular carcinoma metastasis. therapeutic target hsa-mir-133b Carcinoma, Hepatocellular 25811030 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 These results highlight the potential implications of pretreatment miRNAs expression profiling in prediction of the patients' response to TACE treatment in liver cancer. therapeutic target hsa-mir-135b Carcinoma, Hepatocellular 25537516 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 HSF1/miR-135b/RECK&EVI5 axis provides novel insight into the mechanisms of HCC metastasis, which may facilitate the development of new therapeutics against HCC therapeutic target hsa-mir-136 Carcinoma, Hepatocellular 25050974 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-375 and miR-137 may have the miRNA-based therapeutic potential in HBV-associated HCC. therapeutic target hsa-mir-137 Carcinoma, Hepatocellular 25739100 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Further knowledge obtained from this study may provide important evidence for the prevention and targeted therapy of HCC. therapeutic target hsa-mir-139 Carcinoma, Hepatocellular 24190507 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-139 downregulation is common in HCC and that overexpression of miR-139 expression inhibits cell proliferation and invasion, suggesting that miR-139 may provide a therapeutic strategy for the treatment of HCC patients. therapeutic target hsa-mir-141 Carcinoma, Hepatocellular 24551096 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 These findings indicated that miR-141 functions as a tumor suppressor and inhibits the migration and invasion of HCC cells by targeting Tiam1, which may provide novel prognostic and treatment strategies for HCC patients. therapeutic target hsa-mir-143 Carcinoma, Hepatocellular 26468984 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 These findings suggest that the detection of elevated plasma DCLK1 may provide a cost-effective, less invasive tool for confirmation of clinical signs of cirrhosis, and a potential companion diagnostic marker for patients with cirrhosis and HCC. Our results support evaluating DCLK1 as a biomarker for detection and as a therapeutic target for eradicating HCC. therapeutic target hsa-mir-145 Carcinoma, Hepatocellular 26468984 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 These findings suggest that the detection of elevated plasma DCLK1 may provide a cost-effective, less invasive tool for confirmation of clinical signs of cirrhosis, and a potential companion diagnostic marker for patients with cirrhosis and HCC. Our results support evaluating DCLK1 as a biomarker for detection and as a therapeutic target for eradicating HCC. therapeutic target hsa-mir-145 Carcinoma, Hepatocellular 29156696 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 The interaction between pSmad3C/3L and microRNA-145/21 regulates HCC progression and the switch of pSmad3C/3L may serve as an important target for HCC therapy therapeutic target hsa-mir-146a Carcinoma, Hepatocellular 25607648 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 the mechanism responsible for tumor-induced immune suppression highlights the potential application of miR-146a as a novel immunotherapeutic target for HCC. therapeutic target hsa-mir-146b Carcinoma, Hepatocellular 19584283 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 a liver-specific miRNA; down-regulation in HCC; miR-122 can regulate the expression of cyclin G1; by modulating cyclin G1 with doxorubicin, miR-122 influences p53 protein stability and transcriptional activity and reduces invasion capability of HCC-derived cell lines; miR-122, as well as cyclin G1 silencing, increases sensitivity to doxorubicin challenge; miR-122 levels were associated with a shorter TTR (time to recurrence); potential combined chemo- and miRNA-based therapeutic target therapeutic target hsa-mir-148a Carcinoma, Hepatocellular 22496917 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-148a may play a central role in HBx/URG11 mediated HCC, and may be an early diagnostic marker and/or therapeutic target associated with this tumor type. therapeutic target hsa-mir-148a Carcinoma, Hepatocellular 24013226 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 These findings highlight the significance of miR-148a downregulation in tumor progression and implicate miR-148a as an attractive candidate for cancer therapy. therapeutic target hsa-mir-148a Carcinoma, Hepatocellular 26599259 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-148a is an inhibitor of the IκB kinase alpha/NUMB/NOTCH pathway and an inducer of hepatocytic differentiation that when deregulated promotes HCC initiation and progression. Differentiation-targeted therapy may be a promising strategy to treat and prevent HCC. therapeutic target hsa-mir-148b Carcinoma, Hepatocellular 25627001 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 the frequently downregulated miR-148b can regulate WNT1/β-catenin signalling pathway and function as a tumor suppressor in HCC. These findings suggest that miR-148b may serve as a novel therapeutic target for HCC. therapeutic target hsa-mir-148b Carcinoma, Hepatocellular 26530325 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 These results suggested that miR-148 may represent a novel molecular marker and a potential molecular therapeutic for inhibiting metastasis of HCC. therapeutic target hsa-mir-149 Carcinoma, Hepatocellular 25424347 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 The newly identified miR-149/AKT/mTOR axis might be a promising therapeutic target in the prevention and treatment of HCC. therapeutic target hsa-mir-149 Carcinoma, Hepatocellular 26498692 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Taken together, our findings indicates that miR-149 is a potential prognostic biomarker of HCC and that the miR-149/PPM1F regulatory axis represents a novel therapeutic target for HCC treatment. therapeutic target hsa-mir-152 Carcinoma, Hepatocellular 24998573 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Underexpression of miR-152 plays a vital role in hepatocarcinogenesis and lack of miR-152 is related to the progression of HCC through deregulation of cell proliferation, motility and apoptosis. miR-152 may act as a tumor suppressor miRNA by also targeting TNFRSF6B and is therefore a potential candidate biomarker for HCC diagnosis, prognosis and molecular therapy. therapeutic target hsa-mir-15a Carcinoma, Hepatocellular 27059462 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA profiling of distinct tumor foci, coupled with methods that address within-subject tumor heterogeneity, has the potential to significantly improve prediction of HCC recurrence post-transplantation. The development of a clinically applicable HCC biomarker would inform treatment options for patients and contribute to liver transplant selection criteria for practitioners. therapeutic target hsa-mir-15b Carcinoma, Hepatocellular 26259570 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 We identified a molecular expression signature and pathway regulatory mechanisms in HCSCs with potential diagnostic and therapeutic value. therapeutic target hsa-mir-15b Carcinoma, Hepatocellular 19956871 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 These results indicate that miR-15b expression in HCC tissues may predict a low risk of HCC recurrence. In addition, the modulation of miR-15b expression may be useful as an apoptosis-sensitizing strategy for HCC treatment. therapeutic target hsa-mir-17 Carcinoma, Hepatocellular 25617127 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 the molecular mechanisms of how PTENP1 repressed the tumorigenic properties of HCC cells and demonstrated the potential of the SB-BV hybrid vector for PTENP1 lncRNA modulation and HCC therapy. therapeutic target hsa-mir-17 Carcinoma, Hepatocellular 26233958 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Our findings demonstrate an important role of the miR-17-92 cluster in hepatocarcinogenesis and suggest the possibility of targeting this pivotal miRNA cluster for potential therapy. therapeutic target hsa-mir-17 Carcinoma, Hepatocellular 29464015 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Hence, anti-miR-17 is an effective therapy for MYC-driven HCC therapeutic target hsa-mir-18 Carcinoma, Hepatocellular 26233958 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Our findings demonstrate an important role of the miR-17-92 cluster in hepatocarcinogenesis and suggest the possibility of targeting this pivotal miRNA cluster for potential therapy. therapeutic target hsa-mir-181c Carcinoma, Hepatocellular 26259570 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 We identified a molecular expression signature and pathway regulatory mechanisms in HCSCs with potential diagnostic and therapeutic value. therapeutic target hsa-mir-188 Carcinoma, Hepatocellular 25998163 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 These findings collectively demonstrate a tumor suppressor role of miR-188-5p in HCC progression via targeting FGF5, suggesting that miR-188-5p could serve as a potential prognostic biomarker and therapeutic target for HCC. therapeutic target hsa-mir-191 Carcinoma, Hepatocellular 20924108 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Our findings offer a preclinical proof of concept for miR-191 targeting as a rational strategy to pursue for improving HCC treatment. therapeutic target hsa-mir-192 Carcinoma, Hepatocellular 26710269 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 These results elucidate that the miR-192/-204-HOTTIP axis might be an important molecular pathway during hepatic cell tumorigenesis. Our data in clinical HCC samples highlight miR-192, miR-204 and HOTTIP with prognostic and potentially therapeutic implications. therapeutic target hsa-mir-195 Carcinoma, Hepatocellular 25607636 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-195 acts as a tumor suppressor by directly targeting CBX4 in HCC. This finding suggests a potential novel strategy for therapeutic interventions of this disease. therapeutic target hsa-mir-195 Carcinoma, Hepatocellular 19441017 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Our data highlight an important role of miR-195 in cell cycle control and in the molecular etiology of HCC, and implicate the potential application of miR-195 in cancer therapy. therapeutic target hsa-mir-197 Carcinoma, Hepatocellular 24613834 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Taken together, these data suggest that anti-miR-197 suppresses HCC migration and invasion by targeting CD82. The regulation of the miR-197/CD82 axis could be a novel therapeutic target in future HCC effective therapy. therapeutic target hsa-mir-199 Carcinoma, Hepatocellular 25811030 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 These results highlight the potential implications of pretreatment miRNAs expression profiling in prediction of the patients' response to TACE treatment in liver cancer. therapeutic target hsa-mir-199a Carcinoma, Hepatocellular 26346275 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 These data reveal a novel mechanism of reprogramming of cancer energy metabolism in which HuR suppresses miR-199a maturation to link hypoxia to the Warburg effect and suggest a promising therapeutic strategy that targets miR-199a to interrupt cancerous aerobic glycolysis. therapeutic target hsa-mir-199a Carcinoma, Hepatocellular 25811030 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 These results highlight the potential implications of pretreatment miRNAs expression profiling in prediction of the patients' response to TACE treatment in liver cancer. therapeutic target hsa-mir-199a-1 Carcinoma, Hepatocellular 21316602 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Identification of miRNomes in Human Liver and Hepatocellular Carcinoma Reveals miR-199a/b-3p as Therapeutic Target for Hepatocellular Carcinoma therapeutic target hsa-mir-199a-2 Carcinoma, Hepatocellular 21316602 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Identification of miRNomes in Human Liver and Hepatocellular Carcinoma Reveals miR-199a/b-3p as Therapeutic Target for Hepatocellular Carcinoma therapeutic target hsa-mir-199b Carcinoma, Hepatocellular 21316602 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Identification of miRNomes in Human Liver and Hepatocellular Carcinoma Reveals miR-199a/b-3p as Therapeutic Target for Hepatocellular Carcinoma therapeutic target hsa-mir-19a Carcinoma, Hepatocellular 26233958 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Our findings demonstrate an important role of the miR-17-92 cluster in hepatocarcinogenesis and suggest the possibility of targeting this pivotal miRNA cluster for potential therapy. therapeutic target hsa-mir-19a Carcinoma, Hepatocellular 29393488 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR‑19a may have potential as a novel molecular marker for HCC and Pter may be a promising clinical target with the potential to be developed as a HCC therapy therapeutic target hsa-mir-19b-1 Carcinoma, Hepatocellular 26233958 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Our findings demonstrate an important role of the miR-17-92 cluster in hepatocarcinogenesis and suggest the possibility of targeting this pivotal miRNA cluster for potential therapy. therapeutic target hsa-mir-200 Carcinoma, Hepatocellular 26468984 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 These findings suggest that the detection of elevated plasma DCLK1 may provide a cost-effective, less invasive tool for confirmation of clinical signs of cirrhosis, and a potential companion diagnostic marker for patients with cirrhosis and HCC. Our results support evaluating DCLK1 as a biomarker for detection and as a therapeutic target for eradicating HCC. therapeutic target hsa-mir-200a Carcinoma, Hepatocellular 26617701 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Our study reveals an important role of miR-200a in inhibiting EMT,proliferation and migration in HCC cells, suggesting the possibility of miR-200a-based therapeutics in HCC. therapeutic target hsa-mir-200b Carcinoma, Hepatocellular 25811030 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 These results highlight the potential implications of pretreatment miRNAs expression profiling in prediction of the patients' response to TACE treatment in liver cancer. therapeutic target hsa-mir-204 Carcinoma, Hepatocellular 26710269 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 These results elucidate that the miR-192/-204-HOTTIP axis might be an important molecular pathway during hepatic cell tumorigenesis. Our data in clinical HCC samples highlight miR-192, miR-203 and HOTTIP with prognostic and potentially therapeutic implications. therapeutic target hsa-mir-206 Carcinoma, Hepatocellular 25436301 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miRNA-206 could not only be useful as a novel biomarker but also serve as a potential target for gene therapy of HCC. therapeutic target hsa-mir-20a Carcinoma, Hepatocellular 26233958 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Our findings demonstrate an important role of the miR-17-92 cluster in hepatocarcinogenesis and suggest the possibility of targeting this pivotal miRNA cluster for potential therapy. therapeutic target hsa-mir-20a Carcinoma, Hepatocellular 26031366 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-20a induces HCC cell radioresistance by activating the PTEN/PI3K/Akt pathway, which suggests that miR-20a/PTEN/PI3K/Akt might represent a target of investigation for developing effective therapeutic strategies against HCC. therapeutic target hsa-mir-20a Carcinoma, Hepatocellular 25393367 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 The HDACi SAHA epigenetically upregulates MICA expression through regulating the expression of miR-17-92 cluster and MCM7 in hepatoma, thus enhancing the sensitivity of HCC to natural killer cell-mediated lysis. This novel mechanism of action provides promise for HDACi in therapy of HCC. therapeutic target hsa-mir-20a Carcinoma, Hepatocellular 23594563 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Our findings suggest miR-20a may represent a novel potential therapeutic target and biomarker for survival of HCC patients therapeutic target hsa-mir-20b Carcinoma, Hepatocellular 26612965 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 The whole study suggests that miR-20b, HIF-1α, and VEGF serve as a potential therapeutic agent for hepatocellular carcinoma. therapeutic target hsa-mir-21 Carcinoma, Hepatocellular 25428915 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 targeting this signaling pathway would be helpful as a therapeutic strategy for the reversal of chemoresistance in HCC. therapeutic target hsa-mir-21 Carcinoma, Hepatocellular 24939570 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Our results provide new insights into the complexity of EPC-HCC interactions and indicate that anticancer therapies targeting either the MCP-1 released from angiogenic EPCs or the miR-21 biogenesis in HCC cells may prevent the malignant progression of primary tumours. therapeutic target hsa-mir-21 Carcinoma, Hepatocellular 25544773 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Targeting microRNA-21 enhances the effect of chemotherapeutic drugs, thereby suggesting that microRNA-21 suppression in combination with HAIC may be a novel approach for HCC treatment. therapeutic target hsa-mir-21 Carcinoma, Hepatocellular 26311740 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 We conclude that miR-21 participates in the acquired resistance of sorafenib by suppresing autophagy through the Akt/PTEN pathway. MiR-21 could serve as a therapeutic target for overcoming sorafenib resistance in the treatment of HCC. therapeutic target hsa-mir-21 Carcinoma, Hepatocellular 26427512 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 The results show that miR-21 degradation can decrease the viability of cells, mainly by induction of apoptosis and necrosis. These findings suggest that degradation of miR-21 could be used as a novel approach in treatment of HCC. therapeutic target hsa-mir-215 Carcinoma, Hepatocellular 26135967 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-215 is upregulated by treatment with Adriamycin and leads to the chemoresistance of hepatocellular carcinoma cells and tissues. therapeutic target hsa-mir-22 Carcinoma, Hepatocellular 27059462 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA profiling of distinct tumor foci, coupled with methods that address within-subject tumor heterogeneity, has the potential to significantly improve prediction of HCC recurrence post-transplantation. The development of a clinically applicable HCC biomarker would inform treatment options for patients and contribute to liver transplant selection criteria for practitioners. therapeutic target hsa-mir-221 Carcinoma, Hepatocellular 24324033 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma. therapeutic target hsa-mir-221 Carcinoma, Hepatocellular 25483016 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-221 has potential as an miRNA-based therapeutic target for HBV-related HCC. therapeutic target hsa-mir-222 Carcinoma, Hepatocellular 25444921 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 the complex molecular mechanisms underlying the invasion and metastasis of HCC and may provide new therapeutic targets. therapeutic target hsa-mir-26a Carcinoma, Hepatocellular 24259426 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-26a could suppress tumor angiogenesis of HCC through HGF-cMet signaling, and it is a new hopeful therapeutic target and prognostic marker for HCC. therapeutic target hsa-mir-26a Carcinoma, Hepatocellular 25537511 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 ITGA5 is a functional target of miR-26a-induced anoikis in HCC cells. Collectively, our findings reveal that miR-26a is a novel player during anoikis and a potential therapeutic target for the treatment of metastatic HCC. therapeutic target hsa-mir-26a Carcinoma, Hepatocellular 25811030 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 These results highlight the potential implications of pretreatment miRNAs expression profiling in prediction of the patients' response to TACE treatment in liver cancer. therapeutic target hsa-mir-26b Carcinoma, Hepatocellular 26078955 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Our study showed that miR-26b was a negative regulator of Mcl-1 gene and sensitized TRAIL-inducing apoptosis in HCC cells, suggesting that the miR-26b-Mcl-1 pathway might be a novel target for the treatment of HCC. therapeutic target hsa-mir-27a Carcinoma, Hepatocellular 25836616 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Our findings suggested that miRNA-27a promoted HCC cell proliferation by regulating PPAR-γ expression. MiR-27a may provide a potential therapeutic strategy for HCC treatment. therapeutic target hsa-mir-27a Carcinoma, Hepatocellular 25811030 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 These results highlight the potential implications of pretreatment miRNAs expression profiling in prediction of the patients' response to TACE treatment in liver cancer. therapeutic target hsa-mir-27a Carcinoma, Hepatocellular 23621256 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 our results suggest that up-regulation of miR-27a may play an oncogenic role in the development of HCC and might thus be a new therapeutic target in HCC patients. therapeutic target hsa-mir-28 Carcinoma, Hepatocellular 26754294 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 A miR-28-5p-IL-34-macrophage feedback loop modulates HCC metastasis and serves as a novel prognostic factor as well as a therapeutic target for HCC. therapeutic target hsa-mir-29 Carcinoma, Hepatocellular 25616722 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 the roles of feedback of miR-29-TET1 downregulation in HCC development and suggested a potential target in identification of the prognosis and application of cancer therapy for HCC patients. therapeutic target hsa-mir-296 Carcinoma, Hepatocellular 26151503 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 These results suggested that differential miRNA profiling in malignant hepatocytes may account for the variable pathophysiological manifestations associated with the HCV NS5 protein. These differentially expressed miRNAs may offer potential as candidates for the development of miRNA-based therapeutics. therapeutic target hsa-mir-29b Carcinoma, Hepatocellular 26404322 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Our results demonstrate the profound effect of fucoidan not only on the regulation of miR-29b-DNMT3B-MTSS1 axis but also on the inhibition of TGF-β signaling in HCC cells, suggesting the potential of using fucoidan as integrative therapeutics against invasion and metastasis of HCC. therapeutic target hsa-mir-29c Carcinoma, Hepatocellular 26259570 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 We identified a molecular expression signature and pathway regulatory mechanisms in HCSCs with potential diagnostic and therapeutic value. therapeutic target hsa-mir-30a Carcinoma, Hepatocellular 24954667 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-30a as a novel regulator of EMT by targeting SNAI1, indicating its potential therapeutic value for reducing invasion and metastasis of HCC. therapeutic target hsa-mir-30a Carcinoma, Hepatocellular 27059462 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA profiling of distinct tumor foci, coupled with methods that address within-subject tumor heterogeneity, has the potential to significantly improve prediction of HCC recurrence post-transplantation. The development of a clinically applicable HCC biomarker would inform treatment options for patients and contribute to liver transplant selection criteria for practitioners. therapeutic target hsa-mir-30c Carcinoma, Hepatocellular 25811030 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 These results highlight the potential implications of pretreatment miRNAs expression profiling in prediction of the patients' response to TACE treatment in liver cancer. therapeutic target hsa-mir-30e Carcinoma, Hepatocellular 25811030 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 These results highlight the potential implications of pretreatment miRNAs expression profiling in prediction of the patients' response to TACE treatment in liver cancer. therapeutic target hsa-mir-335 Carcinoma, Hepatocellular 25804796 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Our data revealed that miR-335 could inhibit the proliferation and migration invasion of HCC cells via regulating ROCK1, suggesting that miR-335 could be a therapeutic biomarker of HCC in the future. therapeutic target hsa-mir-335 Carcinoma, Hepatocellular 26305026 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Our data suggest that serum miR-335 can be used as a molecular marker to predict the treatment response and clinical outcome in HCC patients receiving TACE. therapeutic target hsa-mir-338 Carcinoma, Hepatocellular 25531114 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-338-3p inhibits HCC tumor growth and sensitizes HCC cells to sorafenib by down-regulating HIF-1α. Our data indicate that miR-338-3p could be a potential candidate for HCC therapeutics. therapeutic target hsa-mir-338 Carcinoma, Hepatocellular 26259570 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 We identified a molecular expression signature and pathway regulatory mechanisms in HCSCs with potential diagnostic and therapeutic value. therapeutic target hsa-mir-342 Carcinoma, Hepatocellular 25580008 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-342-3p has a significant role in HCC cell proliferation and is suitable for investigation of therapeutic targets. therapeutic target hsa-mir-362 Carcinoma, Hepatocellular 25449782 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-362-5p may serve as a novel therapeutic target for miRNA based HCC therapy therapeutic target hsa-mir-363 Carcinoma, Hepatocellular 26143754 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 the combination of miR-363 and cisplatin may represent a novel approach in treatment for HCC, thus offering a new target for chemotherapy of HCC. therapeutic target hsa-mir-367 Carcinoma, Hepatocellular 26772880 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 This study indicated that miR-367 negatively regulates PTEN and promotes proliferation and invasion of HCC cells. Thus, miR-367 may represent a potential therapeutic target for HCC intervention. therapeutic target hsa-mir-375 Carcinoma, Hepatocellular 25050974 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-375 and miR-136 may have the miRNA-based therapeutic potential in HBV-associated HCC. therapeutic target hsa-mir-375 Carcinoma, Hepatocellular 28624193 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-375 and Doxorubicin Co-delivered by Liposomes for Combination Therapy of Hepatocellular Carcinoma. therapeutic target hsa-mir-378 Carcinoma, Hepatocellular 26259570 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 We identified a molecular expression signature and pathway regulatory mechanisms in HCSCs with potential diagnostic and therapeutic value. therapeutic target hsa-mir-425 Carcinoma, Hepatocellular 25040368 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Assessment of miR-425-3p levels in liver biopsies could help in stratifying patients with advanced HCC for sorafenib treatment. These promising results need to be confirmed in a large prospective study. therapeutic target hsa-mir-433 Carcinoma, Hepatocellular 25410752 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 the roles and mechanisms of miRNA-433 in regulating HCC proliferation, and may benefit future development of therapeutics targeting miRNA-433 and PAK4 in HCC. therapeutic target hsa-mir-4458 Carcinoma, Hepatocellular 25833000 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MiR-4458 or IKBKE may be potential predictors of HCC prognosis.Restoration of miR-4458 or inhibition of IKBKE could be a prospective therapeutic approach for HCC. therapeutic target hsa-mir-449a Carcinoma, Hepatocellular 26471185 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Our data highlight an important role of miR-449a in the molecular etiology of HCC, and implicate the potential application of miR-449a in cancer therapy. therapeutic target hsa-mir-450b Carcinoma, Hepatocellular 26259570 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 We identified a molecular expression signature and pathway regulatory mechanisms in HCSCs with potential diagnostic and therapeutic value. therapeutic target hsa-mir-494 Carcinoma, Hepatocellular 23913442 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Our findings identify a new therapeutic target (miR-494) for the treatment of HCC. therapeutic target hsa-mir-501 Carcinoma, Hepatocellular 25917358 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 This study suggests that miR-501-5p may play an important role in the development of hepatocellular carcinoma by promoting cell proliferation, and indicates that miR-501-5p may represent a novel therapeutic target for hepatocellular carcinoma. therapeutic target hsa-mir-506 Carcinoma, Hepatocellular 26474697 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Therefore, our findings collectively suggest that miR-506 acts as a tumor suppressor via regulation of ROCK1 expression and may thus be a promising therapeutic target for HCC. therapeutic target hsa-mir-517a Carcinoma, Hepatocellular 21324318 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-517a is an oncogenic miRNA that promotes tumor progression. There is rationale for developing therapies that miRNA 517 for patients with HCC. therapeutic target hsa-mir-542 Carcinoma, Hepatocellular 20574436 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Expression of the most significant TrkA-correlated miRNA, miR-542-5p, also discriminated between local and metastatic disease and was inversely correlated with MYCN amplification and event-free survival. miR-542-5p might be important in neuroblastoma tumour biology, and qualify as potential therapeutic targets. therapeutic target hsa-mir-622 Carcinoma, Hepatocellular 26467022 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Taken together, miR-622 acts as a tumor suppressor in HCC and restoration of miR-622 may provide therapeutic benefits in the treatment of HCC. therapeutic target hsa-mir-622 Carcinoma, Hepatocellular 26404566 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 This study establishes EZH2/miR-622/CXCR4 as a potential adverse prognostic factor and therapeutic target for HCC patients. therapeutic target hsa-mir-760 Carcinoma, Hepatocellular 26259570 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 We identified a molecular expression signature and pathway regulatory mechanisms in HCSCs with potential diagnostic and therapeutic value. therapeutic target hsa-mir-9 Carcinoma, Hepatocellular 26547929 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Our study suggests that miR-9 functions as a tumor suppressor in HCC progression by inhibiting a series of target genes, including the newly validated miR-9/IGF2BP1/AKT&ERK axis, thus providing potential therapeutic targets and novel prognostic biomarkers for HCC patients. therapeutic target hsa-mir-92-1 Carcinoma, Hepatocellular 26233958 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Our findings demonstrate an important role of the miR-17-92 cluster in hepatocarcinogenesis and suggest the possibility of targeting this pivotal miRNA cluster for potential therapy. therapeutic target hsa-mir-92a Carcinoma, Hepatocellular 26323375 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 In conclusion, the results of the present study suggested that miR-92a promotes the tumor growth of HCC by targeting FBXW7 and may serve as a novel prognostic biomarker and therapeutic target for HCC. therapeutic target hsa-mir-93 Carcinoma, Hepatocellular 25393367 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 The HDACi SAHA epigenetically upregulates MICA expression through regulating the expression of miR-17-92 cluster and MCM7 in hepatoma, thus enhancing the sensitivity of HCC to natural killer cell-mediated lysis. This novel mechanism of action provides promise for HDACi in therapy of HCC. therapeutic target hsa-mir-145 Carcinoma, Hepatocellular, HBV-Related 25260533 Thus, HBx protein differentially modulated the expression of miRNAs. The study throws light into possible way by which HBx protein acts through microRNA and thereby regulates host functioning. It might suggest new therapeutic strategies against hepatic cancer. therapeutic target hsa-mir-15b Carcinoma, Hepatocellular, HBV-Related 24122375 Downregulation of microRNA-15b by hepatitis B virus X enhances hepatoceThe newly identified HBX/miR-15b/FUT2/Globo H axis suggests one possible molecular mechanism of HCC cell proliferation and represents a new potential therapeutic target for HCC treatment.llular carcinoma proliferation via fucosyltransferase 2-induced Globo H expression. therapeutic target hsa-mir-21 Carcinoma, Hepatocellular, HBV-Related 25260533 Thus, HBx protein differentially modulated the expression of miRNAs. The study throws light into possible way by which HBx protein acts through microRNA and thereby regulates host functioning. It might suggest new therapeutic strategies against hepatic cancer. therapeutic target hsa-mir-222 Carcinoma, Hepatocellular, HBV-Related 25260533 Thus, HBx protein differentially modulated the expression of miRNAs. The study throws light into possible way by which HBx protein acts through microRNA and thereby regulates host functioning. It might suggest new therapeutic strategies against hepatic cancer. therapeutic target hsa-mir-152 Carcinoma, Hepatocellular, HCV-Related 24416131 These findings provide important evidence that the reduced miR-152 expression by HCV core protein can indirectly lose an inhibitory effect on Wnt1, which might, at least partially lead to cell proliferation of liver cancer cells.MiR-152 may have a therapeutic potential to suppress liver cancer proliferation. therapeutic target hsa-mir-101 Carcinoma, Laryngeal 26286725 disease of cellular proliferation DOID:2600 C32.3 D007822 21198 HP:0012118 These results indicate that miR-101 is a potent tumour repressor that directly represses CDK8 expression. Thus, detection and targeting of miR-101 may represent a novel diagnostic and therapeutic strategy for LSCC patients. therapeutic target hsa-mir-296 Carcinoma, Laryngeal 26264462 disease of cellular proliferation DOID:2600 C32.3 D007822 21198 HP:0012118 This study indicates that miR-296-5p expression is associated with resistance to radiotherapy and tumor recurrence in early stage LSCC, showing the feasibility of this marker as a novel prognostic factor for this malignance.Furthermore, miR-296-5p expression could be helpful in the identification of tumors resistant to radiotherapy; thus aiding the clinicians in the choice of the best therapeutic scheme to be used in each case. therapeutic target hsa-mir-1244 Carcinoma, Lung 26355845 disease of cellular proliferation DOID:3905 C34.90 D008175 These results suggested that there is an autoregulatory circuit consisting of miR-1244 and MEF2D, which contributes to the progression of lung cancer. Targeting this molecular loop may be a promising strategy for lung carcinoma treatment. therapeutic target hsa-mir-15b Carcinoma, Lung 23517578 disease of cellular proliferation DOID:3905 C34.90 D008175 Up-regulation of miRNA-15b in tumor environment might negatively regulate anti-tumor immunity through inhibiting function of CD8+ T cells.miRNA-15b might be a potential therapeutic target for immunotherapy. therapeutic target hsa-let-7b Carcinoma, Lung, Non-Small-Cell 23029111 C34.90 D002289 HP:0030358 Moreover, the regulation of let-7b and miR-126 expression could have therapeutic potential because it could reduce tumor angiogenesis and therefore suppress tumor growth in lung cancer patients. therapeutic target hsa-let-7c Carcinoma, Lung, Non-Small-Cell 23534758 C34.90 D002289 HP:0030358 these results demonstrate let-7c inhibits NSCLC cell proliferation and tumorigenesis by partial direct targeting of the HOXA1 pathway, which suggests that restoration of let-7c expression may thus offer a potential therapeutic intervention strategy for NSCLC. therapeutic target hsa-mir-126 Carcinoma, Lung, Non-Small-Cell 23029111 C34.90 D002289 HP:0030358 Moreover, the regulation of let-7b and miR-126 expression could have therapeutic potential because it could reduce tumor angiogenesis and therefore suppress tumor growth in lung cancer patients. therapeutic target hsa-mir-140 Carcinoma, Lung, Non-Small-Cell 28739724 C34.90 D002289 HP:0030358 Therapeutic Role of MiR-140-5p for the Treatment of Non-small Cell Lung Cancer. therapeutic target hsa-mir-205 Carcinoma, Lung, Non-Small-Cell 22618509 C34.90 D002289 HP:0030358 we report that miR-93, miR-205, miR-221, and let-7e may represent novel biomarkers for differential diagnosis and prognosis of certain NSCLC subtypes or be new targets of histology-specific treatments. therapeutic target hsa-mir-221 Carcinoma, Lung, Non-Small-Cell 22618509 C34.90 D002289 HP:0030358 we report that miR-93, miR-205, miR-221, and let-7e may represent novel biomarkers for differential diagnosis and prognosis of certain NSCLC subtypes or be new targets of histology-specific treatments. therapeutic target hsa-mir-224 Carcinoma, Lung, Non-Small-Cell 29723992 C34.90 D002289 HP:0030358 MicroRNAs in Smoking-Related Carcinogenesis: Biomarkers, Functions, and Therapy. therapeutic target hsa-mir-93 Carcinoma, Lung, Non-Small-Cell 22618509 C34.90 D002289 HP:0030358 we report that miR-93, miR-205, miR-221, and let-7e may represent novel biomarkers for differential diagnosis and prognosis of certain NSCLC subtypes or be new targets of histology-specific treatments. therapeutic target hsa-mir-1 Carcinoma, Lung, Non-Small-Cell 24486107 C34.90 D002289 HP:0030358 These findings indicate that miR-1 may play an important role in the pathogenesis of NSCLC by regulating PIK3CA through the PI3K/Akt pathway. Increasing miR-1 expression may provide a novel approach for NSCLC treatment. therapeutic target hsa-mir-107 Carcinoma, Lung, Non-Small-Cell 25400821 C34.90 D002289 HP:0030358 miR-107 can be used to predict a patient's response to chemotherapy as well as serve as a novel potential maker for NSCLC therapy. therapeutic target hsa-mir-10b Carcinoma, Lung, Non-Small-Cell 24216130 C34.90 D002289 HP:0030358 In this study, we found that miR-10b is a tumor enhancer in NSCLC.Thus, miR-10b may represent a potential therapeutic target for NSCLC intervention. therapeutic target hsa-mir-130a Carcinoma, Lung, Non-Small-Cell 26398698 C34.90 D002289 HP:0030358 Taken together, the results established miR-130a as a molecular switch during macrophage development and as a potential target for the treatment of NSCLC. therapeutic target hsa-mir-137 Carcinoma, Lung, Non-Small-Cell 26617798 C34.90 D002289 HP:0030358 Taken together, our findings suggested that miR-137/BMP7 axis could contribute to the progression of NSCLC, suggesting miR-137 as a potential therapeutic target for the treatment of NSCLC. therapeutic target hsa-mir-138 Carcinoma, Lung, Non-Small-Cell 24405893 C34.90 D002289 HP:0030358 These findings suggest that miR-138 as a potential tumor suppressor could inhibit cell proliferation by targeting PDK1 in NSCLC cells, which could be employed as a potential therapeutic target for miRNA-based NSCLC therapy. therapeutic target hsa-mir-142 Carcinoma, Lung, Non-Small-Cell 26617792 C34.90 D002289 HP:0030358 These results suggest that miR-142-3p may be a tumor suppressor through the downregulation of HMGB1 in NSCLC. miR-142-3p may be a tumor suppressor and a potential therapeutic agent for patients with NSCLC. therapeutic target hsa-mir-145 Carcinoma, Lung, Non-Small-Cell 25961369 C34.90 D002289 HP:0030358 Our results indicate that low miR-145 expression, due to methylation, promotes NSCLC cell proliferation, migration and invasion by targeting mucin 1. Therefore, miR-145 may be a valuable therapeutic target for NSCLC. therapeutic target hsa-mir-145 Carcinoma, Lung, Non-Small-Cell 25703099 C34.90 D002289 HP:0030358 we identified miRs differentially expressed in cisplatin-resistant cell lines, including miR-145. A predicted target of miR-145 is CDK6, and its expression was found to be downregulated in the resistant sublines, although not directly by miR-145. Inhibition of CDK6 antagonizes cisplatin-induced NSCLC cell cytotoxicity, suggesting that agents that inhibit CDK6 should be avoided during cisplatin therapy. therapeutic target hsa-mir-148a Carcinoma, Lung, Non-Small-Cell 26584284 C34.90 D002289 HP:0030358 Evidence from this study demonstrated that miR-148a exerts tumor-suppressive effects in NSCLC and suggests a new therapeutic option for NSCLC. therapeutic target hsa-mir-149 Carcinoma, Lung, Non-Small-Cell 24625834 C34.90 D002289 HP:0030358 These results suggest miRNA-dependent transcriptional regulation differences play an important role in determining key hallmarks of NSCLC, and may provide new biomarkers for personalized treatment strategies. therapeutic target hsa-mir-185 Carcinoma, Lung, Non-Small-Cell 26617940 C34.90 D002289 HP:0030358 Collectively, we conclude that miR-185 has a critical function by blocking AKT1 in NSCLC cells, and it may be a novel therapeutic agent for miRNA based NSCLC therapy. therapeutic target hsa-mir-200c Carcinoma, Lung, Non-Small-Cell 24997798 C34.90 D002289 HP:0030358 These findings indicate that miR-200c exerts tumor-suppressive effects for NSCLC through the suppression of USP25 expression and suggests a new therapeutic application of miR-200c in the treatment of NSCLC. therapeutic target hsa-mir-204 Carcinoma, Lung, Non-Small-Cell 25412236 C34.90 D002289 HP:0030358 NUAK1 is excessively expressed in NSCLC and plays important roles in NSCLC invasion. The miR-204 acts as a tumour suppressor by inhibiting NUAK1 expression in NSCLC. Both NUAK1 and miR-204 may serve as potential targets of NSCLC therapy. therapeutic target hsa-mir-205 Carcinoma, Lung, Non-Small-Cell 24625834 C34.90 D002289 HP:0030358 These results suggest miRNA-dependent transcriptional regulation differences play an important role in determining key hallmarks of NSCLC, and may provide new biomarkers for personalized treatment strategies. therapeutic target hsa-mir-21 Carcinoma, Lung, Non-Small-Cell 23777591 C34.90 D002289 HP:0030358 miRNA-21 may be considered as a potential novel target for future development of specific therapeutic interventions in NSCLC. therapeutic target hsa-mir-22 Carcinoma, Lung, Non-Small-Cell 25702651 C34.90 D002289 HP:0030358 Our study may provide the groundwork for further clinical molecular target therapy experiments in NSCLC.BAC therapeutic target hsa-mir-23b Carcinoma, Lung, Non-Small-Cell 26314549 C34.90 D002289 HP:0030358 In summary, integration of genomic analysis and microRNA expression profiling could identify novel cancer-related microRNAs, and miR-23b could be a potential prognostic marker for early stage NSCLCs. Further biological studies of miR-23b are warranted for the potential development of targeted therapy. therapeutic target hsa-mir-25 Carcinoma, Lung, Non-Small-Cell 26464659 C34.90 D002289 HP:0030358 In conclusion, miR-25 is up-regulated in NSCLC and promotes NSCLC cells proliferation and motility partially by targeting FBXW7. Our data suggest that miR-25 might serve as a potential therapeutic target for NSCLC treatment in the future. therapeutic target hsa-mir-296 Carcinoma, Lung, Non-Small-Cell 26549165 C34.90 D002289 HP:0030358 Taken together, the present study indicated that miR-296-5p regulated PLK1 expression and could function as a tumor suppressor in NSCLC progression, which provides a potential target for gene therapy of NSCLC. therapeutic target hsa-mir-326 Carcinoma, Lung, Non-Small-Cell 26548724 C34.90 D002289 HP:0030358 Our study demonstrated a direct target relationship between NSBP1 and miR-326 through which miR-326 inhibited cell proliferation and invasion of NSCLC cells. Thus, miR-326-NSBP1 is a promising candidate target for developing novel anticancer therapeutics for NSCLC. therapeutic target hsa-mir-34a Carcinoma, Lung, Non-Small-Cell 24551227 C34.90 D002289 HP:0030358 The data suggest that a majority of NSCLC and other cancers previously not suited for erlotinib may prove sensitive to the drug when used in combination with a miR-34a-based therapy. therapeutic target hsa-mir-34c Carcinoma, Lung, Non-Small-Cell 26261507 C34.90 D002289 HP:0030358 Taken together, our study implicates important roles of miR-34c-3p in NSCLC pathogenesis and implicates its potential application in cancer therapy. therapeutic target hsa-mir-365 Carcinoma, Lung, Non-Small-Cell 26045746 C34.90 D002289 HP:0030358 aberrant expression of mir-365/TTF-1 may be involved in the tumor development in patients with NSCLC. Moreover, mir-365 and TTF-1 could jointly predict the prognosis of patients and their combination may serve as a biomarker to predict risk of poor survival in NSCLC patients. Mir-365/TTF-1 might serve as a potential therapeutic target for clinical treatment of NSCLC. therapeutic target hsa-mir-374a Carcinoma, Lung, Non-Small-Cell 21748820 C34.90 D002289 HP:0030358 The authors show that low expression of miR-374a in early-stage NSCLC is associated with poor patient survival. Theresults demonstrate that expression of miR-374a at early stages of NSCLC progression can serve as a prognostic marker for patient risk stratification and may be a promising therapeutic target for the treatment of lung cancer. therapeutic target hsa-mir-375 Carcinoma, Lung, Non-Small-Cell 24625834 C34.90 D002289 HP:0030358 These results suggest miRNA-dependent transcriptional regulation differences play an important role in determining key hallmarks of NSCLC, and may provide new biomarkers for personalized treatment strategies. therapeutic target hsa-mir-378 Carcinoma, Lung, Non-Small-Cell 24625834 C34.90 D002289 HP:0030358 These results suggest miRNA-dependent transcriptional regulation differences play an important role in determining key hallmarks of NSCLC, and may provide new biomarkers for personalized treatment strategies. therapeutic target hsa-mir-422a Carcinoma, Lung, Non-Small-Cell 24625834 C34.90 D002289 HP:0030358 These results suggest miRNA-dependent transcriptional regulation differences play an important role in determining key hallmarks of NSCLC, and may provide new biomarkers for personalized treatment strategies. therapeutic target hsa-mir-452 Carcinoma, Lung, Non-Small-Cell 26316085 C34.90 D002289 HP:0030358 Our results suggest that miR-452 plays a vital role in development of NSCLC, and this miR-452-BMI1 pathway might generate a novel insight into the treatment of NSCLC. therapeutic target hsa-mir-497 Carcinoma, Lung, Non-Small-Cell 26316081 C34.90 D002289 HP:0030358 miR-497 plays an important role in inhibiting the proliferation of NSCLC by targeting YAP1. Our results suggest that miR-497 is a potential therapeutic target in treating patients with NSCLC. therapeutic target hsa-mir-675 Carcinoma, Lung, Non-Small-Cell 25889562 C34.90 D002289 HP:0030358 miR-675-5p functions as a novel tumor suppressor in NSCLC and the anti-oncogenic activity may involve its inhibition of the target gene GPR55.These findings suggest the possibility for miR-675-5p as a therapeutic target in NSCLC. therapeutic target hsa-mir-708 Carcinoma, Lung, Non-Small-Cell 24625834 C34.90 D002289 HP:0030358 These results suggest miRNA-dependent transcriptional regulation differences play an important role in determining key hallmarks of NSCLC, and may provide new biomarkers for personalized treatment strategies. therapeutic target hsa-mir-9 Carcinoma, Lung, Non-Small-Cell 26593208 C34.90 D002289 HP:0030358 These findings suggest that oncogenic miR-9 targeted FoxO1 to promote cell growth, and downregulation of this axis was involved in erlotinib's growth inhibitory effects. Clarifying the regulation of miRNAs by erlotinib may indicate novel strategies for enhancing EGFR-targeted cancer therapy. therapeutic target hsa-mir-101 Carcinoma, Nasopharyngeal 25607713 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 the identified miR-101/STMN1 pathway contributed to the elucidation of the mechanisms of radioresistance in human NPC and that it may represent a potential therapeutic target. therapeutic target hsa-mir-145 Carcinoma, Nasopharyngeal 26297956 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 This study reveals that miR-145 suppressed the invasion and migration of NPC cells by targeting ADAM17.Thus, miR-145 could be a therapeutic target for NPC. therapeutic target hsa-mir-145 Carcinoma, Nasopharyngeal 25816323 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 Our findings demonstrated that miR-145 function as a tumor suppressor in NPC development and progression via targeting FSCN1, which could sever as a potential novel therapeutic target for patients with NPC. therapeutic target hsa-mir-200b Carcinoma, Nasopharyngeal 24281414 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 These results indicate that miR-200b exerts tumor-suppressive effects in NPC carcinogenesis through the suppression of Notch1 expression and suggest a therapeutic application of miR-200b in NPC. therapeutic target hsa-mir-24 Carcinoma, Nasopharyngeal 26503504 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 Overall, miR-24 acts as a novel tumor suppressor in the development and progression of NPC through targeting FSCN1, which providing new insight into the mechanisms of NPC carcinogenesis and suggesting the possibility of miR-24 as a therapeutic target. therapeutic target hsa-mir-34c Carcinoma, Nasopharyngeal 25611392 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 The newly identified miR-34c/MET pathway provides further insights into the development and progression of NPC, and may represent a novel therapeutic target for NPC treatment. therapeutic target hsa-mir-451 Carcinoma, Nasopharyngeal 24138931 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 The newly identified miR-451/MIF pathway provides insight into NPC initiation and progression, and may represent a novel therapeutic target. therapeutic target hsa-mir-4792 Carcinoma, Nasopharyngeal 26585487 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 These findings suggest that miR-4792 functions as a tumor suppressor in NPC development and progression by targeting FOXC1, which could act as a novel potential therapeutic target for NPC treatment,and miR-4792/FOXC1 pathway that we studied might be used for NPC treatment in future. therapeutic target hsa-mir-634 Carcinoma, Nasopharyngeal 25400759 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 miR-634 inhibited tumor growth and enhanced paclitaxel sensitivity. Thus, our findings provide important information for the development of targeted gene therapy for reversing paclitaxel resistance in NPC. therapeutic target hsa-mir-93 Carcinoma, Nasopharyngeal 24606633 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 The present study reports an involvement of miR-93-mediated TGFβR2 down-regulation in NPC aggressiveness, thus giving extended insights into molecular mechanisms underlying cancer aggressiveness. Approaches aimed at blocking miR-93 may serve as a promising therapeutic strategy for treating NPC patients. therapeutic target hsa-mir-145 Carcinoma, Ovarian 26472353 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 These data confirmed the tumor-suppressing function of miR-145 in EOC and identified TRIM2 as a new miR-145 target. In vivo delivery of agomiR-145 might be a feasible approach for miRNA-directed cancer therapy. therapeutic target hsa-mir-145 Carcinoma, Ovarian 28804560 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 Using miR-145 mimics may be a rational approach for therapeutic applications in ovarian carcinoma in the future therapeutic target hsa-mir-204 Carcinoma, Ovarian 25962115 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 miR-204 up-regulation may be linked directly to the sensitivity of EOC cell anoikis by contributing to BDNF down-regulation. Our findings provide a novel mechanism for manipulating miR-204 levels therapeutically to restore anoikis sensitivity. therapeutic target hsa-mir-506 Carcinoma, Ovarian 26369335 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 Therefore, miR-506 plays a functionally important role in homologous recombination and has important therapeutic value for sensitizing cancer cells to chemotherapy, especially in chemo-resistant patients with attenuated expression of miR-506. therapeutic target hsa-mir-9 Carcinoma, Ovarian 26152689 endocrine system disease DOID:4001 C56.9 C538090 167000 HP:0025318 Methylation-associated miR-9 down-regulation is probably one of the key mechanisms for paclitaxel resistance in EOC cells, via targeting CCNG1. Our findings may also provide a new potential therapeutic target to reversepaclitaxel resistance in EOC patients. therapeutic target hsa-mir-200c Carcinoma, Pancreatic 26081037 C25.3 C562463 260350 HP:0002894 Our study demonstrated that miR-200c may become a new therapeutic target for gene therapy in patients suffered from pancreatic cancer. therapeutic target hsa-mir-195 Carcinoma, Prostate 26080838 disease of cellular proliferation DOID:10286 D07.5 D011471 176807 HP:0012125 The newly identified miR-195-RPS6KB1 axis partially illustrates the molecular mechanism of prostate cancer progression and represents a novel potential therapeutic target for prostate cancer treatment. therapeutic target hsa-mir-21 Carcinoma, Rectal 24039353 disease of cellular proliferation DOID:1993 C20 D012004 In this review,we summarize the latest research findings of the clinicopathological relevance of miRNAs-21 in CRC initiation, development, and progress, highlighting its potential diagnostic, prognostic, and therapeutic application, as well as discussing future prospects. therapeutic target hsa-mir-221 Carcinoma, Rectal 21515467 disease of cellular proliferation DOID:1993 C20 D012004 The miR-221-specific inhibitor shows potent inhibitory effect on the growth of CRC cells, suggesting its value as a potential anti-tumor candidate for treatment of CRC. therapeutic target hsa-mir-101-1 Carcinoma, Renal Cell 22609199 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells. therapeutic target hsa-mir-101-2 Carcinoma, Renal Cell 22609199 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells. therapeutic target hsa-mir-126 Carcinoma, Renal Cell 28257806 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 Pseudohypoxia induced by miR-126 deactivation promotes migration and therapeutic resistance in renal cell carcinoma. therapeutic target hsa-mir-145 Carcinoma, Renal Cell 24384875 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 miR-145 functions as tumor suppressor in RCC, suggesting that miR-145 may be a potential therapeutic target for RCC. therapeutic target hsa-mir-182 Carcinoma, Renal Cell 24886554 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 These findings highlight an important role for miR-182-5p in the pathogenesis of RCC, and restoration of miR-182-5p could be considered as a potential therapeutic strategy for RCC therapy. therapeutic target hsa-mir-204 Carcinoma, Renal Cell 26323722 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 These results suggested that miR-204 may have value as a marker for the early detection of tumor metastasis and a therapeutic target preventing the invasion of renal cell carcinoma. therapeutic target hsa-mir-206 Carcinoma, Renal Cell 26808577 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 All these results suggested that miR-206 functioned as a novel cell cycle regulator and tumor suppressor in ccRCC and could be considered as a potential target for ccRCC therapy. therapeutic target hsa-mir-210 Carcinoma, Renal Cell 25555365 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 might be involved in carcinogenesis and aggressive tumor behavior were identified. miR-210 is a potential therapeutic target and independent marker of poor prognosis of ccRCC therapeutic target hsa-mir-22 Carcinoma, Renal Cell 26499759 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 These findings showed that miR-22 functioned as tumor suppressor in RCC and blocked RCC growth and metastasis by directly targeting SIRT1 in RCC, indicating a potential novel therapeutic role in RCC treatment. therapeutic target hsa-mir-221 Carcinoma, Renal Cell 26191221 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 These findings suggested that miR-221 play an oncogenic role in the renal cancer cell proliferation, migration and invasion by directly inhibiting the tumor suppressor TIMP2, indicating miR-221 act as a potential new therapeutic target for the treatment of ccRCC. therapeutic target hsa-mir-451 Carcinoma, Renal Cell 26779781 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 MiR-451 acts as an anti-oncogene in RCC. Our data offer a new therapeutic target for further research. therapeutic target hsa-mir-451a Carcinoma, Renal Cell 25405789 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 miR-451a may have an important role as a tumor enhancer in RCC. These results imply that miR-451a may be a promising therapeutic target for the treatment of RCC. therapeutic target hsa-mir-107 Carcinoma, Renal Cell, Clear-Cell 25758424 disease of cellular proliferation DOID:4467 HP:0006770 In summary, our results showed that miR-107 can inhibit cell proliferation and invasiveness of renal cell carcinoma. Furthermore, this study may provide a potential therapeutic regimen for clear cell renal cell carcinoma treatment. therapeutic target hsa-mir-10b Carcinoma, Renal Cell, Clear-Cell 26617769 disease of cellular proliferation DOID:4467 HP:0006770 Our results suggest that miR-10b plays a tumor-suppressive role in ccRCC. Demethylation of miR-10b may be therapeutically beneficial for ccRCC treatment. therapeutic target hsa-mir-124 Carcinoma, Renal Cell, Clear-Cell 26002553 disease of cellular proliferation DOID:4467 HP:0006770 We hypothesize that these three miRNAs are fundamentalcontributing to ccRCC aggressive/metastatic behavior; and miR-124-3p especially has a key role through regulating CAV1 and FLOT1 expression. Restoration of the levels of these miRNAs could be considered as a potential therapeutic strategy for ccRCC. therapeutic target hsa-mir-136 Carcinoma, Renal Cell, Clear-Cell 25450277 disease of cellular proliferation DOID:4467 HP:0006770 This integrative network approach revealed important miRNAs in the ccRCC that can identify specific disease biomarkers, which can be used as targets for cancer treatment. therapeutic target hsa-mir-155 Carcinoma, Renal Cell, Clear-Cell 29534467 disease of cellular proliferation DOID:4467 HP:0006770 Our results further support a role for miR-155 as a promising cancer classifier and potentially as a therapeutic target in ccRCC that merits further investigation therapeutic target hsa-mir-223 Carcinoma, Renal Cell, Clear-Cell 25818776 disease of cellular proliferation DOID:4467 HP:0006770 miR-223 promotes renal cancer cell migration and proliferation and may serve as a potential therapeutic target for ccRcc. therapeutic target hsa-mir-320d Carcinoma, Renal Cell, Clear-Cell 25450277 disease of cellular proliferation DOID:4467 HP:0006770 This integrative network approach revealed important miRNAs in the ccRCC that can identify specific disease biomarkers, which can be used as targets for cancer treatment. therapeutic target hsa-mir-335 Carcinoma, Renal Cell, Clear-Cell 25450277 disease of cellular proliferation DOID:4467 HP:0006770 This integrative network approach revealed important miRNAs in the ccRCC that can identify specific disease biomarkers, which can be used as targets for cancer treatment. therapeutic target hsa-mir-340 Carcinoma, Renal Cell, Clear-Cell 25450277 disease of cellular proliferation DOID:4467 HP:0006770 This integrative network approach revealed important miRNAs in the ccRCC that can identify specific disease biomarkers, which can be used as targets for cancer treatment. therapeutic target hsa-mir-425 Carcinoma, Renal Cell, Clear-Cell 25450277 disease of cellular proliferation DOID:4467 HP:0006770 This integrative network approach revealed important miRNAs in the ccRCC that can identify specific disease biomarkers, which can be used as targets for cancer treatment. therapeutic target hsa-mir-492 Carcinoma, Renal Cell, Clear-Cell 25815441 disease of cellular proliferation DOID:4467 HP:0006770 Upregulation of microRNA-492 induced by epigenetic drug treatment inhibits the malignant phenotype of clear cell renal cell carcinoma in vitro. therapeutic target hsa-mir-506 Carcinoma, Renal Cell, Clear-Cell 25793370 disease of cellular proliferation DOID:4467 HP:0006770 miR-506 exerts its anti-cancer function by directly targeting FLOT1 in renal cancer, indicating a potential novel therapeutic role in renal cancer treatment. therapeutic target hsa-mir-21 Carcinoma, Salivary Adenoid Cystic 26367487 disease of cellular proliferation DOID:4866 C08.9 D003528 Therefore, suppression of miR-21 may provide a potential approach for the treatment of advanced SACC patients. therapeutic target hsa-mir-320a Carcinoma, Salivary Adenoid Cystic 25924850 disease of cellular proliferation DOID:4866 C08.9 D003528 MiR-320a inhibits metastasis in SACCs by targeting ITGB3 and may serve as a therapeutic target and prognostic marker in salivary cancers. therapeutic target hsa-mir-126 Carcinoma, Thyroid 26384552 disease of cellular proliferation DOID:3963 C73 D013964 188550 HP:0002890 Expression of miR-126 was down-regulated in BRAF(V600E) mutated undifferentiated thyroid carcinoma. In addition, miR-126 was found to act as proliferation suppressor targeting PIK3R2 gene and reducing p85β (a regulatory subunit of PI3K kinase) protein translation and lower AKT kinase activity.Therefore, miR-126 could be a potential therapeutic tool in the treatment of undifferentiated thyroid carcinoma. therapeutic target hsa-mir-146b Carcinoma, Thyroid 26282166 disease of cellular proliferation DOID:3963 C73 D013964 188550 HP:0002890 In conclusion, our study has uncovered the existence of a miR-146b-3p/PAX8/NIS regulatory circuit that may be exploited therapeutically to modulate thyroid cell differentiation and iodide uptake for improved treatment of advanced thyroid cancer. therapeutic target hsa-mir-204 Carcinoma, Thyroid 25603050 disease of cellular proliferation DOID:3963 C73 D013964 188550 HP:0002890 miR-204-5p acts as a tumor suppressor in PTC by regulating IGFBP5 expression and that miR-204-5p can potentially serve as an antitumorigenic agent in the treatment of PTC. therapeutic target hsa-mir-221 Carcinoma, Thyroid 29351231 disease of cellular proliferation DOID:3963 C73 D013964 188550 HP:0002890 These ceRNAs are critical in revealing the secrets behind thyroid cancer progression and may serve as future therapeutic biomarkers therapeutic target hsa-mir-222 Carcinoma, Thyroid 29351231 disease of cellular proliferation DOID:3963 C73 D013964 188550 HP:0002890 These ceRNAs are critical in revealing the secrets behind thyroid cancer progression and may serve as future therapeutic biomarkers therapeutic target hsa-mir-34b Carcinoma, Thyroid 28840508 disease of cellular proliferation DOID:3963 C73 D013964 188550 HP:0002890 It could be a target for developing treatment strategies of thyroid carcinoma with aggressive clinical behaviour therapeutic target hsa-mir-375 Carcinoma, Thyroid 29351231 disease of cellular proliferation DOID:3963 C73 D013964 188550 HP:0002890 These ceRNAs are critical in revealing the secrets behind thyroid cancer progression and may serve as future therapeutic biomarkers therapeutic target hsa-mir-122 Carcinoma, Thyroid, Anaplastic 23598436 C73 D065646 188550 HP:0011779 Redifferentiation and induction of tumor suppressors miR-122 and miR-375 by the PAX8/PPARγ fusion protein inhibits anaplastic thyroid cancer: a novel therapeutic strategy. therapeutic target hsa-mir-17 Carcinoma, Thyroid, Anaplastic 18429962 C73 D065646 188550 HP:0011779 Thus, we have clarified functional differences among the members of the cluster in ATC cells. In conclusion, these findings suggest that the miR-17-92 cluster plays an important role in certain types of ATCs and could be a novel target for ATC treatment. therapeutic target hsa-mir-18 Carcinoma, Thyroid, Anaplastic 18429962 C73 D065646 188550 HP:0011779 Thus, we have clarified functional differences among the members of the cluster in ATC cells. In conclusion, these findings suggest that the miR-17-92 cluster plays an important role in certain types of ATCs and could be a novel target for ATC treatment. therapeutic target hsa-mir-19a Carcinoma, Thyroid, Anaplastic 18429962 C73 D065646 188550 HP:0011779 Thus, we have clarified functional differences among the members of the cluster in ATC cells. In conclusion, these findings suggest that the miR-17-92 cluster plays an important role in certain types of ATCs and could be a novel target for ATC treatment. therapeutic target hsa-mir-19b-1 Carcinoma, Thyroid, Anaplastic 18429962 C73 D065646 188550 HP:0011779 Thus, we have clarified functional differences among the members of the cluster in ATC cells. In conclusion, these findings suggest that the miR-17-92 cluster plays an important role in certain types of ATCs and could be a novel target for ATC treatment. therapeutic target hsa-mir-205 Carcinoma, Thyroid, Anaplastic 29317480 C73 D065646 188550 HP:0011779 This may open avenues to exploit miR-205 as an alternative cancer therapeutic strategy in the future therapeutic target hsa-mir-20a Carcinoma, Thyroid, Anaplastic 18429962 C73 D065646 188550 HP:0011779 Thus, we have clarified functional differences among the members of the cluster in ATC cells. In conclusion, these findings suggest that the miR-17-92 cluster plays an important role in certain types of ATCs and could be a novel target for ATC treatment. therapeutic target hsa-mir-375 Carcinoma, Thyroid, Anaplastic 23598436 C73 D065646 188550 HP:0011779 Redifferentiation and induction of tumor suppressors miR-122 and miR-375 by the PAX8/PPARγ fusion protein inhibits anaplastic thyroid cancer: a novel therapeutic strategy. therapeutic target hsa-mir-92-1 Carcinoma, Thyroid, Anaplastic 18429962 C73 D065646 188550 HP:0011779 Thus, we have clarified functional differences among the members of the cluster in ATC cells. In conclusion, these findings suggest that the miR-17-92 cluster plays an important role in certain types of ATCs and could be a novel target for ATC treatment. therapeutic target hsa-mir-146a Carcinoma, Thyroid, Papillary 29048684 disease of cellular proliferation DOID:3969 C73 C536915 188550 HP:0002895 miR-146a and miR-146b in the diagnosis and prognosis of papillary thyroid carcinoma. therapeutic target hsa-mir-146b Carcinoma, Thyroid, Papillary 27533309 disease of cellular proliferation DOID:3969 C73 C536915 188550 HP:0002895 In conjunction with current therapeutic regimens, targeting the miR-146b-IRAK1 axis may provide a potential approach for PTC management. therapeutic target hsa-mir-146b Carcinoma, Thyroid, Papillary 28294980 disease of cellular proliferation DOID:3969 C73 C536915 188550 HP:0002895 MicroRNA-146b: A Novel Biomarker and Therapeutic Target for Human Papillary Thyroid Cancer. therapeutic target hsa-mir-146b Carcinoma, Thyroid, Papillary 29048684 disease of cellular proliferation DOID:3969 C73 C536915 188550 HP:0002895 miR-146a and miR-146b in the diagnosis and prognosis of papillary thyroid carcinoma. therapeutic target hsa-mir-181b Carcinoma, Thyroid, Papillary 25550803 disease of cellular proliferation DOID:3969 C73 C536915 188550 HP:0002895 downregulation of miR-181b results in the upregulation of CYLD at protein levels. Taken together, downregulation of miR-181b expression causes cellular growth inhibition, promoting cellular apoptosis by targeting CYLD. These findings suggest that downregulation of the expression of miR-181b may be a therapeutic target for the treatment of human thyroid papillary cancer. therapeutic target hsa-mir-21 Carcinoma, Thyroid, Papillary 24650454 disease of cellular proliferation DOID:3969 C73 C536915 188550 HP:0002895 These data suggest that miRNA-21 may play an oncogenic role by directly targeting PDCD4 in the cellular processes of PTC. In addition, the findings in our present study also may represent new clues for the diagnostic and therapeutic strategies in the treatment of PTC. therapeutic target hsa-mir-96 Carcinoma, Thyroid, Papillary 26617698 disease of cellular proliferation DOID:3969 C73 C536915 188550 HP:0002895 The data from the present study demonstrated that miR-96 can promote proliferation, and inhibit apoptosis in PTC cell lines K1 and TPC1, thus miR-96 may play an oncogenic role in PTC by inhibiting the FOXO1 and regulating AKT/FOXO1/Bim pathway, and it may serve as a novel therapeutic target for miRNA-based PTC therapy. therapeutic target hsa-mir-17 Carcinoma, Vulvar 26297962 disease of cellular proliferation DOID:1294 C51.9 D014846 Design of a miRNA sponge for the miR-17 miRNA family as a therapeutic strategy against vulvar carcinoma. therapeutic target hsa-mir-130a Cardiac Fibrosis 29114000 MicroRNA-130a, a Potential Antifibrotic Target in Cardiac Fibrosis. therapeutic target hsa-mir-150 Cardiomegaly 25639779 I51.7 D006332 HP:0001640 miR-150 may be a new therapeutic target for cardiac hypertrophy. therapeutic target hsa-mir-33 Cardiometabolic Disorders 20466882 Our findings indicate that miR-33 acts in concert with the SREBP host genes to control cholesterol homeostasis and suggest that miR-33 may represent a therapeutic target for ameliorating cardiometabolic diseases. therapeutic target hsa-mir-1290 Cardiomyopathy 25761932 cardiovascular system disease DOID:0050700 I42 D009202 An immediate clinical application of the data is cardiac miR profiling to assess the risk of virus persistence and progressive clinical deterioration in CVB3 cardiomyopathy. Patients at risk are eligible for immediate antiviral therapy to minimize irreversible cardiac damage. therapeutic target hsa-mir-135b Cardiomyopathy 25761932 cardiovascular system disease DOID:0050700 I42 D009202 An immediate clinical application of the data is cardiac miR profiling to assess the risk of virus persistence and progressive clinical deterioration in CVB3 cardiomyopathy. Patients at risk are eligible for immediate antiviral therapy to minimize irreversible cardiac damage. therapeutic target hsa-mir-155 Cardiomyopathy 25761932 cardiovascular system disease DOID:0050700 I42 D009202 An immediate clinical application of the data is cardiac miR profiling to assess the risk of virus persistence and progressive clinical deterioration in CVB3 cardiomyopathy. Patients at risk are eligible for immediate antiviral therapy to minimize irreversible cardiac damage. therapeutic target hsa-mir-190 Cardiomyopathy 25761932 cardiovascular system disease DOID:0050700 I42 D009202 An immediate clinical application of the data is cardiac miR profiling to assess the risk of virus persistence and progressive clinical deterioration in CVB3 cardiomyopathy. Patients at risk are eligible for immediate antiviral therapy to minimize irreversible cardiac damage. therapeutic target hsa-mir-422a Cardiomyopathy 25761932 cardiovascular system disease DOID:0050700 I42 D009202 An immediate clinical application of the data is cardiac miR profiling to assess the risk of virus persistence and progressive clinical deterioration in CVB3 cardiomyopathy. Patients at risk are eligible for immediate antiviral therapy to minimize irreversible cardiac damage. therapeutic target hsa-mir-489 Cardiomyopathy 25761932 cardiovascular system disease DOID:0050700 I42 D009202 An immediate clinical application of the data is cardiac miR profiling to assess the risk of virus persistence and progressive clinical deterioration in CVB3 cardiomyopathy. Patients at risk are eligible for immediate antiviral therapy to minimize irreversible cardiac damage. therapeutic target hsa-mir-590 Cardiomyopathy 25761932 cardiovascular system disease DOID:0050700 I42 D009202 An immediate clinical application of the data is cardiac miR profiling to assess the risk of virus persistence and progressive clinical deterioration in CVB3 cardiomyopathy. Patients at risk are eligible for immediate antiviral therapy to minimize irreversible cardiac damage. therapeutic target hsa-mir-601 Cardiomyopathy 25761932 cardiovascular system disease DOID:0050700 I42 D009202 An immediate clinical application of the data is cardiac miR profiling to assess the risk of virus persistence and progressive clinical deterioration in CVB3 cardiomyopathy. Patients at risk are eligible for immediate antiviral therapy to minimize irreversible cardiac damage. therapeutic target hsa-mir-195 Cardiomyopathy, Hypertrophic 22844503 cardiovascular system disease DOID:11984 I42.2 D002312 192600 HP:0001639 Elevated miR-195 targets the LKB1/AMPK signaling axis in HCM progression and implicates a functional role in HCM disease progression.MiR-195 may serve as potential therapeutics or therapeutic targets for heart disease. therapeutic target hsa-mir-21 Cardiomyopathy, Hypertrophic 20560046 cardiovascular system disease DOID:11984 I42.2 D002312 192600 HP:0001639 miR-21 is found to play important roles in vascular smooth muscle cell proliferation and apoptosis, cardiac cell growth and death, and cardiac fibroblast functions therapeutic target hsa-mir-1 Cardiovascular Diseases [unspecific] 26431632 D002318 The possibility of harnessing the miRNA network to achieve cardiac regeneration paves the way to exciting therapeutic applications. This could be achieved by either administering miRNA mimics or inhibitors, or transducing the heart with viral vectors expressing miRNA-encoding genes. therapeutic target hsa-mir-133a Cardiovascular Diseases [unspecific] 25421410 D002318 the roles of miR-133a in hypoxia-induced apoptotic and implicate its potential in cardiac dysfunctions therapy. therapeutic target hsa-mir-146 Cardiovascular Diseases [unspecific] 28407626 D002318 Exogenous miRNA-146a Enhances the Therapeutic Efficacy of Human Mesenchymal Stem Cells by Increasing Vascular Endothelial Growth Factor Secretion in the Ischemia/Reperfusion-Injured Heart. therapeutic target hsa-mir-146a Cardiovascular Diseases [unspecific] 26112171 D002318 miR-146a might be a new and promising therapeutic tool for treating cardiac disorders associated with enhanced inflammation in the heart. therapeutic target hsa-mir-15 Cardiovascular Diseases [unspecific] 26431632 D002318 The possibility of harnessing the miRNA network to achieve cardiac regeneration paves the way to exciting therapeutic applications. This could be achieved by either administering miRNA mimics or inhibitors, or transducing the heart with viral vectors expressing miRNA-encoding genes. therapeutic target hsa-mir-16 Cardiovascular Diseases [unspecific] 29104843 D002318 miR-16 was a potential therapeutic target by participating in the Ang II-associated multiple signaling pathways in cardiovascular diseases therapeutic target hsa-mir-199a Cardiovascular Diseases [unspecific] 26431632 D002318 The possibility of harnessing the miRNA network to achieve cardiac regeneration paves the way to exciting therapeutic applications. This could be achieved by either administering miRNA mimics or inhibitors, or transducing the heart with viral vectors expressing miRNA-encoding genes. therapeutic target hsa-mir-21 Cardiovascular Diseases [unspecific] 25738901 D002318 miR-21 is sensitive to high-concentration glucose treatment in macrophages, and appears to have a protective effect in macrophage apoptosis induced by high concentrations of glucose via programmed cell death 4 (PDCD4). therapeutic target hsa-mir-21 Cardiovascular Diseases [unspecific] 20560046 D002318 miR-21:miR-21 might be a novel therapeutic target in cardiovascular diseases therapeutic target hsa-mir-21 Cardiovascular Diseases [unspecific] 26048714 D002318 our study uncovers a novel regulatory mechanism of VSMC migration by kaempferol and suggests that miRNA modulation by kaempferol is a potential therapy for cardiovascular diseases. therapeutic target hsa-mir-21 Cardiovascular Diseases [unspecific] 25069679 D002318 MicroRNA-21 coordinates human multipotent cardiovascular progenitors therapeutic potential. therapeutic target hsa-mir-21 Cardiovascular Diseases [unspecific] 20649511 D002318 We here overview the current patent situation about the therapeutic use of miR-21 modulation in cancer and cardiovascular disease. therapeutic target hsa-mir-29b Cardiovascular Diseases [unspecific] 24569834 D002318 In conclusion, miR-29b plays a protective role in AngII-mediated cardiac remodeling and may be a therapeutic agent for cardiac fibrosis by targeting the TGF-β/Smad3 pathway. therapeutic target hsa-mir-302 Cardiovascular Diseases [unspecific] 26431632 D002318 The possibility of harnessing the miRNA network to achieve cardiac regeneration paves the way to exciting therapeutic applications. This could be achieved by either administering miRNA mimics or inhibitors, or transducing the heart with viral vectors expressing miRNA-encoding genes. therapeutic target hsa-mir-324 Cardiovascular Diseases [unspecific] 26633713 D002318 Our study defines the NFAT4/ miR-324-5p/Mtfr1 axis, which participates in the regulation of mitochondrial fission and cardiomyocyte apoptosis, and suggests potential new treatment avenues for cardiac diseases. therapeutic target hsa-mir-367 Cardiovascular Diseases [unspecific] 26431632 D002318 The possibility of harnessing the miRNA network to achieve cardiac regeneration paves the way to exciting therapeutic applications. This could be achieved by either administering miRNA mimics or inhibitors, or transducing the heart with viral vectors expressing miRNA-encoding genes. therapeutic target hsa-mir-499 Cardiovascular Diseases [unspecific] 28627982 D002318 miRNAs as potential therapeutic targets and diagnostic biomarkers for cardiovascular disease with a particular focus on WO2010091204. therapeutic target hsa-mir-637 Cardiovascular Diseases [unspecific] 26438598 D002318 Taken together, we have uncovered an important posttranscriptional mechanism that modulates the expression of the inflammatory marker CRP, which may be utilized in the development of treatments for inflammatory processes that cause CVD and age-related diseases. therapeutic target hsa-mir-100 Carotid Atherosclerosis 26238333 I65.29 D002340 This pilot study evaluated the expression of seven selected miRNAs in human carotid plaques from a small group of patients and suggested a potential regulatory role for these miRNAs in evolution of the plaque towards growth,instability and rupture. Studies based on larger sample sizes are required to determine the potential use of miR-100, miR-125a, miR-127, miR-133a, miR-145, and miR-221 as biomarkers or therapeutic targets for stroke. therapeutic target hsa-mir-125a Carotid Atherosclerosis 26238333 I65.29 D002340 This pilot study evaluated the expression of seven selected miRNAs in human carotid plaques from a small group of patients and suggested a potential regulatory role for these miRNAs in evolution of the plaque towards growth,instability and rupture. Studies based on larger sample sizes are required to determine the potential use of miR-100, miR-125a, miR-127, miR-133a, miR-145, and miR-221 as biomarkers or therapeutic targets for stroke. therapeutic target hsa-mir-127 Carotid Atherosclerosis 26238333 I65.29 D002340 This pilot study evaluated the expression of seven selected miRNAs in human carotid plaques from a small group of patients and suggested a potential regulatory role for these miRNAs in evolution of the plaque towards growth,instability and rupture. Studies based on larger sample sizes are required to determine the potential use of miR-100, miR-125a, miR-127, miR-133a, miR-145, and miR-221 as biomarkers or therapeutic targets for stroke. therapeutic target hsa-mir-133a Carotid Atherosclerosis 26238333 I65.29 D002340 This pilot study evaluated the expression of seven selected miRNAs in human carotid plaques from a small group of patients and suggested a potential regulatory role for these miRNAs in evolution of the plaque towards growth,instability and rupture. Studies based on larger sample sizes are required to determine the potential use of miR-100, miR-125a, miR-127, miR-133a, miR-145, and miR-221 as biomarkers or therapeutic targets for stroke. therapeutic target hsa-mir-145 Carotid Atherosclerosis 26238333 I65.29 D002340 This pilot study evaluated the expression of seven selected miRNAs in human carotid plaques from a small group of patients and suggested a potential regulatory role for these miRNAs in evolution of the plaque towards growth,instability and rupture. Studies based on larger sample sizes are required to determine the potential use of miR-100, miR-125a, miR-127, miR-133a, miR-145, and miR-221 as biomarkers or therapeutic targets for stroke. therapeutic target hsa-mir-221 Carotid Atherosclerosis 26238333 I65.29 D002340 This pilot study evaluated the expression of seven selected miRNAs in human carotid plaques from a small group of patients and suggested a potential regulatory role for these miRNAs in evolution of the plaque towards growth,instability and rupture. Studies based on larger sample sizes are required to determine the potential use of miR-100, miR-125a, miR-127, miR-133a, miR-145, and miR-221 as biomarkers or therapeutic targets for stroke. therapeutic target hsa-mir-29b Cerebral Ischemia 26126866 cardiovascular system disease DOID:2316 I67.82 D002545 HP:0002637 MicroRNA-29b is a therapeutic target in cerebral ischemia associated with aquaporin 4. therapeutic target hsa-mir-19a Cervical Neoplasms 29332345 disease of cellular proliferation DOID:4362 C53.9 D002583 603956 HP:0030159 Overall, inhibiting miR-19a significantly improves the sensitivity of SiHa cells to radiotherapy, which could lead to new methods for the treatment of cervical cancer therapeutic target hsa-mir-215 Cervical Neoplasms 27295129 disease of cellular proliferation DOID:4362 C53.9 D002583 603956 HP:0030159 dysregulation of miR-29C, miR-34A, miR-98, and miR-215 therapeutic target hsa-mir-29c Cervical Neoplasms 27295129 disease of cellular proliferation DOID:4362 C53.9 D002583 603956 HP:0030159 dysregulation of miR-29C, miR-34A, miR-98, and miR-215 therapeutic target hsa-mir-34a Cervical Neoplasms 27295129 disease of cellular proliferation DOID:4362 C53.9 D002583 603956 HP:0030159 dysregulation of miR-29C, miR-34A, miR-98, and miR-215 therapeutic target hsa-mir-98 Cervical Neoplasms 27295129 disease of cellular proliferation DOID:4362 C53.9 D002583 603956 HP:0030159 dysregulation of miR-29C, miR-34A, miR-98, and miR-215 therapeutic target hsa-mir-122 Cholangiocarcinoma 26686459 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 MiR-122 expression was significantly weaker in CC tissues, and miR-122 overexpression might play pivotal roles in inhibiting proliferation, stimulating apoptosis and suppressing invasion of CC cells, suggesting a new target for CC diagnosis and treatment. therapeutic target hsa-mir-122 Cholangiocarcinoma 26825606 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 The results indicate that HNF6 may serve as a tumor suppressor by regulating miR-122, and its overexpression may represent a mechanism-based therapy for CCA. therapeutic target hsa-mir-122 Cholangiocarcinoma 28832247 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 miRNA profiling for diagnosis, prognosis and stratification of cancer treatment in cholangiocarcinoma. therapeutic target hsa-mir-200c Cholangiocarcinoma 26855082 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 The ability of the combined PCX/miR-200c treatment to obstruct two migratory pathways represents a promising antimetastatic strategy in cholangiocarcinoma. therapeutic target hsa-mir-203 Cholangiocarcinoma 26464713 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 Our findings suggest that miR-203 expression was an independent poor prognostic factor for CCA patient overall survival. Therefore, miR-203 may serve as a valuable prognostic marker and promising treatment target for CCA. therapeutic target hsa-mir-224 Cholangiocarcinoma 26573191 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 IL-6 may promote the invasive and metastatic properties of CCA through upregulated miR-224. Studies of the differentially expressed serum miRNAs in CCA may help to further elucidate the pathogenic processes of this disease and aid in the development of a novel and effective therapeutic strategy. therapeutic target hsa-mir-29a Cholangiocarcinoma 26441331 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 TGF-β1/miR-29a/HDAC4 pathway contributes to the pathogenesis of cholangiocarcinoma and our data provide new therapeutic targets for cholangiocarcinoma. therapeutic target hsa-mir-371b Chondrosarcoma 26214773 disease of cellular proliferation DOID:3371 M91-M94 D002813 215300 HP:0006765 It has been proposed that miRNA expression studies might be used as diagnostic, prognostic marker in cancer. miRNA expression data produced in our study may contribute future chondrosarcoma diagnosis and therapy. therapeutic target hsa-mir-1 Chordoma 24501096 musculoskeletal system disease DOID:3302 C41.0 D002817 215400 HP:0010762 These results indicate that suppressed miR-1 expression in chordoma may in part be a driver for tumor growth, and that miR-1 has potential to serve as prognostic biomarker and therapeutic target for chordoma patients. therapeutic target hsa-mir-155 Chordoma 25823817 musculoskeletal system disease DOID:3302 C41.0 D002817 215400 HP:0010762 We have shown miR-155 expression to independently affect prognosis in chordoma. These results collectively indicate that miR-155 expression may serve not only as a prognostic marker, but also as a potential therapeutic target in chordoma. therapeutic target hsa-mir-200c Chronic Hepatitis B 29593314 B18.0-.1 D019694 610424 an HBV-pSTAT3-SALL4-miR-200c axis regulates PD-L1. Therapeutic strategies to influence this axis might reverse virus-induced immune exhaustion therapeutic target hsa-mir-548 Chronic Hepatitis B 25196343 B18.0-.1 D019694 610424 The abnormal expression profiles of miRNA in PBMCs could be closely associated with immune activation of chronic HBV infection. miR-548, by targeting IFN-γR1, may represent a mechanism that can facilitate viral pathogenesis and help determine new therapeutic molecular targets. therapeutic target hsa-mir-122 Chronic Hepatitis C 27485847 B18.2 D019698 609532 First clinical trials using the blockade of liver specific miR-122 showed very promising results in the treatment of chronic hepatitis C virus infection. Results of preclinical and animal studies are also promising providing future rationale for the development of new therapeutics for various internal diseases including heart failure, bronchial asthma or inflammatory bowel diseases. therapeutic target hsa-mir-122 Chronic Hepatitis C 28993299 B18.2 D019698 609532 Circulating microRNAs as a biomarker to predict therapy efficacy in hepatitis C patients with different genotypes. therapeutic target hsa-mir-17 Chronic Hepatitis C 24819603 B18.2 D019698 609532 Involvement of MAP3K8 and miR-17-5p in poor virologic response to interferon-based combination therapy for chronic hepatitis C. therapeutic target hsa-mir-143 Chronic Inflammation 23811549 miR-143 can lead to increased expression of AIM2 and ASC mRNAs. Considering the significance of AIM2 and ASC in DNA sensing and inflammosome formation, it can be considered as a therapeutic agent for the treatment of chronic infectious diseases, especially viral infections. therapeutic target hsa-mir-155 Chronic Inflammation 19596814 Finally, we report for the first time on miR-155 silencing in vivo in a mouse inflammation model, which underscores the potential of miR-155 antagonists in the development of novel therapeutics for treatment of chronic inflammatory diseases. therapeutic target hsa-mir-150 Chronic Obstructive Pulmonary Disease 29205062 respiratory system disease DOID:3083 J44.9 D029424 606963 HP:0006510 Restoration of miR-150 expression may represent a potential therapeutic strategy for CS-related COPD therapeutic target hsa-mir-193 Chronic Obstructive Pulmonary Disease 24963038 respiratory system disease DOID:3083 J44.9 D029424 606963 HP:0006510 These studies establish the importance of microRNAs as downstream effectors of an apolipoprotein A-I mimetic peptide in the rescue of PH and suggest that treatment with apolipoprotein A-I mimetic peptides or miR193 may have therapeutic value. therapeutic target hsa-mir-328 Chronic Obstructive Pulmonary Disease 25894560 respiratory system disease DOID:3083 J44.9 D029424 606963 HP:0006510 inhibition of miR-328 in respiratory models of infection, steroid-induced immunosuppression, and smoke-induced emphysema enhances bacterial clearance.Thus, miRNA pathways can be targeted in the lung to enhance host defence against a clinically relevant microbial infection and offer a potential new anti-microbial approach for the treatment of respiratory diseases. therapeutic target hsa-mir-1288 Chronic Pain 26166255 G89.29 D059350 HP:0012532 These results suggest that miRNAs represent a valuable tool for differentiating VBD subtypes (localized pain with apparent peripheral neurosensory disruption vs widespread pain with a central sensory contribution) that may require different treatment approaches. therapeutic target hsa-mir-1294 Chronic Pain 26166255 G89.29 D059350 HP:0012532 These results suggest that miRNAs represent a valuable tool for differentiating VBD subtypes (localized pain with apparent peripheral neurosensory disruption vs widespread pain with a central sensory contribution) that may require different treatment approaches. therapeutic target hsa-mir-1825 Chronic Pain 26166255 G89.29 D059350 HP:0012532 These results suggest that miRNAs represent a valuable tool for differentiating VBD subtypes (localized pain with apparent peripheral neurosensory disruption vs widespread pain with a central sensory contribution) that may require different treatment approaches. therapeutic target hsa-mir-645 Chronic Pain 26166255 G89.29 D059350 HP:0012532 These results suggest that miRNAs represent a valuable tool for differentiating VBD subtypes (localized pain with apparent peripheral neurosensory disruption vs widespread pain with a central sensory contribution) that may require different treatment approaches. therapeutic target hsa-mir-155 Colitis 27395764 gastrointestinal system disease DOID:0060180 K52.9 D003092 191390 HP:0002583 IL-10/miR-155/SHIP-1 pathways play a critical role in commensal bacteria induced colitis and miR-15 therapeutic target hsa-mir-200c Colitis, Ulcerative 25546151 gastrointestinal system disease DOID:8577 K51 D003093 Integrated analysis of miRNA and mRNA expression profiles revealed hsa-miR-200c-3p for use of miRNA mimics as therapeutics. therapeutic target hsa-mir-132 Colon Neoplasms 29017096 D12.6 D003110 HP:0100273 miR-132 as a promising therapeutic candidate to control autoimmune inflammation and tumorigenesis in CAC patients therapeutic target hsa-mir-143 Colon Neoplasms 17504027 D12.6 D003110 HP:0100273 Further, we discuss the expression of miRNA-143 and -145 in colon cancer and their roles in carcinogenesis. The available data suggest that miRNAs would be potentially useful as diagnostic and therapeutic tools. therapeutic target hsa-mir-143 Colon Neoplasms 19464056 D12.6 D003110 HP:0100273 On the contrary, an extracellular signal-regulated protein kinase 5 (ERK5), which was determined to be a target of miR-143 in colon cancer DLD-1 cells, was time-dependently down-regulated at the translational level after the treatment. therapeutic target hsa-mir-21 Colon Neoplasms 24039353 D12.6 D003110 HP:0100273 In this review,we summarize the latest research findings of the clinicopathological relevance of miRNAs-21 in CRC initiation, development, and progress, highlighting its potential diagnostic, prognostic, and therapeutic application, as well as discussing future prospects. therapeutic target hsa-let-7 Colorectal Carcinoma 26084510 disease of cellular proliferation DOID:0080199 C19 D015179 114500 In summary,the results reveal that detailed molecular events can be combined with individual genetic data, including gene/miRNA expression data, to enhance in silico prediction of therapeutic response of individual CRC tumors.The study demonstrates that miRNA information can be applied as actionable information regarding individual therapeutic response. therapeutic target hsa-let-7a Colorectal Carcinoma 27737877 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Our data support the role of let-7a in suppressing antitumor immunity in colorectal cancer and suggest let-7a as a potential target of immunotherapy therapeutic target hsa-let-7c Colorectal Carcinoma 24503111 disease of cellular proliferation DOID:0080199 C19 D015179 114500 The MiR-99a/Let-7c/miR-125b signature may improve the selection of patients with KRAS wild-type mCRC as good candidates for anti-EGFR therapy. therapeutic target hsa-mir-106b Colorectal Carcinoma 26223867 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Our findings indicate that miR-106b promotes CRC cell migration and invasion by targeting DLC1. This miRNA may serve as a potential prognostic biomarker and therapeutic target for CRC. therapeutic target hsa-mir-124 Colorectal Carcinoma 24949825 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Our results make sense for the prevention and treatment of intestinal-related chronic inflammation or cancer. therapeutic target hsa-mir-1246 Colorectal Carcinoma 26573378 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Consequently, these findings provided a molecular basis for the role of miR-1246/CCNG2 in the progression of human CRC and suggested a novel target for the treatment of CRC. therapeutic target hsa-mir-125b Colorectal Carcinoma 24949825 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Our results make sense for the prevention and treatment of intestinal-related chronic inflammation or cancer. therapeutic target hsa-mir-125b Colorectal Carcinoma 24503111 disease of cellular proliferation DOID:0080199 C19 D015179 114500 The MiR-99a/Let-7c/miR-125b signature may improve the selection of patients with KRAS wild-type mCRC as good candidates for anti-EGFR therapy. therapeutic target hsa-mir-126 Colorectal Carcinoma 25584492 disease of cellular proliferation DOID:0080199 C19 D015179 114500 changes in cir-miRNA-126 during treatment are related to the response to chemotherapy and bevacizumab in patients with mCRC, thus representing a possible biomarker for the resistance to anti-angiogenic containing treatments. therapeutic target hsa-mir-1269a Colorectal Carcinoma 25872451 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Our findings suggest that miR-1269a is a potential marker to inform adjuvant chemotherapy decisions for CRC patients and a potential therapeutic target to deter metastasis. therapeutic target hsa-mir-128 Colorectal Carcinoma 24046120 disease of cellular proliferation DOID:0080199 C19 D015179 114500 NEK2 may be an independent prognostic factor for CRC and was regulated by miR-128, a microRNA that was subjected to epigenetic regulation.Thus, this miR-128/NEK2 pathway may be a prospective therapeutic target for patients with CRC. therapeutic target hsa-mir-1297 Colorectal Carcinoma 25422199 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-1297 has the potential to provide a new approach to colorectal cancer therapy by directly inhibiting Cox-2 expression. therapeutic target hsa-mir-140 Colorectal Carcinoma 25567303 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-140 regulates the Smad3 expression at the post-transcriptional level. miR-140 suppresses the migrating and invasive abilities of CRC cells, possibly through down-regulation of Smad3. The findings of this study suggest that miR-140 may have a unique potential as a possible biomarker candidate for diagnosis and therapy of tumor metastasis. therapeutic target hsa-mir-141 Colorectal Carcinoma 26125745 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Some of these TFs, mRNAs, or miRNAs have previously been identified as critical targets in colorectal cancer metastasis.Additionally, several new targets were identified in our study, which may be helpful to improve metastatic colorectal cancer treatment. therapeutic target hsa-mir-143 Colorectal Carcinoma 26266366 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Our findings represent the first comprehensive miRNA and snoRNA expression signatures for synchronous CRC, implicating that the miRNAs and snoRNAs may present therapeutic targets for synchronous CRC. therapeutic target hsa-mir-144 Colorectal Carcinoma 26349975 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Our findings suggested that microRNA 144 might be an important element to control the status of colorectal cancer, which has provided a new insight into the mechanism of proliferation and migration and a new target in therapy against colorectal cancer. therapeutic target hsa-mir-146a Colorectal Carcinoma 24949825 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Our results make sense for the prevention and treatment of intestinal-related chronic inflammation or cancer. therapeutic target hsa-mir-149 Colorectal Carcinoma 28370854 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-149 may serve as a therapeutic target for colorectal cancer treatment therapeutic target hsa-mir-155 Colorectal Carcinoma 24949825 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Our results make sense for the prevention and treatment of intestinal-related chronic inflammation or cancer. therapeutic target hsa-mir-17 Colorectal Carcinoma 26266366 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Our findings represent the first comprehensive miRNA and snoRNA expression signatures for synchronous CRC, implicating that the miRNAs and snoRNAs may present therapeutic targets for synchronous CRC. therapeutic target hsa-mir-18 Colorectal Carcinoma 26266366 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Our findings represent the first comprehensive miRNA and snoRNA expression signatures for synchronous CRC, implicating that the miRNAs and snoRNAs may present therapeutic targets for synchronous CRC. therapeutic target hsa-mir-1914 Colorectal Carcinoma 26695693 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Plasma miR-1914* and -1915 interact with NFIX RNA and reduce its level in chemoresistant CRC cells to first-line chemotherapy. Up-regulation of miR-1914* and -1915 decreased the chemoresistance abilities of chemoresistant CRC cells. The plasma miR-1914* and -1915 may play a role in colorectal cancer therapy and diagnosis. therapeutic target hsa-mir-1915 Colorectal Carcinoma 26695693 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Plasma miR-1914* and -1915 interact with NFIX RNA and reduce its level in chemoresistant CRC cells to first-line chemotherapy. Up-regulation of miR-1914* and -1915 decreased the chemoresistance abilities of chemoresistant CRC cells. The plasma miR-1914* and -1915 may play a role in colorectal cancer therapy and diagnosis. therapeutic target hsa-mir-194 Colorectal Carcinoma 25602366 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-194, regulating the MAP4K4/c-Jun/MDM2 signaling pathway, might act as a tumor suppressor and serve as a novel target for CRC prevention and therapy. therapeutic target hsa-mir-196b Colorectal Carcinoma 25605245 disease of cellular proliferation DOID:0080199 C19 D015179 114500 the up-regulation of MIR196B modulates apoptosis in colorectal cancer cells by partially repressing FAS expression and that anti-MIR196B could be a potential candidate as an anti-cancer drug in colorectal cancer therapy. therapeutic target hsa-mir-199a Colorectal Carcinoma 23173124 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Pre-miR-34a and pre-miR-199a decreased the level of Axl, a tyrosine-protein kinase receptor, so they can be considered as drugs in antimetastatic therapy therapeutic target hsa-mir-19a Colorectal Carcinoma 26266366 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Our findings represent the first comprehensive miRNA and snoRNA expression signatures for synchronous CRC, implicating that the miRNAs and snoRNAs may present therapeutic targets for synchronous CRC. therapeutic target hsa-mir-19b-1 Colorectal Carcinoma 26266366 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Our findings represent the first comprehensive miRNA and snoRNA expression signatures for synchronous CRC, implicating that the miRNAs and snoRNAs may present therapeutic targets for synchronous CRC. therapeutic target hsa-mir-200a Colorectal Carcinoma 29388209 disease of cellular proliferation DOID:0080199 C19 D015179 114500 The miR200 family has potential for both prognostic and therapeutic management of CRC. therapeutic target hsa-mir-200c Colorectal Carcinoma 29388209 disease of cellular proliferation DOID:0080199 C19 D015179 114500 The miR201 family has potential for both prognostic and therapeutic management of CRC. therapeutic target hsa-mir-203 Colorectal Carcinoma 25482885 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-203 has the potential as a therapeutic strategy for 5-FU-resistant colorectal cancer therapeutic target hsa-mir-203 Colorectal Carcinoma 26361147 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Taken together, our findings imply that posttranscriptional deregulation of CPEB4 contributes to the inhibited cell proliferation and the enhanced cell apoptosis in colorectal cancer, and directly targeting CPEB4 by miR-203 might be a novel strategy in colorectal cancer treatment. therapeutic target hsa-mir-203 Colorectal Carcinoma 25621839 disease of cellular proliferation DOID:0080199 C19 D015179 114500 ZNF217 has an oncogenic role in CRC and is regulated by miR-203, and open up the possibility of ZNF217- and miR-203-targeted therapy for CRC. therapeutic target hsa-mir-206 Colorectal Carcinoma 25607234 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-206 as a tumor suppressor in CRC and suggest a potential therapeutic target for clinical intervention. therapeutic target hsa-mir-206 Colorectal Carcinoma 26406866 disease of cellular proliferation DOID:0080199 C19 D015179 114500 These findings suggest that miR-206 may be useful as a new potential therapeutic target for CRC. therapeutic target hsa-mir-206 Colorectal Carcinoma 26515696 disease of cellular proliferation DOID:0080199 C19 D015179 114500 This study revealed functional and mechanistic links between miR-206 and oncogene FMNL2 and c-MET in the progression of CRC. miR-206 functioned as a tumor suppressor in the progression of CRC by targeting FMNL2 and c-MET.Restoration of miR-206 expression may represent a promising therapeutic approach for targeting malignant CRC. therapeutic target hsa-mir-20a Colorectal Carcinoma 26266366 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Our findings represent the first comprehensive miRNA and snoRNA expression signatures for synchronous CRC, implicating that the miRNAs and snoRNAs may present therapeutic targets for synchronous CRC. therapeutic target hsa-mir-21 Colorectal Carcinoma 25603978 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miRNA-21 regulates hTERT expression via the PTEN/ERK1/2 signaling pathway, therefore controlling CRC cell line growth. MiRNA-21 may serve as a novel therapeutic target in CRC. therapeutic target hsa-mir-21 Colorectal Carcinoma 25609245 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Stromal miR-21 expression is related to the expression of E-cadherin and metastasis-associated protein1 in colorectal cancer. Stage II colorectal cancer patients with high levels of miR-21 are at higher risk for tumor recurrence and should be considered for more intensive treatment. therapeutic target hsa-mir-21 Colorectal Carcinoma 25769454 disease of cellular proliferation DOID:0080199 C19 D015179 114500 we will focus on the critical role of miR-21 in CRC. Hopefully, the information obtained may lead to a better understanding of the pathogenesis and development of novel therapeutic strategies for this disease. therapeutic target hsa-mir-21 Colorectal Carcinoma 26084510 disease of cellular proliferation DOID:0080199 C19 D015179 114500 In summary,the results reveal that detailed molecular events can be combined with individual genetic data, including gene/miRNA expression data, to enhance in silico prediction of therapeutic response of individual CRC tumors.The study demonstrates that miRNA information can be applied as actionable information regarding individual therapeutic response. therapeutic target hsa-mir-217 Colorectal Carcinoma 26016795 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Our findings suggest that miR-217 has considerable value as a prognostic marker and potential therapeutic target in CRC. therapeutic target hsa-mir-218 Colorectal Carcinoma 26442524 disease of cellular proliferation DOID:0080199 C19 D015179 114500 These suggest the unique potential of miR-218 as a novel candidate for developing miR-218-based therapeutic strategies in CRC. therapeutic target hsa-mir-22 Colorectal Carcinoma 25449431 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-22 could be considered as both a predictor of 5-FU sensitivity for personalized treatment and a therapeutic target for colorectal cancer. therapeutic target hsa-mir-221 Colorectal Carcinoma 24949825 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Our results make sense for the prevention and treatment of intestinal-related chronic inflammation or cancer. therapeutic target hsa-mir-222 Colorectal Carcinoma 24949825 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Our results make sense for the prevention and treatment of intestinal-related chronic inflammation or cancer. therapeutic target hsa-mir-224 Colorectal Carcinoma 23846336 disease of cellular proliferation DOID:0080199 C19 D015179 114500 This study reveals functional and mechanistic links between miRNA-224 and the tumor suppressors PHLPP1 and PHLPP2 in the pathogenesis of colorectal cancer. miR-224 not only plays important roles in the regulation of cell proliferation and tumor growth in colorectal cancer, but also has potential as a prognostic marker or therapeutic target for colorectal cancer. therapeutic target hsa-mir-23b Colorectal Carcinoma 26269151 disease of cellular proliferation DOID:0080199 C19 D015179 114500 To conclude, the miRNA/mRNA deregulations pairs identified in this study have high potentials to be further applied in diagnosis and treatment of CRC. therapeutic target hsa-mir-24 Colorectal Carcinoma 25502080 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Down-regulation of miR-24-3p contributes to the development and progression of CRC and may have a potential role in prognosis and therapy. therapeutic target hsa-mir-26b Colorectal Carcinoma 20831567 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MetaCore network analysis further showed that the regulatory pathways of miR-26b were significantly associated with the invasiveness and metastasis of CRC cells. These data suggest that miR-26b might serve as a novel prognostic factor and a potential therapeutic target for CRC. therapeutic target hsa-mir-301a Colorectal Carcinoma 25591765 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-301a promotes CRC progression by directly downregulating SOCS6 expression, and miR-301a may represent a novel biomarker for the prevention and treatment of CRC. therapeutic target hsa-mir-30a Colorectal Carcinoma 26333808 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Our results identify a new miR-30a/HP1γ/p21 regulatory axis controlling colorectal cancer development, which may offer prognostic and therapeutic opportunities. therapeutic target hsa-mir-31 Colorectal Carcinoma 25472647 disease of cellular proliferation DOID:0080199 C19 D015179 114500 in CRCs carrying all wild-type genes, high miR-31-5p was associated with shorter PFS, suggesting that it may be a useful and additional prognostic biomarker for anti-EGFR therapy. therapeutic target hsa-mir-320b Colorectal Carcinoma 26487644 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Our identification of c-MYC as a target gene of miR-320b provides new insights into the pathophysiology of CRC proliferation, and identifies miR-320b as a novel therapeutic target for the treatment of CRC. therapeutic target hsa-mir-326 Colorectal Carcinoma 25412953 disease of cellular proliferation DOID:0080199 C19 D015179 114500 The miRNAs, such as miRNA-1, miRNA-338-5p, and miRNA-326 may be used as potential targets for CRC diagnosis and treatment. therapeutic target hsa-mir-335 Colorectal Carcinoma 24829139 disease of cellular proliferation DOID:0080199 C19 D015179 114500 our results demonstrate that miR-335 functions as a tumor suppressor and play a role in inhibiting metastasis of CRC cells through targeting ZEB2. These findings suggest that miR-335 may be useful as a new potential therapeutic target for CRC. therapeutic target hsa-mir-335 Colorectal Carcinoma 24949825 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Our results make sense for the prevention and treatment of intestinal-related chronic inflammation or cancer. therapeutic target hsa-mir-338 Colorectal Carcinoma 25412953 disease of cellular proliferation DOID:0080199 C19 D015179 114500 The miRNAs, such as miRNA-1, miRNA-338-5p, and miRNA-326 may be used as potential targets for CRC diagnosis and treatment. therapeutic target hsa-mir-34a Colorectal Carcinoma 23173124 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Pre-miR-34a and pre-miR-199a decreased the level of Axl, a tyrosine-protein kinase receptor, so they can be considered as drugs in antimetastatic therapy therapeutic target hsa-mir-365-1 Colorectal Carcinoma 26269151 disease of cellular proliferation DOID:0080199 C19 D015179 114500 To conclude, the miRNA/mRNA deregulations pairs identified in this study have high potentials to be further applied in diagnosis and treatment of CRC. therapeutic target hsa-mir-365-2 Colorectal Carcinoma 26269151 disease of cellular proliferation DOID:0080199 C19 D015179 114500 To conclude, the miRNA/mRNA deregulations pairs identified in this study have high potentials to be further applied in diagnosis and treatment of CRC. therapeutic target hsa-mir-376a Colorectal Carcinoma 25422250 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-376a may be a meaningful prognostic biomarker and potential therapeutic target in colorectal cancer. therapeutic target hsa-mir-378 Colorectal Carcinoma 24555885 disease of cellular proliferation DOID:0080199 C19 D015179 114500 In conclusion, miR-378 may function as a tumor suppressor and plays an important role in inhibiting tumor growth and invasion. Our present results implicate the potential effects of miR-378 on prognosis and treatment of CRC cancer. therapeutic target hsa-mir-409 Colorectal Carcinoma 26084278 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Our results suggest that miR-409-3p functions as a tumor suppressor by inhibiting the development and metastasis of CRC, suggesting that miR-409-3p is expected to become a new diagnostic marker and a new target of the treatment of CRC. therapeutic target hsa-mir-451 Colorectal Carcinoma 26497997 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Taken together, these findings suggest that lncRNAs may be promising therapeutic molecules to eradicate CSCs and MREs of tumor-suppressor miRNAs, such as miR-451,may be exploited to ensure the specificity of CSC-targeting strategies. therapeutic target hsa-mir-490 Colorectal Carcinoma 25412953 disease of cellular proliferation DOID:0080199 C19 D015179 114500 The miRNAs, such as miRNA-1, miRNA-338-5p, and miRNA-326 may be used as potential targets for CRC diagnosis and treatment. therapeutic target hsa-mir-503 Colorectal Carcinoma 26722476 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-503 inhibits cell proliferation and induces apoptosis by directly targeting E2F3 in CRC cells, indicating its potential application in CRC diagnosis and therapy. therapeutic target hsa-mir-520g Colorectal Carcinoma 25616665 disease of cellular proliferation DOID:0080199 C19 D015179 114500 A major implication of our studies is that inhibition of miR-520g or restoration of p21 expression may have considerable therapeutic potential to overcome drug resistance in colorectal cancer patients, especially in those with mutant p53. therapeutic target hsa-mir-7 Colorectal Carcinoma 24185687 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Our study suggests that as a novel target of miR-7, PAX6 may serve as a promising therapeutic target for colorectal cancer. therapeutic target hsa-mir-7 Colorectal Carcinoma 25503932 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-7 is a meaningful prognostic marker. Furthermore, these data indicate that miR-7 precursor, alone or in combination with cetuximab, may be useful in therapy against CRC therapeutic target hsa-mir-7 Colorectal Carcinoma 29549306 disease of cellular proliferation DOID:0080199 C19 D015179 114500 therapeutic targeting of the c-Myb/circHIPK3/miR-7 axis may be a promising treatment approach for CRC patients therapeutic target hsa-mir-874 Colorectal Carcinoma 26875895 disease of cellular proliferation DOID:0080199 C19 D015179 114500 These data demonstrate that miR-874 functions as a tumor suppressor by repression of STAT3, suggesting its potential therapeutic value in CRC treatment. therapeutic target hsa-mir-92-1 Colorectal Carcinoma 26266366 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Our findings represent the first comprehensive miRNA and snoRNA expression signatures for synchronous CRC, implicating that the miRNAs and snoRNAs may present therapeutic targets for synchronous CRC. therapeutic target hsa-mir-92a Colorectal Carcinoma 24026406 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-92a induced EMT and regulated cell growth, migration and invasion in the SW480 cells, at least partially, via suppression of PTEN expression. MiR-92a may serve as a novel therapeutic target in colorectal cancer. therapeutic target hsa-mir-99a Colorectal Carcinoma 24503111 disease of cellular proliferation DOID:0080199 C19 D015179 114500 The MiR-99a/Let-7c/miR-125b signature may improve the selection of patients with KRAS wild-type mCRC as good candidates for anti-EGFR therapy. therapeutic target hsa-mir-1 Colorectal Carcinoma 23874421 disease of cellular proliferation DOID:0080199 C19 D015179 114500 High-throughput miRNA and mRNA sequencing of paired colorectal normal, tumor and metastasis tissues and bioinformatic modeling of miRNA-1 therapeutic applications. therapeutic target hsa-mir-129 Colorectal Carcinoma 23874421 disease of cellular proliferation DOID:0080199 C19 D015179 114500 High-throughput miRNA and mRNA sequencing of paired colorectal normal, tumor and metastasis tissues and bioinformatic modeling of miRNA-1 therapeutic applications. therapeutic target hsa-mir-145 Colorectal Carcinoma 21690566 disease of cellular proliferation DOID:0080199 C19 D015179 114500 The authors' findings show that chemically unmodified miRNAs complexed with PEI can be used in an efficient and biocompatible strategy of miRNA replacement therapy, as illustrated by efficacious delivery of PEI/miR-145 and PEI/miR-33a complexes in colon carcinoma. therapeutic target hsa-mir-182 Colorectal Carcinoma 24884732 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Our results illustrated that the up-regulation of miR-182 played a pivotal role in CRC tumorigenesis and metastasis, which suggesting a potential implication of miR-182 in the molecular therapy for CRC. therapeutic target hsa-mir-215 Colorectal Carcinoma 23874421 disease of cellular proliferation DOID:0080199 C19 D015179 114500 High-throughput miRNA and mRNA sequencing of paired colorectal normal, tumor and metastasis tissues and bioinformatic modeling of miRNA-1 therapeutic applications. therapeutic target hsa-mir-223 Colorectal Carcinoma 25867276 disease of cellular proliferation DOID:0080199 C19 D015179 114500 These results identify that C/EBP-β-activated miR-223 contributes to tumour growth by targeting RASA1 in CRC and miR-223-targeted inhibitors may have clinical promise for CRC treatment via suppression of miR-223. therapeutic target hsa-mir-24 Colorectal Carcinoma 26297223 disease of cellular proliferation DOID:0080199 C19 D015179 114500 The plasma levels of miR-24, miR-320a, and miR-423-5p have promising potential to serve as novel biomarkers for CRC detection, especially for early stage of CRC, which are superior to the currently used clinical biomarkers for CRC detection, such as CEA and CA19-9. Further efforts to develop the three microRNAs as biomarkers for early CRC diagnosis and prediction of surgical treatment outcomes are warrant. therapeutic target hsa-mir-30a Colorectal Carcinoma 25582198 disease of cellular proliferation DOID:0080199 C19 D015179 114500 miR-30a might serve as a promising therapeutic strategy for colon cancer treatment. therapeutic target hsa-mir-320a Colorectal Carcinoma 26297223 disease of cellular proliferation DOID:0080199 C19 D015179 114500 The plasma levels of miR-24, miR-320a, and miR-423-5p have promising potential to serve as novel biomarkers for CRC detection, especially for early stage of CRC, which are superior to the currently used clinical biomarkers for CRC detection, such as CEA and CA19-9. Further efforts to develop the three microRNAs as biomarkers for early CRC diagnosis and prediction of surgical treatment outcomes are warrant. therapeutic target hsa-mir-33a Colorectal Carcinoma 21690566 disease of cellular proliferation DOID:0080199 C19 D015179 114500 The authors' findings show that chemically unmodified miRNAs complexed with PEI can be used in an efficient and biocompatible strategy of miRNA replacement therapy, as illustrated by efficacious delivery of PEI/miR-145 and PEI/miR-33a complexes in colon carcinoma. therapeutic target hsa-mir-423 Colorectal Carcinoma 26297223 disease of cellular proliferation DOID:0080199 C19 D015179 114500 The plasma levels of miR-24, miR-320a, and miR-423-5p have promising potential to serve as novel biomarkers for CRC detection, especially for early stage of CRC, which are superior to the currently used clinical biomarkers for CRC detection, such as CEA and CA19-9. Further efforts to develop the three microRNAs as biomarkers for early CRC diagnosis and prediction of surgical treatment outcomes are warrant. therapeutic target hsa-mir-497 Colorectal Carcinoma 23874421 disease of cellular proliferation DOID:0080199 C19 D015179 114500 High-throughput miRNA and mRNA sequencing of paired colorectal normal, tumor and metastasis tissues and bioinformatic modeling of miRNA-1 therapeutic applications. therapeutic target hsa-mir-582 Colorectal Carcinoma 26384136 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Our data suggest that miR-582-5p may function as a tumor suppressor in the development of CRC by targeting Rab27a, indicating a novel therapeutic strategy for patients with CRC. therapeutic target hsa-mir-625 Colorectal Carcinoma 26314959 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Our findings indicate the pivotal role of miR-625-3p in invasion that warrants further exploration whether targeting miR-625-3p could be a promising approach for the treatment of CRC. therapeutic target hsa-mir-95 Colorectal Carcinoma 25871428 disease of cellular proliferation DOID:0080199 C19 D015179 114500 This study demonstrates that genistein has an inhibitory effect on CRC involved in reducing miR-95, Akt and SGK1, offering novel insights into the mechanisms of genistein therapeutic actions. therapeutic target hsa-mir-548d Complex Regional Pain Syndrome 26072390 nervous system disease DOID:3223 G90.50 D020918 This study suggests the usefulness of circulating miRNAs as potential biomarkers. Assessing miRNA signatures before and after treatment demonstrated miRNA alterations from therapy; differences in miRNA signature in responders and poor responders before therapy indicate prognostic value. Mechanistic studies on altered miRNAs can provide new insights into disease. therapeutic target hsa-mir-1246 Corneal Neovascularization 27625050 nervous system disease DOID:11382 H16.4 D016510 HP:0011496 Curcumin inhibits angiogenesis by up-regulation of microRNA-1275 and microRNA-1246: a promising therapy for treatment of corneal neovascularization. therapeutic target hsa-mir-1275 Corneal Neovascularization 27625050 nervous system disease DOID:11382 H16.4 D016510 HP:0011496 Curcumin inhibits angiogenesis by up-regulation of microRNA-1275 and microRNA-1246: a promising therapy for treatment of corneal neovascularization. therapeutic target hsa-mir-223 Coronary Artery Disease 25350775 cardiovascular system disease DOID:3393 I20-I25 D003324 608320 Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: A preliminary report. therapeutic target hsa-mir-2909 Coronary Artery Disease 24634009 cardiovascular system disease DOID:3393 I20-I25 D003324 608320 Based upon these results, we propose that miR-2909 RNomics may be a step forward in understanding human CHD at the epigenomic level and can be exploited for designing new therapeutic strategies as well as diagnostic and prognostic markers for this disease in future. therapeutic target hsa-mir-31 Coronary Artery Disease 24558106 cardiovascular system disease DOID:3393 I20-I25 D003324 608320 Manipulating the expression of the miR-31-miR-720 pathway in malfunction EPCs should help develop novel therapeutic modalities. therapeutic target hsa-mir-361 Coronary Artery Disease 24865854 cardiovascular system disease DOID:3393 I20-I25 D003324 608320 miR-361-5p/VEGF-dependent regulation that could help to develop new therapeutic modalities not only for ischemia-related diseases but also for tumor angiogenesis. therapeutic target hsa-mir-720 Coronary Artery Disease 24558106 cardiovascular system disease DOID:3393 I20-I25 D003324 608320 Manipulating the expression of the miR-31-miR-720 pathway in malfunction EPCs should help develop novel therapeutic modalities. therapeutic target hsa-let-7d Crohn Disease 24447044 gastrointestinal system disease DOID:8778 K50 D003424 266600 HP:0100280 let-7d and let-7e might be possible therapeutic biomarkers in patients with CD, who are treated by infliximab. therapeutic target hsa-let-7e Crohn Disease 24447044 gastrointestinal system disease DOID:8778 K50 D003424 266600 HP:0100280 let-7d and let-7e might be possible therapeutic biomarkers in patients with CD, who are treated by infliximab. therapeutic target hsa-mir-16 Cystic Fibrosis 26133785 genetic disease DOID:1485 E84 D003550 219700 We interpret these findings to suggest that these miRs may constitute novel targets for CF therapy. therapeutic target hsa-mir-17 Cystic Fibrosis 26160865 genetic disease DOID:1485 E84 D003550 219700 Modulating miR-17 expression in cystic fibrosis bronchial epithelial cells may be a novel anti-inflammatory strategy for cystic fibrosis and other chronic inflammatory airway diseases. therapeutic target hsa-mir-31 Cystic Fibrosis 24940638 genetic disease DOID:1485 E84 D003550 219700 The miR-31/IRF-1/CTSS pathway may play a functional role in the pathogenesis of CF lung disease and may open up new avenues for exploration in the search for an effective therapeutic target. therapeutic target hsa-mir-335 Depression Disorder 26314506 disease of mental health DOID:1596 F32.9 D003866 These results suggest that miR-335 is associated with the pathophysiology of depression and is a potential target for new antidepressant treatments. therapeutic target hsa-mir-511 Depression Disorder 25689572 disease of mental health DOID:1596 F32.9 D003866 these results suggest that microRNA-mediated reductions of GFRα1a in depression change the quality, rather than the quantity, of GDNF signalling.They also suggest that central GDNF signalling may represent a novel target for antidepressant treatment. therapeutic target hsa-mir-122 Diabetes Mellitus 27966196 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 MicroRNAs 33, 122, and 208: a potential novel targets in the treatment of obesity, diabetes, and heart-related diseases. therapeutic target hsa-mir-126 Diabetes Mellitus 28440196 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 miR-126 as a Therapeutic Agent for Diabetes Mellitus. therapeutic target hsa-mir-19a Diabetes Mellitus 25887942 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 The five miRNAs that were differentially expressed in GDM could serve as noninvasive biomarkers. The results also provide insights into the molecular mechanisms that underlie GDM, thereby contributing to the diagnosis and treatment of this disease. therapeutic target hsa-mir-19b Diabetes Mellitus 25887942 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 The five miRNAs that were differentially expressed in GDM could serve as noninvasive biomarkers. The results also provide insights into the molecular mechanisms that underlie GDM, thereby contributing to the diagnosis and treatment of this disease. therapeutic target hsa-mir-208 Diabetes Mellitus 27966196 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 MicroRNAs 33, 122, and 208: a potential novel targets in the treatment of obesity, diabetes, and heart-related diseases. therapeutic target hsa-mir-20a Diabetes Mellitus 25887942 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 The five miRNAs that were differentially expressed in GDM could serve as noninvasive biomarkers. The results also provide insights into the molecular mechanisms that underlie GDM, thereby contributing to the diagnosis and treatment of this disease. therapeutic target hsa-mir-21 Diabetes Mellitus 26655730 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 These results suggest that endogenous miRNAs involved in the formation of IPCs from PPCs should be considered in the development of an effective cell transplant therapy for diabetes. therapeutic target hsa-mir-223 Diabetes Mellitus 26273679 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 In conclusion, in AT miR-223 is an IR-related miRNA that may serve as a potential therapeutic target for the treatment of IR-related disorders. therapeutic target hsa-mir-29 Diabetes Mellitus 25689084 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 In light of increasing awareness of the interconnection of diabetes mellitus, CVD, and cancer, it is of utmost importance to understand the mechanism of action of current treatment options on all of the comorbidities and careful evaluation of cardiovascular toxicity must accompany any treatment paradigm that increases miR-29 levels. therapeutic target hsa-mir-320 Diabetes Mellitus 18986336 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 Transfection of an miR-320 inhibitor may be a therapeutic approach for the treatment of impaired angiogenesis in diabetes. therapeutic target hsa-mir-320a Diabetes Mellitus 26031505 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 This study is the first to report miRs associated with response to a pharmacologic intervention for insulin resistance. MiR-320a and miR-486-5p identified responders to thiazolidinedione therapy among the insulin resistant group. therapeutic target hsa-mir-33 Diabetes Mellitus 27966196 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 MicroRNAs 33, 122, and 208: a potential novel targets in the treatment of obesity, diabetes, and heart-related diseases. therapeutic target hsa-mir-375 Diabetes Mellitus 26047014 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 These findings highlight miRNAs functions in stem cells differentiation and suggest that they could be used as therapeutic tools for gene-based therapy in diabetes mellitus. therapeutic target hsa-mir-375 Diabetes Mellitus 15538371 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 Thus, miR-375 is a regulator of insulin secretion and may thereby constitute a novel pharmacological target for the treatment of diabetes. therapeutic target hsa-mir-486 Diabetes Mellitus 26031505 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 This study is the first to report miRs associated with response to a pharmacologic intervention for insulin resistance. MiR-320a and miR-486-5p identified responders to thiazolidinedione therapy among the insulin resistant group. therapeutic target hsa-mir-9 Diabetes Mellitus 26047014 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 These findings highlight miRNAs functions in stem cells differentiation and suggest that they could be used as therapeutic tools for gene-based therapy in diabetes mellitus. therapeutic target hsa-mir-92a Diabetes Mellitus 28462946 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 Light-inducible antimiR-92a as a therapeutic strategy to promote skin repair in healing-impaired diabetic mice. therapeutic target hsa-mir-21 Diabetes Mellitus, Type 1 23506112 disease of metabolism DOID:9744 E10 D003922 222100 HP:0100651 Though the exact roles of miR-21 in autoimmune diseases have not been fully elucidated, targeting miR-21 may serve as a promising therapy therapeutic target hsa-mir-22 Diabetes Mellitus, Type 2 26193896 disease of metabolism DOID:9352 E11 D003924 125853 HP:0005978 Our results support a critical role for miR-22-3p and its target, Tcf7, in the pathogenesis of diabetes by upregulating gluconeogenesis. Moreover, targeting the miR-22/Tcf7/Wnt axis might hold therapeutic potential for the treatment of altered hepatic physiology during insulin resistance and type 2 diabetes. therapeutic target hsa-mir-26a Diabetes Mellitus, Type 2 25961460 disease of metabolism DOID:9352 E11 D003924 125853 HP:0005978 These findings reveal miR-26a as a regulator of liver metabolism and suggest miR-26a should be further explored as a potential target for the treatment of T2D. therapeutic target hsa-mir-135a Diabetic Nephropathy 24908566 E10-11.21 D003928 These findings suggest an important role for miR-135a in renal fibrosis and inhibition of miR-135a might be an effective therapy for diabetic nephropathy. therapeutic target hsa-mir-21 Diabetic Nephropathy 28129112 E10-11.21 D003928 Therapeutic miR-21 Silencing Ameliorates Diabetic Kidney Disease in Mice. therapeutic target hsa-mir-23b Diabetic Nephropathy 26646104 E10-11.21 D003928 Taken together, we showed for the first time that miR-23b acts as a suppressor of EMT in diabetic nephropathy through repressing PI3K-AKT signalling pathway activation by targeting HMGA2, which maybe a potential therapeutic target for diabetes-induced renal dysfunction. therapeutic target hsa-mir-26a Diabetic Nephropathy 25797045 E10-11.21 D003928 Together our results provide the first evidence for the involvement of miR-26a in high glucose-induced mesangial cell hypertrophy and matrix protein expression. These data indicate the potential therapeutic utility of anti-miR-26a for the complications of diabetic kidney disease. therapeutic target hsa-mir-106a Diabetic Retinopathy 24018047 nervous system disease DOID:8947 E10-11.31 D003930 There is a cross-talk between HIF1α and VEGF through interactions with their common miRNAs. miRNA based therapy can affect the expression of both HIF1α and VEGF and may represent a therapeutic potential for the treatment of DR. therapeutic target hsa-mir-126 Diabetic Retinopathy 25616704 nervous system disease DOID:8947 E10-11.31 D003930 The A allele of rs4636297, known to be the non-functional allele for post-translational regulation of miR-126, is associated with STDR. This finding suggests that this locus would be a potential therapeutic target for inhibiting the development of DR. therapeutic target hsa-mir-24 Diabetic Vasculopathy 27085480 cardiovascular system disease DOID:11713 D003925 elevation of miR-24 in vascular system may be a novel therapeutic strategy to prevent the development of diabetic atherosclerosis. therapeutic target hsa-mir-33 Disease of Metabolism 24591767 disease of metabolism DOID:0014667 E88.9 D008659 In patients with low HDL-C levels, XZK therapy raised plasma levels of miR-33a and miR-33b, which may inhibit cellular cholesterol export and limit the HDL-raising effect of XZK. therapeutic target hsa-mir-9 Disease of Metabolism 26459099 disease of metabolism DOID:0014667 E88.9 D008659 Therefore, these findings demonstrated that the inhibition of miRNA-9-3p reduced the proliferation of HepG2 cells and lipid accumulation by upregulating the expression of SIRT1, indicating its potential as a therapeutic target. therapeutic target hsa-mir-106a Early-Stage Colon Carcinoma 24746948 C18.9 The present results implied that miR-106a and the miR-125b were associated with the formation and invasion of colorectal tumors. Thus, these miRNAs might be used as significant prognostic factors and indicators of early-stage CRC. Further studies and validations are required; these miRNAs may provide novel molecular targets for CRC treatment. therapeutic target hsa-mir-125b Early-Stage Colon Carcinoma 24746948 C18.9 The present results implied that miR-106a and the miR-125b were associated with the formation and invasion of colorectal tumors. Thus, these miRNAs might be used as significant prognostic factors and indicators of early-stage CRC. Further studies and validations are required; these miRNAs may provide novel molecular targets for CRC treatment. therapeutic target hsa-mir-143 Endometrial Neoplasms 29661100 reproductive system disease DOID:1380 C54.1 D016889 608089 these miRNAs are potential candidates for the diagnosis of endometrial cancer and therapeutic targets therapeutic target hsa-mir-145 Endometrial Neoplasms 29661100 reproductive system disease DOID:1380 C54.1 D016889 608089 these miRNAs are potential candidates for the diagnosis of endometrial cancer and therapeutic targets therapeutic target hsa-mir-29c Endometriosis 25625784 reproductive system disease DOID:289 N80.0 D004715 131200 HP:0030127 miR-29c exerts its effects on endometrial cell proliferation, apoptosis and invasion by inhibiting the expression of c-Jun. Our data may provide a novel potential therapeutic target for the treatment of endometriosis therapeutic target hsa-mir-503 Endometriosis 28720098 reproductive system disease DOID:289 N80.0 D004715 131200 HP:0030127 Arcyriaflavin a, a cyclin D1-cyclin-dependent kinase4 inhibitor, induces apoptosis and inhibits proliferation of human endometriotic stromal cells: a potential therapeutic agent in endometriosis therapeutic target hsa-mir-125b Endomyocardial Fibrosis 26585673 cardiovascular system disease DOID:12932 I42.3 D004719 HP:0006685 In conclusion, miR-125b is critical for induction of cardiac fibrosis and acts as a potent repressor of multiple anti-fibrotic mechanisms.Inhibition of miR-125b may represent a novel therapeutic approach for the treatment of human cardiac fibrosis and other fibrotic diseases. therapeutic target hsa-mir-433 Endomyocardial Fibrosis 28740551 cardiovascular system disease DOID:12932 I42.3 D004719 HP:0006685 Modulating microRNAs as Novel Therapeutic Targets in Cardiac Fibrosis. therapeutic target hsa-mir-210 Enteropathy 24290534 B80 D007410 MiR-210: A potential therapeutic target against radiation-induced enteropathy. therapeutic target hsa-mir-134 Epilepsy 29069823 nervous system disease DOID:1826 G40 D004827 PS601068 HP:0001250 MicroRNA-134 plasma levels before and after treatment with valproic acid for epilepsy patients. therapeutic target hsa-mir-17 Epilepsy 26343596 nervous system disease DOID:1826 G40 D004827 PS601068 HP:0001250 Research should be performed on miR-320-related pathways and their relationship to depression. Additionally, miR-451a could serve as a candidate biomarker for depression based on the acting mechanism of ketamine. Studies targeting miR-451a levels before and after treatment could be helpful. therapeutic target hsa-mir-223 Epilepsy 26343596 nervous system disease DOID:1826 G40 D004827 PS601068 HP:0001250 Research should be performed on miR-320-related pathways and their relationship to depression. Additionally, miR-451a could serve as a candidate biomarker for depression based on the acting mechanism of ketamine. Studies targeting miR-451a levels before and after treatment could be helpful. therapeutic target hsa-mir-320a Epilepsy 26343596 nervous system disease DOID:1826 G40 D004827 PS601068 HP:0001250 Research should be performed on miR-320-related pathways and their relationship to depression. Additionally, miR-451a could serve as a candidate biomarker for depression based on the acting mechanism of ketamine. Studies targeting miR-451a levels before and after treatment could be helpful. therapeutic target hsa-mir-451a Epilepsy 26343596 nervous system disease DOID:1826 G40 D004827 PS601068 HP:0001250 Research should be performed on miR-320-related pathways and their relationship to depression. Additionally, miR-451a could serve as a candidate biomarker for depression based on the acting mechanism of ketamine. Studies targeting miR-451a levels before and after treatment could be helpful. therapeutic target hsa-mir-182 Epithelioid Sarcoma 26314219 disease of cellular proliferation DOID:6193 D012509 Thus, our findings suggest that demethylating agents could potentially be used to modulate miR-182 levels as a therapeutic strategy. therapeutic target hsa-mir-192 Esophageal Neoplasms 23649428 C15.9 D004938 133239 HP:0100751 The expression of miR-192, miR-194 and miR-622 was significantly reduced after neoadjuvant therapy confirming the array profiling data. therapeutic target hsa-let-7a Ewing Sarcoma 26393798 musculoskeletal system disease DOID:3369 D012512 612219 HP:0012254 These findings suggests that the up-regulation of c-Myc inhibited the expression of let-7a, miR-16 and miR-29b subsequently induced CCND2 expression in ES cells. The present study might identify a novel oncogenic axis that c-Myc regulates the expression of CCND2 via let-7a, miR-16 and miR-29b,leading to the development new therapeutic targets for ES. therapeutic target hsa-mir-125b Ewing Sarcoma 24517182 musculoskeletal system disease DOID:3369 D012512 612219 HP:0012254 Collectively, these data suggest that miR-125b functions as a tumor suppressor by targeting the PI3K/Akt/mTOR signaling pathway, and may provide potential therapy strategy for ES patients by targeting miRNA expression. therapeutic target hsa-mir-16 Ewing Sarcoma 26393798 musculoskeletal system disease DOID:3369 D012512 612219 HP:0012254 These findings suggests that the up-regulation of c-Myc inhibited the expression of let-7a, miR-16 and miR-29b subsequently induced CCND2 expression in ES cells. The present study might identify a novel oncogenic axis that c-Myc regulates the expression of CCND2 via let-7a, miR-16 and miR-29b,leading to the development new therapeutic targets for ES. therapeutic target hsa-mir-29b Ewing Sarcoma 26393798 musculoskeletal system disease DOID:3369 D012512 612219 HP:0012254 These findings suggests that the up-regulation of c-Myc inhibited the expression of let-7a, miR-16 and miR-29b subsequently induced CCND2 expression in ES cells. The present study might identify a novel oncogenic axis that c-Myc regulates the expression of CCND2 via let-7a, miR-16 and miR-29b,leading to the development new therapeutic targets for ES. therapeutic target hsa-mir-17 Fatty Liver, Non-Alcoholic 25896250 disease of metabolism DOID:0080208 K75.81 D065626 613282 Our studies show that miR-17-5p inhibitor and agents used in metabolic disorders may be applied in combination with Dexamethasone in the treatment of anti-inflammation, immunosuppression, and cancer patients. therapeutic target hsa-mir-34a Fatty Liver, Non-Alcoholic 26330104 disease of metabolism DOID:0080208 K75.81 D065626 613282 Taken together, our data indicated that decreased expression of miR-34a potentially contributes to altered lipid metabolism in NAFLD. Downregulation of miR-34a may be a therapeutic strategy against NAFLD by regulating its target PPARα and SIRT1. therapeutic target hsa-mir-451 Fatty Liver, Non-Alcoholic 25957914 disease of metabolism DOID:0080208 K75.81 D065626 613282 These results provide new insights into the negative regulation of miR-451 in fatty acid-induced inflammation via the AMPK/AKT pathway and demonstrate potential therapeutic applications for miR-451 in preventing the progression from simple steatosis to severely advanced liver disease. therapeutic target hsa-mir-130b Fragile X Syndrome 24021279 genetic disease DOID:14261 Q99.2 D005600 300624 antagonizing miR-130b may be a new therapeutic entry point for treating Fragile X syndrome. therapeutic target hsa-mir-142 Fungal Keratitis 26720440 H15.8 D007634 This is, to our knowledge, the first report on comprehensive human corneal miRNA expression profile in fungal keratitis. Several miRNAs with high expression in fungal keratitis point toward their potential role in regulation of pathogenesis. Further insights in understanding their role in corneal wound inflammation may help design new therapeutic strategies. therapeutic target hsa-mir-155 Fungal Keratitis 26720440 H15.8 D007634 This is, to our knowledge, the first report on comprehensive human corneal miRNA expression profile in fungal keratitis. Several miRNAs with high expression in fungal keratitis point toward their potential role in regulation of pathogenesis. Further insights in understanding their role in corneal wound inflammation may help design new therapeutic strategies. therapeutic target hsa-mir-451a Fungal Keratitis 26720440 H15.8 D007634 This is, to our knowledge, the first report on comprehensive human corneal miRNA expression profile in fungal keratitis. Several miRNAs with high expression in fungal keratitis point toward their potential role in regulation of pathogenesis. Further insights in understanding their role in corneal wound inflammation may help design new therapeutic strategies. therapeutic target hsa-mir-511 Fungal Keratitis 26720440 H15.8 D007634 This is, to our knowledge, the first report on comprehensive human corneal miRNA expression profile in fungal keratitis. Several miRNAs with high expression in fungal keratitis point toward their potential role in regulation of pathogenesis. Further insights in understanding their role in corneal wound inflammation may help design new therapeutic strategies. therapeutic target hsa-let-7 Gastric Neoplasms 25860484 disease of cellular proliferation DOID:10534 C16 D013274 137215 these data provided the first evidence to illustrate that altered gene network was associated with gastric cancer invasion. Further study with a large sample size and more functional experiments is needed to confirm these data and contribute to diagnostic and treatment strategies for gastric cancer. therapeutic target hsa-let-7b Gastric Neoplasms 25613480 disease of cellular proliferation DOID:10534 C16 D013274 137215 the molecular mechanisms involved in gastric cancer metastasis and indicate that let-7b modulation may be a bona fide treatment of gastric cancer. therapeutic target hsa-let-7i Gastric Neoplasms 26349984 disease of cellular proliferation DOID:10534 C16 D013274 137215 This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers. therapeutic target hsa-mir-106a Gastric Neoplasms 26349984 disease of cellular proliferation DOID:10534 C16 D013274 137215 This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers. therapeutic target hsa-mir-106b Gastric Neoplasms 24842611 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-106b might be a novel candidate target for the treatment of gastric cancer. therapeutic target hsa-mir-10a Gastric Neoplasms 24498243 disease of cellular proliferation DOID:10534 C16 D013274 137215 Our data indicate that miR-10a acts as a tumor suppressor in GC cells and is partially silenced by DNA hypermethylation in GC,suggesting that miR-10a may serve as a potential diagnostic or therapeutic target of GC. therapeutic target hsa-mir-126 Gastric Neoplasms 25027343 disease of cellular proliferation DOID:10534 C16 D013274 137215 Our results demonstrated that overexpression of miR-126 inhibited GC cells invasion in part by targeting Crk. These findings suggested that miR-126 played major roles in the malignant behavior of GC and it might be a promising therapeutic target of GC. therapeutic target hsa-mir-126 Gastric Neoplasms 25428912 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-126 could suppress tumor growth and tumor angiogenesis of GC through VEGF-A signaling, and it is a novel potential therapeutic target for GC. therapeutic target hsa-mir-128 Gastric Neoplasms 26334097 disease of cellular proliferation DOID:10534 C16 D013274 137215 Our data suggest that cMET, PIK3CA and target-related miRNAs play an important role in GC and may serve as potential targets for therapy. therapeutic target hsa-mir-128b Gastric Neoplasms 26478435 disease of cellular proliferation DOID:10534 C16 D013274 137215 Taken together, our results indicate that miR-128b could serve as a potential diagnostic biomarker and therapeutic option for human GC in the near future. therapeutic target hsa-mir-130a Gastric Neoplasms 26375442 disease of cellular proliferation DOID:10534 C16 D013274 137215 In conclusion, targeting miR-130a and miR-495 could be a potential therapeutics to recover RUNX3 expression under hypoxic conditions and in early tumorigenic progression. therapeutic target hsa-mir-132 Gastric Neoplasms 26324336 disease of cellular proliferation DOID:10534 C16 D013274 137215 Therefore, the present results indicate that the miR-132/RB1 regulatory axis may be a potential novel diagnostic and therapeutic target for the treatment of gastric cancer. therapeutic target hsa-mir-133a Gastric Neoplasms 25620172 disease of cellular proliferation DOID:10534 C16 D013274 137215 Overexpression of miR-133a inhibits cell growth and invasion and induces cell apoptosis and cycle arrest through repressing TAGLN2 gene, suggesting that miR-133a might be used as a biomarker or therapeutic target for the treatment of gastric cancer. therapeutic target hsa-mir-133a Gastric Neoplasms 26276722 disease of cellular proliferation DOID:10534 C16 D013274 137215 Identification of miRNomes in human stomach and gastric carcinoma reveals miR-133b/a-3p as therapeutic target for gastric cancer. therapeutic target hsa-mir-133a Gastric Neoplasms 26629938 disease of cellular proliferation DOID:10534 C16 D013274 137215 These outcomes might be secondary to the increased expression of miR-133a after the treatment with UA. therapeutic target hsa-mir-133b Gastric Neoplasms 25433493 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-133b was significantly down-regulated in GC tissues and exerted its tumor suppressor role in GC cells.The investigation of the detailed mechanism showed that miR-133b directly targeted FSCN1 which functioned as an oncogenic gene in GC cells. These results suggested that miR-133b can be developed as a new diagnostic marker or therapeutic target for GC. therapeutic target hsa-mir-133b Gastric Neoplasms 26276722 disease of cellular proliferation DOID:10534 C16 D013274 137215 Identification of miRNomes in human stomach and gastric carcinoma reveals miR-133b/a-3p as therapeutic target for gastric cancer. therapeutic target hsa-mir-137 Gastric Neoplasms 26545111 disease of cellular proliferation DOID:10534 C16 D013274 137215 In conclusion, the results reinforced the critical role for the down-regulated miR-137 expression in gastric cancer and suggested that miR-137 expression could be a prognostic indicator for this disease. In addition, these patients with TNM stage III gastric cancer and low miR-137 expression might need more aggressive postoperative treatment and closer follow-up. therapeutic target hsa-mir-141 Gastric Neoplasms 26233544 disease of cellular proliferation DOID:10534 C16 D013274 137215 These findings together suggested that miR-141 could be interacting with MEG3 and targeting E2F3, and these factors may play important anti-tumor effects in GC pathogenesis and provide therapeutic targets in the clinics. therapeutic target hsa-mir-141 Gastric Neoplasms 25633292 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-141 might be employed as novel prognostic markers and therapeutic targets of GC. therapeutic target hsa-mir-142 Gastric Neoplasms 26232716 disease of cellular proliferation DOID:10534 C16 D013274 137215 These findings together suggested that miR-141 could be interacting with MEG3 and targeting E2F4, and these factors may play important anti-tumor effects in GC pathogenesis and provide therapeutic targets in the clinics. therapeutic target hsa-mir-143 Gastric Neoplasms 26231888 disease of cellular proliferation DOID:10534 C16 D013274 137215 These findings together suggested that miR-141 could be interacting with MEG3 and targeting E2F5, and these factors may play important anti-tumor effects in GC pathogenesis and provide therapeutic targets in the clinics. therapeutic target hsa-mir-143 Gastric Neoplasms 26349981 disease of cellular proliferation DOID:10534 C16 D013274 137215 In conclusion, we determined miR-143 as a potent inhibitor of autophagy via targeting GABARAPL1 and miR-143 could improve the efficacy of Quercetin though autophagy inhibition in GC cell lines, thus representing a novel potential therapeutic target for gastric cancer. therapeutic target hsa-mir-148a Gastric Neoplasms 24659367 disease of cellular proliferation DOID:10534 C16 D013274 137215 MiR-148a may serve as a novel biomarker for the diagnosis and as a new therapeutic target in gastric cancer. therapeutic target hsa-mir-152 Gastric Neoplasms 26627200 disease of cellular proliferation DOID:10534 C16 D013274 137215 TGF-β could induce HLA-G expression in GC by inhibiting miR-152,involving its negative regulation on HLA-G. Since TGF-β induced HLA-G up-regulation plays important role in immune escape, a potential application of miR-152 was suggested in GC treatment, or miR-152 might be one potential biomarker for GC. therapeutic target hsa-mir-155 Gastric Neoplasms 26056431 disease of cellular proliferation DOID:10534 C16 D013274 137215 rosmarinic acid (RA) might potentially be a therapeutic agent for suppressing the Warburg effect in gastric carcinoma. therapeutic target hsa-mir-15b Gastric Neoplasms 26349984 disease of cellular proliferation DOID:10534 C16 D013274 137215 This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers. therapeutic target hsa-mir-16 Gastric Neoplasms 26349984 disease of cellular proliferation DOID:10534 C16 D013274 137215 This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers. therapeutic target hsa-mir-181b Gastric Neoplasms 26349984 disease of cellular proliferation DOID:10534 C16 D013274 137215 This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers. therapeutic target hsa-mir-18a Gastric Neoplasms 24624454 disease of cellular proliferation DOID:10534 C16 D013274 137215 These data highlighted an important role for miR-18a in controlling gastric cancer growth and angiogenesis, therefore offering a possible therapeutic strategy against this malignancy. therapeutic target hsa-mir-19a Gastric Neoplasms 25400827 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-19a could be used as a promising therapeutic target in the treatment of GC. therapeutic target hsa-mir-19a Gastric Neoplasms 26334097 disease of cellular proliferation DOID:10534 C16 D013274 137215 Our data suggest that cMET, PIK3CA and target-related miRNAs play an important role in GC and may serve as potential targets for therapy. therapeutic target hsa-mir-19a Gastric Neoplasms 26349984 disease of cellular proliferation DOID:10534 C16 D013274 137215 This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers. therapeutic target hsa-mir-19a Gastric Neoplasms 25914465 disease of cellular proliferation DOID:10534 C16 D013274 137215 All together, our results suggest that miR-19a could be used as a promising therapeutic target in the treatment of GC. therapeutic target hsa-mir-19b Gastric Neoplasms 26349984 disease of cellular proliferation DOID:10534 C16 D013274 137215 This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers. therapeutic target hsa-mir-200 Gastric Neoplasms 25595591 disease of cellular proliferation DOID:10534 C16 D013274 137215 EZH2 and DNMT1-mediated epigenetic silencing contributed to the progression of gastric cancer and glioblastoma, and therefore represents a novel therapeutic target for malignant tumors. therapeutic target hsa-mir-200b Gastric Neoplasms 23995857 disease of cellular proliferation DOID:10534 C16 D013274 137215 Our findings suggest that miR-200b and miR-200c, as valuable markers of gastric cancer prognosis, may be a promising approach to human gastric cancer treatment. therapeutic target hsa-mir-200b Gastric Neoplasms 25411357 disease of cellular proliferation DOID:10534 C16 D013274 137215 CAFs reduce miR-200b expression and promote tumor invasion through epigenetic changes of miR-200b in gastric cancer. Thus, CAFs might be a therapeutic target for inhibition of gastric cancer. therapeutic target hsa-mir-200b Gastric Neoplasms 26349984 disease of cellular proliferation DOID:10534 C16 D013274 137215 This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers. therapeutic target hsa-mir-200c Gastric Neoplasms 23995857 disease of cellular proliferation DOID:10534 C16 D013274 137215 Our findings suggest that miR-200b and miR-200c, as valuable markers of gastric cancer prognosis, may be a promising approach to human gastric cancer treatment. therapeutic target hsa-mir-204 Gastric Neoplasms 26349984 disease of cellular proliferation DOID:10534 C16 D013274 137215 This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers. therapeutic target hsa-mir-206 Gastric Neoplasms 25960238 disease of cellular proliferation DOID:10534 C16 D013274 137215 Our data provide evidence that the dysregulation of miR-206-CCND2 axis may contribute to the aggressive progression and poor prognosis of human gastric cancer in clinical settings. Combined detection of their expression might be particularly helpful for surveillance of disease progression and treatment stratification. therapeutic target hsa-mir-20a Gastric Neoplasms 27357419 disease of cellular proliferation DOID:10534 C16 D013274 137215 Altering miR鈥?0a expression may be a potential therapeutic strategy for the treatment of chemoresistance in GC in the future. therapeutic target hsa-mir-21 Gastric Neoplasms 25041158 disease of cellular proliferation DOID:10534 C16 D013274 137215 Stromal miR-21 is closely related to tumour progression in GC.Stromal miR-21 of tumours might be a target of treatment. therapeutic target hsa-mir-21 Gastric Neoplasms 26349984 disease of cellular proliferation DOID:10534 C16 D013274 137215 This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers. therapeutic target hsa-mir-22 Gastric Neoplasms 26610210 disease of cellular proliferation DOID:10534 C16 D013274 137215 These findings provide a better understanding of the development and progression of GC and may be an important implication for future therapy of the GC. therapeutic target hsa-mir-223 Gastric Neoplasms 26334097 disease of cellular proliferation DOID:10534 C16 D013274 137215 Our data suggest that cMET, PIK3CA and target-related miRNAs play an important role in GC and may serve as potential targets for therapy. therapeutic target hsa-mir-23b Gastric Neoplasms 26835790 disease of cellular proliferation DOID:10534 C16 D013274 137215 Our results indicated that plasma miR-23b was overexpressed in GC patients and high plasma miR-23b expression was associated with poor clinical outcome. Thus, plasma miR-23b may serve as a potential diagnostic biomarker and therapeutic target for GC. therapeutic target hsa-mir-24 Gastric Neoplasms 24886316 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-24 functions as a novel tumor suppressor in GC and the anti-oncogenic activity may involve its inhibition of the target gene RegIV.These findings suggest the possibility for miR-24 as a therapeutic target in GC. therapeutic target hsa-mir-26a Gastric Neoplasms 24015269 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-26a functions as a tumor suppressor in GC development and progression, and holds promise as a prognostic biomarker and potential therapeutic target for GC. therapeutic target hsa-mir-27a Gastric Neoplasms 26349984 disease of cellular proliferation DOID:10534 C16 D013274 137215 This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers. therapeutic target hsa-mir-27b Gastric Neoplasms 26576539 disease of cellular proliferation DOID:10534 C16 D013274 137215 These results show that miR-27b-3p suppresses ROR1 expression through the binding site in the 3'UTR inhibiting the cell proliferation. These findings indicate that miR-27b-3p exerts tumor-suppressive effects in GC through the suppression of oncogene ROR1 expression and suggest a therapeutic application of miR-27b-3p in GC. therapeutic target hsa-mir-28 Gastric Neoplasms 25860484 disease of cellular proliferation DOID:10534 C16 D013274 137215 these data provided the first evidence to illustrate that altered gene network was associated with gastric cancer invasion. Further study with a large sample size and more functional experiments is needed to confirm these data and contribute to diagnostic and treatment strategies for gastric cancer. therapeutic target hsa-mir-29 Gastric Neoplasms 24130168 disease of cellular proliferation DOID:10534 C16 D013274 137215 Take together, our finding characterized the expression properties of miR-29 family, contributed to the function and molecular mechanism of miR-29 family in GC and implied that miR-29 family might be employed as novel prognostic markers and therapeutic targets of GC. therapeutic target hsa-mir-30b Gastric Neoplasms 25170877 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-30b may function as a novel tumor suppressor gene in gastric cancer by targeting PAI-1 and regulating the apoptosis of cancer cells. miR-30b could serve as a potential biomarker and therapeutic target against gastric cancer. therapeutic target hsa-mir-30e Gastric Neoplasms 27372603 disease of cellular proliferation DOID:10534 C16 D013274 137215 DIM may through the miR-30e-ATG5 modulating autophagy inhibit the proliferation of gastric cancer cells. therapeutic target hsa-mir-331 Gastric Neoplasms 24775712 disease of cellular proliferation DOID:10534 C16 D013274 137215 HOTAIR overexpression represents a biomarker of poor prognosis in gastric cancer, and may confer malignant phenotype to tumor cells. The ceRNA regulatory network involving HOTAIR and the positive interaction between HOTAIR and HER2 may contribute to a better understanding of gastric cancer pathogenesis and facilitate the development of lncRNA-directed diagnostics and therapeutics against this disease. therapeutic target hsa-mir-338 Gastric Neoplasms 26617808 disease of cellular proliferation DOID:10534 C16 D013274 137215 Our study suggested that miR-338-3p is significantly decreased in gastric cancer, and inhibits cell proliferation, migration and invasion partially via the downregulation of ADAM17. Thus, miR-338-3p may represent a potential therapeutic target for gastric cancer intervention. therapeutic target hsa-mir-34 Gastric Neoplasms 26349984 disease of cellular proliferation DOID:10534 C16 D013274 137215 This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers. therapeutic target hsa-mir-34a Gastric Neoplasms 26464633 disease of cellular proliferation DOID:10534 C16 D013274 137215 Therefore, we concluded that miR-34a could inhibit tumor invasion and metastasis in gastric cancer by targeting Tgif2 and may be a novel therapeutic candidate for gastric cancer. therapeutic target hsa-mir-34c Gastric Neoplasms 26349984 disease of cellular proliferation DOID:10534 C16 D013274 137215 This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers. therapeutic target hsa-mir-367 Gastric Neoplasms 25489984 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-367 is a key negative regulator of the invasion and metastasis of gastric cancer and establishes a strong rationale for developing miR-367 as a novel therapeutic agent against gastric cancer. therapeutic target hsa-mir-374a Gastric Neoplasms 25554419 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-374a functions as a candidate oncogene in GC by directly targeting SRCIN1. miR-374a may therefore be useful as a promising therapeutic target for malignant GC. therapeutic target hsa-mir-409 Gastric Neoplasms 25860484 disease of cellular proliferation DOID:10534 C16 D013274 137215 these data provided the first evidence to illustrate that altered gene network was associated with gastric cancer invasion. Further study with a large sample size and more functional experiments is needed to confirm these data and contribute to diagnostic and treatment strategies for gastric cancer. therapeutic target hsa-mir-429 Gastric Neoplasms 26349984 disease of cellular proliferation DOID:10534 C16 D013274 137215 This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers. therapeutic target hsa-mir-429 Gastric Neoplasms 23554776 disease of cellular proliferation DOID:10534 C16 D013274 137215 miRNA-429 may serve as a tumor suppressor during tumorigenesis of gastric cancer and may be a potential gastric cancer therapeutic target therapeutic target hsa-mir-449a Gastric Neoplasms 25871967 disease of cellular proliferation DOID:10534 C16 D013274 137215 This study indicates that the miR-449a/E2F3 axis plays an important role in proliferation and apoptosis in gastric cancer. Therefore, miR-449a represents a novel target for gastric cancer therapy. therapeutic target hsa-mir-449a Gastric Neoplasms 26576674 disease of cellular proliferation DOID:10534 C16 D013274 137215 Our results demonstrated that miR-449a suppressed Flot2 expression results in decreased cell invasion through repressing TGF-β-mediated-EMT, and provides a new theoretical basis to further investigate miR-449a-regulated Flot2 as a potential biomarker and a promising approach for GC treatment. therapeutic target hsa-mir-451 Gastric Neoplasms 26464660 disease of cellular proliferation DOID:10534 C16 D013274 137215 Our findings indicated that miR-451 may act as a novel prognostic marker and potential therapeutic target in human GC. therapeutic target hsa-mir-495 Gastric Neoplasms 26375442 disease of cellular proliferation DOID:10534 C16 D013274 137215 In conclusion, targeting miR-130a and miR-495 could be a potential therapeutics to recover RUNX3 expression under hypoxic conditions and in early tumorigenic progression. therapeutic target hsa-mir-495 Gastric Neoplasms 25475733 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-495 have tumor suppressor properties and are partially silenced by DNA hypermethylation in GC, will provide new strategies for prevention and treatment of GC peritoneal metastasis. therapeutic target hsa-mir-497 Gastric Neoplasms 26349984 disease of cellular proliferation DOID:10534 C16 D013274 137215 This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers. therapeutic target hsa-mir-506 Gastric Neoplasms 25707493 disease of cellular proliferation DOID:10534 C16 D013274 137215 The EMT was directly suppressed by miR-506, and its low expression was an independent prognostic factor in gastric cancer patients. The data indicated that miR-506 may act as a tumor suppressor and could be a novel therapeutic agent. therapeutic target hsa-mir-508 Gastric Neoplasms 26349984 disease of cellular proliferation DOID:10534 C16 D013274 137215 This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers. therapeutic target hsa-mir-516a-1 Gastric Neoplasms 21169410 disease of cellular proliferation DOID:10534 C16 D013274 137215 The metastasis associated microRNA miR-516a-3p is a novel therapeutic target for inhibiting peritoneal dissemination of human scirrhous gastric cancer. therapeutic target hsa-mir-516a-2 Gastric Neoplasms 21169410 disease of cellular proliferation DOID:10534 C16 D013274 137215 The metastasis associated microRNA miR-516a-3p is a novel therapeutic target for inhibiting peritoneal dissemination of human scirrhous gastric cancer. therapeutic target hsa-mir-520d Gastric Neoplasms 25063221 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-520d-3p appears to contribute to GC progression via the regulation of EphA2 and could serve as a novel prognostic and potential therapeutic marker. therapeutic target hsa-mir-542 Gastric Neoplasms 25432696 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-542-3p might function as a tumor suppressor in gastric cancer, potentially by targeting the oncogene AEG-1, implying a potential role for miR-542-3p in the development of therapeutic methods for gastric cancer. therapeutic target hsa-mir-543 Gastric Neoplasms 26612257 disease of cellular proliferation DOID:10534 C16 D013274 137215 Our results identify a new regulatory mechanism of miR-543 on SIRT1 expression in gastric cancer, and raise the possibility that the miR-543/SIRT1 pathway may serve as a potential target for the treatment of gastric cancer. therapeutic target hsa-mir-544a Gastric Neoplasms 26264654 disease of cellular proliferation DOID:10534 C16 D013274 137215 Our findings raise the possibility that inhibition of miR-544a may be a therapeutic target of metastatic GC. therapeutic target hsa-mir-625 Gastric Neoplasms 25860484 disease of cellular proliferation DOID:10534 C16 D013274 137215 these data provided the first evidence to illustrate that altered gene network was associated with gastric cancer invasion. Further study with a large sample size and more functional experiments is needed to confirm these data and contribute to diagnostic and treatment strategies for gastric cancer. therapeutic target hsa-mir-638 Gastric Neoplasms 24623314 disease of cellular proliferation DOID:10534 C16 D013274 137215 Our results demonstrated that miR-638 suppressed GC cell proliferation by targeting Sp2 with influence on the expression of cyclin D1. We suggest that miR-638 might be a candidate predictor or an anticancer therapeutic target for GC patients. therapeutic target hsa-mir-874 Gastric Neoplasms 25596740 disease of cellular proliferation DOID:10534 C16 D013274 137215 down-regulation of miR-874 contributes to tumor angiogenesis through STAT3 in GC, highlighting the potential of miR-874 as a target for human GC therapy. therapeutic target hsa-mir-106b Gastrointestinal Neoplasms 23510949 D37.9 D005770 Focus on the essential role in tumorgenisis and extremely low expression of miRNA-106b ∼ 25 in normal tissues, it maybe an appropriate target of gastric cancer treatment and a novel biomarkers for detecting gastric cancer. therapeutic target hsa-mir-221 Gastrointestinal Neoplasms 20618998 D37.9 D005770 Our study suggests that inhibition of miR-221 and miR-222 might form a novel therapeutic strategy for human gastric cancer. therapeutic target hsa-mir-222 Gastrointestinal Neoplasms 20618998 D37.9 D005770 Our study suggests that inhibition of miR-221 and miR-222 might form a novel therapeutic strategy for human gastric cancer. therapeutic target hsa-mir-483 Glaucoma 26747772 nervous system disease DOID:1686 H40 D005901 137750 MicroRNA-483-3p has an inhibitory effect on ECM production in HTMCs through downregulating Smad4, which indicates that miR-483-3p may serve as a potential therapeutic target in glaucoma. therapeutic target hsa-let-7a Glioblastoma 26502847 D005909 HP:0100843 DEMs like hsa-miR-320a, hsa-miR-139-5p, has-miR-128,hsa-miR-146b-5p, hsa-let-7c, hsa-miR-128, and hsa-let-7a might participate in recurrent GBM. These results would pave ways for further study of recurrent GBM mechanism, and for the prevention and treatment of recurrent GBM. However, more experimental verifications are required to prove these predictions. therapeutic target hsa-let-7c Glioblastoma 26502847 D005909 HP:0100843 DEMs like hsa-miR-320a, hsa-miR-139-5p, has-miR-128,hsa-miR-146b-5p, hsa-let-7c, hsa-miR-128, and hsa-let-7a might participate in recurrent GBM. These results would pave ways for further study of recurrent GBM mechanism, and for the prevention and treatment of recurrent GBM. However, more experimental verifications are required to prove these predictions. therapeutic target hsa-mir-101 Glioblastoma 25230316 D005909 HP:0100843 Our findings provided a comprehensive analysis of miR-101 and further defining it as a potential therapeutic candidate for GBM. therapeutic target hsa-mir-124 Glioblastoma 24519663 D005909 HP:0100843 Our results provide new clues for the potential mechanisms involved in the origin and development of glioma. Clinically, the altered miRNAs may serve as potential targets and diagnostic tools for novel therapeutic strategies of glioblastoma. therapeutic target hsa-mir-124 Glioblastoma 18577221 D005909 HP:0100843 In this commentary, we discuss the known functions of miRNAs in cancer and stem cells, their therapeutic potential and how the findings of Silber et al provide insight into the role of miR-124/miR-137 dysregulation in glioblastomas. therapeutic target hsa-mir-124 Glioblastoma 25200130 D005909 HP:0100843 These results demonstrate that engineered miR-124 responsiveness can eliminate off-target replication by unattenuated oHSV without compromising oncolytic activity, thereby providing increased safety. therapeutic target hsa-mir-124 Glioblastoma 27765835 D005909 HP:0100843 Immune modulatory nanoparticle therapeutics for intracerebral glioma. therapeutic target hsa-mir-124 Glioblastoma 29185191 D005909 HP:0100843 MicroRNAs (miRs) are potential therapeutic targets in glioblastoma multiforme (GBM) therapeutic target hsa-mir-124a Glioblastoma 29016843 D005909 HP:0100843 Mesenchymal stem cells as natural biofactories for exosomes carrying miR-124a in the treatment of gliomas. therapeutic target hsa-mir-128 Glioblastoma 26502847 D005909 HP:0100843 DEMs like hsa-miR-320a, hsa-miR-139-5p, has-miR-128,hsa-miR-146b-5p, hsa-let-7c, hsa-miR-128, and hsa-let-7a might participate in recurrent GBM. These results would pave ways for further study of recurrent GBM mechanism, and for the prevention and treatment of recurrent GBM. However, more experimental verifications are required to prove these predictions. therapeutic target hsa-mir-128 Glioblastoma 25897645 D005909 HP:0100843 MicroRNA-128 (miR-128) is an attractive therapeutic molecule with powerful glioblastoma regulation properties therapeutic target hsa-mir-129-1 Glioblastoma 26510428 D005909 HP:0100843 This is the first study to propose miR129-1 as a negative regulator of IGF2BP3 and MAPK1 and also a cell cycle arrest inducer in GBM cells. Our data suggests miR-129-1 as a potential tumour suppressor and presents a rationale for the use of miR-129-1 as a novel strategy to improve treatment response in GBM. therapeutic target hsa-mir-130a Glioblastoma 25890369 D005909 HP:0100843 Our data suggested that miR-130a could be a predictive marker for TMZ response in patients with GBM, independently of the mechanism by which MGMT acts as a biomarker. miR-130a could serve as a guide for treatment strategy selection in cases of GBM. therapeutic target hsa-mir-135b Glioblastoma 26437223 D005909 HP:0100843 Our results identify a critical role of miR-135b in the regulation of GBM development, suggesting that miR-135b might act as a tumor-suppressor factor and thus providing a potential candidate for the treatment of GBM patients. therapeutic target hsa-mir-137 Glioblastoma 18577221 D005909 HP:0100843 In this commentary, we discuss the known functions of miRNAs in cancer and stem cells, their therapeutic potential and how the findings of Silber et al provide insight into the role of miR-124/miR-137 dysregulation in glioblastomas. therapeutic target hsa-mir-139 Glioblastoma 26502847 D005909 HP:0100843 DEMs like hsa-miR-320a, hsa-miR-139-5p, has-miR-128,hsa-miR-146b-5p, hsa-let-7c, hsa-miR-128, and hsa-let-7a might participate in recurrent GBM. These results would pave ways for further study of recurrent GBM mechanism, and for the prevention and treatment of recurrent GBM. However, more experimental verifications are required to prove these predictions. therapeutic target hsa-mir-143 Glioblastoma 26541455 D005909 HP:0100843 Taken together, for the first time, our results demonstrate that miR-143 could enhance the antitumor activity of shikonin toward GSCs through reducing BAG3 expression, which may provide a novel therapeutic strategy for enhancing the treatment efficacy of shikonin toward GSCs. therapeutic target hsa-mir-146b Glioblastoma 26502847 D005909 HP:0100843 DEMs like hsa-miR-320a, hsa-miR-139-5p, has-miR-128,hsa-miR-146b-5p, hsa-let-7c, hsa-miR-128, and hsa-let-7a might participate in recurrent GBM. These results would pave ways for further study of recurrent GBM mechanism, and for the prevention and treatment of recurrent GBM. However, more experimental verifications are required to prove these predictions. therapeutic target hsa-mir-153-1 Glioblastoma 23397238 D005909 HP:0100843 reactivation of miR-153 expression suggests novel therapeutic strategies for GBM-SCs therapeutic target hsa-mir-153-2 Glioblastoma 23397238 D005909 HP:0100843 reactivation of miR-153 expression suggests novel therapeutic strategies for GBM-SCs therapeutic target hsa-mir-155 Glioblastoma 22276743 D005909 HP:0100843 The data suggest that miR-155 blockage increased the chemosensitivity to taxol in GBM cells, making combined treatment an effective therapeutic strategy for controlling the growth by inhibiting EAG1 expression. therapeutic target hsa-mir-181b Glioblastoma 26283154 D005909 HP:0100843 Our results showed that miR-181 family expression was closely correlated with TCGA subtypes and patients' overall survival, indicating that miR-181b, a tumor-suppressive miRNA, could be a novel therapeutic candidate for treating gliomas. therapeutic target hsa-mir-181c Glioblastoma 26682928 D005909 HP:0100843 our study found that miR-181c plays a key role in glioblastoma cell invasion, migration and mesenchymal transition suggesting potential therapeutic applications. therapeutic target hsa-mir-182 Glioblastoma 26506113 D005909 HP:0100843 Thus, miR-182-based SNAs represent a tool for systemic delivery of miRNAs and a novel approach for the precision treatment of malignant brain cancers. therapeutic target hsa-mir-195 Glioblastoma 26537083 D005909 HP:0100843 This study revealed a significant role of miR-195 in the molecular pathology of glioma cells which can also implicate potential application of miR-195 in cancer therapy. Rather than downregulation of miR-195 alone to exhibit cytotoxicity, treatment with CsA could be more effective especially on temozolomide-resistant cells. therapeutic target hsa-mir-198 Glioblastoma 24519663 D005909 HP:0100843 Our results provide new clues for the potential mechanisms involved in the origin and development of glioma. Clinically, the altered miRNAs may serve as potential targets and diagnostic tools for novel therapeutic strategies of glioblastoma. therapeutic target hsa-mir-21 Glioblastoma 25625875 D005909 HP:0100843 combining DOX and miR-21i is a new strategy for the therapy of GBM. therapeutic target hsa-mir-21 Glioblastoma 25572456 D005909 HP:0100843 the R3V6 peptide may be a useful carrier of antisense-ODN for glioblastoma gene therapy. therapeutic target hsa-mir-21 Glioblastoma 20048743 D005909 HP:0100843 Taken together, our studies provide evidence that miR-21 may serve as a novel therapeutic target for malignant gliomas independent of PTEN status. therapeutic target hsa-mir-21 Glioblastoma 25861727 D005909 HP:0100843 MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma. therapeutic target hsa-mir-21 Glioblastoma 27079911 D005909 HP:0100843 Here we show that rationally designed hammerhead ribozymes and DNAzymes can target miR-21 and/or its precursors. therapeutic target hsa-mir-21 Glioblastoma 27277750 D005909 HP:0100843 co-delivery of anti-miR-21 significantly improved accumulation of LPNs in the nucleus of U87MG cells. therapeutic target hsa-mir-21 Glioblastoma 27355932 D005909 HP:0100843 Anti-cancer effect of R3V6 peptide-mediated delivery of an anti-microRNA-21 antisense-oligodeoxynucleotide in a glioblastoma animal model. therapeutic target hsa-mir-21 Glioblastoma 27508339 D005909 HP:0100843 Coinhibition of miR-21 and miR-10b significantly reduced the number of viable cells (by 24%; p < 0.01) and increased (2.9-fold) cell cycle arrest at G2/M phase upon Temozolomide treatment in U87 MG cells. therapeutic target hsa-mir-21 Glioblastoma 28109960 D005909 HP:0100843 RNA Nanoparticle-Based Targeted Therapy for Glioblastoma through Inhibition of Oncogenic miR-21. therapeutic target hsa-mir-21 Glioblastoma 28840962 D005909 HP:0100843 Biomarkers and therapeutic advances in glioblastoma multiforme. therapeutic target hsa-mir-21 Glioblastoma 29340361 D005909 HP:0100843 DP-Cur is an efficient carrier of miR21ASO and the combined delivery of miR21ASO and curcumin may be useful in the development of combination therapy for glioblastoma therapeutic target hsa-mir-29b Glioblastoma 29176935 D005909 HP:0100843 miR-29b may serve as a putative therapeutic molecule when its expression is restored using a nanoparticle delivery system in GBM therapeutic target hsa-mir-29c Glioblastoma 26450587 D005909 HP:0100843 Our findings suggest a rationale for targeting the c-Myc/miR-29c/REV3L signalling pathway as a promising therapeutic approach for glioblastoma, even in recurrent,treatment-refractory settings. therapeutic target hsa-mir-30e Glioblastoma 27388765 D005909 HP:0100843 Collectively, combination of miR-30e and PAC is a promising therapeutic strategy to inhibit autophagy and increase apoptosis in GSC and SNB19 cells. therapeutic target hsa-mir-31 Glioblastoma 26310668 D005909 HP:0100843 Taken together, our results indicate that miR-31 triggers mitochondrial apoptosis and potentiates TMZ cytotoxicity in GBM cells largely through the suppression of STAT3 activation.Thus, the restoration of miR-31 expression may be of therapeutic beenefit in the treatment of GBM. therapeutic target hsa-mir-320a Glioblastoma 26502847 D005909 HP:0100843 DEMs like hsa-miR-320a, hsa-miR-139-5p, has-miR-128,hsa-miR-146b-5p, hsa-let-7c, hsa-miR-128, and hsa-let-7a might participate in recurrent GBM. These results would pave ways for further study of recurrent GBM mechanism, and for the prevention and treatment of recurrent GBM. However, more experimental verifications are required to prove these predictions. therapeutic target hsa-mir-34a Glioblastoma 27569663 D005909 HP:0100843 Functionalized nanogels carrying an anticancer microRNA for glioblastoma therapy. therapeutic target hsa-mir-377 Glioblastoma 24951112 D005909 HP:0100843 These findings reveal that miR-377/Sp1 signaling that may be required for GBM development and may consequently serve as a therapeutic target for the treatment of GBM. therapeutic target hsa-mir-449a Glioblastoma 25487955 D005909 HP:0100843 results elucidated a novel molecular mechanism of GBM progression, and may thus suggest a promising application for GBM treatment. therapeutic target hsa-mir-486 Glioblastoma 21737610 D005909 HP:0100843 Nineteen and 26 microRNAs exhibited cohort-dependent (including hsa-miR-10b with therapy and hsa-miR-486 with race) and independent associations with glioblastoma, respectively. therapeutic target hsa-mir-566 Glioblastoma 24650032 D005909 HP:0100843 miR-566 activated EGFR signaling and its inhibition sensitized glioblastoma cells to anti-EGFR therapy. therapeutic target hsa-mir-663 Glioblastoma 24523440 D005909 HP:0100843 miR-663 is a novel prognostic biomarker and a potential therapeutic candidate for glioblastoma. therapeutic target hsa-let-7 Glioma 26307768 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma therapeutic target hsa-mir-106a Glioma 26307768 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma therapeutic target hsa-mir-10a Glioma 26307768 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma therapeutic target hsa-mir-124 Glioma 24861879 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Taken together, these results revealed that miR-124 levels in tumor tissues are associated with glioma occurrence, angiogenesis, and chemoresistance and that miR-124 may be used as a new diagnostic marker and therapeutic target for glioma in the future. therapeutic target hsa-mir-124 Glioma 25051157 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 adenovirus-mediated TIKI2 therapy may be used for glioma treatment therapeutic target hsa-mir-124 Glioma 24497408 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 The findings indicate that miR-124-5p functions as a tumor suppressor and could serve as a molecular marker for glioma diagnosis and as a potential therapeutic target in GBM treatment. therapeutic target hsa-mir-125a Glioma 25560389 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 potential target for diagnosis and treatment of malignant glioma. therapeutic target hsa-mir-125b Glioma 24479808 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Our present study suggests that As2O3 could be a potential therapeutic agent for treatment of human glioma. therapeutic target hsa-mir-125b-2 Glioma 26307768 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma therapeutic target hsa-mir-126 Glioma 26617742 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Taken together, these findings showed that miR-126 functions as a tumor suppressor in glioma cells by targeting IRS-1 expression via the PI3K/AKT signaling pathways, suggesting that miR-126 might be a novel target for therapeutic strategies in glioma. therapeutic target hsa-mir-128 Glioma 26307768 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma therapeutic target hsa-mir-129-2 Glioma 26320507 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 These results reveal that miR-129-2 is epigenetically regulated and functions as a tumor suppressor gene in GBMs, suggesting it may serve as a potential therapeutic target for GBM treatment. therapeutic target hsa-mir-134 Glioma 25564273 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 the reduced expression of miR-134 may predict aggressive progression and poor prognosis in human gliomas. miR-134 may represent both a prognostic marker and a novel therapeutic target for this malignancy. therapeutic target hsa-mir-137 Glioma 26307768 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma therapeutic target hsa-mir-140 Glioma 26619802 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Taken together, we have demonstrated the fact that knockdown of MALAT1 resulted in the increased permeability of BTB, which might contribute to establishing potential therapeutic strategies for human gliomas. therapeutic target hsa-mir-145 Glioma 24573110 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 In conclusion, this is the first study to report that ROCK1, as a novel target of miR-145, acts as a positive regulator of glioma cell invasion. Therefore, ROCK1 may constitute a promising target for glioma treatment. therapeutic target hsa-mir-146b Glioma 26307768 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma therapeutic target hsa-mir-146b Glioma 26320176 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Our findings identify miR-146b-5p as a tumor suppressor and novel prognostic biomarker of gliomas, and suggest miR-146b-5p and TRAF6 as potential therapeutic candidates for malignant gliomas. therapeutic target hsa-mir-146b Glioma 26983831 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 a novel treatment whereby mesenchymal stromal cells were employed to package tumor-suppressing miR-146b into exosomes therapeutic target hsa-mir-148a Glioma 26307768 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma therapeutic target hsa-mir-155 Glioma 24623016 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 These findings reveal that miR-155 expression might be an independent prognostic factor and a therapeutic target for human glioma. therapeutic target hsa-mir-15b Glioma 24995320 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Our findings identified that miR-15b may function as a glioma suppressor by targeting the Cyclin D1, which may provide a novel therapeutic strategy for treatment of glioma. therapeutic target hsa-mir-15b Glioma 26307768 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma therapeutic target hsa-mir-16 Glioma 26722459 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 In conclusion, MiR-16 mediated temozolomide-resistance in glioma cells by modulation of apoptosis via targeting Bcl-2, which suggesting that miR-16 and Bcl-2 would be potential therapeutic targets for glioma therapy. therapeutic target hsa-mir-17 Glioma 26307768 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma therapeutic target hsa-mir-181b Glioma 25151861 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-181b is an important positive regulator on glioma cell sensitivity to teniposide. It confers glioma cell sensitivity to teniposide through binding to the 3'-UTR region of MDM2 leading to its reduced expression. Our findings not only reveal the novel mechanism involved in teniposide resistance, but also shed light on the optimization of glioma treatment in the future. therapeutic target hsa-mir-181b Glioma 23645289 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-181b independently predicted chemoresponse to temozolomide and enhanced temozolomide sensitivity via MEK1 downregulation. A combination of miR-181b and temozolomide may be an effective therapeutic strategy for gliomas. therapeutic target hsa-mir-181d Glioma 25007077 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Identification of a core miRNA-pathway regulatory network in glioma by therapeutically targeting miR-181d, miR-21, miR-23b, β-Catenin, CBP, and STAT3. therapeutic target hsa-mir-181d Glioma 26307768 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma therapeutic target hsa-mir-184 Glioma 25216670 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Our study is the first to show a novel regulatory role of SND1, a direct target of miR-184, in glioma progression, suggesting that the miR-184/SND1 axis may be a useful diagnostic and therapeutic tool for malignant glioma. therapeutic target hsa-mir-184 Glioma 25888093 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-184 could regulate TNFAIP2 expression and affected its translation in glioma. miR-184 could also inhibit glioma progression and might serve as a novel therapeutic target in glioma. therapeutic target hsa-mir-18a Glioma 25452107 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-18a increased the permeability of BTB via RUNX1 mediated down-regulation of tight junction related proteins ZO-1, occludin and claudin-5, which would attract more attention to miR-18a and RUNX1 as potential targets of drug delivery across BTB and provide novel strategies for glioma treatment. therapeutic target hsa-mir-18a Glioma 26356851 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MiR-18a should garner growing attention because it might serve as a potential target in opening the BTB and providing a new strategy for the treatment of gliomas. therapeutic target hsa-mir-193a Glioma 26307768 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma therapeutic target hsa-mir-200b Glioma 26307768 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma therapeutic target hsa-mir-203 Glioma 25515700 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-203 may function as a tumor suppressor in glioma progression and that the miR-203/E2F3 axis may be a novel candidate in the development of rational therapeutic strategies for glioma. therapeutic target hsa-mir-20a Glioma 26307768 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma therapeutic target hsa-mir-21 Glioma 24326156 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Our data show that miR-21 may be a candidate independent marker for gliomas, especially those with high pathological grades, and this could also be a potential therapeutic target for molecular glioma therapy. therapeutic target hsa-mir-21 Glioma 25007077 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Identification of a core miRNA-pathway regulatory network in glioma by therapeutically targeting miR-181d, miR-21, miR-23b, β-Catenin, CBP, and STAT3. therapeutic target hsa-mir-21 Glioma 26307768 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma therapeutic target hsa-mir-21 Glioma 25446261 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 CASC2 plays a tumor suppressive role in glioma via negative regulation of miR-21, which may be a novel therapeutic target for treating gliomas. therapeutic target hsa-mir-21 Glioma 27079911 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Here we show that rationally designed hammerhead ribozymes and DNAzymes can target miR-21 and/or its precursors. therapeutic target hsa-mir-210 Glioma 24930954 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-210 might be a potential therapeutic target to eliminate GSCs located in hypoxic niches. therapeutic target hsa-mir-210 Glioma 25481483 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Aberrantly expressed miR-210 regulates human U251 glioma cells apoptosis and proliferation partly through directly down-regulating SIN3A protein expression. This might offer a new potential therapeutic stratagem for glioma. therapeutic target hsa-mir-221 Glioma 26307768 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma therapeutic target hsa-mir-221 Glioma 26708164 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 increased pro-apoptotic effects were obtained with the co-administration of both anti-miR鈥?21 and anti-miR鈥?22 PNAs. therapeutic target hsa-mir-222 Glioma 26307768 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma therapeutic target hsa-mir-222 Glioma 26370254 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 In summary, we show that Gas5 suppresses tumor malignancy by downregulating miR-222, which may serve as a promising therapy for glioma. therapeutic target hsa-mir-23a Glioma 26307768 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma therapeutic target hsa-mir-23b Glioma 25007077 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Identification of a core miRNA-pathway regulatory network in glioma by therapeutically targeting miR-181d, miR-21, miR-23b, β-Catenin, CBP, and STAT3. therapeutic target hsa-mir-30b Glioma 26307768 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma therapeutic target hsa-mir-30c Glioma 26307768 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma therapeutic target hsa-mir-31 Glioma 26307768 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma therapeutic target hsa-mir-326 Glioma 25173582 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 This work suggests a possible molecular mechanism of the miR-326/SMO axis, which can be a potential alternative therapeutic pathway for gliomas. therapeutic target hsa-mir-326 Glioma 26307768 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma therapeutic target hsa-mir-328 Glioma 25562367 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 loss of miR-328 expression may stimulate advanced tumor progression and adverse outcome via promoting cellular proliferation and invasion. We propose a tumor suppressive role of miR-328 and its potential therapeutic value in human glioma. therapeutic target hsa-mir-34a Glioma 26307768 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma therapeutic target hsa-mir-373 Glioma 28617546 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Down-expression of miR-373 predicts poor prognosis of glioma and could be a potential therapeutic target. therapeutic target hsa-mir-381 Glioma 25605243 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 the miR-381-NEFL axis is important for TMZ resistance in GBM and may potentially serve as a novel therapeutic target for glioma. therapeutic target hsa-mir-425 Glioma 26307768 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma therapeutic target hsa-mir-455 Glioma 26307768 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma therapeutic target hsa-mir-506 Glioma 26554866 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 These results showed that miR-506 functions as a tumor suppressor in glioma by targeting STAT3, suggesting that miR-506 may serve as a potential target in the treatment of human glioma. therapeutic target hsa-mir-5096 Glioma 25978028 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Our findings reveal the potential for therapeutic interventions based on abolishing alteration of stromal cells by tumor cells via manipulation of microRNA and gap junction channel activity. therapeutic target hsa-mir-548 Glioma 26307768 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma therapeutic target hsa-mir-637 Glioma 25597410 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 the role of miR-637 in the development of gliomas, and implicate the potential application of miR-637 in cancer therapy. therapeutic target hsa-mir-7 Glioma 25394492 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miR-7 inhibits cellular growth and glucose metabolism in gliomas, at least partially, by regulating the IGF-1R/Akt signaling pathway. Therefore, miR-7 is a promising molecular drug for glioma treatment therapeutic target hsa-mir-7-1 Glioma 22120825 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 The absence of miR-7 function could cause downstream molecules to switch on or off, resulting in glioma development, invasion, and metastases. MiR-7-based gene treatment may be a novel anti-invasion therapeutic strategy for malignant glioma. therapeutic target hsa-mir-7-2 Glioma 22120825 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 The absence of miR-7 function could cause downstream molecules to switch on or off, resulting in glioma development, invasion, and metastases. MiR-7-based gene treatment may be a novel anti-invasion therapeutic strategy for malignant glioma. therapeutic target hsa-mir-7-3 Glioma 22120825 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 The absence of miR-7 function could cause downstream molecules to switch on or off, resulting in glioma development, invasion, and metastases. MiR-7-based gene treatment may be a novel anti-invasion therapeutic strategy for malignant glioma. therapeutic target hsa-mir-873 Glioma 26323558 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Taken together, these data suggest that miR-873 might be a potential marker for cisplatin resistance and a promising sensitizer in cisplatin treatment. therapeutic target hsa-mir-93 Glioma 24721397 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 MicroRNA-93 was aberrantly over-expressed in glioma tissues and cell lines. Transient transfection of microRNA-93 mimic led to increased proliferation, G1-to-S cell cycle progression and reduced apoptosis in A172 glioma cells, indicating that micro-RNA-93 might be a new target for the diagnosis and treatment of glioma. therapeutic target hsa-mir-93 Glioma 26307768 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma therapeutic target hsa-mir-95 Glioma 26307768 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma therapeutic target hsa-mir-98 Glioma 26502849 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 These findings demonstrated that miR-98 functions as a tumor suppressor in gliomas. Furthermore, miR-98 may act as a potential therapeutic biomarker for glioma patients. therapeutic target hsa-mir-30 Glomerulosclerosis 24086574 urinary system disease DOID:0050851 D005923 603278 The therapeutic replacement of miR-30 as a novel strategy to prevent the podocyte apoptosis that is characteristic of progressive glomerular diseases. therapeutic target hsa-mir-150 Graft-Versus-Host Disease 27329362 D89.813 D006086 614395 microRNA-150 (miR-150) induces immunological tolerance in CD4(+) T cells after transplantation therapeutic target hsa-mir-200b Graft-Versus-Host Disease 25510861 D89.813 D006086 614395 miR-200b in the negative regulation of DC development and provide a potential form of miRNA-mediated cell therapy for diseases that range from auto-immunity to graft-versus-host disease. therapeutic target hsa-mir-212 Habitual Abortion 26722471 N96 D000026 In summary, we describe a unique myometrial miRNA expression pattern in human spontaneous preterm labor and discuss their possible role by predicting the target genes of each miRNA. Our results suggest that miRNA play a critical role in the process of partuition in myometrium. The identification of myometrial miRNA profile throws a new light upon the molecule mechanism and provides an insight into the potential diagnosis and treatment of preterm labor. therapeutic target hsa-mir-223 Habitual Abortion 26722471 N96 D000026 In summary, we describe a unique myometrial miRNA expression pattern in human spontaneous preterm labor and discuss their possible role by predicting the target genes of each miRNA. Our results suggest that miRNA play a critical role in the process of partuition in myometrium. The identification of myometrial miRNA profile throws a new light upon the molecule mechanism and provides an insight into the potential diagnosis and treatment of preterm labor. therapeutic target hsa-mir-5096 Habitual Abortion 26722471 N96 D000026 In summary, we describe a unique myometrial miRNA expression pattern in human spontaneous preterm labor and discuss their possible role by predicting the target genes of each miRNA. Our results suggest that miRNA play a critical role in the process of partuition in myometrium. The identification of myometrial miRNA profile throws a new light upon the molecule mechanism and provides an insight into the potential diagnosis and treatment of preterm labor. therapeutic target hsa-mir-203 Head And Neck Neoplasms 26265694 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 These findings indicate that EMT and low expression of EMT-inhibiting miRs, especially miR-203, measured in pretreatment material,causes intrinsic radioresistance of HNSCC, which could enable identification and treatment modification of radioresistant tumors. therapeutic target hsa-mir-205 Head And Neck Neoplasms 25422181 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 LNA-ISH revealed that miR-205 exhibited significant differential cytoplasmic and nuclear staining among inflammation, benign and malignant tumors of head and neck. miR-205 was not only exclusively expressed in squamous epithelial malignancy. This study offers information and a basis for a comprehensive study of the role of miR-205 that may be useful as a biomarker and/or therapeutic target in head and neck tumors. therapeutic target hsa-mir-100 Heart Diseases [unspecific] 25736855 I51.9 D006333 Results from this study point to a role for miR-100 in the regulation of Natriuretic peptide receptor 3 (NPR3) expression, and suggest a possible therapeutic target for modulation of Natriuretic peptide(NP) bioactivity in heart disease. therapeutic target hsa-mir-23a Heart Diseases [unspecific] 22136461 I51.9 D006333 miRNA-23/27/24 cluster has potential therapetic application in vascular disorders and ischemic heart disease therapeutic target hsa-mir-24-2 Heart Diseases [unspecific] 22136461 I51.9 D006333 miRNA-23/27/24 cluster has potential therapetic application in vascular disorders and ischemic heart disease therapeutic target hsa-mir-27a Heart Diseases [unspecific] 22136461 I51.9 D006333 miRNA-23/27/24 cluster has potential therapetic application in vascular disorders and ischemic heart disease therapeutic target hsa-mir-34a Heart Diseases [unspecific] 29302057 I51.9 D006333 inhibition of miR-34a activity has differential effects depending on the cell type, thereby warranting the need to eliminate off-target effects when introducing miR-based therapy therapeutic target hsa-mir-1 Heart Failure 23612897 I50 D006331 HP:0001635 Taken together, our findings suggest that restoration of miR-1 gene expression is a potential novel therapeutic strategy to reverse pressure-induced cardiac hypertrophy and prevent maladaptive cardiac remodeling. therapeutic target hsa-mir-122 Heart Failure 27485847 I50 D006331 HP:0001635 First clinical trials using the blockade of liver specific miR-122 showed very promising results in the treatment of chronic hepatitis C virus infection. Results of preclinical and animal studies are also promising providing future rationale for the development of new therapeutics for various internal diseases including heart failure, bronchial asthma or inflammatory bowel diseases. therapeutic target hsa-mir-208a Heart Failure 21900086 I50 D006331 HP:0001635 Therapeutic Inhibition of miR-208a Improves Cardiac Function and Survival During Heart Failure. therapeutic target hsa-mir-21 Heart Failure 20560046 I50 D006331 HP:0001635 miR-21 is found to play important roles in vascular smooth muscle cell proliferation and apoptosis, cardiac cell growth and death, and cardiac fibroblast functions therapeutic target hsa-mir-21 Heart Failure 20978356 I50 D006331 HP:0001635 recent reports have suggested that an miR-21 antagomir might be therapeutically useful in preventing heart failure in mice therapeutic target hsa-mir-22 Heart Failure 29486470 I50 D006331 HP:0001635 Our findings demonstrate that miR-22 accelerates cardiac fibrosis through the miR-22-Cav3-PKCε pathway, which, therefore, may represent a new therapeutic target for treatment of excessive fibrosis-associated cardiac diseases therapeutic target hsa-mir-340 Heart Failure 23998897 I50 D006331 HP:0001635 Our study provided a comprehensive miRNA expression profiling in the end-stage heart failure and identified miR-340 as a key miRNA contributing to the occurrence and progression of heart failure. Our discoveries provide novel therapeutic targets for patients with heart failure therapeutic target hsa-mir-499 Heart Failure 21403094 I50 D006331 HP:0001635 The recognition that miR-499 promotes the differentiation of hCSCs into mechanically integrated cardiomyocytes has important clinical implications for the treatment of human heart failure. therapeutic target hsa-let-7 Hemangioma 26772808 disease of cellular proliferation DOID:255 D18.0 D006391 602089 microRNA-regulated pathways may play a role in infantile hemangioma development and progression and may be potentially useful for future development of novel therapeutic strategies for patients with infantile hemangioma. therapeutic target hsa-mir-9 Hemangioma 26772808 disease of cellular proliferation DOID:255 D18.0 D006391 602089 microRNA-regulated pathways may play a role in infantile hemangioma development and progression and may be potentially useful for future development of novel therapeutic strategies for patients with infantile hemangioma. therapeutic target hsa-mir-939 Hemangioma 26772808 disease of cellular proliferation DOID:255 D18.0 D006391 602089 microRNA-regulated pathways may play a role in infantile hemangioma development and progression and may be potentially useful for future development of novel therapeutic strategies for patients with infantile hemangioma. therapeutic target hsa-mir-223 Hematologic Neoplasms 28322994 disease of cellular proliferation DOID:2531 C96.9 D019337 HP:0004377 The role of miRNA-223 in cancer: Function, diagnosis and therapy. therapeutic target hsa-mir-29 Hematologic Neoplasms 24993745 disease of cellular proliferation DOID:2531 C96.9 D019337 HP:0004377 MiR-29 family members appear to govern some general features in commonly heterogenous hematological malignancies and therefore form a potential target for treatment. therapeutic target hsa-mir-146a Hemoglobin Diseases 21901398 D58.2 D006450 141900 We suggest that manipulation of miR-146a expression may represent a potential new therapy for several hematopoietic diseases, and may further serve as a biomarker for diagnosis,prevention, and treatment of such disease. therapeutic target hsa-mir-223 Hemoglobinopathy 26080908 hematopoietic system disease DOID:2860 D58.2 D006453 These findings have important implications in future design of shRNA(miR)s for RNAi-based therapy in hemoglobinopathies and other diseases requiring lineage-specific expression of gene silencing sequences. therapeutic target hsa-mir-30 Hemoglobinopathy 26080908 hematopoietic system disease DOID:2860 D58.2 D006453 These findings have important implications in future design of shRNA(miR)s for RNAi-based therapy in hemoglobinopathies and other diseases requiring lineage-specific expression of gene silencing sequences. therapeutic target hsa-mir-101 Hemophagocytic Lymphohistiocytosis 26194545 immune system disease DOID:0050120 D76.1 D051359 267700 MicroRNA activation signature in patients with hemophagocytic lymphohistiocytosis and reversibility with disease-specific therapy. therapeutic target hsa-mir-106b Hemophagocytic Lymphohistiocytosis 26194545 immune system disease DOID:0050120 D76.1 D051359 267700 MicroRNA activation signature in patients with hemophagocytic lymphohistiocytosis and reversibility with disease-specific therapy. therapeutic target hsa-mir-142 Hemophagocytic Lymphohistiocytosis 26194545 immune system disease DOID:0050120 D76.1 D051359 267700 MicroRNA activation signature in patients with hemophagocytic lymphohistiocytosis and reversibility with disease-specific therapy. therapeutic target hsa-mir-143 Hemophagocytic Lymphohistiocytosis 26194545 immune system disease DOID:0050120 D76.1 D051359 267700 MicroRNA activation signature in patients with hemophagocytic lymphohistiocytosis and reversibility with disease-specific therapy. therapeutic target hsa-mir-144 Hemophagocytic Lymphohistiocytosis 26194545 immune system disease DOID:0050120 D76.1 D051359 267700 MicroRNA activation signature in patients with hemophagocytic lymphohistiocytosis and reversibility with disease-specific therapy. therapeutic target hsa-mir-16 Hemophagocytic Lymphohistiocytosis 26194545 immune system disease DOID:0050120 D76.1 D051359 267700 MicroRNA activation signature in patients with hemophagocytic lymphohistiocytosis and reversibility with disease-specific therapy. therapeutic target hsa-mir-19a Hemophagocytic Lymphohistiocytosis 26194545 immune system disease DOID:0050120 D76.1 D051359 267700 MicroRNA activation signature in patients with hemophagocytic lymphohistiocytosis and reversibility with disease-specific therapy. therapeutic target hsa-mir-19b Hemophagocytic Lymphohistiocytosis 26194545 immune system disease DOID:0050120 D76.1 D051359 267700 MicroRNA activation signature in patients with hemophagocytic lymphohistiocytosis and reversibility with disease-specific therapy. therapeutic target hsa-mir-21 Hemophagocytic Lymphohistiocytosis 26194545 immune system disease DOID:0050120 D76.1 D051359 267700 MicroRNA activation signature in patients with hemophagocytic lymphohistiocytosis and reversibility with disease-specific therapy. therapeutic target hsa-mir-223 Hemophagocytic Lymphohistiocytosis 26194545 immune system disease DOID:0050120 D76.1 D051359 267700 MicroRNA activation signature in patients with hemophagocytic lymphohistiocytosis and reversibility with disease-specific therapy. therapeutic target hsa-mir-423 Hemophagocytic Lymphohistiocytosis 26194545 immune system disease DOID:0050120 D76.1 D051359 267700 MicroRNA activation signature in patients with hemophagocytic lymphohistiocytosis and reversibility with disease-specific therapy. therapeutic target hsa-mir-451 Hemophagocytic Lymphohistiocytosis 26194545 immune system disease DOID:0050120 D76.1 D051359 267700 MicroRNA activation signature in patients with hemophagocytic lymphohistiocytosis and reversibility with disease-specific therapy. therapeutic target hsa-mir-126 Hepatic Ischemia-Reperfusion Injury 24457599 Systemic delivery of miR-126 by miRNA-loaded Bubble liposomes for the treatment of hindlimb ischemia. therapeutic target hsa-mir-494 Hepatic Ischemia-Reperfusion Injury 24364919 miR-494 might be a target of therapy for hepatic hypoxia/ischemia injury. therapeutic target hsa-mir-132 Hepatitis B Virus Infection 23376496 disease by infectious agent DOID:2043 B16/18 D006509 610424 serum;miR-132 may be a promising biochemical marker and may have therapeutic applications in HBV-related HCC therapeutic target hsa-mir-33a Hepatitis B Virus Infection 25155445 disease by infectious agent DOID:2043 B16/18 D006509 610424 miR-33a may be a novel marker for HSC activation and hepatic fibrosis progress, suggesting a new therapeutic target in liver fibrosis. therapeutic target hsa-mir-122 Hepatitis C Virus Infection 24385319 disease by infectious agent DOID:1883 B19.2 D006526 609532 MicroRNA-targeting therapeutics for hepatitis C. therapeutic target hsa-mir-122 Hepatitis C Virus Infection 25385103 disease by infectious agent DOID:1883 B19.2 D006526 609532 In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122. therapeutic target hsa-mir-122 Hepatitis C Virus Infection 25518710 disease by infectious agent DOID:1883 B19.2 D006526 609532 targeting miR-122, using antisense oligonucleotides (ASOs), can be a new anti-HCV treatment. therapeutic target hsa-mir-122 Hepatitis C Virus Infection 22545703 disease by infectious agent DOID:1883 B19.2 D006526 609532 In conclusion, the maximal inhibition of miR-122 was associated with limited phenotypic changes, indicating that the clinical assessment of miravirsen as host factor antagonist for treatment of HCV infections is warranted. therapeutic target hsa-mir-125b Hepatitis C Virus Infection 29541414 disease by infectious agent DOID:1883 B19.2 D006526 609532 This study elucidates a novel pathway for miR-125b in the pathogenesis of chronic HCV infection and suggests it as a possible target for treating HCV infection therapeutic target hsa-mir-34a Hepatoblastoma 21553024 disease of cellular proliferation DOID:687 C22.2 D018197 HP:0002884 All these results suggest that miR-34a plays multiple tumor suppressive roles in murine hepatocarcinoma, not only inhibiting cell growth by cell cycle arrest, but also repressing metastasis, and may serve as a novel therapeutic target for hepatocarcinoma. therapeutic target hsa-let-7 Human Immunodeficiency Virus Infection 25023625 B20 D015658 609423 miRNAs have emerged as important players in the T cell dysfunction observed with HIV-1 infection. It is likely that they may emerge as novel markers of T cell dysfunction and provide potential targets for new therapeutics to reverse dysfunction. therapeutic target hsa-mir-146a Human Immunodeficiency Virus Infection 25705792 B20 D015658 609423 Our findings improve the prospects of developing new therapeutic strategies to prevent HIV-1 entry via CXCR4 by using the PLZF/miR-146a axis. therapeutic target hsa-mir-146b Human Immunodeficiency Virus Infection 24828336 B20 D015658 609423 We report for the first time that PBMC and plasma levels of miR-150 and miR-146b-5p are predictive of HIV/AIDS disease progression and therapy. therapeutic target hsa-mir-150 Human Immunodeficiency Virus Infection 24828336 B20 D015658 609423 We report for the first time that PBMC and plasma levels of miR-150 and miR-146b-5p are predictive of HIV/AIDS disease progression and therapy. therapeutic target hsa-mir-128 Huntington Disease 24929669 nervous system disease DOID:12858 G10 D006816 143100 Our studies found that miR-128a may play a critical role in HD and could be a viable candidate as a therapeutic or biomarker of the disease. therapeutic target hsa-mir-200a Huntington Disease 22906125 nervous system disease DOID:12858 G10 D006816 143100 Altered expression of miR-200a and miR-200c may interrupt the production of proteins involved in neuronal plasticity and survival, and further investigation of the involvement of perturbed miRNA expression in HD pathogenesis is warranted, and may lead to reveal novel approaches for HD therapy. therapeutic target hsa-mir-200c Huntington Disease 22906125 nervous system disease DOID:12858 G10 D006816 143100 Altered expression of miR-200a and miR-200c may interrupt the production of proteins involved in neuronal plasticity and survival, and further investigation of the involvement of perturbed miRNA expression in HD pathogenesis is warranted, and may lead to reveal novel approaches for HD therapy. therapeutic target hsa-mir-30c Hyperlipidemia 25692340 E78.4 D006949 HP:0003077 These studies highlight the important role miR-30c plays in lipid metabolism, adipogenesis, and cell proliferation and differentiation. Further,they point to pathologic outcomes associated with reduced expression in cancer and cardiac hypertrophy. Additionally, they suggest that increasing miR-30c expression in the liver and cancerous tissue might reduce hyperlipidemia and atherosclerosis, and cancer progression and metastasis, respectively. Studies are needed to evaluate the efficacy of miR-30c mimic in the treatment of these disorders. therapeutic target hsa-mir-145 Hypertension 29434681 cardiovascular system disease DOID:10763 I10 D006973 145500 HP:0000822 miR-145 is a potential target for the treatment of hypertension therapeutic target hsa-mir-204 Hypertension 21321078 cardiovascular system disease DOID:10763 I10 D006973 145500 HP:0000822 Reestablishing miR-204 expression should be explored as a potential new therapy for this disease therapeutic target hsa-mir-421 Hypertension 24564768 cardiovascular system disease DOID:10763 I10 D006973 145500 HP:0000822 In conclusion, the present study is the first to demonstrate that ACE2 may be subject to post-transcriptional regulation and reveals a novel potential therapeutic target, miR-421, which could be exploited to modulate ACE2 expression in disease. therapeutic target hsa-mir-543 Hypertension 26562529 cardiovascular system disease DOID:10763 I10 D006973 145500 HP:0000822 In summary, our study suggested that the downregulation of the miR-543 could alleviate the insulin resistance via the modulation of the SIRT1 expression, which might be a potential new strategy for treating insulin resistance and a promising therapeutic method for hypertension. therapeutic target hsa-mir-145 Hypertrophic Scar 25876136 L91.0 D017439 these results suggest that miR-145 is a promising therapeutic target to prevent or reduce hypertrophic scarring of the skin. therapeutic target hsa-mir-181b Hypertrophic Scar 25837671 L91.0 D017439 MicroRNA 181b regulates decorin production by dermal fibroblasts and may be a potential therapy for hypertrophic scar. therapeutic target hsa-mir-21 Hypertrophic Scar 28075443 L91.0 D017439 MicroRNA expression signature and the therapeutic effect of the microRNA‑21 antagomir in hypertrophic scarring. therapeutic target hsa-mir-92a Hyperuricemia 26299712 disease of metabolism DOID:1920 E79.0 D033461 240000 This study reported that there is a novel pathway regulating angiogenesis under HUA conditions. In the presence of HUA, miR-92a downregulation increased KLF2 expression, subsequently inhibiting VEGFA, which resulted in decreased angiogenesis. Thus, this study reports a possible mechanism for cardiovascular injury caused by hyperuricemia and suggests that the miR-92a-KLF2-VEGFA axis may be a target for hyperuricemia treatment. therapeutic target hsa-mir-210 Hypoxic-Ischemic Encephalopathy 24089674 P91.60 D020925 Recent study demonstrated that microRNA-210 has neuroprotective effects through inhibiting apoptosis in a murine model of HIE. It represents a potential novel therapeutic approach for the treatment of HIE. therapeutic target hsa-mir-133b Infertility 24959893 reproductive system disease DOID:5223 N46.9/N97.9 D007246 MiR-133b regulates the expression of the Actin protein TAGLN2 during oocyte growth and maturation: a potential target for infertility therapy. therapeutic target hsa-mir-155 Inflammation 23239035 D007249 microRNA-155 can be used as a potential biomarker or therapeutic in the autoimmune diseases,especially rheumatoid arthritis therapeutic target hsa-mir-21 Inflammation 29620442 D007249 It may provide a novel therapeutic strategy to regulate the odontoblast differentiation of DPSCs therapeutic target hsa-mir-710 Inflammation 20005208 D007249 Our findings demonstrate that CO treatment to MF increased FGF15 expression via inhibition of miR-710 and FGF15 enhanced colonic epithelial cell restitution. therapeutic target hsa-mir-124 Inflammation 23979021 D007249 miR-124 is a potential therapeutic target for the treatment of inflammatory diseases therapeutic target hsa-mir-142 Inflammation 26721185 D007249 These results suggest that PPARγ-mediated upregulation of miR-142-3p inhibits the HMGB1 expression, which,in turn, is a novel anti-inflammatory mechanism of PPARγ and has an important role in the treatment of inflammatory diseases. therapeutic target hsa-mir-146a Inflammation 25896300 D007249 our studies showed that miR-146a was crucial for monocytic cell-based IL-1β tolerance and cross-tolerance, and thus opens the way for future research in the development of therapeutics for inflammatory diseases. therapeutic target hsa-mir-155 Inflammation 26697483 D007249 Taken together, our results suggest that genome editing of miR-155 holds the potential as a therapeutic strategy in RA. therapeutic target hsa-mir-122 Inflammatory Bowel Diseases 27485847 gastrointestinal system disease DOID:0050589 D015212 PS266600 HP:0002037 First clinical trials using the blockade of liver specific miR-122 showed very promising results in the treatment of chronic hepatitis C virus infection. Results of preclinical and animal studies are also promising providing future rationale for the development of new therapeutics for various internal diseases including heart failure, bronchial asthma or inflammatory bowel diseases. therapeutic target hsa-mir-1246 Inflammatory Bowel Diseases 25628040 gastrointestinal system disease DOID:0050589 D015212 PS266600 HP:0002037 miR-595 and miR-1246 warrant testing as potential targets for therapeutic intervention in the treatment of inflammatory bowel disease. therapeutic target hsa-mir-133 Inflammatory Bowel Diseases 25112884 gastrointestinal system disease DOID:0050589 D015212 PS266600 HP:0002037 NT-associated colitis and inflammatory signalling are regulated by miR-133α-AFTPH interactions. Targeting of miR-133α or AFTPH may represent a novel therapeutic approach in inflammatory bowel disease. therapeutic target hsa-mir-595 Inflammatory Bowel Diseases 25628040 gastrointestinal system disease DOID:0050589 D015212 PS266600 HP:0002037 miR-595 and miR-1246 warrant testing as potential targets for therapeutic intervention in the treatment of inflammatory bowel disease. therapeutic target hsa-mir-494 Intervertebral Disc Degeneration 25906693 musculoskeletal system disease DOID:90 M51 D055959 603932 HP:0008419 These results indicated that miR-494 is a novel regulator of HNPC apoptosis induced by TNF-α. The knock-out of miR-494 expression protected the HNPCs from apoptosis via the up-regulation of JunD, which was possibly mediated via cytochrome C apoptotic signaling. These findings suggest that the miR-494/JunD signaling pathway might represent a novel therapeutic target for the prevention of IVDD. therapeutic target hsa-let-7b Intestinal Barrier Dysfunction 29402773 Let-7b was identified as a novel diagnosis biomarker or a potential treatment target for preventing intestinal barrier dysfunction therapeutic target hsa-mir-26a-1 Intracerebral Hemorrhage 21764522 I60.1 D002543 HP:0001342 Circulating miR-26a is a potential predictors and therapeutic targets for non-hypertensive ICH (intracerebral hemorrhage). therapeutic target hsa-mir-26a-2 Intracerebral Hemorrhage 21764522 I60.1 D002543 HP:0001342 Circulating miR-26a is a potential predictors and therapeutic targets for non-hypertensive ICH (intracerebral hemorrhage). therapeutic target hsa-mir-1 Intracranial Aneurysm 24079748 cardiovascular system disease DOID:10941 I67.1 D002532 105800 These data support common disease mechanisms that may be under miRNA control and provide exciting directions for further investigations aimed at elucidating the miRNA mechanisms and targets that may yield new therapies for IA. therapeutic target hsa-mir-133a Intracranial Aneurysm 24079748 cardiovascular system disease DOID:10941 I67.1 D002532 105800 These data support common disease mechanisms that may be under miRNA control and provide exciting directions for further investigations aimed at elucidating the miRNA mechanisms and targets that may yield new therapies for IA. therapeutic target hsa-mir-133b Intracranial Aneurysm 24079748 cardiovascular system disease DOID:10941 I67.1 D002532 105800 These data support common disease mechanisms that may be under miRNA control and provide exciting directions for further investigations aimed at elucidating the miRNA mechanisms and targets that may yield new therapies for IA. therapeutic target hsa-mir-143 Intracranial Aneurysm 24079748 cardiovascular system disease DOID:10941 I67.1 D002532 105800 These data support common disease mechanisms that may be under miRNA control and provide exciting directions for further investigations aimed at elucidating the miRNA mechanisms and targets that may yield new therapies for IA. therapeutic target hsa-mir-145 Intracranial Aneurysm 24079748 cardiovascular system disease DOID:10941 I67.1 D002532 105800 These data support common disease mechanisms that may be under miRNA control and provide exciting directions for further investigations aimed at elucidating the miRNA mechanisms and targets that may yield new therapies for IA. therapeutic target hsa-mir-23b Intracranial Aneurysm 24079748 cardiovascular system disease DOID:10941 I67.1 D002532 105800 These data support common disease mechanisms that may be under miRNA control and provide exciting directions for further investigations aimed at elucidating the miRNA mechanisms and targets that may yield new therapies for IA. therapeutic target hsa-mir-24-1 Intracranial Aneurysm 24079748 cardiovascular system disease DOID:10941 I67.1 D002532 105800 These data support common disease mechanisms that may be under miRNA control and provide exciting directions for further investigations aimed at elucidating the miRNA mechanisms and targets that may yield new therapies for IA. therapeutic target hsa-mir-29b-2 Intracranial Aneurysm 24079748 cardiovascular system disease DOID:10941 I67.1 D002532 105800 These data support common disease mechanisms that may be under miRNA control and provide exciting directions for further investigations aimed at elucidating the miRNA mechanisms and targets that may yield new therapies for IA. therapeutic target hsa-mir-455 Intracranial Aneurysm 24079748 cardiovascular system disease DOID:10941 I67.1 D002532 105800 These data support common disease mechanisms that may be under miRNA control and provide exciting directions for further investigations aimed at elucidating the miRNA mechanisms and targets that may yield new therapies for IA. therapeutic target hsa-mir-155 Intraductal Papillary Mucinous Neoplasms 28938594 D01.7 these miRNAs might serve as new risk biomarkers of IPMN and could be useful for future targeted therapies therapeutic target hsa-mir-1 Intrahepatic Cholangiocarcinoma 28098904 disease of cellular proliferation DOID:4928 C22.1 D018281 615619 has-miR-96, has-miR-1 and has-miR-25, may be potential therapeutic targets for the future treatment of ICC therapeutic target hsa-mir-101 Intrahepatic Cholangiocarcinoma 26299768 disease of cellular proliferation DOID:4928 C22.1 D018281 615619 In conclusion, the present study identified important roles for miR-101 and VEGF-C in ICC, suggesting that miR-101/VEGF-C signaling may be a promising diagnostic and/or therapeutic target for ICC. therapeutic target hsa-mir-25 Intrahepatic Cholangiocarcinoma 28098904 disease of cellular proliferation DOID:4928 C22.1 D018281 615619 has-miR-96, has-miR-1 and has-miR-25, may be potential therapeutic targets for the future treatment of ICC therapeutic target hsa-mir-96 Intrahepatic Cholangiocarcinoma 28098904 disease of cellular proliferation DOID:4928 C22.1 D018281 615619 has-miR-96, has-miR-1 and has-miR-25, may be potential therapeutic targets for the future treatment of ICC therapeutic target hsa-mir-320a Ischemia 20628061 cardiovascular system disease DOID:326 D007511 601367 MicroRNA 320a functions as a novel endogenous modulator of aquaporins 1 and 4 as well as a potential therapeutic target in cerebral ischemia therapeutic target hsa-mir-483 Ischemia 21893058 cardiovascular system disease DOID:326 D007511 601367 These findings indicated that the miR-483-5p-SRF pathway may offer a novel strategy for treatment with angiogenesis in ischemic heart disease patients. therapeutic target hsa-mir-126 Ischemia-Reperfusion Injury 26381870 D015427 UTMD of miR-126 results in improved tissue perfusion and vascular density in the setting of chronic ischemia by repressing sprouty-related protein-1 and phosphatidylinositol-3-kinase regulatory subunit 2 and enhancing vascular endothelial growth factor and angiopoietin-1 signaling, with no effect on miR-126-5p. UTMD is a promising platform for microRNA delivery, with applications for therapeutic angiogenesis. therapeutic target hsa-mir-145 Ischemia-Reperfusion Injury 23028672 D015427 MiR-145 may represent a potential therapeutic target for treatment of oxidative stress-associated cardiovascular diseases, such as myocardial ischemia/reperfusion injury. therapeutic target hsa-mir-146a Ischemia-Reperfusion Injury 29505740 D015427 our findings demonstrate that the elevation of miR-146a may be one of the compensatory responses after the cerebral I/R injury and suggest miR-146a as a potential therapeutic target for cerebral I/R injury therapeutic target hsa-mir-7 Ischemia-Reperfusion Injury 24594984 D015427 miR-7a/b is sensitive to I/R injury and protects myocardial cells against I/R-induced apoptosis by negatively regulating PARP expression in vivo and in vitro. miR-7a/b may provide a new therapeutic approach for treatment of myocardial I/R injury. Poly(ADP-ribose) polymerase. therapeutic target hsa-mir-30 Ischemic Diseases [unspecific] 25203395 D007511 601367 Our findings reveal a novel molecular mechanism for endogenous H2S production in the heart at the miRNA level and demonstrate the therapeutic potential of miR-30 family inhibition for ischemic heart diseases by increasing H2S production. therapeutic target hsa-mir-92a Ischemic Diseases [unspecific] 19460962 D007511 601367 Thus, miR-92a may serve as a valuable therapeutic target in the setting of ischemic disease. therapeutic target hsa-mir-144 Ischemic Heart Disease 20708014 I25.9/I24.9 D017202 Thus, both miR-144 and miR-451 may represent new therapeutic agents for the treatment of ischemic heart disease. therapeutic target hsa-mir-320 Ischemic Heart Disease 25724494 I25.9/I24.9 D017202 we conclude that PDGF enhances MSC-mediated cardioprotection via a c-Jun/miR-320 signaling mechanism and PDGF MSC preconditioning may be an effective therapeutic strategy for cardiac ischemia. therapeutic target hsa-mir-451 Ischemic Heart Disease 20708014 I25.9/I24.9 D017202 Thus, both miR-144 and miR-451 may represent new therapeutic agents for the treatment of ischemic heart disease. therapeutic target hsa-let-7a Kaposi Sarcoma 26197270 disease of cellular proliferation DOID:8632 C46 D012514 Our results establish that let-7a specifically suppresses MAP4K4 expression, and further inhibits KSHV reactivation by interfering with the function of MAP4K4 on the MAPK pathway, highlighting let-7a as a potential treatment for KS. therapeutic target hsa-mir-891a Kaposi Sarcoma 26446987 disease of cellular proliferation DOID:8632 C46 D012514 Our results illustrate that, by targeting IκBα to activate the NF-κB pathway, miR-891a-5p mediates Tat and K1 synergistic induction of angiogenesis. Therefore, the miR-891a-5p/NF-κB pathway is important in the pathogenesis of AIDS-KS, which could be an attractive therapeutic target for AIDS-KS. therapeutic target hsa-mir-21 Keloid 29190966 L91.0 D007627 148100 HP:0010562 inhibition of microRNA-21 induces mitochondrial-mediated apoptosis in keloid fibroblasts, proposing microRNA-21 as a potential therapeutic target in keloid fibroblasts therapeutic target hsa-mir-17 Kidney Diseases [unspecific] 28399020 N18.9 D007674 Therapeutic microRNAs in polycystic kidney disease. therapeutic target hsa-mir-126 Kidney Injury 27832640 S37.0 D058186 non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have significant potential to aid the development of diagnostic and therapeutic strategies of AKI therapeutic target hsa-mir-127 Kidney Injury 27832640 S37.0 D058186 non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have significant potential to aid the development of diagnostic and therapeutic strategies of AKI therapeutic target hsa-mir-150 Kidney Injury 27832640 S37.0 D058186 non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have significant potential to aid the development of diagnostic and therapeutic strategies of AKI therapeutic target hsa-mir-21 Kidney Injury 27832640 S37.0 D058186 non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have significant potential to aid the development of diagnostic and therapeutic strategies of AKI therapeutic target hsa-mir-24 Kidney Injury 27832640 S37.0 D058186 non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have significant potential to aid the development of diagnostic and therapeutic strategies of AKI therapeutic target hsa-mir-30 Kidney Injury 27832640 S37.0 D058186 non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have significant potential to aid the development of diagnostic and therapeutic strategies of AKI therapeutic target hsa-mir-494 Kidney Injury 27832640 S37.0 D058186 non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have significant potential to aid the development of diagnostic and therapeutic strategies of AKI therapeutic target hsa-mir-687 Kidney Injury 27832640 S37.0 D058186 non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have significant potential to aid the development of diagnostic and therapeutic strategies of AKI therapeutic target hsa-mir-34a Kidney Neoplasms 24866595 disease of cellular proliferation DOID:263 C64 D007680 Our findings indicate that miR-34a targets CD44 in renal cancer cells and suppresses renal cancer cell growth, tube formation and metastasis invitro and in vivo. Thus, miR-34a may be a potential molecular target for novel therapeutic strategies for clear cell renal carcinoma. therapeutic target hsa-mir-362 Kidney Neoplasms 26647877 disease of cellular proliferation DOID:263 C64 D007680 These results suggested that miR-362-3p functions as a tumor suppressor in RCC, and may serve as a potential molecular target in the treatment of RCC. therapeutic target hsa-mir-497 Kidney Neoplasms 25755771 disease of cellular proliferation DOID:263 C64 D007680 Our results demonstrated that miR-497 was decreased in ccRCC tissues and may provide a potential prognostic biomarker and a potential target for therapeutic intervention. therapeutic target hsa-mir-196a Laryngeal Neoplasms 23967217 C32.3 D007822 Our study provided the possibilities that miR-196a might be very useful in diagnosing and treating laryngeal cancer. therapeutic target hsa-mir-221 Laryngeal Neoplasms 25586265 C32.3 D007822 miR-221 inhibition caused elevated expression levels of the Apaf-1 apoptotic pathway proteins caspase-3, -8 and -9. miR-221 may therefore be used as a novel therapeutic target for laryngeal cancer. therapeutic target hsa-mir-27a Laryngeal Neoplasms 25239093 C32.3 D007822 miR-27a acts as an oncogene in laryngeal squamous cell carcinoma through down-regulation of PLK2 and may provide a novel clue into the potential mechanism of LSCC oncogenesis or serve as a useful biomarker in diagnosis and therapy in laryngeal cancer. therapeutic target hsa-mir-221 Laryngeal Neoplasms 25945817 C32.3 D007822 Plasma miR-221 may have a potential as a novel diagnostic/prognostic marker and might be considered as a therapeutic target in LCa.LEVEL OF EVIDENCE: N/A. therapeutic target hsa-mir-125b Leukemia 24369155 C95 D007938 613065 HP:0001909 BAK1 was a downstream target gene of miR-125b, and miR-125b promoted proliferation in human AML cells at least partially by targeting Bak1, so we speculated that miR-125b as an oncogene could be a potential therapeutic target for treating AML. therapeutic target hsa-mir-15 Leukemia 16616063 C95 D007938 613065 HP:0001909 Therefore, miR-15 and miR-16 are natural antisense Bcl2 interactors that could be used for therapy of Bcl2-overexpressing tumors. therapeutic target hsa-mir-155 Leukemia 25543473 C95 D007938 613065 HP:0001909 miR-155 inhibition may be a promising therapy strategy for treating acute myeloid leukemia (AML). therapeutic target hsa-mir-15a Leukemia 21056550 C95 D007938 613065 HP:0001909 these findings suggested that the combined regiment of miR-15a/16-1 and ATO might be a potential therapeutic remedy for the treatment of leukemia. therapeutic target hsa-mir-16 Leukemia 16616063 C95 D007938 613065 HP:0001909 Therefore, miR-15 and miR-16 are natural antisense Bcl2 interactors that could be used for therapy of Bcl2-overexpressing tumors. therapeutic target hsa-mir-16-1 Leukemia 21056550 C95 D007938 613065 HP:0001909 these findings suggested that the combined regiment of miR-15a/16-1 and ATO might be a potential therapeutic remedy for the treatment of leukemia. therapeutic target hsa-mir-17 Leukemia 21239610 C95 D007938 613065 HP:0001909 our work demonstrating that inhibition of miR-17∼92 increases lucocorticoid-induced apoptosis highlights the potential importance of miR-17∼92 as a therapeutic target in leukemias and lymphomas. therapeutic target hsa-mir-18 Leukemia 21239610 C95 D007938 613065 HP:0001909 our work demonstrating that inhibition of miR-17∼92 increases lucocorticoid-induced apoptosis highlights the potential importance of miR-17∼92 as a therapeutic target in leukemias and lymphomas. therapeutic target hsa-mir-181a Leukemia 21079133 C95 D007938 613065 HP:0001909 Targeted treatments that increase endogenous levels of miR-181a might represent novel therapeutic strategies. therapeutic target hsa-mir-19a Leukemia 21239610 C95 D007938 613065 HP:0001909 our work demonstrating that inhibition of miR-17∼92 increases lucocorticoid-induced apoptosis highlights the potential importance of miR-17∼92 as a therapeutic target in leukemias and lymphomas. therapeutic target hsa-mir-19b-1 Leukemia 21239610 C95 D007938 613065 HP:0001909 our work demonstrating that inhibition of miR-17∼92 increases lucocorticoid-induced apoptosis highlights the potential importance of miR-17∼92 as a therapeutic target in leukemias and lymphomas. therapeutic target hsa-mir-20a Leukemia 21239610 C95 D007938 613065 HP:0001909 our work demonstrating that inhibition of miR-17∼92 increases lucocorticoid-induced apoptosis highlights the potential importance of miR-17∼92 as a therapeutic target in leukemias and lymphomas. therapeutic target hsa-mir-21 Leukemia 26248946 C95 D007938 613065 HP:0001909 These findings indicate that miR-21 is required for maintaining the imatinib-resistant phenotype of CML CD34+ cells through PI3K/AKT signaling pathway, thus providing the basis for a promising therapeutic approach to eliminate CML leukemia stem cells(LSCs). therapeutic target hsa-mir-223 Leukemia 17996649 C95 D007938 613065 HP:0001909 Ectopic miR-223 expression, RNAi against AML1/ETO, or demethylating treatment enhances miR-223 levels and restores cell differentiation. Here, we identify an additional action for a leukemia fusion protein linking the epigenetic silencing of a microRNA locus to the differentiation block of leukemia. therapeutic target hsa-mir-23a Leukemia 26378023 C95 D007938 613065 HP:0001909 Our findings thus connect a novel regulation pathway of the p65/miR-23a-27a-24 cluster with the erythroid proteome and provide an applicable approach for treating leukemia. therapeutic target hsa-mir-24 Leukemia 26378023 C95 D007938 613065 HP:0001909 Our findings thus connect a novel regulation pathway of the p65/miR-23a-27a-24 cluster with the erythroid proteome and provide an applicable approach for treating leukemia. therapeutic target hsa-mir-27a Leukemia 26378023 C95 D007938 613065 HP:0001909 Our findings thus connect a novel regulation pathway of the p65/miR-23a-27a-24 cluster with the erythroid proteome and provide an applicable approach for treating leukemia. therapeutic target hsa-mir-638 Leukemia 25451924 C95 D007938 613065 HP:0001909 miR-638 regulates proliferation and myeloid differentiation by targeting CDK2 and may serve as a novel target for leukemia therapy or marker for AML diagnosis and prognosis. therapeutic target hsa-mir-92-1 Leukemia 21239610 C95 D007938 613065 HP:0001909 our work demonstrating that inhibition of miR-17∼92 increases lucocorticoid-induced apoptosis highlights the potential importance of miR-17∼92 as a therapeutic target in leukemias and lymphomas. therapeutic target hsa-mir-128b Leukemia, Lymphoblastic 19749093 disease of cellular proliferation DOID:1037 C91.0 D007945 613065 These results demonstrate that down-regulation of miR-128b and miR-221 is implicated in glucocorticoid resistance and that restoration of their levels is a potentially promising therapeutic in MLL-AF4 ALL. therapeutic target hsa-mir-221 Leukemia, Lymphoblastic 19749093 disease of cellular proliferation DOID:1037 C91.0 D007945 613065 These results demonstrate that down-regulation of miR-128b and miR-221 is implicated in glucocorticoid resistance and that restoration of their levels is a potentially promising therapeutic in MLL-AF4 ALL. therapeutic target hsa-let-7b Leukemia, Lymphoblastic, Acute 26708866 disease of cellular proliferation DOID:9952 C91.0 D054198 247640 HP:0006721 In the patients with ALL, the expression of microRNA let-7b is regulated by methylation of CpG islands in the region of genomic promoter. The microRNA let-7b may act as a tumor suppressor, whose low expression is involved in ALL development, indicating the microRNA let-7b may become a new therapeutic target for ALL. therapeutic target hsa-mir-126 Leukemia, Lymphoblastic, Acute 26361793 disease of cellular proliferation DOID:9952 C91.0 D054198 247640 HP:0006721 Our data demonstrate that miR-126 plays a critical but 2-faceted role in leukemia and thereby uncover a new layer of miRNA regulation in cancer.Moreover, because miR-126 depletion can sensitize AML cells to standard chemotherapy, our data also suggest that miR-126 represents a promising therapeutic target. therapeutic target hsa-mir-17 Leukemia, Lymphoblastic, Acute 24280866 disease of cellular proliferation DOID:9952 C91.0 D054198 247640 HP:0006721 Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia. therapeutic target hsa-mir-221 Leukemia, Lymphoblastic, Acute 27358112 disease of cellular proliferation DOID:9952 C91.0 D054198 247640 HP:0006721 Niche-influenced miR-221/222 may define a novel therapeutic target in ALL therapeutic target hsa-mir-222 Leukemia, Lymphoblastic, Acute 27358112 disease of cellular proliferation DOID:9952 C91.0 D054198 247640 HP:0006721 Niche-influenced miR-221/222 may define a novel therapeutic target in ALL therapeutic target hsa-mir-1290 Leukemia, Lymphoblastic, Acute, B-Cell 26684414 disease of cellular proliferation DOID:0060592 C91.0 613065 HP:0004812 Our results identify an expression profile of miR-151-5p, miR-451, and miR-1290 as a novel biomarker for outcome in pediatric precursor B-cell ALL patients, regardless of treatment protocol. The use of these markers may lead to improved risk stratification at diagnosis and allow early therapeutic interventions in an attempt to improve survival of high risk patients. therapeutic target hsa-mir-151 Leukemia, Lymphoblastic, Acute, B-Cell 26684414 disease of cellular proliferation DOID:0060592 C91.0 613065 HP:0004812 Our results identify an expression profile of miR-151-5p, miR-451, and miR-1290 as a novel biomarker for outcome in pediatric precursor B-cell ALL patients, regardless of treatment protocol. The use of these markers may lead to improved risk stratification at diagnosis and allow early therapeutic interventions in an attempt to improve survival of high risk patients. therapeutic target hsa-mir-199a Leukemia, Lymphoblastic, Acute, B-Cell 26406572 disease of cellular proliferation DOID:0060592 C91.0 613065 HP:0004812 Measuring circulating levels of specific miRNA implicated in regulation of cell differentiation and/or cell proliferation such as hsa-miRNA-511, offers high sensitivity and specificity in B-ALL detection and may be potentially useful for detection of disease progression, as indicator of therapeutic response, and in the assessment of biological and/or therapeutic targets for patients with B-ALL. therapeutic target hsa-mir-221 Leukemia, Lymphoblastic, Acute, B-Cell 26406572 disease of cellular proliferation DOID:0060592 C91.0 613065 HP:0004812 Measuring circulating levels of specific miRNA implicated in regulation of cell differentiation and/or cell proliferation such as hsa-miRNA-511, offers high sensitivity and specificity in B-ALL detection and may be potentially useful for detection of disease progression, as indicator of therapeutic response, and in the assessment of biological and/or therapeutic targets for patients with B-ALL. therapeutic target hsa-mir-223 Leukemia, Lymphoblastic, Acute, B-Cell 26406572 disease of cellular proliferation DOID:0060592 C91.0 613065 HP:0004812 Measuring circulating levels of specific miRNA implicated in regulation of cell differentiation and/or cell proliferation such as hsa-miRNA-511, offers high sensitivity and specificity in B-ALL detection and may be potentially useful for detection of disease progression, as indicator of therapeutic response, and in the assessment of biological and/or therapeutic targets for patients with B-ALL. therapeutic target hsa-mir-26a Leukemia, Lymphoblastic, Acute, B-Cell 26406572 disease of cellular proliferation DOID:0060592 C91.0 613065 HP:0004812 Measuring circulating levels of specific miRNA implicated in regulation of cell differentiation and/or cell proliferation such as hsa-miRNA-511, offers high sensitivity and specificity in B-ALL detection and may be potentially useful for detection of disease progression, as indicator of therapeutic response, and in the assessment of biological and/or therapeutic targets for patients with B-ALL. therapeutic target hsa-mir-451 Leukemia, Lymphoblastic, Acute, B-Cell 26684414 disease of cellular proliferation DOID:0060592 C91.0 613065 HP:0004812 Our results identify an expression profile of miR-151-5p, miR-451, and miR-1290 as a novel biomarker for outcome in pediatric precursor B-cell ALL patients, regardless of treatment protocol. The use of these markers may lead to improved risk stratification at diagnosis and allow early therapeutic interventions in an attempt to improve survival of high risk patients. therapeutic target hsa-mir-204 Leukemia, Lymphoblastic, Acute, T-Cell 26464665 disease of cellular proliferation DOID:5602 C91.0 613065 HP:0006727 Our findings indicated that miR-204 negatively regulates SOX4 and inhibited proliferation, migration and invasion of T-ALL cell lines. Thus,miR-204 might represent a potential therapeutic target for T-ALL intervention. therapeutic target hsa-mir-15 Leukemia, Lymphocytic, Chronic, B-Cell 24014303 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 the role of microRNAs in CLL pathogenesis, and how this knowledge can be used to identify new approaches to treat CLL. therapeutic target hsa-mir-15a Leukemia, Lymphocytic, Chronic, B-Cell 23995789 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 Therapeutic implications of activation of the host gene (Dleu2) promoter for miR-15a/16-1 in chronic lymphocytic leukemia. therapeutic target hsa-mir-15a Leukemia, Lymphocytic, Chronic, B-Cell 19723889 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 a role for the mir-15a/16-1 cluster in cell cycle regulation and suggest that these mature microRNAs in both the New Zealand Black model and human CLL may be targets for therapeutic efficacy in this disease. therapeutic target hsa-mir-16 Leukemia, Lymphocytic, Chronic, B-Cell 24014303 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 the role of microRNAs in CLL pathogenesis, and how this knowledge can be used to identify new approaches to treat CLL. therapeutic target hsa-mir-16-1 Leukemia, Lymphocytic, Chronic, B-Cell 23995789 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 Therapeutic implications of activation of the host gene (Dleu2) promoter for miR-15a/16-1 in chronic lymphocytic leukemia. therapeutic target hsa-mir-16-1 Leukemia, Lymphocytic, Chronic, B-Cell 19723889 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 a role for the mir-15a/16-1 cluster in cell cycle regulation and suggest that these mature microRNAs in both the New Zealand Black model and human CLL may be targets for therapeutic efficacy in this disease. therapeutic target hsa-mir-16-2 Leukemia, Lymphocytic, Chronic, B-Cell 19723889 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 a role for the mir-15a/16-1 cluster in cell cycle regulation and suggest that these mature microRNAs in both the New Zealand Black model and human CLL may be targets for therapeutic efficacy in this disease. therapeutic target hsa-mir-223 Leukemia, Lymphocytic, Chronic, B-Cell 25880332 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 HSP90B1 is a direct target gene of miR-223. Our results provide a plausible explanation of why CLL patients harboring miR-223 downregulation are associated with a poor outcome, pointing out HSP90B1 as a new pathogenic mechanism in CLL and a promising therapeutic target. therapeutic target hsa-mir-34a Leukemia, Lymphocytic, Chronic, B-Cell 20089965 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 overexpression of miR-34a in primary B-CLL cells induced apoptosis therapeutic target hsa-mir-15a Leukemia, Lymphocytic, Chronic, B-Cell 28053325 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy. therapeutic target hsa-mir-16 Leukemia, Lymphocytic, Chronic, B-Cell 28053325 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy. therapeutic target hsa-mir-362 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 26545365 C92.1 D015464 miR-362-5p acts as an oncomiR that down-regulates GADD45α, which consequently activates the JNK1/2 and P38 signalling. This finding provides novel insights into CML leukaemogenesis and may help identify new diagnostic and therapeutic targets. therapeutic target hsa-mir-520a Leukemia, Myelogenous, Chronic, BCR-ABL Positive 24870597 C92.1 D015464 MicroRNA-520a-5p displays a therapeutic effect upon chronic myelogenous leukemia cells by targeting STAT3 and enhances the anticarcinogenic role of capsaicin. therapeutic target hsa-mir-150 Leukemia, Myeloid 26644403 disease of cellular proliferation DOID:8692 C92 D007951 HP:0012324 Our findings indicate that decreased KLF4 expression mediates antileukemic effects through regulation of gene and microRNA networks,containing miR-150, CDKN1A, and MYC, and provide mechanistic support for therapeutic strategies increasing KLF4 expression. therapeutic target hsa-mir-122 Leukemia, Myeloid, Acute 28822593 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 Decreased expression of microRNA-122 is associated with an unfavorable prognosis in childhood acute myeloid leukemia and function analysis indicates a therapeutic potential. therapeutic target hsa-mir-150 Leukemia, Myeloid, Acute 27280396 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 using FLT3L-guided miR-150-based nanoparticles, to treat FLT3-overexpressing AML with high efficacy and minimal side effects. therapeutic target hsa-mir-199b Leukemia, Myeloid, Acute 26340914 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 We detected a therapy sensitive miRNA signature in plasma of patients with AML. therapeutic target hsa-mir-24 Leukemia, Myeloid, Acute 25550847 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 miR-24 high regulation is a common event in AML with t(8;21), and it might serve as a novel and selective therapeutic target for the treatment of AML with t(8;21). therapeutic target hsa-mir-29 Leukemia, Myeloid, Acute 24076586 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 Taken together, our finding revealed a pivotal role of miR-29 family in AML development and rescue of miR-29 family expression in AML patients could provide a new therapeutic strategy. therapeutic target hsa-mir-301b Leukemia, Myeloid, Acute 26340914 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 We detected a therapy sensitive miRNA signature in plasma of patients with AML. therapeutic target hsa-mir-326 Leukemia, Myeloid, Acute 26340914 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 We detected a therapy sensitive miRNA signature in plasma of patients with AML. therapeutic target hsa-mir-331 Leukemia, Myeloid, Acute 25620533 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 we showed for the first time that miR-331 higher expression appears to be correlated with worse response to therapy and shorter survival of AML patients. therapeutic target hsa-mir-34a Leukemia, Myeloid, Acute 25499621 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 the complex regulation of PD-L1 in human tumors, and on miR-34a in cancer immuno-based therapy. therapeutic target hsa-mir-34a Leukemia, Myeloid, Acute 20889924 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 These results define miR-34a as a novel therapeutic target in AML with CEBPA mutations. therapeutic target hsa-mir-361 Leukemia, Myeloid, Acute 26340914 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 We detected a therapy sensitive miRNA signature in plasma of patients with AML. therapeutic target hsa-mir-378 Leukemia, Myeloid, Acute 26191124 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 Our findings suggest that miR-378 is reactivated by demethylation after 5-aza-dC treatment. 5'-flanking region of miR-378 is hypomethylated in AML especially in those with t(8;21). therapeutic target hsa-mir-511 Leukemia, Myeloid, Acute 26762252 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 Our study provides new insights into the understanding of miRNAs as functional mediators of the leukemogenic fusion gene MLL-AF9 and opens new opportunities to further investigate specific therapeutic options for AML via the miRNA level. therapeutic target hsa-mir-625 Leukemia, Myeloid, Acute 26340914 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 We detected a therapy sensitive miRNA signature in plasma of patients with AML. therapeutic target hsa-mir-655 Leukemia, Myeloid, Acute 26340914 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 We detected a therapy sensitive miRNA signature in plasma of patients with AML. therapeutic target hsa-mir-155 Leukemia, Myeloid, Acute, Pediatric 25730818 C92.0 This study may promote the development of a personalized effective antileukemia therapy, in particular for the patients exhibiting higher expression levels of G-CSFRIV, and further highlights the necessity of pre-screening the patients for G-CSFR isoforms expression patterns before G-CSF administration. therapeutic target hsa-mir-148b Leukemia, Myeloid, Chronic 25187697 disease of cellular proliferation DOID:8552 C92.1 D015464 HP:0005506 Downregulated miR-148 may contribute to immune surveillance in STOP-IM patients and may therefore have potential as additive information in managing CML patients undergoing treatment with IM. therapeutic target hsa-mir-17 Leukemia, Myeloid, Chronic 23818358 disease of cellular proliferation DOID:8552 C92.1 D015464 HP:0005506 These results may imply that miR-17 can be used for diagnosis and treatment of CML. therapeutic target hsa-mir-30e Leukemia, Myeloid, Chronic 25305453 disease of cellular proliferation DOID:8552 C92.1 D015464 HP:0005506 MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein. therapeutic target hsa-mir-424 Leukemia, Myeloid, Chronic 25697481 disease of cellular proliferation DOID:8552 C92.1 D015464 HP:0005506 These findings strongly suggest that miR-424 acts as a tumor suppressor by downregulating BCR-ABL expression. Up-regulation of miR-424 in CML cells may therefore have a therapeutic effect against this disease. therapeutic target hsa-mir-17 Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic 22475310 disease of cellular proliferation DOID:5599 C83.5 D054218 Down-regulation of miR17 plays an important role in glucocorticoid-induced cell death suggesting that targeting miR17 may improve the current ALL combination therapy. therapeutic target hsa-mir-182 Light-Induced Retinal Injury 25955435 The present study suggests that BDNF is a target gene of the has-miR-183-96-182 cluster in RPE cells. The present study suggests an underlying protective mechanism against retinal light injury and may provide a novel target for the prevention and treatment of light-induced retinal injury. therapeutic target hsa-mir-183 Light-Induced Retinal Injury 25955435 The present study suggests that BDNF is a target gene of the has-miR-183-96-182 cluster in RPE cells. The present study suggests an underlying protective mechanism against retinal light injury and may provide a novel target for the prevention and treatment of light-induced retinal injury. therapeutic target hsa-mir-96 Light-Induced Retinal Injury 25955435 The present study suggests that BDNF is a target gene of the has-miR-183-96-182 cluster in RPE cells. The present study suggests an underlying protective mechanism against retinal light injury and may provide a novel target for the prevention and treatment of light-induced retinal injury. therapeutic target hsa-mir-33a Lipid Metabolism Disorder 22012398 disease of metabolism DOID:3146 E75 D008052 These data establish, in a model that is highly relevant to humans, that pharmacological inhibition of miR-33a and miR-33b is a promising therapeutic strategy to raise plasma HDL and lower VLDL triglyceride levels for the treatment of dyslipidaemias that increase cardiovascular disease risk. therapeutic target hsa-mir-33b Lipid Metabolism Disorder 22012398 disease of metabolism DOID:3146 E75 D008052 These data establish, in a model that is highly relevant to humans, that pharmacological inhibition of miR-33a and miR-33b is a promising therapeutic strategy to raise plasma HDL and lower VLDL triglyceride levels for the treatment of dyslipidaemias that increase cardiovascular disease risk. therapeutic target hsa-mir-122 Liver Cirrhosis 25909171 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 These findings disclose a novel TGF-β-miR-122-FN1/SRF signaling cascade and its implication in hepatic fibrogenesis, and suggest miR-122 as a promising molecular target for anti-fibrosis therapy. therapeutic target hsa-mir-21 Liver Cirrhosis 25661333 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 our results identify miR-21 as a key regulator of fibrogenic EMT in hepatocytes via PTEN/Akt pathway. Targeting miR-21 may provide a new therapeutic strategy against hepatic fibrosis. therapeutic target hsa-mir-34a Liver Cirrhosis 26437572 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 miR-34a appears to play an important role in the process of liver fibrosis by targeting ACSL1 and may show promise as a therapeutic molecular target for hepatic fibrosis. therapeutic target hsa-mir-370 Liver Cirrhosis 25686745 endocrine system disease DOID:5082 K74 D008103 215600 HP:0001394 Our study demonstrated that miR-370 plays an inhibitory role in hepatic fibrogenesis by targeting SMO. Restoration of miR-370 may have beneficial effects on the treatment of liver fibrosis. therapeutic target hsa-mir-103 Liver Diseases [unspecific] 25593466 K76.9 D008107 miR-103 is involved in insulin resistance and NAFLD, and may be a molecular link between insulin resistance and NAFLD and a therapeutic target for these disorders. therapeutic target hsa-mir-122 Liver Diseases [unspecific] 25308172 K76.9 D008107 miR-122--a key factor and therapeutic target in liver disease. therapeutic target hsa-mir-122 Liver Diseases [unspecific] 26636761 K76.9 D008107 Taken together, our study indicates that miR-122 may downregulate cytokine production in HSCs and macrophage chemotaxis and that the targeting of miR-122 may have therapeutic potential for preventing the progression of liver diseases. therapeutic target hsa-mir-122 Liver Diseases [unspecific] 26019030 K76.9 D008107 microRNAs are promising tools in the diagnosis and treatment of hepatitis B virus -related liver diseases. therapeutic target hsa-mir-21 Liver Diseases [unspecific] 25605429 K76.9 D008107 miR-21 may be a useful biomarker for the diagnosis and treatment of NAFLD. therapeutic target hsa-mir-221 Liver Failure 21400558 K72 D017093 613070 HP:0001399 We identified miR-221 as a potent posttranscriptional regulator of FAS-induced apoptosis. miR-221 may serve as a potential therapeutic target for the treatment of hepatitis and liver failure. therapeutic target hsa-mir-17 Liver Fibrosis 25915722 K74 D008103 Our results collectively indicate that miR-17-5p promotes HSC proliferation and activation, at least in part, via reduction of Smad7, supporting its potential utility as a novel therapeutic target for liver fibrosis. therapeutic target hsa-mir-454 Liver Fibrosis 24685242 K74 D008103 All the results suggested that miR-454 could provide a novel therapeutic approach for treating liver fibrosis, especially the liver fibrosis induced by Schistosoma japonicum. therapeutic target hsa-mir-155 Liver Injury 29420849 S36.11 D056486 maintaining miR-155 expression in inflammatory cells might be a potential strategy to modulate liver injury therapeutic target hsa-mir-122 Liver Neoplasms 25885701 disease of cellular proliferation DOID:916 C22.0 D008113 HP:0002896 In conclusion, our results collectively suggested that GGMPN could serve as a novel therapeutic approach to control tumor cell apoptosis and growth. therapeutic target hsa-mir-132 Liver Neoplasms 25676267 disease of cellular proliferation DOID:916 C22.0 D008113 HP:0002896 miR-132 is down-regulated in human liver cancer tissues miR-132 transfection can effectively inhibit proliferation and promote apoptosis of MHCC97H cells in vitro and in vivo. Therefore, miR-132 may become a new target in liver cancer treatment. therapeutic target hsa-mir-216a Liver Neoplasms 24322754 disease of cellular proliferation DOID:916 C22.0 D008113 HP:0002896 MicroRNA-216a: a potential therapeutic target for drug resistance and recurrent of liver cancer. therapeutic target hsa-mir-1343 Lung Fibrosis 26542979 respiratory system disease DOID:3770 J84.10 D011658 178500 As a result, the abundance of fibrotic markers is reduced, cell migration into a scratch wound impaired and epithelial-to-mesenchymal transition (EMT) repressed. Mature miR-1343 is readily detected in human neutrophils and HL-60 cells and is activated in response to stress in A549 lung epithelial cells. miR-1343 may have direct therapeutic applications in fibrotic lung disease. therapeutic target hsa-mir-200 Lung Fibrosis 22189082 respiratory system disease DOID:3770 J84.10 D011658 178500 Thus, the miR-200 family members participate importantly in fibrotic lung diseases and suggest that restoring miR-200 expression in the lungs may represent a novel therapeutic approach in treating pulmonary fibrotic diseases. therapeutic target hsa-mir-27b Lung Fibrosis 26311239 respiratory system disease DOID:3770 J84.10 D011658 178500 Taken together,these results suggest that 1,25(OH)2D3 inhibits lung fibroblast differentiation induced by TGF-β1 via miR-27b targeting VDR 3'UTR, which may be used as a novel treatment strategy in differentiation pathways. therapeutic target hsa-mir-29 Lung Fibrosis 25454218 respiratory system disease DOID:3770 J84.10 D011658 178500 the antifibrotic activity of miR-29 in animal models of fibrosis and highlight miR-29 as a promising therapeutic reagent or target for the treatment of pulmonary fibrosis. therapeutic target hsa-let-7 Lung Injury [unspecific] 26318567 S27.309D D055370 Taken together, the present results propose an involvement of let-7 microRNA and K-ras in radon induced lung damage both in vivo and in vitro, which may thus be of potential value in early diagnosis and therapy of radon-induced lung tumorgenesis. therapeutic target hsa-mir-20a Lung Injury [unspecific] 26525353 S27.309D D055370 Our findings may provide a differential diagnostic method that is effective for diagnosing lung diseases caused by SM exposure. Additionally, these miRNAs may be regarded as probable targets for treatment of lung injuries. therapeutic target hsa-mir-92a Lung Injury [unspecific] 26525353 S27.309D D055370 Our findings may provide a differential diagnostic method that is effective for diagnosing lung diseases caused by SM exposure. Additionally, these miRNAs may be regarded as probable targets for treatment of lung injuries. therapeutic target hsa-let-7 Lung Neoplasms 26323902 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 In this review, we summarize the newest investigations on let-7 and LC, the regulation of let-7 and its targets gene have been discussed, and the attempts for new therapy for LC have also been summarized. therapeutic target hsa-mir-1 Lung Neoplasms 25342548 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Pim-1 kinase could be a critical survival signaling factor in NSCLC,and regulated by miR-486-5p and eIF4E. Pim-1 kinase may provide a potential target for diagnosis and treatment for lung cancer. therapeutic target hsa-mir-125b Lung Neoplasms 26686386 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 these results show tremendous promise of wt-p53 and miR-125b gene therapy using dual CD44/EGFR-targeting HA NP vector for effective treatment of lung cancer. therapeutic target hsa-mir-132 Lung Neoplasms 25435090 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-212/132 may mediate proliferation and cell cycle arrest through p21 and cyclin D1. Our study provides insight into the biological function of the miR-212/132 cluster in lung cancer. The present study may provide a potential therapeutic target for the treatment of lung cancer. therapeutic target hsa-mir-132 Lung Neoplasms 25607827 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-132 may be a novel diagnostic and prognostic marker, as well as a potential target for molecular therapy in NSCLC. therapeutic target hsa-mir-134 Lung Neoplasms 26642897 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Altogether, our data demonstrated an altered expression of two development-related miRNAs namely miR-134 and miR-187 in lung tumors for the first time. Moreover we have shown that miR-134 and miR-187 expression alternation were in accordance with their approved regulatory roles, therefore these miRNAs could serve as new biomarkers with potential usefulness in lung cancer diagnosis and treatments. In addition, miR-187 expression in tumor cells could perturb cell cycle which supported its possible role as tumor suppressor. therapeutic target hsa-mir-137 Lung Neoplasms 26101014 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-137 downregulation was related to its promoter hypermethylation in lung cancer. Further studies are needed to assess its value as a prognostic factor and potential therapeutic applications in lung cancer. therapeutic target hsa-mir-143 Lung Neoplasms 26586766 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 This study shows that miR-143/145 expressed from the tumor microenvironment stimulates neoangiogenesis and supports tumor expansion in the lung, demonstrating a surprising role for the putative tumor suppressor miRNA cluster in promoting tumorigenesis. We propose inhibition of miR-143/145 as a therapeutic avenue to modulate tumor neoangiogenesis. therapeutic target hsa-mir-144 Lung Neoplasms 26395400 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 These results indicate that down-regulation of miR-144 is critical for air pollution-related lung cancer, and the miR-144-Zeb1 signalling pathway could represent a potential therapeutic target. therapeutic target hsa-mir-145 Lung Neoplasms 25428378 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 These findings provide novel insights with potential therapeutic applications for the treatment of NSCLC. therapeutic target hsa-mir-145 Lung Neoplasms 26586766 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 This study shows that miR-143/145 expressed from the tumor microenvironment stimulates neoangiogenesis and supports tumor expansion in the lung, demonstrating a surprising role for the putative tumor suppressor miRNA cluster in promoting tumorigenesis. We propose inhibition of miR-143/145 as a therapeutic avenue to modulate tumor neoangiogenesis. therapeutic target hsa-mir-150 Lung Neoplasms 26498874 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Thus, our findings identified that JMJD2A played an oncogenic role in NSCLC via regulating miR-150. JMJD2A could possibly serve as a prognostic factor and potential target for NSCLC therapy. therapeutic target hsa-mir-155 Lung Neoplasms 26543233 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Our findings suggested that rs767649 A > T might contribute to the increased risk and poor prognosis of NSCLC, highlighting the importance of rs767649 in the prevention and therapy of NSCLC. therapeutic target hsa-mir-155 Lung Neoplasms 27315591 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Inhibition of microRNA-155 sensitizes lung cancer cells to irradiation therapeutic target hsa-mir-15a Lung Neoplasms 25442346 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miRNA-15a/16 can enhance radiation sensitivity by regulating the TLR1/NF-κB signaling pathway and act as a potential therapeutic approach to overcome radioresistance for lung cancer treatment. therapeutic target hsa-mir-16 Lung Neoplasms 25442346 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miRNA-15a/16 can enhance radiation sensitivity by regulating the TLR1/NF-κB signaling pathway and act as a potential therapeutic approach to overcome radioresistance for lung cancer treatment. therapeutic target hsa-mir-186 Lung Neoplasms 20627087 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-186:miR-186 * may serve as a potential gene therapy target for refractory lung cancer that is sensitive to curcumin therapeutic target hsa-mir-186 Lung Neoplasms 20878113 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miRNA-186* could serve as a potential gene therapy target in curcumin treatment. therapeutic target hsa-mir-187 Lung Neoplasms 26642897 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Altogether, our data demonstrated an altered expression of two development-related miRNAs namely miR-134 and miR-187 in lung tumors for the first time. Moreover we have shown that miR-134 and miR-187 expression alternation were in accordance with their approved regulatory roles, therefore these miRNAs could serve as new biomarkers with potential usefulness in lung cancer diagnosis and treatments. In addition, miR-187 expression in tumor cells could perturb cell cycle which supported its possible role as tumor suppressor. therapeutic target hsa-mir-192 Lung Neoplasms 25444916 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 the proapoptotic effects of curcumin depend on miR-192-5p/215 induction and the p53-miR-192-5p/215-XIAP pathway is an important therapeutic target for non-small cell lung cancer. therapeutic target hsa-mir-193a Lung Neoplasms 24356455 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Methylation-silencing of miR-9-3 and miR-193a may be an important epigenetic mechanisms favoring NSCLC cell growth and survival for carcinogenesis and cancer progression, and demethylation to reactivate expression of miR-9-3 and miR-193a genes contributes, at least partially, to the anti-cancer properties of 5-AzaC and thereby may be worthy of future studies for the possibility of being a new therapeutic strategy for the treatment of human NSCLCs. therapeutic target hsa-mir-197 Lung Neoplasms 25597412 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 the miR-197/CKS1B/STAT3-mediated network can drive tumor PD-L1 expression as a biomarker of this cascade, and miR-197 replacement therapy may be a potential treatment strategy for chemoresistant NSCLC. therapeutic target hsa-mir-19a Lung Neoplasms 25604748 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 mechanism of action of miR-19a in the development of NSCLC and suggest that miR-19a may be a novel and promising target for therapeutic intervention in NSCLC. therapeutic target hsa-mir-200 Lung Neoplasms 26314828 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Our findings also provide evidence that increased miR-200 expression may contribute to early lung tumorigenesis and that AKT inhibitors may be useful for the treatment of miR-200-dependent tumor cell growth. therapeutic target hsa-mir-208a Lung Neoplasms 26754670 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 The present study provides evidence that miR-208a can affect the proliferation and radiosensitivity of human lung cancer cells by targeting p21 and can be transported by exosomes. Thus, miR-208a may serve as a potential therapeutic target for lung cancer patients. therapeutic target hsa-mir-21 Lung Neoplasms 24691929 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-21: a non-invasive biomarker and potential therapeutic target for lung cancer therapeutic target hsa-mir-21 Lung Neoplasms 25477028 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-21 is highly expressed in patients with NSCLC and inhibition of miR-21 expression reduces proliferation, migration, and invasion of A549 cells by upregulating PDCD4 expression. Modulation of miR-21 or PDCD4 expression may provide a potentially novel therapeutic approach for NSCLC. therapeutic target hsa-mir-21 Lung Neoplasms 25563770 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Inhibition of NADPH oxidase protected against metastasis of human lung cancer cells by decreasing miR-21 expression, which could facilitate the understanding of lung cancer pathogenesis and provided clues for the development of novel therapeutics for lung cancer patients. therapeutic target hsa-mir-21 Lung Neoplasms 20338946 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Aberrantly increased expression of miR-21 plays a significant role in lung carcinogenesis and is a potential therapeutic target in both epidermal growth factor receptor-mutant and wild-type cases. therapeutic target hsa-mir-212 Lung Neoplasms 25435090 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-212/132 may mediate proliferation and cell cycle arrest through p21 and cyclin D1. Our study provides insight into the biological function of the miR-212/132 cluster in lung cancer. The present study may provide a potential therapeutic target for the treatment of lung cancer. therapeutic target hsa-mir-215 Lung Neoplasms 25444916 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 the proapoptotic effects of curcumin depend on miR-192-5p/215 induction and the p53-miR-192-5p/215-XIAP pathway is an important therapeutic target for non-small cell lung cancer. therapeutic target hsa-mir-224 Lung Neoplasms 25410592 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-224 may act not only as a novel diagnostic and prognostic marker, but also as a potential target for miR-based therapy of NSCLC. therapeutic target hsa-mir-224 Lung Neoplasms 26307684 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Our study provides new insight in understanding of oncogenic role of miR-224 in the lung cancer pathogenesis and suggests that NF-κB/miR-224/CASP3, 7 pathway could be a putative therapeutic target in lung cancer. therapeutic target hsa-mir-26b Lung Neoplasms 26744864 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Taken together, our results demonstrate that miR-26b could suppress lung cancer cells proliferation, migration and invasion by directly negative regulation of COX-2. MiR-26b could serve as a novel potential marker for NSCLC therapy. therapeutic target hsa-mir-299 Lung Neoplasms 26617714 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Therefore, the disordered decreased of miR-299-3p and resulting ABCE1 up-expression may contribute to chemoresistance of lung cancer, and miR-299-3p-ABCE1 may represent a new potential therapeutic target for the treatment of chemoresistance of lung cancer. therapeutic target hsa-mir-29b Lung Neoplasms 26063204 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Taken together, our results demonstrate that miR-29b serves as a tumor metastasis suppressor, which suppresses NSCLC cell metastasis by directly inhibiting MMP2 expression. The results show that miR-29b may be a novel therapeutic candidate target to slow NSCLC metastasis. therapeutic target hsa-mir-30a Lung Neoplasms 25484183 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 a competitive endogenous RNAs regulatory network which will help understand the metastasis mechanisms of lung cancer and improve the prevention and treatment of lung cancer. therapeutic target hsa-mir-30a Lung Neoplasms 26305739 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MiR-30a may be regarded as a tumor suppressor in NSCLC, and it could become a prognostic marker and potential therapeutic target for NSCLC. therapeutic target hsa-mir-31 Lung Neoplasms 24726065 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Our data may help researchers to predict the molecular mechanisms of miR-31 in the molecular mechanism of lung cancer comprehensively. Moreover, the present data indicate that the interaction of miR-31 targets may be promising candidates as biomarkers for the diagnosis, prognosis and personalized therapy of lung cancer. therapeutic target hsa-mir-34a Lung Neoplasms 26022002 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 These findings provoke a conversation on producing biologic miRNAs to perform miRNA actions, and point toward a new direction in developing miRNA-based therapies. therapeutic target hsa-mir-34a Lung Neoplasms 20570894 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-34a:Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34 therapeutic target hsa-mir-373 Lung Neoplasms 25591738 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-512 and miR-373 exert cell-autonomous and non-autonomous tumor-suppressive effects in lung cancer cells, where their re-expression may benefit epigenetic cancer therapy. therapeutic target hsa-mir-4500 Lung Neoplasms 25277326 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Low expression of miR-4500 in NSCLC promoted tumor growth by targeting LIN28B and NRAS. MiR-4500 may be a prognosis predictor and potential target for NSCLC therapy. therapeutic target hsa-mir-451 Lung Neoplasms 25812923 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Systemic delivery of synthetic microRNA-451 is an effective therapeutic strategy for the treatment of lung cancer. therapeutic target hsa-mir-487b Lung Neoplasms 27097129 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-487b-5p inhibition can be further explored as a chemotherapy target in the treatment of TMZ-resistant lung carcinoma. therapeutic target hsa-mir-498 Lung Neoplasms 26323905 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Our data indicated that miR-498 is downregulated and correlated with tumor progression, which might be a putitive therapeutic target in NSCLC treatment. therapeutic target hsa-mir-512 Lung Neoplasms 25591738 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-512 and miR-373 exert cell-autonomous and non-autonomous tumor-suppressive effects in lung cancer cells, where their re-expression may benefit epigenetic cancer therapy. therapeutic target hsa-mir-520e Lung Neoplasms 25661366 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Developing an effective therapeutic by delivery of synthetic microRNA-520e in lung cancer treatment. therapeutic target hsa-mir-526b Lung Neoplasms 25596743 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 hsa-mir-526b overexpression or Ku80 knockdown increased p53 and p21CIP1/WAF1 expression. These findings reveal that hsa-miR-526b is a potential target in cancer therapy. therapeutic target hsa-mir-564 Lung Neoplasms 26498524 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Taken together, our present study revealed the tumor suppressor role of miR-564, indicating restoration of miR-564 as a potential therapeutic strategy for the treatment of lung cancer. therapeutic target hsa-mir-582 Lung Neoplasms 26468775 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 These findings suggest that miR-582-3p mediates the constitutive activation of Wnt/β-catenin signalling, likely serving as a potential therapeutic target for NSCLC. therapeutic target hsa-mir-660 Lung Neoplasms 25501825 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 mir-660 acts as a tumor suppressor miRNA and we suggest the replacement of mir-660 as a new therapeutic approach for p53 wild-type lung cancer treatment. therapeutic target hsa-mir-9-3 Lung Neoplasms 24356455 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 Methylation-silencing of miR-9-3 and miR-193a may be an important epigenetic mechanisms favoring NSCLC cell growth and survival for carcinogenesis and cancer progression, and demethylation to reactivate expression of miR-9-3 and miR-193a genes contributes, at least partially, to the anti-cancer properties of 5-AzaC and thereby may be worthy of future studies for the possibility of being a new therapeutic strategy for the treatment of human NSCLCs. therapeutic target hsa-mir-15a Lymphoma 23307249 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 Our study implies that the combination of Bcl-2 siRNA and miR-15a may be a useful approach in treatment for lymphoma. therapeutic target hsa-mir-17 Lymphoma 21239610 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 our work demonstrating that inhibition of miR-17∼92 increases lucocorticoid-induced apoptosis highlights the potential importance of miR-17∼92 as a therapeutic target in leukemias and lymphomas. therapeutic target hsa-mir-18 Lymphoma 21239610 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 our work demonstrating that inhibition of miR-17∼92 increases lucocorticoid-induced apoptosis highlights the potential importance of miR-17∼92 as a therapeutic target in leukemias and lymphomas. therapeutic target hsa-mir-19a Lymphoma 21239610 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 our work demonstrating that inhibition of miR-17∼92 increases lucocorticoid-induced apoptosis highlights the potential importance of miR-17∼92 as a therapeutic target in leukemias and lymphomas. therapeutic target hsa-mir-19b-1 Lymphoma 21239610 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 our work demonstrating that inhibition of miR-17∼92 increases lucocorticoid-induced apoptosis highlights the potential importance of miR-17∼92 as a therapeutic target in leukemias and lymphomas. therapeutic target hsa-mir-20a Lymphoma 21239610 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 our work demonstrating that inhibition of miR-17∼92 increases lucocorticoid-induced apoptosis highlights the potential importance of miR-17∼92 as a therapeutic target in leukemias and lymphomas. therapeutic target hsa-mir-365 Lymphoma 26406949 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 Our data suggest that miR-365 functions as a tumor suppressor in MM development and progression, and holds promise as a prognostic biomarker and potential therapeutic target for MM. therapeutic target hsa-mir-466 Lymphoma 25573115 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 miR-446 may have a protective effect on transplanted corneas by suppressing Prox1 expression at the post-transcriptional level. The results of the current study may provide insights into the mechanisms of lymphangiogenesis resulting from corneal graft rejection and alkali-burn injuries, as well as into the development of new treatments for lymphangiogenic eye diseases. therapeutic target hsa-mir-92-1 Lymphoma 21239610 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 our work demonstrating that inhibition of miR-17∼92 increases lucocorticoid-induced apoptosis highlights the potential importance of miR-17∼92 as a therapeutic target in leukemias and lymphomas. therapeutic target hsa-mir-155 Lymphoma, B-Cell 25498913 disease of cellular proliferation DOID:707 D016393 109565 HP:0012191 high expression of miR-155 sensitizes cells to v-akt murine thymoma viral oncogene homolog-1 inhibitors in vitro, suggesting a novel treatment option for resistant DLBCL. therapeutic target hsa-mir-29a Lymphoma, B-Cell 23079660 disease of cellular proliferation DOID:707 D016393 109565 HP:0012191 Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas therapeutic target hsa-mir-29b-1 Lymphoma, B-Cell 23079660 disease of cellular proliferation DOID:707 D016393 109565 HP:0012191 Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas therapeutic target hsa-mir-29b-2 Lymphoma, B-Cell 23079660 disease of cellular proliferation DOID:707 D016393 109565 HP:0012191 Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas therapeutic target hsa-mir-34a Lymphoma, B-Cell 21460242 disease of cellular proliferation DOID:707 D016393 109565 HP:0012191 our results elucidate a novel Myc- and FoxP1-dependent pathway of malignant transformation and suggest miR-34a replacement therapy as a promising strategy in lymphoma treatment. therapeutic target hsa-mir-150 Lymphoma, Burkitt 24613688 disease of cellular proliferation DOID:8584 C83.7 D002051 113970 HP:0030080 Deregulation of miR-150 may be useful as a diagnostic tool in BL,based on miRNA profile screening, qRT-PCR and miRNA-ISH. miR-150 plays an important role in BL by targeting c-Myb and Survivin. Re-expression of miR-150 reduced the proliferation of Raji cells, which suggests it to be a promising novel candidate for tumor treatment. therapeutic target hsa-mir-155 Lymphoma, Extranodal NK-T-Cell 19641183 C86.0 D054391 miR-21 or miR-155 led to down-regulation of PTEN and PDCD4 or SHIP1 with up-regulation of phosphorylated AKT(ser473). therapeutic target hsa-mir-27a Lymphoma, Extranodal NK-T-Cell 19641183 C86.0 D054391 miR-21 or miR-155 led to down-regulation of PTEN and PDCD4 or SHIP1 with up-regulation of phosphorylated AKT(ser473). therapeutic target hsa-mir-15a Lymphoma, Follicular 28653191 disease of cellular proliferation DOID:0050873 C82 D008224 613024 MicroRNA Dysregulation to Identify Novel Therapeutic Targets. therapeutic target hsa-mir-618 Lymphoma, Follicular 24503492 disease of cellular proliferation DOID:0050873 C82 D008224 613024 Taken together, our findings implicate miR-618 in follicular lymphomagenesis, identify miR-618 as a potential risk biomarker for follicular lymphoma, and illuminate miR-618-regulated lymphomagenic pathways that can serve as therapeutic targets for follicular lymphoma. therapeutic target hsa-mir-1973 Lymphoma, Hodgkin 24222179 disease of cellular proliferation DOID:8567 C81 D006689 236000 HP:0012189 Our results demonstrate that in patients with cHL, circulating cell-free miRNAs can reflect disease response once therapy has commenced. therapeutic target hsa-mir-21 Lymphoma, Hodgkin 24222179 disease of cellular proliferation DOID:8567 C81 D006689 236000 HP:0012189 Our results demonstrate that in patients with cHL, circulating cell-free miRNAs can reflect disease response once therapy has commenced. therapeutic target hsa-mir-494 Lymphoma, Hodgkin 24222179 disease of cellular proliferation DOID:8567 C81 D006689 236000 HP:0012189 Our results demonstrate that in patients with cHL, circulating cell-free miRNAs can reflect disease response once therapy has commenced. therapeutic target hsa-mir-124 Lymphoma, Large B-Cell 25576220 C83.3 D016403 109565 notion that miR-124 could be an attractive therapeutic target for overcoming GC resistance in DLBCL. therapeutic target hsa-mir-21 Lymphoma, Large B-Cell 25543482 C83.3 D016403 109565 the miR-21 can regulate proliferation, invasion, and apoptosis, so it has a potential therapeutic application in DLBCL. therapeutic target hsa-mir-138 Lymphoma, Large B-Cell, Diffuse 24914240 disease of cellular proliferation DOID:0050745 C83.3 D016403 109565 These data reveal molecular differences in diffuse DLBCL patients according to HCV presence, potentially useful as novel prognostic or therapeutic biomarkers. therapeutic target hsa-mir-146b Lymphoma, Large B-Cell, Diffuse 25544772 disease of cellular proliferation DOID:0050745 C83.3 D016403 109565 a miRNA signature for EBV+DLBCLe and our findings suggest that hsa-miR-146b and hsa-miR-222 could be biomarkers and therapeutic targets. therapeutic target hsa-mir-147a Lymphoma, Large B-Cell, Diffuse 24914240 disease of cellular proliferation DOID:0050745 C83.3 D016403 109565 These data reveal molecular differences in diffuse DLBCL patients according to HCV presence, potentially useful as novel prognostic or therapeutic biomarkers. therapeutic target hsa-mir-147b Lymphoma, Large B-Cell, Diffuse 24914240 disease of cellular proliferation DOID:0050745 C83.3 D016403 109565 These data reveal molecular differences in diffuse DLBCL patients according to HCV presence, potentially useful as novel prognostic or therapeutic biomarkers. therapeutic target hsa-mir-222 Lymphoma, Large B-Cell, Diffuse 25544772 disease of cellular proliferation DOID:0050745 C83.3 D016403 109565 a miRNA signature for EBV+DLBCLe and our findings suggest that hsa-miR-146b and hsa-miR-222 could be biomarkers and therapeutic targets. therapeutic target hsa-mir-511 Lymphoma, Large B-Cell, Diffuse 24914240 disease of cellular proliferation DOID:0050745 C83.3 D016403 109565 These data reveal molecular differences in diffuse DLBCL patients according to HCV presence, potentially useful as novel prognostic or therapeutic biomarkers. therapeutic target hsa-mir-21 Lymphoma, Non-Hodgkin 26439034 disease of cellular proliferation DOID:0060060 C85.9 D008228 605027 HP:0012539 Overexpression of miR-21 is associated with disease stage and treatment outcome of B-NHL. This potentially involves negative modulation of PTEN. therapeutic target hsa-mir-374b Lymphoma, Non-Hodgkin 26100275 disease of cellular proliferation DOID:0060060 C85.9 D008228 605027 HP:0012539 Our data highlight the molecular etiology and clinical significance of miR-374b in T-LBL. Targeting miR-374b may represent a new therapeutic strategy to improve therapy and survival for T-LBL patients. therapeutic target hsa-mir-1202 Major Depressive Disorder 24908571 disease of mental health DOID:1470 F32 D003865 608520 miR-1202 is a primate-specific and brain-enriched microRNA involved in major depression and antidepressant treatment. therapeutic target hsa-mir-138 Malignant Neoplasms [unspecific] 28378633 C80.1 D009369 MiR-138: A promising therapeutic target for cancer. therapeutic target hsa-mir-221 Malignant Neoplasms [unspecific] 24475314 C80.1 D009369 Our findings demonstrate that miR-221 is more suitable to predict cancer prognosis in Asians, and it is a promising prognostic biomarker for HCC.The detection of miR-221 in serum or plasma samples may make it become an effective method for monitoring patients' prognosis and assessing therapeutic efficacy in the future. therapeutic target hsa-mir-29a Malignant Neoplasms [unspecific] 25968566 C80.1 D009369 miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies. therapeutic target hsa-mir-29b Malignant Neoplasms [unspecific] 25968566 C80.1 D009369 miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies. therapeutic target hsa-mir-29c Malignant Neoplasms [unspecific] 25968566 C80.1 D009369 miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies. therapeutic target hsa-mir-30a Malignant Peripheral Nerve Sheath Tumor 25890085 disease of cellular proliferation DOID:5940 D009442 HP:0100697 These findings demonstrated that DZNep, an inhibitor of S-adenosyl-methionine-dependent methyltransferase, suppressed EZH2/miR-30a,d/KPNB1 signaling and blocked MPNST tumor cell growth and survival in vitro and in vivo. More importantly, our study indicated that pharmacological interference of EZH2 is a potential therapeutic approach for MPNST. therapeutic target hsa-mir-9 Mast Cell Neoplasm 24517413 disease of cellular proliferation DOID:3664 D47.0 Our findings demonstrate that unique miRNA expression profiles correlate with the biological behavior of canine MCTs. Furthermore, dysregulation of miR-9 is associated with MCT metastasis potentially through the induction of an invasive phenotype, identifying a potentially novel pathway for therapeutic intervention. therapeutic target hsa-mir-124 Medulloblastoma 26840408 disease of cellular proliferation DOID:0050902 C71.6 D008527 155255 HP:0002885 In all, we have discovered miR-124 to be downregulated in instances of medulloblastoma in which Nur77 is upregulated, resulting in a proliferative state that abets cancer progression. This study provides evidence for increasing miR-124 expression as a potential therapy for cancers with elevated levels of Nur77. therapeutic target hsa-mir-1280 Medulloblastoma 25576913 disease of cellular proliferation DOID:0050902 C71.6 D008527 155255 HP:0002885 the role of PDGFRs in MB and unveils JAG2 as a key downstream effector of a PDGFRβ-driven signaling cascade and a potential therapeutic target. therapeutic target hsa-let-7b Melanoma 28167449 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 Curcumin and treatment of melanoma: The potential role of microRNAs. therapeutic target hsa-mir-142 Melanoma 25490969 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 Robust association of miR-150-5p and the miR-142 duplex with good prognosis and earlier stage metastatic melanoma supports their potential as biomarkers. miRNAs overexpressed in association with PP in an autoregulatory fashion will not be suitable therapeutic targets. therapeutic target hsa-mir-145 Melanoma 23404256 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-145 is an invasion suppressor in metastatic melanoma cells. Despite the fact that it remains unclear which genes or pathways are regulated by miR-145 in melanoma, miR-145 may serve as a useful therapeutic agent in melanoma when re-expressed in situ therapeutic target hsa-mir-146a Melanoma 27059647 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 two miRNAs that are particularly relevant in human melanoma progression, miR-146a and miR-214. therapeutic target hsa-mir-150 Melanoma 25490969 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 Robust association of miR-150-5p and the miR-142 duplex with good prognosis and earlier stage metastatic melanoma supports their potential as biomarkers. miRNAs overexpressed in association with PP in an autoregulatory fashion will not be suitable therapeutic targets. therapeutic target hsa-mir-150 Melanoma 26089374 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 A prognostic assay based on the described miRNA expression signature combined with the currently used staging criteria may improve accuracy of primary melanoma patient prognoses and aid clinical management of patients, including selection for adjuvant treatment or clinical trials of adjuvant therapies. therapeutic target hsa-mir-15a Melanoma 26631117 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 Our results support a key role of IL-10Rα in the development and progression of melanoma and suggest that the IL-10/IL-10 receptor system may become a new therapeutic target for melanoma treatment. therapeutic target hsa-mir-15b Melanoma 26089374 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 A prognostic assay based on the described miRNA expression signature combined with the currently used staging criteria may improve accuracy of primary melanoma patient prognoses and aid clinical management of patients, including selection for adjuvant treatment or clinical trials of adjuvant therapies. therapeutic target hsa-mir-16 Melanoma 26089374 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 A prognostic assay based on the described miRNA expression signature combined with the currently used staging criteria may improve accuracy of primary melanoma patient prognoses and aid clinical management of patients, including selection for adjuvant treatment or clinical trials of adjuvant therapies. therapeutic target hsa-mir-182 Melanoma 21102518 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 Our results demonstrate that the use of anti-miR-182 is a promising therapeutic strategy for metastatic melanoma and provide a solid basis for testing similar strategies in human metastatic tumors. therapeutic target hsa-mir-185 Melanoma 26631117 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 Our results support a key role of IL-10Rα in the development and progression of melanoma and suggest that the IL-10/IL-10 receptor system may become a new therapeutic target for melanoma treatment. therapeutic target hsa-mir-186 Melanoma 29578151 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-186 exhibit an inhibitory effect on CMM cell proliferation, migration, and invasion; thus, may serve as a potential therapeutic target for human CMM intervention therapeutic target hsa-mir-200c Melanoma 25903073 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 our data identify miR-200c as a critical signaling node in BRAFi-resistant melanomas impacting the MAPK and PI3K/AKT pathways, suggesting miR-200c as a potential therapeutic target for overcoming acquired BRAFi resistance. therapeutic target hsa-mir-203 Melanoma 26722525 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 This study for the first time provided evidence that miR-203 could be an independent potential prognostic marker for patients with melanoma, and might even become a new therapeutic target for the treatment of melanoma. therapeutic target hsa-mir-21 Melanoma 28167449 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 Curcumin and treatment of melanoma: The potential role of microRNAs. therapeutic target hsa-mir-211 Melanoma 26631117 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 Our results support a key role of IL-10Rα in the development and progression of melanoma and suggest that the IL-10/IL-10 receptor system may become a new therapeutic target for melanoma treatment. therapeutic target hsa-mir-211 Melanoma 26787841 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 These findings highlight a novel mechanism of melanoma formation: miR-211 is a molecular switch that is turned off in melanoma cells, raising the hope that in the future we might be able to turn the switch back on, thus providing a better treatment option for melanoma. therapeutic target hsa-mir-221 Melanoma 18983236 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 In particular, the inhibition of miRNA-221 and -222, which are abnormally expressed in melanoma and favor the induction of the malignant phenotype by downregulating c-KIT receptor and p27Kip, might in the future represent an efficient treatment for translation into the clinical setting. therapeutic target hsa-mir-222 Melanoma 18983236 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 In particular, the inhibition of miRNA-221 and -222, which are abnormally expressed in melanoma and favor the induction of the malignant phenotype by downregulating c-KIT receptor and p27Kip, might in the future represent an efficient treatment for translation into the clinical setting. therapeutic target hsa-mir-33a Melanoma 25891797 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 The newly identified miR-33a/HIF-1α axis might provide a new strategy for the treatment of melanoma. therapeutic target hsa-mir-34a Melanoma 25403318 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-34a is involved in the tumor inhibition of melanoma by directly targeting FLOT2 gene. This finding provides potential novel strategies for therapeutic interventions of melanoma. therapeutic target hsa-mir-374b Melanoma 26089374 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 A prognostic assay based on the described miRNA expression signature combined with the currently used staging criteria may improve accuracy of primary melanoma patient prognoses and aid clinical management of patients, including selection for adjuvant treatment or clinical trials of adjuvant therapies. therapeutic target hsa-mir-7 Melanoma 27448964 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 Collectively, our study demonstrated that miR-7 could reverse the resistance to BRAF inhibitors in certain vemurafenib resistant melanoma cell lines. therapeutic target hsa-mir-34a Metabolic Syndrome 20689156 disease of metabolism DOID:14221 E88.81 D024821 605552 The FXR/miR-34a pathway and other miRs controlling SIRT1 may be useful therapeutic targets for age-related diseases, including metabolic disorders. therapeutic target hsa-mir-379 Metabolic Syndrome 25510864 disease of metabolism DOID:14221 E88.81 D024821 605552 the identification of a GC/GR-controlled miRNA cluster not only defines a novel layer of hormone-dependent metabolic control but also paves the way to alternative miRNA-based therapeutic approaches in metabolic dysfunction. therapeutic target hsa-mir-499 Mitochondrial Encephalomyopathy 26535630 musculoskeletal system disease DOID:890 G93.4 D017237 blood miRNAs are deregulated in the pathogenesis of MNGIE and these changes may have therapeutic implications. Further experimental studies will be required to elucidate the functional miRNA-mRNA interactions in MNGIE. therapeutic target hsa-mir-181a Mitochondrial Metabolism Disease 27281615 disease of metabolism DOID:700 E88.40 D028361 Knock down of endogenous miR-181a accelerates the autophagic degradation of damaged mitochondria. therapeutic target hsa-mir-95 Mucosulfatidosis 25524633 disease of metabolism DOID:0050441 D052517 272200 this regulatory mechanism opens the opportunity for a unique therapeutic approach in MSD patients where the need for exogenous enzyme replacement is circumvented. therapeutic target hsa-mir-150 Multiple Myeloma 25474406 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 Altogether GC-inducible mir-150-5p adds another level of regulation to GC specific therapeutic responses in multiple myeloma. therapeutic target hsa-mir-152 Multiple Myeloma 26400224 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 Our study contributes better understanding of the regulation mechanism of DKK-1 in MM, and opens up the potential for developing newer therapeutic strategies in the MM treatment. therapeutic target hsa-mir-155 Multiple Myeloma 25185784 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 miR-155 in RPMI-8266 cells is a critical oncomiR in multiple myeloma and seed-targeting t-anti-miR-155 might be a novel strategy for miR-155-based therapeutics. therapeutic target hsa-mir-182 Multiple Myeloma 25874214 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 These subtype specific MFRMs may aid in the further elucidation of the pathogenesis of each subtype and may serve to guide MM subtype diagnosis and treatment. therapeutic target hsa-mir-186 Multiple Myeloma 26679605 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 Our collective results clearly indicate that miR-186 functions as a tumor suppressor in MM, supporting its potential as a therapeutic target for the disease. therapeutic target hsa-mir-192 Multiple Myeloma 25489847 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 the IL-17/miR-192/IL-17Rs regulatory feedback loop is manifest in MM and might represent a promising and efficient prognostic marker and therapeutic target for MM. therapeutic target hsa-mir-21 Multiple Myeloma 26160841 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 miR-21 is an oncogenic microRNA (miRNA) with an emerging role as therapeutic target in human malignancies, including multiple myeloma (MM) therapeutic target hsa-mir-21 Multiple Myeloma 22316494 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 This elucidation of the role of PIAS3 in the miR-21-STAT3 positive regulatory loop not only may shed light on the molecular basis of the biological effects of miR-21 observed in MM cells but also has direct implications for the development of novel anti-MM therapeutic strategies. therapeutic target hsa-mir-215 Multiple Myeloma 25489847 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 the IL-17/miR-192/IL-17Rs regulatory feedback loop is manifest in MM and might represent a promising and efficient prognostic marker and therapeutic target for MM. therapeutic target hsa-mir-221 Multiple Myeloma 24586944 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 LNA-i-miR-221 is a highly stable, effective agent against t(4;14) MM cells, and is suitable for systemic use. These data provide the rationale for the clinical development of LNA-i-miR-221 for the treatment of MM. therapeutic target hsa-mir-221 Multiple Myeloma 26527748 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 LNA-i-miR-221 can reverse melphalan resistance in preclinical models of multiple myeloma therapeutic target hsa-mir-29b Multiple Myeloma 27196750 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 miR-29b-based epi-therapeutic approaches in the treatment of this malignancy therapeutic target hsa-mir-301a Multiple Myeloma 26464662 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 MiR-301a promotes cell proliferation and inhibits apoptosis by direct targeting TIMP2 in MM, and miR-301a might represent a novel molecular in MM and may provide helpful therapeutic strategies for MM treatment. therapeutic target hsa-mir-34a Multiple Myeloma 24683542 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 Transferrin-conjugated SNALPs encapsulating 2'-O-methylated miR-34a for the treatment of multiple myeloma. therapeutic target hsa-mir-34a Multiple Myeloma 26620594 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma. therapeutic target hsa-mir-34a Multiple Myeloma 29263373 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment therapeutic target hsa-mir-96 Multiple Myeloma 25874214 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 These subtype specific MFRMs may aid in the further elucidation of the pathogenesis of each subtype and may serve to guide MM subtype diagnosis and treatment. therapeutic target hsa-mir-99a Multiple Myeloma 25826415 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 our results suggest that BBR suppresses multiple myeloma cells,partly by down-regulating the 3 miRNA clusters and many mRNAs, possibly through TP53, Erb and MAPK signaling pathways. The mir-99a/125b cluster might be a novel target for MM treatment. These findings provide new mechanistic insight into the anticancer effects of certain traditional Chinese herbal medicine compounds. therapeutic target hsa-mir-100 Multiple Sclerosis 26943961 nervous system disease DOID:2377 G35 D009103 PS126200 Dicer and microRNA expression in multiple sclerosis and response to interferon therapy. therapeutic target hsa-mir-107 Multiple Sclerosis 26943961 nervous system disease DOID:2377 G35 D009103 PS126200 Dicer and microRNA expression in multiple sclerosis and response to interferon therapy. therapeutic target hsa-mir-145 Multiple Sclerosis 26943961 nervous system disease DOID:2377 G35 D009103 PS126200 Dicer and microRNA expression in multiple sclerosis and response to interferon therapy. therapeutic target hsa-mir-146b Multiple Sclerosis 26943961 nervous system disease DOID:2377 G35 D009103 PS126200 Dicer and microRNA expression in multiple sclerosis and response to interferon therapy. therapeutic target hsa-mir-21 Multiple Sclerosis 23506112 nervous system disease DOID:2377 G35 D009103 PS126200 Though the exact roles of miR-21 in autoimmune diseases have not been fully elucidated, targeting miR-21 may serve as a promising therapy therapeutic target hsa-mir-320 Multiple Sclerosis 24852919 nervous system disease DOID:2377 G35 D009103 PS126200 Natalizumab modified the expression levels of three miRNAs after a 6-month treatment. We suggest miR-320, miR-320b and miR-629 as possible biomarkers for individual PML risk assessment. therapeutic target hsa-mir-320b Multiple Sclerosis 24852919 nervous system disease DOID:2377 G35 D009103 PS126200 Natalizumab modified the expression levels of three miRNAs after a 6-month treatment. We suggest miR-320, miR-320b and miR-629 as possible biomarkers for individual PML risk assessment. therapeutic target hsa-mir-323 Multiple Sclerosis 26943961 nervous system disease DOID:2377 G35 D009103 PS126200 Dicer and microRNA expression in multiple sclerosis and response to interferon therapy. therapeutic target hsa-mir-3614 Multiple Sclerosis 26943961 nervous system disease DOID:2377 G35 D009103 PS126200 Dicer and microRNA expression in multiple sclerosis and response to interferon therapy. therapeutic target hsa-mir-369 Multiple Sclerosis 26943961 nervous system disease DOID:2377 G35 D009103 PS126200 Dicer and microRNA expression in multiple sclerosis and response to interferon therapy. therapeutic target hsa-mir-494 Multiple Sclerosis 26943961 nervous system disease DOID:2377 G35 D009103 PS126200 Dicer and microRNA expression in multiple sclerosis and response to interferon therapy. therapeutic target hsa-mir-629 Multiple Sclerosis 24852919 nervous system disease DOID:2377 G35 D009103 PS126200 Natalizumab modified the expression levels of three miRNAs after a 6-month treatment. We suggest miR-320, miR-320b and miR-629 as possible biomarkers for individual PML risk assessment. therapeutic target hsa-mir-874 Multiple Sclerosis 26943961 nervous system disease DOID:2377 G35 D009103 PS126200 Dicer and microRNA expression in multiple sclerosis and response to interferon therapy. therapeutic target hsa-mir-9 Multiple Sclerosis 26943961 nervous system disease DOID:2377 G35 D009103 PS126200 Dicer and microRNA expression in multiple sclerosis and response to interferon therapy. therapeutic target hsa-mir-1 Muscle Diseases [unspecific] 19754672 M63.80 D009135 Local injection of miR-1, 133 and 206 could be a novel therapeutic strategy in the treatment of skeletal muscle injury. therapeutic target hsa-mir-133 Muscle Diseases [unspecific] 19754672 M63.80 D009135 Local injection of miR-1, 133 and 206 could be a novel therapeutic strategy in the treatment of skeletal muscle injury. therapeutic target hsa-mir-206 Muscle Diseases [unspecific] 19754672 M63.80 D009135 Local injection of miR-1, 133 and 206 could be a novel therapeutic strategy in the treatment of skeletal muscle injury. therapeutic target hsa-mir-30a Mycobacterium tuberculosis Infection 25866116 A18 D014376 607948 Our results indicate that miR-30A plays a key role in immune response against MTB and, therefore, may serve as a potential target for future treatments of tuberculosis infection. therapeutic target hsa-mir-20a Myeloma 28979138 C90.0 D009101 254500 miR-20a plays a crucial role in the biology of MM and represents a potential target for novel therapies for MM patients therapeutic target hsa-mir-1 Myocardial Infarction 29269324 cardiovascular system disease DOID:5844 I21 D009203 608557 HP:0001658 Delivery of microRNA-1 inhibitor by dendrimer-based nanovector: An early targeting therapy for myocardial infarction in mice therapeutic target hsa-mir-130a Myocardial Infarction 28498815 cardiovascular system disease DOID:5844 I21 D009203 608557 HP:0001658 The optimization of cell therapy by combinational application with apicidin-treated mesenchymal stem cells after myocardial infarction. therapeutic target hsa-mir-155 Myocardial Infarction 26258537 cardiovascular system disease DOID:5844 I21 D009203 608557 HP:0001658 Our study will aid in deciphering the complex regulatory mechanisms involved in MI and provide putative therapeutic targets for MI. therapeutic target hsa-mir-21 Myocardial Infarction 26258537 cardiovascular system disease DOID:5844 I21 D009203 608557 HP:0001658 Our study will aid in deciphering the complex regulatory mechanisms involved in MI and provide putative therapeutic targets for MI. therapeutic target hsa-mir-21 Myocardial Infarction 22960625 cardiovascular system disease DOID:5844 I21 D009203 608557 HP:0001658 we found a novel reciprocal loop between miR-21 and TGFβRIII in cardiac fibrosis caused by myocardial infarction in mice, and targeting this pathway could be a new strategy for the prevention and treatment of myocardial remodeling. therapeutic target hsa-mir-210 Myocardial Infarction 22171547 cardiovascular system disease DOID:5844 I21 D009203 608557 HP:0001658 Given the fact that miR-210 is aberrantly expressed in a number of diseases such as tumor progression, myocardial infarction and cutaneous ischemic wounds, miR-210 could serve as an excellent candidate for prognostic purposes and therapeutic intervention. therapeutic target hsa-mir-29 Myocardial Infarction 26258537 cardiovascular system disease DOID:5844 I21 D009203 608557 HP:0001658 Our study will aid in deciphering the complex regulatory mechanisms involved in MI and provide putative therapeutic targets for MI. therapeutic target hsa-mir-34a Myocardial Infarction 25322725 cardiovascular system disease DOID:5844 I21 D009203 608557 HP:0001658 Our findings provide evidence that miR-34a plays a critical role in the progression of cardiac tissue fibrosis by directly targeting Smad4, which suggests that miR-34a may be new marker for cardiac fibrosis progression and that inhibition of miR-34a may be a promising strategy in the treatment of cardiac fibrosis. therapeutic target hsa-mir-34c Myocardial Infarction 26232617 cardiovascular system disease DOID:5844 I21 D009203 608557 HP:0001658 Involvement of miR-34c in high glucose-insulted mesenchymal stem cells leads to inefficient therapeutic effect on myocardial infarction. therapeutic target hsa-mir-145 Nasopharyngeal Neoplasms 25578496 C11.9 D009303 607107 HP:0100630 miR-145 overexpression might be a potential therapeutic strategy of NPC intervention. therapeutic target hsa-mir-21 Nasopharyngeal Neoplasms 25544502 C11.9 D009303 607107 HP:0100630 NPC-derived miR-21 induces IL-10(+) B cells; the latter is capable of suppressing CD8(+) T-cell activities. miR-21 may be a potential target in the treatment of NP EBV-hsa-mir-BArT10-3p therapeutic target hsa-let-7 Neoplasms [unspecific] 24816444 C80.1 D009369 Therapeutic potential of microRNA let-7: tumor suppression or impeding normal stemness. therapeutic target hsa-let-7 Neoplasms [unspecific] 26256260 C80.1 D009369 Small molecules targeting microRNA for cancer therapy: Promises and obstacles. therapeutic target hsa-let-7 Neoplasms [unspecific] 26284568 C80.1 D009369 To this end, we discuss the potential for miR-based therapies focused on three prominent miRs including the pan-RAS regulator let-7 and the GAP regulator comprised of miR-206 and miR-21 (miR-206/21). therapeutic target hsa-let-7a Neoplasms [unspecific] 26348204 C80.1 D009369 Overall, our study provides a novel rationale of targeting miR let-7a-USP35-ABIN-2 pathway for the therapy of cancer patients. therapeutic target hsa-let-7i Neoplasms [unspecific] 27588466 C80.1 D009369 Involvement of let-7 microRNA for the therapeutic effects of Rhenium-188-embedded liposomal nanoparticles on orthotopic human head and neck cancer model. therapeutic target hsa-mir-1 Neoplasms [unspecific] 24949449 C80.1 D009369 Role of microRNA-1 in human cancer and its therapeutic potentials. therapeutic target hsa-mir-100 Neoplasms [unspecific] 25740059 C80.1 D009369 Potential role of miR-100 in cancer diagnosis, prognosis, and therapy. therapeutic target hsa-mir-106b Neoplasms [unspecific] 25692889 C80.1 D009369 These preliminary findings warrant testing in a larger cohort of relapse patients to confirm whether the miRNA based predictor can select the optimal second line treatment and increase survival. therapeutic target hsa-mir-122 Neoplasms [unspecific] 25687306 C80.1 D009369 This study demonstrates that ultrasound induced microbubble cavitation can be a useful tool for delivery of therapeutic miR loaded nanocarriers into cancer in vivo. therapeutic target hsa-mir-122 Neoplasms [unspecific] 25910843 C80.1 D009369 The other strategy is increasing miRNA aims at decreasing target genes using miRNA mimic. This thematic issue will spur the interest of developing novel microRNA therapeutics and enhance the enthusiasm for targeting miRNAs as a novel class of drugs. therapeutic target hsa-mir-122 Neoplasms [unspecific] 25935978 C80.1 D009369 Glutathione-mediated release of functional miR-122 from gold nanoparticles for targeted induction of apoptosis in cancer treatment. therapeutic target hsa-mir-122 Neoplasms [unspecific] 26256260 C80.1 D009369 Small molecules targeting microRNA for cancer therapy: Promises and obstacles. therapeutic target hsa-mir-122 Neoplasms [unspecific] 28209991 C80.1 D009369 MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. therapeutic target hsa-mir-124 Neoplasms [unspecific] 26115122 C80.1 D009369 miR-124 could potentially be used as a therapeutic agent to improve the efficacy of chemotherapy with DNA-damaging agents. therapeutic target hsa-mir-124 Neoplasms [unspecific] 29602831 C80.1 D009369 This novel ncRNA bioengineering platform can be easily adapted to produce various ncRNA molecules, and biologic ncRNAs hold the promise as new cancer therapeutics therapeutic target hsa-mir-126 Neoplasms [unspecific] 25571061 C80.1 D009369 miRNAs could serve not only as prognostic biomarkers for cancer treatment outcome but also as interventional agents to modulate desired chemosensitivity. therapeutic target hsa-mir-126 Neoplasms [unspecific] 25572155 C80.1 D009369 miR-126 has potential therapeutic applications. therapeutic target hsa-mir-1268a Neoplasms [unspecific] 29435930 C80.1 D009369 Quantum Language of MicroRNA: Application for New Cancer Therapeutic Targets(the top 5 of high DNS were in rmiRNAs, rmiR-4466 in 5′ETS, rmiR-3656 in 28S, rmiR-1268a and rmiR-1268b in 3′ETS, and rmiR-6729) therapeutic target hsa-mir-1268b Neoplasms [unspecific] 29435930 C80.1 D009369 Quantum Language of MicroRNA: Application for New Cancer Therapeutic Targets(the top 5 of high DNS were in rmiRNAs, rmiR-4466 in 5′ETS, rmiR-3656 in 28S, rmiR-1268a and rmiR-1268b in 3′ETS, and rmiR-6729) therapeutic target hsa-mir-128 Neoplasms [unspecific] 24555688 C80.1 D009369 Brain microRNAs and insights into biological functions and therapeutic potential of brain enriched miRNA-128. therapeutic target hsa-mir-128 Neoplasms [unspecific] 25916109 C80.1 D009369 The use of miR-128 as a diagnostic and/or therapeutic tool may result in improvements in diagnosis, prognosis, and treatment of numerous cancers. therapeutic target hsa-mir-129 Neoplasms [unspecific] 25571061 C80.1 D009369 miRNAs could serve not only as prognostic biomarkers for cancer treatment outcome but also as interventional agents to modulate desired chemosensitivity. therapeutic target hsa-mir-129 Neoplasms [unspecific] 24307696 C80.1 D009369 The impact of miRNA-based molecular diagnostics and treatment of NRF2-stabilized tumors. therapeutic target hsa-mir-129 Neoplasms [unspecific] 27802440 C80.1 D009369 we summarized the roles of miR-129 family members and their target genes in tumorigenesis and clinical treatment of human cancers therapeutic target hsa-mir-133 Neoplasms [unspecific] 24975488 C80.1 D009369 microRNA-133: expression, function and therapeutic potential in muscle diseases and cancer. therapeutic target hsa-mir-133b Neoplasms [unspecific] 25743594 C80.1 D009369 Our results hence attempt to explain why miR-133b is generally downregulated in tumours and lay out the potential for Nup214 as a therapeutic target in the treatment of cancer. therapeutic target hsa-mir-138 Neoplasms [unspecific] 25571061 C80.1 D009369 miRNAs could serve not only as prognostic biomarkers for cancer treatment outcome but also as interventional agents to modulate desired chemosensitivity. therapeutic target hsa-mir-143 Neoplasms [unspecific] 26256260 C80.1 D009369 Small molecules targeting microRNA for cancer therapy: Promises and obstacles. therapeutic target hsa-mir-143 Neoplasms [unspecific] 28448866 C80.1 D009369 Function of microRNA-143 in different signal pathways in cancer: New insights into cancer therapy. therapeutic target hsa-mir-145 Neoplasms [unspecific] 26256260 C80.1 D009369 Small molecules targeting microRNA for cancer therapy: Promises and obstacles. therapeutic target hsa-mir-145 Neoplasms [unspecific] 20407606 C80.1 D009369 This unique feature of miR-145-mediaed gene silencing may suggest that miR-145 is a potential cancer biomarker and serves as a novel target for cancer therapy. therapeutic target hsa-mir-145 Neoplasms [unspecific] 27655328 C80.1 D009369 our results indicated that mir-145, through targeting its common potential targets, may significantly contribute to tumor pathogenesis in distinct cancer types and might serve as an important target for cancer therapy therapeutic target hsa-mir-146b Neoplasms [unspecific] 27533309 C80.1 D009369 In conjunction with current therapeutic regimens, targeting the miR-146b-IRAK1 axis may provide a potential approach for PTC management. therapeutic target hsa-mir-150 Neoplasms [unspecific] 24698324 C80.1 D009369 Our results indicate that miR-150 is a common posttranscriptional regulator for Prf1 in mouse and human NK cells that represses NK cell lytic activity. Thus the therapeutic control of miR-150 in NK cells could enhance NK cell-based immunotherapy against cancer, providing a better clinical outcome. therapeutic target hsa-mir-155 Neoplasms [unspecific] 25892205 C80.1 D009369 pHLIP-mediated tumor targeting and anti-miR-155 PNA therapy was also effective in other tumor types, providing a bright perspective for future anti-miR conjugate medicines. therapeutic target hsa-mir-155 Neoplasms [unspecific] 26284487 C80.1 D009369 Altogether, our study demonstrates the multi-potent miRNA sponge is a useful tool to examine the functional impact of simultaneous inhibition of multiple miRNAs and proposes a therapeutic potential. therapeutic target hsa-mir-155 Neoplasms [unspecific] 25401928 C80.1 D009369 These results tie ELK3 into the hypoxia response pathway through an oncogenic microRNA and into a circuit implicated in the dynamics of the hypoxic response. This crosstalk could be important for the development of new treatments for a range of pathologies. therapeutic target hsa-mir-155 Neoplasms [unspecific] 19811312 C80.1 D009369 Therefore, designing miR-155 based therapies will require a better understanding of the molecular basis of its action as well as of how miR-155 levels are regulated in a cell-specific manner. therapeutic target hsa-mir-155 Neoplasms [unspecific] 29282605 C80.1 D009369 miR-155 in cancer drug resistance and as target for miRNA-based therapeutics therapeutic target hsa-mir-15b Neoplasms [unspecific] 25888955 C80.1 D009369 miR-15b and miR-16 play a role in the inhibition of insulin resistance via reduced TNFα and SOCS3 signaling and increased IGFBP-3 levels,resulting in REC protection from hyperglycemia-induced apoptosis. This outcome suggests that both miR-15b and miR-16 are potential therapeutic targets for therapeutics for the diabetic retina. therapeutic target hsa-mir-15b Neoplasms [unspecific] 25571061 C80.1 D009369 miRNAs could serve not only as prognostic biomarkers for cancer treatment outcome but also as interventional agents to modulate desired chemosensitivity. therapeutic target hsa-mir-16 Neoplasms [unspecific] 25888955 C80.1 D009369 miR-15b and miR-16 play a role in the inhibition of insulin resistance via reduced TNFα and SOCS3 signaling and increased IGFBP-3 levels,resulting in REC protection from hyperglycemia-induced apoptosis. This outcome suggests that both miR-15b and miR-16 are potential therapeutic targets for therapeutics for the diabetic retina. therapeutic target hsa-mir-16 Neoplasms [unspecific] 19944013 C80.1 D009369 Together, all these results demonstrate that miR-16-1 plays a vital role in modulating cellular process in human cancers and indicate the therapeutic potential of miR-16-1 in cancer therapy. therapeutic target hsa-mir-16-2 Neoplasms [unspecific] 25571061 C80.1 D009369 miRNAs could serve not only as prognostic biomarkers for cancer treatment outcome but also as interventional agents to modulate desired chemosensitivity. therapeutic target hsa-mir-17 Neoplasms [unspecific] 24419145 C80.1 D009369 microRNA-17~92 is a powerful cancer driver and a therapeutic target. therapeutic target hsa-mir-17 Neoplasms [unspecific] 26256260 C80.1 D009369 Small molecules targeting microRNA for cancer therapy: Promises and obstacles. therapeutic target hsa-mir-18 Neoplasms [unspecific] 26256260 C80.1 D009369 Small molecules targeting microRNA for cancer therapy: Promises and obstacles. therapeutic target hsa-mir-193a Neoplasms [unspecific] 27669434 C80.1 D009369 the broader applicability of using miR-193a-3p as a therapeutic agent to target KRas-mutant cancer therapeutic target hsa-mir-195 Neoplasms [unspecific] 24446485 C80.1 D009369 The results suggest that miRNA expression profiles can distinguish different subtypes of ACA, which may contribute to a deeper understanding of ACA development and potential therapeutics. therapeutic target hsa-mir-196a Neoplasms [unspecific] 25571061 C80.1 D009369 miRNAs could serve not only as prognostic biomarkers for cancer treatment outcome but also as interventional agents to modulate desired chemosensitivity. therapeutic target hsa-mir-19a Neoplasms [unspecific] 26256260 C80.1 D009369 Small molecules targeting microRNA for cancer therapy: Promises and obstacles. therapeutic target hsa-mir-19b-1 Neoplasms [unspecific] 26256260 C80.1 D009369 Small molecules targeting microRNA for cancer therapy: Promises and obstacles. therapeutic target hsa-mir-200 Neoplasms [unspecific] 25762624 C80.1 D009369 The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy. therapeutic target hsa-mir-200 Neoplasms [unspecific] 23888967 C80.1 D009369 A family of pleiotropically acting microRNAs in cancer progression, miR-200: potential cancer therapeutic targets. therapeutic target hsa-mir-200 Neoplasms [unspecific] 25401465 C80.1 D009369 This study provides a strong rationale for detailed assessment of the prognostic and predictive value of circulating extracellular vesicle-bound miR-200s in breast cancer progression and treatment. therapeutic target hsa-mir-205 Neoplasms [unspecific] 25308719 C80.1 D009369 The important roles of miR-205 in normal physiology, cancers and as a potential therapeutic target. therapeutic target hsa-mir-205 Neoplasms [unspecific] 24568460 C80.1 D009369 The aim of this review is to discuss miR-205 roles in different types of cancers. Given the critical effects of deregulated miR-205 on processes involved in tumorigenesis, they hold potential as novel therapeutic targets and biomarkers. therapeutic target hsa-mir-205 Neoplasms [unspecific] 25476932 C80.1 D009369 miR-205 as a radiosensitizing miRNA and reveal a new therapeutic strategy for radioresistant tumours. therapeutic target hsa-mir-206 Neoplasms [unspecific] 26284568 C80.1 D009369 To this end, we discuss the potential for miR-based therapies focused on three prominent miRs including the pan-RAS regulator let-7 and the GAP regulator comprised of miR-206 and miR-21 (miR-206/21). therapeutic target hsa-mir-20a Neoplasms [unspecific] 26256260 C80.1 D009369 Small molecules targeting microRNA for cancer therapy: Promises and obstacles. therapeutic target hsa-mir-21 Neoplasms [unspecific] 25942410 C80.1 D009369 These findings highlight the promise of the highly versatile multifunctional nanocomposite in biomedical application of intracellular molecules analysis and clinical gene therapeutics. therapeutic target hsa-mir-21 Neoplasms [unspecific] 25991670 C80.1 D009369 these studies highlight a stronger role for miR-21 in the pathogenesis of multiple autoimmune and chronic inflammatory disorders. However, the complete molecular mechanisms by which miR-21 regulates these pathologies remains to be investigated. Thus, a better understanding of the role of miR-21 in the innate and adaptive immune systems, during healthy states as well as during infection, chronic inflammation, and autoimmunity, is required before we design any therapeutic strategies aimed at targeting miR-21. therapeutic target hsa-mir-21 Neoplasms [unspecific] 24446181 C80.1 D009369 MicroRNA-21 is a novel promising target in cancer radiation therapy. therapeutic target hsa-mir-21 Neoplasms [unspecific] 26256260 C80.1 D009369 Small molecules targeting microRNA for cancer therapy: Promises and obstacles. therapeutic target hsa-mir-21 Neoplasms [unspecific] 20560046 C80.1 D009369 miR-21 is found to play important roles in vascular smooth muscle cell proliferation and apoptosis, cardiac cell growth and death, and cardiac fibroblast functions therapeutic target hsa-mir-21 Neoplasms [unspecific] 23865553 C80.1 D009369 MicroRNA-21: a therapeutic target for reversing drug resistance in cancer. therapeutic target hsa-mir-21 Neoplasms [unspecific] 26284487 C80.1 D009369 Altogether, our study demonstrates the multi-potent miRNA sponge is a useful tool to examine the functional impact of simultaneous inhibition of multiple miRNAs and proposes a therapeutic potential. therapeutic target hsa-mir-21 Neoplasms [unspecific] 25827073 C80.1 D009369 our work demonstrated that AC1MMYR2 appeared to be a promising strategy in combating taxol induced cancer metastasis by targeting miR-21/CDK5 axis, which highlighted the potential for development of therapeutic modalities for better clinic taxol application. therapeutic target hsa-mir-21 Neoplasms [unspecific] 26028073 C80.1 D009369 These findings contribute to our understanding of the functions of miR-21 and exosomes as a carrier for therapy of gastric cancer. therapeutic target hsa-mir-21 Neoplasms [unspecific] 26284568 C80.1 D009369 To this end, we discuss the potential for miR-based therapies focused on three prominent miRs including the pan-RAS regulator let-7 and the GAP regulator comprised of miR-206 and miR-21 (miR-206/21). therapeutic target hsa-mir-21 Neoplasms [unspecific] 27428511 C80.1 D009369 Targeted inhibition of oncogenic miR-21 maturation with designed RNA-binding proteins therapeutic target hsa-mir-21 Neoplasms [unspecific] 28096467 C80.1 D009369 Our results not only elucidate miR-21-mediated radioresistance, but also provide potential new targets for improving radiotherapy therapeutic target hsa-mir-214 Neoplasms [unspecific] 26108246 C80.1 D009369 miRNA-214: expression, therapeutic and diagnostic potential in cancer. therapeutic target hsa-mir-214 Neoplasms [unspecific] 25501033 C80.1 D009369 miR-214 is a molecular hub involved in the control of cancer networks and, as such, could be a potential diagnostic/prognostic biomarker and target for therapeutic intervention. therapeutic target hsa-mir-214 Neoplasms [unspecific] 25591843 C80.1 D009369 miR-214: a potential biomarker and therapeutic for different cancers. therapeutic target hsa-mir-218 Neoplasms [unspecific] 26407971 C80.1 D009369 This system offers an efficient approach to cancer therapy and holds significant potential to improve the treatment of cancer in the future. therapeutic target hsa-mir-218 Neoplasms [unspecific] 25857406 C80.1 D009369 we provide a complex overview of miR-218, including its regulatory mechanisms, known functions in cancer and future challenges as a potential therapeutic target in human cancers. therapeutic target hsa-mir-221 Neoplasms [unspecific] 24474451 C80.1 D009369 The meta-analysis demonstrates that the elevated expression of miR-221 and miR-222 is associated with poor OS in patients with cancer. The miR-221/222 cluster might be used as a potential therapeutic strategy in clinical practice. More work is required to fully elucidate the role of the miR-221/222 family in human tumors. therapeutic target hsa-mir-221 Neoplasms [unspecific] 25431954 C80.1 D009369 Notch3 silencing strongly increases the effects of Nutilin-3.With regard to therapeutic implications, Notch3-specific drugs could represent a valuable strategy to limit Notch signaling in the context of hepatocellular carcinoma over-expressing this receptor. therapeutic target hsa-mir-221 Neoplasms [unspecific] 26256260 C80.1 D009369 Small molecules targeting microRNA for cancer therapy: Promises and obstacles. therapeutic target hsa-mir-221 Neoplasms [unspecific] 26284487 C80.1 D009369 Altogether, our study demonstrates the multi-potent miRNA sponge is a useful tool to examine the functional impact of simultaneous inhibition of multiple miRNAs and proposes a therapeutic potential. therapeutic target hsa-mir-222 Neoplasms [unspecific] 24474451 C80.1 D009369 The meta-analysis demonstrates that the elevated expression of miR-221 and miR-222 is associated with poor OS in patients with cancer. The miR-221/222 cluster might be used as a potential therapeutic strategy in clinical practice. More work is required to fully elucidate the role of the miR-221/222 family in human tumors. therapeutic target hsa-mir-222 Neoplasms [unspecific] 26284487 C80.1 D009369 Altogether, our study demonstrates the multi-potent miRNA sponge is a useful tool to examine the functional impact of simultaneous inhibition of multiple miRNAs and proposes a therapeutic potential. therapeutic target hsa-mir-223 Neoplasms [unspecific] 24606854 C80.1 D009369 miR-223 overexpression downregulates ATM expression and sensitizes U87 cells to radiation in vitro and in vivo. MicroRNA-223 may be a novel cancer-targeting therapy, although its cancer- and patient-specific roles are currently undefined. therapeutic target hsa-mir-224 Neoplasms [unspecific] 26254100 C80.1 D009369 MicroRNA-224: as a potential target for miR-based therapy of cancer. therapeutic target hsa-mir-25 Neoplasms [unspecific] 25692889 C80.1 D009369 These preliminary findings warrant testing in a larger cohort of relapse patients to confirm whether the miRNA based predictor can select the optimal second line treatment and increase survival. therapeutic target hsa-mir-26a Neoplasms [unspecific] 25395662 C80.1 D009369 These studies reveal a tumor suppressor role for miR-26 in intestinal cancer that overrides putative oncogenic activity, highlighting the therapeutic potential of miR-26 delivery to this tumor type. therapeutic target hsa-mir-26b Neoplasms [unspecific] 25571061 C80.1 D009369 miRNAs could serve not only as prognostic biomarkers for cancer treatment outcome but also as interventional agents to modulate desired chemosensitivity. therapeutic target hsa-mir-27b Neoplasms [unspecific] 28351320 C80.1 D009369 Promising therapeutic role of miR-27b in tumor. therapeutic target hsa-mir-28 Neoplasms [unspecific] 26485640 C80.1 D009369 Moreover, miR-608 was determined to have a suppressive function on tumor growth in an NCI-H460 xenograft model. These findings provide insights into the roles of five miRNAs in growth inhibition and their potential function as cancer therapeutics. therapeutic target hsa-mir-296 Neoplasms [unspecific] 25577262 C80.1 D009369 miRNAs might provide new diagnostic markers and new therapeutic approaches by developing molecular miRNA-targeted therapies for the cure of parathyroid tumours, whose unique option is surgery. therapeutic target hsa-mir-29a Neoplasms [unspecific] 25846459 C80.1 D009369 Our findings may provide new insight into the pathogenesis of the bone metabolism disorder in inflammation environment and provide promising therapeutic target. therapeutic target hsa-mir-30 Neoplasms [unspecific] 25810374 C80.1 D009369 These findings illuminate a novel mechanism for the modulation of premetastatic niches by miR-30s, which suggest that miR-30s represent not only promising targets for antimetastasis therapy but also indicators for metastasis. therapeutic target hsa-mir-300 Neoplasms [unspecific] 24885626 C80.1 D009369 Down-regulation of miR-300 is required for EMT initiation and maintenance. MiR-300 may negatively regulate EMT by direct targeting Twist and therefore inhibit cancer cell invasion and metastasis, which implicates miR-300 as an attractive candidate for cancer therapy. therapeutic target hsa-mir-30a Neoplasms [unspecific] 28359057 C80.1 D009369 miR-30a may serve as a potential target in the diagnosis and therapy of human cancer therapeutic target hsa-mir-30e Neoplasms [unspecific] 25571061 C80.1 D009369 miRNAs could serve not only as prognostic biomarkers for cancer treatment outcome but also as interventional agents to modulate desired chemosensitivity. therapeutic target hsa-mir-31 Neoplasms [unspecific] 24771647 C80.1 D009369 Hsa-miR-31-3p seems to be a new mCRC biomarker whose expression level allows for the identification of patients with wild-type KRAS mCRC who are more likely to respond to anti-EGFR therapy. therapeutic target hsa-mir-3175 Neoplasms [unspecific] 26565624 C80.1 D009369 Our results suggest that HOXB1 functions as a tumor suppressor, regulated by miR-3175 in glioma. These results clarify the pathogenesis of glioma and offer a potential target for its treatment. therapeutic target hsa-mir-3189 Neoplasms [unspecific] 25698447 C80.1 D009369 our study identified miR-3189 as a novel, primate-specific miRNA whose effects are mediated by both p53-dependent and p53-independent mechanisms. miR-3189 may, therefore,represent a novel tool that can be utilized therapeutically to induce a potent proapoptotic effect even in p53-deficient tumors. therapeutic target hsa-mir-32 Neoplasms [unspecific] 25571061 C80.1 D009369 miRNAs could serve not only as prognostic biomarkers for cancer treatment outcome but also as interventional agents to modulate desired chemosensitivity. therapeutic target hsa-mir-323 Neoplasms [unspecific] 26485640 C80.1 D009369 Moreover, miR-608 was determined to have a suppressive function on tumor growth in an NCI-H460 xenograft model. These findings provide insights into the roles of five miRNAs in growth inhibition and their potential function as cancer therapeutics. therapeutic target hsa-mir-323a Neoplasms [unspecific] 25556445 C80.1 D009369 increased expression of miR-323-5p might be related to glioma progression, which indicates a potential role of miR-323-5p for clinical therapy. therapeutic target hsa-mir-34 Neoplasms [unspecific] 25892205 C80.1 D009369 pHLIP-mediated tumor targeting and anti-miR-155 PNA therapy was also effective in other tumor types, providing a bright perspective for future anti-miR conjugate medicines. therapeutic target hsa-mir-34 Neoplasms [unspecific] 24884974 C80.1 D009369 P53/microRNA-34-induced metabolic regulation: new opportunities in anticancer therapy. therapeutic target hsa-mir-34 Neoplasms [unspecific] 24657911 C80.1 D009369 we review the miR-34 family and their role in tumor biology, and discuss the potential therapeutic applications of miR-34a mimic. therapeutic target hsa-mir-34 Neoplasms [unspecific] 28209991 C80.1 D009369 MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. therapeutic target hsa-mir-34a Neoplasms [unspecific] 25032850 C80.1 D009369 MicroRNA-34a: a potential therapeutic target in human cancer. therapeutic target hsa-mir-34a Neoplasms [unspecific] 25585539 C80.1 D009369 miR-34a regulates the expression of a number of critical proteins involved in apoptosis, proliferation and the response to chemotherapy. In summary, miR-34a increases the sensitivity of colon cancer cells to 5-FU treatment through specific regulation of the SIRT1/p53 pathway. therapeutic target hsa-mir-34a Neoplasms [unspecific] 26454548 C80.1 D009369 Overall,CS-PEI is potentially employed as a promising tumor-targeting system for miR-34a delivery in tumor gene therapy. therapeutic target hsa-mir-34a Neoplasms [unspecific] 26580663 C80.1 D009369 microRNA-34a as a Therapeutic Agent against Human Cancer. therapeutic target hsa-mir-34a Neoplasms [unspecific] 20883704 C80.1 D009369 This circuitry mechanism for p53 activation is of interest in understanding the tumor suppressive function of miR-34a in colon carcinogenesis. miRNA should also be considered as novel anti-cancer agents in tumor suppressive therapeutic applications. therapeutic target hsa-mir-34a Neoplasms [unspecific] 28010900 C80.1 D009369 Emergence of miR-34a in radiation therapy. therapeutic target hsa-mir-34a Neoplasms [unspecific] 29602831 C80.1 D009369 This novel ncRNA bioengineering platform can be easily adapted to produce various ncRNA molecules, and biologic ncRNAs hold the promise as new cancer therapeutics therapeutic target hsa-mir-3656 Neoplasms [unspecific] 29435930 C80.1 D009369 Quantum Language of MicroRNA: Application for New Cancer Therapeutic Targets(the top 5 of high DNS were in rmiRNAs, rmiR-4466 in 5′ETS, rmiR-3656 in 28S, rmiR-1268a and rmiR-1268b in 3′ETS, and rmiR-6729) therapeutic target hsa-mir-4466 Neoplasms [unspecific] 29435930 C80.1 D009369 Quantum Language of MicroRNA: Application for New Cancer Therapeutic Targets(the top 5 of high DNS were in rmiRNAs, rmiR-4466 in 5′ETS, rmiR-3656 in 28S, rmiR-1268a and rmiR-1268b in 3′ETS, and rmiR-6729) therapeutic target hsa-mir-449a Neoplasms [unspecific] 29023247 C80.1 D009369 miR-449a: a potential therapeutic agent for cancer. therapeutic target hsa-mir-450a Neoplasms [unspecific] 24307696 C80.1 D009369 The impact of miRNA-based molecular diagnostics and treatment of NRF2-stabilized tumors. therapeutic target hsa-mir-451 Neoplasms [unspecific] 23814177 C80.1 D009369 The potential role of miR-451 in cancer diagnosis, prognosis, and therapy. therapeutic target hsa-mir-495 Neoplasms [unspecific] 27697751 C80.1 D009369 MiR-495 functions as an adjuvant to radiation therapy by reducing the radiation-induced bystander effect. therapeutic target hsa-mir-497 Neoplasms [unspecific] 26345385 C80.1 D009369 In summary, miR-497 inhibits tumor angiogenesis and growth via targeting VEGFR2, indicating miR-497 can be explored as a potential drug candidate for cancer therapy. therapeutic target hsa-mir-497 Neoplasms [unspecific] 24446485 C80.1 D009369 The results suggest that miRNA expression profiles can distinguish different subtypes of ACA, which may contribute to a deeper understanding of ACA development and potential therapeutics. therapeutic target hsa-mir-507 Neoplasms [unspecific] 24307696 C80.1 D009369 The impact of miRNA-based molecular diagnostics and treatment of NRF2-stabilized tumors. therapeutic target hsa-mir-510 Neoplasms [unspecific] 26485640 C80.1 D009369 Moreover, miR-608 was determined to have a suppressive function on tumor growth in an NCI-H460 xenograft model. These findings provide insights into the roles of five miRNAs in growth inhibition and their potential function as cancer therapeutics. therapeutic target hsa-mir-519d Neoplasms [unspecific] 25404641 C80.1 D009369 resistin promotes chondrosarcoma metastasis and MMP-2 expression through activation of the AMPK/p38 signaling pathway and down-regulation of miR-519d expression. Therefore, resistin may represent a potential novel molecular therapeutic target in chondrosarcoma metastasis. therapeutic target hsa-mir-519e Neoplasms [unspecific] 25571061 C80.1 D009369 miRNAs could serve not only as prognostic biomarkers for cancer treatment outcome but also as interventional agents to modulate desired chemosensitivity. therapeutic target hsa-mir-520d Neoplasms [unspecific] 25303886 C80.1 D009369 In vitro data indicate the potent usefulness of this small molecule as a therapeutic biomaterial in normal cells and cancer cells because CD105+ cells never converted to iPSCs despite repeated transfections and all types of transfectants lost their tumorigenicity. This maintenance of a benign state following miR-520d-5p transfection appears to be caused by p53 upregulation. We conclude that miR-520d-5p may be a useful biomaterial at an in vitro level. therapeutic target hsa-mir-532 Neoplasms [unspecific] 25766316 C80.1 D009369 the development of new therapeutic strategies based on caspase recruitment domain (ARC) and miR-532-3p is promising for overcoming the cardiotoxicity of chemotherapy for cancer therapy. therapeutic target hsa-mir-542 Neoplasms [unspecific] 24762395 C80.1 D009369 Our results define miR-542-3p as an important new positive regulator of p53 with potential applications in cancer treatment. therapeutic target hsa-mir-542 Neoplasms [unspecific] 26203762 C80.1 D009369 Our novel framework impartially identifies therapeutically relevant miRNA candidates from transcriptomic data sets. therapeutic target hsa-mir-542 Neoplasms [unspecific] 26272182 C80.1 D009369 Together, these findings reveal a novel regulatory pathway whereby tumor-derived angiogenin directly activates angiogenesis through inhibition of miR-542-3p, suggesting that angiogenin may represent a promising target for anti-angiogenic therapy and a potential marker for monitoring disease progression. therapeutic target hsa-mir-552 Neoplasms [unspecific] 26485640 C80.1 D009369 Moreover, miR-608 was determined to have a suppressive function on tumor growth in an NCI-H460 xenograft model. These findings provide insights into the roles of five miRNAs in growth inhibition and their potential function as cancer therapeutics. therapeutic target hsa-mir-590 Neoplasms [unspecific] 26052692 C80.1 D009369 We believe that analyzing the cooperative mechanism of the miRNAs in modules rather than focusing on only single miRNAs may help us know more about the complicated relationship between miRNAs and cancers and develop more effective treatment strategies for cancers. therapeutic target hsa-mir-608 Neoplasms [unspecific] 26485640 C80.1 D009369 Moreover, miR-608 was determined to have a suppressive function on tumor growth in an NCI-H460 xenograft model. These findings provide insights into the roles of five miRNAs in growth inhibition and their potential function as cancer therapeutics. therapeutic target hsa-mir-624 Neoplasms [unspecific] 25571061 C80.1 D009369 miRNAs could serve not only as prognostic biomarkers for cancer treatment outcome but also as interventional agents to modulate desired chemosensitivity. therapeutic target hsa-mir-629 Neoplasms [unspecific] 26052692 C80.1 D009369 We believe that analyzing the cooperative mechanism of the miRNAs in modules rather than focusing on only single miRNAs may help us know more about the complicated relationship between miRNAs and cancers and develop more effective treatment strategies for cancers. therapeutic target hsa-mir-634 Neoplasms [unspecific] 26216549 C80.1 D009369 Our findings illustrate how reversing miR-634-mediated cytoprotective processes may offer a broadly useful approach to improving cancer therapy. therapeutic target hsa-mir-634 Neoplasms [unspecific] 24307696 C80.1 D009369 The impact of miRNA-based molecular diagnostics and treatment of NRF2-stabilized tumors. therapeutic target hsa-mir-6729 Neoplasms [unspecific] 29435930 C80.1 D009369 Quantum Language of MicroRNA: Application for New Cancer Therapeutic Targets(the top 5 of high DNS were in rmiRNAs, rmiR-4466 in 5′ETS, rmiR-3656 in 28S, rmiR-1268a and rmiR-1268b in 3′ETS, and rmiR-6729) therapeutic target hsa-mir-7 Neoplasms [unspecific] 24907395 C80.1 D009369 microRNA-7: a tumor suppressor miRNA with therapeutic potential. therapeutic target hsa-mir-7 Neoplasms [unspecific] 25434362 C80.1 D009369 With the increasing understanding of molecular mechanisms of miR-7-mediated regulatory networks and the advancement of miRNA-based therapeutics, targeting miR-7 may be a potential and promising strategy for cancer therapy. therapeutic target hsa-mir-885 Neoplasms [unspecific] 26554827 C80.1 D009369 Our work shows how DNp73 promotes cancer stem-like features and provides a mechanistic rationale to target the DNp73-IGF1R cascade as a therapeutic strategy to eradicate CSC. therapeutic target hsa-mir-9 Neoplasms [unspecific] 25571061 C80.1 D009369 miRNAs could serve not only as prognostic biomarkers for cancer treatment outcome but also as interventional agents to modulate desired chemosensitivity. therapeutic target hsa-mir-9 Neoplasms [unspecific] 25596753 C80.1 D009369 Aberrantly expressed miR-9 contributes to T24 cells invasion, partly through directly down-regulating CBX7 protein expression in TCC. This miRNA signature offers a new potential therapeutic target for TCC. therapeutic target hsa-mir-92-1 Neoplasms [unspecific] 26256260 C80.1 D009369 Small molecules targeting microRNA for cancer therapy: Promises and obstacles. therapeutic target hsa-mir-92a-1 Neoplasms [unspecific] 23239404 C80.1 D009369 Development of miR-92a delivery system for antiangiogenesis-based cancer therapy therapeutic target hsa-mir-92a-2 Neoplasms [unspecific] 23239404 C80.1 D009369 Development of miR-92a delivery system for antiangiogenesis-based cancer therapy therapeutic target hsa-mir-93 Neoplasms [unspecific] 25692889 C80.1 D009369 These preliminary findings warrant testing in a larger cohort of relapse patients to confirm whether the miRNA based predictor can select the optimal second line treatment and increase survival. therapeutic target hsa-mir-487b Nervous System Diseases [unspecific] 25660232 C72.9 D009422 These results demonstrate that miR-487b regulates angiogenesis by directly targeting THBS1 in HUVECs, indicating that miR-487b may contribute to angiogenesis and the functional recovery from ischemic stroke. miR-487b could represent a potential therapeutic option for neurovascular disease. therapeutic target hsa-mir-210 Neurilemmoma 28440459 disease of cellular proliferation DOID:3192 D36.10 D009442 miR-210 could be a potential marker for judging tumor malignancy and be taken as an effective target for clinical auxiliary treatment of neurilemmoma therapeutic target hsa-mir-200a Neuroblastoma 24969902 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 Our study revealed that miR-200a is a candidate tumor suppressor in neuroblastoma, through direct targeting of AP-2γ. These findings re-enforce the proposal of AP-2γ as a therapeutic target in neuroblastoma. therapeutic target hsa-mir-34a Neuroblastoma 24912852 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 proteome analysis has here identified early targets of miR-34a with relevance to NBL tumorigenesis. Along with the results of previous studies, our data strongly suggest miR-34a as a useful tool for improving the chance of therapeutic success with NBL. therapeutic target hsa-mir-34a Neuroblastoma 19199973 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 MiR-17-5p-92 family members act in an oncogenic manner while miR-34a has tumor suppressor functions. The evidence for the contribution of miRNAs in the aggressive neuroblastoma phenotype is reviewed in this article, along with exciting possibilities for miRNA mediated therapeutics. therapeutic target hsa-mir-542 Neuroblastoma 25046253 disease of cellular proliferation DOID:769 C74.90 D009447 256700 HP:0003006 miR-542-3p exerts its tumor suppressive function in neuroblastoma, at least in part, by targeting Survivin. Expression of miR-542-3p could be a promising therapeutic strategy for treating aggressive neuroblastoma. therapeutic target hsa-mir-302 Neurodegenerative Diseases [unspecific] 26414965 D019636 HP:0002180 The combination of the proved pluripotency-inducing miRNA-302/367 cluster and cell-specific miRNAs provides a unique strategy for one-step cellular conversion that could have important implications for studies of neuron development and neurological disease therapy. therapeutic target hsa-mir-367 Neurodegenerative Diseases [unspecific] 26414965 D019636 HP:0002180 The combination of the proved pluripotency-inducing miRNA-302/367 cluster and cell-specific miRNAs provides a unique strategy for one-step cellular conversion that could have important implications for studies of neuron development and neurological disease therapy. therapeutic target hsa-mir-23b Neuropathic Pain 23152062 D009437 We finally suggest that infusion of miR23b and NOX4 antibody may provide attractive diagnostic and therapeutic resources for effective pain modulation in neuropathic pain. therapeutic target hsa-mir-126 Obesity 26122028 disease of metabolism DOID:9970 E66 D009765 601665 HP:0001513 These results indicate that obesity impacts on EV pro-angiogenic potential and may raise concerns about the use of adipose tissue-derived EVs in cell-based therapy in the obese setting. therapeutic target hsa-mir-143 Obesity 27623943 disease of metabolism DOID:9970 E66 D009765 601665 HP:0001513 Tumour biology of obesity-related cancers: understanding the molecular concept for better diagnosis and treatment. therapeutic target hsa-mir-1908 Obesity 26349979 disease of metabolism DOID:9970 E66 D009765 601665 HP:0001513 Our findings demonstrated that miR-1908 has its own transcription unit, and revealed the transcriptional mechanisms of miR-1908 expression based on NF-kappaB signaling. This study offers a theoretical basis for understanding the transcriptional mechanism of miR-1908 expression and may provide a new strategy for obesity clinical therapy. therapeutic target hsa-mir-200a Obesity 24394757 disease of metabolism DOID:9970 E66 D009765 601665 HP:0001513 These findings link the alteration of leptin and insulin signaling to the up-regulation of hypothalamic miR-200a which could be a new target for treatment of obesity. therapeutic target hsa-mir-223 Obesity 25842981 disease of metabolism DOID:9970 E66 D009765 601665 HP:0001513 The findings in this study suggest that miR-223 is a factor of obesity. The level of miR-223 in the serum can be used as a biomarker of obesity and therapeutic response. therapeutic target hsa-mir-101 Osteoarthritis 24018042 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 non-coding RNAs could be a potent predictive biomarker for OA as well as a therapeutic target for preventing cartilage-related diseases. therapeutic target hsa-mir-130a Osteoarthritis 26045761 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 Our results indicated that miR-130a played an important role in regulating the expression of TNF-α in human chondrocytes and identified miR-130a as a novel therapeutic target in OA. therapeutic target hsa-mir-139 Osteoarthritis 26450708 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 These results support our hypothesis that miR-139-mediated downregulation of MCPIP1 promotes IL-6 expression in OA. Therefore, targeting miR-139 could be therapeutically beneficial in the management of OA. therapeutic target hsa-mir-140 Osteoarthritis 26608362 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 miR-29a and miR-140 combination treatment may be a possible treatment for OA therapeutic target hsa-mir-146a Osteoarthritis 21397669 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 miR-146a controls knee joint homeostasis and OA associated algesia by balancing inflammatory responses in cartilage and synovium with pain-related factors in glial cells. Hence, miR-146a may be useful for the treatment of both cartilage regeneration and pain symptoms caused by OA (osteoarthritis). therapeutic target hsa-mir-335 Osteoarthritis 24582835 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 Given that miR-335 has the different genes involved in the Wnt signalling pathway as potential targets, the observed trend may help to ascertain, at least partially, some of the alterations which determine the onset or progression of osteoarthritis, and can therefore serve for the design of future therapeutic targets for the treatment of this disease. therapeutic target hsa-mir-150 Osteoporosis 26212040 musculoskeletal system disease DOID:11476 M80 D010024 166710 HP:0000939 miR-150 may have potential therapeutic applications in promoting bone formation in certain disease settings, such as in osteoporosis and in elderly patients. therapeutic target hsa-mir-216a Osteoporosis 26206089 musculoskeletal system disease DOID:11476 M80 D010024 166710 HP:0000939 our findings suggest that miR-216a may serve as a novel therapeutic agent for the prevention and treatment of osteoporosis and other bone metabolism-related diseases. therapeutic target hsa-mir-320a Osteoporosis 26555194 musculoskeletal system disease DOID:11476 M80 D010024 166710 HP:0000939 We identified two osteoblast miRNAs over-expressed in osteoporotic fractures, which opens novel prospects for research and therapy. therapeutic target hsa-mir-483 Osteoporosis 26555194 musculoskeletal system disease DOID:11476 M80 D010024 166710 HP:0000939 We identified two osteoblast miRNAs over-expressed in osteoporotic fractures, which opens novel prospects for research and therapy. therapeutic target hsa-mir-101 Osteosarcoma 25480586 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-101 may act as a tumor suppressor, which is commonly downregulated in both osteosarcoma tissues and cells. mTOR plays an important role in mediating miR-101 dependent biological functions in osteosarcoma. Reintroduction of miR-101 may be a novel therapeutic strategy by down-regulating mTOR expression. therapeutic target hsa-mir-127 Osteosarcoma 26707641 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Overall, the results revealed that miR-127-3p acts as a tumor suppressor and that its down-regulation in cancer may contribute to OS progression and metastasis, suggesting that miR-127-3p could be a potential therapeutic target in the treatment of OS. therapeutic target hsa-mir-129 Osteosarcoma 25566966 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 increased miR-129-5p may be mediated by demethylation and inhibit OS cell migration and invasion by targeting VCP in OS, and targeting miR-129-5p/VCP signaling pathway may serve as a therapeutic strategy for OS management, although further studies will be necessary. therapeutic target hsa-mir-133a Osteosarcoma 24715690 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Clinical relevance and therapeutic significance of microRNA-133a expression profiles and functions in malignant osteosarcoma-initiating cells. therapeutic target hsa-mir-134 Osteosarcoma 26681023 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 These findings indicate that miR-134 may act as a tumor suppressor in osteosarcoma and could serve as a novel therapeutic agent for miRNA-based therapy. therapeutic target hsa-mir-142 Osteosarcoma 25530132 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 overexpression of miR-142 and/or knockdown of Rac1 would be a novel target for OS therapy in the future. therapeutic target hsa-mir-146b Osteosarcoma 26549292 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 These results indicated that miR-146b-5p promoted proliferation, migration and invasiveness. It also increased resistance to chemotherapy through the regulation of ZNRF3, and suggested novel potential therapeutic targets for the treatment of osteosarcoma. therapeutic target hsa-mir-150 Osteosarcoma 26361218 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 In conclusion, miR-150 inhibits cell proliferation, invasion, and metastasis and stimulates cell apoptosis by regulating the expression of Sp1. Therefore, miR-150 may be a potential clinical target for the treatment of OS patients. therapeutic target hsa-mir-182 Osteosarcoma 25973950 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Down-expression of miR-182 in osteosarcoma promoted tumor growth,migration and invasion by targeting TIAM1. MiR-182 might act as a tumor suppressor gene whose down-regulation contributes to the progression and metastasis of osteosarcoma, providing a potential therapy target for osteosarcoma patients. therapeutic target hsa-mir-195 Osteosarcoma 25498513 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Decreased expression of miR-195 in serum may be a novel biomarker for screening osteosarcoma and can predict poor prognosis. Detection of serum miR-195 expression may have potential applications for the diagnosis, prognosis, and treatment of osteosarcoma. therapeutic target hsa-mir-203 Osteosarcoma 26584294 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Taken together, these findings suggest that miR-203 acts as a tumor suppressor via regulation of TBK1 expression in OS progression, and miR-203 may be a promising therapeutic target for OS. therapeutic target hsa-mir-205 Osteosarcoma 25784290 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 This is the first study to identify plasma miRNAs that could be used to prospectively identify disease, potentially monitor therapeutic efficacy and have prognostic implications for OS patients. therapeutic target hsa-mir-214 Osteosarcoma 25784290 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 This is the first study to identify plasma miRNAs that could be used to prospectively identify disease, potentially monitor therapeutic efficacy and have prognostic implications for OS patients. therapeutic target hsa-mir-217 Osteosarcoma 25960216 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 These findings indicate that miR-217 may act as a tumor suppressor in osteosarcoma and would serve as a novel therapeutic agent for miRNA-based therapy. therapeutic target hsa-mir-335 Osteosarcoma 25784290 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 This is the first study to identify plasma miRNAs that could be used to prospectively identify disease, potentially monitor therapeutic efficacy and have prognostic implications for OS patients. therapeutic target hsa-mir-34a Osteosarcoma 26518752 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth. therapeutic target hsa-mir-374a Osteosarcoma 26617789 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Our study suggested that miR-374a functions as an oncogene in OS, and the miR-374a/Axin2 axis might represent a potential therapeutic target for OS intervention. therapeutic target hsa-mir-429 Osteosarcoma 24633485 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 In conclusion, miR-429 serves as a tumor suppressor via interaction with ZEB1. Our finding may provide a new target for osteosarcoma therapy. therapeutic target hsa-mir-451 Osteosarcoma 25471786 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-451 may act not only as a novel diagnostic and prognostic marker, but also as a potential target for molecular therapy of osteosarcoma. therapeutic target hsa-mir-454 Osteosarcoma 25880599 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Reduced-expression of miR-454 in osteosarcoma cells promoted tumour growth by targeting c-Met, thus miR-454 may be a potential therapy target for this tumour. therapeutic target hsa-mir-490 Osteosarcoma 26341146 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Taken together, our results suggest that miR-490-3p functions as a potential tumor suppressor by down-regulating HMGA2 expression directly, and it may represent a potential therapeutic target for patients with osteosarcoma. therapeutic target hsa-mir-503 Osteosarcoma 25536034 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-503 in osteosarcoma pathogenesis, indicating its potential application in cancer therapy. therapeutic target hsa-mir-539 Osteosarcoma 26339374 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 These findings provide evidence that miR-539 plays a key role in inhibiting osteosarcoma cell invasion and migration and can regulating MMP8 expression in osteosarcoma cells. These strongly suggest that exogenous miR-539 may have therapeutic value in treating osteosarcoma. therapeutic target hsa-mir-574 Osteosarcoma 25784290 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 This is the first study to identify plasma miRNAs that could be used to prospectively identify disease, potentially monitor therapeutic efficacy and have prognostic implications for OS patients. therapeutic target hsa-mir-9 Osteosarcoma 25592968 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 the high dose of E2 treatment upregulated miR-9 thus posttranscriptionally regulated MALAT-1 RNA level in OS cells, and then the downregulation of MALAT-1 inhibited cell proliferation, migration, invasion and epithelial-mesenchymal transition (EMT) processes in the E2-dose dependent and ER-independent ways. miR-143 therapeutic target hsa-mir-93 Osteosarcoma 26243299 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 Ectopic expression of miR-93 decreased PTEN protein levels.Furthermore, miR-93 increased proliferation and decreased apoptosis in OS cells, whereas its silencing in these cells inhibited such carcinogenic processes.Taking these observations together, miR-93 can be seen to play a critical role in carcinogenesis through suppression of PTEN, and may serve as a therapeutic target for the treatment of OS. therapeutic target hsa-let-7i Ovarian Neoplasms 19074899 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 let-7i: a novel biomarker and therapeutic target therapeutic target hsa-mir-1 Ovarian Neoplasms 26247403 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 LAPTM4B-miRNA-transfected NIH:OVCAR3 cells exhibited significant decreases in cell motility and invasion. therapeutic target hsa-mir-128 Ovarian Neoplasms 25248111 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Taken together, our findings suggest that miR-128 may act as a promising therapeutic target for improvement of tumor sensitivity to cisplatin. therapeutic target hsa-mir-141 Ovarian Neoplasms 25872328 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 The present results suggest that miR-141-3p might be used as a therapeutic target to modulate platinum-based chemotherapy and as a biomarker to predict chemotherapy response. therapeutic target hsa-mir-143 Ovarian Neoplasms 25485872 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Viral miRNAs can be useful to develop biomarkers for early diagnosis and as a potential therapeutic tool to reduce SEOC lethality. therapeutic target hsa-mir-16 Ovarian Neoplasms 26393886 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Our data indicate the diagnostic potential of miR-7, miR-25, miR-93 and miR-429 in EOC and the prognostic potential of miR-429. This microRNA panel may be promising molecules to be targeted in the treatment of EOC. therapeutic target hsa-mir-16 Ovarian Neoplasms 19903841 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 These findings suggest the development of therapeutic strategies by restoring miR-15a and miR-16 expression in ovarian cancer and in other cancers that involve upregulation of Bmi-1. therapeutic target hsa-mir-17 Ovarian Neoplasms 25510663 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 mature miR-17 expression may have an important role in the pathogenesis of human ovarian tumors through its interference with the LKB1-p53-p21/WAF1 pathway expression by epigenetic modification. These findings are of potential importance in the identification of novel therapeutic targets in human ovarian cancer. therapeutic target hsa-mir-182 Ovarian Neoplasms 26393886 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Our data indicate the diagnostic potential of miR-7, miR-25, miR-93 and miR-429 in EOC and the prognostic potential of miR-429. This microRNA panel may be promising molecules to be targeted in the treatment of EOC. therapeutic target hsa-mir-184 Ovarian Neoplasms 26601424 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Altogether, our results suggest that miR-184 together with pathologic diagnosis is critical for prognosis determination in EOC patients and help select treatment strategy. therapeutic target hsa-mir-193a Ovarian Neoplasms 25545504 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 a simultaneous EZH2 inhibition and anti-estrogen therapy can constitute an effective combine therapeutic strategy against ovarian cancer. therapeutic target hsa-mir-200 Ovarian Neoplasms 24952258 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Epithelial-mesenchymal transition-associated miRNAs in ovarian carcinoma, with highlight on the miR-200 family: prognostic value and prospective role in ovarian cancer therapeutics. therapeutic target hsa-mir-200c Ovarian Neoplasms 26260454 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 These data suggested that miR-200c and miR-31 may play roles in the SEOC metastasis biology and could be considered as promising targets for therapeutic purposes. therapeutic target hsa-mir-205 Ovarian Neoplasms 26275944 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MiR-205, acting as an oncogenic miRNA, may promote the clinical progression of EOC patients and enhance the cellular motility in vitro by directly and negatively regulating ZEB1, providing a potential therapeutic strategy for suppression of EOC metastasis. therapeutic target hsa-mir-21 Ovarian Neoplasms 24472409 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Our data suggest that miR-21 regulates drug resistance via apoptosis and cellular survival pathways. Targeting miR-21 may have clinical utility in the treatment of resistant ovarian cancer. therapeutic target hsa-mir-214 Ovarian Neoplasms 24822185 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Application of microRNA in diagnosis and treatment of ovarian cancer. therapeutic target hsa-mir-25 Ovarian Neoplasms 26393886 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Our data indicate the diagnostic potential of miR-7, miR-25, miR-93 and miR-429 in EOC and the prognostic potential of miR-429. This microRNA panel may be promising molecules to be targeted in the treatment of EOC. therapeutic target hsa-mir-29b Ovarian Neoplasms 24662327 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Id-1, a protein repressed by miR-29b, facilitates TGFβ1-induced EMT in human ovarian cancer cells and represents a promising therapeutic target for treating ovarian cancer. therapeutic target hsa-mir-29b Ovarian Neoplasms 26512921 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Taken together, our study suggests that miR-29b regulates the Warburg effect in EOC via AKT2/AKT3 and may provide novel options for future treatments for EOC. therapeutic target hsa-mir-30d Ovarian Neoplasms 26501435 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Our results revealed that miR-30d functioned as a suppressor of ovarian cancer progression by decreasing Snail expression and thus blocking TGF-β1-induced EMT process, suggesting the potentiality of miR-30d analogs to be used as therapeutics for ovarian cancer. therapeutic target hsa-mir-31 Ovarian Neoplasms 24822185 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Application of microRNA in diagnosis and treatment of ovarian cancer. therapeutic target hsa-mir-31 Ovarian Neoplasms 26260454 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 These data suggested that miR-200c and miR-31 may play roles in the SEOC metastasis biology and could be considered as promising targets for therapeutic purposes. therapeutic target hsa-mir-373 Ovarian Neoplasms 25460499 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 miR-373 suppresses EOC invasion and metastasis by directly targeting Rab22a gene, a new potential therapeutic target in EOC. therapeutic target hsa-mir-376a Ovarian Neoplasms 26393886 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Our data indicate the diagnostic potential of miR-7, miR-25, miR-93 and miR-429 in EOC and the prognostic potential of miR-429. This microRNA panel may be promising molecules to be targeted in the treatment of EOC. therapeutic target hsa-mir-378 Ovarian Neoplasms 24680769 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Our data suggest that miR-378 is overexpressed in ovarian cancer cells and tumors vs. normal ovarian epithelial cells. MiR-378 and its downstream targets may serve as markers for response to anti-angiogenic therapy. therapeutic target hsa-mir-429 Ovarian Neoplasms 26393886 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Our data indicate the diagnostic potential of miR-7, miR-25, miR-93 and miR-429 in EOC and the prognostic potential of miR-429. This microRNA panel may be promising molecules to be targeted in the treatment of EOC. therapeutic target hsa-mir-451 Ovarian Neoplasms 26390704 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 miR-451 may act not only as a novel diagnostic and prognostic marker, but also as a potential target for molecular therapy of EOC. therapeutic target hsa-mir-506 Ovarian Neoplasms 25995442 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 MiR-506 is a robust clinical marker for chemotherapy response and survival in serous ovarian cancers and has important therapeutic value in sensitizing cancer cells to chemotherapy. therapeutic target hsa-mir-509 Ovarian Neoplasms 26786897 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Our data suggest that restoring certain dysregulated miRNAs to their normal levels could increase the therapeutic effects of anticancer drugs. therapeutic target hsa-mir-548c Ovarian Neoplasms 26762267 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 These findings suggest that miR-548c directly downregulates Twist,and provide a novel mechanism for Twist upregulation in both endometrial and ovarian cancers. The use of miR-548c may hold therapeutic potential for the treatment of Twist-overexpressing tumors. therapeutic target hsa-mir-634 Ovarian Neoplasms 26576679 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 miR-634 levels determine chemosensitivity in ovarian cancer cells. We identify miR-634 as a therapeutic candidate to resensitize chemotherapy resistant ovarian tumors. therapeutic target hsa-mir-7 Ovarian Neoplasms 26393886 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Our data indicate the diagnostic potential of miR-7, miR-25, miR-93 and miR-429 in EOC and the prognostic potential of miR-429. This microRNA panel may be promising molecules to be targeted in the treatment of EOC. therapeutic target hsa-mir-708 Ovarian Neoplasms 25569036 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 glucocorticoids and their downstream mediators, miR-708 or Rap1B, as therapeutic modalities against metastatic ovarian epithelial cancer. therapeutic target hsa-mir-93 Ovarian Neoplasms 26393886 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 Our data indicate the diagnostic potential of miR-7, miR-25, miR-93 and miR-429 in EOC and the prognostic potential of miR-429. This microRNA panel may be promising molecules to be targeted in the treatment of EOC. therapeutic target hsa-mir-103a-1 Pain 21804529 R52 D010146 knocking-down or over-expressing miR-103, respectively, up- or down-regulate the level of Cav1.2-LTC translation.miR-103 knockdown in naive rats results in hypersensitivity to pain. Moreover, we demonstrate that miR-103 is down-regulated in neuropathic animals and that miR-103 intrathecal applications successfully relieve pain, identifying miR-103 as a novel possible therapeutic target in neuropathic chronic pain. therapeutic target hsa-mir-103a-2 Pain 21804529 R52 D010146 knocking-down or over-expressing miR-103, respectively, up- or down-regulate the level of Cav1.2-LTC translation.miR-103 knockdown in naive rats results in hypersensitivity to pain. Moreover, we demonstrate that miR-103 is down-regulated in neuropathic animals and that miR-103 intrathecal applications successfully relieve pain, identifying miR-103 as a novel possible therapeutic target in neuropathic chronic pain. therapeutic target hsa-mir-126 Pancreatic Adenocarcinoma 29200874 disease of cellular proliferation DOID:4074 C25.3 The therapeutic system co-expressing miR-126 and miR-34a mediated by oncolytic adenovirus is a promising system for PAC target therapy therapeutic target hsa-mir-34a Pancreatic Adenocarcinoma 29200874 disease of cellular proliferation DOID:4074 C25.3 The therapeutic system co-expressing miR-126 and miR-34a mediated by oncolytic adenovirus is a promising system for PAC target therapy therapeutic target hsa-let-7b Pancreatic Neoplasms 26516699 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets. therapeutic target hsa-mir-100 Pancreatic Neoplasms 26516699 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets. therapeutic target hsa-mir-101 Pancreatic Neoplasms 25841339 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Two independent microRNA backgrounds showed promise in therapeutic intervention of gemcitabine sensitive, MIA PaCa-2 and resistant, PANC-1 pancreatic cancer cells, in combination with dietary agents and drug. therapeutic target hsa-mir-1261 Pancreatic Neoplasms 25722110 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 these data may be useful for the detection and treatment of drug resistance in pancreatic cancer patients, and the microRNA-mRNA network-based analysis is expected to be more effective and provides deep insights into the molecular mechanism of drug resistance. therapeutic target hsa-mir-1273 Pancreatic Neoplasms 26516699 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets. therapeutic target hsa-mir-138 Pancreatic Neoplasms 25875420 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Our data indicate that miR-138-5p may play an important role in regulating pancreatic cancer cell growth, possibly through targeting FOXC1.Over-expression of miR-138-5p may serve as a novel approach for the treatment of patients with pancreatic cancer. therapeutic target hsa-mir-141 Pancreatic Neoplasms 26516699 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets. therapeutic target hsa-mir-145 Pancreatic Neoplasms 27507554 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 miR-145 re-expression resulted in downregulation of MUC13, HER2, pAKT, and inhibition of cell proliferation, clonogenicity, migration, and invasion of pancreatic cancer cells. therapeutic target hsa-mir-146b Pancreatic Neoplasms 26516699 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets. therapeutic target hsa-mir-150 Pancreatic Neoplasms 24971005 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Synthesis, characterization, and evaluation of poly (D,L-lactide-co-glycolide)-based nanoformulation of miRNA-150: potential implications for pancreatic cancer therapy. therapeutic target hsa-mir-150 Pancreatic Neoplasms 26516699 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets. therapeutic target hsa-mir-195 Pancreatic Neoplasms 26516699 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets. therapeutic target hsa-mir-200c Pancreatic Neoplasms 26261532 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Our study demonstrated that miR-200c overexpression could decrease colony formation, invasion and chemoresistance of PCSCs. It may become a new therapeutic target for gene therapy in patients suffered from pancreatic cancer. therapeutic target hsa-mir-200c Pancreatic Neoplasms 26493507 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 The expression of miR-200c may be an important prognosis factor in pancreatic cancer, and it could be a novel therapeutic target of pancreatic cancer. therapeutic target hsa-mir-205 Pancreatic Neoplasms 24836307 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer. therapeutic target hsa-mir-205 Pancreatic Neoplasms 26516699 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets. therapeutic target hsa-mir-21 Pancreatic Neoplasms 26516699 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets. therapeutic target hsa-mir-21 Pancreatic Neoplasms 28444967 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Co-delivery of microRNA-21 antisense oligonucleotides and gemcitabine using nanomedicine for pancreatic cancer therapy. therapeutic target hsa-mir-215 Pancreatic Neoplasms 26662405 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 These findings indicate that miR-215 may act as a tumor suppressor in pancreatic cancer cells, and could serve as a novel therapeutic target for miR-based therapy. therapeutic target hsa-mir-216 Pancreatic Neoplasms 26516699 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets. therapeutic target hsa-mir-217 Pancreatic Neoplasms 26516699 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets. therapeutic target hsa-mir-223 Pancreatic Neoplasms 25638153 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 down-regulation of miR-223 could be a novel therapy for pancreatic cancer. therapeutic target hsa-mir-223 Pancreatic Neoplasms 26516699 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets. therapeutic target hsa-mir-24-2 Pancreatic Neoplasms 25841339 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Two independent microRNA backgrounds showed promise in therapeutic intervention of gemcitabine sensitive, MIA PaCa-2 and resistant, PANC-1 pancreatic cancer cells, in combination with dietary agents and drug. therapeutic target hsa-mir-26a Pancreatic Neoplasms 24116110 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 miR-26a is an important suppressor of pancreatic ductal carcinoma, and can prove to be a novel prognostic factor and therapeutic target for pancreatic cancer treatment. therapeutic target hsa-mir-26b Pancreatic Neoplasms 26516699 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets. therapeutic target hsa-mir-27a Pancreatic Neoplasms 20638779 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 This suggests the potential for miR-27a to be used as a target in the diagnosis and treatment of pancreatic adenocarcinoma. therapeutic target hsa-mir-29a Pancreatic Neoplasms 26356262 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Our results suggest that miR-29a acts as an oncogene by down regulating TTP and provide the basis for further studies exploring the potential of miR-29a and TTP as biomarkers and targets for the treatment of pancreatic cancer. therapeutic target hsa-mir-320c Pancreatic Neoplasms 23799850 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 The results indicate that miR-320c regulates the resistance of pancreatic cancer cells to gemcitabine through SMARCC1, suggesting that miR-320c/SMARCC1 could be suitable for prediction of the clinical response and potential therapeutic target in pancreatic cancer patients on gemcitabine-based therapy. therapeutic target hsa-mir-345 Pancreatic Neoplasms 26247574 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 miR-345 downregulation confers apoptosis resistance to PC cells, and its restoration could be exploited for therapeutic benefit. therapeutic target hsa-mir-345 Pancreatic Neoplasms 26516699 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets. therapeutic target hsa-mir-34a Pancreatic Neoplasms 21909380 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 miR-34a is a critical regulator of pancreatic cancer progression by the regulating CSC characteristics. The restoration of its expression by 5-Aza-dC and SAHA in CSCs will not only provide mechanistic insight and therapeutic targets for pancreatic cancer but also promising reagents to boost patient response to existing chemotherapies or as a standalone cancer drug by eliminating the CSC characteristics. therapeutic target hsa-mir-34c Pancreatic Neoplasms 26516699 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets. therapeutic target hsa-mir-3676 Pancreatic Neoplasms 25722110 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 these data may be useful for the detection and treatment of drug resistance in pancreatic cancer patients, and the microRNA-mRNA network-based analysis is expected to be more effective and provides deep insights into the molecular mechanism of drug resistance. therapeutic target hsa-mir-4455 Pancreatic Neoplasms 25722110 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 these data may be useful for the detection and treatment of drug resistance in pancreatic cancer patients, and the microRNA-mRNA network-based analysis is expected to be more effective and provides deep insights into the molecular mechanism of drug resistance. therapeutic target hsa-mir-4644 Pancreatic Neoplasms 25722110 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 these data may be useful for the detection and treatment of drug resistance in pancreatic cancer patients, and the microRNA-mRNA network-based analysis is expected to be more effective and provides deep insights into the molecular mechanism of drug resistance. therapeutic target hsa-mir-4650 Pancreatic Neoplasms 25722110 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 these data may be useful for the detection and treatment of drug resistance in pancreatic cancer patients, and the microRNA-mRNA network-based analysis is expected to be more effective and provides deep insights into the molecular mechanism of drug resistance. therapeutic target hsa-mir-483 Pancreatic Neoplasms 26516699 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets. therapeutic target hsa-mir-643 Pancreatic Neoplasms 25722110 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 these data may be useful for the detection and treatment of drug resistance in pancreatic cancer patients, and the microRNA-mRNA network-based analysis is expected to be more effective and provides deep insights into the molecular mechanism of drug resistance. therapeutic target hsa-mir-663 Pancreatic Neoplasms 25744894 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 miR-663 attenuated the proliferation and invasion of pancreatic cells both in vitro and in vivo by directly targeting eEF1A2. miR-663 and eEF1A2 might be potential targets for the treatment of pancreatic cancer in the future. therapeutic target hsa-mir-744 Pancreatic Neoplasms 26485754 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 These findings suggest that miR-744 plays a vital role in promoting the stem cell-like phenotype of pancreatic cancer cells, and may represent a novel prognostic biomarker and therapeutic target. therapeutic target hsa-mir-96 Pancreatic Neoplasms 25071021 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 miR-96 acts as a tumor suppressor in pancreatic cancer and may therefore serve as a useful therapeutic target for the development of new anticancer therapy. therapeutic target hsa-mir-129 Parkinson Disease 25465742 nervous system disease DOID:14330 G20 D010300 PS168600 miRNAs are very sensitive to drug therapy and that the effects of therapy observed may be associated with changes in the levels of these miRNAs and their target genes in patients with Parkinson's disease. therapeutic target hsa-mir-132 Parkinson Disease 25465742 nervous system disease DOID:14330 G20 D010300 PS168600 miRNAs are very sensitive to drug therapy and that the effects of therapy observed may be associated with changes in the levels of these miRNAs and their target genes in patients with Parkinson's disease. therapeutic target hsa-mir-221 Parkinson Disease 29405726 nervous system disease DOID:14330 G20 D010300 PS168600 miR-221 may serve as a potential therapeutic target for Parkinson's disease treatment therapeutic target hsa-mir-7 Parkinson Disease 25465742 nervous system disease DOID:14330 G20 D010300 PS168600 miRNAs are very sensitive to drug therapy and that the effects of therapy observed may be associated with changes in the levels of these miRNAs and their target genes in patients with Parkinson's disease. therapeutic target hsa-mir-7-1 Parkinson Disease 19628698 nervous system disease DOID:14330 G20 D010300 PS168600 expression decreases; miR-7 down-regulates of alpha-expression decreases synuclein, protects cells against oxidative stress therapeutic target hsa-mir-7-2 Parkinson Disease 19628698 nervous system disease DOID:14330 G20 D010300 PS168600 expression decreases; miR-7 down-regulates of alpha-expression decreases synuclein, protects cells against oxidative stress therapeutic target hsa-mir-7-3 Parkinson Disease 19628698 nervous system disease DOID:14330 G20 D010300 PS168600 expression decreases; miR-7 down-regulates of alpha-expression decreases synuclein, protects cells against oxidative stress therapeutic target hsa-mir-9 Parkinson Disease 25465742 nervous system disease DOID:14330 G20 D010300 PS168600 miRNAs are very sensitive to drug therapy and that the effects of therapy observed may be associated with changes in the levels of these miRNAs and their target genes in patients with Parkinson's disease. therapeutic target hsa-mir-30d Pelvic Organ Prolapse 25630974 D056887 176780 both miR-30d and 181a are important posttranscriptional regulators of HOXA11 in the USLs and could be a potential therapeutic target for POP. therapeutic target hsa-mir-138 Periodontal Diseases 26518300 gastrointestinal system disease DOID:3388 K05.6 D010510 HP:0000704 Our data establish miR-138 inhibitor as a potential therapeutic agent for the prevention of the bone loss associated with advanced periodontal disease. therapeutic target hsa-mir-223 Periodontal Diseases 27552373 gastrointestinal system disease DOID:3388 K05.6 D010510 HP:0000704 Knowledge gained from future studies will be beneficial in developing alternative therapeutic approaches, especially ones that use miRNA delivery systems to treat periodontal disease therapeutic target hsa-mir-200b Periodontitis 25630869 gastrointestinal system disease DOID:824 K05.4 D010518 260950 HP:0000704 Functional studies to explore the role of miR-200b in the above processes may offer new insights on putative therapeutic targets for this group of patients. therapeutic target hsa-mir-142 Peritoneal Fibrosis 26616819 D056627 These results suggest that several miRNAs are involved in PF and that they may be useful as novel diagnostic biomarkers and therapeutic targets for PF. therapeutic target hsa-mir-21 Peritoneal Fibrosis 26616819 D056627 These results suggest that several miRNAs are involved in PF and that they may be useful as novel diagnostic biomarkers and therapeutic targets for PF. therapeutic target hsa-mir-221 Peritoneal Fibrosis 26616819 D056627 These results suggest that several miRNAs are involved in PF and that they may be useful as novel diagnostic biomarkers and therapeutic targets for PF. therapeutic target hsa-mir-223 Peritoneal Fibrosis 26616819 D056627 These results suggest that several miRNAs are involved in PF and that they may be useful as novel diagnostic biomarkers and therapeutic targets for PF. therapeutic target hsa-mir-34a Peritoneal Fibrosis 26616819 D056627 These results suggest that several miRNAs are involved in PF and that they may be useful as novel diagnostic biomarkers and therapeutic targets for PF. therapeutic target hsa-mir-300 Pituitary Neoplasms 26320179 disease of cellular proliferation DOID:1785 C75.1 D010911 HP:0040277 Together, these findings suggest that these PTTG1-targeting miRNAs are important players in the regulation of pituitary tumorigenesis and that these miRNAs may serve as valuable therapeutic targets for cancer treatment. therapeutic target hsa-mir-329 Pituitary Neoplasms 26320179 disease of cellular proliferation DOID:1785 C75.1 D010911 HP:0040277 Together, these findings suggest that these PTTG1-targeting miRNAs are important players in the regulation of pituitary tumorigenesis and that these miRNAs may serve as valuable therapeutic targets for cancer treatment. therapeutic target hsa-mir-381 Pituitary Neoplasms 26320179 disease of cellular proliferation DOID:1785 C75.1 D010911 HP:0040277 Together, these findings suggest that these PTTG1-targeting miRNAs are important players in the regulation of pituitary tumorigenesis and that these miRNAs may serve as valuable therapeutic targets for cancer treatment. therapeutic target hsa-mir-655 Pituitary Neoplasms 26320179 disease of cellular proliferation DOID:1785 C75.1 D010911 HP:0040277 Together, these findings suggest that these PTTG1-targeting miRNAs are important players in the regulation of pituitary tumorigenesis and that these miRNAs may serve as valuable therapeutic targets for cancer treatment. therapeutic target hsa-mir-126 Pleural Mesothelioma 26504055 disease of cellular proliferation DOID:7474 C45.0 D054363 HP:0100002 In MPM, DNA-hypermethylation down-regulates miR-126 and its host gene EGFL7, therefore is a poor prognostic factor, and may represent a future therapeutic target for de-methylating strategies re-establishing EGFL7 and miR-126 expression. therapeutic target hsa-mir-15 Pleural Mesothelioma 26075427 disease of cellular proliferation DOID:7474 C45.0 D054363 HP:0100002 this proof-of-concept case illustrates the promise of this novel strategy using targeted EDV nanocells to restore the expression of down-regulated miRs in MPM. Such an approach, if supported by further evaluation, has the potential for a paradigm shift in the management of treatment-resistant tumors such as MPM. We are eagerly awaiting the determination of the maximum tolerated dose of TargomiRs and commencement of subsequent phase 2 studies to confirm the efficacy of this novel therapeutic approach. therapeutic target hsa-mir-16 Pleural Mesothelioma 26075427 disease of cellular proliferation DOID:7474 C45.0 D054363 HP:0100002 this proof-of-concept case illustrates the promise of this novel strategy using targeted EDV nanocells to restore the expression of down-regulated miRs in MPM. Such an approach, if supported by further evaluation, has the potential for a paradigm shift in the management of treatment-resistant tumors such as MPM. We are eagerly awaiting the determination of the maximum tolerated dose of TargomiRs and commencement of subsequent phase 2 studies to confirm the efficacy of this novel therapeutic approach. therapeutic target hsa-mir-155 Pneumonia 26589478 respiratory system disease DOID:552 J18.9 D011014 HP:0002090 Our findings suggest that antagonizing certain microRNA might serve as a potential therapeutic strategy against secondary bacterial infection. therapeutic target hsa-mir-199a Polycystic Kidney Disease 25588980 Q61.19 D007690 PS173900 HP:0000113 Up-regulation of miR-199a-5p in ADPKD tissues might promote cell proliferation through suppressing CDKN1C, suggesting miR-199a-5p as a novel target for ADPKD treatment. therapeutic target hsa-mir-204 Preeclampsia 26003727 cardiovascular system disease DOID:10591 O14 D011225 PS189800 HP:0100602 our study indicates that miR-204 may contribute to the development of preeclampsia by inhibiting trophoblastic invasion, and that MMP9 is involved in miR-204-mediated trophoblast cell invasion. Our study suggests miR-204 as a novel therapeutic target for preeclampsia. therapeutic target hsa-mir-519d Preeclampsia 25803859 cardiovascular system disease DOID:10591 O14 D011225 PS189800 HP:0100602 Our present findings suggest that upregulation of miR-519d-3p may contribute to the development of PE by inhibiting trophoblast cell migration and invasion via targeting MMP-2; miR-519d-3p may represent a potential predictive and therapeutic target for PE. therapeutic target hsa-mir-375 Primary Aldosteronism 25944465 disease of cellular proliferation DOID:12028 E26.0 D006929 615474 Our findings suggest that miR-375 exerts its tumour-suppressive function via targeting MTDH/Akt pathway and implicate a potential therapeutic target in PA. therapeutic target hsa-mir-5338 Prostate Disease 29382326 reproductive system disease DOID:47 N42.9 D011469 Study on the inhibition of Mfn1 by plant-derived miR5338 mediating the treatment of BPH with rape bee pollen. therapeutic target hsa-let-7a Prostate Neoplasms 24480926 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 MicroRNA let-7a: a novel therapeutic candidate in prostate cancer. therapeutic target hsa-let-7a Prostate Neoplasms 29236328 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 the therapeutic potential of Let-7a as an antitumor and antimetastatic manager in prostate cancer and CCR7 may be regarded as a therapeutic target for the prostate cancer treatment therapeutic target hsa-let-7a Prostate Neoplasms 20418948 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Let-7a may also be novel therapeutic candidate for prostate cancer given its ability to induce cell-cycle arrest and inhibit cell growth, especially in hormone-refractory prostate cancer. therapeutic target hsa-let-7a-1 Prostate Neoplasms 23974362 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 let-7a may be novel therapeutic candidate for prostate cancer therapeutic target hsa-mir-100 Prostate Neoplasms 23778488 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 We demonstrate that miR-100 is a context-dependent miRNA controlling BAZ2, mTOR, FGFR3, SMARCA5 and THAP2 that might be involved in PC progression. The elucidation of the roles of miRNAs in tumors is important because they can be used as therapeutic targets in the future. therapeutic target hsa-mir-101 Prostate Neoplasms 26242038 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miRNA-101, with its inhibitory effect on the expression of EZH2 in LNCaP cells, is a potential biotherapeutic for prostate cancer. therapeutic target hsa-mir-101 Prostate Neoplasms 26473737 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Our results demonstrate that AR inhibits autophagy via transactivation of miR-101, thus combination of miR-101 mimics with celastrol may represent a promising therapeutic approach for treating prostate cancer. therapeutic target hsa-mir-101-1 Prostate Neoplasms 20478051 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-101:miR-101 introduction is a potential therapeutic strategy to combat PCa therapeutic target hsa-mir-101-2 Prostate Neoplasms 20478051 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-101:miR-101 introduction is a potential therapeutic strategy to combat PCa therapeutic target hsa-mir-103 Prostate Neoplasms 26771762 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Therefore, our data collectively demonstrate that miR-103 is a proto-oncogene miRNA that can suppress prostate cancer proliferation and migration by down-regulating the oncogene PDCD10, indicating that miR-103 may represent a new potential diagnostic and therapeutic target for prostate cancer treatment. therapeutic target hsa-mir-122 Prostate Neoplasms 26186079 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 The aim of this review is to survey studies conducted on human prostate tissue and biofluids and to consolidate trustworthy data on the role of miRNA in the occurrence and progression of PCa,with a delineation of differentially expressed miRNAs and an analysis of their association with PCa prognosis, progression to CRPC and metastatic disease, as well as their correlation with response to chemotherapy and hormonal therapy. Changes in circulating miRNAs may represent potentially useful non-invasive biomarkers for PCa diagnosis, staging and prediction of outcome. therapeutic target hsa-mir-122 Prostate Neoplasms 24292881 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 we successfully generated an adenoviral vector that expresses TRAIL in miRNA-regulated mechanism. This miRNA-based gene therapy may be promising for prostate carcinoma treatment. therapeutic target hsa-mir-124 Prostate Neoplasms 26573802 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Taken together, our results offer a preclinical rationale to evaluate miR-124 for cancer treatment. therapeutic target hsa-mir-125b Prostate Neoplasms 20886540 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Data obtained in this study demonstrate that miR-125b promotes growth of prostatic xenograft tumors by down-regulating three key pro-apoptotic genes.This suggests that miR-125b is oncogenic and makes it an attractive therapeutic target in CaP. therapeutic target hsa-mir-128 Prostate Neoplasms 25921099 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-128 functions as a potential cancer suppressor in prostate cancer progression and rational therapeutic strategies for prostate cancer would be developed based on miR-128/zinc-finger E-box-binding homeobox 1 axis. therapeutic target hsa-mir-143 Prostate Neoplasms 24292881 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 we successfully generated an adenoviral vector that expresses TRAIL in miRNA-regulated mechanism. This miRNA-based gene therapy may be promising for prostate carcinoma treatment. therapeutic target hsa-mir-143 Prostate Neoplasms 19855844 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-143 is as a new target for prostate cancer treatment. therapeutic target hsa-mir-145 Prostate Neoplasms 26054847 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 we establish a novel and prostate cancer-specific targeting system for the systemic in vivo application of microRNAs through R11-SSPEI complexation as a powerful tool for future therapeutic use. therapeutic target hsa-mir-145 Prostate Neoplasms 26632856 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 This novel study shows a role for miR-145 in modulating radiosensitivity in vivo and highlights the need for further study investigating the potential role of miR-145 as both a predictive marker of response and a novel therapeutic agent with which to enhance the efficacy of radiation therapy. therapeutic target hsa-mir-145 Prostate Neoplasms 24292881 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 we successfully generated an adenoviral vector that expresses TRAIL in miRNA-regulated mechanism. This miRNA-based gene therapy may be promising for prostate carcinoma treatment. therapeutic target hsa-mir-145 Prostate Neoplasms 20588276 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-145:modulation of miR-145 may be an important therapeutic approach for the management of prostate cancer therapeutic target hsa-mir-146a Prostate Neoplasms 26306811 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-146a has a critical role in the process of AIPC prostate cancer cells apoptosis through regulation of ROCK/Caspase 3 pathway. Targeting this pathway may be a promising therapeutic strategy for future personalized anti-cancer treatment. therapeutic target hsa-mir-146b Prostate Neoplasms 25214035 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Our data suggest that miR-146a plays a suppressive role in prostate cancer through down-regulation of Rac1. The miR-146a/Rac1 signaling axis may be a potential therapeutic target to prevent prostate cancer progression. therapeutic target hsa-mir-15 Prostate Neoplasms 26073083 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 These findings establish a new molecular circuitry for prostate cancer metastasis that was validated in patients' cohorts. Our data indicate a network of biomarkers and druggable pathways to improve patient treatment. therapeutic target hsa-mir-16 Prostate Neoplasms 26073083 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 These findings establish a new molecular circuitry for prostate cancer metastasis that was validated in patients' cohorts. Our data indicate a network of biomarkers and druggable pathways to improve patient treatment. therapeutic target hsa-mir-17 Prostate Neoplasms 26318586 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Our findings implicate dietary stilbenes as an attractive miRNA-mediated chemopreventive and therapeutic strategy, and circulating miRNAs as potential chemopreventive and predictive biomarkers for clinical development in prostate cancer. therapeutic target hsa-mir-17 Prostate Neoplasms 27125502 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 RNA nanoparticles were constructed by bottom-up self-assembly containing the anti-prostate-specific membrane antigen (PSMA) RNA aptamer as a targeting ligand and anti-miR17 or anti-miR21 as therapeutic modules. therapeutic target hsa-mir-181b Prostate Neoplasms 23613247 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 As miR-181b is over-expressed in prostate cancer, its down-regulation could have potential as gene therapy for prostate cancer by inducing apoptosis, inhibiting proliferation and depressing invasion by cancer cells. therapeutic target hsa-mir-195 Prostate Neoplasms 26337460 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-195 can repress the migration and invasion of prostate cancer cells via regulating Fra-1. Our results indicate that miR-195 could be a tumor suppressor and may have a potential to be a diagnostics or therapeutic target in prostate cancer. therapeutic target hsa-mir-199a Prostate Neoplasms 24631181 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-199a-3p inhibits aurora kinase A and attenuates prostate cancer growth: new avenue for prostate cancer treatment. therapeutic target hsa-mir-205 Prostate Neoplasms 26813458 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 The miR-205/TP53INP1 mediated autophagy pathway might be an important molecular mechanism regulating radiosensitivity of prostate cancer cells and represents a potential therapeutic target for prostate cancer. therapeutic target hsa-mir-21 Prostate Neoplasms 25401698 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 High stromal expression of miR-21 was associated with poor biochemical recurrence-free survival after RP. For patients with Gleason score 6, miR-21 may help predict the risk of future disease progression and thereby help select patients for potential adjuvant treatment or a more stringent follow-up. therapeutic target hsa-mir-21 Prostate Neoplasms 26073083 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 These findings establish a new molecular circuitry for prostate cancer metastasis that was validated in patients' cohorts. Our data indicate a network of biomarkers and druggable pathways to improve patient treatment. therapeutic target hsa-mir-21 Prostate Neoplasms 22341810 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-21 is an Independent Biochemical Recurrence Predictor and Potential Therapeutic Target for Prostate Cancer. therapeutic target hsa-mir-21 Prostate Neoplasms 27125502 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 RNA nanoparticles were constructed by bottom-up self-assembly containing the anti-prostate-specific membrane antigen (PSMA) RNA aptamer as a targeting ligand and anti-miR17 or anti-miR21 as therapeutic modules. therapeutic target hsa-mir-218 Prostate Neoplasms 25511513 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Clearly understanding of oncogenic TPD52 pathways regulated by miR-218 might be elpful to reveal new therapeutic targets for PC. therapeutic target hsa-mir-223 Prostate Neoplasms 25519054 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 we found increasing SEPT6 expression might reverse the biological activity induced by miR-223-3p, which might be a potential therapeutic target for PCa. therapeutic target hsa-mir-23a Prostate Neoplasms 25604141 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-23a and miR-23b in LNCAP and PC3 cell lines, and these two miRNAs decreased IL-6R expression which has a critical role in these pathways. These results suggest the probability of utilizing miR-23a and miR-23b as therapeutic targets for the treatment of prostate cancer. therapeutic target hsa-mir-23b Prostate Neoplasms 25604141 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-23a and miR-23b in LNCAP and PC3 cell lines, and these two miRNAs decreased IL-6R expression which has a critical role in these pathways. These results suggest the probability of utilizing miR-23a and miR-23b as therapeutic targets for the treatment of prostate cancer. therapeutic target hsa-mir-24 Prostate Neoplasms 26847530 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 These findings provide evidence that miR-24 has a tumor suppressor role in prostate cancer and also targets p27 and p16 in prostate cancer cells. We propose that it may be a useful progression biomarker or focus of therapeutic intervention for this disease. therapeutic target hsa-mir-30a Prostate Neoplasms 26074357 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Our results suggested that reduced expression of miR-130a may be involved in the paclitaxel-resistance and that miR-130a could be a therapeutic target for taxane-resistant prostate cancer patients. therapeutic target hsa-mir-340 Prostate Neoplasms 26394192 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 In summary, this study suggests that miR-340 suppresses the tumorigenic potential of prostate cancer cells. Moreover, the decreased miR-340 expression may contribute to the development and progression of prostate cancer through a mechanism that involves HMGN5. Thus, miR340 and its target gene HMGN5 can serve as potentially useful therapeutic candidates for prostate cancer treatment. therapeutic target hsa-mir-340 Prostate Neoplasms 26718483 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Our findings suggest that miR-340 may function as a novel tumor suppressor in PCa through the MDM2-p53 pathway by directly targeting MDM2, which may be a promising miRNA-targeted therapy for PCa. therapeutic target hsa-mir-34a Prostate Neoplasms 25587085 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 The miR-34a-LEF1 axis represents a potential molecular target for novel therapeutic strategies in prostate cancer. therapeutic target hsa-mir-34a Prostate Neoplasms 26313360 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Together, these results provide a new understanding of the biological effects of miR-34a and highlight the clinical potential for miR-34a delivery as a treatment for bone metastatic prostate cancer. therapeutic target hsa-mir-409 Prostate Neoplasms 24963047 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-409-3p/-5p plays an important role in prostate cancer biology by facilitating tumor growth, EMT, and bone metastasis. This finding bears particular translational importance as miR-409-3p/-5p appears to be an attractive biomarker and/or possibly a therapeutic target to treat bone metastatic prostate cancer. therapeutic target hsa-mir-4516 Prostate Neoplasms 25760964 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 two novel miRNAs (miR-4516 and miR-601) were identified that significantly improve prediction of biochemical failure post-salvage radiation therapy compared to clinico-histopathological factors,supporting the use of miRNAs within clinically used predictive models. Both findings warrant further validation studies. therapeutic target hsa-mir-494 Prostate Neoplasms 24644030 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Our results suggested that miR-494-3p might play crucial role in prostate cancer by post-transcriptional regulation to CXCR4 mRNA.MiR-494-3p/CXCR4 pathway may be a potential therapeutic target to prevent prostate cancer progression and metastasis. therapeutic target hsa-mir-601 Prostate Neoplasms 25760964 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 two novel miRNAs (miR-4516 and miR-601) were identified that significantly improve prediction of biochemical failure post-salvage radiation therapy compared to clinico-histopathological factors,supporting the use of miRNAs within clinically used predictive models. Both findings warrant further validation studies. therapeutic target hsa-mir-613 Prostate Neoplasms 26703210 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 In conclusion, our study suggests that miR-613 functions as a tumor suppressor, partially through targeting Fzd7, and is a potential therapeutic target for prostate cancer. therapeutic target hsa-mir-96 Prostate Neoplasms 24633705 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Inhibition of miR-96 caused expression increase of tumor suppressor gene FOXO1, thus manipulating miR-96 expression may be a promising approach in treatment of prostate cancer. therapeutic target hsa-mir-21 Psoriasis 24574341 integumentary system disease DOID:8893 L40.9 D011565 PS177900 HP:0003765 Targeting miR-21 may represent a potential therapeutic option for the treatment of psoriasis. therapeutic target hsa-mir-21 Psoriasis 23506112 integumentary system disease DOID:8893 L40.9 D011565 PS177900 HP:0003765 Though the exact roles of miR-21 in autoimmune diseases have not been fully elucidated, targeting miR-21 may serve as a promising therapy therapeutic target hsa-mir-130b Pulmonary Hypertension 25763574 cardiovascular system disease DOID:6432 I27.20 D006976 PS178600 HP:0002092 miRNAs with established etiologic roles in PH showed context-dependent changes in tissue and circulating levels, which were not consistent across rodent models and human PAH. This suggests different miRNA-dependent mechanisms may contribute to experimental and clinical PH,complicating potential diagnostic and therapeutic applications amenable to these miRNAs. therapeutic target hsa-mir-145 Pulmonary Hypertension 25763574 cardiovascular system disease DOID:6432 I27.20 D006976 PS178600 HP:0002092 miRNAs with established etiologic roles in PH showed context-dependent changes in tissue and circulating levels, which were not consistent across rodent models and human PAH. This suggests different miRNA-dependent mechanisms may contribute to experimental and clinical PH,complicating potential diagnostic and therapeutic applications amenable to these miRNAs. therapeutic target hsa-mir-145 Pulmonary Hypertension 25979327 cardiovascular system disease DOID:6432 I27.20 D006976 PS178600 HP:0002092 AntimiR-145 reduced the degree of pulmonary arteriopathy, reduced the severity of pulmonary hypertension, and reduced the degree of cardiac dysfunction. therapeutic target hsa-mir-17 Pulmonary Hypertension 25763574 cardiovascular system disease DOID:6432 I27.20 D006976 PS178600 HP:0002092 miRNAs with established etiologic roles in PH showed context-dependent changes in tissue and circulating levels, which were not consistent across rodent models and human PAH. This suggests different miRNA-dependent mechanisms may contribute to experimental and clinical PH,complicating potential diagnostic and therapeutic applications amenable to these miRNAs. therapeutic target hsa-mir-199a-2 Pulmonary Hypertension 25389292 cardiovascular system disease DOID:6432 I27.20 D006976 PS178600 HP:0002092 a potential therapeutic approach whereby fenofibrate-induced miR-199a2 expression can ameliorate PH by reduction of ET-1 levels. therapeutic target hsa-mir-204 Pulmonary Hypertension 25763574 cardiovascular system disease DOID:6432 I27.20 D006976 PS178600 HP:0002092 miRNAs with established etiologic roles in PH showed context-dependent changes in tissue and circulating levels, which were not consistent across rodent models and human PAH. This suggests different miRNA-dependent mechanisms may contribute to experimental and clinical PH,complicating potential diagnostic and therapeutic applications amenable to these miRNAs. therapeutic target hsa-mir-21 Pulmonary Hypertension 25763574 cardiovascular system disease DOID:6432 I27.20 D006976 PS178600 HP:0002092 miRNAs with established etiologic roles in PH showed context-dependent changes in tissue and circulating levels, which were not consistent across rodent models and human PAH. This suggests different miRNA-dependent mechanisms may contribute to experimental and clinical PH,complicating potential diagnostic and therapeutic applications amenable to these miRNAs. therapeutic target hsa-mir-210 Pulmonary Hypertension 25851536 cardiovascular system disease DOID:6432 I27.20 D006976 PS178600 HP:0002092 Despite expanding treatment options to ameliorate patients' symptoms, PAH remains a devastating disease with a poor long-term prognosis. therapeutic target hsa-mir-27b Pulmonary Hypertension 25795136 cardiovascular system disease DOID:6432 I27.20 D006976 PS178600 HP:0002092 We showed that miR-27b plays a role endothelial function and NO release and elucidated a potential mechanism by which miR-27b regulates Hsp90-eNOS and NO signaling by modulating PPARγ expression, providing potential therapeutic targets for the treatment of PAH. therapeutic target hsa-mir-29 Pulmonary Hypertension 26487756 cardiovascular system disease DOID:6432 I27.20 D006976 PS178600 HP:0002092 16αOHE promotes the development of HPAH via upregulation of miR-29, which alters molecular and functional indexes of energy metabolism. Antagonism of miR-29 improves in vivo and in vitro features of HPAH and reveals a possible novel therapeutic target. therapeutic target hsa-mir-30c Pulmonary Hypertension 25882492 cardiovascular system disease DOID:6432 I27.20 D006976 PS178600 HP:0002092 These data suggest that the down-regulation of miR-30c accounts for the up-regulation of PDGFRβ expression, and subsequent activation of PDGF signaling results in the hypoxia-induced PASMC proliferation and phenotype switching. Therefore,increasing miR-30c expression levels could be explored as a potential new therapy for hypoxia-induced PAH. therapeutic target hsa-mir-424 Pulmonary Hypertension 25763574 cardiovascular system disease DOID:6432 I27.20 D006976 PS178600 HP:0002092 miRNAs with established etiologic roles in PH showed context-dependent changes in tissue and circulating levels, which were not consistent across rodent models and human PAH. This suggests different miRNA-dependent mechanisms may contribute to experimental and clinical PH,complicating potential diagnostic and therapeutic applications amenable to these miRNAs. therapeutic target hsa-mir-503 Pulmonary Hypertension 25763574 cardiovascular system disease DOID:6432 I27.20 D006976 PS178600 HP:0002092 miRNAs with established etiologic roles in PH showed context-dependent changes in tissue and circulating levels, which were not consistent across rodent models and human PAH. This suggests different miRNA-dependent mechanisms may contribute to experimental and clinical PH,complicating potential diagnostic and therapeutic applications amenable to these miRNAs. therapeutic target hsa-mir-98 Pulmonary Hypertension 26098770 cardiovascular system disease DOID:6432 I27.20 D006976 PS178600 HP:0002092 The results of this study show that PPARγ regulates miR-98 to modulate ET-1 expression and PAEC proliferation. These results further clarify molecular mechanisms by which PPARγ participates in PH pathogenesis and therapy. therapeutic target hsa-mir-155 Rapidly Progressive Glomerulonephritis 24158984 urinary system disease DOID:4776 N01 C538458 MicroRNA-155 a new therapeutic target in crescentic GN. therapeutic target hsa-mir-21 Renal Fibrosis 25541205 urinary system disease DOID:0050855 N26.9 HP:0030760 miR-21 as a potential diagnostic and prognostic marker and therapeutic target for fibrosis diseases. therapeutic target hsa-mir-21 Renal Fibrosis 26376826 urinary system disease DOID:0050855 N26.9 HP:0030760 In summary, our study demonstrates a link between SphK1/S1P and TGF-β-induced miR-21 in renal TECs and may represent a novel therapeutic target in renal fibrosis. therapeutic target hsa-mir-26b Respiratory Syncytial Virus Pneumonia 26222045 disease by infectious agent DOID:1273 J12.1 D018357 This study reveals that RSV infection inhibits TLR4 signaling via up-regulation of miR-26b, which provides a potential therapeutic target for preventing and treating RSV infection. therapeutic target hsa-mir-34a Retinoblastoma 19443717 nervous system disease DOID:768 C69.20 D012175 180200 HP:0009919 miR-34a functions as a tumor suppressor in RB cells and is a potential therapeutic target. therapeutic target hsa-mir-22 Rhabdomyosarcoma 27569217 disease of cellular proliferation DOID:3247 M62.82 D012208 268220 HP:0002859 Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma. therapeutic target hsa-mir-27a Rhabdomyosarcoma 25915942 disease of cellular proliferation DOID:3247 M62.82 D012208 268220 HP:0002859 Study results have demonstrated that miRNA expression signature profiling can be used to classify different RMS subtypes and suggest that miR-27a may have a therapeutic potential in RMS by modulating the expression of retinoic acid receptors. therapeutic target hsa-mir-378 Rhabdomyosarcoma 25427715 disease of cellular proliferation DOID:3247 M62.82 D012208 268220 HP:0002859 MiR-378a-3p may function as a tumour suppressor in RMS and the restoration of its expression would be of therapeutic benefit in RMS. Furthermore, the role of epigenetic modifications in RMS deserves further investigations. therapeutic target hsa-mir-378a Rhabdomyosarcoma 25427715 disease of cellular proliferation DOID:3247 M62.82 D012208 268220 HP:0002859 MiR-378a-3p may function as a tumour suppressor in RMS and the restoration of its expression would be of therapeutic benefit in RMS. Furthermore, the role of epigenetic modifications in RMS deserves further investigations. therapeutic target hsa-mir-106a Rheumatoid Arthritis 27834806 musculoskeletal system disease DOID:7148 M06.9 D001172 180300 HP:0001370 X-linked miRNAs, in the context of sex differences, might provide novel insight into new molecular mechanisms and potential therapeutic targets in RA for disease treatment and prevention therapeutic target hsa-mir-124-1 Rheumatoid Arthritis 21339227 musculoskeletal system disease DOID:7148 M06.9 D001172 180300 HP:0001370 miR-124a is a key miRNA in the post-transcriptional regulatory mechanisms of RA synoviocytes, and has a therapeutic potential. therapeutic target hsa-mir-124-2 Rheumatoid Arthritis 21339227 musculoskeletal system disease DOID:7148 M06.9 D001172 180300 HP:0001370 miR-124a is a key miRNA in the post-transcriptional regulatory mechanisms of RA synoviocytes, and has a therapeutic potential. therapeutic target hsa-mir-124-3 Rheumatoid Arthritis 21339227 musculoskeletal system disease DOID:7148 M06.9 D001172 180300 HP:0001370 miR-124a is a key miRNA in the post-transcriptional regulatory mechanisms of RA synoviocytes, and has a therapeutic potential. therapeutic target hsa-mir-126 Rheumatoid Arthritis 26723864 musculoskeletal system disease DOID:7148 M06.9 D001172 180300 HP:0001370 Our study demonstrated that down-regulation of miR-126 may indirectly inhibit PI3K/AKT signaling pathway to disrupt the imbalance between growth and death of RASFs by targeting PIK3R2, which may be clinically helpful to find therapeutic strategies directed toward miR-126 function for RA patients. therapeutic target hsa-mir-155 Rheumatoid Arthritis 29105307 musculoskeletal system disease DOID:7148 M06.9 D001172 180300 HP:0001370 Hopefully the information obtained will benefit the development of novel therapeutic strategies therapeutic target hsa-mir-221 Rheumatoid Arthritis 27834806 musculoskeletal system disease DOID:7148 M06.9 D001172 180300 HP:0001370 X-linked miRNAs, in the context of sex differences, might provide novel insight into new molecular mechanisms and potential therapeutic targets in RA for disease treatment and prevention therapeutic target hsa-mir-222 Rheumatoid Arthritis 27834806 musculoskeletal system disease DOID:7148 M06.9 D001172 180300 HP:0001370 X-linked miRNAs, in the context of sex differences, might provide novel insight into new molecular mechanisms and potential therapeutic targets in RA for disease treatment and prevention therapeutic target hsa-mir-451 Rheumatoid Arthritis 24574214 musculoskeletal system disease DOID:7148 M06.9 D001172 180300 HP:0001370 These results suggest that miR-451 suppresses neutrophil chemotaxis via p38 MAPK and is a potential target in the treatment of RA. therapeutic target hsa-mir-532 Rheumatoid Arthritis 27834806 musculoskeletal system disease DOID:7148 M06.9 D001172 180300 HP:0001370 X-linked miRNAs, in the context of sex differences, might provide novel insight into new molecular mechanisms and potential therapeutic targets in RA for disease treatment and prevention therapeutic target hsa-mir-92a Rheumatoid Arthritis 27834806 musculoskeletal system disease DOID:7148 M06.9 D001172 180300 HP:0001370 X-linked miRNAs, in the context of sex differences, might provide novel insight into new molecular mechanisms and potential therapeutic targets in RA for disease treatment and prevention therapeutic target hsa-mir-98 Rheumatoid Arthritis 27834806 musculoskeletal system disease DOID:7148 M06.9 D001172 180300 HP:0001370 X-linked miRNAs, in the context of sex differences, might provide novel insight into new molecular mechanisms and potential therapeutic targets in RA for disease treatment and prevention therapeutic target hsa-mir-1290 Rhinosinusitis 26337346 B48.1 By comparing miRNA gene expression patterns in 3 types of CRS patients, we have been able to identify candidate miRNAs that might mediate the core pathogenesis of CRS through regulating dendritic cells. These miRNAs could serve as potential therapeutic targets for CRS. therapeutic target hsa-mir-137 Schizophrenia 24866554 disease of mental health DOID:5419 F20 D012559 181500 HP:0100753 We have identified a miR-137-regulated protein network that contributes to our understanding of the molecular basis of schizophrenia and provides clues for future research into psychopharmacological treatments for schizophrenia. therapeutic target hsa-mir-181b Schizophrenia 24694668 disease of mental health DOID:5419 F20 D012559 181500 HP:0100753 A preliminary analysis of association between the down-regulation of microRNA-181b expression and symptomatology improvement in schizophrenia patients before and after antipsychotic treatment. therapeutic target hsa-mir-30a Schizophrenia 28072411 disease of mental health DOID:5419 F20 D012559 181500 HP:0100753 The early growth response protein 1-miR-30a-5p-neurogenic differentiation factor 1 axis as a novel biomarker for schizophrenia diagnosis and treatment monitoring. therapeutic target hsa-mir-130b Scleroderma, Systemic 25547017 musculoskeletal system disease DOID:418 M34 D012595 181750 miR-130b played important profibrotic roles in SSc fibrosis, and enhanced TGF-β signaling through negative regulation of PPARγ expression. MiR-130b may be a potential therapeutic target in SSc fibrosis. therapeutic target hsa-mir-21 Scleroderma, Systemic 23506112 musculoskeletal system disease DOID:418 M34 D012595 181750 Though the exact roles of miR-21 in autoimmune diseases have not been fully elucidated, targeting miR-21 may serve as a promising therapy therapeutic target hsa-mir-29a Scleroderma, Systemic 25549087 musculoskeletal system disease DOID:418 M34 D012595 181750 miR-29a repressed TAB1-mediated TIMP-1 production in dermal fibroblasts, demonstrating that miR-29a may be a therapeutic target in SSc. therapeutic target hsa-mir-29a Scleroderma, Systemic 20201077 musculoskeletal system disease DOID:418 M34 D012595 181750 These data add the posttranscriptional regulation of collagens by miR-29a as a novel aspect to the fibrogenesis of SSc and suggest miR-29a as a potential therapeutic target. therapeutic target hsa-mir-195 Sepsis 26704614 A41.9 D018805 HP:0100806 Silencing of miR-195 reduced multiple-organ injury and improved the survival in sepsis, and the protective effects of miR-195 inhibition were associated with upregulation of Bcl-2, Sirt1, and Pim-1. Thus, inhibition of miR-195 may represent a new therapeutic approach for sepsis. therapeutic target hsa-mir-19a Sepsis 26017478 A41.9 D018805 HP:0100806 Our study demonstrated that miR-19a and CD22 comprised a feedback loop for B cell response in sepsis, providing a potential therapeutic target to recover the immune homeostasis. therapeutic target hsa-mir-16 Short Bowel Syndrome 29364022 gastrointestinal system disease DOID:10605 D012778 615237 Modulation of these pathways may represent a new therapeutic option for the management of short bowel syndrome therapeutic target hsa-mir-301a Sickle Cell Disease 26460070 D57 D000755 603903 Our studies provide a potential therapeutic approach whereby fenofibrate-induced miR-301a/miR-454 expression can ameliorate PH and lung fibrosis by reduction in ET-1 and PAI-1 levels in SCD. therapeutic target hsa-mir-454 Sickle Cell Disease 26460070 D57 D000755 603903 Our studies provide a potential therapeutic approach whereby fenofibrate-induced miR-301a/miR-454 expression can ameliorate PH and lung fibrosis by reduction in ET-1 and PAI-1 levels in SCD. therapeutic target hsa-mir-378b Skin Injury 26313654 In conclusion, our results demonstrate miR-378b promote keratinocytes differentiation by targeting NKX3.1. Manipulation of miR-378b may afford a new strategy to clinic treatment of skin injury and repair. therapeutic target hsa-mir-383 Skin Neoplasms 26261078 disease of cellular proliferation DOID:4159 C44.90 D012878 HP:0008069 these studies suggest that STAT3 may be a potential target for both the prevention and treatment of human skin cancer. therapeutic target hsa-mir-210 Soft Tissue Sarcoma 24927770 C49.9 D012509 HP:0030448 Here we provide evidence for the miRNA mediated regulation of HIF3α by hypoxia responsive miRNAs in STS, which may help to tightly regulate and fine-tune the hypoxic response. This provides a better insight into the mechanisms underlying the hypoxic response in STS and may ultimately yield information on novel prognostic and predictive markers or targets for treatment. therapeutic target hsa-mir-485 Soft Tissue Sarcoma 24927770 C49.9 D012509 HP:0030448 Here we provide evidence for the miRNA mediated regulation of HIF3α by hypoxia responsive miRNAs in STS, which may help to tightly regulate and fine-tune the hypoxic response. This provides a better insight into the mechanisms underlying the hypoxic response in STS and may ultimately yield information on novel prognostic and predictive markers or targets for treatment. therapeutic target hsa-mir-142 Spinal Cord Injuries 26318123 S34.139A D013119 In this article we suggest, for the first time, imitating sciatic nerve conditioning injury, thereby enhancing central regeneration of primary sensory neurons via interfering with the congenerous upstream regulator AC9 of the 3 above-mentioned signal pathways. We hope to provide a new clinical treatment strategy for the recovery of sensory function in SCI patients. therapeutic target hsa-mir-210 Spinal Cord Injuries 24732841 S34.139A D013119 The administration of miR-210 promoted angiogenesis and astrogliosis, and improved functional recovery after SCI compared with the noninjected controls. therapeutic target hsa-mir-383 Spinal Cord Injuries 28365701 S34.139A D013119 Suppression of MicroRNA-383 Enhances Therapeutic Potential of Human Bone-Marrow-Derived Mesenchymal Stem Cells in Treating Spinal Cord Injury via GDNF. therapeutic target hsa-mir-486 Spinal Cord Injuries 22466292 S34.139A D013119 MicroRNA 486 is a potentially novel target for the treatment of spinal cord injury. therapeutic target hsa-mir-206 Spinal Muscular Atrophy 26030275 nervous system disease DOID:12377 G12.9 D009134 253300 HP:0007269 We speculate that early modulation of miRNA-206 expression might delay SMA neurodegenerative pathway and that miRNA-206 could be an innovative, still relatively unexplored,therapeutic target for SMA. therapeutic target hsa-mir-184 Squamous Cell Carcinoma 19033458 disease of cellular proliferation DOID:1749 D002294 Blockage of miR-205 activity with an antagomir or via ectopic expression of miR-184 could be novel therapeutic approaches for treating aggressive SCCs. therapeutic target hsa-mir-205 Squamous Cell Carcinoma 19033458 disease of cellular proliferation DOID:1749 D002294 Blockage of miR-205 activity with an antagomir or via ectopic expression of miR-184 could be novel therapeutic approaches for treating aggressive SCCs. therapeutic target hsa-mir-494 Squamous Cell Carcinoma 26090866 disease of cellular proliferation DOID:1749 D002294 We conclude that the inhibition of tumor aggressiveness in HNC-TICs by SB was mediated by up-regulation miR-494, suggesting that SB would be a valuable anti-cancer drug for treatment of HNC. therapeutic target hsa-mir-126 Squamous Cell Carcinoma, Cerevial 24641388 endocrine system disease DOID:5531 Six MiRNAs with predicted tumor-associated target genes encoding proteins that are known to be involved in cell adhesion, cytoskeletal remodeling,cell proliferation, cell migration, and apoptosis were identified. These findings suggest that a panel of miRNAs may regulate multiple and various steps of the metastasis cascade by targeting metastasis-associated genes. Since these six miRNAs are predicted to target tumor-associated genes, it is likely that they contribute to the metastatic potential of cervical cancer and may aid in prognosis or molecular therapy. therapeutic target hsa-mir-144 Squamous Cell Carcinoma, Cerevial 24641388 endocrine system disease DOID:5531 Six MiRNAs with predicted tumor-associated target genes encoding proteins that are known to be involved in cell adhesion, cytoskeletal remodeling,cell proliferation, cell migration, and apoptosis were identified. These findings suggest that a panel of miRNAs may regulate multiple and various steps of the metastasis cascade by targeting metastasis-associated genes. Since these six miRNAs are predicted to target tumor-associated genes, it is likely that they contribute to the metastatic potential of cervical cancer and may aid in prognosis or molecular therapy. therapeutic target hsa-mir-323 Squamous Cell Carcinoma, Cerevial 24641388 endocrine system disease DOID:5531 Six MiRNAs with predicted tumor-associated target genes encoding proteins that are known to be involved in cell adhesion, cytoskeletal remodeling,cell proliferation, cell migration, and apoptosis were identified. These findings suggest that a panel of miRNAs may regulate multiple and various steps of the metastasis cascade by targeting metastasis-associated genes. Since these six miRNAs are predicted to target tumor-associated genes, it is likely that they contribute to the metastatic potential of cervical cancer and may aid in prognosis or molecular therapy. therapeutic target hsa-mir-490 Squamous Cell Carcinoma, Cerevial 24641388 endocrine system disease DOID:5531 Six MiRNAs with predicted tumor-associated target genes encoding proteins that are known to be involved in cell adhesion, cytoskeletal remodeling,cell proliferation, cell migration, and apoptosis were identified. These findings suggest that a panel of miRNAs may regulate multiple and various steps of the metastasis cascade by targeting metastasis-associated genes. Since these six miRNAs are predicted to target tumor-associated genes, it is likely that they contribute to the metastatic potential of cervical cancer and may aid in prognosis or molecular therapy. therapeutic target hsa-mir-657 Squamous Cell Carcinoma, Cerevial 24641388 endocrine system disease DOID:5531 Six MiRNAs with predicted tumor-associated target genes encoding proteins that are known to be involved in cell adhesion, cytoskeletal remodeling,cell proliferation, cell migration, and apoptosis were identified. These findings suggest that a panel of miRNAs may regulate multiple and various steps of the metastasis cascade by targeting metastasis-associated genes. Since these six miRNAs are predicted to target tumor-associated genes, it is likely that they contribute to the metastatic potential of cervical cancer and may aid in prognosis or molecular therapy. therapeutic target hsa-mir-96 Squamous Cell Carcinoma, Cerevial 24641388 endocrine system disease DOID:5531 Six MiRNAs with predicted tumor-associated target genes encoding proteins that are known to be involved in cell adhesion, cytoskeletal remodeling,cell proliferation, cell migration, and apoptosis were identified. These findings suggest that a panel of miRNAs may regulate multiple and various steps of the metastasis cascade by targeting metastasis-associated genes. Since these six miRNAs are predicted to target tumor-associated genes, it is likely that they contribute to the metastatic potential of cervical cancer and may aid in prognosis or molecular therapy. therapeutic target hsa-mir-101 Squamous Cell Carcinoma, Esophageal 26556718 disease of cellular proliferation DOID:3748 C562729 Overexpression of miR-101 in ESCC inhibits proliferation and metastasis. Therefore, the miR-101/COX-2 pathway might be a therapeutic target in ESCC. therapeutic target hsa-mir-101 Squamous Cell Carcinoma, Esophageal 26530100 disease of cellular proliferation DOID:3748 C562729 Taken together, our findings revealed a new post-transcriptional mechanism by which CSE regulated COX-2 expression to favor cancer cell proliferation, suggesting miR-101-3p as a potential biomarker and therapeutic target for smoke-related ESCC. therapeutic target hsa-mir-1291 Squamous Cell Carcinoma, Esophageal 26324125 disease of cellular proliferation DOID:3748 C562729 Our results demonstrated the importance of miR-1291 in targeting MUC1 for the regulation of esophagus cancer growth, invasion and apoptosis, and may be helpful for developing new targets for early diagnosis or new therapeutic targets for ESCC. therapeutic target hsa-mir-1294 Squamous Cell Carcinoma, Esophageal 25925090 disease of cellular proliferation DOID:3748 C562729 Down-regulation of miR-1294 correlates with poor prognosis of ESCC. It's partially due to the reduced function of c-MYC. This study may give insight into the understanding of pathogenesis of esophageal cancer and provide evidence for diagnosis and treatment of esophageal cancer. therapeutic target hsa-mir-130b Squamous Cell Carcinoma, Esophageal 25637514 disease of cellular proliferation DOID:3748 C562729 miR-130b plays an oncogenic role in ESCC cells by repressing PTEN expression and Akt phosphorylation, which would be helpful in developing miRNA-based treatments for ESCC. therapeutic target hsa-mir-145 Squamous Cell Carcinoma, Esophageal 26445467 disease of cellular proliferation DOID:3748 C562729 Combined qPCR of the 4 miRNAs provides the possibility of ESCC neo-CRT response prediction, which may facilitate individualized ESCC treatment.Further prospective validation in larger independent cohorts is necessary to fully assess its predictive power. therapeutic target hsa-mir-152 Squamous Cell Carcinoma, Esophageal 26445467 disease of cellular proliferation DOID:3748 C562729 Combined qPCR of the 4 miRNAs provides the possibility of ESCC neo-CRT response prediction, which may facilitate individualized ESCC treatment.Further prospective validation in larger independent cohorts is necessary to fully assess its predictive power. therapeutic target hsa-mir-186 Squamous Cell Carcinoma, Esophageal 26568291 disease of cellular proliferation DOID:3748 C562729 Our findings established that the miR-186 has a suppressive role in ESCC progression via SKP2-mediated pathway, and this implies that miR-186 could be a potential therapeutic target for ESCC. therapeutic target hsa-mir-192 Squamous Cell Carcinoma, Esophageal 26339371 disease of cellular proliferation DOID:3748 C562729 These data suggest an important role of miR-192 in the molecular etiology of ESCC and implicate the potential application of miR-192 in ESCC therapy. therapeutic target hsa-mir-193b Squamous Cell Carcinoma, Esophageal 26445467 disease of cellular proliferation DOID:3748 C562729 Combined qPCR of the 4 miRNAs provides the possibility of ESCC neo-CRT response prediction, which may facilitate individualized ESCC treatment.Further prospective validation in larger independent cohorts is necessary to fully assess its predictive power. therapeutic target hsa-mir-21 Squamous Cell Carcinoma, Esophageal 25400316 disease of cellular proliferation DOID:3748 C562729 miR-21 may be a potential therapeutic target in management of ESCC. therapeutic target hsa-mir-21 Squamous Cell Carcinoma, Esophageal 29568234 disease of cellular proliferation DOID:3748 C562729 MiR-21 is a potential novel target for developing specific treatment interventions in ESCC in future therapeutic target hsa-mir-218 Squamous Cell Carcinoma, Esophageal 25482044 disease of cellular proliferation DOID:3748 C562729 miR-218 regulated the expression of phosphorylated PI3K, AKT and mTOR, which may contribute to suppressed tumor growth of ESCC and enhanced sensitivity of ESCC cells. These findings suggest that miR-218 is a potential therapeutic agent for the treatment of ESCC. therapeutic target hsa-mir-34a Squamous Cell Carcinoma, Esophageal 26523671 disease of cellular proliferation DOID:3748 C562729 In summary, our findings indicated that the intrinsic expression of miR-34a was relatively low and was expressed differently among different p53 backgrounds and ADR treatment times. The anti-tumor effect of miR-34a was primarily dependent on the regulation of SIRT1 and p53/p21 protein,not apoptosis-associated proteins. therapeutic target hsa-mir-376a Squamous Cell Carcinoma, Esophageal 26445467 disease of cellular proliferation DOID:3748 C562729 Combined qPCR of the 4 miRNAs provides the possibility of ESCC neo-CRT response prediction, which may facilitate individualized ESCC treatment.Further prospective validation in larger independent cohorts is necessary to fully assess its predictive power. therapeutic target hsa-mir-382 Squamous Cell Carcinoma, Esophageal 26078564 disease of cellular proliferation DOID:3748 C562729 miR-382 levels are reverse-correlated with ESCC poor outcomes,suggesting that miR-382 could be a potential predictive biomarker for both prognosis and treatment of ESCC. therapeutic target hsa-let-7a Squamous Cell Carcinoma, Head and Neck 26323893 disease of cellular proliferation DOID:5520 C76.0 C535575 In conclusion, we identified a subset of microRNAs that were differentially expressed in ALDH1-high subpopulation, providing new microRNA targets to study dysregulation of HNSCC-initiating cells and develop therapeutic strategies aimed at eradicating the tumorigenic stem cells in HNSCC. therapeutic target hsa-mir-10b Squamous Cell Carcinoma, Head and Neck 19540661 disease of cellular proliferation DOID:5520 C76.0 C535575 tumor suppresser; suppressed cell invasion and led to cell cycle arrest and apoptosis; potential theraeutic target therapeutic target hsa-mir-138 Squamous Cell Carcinoma, Head and Neck 24747032 disease of cellular proliferation DOID:5520 C76.0 C535575 MicroRNA-138: a potential therapeutic target for head and neck squamous cell carcinoma (HNSCC). therapeutic target hsa-mir-147b Squamous Cell Carcinoma, Head and Neck 26323893 disease of cellular proliferation DOID:5520 C76.0 C535575 In conclusion, we identified a subset of microRNAs that were differentially expressed in ALDH1-high subpopulation, providing new microRNA targets to study dysregulation of HNSCC-initiating cells and develop therapeutic strategies aimed at eradicating the tumorigenic stem cells in HNSCC. therapeutic target hsa-mir-21 Squamous Cell Carcinoma, Head and Neck 26690371 disease of cellular proliferation DOID:5520 C76.0 C535575 miR-21 cooperates with CDK5 to promote EMT and invasion in HNSCC.This finding suggests that CDK5 may be an important cofactor for targeting when designing metastasis-blocking therapy by targeting STAT3/miR-21 axis with STAT3 inhibitor or miR-21 antisense oligonucleotide. This is the first demonstration of the novel role of STAT3/miR-21 axis and CDK5/CDK5R1 (p35) in metastasis of HNSCC. therapeutic target hsa-mir-221 Squamous Cell Carcinoma, Head and Neck 26464363 disease of cellular proliferation DOID:5520 C76.0 C535575 Expression of mirR221/222 is correlated to cell cycle regulation,carcinogenesis, and chemoresistance. Detailed knowledge of the molecular mechanisms and effects ofmiRNAs is important for identifying miRNAs as cancermarkers, as well as for increasing the efficiency of cancer therapeutics. therapeutic target hsa-mir-222 Squamous Cell Carcinoma, Head and Neck 26464363 disease of cellular proliferation DOID:5520 C76.0 C535575 Expression of mirR221/222 is correlated to cell cycle regulation,carcinogenesis, and chemoresistance. Detailed knowledge of the molecular mechanisms and effects ofmiRNAs is important for identifying miRNAs as cancermarkers, as well as for increasing the efficiency of cancer therapeutics. therapeutic target hsa-mir-30a Squamous Cell Carcinoma, Head and Neck 26472042 disease of cellular proliferation DOID:5520 C76.0 C535575 Alcohol induces the dysregulation of miR-30a and miR-934, which may play crucial roles in HNSCC pathogenesis and progression. Future investigation of the alcohol-mediated pathways effecting these transformations will prove valuable for furthering the understanding and treatment of alcohol-associated HNSCC. therapeutic target hsa-mir-424 Squamous Cell Carcinoma, Head and Neck 26323893 disease of cellular proliferation DOID:5520 C76.0 C535575 In conclusion, we identified a subset of microRNAs that were differentially expressed in ALDH1-high subpopulation, providing new microRNA targets to study dysregulation of HNSCC-initiating cells and develop therapeutic strategies aimed at eradicating the tumorigenic stem cells in HNSCC. therapeutic target hsa-mir-6836 Squamous Cell Carcinoma, Head and Neck 26323893 disease of cellular proliferation DOID:5520 C76.0 C535575 In conclusion, we identified a subset of microRNAs that were differentially expressed in ALDH1-high subpopulation, providing new microRNA targets to study dysregulation of HNSCC-initiating cells and develop therapeutic strategies aimed at eradicating the tumorigenic stem cells in HNSCC. therapeutic target hsa-mir-6873 Squamous Cell Carcinoma, Head and Neck 26323893 disease of cellular proliferation DOID:5520 C76.0 C535575 In conclusion, we identified a subset of microRNAs that were differentially expressed in ALDH1-high subpopulation, providing new microRNA targets to study dysregulation of HNSCC-initiating cells and develop therapeutic strategies aimed at eradicating the tumorigenic stem cells in HNSCC. therapeutic target hsa-mir-7152 Squamous Cell Carcinoma, Head and Neck 26323893 disease of cellular proliferation DOID:5520 C76.0 C535575 In conclusion, we identified a subset of microRNAs that were differentially expressed in ALDH1-high subpopulation, providing new microRNA targets to study dysregulation of HNSCC-initiating cells and develop therapeutic strategies aimed at eradicating the tumorigenic stem cells in HNSCC. therapeutic target hsa-mir-934 Squamous Cell Carcinoma, Head and Neck 26472042 disease of cellular proliferation DOID:5520 C76.0 C535575 Alcohol induces the dysregulation of miR-30a and miR-934, which may play crucial roles in HNSCC pathogenesis and progression. Future investigation of the alcohol-mediated pathways effecting these transformations will prove valuable for furthering the understanding and treatment of alcohol-associated HNSCC. therapeutic target hsa-mir-107 Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal 26822763 disease of cellular proliferation DOID:2876 NEAT1 plays an oncogenic role in the tumorigenesis of LSCC and may serve as a potential target for therapeutic intervention. therapeutic target hsa-mir-205 Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal 26515287 disease of cellular proliferation DOID:2876 These findings help us to better elucidate the molecular mechanisms of LSCC progression and provide a new theoretical basis to further investigate miR-205 as a potential biomarker and a promising approach for LSCC treatment. therapeutic target hsa-mir-206 Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal 26221902 disease of cellular proliferation DOID:2876 Altogether, our results identify a crucial tumour suppressive role of miR-206 in LSCC growth, at least partly via up-regulation of cyclinD2 protein levels, and suggest that miR-206 might be a candidate prognostic predictor or an anticancer therapeutic target for LSCC patients. therapeutic target hsa-mir-340 Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal 26656176 disease of cellular proliferation DOID:2876 Taken together, these data suggest that miR-340 impedes LSCC progression by targeting EZH2 with the possible mechanism to enhance the expression of anti-oncogene p27 and suppress PI3K/Akt activation, providing a novel target and a potential therapeutic pathway against LSCC. therapeutic target hsa-mir-519a Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal 24300127 disease of cellular proliferation DOID:2876 MicroRNA-519a may function as a tumour suppressor by inhibiting HuR expression, and may serve as a therapeutic target for laryngeal squamous cell carcinoma. therapeutic target hsa-mir-183 Squamous Cell Carcinoma, Lung 25813410 disease of cellular proliferation DOID:3907 C34.91 This study describes the use of deep sequencing for comprehensive profiling of microRNAs in lung squamous cell carcinoma. The identified microRNA signatures may provide biomarkers for early detection, subclassification, and potential therapeutic targets of lung squamous cell carcinoma. This study also provides some insights into the molecular mechanism underlying the development and progression of lung squamous cell carcinoma, which may prove helpful for early diagnosis and treatment of the disease. therapeutic target hsa-mir-206 Squamous Cell Carcinoma, Lung 25522678 disease of cellular proliferation DOID:3907 C34.91 the novel molecular mechanisms of lung-SCC oncogenesis and new therapeutic approaches for the treatment of this disease. therapeutic target hsa-mir-218 Squamous Cell Carcinoma, Lung 25813410 disease of cellular proliferation DOID:3907 C34.91 This study describes the use of deep sequencing for comprehensive profiling of microRNAs in lung squamous cell carcinoma. The identified microRNA signatures may provide biomarkers for early detection, subclassification, and potential therapeutic targets of lung squamous cell carcinoma. This study also provides some insights into the molecular mechanism underlying the development and progression of lung squamous cell carcinoma, which may prove helpful for early diagnosis and treatment of the disease. therapeutic target hsa-mir-425 Squamous Cell Carcinoma, Lung 25813410 disease of cellular proliferation DOID:3907 C34.91 This study describes the use of deep sequencing for comprehensive profiling of microRNAs in lung squamous cell carcinoma. The identified microRNA signatures may provide biomarkers for early detection, subclassification, and potential therapeutic targets of lung squamous cell carcinoma. This study also provides some insights into the molecular mechanism underlying the development and progression of lung squamous cell carcinoma, which may prove helpful for early diagnosis and treatment of the disease. therapeutic target hsa-mir-1254 Squamous Cell Carcinoma, Oral 28161631 disease of cellular proliferation DOID:0050866 miR-1254 is a potential target for the treatment of OSCCs therapeutic target hsa-mir-143 Squamous Cell Carcinoma, Oral 25953639 disease of cellular proliferation DOID:0050866 miR-143 could exert significantly suppressive effects on the ability of migration and invasion in OSCC cell lines, and the mechanism of this might be related to the activity of phospho-c-met though the CD44 v3/HGF signal. miR-143 could thus provide new applications for the treatment of OSCC. therapeutic target hsa-mir-21 Squamous Cell Carcinoma, Oral 25514838 disease of cellular proliferation DOID:0050866 STAT3/miR-21 axis could be a candidate therapeutic target for OSCC chemoresistance. therapeutic target hsa-mir-222 Squamous Cell Carcinoma, Oral 25474084 disease of cellular proliferation DOID:0050866 down-regulation of miR-222 could enhance the chemosensitivity of human OSCC cells to CDDP, and that the combination of As-miR-222 and CDDP could be an effective therapeutic strategy by boosting the expression of PUMA for controlling the growth of OSCC. therapeutic target hsa-mir-29b Squamous Cell Carcinoma, Oral 25435433 disease of cellular proliferation DOID:0050866 MiR-29b acts as an oncomir, promoting cell migration through CX3CL1 suppression, and could be a potential therapeutic target for preventing OSCC progression. therapeutic target hsa-mir-32 Squamous Cell Carcinoma, Oral 25472588 disease of cellular proliferation DOID:0050866 miR-32 may act as a tumor suppressor in OSCC and could serve as a novel therapeutic agent for miR-based therapy. therapeutic target hsa-mir-375 Squamous Cell Carcinoma, Oral 26474386 disease of cellular proliferation DOID:0050866 Our findings provide novel insights into the involvement of microRNAs in progression of inflammation to carcinoma and suggest a potential early-stage biomarker or therapy target for oral carcinoma. therapeutic target hsa-mir-429 Squamous Cell Carcinoma, Oral 25640197 disease of cellular proliferation DOID:0050866 the tumor suppressor role of miR-429 in OSCC,and may provide a potential therapeutic target that warrants further investigation. therapeutic target hsa-mir-433 Squamous Cell Carcinoma, Oral 25962939 disease of cellular proliferation DOID:0050866 Our data suggest that miR-433 exerts its tumor suppressor function by targeting HDAC6, leading to the inhibition of OSCC cell growth, invasion and migration, which suggest that miR-433 may be potential target for diagnostic and therapeutic applications in OSCC. therapeutic target hsa-mir-199a Squamous Cell Carcinoma, Skin or Unspecific 25400809 disease of cellular proliferation DOID:3151 C44.92 HP:0006739 increased expression of endogenous mature miR-199a might prevent the growth and migration of human cSCC via decreasing the expression of CD44 and regulating the interaction between CD44 and Ezrin, which may provide a potentially important therapeutic target for human cSCC. therapeutic target hsa-mir-20a Squamous Cell Carcinoma, Skin or Unspecific 25019203 disease of cellular proliferation DOID:3151 C44.92 HP:0006739 Our study demonstrated that miR-20a is involved in the tumor inhibition of CSCC by directly targeting LIMK1 gene. This finding provides potential novel strategies for therapeutic interventions of CSCC. therapeutic target hsa-mir-27a Squamous Cell Carcinoma, Skin or Unspecific 23963114 disease of cellular proliferation DOID:3151 C44.92 HP:0006739 These findings identify miR-27a* as a functional star sequence that exhibits novel coordinated regulation of the EGFR pathway in solid tumors and potentially represents a novel therapeutic option. therapeutic target hsa-mir-31 Squamous Cell Carcinoma, Skin or Unspecific 25068518 disease of cellular proliferation DOID:3151 C44.92 HP:0006739 miR-31 regulates cancer-associated phenotypes of cSCC and identify miR-31 as a potential target for cSCC treatment. therapeutic target hsa-mir-26b Squamous Cell Carcinoma, Tongue 25483152 disease of cellular proliferation DOID:0050865 C02.9 miR-26b serves as a tumor suppressor by targeting COX-2 and calls for the use of miR-26b as a potential therapeutic tool for human tongue squamous cell carcinoma, where COX-2 is often hyperactivated. therapeutic target hsa-mir-29a Squamous Cell Carcinoma, Tongue 25127200 disease of cellular proliferation DOID:0050865 C02.9 miR-29b functions as a tumor suppressor in TSCC, and the miR-29b/Sp1/PTEN/AKT axis might represent a potential therapeutic target for TSCC intervention. therapeutic target hsa-mir-34a Squamous Cell Carcinoma, Tongue 25268950 disease of cellular proliferation DOID:0050865 C02.9 miR-34a plays an important role in lymph node metastases of TSCC through targeting MMP9 and MMP14 and may have potential applications in prognosis prediction and gene therapy for lymph node metastases of TSCC patients. therapeutic target hsa-mir-107 Stroke 26294080 I64 D020521 601367 HP:0001297 This process might be a protective mechanism for ischemia-induced cerebral injury and miR-107 might be used as a novel tool in stroke treatment. therapeutic target hsa-mir-124 Stroke 27031810 I64 D020521 601367 HP:0001297 These neuroprotective and anti-inflammatory effects of the early miR-124 treatment were pronounced during the first week with Arg-1. therapeutic target hsa-mir-181b Stroke, Ischemic 23900885 I63.9 HP:0002140 These results suggest that the downregulated miR-181b induces neuroprotection against ischemic injury through negatively regulating HSPA5 and UCHL1 protein levels, providing a potential therapeutic target for ischemic stroke. therapeutic target hsa-mir-21 Systemic Lupus Erythematosus 23506112 musculoskeletal system disease DOID:9074 M32.9 D008180 152700 HP:0002725 Though the exact roles of miR-21 in autoimmune diseases have not been fully elucidated, targeting miR-21 may serve as a promising therapy therapeutic target hsa-mir-219 Tauopathy 25574843 nervous system disease DOID:680 D024801 silencing of tau by miR-219 is an ancient regulatory mechanism that may become perturbed during neurofibrillary degeneration and suggest that this regulatory pathway may be useful for developing therapeutics for tauopathies. therapeutic target hsa-mir-367 Testicular Germ Cell Tumor 25046619 disease of cellular proliferation DOID:5557 C563236 273300 miR-371a-3p allows for better identification of testicular germ cell tumor than α1-fetoprotein and human chorionic gonadotropin. It could be helpful for clinically managing testicular germ cell tumor, especially for monitoring surveillance therapy and residual disease after chemotherapy. therapeutic target hsa-mir-371a Testicular Germ Cell Tumor 25046619 disease of cellular proliferation DOID:5557 C563236 273300 miR-371a-3p allows for better identification of testicular germ cell tumor than α1-fetoprotein and human chorionic gonadotropin. It could be helpful for clinically managing testicular germ cell tumor, especially for monitoring surveillance therapy and residual disease after chemotherapy. therapeutic target hsa-mir-372 Testicular Germ Cell Tumor 25046619 disease of cellular proliferation DOID:5557 C563236 273300 miR-371a-3p allows for better identification of testicular germ cell tumor than α1-fetoprotein and human chorionic gonadotropin. It could be helpful for clinically managing testicular germ cell tumor, especially for monitoring surveillance therapy and residual disease after chemotherapy. therapeutic target hsa-mir-373 Testicular Germ Cell Tumor 25046619 disease of cellular proliferation DOID:5557 C563236 273300 miR-371a-3p allows for better identification of testicular germ cell tumor than α1-fetoprotein and human chorionic gonadotropin. It could be helpful for clinically managing testicular germ cell tumor, especially for monitoring surveillance therapy and residual disease after chemotherapy. therapeutic target hsa-mir-126 Thrombosis 26659078 cardiovascular system disease DOID:0060903 D013927 Overexpressed miR-126 inhibits apoptosis of VECs and DVT through targeting the anti-apoptotic pathway PI3K/Akt via PIK3R2.GENERAL SIGNIFICANCE: These findings may provide a new target for the therapy of DVT. therapeutic target hsa-mir-148a Thrombosis 26516227 cardiovascular system disease DOID:0060903 D013927 Our work suggests that modulating miR-148a expression is a potential therapeutic approach for thrombosis. therapeutic target hsa-mir-483 Thrombosis 26801758 cardiovascular system disease DOID:0060903 D013927 miR-483-3p is upregulated in EPCs from DVT patients, and it targets SRF to decrease EPCs migration and tube formation and increase apoptosis in vitro, while decrease EPCs homing and thrombus resolution in vivo. MiR-483-3p is a potential therapeutic target in DVT treatment. therapeutic target hsa-mir-100 Thyroid Neoplasms 24785011 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 (131)I treatment inhibited the expression of miR-100, which modulated RBSP3 in FTC cells. The new mechanism of suppression of the proliferation of FTC cells by I described here might occur through the downregulation of miR-100. therapeutic target hsa-mir-106b Thyroid Neoplasms 26317551 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 In summary, our findings not only provide new insights into molecular mechanism associated with C1orf24 overexpression in thyroid carcinomas but also show that C1orf24 might increase proliferation and cell migration. Thus, decreasing C1orf24 levels, by restoring miR-106b function, may have therapeutic implications. therapeutic target hsa-mir-146b Thyroid Neoplasms 25547151 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 miR-146b-5p induces EMT and may promote PTC metastasis through the regulation of Wnt/β-catenin signaling, and suggest novel potential therapeutic targets for the treatment of PTC. therapeutic target hsa-mir-204 Thyroid Neoplasms 26406941 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 Our findings suggest that miR-204 plays a protective role by inhibiting thyroid cancer cell proliferation, and may identify new targets for anti-cancer treatment. therapeutic target hsa-mir-20a Thyroid Neoplasms 24858712 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 To our knowledge, this is the first study to demonstrate that miR-20a plays a role as a tumor suppressor in thyroid cancer cells and targets LIMK1. Our findings suggest the upregulated expression of miR-20a in anaplastic thyroid cancer counteracts thyroid cancer progression and may have therapeutic potential. therapeutic target hsa-mir-339 Thyroid Neoplasms 25404690 disease of cellular proliferation DOID:1781 C73 D013964 188550 HP:0100031 hNIS-mediated RAIU can be modulated by miRs, and that the same miRs may also play roles in the development or maintenance of thyroid malignancy. Accordingly, miRs may serve as emerging targets to halt the progression of thyroid cancer and to enhance the efficacy of radioiodine therapy. therapeutic target hsa-mir-21 Thyroid-Associated Ophthalmopathy 25873777 D049970 The present study shows that miR-21 regulates cell proliferation,apoptosis, and differentiation in orbital fibroblasts from TAO, and acts as amediator in TGF-β1-induced collagen production. These data predict a close association between miR-21 and orbital muscle fibrosis, and provide a novel therapeutic target for TAO. therapeutic target hsa-mir-155 Uremic Neuropathy 26267685 urinary system disease DOID:4675 Serum miRNA-155 and IL-6 in uremic dialysis patients were remarkably increased compared to healthy objects. Serum miRNA-155 was positively correlated with the level of IL-6 as well as hs-CRP, while miR-155 was negatively correlated with HDL and albumin. Alprostadil could ameliorate the inflammatory conditions of uremic dialysis patients by inhibition of the IL-6 expression. Serum miRNA-155 may be a novel target for the treatment of uremic dialysis patients. therapeutic target hsa-mir-145 Urinary Bladder Cancer 29723992 urinary system disease DOID:11054 C67 D001749 109800 MicroRNAs in Smoking-Related Carcinogenesis: Biomarkers, Functions, and Therapy. therapeutic target hsa-mir-200c Uterine Carcinosarcoma 28620240 disease of cellular proliferation DOID:6171 D06.9 HP:0010784 miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas. therapeutic target hsa-mir-197 Uterine Leiomyoma 25960207 D25.9 D007889 150699 HP:0000131 In this study, the data showed that miR-197 could play an anti-oncogenic role in human uterus leiomyoma cells, and cooperate with LNG on the cell proliferation and apoptosis, which suggested that miR-197 might be a potential target and provided database for clinical treatment. therapeutic target hsa-mir-15a Uterine Leiomyosarcoma 26768834 HP:0002891 Differential miRNA signatures of ESS and LMS provide novel data regarding transcriptional regulation in these cancers, based on which new potential diagnostic markers, prognostic biomarkers and therapeutic targets may be explored. Differences in miRNA profiles of primary and metastatic LMS may improve our understanding of disease progression in this aggressive malignancy. therapeutic target hsa-mir-31 Uterine Leiomyosarcoma 26768834 HP:0002891 Differential miRNA signatures of ESS and LMS provide novel data regarding transcriptional regulation in these cancers, based on which new potential diagnostic markers, prognostic biomarkers and therapeutic targets may be explored. Differences in miRNA profiles of primary and metastatic LMS may improve our understanding of disease progression in this aggressive malignancy. therapeutic target hsa-mir-92a Uterine Leiomyosarcoma 26768834 HP:0002891 Differential miRNA signatures of ESS and LMS provide novel data regarding transcriptional regulation in these cancers, based on which new potential diagnostic markers, prognostic biomarkers and therapeutic targets may be explored. Differences in miRNA profiles of primary and metastatic LMS may improve our understanding of disease progression in this aggressive malignancy. therapeutic target hsa-mir-106a Vascular Disease [unspecific] 26004384 cardiovascular system disease DOID:178 I72.9 D000783 The results of the present study suggest that miRNAs are vital in the process of endothelial dysfunction and are involved in the pathogenesis of VGF. Thus, using miRNAs as biomarkers and therapeutic targets has the potential to improve early diagnosis and prognosis of patients with VGF. therapeutic target hsa-mir-145 Vascular Disease [unspecific] 23611811 cardiovascular system disease DOID:178 I72.9 D000783 Forced expression of miR-145 emerges as a promising strategy for reduction and stabilization of atherosclerotic plaques as well as for reducing neointimal hyperplasia. therapeutic target hsa-mir-204 Vascular Disease [unspecific] 25806689 cardiovascular system disease DOID:178 I72.9 D000783 these data suggested miR-204 as a possible molecular switch inhibiting osteoblastic transdifferentiation of human aortic VICs and targeting miR-204 may have therapeutic potential for human aortic valve calcification. therapeutic target hsa-mir-21 Vascular Disease [unspecific] 20560046 cardiovascular system disease DOID:178 I72.9 D000783 miR-21 is found to play important roles in vascular smooth muscle cell proliferation and apoptosis, cardiac cell growth and death, and cardiac fibroblast functions therapeutic target hsa-mir-23a Vascular Disease [unspecific] 22136461 cardiovascular system disease DOID:178 I72.9 D000783 miRNA-23/27/24 cluster has potential therapetic application in vascular disorders and ischemic heart disease therapeutic target hsa-mir-24-2 Vascular Disease [unspecific] 22136461 cardiovascular system disease DOID:178 I72.9 D000783 miRNA-23/27/24 cluster has potential therapetic application in vascular disorders and ischemic heart disease therapeutic target hsa-mir-27a Vascular Disease [unspecific] 22136461 cardiovascular system disease DOID:178 I72.9 D000783 miRNA-23/27/24 cluster has potential therapetic application in vascular disorders and ischemic heart disease therapeutic target hsa-mir-363 Vascular Disease [unspecific] 26004384 cardiovascular system disease DOID:178 I72.9 D000783 The results of the present study suggest that miRNAs are vital in the process of endothelial dysfunction and are involved in the pathogenesis of VGF. Thus, using miRNAs as biomarkers and therapeutic targets has the potential to improve early diagnosis and prognosis of patients with VGF. therapeutic target hsa-mir-145 Vascular Disease [unspecific] 19542014 cardiovascular system disease DOID:178 I72.9 D000783 We conclude that miR-145 is a novel VSMC phenotypic marker and modulator that is able of controlling vascular neointimal lesion formation. These novel findings may have extensive implications for the diagnosis and therapy of a variety of proliferative vascular diseases. therapeutic target hsa-mir-145 Vascular Disease [unspecific] 19829088 cardiovascular system disease DOID:178 I72.9 D000783 This review article summarizes the current research progress regarding the roles of miR-145 in VSMC biology and discusses the potential therapeutic opportunities surrounding this miRNA in vascular disease. therapeutic target hsa-mir-27b Vascular Disease [unspecific] 18068232 cardiovascular system disease DOID:178 I72.9 D000783 Expression of let7-f and miR-27b contributes to in vitro angiogenesis. We review recent studies on the involvement of miRNA in angiogenesis and discuss their implications for miRNA-based therapeutic strategies targeting this process in disease. therapeutic target hsa-mir-21 Vascular Hypertrophy 22227207 Our data suggest that miR-21 plays an important role in the pathogenesis of chronic hypoxia-induced pulmonary vascular remodeling and also suggest that miR-21 is a potential target for novel therapeutics to treat chronic hypoxia associated pulmonary diseases. therapeutic target hsa-mir-23a Viral Infectious Disease 25461762 disease by infectious agent DOID:934 A94 D001102 miR-23a may represent a promising target for antiviral treatments. therapeutic target hsa-mir-555 Viral Infectious Disease 26683768 disease by infectious agent DOID:934 A94 D001102 These findings provide the first evidence for the role of miR-555 in PV replication and reveal that miR-555 could contribute to the development of antiviral therapeutic strategies against PV. therapeutic target hsa-mir-155 Viral Myocarditis 25219837 B33.2 D009205 So, our study indicated that miR-155 is a potential therapeutic target for viral myocarditis. therapeutic target hsa-mir-155 Waldenstrom Macroglobulinemia 23474146 C88.0 D008258 153600 HP:0005508 Among deregulated miRNAs, miRNA-155 has been shown to play a pivotal role in the biological characteristics of this disease both in vitro and in vivo, thus providing the rationale for testing miRNA-based therapeutic approaches for the treatment of WM. therapeutic target hsa-mir-132 Wound Healing 28807666 D014945 HP:0001058 MicroRNA-132 with Therapeutic Potential in Chronic Wounds. transcription factor target hsa-mir-200b Adenocarcinoma, Lung 24830600 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 the HDAC1/4/Sp1/miR-200b/E2F3 pathway is responsible for chemoresistance of docetaxel-resistant LAD cells. transcription factor target hsa-mir-200b Adenocarcinoma, Lung 25279705 disease of cellular proliferation DOID:3910 C78.00 C538231 211980 HP:0030078 Histone deacetylase 1/Sp1/microRNA-200b signaling accounts for maintenance of cancer stem-like cells in human lung adenocarcinoma. transcription factor target hsa-mir-144 Alzheimer Disease 23546882 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 MicroRNA-144 Is Regulated by Activator Protein-1 (AP-1) and Decreases Expression of Alzheimer's Disease-related A Disintegrin And Metalloprotease 10 (ADAM10) transcription factor target hsa-mir-188 Alzheimer Disease 25378159 nervous system disease DOID:10652 G30.9 D000544 104300 HP:0002511 Synaptic and cognitive improvements by inhibition of 2-AG metabolism are through upregulation of microRNA-188-3p in a mouse model of Alzheimer's disease. transcription factor target hsa-mir-222 Brain Neoplasms 19351827 disease of cellular proliferation DOID:1319 C71 D001932 603688 HP:0030692 miR-222: Overexpression transcription factor target hsa-let-7a-1 Breast Neoplasms 22388088 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes. transcription factor target hsa-let-7a-2 Breast Neoplasms 22388088 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes. transcription factor target hsa-let-7a-3 Breast Neoplasms 22388088 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes. transcription factor target hsa-let-7b Breast Neoplasms 22388088 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes. transcription factor target hsa-let-7c Breast Neoplasms 22388088 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes. transcription factor target hsa-let-7c Breast Neoplasms 25388283 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 HER2 protein expression and activity are negatively correlated with let-7c expression in TCGA. In summary, we identified an ER-regulated miRNA cluster that regulates HER2, is lost with progression to estrogen independence, and may serve as a biomarker of poor outcome in ER(+) luminal A breast cancer patients. transcription factor target hsa-let-7d Breast Neoplasms 22388088 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes. transcription factor target hsa-let-7e Breast Neoplasms 22388088 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes. transcription factor target hsa-let-7f-1 Breast Neoplasms 22388088 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes. transcription factor target hsa-let-7f-2 Breast Neoplasms 22388088 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes. transcription factor target hsa-let-7g Breast Neoplasms 22388088 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes. transcription factor target hsa-let-7i Breast Neoplasms 22388088 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes. transcription factor target hsa-mir-106b Breast Neoplasms 24292682 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 high level of miR-106b induced by TGF-β determines the tumor-promoting effects of TGF-β in breast cancer. transcription factor target hsa-mir-10b Breast Neoplasms 22286762 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs. transcription factor target hsa-mir-125b Breast Neoplasms 25388283 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 HER2 protein expression and activity are negatively correlated with let-7c expression in TCGA. In summary, we identified an ER-regulated miRNA cluster that regulates HER2, is lost with progression to estrogen independence, and may serve as a biomarker of poor outcome in ER(+) luminal A breast cancer patients. transcription factor target hsa-mir-129 Breast Neoplasms 26460733 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Thus,miR-129-5p down-regulation fosters EMT in breast cancer by increasing Twist1-Snail and activating a negative feedback loop. transcription factor target hsa-mir-132 Breast Neoplasms 26377202 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Taken together, the findings provide the first evidences of the synergistic anti-metastatic properties of miR-212/132 cluster through suppression of SOX4. Also, current study suggest a new miRNA-based mechanism elucidating the anti-metastatic properties of Ahr agonists, suggesting possibility of using miR-212/132 to control metastasis in breast cancer patients. transcription factor target hsa-mir-141 Breast Neoplasms 23975430 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer. transcription factor target hsa-mir-146 Breast Neoplasms 25712342 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 FOXP3 Controls an miR-146/NF-κB Negative Feedback Loop That Inhibits Apoptosis in Breast Cancer Cells. transcription factor target hsa-mir-146a Breast Neoplasms 19190326 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-146: Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis transcription factor target hsa-mir-146b Breast Neoplasms 19190326 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-146: Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis transcription factor target hsa-mir-155 Breast Neoplasms 24080728 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-155 broadly orchestrates inflammation-induced changes of microRNA expression in breast cancer transcription factor target hsa-mir-155 Breast Neoplasms 22797073 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Mutant p53 drives invasion in breast tumors through up-regulation of miR-155. transcription factor target hsa-mir-17 Breast Neoplasms 22286762 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs. transcription factor target hsa-mir-182 Breast Neoplasms 25873390 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Autocrine/Paracrine Human Growth Hormone-stimulated MicroRNA 96-182-183 Cluster Promotes Epithelial-Mesenchymal Transition and Invasion in Breast Cancer. transcription factor target hsa-mir-182 Breast Neoplasms 25394902 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The miR-183/-96/-182 cluster is up-regulated in most breast cancer. It functions as an oncogene in breast cancer as it increases cell proliferation and migration. transcription factor target hsa-mir-183 Breast Neoplasms 25873390 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Autocrine/Paracrine Human Growth Hormone-stimulated MicroRNA 96-182-183 Cluster Promotes Epithelial-Mesenchymal Transition and Invasion in Breast Cancer. transcription factor target hsa-mir-183 Breast Neoplasms 25394902 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The miR-183/-96/-182 cluster is up-regulated in most breast cancer. It functions as an oncogene in breast cancer as it increases cell proliferation and migration. transcription factor target hsa-mir-191 Breast Neoplasms 25867965 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 HIF-inducible miR-191 promotes migration in breast cancer through complex regulation of TGFβ-signaling in hypoxic microenvironment. transcription factor target hsa-mir-191 Breast Neoplasms 23542418 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MicroRNA-191, an estrogen responsive microRNA, functions as an oncogenic regulator in human breast cancer transcription factor target hsa-mir-200a Breast Neoplasms 23975430 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer. transcription factor target hsa-mir-200a Breast Neoplasms 25972084 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 our results suggest that Restin inhibits EMT and tumor metastasis by controlling the expression of the tumor metastasis suppressor mir-200a/b via association with p73. Our findings not only establish a mechanistic link between Restin, EMT and tumor metastasis, but also provide strong evidence supporting the notion that MAGE Group II proteins may exert a tumor suppressive effect in vivo. transcription factor target hsa-mir-200b Breast Neoplasms 25972084 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 our results suggest that Restin inhibits EMT and tumor metastasis by controlling the expression of the tumor metastasis suppressor mir-200a/b via association with p73. Our findings not only establish a mechanistic link between Restin, EMT and tumor metastasis, but also provide strong evidence supporting the notion that MAGE Group II proteins may exert a tumor suppressive effect in vivo. transcription factor target hsa-mir-203 Breast Neoplasms 23447531 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Signaling between TGF-beta and Transcription factor SNAI2 Represses Expression of microRNA miR-203 to Promote Epithelial-Mesenchymal Transition and Tumor Metastasis transcription factor target hsa-mir-20b Breast Neoplasms 23945289 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Crucial role for early growth response-1 in the transcriptional regulation of miR-20b in breast cancer. transcription factor target hsa-mir-21 Breast Neoplasms 19264808 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-21: Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. transcription factor target hsa-mir-21 Breast Neoplasms 19308091 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-21: BMP-6 inhibits microRNA-21 expression in breast cancer through repressing deltaEF1 and AP-1 transcription factor target hsa-mir-21 Breast Neoplasms 22286762 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs. transcription factor target hsa-mir-210 Breast Neoplasms 18316553 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 induced transcription factor target hsa-mir-212 Breast Neoplasms 26377202 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Taken together, the findings provide the first evidences of the synergistic anti-metastatic properties of miR-212/132 cluster through suppression of SOX4. Also, current study suggest a new miRNA-based mechanism elucidating the anti-metastatic properties of Ahr agonists, suggesting possibility of using miR-212/132 to control metastasis in breast cancer patients. transcription factor target hsa-mir-221 Breast Neoplasms 20388878 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 These findings suggest that the negative regulatory loop involving miR-221-222 and ERalpha may confer proliferative advantage and migratory activity to breast cancer cells and promote the transition from ER-positive to ER-negative tumors transcription factor target hsa-mir-222 Breast Neoplasms 20388878 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 These findings suggest that the negative regulatory loop involving miR-221-222 and ERalpha may confer proliferative advantage and migratory activity to breast cancer cells and promote the transition from ER-positive to ER-negative tumors transcription factor target hsa-mir-23b Breast Neoplasms 22231442 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 ERalpha downregulates miR-30a by binding to two specific sites proximal to the gene and thereby inhibiting pri-miR synthesis. On the other hand, the receptor promotes miR-23b, -27b and 24-1 accumulation in the cell by binding in close proximity of the corresponding gene cluster and preventing in situ the inhibitory effects of ERж┿on pri-miR maturation by the p68/DDX5-Drosha microprocessor complex. transcription factor target hsa-mir-24-1 Breast Neoplasms 22231442 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 ERalpha downregulates miR-30a by binding to two specific sites proximal to the gene and thereby inhibiting pri-miR synthesis. On the other hand, the receptor promotes miR-23b, -27b and 24-1 accumulation in the cell by binding in close proximity of the corresponding gene cluster and preventing in situ the inhibitory effects of ERж┿on pri-miR maturation by the p68/DDX5-Drosha microprocessor complex. transcription factor target hsa-mir-27a Breast Neoplasms 23752185 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-27a regulates endothelial differentiation of breast cancer stem like cells. transcription factor target hsa-mir-27b Breast Neoplasms 22231442 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 ERalpha downregulates miR-30a by binding to two specific sites proximal to the gene and thereby inhibiting pri-miR synthesis. On the other hand, the receptor promotes miR-23b, -27b and 24-1 accumulation in the cell by binding in close proximity of the corresponding gene cluster and preventing in situ the inhibitory effects of ERж┿on pri-miR maturation by the p68/DDX5-Drosha microprocessor complex. transcription factor target hsa-mir-30a Breast Neoplasms 22231442 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 ERalpha downregulates miR-30a by binding to two specific sites proximal to the gene and thereby inhibiting pri-miR synthesis. On the other hand, the receptor promotes miR-23b, -27b and 24-1 accumulation in the cell by binding in close proximity of the corresponding gene cluster and preventing in situ the inhibitory effects of ERж┿on pri-miR maturation by the p68/DDX5-Drosha microprocessor complex. transcription factor target hsa-mir-31 Breast Neoplasms 24582497 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The breast cancer oncogene EMSY represses transcription of antimetastatic microRNA miR-31. transcription factor target hsa-mir-31 Breast Neoplasms 25927669 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 A novel mechanism of regulation of the anti-metastatic miR-31 by EMSY in breast cancer. transcription factor target hsa-mir-373 Breast Neoplasms 26196741 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 MiR-373 drives the epithelial-to-mesenchymal transition and metastasis via the miR-373-TXNIP-HIF1α-TWIST signaling axis in breast cancer. transcription factor target hsa-mir-506 Breast Neoplasms 23717581 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 miR-506 Regulates Epithelial Mesenchymal Transition in Breast Cancer Cell Lines. transcription factor target hsa-mir-590 Breast Neoplasms 25150595 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 A feedback expression of microRNA-590 and activating transcription factor-3 in human breast cancer cells. transcription factor target hsa-mir-9-1 Breast Neoplasms 22286762 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs. transcription factor target hsa-mir-9-2 Breast Neoplasms 22286762 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs. transcription factor target hsa-mir-9-3 Breast Neoplasms 22286762 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs. transcription factor target hsa-mir-96 Breast Neoplasms 25873390 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 Autocrine/Paracrine Human Growth Hormone-stimulated MicroRNA 96-182-183 Cluster Promotes Epithelial-Mesenchymal Transition and Invasion in Breast Cancer. transcription factor target hsa-mir-96 Breast Neoplasms 25394902 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 The miR-183/-96/-182 cluster is up-regulated in most breast cancer. It functions as an oncogene in breast cancer as it increases cell proliferation and migration. transcription factor target hsa-mir-99a Breast Neoplasms 25388283 thoracic disease DOID:1612 C50 D001943 114480 HP:0100013 HER2 protein expression and activity are negatively correlated with let-7c expression in TCGA. In summary, we identified an ER-regulated miRNA cluster that regulates HER2, is lost with progression to estrogen independence, and may serve as a biomarker of poor outcome in ER(+) luminal A breast cancer patients. transcription factor target hsa-mir-31 Carcinoma, Breast 25737447 D05 D001943 114480 HP:0003002 These studies further suggest that manipulation of miR-31 expression can be used to modulate senescence-related pathological conditions such as cancer,and the aging process. transcription factor target hsa-mir-100 Carcinoma, Cervical 25757558 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 Transcriptional regulation of microRNA-100, -146a, and -150 genes by p53 and NFκB p65/RelA in mouse striatal STHdh(Q7)/ Hdh(Q7) cells and human cervical carcinoma HeLa cells. transcription factor target hsa-mir-125b Carcinoma, Cervical 23928699 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 OCT4 promotes tumorigenesis and inhibits apoptosis of cervical cancer cells by miR-125b/BAK1 pathway. transcription factor target hsa-mir-146a Carcinoma, Cervical 25757558 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 Transcriptional regulation of microRNA-100, -146a, and -150 genes by p53 and NFκB p65/RelA in mouse striatal STHdh(Q7)/ Hdh(Q7) cells and human cervical carcinoma HeLa cells. transcription factor target hsa-mir-150 Carcinoma, Cervical 25757558 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 Transcriptional regulation of microRNA-100, -146a, and -150 genes by p53 and NFκB p65/RelA in mouse striatal STHdh(Q7)/ Hdh(Q7) cells and human cervical carcinoma HeLa cells. transcription factor target hsa-mir-203 Carcinoma, Cervical 25658920 disease of cellular proliferation DOID:2893 D06.9 D002583 603956 HP:0030159 BANF1 is downregulated by IRF1-regulated microRNA-203 in cervical cancer. transcription factor target hsa-mir-130b Carcinoma, Colon 27082112 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 The infinity software that we have developed is a powerful tool to underscore new TF/miRNA regulatory networks. transcription factor target hsa-mir-17 Carcinoma, Colon 27082112 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 The infinity software that we have developed is a powerful tool to underscore new TF/miRNA regulatory networks. transcription factor target hsa-mir-181b Carcinoma, Colon 27082112 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 The infinity software that we have developed is a powerful tool to underscore new TF/miRNA regulatory networks. transcription factor target hsa-mir-200 Carcinoma, Colon 25371200 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 MicroRNA-200 (miR-200) cluster regulation by achaete scute-like 2 (Ascl2): impact on the epithelial-mesenchymal transition in colon cancer cells. transcription factor target hsa-mir-203 Carcinoma, Colon 24145190 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 Maintenance of the stemness in CD44(+) HCT-15 and HCT-116 human colon cancer cells requires miR-203 suppression. transcription factor target hsa-mir-21 Carcinoma, Colon 27082112 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 The infinity software that we have developed is a powerful tool to underscore new TF/miRNA regulatory networks. transcription factor target hsa-mir-301b Carcinoma, Colon 27082112 gastrointestinal system disease DOID:1520 D01.0 C028885 HP:0003003 The infinity software that we have developed is a powerful tool to underscore new TF/miRNA regulatory networks. transcription factor target hsa-mir-146b Carcinoma, Esophageal 24589738 disease of cellular proliferation DOID:1107 C15.9 D004938 133239 HP:0011459 Transcriptional regulation of miR-146b by C/EBPβ LAP2 in esophageal cancer cells. transcription factor target hsa-mir-31 Carcinoma, Esophageal 25644061 disease of cellular proliferation DOID:1107 C15.9 D004938 133239 HP:0011459 SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells. transcription factor target hsa-mir-23b Carcinoma, Gastric 26041881 disease of cellular proliferation DOID:5517 C16.9 D013274 HP:0012126 The reciprocal regulation loop of Notch2 pathway and miR-23b in controlling gastric carcinogenesis. transcription factor target hsa-let-7a-1 Carcinoma, Hepatocellular 21903590 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 C-myc Inhibits the Transcription of the MicroRNA Cluster MC-let-7a-1~let-7d via a Non-Canonical E-box. transcription factor target hsa-let-7d Carcinoma, Hepatocellular 21903590 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 C-myc Inhibits the Transcription of the MicroRNA Cluster MC-let-7a-1~let-7d via a Non-Canonical E-box. transcription factor target hsa-let-7f-1 Carcinoma, Hepatocellular 21903590 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 C-myc Inhibits the Transcription of the MicroRNA Cluster MC-let-7a-1~let-7d via a Non-Canonical E-box. transcription factor target hsa-mir-101 Carcinoma, Hepatocellular 26718325 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 These findings show that elevated EZH2 contributes to miR-101 deregulation in HCC and highlight the coordinated role of miR-101 and EZH2 in hepatocarcinogenesis. transcription factor target hsa-mir-101-1 Carcinoma, Hepatocellular 26718325 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 These findings show that elevated EZH2 contributes to miR-101 deregulation in HCC and highlight the coordinated role of miR-101 and EZH2 in hepatocarcinogenesis. transcription factor target hsa-mir-122 Carcinoma, Hepatocellular 21654638 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA122 is a key regulator of alpha-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. transcription factor target hsa-mir-122 Carcinoma, Hepatocellular 24038073 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Reciprocal regulation of microRNA-122 and c-Myc in hepatocellular cancer: role of E2F1 and transcription factor dimerization partner 2. transcription factor target hsa-mir-127 Carcinoma, Hepatocellular 23762330 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 A Feedback Inhibition between miRNA-127 and TGFbeta/c-Jun Cascade in HCC Cell Migration via MMP13. transcription factor target hsa-mir-134 Carcinoma, Hepatocellular 23775631 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Hepatocyte nuclear factor-4α reverses malignancy of hepatocellular carcinoma through regulating mir-134 in the DLK1-DIO3 region. transcription factor target hsa-mir-135a-1 Carcinoma, Hepatocellular 21888875 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-135a Contributes to the Development of Portal Vein Tumor Thrombus by Promoting Metastasis in Hepatocellular Carcinoma. transcription factor target hsa-mir-135a-2 Carcinoma, Hepatocellular 21888875 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 MicroRNA-135a Contributes to the Development of Portal Vein Tumor Thrombus by Promoting Metastasis in Hepatocellular Carcinoma. transcription factor target hsa-mir-181a-2 Carcinoma, Hepatocellular 21711587 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma. transcription factor target hsa-mir-181b-1 Carcinoma, Hepatocellular 21711587 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma. transcription factor target hsa-mir-181b-2 Carcinoma, Hepatocellular 21711587 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma. transcription factor target hsa-mir-181c Carcinoma, Hepatocellular 21711587 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma. transcription factor target hsa-mir-181d Carcinoma, Hepatocellular 21711587 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma. transcription factor target hsa-mir-182 Carcinoma, Hepatocellular 25813403 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Wnt/β-Catenin activates MiR-183/96/182 expression in hepatocellular carcinoma that promotes cell invasion. transcription factor target hsa-mir-183 Carcinoma, Hepatocellular 25813403 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Wnt/β-Catenin activates MiR-183/96/182 expression in hepatocellular carcinoma that promotes cell invasion. transcription factor target hsa-mir-195 Carcinoma, Hepatocellular 27179445 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Expression of microRNA-195 is transactivated by Sp1 but inhibited by histone deacetylase 3 in hepatocellular carcinoma cells. transcription factor target hsa-mir-199a-1 Carcinoma, Hepatocellular 22359598 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 ER Stress Negatively Modulates the Expression of the miR-199a/214 Cluster to Regulates Tumor Survival and Progression in Human Hepatocellular Cancer. transcription factor target hsa-mir-199a-2 Carcinoma, Hepatocellular 22359598 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 ER Stress Negatively Modulates the Expression of the miR-199a/214 Cluster to Regulates Tumor Survival and Progression in Human Hepatocellular Cancer. transcription factor target hsa-mir-21 Carcinoma, Hepatocellular 25087183 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Hepatitis B virus X protein promotes hepatocellular carcinoma transformation through interleukin-6 activation of microRNA-21 expression. transcription factor target hsa-mir-214 Carcinoma, Hepatocellular 22359598 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 ER Stress Negatively Modulates the Expression of the miR-199a/214 Cluster to Regulates Tumor Survival and Progression in Human Hepatocellular Cancer. transcription factor target hsa-mir-224 Carcinoma, Hepatocellular 23988648 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 miR-224 is critical for celastrol-induced inhibition of migration and invasion of hepatocellular carcinoma cells. transcription factor target hsa-mir-224 Carcinoma, Hepatocellular 22178270 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Transcriptional regulation of mir-224 upregulated in human HCCs by NFkB inflammatory pathways. transcription factor target hsa-mir-338 Carcinoma, Hepatocellular 26082033 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Mineralocorticoid receptor suppresses cancer progression and the Warburg effect by modulating the miR-338-3p-PKLR axis in hepatocellular carcinoma. transcription factor target hsa-mir-370 Carcinoma, Hepatocellular 23728999 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Perturbation of miR-370-LIN28A-NF-κB regulatory circuit contributes to the development of hepatocellular carcinoma. transcription factor target hsa-mir-509 Carcinoma, Hepatocellular 24882622 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 The oncoprotein HBXIP up-regulates SCG3 through modulating E2F1 and miR-509-3p in hepatoma cells. transcription factor target hsa-mir-615 Carcinoma, Hepatocellular 25987019 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 PU.1 Is Identified as a Novel Metastasis Suppressor in Hepatocellular Carcinoma Regulating the miR-615-5p/IGF2 Axis. transcription factor target hsa-mir-96 Carcinoma, Hepatocellular 25813403 disease of cellular proliferation DOID:684 C22.0 D006528 114550 HP:0001402 Wnt/β-Catenin activates MiR-183/96/182 expression in hepatocellular carcinoma that promotes cell invasion. transcription factor target hsa-mir-124 Carcinoma, Lung, Non-Small-Cell 26818357 C34.90 D002289 HP:0030358 The feedback loop between miR-124 and TGF-β pathway plays a significant role in non-small cell lung cancer metastasis. transcription factor target hsa-mir-21 Carcinoma, Lung, Non-Small-Cell 25799148 C34.90 D002289 HP:0030358 Modulation of the NF-κB/miR-21/PTEN pathway in NSCLC showed that inhibition of this pathway may increase cisplatin sensitivity. transcription factor target hsa-mir-1 Carcinoma, Nasopharyngeal 25237831 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 EZH2 promotes angiogenesis through inhibition of miR-1/Endothelin-1 axis in nasopharyngeal carcinoma. transcription factor target hsa-mir-184 Carcinoma, Nasopharyngeal 24157866 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 Tumor suppressor PDCD4 modulates miR-184-mediated direct suppression of C-MYC and BCL2 blocking cell growth and survival in nasopharyngeal carcinoma. transcription factor target hsa-mir-204 Carcinoma, Nasopharyngeal 24613926 disease of cellular proliferation DOID:9261 C11 C538339 607107 HP:0100630 Down-regulation of miRNA-204 by LMP-1 enhances CDC42 activity and facilitates invasion of EBV-associated nasopharyngeal carcinoma cells. transcription factor target hsa-mir-31 Carcinoma, Oral 25229239 gastrointestinal system disease DOID:0050610 EGF up-regulates miR-31 through the C/EBPβ signal cascade in oral carcinoma. transcription factor target hsa-mir-145 Carcinoma, Renal Cell 26304926 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 Androgen receptor (AR) suppresses miRNA-145 to promote renal cell carcinoma (RCC) progression independent of VHL status. transcription factor target hsa-mir-30d Carcinoma, Renal Cell 23416459 disease of cellular proliferation DOID:4450 D002292 144700 HP:0005584 MiR-30d induces apoptosis and is regulated by the Akt/FOXO pathway in renal cell carcinoma transcription factor target hsa-mir-23a Cardiomyopathy, Hypertrophic 19574461 cardiovascular system disease DOID:11984 I42.2 D002312 192600 HP:0001639 miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy transcription factor target hsa-mir-17 Cardiovascular Diseases [unspecific] 24378993 D002318 Crosstalk between TGF-β/Smad3 and BMP/BMPR2 signaling pathways via miR-17-92 cluster in carotid artery restenosis. transcription factor target hsa-mir-18 Cardiovascular Diseases [unspecific] 24378993 D002318 Crosstalk between TGF-β/Smad3 and BMP/BMPR2 signaling pathways via miR-17-92 cluster in carotid artery restenosis. transcription factor target hsa-mir-19a Cardiovascular Diseases [unspecific] 24378993 D002318 Crosstalk between TGF-β/Smad3 and BMP/BMPR2 signaling pathways via miR-17-92 cluster in carotid artery restenosis. transcription factor target hsa-mir-19b-1 Cardiovascular Diseases [unspecific] 24378993 D002318 Crosstalk between TGF-β/Smad3 and BMP/BMPR2 signaling pathways via miR-17-92 cluster in carotid artery restenosis. transcription factor target hsa-mir-20a Cardiovascular Diseases [unspecific] 24378993 D002318 Crosstalk between TGF-β/Smad3 and BMP/BMPR2 signaling pathways via miR-17-92 cluster in carotid artery restenosis. transcription factor target hsa-mir-92-1 Cardiovascular Diseases [unspecific] 24378993 D002318 Crosstalk between TGF-β/Smad3 and BMP/BMPR2 signaling pathways via miR-17-92 cluster in carotid artery restenosis. transcription factor target hsa-mir-373 Cholangiocarcinoma 22876037 disease of cellular proliferation DOID:4947 C22.1 D018281 615619 HP:0030153 Mutual regulation between microRNA-373 and methyl-CpG-binding domain protein 2 in hilar cholangiocarcinoma. transcription factor target hsa-mir-10b Colon Neoplasms 22286762 D12.6 D003110 HP:0100273 Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs. transcription factor target hsa-mir-17 Colon Neoplasms 22286762 D12.6 D003110 HP:0100273 Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs. transcription factor target hsa-mir-192 Colon Neoplasms 19088023 D12.6 D003110 HP:0100273 miR-192: the effect of miR-192 on cellular proliferation is mainly p53 dependent transcription factor target hsa-mir-21 Colon Neoplasms 22286762 D12.6 D003110 HP:0100273 Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs. transcription factor target hsa-mir-9-1 Colon Neoplasms 22286762 D12.6 D003110 HP:0100273 Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs. transcription factor target hsa-mir-9-1 Colon Neoplasms 23045246 D12.6 D003110 HP:0100273 Prospero homeobox 1 promotes epithelial-mesenchymal transition in colon cancer cells by inhibiting E-cadherin via miR-9 transcription factor target hsa-mir-9-2 Colon Neoplasms 22286762 D12.6 D003110 HP:0100273 Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs. transcription factor target hsa-mir-9-2 Colon Neoplasms 23045246 D12.6 D003110 HP:0100273 Prospero homeobox 1 promotes epithelial-mesenchymal transition in colon cancer cells by inhibiting E-cadherin via miR-9 transcription factor target hsa-mir-9-3 Colon Neoplasms 22286762 D12.6 D003110 HP:0100273 Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs. transcription factor target hsa-mir-124 Colorectal Carcinoma 24619225 disease of cellular proliferation DOID:0080199 C19 D015179 114500 The pro-apoptotic role of the regulatory feedback loop between miR-124 and PKM1/HNF4α in colorectal cancer cells. transcription factor target hsa-mir-145 Colorectal Carcinoma 24631504 disease of cellular proliferation DOID:0080199 C19 D015179 114500 Peroxisome proliferator-activated receptor γ-mediated induction of microRNA-145 opposes tumor phenotype in colorectal cancer. transcription factor target hsa-mir-15a Colorectal Carcinoma 24285725 disease of cellular proliferation DOID:0080199 C19 D015179 114500 p53-induced miR-15a/16-1 and AP4 form a double-negative feedback loop to regulate epithelial-mesenchymal transition and metastasis in colorectal cancer. transcription factor target hsa-mir-16-1 Colorectal Carcinoma 24285725 disease of cellular proliferation DOID:0080199 C19 D015179 114500 p53-induced miR-15a/16-1 and AP4 form a double-negative feedback loop to regulate epithelial-mesenchymal transition and metastasis in colorectal cancer. transcription factor target hsa-mir-320a Colorectal Carcinoma 24454819 disease of cellular proliferation DOID:0080199 C19 D015179 114500 E2A predicts prognosis of colorectal cancer patients and regulates cancer cell growth by targeting miR-320a. transcription factor target hsa-mir-34a Colorectal Carcinoma 24642471 disease of cellular proliferation DOID:0080199 C19 D015179 114500 IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. transcription factor target hsa-mir-371 Colorectal Carcinoma 25868860 disease of cellular proliferation DOID:0080199 C19 D015179 114500 The SOX17/miR-371-5p/SOX2 axis inhibits EMT, stem cell properties and metastasis in colorectal cancer. transcription factor target hsa-mir-146a Colorectal Carcinoma 24561623 disease of cellular proliferation DOID:0080199 C19 D015179 114500 MicroRNA-146a directs the symmetric division of Snail-dominant colorectal cancer stem cells. transcription factor target hsa-mir-200a Colorectal Carcinoma 22286765 disease of cellular proliferation DOID:0080199 C19 D015179 114500 SIX1-induced CDH1 repression and EMT in CRC cells were correlated at least in part with posttranscriptional ZEB1 activation and miR-200-family transcriptional repression. transcription factor target hsa-mir-200b Colorectal Carcinoma 22286765 disease of cellular proliferation DOID:0080199 C19 D015179 114500 SIX1-induced CDH1 repression and EMT in CRC cells were correlated at least in part with posttranscriptional ZEB1 activation and miR-200-family transcriptional repression. transcription factor target hsa-mir-200c Colorectal Carcinoma 22286765 disease of cellular proliferation DOID:0080199 C19 D015179 114500 SIX1-induced CDH1 repression and EMT in CRC cells were correlated at least in part with posttranscriptional ZEB1 activation and miR-200-family transcriptional repression. transcription factor target hsa-mir-204 Diabetes Mellitus 23975026 disease of metabolism DOID:9351 E10-E14 D003920 222100 HP:0000819 The newly identified TXNIP-miR-204-MAFA-insulin pathway may contribute to diabetes progression and provides new insight into TXNIP function and microRNA biology in health and disease. transcription factor target hsa-mir-145 Diabetes Mellitus, Type 2 24548410 disease of metabolism DOID:9352 E11 D003924 125853 HP:0005978 miR-145 plays a role in the development of resistin-induced insulin resistance via the p65 pathway. transcription factor target hsa-mir-29 Diabetes Mellitus, Type 2 24722248 disease of metabolism DOID:9352 E11 D003924 125853 HP:0005978 MicroRNA-29 fine-tunes the expression of key FOXA2-activated lipid metabolism genes and is dysregulated in animal models of insulin resistance and diabetes. transcription factor target hsa-mir-34a Disease of Metabolism 20185821 disease of metabolism DOID:0014667 E88.9 D008659 Our study demonstrates an unexpected role of the FXR/SHP pathway in controlling SIRT1 levels via miR-34a inhibition and that elevated miR-34a levels in obese mice contribute to decreased SIRT1 levels transcription factor target hsa-mir-22 Emphysema 26437241 J43 D004646 130700 HP:0002097 Thus, miR-22 is a critical regulator of both emphysema and T(H)17 responses. transcription factor target hsa-mir-34a Esophageal Neoplasms 22292433 C15.9 D004938 133239 HP:0100751 Transcriptional activation of microRNA-34a by NF-kappa B in human esophageal cancer cells. transcription factor target hsa-mir-720 Esophageal Neoplasms 23154181 C15.9 D004938 133239 HP:0100751 SnoN/SKIL modulates proliferation through control of hsa-miR-720 transcription in esophageal cancer cells transcription factor target hsa-mir-139 Gastric Neoplasms 25499265 disease of cellular proliferation DOID:10534 C16 D013274 137215 Given that miR-139 and Jun are deregulated in many cancers, our findings here might have broader implication in other types of human cancers transcription factor target hsa-mir-183 Gastric Neoplasms 24335145 disease of cellular proliferation DOID:10534 C16 D013274 137215 Glycogen synthase kinase 3 beta inhibits microRNA-183-96-182 cluster via the β-Catenin/TCF/LEF-1 pathway in gastric cancer cells. transcription factor target hsa-mir-196b Gastric Neoplasms 22298639 disease of cellular proliferation DOID:10534 C16 D013274 137215 miR-196b expression was significantly repressed by ETS2 during gastric cancer oncogenesis. transcription factor target hsa-mir-199a Gastric Neoplasms 25080937 disease of cellular proliferation DOID:10534 C16 D013274 137215 SRF expedites metastasis and modulates the epithelial to mesenchymal transition by regulating miR-199a-5p expression in human gastric cancer. transcription factor target hsa-mir-27a Gastric Neoplasms 26292288 disease of cellular proliferation DOID:10534 C16 D013274 137215 HIF-1α Induces Multidrug Resistance in Gastric Cancer Cells by Inducing MiR-27a. transcription factor target hsa-mir-365 Gastric Neoplasms 24149576 disease of cellular proliferation DOID:10534 C16 D013274 137215 Akt-p53-miR-365-cyclin D1/cdc25A axis contributes to gastric tumorigenesis induced by PTEN deficiency. transcription factor target hsa-mir-425 Gastric Neoplasms 25154996 disease of cellular proliferation DOID:10534 C16 D013274 137215 There is a critical role for NF-kappa B-dependent up-regulation of miR-425. And it represents a new pathway for the repression of phosphatase and tensin homolog activation and the promotion of cell survival upon IL-1β induction. transcription factor target hsa-mir-96 Gastric Neoplasms 24335145 disease of cellular proliferation DOID:10534 C16 D013274 137215 Glycogen synthase kinase 3 beta inhibits microRNA-183-96-182 cluster via the β-Catenin/TCF/LEF-1 pathway in gastric cancer cells. transcription factor target hsa-mir-23a Gastrointestinal Neoplasms 23929433 D37.9 D005770 miR-23a inhibits E-cadherin expression and is regulated by AP-1 and NFAT4 complex during Fas-induced EMT in gastrointestinal cancer. transcription factor target hsa-mir-29b Glaucoma 26191170 nervous system disease DOID:1686 H40 D005901 137750 This study suggests that TGF-β2 has a time-effect relationship with Tenon's capsule fibroblasts proliferation from glaucoma patients, and it stimulates Tenon's capsule fibroblast proliferation via suppression of miR-29b expression regulated by Nrf2. transcription factor target hsa-mir-134 Glioblastoma 24440911 D005909 HP:0100843 Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS,STAT5B, and glioblastoma. transcription factor target hsa-mir-218 Glioblastoma 25943352 D005909 HP:0100843 Feedback circuitry between miR-218 repression and RTK activation in glioblastoma. transcription factor target hsa-mir-221 Glioblastoma 21245048 D005909 HP:0100843 NF-kB and c-Jun induce the expression of the oncogenic miR-221 and miR-222 in prostate carcinoma and glioblastoma cells. transcription factor target hsa-mir-221 Glioblastoma 24295494 D005909 HP:0100843 miR-221/222 confers radioresistance in glioblastoma cells through activating Akt independent of PTEN status. transcription factor target hsa-mir-222 Glioblastoma 24295494 D005909 HP:0100843 miR-221/222 confers radioresistance in glioblastoma cells through activating Akt independent of PTEN status. transcription factor target hsa-mir-26a Glioblastoma 24140063 D005909 HP:0100843 C-Myc negatively controls the tumor suppressor PTEN by upregulating miR-26a in glioblastoma multiforme cells. transcription factor target hsa-mir-425 Glioblastoma 18765229 D005909 HP:0100843 up-regulation in the CD133-cells transcription factor target hsa-mir-451 Glioblastoma 25937278 D005909 HP:0100843 These findings uncover miR-451 as a major effector of glucose-regulated AMPK signaling, allowing tumor cell adaptation to variations in nutrient availability in the tumor microenvironment. transcription factor target hsa-mir-451a Glioblastoma 18765229 D005909 HP:0100843 miR-451: MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells transcription factor target hsa-mir-486 Glioblastoma 18765229 D005909 HP:0100843 up-regulation in the CD133-cells transcription factor target hsa-mir-128 Glioma 24959930 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 An axis involving SNAI1, microRNA-128 and SP1 modulates glioma progression. transcription factor target hsa-mir-128a Glioma 26324126 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 IDH1R132H decreases the proliferation of U87 glioma cells through upregulation of microRNA-128a. transcription factor target hsa-mir-21 Glioma 25305446 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 Krüppel-like factor 9 inhibits glioma cell proliferation and tumorigenicity via downregulation of miR-21. transcription factor target hsa-mir-9-1 Glioma 23185366 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 The CREB-miR-9 negative feedback minicircuitry coordinates the migration and proliferation of glioma cells transcription factor target hsa-mir-9-2 Glioma 23185366 disease of cellular proliferation DOID:3070 D005910 PS137800 HP:0009733 The CREB-miR-9 negative feedback minicircuitry coordinates the migration and proliferation of glioma cells transcription factor target hsa-mir-302a Head And Neck Neoplasms 22847005 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 Hyaluronan-CD44v3 interaction with Oct4/Sox2/Nanog promotes miR-302 expression leading to self-renewal, clonal formation and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. transcription factor target hsa-mir-302b Head And Neck Neoplasms 22847005 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 Hyaluronan-CD44v3 interaction with Oct4/Sox2/Nanog promotes miR-302 expression leading to self-renewal, clonal formation and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. transcription factor target hsa-mir-302c Head And Neck Neoplasms 22847005 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 Hyaluronan-CD44v3 interaction with Oct4/Sox2/Nanog promotes miR-302 expression leading to self-renewal, clonal formation and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. transcription factor target hsa-mir-302d Head And Neck Neoplasms 22847005 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 Hyaluronan-CD44v3 interaction with Oct4/Sox2/Nanog promotes miR-302 expression leading to self-renewal, clonal formation and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. transcription factor target hsa-mir-302e Head And Neck Neoplasms 22847005 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 Hyaluronan-CD44v3 interaction with Oct4/Sox2/Nanog promotes miR-302 expression leading to self-renewal, clonal formation and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. transcription factor target hsa-mir-302f Head And Neck Neoplasms 22847005 disease of cellular proliferation DOID:11934 C76.0 D006258 HP:0012288 Hyaluronan-CD44v3 interaction with Oct4/Sox2/Nanog promotes miR-302 expression leading to self-renewal, clonal formation and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. transcription factor target hsa-mir-199b Heart Failure 21102440 I50 D006331 HP:0001635 miR-199b is a direct calcineurin/NFAT target gene that increases in expression in mouse and human heart failure, and targets the nuclear NFAT kinase dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1a (Dyrk1a) transcription factor target hsa-mir-21 Heart Failure 20546595 I50 D006331 HP:0001635 We show that the transcription factor p53 piggy-backs onto NF-kappaB/RELA and utilizes the kappaB-motif at a cis-regulatory region to control mir-21 expression. transcription factor target hsa-mir-30 Heart Failure 25950484 I50 D006331 HP:0001635 we describe that DOX causes acute and sustained miR-30 downregulation in cardiomyocytes via GATA-6. miR-30 overexpression protects cardiac cells from DOX-induced apoptosis, and its maintenance represents a potential cardioprotective and anti-tumorigenic strategy for anthracyclines. transcription factor target hsa-mir-203 Helicobacter pylori Infection 25689935 B96.81 D016480 600263 HP:0005202 Our results demonstrated that H. pylori infection induced hepatic insulin resistance by the c-Jun/miR-203/SOCS3 signaling pathway and provide possible implications with regard to resolving insulin resistance. transcription factor target hsa-mir-125b-1 Hematologic Neoplasms 21903586 disease of cellular proliferation DOID:2531 C96.9 D019337 HP:0004377 Mir-125b, a target of CDX2, regulates cell differentiation through the repression of the core binding factor in hematopoietic malignancies. transcription factor target hsa-mir-125b-2 Hematologic Neoplasms 21903586 disease of cellular proliferation DOID:2531 C96.9 D019337 HP:0004377 Mir-125b, a target of CDX2, regulates cell differentiation through the repression of the core binding factor in hematopoietic malignancies. transcription factor target hsa-mir-181c Hepatitis C Virus Infection 24789793 disease by infectious agent DOID:1883 B19.2 D006526 609532 Transcriptional suppression of miR-181c by hepatitis C virus enhances homeobox A1 expression. transcription factor target hsa-mir-29 Human Immunodeficiency Virus Infection 26108174 B20 D015658 609423 IL-21 induces antiviral microRNA-29 in CD4 T cells to limit HIV-1 infection. transcription factor target hsa-mir-210 Idiopathic Pulmonary Fibrosis 24951777 respiratory system disease DOID:0050156 J84.112 D054990 178500 miR-210 promotes IPF fibroblast proliferation in response to hypoxia. transcription factor target hsa-mir-26a Idiopathic Pulmonary Fibrosis 24594795 respiratory system disease DOID:0050156 J84.112 D054990 178500 The antifibrotic effects and mechanisms of microRNA-26a action in idiopathic pulmonary fibrosis. transcription factor target hsa-mir-146a Inflammation 26855180 D007249 Super enhancers at the miR-146a and miR-155 genes contribute to self-regulation of inflammation. transcription factor target hsa-mir-155 Inflammation 22170100 D007249 Interferon regulatory factor 3 inhibits astrocyte inflammatory gene expression through suppression of the proinflammatory miR-155 and miR-155*. transcription factor target hsa-mir-155 Inflammation 26855180 D007249 Super enhancers at the miR-146a and miR-155 genes contribute to self-regulation of inflammation. transcription factor target hsa-mir-29c Influenza 22850539 respiratory system disease DOID:8469 J09-J11 D007251 614680 Induction of the cellular microRNA-29c by influenza virus contributes to virus-mediated apoptosis through repression of antiapoptotic factors BCL2L2. transcription factor target hsa-mir-210 Ischemia 20308562 cardiovascular system disease DOID:326 D007511 601367 demonstrated a key role of miR-210 in limiting keratinocyte proliferation transcription factor target hsa-mir-146a Leukemia 26045293 C95 D007938 613065 HP:0001909 Differential hypoxic regulation of the microRNA-146a/CXCR4 pathway in normal and leukemic monocytic cells: impact on response to chemotherapy. transcription factor target hsa-mir-223 Leukemia, Lymphoblastic, Acute, T-Cell 24727676 disease of cellular proliferation DOID:5602 C91.0 613065 HP:0006727 Notch and NF-kB signaling pathways regulate miR-223/FBXW7 axis in T-cell acute lymphoblastic leukemia. transcription factor target hsa-mir-155 Leukemia, Lymphocytic, Chronic, B-Cell 21296997 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. transcription factor target hsa-mir-155 Leukemia, Lymphocytic, Chronic, B-Cell 23750211 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 Signal Transducer and Activator of Transcription-3 Induces MicroRNA-155 Expression in Chronic Lymphocytic Leukemia. transcription factor target hsa-mir-221 Leukemia, Lymphocytic, Chronic, B-Cell 20203269 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 miR-221:miR-221/222 and p27 may represent a regulatory loop that helps maintaining CLL cells in a resting condition transcription factor target hsa-mir-222 Leukemia, Lymphocytic, Chronic, B-Cell 20203269 disease of cellular proliferation DOID:1040 C91.1 D015451 151400 HP:0005550 miR-222:miR-221/222 and p27 may represent a regulatory loop that helps maintaining CLL cells in a resting condition transcription factor target hsa-mir-138-1 Leukemia, Myeloid 23208504 disease of cellular proliferation DOID:8692 C92 D007951 HP:0012324 BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia transcription factor target hsa-mir-138-2 Leukemia, Myeloid 23208504 disease of cellular proliferation DOID:8692 C92 D007951 HP:0012324 BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia transcription factor target hsa-mir-23a Leukemia, Myeloid 20399246 disease of cellular proliferation DOID:8692 C92 D007951 HP:0012324 the 23a cluster is the first downstream miRNA target implicated in regulating the development of myeloid versus lymphoid cells. transcription factor target hsa-mir-125b Leukemia, Myeloid, Acute 25982911 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 The deregulated expression of miR-125b in acute myeloid leukemia is dependent on the transcription factor C/EBPα. transcription factor target hsa-mir-125b-1 Leukemia, Myeloid, Acute 25323587 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 NRF2-driven miR-125B1 and miR-29B1 transcriptional regulation controls a novel anti-apoptotic miRNA regulatory network for AML survival. transcription factor target hsa-mir-143 Leukemia, Myeloid, Acute 22093444 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 miR-143 and miR-145 expression is significantly repressed in primary AML patient samples as compared to neutrophils of healthy donors. Further analysis revealed impaired neutrophil differentiation of APL cells upon inhibition of miR-145 expression. Lastly, we identified p73 as transcriptional regulator of miR-143/145 during neutrophil differentiation of APL cells. Our data suggest that low miR-145 levels in APL, possibly due to aberrant expression of p73 transcription factors, contribute to the differentiation block seen in this disease. transcription factor target hsa-mir-145 Leukemia, Myeloid, Acute 22093444 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 miR-143 and miR-145 expression is significantly repressed in primary AML patient samples as compared to neutrophils of healthy donors. Further analysis revealed impaired neutrophil differentiation of APL cells upon inhibition of miR-145 expression. Lastly, we identified p73 as transcriptional regulator of miR-143/145 during neutrophil differentiation of APL cells. Our data suggest that low miR-145 levels in APL, possibly due to aberrant expression of p73 transcription factors, contribute to the differentiation block seen in this disease. transcription factor target hsa-mir-155 Leukemia, Myeloid, Acute 25092123 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 LIFRα-CT3 induces differentiation of a human acute myelogenous leukemia cell line HL-60 by suppressing miR-155 expression through the JAK/STAT pathway. transcription factor target hsa-mir-17 Leukemia, Myeloid, Acute 25612891 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 the extent of KIT-induced proliferation itself can modulate myeloid differentiation of cells with wild type RUNX1 function. transcription factor target hsa-mir-223 Leukemia, Myeloid, Acute 20018373 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 miR-223:miR-223 suppression in AML is caused by impaired miR-223 upstream factors transcription factor target hsa-mir-29b-1 Leukemia, Myeloid, Acute 25323587 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 NRF2-driven miR-125B1 and miR-29B1 transcriptional regulation controls a novel anti-apoptotic miRNA regulatory network for AML survival. transcription factor target hsa-mir-30c Leukemia, Myeloid, Acute 23974200 disease of cellular proliferation DOID:9119 C92.0 D015470 HP:0004820 Transcription factor C/EBPα-induced microRNA-30c inactivates Notch1 during granulopoiesis and is downregulated in acute myeloid leukemia. transcription factor target hsa-mir-17 Leukemia-Lymphoma, Adult T-Cell 19148830 C91.51 D015459 HP:0005517 miR-17: Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia transcription factor target hsa-mir-18a Leukemia-Lymphoma, Adult T-Cell 19148830 C91.51 D015459 HP:0005517 miR-18a: Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia transcription factor target hsa-mir-19a Leukemia-Lymphoma, Adult T-Cell 19148830 C91.51 D015459 HP:0005517 miR-19a: Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia transcription factor target hsa-mir-19b-1 Leukemia-Lymphoma, Adult T-Cell 19148830 C91.51 D015459 HP:0005517 miR-19b: Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia transcription factor target hsa-mir-19b-2 Leukemia-Lymphoma, Adult T-Cell 19148830 C91.51 D015459 HP:0005517 miR-19b: Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia transcription factor target hsa-mir-20a Leukemia-Lymphoma, Adult T-Cell 19148830 C91.51 D015459 HP:0005517 miR-20a: Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia transcription factor target hsa-mir-451a Leukemia-Lymphoma, Adult T-Cell 21464222 C91.51 D015459 HP:0005517 Repression of tumor suppressor miR-451 is essential for NOTCH1-induced oncogenesis in T-ALL. transcription factor target hsa-mir-92a-1 Leukemia-Lymphoma, Adult T-Cell 19148830 C91.51 D015459 HP:0005517 miR-92a: Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia transcription factor target hsa-mir-92a-2 Leukemia-Lymphoma, Adult T-Cell 19148830 C91.51 D015459 HP:0005517 miR-92a: Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia transcription factor target hsa-mir-214 Liver Fibrosis 26229009 K74 D008103 These findings reveal a unique function for cellular or exosomal Twist1 in CCN2-dependent fibrogenesis. transcription factor target hsa-mir-21 Liver Neoplasms 23355454 disease of cellular proliferation DOID:916 C22.0 D008113 HP:0002896 microRNA 21-mediated suppression of Sprouty1 by Pokemon affects liver cancer cell growth and proliferation transcription factor target hsa-mir-140 Lung Fibrosis 26300493 respiratory system disease DOID:3770 J84.10 D011658 178500 Using these models we showed that IR induces overexpression of Brca1, Nrf2 and miR-140 in lung tissue after irradiation. These data reveal a novel radioprotective mechanism in which IR promotes NRF2 nuclear translocation and subsequent activation of miR-140 transcription in HLFs. transcription factor target hsa-let-7a-2 Lung Neoplasms 21365266 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 9-cis-RA, all-trans-RA,lithium chloride and CEBP might play important regulatory roles in let-7a2 gene expression in A549 cells transcription factor target hsa-mir-1-1 Lung Neoplasms 18818206 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-1: Down-regulation transcription factor target hsa-mir-1-2 Lung Neoplasms 18818206 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 miR-1: Down-regulation transcription factor target hsa-mir-200a Lung Neoplasms 21403400 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. transcription factor target hsa-mir-200b Lung Neoplasms 21403400 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. transcription factor target hsa-mir-200c Lung Neoplasms 21403400 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. transcription factor target hsa-mir-222 Lung Neoplasms 21656127 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 High-mobility group A1 proteins enhance the expression of the oncogenic miR-222 in lung cancer cells. transcription factor target hsa-mir-224 Lung Neoplasms 26187928 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-224 promotes tumor progression in nonsmall cell lung cancer. transcription factor target hsa-mir-29b-1 Lung Neoplasms 22249264 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma. transcription factor target hsa-mir-29b-2 Lung Neoplasms 22249264 disease of cellular proliferation DOID:1324 C34.1-.3 D008175 HP:0100526 MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma. transcription factor target hsa-mir-135b Lymphoma 22042699 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma. transcription factor target hsa-mir-204 Lymphoma 26350953 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 This study demonstrated that HIF-1α-miR-204-BCL-2 pathway contributed to apoptosis of neuronal cells induced by hypoxia, which could potentially be exploited to prevent spinal cord ischemia-reperfusion injury. transcription factor target hsa-mir-22 Lymphoma 26244872 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma. transcription factor target hsa-mir-26a-1 Lymphoma 19197161 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 miR-26a: repressed by MYC transcription factor target hsa-mir-26a-2 Lymphoma 19197161 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 miR-26a: repressed by MYC transcription factor target hsa-mir-494 Lymphoma 25907832 disease of cellular proliferation DOID:0060058 C85.9 D008223 HP:0002665 The PTEN-AKT-mTOR/RICTOR Pathway in Nasal Natural Killer Cell Lymphoma Is Activated by miR-494-3p via PTEN But Inhibited by miR-142-3p via RICTOR. transcription factor target hsa-mir-124 Lymphoma, B-Cell 25915824 disease of cellular proliferation DOID:707 D016393 109565 HP:0012191 MicroRNA-124 links p53 to the NF-κB pathway in B-cell lymphomas. transcription factor target hsa-mir-146a Lymphoma, B-Cell 18066065 disease of cellular proliferation DOID:707 D016393 109565 HP:0012191 c-Myc repressed this miRNA transcription factor target hsa-mir-150 Lymphoma, B-Cell 18066065 disease of cellular proliferation DOID:707 D016393 109565 HP:0012191 c-Myc repressed this miRNA transcription factor target hsa-mir-15a Lymphoma, B-Cell 18066065 disease of cellular proliferation DOID:707 D016393 109565 HP:0012191 c-Myc repressed this miRNA transcription factor target hsa-mir-195 Lymphoma, B-Cell 18066065 disease of cellular proliferation DOID:707 D016393 109565 HP:0012191 c-Myc repressed this miRNA transcription factor target hsa-mir-22 Lymphoma, B-Cell 18066065 disease of cellular proliferation DOID:707 D016393 109565 HP:0012191 c-Myc repressed this miRNA transcription factor target hsa-mir-26b Lymphoma, B-Cell 18066065 disease of cellular proliferation DOID:707 D016393 109565 HP:0012191 c-Myc repressed this miRNA transcription factor target hsa-mir-28 Lymphoma, B-Cell 24843176 disease of cellular proliferation DOID:707 D016393 109565 HP:0012191 MicroRNA 28 controls cell proliferation and is down-regulated in B-cell lymphomas. transcription factor target hsa-mir-29a Lymphoma, B-Cell 18066065 disease of cellular proliferation DOID:707 D016393 109565 HP:0012191 c-Myc repressed this miRNA transcription factor target hsa-mir-29c Lymphoma, B-Cell 18066065 disease of cellular proliferation DOID:707 D016393 109565 HP:0012191 c-Myc repressed this miRNA transcription factor target hsa-mir-30e Lymphoma, B-Cell 18066065 disease of cellular proliferation DOID:707 D016393 109565 HP:0012191 c-Myc repressed this miRNA transcription factor target hsa-mir-34a Lymphoma, B-Cell 18066065 disease of cellular proliferation DOID:707 D016393 109565 HP:0012191 c-Myc repressed this miRNA transcription factor target hsa-mir-150 Lymphoma, Large-Cell, Anaplastic 26258416 disease of cellular proliferation DOID:0050744 C84.70 D017728 105590 HP:0012193 our results suggest that hypomethylating drugs,alone or in combination with other agents, may benefit ALK(+) patients harboring tumors resistant to crizotinib and other anti-ALK tyrosine kinase inhibitors (TKIs). Moreover, these results support further work on miR-150 in these and other ALK(+) malignancies. transcription factor target hsa-mir-548 Lymphoma, Non-Hodgkin 24216476 disease of cellular proliferation DOID:0060060 C85.9 D008228 605027 HP:0012539 A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas. transcription factor target hsa-mir-125b-1 Lymphoma, T-Cell 23527180 disease of cellular proliferation DOID:0050749 C84.4 D016399 186960 HP:0012190 cMyc/miR-125b-5p Signalling Determines Sensitivity to Bortezomib in Preclinical Model of Cutaneous T-Cell Lymphomas transcription factor target hsa-mir-125b-2 Lymphoma, T-Cell 23527180 disease of cellular proliferation DOID:0050749 C84.4 D016399 186960 HP:0012190 cMyc/miR-125b-5p Signalling Determines Sensitivity to Bortezomib in Preclinical Model of Cutaneous T-Cell Lymphomas transcription factor target hsa-mir-17 Medulloblastoma 19351822 disease of cellular proliferation DOID:0050902 C71.6 D008527 155255 HP:0002885 miR-17: the most highly up-regulated miRNAs in medulloblastoma transcription factor target hsa-mir-18a Medulloblastoma 19351822 disease of cellular proliferation DOID:0050902 C71.6 D008527 155255 HP:0002885 miR-18a: the most highly up-regulated miRNAs in medulloblastoma transcription factor target hsa-mir-19a Medulloblastoma 19351822 disease of cellular proliferation DOID:0050902 C71.6 D008527 155255 HP:0002885 miR-19a: the most highly up-regulated miRNAs in medulloblastoma transcription factor target hsa-mir-19b-1 Medulloblastoma 19351822 disease of cellular proliferation DOID:0050902 C71.6 D008527 155255 HP:0002885 miR-19b: the most highly up-regulated miRNAs in medulloblastoma transcription factor target hsa-mir-19b-2 Medulloblastoma 19351822 disease of cellular proliferation DOID:0050902 C71.6 D008527 155255 HP:0002885 miR-19b: the most highly up-regulated miRNAs in medulloblastoma transcription factor target hsa-mir-20a Medulloblastoma 19351822 disease of cellular proliferation DOID:0050902 C71.6 D008527 155255 HP:0002885 miR-20a: the most highly up-regulated miRNAs in medulloblastoma transcription factor target hsa-mir-92a-1 Medulloblastoma 19351822 disease of cellular proliferation DOID:0050902 C71.6 D008527 155255 HP:0002885 miR-92a: the most highly up-regulated miRNAs in medulloblastoma transcription factor target hsa-mir-92a-2 Medulloblastoma 19351822 disease of cellular proliferation DOID:0050902 C71.6 D008527 155255 HP:0002885 miR-92a: the most highly up-regulated miRNAs in medulloblastoma transcription factor target hsa-mir-210 Melanoma 24767210 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 Distinct microRNA expression signatures are associated with melanoma subtypes and are regulated by HIF1A. transcription factor target hsa-mir-218 Melanoma 24767210 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 Distinct microRNA expression signatures are associated with melanoma subtypes and are regulated by HIF1A. transcription factor target hsa-mir-221 Melanoma 18417445 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 suppressing transcription factor target hsa-mir-221 Melanoma 23400877 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miR-221&222-c-FOS pathway transcription factor target hsa-mir-222 Melanoma 18417445 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 suppressing transcription factor target hsa-mir-222 Melanoma 23400877 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miR-221&222-c-FOS pathway transcription factor target hsa-mir-224 Melanoma 25341426 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 E2F1 induces miR-224/452 expression to drive EMT through TXNIP downregulation. transcription factor target hsa-mir-224 Melanoma 24767210 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 Distinct microRNA expression signatures are associated with melanoma subtypes and are regulated by HIF1A. transcription factor target hsa-mir-452 Melanoma 25341426 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 E2F1 induces miR-224/452 expression to drive EMT through TXNIP downregulation. transcription factor target hsa-mir-452 Melanoma 24767210 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 Distinct microRNA expression signatures are associated with melanoma subtypes and are regulated by HIF1A. transcription factor target hsa-mir-638 Melanoma 25650662 disease of cellular proliferation DOID:1909 C43.9 D008545 155601 HP:0002861 miR-638 promotes melanoma metastasis and protects melanoma cells from apoptosis and autophagy. transcription factor target hsa-mir-9 MELAS Syndrome 25149473 musculoskeletal system disease DOID:3687 E88.41 D017241 540000 The ROS-sensitive microRNA-9/9* controls the expression of mitochondrial tRNA-modifying enzymes and is involved in the molecular mechanism of MELAS syndrome. transcription factor target hsa-mir-23b Multiple Myeloma 26771806 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth. transcription factor target hsa-mir-29b-1 Multiple Myeloma 23190608 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1 transcription factor target hsa-mir-29b-2 Multiple Myeloma 23190608 disease of cellular proliferation DOID:9538 D009101 254500 HP:0006775 miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1 transcription factor target hsa-mir-206 Muscle Diseases [unspecific] 26272918 M63.80 D009135 MyoD transcription factor induces myogenesis by inhibiting Twist-1 through miR-206. transcription factor target hsa-mir-199a-1 Muscular Dystrophy, Duchenne 23764775 musculoskeletal system disease DOID:11723 G71.0 D020388 310200 MicroRNA-199a is induced in dystrophic muscle and affects WNT signaling, cell proliferation, and myogenic differentiation. transcription factor target hsa-mir-199a-2 Muscular Dystrophy, Duchenne 23764775 musculoskeletal system disease DOID:11723 G71.0 D020388 310200 MicroRNA-199a is induced in dystrophic muscle and affects WNT signaling, cell proliferation, and myogenic differentiation. transcription factor target hsa-mir-132 Myocardial Infarction 21868695 cardiovascular system disease DOID:5844 I21 D009203 608557 HP:0001658 Transplantation of Human Pericyte Progenitor Cells Improves the Repair of Infarcted Heart Through Activation of an Angiogenic Program Involving Micro-RNA-132. transcription factor target hsa-mir-21 Myocardial Ischemic-Reperfusion Injury 24983504 D015428 A feedback regulatory loop between HIF-1α and miR-21 in response to hypoxia in cardiomyocytes. transcription factor target hsa-mir-10b Nasopharyngeal Neoplasms 20732742 C11.9 D009303 607107 HP:0100630 MicroRNA-10b induced by Epstein-Barr virus-encoded latent membrane protein-1 promotes the metastasis of human nasopharyngeal carcinoma cells transcription factor target hsa-let-7a-1 Neoplasms [unspecific] 20404092 C80.1 D009369 let-7a:let-7a-d, let-7i, mir-15b-16-2, and mir-106b-25, are direct targets of E2F1 and E2F3 during G(1)/S and are repressed in E2F1/3-null cells transcription factor target hsa-let-7a-2 Neoplasms [unspecific] 20404092 C80.1 D009369 let-7a:let-7a-d, let-7i, mir-15b-16-2, and mir-106b-25, are direct targets of E2F1 and E2F3 during G(1)/S and are repressed in E2F1/3-null cells transcription factor target hsa-let-7a-3 Neoplasms [unspecific] 20404092 C80.1 D009369 let-7a:let-7a-d, let-7i, mir-15b-16-2, and mir-106b-25, are direct targets of E2F1 and E2F3 during G(1)/S and are repressed in E2F1/3-null cells transcription factor target hsa-let-7i Neoplasms [unspecific] 20404092 C80.1 D009369 let-7i:let-7a-d, let-7i, mir-15b-16-2, and mir-106b-25, are direct targets of E2F1 and E2F3 during G(1)/S and are repressed in E2F1/3-null cells transcription factor target hsa-mir-1 Neoplasms [unspecific] 23921124 C80.1 D009369 Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. transcription factor target hsa-mir-100 Neoplasms [unspecific] 24586203 C80.1 D009369 miR-100 induces epithelial-mesenchymal transition but suppresses tumorigenesis, migration and invasion. transcription factor target hsa-mir-106b Neoplasms [unspecific] 20404092 C80.1 D009369 mir-106b-25:let-7a-d, let-7i, mir-15b-16-2, and mir-106b-25, are direct targets of E2F1 and E2F3 during G(1)/S and are repressed in E2F1/3-null cells transcription factor target hsa-mir-130a Neoplasms [unspecific] 26272168 C80.1 D009369 These findings reveal an evolutionarily conserved positive feedback mechanism underlying robustness of the Hippo pathway in size control and tumorigenesis. transcription factor target hsa-mir-143 Neoplasms [unspecific] 23932921 C80.1 D009369 DDX6 post-transcriptionally down-regulates miR-143/145 expression through host gene NCR143/145 in cancer cells. transcription factor target hsa-mir-145 Neoplasms [unspecific] 19202062 C80.1 D009369 miR-145: putative tumor suppressor, miR-145 provides a direct link between p53 and c-Myc in this gene regulatory network transcription factor target hsa-mir-145 Neoplasms [unspecific] 23932921 C80.1 D009369 DDX6 post-transcriptionally down-regulates miR-143/145 expression through host gene NCR143/145 in cancer cells. transcription factor target hsa-mir-148a Neoplasms [unspecific] 25703326 C80.1 D009369 Regulatory circuit of PKM2/NF-κB/miR-148a/152-modulated tumor angiogenesis and cancer progression. transcription factor target hsa-mir-152 Neoplasms [unspecific] 25703326 C80.1 D009369 Regulatory circuit of PKM2/NF-κB/miR-148a/152-modulated tumor angiogenesis and cancer progression. transcription factor target hsa-mir-155 Neoplasms [unspecific] 26156524 C80.1 D009369 the losing equilibrium of the regulatory feedback loop between STAT1 and miR-155-5p influencing tumorigenesis. transcription factor target hsa-mir-15b Neoplasms [unspecific] 20404092 C80.1 D009369 mir-15b-16-2:let-7a-d, let-7i, mir-15b-16-2, and mir-106b-25, are direct targets of E2F1 and E2F3 during G(1)/S and are repressed in E2F1/3-null cells transcription factor target hsa-mir-183 Neoplasms [unspecific] 24277930 C80.1 D009369 A p21-ZEB1 complex inhibits epithelial-mesenchymal transition through the microRNA 183-96-182 cluster. transcription factor target hsa-mir-18a Neoplasms [unspecific] 19706389 C80.1 D009369 significantly upregulated, downregulate Eralpha transcription factor target hsa-mir-200a Neoplasms [unspecific] 23759590 C80.1 D009369 KDM5B histone demethylase controls epithelial-mesenchymal transition of cancer cells by regulating the expression of the microRNA-200 family. transcription factor target hsa-mir-200b Neoplasms [unspecific] 23759590 C80.1 D009369 KDM5B histone demethylase controls epithelial-mesenchymal transition of cancer cells by regulating the expression of the microRNA-200 family. transcription factor target hsa-mir-200c Neoplasms [unspecific] 23759590 C80.1 D009369 KDM5B histone demethylase controls epithelial-mesenchymal transition of cancer cells by regulating the expression of the microRNA-200 family. transcription factor target hsa-mir-206 Neoplasms [unspecific] 23921124 C80.1 D009369 Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. transcription factor target hsa-mir-21 Neoplasms [unspecific] 18850008 C80.1 D009369 miR-21: oncomir, An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation transcription factor target hsa-mir-25 Neoplasms [unspecific] 20404092 C80.1 D009369 mir-106b-25:let-7a-d, let-7i, mir-15b-16-2, and mir-106b-25, are direct targets of E2F1 and E2F3 during G(1)/S and are repressed in E2F1/3-null cells transcription factor target hsa-mir-34a Neoplasms [unspecific] 20185821 C80.1 D009369 Our study demonstrates an unexpected role of the FXR/SHP pathway in controlling SIRT1 levels via miR-34a inhibition and that elevated miR-34a levels in obese mice contribute to decreased SIRT1 levels transcription factor target hsa-mir-370 Neoplasms [unspecific] 23333300 C80.1 D009369 Stat3 inhibits WTX expression through up-regulation of microRNA-370 in Wilms tumor transcription factor target hsa-mir-519c Neoplasms [unspecific] 20233879 C80.1 D009369 MicroRNA-519c suppresses hypoxia-inducible factor-1alpha expression and tumor angiogenesis transcription factor target hsa-mir-93 Neoplasms [unspecific] 20404092 C80.1 D009369 mir-106b-25:let-7a-d, let-7i, mir-15b-16-2, and mir-106b-25, are direct targets of E2F1 and E2F3 during G(1)/S and are repressed in E2F1/3-null cells transcription factor target hsa-mir-148a Obesity 26001136 disease of metabolism DOID:9970 E66 D009765 601665 HP:0001513 The results suggest that miR-148a is a biomarker of obesity in human subjects and mouse model, which represents a CREB-modulated miRNA that acts to repress Wnt1, thereby promoting adipocyte differentiation. transcription factor target hsa-mir-210 Obesity 25833255 disease of metabolism DOID:9970 E66 D009765 601665 HP:0001513 Our data suggest that the inflammatory intrauterine environment associated with maternal obesity induces an NFκB1-mediated increase in miR-210 in a fetal sex-dependent manner, leading to inhibition of mitochondrial respiration and placental dysfunction in the placentas of female fetuses. transcription factor target hsa-mir-34a Obesity 26036628 disease of metabolism DOID:9970 E66 D009765 601665 HP:0001513 These data provide first in vitro and in vivo evidence for the leptin-antagonist potential of honokiol (HNK) revealing a crosstalk between HNK and miR34a and Wnt1-MTA1-β-catenin axis. transcription factor target hsa-mir-146a Osteoarthritis 19333945 musculoskeletal system disease DOID:8398 M19.9 D010003 165720 HP:0002758 miR-146a: miR-146 is intensely expressed in low-grade OA cartilage and that its expression is induced by stimulation of IL-1beta transcription factor target hsa-mir-125b-1 Osteosarcoma 22093834 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-125b suppresses the proliferation and migration of osteosarcoma cells through down-regulation of STAT3. transcription factor target hsa-mir-125b-2 Osteosarcoma 22093834 disease of cellular proliferation DOID:3347 D012516 259500 HP:0002669 miR-125b suppresses the proliferation and migration of osteosarcoma cells through down-regulation of STAT3. transcription factor target hsa-mir-125b Ovarian Neoplasms 25944662 endocrine system disease DOID:2394 C56 D010051 167000 HP:0100615 PPARγ inhibits ovarian cancer cells proliferation through upregulation of miR-125b. transcription factor target hsa-mir-155 Pancreatic Neoplasms 20871480 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 miR-155:Human SMG-1 is Involved in Gemcitabine-Induced Primary microRNA-155/BIC Up-Regulation in Human Pancreatic Cancer PANC-1 Cells transcription factor target hsa-mir-191 Pancreatic Neoplasms 25119596 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 The clinical significance and regulation mechanism of hypoxia-inducible factor-1 and miR-191 expression in pancreatic cancer. transcription factor target hsa-mir-198 Pancreatic Neoplasms 23989979 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 miR-198 acts as a central tumor suppressor and modulates the molecular makeup of a critical interactome in pancreatic cancer, indicating a potential prognostic marker signature and the therapeutic potential of attacking this tumorigenic network through a central vantage point. transcription factor target hsa-mir-19a Pancreatic Neoplasms 26041879 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 Sp1-driven up-regulation of miR-19a decreases RHOB and promotes pancreatic cancer. transcription factor target hsa-mir-373 Pancreatic Neoplasms 23857777 disease of cellular proliferation DOID:1793 C25.0-.2 D010190 260350 A novel epigenetic CREB-miR-373 axis mediates ZIP4-induced pancreatic cancer growth. transcription factor target hsa-mir-1 Prostate Neoplasms 26071255 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 EGF Receptor Promotes Prostate Cancer Bone Metastasis by Downregulating miR-1 and Activating TWIST1. transcription factor target hsa-mir-106b Prostate Neoplasms 20388916 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 We showed that miR-22 and the miR-106b~25 cluster are aberrantly overexpressed in human prostate cancer transcription factor target hsa-mir-125b-1 Prostate Neoplasms 23503464 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Regulation of several androgen-induced genes through the repression of the miR-99a/let-7c/miR-125b-2 miRNA cluster in prostate cancer cells transcription factor target hsa-mir-125b-2 Prostate Neoplasms 23503464 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Regulation of several androgen-induced genes through the repression of the miR-99a/let-7c/miR-125b-2 miRNA cluster in prostate cancer cells transcription factor target hsa-mir-132 Prostate Neoplasms 22916239 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Luteolin Induces microRNA-132 Expression and Modulates Neurite Outgrowth in PC12 Cells. transcription factor target hsa-mir-190a Prostate Neoplasms 26314494 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Taken together, our findings identified a biochemical and functional link between miR-190a with reduced expression in advanced prostate cancer, YB-1 and AR signaling in prostate cancer. transcription factor target hsa-mir-200c Prostate Neoplasms 24186205 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c. transcription factor target hsa-mir-205 Prostate Neoplasms 23924028 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 The evidence that miR-205 replacement in PCa cells is able not only to prevent but also to revert the oxidative/pro-inflammatory axis leading to EMT induced by CAFs sets the rationale for developing miRNA-based approaches to prevent and treat metastatic disease. transcription factor target hsa-mir-21 Prostate Neoplasms 19738047 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 hsa-mir-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth transcription factor target hsa-mir-22 Prostate Neoplasms 20388916 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 We showed that miR-22 and the miR-106b~25 cluster are aberrantly overexpressed in human prostate cancer transcription factor target hsa-mir-221 Prostate Neoplasms 21245048 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 NF-kB and c-Jun induce the expression of the oncogenic miR-221 and miR-222 in prostate carcinoma and glioblastoma cells. transcription factor target hsa-mir-222 Prostate Neoplasms 19351827 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 miR-222: Overexpression transcription factor target hsa-mir-25 Prostate Neoplasms 20388916 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 We showed that miR-22 and the miR-106b~25 cluster are aberrantly overexpressed in human prostate cancer transcription factor target hsa-mir-31 Prostate Neoplasms 25341040 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31. transcription factor target hsa-mir-93 Prostate Neoplasms 20388916 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 We showed that miR-22 and the miR-106b~25 cluster are aberrantly overexpressed in human prostate cancer transcription factor target hsa-mir-96 Prostate Neoplasms 25531317 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 a novel mechanism accounting for the TGFβ signaling and bone metastasis. transcription factor target hsa-mir-99a Prostate Neoplasms 23503464 disease of cellular proliferation DOID:10283 C51 D011471 176807 HP:0100787 Regulation of several androgen-induced genes through the repression of the miR-99a/let-7c/miR-125b-2 miRNA cluster in prostate cancer cells transcription factor target hsa-mir-19a PTEN Hamartoma Tumor Tyndrome 18460397 syndrome DOID:0080191 Q85.9 C566636 overexpressed transcription factor target hsa-mir-21 PTEN Hamartoma Tumor Tyndrome 18460397 syndrome DOID:0080191 Q85.9 C566636 overexpressed transcription factor target hsa-mir-143 Pulmonary Hypertension 26311719 cardiovascular system disease DOID:6432 I27.20 D006976 PS178600 HP:0002092 MiR-143-3p modulated both cellular and exosome-mediated responses in pulmonary vascular cells, whereas inhibition of miR-143-3p blocked experimental pulmonary hypertension. Taken together, these findings confirm an important role for the miR-143/145 cluster in PAH pathobiology. transcription factor target hsa-mir-648 Pulmonary Hypertension 25403488 cardiovascular system disease DOID:6432 I27.20 D006976 PS178600 HP:0002092 These studies provide a novel link wherein PlGF-mediated downregulation of PAX5 attenuates miR-648 expression leading to increased ET-1 levels that are known to induce PHT in SCA. transcription factor target hsa-mir-192 Renal Fibrosis 20488955 urinary system disease DOID:0050855 N26.9 HP:0030760 miR-192:miR-192 mediates TGF-beta/Smad3-driven renal fibrosis transcription factor target hsa-mir-29a Rhabdomyosarcoma 18977326 disease of cellular proliferation DOID:3247 M62.82 D012208 268220 HP:0002859 miR-29: NF-kappaB-YY1-miR-29 regulatory circuitry transcription factor target hsa-mir-195 Schizophrenia 20156358 disease of mental health DOID:5419 F20 D012559 181500 HP:0100753 EGR3 and hsa-miR-195 were core regulators transcription factor target hsa-mir-150 Scleroderma, Systemic 23159943 musculoskeletal system disease DOID:418 M34 D012595 181750 miR-150 Down-Regulation Contributes to the Constitutive Type I Collagen Overexpression in Scleroderma Dermal Fibroblasts via the Induction of Integrin ж┿ transcription factor target hsa-mir-214 Sickle Cell Disease 25876995 D57 D000755 603903 Erythropoietin-mediated expression of placenta growth factor is regulated via activation of hypoxia-inducible factor-1α and post-transcriptionally by miR-214 in sickle cell disease. transcription factor target hsa-mir-182 Soft Tissue Sarcoma 26234681 C49.9 D012509 HP:0030448 these results suggest that sarcoma metastasis can be partially controlled through Pax7/MyoD-dependent activation of miR-182 and provide insight into the role that myogenic transcription factors have in sarcoma progression. transcription factor target hsa-mir-203 Squamous Cell Carcinoma, Esophageal 24994936 disease of cellular proliferation DOID:3748 C562729 EGF-induced C/EBPβ participates in EMT by decreasing the expression of miR-203 in esophageal squamous cell carcinoma cells. transcription factor target hsa-mir-593 Squamous Cell Carcinoma, Tongue 25912308 disease of cellular proliferation DOID:0050865 C02.9 Mitochondrial fission determines cisplatin sensitivity in tongue squamous cell carcinoma through the BRCA1-miR-593-5p-MFF axis. transcription factor target hsa-mir-199a Testicular Germ Cell Tumor 24391856 disease of cellular proliferation DOID:5557 C563236 273300 Molecular mechanisms of regulation and action of microRNA-199a in testicular germ cell tumor and glioblastomas. transcription factor target hsa-mir-205 Urinary Bladder Cancer 23239884 urinary system disease DOID:11054 C67 D001749 109800 The p63 isoform deltaNp63ж┿inhibits epithelial-mesenchymal transition in human bladder cancer cells: Role of miR205 transcription factor target hsa-mir-143 Wounds and Injuries [unspecific] 19720868 D014947 modulate cytoskeletal dynamics and responsiveness transcription factor target hsa-mir-145 Wounds and Injuries [unspecific] 19720868 D014947 modulate cytoskeletal dynamics and responsiveness